<SEC-DOCUMENT>0001493152-21-005583.txt : 20210308
<SEC-HEADER>0001493152-21-005583.hdr.sgml : 20210308
<ACCEPTANCE-DATETIME>20210308164059
ACCESSION NUMBER:		0001493152-21-005583
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		110
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210308
DATE AS OF CHANGE:		20210308

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HARROW HEALTH, INC.
		CENTRAL INDEX KEY:			0001360214
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				450567010
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35814
		FILM NUMBER:		21722491

	BUSINESS ADDRESS:	
		STREET 1:		102 WOODMONT BLVD
		STREET 2:		SUITE 610
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37215
		BUSINESS PHONE:		615.733.4731

	MAIL ADDRESS:	
		STREET 1:		102 WOODMONT BLVD
		STREET 2:		SUITE 610
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37215

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Imprimis Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20120301

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRANSDEL PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20070912

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bywater Resources, Inc
		DATE OF NAME CHANGE:	20060421
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:HROW="http://harrowinc.com/20201231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_HROW_harrowinc.com_20201231 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20200101_20201231 -->
<!-- Field: Set; Name: xdx; ID: xdx_05B_edei%2D%2DEntityCentralIndexKey_0001360214 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DDocumentFiscalYearFocus_2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityFilerCategory_Non%2Daccelerated Filer -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_065_Percent_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06E_Segment_5_Segment -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Sqft_0_utr%2D%2Dsqft -->
<body>
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityCentralIndexKey">0001360214</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:DocumentFiscalYearFocus">2020</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityFilerCategory">Non-accelerated Filer</ix:nonNumeric>
    <ix:nonFraction name="us-gaap:LoansPayableCurrent" contextRef="AsOf2019-12-31" id="xdx2ixbrl0109" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:LongTermLoansPayable" contextRef="AsOf2019-12-31" id="xdx2ixbrl0133" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2018-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="HROW:StockIssuedDuringPeriodForExerciseOfWarrants" contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="HROW:StockIssuedDuringPeriodForExerciseOfWarrants" contextRef="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2019-01-012019-12-31_us-gaap_ParentMember" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0304" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0305" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0307" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0360" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-01-012020-12-31_us-gaap_ParentMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-01-01to2020-12-31" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0368" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0385" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:PaidInKindInterest" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ProceedsFromOtherDebt" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0494" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="HROW:PaymentsOfCostsRelatedToAmendmentOfLoanPayable" contextRef="From2020-01-01to2020-12-31" id="xdx2ixbrl0499" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl0503" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonNumeric contextRef="From2020-01-012020-12-31_srt_MinimumMember" id="xdx2ixbrl0633" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">P3Y</ix:nonNumeric>
    <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_custom_CommissionsMember" id="xdx2ixbrl0706" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-12-31_custom_MeltPharmaceuticalsIncMember" id="xdx2ixbrl0725" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_custom_MeltPharmaceuticalsIncMember" id="xdx2ixbrl0727" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-12-31_custom_SurfacePharmaceuticalsIncMember" id="xdx2ixbrl0770" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_custom_SurfacePharmaceuticalsIncMember" id="xdx2ixbrl0772" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="HROW:FiniteLivedIntangibleAssetsImpairment" contextRef="AsOf2019-12-31_custom_LicensesMember" id="xdx2ixbrl0891" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2019-12-31_us-gaap_TrademarksMember" id="xdx2ixbrl0898" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="HROW:FiniteLivedIntangibleAssetsImpairment" contextRef="AsOf2019-12-31_us-gaap_TrademarksMember" id="xdx2ixbrl0900" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2019-12-31_us-gaap_TradeNamesMember" id="xdx2ixbrl0921" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2019-12-31_custom_NonCompetitionClauseMember" id="xdx2ixbrl0931" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-12-31_us-gaap_TrademarksMember" id="xdx2ixbrl0967" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-12-31_us-gaap_TrademarksMember" id="xdx2ixbrl0974" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="HROW:FiniteLivedIntangibleAssetsImpairment" contextRef="AsOf2020-12-31_us-gaap_TrademarksMember" id="xdx2ixbrl0976" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="HROW:FiniteLivedIntangibleAssetsImpairment" contextRef="AsOf2020-12-31_us-gaap_CustomerRelationshipsMember" id="xdx2ixbrl0986" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="HROW:FiniteLivedIntangibleAssetsImpairment" contextRef="AsOf2020-12-31_us-gaap_TradeNamesMember" id="xdx2ixbrl0995" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2020-12-31_us-gaap_TradeNamesMember" id="xdx2ixbrl0997" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="HROW:FiniteLivedIntangibleAssetsImpairment" contextRef="AsOf2020-12-31_custom_NonCompetitionClauseMember" id="xdx2ixbrl1005" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2020-12-31_custom_NonCompetitionClauseMember" id="xdx2ixbrl1007" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="HROW:FiniteLivedIntangibleAssetsImpairment" contextRef="AsOf2020-12-31_custom_StatePharmacyLicensesMember" id="xdx2ixbrl1014" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2020-01-012020-12-31_us-gaap_TradeNamesMember" id="xdx2ixbrl1041" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2020-01-012020-12-31_custom_StatePharmacyLicensesMember" id="xdx2ixbrl1045" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonNumeric contextRef="AsOf2020-12-31_custom_OfficeAndLaboratorySpaceMember_srt_MinimumMember" id="xdx2ixbrl1169" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">P1Y</ix:nonNumeric>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-01-012020-12-31_custom_OptionsEmployeesMember" id="xdx2ixbrl1448" unitRef="Percent" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2019-01-012019-12-31_custom_OptionsEmployeesMember" id="xdx2ixbrl1450" unitRef="Percent" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1554" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1580" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1652" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1654" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1656" unitRef="Shares" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2020-01-01to2020-12-31" id="xdx2ixbrl1706" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl1708" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2020-01-01to2020-12-31" id="xdx2ixbrl1730" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2019-01-012019-12-31" id="xdx2ixbrl1732" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2020-12-31" id="xdx2ixbrl1811" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2019-12-31" id="xdx2ixbrl1812" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalDrugDevelopmentMember" id="xdx2ixbrl1930" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalDrugDevelopmentMember" id="xdx2ixbrl1936" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalDrugDevelopmentMember" id="xdx2ixbrl1942" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_custom_PharmaceuticalDrugDevelopmentMember_us-gaap_OperatingSegmentsMember" id="xdx2ixbrl1974" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2019-01-012019-12-31_custom_PharmaceuticalDrugDevelopmentMember_us-gaap_OperatingSegmentsMember" id="xdx2ixbrl1980" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2019-01-012019-12-31_custom_PharmaceuticalDrugDevelopmentMember_us-gaap_OperatingSegmentsMember" id="xdx2ixbrl1986" unitRef="USD" xs:nil="true"></ix:nonFraction>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="hrow-20201231.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2020-01-01to2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SurfaceOphthalmicsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:SurfaceOphthalmicsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_SurfaceOphthalmicsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:SurfaceOphthalmicsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_MeltPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MeltPharmaceuticalsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_MeltPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MeltPharmaceuticalsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_ProductSalesNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:ProductSalesNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_ProductSalesNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:ProductSalesNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OtherRevenuesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:OtherRevenuesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_OtherRevenuesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:OtherRevenuesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_MeltPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MeltPharmaceuticalsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_MeltPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MeltPharmaceuticalsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_SurfaceOphthalmicsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:SurfaceOphthalmicsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_SurfaceOphthalmicsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:SurfaceOphthalmicsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_EtonPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:EtonPharmaceuticalsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_EtonPharmaceuticalsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:EtonPharmaceuticalsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_ParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_MayfieldPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">HROW:MayfieldPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_StowePharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">HROW:StowePharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_MayfieldPharmaceuticalsIncMember_custom_TGVHealthLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">HROW:MayfieldPharmaceuticalsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:TGVHealthLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_StowePharmaceuticalsIncMember_custom_TGVHealthLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:OwnershipAxis">HROW:StowePharmaceuticalsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:TGVHealthLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_VisionologyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:VisionologyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_EtonPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:EtonPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_EtonPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:EtonPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_EtonPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:EtonPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_EtonPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:EtonPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_MeltPharmaceuticalsIncMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_MeltPharmaceuticalsIncMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-01-31_custom_MeltPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_MeltPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_MeltPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_MeltPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:SurfacePharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_SurfacePharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:SurfacePharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_SurfacePharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:SurfacePharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_SurfacePharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:SurfacePharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_ParkCompoundingIncAndNoiceRxLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:ParkCompoundingIncAndNoiceRxLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_StockOptionsUnvestedRSUsAndWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">HROW:StockOptionsUnvestedRSUsAndWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_StockOptionsUnvestedRSUsAndWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">HROW:StockOptionsUnvestedRSUsAndWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">HROW:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CommissionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:CommissionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CommissionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:CommissionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-02-012019-02-28_custom_MeltPharmaceuticalsIncMember_custom_ManagementServicesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:ManagementServicesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-02-01</xbrli:startDate>
        <xbrli:endDate>2019-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember_custom_ManagementServicesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:ManagementServicesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_MeltPharmaceuticalsIncMember_custom_ManagementServicesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:ManagementServicesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_SurfacePharmaceuticalsIncMember_custom_MSAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:SurfacePharmaceuticalsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:MSAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_SurfacePharmaceuticalsIncMember_custom_DrLindstromMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:SurfacePharmaceuticalsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:DrLindstromMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_PatentsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_PatentsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_LicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:LicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_LicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:LicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_TrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_TrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_CustomerRelationshipsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_CustomerRelationshipsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_TradeNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_TradeNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_NonCompetitionClauseMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:NonCompetitionClauseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_NonCompetitionClauseMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:NonCompetitionClauseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_NonCompetitionClauseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:NonCompetitionClauseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_StatePharmacyLicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:StatePharmacyLicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_StatePharmacyLicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:StatePharmacyLicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember_custom_ParkCompoundingIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:ParkCompoundingIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_PatentsMember_custom_ParkCompoundingIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:ParkCompoundingIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_PatentsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_PatentsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_LicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:LicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_LicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:LicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_TrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_TrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_CustomerRelationshipsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_CustomerRelationshipsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_TradeNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_TradeNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_NonCompetitionClauseMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:NonCompetitionClauseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_NonCompetitionClauseMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:NonCompetitionClauseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NonCompetitionClauseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:NonCompetitionClauseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_StatePharmacyLicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:StatePharmacyLicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_StatePharmacyLicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:StatePharmacyLicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_PatentsFilingsAndTrademarksMember_custom_ParkCompoundingIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:PatentsFilingsAndTrademarksMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:ParkCompoundingIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-07-31_custom_TermLoanAndSecurityAgreementMember_custom_SWKFundingLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:TermLoanAndSecurityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:SWKFundingLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-012017-07-31_custom_TermLoanAndSecurityAgreementMember_custom_SWKFundingLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:TermLoanAndSecurityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:SWKFundingLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2017-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-04-30_us-gaap_LondonInterbankOfferedRateLIBORMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-04-30_us-gaap_LondonInterbankOfferedRateLIBORMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-04-30_us-gaap_LondonInterbankOfferedRateLIBORMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-292019-04-30_custom_SWKLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SWKLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-29</xbrli:startDate>
        <xbrli:endDate>2019-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-30_custom_SWKLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SWKLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-07-31_custom_LenderWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">HROW:LenderWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-08-31_custom_LenderWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">HROW:LenderWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-08-31_us-gaap_WarrantMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-08-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-08-31_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-05-012019-05-31_custom_JoinderAndAmendmentMember_us-gaap_LondonInterbankOfferedRateLIBORMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:JoinderAndAmendmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-05-01</xbrli:startDate>
        <xbrli:endDate>2019-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-05-012019-05-31_custom_JoinderAndAmendmentMember_custom_MarginRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:JoinderAndAmendmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">HROW:MarginRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-05-01</xbrli:startDate>
        <xbrli:endDate>2019-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-05-012019-05-31_custom_JoinderAndAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:JoinderAndAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-05-01</xbrli:startDate>
        <xbrli:endDate>2019-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-05-31_custom_JoinderAndAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:JoinderAndAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-02_custom_SWKSecondAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SWKSecondAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-132020-05-14_custom_SWKSecondAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SWKSecondAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-13</xbrli:startDate>
        <xbrli:endDate>2020-05-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_SWKSecondAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SWKSecondAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_SWKSecondAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SWKSecondAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-30_custom_BusinessLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:BusinessLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-032020-04-30_custom_BusinessLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:BusinessLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-03</xbrli:startDate>
        <xbrli:endDate>2020-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OfficeAndLaboratorySpaceMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">HROW:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OfficeAndLaboratorySpaceMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">HROW:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SanDiegoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:SanDiegoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_SanDiegoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:SanDiegoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_LedgewoodMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:LedgewoodMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_LedgewoodMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:LedgewoodMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NashvilleMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:NashvilleMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_NashvilleMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:NashvilleMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_IrvineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:IrvineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_IrvineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:IrvineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CommonStockWarrantsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">HROW:CommonStockWarrantsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_CommonStockWarrantsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">HROW:CommonStockWarrantsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_CommonStockWarrantsTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">HROW:CommonStockWarrantsTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_CommonStockWarrantsTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">HROW:CommonStockWarrantsTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">HROW:TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_StockOptionPlanOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_StockOptionPlanOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_StockOptionPlanOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_StockOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_StockOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_StockOptionPlanMember_custom_EmployeesAndConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:EmployeesAndConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-07-302015-07-31_custom_BaumPerformanceOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:BaumPerformanceOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-07-30</xbrli:startDate>
        <xbrli:endDate>2015-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-07-31_custom_BaumPerformanceOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:BaumPerformanceOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-07-31_custom_BaumPerformanceOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:BaumPerformanceOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-032020-06-04_custom_BaumPerformanceOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:BaumPerformanceOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-03</xbrli:startDate>
        <xbrli:endDate>2020-06-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:OptionsEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_OptionsEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:OptionsEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsEmployeesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:OptionsEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_OptionsEmployeesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:OptionsEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_OptionsEmployeesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:OptionsEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_OptionsEmployeesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:OptionsEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_RangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_RangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_StockOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_BoardOfDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:BoardOfDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_BoardOfDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:BoardOfDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_UnvestedRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:UnvestedRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_UnvestedRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:UnvestedRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_UnvestedRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:UnvestedRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-02-022019-02-28_custom_MayfieldPharmaceuticalsIncMember_custom_EllePharmaceuticalLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MayfieldPharmaceuticalsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:EllePharmaceuticalLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-02-02</xbrli:startDate>
        <xbrli:endDate>2019-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-07-31_custom_MayfieldPharmaceuticalsIncMember_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MayfieldPharmaceuticalsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_MayfieldPharmaceuticalsIncMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MayfieldPharmaceuticalsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_MayfieldPharmaceuticalsIncMember_custom_MarkBaumCEOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MayfieldPharmaceuticalsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:MarkBaumCEOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_MayfieldPharmaceuticalsIncMember_custom_AndrewBollCFOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MayfieldPharmaceuticalsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:AndrewBollCFOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_MayfieldPharmaceuticalsIncMember_custom_EllePharmaceuticalLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MayfieldPharmaceuticalsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:EllePharmaceuticalLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_MayfieldPharmaceuticalsIncMember_us-gaap_RestrictedStockMember_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MayfieldPharmaceuticalsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_MayfieldPharmaceuticalsIncMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MayfieldPharmaceuticalsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_MayfieldPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MayfieldPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-07-31_custom_StowePharmaceuticalsIncMember_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:StowePharmaceuticalsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_VisionologyIncMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:VisionologyIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_VisionologyIncMember_custom_MarkBaumCEOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:VisionologyIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:MarkBaumCEOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_VisionologyIncMember_custom_AndrewBollCFOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:VisionologyIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:AndrewBollCFOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_EmployeesMember_custom_SellingGeneralAndAdministrativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">HROW:SellingGeneralAndAdministrativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_EmployeesMember_custom_SellingGeneralAndAdministrativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">HROW:SellingGeneralAndAdministrativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_srt_DirectorMember_custom_SellingGeneralAndAdministrativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">HROW:SellingGeneralAndAdministrativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_srt_DirectorMember_custom_SellingGeneralAndAdministrativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">HROW:SellingGeneralAndAdministrativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_ConsultantMember_custom_SellingGeneralAndAdministrativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:ConsultantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">HROW:SellingGeneralAndAdministrativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_ConsultantMember_custom_SellingGeneralAndAdministrativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:ConsultantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">HROW:SellingGeneralAndAdministrativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_LenderWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:LenderWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_LenderWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:LenderWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_SettlementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:SettlementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SettlementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:SettlementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_LenderWarrantsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:LenderWarrantsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_LenderWarrantsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:LenderWarrantsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_SettlementAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SettlementAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_SettlementAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SettlementAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-022019-10-31_custom_SettlementAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SettlementAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-02</xbrli:startDate>
        <xbrli:endDate>2019-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-05-012019-05-31_custom_AllerganUSAIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:AllerganUSAIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-05-01</xbrli:startDate>
        <xbrli:endDate>2019-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012019-12-31_custom_SalesAndMarketingAgreementsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SalesAndMarketingAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012019-12-31_custom_SalesAndMarketingAgreementsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SalesAndMarketingAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_SalesAndMarketingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SalesAndMarketingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_SalesAndMarketingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SalesAndMarketingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-07-31_custom_MayfieldPharmaceuticalsIncMember_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MayfieldPharmaceuticalsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-07-31_custom_StowePharmaceuticalsIncMember_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:StowePharmaceuticalsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-04-012017-04-30_custom_KlarityLicenseAgreementMember_custom_RichardLLindstromMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:KlarityLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-04-01</xbrli:startDate>
        <xbrli:endDate>2017-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-04-012017-04-30_custom_InitialPaymentMember_custom_LicenseAgreementMember_custom_RichardLLindstromMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">HROW:InitialPaymentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-04-01</xbrli:startDate>
        <xbrli:endDate>2017-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-04-012017-04-30_custom_SecondPaymentMember_custom_LicenseAgreementMember_custom_RichardLLindstromMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">HROW:SecondPaymentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-04-01</xbrli:startDate>
        <xbrli:endDate>2017-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-04-012017-04-30_custom_FinalPaymentMember_custom_LicenseAgreementMember_custom_RichardLLindstromMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">HROW:FinalPaymentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-04-01</xbrli:startDate>
        <xbrli:endDate>2017-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_RichardLLindstromMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_RichardLLindstromMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_KlarityLicenseAgreementMember_custom_RichardLLindstromMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:KlarityLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_KlarityLicenseAgreementMember_custom_RichardLLindstromMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:KlarityLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-012019-12-31_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:InjectableAssetPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-012019-12-31_custom_InitialPaymentMember_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">HROW:InitialPaymentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:InjectableAssetPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:InjectableAssetPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:InjectableAssetPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-012019-12-31_custom_PresbyopiaAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:PresbyopiaAssetPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-12-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_PresbyopiaAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:PresbyopiaAssetPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_PresbyopiaAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:PresbyopiaAssetPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_DexycuAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:DexycuAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">HROW:PharmaceuticalCompoundingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalDrugDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">HROW:PharmaceuticalDrugDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_CorporateNonSegmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">HROW:PharmaceuticalCompoundingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_PharmaceuticalDrugDevelopmentMember_us-gaap_OperatingSegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">HROW:PharmaceuticalDrugDevelopmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_CorporateNonSegmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_ThreeMainSuppliersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">HROW:ThreeMainSuppliersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31_custom_ThreeMainSuppliersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">HROW:ThreeMainSuppliersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-012021-03-31_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-012021-03-31_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-03-012020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-03-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-012021-02-28_us-gaap_RestrictedStockUnitsRSUMember_custom_AndrewRBollMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:AndrewRBollMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-01</xbrli:startDate>
        <xbrli:endDate>2021-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-012021-02-28_us-gaap_RestrictedStockUnitsRSUMember_custom_MarkLBaumMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:MarkLBaumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-01</xbrli:startDate>
        <xbrli:endDate>2021-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Percent">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segment">
      <xbrli:measure>HROW:Segment</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 35%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>FORM
<span id="xdx_907_edei--DocumentType_c20200101__20201231_zPmm8h1rSC5l"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Mark
One)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><b><span id="xdx_901_edei--DocumentAnnualReport_c20200101__20201231_zcTUeqAyyTbe"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></b></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANNUAL
                                         REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For
    the fiscal year ended <span id="xdx_90D_edei--DocumentPeriodEndDate_c20200101__20201231_zCAkTezKv1Na"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 31, 2020</ix:nonNumeric></span></b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>OR</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90E_edei--DocumentTransitionReport_c20200101__20201231_z3Isf7K6Fxzg"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For
the transition period from to </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Commission
File Number: <span id="xdx_90C_edei--EntityFileNumber_c20200101__20201231_zoa3KBIR6Ym7"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityFileNumber">001-35814</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="xdx_907_edei--EntityRegistrantName_c20200101__20201231_zhNzOfnKQxG2" style="font: 18pt Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityRegistrantName">HARROW
HEALTH, INC.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20200101__20201231_zmm2Q8wmVBa3"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span id="xdx_909_edei--EntityTaxIdentificationNumber_c20200101__20201231_z1eJc6oOApE8" style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityTaxIdentificationNumber">45-0567010</ix:nonNumeric></b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State
    or other jurisdiction of</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(IRS
    Employer </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">incorporation
    or organization)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Identification
    No.)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="xdx_900_edei--EntityAddressAddressLine1_c20200101__20201231_zVRnUT6MGHNj" style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityAddressAddressLine1">102
Woodmont Blvd.</ix:nonNumeric></b></span><b><span style="font: 10pt Times New Roman, Times, Serif">, <span id="xdx_90A_edei--EntityAddressAddressLine2_c20200101__20201231_zyl8DHy3I0Z"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityAddressAddressLine2">Suite
610</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="xdx_909_edei--EntityAddressCityOrTown_c20200101__20201231_z5GHZuwstRll" style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityAddressCityOrTown">Nashville</ix:nonNumeric></b></span><b><span style="font: 10pt Times New Roman, Times, Serif">,
<span id="xdx_900_edei--EntityAddressStateOrProvince_c20200101__20201231_zx9GkuHHfO68"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityAddressStateOrProvince">TN</ix:nonNumeric></span></span></b><b> <span id="xdx_908_edei--EntityAddressPostalZipCode_c20200101__20201231_zFhP6ggDjtkd" style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityAddressPostalZipCode">37205</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Address
of Principal Executive Offices)(Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="xdx_906_edei--CityAreaCode_c20200101__20201231_zTkfmicQQbI2" style="font: 10pt Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:CityAreaCode">(615)</ix:nonNumeric>
</b></span><b><span id="xdx_90C_edei--LocalPhoneNumber_c20200101__20201231_zPI6brlBOpb9" style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:LocalPhoneNumber">733-4730</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Securities
registered pursuant to Section 12(b) of the Act:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 38%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title
    of Each Class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 20%"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Symbol</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center; width: 38%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name
                                         of Each Exchange on Which Registered</b></span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90A_edei--Security12bTitle_c20200101__20201231_zj2bafylSjX7" style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:Security12bTitle">Common
    Stock, $0.001 par value per share</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90E_edei--TradingSymbol_c20200101__20201231_zKMWYffAX0if" style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:TradingSymbol">HROW</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
    <span id="xdx_90E_edei--SecurityExchangeName_c20200101__20201231_zEi2s1Ne5qXg"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span></span> <span style="font: 10pt Times New Roman, Times, Serif">Global
    Market</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Securities
registered pursuant to Section 12(g) of the Act: None</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <b>Yes</b> &#9744;
<b><span id="xdx_902_edei--EntityWellKnownSeasonedIssuer_c20200101__20201231_zx3HAUoFEoOc"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span></b></span> <span style="font: 10pt Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. <b>Yes
</b>&#9744; <b><span id="xdx_907_edei--EntityVoluntaryFilers_c20200101__20201231_zwW4KNXH3GI9"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span></b></span> <span style="font: 10pt Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. <b><span id="xdx_90D_edei--EntityCurrentReportingStatus_c20200101__20201231_z3qcp1yhR6L6"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>
</b>&#9746;</span> <span style="font: 10pt Times New Roman, Times, Serif"><b>No </b>&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (&#167; 229.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit such files). <b><span id="xdx_901_edei--EntityInteractiveDataCurrent_c20200101__20201231_zbEK1D5hdTwe"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>
</b></span><span style="font: 10pt Times New Roman, Times, Serif">&#9746; <b>No</b> &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">Accelerated
    filer &#9744;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Non-accelerated
    filer &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Smaller
    reporting company <span id="xdx_901_edei--EntitySmallBusiness_c20200101__20201231_zQDqhwHuiPIj"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Emerging
    growth company <span id="xdx_901_edei--EntityEmergingGrowthCompany_c20200101__20201231_z0Zi0sQhjir3"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). <b>Yes</b> &#9744; <b><span id="xdx_904_edei--EntityShellCompany_c20200101__20201231_zjTDC7AfQ49d"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span>
</b></span><span style="font: 10pt Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2020, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate
market value of the common stock held by non-affiliates of the registrant was approximately $<span id="xdx_903_edei--EntityPublicFloat_iI_pin6_c20200630_zFRUXZ5Jw6lh"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">125</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million, based on the closing price of
$5.21 for the registrant&#8217;s common stock as quoted on The NASDAQ Capital Market on that date. For purposes of this calculation,
it has been assumed that shares of common stock held by each director, each officer and each person who owns 10% or more of the
outstanding common stock of the registrant are held by affiliates of the registrant. The treatment of these persons as affiliates
for purposes of this calculation is not conclusive as to whether such persons are affiliates of the registrant for any other purpose.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of March 8, 2021, there were <span id="xdx_903_edei--EntityCommonStockSharesOutstanding_iI_c20210308_zJGT6k8JVmU7"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2021-03-08" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,983,364</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of the registrant&#8217;s common
stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Portions
of the registrant&#8217;s definitive proxy statement for its 2021 Annual Meeting of Stockholders are incorporated by reference
in Part III of this annual report on Form 10-K, to the extent stated herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>TABLE
OF CONTENTS </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Page</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b><a href="#b_001">PART
    I</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#b_002">Business</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#b_003">Risk
    Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">12</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#b_004">Unresolved
    Staff Comments</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">34</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#b_005">Properties</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">34</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#b_006">Legal
    Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">34</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#b_007">Mine
    Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">34</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b><a href="#b_008">PART
    II</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#b_009">Market
    for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">35</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#b_010">Selected
    Financial Data</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">35</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#b_011">Management&#8217;s
    Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">36</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#b_026">Quantitative
    and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">48</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#b_012">Financial
    Statements and Supplementary Data</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">48</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#b_013">Changes
    in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">48</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    9A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#b_014">Controls
    and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">48</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    9B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#b_015">Other
    Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">48</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b><a href="#b_016">PART
    III</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#b_017">Directors,
    Executive Officers and Corporate Governance</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">49</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#b_018">Executive
    Compensation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">49</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#b_019">Security
    Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">49</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#b_020">Certain
    Relationships and Related Transactions, and Director Independence</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">49</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#b_021">Principal
    Accountant Fees and Services</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">49</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b><a href="#b_022">PART
    IV</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#b_023">Exhibits,
    Financial Statement Schedules</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">50</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    16.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#b_024">Form
    10-K Summary</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">54</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#b_025">SIGNATURES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">55</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>As
used in this Annual Report, unless indicated or the context requires otherwise, the terms the &#8220;Company,&#8221; &#8220;Harrow,&#8221;
&#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Harrow Health, Inc. and its consolidated subsidiaries.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>In
addition to historical information, the following discussion contains forward-looking statements regarding future events and our
future performance. In some cases, you can identify forward-looking statements by terminology such as &#8220;will,&#8221; &#8220;may,&#8221;
&#8220;should,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221;
&#8220;predicts,&#8221; &#8220;forecasts,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms
or other comparable terminology. All statements made in this Annual Report other than statements of historical fact are forward-looking
statements. These forward-looking statements involve risks and uncertainties and reflect only our current views, expectations
and assumptions with respect to future events and our future performance. If risks or uncertainties materialize or assumptions
prove incorrect, actual results or events could differ materially from those expressed or implied by such forward-looking statements.
Risks that could cause actual results to differ from those expressed or implied by the forward-looking statements we make include,
among others, risks related to: the impact of the COVID-19 pandemic on our financial condition, liquidity or results of operations,
our ability to successfully implement our business plan, develop and commercialize our proprietary formulations in a timely manner
or at all, identify and acquire additional proprietary formulations, manage our pharmacy operations, service our debt, obtain
financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully
realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition
from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions; regulatory and
legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general; physician
interest in and market acceptance of our current and any future formulations and compounding pharmacies generally; our limited
operating history; and the other risks and uncertainties described under the heading &#8220;Risk Factors&#8221; in Part I, Item
1A of this Annual Report. You should not place undue reliance on forward-looking statements. Forward-looking statements speak
only as of the date they are made and, except as required by law, we undertake no obligation to revise or publicly update any
forward-looking statement for any reason.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have registered trademarks, copyrights and/or pending trademark and copyright applications for a number of proprietary names in
the United States, including, but not limited to: Imprimis<sup>&#174;</sup>, ImprimisRx<sup>&#174;</sup>, Harrow Health<sup>&#174;</sup>,
Visionology<sup>&#174;</sup>, Dropless<sup>&#174;</sup>, LessDrops<sup>&#174;</sup>, Dropless Cataract Surgery<sup>&#174;</sup>, Klarity-C<sup>&#174;</sup>,
Dropless Therapy<sup>&#174;</sup>, MKO Melt<sup>&#174;</sup>, and Simple Drops<sup>&#174;</sup>. We may choose to pursue trademark
protection in other jurisdictions for one or more of these or other marks in the future. All other trademarks, service marks and
trade names included or incorporated by reference into this Annual Report, are the property of their respective owners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="b_001"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="b_002"></span>ITEM
1. BUSINESS </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Overview
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
business specializes in the development, production and sale of innovative medications that offer unique competitive advantages
and serve unmet needs in the marketplace through our subsidiaries and deconsolidated companies. We own and operate one of the
nation&#8217;s leading ophthalmic pharmaceutical businesses, ImprimisRx. In addition to wholly owning ImprimisRx, we also have
non-controlling equity positions in Eton Pharmaceuticals, Inc. (&#8220;Eton&#8221;), Surface Ophthalmics, Inc. (&#8220;Surface&#8221;),
and Melt Pharmaceuticals, Inc. (&#8220;Melt&#8221;), all companies that began as subsidiaries of Harrow. We also recently launched
a new business called Visionology and are exploring opportunities to launch other subsidiaries. We own royalty rights in various
drug candidates being developed by Surface and Melt. We intend to continue to create and hold equity and royalty rights in new
businesses that commercialize drug candidates that are internally developed or otherwise acquired or licensed from third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>ImprimisRx</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">ImprimisRx
is our ophthalmic focused prescription pharmaceutical business. We offer to over 9,000 physician customers and their patients
medically necessary prescription drugs to meet their needs that are otherwise unmet by commercially available drugs. We make our
formulations available at prices that are, in most cases, lower than non-customized commercial drugs. Our current ophthalmic formulary
includes over twenty compounded formulations, many of which are patented or patent-pending, and are customizable for the specific
needs of a patient. Some examples of our compounded medications are various combinations of drugs formulated into one bottle and
numerous preservative-free formulations. Depending on the formulation, the regulations of a specific state, and ultimately the
needs of the patient, ImprimisRx products may be dispensed as patient-specific medications from our 503A pharmacy, or for in-office
use, made according to federal current good manufacturing practices (or cGMPs) or other FDA guidance documents, in our FDA-registered
New Jersey Outsourcing Facility (&#8220;NJOF&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">On
August 1, 2020, ImprimisRx entered into a Commercial Alliance Agreement (the &#8220;Dexycu Agreement&#8221;) with Eyepoint Pharmaceuticals,
Inc. (&#8220;Eyepoint&#8221;), pursuant to which Eyepoint granted ImprimisRx the non-exclusive right to co-promote DEXYCU<sup>&#174;
</sup>(dexamethasone intraocular suspension) 9% for the treatment of post-operative inflammation following ocular surgery in the
United States.</span> <span style="font: 10pt Times New Roman, Times, Serif">Pursuant to the <span style="background-color: white">Dexycu
Agreement</span>, Eyepoint pays <span style="background-color: white">ImprimisRx </span>a fee that is calculated based on the
quarterly sales of DEXCYU in excess of predefined volumes to specific customers of <span style="background-color: white">ImprimisRx
</span>in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">We
expect to acquire and/or develop additional FDA-approved ophthalmic drugs that allow us to leverage the commercial infrastructure
of ImprimisRx to promote, sell, and ultimately bring these products to market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Visionology
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Visionology
is a membership-based online eye health and medication platform. Visionology leverages our experience in the ophthalmic pharmaceutical
business, our relationships with eyecare professionals across the United States, and our expertise in developing and deploying
telemedicine software. We recently launched a proof-of-concept for Visionology in certain states in the southeast area of the
U.S. If successful, we expect Visionology will expand access to its service later in 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Ophthalmology
Market</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
any ocular procedure, a surgeon may require drugs for sedation, dilation, and inflammation and infection prevention. The cataract
surgery market continues to experience significant growth. According to Market Scope, approximately 4.2 million cataract surgeries
were performed in the U.S. in 2019. The National Eye Institute estimates that over 24 million Americans currently have cataracts
and that this number will grow to 38 million by 2030 and reach more than 50 million by 2050. In addition, the American Academy
of Ophthalmology (AAO) estimates that over one-half of Americans require some form of vision correction and 43 million of these
individuals are candidates for refractive surgery. Nearly 96 percent of the refractive surgery procedures performed are LASIK
(laser in situ keratomileusis) surgeries, an outpatient surgical procedure used to treat nearsightedness, farsightedness, and
astigmatism. According to Statista, an estimated 600,000 LASIK procedures were performed in the U.S. in 2015.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">According
to the Glaucoma Research Foundation, there are over 3 million Americans with glaucoma but only half are aware they have it. Open-angle
glaucoma (the most common type of glaucoma) is a condition of increased intraocular pressure that causes gradual loss of sight.
Glaucoma is incurable, and if not managed can lead to blindness. Generally, the first line of treatment consists of a prostaglandin
analogue (PGA) eye drop regimen. As the disease progresses, non-PGA products are generally added as a second line treatment. Topical
agents, other than PGAs, include beta blockers, alpha agonists, miotics and steroids. According to a 2013 article in <i>Glaucoma
Today</i>, up to 50 percent of glaucoma patients require more than one drug following a few months of initial treatment and there
is a direct correlation between the number of glaucoma bottles and decreased adherence; however, the FDA has yet to approve a
PGA combination product despite combination products including a PGA (Xalacom<sup>&#174;</sup>, DuoTrav<sup>&#174;</sup> and Ganfort<sup>&#174;</sup>)
available outside of the U.S. According to a 2017 Market Scope report, the glaucoma pharmaceuticals market is expected to reach
$5.3 billion in 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Dry
eye occurs when the eye does not produce enough tears, or when the tears are not of the correct consistency and evaporate too
quickly. Inflammation of the surface of the eye may also occur. We believe that dry eye disease, or DED, affects over 30 million
people in the U.S., and a major epidemiological study, the Beaver Dam Offspring Study, published in 2014 in the American Journal
of Ophthalmology, reported that in a cohort of over 3,000 patients, DED was self-reported by 14.5% of the patients. According
to a 2017 Market Scope report, the global dry eye treatments market is expected to grow from $3.7 billion in 2017 to $4.9 billion
in 2022. Dry eye is among the most common conditions seen by eye care professionals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Presbyopia
is the normal loss of near focusing ability that occurs with age. Most people begin to notice the effects of presbyopia sometime
after age 40, when they start having trouble seeing small print clearly. According to an American Academy of Ophthalmology report
from 2018, there are an estimated 1.8 billion people worldwide who suffer from presbyopia, with eye glasses (more commonly referred
to as &#8220;readers&#8221;) being the most common treatment option. Based on our understanding, there are currently four eyedrops
undergoing clinical trials/development in the U.S. aiming to be first to market topical eye drops to treat the symptoms associated
with presbyopia. We believe most of these are designed to enhance depth of field via a &#8220;pinhole effect&#8221; and in one
case to reduce lens stiffening; and some of these medications could be synergistic with each other or combined with refractive
surgery to enhance outcomes. However, as of the date of this Annual Report, none of these drug candidates has received market
approval from the FDA. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Pharmaceutical
Compounding Businesses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Pharmaceutical
Compounding</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pharmaceutical
compounding is the science of combining different active pharmaceutical ingredients (APIs), all of which are approved by the FDA
(either as a finished form product or as a bulk drug ingredient), and excipients to create specialized pharmaceutical preparations.
Physicians and healthcare institutions use compounded drugs when commercially available drugs do not optimally treat a patient&#8217;s
medical needs. In many cases, compounded drugs, such as ours, have wide market utility and may be clinically appropriate for large
patient populations. Examples of compounded formulations include medications with alternative dosage strengths or unique dosage
forms, such as topical creams or gels, suspensions, or solutions with more tolerable drug delivery vehicles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Almost
all of our sales revenue is derived from making, selling and dispensing our compounded prescription drug formulations as cash
pay transactions between us and our end-user customer. As such, the majority of our commercial transactions do not involve distributors,
wholesalers, insurance companies, pharmacy benefit managers or other middle parties. By not being reliant on insurance company
formulary inclusion and pharmacy benefit manager payment clawbacks, we are able to simplify the prescription transaction process.
We believe the outcome of our business model is a simple and transparent transaction, involving a patient-in-need, a physician&#8217;s
diagnosis, a fair price and great service for a quality pharmaceutical product. We sell our products through a network of employees
and independent contractors, and we dispense our formulations in all 50 states, Puerto Rico and in selected markets outside the
United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our
Compounding Facilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pharmaceutical
compounding businesses are governed by Sections 503A and 503B of the Federal Food Drug and Cosmetic Act (the &#8220;FDCA&#8221;).
Section 503A of the FDCA provides that a pharmacy is only permitted to compound a drug for an individually identified patient
based on a prescription for a patient and is only permitted to distribute the drug interstate if the pharmacy is licensed to do
so in the states where it is compounded and where the medication is received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Section
503B of the FDCA provides that a pharmacy engaged in preparing sterile compounded drug formulations may voluntarily elect to register
as an &#8220;outsourcing facility.&#8221; Outsourcing facilities are permitted to compound large quantities of drugs without a
prescription and distribute them out of state with certain limitations such as the formulation appearing on the FDA&#8217;s drug
shortage list or the bulk drug substances contained in the formulations appearing on the FDA&#8217;s &#8220;clinical need&#8221;
list. Entities voluntarily registering with FDA as outsourcing facilities are subject to additional requirements that do not apply
to compounding pharmacies (operating under Section 503A of the FDCA), including adhering to standards such as current good manufacturing
practices (cGMP) or other FDA guidance documents and being subject to regular FDA inspection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
operate two compounding facilities located in Ledgewood, New Jersey. Our New Jersey operations are comprised of two separate entities
and facilities, one of which is registered with the FDA as an outsourcing facility under Section 503B of the FDCA. The other New
Jersey facility (&#8220;RxNJ&#8221;) is a licensed pharmacy operating under Section 503A of the FDCA. All products that we sell,
produce and dispense are made in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
believe that, with our current compounding pharmacy facilities and licenses and FDA registration of NJOF, we have the infrastructure
to scale our business appropriately under the current regulatory landscape and meet the potential growth in demand we are targeting.
We plan to invest in one or both of our facilities to further their capacity and efficiencies. Also, we may seek to access greater
pharmacy, production related redundancy, and distribution through acquisitions, partnerships or other strategic transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Pharmaceutical
Development Businesses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have ownership interests in Eton, Surface and Melt and hold royalty interests in some of Surface&#8217;s and Melt&#8217;s drug
candidates. These companies are pursuing market approval for their drug candidates under the FDCA, including in some instances
under the abbreviated pathway described in Section 505(b)(2) which permits the submission of a new drug application (&#8220;NDA&#8221;)
where at least some of the information required for approval comes from studies not conducted by or for the applicant and for
which the applicant has not obtained a right of reference. In 2018 and 2019, we formed and created subsidiaries named Radley Pharmaceuticals,
Inc. (&#8220;Radley&#8221;), Mayfield Pharmaceuticals, Inc. (&#8220;Mayfield&#8221;) and Stowe Pharmaceuticals, Inc. (&#8220;Stowe&#8221;).
In addition, we may create additional subsidiaries that will be focused on the development and FDA approval of certain proprietary
drug formulations that we currently own, will in-license/acquire and/or otherwise develop. We expect any new subsidiaries to be
focused on eye care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>De-Consolidated
Businesses (Noncontrolling Equity Interests)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Surface
Ophthalmics, Inc. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Surface
is a clinical-stage pharmaceutical company focused on development and commercialization of innovative therapeutics for ocular
surface diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
January 2021, Surface announced positive top-line results from a phase 2 trial of its drug candidate SURF-201, a 0.2% betamethasone,
preservative-free ophthalmic solution in the Klarity delivery vehicle for the treatment of post cataract surgery pain and inflammation.
According to the Surface results, SURF-201 was dosed twice daily, met its primary endpoints of absence of inflammation at both
Day 8 and Day 15 and was found to be safe and well-tolerated by the patient group. In addition, a secondary endpoint showed almost
90% of patients given SURF-201 were pain free at Day 15. SURF-201 marks the first ophthalmic therapeutic in the United States
to utilize betamethasone as well as being the first preservative-free unit dose therapy for the treatment of post-operative pain
and inflammation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Also
in January 2021, Surface announced the first patient dosed in a head-to-head phase 2 trial for its drug candidate SURF-100 (mycophenolate
sodium and betamethasone in Klarity vehicle) for the treatment of chronic dry eye disease. The head-to-head study will compare
SURF-100 against leading on-market competitors lifitegrast ophthalmic solution 5% (marketed as Xiidra&#174;) and cyclosporine ophthalmic
emulsion 0.05% (marketed as Restasis&#174;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">In
February 2021, Surface announced the first patient dosed in a phase 2 trial for its drug candidate SURF-200 (betamethasone in
Klarity vehicle) for the treatment of episodic dry eye flares. The dose ranging study for SURF-200 will be administered in two
different low concentration formulations of betamethasone in the Klarity vehicle. The trial will enroll 120 to 140 patients with
a primary endpoint of Symptom Improvement of one unit based on the University of North Carolina Dry Eye Management Scale by the
eighth day.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
2018, Surface closed on an offering of its Series A Preferred Stock. At that time, we lost our controlling interest and deconsolidated
Surface from our consolidated financial statements. We own 3,500,000 shares of Surface, which was approximately 30% of the equity
and voting interests as of December 31, 2020. Harrow owns mid-single digit royalty rights on net sales of SURF-100, SURF-200 and
SURF-201. We expect Surface to complete another round of financing within the next twelve months. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Melt
Pharmaceuticals, Inc. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Melt
is a clinical-stage pharmaceutical company focused on the development and commercialization of proprietary non-intravenous, sedation
and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. Melt intends to seek
regulatory approval for its proprietary technologies, where possible. In December 2018, we entered into an Asset Purchase Agreement
with Melt (the &#8220;Melt Asset Purchase Agreement&#8221;), and Harrow assigned to Melt the underlying intellectual property
for Melt&#8217;s current pipeline, including its lead drug candidate MELT-100. The core intellectual property Melt owns is a patented
series of combination non-opioid sedation drug formulations that we estimate to have multitudinous applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">MELT-100
is a novel, sublingually delivered, non-IV, opioid-free drug candidate being developed for procedural sedation. Melt filed an
investigational new drug application (&#8220;IND&#8221;) with the FDA in June 2020 and began its clinical program for MELT-100.
In February 2021, Melt announced data from, and the successful completion of, its phase 1 study. Melt expects to begin its phase
2 study for MELT-100 in the second half of 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
January 2019, Melt closed an offering of its Series A Preferred Stock. At that time, we lost our controlling interest and deconsolidated
Melt from our consolidated financial statements. We own 3,500,000 shares of Melt common stock, which was approximately 44% of
the equity and voting interests issued and outstanding as of December 31, 2020. We expect Melt to complete another round of financing
within the next twelve months. Pursuant to the terms of the Melt Asset Purchase Agreement, Melt is required to make mid-single
digit royalty payments to the Company on net sales of MELT-100, while any patent rights remain outstanding, subject to other conditions.
Melt can require the Company to cease compounding like products at the time of FDA approval of MELT-100. If approved, we do not
expect a cessation of compounding like products to have a material impact on our operations and financial performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Eton
Pharmaceuticals, Inc. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Eton
is a commercial-stage pharmaceutical company focused on developing and commercializing innovative drug products. Its pipeline
includes several products and drug candidates in various stages of development across a variety of dosage forms. In May 2017,
Eton closed an offering of its Series A Preferred Stock. At that time, we gave up our controlling interest and deconsolidated
Eton from our consolidated financial statements. In November 2019, Eton completed an initial public offering of its common stock.
We own 3,500,000 shares of Eton common stock, which was less than 20% of the equity and voting interests issued and outstanding
as of December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Consolidated
Businesses (Controlling Equity Interests)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Mayfield,
Stowe and Radley are consolidated subsidiaries of Harrow. Mayfield is a development-stage pharmaceutical company focused on developing
urology related drug candidates. Stowe is focused on the development of proprietary ophthalmic drug candidates. Radley is a development-stage
pharmaceutical company that has been focused on the development of proprietary drug candidates focused on rare diseases. Recently, we discontinued nearly all of the activities related to Mayfield, Stowe and
Radley, and may not resume those activities in the near term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
control over 50% of the equity and voting interests issued and outstanding of Mayfield, Stowe and Radley as of the date of this
Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Section
505(b)(2) New Drug Applications</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
an alternate path for FDA approval of new indications or new formulations of previously-approved products, a company may file
a Section 505(b)(2) NDA instead of a &#8220;stand-alone&#8221; or &#8220;full&#8221; NDA. Section 505(b)(2) of the FDCA was enacted
as part of the Drug Price Competition and Patent Term Restoration Act of 1984, otherwise known as the Hatch-Waxman Amendments.
Section 505(b)(2) permits the submission of an NDA where at least some of the information required for approval comes from studies
not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Some examples of products
that may be allowed to follow a 505(b)(2) path to approval are drugs that have a new dosage form, strength, route of administration,
formulation or indication.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Hatch-Waxman Amendments permit the applicant to rely upon certain published nonclinical or clinical studies conducted for an approved
product or the FDA&#8217;s conclusions from prior review of such studies. The FDA may require companies to perform additional
studies or measurements to support any changes from the approved product. The FDA may then approve the new product for all or
some of the labeled indications for which the reference product has been approved, as well as for any new indication supported
by the Section 505(b)(2) application. While references to nonclinical and clinical data not generated by the applicant or for
which the applicant does not have a right of reference are allowed, all development, process, stability, qualification and validation
data related to the manufacturing and quality of the new product must be included in an NDA submitted under Section 505(b)(2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">To
the extent that the Section 505(b)(2) applicant is relying on the FDA&#8217;s conclusions regarding studies conducted for an already
approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the
FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. Specifically, the applicant must
certify that: (i) the required patent information has not been filed; (ii) the listed patent has expired; (iii) the listed patent
has not expired, but will expire on a particular date and approval is sought after patent expiration; or (iv) the listed patent
is invalid or will not be infringed by the new product. The Section 505(b)(2) application also will not be approved until any
non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the
reference product has expired. Thus, the Section 505(b)(2) applicant may invest a significant amount of time and expense in the
development of its products only to be subject to significant delay and patent litigation before its products may be commercialized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Sales
and Marketing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
focus of our sales and marketing is in the United States. We do, however, believe that our proprietary drug formulations could
have commercial appeal in international markets, and we have engaged distributors and entered into out-licensing arrangements
for certain of our proprietary formulations in certain non-U.S. markets, including Canada. Our sales and marketing efforts are
currently organized into two teams, the larger of which focuses on our ophthalmology pharmaceutical business and the other on
our non-ophthalmology pharmaceutical compounding business. Our sales and marketing activities consist primarily of efforts to
educate doctors, ambulatory surgery centers, healthcare systems, hospitals and other users throughout the U.S. about our compounded
formulations. We expect that we may experience growth in the sales of our proprietary pharmaceutical compounded formulations in
future periods, particularly in light of our current and planned launches of new formulations and commercialization campaigns.
However, we may not be successful in doing so, whether due to the safety, quality or availability of our proprietary compounded
formulations, the size of the markets for such formulations, which could be smaller than we expect, the timing of market entry
relative to competitive products, the availability of alternative compounded formulations or FDA-approved drugs, the price of
our compounded formulations relative to alternative products or the success of our sales and marketing efforts, which is dependent
on our ability to build and grow a qualified and adequate internal sales function.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">We
expect to acquire and/or develop additional FDA-approved ophthalmic drugs that allow us to leverage the commercial infrastructure
of ImprimisRx to promote, sell, and ultimately bring these products to market. As we execute this strategy, we will likely expand
our sales and marketing team, expertise and expenses. This would include the addition of market access expertise and team members,
where roles include discussions with payors regarding the costs and benefits of our products for their members, assisting with
the addition of our products to the medical policy of payors, and providing the market with assistance regarding reimbursement
queries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have entered into various sales and marketing agreements with certain organizations to provide exclusive sales and marketing representation
services to ImprimisRx in select geographies in the U.S., in connection with our pharmaceutical products and compounded formulations.
Under the terms of the sales and marketing agreements, we are required to make commission payments, generally equal to 10% to
14% of net sales for products above and beyond the initial existing sales amounts. In addition, we are required to make periodic
milestone payments to certain organizations in shares of our restricted common stock if net sales in the assigned territory reach
certain future levels by the end of their terms, as applicable. We believe these sales and marketing agreements will continue
to accelerate launches of our new ophthalmology programs and limit our initial capital requirements commonly associated with new
product launches and increased sizes of sales forces.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
pharmaceutical and pharmacy industries are highly competitive. We compete against branded drug companies, generic drug companies,
outsourcing facilities and other compounding pharmacies. We are significantly smaller than some of our competitors, and we may
lack the financial and other resources needed to develop, produce, distribute, market and commercialize any of our proprietary
formulations or compete for market share in these sectors. The drug products available through branded and generic drug companies
with which our formulations compete have been approved for marketing and sale by the FDA and are required to be manufactured in
facilities compliant with cGMP standards. Although we prepare some of our compounded formulations in accordance with cGMP standards
and our other formulations are produced according to the standards provided by United States Pharmacopoeia (USP) &lt;795&gt; and
USP &lt;797&gt; and applicable state and federal law, our proprietary compounded formulations are not required to be, and have
not been, approved for marketing and sale by the FDA. As a result, some physicians may be unwilling to prescribe, and some patients
may be unwilling to use, our formulations. Additionally, under federal and state laws applicable to our current compounding pharmacy
operations operating under Section 503A of the FDCA, we are not permitted to prepare significant amounts of a specific formulation
in advance of a prescription, compound quantities for office use or utilize a wholesaler for distribution of our formulations;
instead, our compounded formulations must be prepared and dispensed in connection with a physician prescription for an individually
identified patient. Pharmaceutical companies, on the other hand, are able to sell their FDA-approved products to large pharmaceutical
wholesalers, who can in turn sell to and supply hospitals and retail pharmacies. Even though we have registered NJOF with the
FDA, our business may not be scalable on the scope available to our competitors that produce FDA-approved drugs, which may limit
our potential for profitable operations. These facets of our operations may subject our business to limitations our competitors
offering FDA-approved drugs may not face.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Biotechnology
and related pharmaceutical technologies are subject to rapid and significant change. Our future success will depend in large part
on our ability to maintain a competitive position with respect to these technologies. Products developed by our competitors, including
FDA-approved drugs and compounded formulations created by other pharmacies, could render our products and technologies obsolete
or unable to compete. Any products that we develop may become obsolete before we recover expenses incurred in developing the products,
which may require that we seek additional funds that may or may not be available to continue our operations. The competitive environment
requires an ongoing, extensive search for medical and technological innovations and the ability to develop and market these innovations
effectively, and we may not be competitive with respect to these factors. Other competitive factors include the safety and efficacy
of a product, the size of the market for a product, the timing of market entry relative to competitive products, the availability
of alternative compounded formulations or approved drugs, the price of a product relative to alternative products, the availability
of third-party reimbursement, the success of sales and marketing efforts, brand recognition and the availability of scientific
and technical information about a product. Although we believe we are positioned to compete favorably with respect to many of
these factors, if our proprietary formulations are unable to compete with the products of our competitors, we may never gain market
share or achieve profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Factors
Affecting Our Performance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
believe the primary factors affecting our performance are our ability to increase revenues of our proprietary compounded formulations
and certain non-proprietary products, grow and gain operating efficiencies in our pharmacy operations, optimize pricing and obtain
reimbursement options for our proprietary compounded formulations, and continue to pursue development and commercialization opportunities
for certain of our ophthalmology and other assets that we have not yet made commercially available as compounded formulations.
We believe we have built a tangible and intangible infrastructure that will allow us to scale revenues efficiently in the long-term.
All of these activities will require significant costs and other resources, which we may not have or be able to obtain from operations
or other sources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Reimbursement
Options and Pricing Optimization</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
proprietary ophthalmic compounded formulations are currently primarily available on a cash-pay basis. However, we work with third-party
insurers, pharmacy benefit managers and buying groups to offer patient-specific customizable compounded formulations at accessible
prices. We may devote time and other resources to seek reimbursement and patient pay opportunities for these and other compounded
formulations, and we have hired pharmacy billers to process certain existing reimbursement opportunities for certain formulations.
However, we may be unsuccessful in achieving these goals, as many third-party payors have imposed significant restrictions on
reimbursement for compounded formulations in recent years. Moreover, third-party payors, including Medicare, are increasingly
attempting to contain health care costs by limiting coverage and the level of reimbursement for new drugs and by refusing, in
some cases, to provide coverage for uses of approved products for disease indications for which the FDA has not granted labeling
approval. Further, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation
Act of 2010 (collectively, the &#8220;Health Care Reform Law&#8221;), may have a considerable impact on the existing U.S. system
for the delivery and financing of health care and could conceivably have a material effect on our business. As a result, reimbursement
from Medicare, Medicaid and other third-party payors may never be available for any of our products or, if available, may not
be sufficient to allow us to sell the products on a competitive basis and at desirable price points. We are communicating with
government and third-payor payors in order to make our formulations available to more patients and at optimized pricing levels.
However, if government and other third-party payors do not provide adequate coverage and reimbursement levels for our formulations,
the market acceptance and opportunity for our formulations may be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Additionally,
we have previously made efforts to receive reimbursement and/or optimize the pricing for some of our currently available pharmaceutical
compounded formulations, including applying for transitional pass-through reimbursement status for one of our formulations. Pass-through
status allows for separate payment (i.e., outside the bundled payment) under Medicare Part B for new drugs and other medical technologies
that meet well-established criteria specified by federal regulations governing CMS spending. In September 2020, we were informed
by CMS that our application for pass-through payment was denied for one of our formulations. Any future efforts to attain optimized
pricing or reimbursement of our other proprietary compounded formulations could fail, which could make our products less attractive
or unavailable to some patients or could reduce our margins.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
success and ability to compete depends upon our ability to protect our intellectual property. We conduct a fulsome analysis of
the intellectual property landscape prior to acquiring rights to formulations and filing patent applications. In addition, as
of March 1, 2021, we owned and/or licensed 105 total issued and pending patent applications, which include 16 U.S. issued patents,
10 international issued patents, and 79 U.S. and foreign/international patent pending applications. We expect to file additional
patent applications in the U.S. and pursue patent protection for certain of our formulations in other important international
jurisdictions in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of March 1, 2021, we had, on a worldwide basis, 275 issued trademarks, pending trademark and copyright applications, or
registered copyright and/or trademarks including, but not limited to: Imprimis<sup>&#174;</sup>, ImprimisRx<sup>&#174;</sup>, Harrow
Health<sup>&#174;</sup>, Dropless<sup>&#174;</sup>, LessDrops<sup>&#174;</sup>, Dropless Cataract Surgery<sup>&#174;</sup>, Dropless
Cataract Therapy<sup>&#174;</sup>, Dropless Therapy<sup>&#174;</sup>, MKO Melt<sup>&#174;</sup>, and Simple Drops<sup>&#174;</sup>.
We may choose to pursue trademark protection in other jurisdictions for any one or more of these or other marks in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
also rely on unpatented trade secrets and know-how and continuing technological innovation in order to develop our formulations,
which we seek to protect, in part, by confidentiality agreements with our employees, consultants, collaborators and others, including
certain service providers. We also have invention or patent assignment agreements with our current employees and certain consultants.
However, our employees and consultants may breach these agreements, and we may not have adequate remedies for any breach, or our
trade secrets may otherwise become known or be independently discovered by competitors. In addition, inventions relevant to us
could be developed by a person not bound by an invention assignment agreement with us, in which case we may have no rights to
use the applicable invention.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Governmental
Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
business is subject to federal, state and local laws, regulations, and administrative practices, including, among others: federal,
state and local licensure and registration requirements concerning the operation of pharmacies and the practice of pharmacy; the
Health Insurance Portability and Accountability Act (&#8220;HIPAA&#8221;); the Health Care Reform Law; statutes and regulations
of the FDA, the U.S. Federal Trade Commission, the U.S. Drug Enforcement Administration and the U.S. Consumer Product Safety Commission,
as well as regulations promulgated by comparable state agencies concerning the sale, advertisement and promotion of the products
we sell. The regulatory and quality compliance environment for compounded drugs has become significantly more rigorous, complex
and strict since the passage of The Drug Quality and Security Act of 2013. The complexity of the current state and federal regulatory
environment, as well as the expected continued evolution of state and federal laws governing pharmaceutical compounding, have
and will continue to present potentially significant challenges to our business model and the fulfillment of our mission as a
company. Below are descriptions of some of the various federal and state laws and regulations which may govern or impact our current
and planned operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Pharmacy
Regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
pharmacy operations are regulated by both individual states and the federal government. Every state has laws and regulations addressing
pharmacy operations, including regulations relating specifically to compounding pharmacy operations. These regulations generally
include licensing requirements for pharmacists, pharmacy technicians and pharmacies, as well as regulations related to compounding
processes, safety protocols, purity, sterility, storage, controlled substances, recordkeeping and regular inspections, among other
things. State rules and regulations are updated periodically, generally under the jurisdiction of individual state boards of pharmacy.
Failure to comply with the state pharmacy regulations of a particular state could result in a pharmacy being prohibited from operating
in that state, financial penalties and/or becoming subject to additional oversight from that state&#8217;s board of pharmacy.
In addition, many states are considering imposing, or have already begun to impose, more stringent requirements on compounding
pharmacies. If our pharmacy operations become subject to additional licensure requirements, are unable to maintain their required
licenses or if states place burdensome restrictions or limitations on pharmacies, our ability to operate in some states could
be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Federal
law limits compounding pharmacies from engaging in the practice of anticipatory compounding, which involves preparing compounded
medications before the actual receipt of a prescription or practitioner&#8217;s order, unless the compounding pharmacy has a history
of filling certain prescriptions for a customer. In such cases, it is acceptable to engage in anticipatory compounding or the
preparation of larger batches so that medications will be ready when they are needed. Anticipatory compounding also reduces the
cost of compounded medications, as economies of scale can be realized by producing larger batches. Anticipatory compounding also
leads to less wasted chemicals, dilutions, fillers, and other associated products are produced, and greater accuracy and uniformity
in finished medications, as larger batches decrease the variation caused by preparing multiple, smaller batches. Based on our
history of meeting the needs of our customers, we are able to anticipatorily compound batches of our formulations for our customers,
per the applicable regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Many
of the states into which we deliver pharmaceuticals have laws and regulations that require out-of-state pharmacies to register
with, or be licensed by, the boards of pharmacy or similar regulatory bodies in those states. These states generally permit the
dispensing pharmacy to follow the laws of the state within which the dispensing pharmacy is located. However, various state pharmacy
boards have enacted laws and/or adopted rules or regulations directed at restricting or prohibiting the operation of out-of-state
pharmacies by, among other things, requiring compliance with all laws of the states into which the out-of-state pharmacy dispenses
medications, whether or not those laws conflict with the laws of the state in which the pharmacy is located, or requiring the
pharmacist-in-charge to be licensed in that state. To the extent that such laws or regulations are found to be applicable to our
operations, we believe we comply with them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Further,
under federal law, Section 503A of the FDCA previously had language that implied a limitation of the amount of compounded products
that a pharmacy can distribute interstate. The interpretation and enforcement of this provision is dependent on the FDA entering
into a standard Memorandum of Understanding (&#8220;MOU&#8221;) with each state setting forth limits on shipments of interstate
compounding. In January of 2019, the FDA released a &#8220;2018 Compounding Policy Priorities Plan&#8221; (the &#8220;2018 Compounding
Plan&#8221;) which provided an overview of the key priorities the FDA planned to focus on in 2018 in connection with compounding
regulations. One of the priorities outlined in the 2018 Compounding Plan addressed the FDA&#8217;s plan to release a revised MOU
(the &#8220;Revised MOU&#8221;). Pursuant to the statements in the 2018 Compounding Plan, the Revised MOU would consider amounts
shipped interstate by a compounder to be inordinate amounts if the &#8220;number of prescriptions of compounded drugs distributed
interstate during any calendar month is greater than 50 percent.&#8221; Importantly, instead of that number serving as a &#8220;hard
limit, for state action,&#8221; the 50% target would trigger certain additional reporting requirements. On October 27, 2020, the
FDA announced availability of a final MOU, Addressing Certain Distributions of Compounded Human Drug Products Between the State
Board of Pharmacy or Other Appropriate State Agency and the Food and Drug Administration (the &#8220;Final MOU&#8221;). The Final
MOU describes the responsibilities of a state board of pharmacy, or other appropriate state agency that chooses to sign the Final
MOU, in investigating and responding to complaints related to drug products compounded in such state and distributed outside such
state and in addressing the interstate distribution of inordinate amounts of compounded human drug products. Additionally, as
part of the Final MOU, FDA refined the definition of &#8220;inordinate amount,&#8221; a threshold for certain information identification
and sharing which does not place a limit on the distribution of compounded human drug products interstate by a pharmacy located
in a state that has entered into the Final MOU. Section 503A of the FDCA sets a five percent limit on compounded drugs distributed
outside the state by a pharmacist, pharmacy or physician located in a state that has not entered into the Final MOU. States have
365 days to sign the Final MOU, before the FDA intends to enforce the five percent limit described in Section 503A of the FDCA
in states that have not signed the Final MOU. Our pharmacy is based in the state of New Jersey, and based on feedback we have
received from the state board of pharmacy in New Jersey, we believe the state board of pharmacy in New Jersey will sign the MOU
and as a result, our operations will not be materially affected by the Final MOU. In the event New Jersey does not sign the Final
MOU, our pharmacy that operates under Section 503A may be materially affected and we will transition as many prescription orders
as possible to our outsourcing facility, which is not subject to the Final MOU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Certain
provisions of the FDCA govern the preparation, handling, storage, marketing and distribution of pharmaceutical products. The Drug
Quality and Security Act of 2013 (DQSA) clarifies and strengthens the federal regulatory framework governing compounding pharmacies.
Title 1 of the DQSA, the Compounding Quality Act, modifies provisions of the Section 503A of the FDCA that were found to be unconstitutional
by the U.S. Supreme Court in 2002. In general, Section 503A provides that pharmacies are exempt from the provisions of the FDCA
requiring compliance with cGMP, labeling with adequate directions for use and FDA approval prior to marketing if the pharmacy
complies with certain other requirements. Among other things, to comply with Section 503A, a compounded drug must be compounded
by a licensed pharmacist for an identified individual patient on the basis of a valid prescription. Pharmacies may only compound
in limited quantities before receipt of a prescription for an individual patient and are subject to limitations on anticipatory
compounding for distribution, which generally permit anticipatory compounding only based on historical prescription volumes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
DQSA also contained new Section 503B of the FDCA, which established an outsourcing facility as a new form of entity that is permitted
to compound larger quantities of drug formulations without a prescription, thus permitting the practice of anticipatory compounding,
and distributing them out of state without limitation, if the drug formulations appear on the FDA&#8217;s drug shortage list or
the bulk drug substances contained in the formulations appear on a &#8220;clinical need&#8221; list to be established by the FDA.
In January 2017, the FDA issued an <i>Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the FFDCA
</i>(&#8220;Interim Policy&#8221;) that informs stakeholders about how the FDA intends to exercise its enforcement discretion
for compounding with those substances on a &#8220;Category 1 list&#8221; while the agency compiles and evaluates its clinical
needs list, as well as in March 2019 the FDA issued guidance for industry <i>Evaluation of Bulk Substances Nominated for Use in
Compounding Under Section 503B of the Federal Food, Drug and Cosmetic Act</i>, which further describes the FDA&#8217;s policy
for evaluating bulk drug substances nominated for use in compounding by outsourcing facilities. Entities voluntarily registering
as outsourcing facilities are subject to cGMP requirements and regular FDA inspection, among other requirements. As described
above, our current pharmacy operations in NJ are governed by Section 503A of the FDCA, and our NJ based outsourcing facility is
governed by Section 503B of the FDCA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
July 30, 2020, the FDA issued a notice for comments related to certain bulk drug substances to be removed from the 503B Bulk&#8217;s
List (or Category 1 List). Included in this notice for comment were certain bulk drug substances which we currently use in some
of our compounded products. In the event one or more of these bulk substances are ultimately removed from the Category 1 List,
we intend to utilize commercially available versions of these substances or similar active pharmaceutical ingredients as replacements
of the bulk powders contained in our sterile products. In addition, nothing in the FDA&#8217;s notice affects the dispensing of
bulk powder-containing products from our 503A pharmacy. Nonetheless, if all or some of the bulk drug substances we use are removed
from the 503B Bulk&#8217;s List, this may result in a disruption in our operations, revenues and cash flows. In addition, during
September 2020 through January 2021, NJOF was inspected by the FDA (the &#8220;2020 Inspection&#8221;) and certain observations
were made by FDA in a Form 483. Five observations made during the 2020 Inspection were considered repeat observations from a 2017
FDA inspection of NJOF. In addition, during the 2020 Inspection, the FDA noted that we were compounding drugs for which there
is no change that produces for an individual patient a clinical difference, as determined by a prescribing practitioner between
a compounded drug and the comparable approved drug. We have responded to the FDA regarding all of their observations from the
2020 Inspection, including providing documentation from prescribing clinicians that indicate a clinical difference between our
compounded drugs and the comparable approved drugs, while also committing to amend our order process to collect &#8220;medical
necessity/clinical difference&#8221; information for each order of our compounded drugs on a go-forward basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
two recent California federal court decisions, <i>Allergan USA, Inc. v. Prescribers Choice, Inc. </i>and <i>Allergan USA, Inc.
v. Imprimis Pharmaceuticals, Inc., </i>the Court made rulings which impact 503B and 503A facilities operating in and shipping
to the state of California. In the <i>Prescribers Choice</i> case, the Court determined that while the FDA&#8217;s interim policies
do not override the statutory obligations of the DQSA, the Court supported the FDA&#8217;s authority and flexibility as it determines
what clinical needs exist and finalizes the bulk drug substances list. The Court would not hold a party liable under California&#8217;s
Sherman Food, Drug and Cosmetic Law (&#8220;Sherman Law&#8221;) for selling, delivering, or giving away any new drug that has
not been approved by the California Department of Health Services or FDA if that party has complied with the FDA&#8217;s Interim
Policy. In other words, it is not unlawful in California to utilize bulk drugs appearing on the Category 1 list while the FDA
finalizes its clinical needs list. In the <i>Imprimis Pharmaceuticals</i> case, the Court made clear that its rulings related
to violations of California&#8217;s Unfair Competition Law (&#8220;UCL&#8221;) (Cal. Bus. Prof. Code &#167;17200) were limited
in geographical scope to drugs prepared in, dispensed from within or shipped to the State of California. With respect to 503A
facilities, the Court followed FDA&#8217;s guidance allowing compounding pharmacies to ship more than 5% of its medications out
of state while finalizing the MOUs. It further held that 503A facilities operating within or shipping into the state of California
must follow statutory guidance found in 21 U.S.C. 353(a). With respect to the statutory guidance related to compounding in response
to valid prescription orders, the Court added a requirement that the valid prescription order must contain language that &#8220;an
FDA-approved drug is not medically appropriate.&#8221; The practical effect of these two rulings is that 503A and 503B facilities
operating within or shipping drugs into the State of California now have clear guidance as to what is, and is not, lawful behavior
with respect the California&#8217;s UCL and Sherman Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Confidentiality,
Privacy and HIPAA</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
pharmacy operations involve the receipt, use and disclosure of confidential medical, pharmacy and other health-related information.
In addition, we use aggregated and blinded (anonymous) data for research and analysis purposes. The federal privacy regulations
under HIPAA are designed to protect the medical information of a healthcare patient or health plan enrollee that could be used
to identify the individual. Among other things, HIPAA limits certain uses and disclosures of protected health information and
requires compliance with federal security regulations regarding the storage, utilization and transmission of and access to electronic
protected health information. The requirements imposed by HIPAA are extensive. In addition, most states and certain other countries
have enacted privacy and security laws that protect identifiable patient information that is not health-related. For example,
California recently enacted the California Consumer Privacy Act, or CCPA, that creates new individual privacy rights for consumers
and places increased privacy and security obligations on entities handling personal data of consumers or households. Effective
January 1, 2020, the CCPA gives California residents expanded privacy rights and protections, and provides civil penalties for
violations and a private right of action for data breaches. The CCPA will likely impact our business activities and exemplifies
the vulnerability of our business to not only cyber threats but also the evolving regulatory environment related to personal data
and protected health information. Other countries also have, or are developing, laws governing the collection, use and transmission
of personal information, such as the General Data Protection Regulation (&#8220;GDPR&#8221;) in the European Union (the &#8220;EU&#8221;)
that became effective in May 2018 and the Personal Information Protection and Electronic Documents Act that became effective in
Canada in April 2000. Further, several states have enacted more protective and comprehensive pharmacy-related privacy legislation
that not only applies to patient records but also prohibits the transfer or use for commercial purposes of pharmacy data that
identifies prescribers. These regulations impose substantial requirements on covered entities and their business associates regarding
the storage, utilization and transmission of and access to personal health and non-health information. Many of these laws apply
to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Medicare
and Medicaid Reimbursement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Medicare
is a federally funded program that provides health insurance coverage for qualified persons age 65 or older and for some disabled
persons with certain specific conditions. State-funded Medicaid programs provide medical benefits to groups of low-income and
disabled individuals, some of whom may have inadequate or no medical insurance. Currently, most of our compounded formulations
are sold in cash transactions, and the customers decide whether or not to seek reimbursement opportunities from Medicare, Medicaid
and other third parties. We work with third-party insurers, pharmacy benefit managers and buying groups to offer patient-specific
customizable compounded formulations at accessible prices. We plan to continue to devote time and other resources to seek reimbursement
and patient pay opportunities for these and other compounded formulations, and we have hired pharmacy billers to process certain
existing reimbursement opportunities for certain formulations. Moreover, third-party payors, including Medicare, are increasingly
attempting to contain health care costs by limiting coverage and the level of reimbursement for new drugs and by refusing, in
some cases, to provide coverage for uses of approved products for disease indications for which the FDA has not granted labeling
approval. Further, the Health Care Reform Law may have a considerable impact on the existing U.S. system for the delivery and
financing of health care and could conceivably have a material effect on our business. As a result, reimbursement from Medicare,
Medicaid and other third-party payors may never be available for any of our products or, if available, may not be sufficient to
allow us to sell the products on a competitive basis and at desirable price points.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">To
the extent we obtain third-party reimbursement for our compounded formulations, we may become subject to Medicare, Medicaid and
other publicly financed health benefit plan regulations prohibiting kickbacks, beneficiary inducement and the submission of false
claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>FDA
New Drug Application Process</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
discussed in other sections of this report, we are and may continue to, alone or with project partners, pursue FDA approval to
market and sell one or more of our formulations through the FDA&#8217;s NDA process. To the extent that the Section 505(b)(2)
applicant is relying on the FDA&#8217;s conclusions regarding studies conducted for an already approved product, the applicant
is required to certify to the FDA concerning any patents listed for the approved product in the FDA&#8217;s Orange Book publication.
As a condition of approval, the FDA or other regulatory authorities may require further studies, including Phase 4 post-marketing
studies, to provide additional data. Other post-marketing studies may be required to gain approval for the use of a product as
a treatment for clinical indications other than those for which the product was initially tested and approved. Also, the FDA or
other regulatory authorities require post-marketing reporting to monitor the adverse effects of a drug. Results of post-marketing
programs may limit or expand the further marketing of a product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer
advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving
the Internet. A company can make only those claims relating to safety and efficacy that are approved by the FDA. Failure to comply
with these requirements can result in adverse publicity, warning letters, corrective advertising, fines and potential civil and
criminal penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>International
Regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">If
we pursue commercialization of our proprietary formulations in countries other than the United States, then we may need to obtain
the approvals required by the regulatory authorities of such foreign countries that are comparable to the FDA and state boards
of pharmacy, and we would be subject to a variety of other foreign statutes and regulations comparable to those relating to our
U.S. operations. Regulatory frameworks and requirements vary by country and could involve significant additional licensing requirements
and product testing and review periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Environmental
and Other Matters</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
are or may become subject to environmental laws and regulations governing, among other things, any use and disposal by us of hazardous
or potentially hazardous substances in connection with our research and preparation of our formulations. In addition, we are subject
to work safety and labor laws that govern certain of our operations and our employee relations. In each of these areas, as described
above, the FDA and other government agencies have broad regulatory and enforcement powers, including, among other things, the
ability to levy fines and civil penalties, suspend or delay issuance of approvals, licenses or permits, seize or recall products,
and withdraw approvals, any one or more of which could have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>COVID-19
Pandemic </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">A
novel strain of coronavirus was first identified in Wuhan, China in December 2020. The disease caused by it, COVID-19, was declared
a global pandemic by the World Health Organization in March 2020. On March 18, 2020, CMS released guidance for U.S. healthcare
providers to limit all elective medical procedures in order to conserve personal protective equipment and limit exposure to COVID-19
during the pendency of the pandemic. In addition to limiting elective medical procedures, many hospitals and other healthcare
providers have strictly limited access to their facilities during the pandemic. The COVID-19 pandemic has negatively impacted
the global economy, disrupted global supply chains and healthcare delivery, led to social distancing recommendation, and created
significant volatility in financial markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
response to the pandemic and business disruptions, first and foremost, we have prioritized the health and safety of our employees,
customers, suppliers and others with whom we partner in our business activities. We have instructed employees to work from home
when possible and to maintain recommended physical distancing when working in our facilities. We also have eliminated non-essential
in-person contact with customers, suppliers and other third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Many
of the Company&#8217;s customers use its drugs in procedures that were impacted by the CMS guidance to limit elective procedures.
In addition, the Company and our business partners need access to healthcare providers and facilities to conduct clinical trials
and other activities required to achieve regulatory clearance of products under development. We are carefully monitoring rapidly
evolving changes in healthcare delivery systems and may adjust our operating and product development plans accordingly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Given
the unprecedented and dynamic nature of the COVID-19 pandemic, we cannot reasonably estimate the impacts it may have on our financial
condition, results of operations or cash flows in the future. However, the reduction in elective procedures in response to CMS
guidance has had a material adverse impact, on our revenues, profitability and cash flows, in particular during the second quarter
of 2020. The extent and duration of future impact will depend upon the extent of procedure postponements, the duration of the
pandemic and any resurgences of it, especially within certain geographies and states that have retained restrictive measures and
social distancing policies. In May 2020 and the following months, some U.S. states and geographies began easing restrictions associated
with the COVID-19 pandemic including those restrictions related to elective procedures, as restrictions were lifted in those areas
there was a correlation with an increase in our revenues. Despite the recent resurgence of the COVID-19 pandemic in certain parts
of the U.S., we are hopeful that the general trend of easing of restrictions will continue and sales of our products will return
to historical norms and historical growth trends, as other states and governmental authorities continue to ease restrictions associated
with elective procedures and the COVID-19 pandemic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Research
and Development Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
research and development expenses incurred in 2020 and 2019 primarily include expenses related to the development of intellectual
property, researcher and investigator-initiated evaluations, and research and formulation development related primarily to our
ophthalmic formulations and certain other assets, in addition to costs associated with our drug candidate development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020, we incurred $2,413,000 in research and development expenses, compared to $2,083,000 during the
year ended December 31, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Financial
Information About Segments and Geographic Areas</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Beginning
on January 1, 2019, the Company began evaluating performance of the Company based on operating segments. Segment performance for
its two operating segments will be based on segment contribution. Our reportable segments consist of (i) our commercial stage
pharmaceutical business (Pharmaceutical Compounding), generally including the operations of our ImprimisRx business; and (ii)
our start-up operations associated with pharmaceutical drug development business (Pharmaceutical Drug Development). Segment contribution
for our segments represents net revenues less cost of sales, research and development, selling and marketing expenses, and select
general and administrative expenses. The Company does not evaluate the following items at the segment level:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Operating
    expenses within selling, general and administrative expenses that result from the impact of corporate initiatives. Corporate
    initiatives primarily include integration, restructuring, acquisition and other shared costs;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Selling,
    general and administrative expenses that result from shared infrastructure, including certain expenses associated with legal
    matters, our board of directors and principal executive officers, investor relations and other like shared expenses;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Other
    select revenues and operating expenses including R&amp;D expenses, amortization, and asset sales and impairments, net as not
    all such information has been accounted for at the segment level, or such information has not been used by all segments; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Total
    assets including capital expenditures.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.8pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company defines segment net revenues as pharmaceutical compounded drug sales, revenues from licenses and other revenue derived
from related agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.8pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Cost
of sales within segment contribution includes direct and indirect costs to manufacture formulations and sell products, including
active pharmaceutical ingredients, personnel costs, packaging, storage, royalties, shipping and handling costs, manufacturing
equipment and tenant improvements depreciation, the write-off of obsolete inventory and other related expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.8pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.8pt"><span style="font: 10pt Times New Roman, Times, Serif">Selling,
general and administrative expenses consist mainly of personnel-related costs, marketing and promotion costs, distribution costs,
professional service costs, insurance, depreciation, facilities costs, transaction costs, and professional services costs, which
are general in nature and attributable to the segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.8pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.8pt"><span style="font: 10pt Times New Roman, Times, Serif">See
Note 18 to our consolidated financial statements included in this Annual Report for more information about our reportable segments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.8pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Human
Capital</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of March 1, 2021, we had 125 employees. Our employees are engaged in pharmacy operations, sales, marketing, research, development,
and general and administrative functions. We expect to add additional employees in all departmental functions as we carry out
our business plan in the next 12 months. We are not party to any collective bargaining agreements with any of our employees. We
have never experienced a work stoppage, and we believe our employee relations are good. We hire independent contractor labor and
consultants on an as-needed basis, our salesforce is comprised primarily of contract sales organizations and contract labor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Talent
Acquisition and Retention</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
recognize that our employees largely contribute to our success. To this end, we support business growth by seeking to attract
and retain best-in-class talent. Our talent acquisition team uses internal and external resources to recruit highly skilled candidates
in the US. We believe that we continue to attract and retain superior talent as measured by our minimal turnover rate and a high
employee service tenure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Total
Rewards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
total rewards philosophy has been to create investment in our workforce by offering competitive compensation and benefits packages.
We provide employees with compensation packages that include base salary, annual incentive bonuses, and long-term equity awards.
We also offer comprehensive employee benefits, such as life, disability, and health insurance, health savings and flexible spending
accounts, paid time off, and a 401(k) plan. It is our expressed intent to be an employer of choice in our industry by providing
market-competitive compensation and benefits packages.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Health,
Safety, and Wellness</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
health, safety, and wellness of our employees is a priority in which we have always invested and will continue to do so. We provide
our employees and their families with access to a variety of innovative, flexible, and convenient health and wellness programs.
Program benefits are intended to provide protection and security, so employees can have peace of mind concerning events that may
require time away from work or that may impact their financial well-being.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">These
investments and the prioritization of employee health, safety, and wellness took on particular significance in 2020 in light of
COVID-19. To protect and support our essential team members, we have implemented health and safety measures that included maximizing
personal workspaces, changing shift schedules, providing personal protective equipment (PPE), and instituting screening before
accessing buildings. In response to local stay-at-home orders and in alignment with CDC recommendations, we have limited our employees
onsite in our office location based in San Diego, California. To aid in containing the spread of COVID-19, we have implemented
remote-work options when appropriate and are limiting employee travel. We will continue to seek programs to educate and assist
employees whenever possible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Diversity,
Equity, and Inclusion</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
believe a diverse workforce is critical to our success. Our mission is to value differences in races, ethnicities, religions,
nationalities, genders, ages, sexual orientations, as well as education, skill sets and experience. We are focused on inclusive
hiring practices, fair and equitable treatment, organizational flexibility, and training and resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Training
and Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
believe in encouraging employees in becoming lifelong learners by providing ongoing learning, training and leadership opportunities.
We provide our employees with a tuition reimbursement program, and in certain instances onsite training programs. While we strive
to provide real-time recognition of employee performance, we have a formal annual review process not only to determine pay and
equity adjustments tied to individual contributions, but to identify areas where training and development may be needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Company
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
were incorporated in Delaware in January 2006 as Bywater Resources, Inc. In September 2007, we closed a merger transaction with
Transdel Pharmaceuticals Holdings, Inc. and changed our name to Transdel Pharmaceuticals, Inc. We changed our name to Imprimis
Pharmaceuticals, Inc. in February 2012. We changed the name of our company to Harrow Health, Inc. in December 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
June 26, 2011, we suspended our operations and filed a voluntary petition for reorganization relief under Chapter 11 of the United
States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of California, Case No. 11-10497-11. On
December 8, 2011, in connection with our entry into a line of credit agreement and securities purchase agreement with a third
party, our voluntary petition for reorganization relief was dismissed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
the summer of 2019, we relocated our executive office previously based in San Diego, California to its current location at 102
Woodmont Blvd., Suite 610, Nashville, Tennessee and our telephone number at such office is (615) 733-4730. Our website address
is harrowinc.com. Information contained on our website is not deemed part of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="b_003"></span>ITEM
1A. RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Risk
Factors Summary</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
are subject to a variety of risks and uncertainties, including risks related to our financial position and need for additional
capital, the commercialization of our product candidates, our operations, regulatory approval and other legal compliance matters,
human capital, product development, intellectual property and our common stock, which could have a material adverse effect on
our business results of operations, financial condition and prospects. Risks that we deem material are described under &#8220;Risk
Factors&#8221; below and include, but are not limited to, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
    ability to achieve profitability for our business;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
    ability to successfully market, commercialize, and sell current and future products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    potential adverse impact of health epidemics, including the recent coronavirus outbreak;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Securing
    and maintaining patent or other intellectual property protection for our products and related improvements;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Market
    acceptance of compounded drugs and pharmacies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
    ability to successfully research, develop and timely manufacture our current and future products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Governmental
    regulations that burden operations or narrow the market for our products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
    exposure to liabilities and reputation harm if our products give rise to defects, recalls, patient injury or death;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
    current indebtedness and ability to access additional capital;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
    ability to attract customers and increase sales of current and future products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
    ability to obtain marketing approval and ongoing expense associated with it for any of our drug candidates, including those
    we own royalty rights of;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
    reliance on third parties for manufacturing certain components and to conduct clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
    ability to enforce protect our intellectual property rights along with the potential of future legal proceedings filed against
    us claiming intellectual property infringement;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Retention,
    recruitment, and training of senior management and key personnel;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Volatility
    of the price of our common stock; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
    stock price falling as a result of future offerings or sales.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>You
should carefully consider the following risk factors in addition to the other information contained in this Annual Report. Our
business, financial condition, results of operations and stock price could be materially adversely affected by any of these risks.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Risks
Related to Our Financial Position and Need for Additional Capital</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Until
2018, we incurred losses in every year of our operations, and we may not be profitable in the future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Until
2018, we incurred losses in every year of our operations. As of December 31, 2020, our accumulated deficit was $(77,400,000).
Our current projections indicate that we will have operating income and/or net income during 2021; however, these projections
may not be correct and our plans could change. Also, we could incur increasing operating losses in the foreseeable future for
our commercialization activities, research and development and our pharmaceutical compounding business which would impact net
income. Recent changes to the accounting for equity investments require those investments to be measured at fair market value,
which may cause our earnings (losses) to become volatile as the stock prices of those equity investments fluctuate. Although we
have been generating revenue from our pharmaceutical compounding operations, our ability to generate the revenues necessary to
achieve profitability will depend on many factors, including those discussed in this &#8220;Risk Factors&#8221; section. Our business
plan and strategies involve costly activities that are susceptible to failure, and, therefore, we may not be able to generate
sufficient revenue to support and sustain our business or reach the level of sales and revenues necessary to achieve and sustain
profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
may not receive sufficient revenue to fund our operations and recover our development costs. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
business plan involves the preparation and sale of our proprietary formulations through our compounding pharmacies and outsourcing
facilities. We have limited experience operating pharmacies and commercializing compounded formulations, and we may be unable
to successfully manage this business or generate sufficient revenue to recover our development costs and operational expenses.
We may have only limited success in marketing and selling our proprietary formulations. Although we have established and plan
to grow our internal sales teams to market and sell our proprietary formulations and other non-proprietary products, we have limited
experience with such activities and may not be able to generate sufficient physician and patient interest in our formulations
to generate significant revenue from sales of these products. In addition, we are substantially dependent on our ImprimisRx compounding
pharmacies and outsourcing facilities, along with any pharmacy partners with which we may contract to compound and sell our formulations
using our quality standards and specifications, in a timely manner and sufficient volumes to accommodate the number of prescriptions
they receive. Our pharmacies may be unable to compound our formulations successfully, and we may be unable to acquire, build or
enter into arrangements with pharmacies or outsourcing facilities of sufficient size, reputation and quality to implement our
business plan, which would cause our business to suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our
loan under the Paycheck Protection Program may not be forgiven or may subject us to challenges and investigations regarding qualification
for the loan.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.3pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
April 2020, we entered into an unsecured promissory note and related Business Loan Agreement with Renasant Bank, as lender, for
a loan (the &#8220;PPP Loan&#8221;), which was established under the Federal Coronavirus Aid, Relief, and Economic Security Act
(the &#8220;CARES Act&#8221;) in the principal amount of $1,967,000. Pursuant to Section 1106 of the CARES Act, during the year
ended December 31 ,2020, we applied for forgiveness for all of the PPP Loan, however as of the date of this Annual Report the
U.S. Small Business Administration (the &#8220;SBA&#8221;) has not made a decision related to our application for forgiveness.
Such forgiveness will be determined, subject to limitations, based on the use of the loan proceeds for qualifying expenses, which
include payroll costs, rent, and utility costs over the allowable measurement period following receipt of the loan proceeds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.3pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.3pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
SBA continues to develop and issue new and updated guidance regarding the PPP Loan application and forgiveness process, including
guidance regarding required borrower certifications and requirements for forgiveness of loans made under the program. Given the
evolving nature of the guidance and depending upon our ability to use the loan proceeds for qualifying expenses, we cannot give
any assurance that our PPP Loan will be forgiven in whole or in part.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.3pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.3pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Additionally,
the PPP Loan application required us to certify that the current economic uncertainty made the PPP Loan request necessary to support
our ongoing operations. While we made this certification in good faith after analyzing, among other things, our financial situation
and access to alternative forms of capital, and believe that we satisfied all eligibility criteria for the PPP Loan and that our
receipt of the PPP Loan is consistent with the broad objectives of the Paycheck Protection Program of the CARES Act, the certification
described above does not contain any objective criteria and is subject to interpretation. In addition, the SBA has stated that
it is unlikely that a public company with substantial market value and access to capital markets will be able to make the required
certification in good faith. The lack of clarity regarding loan eligibility under the program has resulted in significant media
coverage and controversy with respect to public companies applying for and receiving loans. If, despite our good faith belief
that we satisfied all eligibility requirements for the PPP Loan, we are found to have been ineligible to receive the PPP Loan
or in violation of any of the laws or regulations that apply to us in connection with the PPP Loan, including the False Claims
Act, we may be subject to penalties, including significant civil, criminal and administrative penalties, and would be required
to repay the PPP Loan. We were also required to make certain certifications in our application for forgiveness, which will be
subject to audit and review by governmental entities and could subject us to significant penalties and liabilities if found to
be inaccurate, including being required to repay the PPP loan. In addition, our receipt of the PPP Loan may result in adverse
publicity and damage to our reputation, and a review or audit by the SBA or other government entity or claims under the False
Claims Act could consume significant financial and management resources. Any of these events could materially harm our business,
results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.3pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
may not be able to correctly estimate our future operating expenses, which could lead to cash shortfalls.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
estimates of our future operating and capital expenditures are based upon our current business plan, our current operations and
our current expectations regarding the commercialization of our proprietary formulations. Our projections have varied significantly
in the past as a result of changes to our business model and strategy, our termination of efforts to pursue FDA approval of a
drug candidate in November 2013, our acquisitions of compounding facilities and various product and corporate development opportunities
since 2014, and the expenses in developing our pharmacy facilities into outsourcing facilities and registering them as such with
the FDA. We may not accurately estimate the potential revenues and expenses of our operations. If we are unable to correctly estimate
the amount of cash necessary to fund our business, we could spend our available financial resources much faster than we expect.
If we do not have sufficient funds to continue to operate and develop our business, we could be required to seek additional financing
earlier than we expect, which may not be available when needed or at all, or be forced to delay, scale back or eliminate some
or all of our proposed operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
have incurred significant indebtedness, which will require substantial cash to service and which subjects us to certain financial
requirements and business restrictions. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
ability to make scheduled payments on our indebtedness depends on our future performance and ability to raise additional capital,
which is subject to economic, financial, competitive and other factors, some of which are beyond our control. If we are unable
to generate sufficient cash to service our debt, we may be required to adopt one or more alternatives, such as selling assets,
restructuring our debt or obtaining additional capital through equity sales or incurrence of additional debt on terms that may
be onerous or highly dilutive to our stockholders. Our ability to engage in any of these activities would depend on the capital
markets and our financial condition at such time, and we may not be able to do so when needed, on desirable terms or at all, which
could result in a default on our debt obligations. Additionally, our debt instrument with SWK Funding LLC (&#8220;SWK&#8221;)
contains various restrictive covenants, including, among others, our obligation to deliver to SWK certain financial and other
information, our obligation to comply with certain notice and insurance requirements, and our inability, without SWK&#8217;s prior
consent, to dispose of certain of our assets, incur certain additional indebtedness, enter into certain merger, acquisition or
change of control transactions, pay certain dividends or distributions on or repurchase any of our capital stock or incur any
lien or other encumbrance on our assets, subject to certain permitted exceptions. Any failure by us to comply with any of these
covenants, subject to certain cure periods, or to make all payments under the debt instruments when due, would cause us to be
in default under the applicable debt instrument. In the event of any such default, SWK may be able to foreclose on our assets
that secure the debt or declare all borrowed funds, together with accrued and unpaid interest, immediately due and payable, thereby
potentially causing all of our available cash to be used to pay our indebtedness or forcing us into bankruptcy or liquidation
if we do not then have sufficient cash available. Any such event or occurrence could severely and negatively impact our operations
and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
may need additional capital in order to continue operating our business, and such additional funds may not be available when needed,
on acceptable terms, or at all.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
only recently started generating cash from operations, but we do not currently earn sufficient revenues to support our operations.
We may need significant additional capital to execute our business plan and fund our proposed business operations. Additionally,
our plans may change or the estimates of our operating expenses and working capital requirements could be inaccurate, we may pursue
acquisitions of pharmacies or other strategic transactions that involve large expenditures, or we may experience growth more quickly
or on a larger scale than we expect, any of which may result in the depletion of capital resources more rapidly than anticipated
and could require us to seek additional financing earlier than we expect to support our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have raised over $59,000,000 in funds through equity and debt financings since January 2015. We may seek to obtain additional
capital through equity or debt financings, funding from corporate partnerships or licensing arrangements, sales of assets or other
financing transactions. If we issue additional equity or convertible debt securities to raise funds, our existing stockholders
may experience substantial dilution, and the newly issued equity or debt securities may have more favorable terms or rights, preferences
and privileges senior to those of our existing stockholders. If we raise additional funds through collaboration and licensing
arrangements or sales of assets, we may have to relinquish potentially valuable rights to our drug candidates or proprietary technologies,
or grant licenses on terms that are not favorable to us. If we raise funds by incurring additional debt, we may be required to
pay significant interest expenses and our leverage relative to our earnings or to our equity capitalization may increase. Obtaining
commercial loans, assuming those loans would be available, would increase our liabilities and future cash commitments and may
impose restrictions on our activities, such as the financial and operating covenants included in our loan agreement with SWK.
Further, we may incur substantial costs in pursuing future capital and/or financing transactions, including investment banking
fees, legal fees, accounting fees, printing and distribution expenses and other costs. We may also be required to recognize non-cash
expenses in connection with certain securities we may issue, such as options, convertible notes and warrants, which would adversely
impact our financial results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Risks
Related to the Commercialization of our Product Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
are dependent on market acceptance of compounding pharmacies and compounded formulations, and physicians may be unwilling to prescribe,
and patients may be unwilling to use, our proprietary customizable compounded formulations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">We
currently distribute our proprietary formulations through compounding pharmacies and an outsourcing facility. Formulations prepared
and dispensed by compounding pharmacies contain FDA-approved ingredients, but are not themselves approved by the FDA. Thus, our
compounded formulations have not undergone the FDA approval process and only limited data, if any, may be available about the
safety and efficacy of our formulations for any particular indication. Certain compounding pharmacies have been subject to widespread
negative media coverage in recent years, and the actions of these pharmacies have resulted in increased scrutiny of compounding
pharmacy activities from the FDA and state governmental agencies. For example, the FDA has issued formal requests to compounding
pharmacies and outsourcing facilities to conduct a recall of all non-expired, purportedly sterile drug products and to cease sterile
compounding operations due to lack of sterility assurance. As a result, some health care providers may be reluctant to purchase
and use compounded drugs. Our growth and future sales depend not only on our ability to demonstrate in the face of increased scrutiny
the quality and safety of our pharmacies and outsourcing facilities and our compliance with more stringent regulatory standards
at the federal and state levels, but also on the continued acceptance of compounded drugs and formulations, particularly outsourced
compounded drugs and formulations, in the marketplace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">An
incident similar to the fungal meningitis outbreak in 2012, which was caused by a compounding pharmacy employing a non-sterile-to-sterile
business model, could cause our customers to reduce their use of compounded formulations significantly or even stop using compounded
drugs altogether. States have in the past, and could in the future, enact regulation prohibiting or restricting the use of compounding
pharmacies and outsourcing facilities in response to such incidents. Such prohibitions or restrictions by states or reduced customer
demand as a result of an incident with compounded drugs and formulations could have a material adverse effect on our business,
results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2017, the FDA issued a MedWatch notification regarding our curcumin emulsion and two adverse events that had been associated
with the use of these emulsions by prescribing physicians. We issued a press release on August 7, 2017, clarifying certain facts
regarding the notice which outlined our belief that the adverse events associated with the two patients occurred due to an allergic
reaction caused by the products being inappropriately administered and obtained by the prescribing physician, and our use of curcumin
and excipients in our curcumin emulsion formulation met regulatory standards required for dispensing of the curcumin emulsion.
In September 2017, the FDA released a letter confirming that the alleged misuse of certain ingredients in our curcumin emulsions
were due to mislabeling by the underlying supplier, and not of our own misdoing. We no longer compound curcumin emulsion products.
Separately, in December 2017, we were issued a warning letter from the FDA alleging that, in their interpretation of our public
communications, we had made false or misleading claims and omitted risk and side effect information regarding certain of our ophthalmology
focused compounded medications. We immediately performed a full review of our public communications referenced in the warning
letter and responded to the FDA in January 2018. Notwithstanding our continued belief that our public communications were not
in fact false and misleading, we have been in communication with the FDA and are taking steps to address the items outlined in
the FDA letter. In June 2019, our outsourcing facility was issued a warning letter related to an April 2017 inspection and our
use of certain active pharmaceutical ingredients in our compounded medications. During September 2020 through January 2021, our
New Jersey based outsourcing facility was inspected by the FDA (the &#8220;2020 Inspection&#8221;) and certain observations
were made by the FDA in a Form 483. Five observations made during the 2020 Inspection were considered repeat observations
from a 2017 FDA inspection. In addition, during the 2020 Inspection, the FDA noted that we were compounding drugs for which
there is no change that produces for an individual patient a clinical difference, as determined by a prescribing practitioner
between a compounded drug and the comparable approved drug. We have responded to the FDA regarding all of their observations
from the 2020 Inspection, including providing documentation from prescribing clinicians that indicate a clinical difference between
our compounded drugs and the comparable approved drugs, while also committing to amend our order process to collect &#8220;medical
necessity/clinical difference&#8221; information for each order of our compounded drugs on a go-forward basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
will continue to work and communicate with the FDA to assure that all allegations in the warning letters and 483s have been addressed.
We believe, to date, we have addressed all of the material items of concern in the FDA&#8217;s 483, warning letters and those
related to the MedWatch notification (and any other requirements observed by the FDA and noted to us), and we do not believe
there will be any further action taken by the FDA in these matters. Nonetheless, these items increased further scrutiny
and negative publicity on us as a company. As part of our commitment to actively work with regulators, at times, we have become
aware of concerns related to certain formulations, and as a result, discontinued compounding certain drug formulations in an attempt
to help mitigate potential regulatory risk. As a result of the MedWatch notice, warning letters and other regulatory notifications,
some physicians may be hesitant to prescribe and some patients may be hesitant to purchase and use non-FDA-approved compounded
formulations, particularly when an FDA-approved potential alternative is available. For other reasons, physicians may be unwilling
to prescribe or patients may be unwilling to use our proprietary compounded formulations, including the following: legal prohibitions
on our ability to discuss the efficacy or safety of our formulations with potential users to the extent applicable data is available;
our pharmacy operations are primarily operating on a cash-pay basis and reimbursement may or may not be available from third-party
payors, including the government Medicare and Medicaid programs; and certain formulations are not required to be prepared and
are not presently being prepared in a manufacturing facility governed by cGMP requirements. Any failure by physicians, patients
and/or third-party payors to accept and embrace compounded formulations could substantially limit our market and cause our operations
to suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>There
are many competitive risks related to marketing and selling our proprietary formulations and operating our compounding pharmacy
business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
pharmaceutical and pharmacy industries are highly competitive. We compete against branded drug companies, generic drug companies,
outsourcing facilities and other compounding pharmacies. We are significantly smaller than some of our competitors. Currently
we lack some of the financial and other resources needed to develop, produce, distribute and market our proprietary formulations
at a level to capture a significant market share in these sectors. The drug products available through branded and generic drug
companies with which our formulations compete have been approved for marketing and sale by the FDA and are required to be manufactured
in facilities compliant with cGMP standards. Although we prepare our compounded formulations in accordance with the standards
provided by the United States Pharmacopeia (&#8220;USP&#8221;) &lt;795&gt; and USP &lt;797&gt; and applicable state and federal
law, our proprietary compounded formulations are not required to be, and have not been, approved for marketing and sale by the
FDA. As a result, some physicians may be unwilling to prescribe, and some patients may be unwilling to use, our formulations.
Additionally, under federal and state laws applicable to our current compounding pharmacy operations, we are not permitted to
prepare significant amounts of a specific formulation in advance of a prescription, compound quantities for office use or utilize
a wholesaler for distribution of our formulations; instead, our compounded formulations must be prepared and dispensed in connection
with a physician prescription for an individually identified patient. Pharmaceutical companies, on the other hand, are able to
sell their FDA-approved products to large pharmaceutical wholesalers, which can in turn sell to and supply hospitals and retail
pharmacies. Even if we are successful in registering certain of our facilities as outsourcing facilities, our business may not
be scalable on the scope available to our competitors that produce FDA-approved drugs, which may limit our potential for profitable
operations. These facets of our operations may subject our business to limitations our competitors with FDA-approved drugs may
not face.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our
future success depends in large part on our ability to maintain a competitive position with respect to biotechnology and related
pharmaceutical technologies</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Biotechnology
and related pharmaceutical technologies have undergone and continue to be subject to rapid and significant change. Our future
success will depend in large part on our ability to maintain a competitive position with respect to these technologies. Products
developed by our competitors, including FDA-approved drugs and compounded formulations created by other pharmacies, could render
our products and technologies obsolete or unable to compete. Any products that we develop may become obsolete before we recover
expenses incurred in their development, which may require us to raise additional funds that may or may not be available. The competitive
environment requires an ongoing, extensive search for medical and technological innovations and the ability to develop and market
these innovations effectively, and we may not be competitive with respect to these factors. Other competitive factors include
the safety and efficacy of a product, the size of the market for a product, the timing of market entry relative to competitive
products, the availability of alternative compounded formulations or approved drugs, the price of a product relative to alternative
products, the availability of third-party reimbursement, the success of sales and marketing efforts, brand recognition and the
availability of scientific and technical information about a product. Although we believe we are positioned to compete favorably
with respect to many of these factors, if our proprietary formulations are unable to compete with the products of our competitors,
we may never gain market share or achieve sustained profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our
ability to generate revenues will be diminished if we fail to obtain acceptable prices or an adequate level of reimbursement from
third-party payors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Currently,
our ImprimisRx compounding pharmacies operate on mostly a cash-pay basis and do not submit large amounts of claims for reimbursement
through Medicare, Medicaid or other third-party payors. As part of our Imprimis Cares initiative, we work with third-party insurers,
pharmacy benefit managers and buying groups to offer patient-specific customizable compounded formulations at accessible prices.
We plan to continue to devote time and other resources to seek reimbursement and patient pay opportunities for these and other
compounded formulations. We have hired pharmacy billers to process certain existing reimbursement opportunities for certain formulations.
However, we may be unsuccessful in achieving these goals, as many third-party payors have imposed significant restrictions on
reimbursement for compounded formulations in recent years. Moreover, third-party payors, including Medicare, are attempting to
contain health care costs by limiting coverage and the level of reimbursement for new drugs and by refusing, in some cases, to
provide coverage for uses of approved products for disease indications for which the FDA has not granted labeling approval. Further,
the Health Care Reform Law may have a considerable impact on the existing U.S. system for the delivery and financing of health
care and could conceivably have a material effect on our business. As a result, reimbursement from Medicare, Medicaid and other
third-party payors may never be available for any of our products or, if available, may not be sufficient to allow us to sell
the products on a competitive basis and at desirable price points. If government and other third-party payors do not provide adequate
coverage and reimbursement levels for our formulations, the market acceptance for our formulations may be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Additionally,
we are making efforts to normalize the pricing for our currently available proprietary compounded formulations. Any efforts to
attain optimized pricing for our Dropless Therapy or any of our other proprietary formulations could fail, which could make our
products less attractive or unavailable to some patients or could reduce our margins.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
may be unable to successfully develop and commercialize our proprietary formulations or any other assets we may acquire. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have acquired assets related to compoundable formulations, and we have entered into one license agreement for rights to commercialize
a compounding formulation. We are currently pursuing development and commercialization opportunities with respect to certain of
these formulations, and we are in the process of assessing certain of our other assets in order to determine whether to pursue
their development or commercialization. In addition, we expect to consider the acquisition of additional intellectual property
rights or other assets in the future. Once we determine to pursue a potential drug candidate, we develop a commercialization strategy
for it, which may include marketing and selling the formulation in compounded form through compounding pharmacies or outsourcing
facilities, or pursuing FDA approval of the drug candidate. We may incorrectly assess the risks and benefits of the commercialization
options or we may not pursue a commercialization strategy that proves to be successful. If we are unable to successfully commercialize
one or more of our proprietary formulations, our operating results would be adversely affected. Even if we are able to successfully
sell one or more proprietary formulations, we may never recoup our investment in acquiring or developing the formulations. Our
failure to identify and expend our resources on formulations and technologies with commercial potential and execute an effective
commercialization strategy for each of our formulations would negatively impact the long-term profitability of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Risks
Related to Our Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>The
COVID-19 pandemic has had an adverse effect on our business and results of operations and is expected to continue to have further
adverse effects, which could be material, on our business, results of operations, financial condition, liquidity, and capital
investments.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On
March 11, 2020, the World Health Organization declared the COVID-19 outbreak a global pandemic. The COVID-19 pandemic has negatively
impacted the global economy, disrupted supply chains and created significant volatility in financial markets. We have implemented
business policies intended to protect our employees from the spread of COVID-19. Those policies include employees working from
home when possible and employees in our facilities increasing physical distancing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On
March 18, 2020, the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) released guidance for U.S. healthcare providers
to limit all elective medical procedures in order to conserve personal protective equipment and limit exposure to COVID-19 during
the pendency of the pandemic. Many of our customers use our products in procedures impacted by the guidance. In addition to limiting
medical procedures, many hospitals and other healthcare providers have strictly limited access to their facilities during the
pandemic. We cannot predict the duration or scope of the pandemic, actions that may be taken by governments and businesses in
response to the pandemic, or the impacts of the pandemic on healthcare systems. The impacts of the pandemic may include, but are
not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Reduced
    revenues from our customers, including our major customers, whose products are impacted by CMS guidance to limit elective
    medical procedures;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Diminished
    ability or willingness of third parties to market, distribute and sell our products, due to reduced demand from, or lack of
    access to, healthcare facilities and providers;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Diminished
    ability, or inability, to complete clinical trials and other activities required to achieve regulatory clearance of our products
    under development due to lack of access to healthcare facilities, healthcare providers and patients;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Diminished
    or lost access to third party service providers that we use in our research and development or marketing efforts;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Reduced
    cash flow from our operations due to reductions in revenues or collections from our customers and increases in operating costs
    related to actions we have taken in response to the pandemic;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Reduced
    business productivity due to inefficiencies in employees working from home or increasing physical distancing and other pandemic
    response protocols in our production facilities;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Increased
    susceptibility to the risk of information technology security breaches and other disruptions due to increased volumes of remote
    access to our information systems from our employees working at home;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Inability
    to source sufficient components used in our products due to disruptions in supply chains;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Diminished
    ability to identify, evaluate and acquire, or effectively integrate, complementary businesses, products, materials or technologies
    due to travel restrictions, physical distancing protocols, and lack of access to third party service providers related to
    our development activities;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Loss
    of manufacturing capacity, which could lead to failures to meet product delivery commitments, or increased operating costs
    if one of our facilities were to experience a COVID-19 outbreak;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Difficulties
    in assessing and securing intellectual property rights due to lack of access to, or delayed responsiveness of, third party
    service providers or governmental agencies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Diminished
    ability to retain personnel over concerns about workplace exposure to COVID-19, or to hire and effectively train new personnel,
    due to physical distancing protocols; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Impairment
    of goodwill or other assets due to reductions in the fair value of our reporting units.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">These
and other factors relating to, or arising from, the pandemic could have material adverse effects on our business, results of operations,
cash flows, financial condition, and capital investments. Actual or anticipated adverse effects on our cash flows or financial
condition may lead us to seek additional funding. Any future debt financing into which we enter may impose upon us covenants that
restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our
common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. We cannot be certain
that additional funding will be available on acceptable terms, if at all. If we do not have, or are not able to obtain, sufficient
funds, we may have to delay development or commercialization of our products or otherwise curtail our operations. Any of these
events could materially harm our business and operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Business
disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.1pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Our
operations, and those of contract research organizations (or CROs), contractors and consultants, could be subject to power shortages,
telecommunications failures, wildfires, water shortages, floods, earthquakes, hurricanes, typhoons, fires, extreme weather conditions,
medical epidemics, such as the COVID-19 pandemic, and other natural or man-made disasters or business interruptions for which
we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and
financial condition and increase our costs and expenses. Our ability to obtain clinical supplies of our product candidates could
be disrupted if the operations of our contract manufacturers, or the contract manufacturers of our development partners, are affected
by a man-made or natural disaster or other business interruption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.1pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
sell our proprietary formulations primarily through pharmaceutical compounding facilities we own, but we may not be successful
in our efforts to integrate these businesses into our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
currently have two compounding facilities in New Jersey. We may plan to expand our pharmacy operations and personnel and develop
our facilities into a unified group compounding pharmacy facilities. We have developed &#8220;ImprimisRx&#8221; as a uniform brand
for our compounding facilities and ophthalmology focused pharmaceutical compounding business. We have limited experience acquiring,
building or operating compounding pharmacies or other prescription dispensing facilities or commercializing our formulations through
ownership of or licensing arrangements with pharmacies. In addition, as we have in the past purchased and operated certain pharmaceutical
compounding businesses and pharmacies and subsequently divested or sold those associated assets, we may pursue similar strategies
in the future. Those things considered, we may experience difficulties implementing and/or executing on our compounding pharmacy
strategy, including difficulties that arise as a result of our lack of experience, and we may be unsuccessful and our plans may
change materially. For instance:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">we
    have experienced delays and increased costs in relation to expansion efforts;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">we
    may not be able to satisfy applicable federal and state licensing and other requirements for any of our pharmacy businesses
    in a timely manner or at all;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">changes
    to federal and state pharmacy regulations may restrict compounding operations or make them more costly;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">we
    may be unable to achieve or maintain a sufficient physician and patient customer base to sustain our pharmacy operations;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">market
    acceptance of compounding pharmacies generally may be curtailed or delayed; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">we
    may not be able to enter into licensing or other arrangements with third-party pharmacies or outsourcing facilities when desired,
    on acceptable terms or at all.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Moreover,
all our efforts to expand pharmacy operations will involve significant costs and other resources, which we may not be able to
afford and may disrupt our other operations and distract management and employees from the other aspects of our business. As a
result, our business could materially suffer if we are unable to further develop a group of unified compounding facilities and,
even if we are successful, we may be unable to generate sufficient revenue to recover our costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>If
we do not successfully identify and acquire rights to potential formulations and successfully integrate them into our operations,
our growth opportunities may be limited.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
plan to pursue the development of new proprietary compounded formulations in the ophthalmology and/or other therapeutic areas,
which may include continued activities to develop and commercialize current assets or, if and as opportunities arise, potential
acquisitions of new intellectual property rights and assets. We also intend to seek opportunities to introduce new lower-cost
compounded formulation alternatives to higher-priced FDA-approved drugs. However, we expect acquisitions of compounding pharmacies
to provide us with only limited research and development support and access to additional novel compounded formulations. We have
historically relied, and we expect to continue to rely, primarily upon third parties to provide us with additional development
opportunities. We may seek to enter into acquisition agreements or licensing arrangements to obtain rights to develop new formulations
in the future, but only if we are able to identify attractive formulations and negotiate acquisition or license agreements on
terms acceptable to us, which we may not be able to do. Moreover, we have limited resources to acquire additional potential product
development assets and integrate them into our business. Acquisition opportunities may involve competition among several potential
purchasers, which could include large multi-national pharmaceutical companies and other competitors that have access to greater
financial resources than we do. If we are unable to obtain rights to development opportunities from third parties and we are unable
to rely upon our compounding pharmacies and current and future relationships with pharmacists, physicians and other inventors
to provide us with additional development opportunities, our growth and prospects could be limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
product development strategy is to focus on a select few therapeutic areas in which we believe there is broad market potential,
large unmet needs and/or unique value to physicians and patients and to develop and offer formulations within these therapeutic
areas that could afford us with gross margins. However, our expectations and assumptions about market potential and patient needs
may prove to be wrong, and we may invest capital and other resources on formulations that do not generate sufficient revenues
for us to recoup our investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
have in the past and may in the future participate in strategic transactions that could impact our liquidity, increase our expenses
and distract our management. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">From
time to time we consider engaging in strategic transactions, such as out-licensing or in-licensing of compounds or technologies,
acquisitions of companies, and asset purchases. We may also consider a variety of different business arrangements in the future,
including strategic partnerships, joint ventures, spin-offs, restructurings, divestitures, business combinations and investments.
In addition, another entity may pursue us or certain of our assets or aspects of our operations as an acquisition target. Any
such transactions may require us to incur expenses specific to the transaction and not incident to our operations, may increase
our near- and long-term expenditures, may pose significant integration challenges, may require us to hire or otherwise engage
personnel with additional expertise, or may result in our selling or licensing of our assets or technologies under terms that
may not prove profitable, any of which could harm our operations and financial results. Such transactions may also entail numerous
other operational and financial risks, including, among others, exposure to unknown liabilities, disruption of our business and
diversion of our management&#8217;s time and attention in order to develop acquired products, drug candidates, technologies or
businesses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
part of our efforts to complete any significant transaction, we would need to expend significant resources to conduct business,
legal and financial due diligence, with the goal of identifying and evaluating material risks involved in the transaction. We
may be unsuccessful in ascertaining or evaluating all the risks and, as a result, we may not realize the expected benefits of
the transaction, whether due to unidentified risks, integration difficulties, regulatory setbacks or other events. We may incur
material liabilities for the past activities of any businesses we partner with or acquire. If any of these events occur, we could
be subject to significant costs and damage to our reputation, business, results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our
business and operations would suffer in the event of cybersecurity or other system failures. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Despite
the implementation of security measures, our internal computer systems and those of any third parties with which we partner are
vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical
failures. While we have not experienced any cybersecurity or system failure, accident or breach to date, if an event were to occur,
it could result in a material disruption of our operations, substantial costs to rectify or correct the failure, if possible,
and potentially violation of HIPAA and other privacy laws applicable to our operations. For example, the CCPA became effective
on January 1, 2020 and gave California residents expanded rights to access and require deletion of their personal information,
opt out of certain personal information sharing and receive detailed information about how their personal information is used.
The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that may increase
data breach litigation. Although the CCPA includes exemptions for certain clinical trials data, and HIPAA-protected health information,
the law may increase our compliance costs and potential liability with respect to other personal information we collect about
California residents. The CCPA has prompted a number of proposals for new federal and state privacy legislation. Other countries
also have, or are developing, laws governing the collection, use and transmission of personal information, such as the GDPR in
the EU that became effective in May 2018 and the Personal Information Protection and Electronic Documents Act that became effective
in Canada in April 2000. We anticipate that over time we may expand our business to include operations outside of the United States.
With such expansion, we would be subject to increased governmental regulation in the EU countries in which we might operate, including
the GDPR. These laws and similar laws adopted in the future could increase our potential liability, increase our compliance costs
and adversely affect our business. If any disruption or security breach resulted in a loss of or damage to our data or applications
or inappropriate disclosure of confidential or protected information, we could incur liability, further development of our proprietary
formulations could be delayed, and our pharmacy operations could be disrupted, subject to restriction or forced to terminate their
operations, any of which could severely harm our business and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Unstable
market and economic conditions may have serious adverse consequences on our business, financial condition and stock price. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.1pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">From
time to time, including recently as a result of the COVID-19 pandemic, global credit and financial markets have experienced extreme
volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence,
declines in economic growth, increases in unemployment rates and uncertainty about economic stability. Our general business strategy
may be adversely affected by any such economic downturn, volatile business environment and continued unpredictable and unstable
market conditions. If the equity and credit markets deteriorate it may make any debt or equity financing more difficult to complete,
more costly, and more dilutive. In the event the Company or one of its subsidiaries needed to access additional capital, failure
to secure financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial
performance and stock price and could require us to delay or abandon development plans. In addition, there is a risk that one
or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly
affect our ability to attain our operating goals on schedule and on budget.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 28.1pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Risks
Related to Regulatory Approval and Other Legal Compliance Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our
business is significantly impacted by state and federal statutes and regulations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
proprietary formulations are comprised of active pharmaceutical ingredients that are components of drugs that have received marketing
approval from the FDA, although our proprietary compounded formulations have not themselves received FDA approval. FDA approval
is not required in order to market and sell our compounded formulations. In the future, we may choose to pursue FDA approval to
market and sell certain potential drug candidates. The marketing and sale of compounded formulations is subject to and must comply
with extensive state and federal statutes and regulations governing compounding pharmacies. These statutes and regulations include,
among other things, restrictions on compounding for office use or in advance of receiving a patient-specific prescription or,
for outsourcing facilities, requirements regarding preparation, such as regular FDA inspections and cGMP requirements, prohibitions
on compounding drugs that are essentially copies of FDA-approved drugs, limitations on the volume of compounded formulations that
may be sold across state lines, and prohibitions on wholesaling or reselling. These and other restrictions on the activities of
compounding pharmacies and outsourcing facilities may significantly limit the market available for compounded formulations, compared
to the market available for FDA-approved drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
pharmacy business is impacted by federal and state laws and regulations governing the following: the purchase, distribution, management,
compounding, dispensing, reimbursement, marketing and labeling of prescription drugs and related services including: FDA and/or
state regulation affecting the pharmacy and pharmaceutical industries, including state pharmacy licensure and registration or
permit standards; rules and regulations issued pursuant to HIPAA and other state and federal laws related to the use, disclosure
and transmission of health information; and state and federal controlled substance laws. Our failure to comply with any of these
laws and regulations could severely limit or curtail our pharmacy operations, which would materially harm our business and prospects.
Further, our business could be adversely affected by changes in these or any newly enacted laws and regulations, and federal and
state agency interpretations of the statutes and regulations. Statutory or regulatory changes could require us to make changes
to our business model and operations and/or could require us to incur significantly increased costs to comply with such regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
July 30, 2020, the FDA issued a notice for comments related to certain bulk drug substances to be removed from the 503B Bulk&#8217;s
List (or Category 1 List). Included in this notice for comment were certain bulk drug substances which we currently use in some
of our compounded products. In the event one or more of these bulk substances are ultimately removed from the Category 1 List,
we intend to utilize commercially available versions of these substances or similar active pharmaceutical ingredients as replacements
of the bulk powders contained in our sterile products. In addition, nothing in the FDA&#8217;s notice affects the dispensing of
bulk powder-containing products from our 503A pharmacy. Nonetheless, if all or some of the bulk drug substances we use are removed
from the 503B Bulk&#8217;s List, this may result in a disruption in our operations, revenues and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On
October 27, 2020, the FDA announced availability of a final Memorandum of Understanding, Addressing Certain Distributions of Compounded
Human Drug Products Between the State Board of Pharmacy or Other Appropriate State Agency and the Food and Drug Administration
(the &#8220;MOU&#8221;). The MOU describes the responsibilities of a state board of pharmacy, or other appropriate state agency
that chooses to sign the MOU, in investigating and responding to complaints related to drug products compounded in such state
and distributed outside such state and in addressing the interstate distribution of inordinate amounts of compounded human drug
products. Additionally, as part of the MOU, FDA refined the definition of &#8220;inordinate amount,&#8221; a threshold for certain
information identification and sharing which does not place a limit on the distribution of compounded human drug products interstate
by a pharmacy located in a state that has entered into the MOU. Section 503A of the FDCA sets a five percent limit on compounded
drugs distributed outside the state by a pharmacist, pharmacy or physician located in a state that has not entered into the MOU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">States
have 365 days to sign the MOU, before the FDA intends to enforce the five percent limit described in Section 503A of the FDCA
in states that have not signed the MOU. Our pharmacy is based in the state of New Jersey, and we believe the state board of pharmacy
in New Jersey will sign the MOU and as a result, our operations will not be materially affected by the MOU. In the event New Jersey
does not sign the MOU, our pharmacy that operates under Section 503A may be materially affected, and we will transition as many
prescription orders as possible to our outsourcing facility, which is not subject to the MOU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>If
one of our pharmacies fails to comply with state statutes and regulations, the pharmacy could be required to cease operations
or become subject to restrictions that could adversely affect our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">State
pharmacy laws require pharmacy locations in those states be licensed as an in-state pharmacy to dispense pharmaceuticals. In addition,
state controlled substance laws require registration and compliance with state pharmacy licensure, registration or permit standards
promulgated by the state&#8217;s pharmacy licensing authority. Pharmacy and controlled substance laws often address the qualification
of an applicant&#8217;s personnel, the adequacy of its prescription fulfillment and inventory control practices and the adequacy
of its facilities. If one of our pharmacies, or one with which we may partner, is found not to comply with state pharmacy and
controlled substance laws and regulations, the pharmacy could be required to cease operations or become subject to burdensome
restrictions and limitations on its business. For example, in March 2018, the California Board of Pharmacy filed an accusation
against our subsidiary Park related to a compounded formulation we believe was legally dispensed and was, without our knowledge,
inappropriately administered to a patient unknown to us, by the prescribing healthcare professionals. While we dispute all claims
against Park, we did enter into a settlement agreement with the California Board of Pharmacy and surrendered Park&#8217;s pharmacy
license and ceased its sterile compounding operations. We have transferred approximately half of Park&#8217;s business to our
New Jersey based pharmacy. Although we distribute our proprietary formulations through other compounding pharmacies, and not solely
through Park, the loss of Park&#8217;s ability to compound sterile formulations could have an adverse impact on our ability to
implement our business plan in a timely manner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>If
we or our partner facilities fail to comply with the Controlled Substances Act, FDCA, or similar state statutes and regulations,
the pharmacy facilities could be required to cease operations or become subject to restrictions that could adversely affect our
business. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">State
pharmacy laws require pharmacy locations in those states to be licensed as an in-state pharmacy to dispense pharmaceuticals. In
addition, state controlled substance laws require registration and compliance with state pharmacy licensure, registration or permit
standards promulgated by the state&#8217;s pharmacy licensing authority. Pharmacy and controlled substance laws often address
the qualification of an applicant&#8217;s personnel, the adequacy of its prescription fulfillment and inventory control practices
and the adequacy of its facilities. These laws also subject pharmacies to oversight by state boards of pharmacy and other regulators
that could impose burdensome requirements or restrictions on operations if a pharmacy is found not in compliance with these laws.
We believe that our compounding pharmacies are in material compliance with applicable regulatory requirements. Further, if any
of our compounding pharmacies (including Park) fail to comply with regulatory requirements, they could be forced to permanently
or temporarily cease or limit their compounding operations, which would severely limit our ability to market and sell our proprietary
formulations and would materially harm our operations and prospects. Any noncompliance could also result in complaints or adverse
actions by other state boards of pharmacy. FDA inspection of a facility to determine compliance with the FDCA, if not successful,
may result in the loss of FDCA exemptions provided under Sections 503A and 503B, warning letters, injunctions, prosecution, fines
and loss of required government licenses, certifications and approvals, any of which could involve significant costs and could
cause us to be unable to realize the expected benefits of these pharmacies&#8217; operations. Additionally, the permanent injunction
entered on July 22, 2019, by the United States District Court of the Central District of California in the Allergan litigation
(also referenced in Item. 3 Legal Proceedings), enjoins the Company from engaging in activities that are inconsistent with current
FDA guidelines for 503A and 503B operations. While the Company believes its operations fully comply with the injunction, if the
Court were to find the Company to be in violation of the injunction, further sanctions including fines and limitations on the
pharmacies&#8217; operations could occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>If
we seek FDA approval to market and sell any of our proprietary formulations, such as drug candidates that we have royalty interests
in that are being developed by Melt and Surface, we may be unable to demonstrate the necessary safety and efficacy to obtain such
FDA approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Historically,
our business strategy was focused on developing and commercializing product opportunities as compounded formulations. We recently
have, and in the future may, alone or with project partners, seek FDA regulatory approval to market and sell one or more of our
assets as a FDA-approved drug. Obtaining FDA approval to market and sell pharmaceutical products is costly, time consuming, uncertain
and subject to unanticipated delays. The FDA or other regulatory agencies may not approve a drug candidate on a timely basis or
at all. Before we obtain FDA approval for the sale of any potential drug candidates, we will be required to demonstrate through
preclinical studies and clinical trials that it is safe and effective for each intended use, which we may not be able to do. A
failure to demonstrate safety and efficacy of a drug candidate to the FDA&#8217;s satisfaction would result in our failure to
obtain FDA approval. Moreover, even if the FDA were to grant regulatory approval of a drug candidate, the approval may be limited
to specific therapeutic areas or limited as to its distribution, which could reduce revenue potential, and we will be subject
to extensive and costly post-approval requirements and oversight with respect to commercialization of the drug candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>If
a compounded drug formulation provided through our compounding services leads to patient injury or death or results in a product
recall, we may be exposed to significant liabilities and reputational harm.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
success of our business, including our proprietary formulations and pharmacy operations, is highly dependent upon medical and
patient perceptions of us and the actual safety and quality of our products. We could be adversely affected if we, any other compounding
pharmacies or our formulations and technologies are subject to negative publicity. We could also be adversely affected if any
of our formulations or other products we sell, any similar products sold by other companies, or any products sold by other compounding
pharmacies prove to be, or are asserted to be, harmful to patients. For instance, if any of the components of approved drugs or
other ingredients used to produce our compounded formulations have quality or other problems that adversely affect the finished
compounded preparations, our sales could be adversely affected. Because of our dependence upon medical and patient perceptions,
adverse publicity associated with illness or other adverse effects resulting from the use or misuse of our products, any similar
products sold by other companies, or any other compounded formulations could have a material adverse impact on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">To
assure compliance with USP guidelines, we have a policy whereby 100% of all sterile compound batches produced by our ImprimisRx
compounding pharmacies are tested prior to their delivery to patients and physicians both in-house and externally by an independent,
FDA-registered laboratory that has represented to us that it operates in compliance with current good laboratory practices. However,
we could still become subject to product recalls and termination or suspension of our state pharmacy licenses if we fail to fully
implement this policy, if the laboratory testing does not identify all contaminated products, or if our products otherwise cause
or appear to have caused injury or harm to patients. In addition, laboratory testing may produce false positives, which could
harm our business and impact our pharmacy operations and licensure even if the impacted formulations are ultimately found to be
sterile and no patients are harmed by them. If adverse events or deaths or a product recall, either voluntarily or as required
by the FDA or a state board of pharmacy, were associated with one of our proprietary formulations or any compounds prepared by
our ImprimisRx compounding pharmacies or any pharmacy partner, our reputation could suffer, physicians may be unwilling to prescribe
our proprietary formulations or order any prescriptions from such pharmacies, we could become subject to product and professional
liability lawsuits, and our state pharmacy licenses could be terminated or restricted. If any of these events were to occur, we
may be subject to significant litigation or other costs and loss of revenue, and we may be unable to continue our pharmacy operations
and further develop and commercialize our proprietary formulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
carry product and professional liability insurance which may be inadequate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Although
we have secured product and professional liability insurance for our pharmacy operations and the marketing and sale of our formulations,
our current or future insurance coverage may prove insufficient to cover any liability claims brought against us. Because of the
increasing costs of insurance coverage, we may not be able to maintain insurance coverage at a reasonable cost or at a level adequate
to satisfy liabilities that may arise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Risks
Related to Human Capital Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
are dependent on our Chief Executive Officer, Mark L. Baum, and other key persons for the continued growth and development of
our Company.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
Chief Executive Officer, Mark L. Baum, has played a primary role in creating and developing our current business model. Further,
Mr. Baum has played a primary role in securing much of our material intellectual property rights and related assets, as well as
the means to make and distribute our current products. We are highly dependent on Mr. Baum for the implementation of our business
plan and the future development of our assets and our business, and the loss of Mr. Baum&#8217;s services and leadership would
likely materially adversely impact our Company. We presently maintain key man insurance for Mr. Baum. In addition, our loan agreement
identifies other key persons including, but not limited to, our Chief Financial Officer, Andrew R. Boll, and the President of
ImprimisRx, John P. Saharek.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>If
we are unable to attract and retain key personnel and consultants, we may be unable to maintain or expand our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have been focusing on building our management, pharmacy, research and development, sales and marketing and other personnel to
pursue our current business model. To achieve our planned growth, we may have significant difficulty attracting and retaining
necessary employees. Because of the specialized nature of our business, the ability to develop products and to compete will remain
highly dependent upon our ability to attract and retain qualified pharmacy, scientific, technical and commercial employees and
consultants. There is intense competition to hire qualified personnel in our industry, and we may be unable to continue to attract
and retain the qualified personnel necessary for the development of our business. The loss of key employees or consultants or
the failure to recruit or engage new employees and consultants could have a material adverse effect on our business. In addition,
any <span style="background-color: white">staffing interruptions resulting from geopolitical actions, including war and terrorism,
adverse public health developments such as the outbreak of the COVID-19 novel coronavirus, or natural disasters including earthquakes,
typhoons, floods and fires, could have a material adverse effect on our business.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>If
we are unable to establish, train and maintain an effective sales and marketing infrastructure, we will not be able to commercialize
our drug candidates successfully.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have started to build an internal sales and marketing infrastructure to implement our business plan by developing internal sales
teams and education campaigns to market our proprietary formulations. We will need to expend significant resources to further
establish and grow this internal infrastructure and properly train sales personnel with respect to regulatory compliance matters.
We may also choose to engage or enter into other arrangements with third parties to provide sales and marketing services for us
in place of or to supplement our internal commercialization infrastructure. We may not be able to secure sales personnel or relationships
with third-party sales organizations that are adequate in number or expertise to successfully market and sell our proprietary
formulations and pharmacy services. Further, any third-party organizations we may seek to partner with or engage may not be able
to provide sales and marketing services in accordance with our expectations and standards, may be more expensive than we can afford
or may not be available on otherwise acceptable terms or at all. If we are unable to establish and maintain compliant and adequate
sales and marketing capabilities, through our own internal infrastructure or third-party services or other arrangements, we may
be unable to sell our formulations or services or generate meaningful revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
depend upon consultants, outside contractors and other third-party service providers for key aspects of our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
are substantially dependent on consultants and other outside contractors and service providers for key aspects of our business.
For instance, we rely upon pharmacist, physician and research consultants and advisors to provide us with significant assistance
in the evaluation of product development opportunities, and we have engaged or supported, and expect to continue to engage or
support, consultants, advisors, clinical research organizations (&#8220;CROs&#8221;) and others to design, conduct, analyze and
interpret the results of any clinical or non-clinical trials or other studies in connection with the research and development
of our products. If any of our consultants or other service providers terminates its engagement with us, or if we are unable to
engage highly qualified replacements as needed on commercially reasonable terms, we may be unable to successfully execute our
business plan. We must effectively manage these third-party service providers to ensure that they successfully carry out their
contractual obligations and meet expected deadlines. However, these third parties often engage in other business activities and
may not devote sufficient time and attention to our activities, and we may have only limited contractual rights in connection
with the conduct of the activities we have engaged the service providers to perform. If we are unable to effectively manage our
outsourced activities or if the quality, timeliness or accuracy of the services provided by third-party service providers is compromised
for any reason, our development activities may be extended, delayed or terminated, and we may not be able to commercialize our
formulations or advance our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Risks
Related to Product Development </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Delays
in the completion of, or the termination of, any clinical or non-clinical trials for any drug candidates for which we may seek
FDA approval could adversely affect our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Clinical
trials are very expensive, time consuming, unpredictable and difficult to design and implement. The results of clinical trials
may be unfavorable, they may continue for several years, and they may take significantly longer to complete and involve significantly
more costs than expected. Delays in the commencement or completion of clinical testing could significantly affect product development
costs and plans with respect to any drug candidate for which we seek FDA approval. The commencement and completion of clinical
trials can be delayed and experience difficulties for a number of reasons, including delays and difficulties caused by circumstances
over which we may have no control. For instance, approvals of the scope, design or trial site may not be obtained from the FDA
and other required bodies in a timely manner or at all, agreements with acceptable terms may not be reached in a timely manner
or at all with CROs to conduct the trials, a sufficient number of subjects may not be recruited and enrolled in the trials, and
third-party manufacturers of the materials for use in the trials may encounter delays and problems in the manufacturing process,
including failure to produce materials in sufficient quantities or of an acceptable quality to complete the trials. If we were
to experience delays in the commencement or completion of, or if we were to terminate, any clinical or non-clinical trials we
pursue in the future, the commercial prospects for the applicable drug candidates may be limited or eliminated, which may prevent
us from recouping our investment in research and development efforts for the drug candidate and would have a material adverse
effect on our business, results of operations, financial condition and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
depend on the success of our drug candidates, and those we have royalty rights to, which have not yet demonstrated efficacy for
their target or any other indications. If we are unable to generate revenues from our drug candidates, our ability to create stockholder
value will be limited. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
drug candidates are in the early stages of clinical development. We do not generate revenues from any FDA-approved drug products.
We expect to submit an IND or foreign equivalent to the FDA or international regulatory authorities seeking approval to initiate
our clinical trials in humans in the United States or other countries yet to be determined. We plan on submitting our clinical
trial protocols and receive approvals from the FDA and international regulatory authorities before we can commence any clinical
trials. We may not be successful in obtaining acceptance from the FDA or comparable foreign regulatory authorities to start our
clinical trials. If we do not obtain such acceptance, the time in which we expect to commence clinical programs for any drug candidate
will be extended and such extension will increase our expenses and increase our need for additional capital. Moreover, there is
no guarantee that our clinical trials will be successful or that we will continue clinical development in support of an approval
from the FDA or comparable foreign regulatory authorities for any indication. We note that most drug candidates never reach the
clinical development stage and even those that do commence clinical development have only a small chance of successfully completing
clinical development and gaining regulatory approval. Therefore, our business currently depends entirely on the successful development,
regulatory approval and commercialization of our drug candidates, which may never occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>If
we are not able to obtain any required regulatory approvals for our drug candidates, we will not be able to commercialize our
drug candidate and our ability to generate revenue will be limited. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
must successfully complete clinical trials for our drug candidates before we can apply for marketing approval. Even if we complete
our clinical trials, it does not assure marketing approval. Our clinical trials may be unsuccessful, which would materially harm
our business. Even if our initial clinical trials are successful, we are required to conduct additional clinical trials to establish
our drug candidates&#8217; safety and efficacy, before an NDA or Biologics License Application (&#8220;BLA&#8221;), or their foreign
equivalents can be filed with the FDA or comparable foreign regulatory authorities for marketing approval of our drug candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Clinical
testing is expensive, is difficult to design and implement, can take many years to complete and is uncertain as to outcome. Success
in early phases of pre-clinical and clinical trials does not ensure that later clinical trials will be successful, and interim
results of a clinical trial do not necessarily predict final results. A failure of one or more of our clinical trials can occur
at any stage of testing. We may experience numerous unforeseen events during, or as a result of, the clinical trial process that
could delay or prevent our ability to receive regulatory approval or commercialize our drug candidates. The research, testing,
manufacturing, labeling, packaging, storage, approval, sale, marketing, advertising and promotion, pricing, export, import and
distribution of drug products are subject to extensive regulation by the FDA and other regulatory authorities in the United States
and other countries, which regulations differ from country to country. We are not permitted to market our drug candidates as prescription
pharmaceutical products in the United States until we receive approval of an NDA from the FDA, or in any foreign countries until
we receive the requisite approval from such countries. In the United States, the FDA generally requires the completion of clinical
trials of each drug to establish its safety and efficacy and extensive pharmaceutical development to ensure its quality before
an NDA is approved. Regulatory authorities in other jurisdictions impose similar requirements. Of the large number of drugs in
development, only a small percentage result in the submission of an NDA to the FDA and even fewer are eventually approved for
commercialization. We have not submitted an NDA to the FDA or comparable applications to other regulatory authorities. If our
development efforts for our drug candidates, including regulatory approval, are not successful for their planned indications,
or if adequate demand for our drug candidates is not generated, our business will be materially adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
success depends on the receipt of regulatory approval and the issuance of such regulatory approvals is uncertain and subject to
a number of risks, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    results of toxicology studies may not support the filing of an IND for our drug candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    FDA or comparable foreign regulatory authorities or Institutional Review Boards, or &#8220;IRB,&#8221; may disagree with the
    design or implementation of our clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">we
    may not be able to provide acceptable evidence of our drug candidates&#8217; safety and efficacy;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    results of our clinical trials may not be satisfactory or may not meet the level of statistical or clinical significance required
    by the FDA, European Medicines Agency (the &#8220;EMA&#8221;), or other regulatory agencies for marketing approval;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    dosing of our drug candidates in a particular clinical trial may not be at an optimal level;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">patients
    in our clinical trials may suffer adverse effects for reasons that may or may not be related to our drug candidates;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    data collected from clinical trials may not be sufficient to support the submission of an NDA, BLA or other submission or
    to obtain regulatory approval in the United States or elsewhere;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party
    manufacturers with which we contract for clinical and commercial supplies; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner
    rendering our clinical data insufficient for approval.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Failure
to obtain regulatory approval for our drug candidates for the foregoing, or any other reasons, will prevent us from commercializing
our drug candidates, and our ability to generate revenue will be materially impaired. We cannot guarantee that regulators will
agree with our assessment of the results of the clinical trials we intend to conduct in the future or that such trials will be
successful. The FDA, EMA and other regulators have substantial discretion in the approval process and may refuse to accept any
application or may decide that our data is insufficient for approval and require additional clinical trials, or pre-clinical or
other studies. In addition, varying interpretations of the data obtained from pre-clinical and clinical testing could delay, limit
or prevent regulatory approval of our drug candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Excluding
any activities through our ownership interest in Eton, we have not submitted an NDA or received regulatory approval to market
our drug candidates in any jurisdiction. We have only limited experience in filing the applications necessary to gain regulatory
approvals and expect to rely on consultants and third party contract research organizations, or &#8220;CROs,&#8221; with expertise
in this area to assist us in this process. Securing regulatory approvals to market a product requires the submission of pre-clinical,
clinical, and/or pharmacokinetic data, information about product manufacturing processes and inspection of facilities and supporting
information to the appropriate regulatory authorities for each therapeutic indication to establish a drug candidate&#8217;s safety
and efficacy for each indication. Our drug candidates may prove to have undesirable or unintended side effects, toxicities or
other characteristics that may preclude us from obtaining regulatory approval or prevent or limit commercial use with respect
to one or all intended indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
process of obtaining regulatory approvals is expensive, often takes many years, if approval is obtained at all, and can vary substantially
based upon, among other things, the type, complexity and novelty of the drug candidates involved, the jurisdiction in which regulatory
approval is sought and the substantial discretion of the regulatory authorities. Changes in regulatory approval policies during
the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for
a submitted product application may cause delays in the approval or rejection of an application. Regulatory approval obtained
in one jurisdiction does not necessarily mean that a drug candidate will receive regulatory approval in all jurisdictions in which
we may seek approval, but the failure to obtain approval in one jurisdiction may negatively impact our ability to seek approval
in a different jurisdiction. Failure to obtain regulatory marketing approval for our drug candidates in any indication will prevent
us from commercializing the drug candidate, and our ability to generate revenue will be materially impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>If
we fail to successfully commercialize any of our drug candidates, we may need to acquire additional drug candidates and our business
will be adversely affected. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have never commercialized any drug candidates and do not have any other compounds in pre-clinical testing, lead optimization or
lead identification stages beyond our drug candidates. We cannot be certain that any of our drug candidates will prove to be sufficiently
effective and safe to meet applicable regulatory standards for any indication. If we fail to successfully commercialize any of
our drug candidates for their targeted indications, whether as stand-alone therapies or in combination with other therapeutic
agents, our business would be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Even
if we receive regulatory approval for any of our drug candidates, we may not be able to successfully commercialize the product
and the revenue that we generate from its sales, if any, may be limited. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">If
approved for marketing, the commercial success of our drug candidates will depend upon each product&#8217;s acceptance by the
medical community, including physicians, patients and health care payors. The degree of market acceptance for any of our drug
candidates will depend on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">demonstration
    of clinical safety and efficacy;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">relative
    convenience, dosing burden and ease of administration;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    prevalence and severity of any adverse effects;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    willingness of physicians to prescribe our drug candidates, and the target patient population to try new therapies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">efficacy
    of our drug candidates compared to competing products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    introduction of any new products that may in the future become available targeting indications for which our drug candidates
    may be approved;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">new
    procedures or therapies that may reduce the incidences of any of the indications in which our drug candidates may show utility;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">pricing
    and cost-effectiveness;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    inclusion or omission of our drug candidates in applicable therapeutic and vaccine guidelines;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    effectiveness of our own or any future collaborators&#8217; sales and marketing strategies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">limitations
    or warnings contained in approved labeling from regulatory authorities;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    ability to obtain and maintain sufficient third-party coverage or reimbursement from government health care programs, including
    Medicare and Medicaid, private health insurers and other third-party payors or to receive the necessary pricing approvals
    from government bodies regulating the pricing and usage of therapeutics; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    willingness of patients to pay out-of-pocket in the absence of third-party coverage or reimbursement or government pricing
    approvals.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">If
any of our drug candidates are approved, but do not achieve an adequate level of acceptance by physicians, health care payors,
and patients, we may not generate sufficient revenue and we may not be able to achieve or sustain profitability. Our efforts to
educate the medical community and third-party payors on the benefits of our drug candidates may require significant resources
and may never be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, even if we obtain regulatory approvals, the timing or scope of any approvals may prohibit or reduce our ability to commercialize
our drug candidates successfully. For example, if the approval process takes too long, we may miss market opportunities and give
other companies the ability to develop competing products or establish market dominance. Any regulatory approval we ultimately
obtain may be limited or subject to restrictions or post-approval commitments that render our drug candidates not commercially
viable. For example, regulatory authorities may approve any of our drug candidates for fewer or more limited indications than
we request, may not approve the price we intend to charge for any of our drug candidates, may grant approval contingent on the
performance of costly post-marketing clinical trials, or may approve any of our drug candidates with a label that does not include
the labeling claims necessary or desirable for the successful commercialization of that indication. Further, the FDA or comparable
foreign regulatory authorities may place conditions on approvals or require risk management plans or a Risk Evaluation and Mitigation
Strategy (&#8220;REMS&#8221;) to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA
must submit a proposed REMS; the FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication
guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries
and other risk minimization tools. The FDA may also require a REMS for an approved product when new safety information emerges.
Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing
of our drug candidates. Moreover, product approvals may be withdrawn for non-compliance with regulatory standards or if problems
occur following the initial marketing of the product. Any of the foregoing scenarios could materially harm the commercial success
of our drug candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Even
if we obtain marketing approval for any of our drug candidates, we will be subject to ongoing obligations and continued regulatory
review, which may result in significant additional expense. Additionally, our drug candidates could be subject to labeling and
other restrictions and withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements
or if we experience unanticipated problems with our drug candidates. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Even
if we obtain regulatory approval for any of our drug candidates for an indication, the FDA or foreign equivalent may still impose
significant restrictions on their indicated uses or marketing or the conditions of approval, or impose ongoing requirements for
potentially costly and time-consuming post-approval studies, including Phase 4 clinical trials, and post-market surveillance to
monitor safety and efficacy. Our drug candidates will also be subject to ongoing regulatory requirements governing the manufacturing,
labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, recordkeeping and reporting of adverse
events and other post-market information. These requirements include registration with the FDA, as well as continued compliance
with current Good Clinical Practices regulations, or &#8220;cGCPs,&#8221; for any clinical trials that we conduct post-approval.
In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the
FDA and other regulatory authorities for compliance with current cGMP, requirements relating to quality control, quality assurance
and corresponding maintenance of records and documents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
FDA has the authority to require a REMS as part of an NDA or after approval, which may impose further requirements or restrictions
on the distribution or use of an approved drug, such as limiting prescribing to certain physicians or medical centers that have
undergone specialized training, limiting treatment to patients who meet certain safe-use criteria or requiring patient testing,
monitoring and/or enrollment in a registry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">With
respect to sales and marketing activities by us or any future partner, advertising and promotional materials must comply with
FDA rules in addition to other applicable federal, state and local laws in the United States and similar legal requirements in
other countries. In the United States, the distribution of product samples to physicians must comply with the requirements of
the U.S. Prescription Drug Marketing Act. Application holders must obtain FDA approval for product and manufacturing changes,
depending on the nature of the change. We may also be subject, directly or indirectly through our customers and partners, to various
fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute, U.S. False Claims Act, and similar state
laws, which impact, among other things, our proposed sales, marketing, and scientific/educational grant programs. If we participate
in the U.S. Medicaid Drug Rebate Program, the Federal Supply Schedule of the U.S. Department of Veterans Affairs, or other government
drug programs, we will be subject to complex laws and regulations regarding reporting and payment obligations. All of these activities
are also potentially subject to U.S. federal and state consumer protection and unfair competition laws. Similar requirements exist
in many of these areas in other countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, if any of our drug candidates are approved for a particular indication, our product labeling, advertising and promotion
would be subject to regulatory requirements and continuing regulatory review. The FDA strictly regulates the promotional claims
that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the
FDA as reflected in the product&#8217;s approved labeling. If we receive marketing approval for our drug candidates, physicians
may nevertheless legally prescribe our products to their patients in a manner that is inconsistent with the approved label. If
we are found to have promoted such off-label uses, we may become subject to significant liability and government fines. The FDA
and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is
found to have improperly promoted off-label uses may be subject to significant sanctions. The federal government has levied large
civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in
off-label promotion. The FDA has also requested that companies enter into consent decrees of permanent injunctions under which
specified promotional conduct is changed or curtailed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">If
we or a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity
or frequency, problems with the facility where the product is manufactured, or we or our manufacturers fail to comply with applicable
regulatory requirements, we may be subject to the following administrative or judicial sanctions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">restrictions
    on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product
    recalls; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">issuance
    of warning letters or untitled letters; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">clinical
    holds; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">injunctions
    or the imposition of civil or criminal penalties or monetary fines; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">suspension
    or withdrawal of regulatory approval; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">suspension
    of any ongoing clinical trials; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">refusal
    to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product
    license approvals; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">suspension
    or imposition of restrictions on operations, including costly new manufacturing requirements; or </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">product
    seizure or detention or refusal to permit the import or export of product. </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
occurrence of any event or penalty described above may inhibit our ability to commercialize our drug candidates and generate revenue.
Adverse regulatory action, whether pre- or post-approval, can also potentially lead to product liability claims and increase our
product liability exposure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Obtaining
and maintaining regulatory approval of our drug candidates in one jurisdiction does not mean that we will be successful in obtaining
regulatory approval of our drug candidates in other jurisdictions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Obtaining
and maintaining regulatory approval of our drug candidates in one jurisdiction does not guarantee that we will be able to obtain
or maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction
may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval
of a drug candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing
and promotion of the drug candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements
and administrative review periods different from those in the United States, including additional preclinical studies or clinical
trials, as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions.
In many jurisdictions outside the United States, a drug candidate must be approved for reimbursement before it can be approved
for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Obtaining
foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties
and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the
regulatory requirements in international markets and/ or to receive applicable marketing approvals, our target market will be
reduced and our ability to realize the full market potential of our drug candidates will be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Current
and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our drug
candidates and affect the prices we may obtain. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed
changes regarding the healthcare system that could prevent or delay marketing approval for our drug candidates, restrict or regulate
post-approval activities and affect our ability to profitably sell our drug candidates. Legislative and regulatory proposals have
been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We do
not know whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will
be changed, or what the impact of such changes on the marketing approvals of our drug candidates, if any, may be. In addition,
increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval,
as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
the United States, the Medicare Modernization Act (&#8220;MMA&#8221;) changed the way Medicare covers and pays for pharmaceutical
products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology
based on average sales prices for drugs. In addition, this legislation authorized Medicare Part D prescription drug plans to use
formularies where they can limit the number of drugs that will be covered in any therapeutic class. As a result of this legislation
and the expansion of federal coverage of drug products, we expect that there will be additional pressure to contain and reduce
costs. These cost reduction initiatives and other provisions of this legislation could decrease the coverage and price that we
receive for our drug candidates and could seriously harm our business. While the MMA applies only to drug benefits for Medicare
beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement
rates, and any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private
payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Health Care Reform Law is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare
spending, enhance remedies against fraud and abuse, add new transparency requirements for healthcare and health insurance industries,
impose new taxes and fees on the health industry and impose additional health policy reforms. The Health Care Reform Law revised
the definition of &#8220;average manufacturer price&#8221; for reporting purposes, which could increase the amount of Medicaid
drug rebates to states. Further, the law imposed a significant annual fee on companies that manufacture or import branded prescription
drug products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
Health Care Reform Law remains subject to legislative efforts to repeal, modify or delay the implementation of the law. Efforts
to date have generally been unsuccessful. If the Health Care Reform Law is repealed or modified, or if implementation of certain
aspects of the Health Care Reform Law are delayed, such repeal, modification or delay may materially adversely impact our business,
strategies, prospects, operating results or financial condition. We are unable to predict the full impact of any repeal or modification
in the implementation of the Health Care Reform Law on us at this time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, other legislative changes have been proposed and adopted in the United States since the Health Care Reform Law was enacted.
We expect that additional federal healthcare reform measures will be adopted in the future, any of which could limit the amounts
that federal and state governments will pay for healthcare products and services, and in turn could significantly reduce the projected
value of certain development projects and reduce or eliminate our profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our
drug candidates may face competition sooner than expected. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
success will depend in part on our ability to obtain and maintain patent protection for our certain of our drug candidates and
technologies and to prevent third parties from infringing upon our proprietary rights. We must also operate without infringing
upon patents and proprietary rights of others, including by obtaining appropriate licenses to patents or other proprietary rights
held by third parties, if necessary. However, the applications we have filed or may file in the future may never yield patents
that protect our inventions and intellectual property assets. Failure to obtain patents that sufficiently cover our formulations
and technologies would limit our protection against compounding pharmacies, outsourcing facilities, generic drug manufacturers,
pharmaceutical companies and other parties who may seek to copy our products, produce products substantially similar to ours or
use technologies substantially similar to those we own.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
also intend to seek data exclusivity or market exclusivity for our drug candidates provided under the FDCA, and similar laws in
other countries. The FDCA provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing
NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are
deemed by the FDA to be essential to the approval of the application, for example, for new indications, dosages, or strengths
of an existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations and
does not prohibit the FDA from approving NDAs for drugs containing the original active agent. Even if our drug candidates are
considered to be reference products eligible for three years of exclusivity under the FDCA, another company could market competing
products if the FDA approves a full NDA for such product containing the sponsor&#8217;s own preclinical data and data from adequate
and well-controlled clinical trials to demonstrate the safety, purity and potency of the products. Moreover, an amendment or repeal
of the FDCA could result in a shorter exclusivity period for our drug candidates, which would have a material adverse effect on
our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>If
we market any of our drug candidates in a manner that violates healthcare fraud and abuse laws, or if we violate government price
reporting laws, we may be subject to civil or criminal penalties. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
FDA enforces laws and regulations which require that the promotion of pharmaceutical products be consistent with the approved
prescribing information. While physicians may prescribe an approved product for a so-called &#8220;off label&#8221; use, it is
unlawful for a pharmaceutical company to promote its products in a manner that is inconsistent with its approved label and any
company which engages in such conduct can subject that company to significant liability. Similarly, industry codes in the EU and
other foreign jurisdictions prohibit companies from engaging in off-label promotion and regulatory agencies in various countries
enforce violations of the code with civil penalties. While we intend to ensure that our promotional materials are consistent with
our label, regulatory agencies may disagree with our assessment and may issue untitled letters, warning letters or may institute
other civil or criminal enforcement proceedings. In addition to FDA restrictions on marketing of pharmaceutical products, several
other types of state and federal healthcare fraud and abuse laws have been applied in recent years to restrict certain marketing
practices in the pharmaceutical industry. These laws include the U.S. Anti-Kickback Statute, U.S. False Claims Act and similar
state laws. Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business
activities could be subject to challenge under one or more of these laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
U.S. Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration
to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item
or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted
broadly to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary
managers on the other. Although there are several statutory exemptions and regulatory safe harbors protecting certain common activities
from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce
prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Our
practices may not, in all cases, meet all of the criteria for safe harbor protection from anti-kickback liability. Moreover, recent
health care reform legislation has strengthened these laws. For example, the Health Care Reform Law, among other things, amends
the intent requirement of the U.S. Anti-Kickback Statute and criminal health care fraud statutes; a person or entity no longer
needs to have actual knowledge of this statute or specific intent to violate it. In addition, the Health Care Reform Law provides
that the government may assert that a claim including items or services resulting from a violation of the U.S. Anti-Kickback Statute
constitutes a false or fraudulent claim for purposes of the U.S. False Claims Act. Federal false claims laws prohibit any person
from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making,
or causing to be made, a false statement to get a false claim paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Over
the past few years, several pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety
of alleged promotional and marketing activities, such as: allegedly providing free trips, free goods, sham consulting fees and
grants and other monetary benefits to prescribers; reporting to pricing services inflated average wholesale prices that were then
used by federal programs to set reimbursement rates; engaging in off-label promotion that caused claims to be submitted to Medicare
or Medicaid for non-covered, off-label uses; and submitting inflated best price information to the Medicaid Rebate Program to
reduce liability for Medicaid rebates. Most states also have statutes or regulations similar to the U.S. Anti-Kickback Statute
and the U.S. False Claims Act, which apply to items and services reimbursed under Medicaid and other state programs, or, in several
states, apply regardless of the payor. Sanctions under these federal and state laws may include substantial civil monetary penalties,
exclusion of a manufacturer&#8217;s products from reimbursement under government programs, substantial criminal fines and imprisonment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
will be completely dependent on third parties to manufacture our drug candidates, and our commercialization of our drug candidates
could be halted, delayed or made less profitable if those third parties fail to obtain manufacturing approval from the FDA or
comparable foreign regulatory authorities, fail to provide us with sufficient quantities of our drug candidates or fail to do
so at acceptable quality levels or prices. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
do not currently have, nor do we plan to acquire, the capability or infrastructure to manufacture the active pharmaceutical ingredient,
(&#8220;API&#8221;), in our drug candidates for use in our clinical trials or for commercial product, if any. In addition, we
do not have the capability to encapsulate any of our drug candidates as a finished drug product for commercial distribution. As
a result, we will be obligated to rely on contract manufacturers, if and when any of our drug candidates are approved for commercialization.
We have not entered into an agreement with any contract manufacturers for commercial supply and may not be able to engage a contract
manufacturer for commercial supply of any of our drug candidates on favorable terms to us, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
facilities used by our contract manufacturers to manufacture our drug candidates must be approved by the FDA or comparable foreign
regulatory authorities pursuant to inspections that will be conducted after we submit an NDA or BLA to the FDA or their equivalents
to other relevant regulatory authorities. We will not control the manufacturing process of, and will be completely dependent on,
our contract manufacturing partners for compliance with cGMPs for manufacture of both active drug substances and finished drug
products. These cGMP regulations cover all aspects of the manufacturing, testing, quality control and record keeping relating
to our drug candidates. If our contract manufacturers do not successfully manufacture material that conforms to our specifications
and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain regulatory approval
for their manufacturing facilities. If the FDA or a comparable foreign regulatory authority does not approve these facilities
for the manufacture of our drug candidates or if it withdraws any such approval in the future, we may need to find alternative
manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our
drug candidates, if approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
contract manufacturers will be subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign
agencies for compliance with cGMPs and similar regulatory requirements. We will not have control over our contract manufacturers&#8217;
compliance with these regulations and standards. Failure by any of our contract manufacturers to comply with applicable regulations
could result in sanctions being imposed on us, including fines, injunctions, civil penalties, failure to grant approval to market
any of our drug candidates, delays, suspensions or withdrawals of approvals, operating restrictions and criminal prosecutions,
any of which could significantly and adversely affect our business. In addition, we will not have control over the ability of
our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. Failure by our contract
manufacturers to comply with or maintain any of these standards could adversely affect our ability to develop, obtain regulatory
approval for or market any of our drug candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">If,
for any reason, these third parties are unable or unwilling to perform, we may not be able to terminate our agreements with them,
and we may not be able to locate alternative manufacturers or formulators or enter into favorable agreements with them and we
cannot be certain that any such third parties will have the manufacturing capacity to meet future requirements. If these manufacturers
or any alternate manufacturer of finished drug product experiences any significant difficulties in its respective manufacturing
processes for our API or finished products or should cease doing business with us, we could experience significant interruptions
in the supply of any of our drug candidates or may not be able to create a supply of our drug candidates at all. Were we to encounter
manufacturing issues, our ability to produce a sufficient supply of any of our drug candidates might be negatively affected. Our
inability to coordinate the efforts of our third party manufacturing partners, or the lack of capacity available at our third
party manufacturing partners, could impair our ability to supply any of our drug candidates at required levels. Because of the
significant regulatory requirements that we would need to satisfy in order to qualify a new bulk or finished product manufacturer,
if we face these or other difficulties with our current manufacturing partners, we could experience significant interruptions
in the supply of any of our drug candidates if we decided to transfer the manufacture of any of our drug candidates to one or
more alternative manufacturers in an effort to deal with the difficulties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Any
manufacturing problem or the loss of a contract manufacturer could be disruptive to our operations and result in lost sales. Additionally,
we rely on third parties to supply the raw materials needed to manufacture our existing and potential products. Any <span style="background-color: white">business
interruptions resulting from geopolitical actions, including war and terrorism, adverse public health developments such as the
outbreak of the COVID-19 coronavirus, or natural disasters including earthquakes, typhoons, floods and fires, could affect our
supply chain.</span> Any reliance on suppliers may involve several risks, including a potential inability to obtain critical materials
and reduced control over production costs, delivery schedules, reliability and quality. Any unanticipated disruption to a future
contract manufacturer caused by problems at suppliers could delay shipment of any of our drug candidates, increase our cost of
goods sold and result in lost sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
cannot guarantee that our future manufacturing and supply partners will be able to reduce the costs of commercial scale manufacturing
of any of our drug candidates over time. If the commercial-scale manufacturing costs of any of our drug candidates are higher
than expected, these costs may significantly impact our operating results. In order to reduce costs, we may need to develop and
implement process improvements. However, in order to do so, we will need, from time to time, to notify or make submissions with
regulatory authorities, and the improvements may be subject to approval by such regulatory authorities. We cannot be sure that
we will receive these necessary approvals or that these approvals will be granted in a timely fashion. We also cannot guarantee
that we will be able to enhance and optimize output in our commercial manufacturing process. If we cannot enhance and optimize
output, we may not be able to reduce our costs over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
expect to rely on third parties to conduct clinical trials for our drug candidates. If these third parties do not successfully
carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize
any of our drug candidates and our business would be substantially harmed. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
expect to enter into agreements with third-party CROs to conduct and manage our clinical programs including contracting with clinical
sites to perform our clinical studies. We plan to rely heavily on these parties for execution of clinical studies for our drug
candidates and will control only certain aspects of their activities. Nevertheless, we will be responsible for ensuring that each
of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance
on CROs and clinical sites will not relieve us of our regulatory responsibilities. We and our CROs will be required to comply
with cGCPs, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European
Economic Area and comparable foreign regulatory authorities for any products in clinical development. The FDA and its foreign
equivalents enforce these cGCP regulations through periodic inspections of trial sponsors, principal investigators and trial sites.
If we or our CROs fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable
and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving
our marketing applications. We cannot assure you that, upon inspection, the FDA or other regulatory authorities will determine
that any of our clinical trials comply with cGCPs. In addition, our clinical trials must be conducted with products produced under
cGMP regulations and will require a large number of test subjects. Our failure or the failure of our CROs or clinical sites to
comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process and
could also subject us to enforcement action up to and including civil and criminal penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Although
we intend to design the clinical trials for our drug candidates in consultation with CROs, we expect that the CROs will manage
all of the clinical trials conducted at contracted clinical sites. As a result, many important aspects of our drug development
programs would be outside of our direct control. In addition, the CROs and clinical sites may not perform all of their obligations
under arrangements with us or in compliance with regulatory requirements. If the CROs or clinical sites do not perform clinical
trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development
and commercialization of any of our drug candidates for the subject indication may be delayed or our development program materially
and irreversibly harmed. We cannot control the amount and timing of resources these CROs and clinical sites will devote to our
program or any of our drug candidates. If we are unable to rely on clinical data collected by our CROs, we could be required to
repeat, extend the duration of, or increase the size of our clinical trials, which could significantly delay commercialization
and require significantly greater expenditures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">If
any of our relationships with these third-party CROs or clinical sites terminate, we may not be able to enter into arrangements
with alternative CROs or clinical sites. If CROs do not successfully carry out their contractual duties or obligations or meet
expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised
due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, any such clinical trials
may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize
our drug candidates. As a result, our financial results and the commercial prospects for any of our drug candidates would be harmed,
our costs could increase and our ability to generate revenue could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Any
termination or suspension of, or delays in the commencement or completion of, any necessary studies of any of our drug candidates
for any indications could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect
our commercial prospects. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
commencement and completion of clinical studies can be delayed for a number of reasons, including delays related to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    FDA or a comparable foreign regulatory authority failing to grant permission to proceed and placing the clinical study on
    hold; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">subjects
    for clinical testing failing to enroll or remain in our trials at the rate we expect;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">a
    facility manufacturing any of our drug candidates being ordered by the FDA or other government or regulatory authorities to
    temporarily or permanently shut down due to violations of cGMP requirements or other applicable requirements, or cross-contaminations
    of drug candidates in the manufacturing process; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">any
    changes to our manufacturing process that may be necessary or desired; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">subjects
    choosing an alternative treatment for the indications for which we are developing our drug candidates, or participating in
    competing clinical studies; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">subjects
    experiencing severe or unexpected drug-related adverse effects; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">reports
    from clinical testing on similar technologies and products raising safety and/or efficacy concerns; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">third-party
    clinical investigators losing their license or permits necessary to perform our clinical trials, not performing our clinical
    trials on our anticipated schedule or employing methods consistent with the clinical trial protocol, cGMP requirements, or
    other third parties not performing data collection and analysis in a timely or accurate manner; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">inspections
    of clinical study sites by the FDA, comparable foreign regulatory authorities, or IRBs finding regulatory violations that
    require us to undertake corrective action, result in suspension or termination of one or more sites or the imposition of a
    clinical hold on the entire study, or that prohibit us from using some or all of the data in support of our marketing applications;
    </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">third-party
    contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities
    for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able
    to use some or any of the data produced by such contractors in support of our marketing applications; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">one
    or more IRBs refusing to approve, suspending or terminating the study at an investigational site, precluding enrollment of
    additional subjects, or withdrawing its approval of the trial; reaching agreement on acceptable terms with prospective CROs
    and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different
    CROs and trial sites; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">deviations
    of the clinical sites from trial protocols or dropping out of a trial; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">adding
    new clinical trial sites; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    inability of the CRO to execute any clinical trials for any reason; and </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">government
    or regulatory delays or &#8220;clinical holds&#8221; requiring suspension or termination of a trial. </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Product
development costs for any of our drug candidates will increase if we have delays in testing or approval or if we need to perform
more or larger clinical studies than planned. Additionally, changes in regulatory requirements and policies may occur and we may
need to amend study protocols to reflect these changes. Amendments may require us to resubmit our study protocols to the FDA,
comparable foreign regulatory authorities, and IRBs for reexamination, which may impact the costs, timing or successful completion
of that study. If we experience delays in completion of, or if we, the FDA or other regulatory authorities, the IRB, or other
reviewing entities, or any of our clinical study sites suspend or terminate any of our clinical studies of any of our drug candidates,
its commercial prospects may be materially harmed and our ability to generate product revenues will be delayed. Any delays in
completing our clinical trials will increase our costs, slow down our development and approval process and jeopardize our ability
to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and prospects
significantly. In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement
or completion of, clinical studies may also ultimately lead to the denial of regulatory approval of our drug candidates. In addition,
if one or more clinical studies are delayed, our competitors may be able to bring products to market before we do, and the commercial
viability of any of our drug candidates could be significantly reduced.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Clinical
drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials
may not be predictive of future trial results. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Clinical
testing of drug candidates is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure
can occur at any time during the clinical trial process. The results of pre-clinical studies and early clinical trials may not
be predictive of the results of later-stage clinical trials. We cannot assure you that the FDA or comparable foreign regulatory
authorities will view the results as we do or that any future trials of any of our drug candidates will achieve positive results.
Drug candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed
through pre-clinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered
significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising
results in earlier trials. Any future clinical trial results for our drug candidates may not be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, a number of factors could contribute to a lack of favorable safety and efficacy results for any of our drug candidates.
For example, such trials could result in increased variability due to varying site characteristics, such as local standards of
care, differences in evaluation period and surgical technique, and due to varying patient characteristics including demographic
factors and health status.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Even
though we may apply for orphan drug designation for a drug candidate, we may not be able to obtain orphan drug marketing exclusivity.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">There
is no guarantee that the FDA, EMA or their foreign equivalents will grant any future application for orphan drug designation for
any of our drug candidates, which would make us ineligible for the additional exclusivity and other benefits of orphan drug designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Under
the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which
is generally a disease or condition that affects fewer than 200,000 individuals in the United States and for which there is no
reasonable expectation that the cost of developing and making a drug available in the Unites States for this type of disease or
condition will be recovered from sales of the product. Orphan drug designation must be requested before submitting an NDA. After
the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly
by the FDA. Orphan product designation does not convey any advantage in or shorten the duration of regulatory review and approval
process. In addition to the potential period of exclusivity, orphan designation makes a company eligible for grant funding of
up to $400,000 per year for four years to defray costs of clinical trial expenses, tax credits for clinical research expenses
and potential exemption from the FDA application user fee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">If
a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has
such designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other applications
to market the same drug for the same indication for seven years, except in limited circumstances, such as (i) the drug&#8217;s
orphan designation is revoked; (ii) its marketing approval is withdrawn; (iii) the orphan exclusivity holder consents to the approval
of another applicant&#8217;s product; (iv) the orphan exclusivity holder is unable to assure the availability of a sufficient
quantity of drug; or (v) a showing of clinical superiority to the product with orphan exclusivity by a competitor product. If
a drug designated as an orphan product receives marketing approval for an indication broader than what is designated, it may not
be entitled to orphan drug exclusivity. There can be no assurance that we will receive orphan drug designation for any of our
drug candidates in the indications for which we think they might qualify, if we elect to seek such applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Although
we may pursue expedited regulatory approval pathways for a drug candidate, it may not qualify for expedited development or, if
it does qualify for expedited development, it may not actually lead to a faster development or regulatory review or approval process.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Although
we believe there may be an opportunity to accelerate the development of certain of our drug candidates through one or more of
the FDA&#8217;s expedited programs, such as fast track, breakthrough therapy, accelerated approval or priority review, we cannot
be assured that any of our drug candidates will qualify for such programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For
example, a drug may be eligible for designation as a breakthrough therapy if the drug is intended, alone or in combination with
one or more other drugs, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the
drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Although
breakthrough designation or access to any other expedited program may expedite the development or approval process, it does not
change the standards for approval. If we apply for breakthrough therapy designation or any other expedited program for our drug
candidates, the FDA may determine that our proposed target indication or other aspects of our clinical development plans do not
qualify for such expedited program. Even if we are successful in obtaining a breakthrough therapy designation or access to any
other expedited program, we may not experience faster development timelines or achieve faster review or approval compared to conventional
FDA procedures. Access to an expedited program may also be withdrawn by the FDA if it believes that the designation is no longer
supported by data from our clinical development program. Additionally, qualification for any expedited review procedure does not
ensure that we will ultimately obtain regulatory approval for such drug candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Risks
Related to Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>If
we are unable to protect our proprietary rights, we may not be able to prevent others from using our intellectual property, which
may reduce the competitiveness and value of the related assets.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
success will depend in part on our ability to obtain and maintain patent protection for our formulations and technologies and
to prevent third parties from infringing upon our proprietary rights. We must also operate without infringing upon patents and
proprietary rights of others, including by obtaining appropriate licenses to patents or other proprietary rights held by third
parties, if necessary. The primary means by which we will be able to protect our formulations and technologies from unauthorized
use by third parties is to obtain valid and enforceable patents that cover them. However, the applications we have filed or may
file in the future may never yield patents that protect our inventions and intellectual property assets. Failure to obtain patents
that sufficiently cover our formulations and technologies would limit our protection against other compounding pharmacies and
outsourcing facilities, generic drug manufacturers, pharmaceutical companies and other parties who may seek to copy our products,
produce products substantially similar to ours or use technologies substantially similar to those we own. We have made, and expect
to continue to make, significant investments in certain of our proprietary formulations prior to the grant of any patents covering
these formulations, and we may not receive a sufficient return on these investments if patent coverage or other appropriate intellectual
property protection is not obtained and their competitiveness and value decreases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
patent and intellectual property positions of pharmacies and pharmaceutical companies, including ours, are uncertain and involve
complex legal and factual questions. There is no guarantee that we have developed or obtained or will in the future develop or
obtain the rights to products or processes that are patentable, that patents will issue from any pending applications or that
claims allowed will be sufficient to protect the technology we have developed or may in the future develop or to which we have
acquired or may in the future acquire development rights. In addition, we cannot be certain that patents issued to us will not
be challenged, invalidated, infringed or circumvented, including by our competitors, or that the rights granted thereunder will
provide competitive advantages to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
also rely on unpatented trade secrets and know-how and continuing technological innovation in order to develop our formulations,
which we seek to protect, in part, by confidentiality agreements with our employees, consultants, collaborators and others, including
certain service providers. We also have invention or patent assignment agreements with our current employees and certain consultants.
Nonetheless, our employees and consultants may breach these agreements, and we may not have adequate remedies for the breach.
Our trade secrets may otherwise become known or be independently discovered by competitors or could be developed by a person not
bound by an invention assignment agreement with us, in which case we may have no rights to use the applicable invention.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
may face additional competition outside of the U.S. as a result of a lack of patent coverage in some territories and differences
in patent prosecution and enforcement laws in foreign counties. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Filing,
prosecuting, defending and enforcing patents on our proprietary formulations throughout the world is extremely expensive. We do
not currently have patent protection outside of the U.S. that covers any of our proprietary formulations or other assets that
we are currently pursuing. Competitors may use our technologies to develop their own products in jurisdictions where we have not
obtained patent protection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Even
if the international patent applications we have filed or may in the future file are issued or approved, it is likely that the
scope of protection provided by such patents would be different from, and possibly less than, the scope provided by corresponding
U.S. patents. As a result, patent rights we are able to obtain may not be sufficient to prevent generic competition. Further,
the extent of our international market opportunity may be dependent upon the enforcement of patent rights in various other countries.
A number of countries in which we could file patent applications have a history of weak enforcement and/or compulsory licensing
of intellectual property rights. Moreover, the legal systems of certain countries, particularly certain developing countries,
do not favor the aggressive enforcement of patents and other intellectual property protection, particularly those relating to
biotechnology and/or pharmaceuticals, which would make it difficult for us to stop a third party from infringing any of our intellectual
property rights. Moreover, attempting to enforce our patent rights in foreign jurisdictions could result in substantial costs
and divert our efforts and attention from other aspects of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our
proprietary formulations and technologies could potentially conflict with the rights of others.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
preparation or sale of our proprietary formulations and use of our technologies may infringe on the patent or other intellectual
property rights of others. If our products infringe or conflict with the patent or other intellectual property rights of others,
third parties could bring legal actions against us claiming damages and seeking to enjoin our manufacturing and marketing of our
affected products. Patent litigation is costly and time consuming and may divert management&#8217;s attention and our resources.
We may not have sufficient resources to bring any actions to a successful conclusion. If we are not successful in defending against
these legal actions should they arise, we may be subject to monetary liability or be forced to alter our products, cease some
or all of our operations relating to the affected products, or seek to obtain a license in order to continue manufacturing and
marketing the affected products, which may not available on acceptable terms or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Risks
Related to Our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>If
we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results, which
could cause our stock price to fall. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Effective
internal controls are necessary for us to provide reliable financial results. If we cannot provide reliable financial results,
our consolidated financial statements could be misstated, our reputation may be harmed and the trading price of our common stock
could decline. As we discussed in Item 9A of this Annual Report, our management concluded that our internal controls over financial
reporting were effective as of December 31, 2020. However, our controls over financial processes and reporting may not continue
to be effective or we may identify material weaknesses or significant deficiencies in our internal controls in the future. Any
failure to remediate any future material weaknesses or successfully implement required new or improved controls, could harm our
operating results, cause us to fail to meet our reporting obligations or result in material misstatements in our consolidated
financial statements or other public disclosures. Inferior internal controls could also cause investors to lose confidence in
our reported financial information, which could have a negative effect on the trading price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>A
consistently active trading market for shares of our common stock may not be sustained.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Historically,
trading in our common stock has been sporadic and volatile and our common stock has been &#8220;thinly-traded.&#8221; There have
been, and may in the future be, extended periods when trading activity in our shares is minimal, compared to a seasoned issuer
with a large and steady volume of trading activity. The market for our common stock is also characterized by significant price
volatility compared to seasoned issuers, and we expect that such volatility may continue. As a result, the trading of relatively
small quantities of shares may disproportionately influence the market price of our common stock. A consistently active and liquid
trading market in our securities may never develop or be sustained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our
stock price may be volatile.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
market price of our common stock is likely to be highly volatile and could fluctuate widely in response to various factors, many
of which are beyond our control, including the following: our ability to execute our business plan; operating results that fall
below expectations; industry or regulatory developments; investor perception of our industry or our prospects; economic and other
external factors; and the other risk factors discussed in this &#8220;Risk Factors&#8221; section.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, the securities markets have from time to time experienced significant price and volume fluctuations that are unrelated
to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market
price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
have the right to issue shares of preferred stock without obtaining stockholder approval. If we were to issue preferred stock,
it may have rights, preferences and privileges superior to those of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
are authorized to issue 5,000,000 shares of &#8220;blank check&#8221; preferred stock, with such rights, preferences and privileges
as may be determined from time to time by our board of directors. Our board of directors is empowered, without stockholder approval,
to issue preferred stock at any time in one or more series and to fix the dividend rights, dissolution or liquidation preferences,
redemption prices, conversion rights, voting rights and other rights, preferences and privileges for any series of our preferred
stock that may be issued. The issuance of shares of preferred stock, depending on the rights, preferences and privileges attributable
to the preferred stock, could reduce the voting rights and powers of our common stockholders and the portion of our assets allocated
for distribution to our common stockholders in a liquidation event, and could also result in dilution to the book value per share
of our common stock. The preferred stock could also be utilized, under certain circumstances, as a method for raising additional
capital or discouraging, delaying or preventing a change in control of our Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
have not paid dividends in the past and do not expect to pay dividends in the future. Any return on an investment will be limited
to any appreciation in the value of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have never paid cash dividends on our common stock and do not anticipate doing so in the foreseeable future. Any payment of dividends
on our common stock would depend on contractual restrictions, such as those contained in our SWK loan agreement, as well as our
earnings, financial condition and other business and economic factors as our board of directors may consider relevant. If we do
not pay dividends, our common stock may be less valuable because a return on your investment will only occur if our stock price
appreciates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Offers
or availability for sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
sale of substantial amounts of our common stock in the public market, or the perception that sales could occur, may cause the
market price of our common stock to fall. Sales could occur upon the expiration of any statutory holding period, such as under
Rule 144 under the Securities Act of 1933, as amended, applicable to outstanding shares, upon expiration of any lock-up periods
applicable to outstanding shares, upon our issuance of shares upon the exercise of outstanding options or warrants, or upon our
issuance of shares pursuant offerings of our equity securities. The availability for sale of a substantial number of shares of
our common stock, whether or not sales have occurred or are occurring, also could make it more difficult for us to raise additional
financing through the sale of equity or equity-related securities in the future when needed, on acceptable terms or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="b_004"></span>ITEM
1B. UNRESOLVED STAFF COMMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="b_005"></span>ITEM
2. PROPERTIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
lease approximately 10,200 square feet of office space in San Diego, California, the current lease term for which expires on December
31, 2021 and includes an option to extend the lease through December 31, 2026. This office generally supports the sales, general
and administrative functions of ImprimisRx.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
lease approximately 26,400 square feet of lab, warehouse and office space in Ledgewood, New Jersey, in two separate suites. The
current lease term expires on July 31, 2026 and includes options to extend the lease term through 2036. This space serves as an
outsourcing facility and pharmacy for ImprimisRx.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
lease approximately 5,500 square feet of office space in Nashville, Tennessee. The current lease term expires on December 31,
2024 and includes options to extend the lease term through 2034. This office serves as our corporate headquarters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
do not believe additional space will be required in the near-term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="b_006"></span>ITEM
3. LEGAL PROCEEDINGS </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">See
Note 17 to our consolidated financial statements included in this Annual Report for information on various legal proceedings,
which is incorporated into this Item by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="b_007"></span>ITEM
4. MINE SAFETY DISCLOSURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 36 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="b_008"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="b_009"></span>ITEM
5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Market
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
common stock is listed on The NASDAQ Global Market under the symbol &#8220;HROW&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Holders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of March 1, 2021, there were approximately 96 stockholders of record (excluding an indeterminable number of stockholders whose
shares are held in street or &#8220;nominee&#8221; name) of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have not paid any dividends on our common stock since our inception and do not expect to pay dividends on our common stock in
the foreseeable future. Further, our SWK loan agreement, described in Note 12 to our consolidated financial statements included
in this Annual Report, restricts our ability to pay cash dividends on our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Purchase
of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
did not purchase any of our equity securities during the period covered by this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Recent
Sales of Unregistered Securities </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="b_010"></span>ITEM
6. SELECTED FINANCIAL DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="b_011"></span>ITEM
7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with the
consolidated financial statements and the related notes contained in this annual report on Form 10-K (Annual Report). Our consolidated
financial statements have been prepared and, unless otherwise stated, the information derived therefrom as presented in this discussion
and analysis is presented, in accordance with accounting principles generally accepted in the United States (GAAP). In addition
to historical information, the following discussion contains forward-looking statements based upon our current views, expectations
and assumptions that are subject to risks and uncertainties. Actual results may differ substantially from those expressed or implied
by any forward-looking statements due to a number of factors, including, among others, the risks described in the &#8220;Risk
Factors&#8221; section and elsewhere in this Annual Report.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>As
used in this discussion and analysis, unless the context indicates otherwise, the terms the &#8220;Company,&#8221; &#8220;Harrow&#8221;
&#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Harrow Health, Inc. and its consolidated subsidiaries, consisting
of Imprimis Rx NJ, LLC, Imprimis NJOF, LLC, ImprimisRx, LLC, Radley Pharmaceuticals, Inc., Stowe Pharmaceuticals, Inc. and Mayfield
Pharmaceuticals, Inc. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Overview
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
business specializes in the development, production and sale of innovative medications that offer unique competitive advantages
and serve unmet needs in the marketplace through our subsidiaries and deconsolidated companies. We own and operate one of the
nation&#8217;s leading ophthalmic pharmaceutical businesses, ImprimisRx. In addition to wholly-owning ImprimisRx, we also have
non-controlling equity positions in Eton Pharmaceuticals, Inc. (&#8220;Eton&#8221;), Surface Ophthalmics, Inc. (&#8220;Surface&#8221;),
and Melt Pharmaceuticals, Inc. (&#8220;Melt&#8221;), all companies that began as subsidiaries of Harrow. We also recently launched
a new business called Visionology and are exploring opportunities to launch other subsidiaries. We own royalty rights in various
drug candidates being developed by Surface and Melt. We intend to continue to create and hold equity and royalty rights in new
businesses that commercialize drug candidates that are internally developed or otherwise acquired or licensed from third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>ImprimisRx</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">ImprimisRx
is our ophthalmic focused prescription pharmaceutical business. We offer to over 9,000 physician customers and their patients
medically necessary prescription drugs to meet their needs that are otherwise unmet by commercially available drugs. We make our
formulations available at prices that are, in most cases, lower than non-customized commercial drugs. Our current ophthalmic formulary
includes over twenty compounded formulations, many of which are patented or patent-pending, and are customizable for the specific
needs of a patient. Some examples of our compounded medications are various combinations of drugs formulated into one bottle and
numerous preservative-free formulations. Depending on the formulation, the regulations of a specific state, and ultimately the
needs of the patient, ImprimisRx products may be dispensed as patient-specific medications from our 503A pharmacy, or for in-office
use, made according to federal current good manufacturing practices (or cGMPs) or other FDA guidance documents, in our FDA-registered
New Jersey Outsourcing Facility (&#8220;NJOF&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">On
August 1, 2020, ImprimisRx entered into a Commercial Alliance Agreement (the &#8220;Dexycu Agreement&#8221;) with Eyepoint Pharmaceuticals,
Inc. (&#8220;Eyepoint&#8221;), pursuant to which Eyepoint granted ImprimisRx the non-exclusive right to co-promote DEXYCU<sup>&#174;
</sup>(dexamethasone intraocular suspension) 9% for the treatment of post-operative inflammation following ocular surgery in the
United States.</span> <span style="font: 10pt Times New Roman, Times, Serif">Pursuant to the <span style="background-color: white">Dexycu
Agreement</span>, Eyepoint pays <span style="background-color: white">ImprimisRx </span>a fee that is calculated based on the
quarterly sales of DEXCYU in excess of predefined volumes to specific customers of <span style="background-color: white">ImprimisRx
</span>in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">We
expect to acquire and/or develop additional FDA-approved ophthalmic drugs that allow us to leverage the commercial infrastructure
of ImprimisRx to promote, sell, and ultimately bring these products to market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Visionology
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Visionology
is a membership-based online eye health and medication platform. Visionology leverages our experience in the ophthalmic pharmaceutical
business, our relationships with eyecare professionals across the United States, and our expertise in developing and deploying
telemedicine software. We recently launched a proof-of-concept for Visionology in certain states in the southeast area of the
U.S. If successful, we expect Visionology will expand access to the Visionology service later in 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Pharmaceutical
Compounding Businesses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Pharmaceutical
Compounding</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pharmaceutical
compounding is the science of combining different active pharmaceutical ingredients (APIs), all of which are approved by the FDA
(either as a finished form product or as a bulk drug ingredient) and excipients, to create specialized pharmaceutical preparations.
Physicians and healthcare institutions use compounded drugs when commercially available drugs do not optimally treat a patient&#8217;s
medical needs. In many cases, compounded drugs, such as ours, have wide market utility and may be clinically appropriate for large
patient populations. Examples of compounded formulations include medications with alternative dosage strengths or unique dosage
forms, such as topical creams or gels, suspensions, or solutions with more tolerable drug delivery vehicles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 38 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Almost
all of our sales revenue is derived from making, selling and dispensing our compounded prescription drug formulations as cash
pay transactions between us and our end-user customer. As such, the majority of our commercial transactions do not involve distributors,
wholesalers, insurance companies, pharmacy benefit managers or other middle parties. By not being reliant on insurance company
formulary inclusion and pharmacy benefit manager payment clawbacks, we are able to simplify the prescription transaction process.
We believe the outcome of our business model is a simple and transparent transaction, involving a patient-in-need, a physician&#8217;s
diagnosis, a fair price and great service for a quality pharmaceutical product. We sell our products through a network of employees
and independent contractors, and we dispense our formulations in all 50 states, Puerto Rico and in selected markets outside the
United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our
Compounding Facilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pharmaceutical
compounding businesses are governed by Sections 503A and 503B of the Federal Food Drug and Cosmetic Act (the &#8220;FDCA&#8221;).
Section 503A of the FDCA provides that a pharmacy is only permitted to compound a drug for an individually identified patient
based on a prescription for a patient and is only permitted to distribute the drug interstate if the pharmacy is licensed to do
so in the states where it is compounded and where the medication is received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Section
503B of the FDCA provides that a pharmacy engaged in preparing sterile compounded drug formulations may voluntarily elect to register
as an &#8220;outsourcing facility.&#8221; Outsourcing facilities are permitted to compound large quantities of drugs without a
prescription and distribute them out of state with certain limitations such as the formulation appearing on the FDA&#8217;s drug
shortage list or the bulk drug substances contained in the formulations appearing on the FDA&#8217;s &#8220;clinical need&#8221;
list. Entities voluntarily registering with FDA as outsourcing facilities are subject to additional requirements that do not apply
to compounding pharmacies (operating under Section 503A of the FDCA), including adhering to standards such as current good manufacturing
practices (cGMP) or other FDA guidance documents and being subject to regular FDA inspection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
operate two compounding facilities located in Ledgewood, New Jersey. Our New Jersey operations are comprised of two separate entities
and facilities, one of which is registered with the FDA as an outsourcing facility under Section 503B of the FDCA. The other New
Jersey facility (&#8220;RxNJ&#8221;), is a licensed pharmacy operating under Section 503A of the FDCA. All products that we sell,
produce and dispense are made in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
believe that, with our current compounding pharmacy facilities and licenses and FDA registration of NJOF, we have the infrastructure
to scale our business appropriately under the current regulatory landscape and meet the potential growth in demand we are targeting.
We plan to invest in one or both of our facilities to further their capacity and efficiencies. Also, we may seek to access greater
pharmacy, production related redundancy, and distribution through acquisitions, partnerships or other strategic transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Pharmaceutical
Development Businesses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have ownership interests in Eton, Surface and Melt and hold royalty interests in some of Surface&#8217;s and Melt&#8217;s drug
candidates. These companies are pursuing market approval for their drug candidates under the FDCA, including in some instances
under the abbreviated pathway described in Section 505(b)(2) which permits the submission of a new drug application (&#8220;NDA&#8221;)
where at least some of the information required for approval comes from studies not conducted by or for the applicant and for
which the applicant has not obtained a right of reference. In 2018 and 2019, we formed and created subsidiaries named Radley Pharmaceuticals,
Inc. (&#8220;Radley&#8221;), Mayfield Pharmaceuticals, Inc. (&#8220;Mayfield&#8221;) and Stowe Pharmaceuticals, Inc. (&#8220;Stowe&#8221;).
In addition, we may create additional subsidiaries that will be focused on the development and FDA approval of certain proprietary
drug formulations that we currently own, will in-license/acquire and/or otherwise develop, we expect any new subsidiaries to be
focused on eye care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>De-Consolidated
Businesses (Noncontrolling Equity Interests)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Surface
Ophthalmics, Inc. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Surface
is a clinical-stage pharmaceutical company focused on development and commercialization of innovative therapeutics for ocular
surface diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
January 2021, Surface announced positive top-line results from a phase 2 trial of its drug candidate SURF-201, a 0.2% betamethasone,
preservative-free ophthalmic solution in the Klarity delivery vehicle for the treatment of post cataract surgery pain and inflammation.
According to the Surface, SURF-201 was dosed twice daily, and met its primary endpoints of absence of inflammation at both Day
8 and Day 15 and was found to be safe and well-tolerated by the patient group. In addition, a secondary endpoint showed almost
90% of patients given SURF-201 were pain free at Day 15. SURF-201 marks the first ophthalmic therapeutic in the United States
to utilize betamethasone as well as being the first preservative-free unit dose therapy for the treatment of post-operative pain
and inflammation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Also
in January 2021, Surface announced the first patient dosed in a head-to-head phase 2 trial for its drug candidate SURF-100 (mycophenolate
sodium and betamethasone in Klarity vehicle) for the treatment of chronic dry eye disease. The head-to-head study will compare
SURF-100 against two leading on-market competitors lifitegrast ophthalmic solution 5% and cyclosporine ophthalmic emulsion 0.05%.
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 39 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">In
February 2021, Surface announced the first patient dosed in a phase 2 trial for its drug candidate SURF-200 (betamethasone in
Klarity vehicle) for the treatment of episodic dry eye flares. The dose ranging study for SURF-200 will be administered in two
different low concentration formulations of betamethasone in the Klarity vehicle. The trial will enroll 120 to 140 patients with
a primary endpoint of Symptom Improvement of one unit based on the University of North Carolina Dry Eye Management Scale by the
eighth day.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
2018, Surface closed on an offering of its Series A Preferred Stock. At that time, we lost our controlling interest and deconsolidated
Surface from our consolidated financial statements. We own 3,500,000 shares of Surface which is approximately 30% of the equity
and voting interests as of December 31, 2020. Harrow owns mid-single digit royalty rights on net sales of SURF-100, SURF-200 and
SURF-201. We expect Surface to complete another round of financing within the next twelve months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Melt
Pharmaceuticals, Inc. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Melt
is a clinical-stage pharmaceutical company focused on the development and commercialization of proprietary non-intravenous, sedation
and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. Melt intends to seek
regulatory approval for its proprietary technologies, where possible. In December 2018, we entered into an Asset Purchase Agreement
with Melt (the &#8220;Melt Asset Purchase Agreement&#8221;), and Harrow assigned to Melt the underlying intellectual property
for Melt&#8217;s current pipeline, including its lead drug candidate MELT-100. The core intellectual property Melt owns is a patented
series of combination non-opioid sedation drug formulations that we estimate to have multitudinous applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">MELT-100
is a novel, sublingually delivered, non-IV, opioid-free drug candidate being developed for procedural sedation. Melt filed an
IND in June 2020 and began its clinical program for MELT-100. In February 2021, Melt announced data from, and successful completion
of, its phase 1 study. Melt expects to begin its phase 2 study for MELT-100 in the second half of 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
January 2019, Melt closed an offering of its Series A Preferred Stock. At that time, we lost our controlling interest and deconsolidated
Melt from our consolidated financial statements. We own 3,500,000 shares of Melt common stock, which was approximately 44% of
the equity and voting interests issued and outstanding, as of December 31, 2020. We expect Melt to complete another round of financing
within the next twelve months. Pursuant to the terms of the Melt Asset Purchase Agreement, Melt is required to make mid-single
digit royalty payments to the Company on net sales of MELT-100, while any patent rights remain outstanding, subject to other conditions.
Melt can require the Company to cease compounding like products at the time of FDA approval of MELT-100. If approved, we do not
expect a cessation of compounding like products to have a material impact on our operations and financial performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Eton
Pharmaceuticals, Inc. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Eton
is a commercial-stage pharmaceutical company focused on developing and commercializing innovative drug products. Its pipeline
includes several products and drug candidates in various stages of development across a variety of dosage forms. In May 2017,
Eton closed an offering of its Series A Preferred Stock. At that time, we lost our controlling interest and deconsolidated Eton
from our consolidated financial statements. In November 2019, Eton completed an initial public offering of its common stock. We
own 3,500,000 shares of Eton common stock, which was less than 20% of the equity and voting interests issued and outstanding of
Eton as of December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Consolidated
Businesses (Controlling Equity Interests)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Mayfield,
Stowe and Radley are consolidated subsidiaries of Harrow. Mayfield is a development-stage pharmaceutical company focused on developing
urology related drug candidates. Stowe is focused on the development of proprietary ophthalmic drug candidates. Radley is a development-stage
pharmaceutical company that has been focused on the development of proprietary drug candidates focused on rare diseases. Recently,
and as part of our strategic focus within eyecare, we discontinued nearly all of the activities related to Mayfield, Stowe
and Radley, and may not resume those activities in the near term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
control over 50% of the equity and voting interests issued and outstanding of Mayfield, Stowe and Radley as of the date of this
Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Factors
Affecting Our Performance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
believe the primary factors affecting our performance are our ability to increase revenues of our proprietary compounded formulations
and certain non-proprietary products, grow and gain operating efficiencies in our pharmacy operations, optimize pricing and obtain
reimbursement options for our proprietary compounded formulations, and continue to pursue development and commercialization opportunities
for certain of our ophthalmology and other assets that we have not yet made commercially available as compounded formulations.
We believe we have built a tangible and intangible infrastructure that will allow us to scale revenues efficiently in the long-term.
All of these activities will require significant costs and other resources, which we may not have or be able to obtain from operations
or other sources. See &#8220;Liquidity and Capital Resources&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Recent
Developments </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following describes certain developments in 2020 to date that are important to understand our financial condition and results
of operations. See the notes to our consolidated financial statements included in this report for additional information about
each of these developments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 40 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>COVID-19
Pandemic</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">A
novel strain of coronavirus was first identified in Wuhan, China in December 2020. The disease caused by it, COVID-19, was declared
a global pandemic by the World Health Organization in March 2020. On March 18, 2020, CMS released guidance for U.S. healthcare
providers to limit all elective medical procedures in order to conserve personal protective equipment and limit exposure to COVID-19
during the pendency of the pandemic. In addition to limiting elective medical procedures, many hospitals and other healthcare
providers have strictly limited access to their facilities during the pandemic. The COVID-19 pandemic has negatively impacted
the global economy, disrupted global supply chains and healthcare delivery, led to social distancing recommendation, and created
significant volatility in financial markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
response to the pandemic and business disruptions, first and foremost, we have prioritized the health and safety of our employees,
customers, suppliers and others with whom we partner in our business activities. We have instructed employees to work from home
when possible and to maintain recommended physical distancing when working in our facilities. We also have eliminated non-essential
in-person contact with customers, suppliers and other third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Many
of the Company&#8217;s customers use its drugs in procedures that were impacted by the CMS guidance to limit elective procedures.
In addition, the Company and our business partners need access to healthcare providers and facilities to conduct clinical trials
and other activities required to achieve regulatory clearance of products under development. We are carefully monitoring rapidly
evolving changes in healthcare delivery systems and may adjust our operating and product development plans accordingly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Given
the unprecedented and dynamic nature of the COVID-19 pandemic, we cannot reasonably estimate the impacts it may have on our financial
condition, results of operations or cash flows in the future. However, the reduction in elective procedures in response to CMS
guidance has had a material adverse impact, on our revenues, profitability and cash flows, in particular during the second quarter
of 2020. The extent and duration of that impact will depend upon the extent of procedure postponements, the duration of the pandemic
and any resurgences of it, especially within certain geographies and states that have retained restrictive measures and social
distancing policies. In May 2020, some U.S. states and geographies began easing restrictions associated with the COVID-19 pandemic
including those restrictions related to elective procedures, as restrictions were lifted in those areas there was a correlation
with an increase in our revenues. Despite the recent resurgence of the COVID-19 pandemic in certain parts of the U.S., we are
hopeful that the general trend of easing of restrictions will continue, and sales of our products will return to historical norms
and historical growth trends, as other states and governmental authorities continue to ease restrictions associated with elective
procedures and the COVID-19 pandemic. Assuming the strictest of lockdown scenarios are avoided, we believe we have sufficient
liquidity resources to sustain our planned level of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>SWK
Amendment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
April 2020, the Company and several of its wholly-owned subsidiaries entered into a second amendment (the &#8220;SWK Amendment&#8221;)
to the term loan and security agreement dated as of July 19, 2017, as amended (the &#8220;SWK Loan&#8221;), with SWK Funding LLC,
as lender and collateral agent, and certain other lenders (collectively, &#8220;SWK&#8221;). A summary of the material changes
contained in the SWK Amendment are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">SWK
    agreed to make available to the Company, and the Company drew down on, an additional principal amount of $1,000,000;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    definition of the first amortization date was changed to August 14, 2020, permitting the Company to pay interest only on the
    principal amount loaned for the next payment (payments are due on a quarterly basis) following the SWK Amendment; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    interest payment due May 14, 2020 will be paid in-kind by increasing the principal amount of the term loans by an amount equal
    to the interest that has accrued.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>PPP
Loan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
April 2020, we entered into the PPP Loan with Renasant Bank in the principal amount of $1,967,100 and received cash proceeds of
the same amount, pursuant to the PPP under the CARES Act, which was enacted March 27, 2020. The PPP is administered by the SBA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Under
the terms of the PPP Loan, interest accrues on the outstanding principal at the rate of 1.0% per annum. The term of the PPP Loan
is two years, unless payment is sooner required in connection with an event of default under the PPP Loan. To the extent the PPP
Loan amount is not forgiven under the PPP, the Company is obligated to make equal monthly payments of principal and interest,
beginning seven months from the date of the PPP Loan, until the maturity date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">We
applied for forgiveness for all of the PPP Loan during the year ended December 31, 2020, however as of the date of this Annual
Report the SBA has not made a decision related to the Company&#8217;s application for forgiveness. The amount of loan proceeds
eligible for forgiveness is based on a formula that takes into account a number of factors, including the amount of loan proceeds
used by us during the twenty-four-week period after the loan origination for certain purposes including payroll costs, interest
on certain mortgage obligations, rent payments on certain leases, and certain qualified utility payments (it being anticipated
that at least 75% of the loan amount will be required to be used for eligible payroll costs); the employer maintaining or rehiring
employees and maintaining salaries at certain levels; and other factors. Subject to the other requirements and limitations on
loan forgiveness, only loan proceeds spent on payroll and other eligible expenses during the covered twenty-four-week period will
qualify for forgiveness. While we used proceeds from the PPP Loan for such qualifying expenses, in particular maintaining continuity
of our payroll and workforce (including staff critical to the timely production and dispensing of medicines we make), no assurance
can be provided that we will obtain forgiveness of the PPP Loan in whole or in part.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 41 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b><i>Eyepoint
Commercial Alliance Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">On
August 1, 2020, our wholly owned subsidiary ImprimisRx entered into a Commercial Alliance Agreement (the &#8220;Dexycu Agreement&#8221;)
with Eyepoint Pharmaceuticals, Inc. (&#8220;Eyepoint&#8221;), pursuant to which Eyepoint granted ImprimisRx the non-exclusive
right to co-promote DEXYCU<sup>&#174;</sup> (dexamethasone intraocular suspension) 9% for the treatment of post-operative inflammation
following ocular surgery in the United States.</span> <span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the <span style="background-color: white">Dexycu Agreement</span>, Eyepoint will pay <span style="background-color: white">ImprimisRx
</span>a fee calculated based on the quarterly sales of DEXCYU in excess of predefined volumes to specific customers of <span style="background-color: white">ImprimisRx
</span>in the U.S. Under the terms of the <span style="background-color: white">Dexycu Agreement</span>, <span style="background-color: white">ImprimisRx
</span>shall use commercially reasonable efforts to promote and market DEXCYU in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Subject
to early termination, the <span style="background-color: white">Dexycu Agreement</span> expires on August 1, 2025. Subject to
specified notice periods and specified limitations, either party may terminate the <span style="background-color: white">Dexycu
Agreement</span> in the event of (i) uncured material breach by the other party or (ii) if DEXCYU ceases to have &#8220;pass-through&#8221;
payment status. In addition, subject to certain limitations, <span style="background-color: white">ImprimisRx</span> may terminate
the <span style="background-color: white">Dexycu Agreement</span> (i) for convenience subject to an extended specified notice
period or (ii) in the event Eyepoint undergoes a change of control. Eyepoint may terminate the <span style="background-color: white">Dexycu
Agreement</span>, subject to specified notice periods and specified limitations, if <span style="background-color: white">ImprimisRx
</span>fails to achieve certain minimum sales levels during specified periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following period-to-period comparisons of our financial results are not necessarily indicative of results for any future period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Comparison
of Years Ended December 31, 2020 and 2019</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Revenues
</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
revenues include amounts recorded from sales of proprietary and non-proprietary pharmaceutical compounded drug formulations and
revenues received from royalty and milestone payments owed to us pursuant to out-license arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following presents our revenues for the years ended December 31, 2020 and 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended December 31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Variance</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Product
    sales, net</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">48,479,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,137,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,658,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other revenues</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">392,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">364,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    revenues</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">48,871,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,165,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,294,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
decrease in revenue between periods was largely attributable to the COVID-19 pandemic and CMS guidance to limit elective procedures
during parts of the first and second quarters of 2020. Net revenues generated from our New Jersey based outsourcing facility (&#8220;NJOF&#8221;)
totaled $32,949,000 for the year ended December 31, 2020, compared to $33,240,000 in 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Cost
of Sales</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
cost of sales includes direct and indirect costs to manufacture formulations and sell products, including active pharmaceutical
ingredients, personnel costs, packaging, storage, royalties, shipping and handling costs, manufacturing equipment and tenant improvements
depreciation, the write-off of obsolete inventory and other related expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following presents our cost of sales for the years ended December 31, 2020 and 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Variance</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Cost
    of sales</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,463,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,749,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,286,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
decrease in our cost of sales between periods was largely due to a decrease in unit volumes sold impacted by the COVID-19 pandemic,
partially offset by continued improved utilization of capacity at our compounding facilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 42 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Gross
Profit and Margin</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Variance</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Gross
    Profit</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">34,408,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">34,416,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Gross
    Margin</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">70.4</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">67.3</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.1</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
increase in gross margin between periods is largely attributable to increased utilization of capacities as a result of increased
output, in particular, at NJOF and increased per unit sales prices. We estimate gross margins at NJOF were greater than 71% during
2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Selling,
General and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
selling, general and administrative expenses include personnel costs, including wages and stock-based compensation, corporate
facility expenses, and investor relations, consulting, insurance, filing, legal and accounting fees and expenses as well as costs
associated with our marketing activities and sales of our proprietary compounded formulations and other non-proprietary pharmacy
products and formulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following presents our selling, general and administrative expenses for the years ended December 31, 2020 and 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Variance</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Selling,
    general and administrative</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">31,247,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">33,088,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,841,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
decrease in selling, general and administrative expenses between periods was largely attributable to decreased legal expenses
incurred associated with certain litigation matters that concluded during 2019, and certain expenses that are correlated with
our sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Research
and Development Expenses </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
research and development expenses primarily include expenses related to the development of acquired intellectual property, investigator-initiated
research and evaluations and other costs related to the clinical development of our assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following presents our research and development expenses for the years ended December 31, 2020 and 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Variance</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Research
    and development</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,413,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,083,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">330,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
increase in research and development expenses between periods was primarily attributable to the increase in formulation development
studies with our ImprimisRx subsidiary and the clinical development programs for our subsidiaries Radley, Mayfield and Stowe that
occurred during the year ended December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Impairment
of Long-Lived Assets</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020, we recorded a loss of $363,000 related to the impairment of patents and patent applications.
During the year ended December 31, 2019, we recorded a loss of $4,040,000 related to the impairment and disposal of long-lived
assets. Of these costs $3,781,000 were related to the Park Restructuring and $259,000 of these expenses were related to the impairment
of patents and patent applications related to a terminated asset purchase agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Interest
Expense, net </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Interest
expense, net was $2,236,000 for the year ended December 31, 2020 compared to $2,500,000 in 2019. The decrease during the year
ended December 31, 2020 compared to 2019 was primarily due to interest expense recognition related to a decrease in the amortization
of our finance lease obligations and reduction of the principal balance of our term loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Investment
Gain (Loss) from Melt, net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020, we recorded a loss of $2,313,000 for our share of losses based on our ownership of Melt. During
the year ended December 31, 2019, we recorded a net gain of $3,968,000 related to our investment in Melt. In 2019, we recorded
a gain of $5,810,000 for the deconsolidation of Melt, and a loss of $(1,842,000) for our share of losses based on our ownership
of Melt after its deconsolidation. We began using the equity method accounting for our investment in Melt beginning on January
30, 2019, the date we no longer had a controlling interest. Prior to that date, Melt&#8217;s losses were consolidated within our
statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 43 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Investment
Loss from Surface</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020, we recorded a loss of $2,433,000 for our share of losses based on our ownership of Surface.
During the year ended December 31, 2019, we recorded a loss of $1,200,000 for our share of losses based on our ownership of Surface.
We began using the equity method accounting for our investment in Surface beginning on June 11, 2018, the date we no longer had
a controlling interest. Prior to that date, Surface&#8217;s losses were consolidated within our statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Investment
Gain from Eton, net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
recorded a gain of $3,255,000 related to the change in fair market value of Eton&#8217;s common stock for the year ended December
31, 2020. We recorded a gain of $3,780,000 related to the change in fair market value of Eton&#8217;s common stock for the year
ended December 31, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Other
Income, net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020, we recorded other expense, net of $(73,000). This was primarily the result of income of $13,000
related to equipment from our Park facility that was sold during the year ended December 31, 2020 and $(105,000) related to the
disposal of property, plant and equipment related to the discontinued use of certain computer software and hardware. During the
year ended December 31, 2019, we recorded other income, net of $630,000 related to expenses that were paid by us and were reimbursed
by Melt following its deconsolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Net
Income (Loss) </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table presents our net income (loss) for the years ended December 31, 2020 and 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    (loss) income attributable to Harrow Health, Inc.</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,357,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">168,000</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net income per share, basic</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.13</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.01</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net income per share, diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.13</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.01</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Liquidity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
cash on hand (including restricted cash) at December 31, 2020 was $4,301,000, compared to $4,949,000 at December 31, 2019. Since
inception through December 31, 2020, we have incurred aggregate losses of $77,400,000. These losses are primarily due to selling,
general and administrative and research and development expenses incurred in connection with developing and seeking regulatory
approval for a former drug candidate, which activities we have now discontinued, the development and commercialization of novel
compounded formulations and the development of our pharmacy operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of the date of this Annual Report, we believe that cash and cash equivalents of $4,101,000 and restricted investments of $200,000,
totaling approximately $4,301,000 at December 31, 2020, will be sufficient to sustain our planned level of operations and capital
expenditures for at least the next 12 months. We also may consider the sale of certain assets including, but not limited to, part
of, or all of, our ownership interest in Eton, Surface, Melt, and/or any of our consolidated subsidiaries. However, our plans
for this period may change, our estimates of our operating expenses, capital expenditures and working capital requirements could
be inaccurate, we may pursue acquisitions of pharmacies or other strategic transactions that involve large expenditures or we
may experience growth more quickly or on a larger scale than we expect, any of which could result in the depletion of capital
resources more rapidly than anticipated and could require us to seek additional financing earlier than we expect to support our
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
expect to use our current cash position and funds generated from our operations and any financing to pursue our business plan,
which includes developing and commercializing compounded formulations, FDA-approved products and technologies, integrating and
developing our compounding operations, pursuing potential future strategic transactions as opportunities arise, including potential
acquisitions of products, compounding pharmacies and outsourcing facilities, drug companies and manufacturers, and/or assets or
technologies, and otherwise fund our operations. We may also use our resources to conduct clinical trials or other studies in
support of our formulations or any drug candidate for which we pursue FDA approval, to pursue additional development programs
or to explore other development opportunities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 44 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Net
Cash Flows</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
following provides detailed information about our net cash flows for the years ended December 31, 2020 and 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For
                                         the </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Year
                                         Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>December
                                         31,</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net cash (used in) provided by:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating
    activities</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,100,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">950,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Investing activities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(981,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,833,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Financing
    activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,433,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,006,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net change in cash and cash equivalents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(648,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,889,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash and cash
    equivalents at beginning of the year</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,949,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,838,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash and cash
    equivalents at end of the year</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,301,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,949,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Operating
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Net
cash (used in) provided by operating activities was $(1,100,000) in 2020, compared to $950,000 in the prior year. Net cash (used
in) provided by operating activities during the years ended December 31, 2020 was primarily the result of paydown of aged accounts
payable and accrued expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Investing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Net
cash used in investing activities in 2020 and 2019 was $(981,000) and $(1,833,000), respectively. Cash used in investing activities
in 2020 and 2019 were primarily associated with additional equipment purchases, software upgrades, facility expansions and upgrades,
and investments in our intellectual property portfolio.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Financing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Net
cash provided by (used in) financing activities in 2020 and 2019 was $1,433,000 and $(1,006,000), respectively. The cash provided
by financing activities during 2020 is primarily related to proceeds received from the amendment to our loan and security agreement
with SWK as well as proceeds received from the PPP Loan. The cash used in financing activities during 2019 is primarily attributable
to the principal payments on the SWK loan payable and finance leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Sources
of Capital</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Our
principal sources of cash consist of cash provided by operating activities from our pharmaceutical compounding business. We may
also sell some or all of our ownership interests in Eton, Surface, Melt or our other subsidiaries. We produced cash from operations
during 2019; however, we currently are experiencing a downturn in revenues mostly as a result of the COVID-19 pandemic which will
have an impact on our ability to produce cash in the current year. In addition, prior to 2017, we had not generated sufficient
revenues to support our operations and may not be able to do so in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
changing trends and overall economic outlook in light of the COVID-19 pandemic, including the related interim stay at home orders
and bans on elective surgeries, have created uncertainty surrounding our operating outlook and may impact our future operating
results. As a result, we may need significant additional capital to support our business plan and fund our proposed business operations.
We may receive additional proceeds from the exercise of stock purchase warrants that are currently outstanding. We may also seek
additional financing from a variety of sources, including other equity or debt financings, funding from corporate partnerships
or licensing arrangements, sales of assets or any other financing transaction. If we issue equity or convertible debt securities
to raise additional funds, our existing stockholders may experience substantial dilution, and the newly issued equity or debt
securities may have more favorable terms or rights, preferences and privileges senior to those of our existing stockholders. If
we raise additional funds through collaboration or licensing arrangements or sales of assets, we may be required to relinquish
potentially valuable rights to our product candidates or proprietary technologies or formulations, or grant licenses on terms
that are not favorable to us. If we raise funds by incurring additional debt, we may be required to pay significant interest expenses
and our leverage relative to our earnings or to our equity capitalization may increase. Obtaining commercial loans, assuming they
would be available, would increase our liabilities and future cash commitments and may impose restrictions on our activities,
such as the financial and operating covenants included in the agreements governing the SWK Loan. Further, we may incur substantial
costs in pursuing future capital and/or financing transactions, including investment banking fees, legal fees, accounting fees,
printing and distribution expenses and other costs. We may also be required to recognize non-cash expenses in connection with
certain securities we may issue, such as convertible notes and warrants, which would adversely impact our financial results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">We
may be unable to obtain financing when necessary as a result of, among other things, our performance, general economic conditions,
conditions in the pharmaceuticals and pharmacy industries, or our operating history, including our past bankruptcy proceedings.
In addition, the fact that we have a limited history of profitability could further impact the availability or cost to us of future
financings. As a result, sufficient funds may not be available when needed from any source or, if available, such funds may not
be available on terms that are acceptable to us. If we are unable to raise funds to satisfy our capital needs when needed, then
we may need to forego pursuit of potentially valuable development or acquisition opportunities, we may not be able to continue
to operate our business pursuant to our business plan, which would require us to modify our operations to reduce spending to a
sustainable level by, among other things, delaying, scaling back or eliminating some or all of our ongoing or planned investments
in corporate infrastructure, business development, sales and marketing and other activities, or we may be forced to discontinue
our operations entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 45 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Critical
Accounting Policies </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
rely on the use of estimates and make assumptions that impact our financial condition and results. These estimates and assumptions
are based on historical results and trends as well as our forecasts of how results and trends might change in the future. Although
we believe that the estimates we use are reasonable, actual results could differ materially from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
believe that the accounting policies described below are critical to understanding our business, results of operations and financial
condition because they involve the use of more significant judgments and estimates in the preparation of our consolidated financial
statements. An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on assumptions
about matters that are highly uncertain at the time the estimate is made, and any changes in the assumptions used in making the
accounting estimates that are reasonably likely to occur could materially impact our consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Revenue
Recognition and Deferred Revenue</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
account for contracts with customers in accordance with ASC 606, <i>Revenues from Contracts with Customers.</i> We have three
primary streams of revenue: (1) revenue recognized from our sale of products within our pharmacy services (2) revenue recognized
from a commission agreement with a third party and (3) revenue recognized from intellectual property license and asset
purchase agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Product
Revenues from Pharmacy Services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
sell prescription drugs directly through our pharmacy and outsourcing facility network. Revenue from our pharmacy services divisions
includes: (i) the portion of the price the client pays directly to us, net of any volume-related or other discounts paid back
to the client, (ii) the price paid to us by individuals, and (iii) customer copayments made directly to the pharmacy network.
Sales taxes are not included in revenue. Following the core principles of ASC 606, we have identified the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Identify
    the contract(s) with a customer: A contract exists with a customer at the time the prescription or order is received by the
    Company.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Identify
    the performance obligations in the contract: The order received contains the performance obligations to be met, in almost
    all cases the product the customer is wishing to receive. If we are unable to be meet the performance obligation the customer
    is notified.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Determine
    the transaction price: the transaction price is based on the product being sold to the customer, and any related customer
    discounts. These amounts are pre-determined and built into our order management software.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Allocate
    the transaction price to the performance obligations in the contract: The transaction price associated with the product(s)
    being ordered is allocated according to the pre-determined amounts.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Recognize
    revenue when (or as) the entity satisfies a performance obligation: At the time of shipment from the pharmacy or outsourcing
    facility the performance obligation has been met.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following revenue recognition policy has been established for the pharmacy services division:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Revenues
generated from prescription or office use drugs sold by our pharmacies and outsourcing facility are recognized when the prescription
is shipped. At the time of shipment, the pharmacy services division has performed substantially all of its obligations under its
client contracts and does not experience a significant level of returns or reshipments. Determination of criteria (3) and (4)
is based on management&#8217;s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability
of those amounts. We record reductions to revenue for discounts at the time of the initial sale. Estimated returns and allowances
and other adjustments are provided for in the same period during which the related sales are recorded and are based on actual
returns history. The rate of returns is analyzed annually to determine historical returns experience. If the historical data we
use to calculate these estimates do not properly reflect future returns, then a change in the allowance would be made in the period
in which such a determination is made and revenues in that period could be materially affected. We will defer any revenues received
for a product that has not been delivered or is subject to refund until such time that we and the customer jointly determine that
the product has been delivered and no refund will be required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Commission
Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020, the Company entered into an agreement whereby it is paid a fee calculated based on sales it
generates from a pharmaceutical product that is owned by a third party. The revenue earned from this arrangement is recognized
at the time a customer has ordered the pharmaceutical product and it has shipped from the third party (or one of its distributors
or affiliates), at which point there is no future performance obligation required by the Company and no consequential continuing
involvement on the part of the Company to recognize the associated revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 46 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Intellectual
Property License Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
currently hold four intellectual property license and related agreements in which we have promised to grant a license or sale
which provides a customer with right to access our intellectual property. License arrangements may consist of non-refundable upfront
license fees, data transfer fees, research reimbursement payments, exclusive license rights to patented or patent pending compounds,
technology access fees, and various performance or sales milestones. These arrangements can be multiple element arrangements,
each of which revenue is recognized at the point of time the performance obligation is met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Non-refundable
fees that are not contingent on any future performance by us and require no consequential continuing involvement on our part are
recognized as revenue when the license term commences and the licensed data, technology, compounded drug preparation and/or other
deliverable is delivered. Such deliverables may include physical quantities of compounded drug preparations, design of the compounded
drug preparations and structure-activity relationships, the conceptual framework and mechanism of action, and rights to the patents
or patent applications for such compounded drug preparations. We defer recognition of non-refundable fees if it has continuing
performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable
fee has no utility to the licensee and that are separate and independent of our performance under the other elements of the arrangement.
In addition, if our continued involvement is required, through research and development services that are related to its proprietary
know-how and expertise of the delivered technology or can only be performed by us, then such non-refundable fees are deferred
and recognized over the period of continuing involvement. Guaranteed minimum annual royalties are recognized on a straight-line
basis over the applicable term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Investment
in Eton Pharmaceuticals, Inc. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">We
own 3,500,000 shares of Eton common stock, which represents approximately 14.4% of the equity and voting interests of Eton as
of December 31, 2020. At December 31, 2020, the fair market value of Eton&#8217;s common stock was $8.13 per share. In accordance
with Accounting Standard Update (&#8220;ASU&#8221;) 2016-01, <i>Financial Instruments-Overall (Subtopic 825-10): Recognition and
Measurement of Financial Assets and Financial Liabilities</i>, for the years ended December 31, 2020 and 2019, we recorded an
investment gains from its Eton common stock position of $3,255 and $3,780, respectively, related to the change in fair market
value of our investment in Eton during the measurement periods. As of December 31, 2020 and 2019, the fair market value of our
investment in Eton was $28,455 and $25,200, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Mark
Baum, our Chief Executive Officer, is a member of the board of directors of Eton.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Investment
in Surface Ophthalmics, Inc. &#8211; Related Party</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">We
own 3,500,000 common shares (which is approximately 30% of the equity interests as of December 31, 2020) of Surface and uses the
equity method of accounting for this investment, as management has determined that we have the ability to exercise significant
influence over the operating and financial decisions of Surface. Under this method, we recognize earnings and losses in Surface
in its consolidated financial statements and adjusts the carrying amount of its investment in Surface accordingly. Our share of
earnings and losses are based on our ownership interest of Surface. Any intra-entity profits and losses are eliminated. We recorded
equity in the net loss of Surface of $1,200 during the year ended December 31, 2019. We recorded equity in the net loss of Surface
of $2,433 during the year ended December 31, 2020. As of December 31, 2020 and 2019, the carrying value of our investment in Surface
was $1,314 and $3,747, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Investment
in Melt Pharmaceuticals, Inc. &#8211; Related Party</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
April 2018, we formed Melt as a wholly-owned subsidiary. In January and March of 2019, Melt entered into definitive stock purchase
agreements (collectively, the &#8220;Melt Series A Preferred Stock Agreement&#8221;) with certain investors and closed on the
purchase and sale of Melt&#8217;s Series A Preferred Stock (the &#8220;Melt Series A Stock&#8221;), totaling approximately $11,400,000
of proceeds (collectively the &#8220;Melt Series A Round&#8221;) at a purchase price of $5.00 per share. As a result, we lost
voting and ownership control of Melt and ceased consolidating Melt&#8217;s financial statements. In connection with the Melt Series
A Preferred Stock Agreement, Melt also entered into a Registration Rights Agreement and agreed to use commercially reasonable
efforts to file, or confidentially submit, a registration statement on Form S-1 with the United States Securities and Exchange
Commission (&#8220;SEC&#8221;) by September 30, 2020 relating to an initial public offering of its common stock, however, during
the year ended December 31, 2020 this requirement was waived by the majority of Series A Preferred Stock holders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">At
the time of deconsolidation, we recorded a gain of $5,810,000 and adjusted the carrying value in Melt to reflect the increased
valuation of Melt and our new ownership interest in accordance with ASC 810-10-40-4(c), <i>Consolidation</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
own 3,500,000 common shares (which is approximately 44% of the equity interest as of December 31, 2020) of Melt and uses the equity
method of accounting for this investment, as management has determined that we have the ability to exercise significant influence
over the operating and financial decisions of Melt. Under this method, we recognize earnings and losses of Melt in its consolidated
financial statements and adjusts the carrying amount of its investment in Melt accordingly. Our share of earnings and losses are
based on our ownership interest of Melt. Any intra-entity profits and losses are eliminated. We recorded equity in net loss of
Melt of $2,313,000 during the year ended December 31, 2020. As of December 31, 2020, our investment in Melt was $2,506,000 of
which $1,655,000 was the carrying value of our investment in Melt and $851,000 due from Melt for reimbursable expenses and amounts
due under the Melt Master Service Agreement (&#8220;Melt MSA&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 47 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Stock-Based
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">All
stock-based payments to employees, directors and consultants, including grants of stock options, warrants, restricted stock units
and restricted stock, are recognized in the consolidated financial statements based upon their estimated fair values. We use the
Black-Scholes option pricing model and Monte-Carlo simulation model to estimate the fair value of stock-based awards. Fair value
is determined at the date of grant. The financial statement effect of forfeitures is estimated at the time of grant and revised,
if necessary, if the actual effect differs from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Income
Taxes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
part of the process of preparing our consolidated financial statements, we must estimate the actual current tax assets and liabilities
and assess permanent and temporary differences that result from differing treatment of items for tax and accounting purposes.
The temporary differences result in deferred tax assets and liabilities, which are included within the consolidated balance sheets.
We must assess the likelihood that the deferred tax assets will be recovered from future taxable income and, to the extent we
believe that recovery is not more likely than not, a valuation allowance must be established which reduces the amount of deferred
tax assets recorded on the consolidated balance sheets. To the extent we establish a valuation allowance or increase or decrease
this allowance in a period, the impact will be included in income tax expense in the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
account for income taxes under the provisions of Financial Accounting Standards Board (the &#8220;FASB&#8221;) Accounting Standards
Codification (&#8220;ASC&#8221;) 740, <i>Income Taxes</i>. As of December 31, 2020 and 2019, there were no unrecognized tax benefits
included in the consolidated balance sheets that would, if recognized, affect the effective tax rate. Our practice is to recognize
interest and/or penalties related to income tax matters in income tax expense. We had no accrual for interest or penalties in
its consolidated balance sheets at December 31, 2020 and 2019, and have not recognized interest and/or penalties in the consolidated
statements of operations for the years ended December 31, 2020 and 2019. We are subject to taxation in the United States, California,
Florida, Georgia, Illinois, New Jersey, New York, Tennessee, and Wisconsin. Our tax years since 2000 may be subject to examination
by the federal and state tax authorities due to the carryforward of unutilized net operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Research
and Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
expense all costs related to research and development as they are incurred. Research and development expenses consist of expenses
incurred in performing research and development activities, including salaries and benefits, other overhead expenses, and costs
related to clinical trials, contract services and outsourced contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Intellectual
Property </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
costs of acquiring intellectual property rights to be used in the research and development process, including licensing fees and
milestone payments, are charged to research and development expense as incurred in situations where we have not identified an
alternative future use for the acquired rights, and are capitalized in situations where we have identified an alternative future
use for the acquired rights. Patents and trademarks are recorded at cost and capitalized at a time when the future economic benefits
of such patents and trademarks become more certain (see &#8220;&#8212;Goodwill and Intangible Assets&#8221; below). We began capitalizing
certain costs associated with acquiring intellectual property rights during 2015, if costs are not capitalized, they are expensed
as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Impairment
of Long-Lived Assets </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Long-lived
assets, such as property, plant and equipment, purchased intangibles subject to amortization and patents and trademarks, are reviewed
for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted
future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash
flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the
asset. Assets to be disposed would be separately presented in the consolidated balance sheet and reported at the lower of the
carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposal group
classified as held-for-sale would be presented separately in the appropriate asset and liability sections of the consolidated
balance sheet, if material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Goodwill
and Intangible Assets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Patents
and trademarks are recorded at cost and capitalized at a time when the future economic benefits of such patents and trademarks
become more certain. At that time, we capitalize third party legal costs and filing fees associated with obtaining and prosecuting
claims related to its patents and trademarks. Once the patents have been issued, we amortize these costs over the shorter of the
legal life of the patent or its estimated economic life, generally 20 years, using the straight-line method. Trademarks are an
indefinite life intangible asset and are assessed for impairment based on future projected cash flows as further described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
review our goodwill and indefinite-lived intangible assets for impairment as of January 1 of each year and when an event or a
change in circumstances indicates the fair value of a reporting unit may be below its carrying amount. Events or changes in circumstances
considered as impairment indicators include but are not limited to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">significant
    underperformance of the our business relative to expected operating results;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">significant
    adverse economic and industry trends;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">significant
    decline in the our market capitalization for an extended period of time relative to net book value; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">expectations
    that a reporting unit will be sold or otherwise disposed.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
goodwill impairment test consists of a two-step process as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Step
1. We compare the fair value of each reporting unit to its carrying amount, including the existing goodwill. The fair value of
each reporting unit is determined using a discounted cash flow valuation analysis. The carrying amount of each reporting unit
is determined by specifically identifying and allocating the assets and liabilities to each reporting unit based on headcount,
relative revenues or other methods as deemed appropriate by management. If the carrying amount of a reporting unit exceeds its
fair value, an indication exists that the reporting unit&#8217;s goodwill may be impaired and we then perform the second step
of the impairment test. If the fair value of a reporting unit exceeds its carrying amount, no further analysis is required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Step
2. If further analysis is required, we compare the implied fair value of the reporting unit&#8217;s goodwill, determined by allocating
the reporting unit&#8217;s fair value to all of its assets and its liabilities in a manner similar to a purchase price allocation,
to its carrying amount. If the carrying amount of the reporting unit&#8217;s goodwill exceeds its fair value, an impairment loss
will be recognized in an amount equal to the excess.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Debt
Issuance Costs and Debt Discount </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Debt
issuance costs and the debt discount are recorded net of loans payable in the consolidated balance sheet. Amortization of debt
issuance costs and the debt discount is calculated using the effective interest method over the term of the debt and is recorded
in interest expense in the accompanying consolidated statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Since
our inception, except for standard operating leases, we have not engaged in any off-balance sheet arrangements, including the
use of structured finance, special purpose entities or variable interest entities. We have no off-balance sheet arrangements that
have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues
or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 49 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="b_026"></span>ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="b_012"></span>ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
financial statements and supplementary data required by this item are included in this Annual Report beginning on page F-1 immediately
following the signature page hereto and are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="b_013"></span>ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="b_014"></span>ITEM
9A. CONTROLS AND PROCEDURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Disclosure
Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Our
management, under the supervision and with the participation of our Chief Executive Officer (&#8220;CEO&#8221;), our principal
executive officer, and our Chief Financial Officer (&#8220;CFO&#8221;), our principal financial and accounting officer, conducted
an evaluation of the effectiveness of our disclosure controls and procedures as of December 31, 2020, the end of the period covered
by this Annual Report, pursuant to Rules 13a-15(b) and 15d-15(b) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange
Act&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
connection with that evaluation, our CEO and CFO concluded that, as of December 31, 2020, our disclosure controls and procedures
were effective. For the purpose of this review, disclosure controls and procedures means controls and procedures designed to ensure
that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed,
summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. These disclosure controls and procedures
include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the
reports that we file or submit under the Exchange Act is accumulated and communicated to management, including our principal executive
officer, principal financial officer and principal accounting officer, as appropriate to allow timely decisions regarding required
disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Management&#8217;s
Annual Report on Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules
13a-15(f) and 15d-15(f) under the Exchange Act. Internal control over financial reporting is a process designed by, or under the
supervision of, our CEO and CFO and effected by our board of directors, management and other personnel, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles. Our management, under the supervision and with the participation of
our CEO and CFO, conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework
in <i>Internal Control &#8212; Integrated Framework (2013)</i> issued by the Committee of Sponsoring Organizations. Based on such
evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">This
report does not include an attestation report of our independent registered public accounting firm regarding internal control
over financial reporting, in accordance with applicable SEC rules that permit us to provide only management&#8217;s report in
the annual report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Changes
in Internal Control over Financial Reporting </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">There
has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) during
the year ended December 31, 2020, that has materially affected, or is reasonably likely to materially affect our internal control
over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Inherent
Limitations on Effectiveness of Controls</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
management, including our CEO and CFO, do not expect that our disclosure controls or our internal control over financial reporting
will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only
reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must
reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs.
Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance
that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.
These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur
because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of
two or more people, or by management override of the controls. The design of any system of controls is based in part on certain
assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its
stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods
are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree
of compliance with policies or procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="b_015"></span>ITEM
9B. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 50 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="b_016"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="b_017"></span>ITEM
10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
information required by this item is incorporated by reference to the information set forth under the captions &#8220;Election
of Directors,&#8221; &#8220;Executive Officers,&#8221; &#8220;Corporate Governance,&#8221; &#8220;Corporate Governance &#8212;
Delinquent Section 16(a) Reports,&#8221; and &#8220;Corporate Governance &#8212; Code of Business Conduct and Ethics&#8221; in
the Company&#8217;s Proxy Statement for the 2021 Annual Meeting of Stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="b_018"></span>ITEM
11. EXECUTIVE COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
information required by this item is incorporated by reference to the information set forth under the captions &#8220;Executive
Compensation&#8221; and &#8220;Director Compensation&#8221; in the Company&#8217;s Proxy Statement for the 2021 Annual Meeting
of Stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="b_019"></span>ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
information required by this item is incorporated by reference to the information set forth under the captions &#8220;Security
Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; and &#8220;Executive Compensation
&#8212; Securities Authorized for Issuance Under Equity Compensation Plans&#8221; in the Company&#8217;s Proxy Statement for the
2021 Annual Meeting of Stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="b_020"></span>ITEM
13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
information required by this item is incorporated by reference to the information set forth under the captions &#8220;Corporate
Governance &#8212; Transactions with Related Persons&#8221; and &#8220;Corporate Governance &#8212; Director Independence&#8221;
in the Company&#8217;s Proxy Statement for the 2021 Annual Meeting of Stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="b_021"></span>ITEM
14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
information required by this item is incorporated by reference to the information set forth under the caption &#8220;Ratification
of Selection of Independent Registered Public Accounting Firm&#8221; in the Company&#8217;s Proxy Statement for the 2021 Annual
Meeting of Stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 51 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="b_022"></span>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="b_023"></span>ITEM
15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">(a)</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">List
    of the following documents filed as part of the report:</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">See
    the index to our consolidated financial statements on page F-1 for a list of the financial statements being filed in this
    Annual Report.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">All
    financial statement schedules are omitted because they are not applicable or the required information is shown in the consolidated
    financial statements or the notes thereto.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">See
    Item 15(b) below for all exhibits being filed or incorporated by reference herein.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">(b)</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Exhibits:</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>EXHIBIT
INDEX</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.1in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Description
    </b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">2.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1360214/000114420407050619/v088205_ex2-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Agreement and Plan of Merger, dated as of September 17, 2007, by and among Imprimis Pharmaceuticals, Inc., Transdel Pharmaceuticals Holdings, Inc. and Trans-Pharma Acquisition Corp. Incorporation (incorporated herein by reference to Exhibit 2.1 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on September 21, 2007)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1360214/000149315215000811/ex3-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Amended and Restated Certificate of Incorporation, as amended by the Certificate of Amendment to Amended and Restated Certificate of Incorporation effective February 28, 2012, as further amended by the Certificate of Amendment to Amended and Restated Certificate of Incorporation effective February 7, 2013, and as further amended by the Certificate of Amendment to Amended and Restated Certificate of Incorporation effective September 10, 2014</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1360214/000149315214000878/ex3-2.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Amended and Restated Bylaws of Imprimis Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 3.2 to the Annual Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on March 28, 2014)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1360214/000107878211003672/f8k121911_ex3z1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Certificate of Designation of Series A Convertible Preferred Stock of Imprimis Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on December 20, 2011) </span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1360214/000149315218009586/ex3-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Amended and Restated Certificate of Incorporation, filed July 2, 2018 (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on July 2, 2018)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1360214/000149315218018103/ex3-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Amendment to the Restated Certificate of Incorporation for the name change, filed as of December 27, 2018 (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on December 31, 2018)</span></a></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">4.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="ex4-1.htm"><span style="font-size: 10pt">Description
    of the Company&#8217;s Securities</span></a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1360214/000114420407050619/v088205_ex10-8.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Form of Directors and Officers Indemnification Agreement (incorporated herein by reference to Exhibit 10.8 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on September 21, 2007)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.2#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1360214/000135448813002503/immy_ex103.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Imprimis Pharmaceuticals, Inc. Amended and Restated 2007 Stock Incentive and Awards Plan (incorporated herein by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on May 8, 2013)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.3#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1360214/000149315213002218/ex10-3.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Amendment No. 1 to Imprimis Pharmaceuticals, Inc. Amended and Restated 2007 Incentive Stock and Awards Plan (incorporated herein by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on November 6, 2013)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.4#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1360214/000114420407050619/v088205_ex10-12.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Form of Incentive Stock Option Agreement (incorporated herein by reference to Exhibit 10.12 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on September 21, 2007) </span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.5#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1360214/000114420407050619/v088205_ex10-13.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Form of Non-Qualified Stock Option Agreement (incorporated herein by reference to Exhibit 10.13 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on September 21, 2007) </span></a></td></tr>
</table>
<p style="margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 52 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">10.6#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1360214/000135448813002503/immy_ex104.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Form of Restricted Stock Unit Agreement (incorporated herein by reference to Exhibit 10.4 to the Quarterly Report on Form 10-Q of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on May 8, 2013)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.7#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1360214/000135448812003649/tdlp_ex1040.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Stand-alone Restricted Stock Unit Agreement, dated July 18, 2012, granted by Imprimis Pharmaceuticals, Inc. to Mark L. Baum (incorporated herein by reference to Exhibit 10.40 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-182846) filed on July 25, 2012)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.8#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1360214/000135448812003649/tdlp_ex1041.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Stand-alone Restricted Stock Unit Agreement, dated July 18, 2012, granted by Imprimis Pharmaceuticals, Inc. to Robert J. Kammer (incorporated herein by reference to Exhibit 10.41 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-182846) filed on July 25, 2012)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1360214/000135448812005456/immy_ex1044.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Form of Underwriter&#8217;s Warrant (incorporated herein by reference to Exhibit 10.41 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-182846) filed on October 26, 2012)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.10#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1360214/000135448813002503/immy_ex102.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Amended and Restated Employment Agreement, dated May 2, 2013, by and between Imprimis Pharmaceuticals, Inc. and Mark L. Baum (incorporated herein by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on May 8, 2013)</span></a></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">10.11#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1360214/000135448813004603/immy_ex104.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Performance Stock Units Agreement, dated May 2, 2013, by and between Imprimis Pharmaceuticals, Inc. and Mark L. Baum (incorporated herein by reference to Exhibit 10.4 to the Quarterly Report on Form 10-Q of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on August 14, 2013)</span></a></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">10.12#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315215000345/ex10-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Amended and Restated Employment Agreement, effective as of February 1, 2015, by and between Imprimis Pharmaceuticals, Inc. and Andrew R. Boll (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on February 2, 2015)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.13#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315215000345/ex10-2.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Performance Stock Units Award Agreement, effective as of February 1, 2015, by and between Imprimis Pharmaceuticals, Inc. and Andrew R. Boll (incorporated herein by reference to Exhibit 10.2 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on February 2, 2015)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.14#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315215000345/ex10-3.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Employment Agreement, effective as of February 1, 2015, by and between Imprimis Pharmaceuticals, Inc. and John P. Saharek (incorporated herein by reference to Exhibit 10.3 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on February 2, 2015)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315215001853/ex10-2.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Warrant to Purchase Stock, dated May 11, 2015, issued by Imprimis Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 10.2 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on May 12, 2015)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315216016261/ex10-3.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Warrant Amendment to Purchase Stock, dated December 27, 2016, issued by Imprimis Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 10.3 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on December 29, 2016)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315217002715/ex10-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Form of Securities Purchase Agreement, dated March 21, 2017, between the Registrant and the Investors (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on March 22, 2017)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315217003596/ex10-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">License Agreement dated April 1, 2017 between Imprimis Pharmaceuticals, Inc. and Richard L. Lindstrom, M.D. (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on April 6, 2017)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315217004007/ex10-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Strategic Sales &amp; Marketing Agreement dated April 13, 2017 between Imprimis Pharmaceuticals, Inc. and Cameron Ehlen Group, Inc. (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on April 17, 2017)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315217004662/ex10-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Strategic Sales &amp; Marketing Agreement dated April 28, 2017 between Imprimis Pharmaceuticals, Inc. and SightLife Surgical, Inc. (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on May 2, 2017)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.21#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315217008881/ex10-8.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Consulting Agreement dated May 1, 2017 between Eton Pharmaceuticals, Inc. and Mark L. Baum (incorporated herein by reference to Exhibit 10.8 to the Quarterly Report on Form 10-Q of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on August 10, 2017)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.22#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315217008881/ex10-9.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Consulting Agreement dated May 1, 2017 between Eton Pharmaceuticals, Inc. and Andrew R. Boll (incorporated herein by reference to Exhibit 10.9 to the Quarterly Report on Form 10-Q of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on August 10, 2017)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.23#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315217008881/ex10-10.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Consulting Agreement dated May 1, 2017 between Eton Pharmaceuticals, Inc. and John P. Saharek (incorporated herein by reference to Exhibit 10.10 to the Quarterly Report on Form 10-Q of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on August 10, 2017)</span></a></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 53 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">10.24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315217006919/ex10-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Asset Purchase and License Agreement (pentoxifylline) dated May 9, 2017 between Imprimis Pharmaceuticals, Inc. and Eton Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on June 20, 2017)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.25</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315217006919/ex10-2.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Asset Purchase and License Agreement (corticotropin) dated May 9, 2017 between Imprimis Pharmaceuticals, Inc. and Eton Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 10.2 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on June 20, 2017)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.26</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315217006919/ex10-4.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Management Services Agreement dated May 1, 2017 between Imprimis Pharmaceuticals, Inc. and Eton Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 10.4 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on June 20, 2017)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.27</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315217008000/ex10-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Loan and Security Agreement, dated July 19, 2017, by and between Imprimis Pharmaceuticals, Inc. and SWK Funding LLC (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on July 20, 2017)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.28</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315217009907/ex10-1.htm#a_001" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Imprimis Pharmaceuticals, Inc. 2017 Incentive Stock and Awards Plan (incorporated herein by reference to Exhibit 10.1 to the Registration Statement on Form S-8 of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on August 25, 2017) </span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.29</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315217006741/ex10-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Form of Incentive Stock Option Agreement (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on June 16, 2017)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.30</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315217006741/ex10-2.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Form of Non-Statutory Stock Option Agreement (incorporated herein by reference to Exhibit 10.2 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on June 16, 2017)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.31</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315217006741/ex10-3.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Form of Restricted Stock Award Agreement (incorporated herein by reference to Exhibit 10.3 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on June 16, 2017)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.32</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315217006741/ex10-4.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Form of Restricted Stock Unit Agreement (incorporated herein by reference to Exhibit 10.4 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on June 16, 2017)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.33#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315218003095/ex10-53.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Consulting Agreement dated October 27, 2017 between Surface Pharmaceuticals, Inc. and Mark L. Baum (incorporated herein by reference to Exhibit 10.53 to the Annual Report on Form 10-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on March 8, 2018)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.34#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315218003095/ex10-54.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Consulting Agreement dated October 27, 2017 between Surface Pharmaceuticals, Inc. and Andrew R. Boll (incorporated herein by reference to Exhibit 10.54 to the Annual Report on Form 10-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on March 8, 2018)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.35#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315218003095/ex10-55.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Consulting Agreement dated October 27, 2017 between Surface Pharmaceuticals, Inc. and John P. Saharek (incorporated herein by reference to Exhibit 10.55 to the Annual Report on Form 10-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on March 8, 2018)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.36</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315218006896/ex10-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Asset Purchase and License Agreement dated September 28, 2017 between Imprimis Pharmaceuticals, Inc. and Surface Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on May 15, 2018)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.37</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315218006896/ex10-2.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Amended and Restated Asset Purchase and License Agreement dated April 10, 2018 between Imprimis Pharmaceuticals, Inc. and Surface Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 10.2 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on May 15, 2018)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.38</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315218011011/ex10-3.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Amended and Restated License Agreement dated April 10, 2018 between Imprimis Pharmaceuticals, Inc. and Richard L. Lindstrom, M.D. (incorporated herein by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on August 6, 2018)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.39</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315218011011/ex10-4.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Consulting Agreement dated March 1, 2018 between Surface Pharmaceuticals, Inc. and Richard L. Lindstrom, M.D. (incorporated herein by reference to Exhibit 10.4 to the Quarterly Report on Form 10-Q of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on August 6, 2018)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.40#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315218015757/ex10-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Consulting Agreement dated May 1, 2018 between Melt Pharmaceuticals, Inc. and Mark L. Baum (incorporated herein by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on November 13, 2018)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.41#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315218015757/ex10-2.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Consulting Agreement dated May 1, 2018 between Melt Pharmaceuticals, Inc. and Andrew R. Boll (incorporated herein by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on November 13, 2018)</span></a></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">10.42#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315218015757/ex10-3.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Consulting Agreement dated May 1, 2018 between Melt Pharmaceuticals, Inc. and John P. Saharek (incorporated herein by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on November 13, 2018)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.43</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315219001358/ex10-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Asset Purchase Agreement dated December 11, 2018 between Harrow Health, Inc. (fka Imprimis Pharmaceuticals, Inc.) and Melt Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K of Harrow Health, Inc. filed with the Securities and Exchange Commission on February 5, 2019)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.44</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315219006689/ex10-2.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Asset Purchase Agreement dated February 1, 2019 between Harrow Health, Inc. and Mayfield Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q of Harrow Health, Inc. filed with the Securities and Exchange Commission on May 9, 2019)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.45</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315219006689/ex10-3.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Asset Purchase Agreement dated February 1, 2019 between Harrow Health, Inc. and Elle Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q of Harrow Health, Inc. filed with the Securities and Exchange Commission on May 9, 2019)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.46</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315219008319/ex10-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Joinder and First Amendment to Loan and Security Agreement, dated May 24, 2019, by and between Harrow Health, Inc., each of its wholly-owned subsidiaries and SWK Funding LLC. (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K of Harrow Health, Inc. filed with the Securities and Exchange Commission on May 29, 2019)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.47#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315219012535/ex10-3.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Consulting Agreement dated June 3, 2019 between Mayfield Pharmaceuticals, Inc. and Mark L. Baum (incorporated herein by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q of Harrow Health, Inc. filed with the Securities and Exchange Commission on August 14, 2019)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.48#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315219012535/ex10-2.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Consulting Agreement dated June 3, 2019 between Mayfield Pharmaceuticals, Inc. and Andrew R. Boll (incorporated herein by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q of Harrow Health, Inc. filed with the Securities and Exchange Commission on August 14, 2019)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.49#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315219012535/ex10-4.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Consulting Agreement dated June 3, 2019 between Mayfield Pharmaceuticals, Inc. and John P. Saharek (incorporated herein by reference to Exhibit 10.4 to the Quarterly Report on Form 10-Q of Harrow Health, Inc. filed with the Securities and Exchange Commission on August 14, 2019)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.50</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315219017043/ex10-3.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">License Agreement, dated July 28, 2019, among Mayfield Pharmaceuticals, Inc., TGV-Health, LLC and TGV-Gyneconix, LLC (incorporated herein by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q of Harrow Health, Inc. filed with the Securities and Exchange Commission on November 13, 2019)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.51</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315219017043/ex10-4.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">License Agreement, dated July 29, 2019, among Stowe Pharmaceuticals, Inc., TGV-Health, LLC and TGV-Ophthalnix, LLC (incorporated herein by reference to Exhibit 10.4 to the Quarterly Report on Form 10-Q of Harrow Health, Inc. filed with the Securities and Exchange Commission on November 13, 2019)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.52#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315220003862/ex10-64.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Consulting Agreement dated February 13, 2020 between Stowe Pharmaceuticals, Inc. and Mark L. Baum (incorporated herein by reference to Exhibit 10.64 to the Annual Report on Form 10-K of Harrow Health, Inc. filed with the Securities and Exchange Commission on March 13, 2020)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.53#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315220003862/ex10-65.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Consulting Agreement dated February 13, 2020 between Stowe Pharmaceuticals, Inc. and Andrew R. Boll (incorporated herein by reference to Exhibit 10.65 to the Annual Report on Form 10-K of Harrow Health, Inc. filed with the Securities and Exchange Commission on March 13, 2020)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.54#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315220003862/ex10-66.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Consulting Agreement dated February 13, 2020 between Stowe Pharmaceuticals, Inc. and John P. Saharek (incorporated herein by reference to Exhibit 10.66 to the Annual Report on Form 10-K of Harrow Health, Inc. filed with the Securities and Exchange Commission on March 13, 2020)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.55</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315220005750/ex10.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Second Amendment, dated as of April 1, 2020, to the Loan and Security Agreement by and among Harrow Health, Inc., several of its wholly-owned subsidiaries and the Lenders named therein (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K of Harrow Health, Inc. filed with the Securities and Exchange Commission on April 4, 2020)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.56</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315220015093/ex10-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Business Loan Agreement with Renasant Bank pursuant to the Paycheck Protection Program, dated April 27, 2020 (incorporated herein by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q of Harrow Health, Inc. filed with the Securities and Exchange Commission on August 10, 2020)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.57#*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="ex10-57.htm"><span style="font-size: 10pt">Consulting
    Agreement dated July 1, 2020 between Visionology, Inc. and Mark L. Baum </span></a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.58#*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="ex10-58.htm"><span style="font-size: 10pt">Consulting
    Agreement dated July 1, 2020 between Visionology, Inc. and Andrew R. Boll </span></a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.59++</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1360214/000149315220020827/ex10-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Commercial Alliance Agreement between Eyepoint Pharmaceuticals, Inc. and ImprimisRx, LLC dated August 1, 2020. (incorporated herein by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q of Harrow Health, Inc. filed with the Securities and Exchange Commission on November 9, 2020)</span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">10.60*++</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex10-60.htm">First
    Amendment to Commercial Alliance Agreement between Eyepoint Pharmaceuticals, Inc. and
    ImprimisRx, LLC dated November 13, 2020.</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">21.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="ex21-1.htm"><span style="font-size: 10pt">List
    of Subsidiaries </span></a></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 55 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">23.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="ex23-1.htm"><span style="font-size: 10pt">Consent
    of Independent Registered Public Accounting Firm</span></a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">24.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#poa"><span style="font: 10pt Times New Roman, Times, Serif">Power of Attorney (included on the signature page to this Annual Report) </span></a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="ex31-1.htm"><span style="font-size: 10pt">Certification
    of Mark L. Baum, Chief Executive Officer, pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities and Exchange Act of 1934,
    as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="ex31-2.htm"><span style="font-size: 10pt">Certification
    of Andrew R. Boll, Chief Financial Officer, pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities and Exchange Act of
    1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">32.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="ex32-1.htm"><span style="font-size: 10pt">Certification
    pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, executed by Mark
    L. Baum, Chief Executive Officer. </span></a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">32.2**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="ex32-2.htm"><span style="font-size: 10pt">Certification
    pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, executed by Andrew
    R. Boll, Chief Financial Officer.</span></a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">101.INS*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    Instant Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within
    the Inline XBRL document.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">101.SCH*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Inline
    XBRL Taxonomy Extension Schema Document</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">101.CAL*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">101.DEF*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">101.LAB*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Inline
    XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">101.PRE*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    cover page from the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020 has been formatted in
    Inline XBRL </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Management
    contract or compensatory plan or arrangement.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Filed
    herewith.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Furnished
    herewith.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Confidential
    treatment has been granted with respect to portions of this exhibit pursuant to Rule 24b-2 of the Exchange Act and these confidential
    portions have been redacted from the filing that is incorporated herein by reference. A complete copy of this exhibit, including
    the redacted terms, has been separately filed with the Securities and Exchange Commission.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">++</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; background-color: white">Portions
    of this exhibit have been omitted in compliance with item 601 of Regulation S-K</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="b_024"></span>ITEM
16. FORM 10-K SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 56 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="b_025"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">HARROW
    HEALTH, INC. </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
    Mark L. Baum</i></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Name:&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Mark
    L. Baum</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Chief
    Executive Officer (Principal Executive Officer) </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Date:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">March
    8, 2021</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="poa"></span><b>POWER
OF ATTORNEY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Mark L. Baum and Andrew
R. Boll, and each of them individually, as his true and lawful attorneys-in-fact and agents with full power of substitution and
resubstitution, for him and in his name, place and stead, in any and all capacities to any or all amendments to this Annual Report,
and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange
Commission, granting unto said attorneys-in-fact and agents or any of them the full power and authority to do and perform each
and every act and thing requisite and necessary to be done in and about the foregoing, as full to all intents and purposes as
he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or
his substitutes, may lawfully do or cause to be done by virtue thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf
of the registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
    Mark L. Baum</i></span></td>
    <td style="border-bottom: white 3pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: white 3pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Chief
    Executive Officer and Director</span></td>
    <td style="border-bottom: white 3pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: white 3pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">March
    8, 2021</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Mark
    L. Baum</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><i>(Principal
    Executive Officer)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
    Andrew R. Boll </i></span></td>
    <td style="border-bottom: white 3pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: white 3pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Chief
    Financial Officer</span></td>
    <td style="border-bottom: white 3pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: white 3pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">March
    8, 2021</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Andrew
    R. Boll</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><i>(Principal
    Accounting and Financial Officer)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
    Robert J. Kammer </i></span></td>
    <td style="border-bottom: white 3pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: white 3pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Chairman
    of the Board of Directors</span></td>
    <td style="border-bottom: white 3pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">March
    8, 2021</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Robert
    J. Kammer </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
                                         Teresa F. Sparks</i></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">March
    8, 2021</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-top: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Teresa
    F. Sparks</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
                                         Richard L. Lindstrom</i></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">March
    8, 2021</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Richard
    L. Lindstrom</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
                                         R. Lawrence Van Horn</i></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">March
    8, 2021</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">R.
    Lawrence Van Horn </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 57 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>FINANCIAL
STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Harrow
Health, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Index
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_001">Report
    of Independent Registered Public Accounting Firm</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">F-2</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_002">Consolidated
    Balance Sheets at December 31, 2020 and 2019</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">F-3</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_003">Consolidated
    Statements of Operations for the years ended December 31, 2020 and 2019</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">F-4</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_004">Consolidated
    Statements of Stockholders&#8217; Equity for the years ended December 31, 2020 and 2019</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">F-5</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_005">Consolidated
    Statements of Cash Flows for the years ended December 31, 2020 and 2019</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">F-6</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#a_006">Notes
    to the Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">F-7</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_001"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">To
the Stockholders and Board of Directors<br />
Harrow Health, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Opinion
on the Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
have audited the accompanying consolidated balance sheets of Harrow Health, Inc. and subsidiaries (the &#8220;Company&#8221;)
as of December 31, 2020 and 2019, the related consolidated statements of operations, stockholders&#8217; equity and cash flows
for each of the two years in the period ended December 31, 2020, and the related notes (collectively referred to as the &#8220;consolidated
financial statements&#8221;). In our opinion, the consolidated financial statements referred to above present fairly, in all material
respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash
flows for each of the two years in the period ended December 31, 2020, in conformity with accounting principles generally accepted
in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an
opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the
Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange
Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether
due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over
financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting
but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.
Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis,
evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the
accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the
consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Critical
Audit Matter</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements
that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that
are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments.
The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements,
taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical
audit matter or on the accounts or disclosures to which it relates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Stock-Based
Compensation &#8211; Modified Stock Option</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Critical
Audit Matter Description</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
described further in Note 14 to the consolidated financial statements, during the year ended December 31, 2020, the Company amended
an employee option to purchase 600,000 shares of the Company&#8217;s common stock, which is subject to the satisfaction of certain
market-based vesting criteria, by extending the vesting term and contractual term. Management performed a valuation of the stock
option at the date of modification with the assistance of a third-party valuation specialist, which involved estimation
of the fair value of the modified option. The Company estimated the fair value of the modified stock option using the Monte-Carlo
simulation and Black-Scholes option pricing models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Auditing
management&#8217;s valuation of the modified stock option required auditor judgment and required a high degree of subjectivity
as estimates underlying the determination of fair value were based on various inputs and significant assumptions used in the Monte-Carlo
simulation and Black-Scholes option pricing models, including the probability of triggering the market-based targets, and the
number of shares to be vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>How
the Critical Audit Matter Was Addressed in the Audit</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
audit procedures included, among others, reading the relevant Board of Directors minutes and modified stock option agreement for
accuracy and completeness of the modified stock option terms. We involved our valuation specialist to assist in the evaluation
of the Company&#8217;s determination of the fair value of the modified stock option, which included testing the appropriateness
of the methodologies and underlying assumptions used, and whether the methods used for determining fair value were applied consistently
with the valuation of similar grants in prior periods. We evaluated the significant assumptions used by management to calculate
the fair value of the modified stock option, which included the expected option term and an independent calculation of the expected
volatility based upon actual historical stock price movements over a period equal to the expected option term. We developed an
independent estimate of the fair value for the modified stock option with the assistance of our valuation specialist and compared
our estimate of fair value to the fair value determined by management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><i>/s/
</i></span><span style="font-family: Times New Roman, Times, Serif"><i><span style="font-size: 10pt">KMJ Corbin &amp; Company
LLP</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
have served as the Company&#8217;s auditor since 2007.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Irvine,
California<br />
March 8, 2021</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="a_002"></span><span style="font-size: 10pt"><b>HARROW
HEALTH, INC.</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>CONSOLIDATED
BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(In
thousands, except share data)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_111_pn3n3_z66gWhmiMqW2" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20201231_zD75CT3RJAf2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_492_20191231_zdqL1b88Q681" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--AssetsAbstract_iB_zk6AZw3fFE0l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">ASSETS</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--AssetsCurrentAbstract_i01B_zNz5Hi6jW3Ak" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_i02I_pn3n3_maACzBUg_zACBMBh0oGD8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents, including restricted cash of $<span id="xdx_909_eus-gaap--RestrictedCash_iI_pn3n3_c20201231_zgFrr6w1y0kc"><span id="xdx_903_eus-gaap--RestrictedCash_c20191231_pn3n3"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,301</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,949</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--OtherInvestments_i02I_pn3n3_maACzBUg_zPsoORuzyTP3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Investment in Eton
    Pharmaceuticals</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherInvestments" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,455</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherInvestments" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,200</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--AccountsReceivableNetCurrent_i02I_pn3n3_maACzBUg_zX7bjE9uI598" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts receivable,
    net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,662</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,009</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--InventoryNet_i02I_pn3n3_maACzBUg_zXUkjYXGMxkf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Inventories</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,962</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,301</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_pn3n3_maACzBUg_zODj2jMTSsB6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other current assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">751</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">586</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--AssetsCurrent_i02TI_pn3n3_mtACzBUg_maAzRGZ_zb83QeQPHp9i" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40,131</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36,045</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_i01I_pn3n3_maAzRGZ_zs46sQ3LpOr5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property, plant and equipment, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,453</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,375</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_pn3n3_maAzRGZ_ziyNUEm8JKp2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease right-of-use assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,799</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,559</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i01I_pn3n3_maAzRGZ_zC9qxI3NZf8i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intangible assets, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,939</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,337</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Investment in Surface Ophthalmics</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--Investments_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SurfaceOphthalmicsMember_pn3n3" title="Investments" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2020-12-31_custom_SurfaceOphthalmicsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,314</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--Investments_c20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SurfaceOphthalmicsMember_pn3n3" title="Investments" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2019-12-31_custom_SurfaceOphthalmicsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,747</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Investment in Melt Pharmaceuticals</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--Investments_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MeltPharmaceuticalsMember_pn3n3" title="Investments" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2020-12-31_custom_MeltPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,506</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--Investments_c20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MeltPharmaceuticalsMember_pn3n3" title="Investments" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Investments" contextRef="AsOf2019-12-31_custom_MeltPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,690</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--Goodwill_i01I_pn3n3_maAzRGZ_zBtnJtyq5ugg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Goodwill</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">332</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">332</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--Assets_i01TI_pn3n3_mtAzRGZ_znQJBqhVHZPe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    ASSETS</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">57,474</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">59,085</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zNbJ06ukN0Ag" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">LIABILITIES AND STOCKHOLDERS&#8217;
    EQUITY</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--LiabilitiesCurrentAbstract_i01B_zZLw2Mss7al3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_pn3n3_maLCzcJo_zhD4y7p5sSUi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable
    and accrued expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,932</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,702</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--EmployeeRelatedLiabilitiesCurrent_i02I_pn3n3_maLCzcJo_zxuOohv4xsJ" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued payroll
    and related liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,315</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,117</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--ContractWithCustomerLiabilityCurrent_i02I_pn3n3_maLCzcJo_zb1FOJ1ZDp65" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Deferred
    revenue and customer deposits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">66</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">57</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--LoansPayableCurrent_i02I_pn3n3_maLCzcJo_zXv49RBISLFb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current portion
    of paycheck protection program loan payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LoansPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,259</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0109">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--NotesPayableCurrent_i02I_pn3n3_maLCzcJo_zKDgVPwxLIX8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Current
    portion of loan payable, net of unamortized debt discount</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,639</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,772</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_pn3n3_maLCzcJo_zfE17R6ni0Dj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Current
    portion of operating lease liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">580</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">629</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--FinanceLeaseLiabilityCurrent_i02I_pn3n3_maLCzcJo_zpKTyBesiSMg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Current
    portion of finance lease obligations</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--LiabilitiesCurrent_i02TI_pn3n3_mtLCzcJo_maLzVmF_zaF8oedjvgne" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total current liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,799</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,284</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_pn3n3_maLzVmF_zUppc2DUwYy7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease liabilities, net of
    current portion</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,652</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,338</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--FinanceLeaseLiabilityNoncurrent_i01I_pn3n3_maLzVmF_zJ8L4WDzkSJ2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Finance lease obligations, net of current
    portion</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--AccountsPayableAndAccruedLiabilitiesNoncurrent_i01I_pn3n3_maLzVmF_zidkowjt1ek5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued expenses, net of current portion</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">800</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">800</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--LongTermLoansPayable_i01I_pn3n3_maLzVmF_zZEIqR9ySo1d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paycheck protection program loan payable,
    net of current portion</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LongTermLoansPayable" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">708</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0133">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--LongTermNotesPayable_i01I_pn3n3_maLzVmF_znctV3oTwoLc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Loan payable,
    net of current portion and unamortized debt discount</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,670</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,219</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--Liabilities_i01TI_pn3n3_mtLzVmF_maLASEzD8h_zmQfCi9rhXH2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-left: 20pt; font-style: normal; text-align: left; padding-bottom: 1.5pt; font-weight: normal"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    LIABILITIES</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,646</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31,667</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--CommitmentsAndContingencies_i01I_pn3n3_maLASEzD8h_zleoB5N1GGue" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">COMMITMENTS AND CONTINGENCIES</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B_z0vzC96MWQt9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">STOCKHOLDERS&#8217; EQUITY</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--CommonStockValue_i02I_pn3n3_maSEz1uz_zqkb8ISgl9tg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Common stock, $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pii_c20191231_zmWTcXt8mkYd" title="Common stock, par value"><span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pii_c20201231_zhSlvQ63xlA9" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif">par value, <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pii_c20201231_z7zwGd3JHTt3" title="Common stock, sharess authorized"><span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pii_c20191231_z13KtwNmTCv9" title="Common stock, sharess authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></ix:nonFraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif">shares authorized, <span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_pii_c20201231_zImfqPmyCJqb" title="Common stock, shares outstanding"><span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_pii_c20201231_z6ef6kFtfDX8" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,749,875</ix:nonFraction></ix:nonFraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif">and <span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_pii_c20191231_z0BdE1zBw6Z" title="Common stock, shares outstanding"><span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_pii_c20191231_zdTQShgvXblh" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,526,931</ix:nonFraction></ix:nonFraction></span>
    </span></span><span style="font-family: Times New Roman, Times, Serif">shares issued and outstanding at December 31, 2020
    and December 31, 2019, respectively</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--AdditionalPaidInCapital_i02I_pn3n3_maSEz1uz_zTQ8WohEgdMe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Additional paid-in
    capital</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">104,557</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">101,728</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pn3n3_maSEz1uz_zqdZ9qTdLi3a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">77,400</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">74,043</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_406_eus-gaap--StockholdersEquity_i02TI_pn3n3_mtSEz1uz_maSEIPAzJr0_z27vxbqjXvw1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">TOTAL HARROW HEALTH
    STOCKHOLDERS&#8217; EQUITY</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,183</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,711</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--MinorityInterest_i02I_pn3n3_maSEIPAzJr0_znN3uSup3fL3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Noncontrolling
    interests</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">355</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:MinorityInterest" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">293</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_406_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_i02TI_pn3n3_mtSEIPAzJr0_maLASEzD8h_zLTTrgC3bwz9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    EQUITY</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,828</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,418</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pn3n3_mtLASEzD8h_zIZ3gYkEIfC2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; padding-left: 20pt; font-style: normal; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    LIABILITIES AND EQUITY</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">57,474</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">59,085</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying notes are an integral part of these consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="a_003"></span><b>HARROW
HEALTH, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>CONSOLIDATED
STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(In
thousands, except for share and per share data)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_113_pn3n3_zsj9zKRWPlq1" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20200101__20201231_zI7ngPJY65b" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_496_20190101__20191231_zX99wj83RqC" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Years Ended December 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--RevenuesAbstract_iB_zFzE1h5xzqqj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Revenues:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Product
    sales, net</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_pn3n3" title="Total revenues" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-12-31_custom_ProductSalesNetMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48,479</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_pn3n3" title="Total revenues" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_custom_ProductSalesNetMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51,137</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other
    revenues</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ProductOrServiceAxis__custom--OtherRevenuesMember_pn3n3" title="Total revenues" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-12-31_custom_OtherRevenuesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">392</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--OtherRevenuesMember_pn3n3" title="Total revenues" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_custom_OtherRevenuesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i01_pn3n3_maGPzSqM_zU0kovqxPRga" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total revenues</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48,871</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51,165</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_msGPzSqM_zI1og4rHG8fk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Cost of sales</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,463</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,749</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40F_eus-gaap--GrossProfit_iT_pn3n3_mtGPzSqM_maOILzve7_z0Bs1uI507J9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Gross profit</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34,408</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34,416</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_zkLooRpV8u18" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_pn3n3_maOEzjph_z57VkzZ6G5B8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Selling, general
    and administrative</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31,247</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">33,088</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_i01_pn3n3_maOEzjph_zti4uOAql6od" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,413</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,083</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_i01_pn3n3_maOEzjph_zedGR35QakMf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Impairment
    of long-lived assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">363</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,040</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--OperatingExpenses_i01T_pn3n3_mtOEzjph_msOILzve7_z361yfhWJQ59" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total operating
    expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34,023</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39,211</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--OperatingIncomeLoss_iT_pn3n3_mtOILzve7_zEJCr3EKPR6f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Income (loss)
    from operations</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">385</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,795</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_409_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zu8lCnCU9Dsk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other income (expense):</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--InterestIncomeExpenseNet_i01_pn3n3_maNIEzOjz_zwxW1RoyZo02" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest expense,
    net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,236</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Investment (loss)
    gain from Melt Pharmaceuticals, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--GainLossOnInvestments_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MeltPharmaceuticalsMember_pn3n3" title="Investment (loss) gain, net" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2020-01-012020-12-31_custom_MeltPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,313</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--GainLossOnInvestments_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MeltPharmaceuticalsMember_pn3n3" title="Investment (loss) gain, net" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2019-01-012019-12-31_custom_MeltPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,968</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Investment loss
    from Surface Ophthalmics, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--GainLossOnInvestments_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SurfaceOphthalmicsMember_pn3n3" title="Investment (loss) gain, net" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2020-01-012020-12-31_custom_SurfaceOphthalmicsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,433</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--GainLossOnInvestments_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SurfaceOphthalmicsMember_pn3n3" title="Investment (loss) gain, net" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2019-01-012019-12-31_custom_SurfaceOphthalmicsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,200</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Investment gain
    from Eton Pharmaceuticals, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--GainLossOnInvestments_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EtonPharmaceuticalsMember_pn3n3" title="Investment (loss) gain, net" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2020-01-012020-12-31_custom_EtonPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,255</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--GainLossOnInvestments_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EtonPharmaceuticalsMember_pn3n3" title="Investment (loss) gain, net" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2019-01-012019-12-31_custom_EtonPharmaceuticalsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,780</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--OtherNonoperatingIncomeExpense_i01_pn3n3_maNIEzOjz_zUYnIORxDyvk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other
    (loss) income, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">73</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">630</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--NonoperatingIncomeExpense_i01T_pn3n3_mtNIEzOjz_maPLz6Zw_z85Tx3OxUDxj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total other (loss)
    income, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,800</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,678</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_maPLz6Zw_zRVUG2oO6HH9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss before income tax provision</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,415</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">117</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_msPLz6Zw_zvs8QpgryM14" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Income
    tax provision</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"></td></tr>
<tr id="xdx_407_eus-gaap--ProfitLoss_iT_pn3n3_mtPLz6Zw_maNILzCpV_zqKbgysxfxKc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total net loss including
    noncontrolling interests</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,419</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">125</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_409_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_iN_pn3n3_di_msNILzCpV_zTvrvGruY9a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss attributable to noncontrolling interests</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">62</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">293</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--NetIncomeLoss_iT_pn3n3_mtNILzCpV_zQ4spw6ZPjPj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net (loss) income
    attributable to Harrow Health, Inc.</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,357</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">168</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--EarningsPerShareBasic_pii_z6VAOsQlA8H5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Basic net (loss)
    income per share of common stock</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.13</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--EarningsPerShareDiluted_pii_zXdSef1BSEfi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Diluted net (loss)
    income per share of common stock</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.13</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_z5tKAviMJI4j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average number of common
    shares outstanding, basic</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,895,352</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,323,159</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pii_zL9cyGkR6Fk6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average number of common
    shares outstanding, diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,895,352</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,466,098</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying notes are an integral part of these consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="a_004"></span><span style="font-size: 10pt"><b>HARROW
HEALTH, INC. </b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>CONSOLIDATED
STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For
the Years Ended December 31, 2020 and 2019</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(In
thousands, except for share data)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_114_pn3n3_z2JNI80wG9V3" summary="xdx: Statement - Consolidated Statements of Stockholders&apos; Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zj4W75jtoVc8" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zQeSrg6L3fm" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zsLvKA9MtAw3" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--ParentMember_z4mfodu7thtk" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--NoncontrollingInterestMember_zzdHZNbmRn6l" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BA_zF2ANYB9lS3j" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common
    Stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Additional</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="display: none"></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total
    Harrow Health, Inc.</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total
    Noncontrolling</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Par</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Paid-in</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Stockholders&#8217;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Stockholders&#8217;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_439_c20190101__20191231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zKXOIRA3m4F1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%"><span style="font-family: Times New Roman, Times, Serif">Balance at January 1, 2019</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pii_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfWoQE10ntde" title="Balance, shares" style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,339,610</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">98,938</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">74,211</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2018-12-31_us-gaap_ParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,751</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0277">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,751</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance of common stock in connection
    with:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_ecustom--StockIssuedDuringPeriodForExerciseOfWarrants_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Exercise of warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--StockIssuedDuringPeriodSharesForExerciseOfWarrants_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" title="Exercise of warrants, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:StockIssuedDuringPeriodSharesForExerciseOfWarrants" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,142,528</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:StockIssuedDuringPeriodForExerciseOfWarrants" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:StockIssuedDuringPeriodForExerciseOfWarrants" contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">811</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0284">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:StockIssuedDuringPeriodForExerciseOfWarrants" contextRef="From2019-01-012019-12-31_us-gaap_ParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">813</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0286">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:StockIssuedDuringPeriodForExerciseOfWarrants" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">813</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueEmployeeBenefitPlan_iN_pn3n3_di_z4CtInxUW8oh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercise of employee
    options, net of tax withholding</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesEmployeeBenefitPlan_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" title="Exercise of employee options, net of tax withholding, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">29,793</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0291">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0293">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2019-01-012019-12-31_us-gaap_ParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0295">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40D_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_zOrqdmcclOO5" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Issuance of common stock related to vesting of RSUs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pii_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk1ffcZDe0Ba" title="Issuance of common stock related to vesting of RSUs, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0307">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0300">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0301">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0302">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0303">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0304">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0305">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zprt0gwouDkh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based payment
    for services provided</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" title="Stock-based payment for services provided, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0309">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">234</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0311">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2019-01-012019-12-31_us-gaap_ParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">234</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0313">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">234</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zCs2EN4UC8i3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0318">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,789</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0320">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-12-31_us-gaap_ParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,789</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0322">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,789</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--ProfitLoss_zbAJVFHKkMbb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net income (loss)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0325">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0326">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">168</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2019-01-012019-12-31_us-gaap_ParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">168</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">293</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">125</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_437_c20190101__20191231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_z5jvDKpCtcme" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2019</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_pii_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zm0Zmjtzafx1" title="Balance, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,526,931</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">101,728</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">74,043</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31_us-gaap_ParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,711</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">293</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,418</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_43D_c20200101__20201231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iS_zAg5OAkaLiO2" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2019</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td title="Balance, shares" id="xdx_981_eus-gaap--SharesOutstanding_iS_pii_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrGpiDtPdgWg" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,526,931</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">101,728</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">74,043</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31_us-gaap_ParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,711</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">293</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,418</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance of common stock in connection
    with:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueEmployeeBenefitPlan_iN_pn3n3_di_zh7OVh8jeP62" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercise of employee
    options, net of tax withholding</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesEmployeeBenefitPlan_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" title="Exercise of employee stock-based options, net of tax withholding , shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,159</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0350">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0352">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2020-01-012020-12-31_us-gaap_ParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0354">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Issuance of common stock related
    to vesting of</span><span style="font-family: Times New Roman, Times, Serif"> RSUs</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pii_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEa3RRy45RMf" title="Issuance of common stock related to vesting of RSUs, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">185,785</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0359">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0360">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0361">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0362">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0363">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zg5XQy5XweLl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based payment
    for services provided</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" title="Stock-based payment for services provided, shares" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0368">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">83</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0370">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-01-012020-12-31_us-gaap_ParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">83</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0372">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">83</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0377">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,775</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0379">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-12-31_us-gaap_ParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,775</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0381">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,775</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--ProfitLoss_i_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0384">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0385">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,357</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-01-012020-12-31_us-gaap_ParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,357</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">62</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,419</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_435_c20200101__20201231_eus-gaap--StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_iE_z15qz50oHo1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at December 31, 2020</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_pii_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5YhGJLXUIV2" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,749,875</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">104,557</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">77,400</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_ParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,183</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">355</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,828</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying notes are an integral part of these consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_005"></span>HARROW
HEALTH, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(In
thousands)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_112_pn3n3_zYETsarQGrI7" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20200101__20201231_zdADgExG3Fpf" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20190101__20191231_zy6hWy0mGVv8" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Years Ended December 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_ziJ4k0aveisd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">CASH FLOWS FROM OPERATING ACTIVITIES</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--ProfitLoss_i01_maCzllX_zZIhV7qq0av9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    loss (including noncontrolling interests)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,419</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">125</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40A_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zrKVOrvE2sVh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Adjustments to reconcile
    net loss to net cash (used in) provided by operating activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--DepreciationAndAmortization_i02_maCzllX_zlXSoYCrqk2j" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Depreciation and
    amortization of property, plant and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,880</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,936</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_ecustom--AmortizationOfIntangibleAsset_i02_maCzllX_zpVvqZUpytWe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Amortization of
    intangible assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:AmortizationOfIntangibleAsset" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">167</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:AmortizationOfIntangibleAsset" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">209</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_ecustom--AmortizationOfOperatingLeaseRightofuseAssets_i02_maCzllX_zOJC0T5TJvB9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Amortization of
    operating lease right-of-use assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:AmortizationOfOperatingLeaseRightofuseAssets" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">696</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:AmortizationOfOperatingLeaseRightofuseAssets" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">518</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--ProvisionForDoubtfulAccounts_i02_maCzllX_zua2EYPJ4zEb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Provision for bad
    debt expense</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">213</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0419">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--PaidInKindInterest_i02_maCzllX_z9RMiozz3hm5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest paid-in-kind
    on SWK Loan</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PaidInKindInterest" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">358</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0422">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i02_maCzllX_zJmJiL1IqMZ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Amortization of
    debt issuance costs and discount</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">457</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">512</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_ecustom--GainLossOnInvestmentsOne_i02N_di_msCzllX_zuy2n5oQs2zk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Investment gain
    from Eton Pharmaceuticals, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HROW:GainLossOnInvestmentsOne" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,255</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HROW:GainLossOnInvestmentsOne" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,780</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_409_ecustom--GainLossOnInvestmentsTwo_i02N_di_msCzllX_ztywjlr8NRyg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Investment loss
    from Surface Ophthalmics, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:GainLossOnInvestmentsTwo" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,433</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:GainLossOnInvestmentsTwo" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,200</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_ecustom--GainLossOnInvestmentsThree_i02N_di_msCzllX_zolDS6oHj1E8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Investment loss
    (gain) from Melt Pharmaceuticals, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:GainLossOnInvestmentsThree" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,313</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HROW:GainLossOnInvestmentsThree" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,968</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_409_eus-gaap--GainLossOnDispositionOfAssets1_i02N_pn3n3_di_msCzllX_zt8Oxazsgmx2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss on disposal
    of equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">105</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">108</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_ecustom--ImpairmentsOfLongLivedAssetsHeldForUse_i02_maCzllX_zIYEcyYq5FKb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Impairment of long-lived
    assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:ImpairmentsOfLongLivedAssetsHeldForUse" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">363</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:ImpairmentsOfLongLivedAssetsHeldForUse" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,040</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_i02_maCzllX_zd8WevWxaEQ6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based payment
    of consulting services</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">83</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">234</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--ShareBasedCompensation_i02_maCzllX_zuGFnp73Znmb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,775</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,789</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOperatingAssetsAbstract_i02B_zPtpZl2oXhH5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Changes in assets
    and liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_msCzllX_zzzD4mcxtZIb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts receivable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">866</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">95</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40B_eus-gaap--IncreaseDecreaseInInventories_i03N_di_msCzllX_zXiuhgcCYG91" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Inventories</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">661</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,271</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_407_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msCzllX_zbIHHRWhiRV2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid expenses
    and other current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">294</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">471</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40A_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i03_maCzllX_zrv0LBp98fy3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accounts payable
    and accrued expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,655</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,342</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--IncreaseDecreaseInEmployeeRelatedLiabilities_i03_maCzllX_zAo4Ne21z2ug" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued payroll
    and related liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">198</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">166</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_408_eus-gaap--IncreaseDecreaseInContractWithCustomerLiability_i03_maCzllX_zJskQkXxIxh5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Deferred
    revenue and customer deposits</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">62</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtCzllX_maCzPem_zLj47amgnA35" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">NET CASH (USED
    IN) PROVIDED BY OPERATING ACTIVITIES</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,100</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">950</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zFdNuMm9I6bc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">CASH FLOWS FROM INVESTING ACTIVITIES</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--ProceedsFromSaleOfProductiveAssets_i01_maCzNwV_z95MXltYTDSl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds on sale
    and disposal of assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfProductiveAssets" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfProductiveAssets" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_di_msCzNwV_zJRXk3SpVphd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Investment in patent
    and trademark assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">132</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">369</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40B_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCzNwV_zsS4iAuvJuwc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Purchases
    of property, plant and equipment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">862</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,468</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCzNwV_maCzPem_z6OMnhUiTFi6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">NET CASH USED
    IN INVESTING ACTIVITIES</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">981</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,833</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zzIKLGz4rpdl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">CASH FLOWS FROM FINANCING ACTIVITIES</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--FinanceLeasePrincipalPayments_i01N_di_msCz4J2_z0mUBqfe8wZ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Payments on finance
    lease obligations</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">743</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40A_eus-gaap--ProceedsFromOtherDebt_i01_maCz4J2_z12tiApoXqTj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds from SWK
    loan</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromOtherDebt" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0494">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--RepaymentsOfNotesPayable_i01N_di_msCz4J2_zZMdB55iEdid" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Principal payments
    on SWK loan</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,497</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">750</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_400_ecustom--PaymentsOfCostsRelatedToAmendmentOfLoanPayable_i01N_di_msCz4J2_zvFdgrYt2lBb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Payments of costs
    related to amendment of SWK loan</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0499">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HROW:PaymentsOfCostsRelatedToAmendmentOfLoanPayable" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">282</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40B_eus-gaap--ProceedsFromNotesPayable_i01_maCz4J2_zflEOSnFrDr5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Proceeds from Paycheck
    protection program loan payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,967</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0503">&#160;</span></span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_401_ecustom--ProceedsFromExerciseOfWarrantsAndStockOptionsNetOfTaxes_i01_maCz4J2_zwCPdZPaGOE7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net proceeds from
    exercise of warrants and stock options, net of taxes remitted for RSU&#8217;s and options</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HROW:ProceedsFromExerciseOfWarrantsAndStockOptionsNetOfTaxes" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">29</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:ProceedsFromExerciseOfWarrantsAndStockOptionsNetOfTaxes" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">769</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCz4J2_maCzPem_z9AZcamjtmJ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">NET CASH PROVIDED
    BY (USED IN) FINANCING ACTIVITIES</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,433</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,006</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCzPem_za1RjpSmM2J2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">NET CHANGE IN CASH, CASH EQUIVALENTS
    AND RESTRICTED CASH</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">648</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,889</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_z7mj3DMYOkvk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">CASH,
    CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,949</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,838</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_pn3n3_zJapQ5GpyyC3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">CASH,
    CASH EQUIVALENTS AND RESTRICTED CASH, end of period</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,301</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,949</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_ecustom--ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract_iB_zoZFVNrmTAK8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">RECONCILIATION OF CASH, CASH EQUIVALENTS
    AND RESTRICTED CASH</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01E_zH2DmEZQq5Eg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,101</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,749</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--RestrictedCash_i01E_zwXZh2NWVh9j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Restricted
    cash</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_ecustom--CashCashEquivalentsAndRestrictedCashAtEndOfPeriod_i01E_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">CASH, CASH EQUIVALENTS
    AND RESTRICTED CASH AT END OF PERIOD</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:CashCashEquivalentsAndRestrictedCashAtEndOfPeriod" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,301</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:CashCashEquivalentsAndRestrictedCashAtEndOfPeriod" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,949</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zP0yLoR3Q2Fd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">SUPPLEMENTAL DISCLOSURE
    OF CASH FLOW INFORMATION:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--IncomeTaxesPaidNet_i01_zYuWdDSSjpYe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    paid for income taxes</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--InterestPaidNet_i01_zYd0h9YtbOCc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash
    paid for interest</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,791</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,967</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zwK2DQQIL5Y1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">SUPPLEMENTAL DISCLOSURES
    OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_ecustom--PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedExpenses_i01_zNpmRzjo6WPl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Purchase of property,
    plant and equipment included in accounts payable and accrued expenses</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">214</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_ecustom--NewAndRevaluationOfRightofuseAssetObtainedInExchangeForLeaseObligation_i01_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">New
    and revaluation of right-of-use assets obtained in exchange for lease obligation</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:NewAndRevaluationOfRightofuseAssetObtainedInExchangeForLeaseObligation" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">936</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:NewAndRevaluationOfRightofuseAssetObtainedInExchangeForLeaseObligation" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">753</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying notes are an integral part of these consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="a_006"></span><span style="font-size: 10pt"><b>HARROW
HEALTH, INC.</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For
the Year Ended December 31, 2020 and 2019</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(all
dollar amounts are expressed in thousands, except share and per share data)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zyvgbrUmEEH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
1. <span id="xdx_82A_zCKsoyU89C83">ORGANIZATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Harrow
Health, Inc. (together with its subsidiaries, partially owned companies and royalty arrangements unless the context indicates
or otherwise requires, the &#8220;Company&#8221; or &#8220;Harrow&#8221;) specializes in the development, production and sale
of innovative medications that offer unique competitive advantages and serve unmet needs in the marketplace through its subsidiaries
and deconsolidated companies. The Company owns one of the nation&#8217;s leading ophthalmology-focused pharmaceutical businesses,
ImprimisRx. In addition to wholly owning ImprimisRx, the Company also has equity positions in Eton Pharmaceuticals, Inc. (&#8220;Eton&#8221;),
Surface Ophthalmics, Inc. (&#8220;Surface&#8221;), and Melt Pharmaceuticals, Inc. (&#8220;Melt&#8221;), all companies that began
as subsidiaries of Harrow. In 2020, Harrow created Visionology, Inc. (&#8220;Visionology&#8221;), which intends to launch an online
eye health platform business. Harrow also owns royalty rights in various drug candidates being developed by Surface and Melt.
The Company intends to continue to create, and hold equity and royalty rights in, new businesses that commercialize drug candidates
that are internally developed or otherwise acquired or licensed from third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
and subsequent to the year ended December 31, 2020, the Company discontinued the majority of operational efforts related to its
subsidiaries Stowe Pharmaceuticals, Inc. (&#8220;Stowe&#8221;), Radley Pharmaceuticals, Inc. (&#8220;Radley&#8221;) and Mayfield
Pharmaceuticals, Inc. (&#8220;Mayfield&#8221;) to allocate resources to other areas of the Company&#8217;s business. The Company
does not expect the suspension of these operations to have a material impact on the financial results of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_807_eus-gaap--SignificantAccountingPoliciesTextBlock_zj1B6xAxJlNf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
2. <span id="xdx_82D_zBpWLEXAj7Bj">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zB2g7lpJjhz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_866_z5k7PSmrvwA3" style="font: 10pt Times New Roman, Times, Serif"><b>Basis
of Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Harrow
has prepared the accompanying consolidated financial statements in accordance with accounting principles generally accepted in
the United States of America (&#8220;GAAP&#8221;). The accompanying consolidated financial statements include the accounts of
the Company and its wholly-owned subsidiaries, as well as Mayfield, <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__srt--OwnershipAxis__custom--MayfieldPharmaceuticalsIncMember_zzFi1Xe7zli6"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2020-12-31_custom_MayfieldPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">79</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
majority controlled, and Stowe, <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__srt--OwnershipAxis__custom--StowePharmaceuticalsIncMember_zaCIkRXxt1I3"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2020-12-31_custom_StowePharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">70</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
majority controlled as of December 31, 2020. The remaining <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__srt--OwnershipAxis__custom--MayfieldPharmaceuticalsIncMember__dei--LegalEntityAxis__custom--TGVHealthLLCMember_zejqdJASHqdl"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2020-12-31_custom_MayfieldPharmaceuticalsIncMember_custom_TGVHealthLLCMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">21</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of Mayfield is owned by Elle Pharmaceutical, LLC (&#8220;Elle&#8221;), TGV-Health, LLC and its affiliated entities (collectively
&#8220;TGV&#8221;) or other consultants. Mayfield was organized to develop women&#8217;s health and urological focused drug candidates.
The remaining <span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__srt--OwnershipAxis__custom--StowePharmaceuticalsIncMember__dei--LegalEntityAxis__custom--TGVHealthLLCMember_zVvLbLg0IAcb"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2020-12-31_custom_StowePharmaceuticalsIncMember_custom_TGVHealthLLCMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">30</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of Stowe was owned by TGV. Stowe was organized to develop ophthalmic drug candidates. The Company controls <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__dei--LegalEntityAxis__custom--VisionologyMember_zkoNfOuU98G"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2020-12-31_custom_VisionologyMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">100</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of the equity interests in Visionology. All inter-company accounts and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Harrow
consolidates entities in which we have a controlling financial interest. <span id="xdx_90A_ecustom--ConsolidationBasisDescription_c20200101__20201231_zIrQSZmahuie"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="HROW:ConsolidationBasisDescription">We
consolidate subsidiaries in which we hold and/or control, directly or indirectly, more than 50% of the voting rights</ix:nonNumeric></span></span><span style="font: 10pt Times New Roman, Times, Serif">.
All intercompany accounts and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_844_eus-gaap--UseOfEstimates_zpQsid6VybDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_867_z7UJDpJDayr5" style="font: 10pt Times New Roman, Times, Serif"><b>Use
of Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management are, among
others, allowance for doubtful accounts and contractual adjustments, renewal periods and discount rates for leases, realizability
of inventories, valuation of investments, realizability of deferred taxes, recoverability of goodwill and long-lived assets,
valuation of contingent acquisition obligations and deferred acquisition obligations, fair value of loans payable, and valuation
of stock-based transactions with employees and non-employees. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="HROW:RisksUncertaintiesAndLiquidityPolicyTextBlock"><p id="xdx_843_ecustom--RisksUncertaintiesAndLiquidityPolicyTextBlock_zs7OziXE2Ufl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span id="xdx_863_zxtiQMgtw2R2" style="font: 10pt Times New Roman, Times, Serif"><b>Risks,
Uncertainties and Liquidity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. On March 18, 2020, the Centers for Medicare
&amp; Medicaid Services (&#8220;CMS&#8221;) released guidance for U.S. healthcare providers to limit all elective medical procedures
in order to conserve personal protective equipment and limit exposure to COVID-19 during the pendency of the pandemic. In addition
to limiting elective medical procedures, many hospitals and other healthcare providers have strictly limited access to their facilities
during the pandemic. The COVID-19 pandemic has negatively impacted the global economy, disrupted global supply chains and healthcare
delivery, led to social distancing recommendations, stay-at-home orders and other restrictive measures, and created significant
volatility in financial markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Many
of the Company&#8217;s customers use its drugs in procedures impacted by the CMS guidance to limit elective procedures. In addition,
the Company and our business partners need access to healthcare providers and facilities to conduct clinical trials and other
activities required to achieve regulatory clearance of products under development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Management
believes reductions in elective procedures in response to CMS guidance have had, and will continue to have, an adverse impact,
which may be material, on the Company&#8217;s financial condition, liquidity and results of operations. The severity of the impact
of the COVID-19 pandemic on the Company&#8217;s business will depend on a number of factors, including, but not limited to, the
duration and severity of the pandemic and the extent and severity of the impact on its customers, all of which are uncertain and
cannot be predicted. As of the date of the filing of this Annual Report on Form 10-K, the extent to which the COVID-19 pandemic
may materially impact the Company&#8217;s financial condition, liquidity or results of operations is uncertain. In addition, the
Company is subject to certain regulatory standards, guidelines and inspections which could impact the Company&#8217;s ability
to make, dispense, and sell certain products. If the Company was required to cease compounding and selling certain products as
a result of regulatory guidelines or inspections, this may have a material impact on the Company&#8217;s financial condition,
liquidity and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Prior
to 2020, the Company had incurred significant operating losses and negative cash flows from operations since its inception. The
Company recorded operating income of $<span id="xdx_900_eus-gaap--OperatingIncomeLoss_pn3n3_c20200101__20201231_zrqkwi258fMh"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">385</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for the year ended December 31, 2020 and
recorded an operating loss of $<span id="xdx_908_eus-gaap--OperatingIncomeLoss_iN_pn3n3_di_c20190101__20191231_zeWB0DB2LjV2"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,795</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for the year ended December 31, 2019.
The Company has an accumulated deficit of $<span id="xdx_90C_ecustom--RetainedEarningsAccumulatedDeficit1_iI_pn3n3_c20201231_zSluZYSmXt7l"><ix:nonFraction name="HROW:RetainedEarningsAccumulatedDeficit1" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">77,400</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_902_ecustom--RetainedEarningsAccumulatedDeficit1_c20191231_pn3n3"><ix:nonFraction name="HROW:RetainedEarningsAccumulatedDeficit1" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">74,043</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">as of December 31, 2020 and 2019, respectively.
In addition, the Company used cash in operating activities of $<span id="xdx_90A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20200101__20201231_zzvRseKWRTyk"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,100</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for the year ended December 31, 2020 and
cash provided by operating activities was $<span id="xdx_90B_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20190101__20191231_pn3n3"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">950</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for the year ended December 31, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">While
there is no assurance, management of the Company believes existing cash resources and restricted cash of $<span id="xdx_904_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c20201231_pn3n3"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,301</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">at December 31, 2020 together with cash
generated from operations, will be sufficient to sustain the Company&#8217;s planned level of operations for at least the next
twelve months. However, estimates of operating expenses and working capital requirements and the future impact of the COVID-19
pandemic on its business could be incorrect. The Company could use its cash resources faster than anticipated. Further, some or
all of the ongoing or planned activities may not be successful and could result in further losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company may seek to increase liquidity and capital resources through a variety of means which may include, but are not limited
to: the sale of assets, investments and/or businesses, obtaining financing through the issuance of equity, debt, or convertible
securities; and working to increase revenue growth through sales. There is no guarantee that the Company will be able to obtain
capital when needed on terms management deems acceptable, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_846_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zpKEVQaOaRf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_862_zVPS8MSdP6Ni" style="font: 10pt Times New Roman, Times, Serif"><b>Segments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s chief operating decision-maker is its Chief Executive Officer who makes resource allocation decisions and assesses
performance based on financial information presented as operating segments. The Company has identified <span id="xdx_903_eus-gaap--NumberOfReportableSegments_pii_dc_uSegment_c20200101__20201231_zZ5WqNKZm3U2"><ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2020-01-01to2020-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Segment">two
</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">operating segments as reportable segments.
See Note 18 for more information regarding the Company&#8217;s reportable segments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="HROW:NoncontrollingInterestPolicyTextBlock"><p id="xdx_84A_ecustom--NoncontrollingInterestPolicyTextBlock_zmlNb8sMDXV7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_864_ziIUmOoVZ9f7" style="font: 10pt Times New Roman, Times, Serif"><b>Noncontrolling
Interests</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recognizes any noncontrolling interest as a separate line item in equity in the consolidated financial statements. A noncontrolling
interest represents the portion of equity ownership in a less-than-wholly-owned subsidiary not attributable to the Company. <span id="xdx_901_eus-gaap--MinorityInterestDescription_c20200101__20201231"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="us-gaap:MinorityInterestDescription">Generally,
any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there
are other factors, such as decision-making rights, that are considered as well.</ix:nonNumeric></span></span> <span style="font: 10pt Times New Roman, Times, Serif">The
Company includes the amount of net loss attributable to noncontrolling interests in consolidated net loss on the face of the consolidated
statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company provides in the consolidated statements of stockholders&#8217; equity a reconciliation at the beginning and the end of
the period of the carrying amount of total equity, equity attributable to the parent, and equity attributable to the noncontrolling
interests that separately discloses:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">net
    income or loss;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">transactions
    with owners acting in their capacity as owners, showing separately contributions from and distributions to owners; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">each
    component of other income or loss.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_842_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zwbvARH7jyOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86B_zdyYS700LCO1" style="font: 10pt Times New Roman, Times, Serif"><b>Revenue
Recognition and Deferred Revenue</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recognizes revenue at the time of transfer of promised goods to customers in an amount that reflects the consideration
to which the Company expects to be entitled in exchange for those goods or services (see Note 3).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="HROW:CostOfSalePolicyTextBlock"><p id="xdx_84F_ecustom--CostOfSalePolicyTextBlock_zNULLezY0Jaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86C_zVGLpbcWyQqj" style="font: 10pt Times New Roman, Times, Serif"><b>Cost
of Sales</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cost
of sales includes direct and indirect costs to manufacture formulations and other products sold, including active pharmaceutical
ingredients, personnel costs, packaging, storage, royalties, shipping and handling costs and the write-off of obsolete inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_zi0BbAIaxsOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_869_zXwXtE0Lq2Ta" style="font: 10pt Times New Roman, Times, Serif"><b>Research
and Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company expenses all costs related to research and development as they are incurred. Research and development expenses consist
of expenses incurred in performing research and development activities, including salaries and benefits, other overhead expenses,
and costs related to clinical trials, contract services and outsourced contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:DebtPolicyTextBlock"><p id="xdx_84C_eus-gaap--DebtPolicyTextBlock_zUNT5Nkwu00h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86A_zj9yw1nxbvQk" style="font: 10pt Times New Roman, Times, Serif"><b>Debt
Issuance Costs and Debt Discount</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Debt
issuance costs and the debt discount are recorded net of loans payable and finance lease obligations in the consolidated balance
sheets. Amortization of debt issuance costs and the debt discount is calculated using the effective interest method over the term
of the related debt and is recorded in interest expense in the accompanying consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"><p id="xdx_84F_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zxVT0PJq49oi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86D_zju760bhyMl8" style="font: 10pt Times New Roman, Times, Serif"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
costs of acquiring intellectual property rights to be used in the research and development process, including licensing fees and
milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified
an alternative future use for the acquired rights, and are capitalized in situations where we have identified an alternative future
use for the acquired rights. Patents and trademarks are recorded at cost and capitalized at a time when the future economic benefits
of such patents and trademarks become more certain (see &#8220;&#8212;Goodwill and Intangible Assets&#8221; below). The Company
began capitalizing certain costs associated with acquiring intellectual property rights during 2015; if costs are not capitalized
they are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zsSvygYBqgej" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_865_zpB7sR0mJIUh" style="font: 10pt Times New Roman, Times, Serif"><b>Income
Taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for income taxes under the provisions of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting
Standards Codification (&#8220;ASC&#8221;) 740, <i>Income Taxes</i>.</span><span style="font-family: Times New Roman, Times, Serif">
<span style="font-size: 10pt">As part of the process of preparing the Company&#8217;s consolidated financial statements, the Company
must estimate the actual current tax assets and liabilities and assess permanent and temporary differences that result from differing
treatment of items for tax and accounting purposes. The temporary differences result in deferred tax assets and liabilities, which
are included within the consolidated balance sheets. The Company must assess the likelihood that the deferred tax assets will
be recovered from future taxable income and, to the extent the Company believes that recovery is not more likely than not, a valuation
allowance must be established which reduces the amount of deferred tax assets recorded on the consolidated balance sheets. To
the extent the Company establishes a valuation allowance or increase or decrease this allowance in a period, the impact will be
included in income tax expense in the consolidated statements of operations.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zuJwTGl323H2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_865_zZc9Bcgsjwok" style="font: 10pt Times New Roman, Times, Serif"><b>Cash
and Cash Equivalents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cash
equivalents include short-term, highly liquid investments with maturities of three months or less at the time of acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zcW8Et4GKXgc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_866_za6tIB3JWyPe" style="font: 10pt Times New Roman, Times, Serif"><b>Concentrations
of Credit Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company places its cash with financial institutions deemed by management to be of high credit quality. The Federal Deposit Insurance
Corporation (&#8220;FDIC&#8221;) provides basic deposit coverage with limits up to $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_pn3n3_c20201231_zoSZhuyxZU2d"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">250</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per owner. From time to time the Company
has cash deposits in excess of FDIC limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:InvestmentPolicyTextBlock"><p id="xdx_849_eus-gaap--InvestmentPolicyTextBlock_zxoMNsKe1V7l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86D_zv7fnV1OYq7i" style="font: 10pt Times New Roman, Times, Serif"><b>Investment
in Eton Pharmaceuticals, Inc. &#8211; Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company owns <span id="xdx_903_ecustom--NumberOfSharesOwned_c20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pii"><ix:nonFraction name="HROW:NumberOfSharesOwned" contextRef="AsOf2020-12-31_custom_EtonPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,500,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of Eton common stock, which represents
approximately <span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zM8adaGIWvig"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2020-12-31_custom_EtonPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">14.4</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of the equity and voting interests of Eton as of December 31, 2020. At December 31, 2020, the fair market value of Eton&#8217;s
common stock was $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_c20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pii"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2020-12-31_custom_EtonPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.13</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per share. In accordance with Accounting
Standard Update (&#8220;ASU&#8221;) 2016-01, <i>Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of
Financial Assets and Financial Liabilities</i>, for the years ended December 31, 2020 and 2019, the Company recorded investment
gains from its Eton common stock position of $<span id="xdx_900_eus-gaap--GainLossOnInvestments_c20200101__20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pn3n3"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2020-01-012020-12-31_custom_EtonPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,255</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_903_eus-gaap--GainLossOnInvestments_c20190101__20191231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pn3n3"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="From2019-01-012019-12-31_custom_EtonPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,780</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively, related to the change in fair market value of the Company&#8217;s investment in Eton during the measurement periods.
As of December 31, 2020 and 2019, the fair market value of the Company&#8217;s investment in Eton was $<span id="xdx_909_eus-gaap--InvestmentOwnedAtFairValue_c20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pn3n3"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2020-12-31_custom_EtonPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,455</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_905_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3n3_c20191231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zAouulE0m7Wh"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2019-12-31_custom_EtonPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,200</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Mark
Baum, the Company&#8217;s Chief Executive Officer, is a member of the board of directors of Eton.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ReceivablesPolicyTextBlock"><p id="xdx_842_eus-gaap--ReceivablesPolicyTextBlock_zKwwq9dhkrS7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_868_zPimghJtW8eh" style="font: 10pt Times New Roman, Times, Serif"><b>Accounts
Receivable</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Accounts
receivable are stated net of allowances for doubtful accounts and contractual adjustments. The accounts receivable balance primarily
includes amounts due from customers the Company has invoiced or from third-party providers (e.g., insurance companies and governmental
agencies), but for which payment has not been received. Charges to bad debt are based on both historical write-offs and specifically
identified receivables. Accounts receivable are presented net of allowances for doubtful accounts and contractual adjustments
in the amount of $<span id="xdx_90F_eus-gaap--AccountsReceivableNet_iI_pn3n3_c20201231_ze7GjI1AvVz9"><ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">98</ix:nonFraction></span></span> <span style="font: 10pt Times New Roman, Times, Serif">and
$<span id="xdx_905_eus-gaap--AccountsReceivableNet_c20191231_pn3n3"><ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">76</ix:nonFraction></span></span> <span style="font: 10pt Times New Roman, Times, Serif">as
of December 31, 2020 and 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_841_eus-gaap--InventoryPolicyTextBlock_zsJGwgCCeaIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86B_zgKKlzO6KBkg" style="font: 10pt Times New Roman, Times, Serif"><b>Inventories</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Inventories
are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. The Company evaluates
the carrying value of inventories on a regular basis, based on the price expected to be obtained for products in their respective
markets compared with historical cost. Write-downs of inventories are considered to be permanent reductions in the cost basis
of inventories.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company also regularly evaluates its inventories for excess quantities and obsolescence (expiration), taking into account such
factors as historical and anticipated future sales or use in production compared to quantities on hand and the remaining shelf
life of products and active pharmaceutical ingredients on hand. The Company establishes reserves for excess and obsolete inventories
as required based on its analyses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="HROW:InvestmentOnePolicyTextBlock"><p id="xdx_84A_ecustom--InvestmentOnePolicyTextBlock_zZz6UKxpUsPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_864_zDoIglvrr3j6" style="font: 10pt Times New Roman, Times, Serif"><b>Investment
in Melt Pharmaceuticals, Inc. &#8211; Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
April 2018, the Company formed Melt as a wholly-owned subsidiary. In January and March of 2019, Melt entered into definitive stock
purchase agreements (collectively, the &#8220;Melt Series A Preferred Stock Agreement&#8221;) with certain investors and closed
on the sale of Melt&#8217;s Series A Preferred Stock (the &#8220;Melt Series A Stock&#8221;), totaling approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20200101__20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pn3n3"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2020-01-012020-12-31_custom_MeltPharmaceuticalsIncMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,400</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">of proceeds (collectively, the &#8220;Melt
Series A Round&#8221;) at a purchase price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_c20190331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pii"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2019-03-31_custom_MeltPharmaceuticalsIncMember_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per share. As a result, the Company lost
voting and ownership control of Melt and ceased consolidating Melt&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
January 2019, the Company deconsolidated Melt and recorded a gain of $<span id="xdx_902_eus-gaap--DeconsolidationGainOrLossAmount_c20190101__20190131__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3"><ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="From2019-01-012019-01-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,810</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and adjusted the carrying value in Melt
to reflect the increased valuation of Melt and the Company&#8217;s new ownership interest in accordance with ASC 810-10-40-4(c),
<i>Consolidation</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company owns <span id="xdx_907_ecustom--NumberOfSharesOwned_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pii"><ix:nonFraction name="HROW:NumberOfSharesOwned" contextRef="AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,500,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">common shares of Melt (which is approximately
<span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zSd66pRu69Lj"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">44</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of the equity interests as of December 31, 2020) and uses the equity method of accounting for this investment, as management has
determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Melt.
Under this method, the Company recognizes earnings and losses in Melt in its consolidated financial statements and adjusts the
carrying amount of its investment in Melt accordingly. The Company&#8217;s share of earnings and losses are based on the Company&#8217;s
ownership interest of Melt. Any intra-entity profits and losses are eliminated. The Company recorded equity in the net gain of
Melt of $<span id="xdx_90E_eus-gaap--UnrealizedGainLossOnInvestments_c20190101__20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="From2019-01-012019-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,968</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">during the year ended December 31, 2019.
The Company recorded equity in the net loss of Melt of $<span id="xdx_90F_eus-gaap--UnrealizedGainLossOnInvestments_c20200101__20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="From2020-01-012020-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,313</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">during the year ended December 31, 2020.
As of December 31, 2020 and 2019, the Company&#8217;s investment in Melt was $<span id="xdx_90D_eus-gaap--InvestmentOwnedAtFairValue_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,506</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_905_eus-gaap--InvestmentOwnedAtFairValue_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2019-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,690</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively, which includes $<span id="xdx_904_eus-gaap--DueFromRelatedParties_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3"><ix:nonFraction name="us-gaap:DueFromRelatedParties" contextRef="AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">851</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90F_eus-gaap--DueFromRelatedParties_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3"><ix:nonFraction name="us-gaap:DueFromRelatedParties" contextRef="AsOf2019-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">722</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively, due from Melt for reimbursable expenses and amounts due under the Melt Master Services Agreement (&#8220;MSA&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">See
Note 4 for more information and related party disclosure regarding Melt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="HROW:InvestmentTwoPolicyTextBlock"><p id="xdx_847_ecustom--InvestmentTwoPolicyTextBlock_zSDPZ9bcLUy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86C_zzuv4slLijWa" style="font: 10pt Times New Roman, Times, Serif"><b>Investment
in Surface Ophthalmics, Inc. &#8211; Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company owns <span id="xdx_90F_ecustom--NumberOfSharesOwned_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pii"><ix:nonFraction name="HROW:NumberOfSharesOwned" contextRef="AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,500,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">common shares (which is approximately
<span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_z8ILJkeZxVa8"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">30</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of the equity interests as of December 31, 2020) of Surface and uses the equity method of accounting for this investment, as management
has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of
Surface. Under this method, the Company recognizes earnings and losses in Surface in its consolidated financial statements and
adjusts the carrying amount of its investment in Surface accordingly. The Company&#8217;s share of earnings and losses are based
on the Company&#8217;s ownership interest of Surface. Any intra-entity profits and losses are eliminated. The Company recorded
equity in the net loss of Surface of $<span id="xdx_901_eus-gaap--UnrealizedGainLossOnInvestments_c20190101__20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="From2019-01-012019-12-31_custom_SurfacePharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,200</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">during the year ended December 31, 2019.
The Company recorded equity in the net loss of Surface of $<span id="xdx_902_eus-gaap--UnrealizedGainLossOnInvestments_c20200101__20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="From2020-01-012020-12-31_custom_SurfacePharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,433</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">during the year ended December 31, 2020.
As of December 31, 2020 and 2019, the carrying value of the Company&#8217;s investment in Surface was $<span id="xdx_900_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zanCLi0APkHc"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,314</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90E_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3n3_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_ziyzEpkI1lBk"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2019-12-31_custom_SurfacePharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,747</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">See
Note 5 for more information and related party disclosure regarding Surface.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zj1FOkOL4wDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_863_zVg2Wgs9avOk" style="font: 10pt Times New Roman, Times, Serif"><b>Property,
Plant and Equipment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Property,
plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization is calculated
using the straight-line method over the estimated useful life of the asset. Leasehold improvements and capital lease equipment
are amortized over the estimated useful life or remaining lease term, whichever is shorter. Computer software and hardware and
furniture and equipment are depreciated over <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_z6frLmTXqxJd" title="::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0633">three
</span></span></span><span style="font: 10pt Times New Roman, Times, Serif">to <span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_zOKLGLpu2APa"><ix:nonNumeric contextRef="From2020-01-012020-12-31_srt_MaximumMember" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">five years</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:BusinessCombinationsPolicy"><p id="xdx_84A_eus-gaap--BusinessCombinationsPolicy_zmi63BiVPK49" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86F_zkYgk8tkZ8c2" style="font: 10pt Times New Roman, Times, Serif"><b>Business
Combinations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company accounts for business combinations by recognizing the assets acquired, liabilities assumed, contractual contingencies,
and contingent consideration at their fair values on the acquisition date. The purchase price allocation process requires management
to make significant estimates and assumptions, especially with respect to intangible assets, estimated contingent consideration
payments and pre-acquisition contingencies. Examples of critical estimates in valuing certain of the intangible assets the Company
has acquired or may acquire in the future include but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">future
    expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed
    technologies and patents; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">discount
    rates utilized in valuation estimates.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Unanticipated
events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates or actual results.
Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date,
including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets,
will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related
contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have
a material effect on the consolidated financial position, statements of operations or cash flows in the period of the change in
the estimate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock"><p id="xdx_843_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zEJZfx8SqBth" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86E_zkvFkR2slN9h" style="font: 10pt Times New Roman, Times, Serif"><b>Goodwill
and Intangible Assets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Patents
and trademarks are recorded at cost and capitalized at a time when the future economic benefits of such patents and trademarks
become more certain. At that time, the Company capitalizes third-party legal costs and filing fees associated with obtaining and
prosecuting claims related to its patents and trademarks. Once the patents have been issued, the Company amortizes these costs
over the shorter of the legal life of the patent or its estimated economic life, generally <span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231_zFaqwWWcwHJb"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">20</ix:nonNumeric>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">years, using the straight-line method.
Trademarks are an indefinite life intangible asset and are assessed for impairment based on future projected cash flows as further
described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company reviews its goodwill and indefinite-lived intangible assets for impairment as of January 1 of each year and when an event
or a change in circumstances indicates the fair value of a reporting unit may be below its carrying amount. Events or changes
in circumstances considered as impairment indicators include but are not limited to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">significant
    underperformance of the Company&#8217;s business relative to expected operating results;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">significant
    adverse economic and industry trends;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">significant
    decline in the Company&#8217;s market capitalization for an extended period of time relative to net book value; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">expectations
    that a reporting unit will be sold or otherwise disposed.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
goodwill impairment test consists of a two-step process as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Step
1. The Company compares the fair value of each reporting unit to its carrying amount, including the existing goodwill. The fair
value of each reporting unit is determined using a discounted cash flow valuation analysis. The carrying amount of each reporting
unit is determined by specifically identifying and allocating the assets and liabilities to each reporting unit based on headcount,
relative revenues or other methods as deemed appropriate by management. If the carrying amount of a reporting unit exceeds its
fair value, an indication exists that the reporting unit&#8217;s goodwill may be impaired and the Company then performs the second
step of the impairment test. If the fair value of a reporting unit exceeds its carrying amount, no further analysis is required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Step
2. If further analysis is required, the Company compares the implied fair value of the reporting unit&#8217;s goodwill, determined
by allocating the reporting unit&#8217;s fair value to all of its assets and its liabilities in a manner similar to a purchase
price allocation, to its carrying amount. If the carrying amount of the reporting unit&#8217;s goodwill exceeds its fair value,
an impairment loss will be recognized in an amount equal to the excess.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zLkCQtKREeZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_869_zx0R114RXQna" style="font: 10pt Times New Roman, Times, Serif"><b>Impairment
of Long-Lived Assets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Long-lived
assets, such as property, plant and equipment, purchased intangibles subject to amortization and patents and trademarks, are reviewed
for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted
future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash
flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the
asset. Assets to be disposed of would be separately presented in the consolidated balance sheet and reported at the lower of the
carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposal group
classified as held-for-sale would be presented separately in the appropriate asset and liability sections of the consolidated
balance sheet, if material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="HROW:RestructuringPolicyTextBlock"><p id="xdx_843_ecustom--RestructuringPolicyTextBlock_zhaksSxtf4ja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86B_zTQVhvsTGKc2" style="font: 10pt Times New Roman, Times, Serif"><b>Park
Restructuring</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2019, the Company&#8217;s subsidiary, Park Compounding, Inc. (&#8220;Park&#8221;), and Noice Rx, LLC (&#8220;Noice&#8221;)
terminated an Asset Purchase Agreement dated July 26, 2019 (the &#8220;Park Purchase Agreement&#8221;), between the parties. Under
the terms of the Park Purchase Agreement, Park had agreed to sell substantially all its assets associated with its non-ophthalmology
pharmaceutical compounding business to Noice, including its pharmacy facility and equipment located in Irvine, California. The
closing of the sale transaction was dependent on the California State Board of Pharmacy approving of the sale and issuing a temporary
pharmacy and sterile license permit to Noice, which did not occur and led to Park ceasing operations at the close of business
on August 27, 2019. As a result, the Company restructured its Park business, ceased operations at its Irvine, California-based
pharmacy, and facilitated the transition of certain compounded formulations and related equipment from Park to the Company&#8217;s
New Jersey-based compounded pharmaceutical production facilities (the &#8220;Park Restructuring&#8221;). As a result of the Park
Restructuring, the Company incurred non-cash impairment costs of approximately $<span id="xdx_90B_eus-gaap--AssetImpairmentCharges_c20190101__20191231__dei--LegalEntityAxis__custom--ParkCompoundingIncAndNoiceRxLLCMember_pn3n3"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2019-01-012019-12-31_custom_ParkCompoundingIncAndNoiceRxLLCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,781</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">related to assets held at Park, primarily
associated with property, plant, equipment, inventory, goodwill and other intangible assets, and $<span id="xdx_901_eus-gaap--SeveranceCosts1_c20190101__20191231__dei--LegalEntityAxis__custom--ParkCompoundingIncAndNoiceRxLLCMember_pn3n3"><ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="From2019-01-012019-12-31_custom_ParkCompoundingIncAndNoiceRxLLCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">480</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">in one-time costs related to severance
packages and other costs associated with the Park Restructuring during the year ended December 31, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has reduced the Park compounded product formulary to seven base formulations, based on factors including unit order volumes,
revenues and gross margin percentages, and ImprimisRx retained approximately half of Park&#8217;s historical revenues during
the first quarter of 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_84A_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zn2PInmnHdN3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_865_zNTAJLxBgAx1" style="font: 10pt Times New Roman, Times, Serif"><b>Fair
Value Measurements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Fair
value measurements are determined based on the assumptions that market participants would use in pricing an asset or liability.
GAAP establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes
the use of unobservable inputs by requiring that the most observable inputs be used when available. The established fair value
hierarchy prioritizes the use of inputs used in valuation methodologies into the following three levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in
    active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure
    fair value whenever available.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such
    as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are
    observable or can be corroborated by observable market data.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entity&#8217;s
    own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level
    3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2020 and 2019, the Company measured its investment in Eton on a recurring basis. The Company&#8217;s investment in
Eton is classified as Level 1 as the fair value is determined using quoted market prices in active markets for the same securities.
As of December 31, 2020 and 2019, the fair market value of the Company&#8217;s investment in Eton was $<span id="xdx_90B_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zmGvFIrjU5u5"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2020-12-31_custom_EtonPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,455</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90C_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3n3_c20191231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zieiRNKDybR8"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2019-12-31_custom_EtonPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25,200</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s financial instruments include cash and cash equivalents, restricted cash, investment in Eton, accounts receivable,
accounts payable and accrued expenses, accrued payroll and related liabilities, deferred revenue and customer deposits, loans
payable and operating and finance lease liabilities. The carrying amount of these financial instruments, except for loans payable
and operating and finance lease liabilities, approximates fair value due to the short-term maturities of these instruments. The
Company&#8217;s restricted cash which is comprised of short-term investments are carried at amortized cost, which approximates
fair value. Based on borrowing rates currently available to the Company, the carrying values of the loans payable and operating
and finance lease liabilities approximate their respective fair values.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_846_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z0tL4ZLkV5ea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_867_zG75iJYyM3Ff" style="font: 10pt Times New Roman, Times, Serif"><b>Stock-Based
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">All
stock-based payments to employees, directors and consultants, including grants of stock options, warrants, restricted stock units
(&#8220;RSUs&#8221;) and restricted stock, are recognized in the consolidated financial statements based upon their estimated
fair values. The Company uses the Black-Scholes-Merton option pricing model and Monte Carlo simulation model to estimate the fair
value of stock-based awards. The estimated fair value is determined at the date of grant. The financial statement effect of forfeitures
is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_z4ZjFTL2yy96" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86B_zzrhTO0IGfpe" style="font: 10pt Times New Roman, Times, Serif"><b>Basic
and Diluted Net Income (Loss) per Common Share</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic
net income (loss) per common share is computed by dividing income (loss) attributable to common stockholders for the period by
the weighted average number of common shares outstanding during the period. Diluted income (loss) per share is computed
by dividing the income (loss) attributable to common stockholders for the period by the weighted average number of common
and common equivalent shares, such as stock options and warrants, outstanding during the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic
and diluted net income (loss) per share is computed using the weighted average number of shares of common stock outstanding during
the period. Common stock equivalents (using the treasury stock or &#8220;if converted&#8221; method) from stock options, unvested
restricted stock units (&#8220;RSUs&#8221;) and warrants were <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndWarrantsMember_pii"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-12-31_custom_StockOptionsUnvestedRSUsAndWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,411,929</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndWarrantsMember_pii"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-01-012019-12-31_custom_StockOptionsUnvestedRSUsAndWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,848,459</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">at December 31, 2020 and 2019, respectively,
and are excluded in the calculation of diluted net income (loss) per share for the periods presented, because the effect is anti-dilutive
for that time period. Included in the basic and diluted net income (loss) per share calculation were RSUs awarded to directors
that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number of shares underlying
vested RSUs at December 31, 2020 and 2019 was <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,463</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">324,303</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zqanQOau63d3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table shows the computation of basic net income (loss) per share of common stock for the years ended December 31, 2020
and 2019 (in 000&#8217;s, except share and per share amounts):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B1_zLJrrZUGtTT2" style="display: none">SCHEDULE
OF BASIC EARNINGS PER COMMON SHARE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
<tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20200101_20201231" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20190101_20191231" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended December 31,</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--NetIncomeLoss_pn3n3_zmcAh0QiiBul" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; width: 54%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Numerator
    &#8211; net (loss) income attributable to Harrow Health, Inc.</span></td><td style="padding-bottom: 2.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 19%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,357</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 19%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">168</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zL46cNFU7Am2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Denominator &#8211; weighted average
    number of shares outstanding, basic</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,895,352</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,323,159</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--EarningsPerShareBasic_pii_zA4JlFNRV9og" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    (loss) income per share, basic</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.13</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

</ix:nonNumeric><p id="xdx_8AB_zZxuL4amfJk7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ze4eYR6UJYuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For
the year end December 31, 2019, the Company computed diluted net income per share using the weighted-average number of common
shares and dilutive common equivalent shares outstanding during that period. Diluted common equivalent shares for the year ended
December 31, 2019 consisted of the following (in 000&#8217;s, except share and per share amounts):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_z64O4FuEUht4" style="display: none">SCHEDULE
OF DILUTED COMMON EQUIVALENT SHARES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Diluted shares related to:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 74%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_c20190101__20191231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pii" title="Dilutive common equivalent shares" style="width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">488,498</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Stock
    options</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_c20190101__20191231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pii" title="Dilutive common equivalent shares" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="From2019-01-012019-12-31_custom_StockOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">654,441</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Dilutive common
    equivalent shares</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_c20190101__20191231_pii" title="Dilutive common equivalent shares" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,142,939</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AE_zc1WXHrFzthb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_zPt4kPLVPCb3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table shows the computation of diluted net income per share using the weighted-average number of common shares and dilutive
common equivalent shares outstanding for the year ended December 31, 2019 (in 000&#8217;s, except share and per share amounts):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; display: none"><b>&#160;<span id="xdx_8B2_z8V4339e2Hag">SCHEDULE
OF DILUTED EARNINGS PER COMMON SHARE</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
<tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20190101__20191231_zXVzwvokF3d6" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2019</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2019</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--NetIncomeLoss_pn3n3_za3KraIwjsR8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; width: 74%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Numerator
    &#8211; net income</span></td><td style="padding-bottom: 2.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">168</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zyac3j8t4tk1" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Weighted average number of shares outstanding, basic</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,323,159</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_ecustom--IncrementalCommonSharesAttributableDilutiveCommonEquivalents_pii_z2WVbHP00Xv7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dilutive common
    equivalents</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:IncrementalCommonSharesAttributableDilutiveCommonEquivalents" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,142,939</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--IncrementalCommonSharesAttributableToContingentlyIssuableShares_pii_zQSHI8sYiMX2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Denominator &#8211;
    number of shares used for diluted earnings per share computation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,466,098</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--EarningsPerShareDiluted_pii_zj3nKy7HkFoc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Net income per
    share, diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

</ix:nonNumeric><p id="xdx_8A7_zPGABlO5l2jk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="HROW:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock"><p id="xdx_84F_ecustom--RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_zdg1yXLxkuUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_868_zlyKoit7XDYg" style="font: 10pt Times New Roman, Times, Serif"><b>Recently
Adopted Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</i>,
which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13
replaces the existing incurred loss impairment model with a forward-looking expected credit loss model which will result in earlier
recognition of credit losses. The Company adopted ASU 2016-13 on January 1, 2020, and adoption of the standard did not have a
material effect on the Company&#8217;s consolidated financial position, results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
January 2017, the FASB issued ASU 2017-04, <i>Intangibles-Goodwill and Other</i>. This guidance simplifies the accounting for
goodwill impairment for all entities by requiring impairment charges to be based on the first step in the current two-step impairment
test under ASC 350. The updated standard eliminates the requirement to calculate a goodwill impairment charge using Step 2. If
a reporting unit&#8217;s carrying amount exceeds its fair value, an entity will record an impairment charge based on that difference.
The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. The Company adopted ASU 2017-04
on January 1, 2020, and adoption of the standard did not have a material effect on the Company&#8217;s consolidated financial
position, results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2018, the FASB issued ASU 2018-13, <i>Changes to Disclosure Requirements for Fair Value Measurements</i>, which improved
the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies,
and adds certain disclosure requirements. The Company adopted ASU 2018-13 on January 1, 2020, and adoption of the standard did
not have a material effect on the Company&#8217;s consolidated financial position, results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zblzoMl5axM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86B_ze9IvWDrTEAa" style="font: 10pt Times New Roman, Times, Serif"><b>Recently
Issued Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2019, the FASB issued ASU 2019-12, <i>Income Taxes</i>: <i>Simplifying the Accounting for Income Taxes</i>, which simplifies
the accounting for income taxes. This guidance will be effective for the Company in the first quarter of 2021 on a prospective
basis, and early adoption is permitted. The Company does not expect a material impact of the new guidance on its consolidated
financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z4MuVNqxYXnj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86C_z3kWjNHVTIXb" style="font: 10pt Times New Roman, Times, Serif"><b>Reclassifications</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Certain
prior period items and amounts have been reclassified to conform to the classifications used to prepare the consolidated financial
statements for the year ended December 31, 2020. These reclassifications had no material impact on the Company&#8217;s consolidated
financial position, results of operations, or cash flows as previously reported.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:RevenueFromContractWithCustomerTextBlock"><p id="xdx_800_eus-gaap--RevenueFromContractWithCustomerTextBlock_z8KoT16n7bs8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
3. <span id="xdx_828_zqVLltb8COE7">REVENUES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company accounts for contracts with customers in accordance with ASC 606, <i>Revenues from Contracts with Customers.</i> The Company
has three primary streams of revenue: (1) revenue recognized from our sale of products within our pharmacy services (2)
revenue recognized from a commission agreement with a third party and (3) revenue recognized from intellectual property
license and asset purchase agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Product
Revenues from Pharmacy Services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company sells prescription drugs directly through our pharmacy and outsourcing facility network. Revenue from our pharmacy services
divisions includes: (i) the portion of the price the client pays directly to us, net of any volume-related or other discounts
paid back to the client, (ii) the price paid to us by individuals, and (iii) customer copayments made directly to the pharmacy
network. Sales taxes are not included in revenue. Following the core principles of ASC 606, we have identified the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Identify
    the contract(s) with a customer: A contract exists with a customer at the time the prescription or order is received by the
    Company.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Identify
    the performance obligations in the contract: The order received contains the performance obligations to be met, in almost
    all cases the product the customer is wishing to receive. If we are unable to be meet the performance obligation the customer
    is notified.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Determine
    the transaction price: the transaction price is based on the product being sold to the customer, and any related customer
    discounts. These amounts are pre-determined and built into our order management software.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Allocate
    the transaction price to the performance obligations in the contract: The transaction price associated with the product(s)
    being ordered is allocated according to the pre-determined amounts.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Recognize
    revenue when (or as) the entity satisfies a performance obligation: At the time of shipment from the pharmacy or outsourcing
    facility the performance obligation has been met.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following revenue recognition policy has been established for the pharmacy services division:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Revenues
generated from prescription or office use drugs sold by our pharmacies and outsourcing facility are recognized when the prescription
is shipped. At the time of shipment, the pharmacy services division has performed substantially all of its obligations under its
client contracts and does not experience a significant level of returns or reshipments. Determination of criteria (3) and (4)
is based on management&#8217;s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability
of those amounts. The Company records reductions to revenue for discounts at the time of the initial sale. Estimated returns and
allowances and other adjustments are provided for in the same period during which the related sales are recorded and are based
on actual returns history. The rate of returns is analyzed annually to determine historical returns experience. If the historical
data we use to calculate these estimates do not properly reflect future returns, then a change in the allowance would be made
in the period in which such a determination is made and revenues in that period could be materially affected. The Company will
defer any revenues received for a product that has not been delivered or is subject to refund until such time that the Company
and the customer jointly determine that the product has been delivered and no refund will be required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Commission
Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">During
the year ended December 31, 2020, the Company entered into an agreement whereby</span> <span style="font: 10pt Times New Roman, Times, Serif">it
is paid a fee calculated based on sales it generates from a pharmaceutical product that is owned by a third party. The revenue
earned from this arrangement is recognized at the time a customer has ordered the pharmaceutical product and it has shipped from
the third party (or one of its distributors or affiliates), at which point there is no future performance obligation required
by the Company and no consequential continuing involvement on the part of the Company to recognize the associated revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Intellectual
Property License Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company currently holds five intellectual property license and related agreements in which the Company has promised to grant a
license or sale which provides a customer with the right to access the Company&#8217;s intellectual property. License arrangements
may consist of non-refundable upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights
to patented or patent pending compounds, technology access fees, and various performance or sales milestones. These arrangements
can be multiple-element arrangements, the revenue of which is recognized at the point of time the performance obligation is met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Non-refundable
fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on the
part of the Company are recognized as revenue when the license term commences and the licensed data, technology, compounded drug
preparation and/or other deliverable is delivered. Such deliverables may include physical quantities of compounded drug preparations,
design of the compounded drug preparations and structure-activity relationships, the conceptual framework and mechanism of action,
and rights to the patents or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable
fees if it has continuing performance obligations without which the technology, right, product or service conveyed in conjunction
with the non-refundable fee has no utility to the licensee and that are separate and independent of the Company&#8217;s performance
under the other elements of the arrangement. In addition, if the Company&#8217;s continued involvement is required, through research
and development services that are related to its proprietary know-how and expertise of the delivered technology or can only be
performed by the Company, then such non-refundable fees are deferred and recognized over the period of continuing involvement.
Guaranteed minimum annual royalties are recognized on a straight-line basis over the applicable term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock"><p id="xdx_897_eus-gaap--DisaggregationOfRevenueTableTextBlock_ztse0XPjc8Kh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Revenue
disaggregated by revenue source for the years ended December 31, 2020 and 2019, consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B1_zgDCXutC9LY2" style="display: none">SCHEDULE
OF DISAGGREGATED REVENUE</span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20200101__20201231_zXjkmt7RQjS5" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20190101__20191231_zCgJERXstHci" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Years Ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Product
    sales, net</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_z2vy7QHcd335" title="Total Revenues" style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-12-31_custom_ProductSalesNetMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48,479</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20191231__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_zXQYsT0UskV4" title="Total Revenues" style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_custom_ProductSalesNetMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51,137</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Commissions</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--CommissionsMember_z9qdAGyt5GH7" title="Total Revenues" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-12-31_custom_CommissionsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">356</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--CommissionsMember_pn3n3" title="Total Revenues" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0706">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">License</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zam5zkBhjPH1" title="Total Revenues" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-12-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_pn3n3" title="Total Revenues" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_z6WY4vLl8aul" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    revenues</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48,871</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51,165</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AD_zyu4urvGWrfl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Deferred
revenue and customer deposits at December 31, 2020 and 2019, were $<span id="xdx_909_eus-gaap--ContractWithCustomerLiabilityCurrent_c20201231_pn3n3"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">66</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_901_eus-gaap--ContractWithCustomerLiabilityCurrent_c20191231_pn3n3"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">57</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively. All deferred revenue and customer deposit amounts at December 31, 2019 were recognized as revenue during the year
ended December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"><p id="xdx_80A_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zUV64Zjsdnk7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
4. <span id="xdx_825_zcEcINQa0uN2">INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2018, the Company entered into an asset purchase agreement with Melt (the &#8220;Melt Asset Purchase Agreement&#8221;).
Pursuant to the terms of the Melt Asset Purchase Agreement, Melt was assigned certain intellectual property and related rights
from the Company to develop, formulate, make, sell, and sub-license certain Company conscious sedation and analgesia related formulations
(collectively, the &#8220;Melt Products&#8221;). Under the terms of the Melt Asset Purchase Agreement, Melt is required to make
mid-single digit royalty payments to the Company on net sales of the Melt Products while any patent rights remain outstanding,
as well as other conditions. In January and March 2019, the Company entered into the Melt Series A Preferred Stock Agreement,
see also Note 2, under the subheading <i>Investment in Melt Pharmaceuticals, Inc</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
February 2019, the Company and Melt entered into a Management Services Agreement (the &#8220;Melt MSA&#8221;), whereby the Company
provides to Melt certain administrative services and support, including bookkeeping, web services and human resources related
activities, and Melt is required to pay the Company a monthly amount of $<span id="xdx_907_eus-gaap--AdministrativeFeesExpense_pn3n3_c20190201__20190228__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_zC3CEx4f7Ssk"><ix:nonFraction name="us-gaap:AdministrativeFeesExpense" contextRef="From2019-02-012019-02-28_custom_MeltPharmaceuticalsIncMember_custom_ManagementServicesAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020 and 2019, the Company was due $<span id="xdx_906_eus-gaap--DueFromRelatedParties_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_pn3n3"><ix:nonFraction name="us-gaap:DueFromRelatedParties" contextRef="AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember_custom_ManagementServicesAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">851</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90E_eus-gaap--DueFromRelatedParties_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_pn3n3"><ix:nonFraction name="us-gaap:DueFromRelatedParties" contextRef="AsOf2019-12-31_custom_MeltPharmaceuticalsIncMember_custom_ManagementServicesAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">722</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively, from Melt for reimbursable expenses and amounts due under the Melt MSA. Melt did no</span><span style="font: 10pt Times New Roman, Times, Serif">t
make any payments to the Company during the year ended December 31, 2020 and paid the Company $<span id="xdx_902_eus-gaap--RepaymentsOfRelatedPartyDebt_c20190101__20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--MSAMember_pn3n3"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2019-01-012019-12-31_custom_SurfacePharmaceuticalsIncMember_custom_MSAMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">during the year ended December 31, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s Chief Executive Officer, Mark L. Baum, and Chief Medical Officer, Larry Dillaha, are members of the Melt board
of directors, and several employees of the Company (including Mr. Baum, Mr. Dillaha and the Company&#8217;s Chief Financial Officer,
Andrew Boll) entered into consulting agreements and provide consulting services to Melt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="HROW:ScheduleOfCondensedIncomeStatementOneTableTextBlock"><p id="xdx_89A_ecustom--ScheduleOfCondensedIncomeStatementOneTableTextBlock_zRZArcCQNL66" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
unaudited condensed results of operations information of Melt is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BC_zLmh3RyFHgLk" style="font: 10pt Times New Roman, Times, Serif; display: none">SCHEDULE
OF CONDENSED INCOME STATEMENT</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Years Ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Revenues, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Revenues, net" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0725">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Revenues, net" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0727">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    from operations</span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--OperatingIncomeLoss_c20200101__20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Loss from operations" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-012020-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,019</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--OperatingIncomeLoss_c20190101__20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Loss from operations" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2019-01-012019-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,381</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--NetIncomeLoss_c20200101__20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Net loss" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,019</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--NetIncomeLoss_c20190101__20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Net loss" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,381</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A4_zVJzaHs0NPVj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="HROW:ScheduleOfCondensedBalanceSheetOneTableTextBlock"><p id="xdx_89B_ecustom--ScheduleOfCondensedBalanceSheetOneTableTextBlock_zwmQcbAYH4Hd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
unaudited condensed balance sheet information of Melt is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B5_zA39cAzGTzFi" style="font: 10pt Times New Roman, Times, Serif; display: none">SCHEDULE
OF CONDENSED BALANCE SHEET</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Current assets</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--AssetsCurrent_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Current assets" style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,947</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--AssetsCurrent_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Current assets" style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2019-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,449</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Non current
    assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--AssetsNoncurrent_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Non current assets" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--AssetsNoncurrent_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Non current assets" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2019-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--Assets_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Total assets" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,958</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--Assets_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Total assets" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2019-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,454</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--Liabilities_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Total liabilities" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,778</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--Liabilities_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Total liabilities" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2019-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,691</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total preferred
    stock and stockholders&#8217; equity</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--StockholdersEquity_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Total preferred stock and stockholders&apos; equity" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,180</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--StockholdersEquity_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Total preferred stock and stockholders&apos; equity" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,763</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total liabilities
    and stockholders&#8217; equity</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--LiabilitiesAndStockholdersEquity_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Total liabilities and stockholders&apos; equity" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,958</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--LiabilitiesAndStockholdersEquity_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" title="Total liabilities and stockholders&apos; equity" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2019-12-31_custom_MeltPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,454</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A4_zXJ9p3IO4ggh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="HROW:InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock"><p id="xdx_802_ecustom--InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock_z0Zp9bskmkk8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
5. <span id="xdx_82D_zycWZ1Ojflz5">INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company entered into an asset purchase and license agreement with Surface in 2017 and amended it in April 2018 (the &#8220;Surface
License Agreements&#8221;). Pursuant to the terms of the Surface License Agreements, the Company assigned and licensed to Surface
certain intellectual property and related rights associated with Surface&#8217;s drug candidates (collectively, the &#8220;Surface
Products&#8221;). Surface is required to make mid-single-digit royalty payments to the Company on net sales of the Surface
Products while any patent rights remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020, the Company owned <span id="xdx_901_eus-gaap--SharesOutstanding_iI_pii_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zUf2Wpf5UMpe"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,500,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of Surface common stock (approximately
<span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zDa6O5oJ228d"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">30</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of the issued and outstanding equity interests). A Company director, Richard L. Lindstrom, and the Company&#8217;s Chief Executive
Officer, Mark L. Baum, are directors of Surface. Surface is required to make royalty payments to Dr. Lindstrom of <span id="xdx_905_ecustom--RoyaltyPaymentPercentageOnNetSales_pii_dp_uPercent_c20200101__20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember__srt--TitleOfIndividualAxis__custom--DrLindstromMember_zb6EbmhuIKj2"><ix:nonFraction name="HROW:RoyaltyPaymentPercentageOnNetSales" contextRef="From2020-01-012020-12-31_custom_SurfacePharmaceuticalsIncMember_custom_DrLindstromMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">3</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of net sales of certain Surface Products while certain patent rights remain outstanding. Dr. Lindstrom is also a principal of
Flying L Partners, an affiliate of the funding investor who purchased the Surface Series A Preferred Stock. Several employees
and a director of the Company (including Mr. Baum and Dr. Lindstrom) entered into consulting agreements and provided consulting
services to Surface.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="srt:ScheduleOfCondensedIncomeStatementTableTextBlock"><p id="xdx_896_esrt--ScheduleOfCondensedIncomeStatementTableTextBlock_zVSrka9hJfF" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
unaudited condensed results of operations information of Surface is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B5_zaAtubQHO5k8" style="font: 10pt Times New Roman, Times, Serif; display: none">SUMMARY
OF CONDENSED INCOME STATEMENT</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year<b>s</b> Ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Revenues, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" title="Revenues, net" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0770">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" title="Revenues, net" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0772">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    from operations</span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--OperatingIncomeLoss_c20200101__20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" title="Loss from operations" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-012020-12-31_custom_SurfacePharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,109</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--OperatingIncomeLoss_c20190101__20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" title="Loss from operations" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2019-01-012019-12-31_custom_SurfacePharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,000</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--NetIncomeLoss_c20200101__20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" title="Net loss" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_custom_SurfacePharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,109</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--NetIncomeLoss_c20190101__20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" title="Net loss" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-12-31_custom_SurfacePharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A2_zGGDHlBuasi9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="srt:ScheduleOfCondensedBalanceSheetTableTextBlock"><p id="xdx_897_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_zshJRTO0n9Bk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
unaudited condensed balance sheet information of Surface is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B5_zqOuNIJAasqj" style="font: 10pt Times New Roman, Times, Serif; display: none">SUMMARY
OF CONDENSED BALANCE SHEET</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">
    December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Current assets</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AssetsCurrent_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" title="Current assets" style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,074</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--AssetsCurrent_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" title="Current assets" style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2019-12-31_custom_SurfacePharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,942</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Non current
    assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AssetsNoncurrent_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" title="Non current assets" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">45</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--AssetsNoncurrent_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" title="Non current assets" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2019-12-31_custom_SurfacePharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">47</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--Assets_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" title="Total assets" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,119</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--Assets_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" title="Total assets" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2019-12-31_custom_SurfacePharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,989</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--Liabilities_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" title="Total liabilities" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,666</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--Liabilities_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" title="Total liabilities" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2019-12-31_custom_SurfacePharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">619</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total stockholders&#8217;
    equity</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--StockholdersEquity_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" title="Total stockholders equity" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,453</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--StockholdersEquity_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" title="Total stockholders equity" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_custom_SurfacePharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,370</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    liabilities and stockholders&#8217; equity</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--LiabilitiesAndStockholdersEquity_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" title="Total liabilities and stockholders&apos; equity" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,119</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--LiabilitiesAndStockholdersEquity_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" title="Total liabilities and stockholders&apos; equity" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2019-12-31_custom_SurfacePharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,989</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AE_z4SoyS3XYfv5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="HROW:RestrictedCashTextBlock"><p id="xdx_809_ecustom--RestrictedCashTextBlock_zWdfTOfggzq4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
6. <span id="xdx_82F_z9fWDjic99Qa">RESTRICTED CASH</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
restricted cash at December 31, 2020 and 2019 consisted of funds held in a money market account. At December 31, 2020 and 2019,
the restricted cash was recorded at amortized cost, which approximates fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2020 and 2019, the funds held in a money market account of $<span id="xdx_90F_eus-gaap--RestrictedCash_iI_pn3n3_c20201231_zJ7PsU3yXhdj"><span id="xdx_90C_eus-gaap--RestrictedCash_iI_pn3n3_c20191231_zgUbebkvmXca"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200</ix:nonFraction></ix:nonFraction></span>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">were classified as a current asset. The
money market account funds are required as collateral as additional security for the Company&#8217;s New Jersey facility lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:InventoryDisclosureTextBlock"><p id="xdx_809_eus-gaap--InventoryDisclosureTextBlock_zhZ42oWSglNk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
7. <span id="xdx_827_z70OLwL0XVqg">INVENTORIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zVM9xZ4mT2g5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Inventories
are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, commercial pharmaceutical
products, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of December 31,
2020 and 2019 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B0_zIjxVAkLNoc5" style="display: none; font-family: Times New Roman, Times, Serif">SCHEDULE
OF INVENTORIES</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20201231" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20191231" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINz6Re_zTVNBcbUSdw8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Raw materials</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,501</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,405</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINz6Re_z6vJj1koPK5i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Work in progress</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINz6Re_zJzeTHthaeq9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Finished goods</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,444</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">876</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--InventoryNet_iTI_pn3n3_mtINz6Re_znCqFTxzdDdi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total inventories</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,962</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,301</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A0_zVn7719gfAa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:OtherAssetsDisclosureTextBlock"><p id="xdx_80C_eus-gaap--OtherAssetsDisclosureTextBlock_zJnfWJhnF8Il" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
8. <span id="xdx_822_zIDflze9QU82">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="HROW:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"><p id="xdx_890_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zMM0nyOgIy16" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Prepaid
expenses and other current assets consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BB_zlAuHGfL9hd1" style="display: none; font-family: Times New Roman, Times, Serif">SCHEDULE
OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20201231_zIEkQ4Z1pGU2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20191231_zIrCXcI8M0a2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAzQA0_z7lY8f1LmF06" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Prepaid insurance</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">160</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">123</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maPEAOAzQA0_zRr4mVc6ivQl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Other prepaid expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">401</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">358</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--OtherAssetsCurrent_iI_pn3n3_maPEAOAzQA0_z3cZ6ho4SpT6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Deposits and
    other current assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">190</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">105</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzQA0_zIRBNErWxx65" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total prepaid
    expenses and other current assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">751</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">586</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A9_zMiTfBeTWgf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_803_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zOByKcPBfMde" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
9. <span id="xdx_82D_z2jwdajAZQM9">PROPERTY, PLANT AND EQUIPMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_89D_eus-gaap--PropertyPlantAndEquipmentTextBlock_zU7a0HAL9JCh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Property,
plant and equipment, net at December 31, 2020 and 2019 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B8_zJzr49I67J88" style="display: none; font-family: Times New Roman, Times, Serif">SCHEDULE
OF PROPERTY, PLANT AND EQUIPMENT</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20201231_zmAaGU4dJKh9" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20191231_zXOV4No9klFg" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Property, plant and equipment, net:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_maPPAEGzzle_zpt88c4SRsr1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Computer
    software and hardware</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,707</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,732</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAEGzzle_ztjBM8L8AUh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Furniture and
    equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">418</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">363</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_maPPAEGzzle_zSP7XrWC6eq" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Lab and pharmacy
    equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,426</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,164</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--LeaseholdImprovementsGross_iI_pn3n3_maPPAEGzzle_z1SmBOq4b4Dk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Leasehold
    improvements</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LeaseholdImprovementsGross" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,720</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LeaseholdImprovementsGross" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,510</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_mtPPAEGzzle_maPPAENzQqn_zC4fNjsEzm0a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;Property, plant
    and equipment, gross</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,271</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,769</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzQqn_z4uHdoRGQXtk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    depreciation and amortization</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,818</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,394</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzQqn_zVbprQkbhqt3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Property,
    plant and equipment, net&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,453</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,375</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A6_zeuIAuTRzWk8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020, the Company disposed of property, plant and equipment with a net book value of $<span id="xdx_904_eus-gaap--GainLossOnDispositionOfAssets1_iN_pn3n3_di_c20200101__20201231_ziUP7FbpOVo4"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">105</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">related to the discontinued use of certain
computer software and hardware and was included within other (loss) income of the consolidated statements of operations.
The Company recorded depreciation and amortization expense of $<span id="xdx_904_eus-gaap--DepreciationAmortizationAndAccretionNet_c20200101__20201231_pn3n3"><ix:nonFraction name="us-gaap:DepreciationAmortizationAndAccretionNet" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,880</ix:nonFraction></span>
</span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_903_eus-gaap--DepreciationAmortizationAndAccretionNet_c20190101__20191231_pn3n3"><ix:nonFraction name="us-gaap:DepreciationAmortizationAndAccretionNet" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,936</ix:nonFraction></span>
</span><span style="font: 10pt Times New Roman, Times, Serif">during the years ended December 31, 2020
and 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock"><p id="xdx_80E_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zj8WgHcD7qKf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
10. <span id="xdx_822_z8IuEPqvmch2">INTANGIBLE ASSETS AND GOODWILL</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_z9CnciC2W6x1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s intangible assets at December 31, 2019 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BE_z7uGUwecGrci" style="font: 10pt Times New Roman, Times, Serif; display: none">SCHEDULE
OF INTANGIBLE ASSETS</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">periods</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(in
    years)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Cost</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">amortization</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Impairment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Carrying
    value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 21%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; width: 13%; text-align: center"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MinimumMember_zJDQd12aOYyc" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_PatentsMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">17</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif">-<span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MaximumMember_ztZBmwpM1WE8"><ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_PatentsMember_srt_MaximumMember" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">19
    years</ix:nonNumeric></span></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zhbD2JrfAgrk" title="Cost" style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,102</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_ziIZt3BHrsDc" title="Accumulated amortization" style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2019-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">97</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zIqUTTOPJ39h" title="Impairment" style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HROW:FiniteLivedIntangibleAssetsImpairment" contextRef="AsOf2019-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">259</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td title="Net Carrying value" id="xdx_98A_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zna80rxILWI9" style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2019-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">746</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Licenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z3k89bh0bBW1" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_LicensesMember" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">20
    years</ix:nonNumeric></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zY1AHJtP3hO6" title="Cost" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-12-31_custom_LicensesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z99Wqkb89VBg" title="Accumulated amortization" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2019-12-31_custom_LicensesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zbcA2GUkwVLc" title="Impairment" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0891">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zxyIg2UbCCRl" title="Net Carrying value" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2019-12-31_custom_LicensesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">45</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trademarks</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zBY0yKcqo9b3" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_TrademarksMember" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod">Indefinite</ix:nonNumeric></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zw6q7xgAUXgd" title="Cost" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-12-31_us-gaap_TrademarksMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">340</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zWn3zLg1I8Eb" title="Accumulated amortization" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0898">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z1LJRv60q221" title="Impairment" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0900">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zgT4x7HeEPZi" title="Net Carrying value" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2019-12-31_us-gaap_TrademarksMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">340</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Customer relationships</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MinimumMember_zKR67nTo16Fj" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_CustomerRelationshipsMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">3</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif">-<span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MaximumMember_z5kmYX467Uuf"><ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_CustomerRelationshipsMember_srt_MaximumMember" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">15
    years</ix:nonNumeric></span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z1cDt2HRe15c" title="Cost" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-12-31_us-gaap_CustomerRelationshipsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zZmeiVV6yvx6" title="Accumulated amortization" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2019-12-31_us-gaap_CustomerRelationshipsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,165</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zxgKZB53Hakd" title="Impairment" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HROW:FiniteLivedIntangibleAssetsImpairment" contextRef="AsOf2019-12-31_us-gaap_CustomerRelationshipsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">630</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z2SFsTRf6t7d" title="Net Carrying value" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2019-12-31_us-gaap_CustomerRelationshipsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,205</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trade name</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zVZNFy9f5Brd" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2019-01-012019-12-31_us-gaap_TradeNamesMember" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">5
    years</ix:nonNumeric></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zF275xxnyRp1" title="Cost" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-12-31_us-gaap_TradeNamesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zC0NwhC2l5Af" title="Accumulated amortization" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2019-12-31_us-gaap_TradeNamesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zsqVqOTODgV7" title="Impairment" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HROW:FiniteLivedIntangibleAssetsImpairment" contextRef="AsOf2019-12-31_us-gaap_TradeNamesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zs4tRqxbxU4f" title="Net Carrying value" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0921">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-competition clause</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MinimumMember_zKrDhGjvHJdj" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_NonCompetitionClauseMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">3</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif">-<span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MaximumMember_zyrkJ6baCHA9"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_NonCompetitionClauseMember_srt_MaximumMember" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">4
    years</ix:nonNumeric></span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zqn1b3j6nWjj" title="Cost" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-12-31_custom_NonCompetitionClauseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">294</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zEsaUUYHCIHl" title="Accumulated amortization" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2019-12-31_custom_NonCompetitionClauseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">274</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zAfJs3Z6l5Me" title="Impairment" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HROW:FiniteLivedIntangibleAssetsImpairment" contextRef="AsOf2019-12-31_custom_NonCompetitionClauseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">20</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zzJzn6bvsGbi" title="Net Carrying value" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0931">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State pharmacy
    licenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zfur4GTZ1z6j" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_StatePharmacyLicensesMember" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">25
    years</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zgiz2zfbxlZj" title="Cost" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-12-31_custom_StatePharmacyLicensesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">45</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zGhmR1USem05" title="Accumulated amortization" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2019-12-31_custom_StatePharmacyLicensesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zdTRXTlUiIY5" title="Impairment" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HROW:FiniteLivedIntangibleAssetsImpairment" contextRef="AsOf2019-12-31_custom_StatePharmacyLicensesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">35</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zzd4Eso5bG6b" title="Net Carrying value" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2019-12-31_custom_StatePharmacyLicensesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231_zNlAG0V5AI5a" title="Cost" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,847</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231_zOAZLafkIIs9" title="Accumulated amortization" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,564</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231_zfwFghU4otk" title="Impairment" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HROW:FiniteLivedIntangibleAssetsImpairment" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">946</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231_zXhHwMCoYw24" title="Net Carrying value" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,337</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2019, the Company incurred impairment charges of $<span id="xdx_908_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember__dei--LegalEntityAxis__custom--ParkCompoundingIncMember_pn3n3"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2019-01-012019-12-31_custom_CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember_custom_ParkCompoundingIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">612</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">related to intangible assets, including
customer relationships, trade name, and state pharmacy licenses as a part of the Park Restructuring and $<span id="xdx_907_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__dei--LegalEntityAxis__custom--ParkCompoundingIncMember_pn3n3"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2019-01-012019-12-31_us-gaap_PatentsMember_custom_ParkCompoundingIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">259</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">of impairment charges related to patents
associated with the termination of an asset agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s intangible assets at December 31, 2020 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">periods</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(in
    years)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Cost</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">amortization</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Impairment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Carrying
    value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 21%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 13%; text-align: center"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MinimumMember_zhP46VZLxkA5" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_PatentsMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">17</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif">-<span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MaximumMember_zlrwlaXJYgnj"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_PatentsMember_srt_MaximumMember" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">19
    years</ix:nonNumeric></span></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" title="Cost" style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2020-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">929</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" title="Accumulated amortization" style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">93</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" title="Impairment" style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HROW:FiniteLivedIntangibleAssetsImpairment" contextRef="AsOf2020-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">363</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" title="Net Carrying value" style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2020-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">473</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Licenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_ztvth0XwlEM2" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_LicensesMember" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">20
    years</ix:nonNumeric></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" title="Cost" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2020-12-31_custom_LicensesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" title="Accumulated amortization" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-12-31_custom_LicensesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" title="Accumulated amortization" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0967">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" title="Net Carrying value" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2020-12-31_custom_LicensesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trademarks</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_TrademarksMember" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod">Indefinite</ix:nonNumeric></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" title="Cost" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2020-12-31_us-gaap_TrademarksMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">356</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td title="Accumulated amortization" id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zyVZb9RLmQSk" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0974">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" title="Impairment" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0976">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" title="Net Carrying value" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2020-12-31_us-gaap_TrademarksMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">356</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Customer relationships</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MinimumMember_zTIJEmYmkAi1" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_CustomerRelationshipsMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">3</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif">-<span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MaximumMember_zMyTp3xvOvye"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_CustomerRelationshipsMember_srt_MaximumMember" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">15
    years</ix:nonNumeric></span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" title="Cost" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2020-12-31_us-gaap_CustomerRelationshipsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,519</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" title="Accumulated amortization" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-12-31_us-gaap_CustomerRelationshipsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">454</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" title="Impairment" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0986">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" title="Net Carrying value" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2020-12-31_us-gaap_CustomerRelationshipsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,065</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trade name</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zFoEcLU36Rml" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_TradeNamesMember" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">5
    years</ix:nonNumeric></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" title="Cost" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2020-12-31_us-gaap_TradeNamesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" title="Accumulated amortization" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-12-31_us-gaap_TradeNamesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" title="Impairment" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0995">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" title="Net Carrying value" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0997">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-competition clause</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MinimumMember_zHCLJgySguOh" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_NonCompetitionClauseMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">3</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif">-<span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MaximumMember_zz3yOhc7RnC2"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_NonCompetitionClauseMember_srt_MaximumMember" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">4
    years</ix:nonNumeric></span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" title="Cost" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2020-12-31_custom_NonCompetitionClauseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" title="Accumulated amortization" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-12-31_custom_NonCompetitionClauseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">50</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" title="Impairment" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1005">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" title="Net Carrying value" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1007">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State pharmacy
    licenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zspTSXx0fi16" style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_StatePharmacyLicensesMember" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">25
    years</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" title="Cost" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2020-12-31_custom_StatePharmacyLicensesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" title="Accumulated amortization" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-12-31_custom_StatePharmacyLicensesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" title="Impairment" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1014">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" title="Net Carrying value" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2020-12-31_custom_StatePharmacyLicensesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231_pn3n3" title="Cost" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,917</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231_pn3n3" title="Accumulated amortization" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">615</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231_pn3n3" title="Impairment" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HROW:FiniteLivedIntangibleAssetsImpairment" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">363</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231_pn3n3" title="Net Carrying value" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,939</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AE_zzzWCuzuBtXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020, the Company recorded impairment charges of $<span id="xdx_902_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsFilingsAndTrademarksMember__dei--LegalEntityAxis__custom--ParkCompoundingIncMember_pn3n3"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2020-01-012020-12-31_custom_PatentsFilingsAndTrademarksMember_custom_ParkCompoundingIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">363</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">related to patent filings and trademarks
that were abandoned and/or were associated with products the Company was no longer actively selling.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"><p id="xdx_89A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zAj2eB9v1R98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Amortization
expense for intangible assets for the years ended December 31, 2020 and 2019 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BB_zlrxcSZGQuah" style="display: none; font-family: Times New Roman, Times, Serif">SCHEDULE
OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">For
                                         the Years Ended</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">December
                                         31,</span></p></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" title="Amortization of intangible assets" style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2020-01-012020-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" title="Amortization of intangible assets" style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2019-01-012019-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Licenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" title="Amortization of intangible assets" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2020-01-012020-12-31_custom_LicensesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" title="Amortization of intangible assets" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2019-01-012019-12-31_custom_LicensesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Customer relationships</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" title="Amortization of intangible assets" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2020-01-012020-12-31_us-gaap_CustomerRelationshipsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">134</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" title="Amortization of intangible assets" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2019-01-012019-12-31_us-gaap_CustomerRelationshipsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">151</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Trade name</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" title="Amortization of intangible assets" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1041">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" title="Amortization of intangible assets" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2019-01-012019-12-31_us-gaap_TradeNamesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State pharmacy
    licenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" title="Amortization of intangible assets" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1045">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" title="Amortization of intangible assets" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2019-01-012019-12-31_custom_StatePharmacyLicensesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231_pn3n3" title="Amortization of intangible assets" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">167</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231_pn3n3" title="Amortization of intangible assets" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">209</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A3_z80cgrtyrZCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zCrnqtoou5C7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Estimated
future amortization expense for the Company&#8217;s intangible assets at December 31, 2020 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B5_zWrE2YLiAiU1" style="display: none; font-family: Times New Roman, Times, Serif">SCHEDULE
OF ESTIMATED FUTURE AMORTIZATION EXPENSE</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Years
    ending December 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20201231_z08ve1nggkf4" style="display: none; text-align: center; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif">Dec</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzZax_zun3XUYwvgmk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">187</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzZax_zqXKKurZLBq4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">187</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzZax_zClalTV8kFt6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">187</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzZax_zUTxlWzgqgA7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">160</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANzZax_zLNYUz6Wy1q8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">147</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANzZax_z1idoaLAGGd7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">715</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzZax_zGYl8T2Be8Ak" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Intangible assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,583</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AF_zBGCJpC4cQX9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfGoodwillTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfGoodwillTextBlock_zjexslfNY2lb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">There
were <span id="xdx_90D_eus-gaap--GoodwillAndIntangibleAssetImpairment_pn3n3_do_c20200101__20201231_zB80rURDddwl">no</span></span>
<span style="font: 10pt Times New Roman, Times, Serif">changes in the carrying value of the Company&#8217;s
goodwill during the year ended December 31, 2020. Changes in the carrying value of the Company&#8217;s goodwill during the year
ended December 31, 2019 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B9_zfvkaevAckXe" style="display: none; font-family: Times New Roman, Times, Serif">SCHEDULE
OF GOODWILL</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
<tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_49D_20190101__20191231_zFUhKXfZ0Moj" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">Dec</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--Goodwill_iS_pn3n3_zllUwXCIesg3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance at December 31,
    2018</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,227</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--GoodwillImpairmentLoss_iN_pn3n3_di_zWCIoVCs7YF3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Impairment
    of Park goodwill (see Note 2)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,895</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_406_eus-gaap--Goodwill_iE_pn3n3_zn1KMrun4BX1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at
    December 31, 2019</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">332</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A8_zaqi1mldLqdg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p id="xdx_804_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z85dyRTKf31k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
11. <span id="xdx_82A_z4P77nLTTW4d">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zSTbfZT5E0Gh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Accounts
payable and accrued expenses at December 31, 2020 and 2019 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BF_zNnrDhjj9D91" style="font: 10pt Times New Roman, Times, Serif; display: none">SCHEDULE
OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20201231_zOQWq8Mbsmch" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20191231_zJeZIV8iuay5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn3n3_maAPAALzPeR_zPXROrIZN1d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,645</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,409</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maAPAALzPeR_zdhO5q7IVid6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Other accrued expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">49</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">49</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_maAPAALzPeR_zcEkRYmBjvdk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accrued interest (see Note 12)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">238</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">244</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maAPAALzPeR_zOuy8vW3Rud3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued exit
    fee for note payable (see Note 12)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">800</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">800</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_pn3n3_mtAPAALzPeR_zmszDR9tOXkj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total accounts payable and accrued
    expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,732</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,502</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iNI_pn3n3_di_zHTQw7cSETZd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: Current
    portion</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,932</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,702</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_400_eus-gaap--AccountsPayableAndAccruedLiabilitiesNoncurrent_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Non-current
    total accrued expenses</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">800</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">800</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AE_zQNChrfo0NTg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_809_eus-gaap--DebtDisclosureTextBlock_ze5UvGsiekF7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
12. <span id="xdx_82B_zVTvWXWJj8J">DEBT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>SWK
Senior Note &#8211; 2017</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2017, the Company entered into a term loan and security agreement in the principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20170731__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember_zWwKP1oKmQt9"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2017-07-31_custom_TermLoanAndSecurityAgreementMember_custom_SWKFundingLLCMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">(the &#8220;SWK Loan Agreement&#8221;
or &#8220;SWK Loan&#8221;) with SWK Funding LLC and its partners (&#8220;SWK&#8221;), as lender and collateral agent. <span id="xdx_90F_eus-gaap--DebtInstrumentDescription_c20170701__20170731__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember"><ix:nonNumeric contextRef="From2017-07-012017-07-31_custom_TermLoanAndSecurityAgreementMember_custom_SWKFundingLLCMember" name="us-gaap:DebtInstrumentDescription">The
SWK Loan Agreement was fully funded at closing with a five-year term, however, such term could be reduced to four years if certain
revenue requirements are not achieved.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190401__20190430__us-gaap--VariableRateAxis__us-gaap--LondonInterbankOfferedRateLIBORMember" title="Debt instrument interest rate description"><ix:nonNumeric contextRef="From2019-04-012019-04-30_us-gaap_LondonInterbankOfferedRateLIBORMember" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis">Prior
to the loan refinance in May 2019 (see below), the SWK Loan bore interest at a variable rate equal to the three-month London Inter-Bank
Offered Rate (subject to a minimum of <span id="xdx_901_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_uPercent_c20190401__20190430__us-gaap--VariableRateAxis__us-gaap--LondonInterbankOfferedRateLIBORMember__srt--RangeAxis__srt--MinimumMember_zdHatem99rpj" title="Loan bear interest at variable rate"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2019-04-012019-04-30_us-gaap_LondonInterbankOfferedRateLIBORMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">1.50</ix:nonFraction></span>%
and maximum of <span id="xdx_90A_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_uPercent_c20190401__20190430__us-gaap--VariableRateAxis__us-gaap--LondonInterbankOfferedRateLIBORMember__srt--RangeAxis__srt--MaximumMember_zSbc7F7EDeSa" title="Loan bear interest at variable rate"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2019-04-012019-04-30_us-gaap_LondonInterbankOfferedRateLIBORMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">3.00</ix:nonFraction></span>%),
plus an applicable margin of <span id="xdx_90F_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_uPercent_c20190401__20190430__us-gaap--VariableRateAxis__us-gaap--LondonInterbankOfferedRateLIBORMember_z4WLWy8fCz51" title="Loan bear interest at variable rate"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2019-04-012019-04-30_us-gaap_LondonInterbankOfferedRateLIBORMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">10.50</ix:nonFraction></span>%.</ix:nonNumeric></span>
</span><span style="font: 10pt Times New Roman, Times, Serif">The SWK Loan Agreement permitted the Company
to pay interest only on the principal amount borrowed thereunder for the first six payments (payments are due on a quarterly basis),
which interest-only period could have been reduced to four payments if the Company had not met certain minimum revenue requirements.
Following the interest-only period, the Company was required to pay interest, plus repayments of the principal amount borrowed
under the SWK Loan Agreement, in quarterly payments, which shall not exceed $<span id="xdx_90B_eus-gaap--RepaymentsOfDebt_pn3n3_c20190429__20190430__us-gaap--TypeOfArrangementAxis__custom--SWKLoanAgreementMember_z81y6psk9il6"><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="From2019-04-292019-04-30_custom_SWKLoanAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">750</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per quarter. <span id="xdx_903_eus-gaap--DebtInstrumentMaturityDateDescription_c20190429__20190430__us-gaap--TypeOfArrangementAxis__custom--SWKLoanAgreementMember"><ix:nonNumeric contextRef="From2019-04-292019-04-30_custom_SWKLoanAgreementMember" name="us-gaap:DebtInstrumentMaturityDateDescription">All
amounts owed under the SWK Loan Agreement, including an exit fee equal to 5% of the aggregate principal amount loaned thereunder,
were originally due and payable on July 19, 2022.</ix:nonNumeric></span></span> <span style="font: 10pt Times New Roman, Times, Serif">The
Company is obligated under the SWK Loan Agreement to pay for certain expenses incurred by SWK through and after the date of the
SWK Loan Agreement, including certain fees and expenses relating to the preparation and administration of the SWK Loan Agreement.
The Company incurred expenses and an exit fee of approximately $<span id="xdx_90B_eus-gaap--DebtInstrumentFeeAmount_c20190430__us-gaap--TypeOfArrangementAxis__custom--SWKLoanAgreementMember_pn3n3"><ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="AsOf2019-04-30_custom_SWKLoanAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,282</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">in connection with the SWK Loan Agreement.
The exit fee and expenses were recorded as a debt discount and are being amortized as interest expense over the term of the SWK
Loan using the effective interest rate method and the related liability of $<span id="xdx_90D_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_c20201231_zbCQFVx2F7r7"><span id="xdx_908_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_c20191231_pn3n3"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">800</ix:nonFraction></ix:nonFraction></span>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for the exit fee is included in accrued
expenses (see Note 11) in the accompanying consolidated balance sheets as of December 31, 2020 and 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
connection with the SWK Loan Agreement, the Company issued to SWK warrants to purchase up to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20170731__us-gaap--StatementEquityComponentsAxis__custom--LenderWarrantsMember_zlXZJ4EwuSK9"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2017-07-31_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">415,586</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of the Company&#8217;s common stock
(the &#8220;Lender Warrants&#8221;) with an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20170731__us-gaap--StatementEquityComponentsAxis__custom--LenderWarrantsMember_pii"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2017-07-31_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.08</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">.
In August 2017, the Company and SWK amended the warrants, to allow for the purchase of up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20170831__us-gaap--StatementEquityComponentsAxis__custom--LenderWarrantsMember_zy4W0iUAcqD2"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2017-08-31_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">615,386</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">warrants with an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20170831__us-gaap--StatementEquityComponentsAxis__custom--LenderWarrantsMember_pii"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2017-08-31_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.08</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">.
The Lender Warrants are exercisable immediately, and have a term of <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dt_c20170731__us-gaap--StatementEquityComponentsAxis__custom--LenderWarrantsMember_zsck4JNX6Vcj"><ix:nonNumeric contextRef="AsOf2017-07-31_custom_LenderWarrantsMember" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm">seven
years</ix:nonNumeric></span></span><span style="font: 10pt Times New Roman, Times, Serif">. The Lender Warrants are subject
to a cashless exercise feature, with the exercise price and number of shares issuable upon exercise subject to change in connection
with stock splits, dividends, reclassifications and other conditions. The relative fair value of the Lender Warrants was approximately
$<span id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_c20200101__20201231_pn3n3"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">982</ix:nonFraction></span></span> <span style="font: 10pt Times New Roman, Times, Serif">and
was estimated using the Black-Scholes-Merton option pricing model with the following assumptions: fair value of the Company&#8217;s
common stock at issuance of $<span id="xdx_902_eus-gaap--SharesIssued_c20170831__us-gaap--StatementEquityComponentsAxis__custom--LenderWarrantsMember_pii"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2017-08-31_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2.08</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per share; seven-year contractual term;
<span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pii_dp_uPercent_c20170831__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zoKrPzP5lJJg"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2017-08-31_us-gaap_WarrantMember_us-gaap_MeasurementInputPriceVolatilityMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">113.5</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
volatility; <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pii_dp_uPercent_c20170831__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z8iBgC34qAWj"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2017-08-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">0</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
dividend rate; and a risk-free interest rate of <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pii_dp_uPercent_c20170831__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zJGDRNQprik7"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2017-08-31_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">1.77</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%.
The relative fair value of the Lender Warrants was recorded as a debt discount which is being amortized as interest expense over
the term of the SWK Loan using the effective interest rate method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>SWK
Refinance &#8211; May 2019</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
May 2019, the Company entered into a joinder and amendment (the &#8220;Amendment&#8221;) to the SWK Loan and with SWK, as lender
and collateral agent. A summary of the material changes contained in the Amendment are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    interest rate calculation that the loan bears is now equal to the three-month London Inter-Bank Offered Rate (subject to a
    minimum of <span id="xdx_901_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--JoinderAndAmendmentMember__us-gaap--VariableRateAxis__us-gaap--LondonInterbankOfferedRateLIBORMember__srt--RangeAxis__srt--MinimumMember_zeDhU0aeb4b7"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2019-05-012019-05-31_custom_JoinderAndAmendmentMember_us-gaap_LondonInterbankOfferedRateLIBORMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">2.00</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%),
    plus an applicable margin of <span id="xdx_900_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--JoinderAndAmendmentMember__us-gaap--VariableRateAxis__custom--MarginRateMember_znvEES1EYcx8"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2019-05-012019-05-31_custom_JoinderAndAmendmentMember_custom_MarginRateMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">10.00</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
    (the &#8220;Margin Rate&#8221;); provided that, if, two days prior to a payment date, the <span id="xdx_90B_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--JoinderAndAmendmentMember"><ix:nonNumeric contextRef="From2019-05-012019-05-31_custom_JoinderAndAmendmentMember" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis">Company
    provides SWK evidence that the Company has achieved a leverage ratio as of such date of less than 4.00:1:00, the Margin Rate
    shall equal 9.00%; and if the Company has achieved a leverage ratio as of such date of less than 3.00:1:00, the Margin Rate
    shall equal 7.00%;</ix:nonNumeric></span></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Leverage
    ratio in the Amendment means, as of any date of determination, the ratio of: (a) indebtedness as of such date to (b) EBITDA
    (as defined in the SWK Loan), of the Company for the immediately preceding twelve (12) month period, adding-back (i) actual
    litigation expenses for the immediately preceding twelve (12) month period, minus (ii) actual litigation expenses for the
    immediately preceding three (3) month period multiplied by four (4);</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    definition of the first amortization date was changed to May 14, 2020, permitting the Company to pay interest only on the
    principal amount loaned for the next four payments (payments are due on a quarterly basis) following the Amendment; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Subject
    to the satisfaction of certain revenue and market capitalization requirements and conditions, SWK agreed to make available
    to the Company an additional principal amount of up to $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20190531__us-gaap--TypeOfArrangementAxis__custom--JoinderAndAmendmentMember_z16G7gMhLfj6"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2019-05-31_custom_JoinderAndAmendmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,000</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">;
    and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    maturity date was changed to <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--JoinderAndAmendmentMember__us-gaap--VariableRateAxis__custom--MarginRateMember_zTh86uO0sqYd"><ix:nonNumeric contextRef="From2019-05-012019-05-31_custom_JoinderAndAmendmentMember_custom_MarginRateMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">July
    19, 2023</ix:nonNumeric></span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Related
to the Amendment, the Company incurred expenses related to legal and lender costs of $<span id="xdx_90E_eus-gaap--LegalFees_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--JoinderAndAmendmentMember__us-gaap--VariableRateAxis__custom--MarginRateMember_pn3n3"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2019-05-012019-05-31_custom_JoinderAndAmendmentMember_custom_MarginRateMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">282</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">that are included in debt discount and
will be amortized over the remaining term of the SWK Loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
addition to the terms described above, the Amendment joined the Company&#8217;s recently created subsidiaries to the SWK Loan
and added definitions related to excluded subsidiaries that are not considered co-borrowers and are subsidiaries of the Company
which the Company believes it will eventually deconsolidate from its financial statements and lose <span id="xdx_90B_ecustom--DeconsolidationPercentage_pii_dp_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--JoinderAndAmendmentMember__us-gaap--VariableRateAxis__custom--MarginRateMember_z9KbGtnwpbp"><ix:nonFraction name="HROW:DeconsolidationPercentage" contextRef="From2019-05-012019-05-31_custom_JoinderAndAmendmentMember_custom_MarginRateMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">50</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
or more of the equity interests of the subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Second
Amendment to SWK Loan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On
April 1, 2020, the Company and several of its wholly owned subsidiaries entered into a second amendment (the &#8220;SWK Second
Amendment&#8221;) to the SWK Loan with SWK. A summary of the material changes contained in the SWK Second Amendment are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">SWK
    agreed to make available to the Company, and the Company drew down on, an additional principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_c20200402__us-gaap--TypeOfArrangementAxis__custom--SWKSecondAmendmentMember_pn3n3"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-04-02_custom_SWKSecondAmendmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,000</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    definition of the first amortization date was changed to August 14, 2020, permitting the Company to pay interest only on the
    principal amount loaned for the next payment (payments are due on a quarterly basis) following the SWK Second Amendment; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    interest payment of $<span id="xdx_900_eus-gaap--InterestExpenseDebt_c20200513__20200514__us-gaap--TypeOfArrangementAxis__custom--SWKSecondAmendmentMember_pn3n3"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2020-05-132020-05-14_custom_SWKSecondAmendmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">358</ix:nonFraction>
    </span></span><span style="font: 10pt Times New Roman, Times, Serif">due May 14, 2020 was paid in-kind
    by increasing the principal amount of the term loans by an amount equal to the interest accrued as of such date.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Interest
expense related to the SWK Loan Agreement, as amended, amounted to $<span id="xdx_90B_eus-gaap--InterestExpenseDebt_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--SWKSecondAmendmentMember_pn3n3"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2020-01-012020-12-31_custom_SWKSecondAmendmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,768</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90D_eus-gaap--InterestExpenseDebt_pn3n3_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--SWKSecondAmendmentMember_zEDV9TOdVkP"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2019-01-012019-12-31_custom_SWKSecondAmendmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,960</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for the years ended December 31, 2020
and 2019, respectively, and included amortization of debt issuance costs and discount of $<span id="xdx_908_eus-gaap--AmortizationOfDebtDiscountPremium_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--SWKSecondAmendmentMember_pn3n3"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2020-01-012020-12-31_custom_SWKSecondAmendmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">457</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_909_eus-gaap--AmortizationOfDebtDiscountPremium_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--SWKSecondAmendmentMember_pn3n3"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2019-01-012019-12-31_custom_SWKSecondAmendmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">512</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for the years ended December 31, 2020
and 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Paycheck
Protection Program Loan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
April 2020, the Company entered into an unsecured promissory note and related Business Loan Agreement with Renasant Bank, as lender,
for a loan (the &#8220;PPP Loan&#8221;) in the principal amount of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_c20200430__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember_pn3n3"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-04-30_custom_BusinessLoanAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,967</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and received cash proceeds of the same
amount, pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic
Security Act (the &#8220;CARES Act&#8221;), which was enacted March 27, 2020. The PPP is administered by the U.S. Small Business
Administration (the &#8220;SBA&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Under
the terms of the PPP Loan, interest accrues on the outstanding principal at the rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_c20200430__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember_zQ1cZ59nM5U5"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-04-30_custom_BusinessLoanAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">1.0</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
per annum. The term of the PPP Loan is two years, unless payment is sooner required in connection with an event of default under
the PPP Loan. To the extent the PPP Loan amount is not forgiven under the PPP, the Company is obligated to make equal monthly
payments of principal and interest, beginning seven months from the date of the PPP Loan, until the maturity date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
CARES Act and the PPP provide a mechanism for forgiveness of up to the full amount borrowed. Under the PPP, the Company applied
for forgiveness for all of the PPP Loan during the year ended December 31, 2020, however the SBA has not made a decision related
to the Company&#8217;s application for forgiveness. The amount of loan proceeds eligible for forgiveness is based on a formula
that takes into account a number of factors, including the amount of loan proceeds used by the Company during the 24-week period
after the loan origination for certain purposes including payroll costs, interest on certain mortgage obligations, rent payments
on certain leases, and certain qualified utility payments (<span id="xdx_907_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20200403__20200430__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember"><ix:nonNumeric contextRef="From2020-04-032020-04-30_custom_BusinessLoanAgreementMember" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis">it
being anticipated that at least 75% of the loan amount will be required to be used for eligible payroll costs</ix:nonNumeric></span></span><span style="font: 10pt Times New Roman, Times, Serif">);
the employer maintaining or rehiring employees and maintaining salaries at certain levels; and other factors. Subject to the other
requirements and limitations on loan forgiveness, only loan proceeds spent on payroll and other eligible expenses during the covered
twenty-four-week period will qualify for forgiveness. While the Company has used proceeds from the PPP Loan for such qualifying
expenses, in particular maintaining continuity of its payroll and workforce (including staff critical to the timely production
and dispensing of medicines the Company produces), no assurance can be provided that the Company will obtain forgiveness of the
PPP Loan in whole or in part. <span id="xdx_90B_eus-gaap--InterestExpenseDebt_pn3n3_do_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember_z03zsm6G9Z5">No
</span></span><span style="font: 10pt Times New Roman, Times, Serif">interest expense was recognized for the
year ended December 31, 2020 related to the PPP Loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zXNJcHgSyYGf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2020, future minimum payments under the Company&#8217;s debt were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BD_zizdE1NSyEMa" style="font: 10pt Times New Roman, Times, Serif; display: none">SUMMARY
OF FUTURE MINIMUM PAYMENTS</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20201231_zLJmPpoPTFI6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maLTDzahg_zABGlu8wOMFe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,794</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maLTDzahg_zaeVDqElNOY5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,700</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maLTDzahg_zL7MRHjzyf0f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,511</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDzahg_zvgwAcLonrK6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total minimum payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,005</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--InterestPayableCurrent_iNI_pn3n3_di_zN3aVQMerpM8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: amount
    representing interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,927</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_409_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_zvYFCbAYDpB4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Notes payable, gross</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,078</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_zBlvNm0isV8g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: unamortized
    discount</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">802</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_406_eus-gaap--NotesPayable_iTI_pn3n3_zKOyQNKTAAV8" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Notes payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,276</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_ecustom--NotesPayableCurrent1_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: current
    portion, net of unamortized discount</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HROW:NotesPayableCurrent1" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,898</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_409_ecustom--LongTermNotesPayable1_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Note payable,
    net of current portion and unamortized debt discount</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:LongTermNotesPayable1" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,378</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A8_zx7jYDbayZG5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:LeasesOfLesseeDisclosureTextBlock"><p id="xdx_805_eus-gaap--LeasesOfLesseeDisclosureTextBlock_za1ngAJwHxB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
13. <span id="xdx_820_zJpYFUmOR7Lc">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company leases office and laboratory space under the non-cancelable operating leases listed below. These lease agreements have
remaining lease terms between <span id="xdx_90F_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtYxL_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember__srt--RangeAxis__srt--MinimumMember_zV9nVi3OtnBg" title="::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl1169">one
</span></span></span><span style="font: 10pt Times New Roman, Times, Serif">to <span id="xdx_90F_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember__srt--RangeAxis__srt--MaximumMember_zzeGYKmm635f"><ix:nonNumeric contextRef="AsOf2020-12-31_custom_OfficeAndLaboratorySpaceMember_srt_MaximumMember" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">four years</ix:nonNumeric></span> and contain various clauses
for renewal at the Company&#8217;s option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">An
    operating lease for <span id="xdx_904_eus-gaap--AreaOfLand_iI_pii_uSqft_c20201231__srt--StatementGeographicalAxis__custom--SanDiegoMember_zAkrDPYkY75f"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2020-12-31_custom_SanDiegoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Sqft">10,200</ix:nonFraction>
    </span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">square feet
    of office space in San Diego, California, that expires in <span id="xdx_906_ecustom--LeaseExpirationDateDescription_c20200101__20201231__srt--StatementGeographicalAxis__custom--SanDiegoMember_zHw0khCE3uMc"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_SanDiegoMember" name="HROW:LeaseExpirationDateDescription">December
    2021</ix:nonNumeric></span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">, with
    an <span id="xdx_90F_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20200101__20201231__srt--StatementGeographicalAxis__custom--SanDiegoMember_z9i7qTEO1CT4"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_SanDiegoMember" name="us-gaap:LesseeOperatingLeaseOptionToExtend">option
    to extend the term for a five-year period</ix:nonNumeric></span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">An
    operating lease for <span id="xdx_905_eus-gaap--AreaOfLand_iI_pii_uSqft_c20201231__srt--StatementGeographicalAxis__custom--LedgewoodMember_z9Cpzr0f9szl"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2020-12-31_custom_LedgewoodMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Sqft">26,400</ix:nonFraction>
    </span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">square feet
    of lab, warehouse and office space in Ledgewood, New Jersey, that expires in <span id="xdx_90E_ecustom--LeaseExpirationDateDescription_c20200101__20201231__srt--StatementGeographicalAxis__custom--LedgewoodMember_z7HS8z3U0AFh"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_LedgewoodMember" name="HROW:LeaseExpirationDateDescription">July
    2026</ix:nonNumeric></span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">, with
    <span id="xdx_90B_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20200101__20201231__srt--StatementGeographicalAxis__custom--LedgewoodMember_zUkbx8fTEood"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_LedgewoodMember" name="us-gaap:LesseeOperatingLeaseOptionToExtend">an
    option to extend the term for two additional five-year periods</ix:nonNumeric></span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">.
    This includes an amendment that was made effective July 2020 that extended the term of the original lease and added <span id="xdx_902_ecustom--AdditionalAreaOfLand_iI_pii_uSqft_c20201231__srt--StatementGeographicalAxis__custom--LedgewoodMember_zb4ngO58o8Df" title="Additional square footage"><ix:nonFraction name="HROW:AdditionalAreaOfLand" contextRef="AsOf2020-12-31_custom_LedgewoodMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Sqft">1,400</ix:nonFraction>
    </span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">of additional
    square footage to the lease; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An
    operating lease for <span id="xdx_904_eus-gaap--AreaOfLand_iI_pii_uSqft_c20201231__srt--StatementGeographicalAxis__custom--NashvilleMember_zODv94I0Lh8f"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2020-12-31_custom_NashvilleMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Sqft">5,500</ix:nonFraction>
    </span></span><span style="font: 10pt Times New Roman, Times, Serif">square feet of office space in Nashville,
    Tennessee, that expires in <span id="xdx_908_ecustom--LeaseExpirationDateDescription_c20200101__20201231__srt--StatementGeographicalAxis__custom--NashvilleMember"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_NashvilleMember" name="HROW:LeaseExpirationDateDescription">December
    2024</ix:nonNumeric></span></span><span style="font: 10pt Times New Roman, Times, Serif">, with an <span id="xdx_901_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20200101__20201231__srt--StatementGeographicalAxis__custom--NashvilleMember"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_NashvilleMember" name="us-gaap:LesseeOperatingLeaseOptionToExtend">option
    to extend the term for two additional five-year periods</ix:nonNumeric></span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">During
the year ended December 31, 2020, the Company terminated its operating lease for <span id="xdx_909_eus-gaap--AreaOfLand_iI_pii_uSqft_c20201231__srt--StatementGeographicalAxis__custom--IrvineMember_zNVcLKqqULV"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2020-12-31_custom_IrvineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Sqft">4,500</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">square feet of
office and lab space in Irvine, California, that had an expiration date in December 2020. In connection with the termination,
the Company recorded a gain of $<span id="xdx_908_eus-gaap--GainLossOnTerminationOfLease_c20200101__20201231__srt--StatementGeographicalAxis__custom--IrvineMember_pn3n3"><ix:nonFraction name="us-gaap:GainLossOnTerminationOfLease" contextRef="From2020-01-012020-12-31_custom_IrvineMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">which was recognized
in other income (expense) on the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2020 and 2019, the weighted-average discount rate and the weighted-average remaining lease term for the operating
leases held by the Company were <span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_uPercent_c20201231_zNoiPzgLgIc5"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">6.3</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
and <span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_uPercent_c20191231_zpxXjiyJR571"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">6.3</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
and <span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zFigVgEPCSfk"><ix:nonNumeric contextRef="AsOf2020-12-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">11.2</ix:nonNumeric></span></span>
<span style="font: 10pt Times New Roman, Times, Serif">and <span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20191231_z1CXzUB5jLh"><ix:nonNumeric contextRef="AsOf2019-12-31" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">10.21</ix:nonNumeric>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">years, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the years ended December 31, 2020 and 2019, cash paid for amounts included for the operating lease liabilities was $<span id="xdx_906_eus-gaap--OperatingLeasePayments_c20200101__20201231_pn3n3"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,052</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_901_eus-gaap--OperatingLeasePayments_pn3n3_c20190101__20191231_zD9j5V5z3Shj"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">905</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively, and the Company recorded operating lease expense of $<span id="xdx_900_eus-gaap--OperatingLeaseExpense_c20200101__20201231_pn3n3"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,066</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90F_eus-gaap--OperatingLeaseExpense_c20190101__20191231_pn3n3"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">892</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively, included in selling, general and administrative expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zBHaDku5PJ05" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Future
lease payments under operating leases (including options to extend) as of December 31, 2020 were as follows<b>: </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;<span id="xdx_8BA_zCGIKH544meg" style="display: none">SCHEDULE
OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20201231_z7vEciE6mGM9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Dec
    31, 2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Operating
    Leases</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzHYL_ztSvJXG01Clg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td title="2021" style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,017</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzHYL_z7dClBFBQ3Wa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td title="2022" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,038</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzHYL_zbURxCwGXWIi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td title="2023" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,064</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzHYL_z0YO91yBCbig" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,090</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maLOLLPzHYL_zgIv5ehjhyEb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">916</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPzHYL_zM4UDNvZZjrk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,141</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzHYL_zLehlB1IYAz8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total minimum lease payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,266</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_z4XSssBwVWBb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: amount
    representing interest payments</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,034</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zXfD1mp0LnE3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total operating
    lease liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,232</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_zRcbHFWH26Ga" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: current
    portion, operating lease liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">580</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    lease liabilities, net of current portion</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,652</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A5_zepq4jRCP57" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company also has a finance lease for equipment which requires monthly payments of $<span id="xdx_905_ecustom--MonthlyPaymentsOfFinanceLeaseForEquipment_pn3n3_c20200101__20201231_zDMM54Im8Mm5" title="Monthly payments of finance lease"><ix:nonFraction name="HROW:MonthlyPaymentsOfFinanceLeaseForEquipment" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">through January 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock"><p id="xdx_892_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_z8hLwse0aLEb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Future
lease payments under the finance lease as of December 31, 2020 were as follows<b>: </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;<span id="xdx_8B9_zMAS9lkCNBG4" style="display: none">SCHEDULE
OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20201231_zQ8cj1fDi9x3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Dec
    31, 2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Finance
    Lease</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maFLLPDzqJW_zbhPbELo62cb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maFLLPDzqJW_z1r0Hki6hbTf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maFLLPDzqJW_zZY2ZHZ47DF" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maFLLPDzqJW_zlhD50S62qNj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_pn3n3_mtFLLPDzqJW_z6THCmSKI286" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total minimum lease payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zGQmkwS8O0Q8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: amount
    representing interest payments</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40C_eus-gaap--FinanceLeaseLiability_iI_pn3n3_zbbH2BQ1BGz3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Present value of future minimum lease
    payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_pn3n3_di_ze37uSaOytll" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: current
    portion, finance lease obligation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Finance lease
    obligation, net of current portion</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A3_zAa0VS9yabwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2020 and 2019, the weighted-average discount rate and the weighted-average remaining lease term for the finance lease
held by the Company were <span id="xdx_901_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_c20201231_pii"><ix:nonFraction name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Percent">6.36</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
and <span id="xdx_904_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_uPercent_c20191231_zvicejXg1Gh4"><ix:nonFraction name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">6.36</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">%
and <span id="xdx_90E_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zA51YxXsd3j2"><ix:nonNumeric contextRef="AsOf2020-12-31" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1">3.08</ix:nonNumeric></span></span>
<span style="font: 10pt Times New Roman, Times, Serif">and <span id="xdx_904_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20191231_zKZPUyQvCQlb"><ix:nonNumeric contextRef="AsOf2019-12-31" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1">4.08</ix:nonNumeric>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">years, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For
the years ended December 31, 2020 and 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">debt
    discount amortization related to a finance lease obligation was $<span id="xdx_908_eus-gaap--AmortizationOfDebtDiscountPremium_c20200101__20201231_pn3n3"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction>
    </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_909_eus-gaap--AmortizationOfDebtDiscountPremium_c20190101__20191231_pn3n3"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">,
    respectively;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">amortization
    expense related to the equipment held under the finance lease obligations was $<span id="xdx_902_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_c20200101__20201231_pn3n3"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction>
    </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_903_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_c20190101__20191231_pn3n3"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">,
    respectively; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">cash
    paid and expense recognized for interest expense related to the finance lease obligation was $<span id="xdx_906_eus-gaap--FinanceLeaseInterestExpense_c20200101__20201231_pn3n3"><ix:nonFraction name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction>
    </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_907_eus-gaap--FinanceLeaseInterestExpense_c20190101__20191231_pn3n3"><ix:nonFraction name="us-gaap:FinanceLeaseInterestExpense" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">,
    respectively.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock"><p id="xdx_80F_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zNZ3jL7CR8s8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
14. <span id="xdx_822_zYHe9NP6Sdx4">STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2020 and 2019, the Company had <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pii_c20201231_zDDq1EK97VTk" title="Common stock, shares authorized"><span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pii_c20191231_zD0ElZopPIH2" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000,000</ix:nonFraction></ix:nonFraction></span></span> shares of common stock, $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pii_c20201231_zrqPlGwJ7Hh1" title="Common stock, par value"><span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pii_c20191231_zq3KoOUSP7A5" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value, authorized, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Issuances
During the Year Ended December 31, 2019</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" title="Shares issued of restricted common stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000</ix:nonFraction></span> shares of its restricted common stock, with a fair value of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJAfkvI70YOf" title="Fair value of restricted common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75</ix:nonFraction></span>, as consideration for commission expenses
    incurred during the year ended December 31, 2018;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company issued <span id="xdx_90B_ecustom--NumberOfCommonStockIssuedOnCashlessExercise_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Number of common stock issued on cashless exercise"><ix:nonFraction name="HROW:NumberOfCommonStockIssuedOnCashlessExercise" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,671</ix:nonFraction></span> shares of its common stock upon the cashless exercise of options to purchase <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Common shares issued under share-based arrangement"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">82,929</ix:nonFraction></span> shares of common
    stock, with exercise prices ranging from $<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Options exercise price, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.70</ix:nonFraction></span> to $<span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zBMBD7ZEBqu9" title="Options exercise price, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.17</ix:nonFraction></span> per share, net of <span id="xdx_906_ecustom--CommonStockWithheldForPayrollTaxWithholdingsShare_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pii" title="Common stock withheld for payroll tax withholdings, shares"><ix:nonFraction name="HROW:CommonStockWithheldForPayrollTaxWithholdingsShare" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,806</ix:nonFraction></span> shares of common stock withheld for payroll
    tax withholdings totaling $<span id="xdx_907_ecustom--CommonStockWithheldForPayrollTaxWithholdingsValue_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pn3n3" title="Common stock withheld for payroll tax withholdings, value"><ix:nonFraction name="HROW:CommonStockWithheldForPayrollTaxWithholdingsValue" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></span>;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company issued <span id="xdx_902_ecustom--NumberOfCommonStockIssuedOnCashlessExercise_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Number of common stock issued on cashless exercise"><ix:nonFraction name="HROW:NumberOfCommonStockIssuedOnCashlessExercise" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,122</ix:nonFraction></span> shares of its common stock upon the exercise of options to purchase <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Common shares issued under share-based arrangement"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,122</ix:nonFraction></span> shares of common stock, with
    exercise prices ranging from $<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Options exercise price, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.70</ix:nonFraction></span> to $<span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Options exercise price, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.20</ix:nonFraction></span> per share, and received net proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pn3n3" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeTwoMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></span>;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsOneMember_pii" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-01-012019-12-31_custom_CommonStockWarrantsOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">688,473</ix:nonFraction></span> shares of its common stock upon the cashless exercise of warrants to purchase <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsOneMember_pii" title="Common shares issued under share-based arrangement"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2019-01-012019-12-31_custom_CommonStockWarrantsOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">964,532</ix:nonFraction></span> shares of common
    stock with an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20191231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsOneMember_pii" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2019-12-31_custom_CommonStockWarrantsOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.79</ix:nonFraction></span> per share;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company issued <span title="Common shares issued under share-based arrangement"><span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsTwoMember_pii" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-01-012019-12-31_custom_CommonStockWarrantsTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">454,055</ix:nonFraction></span></span> shares of its common stock upon the exercise of warrants to purchase <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsTwoMember_pii" title="Common shares issued under share-based arrangement"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2019-01-012019-12-31_custom_CommonStockWarrantsTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">454,055</ix:nonFraction></span> shares of common stock
    with an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20191231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsTwoMember_pii" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2019-12-31_custom_CommonStockWarrantsTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.79</ix:nonFraction></span> per share, and received net proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromWarrantExercises_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsTwoMember_pn3n3" title="Proceeds from issuance of warrant"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2019-01-012019-12-31_custom_CommonStockWarrantsTwoMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">813</ix:nonFraction></span>; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company issued</span> <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zjNKaEvK4Fx1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">87,610</ix:nonFraction></span> shares of its
    common stock underlying RSUs issued to directors vested, but the issuance and delivery of these shares are deferred until
    the director resigns.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Issuances
During the Year Ended December 31, 2020</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.15pt; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" title="Shares issued of restricted common stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000</ix:nonFraction></span> shares of its restricted common stock, with an initial fair value of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pn3n3" title="Fair value of restricted common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">167</ix:nonFraction></span>, as consideration for commission
    expenses incurred during the year ended December 31, 2019 and the year ended December 31, 2020;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company issued <span id="xdx_904_ecustom--NumberOfCommonStockIssuedOnCashlessExercise_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Number of common stock issued on cashless exercise"><ix:nonFraction name="HROW:NumberOfCommonStockIssuedOnCashlessExercise" contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,161</ix:nonFraction></span> shares of its common stock upon the cashless exercise of options to purchase <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Common shares issued under share-based arrangement"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,750</ix:nonFraction></span> shares of common
    stock, with exercise prices ranging from $<span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Options exercise price, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.70</ix:nonFraction></span> to $<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Options exercise price, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.05</ix:nonFraction></span> per share, net of <span id="xdx_905_ecustom--CommonStockWithheldForPayrollTaxWithholdingsShare_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pii" title="Common stock withheld for payroll tax withholdings, shares"><ix:nonFraction name="HROW:CommonStockWithheldForPayrollTaxWithholdingsShare" contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,564</ix:nonFraction></span> shares of common stock withheld for payroll
    tax withholdings;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company issued <span id="xdx_903_ecustom--NumberOfCommonStockIssuedOnCashlessExercise_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Number of common stock issued on cashless exercise"><ix:nonFraction name="HROW:NumberOfCommonStockIssuedOnCashlessExercise" contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,998</ix:nonFraction></span> shares of its common stock upon the exercise of options to purchase <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Common shares issued under share-based arrangement"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,998</ix:nonFraction></span> shares of common stock, with
    exercise prices ranging from $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Options exercise price, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.04</ix:nonFraction></span> to $<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Options exercise price, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.20</ix:nonFraction></span> per share, and paid $<span id="xdx_906_ecustom--CommonStockWithheldForPayrollTaxWithholdingsValue_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pn3n3" title="Common stock withheld for payroll tax withholdings, value"><ix:nonFraction name="HROW:CommonStockWithheldForPayrollTaxWithholdingsValue" contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction> </span>related to payroll tax withholdings;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" title="Shares issued of restricted common stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">185,785</ix:nonFraction></span> shares of its common stock underlying RSUs held by directors that resigned. The RSUs had previously
    vested, including <span id="xdx_902_ecustom--RestrictedStockUnitsVested_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" title="Restricted stock units vested"><ix:nonFraction name="HROW:RestrictedStockUnitsVested" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,721</ix:nonFraction></span> RSUs during the year ended December 31, 2020, but the issuance and delivery of the shares
    were deferred until the director resigned; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_pii" title="Shares issued of restricted common stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,224</ix:nonFraction></span>
    </span><span style="font: 10pt Times New Roman, Times, Serif">shares of the Company&#8217;s common stock underlying RSUs
    issued to directors vested, but the issuance and delivery of these shares are deferred until the resignation of a director.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Preferred
Stock </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2020 and 2019, the Company had <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_c20201231_pii" title="Preferred stock, shares authorized"><span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_c20191231_pii" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></span></span> shares of preferred stock, $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_c20201231_pii" title="Preferred stock, par value"><span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_c20191231_pii" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value, authorized and <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pii_do_c20201231_zjkHWXQIjgC8" title="Preferred stock, shares issued"><span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pii_do_c20201231_zLFCisVtY8tj" title="Preferred stock, shares outstanding"><span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_pii_do_c20191231_zZUgl1b55R7k" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pii_do_c20191231_zY8BHLZ34SF8" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2019-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2019-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares of
preferred stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Stock
Option Plan </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
September 17, 2007, the Company&#8217;s Board of Directors and stockholders adopted the Company&#8217;s 2007 Incentive Stock and
Awards Plan, which was subsequently amended on November 5, 2008, February 26, 2012, July 18, 2012, May 2, 2013 and September 27,
2013 (as amended, the &#8220;2007 Plan&#8221;). The 2007 Plan reached its term in September 2017, and we can no longer issue additional
awards under this plan, however, options previously issued under the 2007 Plan will remain outstanding until they are exercised,
reach their maturity or are otherwise cancelled/forfeited. On June 13, 2017, the Company&#8217;s Board of Directors and stockholders
adopted the Company&#8217;s 2017 Incentive Stock and Awards Plan (the &#8220;2017 Plan&#8221; together with the 2007 Plan, the
&#8220;Plans&#8221;). As of December 31, 2020, the 2017 Plan provides for the issuance of a maximum of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20201231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_pii" title="Maximum number of common stock issuance under the plan"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2020-12-31_custom_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></span> shares of the
Company&#8217;s common stock. The purpose of the Plans are to attract and retain directors, officers, consultants, advisors and
employees whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of
such persons in the Company&#8217;s development and financial success. Under the Plans, the Company is authorized to issue incentive
stock options intended to qualify under Section 422 of the Internal Revenue Code, non-qualified stock options, restricted stock
units and restricted stock. The Plans are administered by the Compensation Committee of the Company&#8217;s Board of Directors.
The Company had <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20201231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_pii" title="Shares available for future issuances"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2020-12-31_custom_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">342,882</ix:nonFraction></span> shares available for future issuances under the 2017 Plan at December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zFVMg4isXzGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of stock option activity under the Plan for the year ended December 31, 2020 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BA_zXtj7wc3j72" style="display: none">SCHEDULE OF STOCK OPTION PLAN ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Avg. Exercise Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Avg. Remaining Contractual Life</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate
    Intrinsic Value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Options outstanding -
    January 1, 2020</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20191231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z0wvlfZb3Fn5" title="Number of shares, Outstanding, Beginning balance" style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-12-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,656,683</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20191231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z0vDY4ja3755" title="Weighted Avg. Exercise Price, Outstanding, Beginning balance" style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-12-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.31</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Options granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" title="Number of shares, Options granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-01-012020-12-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">414,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" title="Weighted Avg. Exercise Price, Options granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.44</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Options exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zd3fg6nsMnVl" title="Number of shares, Options exercised" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-01-012020-12-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,748</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" title="Weighted Avg. Exercise Price, Options exercised" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.19</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Options cancelled/forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zJClW6EHXCrh" title="Number of shares, Options cancelled/forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2020-01-012020-12-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,402</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" title="Weighted Avg. Exercise Price, Options cancelled/forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-12-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.77</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Options outstanding
    - December 31, 2020</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zPqFOLroBC48" title="Number of shares, Outstanding, Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,030,033</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z8NK6nsAbH8j" title="Weighted Avg. Exercise Price, Outstanding, Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.43</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td title="Weighted Avg. Remaining Contractual Life, Options outstanding" style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zfsq95D078Lf" title="Weighted Avg. Remaining Contractual Life, Options outstanding"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_StockOptionPlanOneMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.72</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zVWtCkyG1Zj8" title="Aggregate Intrinsic Value, Options outstanding" style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,569</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Options exercisable</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zRo6HTPothl3" title="Number of shares, Options exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,908,849</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zZ4f98mY0SBk" title="Weighted Avg. Exercise Price, Exercisable Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.49</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td title="Weighted Avg. Remaining Contractual Life, Options exercisable" style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zA66gTouaDb6" title="Weighted Avg. Remaining Contractual Life, Options exercisable"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_StockOptionPlanOneMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">5.25</ix:nonNumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z0FlgEJo9dy" title="Aggregate Intrinsic Value, Options exercisable" style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,051</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Options vested
    and expected to vest</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zQgK1tz9Qhu9" title="Number of shares, Options vested and expected to vest" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2020-12-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,918,298</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z3JdTHMSppok" title="Weighted Avg. Exercise Price, Vested and expected to vest" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.37</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td title="Weighted Avg. Remaining Contractual Life, Options vested and expected to vest" style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zFknDYG1ZkKf" title="Weighted Avg. Remaining Contractual Life, Options vested and expected to vest"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_StockOptionPlanOneMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">5.69</ix:nonNumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pn3n3_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zWSdyEIPs5ti" title="Aggregate Intrinsic Value, Options vested and expected to vest" style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="AsOf2020-12-31_custom_StockOptionPlanOneMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,519</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A1_zszb1uTZGa52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
aggregate intrinsic value in the table above represents the total pre-tax amount of the proceeds, net of exercise price, which
would have been received by option holders if all option holders had exercised and immediately sold all options with an exercise
price lower than the market price on December 31, 2020, based on the closing price of the Company&#8217;s common stock of $<span id="xdx_90E_ecustom--ClosingPriceOfCommonStockPricePerShare_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_pii" title="Closing price of common stock price per share"><ix:nonFraction name="HROW:ClosingPriceOfCommonStockPricePerShare" contextRef="AsOf2020-12-31_custom_StockOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.86</ix:nonFraction></span>
on that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
intrinsic value of the options exercised in 2020 was $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn3n3_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zYEyXIXZ7lhe" title="Intrinsic value of options exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2020-01-012020-12-31_custom_StockOptionPlanMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020, the Company granted stock options to certain employees and a consultant. The stock options were
granted with an exercise price equal to the current market price of the Company&#8217;s common stock, as reported by the securities
exchange on which the common stock was then listed, at the grant date and have contractual terms of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantMember_zK32wN7Q9pYe" title="Weighted avg. remaining contractual life, options exercisable"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_StockOptionPlanMember_custom_EmployeesAndConsultantMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">10</ix:nonNumeric></span> years. <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantMember" title="Share-based compensation arrangement by share-based payment award, plan modification, description and terms"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_StockOptionPlanMember_custom_EmployeesAndConsultantMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms">Vesting terms for
options granted to employees and consultants during the year ended December 31, 2020 generally included one of the following vesting
schedules: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and
the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over
three years; and 100% of the shares subject to the option vest on a quarterly basis in equal installments over three years. Certain
option awards provide for accelerated vesting if there is a change in control (as defined in the Plans) and in the event of certain
modifications to the option award agreement.</ix:nonNumeric></span></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
July 31, 2015, the Company granted to its Chief Executive Officer, Mark Baum, an option to purchase <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20150730__20150731__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_pii" title="Number of shares, options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2015-07-302015-07-31_custom_BaumPerformanceOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600,000</ix:nonFraction></span> shares of the Company&#8217;s
common stock (the &#8220;Baum Performance Option&#8221;) at an exercise price of $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20150730__20150731__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_pii" title="Exercise price of options"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2015-07-302015-07-31_custom_BaumPerformanceOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.87</ix:nonFraction></span> per share under the 2007 Plan subject to
the satisfaction of certain market-based vesting criteria. The market-based vesting criteria are separated into five tranches
and require that the Company achieve and maintain certain average stock price targets ranging from $<span id="xdx_90D_ecustom--AverageStockPrice_c20150731__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember__srt--RangeAxis__srt--MinimumMember_pii" title="Average stock price"><ix:nonFraction name="HROW:AverageStockPrice" contextRef="AsOf2015-07-31_custom_BaumPerformanceOptionMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9</ix:nonFraction></span> per share to $<span id="xdx_90F_ecustom--AverageStockPrice_c20150731__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember__srt--RangeAxis__srt--MaximumMember_pii" title="Average stock price"><ix:nonFraction name="HROW:AverageStockPrice" contextRef="AsOf2015-07-31_custom_BaumPerformanceOptionMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15</ix:nonFraction></span> per share
during the five year period following the grant date. On June 4, 2020, the Company amended the Baum Performance Option, to extend
the vesting and contractual term by <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200603__20200604__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_zefhTPyjcQ6f" title="Weighted avg. remaining contractual life, options outstanding"><ix:nonNumeric contextRef="From2020-06-032020-06-04_custom_BaumPerformanceOptionMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5</ix:nonNumeric> </span>years. The Company treated this amendment as a modification to the Baum Performance Option
for accounting purposes. The fair value of the modification was $<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20200603__20200604__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_pn3n3" title="Share-based compensation arrangement by share-based payment award, options, vested in period, fair value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="From2020-06-032020-06-04_custom_BaumPerformanceOptionMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,876</ix:nonFraction></span> using a Monte Carlo simulation model with a five-year life,
<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_c20200603__20200604__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_zBs9hKVEyKJ6" title="Share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-06-032020-06-04_custom_BaumPerformanceOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">70</ix:nonFraction>%</span> volatility and a risk-free interest rate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_c20200603__20200604__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_zF2XCLcrqGd8" title="Share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-06-032020-06-04_custom_BaumPerformanceOptionMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">0.40</ix:nonFraction>%</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">With
the exception of the Baum Performance Option, the fair value of each option award is estimated on the date of grant using the
Black-Scholes-Merton option pricing model. Beginning on April 1, 2019, the Company began calculating expected volatility based
solely on the historical volatilities of the common stock of the Company. Prior to April 1, 2019, the expected volatility was
based on the historical volatilities of the common stock of the Company and comparable publicly traded companies. The Company
previously utilized this methodology based on its estimate that it had limited relevant historical data regarding the volatility
of its stock price on which to base a meaningful estimate of expected volatility. The expected term of options granted was determined
in accordance with the &#8220;simplified approach,&#8221; as the Company has limited, relevant, historical data on employee exercises
and post-vesting employment termination behavior. The expected risk-free interest rate is based on the U.S. Treasury yield for
a period consistent with the expected term of the option in effect at the time of the grant. The financial statement effect of
forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates. For
option grants to employees and directors, the Company assigns a forfeiture factor of <span id="xdx_906_ecustom--ForfeitureFactorPercentage_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zLaRI7blgAug" title="Forfeiture factor, percentage"><ix:nonFraction name="HROW:ForfeitureFactorPercentage" contextRef="From2020-01-012020-12-31_custom_StockOptionPlanMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">10</ix:nonFraction>%</span>. These factors could change in the future,
which would affect the determination of stock-based compensation expense in future periods. Utilizing these assumptions, the fair
value is determined at the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zo943NhcDZV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following
assumptions used for valuing options granted to employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B9_z3pOk5YOPvRg" style="display: none">SCHEDULE OF FAIR VALUE ASSUMPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Weighted-average fair
    value of options granted</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_pii" title="Weighted-average fair value of options granted" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-12-31_custom_OptionsEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.86</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_pii" title="Weighted-average fair value of options granted" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2019-01-012019-12-31_custom_OptionsEmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.72</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expected terms (in years)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td title="Expected terms (in years)" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MinimumMember_zznoJH9sHdXh" title="Expected terms (in years)"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsEmployeesMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">0.50</ix:nonNumeric></span>
                                         - <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MaximumMember_zDD1q3hBnOw5" title="Expected terms (in years)"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_OptionsEmployeesMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.11</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MinimumMember_zFrHUthfhXij" title="Expected terms (in years)"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_OptionsEmployeesMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.07</ix:nonNumeric></span>
                                         - <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MaximumMember_ztBeixpcpXRi" title="Expected terms (in years)"><ix:nonNumeric contextRef="From2019-01-012019-12-31_custom_OptionsEmployeesMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">7.00</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td title="Expected volatility, maximum" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_uPercent_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zBN829DrQFaa" title="Expected volatility, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2020-01-012020-12-31_custom_OptionsEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">67</ix:nonFraction></span>
                                         &#8211; <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_uPercent_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zLCFHkowlUWh" title="Expected volatility, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2020-01-012020-12-31_custom_OptionsEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">71</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_uPercent_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zxnFxkILIhF" title="Expected volatility, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2019-01-012019-12-31_custom_OptionsEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">64</ix:nonFraction></span>
                                         - <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_uPercent_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zZ5w84ysMSQ8" title="Expected volatility, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2019-01-012019-12-31_custom_OptionsEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">78</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td title="Risk-free interest rate, maximum" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_uPercent_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zs1woI2aLU04" title="Risk-free interest rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2020-01-012020-12-31_custom_OptionsEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">0.34</ix:nonFraction></span>
                                         &#8211; <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_uPercent_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zwiOkXCUpV07" title="Risk-free interest rate, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2020-01-012020-12-31_custom_OptionsEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">1.64</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_uPercent_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zZ5vHvMSgbuh" title="Risk-free interest rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2019-01-012019-12-31_custom_OptionsEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">1.83</ix:nonFraction></span>
                                         &#8211;<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_uPercent_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_z8MC2kbKhaHl" title="Risk-free interest rate, maximum"> <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2019-01-012019-12-31_custom_OptionsEmployeesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">2.68</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zcfIFI2EDx7b" title="Dividend yield" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1448">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zyXdXXDOsZLf" title="Dividend yield" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1450">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A3_z7YXHk5ckEk3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zTReyUQCrVXk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes information about stock options outstanding and exercisable at December 31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span><span><span id="xdx_8B6_zLHJLptFBOv1" style="display: none">SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Contractual</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Range
    of Exercise Prices</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Outstanding</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Life
    in Years</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercisable</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Range of Exercise Prices, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2020-01-012020-12-31_custom_RangeOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.47</ix:nonFraction></span> - $<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Range of Exercise Prices, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2020-01-012020-12-31_custom_RangeOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.60</ix:nonFraction></span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Number of Options Outstanding" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2020-12-31_custom_RangeOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">770,440</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td title="Weighted Average Remaining Contractual Life in Years" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zFeE8JzfPS8f" title="Weighted Average Remaining Contractual Life in Years"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_RangeOneMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">5.64</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Weighted Average Exercise Price" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2020-12-31_custom_RangeOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.06</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Number Exercisable" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2020-12-31_custom_RangeOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">745,255</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Weighted Average Exercisable Exercise Price" style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2020-12-31_custom_RangeOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.06</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_ziiFjkcDC772" title="Range of Exercise Prices, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2020-01-012020-12-31_custom_RangeTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.04</ix:nonFraction></span> - $<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Range of Exercise Prices, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2020-01-012020-12-31_custom_RangeTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.50</ix:nonFraction></span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Number of Options Outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2020-12-31_custom_RangeTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">517,002</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td title="Weighted Average Remaining Contractual Life in Years" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z9eakblqqQSc" title="Weighted Average Remaining Contractual Life in Years"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_RangeTwoMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">5.75</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Weighted Average Exercise Price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2020-12-31_custom_RangeTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.98</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Number Exercisable" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2020-12-31_custom_RangeTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">438,873</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Weighted Average Exercisable Exercise Price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2020-12-31_custom_RangeTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.98</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Range of Exercise Prices, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2020-01-012020-12-31_custom_RangeThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.49</ix:nonFraction></span> - $<span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Range of Exercise Prices, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2020-01-012020-12-31_custom_RangeThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.36</ix:nonFraction></span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Number of Options Outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2020-12-31_custom_RangeThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">496,350</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td title="Weighted Average Remaining Contractual Life in Years" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_ztoyYSnJsWBa" title="Weighted Average Remaining Contractual Life in Years"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_RangeThreeMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">7.22</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Weighted Average Exercise Price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2020-12-31_custom_RangeThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.10</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Number Exercisable" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2020-12-31_custom_RangeThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">291,919</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Weighted Average Exercisable Exercise Price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2020-12-31_custom_RangeThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.13</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">$<span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zBsCAhJkpYrl" title="Range of Exercise Prices, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2020-01-012020-12-31_custom_RangeFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.64</ix:nonFraction></span> - $<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zRrw9dEctSpd" title="Range of Exercise Prices, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2020-01-012020-12-31_custom_RangeFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.99</ix:nonFraction></span></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" title="Number of Options Outstanding" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2020-12-31_custom_RangeFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,246,241</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td title="Weighted Average Remaining Contractual Life in Years" style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zBhaXCRSQHqa" title="Weighted Average Remaining Contractual Life in Years"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_RangeFourMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">5.17</ix:nonNumeric></span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" title="Weighted Average Exercise Price" style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2020-12-31_custom_RangeFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.85</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" title="Number Exercisable" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2020-12-31_custom_RangeFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">432,802</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" title="Weighted Average Exercisable Exercise Price" style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2020-12-31_custom_RangeFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.09</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">$<span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20200101__20201231_zTE4q6Dtgg96" title="Range of Exercise Prices, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.47</ix:nonFraction></span> - $<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20200101__20201231_znbr9y4z6bkf" title="Range of Exercise Prices, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.99</ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20201231_pii" title="Number of Options Outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,030,033</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td title="Weighted Average Remaining Contractual Life in Years" style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_z2pwY4UTeaQ" title="Weighted Average Remaining Contractual Life in Years"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">5.72</ix:nonNumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20201231_pii" title="Weighted Average Exercise Price" style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.43</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20201231_pii" title="Number Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,908,849</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20201231_pii" title="Weighted Average Exercisable Exercise Price" style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.49</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A0_z8EHcpGJe0a9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020, there was approximately $<span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_pn3n3" title="Unrecognized compensation expense related to unvested stock options granted under the plan"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2020-12-31_custom_StockOptionPlanMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,794</ix:nonFraction></span> of total unrecognized compensation expense related to unvested stock options
granted under the Plan. That expense is expected to be recognized over the weighted-average remaining vesting period of <span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zNhD42KuyV98" title="Expense expected to recognize over the weighted-average remaining vesting period"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_StockOptionPlanMember" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">3.96</ix:nonNumeric></span> years.
The stock-based compensation for all stock options was $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_pn3n3" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-012020-12-31_custom_StockOptionPlanMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,579</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20190101__20191231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_pn3n3" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-012019-12-31_custom_StockOptionPlanMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">889</ix:nonFraction></span> during the years ended December 31, 2020 and 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Restricted
Stock Units </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">RSU
awards are granted subject to certain vesting requirements and other restrictions, including performance and market-based
vesting criteria. The grant-date fair value of the RSUs, which has been determined based upon the market value of the Company&#8217;s
common stock on the grant date, is expensed over the vesting period of the RSUs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Grants
During the Year Ended December 31, 2019</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2019, <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pii" title="Shares issued of restricted common stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">185,000</ix:nonFraction></span> RSUs with a fair market value of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pn3n3" title="Fair value of restricted common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,139</ix:nonFraction></span> were issued to certain employees; the RSUs vest
in full on the third anniversary of the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2019, the Company&#8217;s board of directors were granted <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pii" title="Shares issued of restricted common stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_BoardOfDirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">38,860</ix:nonFraction></span> RSUs with a fair market value of
$<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pn3n3" title="Fair value of restricted common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_BoardOfDirectorsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">300</ix:nonFraction></span> which vests on a quarterly basis, over a one-year term in equal installments, subject to the director&#8217;s
continued service at the vesting date, but the issuance and delivery of these shares are deferred until the director resigns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zSBp8HaToScg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the Company&#8217;s RSU activity and related information for the year ended December 31, 2019 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B0_z1u7f4VdIQV6" style="display: none">SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of RSUs</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Average Grant<br />
    Date Fair Value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">RSUs unvested - January
    1, 2019</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlcKzm3Vy0E1" title="Number of RSUs unvested, Outstanding, Beginning balance" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2018-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,275,680</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_c20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzKbZvFFjXSl" title="Weighted Average Grant Date Fair Value, Beginning balance" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2018-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.16</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">RSUs granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" title="Number of RSUs granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">223,860</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" title="Weighted Average Grant Date Fair Value, RSUs granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.43</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">RSUs vested</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pii_di_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgf1GrYmPyZ1" title="Number of RSUs vested" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">87,610</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" title="Weighted Average Grant Date Fair Value, RSUs vested" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.42</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">RSUs cancelled/forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pii_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztvt0TjCez4h" title="Number of RSUs cancelled/forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1554">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">RSUs unvested
    at December 31, 2019</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAbV7bsMtMHk" title="Number of RSUs unvested, Outstanding, Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,411,930</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zuEsuPx7Uaxl" title="Weighted Average Grant Date Fair Value, Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.76</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Grants
During the Year Ended December 31, 2020</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020, <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pii" title="Shares issued of restricted common stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">161,000</ix:nonFraction></span> RSUs with a fair market value of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pn3n3" title="Fair value of restricted common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,025</ix:nonFraction></span> were issued to certain employees; the RSUs vest
in full on the third anniversary of the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020, the Company&#8217;s board of directors were granted <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pii" title="Shares issued of restricted common stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_BoardOfDirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">90,524</ix:nonFraction></span> RSUs with a fair market value $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pn3n3" title="Fair value of restricted common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_BoardOfDirectorsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">511</ix:nonFraction></span>
which vest on a quarterly basis, over a one-year term in equal installments, subject to the director&#8217;s continued
service at the vesting date, but the issuance and delivery of these shares are deferred until the director resigns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the Company&#8217;s RSU activity and related information for the year ended December 31, 2020 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of RSUs</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Average Grant<br />
    Date Fair Value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">RSUs unvested - January
    1, 2020</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwsDwbtXgcOg" title="Number of RSUs unvested, Outstanding, Beginning balance" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,411,930</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_c20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNNoOi66nuCk" title="Weighted Average Grant Date Fair Value, Beginning balance" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.76</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">RSUs granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" title="Number of RSUs granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">251,524</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" title="Weighted Average Grant Date Fair Value, RSUs granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.11</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">RSUs vested</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pii_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7tVOnlN9F0l" title="Number of RSUs vested" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">61,945</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" title="Weighted Average Grant Date Fair Value, RSUs vested" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.46</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">RSUs cancelled/forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" title="Number of RSUs cancelled/forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1580">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">RSUs unvested
    at December 31, 2020</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgfUfvpFCBck" title="Number of RSUs unvested, Outstanding, Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,601,509</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCql18W0ey1i" title="Weighted Average Grant Date Fair Value, Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.14</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A5_zcKNbdcJgvCc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020, the total unrecognized compensation expense related to unvested RSUs was approximately $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20201231__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_pn3n3" title="Unrecognized compensation expense related to unvested stock options granted under the plan"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2020-12-31_custom_UnvestedRSUMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,363</ix:nonFraction></span> which is expected
to be recognized over a weighted-average period of <span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zl8CNWWZZLz3" title="Expense expected to recognize over the weighted-average remaining vesting period"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_UnvestedRSUMember" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">3.14</ix:nonNumeric></span> years, based on estimated vesting schedules. The stock-based compensation
for RSUs was $<span id="xdx_902_eus-gaap--ShareBasedCompensation_c20200101__20201231__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_pn3n3" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-012020-12-31_custom_UnvestedRSUMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,167</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--ShareBasedCompensation_c20190101__20191231__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_pn3n3" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-012019-12-31_custom_UnvestedRSUMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">879</ix:nonFraction></span> during the years ended December 31, 2020 and 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Subsidiary
Stock-Based Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Mayfield
Pharmaceuticals, Inc. - 2019</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Mayfield
    issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20190202__20190228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__dei--LegalEntityAxis__custom--EllePharmaceuticalLLCMember_pii" title="Stock issued during period, shares, acquisitions"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2019-02-022019-02-28_custom_MayfieldPharmaceuticalsIncMember_custom_EllePharmaceuticalLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares of its common stock to Elle in connection with the acquisition of certain drug candidate intellectual
    property and rights in February 2019;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Mayfield
    issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190701__20190731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_pii" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-07-012019-07-31_custom_MayfieldPharmaceuticalsIncMember_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000</ix:nonFraction></span> shares of its common stock to TGV in connection with the acquisition of certain drug candidate intellectual
    property and rights in July 2019; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company recognized $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pn3n3" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-012019-12-31_custom_MayfieldPharmaceuticalsIncMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26</ix:nonFraction></span> in stock-based compensation related to equity instruments granted by Mayfield for <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pii" title="Shares issued of restricted common stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2019-01-012019-12-31_custom_MayfieldPharmaceuticalsIncMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,450,000</ix:nonFraction></span> shares
    of its restricted common stock that vest upon various performance based milestones and service periods to consultants of Mayfield,
    including Mayfield&#8217;s CEO candidate and to Harrow employees, including <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__srt--TitleOfIndividualAxis__custom--MarkBaumCEOMember_pii" title="Number of common stock issued for consultants services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2019-01-012019-12-31_custom_MayfieldPharmaceuticalsIncMember_custom_MarkBaumCEOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">725,000</ix:nonFraction></span> shares to Mark Baum, CEO of the Company,
    and <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__srt--TitleOfIndividualAxis__custom--AndrewBollCFOMember_pii" title="Number of common stock issued for consultants services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2019-01-012019-12-31_custom_MayfieldPharmaceuticalsIncMember_custom_AndrewBollCFOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">362,500</ix:nonFraction></span> shares to Andrew Boll, CFO of the Company.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Mayfield
Pharmaceuticals, Inc. - 2020</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Mayfield
    repurchased <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__dei--LegalEntityAxis__custom--EllePharmaceuticalLLCMember_pii" title="Number of common stock issued for consultants services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2020-01-012020-12-31_custom_MayfieldPharmaceuticalsIncMember_custom_EllePharmaceuticalLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">650,000</ix:nonFraction></span> shares of its common stock from Elle, for an aggregate purchase price of $<span id="xdx_901_ecustom--AggregatePurchasePrice_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__dei--LegalEntityAxis__custom--EllePharmaceuticalLLCMember_pii" title="Aggregate purchase price"><ix:nonFraction name="HROW:AggregatePurchasePrice" contextRef="From2020-01-012020-12-31_custom_MayfieldPharmaceuticalsIncMember_custom_EllePharmaceuticalLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1</ix:nonFraction></span>;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_pii" title="Shares issued of restricted common stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2020-01-012020-12-31_custom_MayfieldPharmaceuticalsIncMember_us-gaap_RestrictedStockMember_custom_ConsultantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span>
    shares of Mayfield&#8217;s restricted common stock were forfeited by a consultant; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Mayfield
    issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pii" title="Shares issued of restricted common stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2020-01-012020-12-31_custom_MayfieldPharmaceuticalsIncMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">475,000</ix:nonFraction></span> shares of its restricted common stock, with a fair value of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pn3n3" title="Fair value of restricted common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-01-012020-12-31_custom_MayfieldPharmaceuticalsIncMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></span>, that vest upon various performance-based milestones
    and over a four-year service period to Mayfield&#8217;s Chief Executive Officer candidate. </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020, the Company recognized $<span id="xdx_906_eus-gaap--ShareBasedCompensation_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember_pn3n3" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-012020-12-31_custom_MayfieldPharmaceuticalsIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></span> in stock-based compensation for Mayfield stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Stowe
Pharmaceuticals, Inc. - 2019</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2019, Stowe agreed to issue <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20190701__20190731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StowePharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_pii" title="Shares issued of restricted common stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2019-07-012019-07-31_custom_StowePharmaceuticalsIncMember_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,750,000</ix:nonFraction></span> shares of its common stock to TGV in connection with the acquisition of certain drug
candidate intellectual property and rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Visionology,
Inc. - 2020</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020, Visionology granted <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VisionologyIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pii" title="Shares issued of restricted common stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2020-01-012020-12-31_custom_VisionologyIncMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></span> shares of its restricted common stock, with a fair value of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pii_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VisionologyIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1TFs6nM5AP9" title="Number of restrcited shares, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-01-012020-12-31_custom_VisionologyIncMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96</ix:nonFraction></span>
that vest upon various performance based milestones and service periods to consultants of Visionology, including Visionology&#8217;s
CEO candidate and to Harrow employees, including <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VisionologyIncMember__srt--TitleOfIndividualAxis__custom--MarkBaumCEOMember_pii" title="Number of common stock issued for consultants services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2020-01-012020-12-31_custom_VisionologyIncMember_custom_MarkBaumCEOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">700,000</ix:nonFraction></span> shares to Mark Baum, CEO of the Company, and <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VisionologyIncMember__srt--TitleOfIndividualAxis__custom--AndrewBollCFOMember_pii" title="Number of common stock issued for consultants services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2020-01-012020-12-31_custom_VisionologyIncMember_custom_AndrewBollCFOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span> shares to Andrew
Boll, CFO of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ziHtVmVZ22Sj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recorded stock-based compensation (including issuance of common stock for services and accrual for stock-based compensation)
related to equity instruments granted to employees, directors and consultants as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B9_zurPvjdWON1b" style="display: none">SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Years Ended December 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Employees &#8211; selling,
    general and administrative</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" title="Stock based compensation related to equity instruments granted to related parties" style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-012020-12-31_custom_EmployeesMember_custom_SellingGeneralAndAdministrativeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,289</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20191231__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" title="Stock based compensation related to equity instruments granted to related parties" style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-01-012019-12-31_custom_EmployeesMember_custom_SellingGeneralAndAdministrativeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,464</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Directors &#8211; selling, general
    and administrative</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" title="Stock based compensation related to equity instruments granted to related parties" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-012020-12-31_srt_DirectorMember_custom_SellingGeneralAndAdministrativeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">473</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20191231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" title="Stock based compensation related to equity instruments granted to related parties" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-01-012019-12-31_srt_DirectorMember_custom_SellingGeneralAndAdministrativeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">300</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Consultants
    &#8211; selling, general and administrative</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" title="Stock based compensation related to equity instruments granted to related parties" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-012020-12-31_custom_ConsultantMember_custom_SellingGeneralAndAdministrativeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">96</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20191231__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" title="Stock based compensation related to equity instruments granted to related parties" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-01-012019-12-31_custom_ConsultantMember_custom_SellingGeneralAndAdministrativeMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">259</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231_pn3n3" title="Stock based compensation related to equity instruments granted to related parties" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,858</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20191231_pn3n3" title="Stock based compensation related to equity instruments granted to related parties" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,023</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AA_zIhJl73Ks4Gf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Warrants</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">From
time to time, the Company issues warrants to purchase shares of the Company&#8217;s common stock to investors, lenders (see Note
12), underwriters and other non-employees for services rendered or to be rendered in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z3hRwpJQzkLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of warrant activity during the year ended December 31, 2020 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B7_zofGrHQAUGX1" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of Shares Subject to Warrants Outstanding</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Avg. Exercise Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding
    - January 1, 2020</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pii_c20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zF3vPI1IecUi" title="Number of Shares Warrants Outstanding, beginning balance" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">780,386</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_pii_c20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z4zzbdsSTAqe" title="Weighted Avg. Exercise Price, Outstanding, beginning balance" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" contextRef="AsOf2019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.12</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" title="Number of Shares Warrants Outstanding, Granted" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1652">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" title="Number of Shares Warrants Outstanding, Exercised" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1654">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" title="Number of Shares Warrants Outstanding, Expired" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1656">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding
    and exercisable - December 31, 2020</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iE_pii_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zE0fOT4bX2R2" title="Number of Shares Warrants Outstanding and Exercisable, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber" contextRef="AsOf2020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">780,386</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1_iE_pii_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zGy9Yf4BTV6d" title="Weighted Avg. Exercise Price, Outstanding and Exercisable, ending balance" style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1" contextRef="AsOf2020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.12</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average
    remaining contractual life of the outstanding warrants in years - December 31, 2020</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td title="Weighted average remaining contractual life of the outstanding warrants in years" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zPVuFE6Md383" title="Weighted average remaining contractual life of the outstanding warrants in years"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" name="HROW:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1">3.53</ix:nonNumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><p id="xdx_8AD_zduARSswBOKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="HROW:ScheduleofWarrantsOutstandingAndExercisableTableTextBlock"><p id="xdx_893_ecustom--ScheduleofWarrantsOutstandingAndExercisableTableTextBlock_zVJqdE4Kk2Ec" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">All
warrants outstanding as of December 31, 2020 are included in the following table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B5_zdxFJYC54gQf" style="display: none">SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="9" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants
    Outstanding</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants
    Exercisable</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Expiration</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Warrant
    Series</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Issue
    Date</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Outstanding</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercisable</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Date</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Lender warrants</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td title="Issue Date" style="vertical-align: bottom; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_ecustom--WarrantsIssuanceDate_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zcIbfkNbtq0l" title="Issue Date"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_LenderWarrantsMember" format="ixt:datemonthdayyear" name="HROW:WarrantsIssuanceDate">5/11/2015</ix:nonNumeric></span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_pii" title="Warrants Outstanding" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2020-12-31_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">125,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_pii" title="Exercise Price" style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-12-31_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.79</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_pii" title="Warrants Exercisable" style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" contextRef="AsOf2020-12-31_custom_LenderWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">125,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td title="Expiration Date" style="vertical-align: bottom; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_ecustom--WarrantsAndRightsOutstandingMaturityDates_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zASHVdbs6vjf" title="Expiration Date"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_LenderWarrantsMember" format="ixt:datemonthdayyear" name="HROW:WarrantsAndRightsOutstandingMaturityDates">5/11/2025</ix:nonNumeric></span></span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Settlement warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td title="Issue Date" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_ecustom--WarrantsIssuanceDate_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_zIgKPdGA5Qt3" title="Issue Date"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_SettlementWarrantsMember" format="ixt:datemonthdayyear" name="HROW:WarrantsIssuanceDate">8/16/2016</ix:nonNumeric></span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_pii" title="Warrants Outstanding" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2020-12-31_custom_SettlementWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_pii" title="Exercise Price" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-12-31_custom_SettlementWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.75</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_pii" title="Warrants Exercisable" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" contextRef="AsOf2020-12-31_custom_SettlementWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td title="Expiration Date" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_ecustom--WarrantsAndRightsOutstandingMaturityDates_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_zWTTPiDABE55" title="Expiration Date"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_SettlementWarrantsMember" format="ixt:datemonthdayyear" name="HROW:WarrantsAndRightsOutstandingMaturityDates">8/16/2021</ix:nonNumeric></span></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Lender warrants
    (see Note 12)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td title="Issue Date" style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--WarrantsIssuanceDate_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_zwjV334F6VCl" title="Issue Date"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_LenderWarrantsOneMember" format="ixt:datemonthdayyear" name="HROW:WarrantsIssuanceDate">7/19/2017</ix:nonNumeric></span></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_pii" title="Warrants Outstanding" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2020-12-31_custom_LenderWarrantsOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">615,386</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_pii" title="Exercise Price" style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-12-31_custom_LenderWarrantsOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.08</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_pii" title="Warrants Exercisable" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" contextRef="AsOf2020-12-31_custom_LenderWarrantsOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">615,386</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td title="Expiration Date" style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--WarrantsAndRightsOutstandingMaturityDates_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_zrt915HjDe64" title="Expiration Date"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_LenderWarrantsOneMember" format="ixt:datemonthdayyear" name="HROW:WarrantsAndRightsOutstandingMaturityDates">7/19/2024</ix:nonNumeric></span></span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" title="Warrants Outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">780,386</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" title="Exercise Price" style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.12</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" title="Warrants Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" contextRef="AsOf2020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">780,386</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AC_z8t6DKVFp2K" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_801_eus-gaap--IncomeTaxDisclosureTextBlock_zjLNQPii2Bub" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
15. <span id="xdx_82E_zO5a2A3Km4Oh">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zlEm43HAYNHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company is subject to taxation in the United States, California, Florida, Georgia, Illinois, New Jersey, New York, Tennessee and
Wisconsin. The Company&#8217;s income tax provision consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B7_zId0N1D53NX" style="display: none">SCHEDULE OF PROVISION FOR INCOME TAXES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Current:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Federal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--CurrentFederalTaxExpenseBenefit_c20200101__20201231_pn3n3" title="Current: Federal" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1706">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--CurrentFederalTaxExpenseBenefit_c20190101__20191231_pn3n3" title="Current: Federal" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1708">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State</span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_c20200101__20201231_pn3n3" title="Current: State" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_c20190101__20191231_pn3n3" title="Current: State" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total current
    expense</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td id="xdx_989_eus-gaap--CurrentIncomeTaxExpenseBenefit_c20200101__20201231_pn3n3" title="Total current" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td id="xdx_98A_eus-gaap--CurrentIncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" title="Total current" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Deferred:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Federal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"></td><td id="xdx_98C_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20200101__20201231_pn3n3" title="Deferred: Federal" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">771</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"></td><td id="xdx_98D_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" title="Deferred: Federal" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">669</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">State</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_c20200101__20201231_pn3n3" title="Deferred: State" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">138</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" title="Deferred: State" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">148</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Change
    in valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--DeferredIncomeChangeInValuationAllowance_c20200101__20201231_pn3n3" title="Deferred: Change in valuation allowance" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:DeferredIncomeChangeInValuationAllowance" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">633</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--DeferredIncomeChangeInValuationAllowance_c20190101__20191231_pn3n3" title="Deferred: Change in valuation allowance" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HROW:DeferredIncomeChangeInValuationAllowance" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">521</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total deferred
    expense</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--DeferredIncomeTaxExpenseBenefit_pn3n3_c20200101__20201231_zqMusmwdxIfk" title="Total deferred" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1730">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--DeferredIncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" title="Total deferred" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1732">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Income tax provision</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_c20200101__20201231_pn3n3" title="Income tax provision (benefit)" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--IncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" title="Income tax provision (benefit)" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AE_znppQNdXsvyh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z9LbdBssC8ji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
reconciliation of income taxes computed by applying the statutory U.S. income tax rate to the Company&#8217;s loss before income
tax provision to the income tax provision is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zuFkQGm0bTbh" style="display: none">SCHEDULE OF INCOME TAX RECONCILIATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. federal statutory tax
    rate</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercent_c20200101__20201231_zP6vtwy0Dy3c" title="U.S. federal statutory tax rate" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">21.00</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercent_c20190101__20191231_z1PJBplz43el" title="U.S. federal statutory tax rate" style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">21.00</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">State tax benefit, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPercent_c20200101__20201231_z9diswB8uWZ7" title="State tax benefit, net" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Percent">0.11</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPercent_c20190101__20191231_zvEQ9o1W5937" title="State tax benefit, net" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Percent">6.73</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based</span><span style="font-family: Times New Roman, Times, Serif">
    compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends_pii_dp_uPercent_c20200101__20201231_zpefx0bFnuT5" title="Employee stock-based compensation" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">5.52</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends_pii_dp_uPercent_c20190101__20191231_zwJmbjxVw1O8" title="Employee stock-based compensation" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">3.10</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pii_dp_uPercent_c20200101__20201231_ze9Ok1KYy7a4" title="Other" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Percent">0.38</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pii_dp_uPercent_c20190101__20191231_zaxdfNR43jV5" title="Other" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Percent">358.67</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pii_dp_uPercent_c20200101__20201231_zUnkeblpXJOc" title="Valuation allowance" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Percent">26.14</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pii_dp_uPercent_c20190101__20191231_zZO9ilJ98515" title="Valuation allowance" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">334.57</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Effective income
    tax rate</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pii_dp_uPercent_c20200101__20201231_zyVR8plk3ERl" title="Effective income tax rate" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Percent">0.11</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pii_dp_uPercent_c20190101__20191231_zibwEDGEb0Qg" title="Effective income tax rate" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Percent">6.73</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A6_zYlLjCn3Moqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zY7wnvB540ob" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Deferred
tax assets and liabilities reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities
for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred
tax assets are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B5_zwireou6UZee" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20201231_zXNF58WN0wGa" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20191231_znibe2891vBa" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets (liabilities):</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTANzoCx_zrrz0DQDU3t" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%"><span style="font-family: Times New Roman, Times, Serif">NOL&#8217;s</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,685</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,827</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_ecustom--DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization_iI_pn3n3_maDTANzoCx_zCj3ad30Esyj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Depreciation and
    amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">528</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">224</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iI_pn3n3_maDTANzoCx_zbGbREmoj8vf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">413</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">641</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTANzoCx_zYPT1JuSDvs6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development
    credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">596</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">596</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTANzoCx_zqOYVTSFl1uc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred stock-based
    compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,024</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,533</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_ecustom--IncomeTaxBasisDifferenceInRelatedParty_iNI_pn3n3_di_maDTANzoCx_zkseA74WXrj7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basis difference
    in Melt</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HROW:IncomeTaxBasisDifferenceInRelatedParty" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">398</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HROW:IncomeTaxBasisDifferenceInRelatedParty" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,119</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_409_ecustom--IncomeTaxBasisDifferenceInRelatedPartyOne_iNI_pn3n3_di_maDTANzoCx_z97k6sFu57m7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basis difference
    in Surface</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HROW:IncomeTaxBasisDifferenceInRelatedPartyOne" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">502</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HROW:IncomeTaxBasisDifferenceInRelatedPartyOne" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,185</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40A_ecustom--IncomeTaxBasisDifferenceInRelatedPartyTwo_iNI_pn3n3_di_maDTANzoCx_zaCsNCEpnZC9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basis difference
    in Eton</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HROW:IncomeTaxBasisDifferenceInRelatedPartyTwo" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,626</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HROW:IncomeTaxBasisDifferenceInRelatedPartyTwo" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,528</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40F_ecustom--DeferredTaxAssetsTaxDeferredExpenseCapitalLosses_iI_pn3n3_maDTANzoCx_z55YDmrGFiw" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Capital losses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:DeferredTaxAssetsTaxDeferredExpenseCapitalLosses" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">63</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:DeferredTaxAssetsTaxDeferredExpenseCapitalLosses" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">63</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_pn3n3_di_msDTANzoCx_zv0QzbWLAS5a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Park stock purchase
    identifiable intangibles</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">274</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">270</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_409_ecustom--DeferredTaxAssetsTaxDeferredExpenseLimitations_iI_pn3n3_maDTANzoCx_zZ3Wl9pY4vZ1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Limitation under
    163(j)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:DeferredTaxAssetsTaxDeferredExpenseLimitations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">195</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:DeferredTaxAssetsTaxDeferredExpenseLimitations" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">299</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_ecustom--DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability_iI_pn3n3_msDTANzoCx_zgbdDB0ObhZ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">ASC 842 lease
    liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,192</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,082</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_ecustom--DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset_iNI_pn3n3_di_maDTANzoCx_zO2zs3B6UGPh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">ASC
    842 ROU asset</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HROW:DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,061</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HROW:DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,959</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_ziQ8saIOP4Z9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    deferred tax assets, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,835</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,202</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzB4N_zemVr1oMj36i" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Valuation
    allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,835</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,202</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_406_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_zgGZ102KFEkj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    deferred tax assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1811">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1812">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AC_zVLQyOGlHLp" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Realization
of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the
net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by $<span id="xdx_903_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20200101__20201231_pn3n3" title="Deferred tax asset valuation allowance"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">633</ix:nonFraction></span> and
decreased by $<span id="xdx_900_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20190101__20191231_pn3n3" title="Deferred tax asset valuation allowance"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">521</ix:nonFraction></span> during 2020 and 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; background-color: white">At
December 31, 2020, the Company has federal and state net operating loss carryforwards of approximately $<span id="xdx_909_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_c20201231_pn3n3" title="Federal net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">62,856</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_c20201231_pn3n3" title="State net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60,908</ix:nonFraction></span> which
will begin to expire in <span title="Federal research and development tax credits expiration date"><span id="xdx_901_ecustom--StateNetOperatingLossExpirationDate_c20200101__20201231" title="State net operating loss expiration date"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="HROW:StateNetOperatingLossExpirationDate">2027</ix:nonNumeric></span></span>, unless previously utilized, and will begin to expire for state purposes in 2026. <span id="xdx_906_ecustom--FederalNetOperatingLossCarryforwardDescription_c20200101__20201231" title="Federal net operating loss carryforward description"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="HROW:FederalNetOperatingLossCarryforwardDescription">In addition, the
Company has federal net operating loss carryforwards of $3,865 generated after 2017 that can be carried over indefinitely and
may be used to offset up to&#160;80% of federal taxable income.</ix:nonNumeric></span> At December&#160;31, 2020, the Company has federal and state research
and development tax credits of approximately $<span id="xdx_90D_ecustom--FederalResearchAndDevelopmentTaxCredits_c20200101__20201231_pn3n3" title="Federal research and development tax credits"><ix:nonFraction name="HROW:FederalResearchAndDevelopmentTaxCredits" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">354</ix:nonFraction></span> and $<span id="xdx_905_ecustom--StateResearchAndDevelopmentTaxCredits_c20200101__20201231_pn3n3" title="State research and development tax credits"><ix:nonFraction name="HROW:StateResearchAndDevelopmentTaxCredits" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">305</ix:nonFraction></span>, respectively. The federal research tax credit begins to expire in
<span id="xdx_907_ecustom--FederalResearchAndDevelopmentTaxCreditsExpirationDate_c20200101__20201231" title="Federal research and development tax credits expiration date"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="HROW:FederalResearchAndDevelopmentTaxCreditsExpirationDate">2026</ix:nonNumeric></span>, unless previously utilized, and the state research and development  tax credit has no expiration date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Utilization
of the net operating loss (&#8220;NOL&#8221;) and research and development (&#8220;R&amp;D&#8221;) carryforwards maybe subject
to a substantial annual limitation due to ownership change limitations that might have occurred or that could occur in the future,
as required by Section&#160;382 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), as well as similar
state and foreign provisions. These ownership changes may limit the amount of NOL and R&amp;D credit carryforwards that can be
utilized annually to offset future taxable income and tax, respectively. In general, an &#8220;ownership change&#8221; as defined
by Section&#160;382 of the Code results from a transaction or series of transactions over a three-year period resulting in an
ownership change of more than 50&#160;percentage points of the outstanding stock of a company by certain stockholders or public
groups. Since the Company&#8217;s formation, the Company has raised capital through the issuance of capital stock on several occasions
which, combined with the purchasing stockholders&#8217; subsequent disposition of those shares, may have resulted in such an ownership
change, or could result in an ownership change in the future upon subsequent disposition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has not completed a study to assess whether an ownership change or changes have occurred. If the Company has experienced
an ownership change, utilization of the NOL or R&amp;D credit carryforwards would be subject to an annual limitation under Section&#160;382
of the Code, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change
by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation
may result in expiration of a portion of the NOL or R&amp;D credit carryforwards before utilization. Further, until a study is
complete and any limitation is known, no amounts are being considered as an uncertain tax position or disclosed as an unrecognized
tax benefit. Any carryforwards that will expire prior to utilization as a result of such limitations will be removed from deferred
tax assets with a corresponding reduction of the valuation allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2020 and 2019, there were no unrecognized tax benefits included in the consolidated balance sheets that would,
if recognized, affect the effective tax rate. The Company&#8217;s practice is to recognize interest and/or penalties related to
income tax matters in income tax expense. The Company had no accrual for interest or penalties in its consolidated balance sheets
at December 31, 2020 and 2019, and has not recognized interest and/or penalties in the consolidated statements of operations for
the years ended December 31, 2020 and 2019. The Company&#8217;s tax years since 2000 may be subject to examination by the federal
and state tax authorities due to the carryforward of unutilized net operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock"><p id="xdx_80F_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_zbbRN5HtuLa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
16. <span id="xdx_825_zcTJ6Iizbmz7">EMPLOYEE SAVINGS PLAN</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has established an employee savings plan pursuant to Section 401(k) of the Internal Revenue Code, effective January 1,
2014. The plan allows participating employees to deposit into tax deferred investment accounts up to <span id="xdx_907_ecustom--PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount_pii_dp_uPercent_c20200101__20201231_zXnLyOPTysch" title="Percentage of salary deposits in tax deferred investment account"><ix:nonFraction name="HROW:PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">100</ix:nonFraction>%</span> of their salary, subject
to annual limits. The Company makes certain matching contributions to the plan in amounts up to <span id="xdx_903_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_pii_dp_uPercent_c20200101__20201231_zkcDLxUvmHNe" title="Percentage of contributions made by the company"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">4</ix:nonFraction>%</span> of the participants&#8217;
annual cash compensation, subject to annual limits. The Company contributed approximately $<span id="xdx_901_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20200101__20201231_pn3n3" title="Contributions by the company"><ix:nonFraction name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">272</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20190101__20191231_pn3n3" title="Contributions by the company"><ix:nonFraction name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">312</ix:nonFraction> </span>to the plan during the
years ended December 31, 2020 and 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zisERq8VLvB1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
17. <span id="xdx_82B_z1xOJhmiRCyh">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Legal</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Dr.
Sobol </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2016, Louis L. Sobol, M.D. (&#8220;Sobol&#8221;) filed a lawsuit in the U.S. District Court for the Eastern District
of Michigan, Southern Division against the Company, asserting claims on behalf of himself and an as-yet-uncertified class of consumers.
The claims allege violations under the Telephone Consumer Protection Act, 47 U.S.C. &#167; 227 via the Company&#8217;s alleged
transmittal of advertisements to its clients via facsimile. The Court approved the parties&#8217; proposed settlement agreement
in the spring of 2019. During the year ended December 31, 2018, the Company accrued $<span id="xdx_90F_eus-gaap--LossContingencyAccrualAtCarryingValue_c20181231__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_pn3n3" title="Accrued damages"><ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="AsOf2018-12-31_custom_SettlementAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">640</ix:nonFraction></span> for expected damages related to this
matter and the proposed settlement amount. As a result of the low claim rate of approximately <span id="xdx_90B_ecustom--DamagesLowClaimRatePercentage_pii_dp_uPercent_c20180101__20181231__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zYgxfZXJkVP4" title="Damages low claim rate, percentage"><ix:nonFraction name="HROW:DamagesLowClaimRatePercentage" contextRef="From2018-01-012018-12-31_custom_SettlementAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">1.4</ix:nonFraction>%</span>, the Company&#8217;s total
damages were $<span id="xdx_901_eus-gaap--LossContingencyDamagesPaidValue_c20191002__20191031__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_pn3n3" title="Litigation amount paid"><ix:nonFraction name="us-gaap:LossContingencyDamagesPaidValue" contextRef="From2019-10-022019-10-31_custom_SettlementAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">571</ix:nonFraction></span>, which was paid in October 2019. This formally resolved all known disputes between the parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Allergan
USA</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
September 2017, Allergan USA, Inc. (&#8220;Allergan&#8221;) filed a lawsuit in the U.S. District Court for the Central District
of California against the Company, primarily claiming violations under the federal Lanham Act and California&#8217;s Sherman Act.
The Court granted in part and denied in part each parties&#8217; motions for summary judgement, resolving all issues except for
whether Allergan was entitled to damages related to the Company&#8217;s purported Lanham Act violations. The parties went to trial
in May 2019 to litigate damages related to the Lanham Act, and a jury found the Company liable for only $<span id="xdx_901_eus-gaap--LossContingencyDamagesAwardedValue_c20190501__20190531__dei--LegalEntityAxis__custom--AllerganUSAIncMember_pn3n3" title="Lost profit damages"><ix:nonFraction name="us-gaap:LossContingencyDamagesAwardedValue" contextRef="From2019-05-012019-05-31_custom_AllerganUSAIncMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">49</ix:nonFraction></span> in lost profit damages,
which was accrued as an expense during the year ended December 31, 2019 (see Note 11). In July 2019, the Court entered a permanent
injunction, the scope of which is limited to compounded drugs prepared in, dispensed from within, or shipped to the state of California.
The injunction requires the Company to: (1) only dispense drugs from a 503(a) facility with a &#8220;Valid Prescription Order&#8221;;
(2) abide by the FDA&#8217;s anticipatory compounding guidelines; and (3) only use bulk drug substances identified on a list established
by the Secretary of Health and Human Services or FDA&#8217;s interim &#8220;Category 1&#8221; list. The Company believes it was
already in compliance with the order, prior to the injunction being ordered. On October 2, 2019, Allergan and the Company filed
a joint stipulation to voluntarily dismiss each parties&#8217; respective pending appeals arising out of the lawsuit. No economic
consideration was exchanged between the parties related to the filing of the joint stipulation. This formally resolved all known
disputes between the parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>California
Board of Pharmacy</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
March 2018, the California Board of Pharmacy filed an accusation against Park related to a compounded formulation the Company
believes was legally dispensed and was, without its knowledge, inappropriately administered to a patient unknown to Park, by the
prescribing healthcare professional. Park filed a response to the accusation and requested a formal hearing. In April 2019, Park
agreed to, and the California State Board of Pharmacy approved terms of a settlement agreement (the &#8220;Settlement Agreement&#8221;)
that became effective on May 29, 2019. Pursuant to the terms of the Settlement Agreement, Park was required to, and did, surrender
its California pharmacy license by August 27, 2019. This formally resolved all known disputes between the parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Novel
Drug Solutions et al.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">In
April 2018, Novel Drug Solutions, LLC and Eyecare Northwest, PA (collectively &#8220;NDS&#8221;) filed a lawsuit against the Company
in the U.S. District Court of Delaware asserting claims for breach of contract. The claims stem from an asset purchase agreement
between the Company and NDS entered into in 2013. In July 2019, NDS filed a second amended complaint which added a claim related
to its purported termination of the APA. In October 2019, NDS voluntarily dismissed all claims related to breach of contract,
leaving only claims related to the scope of the post-termination obligations to be litigated. On October 29, 2020, at a hearing
on the various dispositive motions before it, the Court found that there were triable issues of fact and reopened discovery for
limited purposes. NDS is seeking unspecified damages, interest, attorney&#8217;s fees and other costs. The Company believes the
claims are meritless and has previously and will continue to dispute all claims asserted against it and intends to vigorously
defend against these allegations. Nonetheless, the Company cannot predict the eventual outcome of this litigation and it could
result in substantial costs, losses and a diversion of management&#8217;s resources and attention, which could harm the Company&#8217;s
business and the value of its common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Product
and Professional Liability</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Product
and professional liability litigation represents an inherent risk to all firms in the pharmaceutical and pharmacy industry. We
utilize traditional third-party insurance policies with regard to our product and professional liability claims. Such insurance
coverage at any given time reflects current market conditions, including cost and availability, when the policy is written.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>John
Erick et al.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
January 2018, John Erick and Deborah Ferrell, successors-in-interest and heirs of Jade Erick, (collectively &#8220;Erick&#8221;)
filed a lawsuit in the San Diego County Superior against Kim Kelly, ND, MPH asserting claims related to the death of Jade Erick.
In April 2018, Erick filed an amendment to the lawsuit, naming the Company as a co-defendant. In September 2018, co-defendant
Dr. Kelly filed a cross-complaint against the Company and various entities affiliated with Spectrum Laboratory Products, Inc.,
Spectrum Chemical Manufacturing Corp. and Spectrum Pharmacy Products, Inc. (collectively &#8220;Spectrum&#8221;). The cross-complaint
seeks indemnity and contribution from the Company and Spectrum. The Company answered the claims filed by Dr. Kelly in October
2018. The case is currently in the discovery phase. Erick is seeking unspecified damages, interest, attorney&#8217;s fees and
other costs. The Company believes the claims are meritless and has previously and will continue to dispute all claims asserted
against it and intends to vigorously defend against these allegations. Nonetheless, the Company cannot predict the eventual outcome
of this litigation, it could result in substantial costs, losses and a diversion of management&#8217;s resources and attention,
which could harm the Company&#8217;s business and the value of its common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Anna
Sue Gaukel et al.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2019, Anna Sue Gaukel and Lawrence Gaukel served the Company with a lawsuit filed in state court in Idaho against Imprimis
Pharmaceuticals, Inc. asserting class action allegations and product liability claims related to Mrs. Gaukel&#8217;s doctor&#8217;s
use of a compounded drug injection in each of her eyes. In June 2019, the Company removed the case to Federal Court and subsequently
answered the complaint. On January 24, 2019, the plaintiffs and the Company filed a joint stipulation, and the case was dismissed
with prejudice. No economic consideration was exchanged between the parties related to the filing of the joint stipulation. This
formally resolved all known disputes between the parties as connected to this matter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>General
and Other</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
the ordinary course of business, the Company may face various claims brought by third parties and it may, from time to time, make
claims or take legal actions to assert its rights, including intellectual property disputes, contractual disputes and other commercial
disputes. Any of these claims could subject the Company to litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Indemnities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
addition to the indemnification provisions contained in the Company&#8217;s charter documents, the Company generally enters into
separate indemnification agreements with each of the Company&#8217;s directors and officers. These agreements require the Company,
among other things, to indemnify the director or officer against specified expenses and liabilities, such as attorneys&#8217;
fees, judgments, fines and settlements, paid by the individual in connection with any action, suit or proceeding arising out of
the individual&#8217;s status or service as the Company&#8217;s director or officer, other than liabilities arising from willful
misconduct or conduct that is knowingly fraudulent or deliberately dishonest, and to advance expenses incurred by the individual
in connection with any proceeding against the individual with respect to which the individual may be entitled to indemnification
by the Company. The Company also indemnifies its lessors in connection with its facility leases for certain claims arising from
the use of the facilities. These indemnities do not provide for any limitation of the maximum potential future payments the Company
could be obligated to make. Historically, the Company has not incurred any payments for these obligations and, therefore, no liabilities
have been recorded for these indemnities in the accompanying consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Sales
and Marketing Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has entered various sales and marketing agreements with certain organizations, to provide sales and marketing representation
services to ImprimisRx in select geographies in the U.S., in connection with the Company&#8217;s ophthalmic compounded formulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
the terms of the sales and marketing agreements, the Company is required to make commission payments generally equal to <span id="xdx_90A_ecustom--CommissionPaymentsPercentage_c20170101__20191231__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember__srt--RangeAxis__srt--MinimumMember_pii" title="Commission payments, percentage"><ix:nonFraction name="HROW:CommissionPaymentsPercentage" contextRef="From2017-01-012019-12-31_custom_SalesAndMarketingAgreementsMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">10</ix:nonFraction>%</span> to
<span id="xdx_908_ecustom--CommissionPaymentsPercentage_c20170101__20191231__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember__srt--RangeAxis__srt--MaximumMember_pii" title="Commission payments, percentage"><ix:nonFraction name="HROW:CommissionPaymentsPercentage" contextRef="From2017-01-012019-12-31_custom_SalesAndMarketingAgreementsMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">14</ix:nonFraction>%</span> of net sales for products above and beyond the initial existing sales amounts. In addition, the Company is required to make
periodic milestone payments to certain organizations in shares of the Company&#8217;s restricted common stock if net sales in
the assigned territory reach certain future levels by the end of their terms, as applicable. The Company accrued and recorded
in additional paid in capital $<span id="xdx_908_ecustom--AdditionalPaidInCapitalAndShareBasedPayments_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_pn3n3" title="Additional paid in capital and stock based payments"><ix:nonFraction name="HROW:AdditionalPaidInCapitalAndShareBasedPayments" contextRef="From2020-01-012020-12-31_custom_SalesAndMarketingAgreementsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">83</ix:nonFraction></span> and $<span id="xdx_909_ecustom--AdditionalPaidInCapitalAndShareBasedPayments_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_pn3n3" title="Additional paid in capital and stock based payments"><ix:nonFraction name="HROW:AdditionalPaidInCapitalAndShareBasedPayments" contextRef="From2019-01-012019-12-31_custom_SalesAndMarketingAgreementsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">159</ix:nonFraction></span> related to stock-based payments for these agreements during the year ended December
31, 2020 and 2019, respectively, and $<span id="xdx_902_eus-gaap--SalesCommissionsAndFees_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_pn3n3" title="Commission expense incurred"><ix:nonFraction name="us-gaap:SalesCommissionsAndFees" contextRef="From2020-01-012020-12-31_custom_SalesAndMarketingAgreementsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,434</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--SalesCommissionsAndFees_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_pn3n3" title="Commission expense incurred"><ix:nonFraction name="us-gaap:SalesCommissionsAndFees" contextRef="From2019-01-012019-12-31_custom_SalesAndMarketingAgreementsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,700</ix:nonFraction></span> were incurred under these agreements for commission expenses during the
years ended December 31, 2020 and 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Asset
Purchase, License and Related Agreements </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has acquired and sourced intellectual property rights related to certain proprietary innovations from certain inventors
and related parties (the &#8220;Inventors&#8221;) through multiple asset purchase agreements, license agreements, strategic agreements
and commission agreements. In general, these agreements provide that the Inventors will cooperate with the Company in obtaining
patent protection for the acquired intellectual property and that the Company will use commercially reasonable efforts to research,
develop and commercialize a product based on the acquired intellectual property. In addition, the Company has acquired a right
of first refusal on additional intellectual property and drug development opportunities presented by these Inventors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--BusinessAcquisitionDescriptionOfAcquiredEntity_c20200101__20201231" title="Business acquisition description"><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity">In
consideration for the acquisition of the intellectual property rights, the Company is obligated to make payments to the Inventors
based on the completion of certain milestones, generally consisting of: (1) a payment payable within 30 days after the issuance
of the first patent in the United States arising from the acquired intellectual property (if any); (2) a payment payable within
30 days after the Company files the first investigational new drug application (&#8220;IND&#8221;) with the FDA for the first
product arising from the acquired intellectual property (if any); (3) for certain of the Inventors, a payment payable within 30
days after the Company files the first new drug application with the FDA for the first product arising from the acquired intellectual
property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection with the sale
or licensing of any product based on the acquired intellectual property (if any), after deducting (among other things) the Company&#8217;s
development costs associated with such product. If, following five years after the date of the applicable asset purchase agreement,
the Company either (a) for certain of the Inventors, has not filed an IND or, for the remaining Inventors, has not initiated a
study where data is derived, or (b) has failed to generate royalty payments to the Inventors for any product based on the acquired
intellectual property, the Inventors may terminate the applicable asset purchase agreement and request that the Company re-assign
the acquired technology to the Inventors.</ix:nonNumeric></span> $<span id="xdx_90D_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_c20201231_pn3n3" title="Accounts payable and accrued expenses"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">224</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_c20191231_pn3n3" title="Accounts payable and accrued expenses"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">371</ix:nonFraction></span> were accrued in accounts payable and accrued expenses under these agreements
during the years ended December 31, 2020 and 2019, respectively, and $<span id="xdx_90A_eus-gaap--RoyaltyExpense_c20200101__20201231_pn3n3" title="Royalty payments"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">682</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--RoyaltyExpense_c20190101__20191231_pn3n3" title="Royalty payments"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">846</ix:nonFraction></span> were incurred under these agreements as royalty
expenses for the years ended December 31, 2020 and 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Mayfield
License</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2020, Mayfield entered into a License Agreement (the &#8220;TGV License&#8221;) with TGV to acquire intellectual property
rights for use in the women&#8217;s health field, related to Mayfield&#8217;s proprietary drug candidate MAY-66. The TGV License
provides that TGV will cooperate with Mayfield in transferring all embodiments of the intellectual property (including know-how)
related to the TGV License, assist in obtaining and protecting its patent rights for the acquired intellectual property and that
Mayfield will use commercially reasonable efforts to research, develop and commercialize products based on the acquired intellectual
property. In connection with the TGV License, Mayfield is obligated to make royalty payments to TGV equal to a low single digit
percentage of net sales received by Mayfield in connection with the sale or licensing of any product based on the licensed intellectual
property. In addition, Mayfield issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200701__20200731__dei--LegalEntityAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_pii" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-07-012020-07-31_custom_MayfieldPharmaceuticalsIncMember_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000</ix:nonFraction></span> shares of its common stock to TGV and is required to make certain milestone payments
to TGV over the development of MAY-66 and any related products based on the licensed intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Stowe
License</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2020, Stowe entered into a License Agreement (the &#8220;Stowe License&#8221;) with TGV, to acquire intellectual property
rights for use in the ophthalmology and otic health field, related to Stowe&#8217;s proprietary drug candidate STE-006. The Stowe
License provides that TGV will cooperate with Stowe in transferring all embodiments of the intellectual property (including know-how)
related to the Stowe License, assist in obtaining and protecting its patent rights for the acquired intellectual property and
that Stowe will use commercially reasonable efforts to research, develop and commercialize products based on the acquired intellectual
property. In connection with the Stowe License, Stowe is obligated to make royalty payments to TGV equal to a low single digit
percentage of net sales received by Stowe in connection with the sale or licensing of any product based on the licensed intellectual
property. In addition, Stowe issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200701__20200731__dei--LegalEntityAxis__custom--StowePharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_pii" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-07-012020-07-31_custom_StowePharmaceuticalsIncMember_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,750,000</ix:nonFraction></span> shares of its common stock to TGV and is required to make certain milestone payments
to TGV over the development of STE-006 and any related products based on the licensed intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Klarity
License Agreement &#8211; Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
April 2017, the Company entered into a license agreement (the &#8220;Klarity License Agreement&#8221;) with Richard L. Lindstrom,
M.D., a member of its Board of Directors. Pursuant to the terms of the Klarity License Agreement, the Company licensed certain
intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license the topical ophthalmic
solution Klarity designed to protect and rehabilitate the ocular surface (the &#8220;Klarity Product&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_90D_ecustom--RoyaltyPaymentDescription_c20170401__20170430__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember" style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2017-04-012017-04-30_custom_KlarityLicenseAgreementMember_custom_RichardLLindstromMDMember" name="HROW:RoyaltyPaymentDescription">Under
the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3%
to 6% of net sales, dependent upon the final formulation of the Klarity Product sold.</ix:nonNumeric></span> <span style="font: 10pt Times New Roman, Times, Serif">In
addition, the Company is required to make certain milestone payments to Dr. Lindstrom including: (i) an initial payment of $<span id="xdx_904_eus-gaap--RoyaltyExpense_c20170401__20170430__srt--StatementScenarioAxis__custom--InitialPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2017-04-012017-04-30_custom_InitialPaymentMember_custom_LicenseAgreementMember_custom_RichardLLindstromMDMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">upon execution of the Klarity License
Agreement, (ii) a second payment of $<span id="xdx_90A_eus-gaap--RoyaltyExpense_c20170401__20170430__srt--StatementScenarioAxis__custom--SecondPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2017-04-012017-04-30_custom_SecondPaymentMember_custom_LicenseAgreementMember_custom_RichardLLindstromMDMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">following the first $<span id="xdx_901_eus-gaap--RoyaltyExpense_c20170401__20170430__srt--StatementScenarioAxis__custom--FinalPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2017-04-012017-04-30_custom_FinalPaymentMember_custom_LicenseAgreementMember_custom_RichardLLindstromMDMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">in net sales of the Klarity Product; and
(iii) a final payment of $<span id="xdx_906_ecustom--NetSalesRevenue_c20170401__20170430__srt--StatementScenarioAxis__custom--SecondPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3"><ix:nonFraction name="HROW:NetSalesRevenue" contextRef="From2017-04-012017-04-30_custom_SecondPaymentMember_custom_LicenseAgreementMember_custom_RichardLLindstromMDMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">following the first $<span id="xdx_909_ecustom--NetSalesRevenue_c20170401__20170430__srt--StatementScenarioAxis__custom--FinalPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3"><ix:nonFraction name="HROW:NetSalesRevenue" contextRef="From2017-04-012017-04-30_custom_FinalPaymentMember_custom_LicenseAgreementMember_custom_RichardLLindstromMDMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">in net sales of the Klarity Product. All
of the above referenced milestone payments were payable at the Company&#8217;s election in cash or shares of the Company&#8217;s
restricted common stock. Dr. Lindstrom was paid $<span id="xdx_90A_eus-gaap--RoyaltyExpense_pn3n3_c20200101__20201231__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zOTin8xI59Pk"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2020-01-012020-12-31_custom_RichardLLindstromMDMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">149</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_902_ecustom--MilestonePaymentInCash_pn3n3_c20190101__20191231__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zizsoZftpNkl"><ix:nonFraction name="HROW:MilestonePaymentInCash" contextRef="From2019-01-012019-12-31_custom_RichardLLindstromMDMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">63</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">in cash during the years ended December
31, 2020 and 2019, respectively, and was due an additional $<span id="xdx_90F_ecustom--MilestonePaymentsOnPayables_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3"><ix:nonFraction name="HROW:MilestonePaymentsOnPayables" contextRef="From2020-01-012020-12-31_custom_KlarityLicenseAgreementMember_custom_RichardLLindstromMDMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_900_ecustom--MilestonePaymentsOnPayables_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3"><ix:nonFraction name="HROW:MilestonePaymentsOnPayables" contextRef="From2019-01-012019-12-31_custom_KlarityLicenseAgreementMember_custom_RichardLLindstromMDMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">55</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">at December 31, 2020 and 2019, respectively.
The Company incurred $<span id="xdx_907_eus-gaap--RoyaltyExpense_pn3n3_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zVczfS5hEP52"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2020-01-012020-12-31_custom_KlarityLicenseAgreementMember_custom_RichardLLindstromMDMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">129</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90B_eus-gaap--RoyaltyExpense_pn3n3_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zio2OpquTpnl"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2019-01-012019-12-31_custom_KlarityLicenseAgreementMember_custom_RichardLLindstromMDMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">103</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for royalty expenses related to the Klarity
License Agreement during the years ended December 31, 2020 and 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Injectable
Asset Purchase Agreement &#8211; Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2019, the Company entered into an asset purchase agreement (the &#8220;Lindstrom APA&#8221;) with Dr. Lindstrom, a member
of its Board of Directors. Pursuant to the terms of the Lindstrom APA, the Company acquired certain intellectual property and
related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license an ophthalmic injectable product (the &#8220;Lindstrom
Product&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
the terms of the Lindstrom APA, t<span id="xdx_906_ecustom--RoyaltyPaymentDescription_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember" title="Royalty payment description"><ix:nonNumeric contextRef="From2019-12-012019-12-31_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember" name="HROW:RoyaltyPaymentDescription">he Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net
sales, dependent upon the final formulation and patent protection of the Lindstrom Product sold.</ix:nonNumeric></span> In addition, the Company is required
to make certain milestone payments to Dr. Lindstrom including an initial payment of $<span id="xdx_908_eus-gaap--RoyaltyExpense_c20191201__20191231__srt--StatementScenarioAxis__custom--InitialPaymentMember__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Royalty payments"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2019-12-012019-12-31_custom_InitialPaymentMember_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">33</ix:nonFraction></span> upon execution of the Lindstrom APA. Dr.
Lindstrom was paid $<span id="xdx_900_ecustom--MilestonePaymentInCash_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payment in cash"><ix:nonFraction name="HROW:MilestonePaymentInCash" contextRef="From2020-01-012020-12-31_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">55</ix:nonFraction></span> and $<span id="xdx_903_ecustom--MilestonePaymentInCash_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payment in cash"><ix:nonFraction name="HROW:MilestonePaymentInCash" contextRef="From2019-01-012019-12-31_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></span> in cash during the years ended December 31, 2020 and 2019, respectively, and was due $<span id="xdx_90B_ecustom--MilestonePaymentsOnPayables_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payments on payables"><ix:nonFraction name="HROW:MilestonePaymentsOnPayables" contextRef="From2020-01-012020-12-31_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></span> and
$<span id="xdx_90A_ecustom--MilestonePaymentsOnPayables_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payments on payables"><ix:nonFraction name="HROW:MilestonePaymentsOnPayables" contextRef="From2019-01-012019-12-31_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40</ix:nonFraction></span> at December 31, 2020 and 2019, respectively. The Company incurred $<span id="xdx_902_eus-gaap--RoyaltyExpense_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Royalty payments"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2020-01-012020-12-31_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">55</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--RoyaltyExpense_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Royalty payments"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2019-01-012019-12-31_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40</ix:nonFraction></span> for royalty expenses related to the Lindstrom
APA during the years ended December 31, 2020 and 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Presbyopia
Asset Purchase Agreement &#8211; Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2019, the Company entered into an asset purchase agreement (the &#8220;Presbyopia APA&#8221;) with Richard L. Lindstrom,
M.D., a member of its Board of Directors. Pursuant to the terms of the Presbyopia APA, the Company acquired certain intellectual
property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license an ophthalmic topical product
to treat presbyopia (the &#8220;Presbyopia Product&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
the terms of the Presbyopia APA, <span id="xdx_904_ecustom--RoyaltyPaymentDescription_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember" title="Royalty payment description"><ix:nonNumeric contextRef="From2019-12-012019-12-31_custom_PresbyopiaAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember" name="HROW:RoyaltyPaymentDescription">the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 4% of net
sales, dependent upon the final formulation and patent protection of the Presbyopia Product sold.</ix:nonNumeric></span> Dr. Lindstrom was paid $<span id="xdx_90B_ecustom--MilestonePaymentInCash_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payment in cash"><span id="xdx_90A_ecustom--MilestonePaymentInCash_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payment in cash"><ix:nonFraction name="HROW:MilestonePaymentInCash" contextRef="From2020-01-012020-12-31_custom_PresbyopiaAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="HROW:MilestonePaymentInCash" contextRef="From2019-01-012019-12-31_custom_PresbyopiaAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></ix:nonFraction></span></span> in
cash during the years ended December 31, 2020 and 2019, and was due $<span id="xdx_904_ecustom--MilestonePaymentsOnPayables_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payments on payables"><span id="xdx_905_ecustom--MilestonePaymentsOnPayables_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payments on payables"><ix:nonFraction name="HROW:MilestonePaymentsOnPayables" contextRef="From2020-01-012020-12-31_custom_PresbyopiaAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="HROW:MilestonePaymentsOnPayables" contextRef="From2019-01-012019-12-31_custom_PresbyopiaAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></ix:nonFraction></span></span> at December 31, 2020 and 2019. The Company incurred $<span id="xdx_902_eus-gaap--RoyaltyExpense_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Royalty payments"><span id="xdx_901_eus-gaap--RoyaltyExpense_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Royalty payments"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2020-01-012020-12-31_custom_PresbyopiaAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2019-01-012019-12-31_custom_PresbyopiaAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></ix:nonFraction></span></span>
for royalty expenses related to the Presbyopia APA during the years ended December 31, 2020 and 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>Eyepoint
Commercial Alliance Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">In
August 2020, the Company, through its wholly owned subsidiary ImprimisRx, LLC, entered into a Commercial Alliance Agreement (the
&#8220;Dexycu Agreement&#8221;) with Eyepoint Pharmaceuticals, Inc. (&#8220;Eyepoint&#8221;), pursuant to which Eyepoint granted
the Company the non-exclusive right to co-promote DEXYCU<sup>&#174;</sup> (dexamethasone intraocular suspension) 9% for the treatment
of post-operative inflammation following ocular surgery in the United States.</span> <span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the <span style="background-color: white">Dexycu Agreement</span>, Eyepoint will pay the Company a fee calculated based on
the quarterly sales of DEXCYU in excess of predefined volumes to specific customers of the Company in the U.S. Under the terms
of the <span style="background-color: white">Dexycu Agreement</span>, the Company shall use commercially reasonable efforts to
promote and market DEXCYU in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Subject
to early termination, the <span style="background-color: white">Dexycu Agreement</span> expires on August 1, 2025, subject to
specified notice periods and specified limitations, either party may terminate the <span style="background-color: white">Dexycu
Agreement</span> in the event of (i) uncured material breach by the other party or (ii) if DEXCYU ceases to have &#8220;pass-through&#8221;
payment status. In addition, subject to certain limitations, the Company may terminate the <span style="background-color: white">Dexycu
Agreement</span> (i) for convenience subject to an extended specified notice period or (ii) in the event Eyepoint undergoes a
change of control. Eyepoint may terminate the <span style="background-color: white">Dexycu Agreement</span>, subject to specified
notice periods and specified limitations, if the Company fails to achieve certain minimum sales levels during specified periods.
During the year ended December 31, 2020, the Company recorded $<span id="xdx_90F_eus-gaap--SalesCommissionsAndFees_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--DexycuAgreementMember_pn3n3" title="Commission expense incurred"><ix:nonFraction name="us-gaap:SalesCommissionsAndFees" contextRef="From2020-01-012020-12-31_custom_DexycuAgreementMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">357</ix:nonFraction></span> in commission revenues related to the Dexycu Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_80D_eus-gaap--SegmentReportingDisclosureTextBlock_za1vyYFAHsCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
18. <span id="xdx_822_zW7oEugK6dV8">SEGMENT INFORMATION AND CONCENTRATIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Beginning
on January 1, 2019, the Company began evaluating performance of the Company based on operating segments. Segment performance for
its <span id="xdx_905_ecustom--NumberOfOperatingSegmentsDescription_c20200101__20201231_zZKE0PNI1s2k" title="Number of operating segments, description."><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" name="HROW:NumberOfOperatingSegmentsDescription">two operating segments</ix:nonNumeric></span> are based on segment contribution. The Company&#8217;s reportable segments consist of (i) its commercial
stage pharmaceutical compounding business (Pharmaceutical Compounding), generally including the operations of ImprimisRx and the
former Park businesses; and (ii) its start-up operations associated with pharmaceutical drug development business (Pharmaceutical
Drug Development). Segment contribution for the segments represents net revenues less cost of sales, research and development,
selling and marketing expenses, and select general and administrative expenses. The Company does not evaluate the following items
at the segment level:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Selling,
    general and administrative expenses that result from shared infrastructure, including certain expenses associated with legal
    matters, public company costs (e.g. investor relations), board of directors and principal executive officers and other like
    shared expenses;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Operating
    expenses within selling, general and administrative expenses that result from the impact of corporate initiatives. Corporate
    initiatives primarily include integration, restructuring, acquisition and other shared costs;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Other
    select revenues and operating expenses including R&amp;D expenses, amortization, and asset sales and impairments, net as not
    all such information has been accounted for at the segment level, or such information has not been used by all segments; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Total
    assets including capital expenditures.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company defines segment net revenues as pharmaceutical compounded drug sales, licenses and other revenue derived from related
agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cost
of sales within segment contribution includes direct and indirect costs to manufacture formulations and sell products, including
active pharmaceutical ingredients, personnel costs, packaging, storage, royalties, shipping and handling costs, manufacturing
equipment and tenant improvements depreciation, the write-off of obsolete inventory and other related expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Selling,
general and administrative expenses consist mainly of personnel-related costs, marketing and promotion costs, distribution costs,
professional service costs, insurance, depreciation, facilities costs, transaction costs, and professional services costs which
are general in nature and attributable to the segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z7Np0d5rM4L" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Segment
net revenues, segment operating expenses and segment contribution information consisted of the following for the years ended December
31, 2020 and 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt"><span id="xdx_8B5_zVhOxt4bJ3l" style="display: none">SCHEDULE OF SEGMENT NET REVENUES, SEGMENT OPERATING EXPENSES AND SEGMENT CONTRIBUTION</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended December 31, 2020</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Pharmaceutical</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Pharmaceutical
    Drug</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Compounding</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Development</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net revenues</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" title="Net Revenues" style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48,871</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" title="Net Revenues" style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1930">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" title="Net Revenues" style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48,871</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Cost of sales</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--CostOfGoodsAndServicesSold_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" title="Cost of sales" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14,463</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--CostOfGoodsAndServicesSold_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" title="Cost of sales" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1936">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zgozMhXwOZ91" title="Cost of sales" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,463</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gross profit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--GrossProfit_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" title="Gross profit" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34,408</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--GrossProfit_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" title="Gross profit" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1942">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--GrossProfit_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" title="Gross profit" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34,408</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Selling, general
    and administrative</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" title="Selling, general and administrative" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,691</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" title="Selling, general and administrative" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalDrugDevelopmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">144</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" title="Selling, general and administrative" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,835</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research
    and development</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" title="Research and development" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">759</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" title="Research and development" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalDrugDevelopmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">88</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" title="Research and development" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">847</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Segment
    contribution</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">$</span></p></td><td id="xdx_987_ecustom--SegmentContribution_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" title="Segment contribution" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:SegmentContribution" contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,958</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">$</span></p></td><td id="xdx_980_ecustom--SegmentContribution_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" title="Segment contribution" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HROW:SegmentContribution" contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalDrugDevelopmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">232</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"></td><td id="xdx_987_ecustom--SegmentContribution_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" title="Segment contribution" style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:SegmentContribution" contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,726</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Corporate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--OperatingIncomeLoss_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_pn3n3" title="Operating income (loss)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_CorporateNonSegmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,245</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--OperatingIncomeLoss_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" title="Operating income (loss)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,566</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--AdjustmentForAmortization_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" title="Amortization" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">167</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Asset sales and
    impairments, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(363</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    income</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_ecustom--ImpairmentAndDisposalOfLonglivedAssets_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" title="Asset sales and impairments, net" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:ImpairmentAndDisposalOfLonglivedAssets" contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">385</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended December 31, 2019</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Pharmaceutical</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Pharmaceutical
    Drug</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Compounding</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Development</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net revenues</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" title="Net Revenues" style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51,165</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" title="Net Revenues" style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1974">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" title="Net Revenues" style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51,165</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Cost of sales</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--CostOfGoodsAndServicesSold_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" title="Cost of sales" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16,749</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--CostOfGoodsAndServicesSold_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" title="Cost of sales" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1980">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zF011mNHMFJ4" title="Cost of sales" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,749</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gross profit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--GrossProfit_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" title="Gross profit" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34,416</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--GrossProfit_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" title="Gross profit" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1986">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--GrossProfit_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" title="Gross profit" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">34,416</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Selling, general
    and administrative</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" title="Selling, general and administrative" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,460</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" title="Selling, general and administrative" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2019-01-012019-12-31_custom_PharmaceuticalDrugDevelopmentMember_us-gaap_OperatingSegmentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">174</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" title="Selling, general and administrative" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,634</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ResearchAndDevelopmentExpense_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" title="Research and development" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,006</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ResearchAndDevelopmentExpense_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" title="Research and development" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2019-01-012019-12-31_custom_PharmaceuticalDrugDevelopmentMember_us-gaap_OperatingSegmentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">361</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ResearchAndDevelopmentExpense_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" title="Research and development" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,367</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Segment
    contribution</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--SegmentContribution_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" title="Segment contribution" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:SegmentContribution" contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,934</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--SegmentContribution_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" title="Segment contribution" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HROW:SegmentContribution" contextRef="From2019-01-012019-12-31_custom_PharmaceuticalDrugDevelopmentMember_us-gaap_OperatingSegmentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">535</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"></td><td id="xdx_980_ecustom--SegmentContribution_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" title="Segment contribution" style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction name="HROW:SegmentContribution" contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,399</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Corporate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--OperatingIncomeLoss_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_pn3n3" title="Operating income (loss)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2019-01-012019-12-31_us-gaap_CorporateNonSegmentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,245</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--OperatingIncomeLoss_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" title="Operating income (loss)" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">716</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AdjustmentForAmortization_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" title="Amortization" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">209</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Asset sales and
    impairments, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--ImpairmentAndDisposalOfLonglivedAssets_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" title="Asset sales and impairments, net" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="HROW:ImpairmentAndDisposalOfLonglivedAssets" contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,040</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    loss</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--OperatingIncomeLoss_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" title="Operating income (loss)" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,795</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AF_zIPAVqlakOli" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company categorizes revenues by geographic area based on selling location. All operations are currently located in the U.S.; therefore,
total revenues are attributed to the U.S. All long-lived assets at December 31, 2020 and December 31, 2019 are located in the
U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Concentrations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company sells its compounded formulations to a large number of customers. There were no customers who comprised more than <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercent_c20200101__20201231_zkRMME5LjXof" title="Percentage of sales derived from large number of customer"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercent_c20190101__20191231_zsO2Z2EGkZq1" title="Percentage of sales derived from large number of customer"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-01-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">10</ix:nonFraction></ix:nonFraction>%</span></span>
of the Company&#8217;s total pharmacy sales for the years ended December 31, 2020 and 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company receives its active pharmaceutical ingredients from three main suppliers. These suppliers collectively accounted for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercent_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--ThreeMainSuppliersMember_zJf5ak088ns9" title="Percentage of sales derived from large number of customer"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2020-01-012020-12-31_custom_ThreeMainSuppliersMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">77</ix:nonFraction>%</span>
of active pharmaceutical ingredient purchases during the year ended December 31, 2020, and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercent_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--ThreeMainSuppliersMember_zLLQwOjuQ5f6" title="Percentage of sales derived from large number of customer"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-12-31_custom_ThreeMainSuppliersMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Percent">73</ix:nonFraction>%</span> during the year ended December
31, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-01-01to2020-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_z0qglOUjWSpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
19. <span id="xdx_820_zilROz9sooWh">SUBSEQUENT EVENTS </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
March 2021, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20210301__20210331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zO0Cwh0QvdJb"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-03-012021-03-31_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,989</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of its common stock upon the exercise
of options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20210301__20210331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPJgXQbXoSRc"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-03-012021-03-31_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,989</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of</span><span style="font: 10pt Times New Roman, Times, Serif">
common stock, with exercise prices ranging between $<span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20210301__20210331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3C1WFfBG3gf"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" contextRef="From2021-03-012021-03-31_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.70</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">to $<span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20210301__20210331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTzZKIyAg7A2"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2021-03-012021-03-31_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.96</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per share, and received net proceeds of
$<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20200301__20200331_pn3n3"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2020-03-012020-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Restricted
stock units granted in February 2015 to Andrew R. Boll, the Company&#8217;s Chief Financial Officer, vested, and in February 2021,
<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20210201__20210228__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--AndrewRBollMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_pii" title="Shares issued of restricted common stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2021-02-012021-02-28_us-gaap_RestrictedStockUnitsRSUMember_custom_AndrewRBollMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,500</ix:nonFraction></span> shares the Company&#8217;s common stock were issued to Mr. Boll, net of <span id="xdx_90E_ecustom--CommonStockWithheldForPayrollTaxWithholdings_c20210201__20210228__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--AndrewRBollMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_pii" title="Common stock withheld for payroll tax withholdings"><ix:nonFraction name="HROW:CommonStockWithheldForPayrollTaxWithholdings" contextRef="From2021-02-012021-02-28_us-gaap_RestrictedStockUnitsRSUMember_custom_AndrewRBollMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,500</ix:nonFraction></span> shares of common stock withheld for payroll
tax withholdings totaling $<span id="xdx_900_ecustom--CommonStockWithheldForPayrollTaxWithholdingsValue_c20210201__20210228__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--AndrewRBollMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_pn3n3" title="Common stock withheld for payroll tax withholdings, value"><ix:nonFraction name="HROW:CommonStockWithheldForPayrollTaxWithholdingsValue" contextRef="From2021-02-012021-02-28_us-gaap_RestrictedStockUnitsRSUMember_custom_AndrewRBollMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Restricted
stock units granted in February 2015 to Mark L. Baum, the Company&#8217;s Chief Executive Officer, vested, and in February 2021,
<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20210201__20210228__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--MarkLBaumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_pii" title="Shares issued of restricted common stock, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2021-02-012021-02-28_us-gaap_RestrictedStockUnitsRSUMember_custom_MarkLBaumMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></span> shares the Company&#8217;s common stock were issued to Mr. Baum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has performed an evaluation of events occurring subsequent to December 31, 2020 through the filing date of this Annual
Report and determined that no subsequent events have occurred that would require recognition in the consolidated financial
statements or disclosures in the notes thereto, other than as disclosed in the accompanying notes.</span></p>

</ix:nonNumeric><p id="xdx_811_zAIk3VdYSvj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 92; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- [encoded data, 4096 characters]
     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 -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex4-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF THE COMPANY&rsquo;S SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTERED
PURSUANT TO SECTION 12 OF THE SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXCHANGE
ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Harrow
Health, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common
stock, par value $0.001 per share.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>In
this exhibit, when we refer to &ldquo;Company&rdquo;, &ldquo;Harrow&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo; and &ldquo;our&rdquo;
or when we otherwise refer to ourselves, we mean Harrow Health, Inc., excluding, unless otherwise expressly stated or the context
requires, our subsidiaries.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the rights of our common and preferred stock and of certain provisions of our Amended and Restated Certificate
of Incorporation and Amended and Restated Bylaws. For more detailed information, please see our Amended and Restated Certificate
of Incorporation and Amended and Restated Bylaws, which are incorporated by reference as exhibits to the Annual Report on Form
10-K to which this description is an exhibit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Authorized
Capital Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
authorized capital stock consists of 55,000,000 shares, 50,000,000 of which are designated as common stock, par value $0.001 per
share, and 5,000,000 of which are designated as preferred stock, par value $0.001 per share. As of March 5, 2021, there were 25,983,364
shares of our common stock and no shares of our preferred stock issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Capital
Stock Issued and Outstanding</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 1, 2021, there were approximately 96 stockholders of record (excluding an indeterminable number of stockholders whose
shares are held in street or &ldquo;nominee&rdquo; name) of our common stock. In addition, as of December 31, 2019, there are
outstanding (i) options to acquire 2,656,683 shares of our common stock with a weighted average exercise price of $5.31 per share,
(ii) warrants to purchase 780,386 shares of common stock with a weighted average exercise price of $2.12 per share, (iii) 1,411,930
unvested restricted stock units and (iv) 324,303 restricted stock units award to directors that had vested, but issuance and delivery
of the shares are deferred until the director resigns or otherwise leaves the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are authorized to issue 50,000,000 shares of common stock, par value $0.001 per share. The holders of our common stock are entitled
to one vote per share on all matters submitted to a vote of the stockholders, including the election of directors. Our Amended
and Restated Certificate of Incorporation does not provide for cumulative voting in the election of directors. Subject to any
preferential rights of any outstanding series of preferred stock created by our Board of Directors from time to time the holders
of our common stock will be entitled to cash dividends as may be declared, if any, by our Board of Directors from funds available.
Subject to any preferential rights of any outstanding series of preferred stock that we may issue, upon liquidation, dissolution
or winding up of our company, the holders of our common stock will be entitled to receive pro rata all assets available for distribution
to the holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
of Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has the authority, without further action by our stockholders, to issue up to 5,000,000 shares of preferred
stock, par value $0.001 per share, in one or more series. Our Board of Directors may designate the rights, preferences, privileges
and restrictions of the preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation
preference, sinking fund terms, and number of shares constituting any series and the designation of any series. The issuance of
preferred stock could have the effect of restricting dividends on our common stock, diluting the voting power of our common stock,
impairing the liquidation rights of our common stock, or delaying or preventing a change in control. The ability to issue preferred
stock could delay or impede a change in control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Anti-Takeover
Provisions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the provisions of Section 203 of the Delaware General Corporation Law, or DGCL, an anti-takeover law. In general,
Section 203 prohibits a publicly held Delaware corporation from engaging in a &ldquo;business combination&rsquo;&rsquo; with an
&ldquo;interested stockholder&rsquo;&rsquo; for a period of three years after the date of the transaction in which such stockholder
became an interested stockholder, unless the business combination is approved in a prescribed manner. For purposes of Section
203, a &ldquo;business combination&rsquo;&rsquo; includes a merger, asset sale or other transaction resulting in a financial benefit
to the interested stockholder, and an &ldquo;interested stockholder&rsquo;&rsquo; is a stockholder who, together with affiliates
and associates, owns, or within three years prior, did own, 15% or more of the voting stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Liability
and Indemnification of Directors and Officers</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145 of the DGCL provides, in general, that a corporation incorporated under the laws of the State of Delaware, such as us, may
indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action,
suit or proceeding (other than a derivative action by or in the right of the corporation) by reason of the fact that such person
is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as
a director, officer, employee or agent of another enterprise, against expenses (including attorneys&rsquo; fees), judgments, fines
and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding
if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests
of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person&rsquo;s
conduct was unlawful. In the case of a derivative action, a Delaware corporation may indemnify any such person against expenses
(including attorneys&rsquo; fees) actually and reasonably incurred by such person in connection with the defense or settlement
of such action or suit if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed
to the best interests of the corporation, except that no indemnification will be made in respect of any claim, issue or matter
as to which such person will have been adjudged to be liable to the corporation unless and only to the extent that the Court of
Chancery of the State of Delaware or any other court in which such action was brought determines such person is fairly and reasonably
entitled to indemnity for such expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws provide that we will indemnify our directors,
officers, employees and agents to the extent and in the manner permitted by the provisions of the DGCL, as amended from time to
time, subject to any permissible expansion or limitation of such indemnification, as may be set forth in any stockholders&rsquo;
or directors&rsquo; resolution or by contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have director and officer indemnification agreements with each of our executive officers and directors that provide, among
other things, for the indemnification to the fullest extent permitted or required by Delaware law, provided that such indemnitee
shall not be entitled to indemnification in connection with any proceedings or claims initiated or brought voluntarily by the
indemnitee and not by way of defense, unless (i) such indemnification is expressly required to be made by law, (ii) the proceeding
was authorized by our Board of Directors, (iii) indemnification is provided by us, in our sole discretion, pursuant to powers
vested in us under the DGCL, or (iv) the proceeding is brought to establish or enforce a right to indemnification under the indemnification
agreement or any other statute or law or otherwise as required under Section 145 of the DGCL. We are not required to indemnify
the indemnitee for any amounts paid in settlement of a proceeding unless we consent to such settlement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
repeal or modification of these provisions approved by our stockholders shall be prospective only, and shall not adversely affect
any limitation on the liability of a director or officer existing as of the time of such repeal or modification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have purchased and intend to maintain insurance on our behalf and on behalf of any person who is or was a director or officer
against any loss arising from any claim asserted against him or her and incurred by him or her in that capacity, subject to certain
exclusions and limits of the amount of coverage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Listing;
Transfer Agent</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on The NASDAQ Global Market under the symbol &ldquo;HROW&rdquo;. The transfer agent and registrar for our
common stock is Action Stock Transfer Corporation, 2469 E. Fort Union Blvd., Suite 214, Salt Lake City, UT 84121.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.57
<SEQUENCE>3
<FILENAME>ex10-57.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
10.57</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VISIONOLOGY,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSULTING
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Consulting Agreement (this &ldquo;<B><I>Agreement</I></B>&rdquo;) is made and entered into as of July 1, 2020 (the &ldquo;<B><I>Effective
Date</I></B>&rdquo;) by and between Visionology, Inc., a Delaware corporation with its principal place of business at 102 Woodmont
Blvd., Suite 610, Nashville, TN 37205 (the &ldquo;<B><I>Company</I></B>&rdquo;), and Mark L. Baum, an individual with a principal
place of business at 102 Woodmont Blvd., Suite 610, Nashville, TN 37205 (&ldquo;<B><I>Consultant</I></B>&rdquo;) (each herein
referred to individually as a &ldquo;<B><I>Party</I></B>,&rdquo; or collectively as the &ldquo;<B><I>Parties</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company desires to retain Consultant as an independent contractor to perform consulting services for the Company, and Consultant
is willing to perform such services, on the terms described below. In consideration of the mutual promises contained herein, the
Parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
Services and Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consultant
shall perform the services described in <B>Exhibit A</B> (the &ldquo;<B><I>Services</I></B>&rdquo;) for the Company (or its designee),
and the Company agrees to pay Consultant the compensation described in <B>Exhibit A</B> for Consultant&rsquo;s performance of
the Services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Confidentiality</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
<B><I>Definition of Confidential Information</I>.</B> &ldquo;<B><I>Confidential Information</I></B>&rdquo; means any information
(including any and all combinations of individual items of information) that relates to the actual or anticipated business and/or
products, research or development of the Company, its affiliates or subsidiaries, or to the Company&rsquo;s, its affiliates&rsquo;
or subsidiaries&rsquo; technical data, trade secrets, or know-how, including, but not limited to, research, product plans, or
other information regarding the Company&rsquo;s, its affiliates&rsquo; or subsidiaries&rsquo; products or services and markets
therefor, customer lists and customers (including, but not limited to, customers of the Company on whom Consultant called or with
whom Consultant became acquainted during the term of this Agreement), software, developments, inventions, discoveries, ideas,
processes, formulas, technology, designs, drawings, engineering, hardware configuration information, marketing, finances, and
other business information disclosed by the Company, its affiliates or subsidiaries, either directly or indirectly, in writing,
orally or by drawings or inspection of premises, parts, equipment, or other property of Company, its affiliates or subsidiaries.
Notwithstanding the foregoing, Confidential Information shall not include any such information which Consultant can establish
(i) was publicly known or made generally available prior to the time of disclosure to Consultant; (ii) becomes publicly known
or made generally available after disclosure to Consultant through no wrongful action or inaction of Consultant; or (iii) is in
the rightful possession of Consultant, without confidentiality obligations, at the time of disclosure as shown by Consultant&rsquo;s
then-contemporaneous written records; provided that any combination of individual items of information shall not be deemed to
be within any of the foregoing exceptions merely because one or more of the individual items are within such exception, unless
the combination as a whole is within such exception.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
<B><I>Nonuse and Nondisclosure</I>.</B> During and after the term of this Agreement, Consultant will hold in the strictest confidence,
and take all reasonable precautions to prevent any unauthorized use or disclosure of Confidential Information, and Consultant
will not (i) use the Confidential Information for any purpose whatsoever other than as necessary for the performance of the Services
on behalf of the Company, or (ii) subject to Consultant&rsquo;s right to engage in Protected Activity (as defined below), disclose
the Confidential Information to any third party without the prior written consent of an authorized representative of the Company,
except that Consultant may disclose Confidential Information to the extent compelled by applicable law; <I>provided however</I>,
prior to such disclosure, Consultant shall provide prior written notice to Company and seek a protective order or such similar
confidential protection as may be available under applicable law. Consultant agrees that no ownership of Confidential Information
is conveyed to the Consultant. Without limiting the foregoing, Consultant shall not use or disclose any Company property, intellectual
property rights, trade secrets or other proprietary know-how of the Company to invent, author, make, develop, design, or otherwise
enable others to invent, author, make, develop, or design identical or substantially similar designs as those developed under
this Agreement for any third party. Consultant agrees that Consultant&rsquo;s obligations under this Section 2.B shall continue
after the termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
<B><I>Other Client Confidential Information</I>.</B> Consultant agrees that Consultant will not improperly use, disclose, or induce
the Company to use any proprietary information or trade secrets of any former or current employer of Consultant or other person
or entity with which Consultant has an obligation to keep in confidence. Consultant also agrees that Consultant will not bring
onto the Company&rsquo;s premises or transfer onto the Company&rsquo;s technology systems any unpublished document, proprietary
information, or trade secrets belonging to any third party unless disclosure to, and use by, the Company has been consented to
in writing by such third party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.
<B><I>Third Party Confidential Information</I>.</B> Consultant recognizes that the Company has received and in the future will
receive from third parties their confidential or proprietary information subject to a duty on the Company&rsquo;s part to maintain
the confidentiality of such information and to use it only for certain limited purposes. Consultant agrees that at all times during
the term of this Agreement and thereafter, Consultant owes the Company and such third parties a duty to hold all such confidential
or proprietary information in the strictest confidence and not to use it or to disclose it to any person, firm, corporation, or
other third party except as necessary in carrying out the Services for the Company consistent with the Company&rsquo;s agreement
with such third party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
Ownership</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
<B><I>Assignment of Inventions</I>.</B> Consultant agrees that all right, title, and interest in and to any copyrightable material,
notes, records, drawings, designs, inventions, improvements, developments, discoveries, ideas and trade secrets conceived, discovered,
authored, invented, developed or reduced to practice by Consultant, solely or in collaboration with others, during the term of
this Agreement and arising out of, or in connection with, performing the Services under this Agreement and any copyrights, patents,
trade secrets, mask work rights or other intellectual property rights relating to the foregoing (collectively, &ldquo;<B><I>Inventions</I></B>&rdquo;),
are the sole property of the Company. Consultant also agrees to promptly make full written disclosure to the Company of any Inventions
and to deliver and assign (or cause to be assigned) and hereby irrevocably assigns fully to the Company all right, title and interest
in and to the Inventions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
<B><I>Pre-Existing Material</I>s.</B> Subject to Section 3.A, Consultant will provide the Company with prior written notice if,
in the course of performing the Services, Consultant incorporates into any Invention or utilizes in the performance of the Services
any invention, discovery, idea, original works of authorship, development, improvements, trade secret, concept, or other proprietary
information or intellectual property right owned by Consultant or in which Consultant has an interest, prior to, or separate from,
performing the Services under this Agreement (&ldquo;<B><I>Prior Inventions</I></B>&rdquo;), and the Company is hereby granted
a nonexclusive, royalty-free, perpetual, irrevocable, transferable, worldwide license (with the right to grant and authorize sublicenses)
to make, have made, use, import, offer for sale, sell, reproduce, distribute, modify, adapt, prepare derivative works of, display,
perform, and otherwise exploit such Prior Inventions, without restriction, including, without limitation, as part of or in connection
with such Invention, and to practice any method related thereto. Consultant will not incorporate any invention, discovery, idea,
original works of authorship, development, improvements, trade secret, concept, or other proprietary information or intellectual
property right owned by any third party into any Invention without Company&rsquo;s prior written permission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
<B><I>Moral Rights</I>.</B> Any assignment to the Company of Inventions includes all rights of attribution, paternity, integrity,
modification, disclosure and withdrawal, and any other rights throughout the world that may be known as or referred to as &ldquo;moral
rights,&rdquo; &ldquo;artist&rsquo;s rights,&rdquo; &ldquo;droit moral,&rdquo; or the like (collectively, &ldquo;<B><I>Moral Rights</I></B>&rdquo;).
To the extent that Moral Rights cannot be assigned under applicable law, Consultant hereby waives and agrees not to enforce any
and all Moral Rights, including, without limitation, any limitation on subsequent modification, to the extent permitted under
applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.
<B><I>Maintenance of Records</I>.</B> Consultant agrees to keep and maintain adequate, current, accurate, and authentic written
records of all Inventions made by Consultant (solely or jointly with others) during the term of this Agreement, and for a period
of three (3) years thereafter. The records will be in the form of notes, sketches, drawings, electronic files, reports, or any
other format that is customary in the industry and/or otherwise specified by the Company. Such records are and remain the sole
property of the Company at all times and upon Company&rsquo;s request, Consultant shall deliver (or cause to be delivered) the
same.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.
<B><I>Further Assurances</I>.</B> Consultant agrees to assist Company, or its designee, at the Company&rsquo;s expense, in every
proper way to secure the Company&rsquo;s rights in Inventions in any and all countries, including the disclosure to the Company
of all pertinent information and data with respect thereto, the execution of all applications, specifications, oaths, assignments
and all other instruments that the Company may deem necessary in order to apply for, register, obtain, maintain, defend, and enforce
such rights, and in order to deliver, assign and convey to the Company, its successors, assigns and nominees the sole and exclusive
right, title, and interest in and to all Inventions and testifying in a suit or other proceeding relating to such Inventions.
Consultant further agrees that Consultant&rsquo;s obligations under this Section 3.E shall continue after the termination of this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.
<B><I>Attorney-in-Fact</I>.</B> Consultant agrees that, if the Company is unable because of Consultant&rsquo;s unavailability,
dissolution, mental or physical incapacity, or for any other reason, to secure Consultant&rsquo;s signature with respect to any
Inventions, including, without limitation, for the purpose of applying for or pursuing any application for any United States or
foreign patents or mask work or copyright registrations covering the Inventions assigned to the Company in Section 3.A, then Consultant
hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as Consultant&rsquo;s agent
and attorney-in-fact, to act for and on Consultant&rsquo;s behalf to execute and file any papers and oaths and to do all other
lawfully permitted acts with respect to such Inventions to further the prosecution and issuance of patents, copyright and mask
work registrations with the same legal force and effect as if executed by Consultant. This power of attorney shall be deemed coupled
with an interest, and shall be irrevocable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
Conflicting Obligations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
Consultant represents and warrants that Consultant has no agreements, relationships, or commitments to any other person or entity
that conflict with the provisions of this Agreement, Consultant&rsquo;s obligations to the Company under this Agreement, and/or
Consultant&rsquo;s ability to perform the Services. Consultant will not enter into any such conflicting agreement during the term
of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
Return of Company Materials</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the termination of this Agreement, or upon Company&rsquo;s earlier request, Consultant will immediately deliver to the Company,
and will not keep in Consultant&rsquo;s possession, recreate, or deliver to anyone else, any and all Company property, including,
but not limited to, Confidential Information, tangible embodiments of the Inventions, all devices and equipment belonging to the
Company, all electronically-stored information and passwords to access such property, those records maintained pursuant to Section
3.D and any reproductions of any of the foregoing items that Consultant may have in Consultant&rsquo;s possession or control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.
Term and Termination</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
<B><I>Term</I>.</B> Consultant commenced providing Services to the Company on or about December 1, 2019 and shall provide the
Services through the earlier of (i) one year from the Effective Date, (ii) a Change in Control (as defined in the Company&rsquo;s
2020 Equity Incentive Plan (the &ldquo;<B><I>Plan</I></B>&rdquo;)), (iii) the date of any underwriting agreement between the Company
and the underwriter(s) managing an initial public offering of Common Stock (as defined in the Plan), pursuant to which the Common
Stock is priced for an initial public offering, (iv) a Qualified Financing (as defined in Exhibit A attached hereto) or (v) such
earlier date as the Services are terminated by the Company or Consultant as provided in Section 6.B (the &ldquo;<B><I>Term</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
<B><I>Termination</I>.</B> The Company may terminate this Agreement upon giving Consultant fourteen (14) days prior written notice
of such termination pursuant to Section 12.G of this Agreement. The Company may terminate this Agreement immediately and without
prior notice if Consultant refuses to or is unable to perform the Services or is in breach of any material provision of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
<B><I>Survival</I>.</B> Upon any termination, all rights and duties of the Company and Consultant toward each other shall cease
except:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The Company will pay, within thirty (30) days after the effective date of termination, all amounts owing to Consultant for Services
completed and accepted by the Company prior to the termination date and related reimbursable expenses, if any, submitted in accordance
with the Company&rsquo;s policies and in accordance with the provisions of Section 1 of this Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Section 2 (Confidentiality), Section 3 (Ownership), Section 5 (Return of Company Materials), Section 6 (Term and Termination),
Section 7 (Independent Contractor; Benefits), Section 8 (Indemnification), Section 9 (Nonsolicitation), Section 10 (Limitation
of Liability), Section 11 (Dispute Resolution), and Section 12 (Miscellaneous) will survive termination or expiration of this
Agreement in accordance with their terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.
Independent Contractor; Benefits</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
<B><I>Independent Contractor.</I></B> It is the express intention of the Company and Consultant that Consultant perform the Services
as an independent contractor to the Company. Nothing in this Agreement shall in any way be construed to constitute Consultant
as an agent, employee or representative of the Company. Without limiting the generality of the foregoing, Consultant is not authorized
to bind the Company to any liability or obligation or to represent that Consultant has any such authority. Consultant agrees to
furnish (or reimburse the Company for) all tools and materials necessary to accomplish this Agreement and shall incur all expenses
associated with performance. Consultant acknowledges and agrees that Consultant is obligated to report as income all compensation
received by Consultant pursuant to this Agreement. Consultant agrees to and acknowledges the obligation to pay all self-employment
and other taxes on such income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
<B><I>Benefits</I>.</B> The Company and Consultant agree that Consultant will receive no Company-sponsored benefits from the Company
such as, but not limited to, paid vacation, sick leave, medical insurance and 401k participation; provided, however, that Consultant
shall be eligible for awards granted under the Plan. If Consultant is reclassified by a state or federal agency or court as the
Company&rsquo;s employee, Consultant will become a reclassified employee and will receive no benefits from the Company, except
those mandated by state or federal law, even if by the terms of the Company&rsquo;s benefit plans or programs of the Company in
effect at the time of such reclassification, Consultant would otherwise be eligible for such benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.
Indemnification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consultant
agrees to indemnify and hold harmless the Company and its affiliates and their directors, officers and employees from and against
all taxes, losses, damages, liabilities, costs and expenses, including attorneys&rsquo; fees and other legal expenses, arising
directly or indirectly from or in connection with (i) any negligent, reckless or intentionally wrongful act of Consultant, (ii)
a determination by a court or agency that the Consultant is not an independent contractor, (iii) any breach by the Consultant
of any of the covenants contained in this Agreement, (iv) any failure of Consultant to perform the Services in accordance with
all applicable laws, rules and regulations, or (v) any violation or claimed violation of a third party&rsquo;s rights resulting
in whole, or in part, from the Company&rsquo;s use of the Inventions or other deliverables of Consultant under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.
Nonsolicitation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the fullest extent permitted under applicable law, from the date of this Agreement until twelve (12) months after the termination
of this Agreement for any reason, Consultant will not, without the Company&rsquo;s prior written consent, directly or indirectly,
solicit any of the Company&rsquo;s employees to leave their employment, or attempt to solicit employees of the Company, either
for Consultant or for any other person or entity. Consultant agrees that nothing in this Section 9 shall affect Consultant&rsquo;s
continuing obligations under this Agreement during and after this twelve (12) month period, including, without limitation, Consultant&rsquo;s
obligations under Section 2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
Limitation of Liability</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
NO EVENT SHALL COMPANY BE LIABLE TO CONSULTANT OR TO ANY OTHER PARTY FOR ANY INDIRECT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES,
OR DAMAGES FOR LOST PROFITS OR LOSS OF BUSINESS, HOWEVER CAUSED AND UNDER ANY THEORY OF LIABILITY, WHETHER BASED IN CONTRACT,
TORT (INCLUDING NEGLIGENCE) OR OTHER THEORY OF LIABILITY, REGARDLESS OF WHETHER COMPANY WAS ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES AND NOTWITHSTANDING THE FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY. IN NO EVENT SHALL COMPANY&rsquo;S LIABILITY
ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT EXCEED THE AMOUNTS PAID BY COMPANY TO CONSULTANT UNDER THIS AGREEMENT FOR
THE SERVICES, DELIVERABLES OR INVENTION GIVING RISE TO SUCH LIABILITY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.
Dispute Resolution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
controversy, dispute or claim arising out of or relating to this Agreement or the breach or alleged breach hereof, including whether
the controversy, dispute or claim is arbitrable (each, a &ldquo;<B><I>Dispute</I></B>&rdquo;), shall be resolved by submitting
such Dispute to binding arbitration administered by the American Health Lawyers Association Dispute Resolution Services or its
successor (&ldquo;<B><I>AHLA</I></B>&rdquo;) and held in Nashville, Tennessee, and judgment on the arbitration award may be entered
in any court having jurisdiction thereof. The arbitration will be conducted in accordance with applicable AHLA rules and procedures
before a single arbitrator selected and appointed in accordance with such rules. Each party will bear and pay equally the fees
and expenses of AHLA (including the fees and expenses of the arbitrator), and each party will bear its own attorneys&rsquo; fees,
costs and other expenses; <I>provided, however</I>, that the arbitrator may award reasonable attorneys&rsquo; fees and expenses
to the prevailing party as contemplated in Section 12.H. Any arbitration will be governed by the Federal Arbitration Act (9 U.S.C.
&sect;&sect; 1 <I>et seq.</I>). The provisions of this Section 11 shall survive expiration or other termination of this Agreement
regardless of the cause of such expiration or termination, and shall not restrict the right of the parties hereto to institute
a proceeding in any court of law or equity to enable such party to obtain or otherwise seek injunctive relief, specific performance
or other equitable remedies during the pendency of any arbitration or without submitting such matter to arbitration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.
Miscellaneous</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
<B><I>Governing Law; Consent to Personal Jurisdiction and Venue; Waiver of Trial by Jury</I>.</B> This Agreement shall be governed
by the laws of the State of Delaware, without regard to the conflicts of law provisions of any jurisdiction. To the extent that
any lawsuit is permitted under this Agreement, the Parties hereby expressly consent to the personal and exclusive jurisdiction
and venue of the state and federal courts located in Nashville, Tennessee. Each party hereby waives any objection to the personal
or subject matter jurisdiction and venue of such courts. EACH PARTY HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE
LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY DISPUTE, ACTION OR CLAIM ARISING OUT OF THIS AGREEMENT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
<B><I>Assignability</I>.</B> This Agreement will be binding upon Consultant&rsquo;s heirs, executors, assigns, administrators,
and other legal representatives, and will be for the benefit of the Company, its successors, and its assigns. There are no intended
third-party beneficiaries to this Agreement, except as expressly stated. Except as may otherwise be provided in this Agreement,
Consultant may not sell, assign or delegate any rights or obligations under this Agreement. Notwithstanding anything to the contrary
herein, Company may assign this Agreement and its rights and obligations under this Agreement to any successor to all or substantially
all of Company&rsquo;s relevant assets, whether by merger, consolidation, reorganization, reincorporation, sale of assets or stock,
change of control or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
<B><I>Entire Agreement</I>.</B> This Agreement constitutes the entire agreement and understanding between the Parties with respect
to the subject matter herein and supersedes all prior written and oral agreements, discussions, or representations between the
Parties. Consultant represents and warrants that Consultant is not relying on any statement or representation not contained in
this Agreement. To the extent any terms set forth in any exhibit or schedule conflict with the terms set forth in this Agreement,
the terms of this Agreement shall control unless otherwise expressly agreed by the Parties in such exhibit or schedule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.
<B><I>Headings</I>.</B> Headings are used in this Agreement for reference only and shall not be considered when interpreting this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.
<B><I>Severability</I>.</B> If a court or other body of competent jurisdiction finds, or the Parties mutually believe, any provision
of this Agreement, or portion thereof, to be invalid or unenforceable, such provision will be enforced to the maximum extent permissible
so as to effect the intent of the Parties, and the remainder of this Agreement will continue in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.
<B><I>Modification, Waiver.</I></B> No modification of or amendment to this Agreement, nor any waiver of any rights under this
Agreement, will be effective unless in a writing signed by the Parties. Waiver by the Company of a breach of any provision of
this Agreement will not operate as a waiver of any other or subsequent breach.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.
<B><I>Notices</I>.</B> Any notice or other communication required or permitted by this Agreement to be given to a Party shall
be in writing and shall be deemed given (i) if delivered personally or by commercial messenger or courier service, (ii) when sent
by confirmed facsimile, or (iii) if mailed by U.S. registered or certified mail (return receipt requested), to the Party at the
Party&rsquo;s address written below or at such other address as the Party may have previously specified by like notice. If by
mail, delivery shall be deemed effective three business days after mailing in accordance with this Section 12.G.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
If to the Company, to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Visionology,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">102
Woodmont Blvd., Suite 610</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nashville,
TN 37205</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
If to Consultant, to the address for notice on the signature page to this Agreement or, if no such address is provided, to the
last address of Consultant provided by Consultant to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.
<B><I>Attorneys&rsquo; Fees</I>.</B> In any court action at law or equity that is brought by one of the Parties to this Agreement
to enforce or interpret the provisions of this Agreement, the prevailing Party will be entitled to reasonable attorneys&rsquo;
fees, in addition to any other relief to which that Party may be entitled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.
<B><I>Signatures.</I></B> This Agreement may be signed in two counterparts, each of which shall be deemed an original, with the
same force and effectiveness as though executed in a single document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.
<B><I>Applicability to Past Activities.</I></B> Consultant agrees that if and to the extent that Consultant provided any services
or made efforts on behalf of or for the benefit of Company, or related to the current or prospective business of Company in anticipation
of Consultant&rsquo;s involvement with the Company, that would have been &ldquo;Services&rdquo; if performed during the term of
this Agreement (the &ldquo;<B><I>Prior Consulting Period</I></B>&rdquo;) and to the extent that during the Prior Consulting Period:
(i) Consultant received access to any information from or on behalf of Company that would have been &ldquo;Confidential Information&rdquo;
if Consultant received access to such information during the term of this Agreement; or (ii) Consultant (a) conceived, created,
authored, invented, developed or reduced to practice any item (including any intellectual property rights with respect thereto)
on behalf of or for the benefit of Company, or related to the current or prospective business of Company in anticipation of Consultant&rsquo;s
involvement with Company, that would have been an Invention if conceived, created, authored, invented, developed or reduced to
practice during the term of this Agreement; or (b) incorporated into any such item any pre-existing invention, improvement, development,
concept, discovery or other proprietary information that would have been a Prior Invention if incorporated into such item during
the term of this Agreement; then any such information shall be deemed Confidential Information hereunder and any such item shall
be deemed an Invention or Prior Invention hereunder, and this Agreement shall apply to such activities, information or item as
if disclosed, conceived, created, authored, invented, developed or reduced to practice during the term of this Agreement. Consultant
further acknowledges that Consultant has been fully compensated for all services provided during any such Prior Consulting Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">K.
<B><I>Protected Activity Not Prohibited.</I></B> Consultant understands that nothing in this Agreement shall in any way limit
or prohibit Consultant from engaging in any Protected Activity. For purposes of this Agreement, &ldquo;<B><I>Protected Activity</I></B>&rdquo;
shall mean filing a charge, complaint, or report with, or otherwise communicating, cooperating, or participating in any investigation
or proceeding that may be conducted by, any federal, state or local government agency or commission, including the Securities
and Exchange Commission (&ldquo;<B><I>Government Agencies</I></B>&rdquo;). Consultant understands that in connection with such
Protected Activity, Consultant is permitted to disclose documents or other information as permitted by law, and without giving
notice to, or receiving authorization from, the Company. Notwithstanding the foregoing, Consultant agrees to take all reasonable
precautions to prevent any unauthorized use or disclosure of any information that may constitute Company confidential information
to any parties other than the Government Agencies. Consultant further understands that &ldquo;<B><I>Protected Activity</I></B>&rdquo;
does not include the disclosure of any Company attorney-client privileged communications. Pursuant to the Defend Trade Secrets
Act of 2016, Consultant is notified that an individual will not be held criminally or civilly liable under any federal or state
trade secret law for the disclosure of a trade secret that (i) is made in confidence to a federal, state, or local government
official (directly or indirectly) or to an attorney <I>solely</I> for the purpose of reporting or investigating a suspected violation
of law, or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if (and only if) such filing
is made under seal. In addition, an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation
of law may disclose the trade secret to the individual&rsquo;s attorney and use the trade secret information in the court proceeding,
if the individual files any document containing the trade secret under seal and does not disclose the trade secret, except pursuant
to court order.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<I>signature
page follows</I>)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Parties hereto have executed this Consulting Agreement as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSULTANT</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Visionology,
    Inc.</B></FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Mark L. Baum</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Andrew R. Boll</I></FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
    L. Baum</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    R. Boll</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CFO</FONT></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 3.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    for Notice:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SERVICES
AND COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<B><I>Contact</I>.</B> Consultant&rsquo;s principal Company contact:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
<U>Andrew R. Boll_____________________</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
<U>CFO______________________________</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
<U>aboll@harrowinc.com_________________</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone:
<U>(615) 733-4731______________________</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<B><I>Services</I></B>. Consultant shall provide management advisory services to the Company relating to its establishment, financing
activities and other related services as may be requested from time to time by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<B><I>Compensation</I>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
Upon or shortly following commencement of Consultant&rsquo;s Services to the Company, and subject to the approval of the Company&rsquo;s
Board of Directors, the Company shall issue to Consultant 700,000 shares of the Company&rsquo;s common stock (&ldquo;<B><I>Common
Stock</I></B>&rdquo;), par value $0.001 per share (the &ldquo;<B><I>Shares</I></B>&rdquo;). The Shares shall be subject to the
terms and conditions of the Plan and a restricted stock award agreement between the Company and Consultant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
The Shares subject to the Restricted Stock Award shall vest upon the earliest of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    Change in Control (as defined in the Plan);</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date of any underwriting agreement between the Company and the underwriter(s) managing an initial public offering of Common
    Stock, pursuant to which the Common Stock is priced for initial public offering; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date of closing of a bona-fide equity financing with third party investors resulting in cash gross proceeds to the Company
    of at least $10,000,000 (the &ldquo;<B><I>Qualified Financing</I></B>&rdquo;);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
in any case of (1), (2) and (3), (each a &ldquo;<B><I>Vesting Event</I></B>&rdquo;), subject to Consultant&rsquo;s continuous
status as a Service Provider (as defined in the Plan) through the date of such Vesting Event; provided, however, in the event
Consultant&rsquo;s continuous status as a Service Provider is terminated by the Company (other than for Cause or by the Consultant
(as defined in the Plan)) prior to the completion of the Term (as defined in this Agreement), the Shares shall vest immediately
upon such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
All payments and benefits provided for under this Agreement are intended to be exempt from or otherwise comply with the requirements
of Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations and guidance thereunder (together, &ldquo;<B><I>Section
409A</I></B>&rdquo;), <FONT STYLE="background-color: white">so that none of the payments and benefits to be provided hereunder
will be subject to the additional tax imposed under Section 409A</FONT>, and any ambiguities or ambiguous terms herein will be
interpreted to be exempt or so comply. Each payment and benefit payable under this Agreement is intended to constitute a separate
payment for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations. In no event will the Company reimburse Consultant
for any taxes that may be imposed on Consultant as a result of Section 409A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
<B>Exhibit A</B> is accepted and agreed upon as of July 1, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSULTANT</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VISIONOLOGY,
    INC.</B></FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Mark L. Baum</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Andrew R. Boll</I></FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
    L. Baum</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    R. Boll</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CFO</FONT></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.58
<SEQUENCE>4
<FILENAME>ex10-58.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
10.58</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VISIONOLOGY,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSULTING
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Consulting Agreement (this &ldquo;<B><I>Agreement</I></B>&rdquo;) is made and entered into as of July 1, 2020 (the &ldquo;<B><I>Effective
Date</I></B>&rdquo;) by and between Visionology, Inc., a Delaware corporation with its principal place of business at 102 Woodmont
Blvd., Suite 610, Nashville, TN 37205 (the &ldquo;<B><I>Company</I></B>&rdquo;), and Andrew Boll, an individual with a principal
place of business at 102 Woodmont Blvd., Suite 610, Nashville, TN 37205 (&ldquo;<B><I>Consultant</I></B>&rdquo;) (each herein
referred to individually as a &ldquo;<B><I>Party</I></B>,&rdquo; or collectively as the &ldquo;<B><I>Parties</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company desires to retain Consultant as an independent contractor to perform consulting services for the Company, and Consultant
is willing to perform such services, on the terms described below. In consideration of the mutual promises contained herein, the
Parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
Services and Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consultant
shall perform the services described in <B>Exhibit A</B> (the &ldquo;<B><I>Services</I></B>&rdquo;) for the Company (or its designee),
and the Company agrees to pay Consultant the compensation described in <B>Exhibit A</B> for Consultant&rsquo;s performance of
the Services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Confidentiality</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
<B><I>Definition of Confidential Information</I>.</B> &ldquo;<B><I>Confidential Information</I></B>&rdquo; means any information
(including any and all combinations of individual items of information) that relates to the actual or anticipated business and/or
products, research or development of the Company, its affiliates or subsidiaries, or to the Company&rsquo;s, its affiliates&rsquo;
or subsidiaries&rsquo; technical data, trade secrets, or know-how, including, but not limited to, research, product plans, or
other information regarding the Company&rsquo;s, its affiliates&rsquo; or subsidiaries&rsquo; products or services and markets
therefor, customer lists and customers (including, but not limited to, customers of the Company on whom Consultant called or with
whom Consultant became acquainted during the term of this Agreement), software, developments, inventions, discoveries, ideas,
processes, formulas, technology, designs, drawings, engineering, hardware configuration information, marketing, finances, and
other business information disclosed by the Company, its affiliates or subsidiaries, either directly or indirectly, in writing,
orally or by drawings or inspection of premises, parts, equipment, or other property of Company, its affiliates or subsidiaries.
Notwithstanding the foregoing, Confidential Information shall not include any such information which Consultant can establish
(i) was publicly known or made generally available prior to the time of disclosure to Consultant; (ii) becomes publicly known
or made generally available after disclosure to Consultant through no wrongful action or inaction of Consultant; or (iii) is in
the rightful possession of Consultant, without confidentiality obligations, at the time of disclosure as shown by Consultant&rsquo;s
then-contemporaneous written records; provided that any combination of individual items of information shall not be deemed to
be within any of the foregoing exceptions merely because one or more of the individual items are within such exception, unless
the combination as a whole is within such exception.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
<B><I>Nonuse and Nondisclosure</I>.</B> During and after the term of this Agreement, Consultant will hold in the strictest confidence,
and take all reasonable precautions to prevent any unauthorized use or disclosure of Confidential Information, and Consultant
will not (i) use the Confidential Information for any purpose whatsoever other than as necessary for the performance of the Services
on behalf of the Company, or (ii) subject to Consultant&rsquo;s right to engage in Protected Activity (as defined below), disclose
the Confidential Information to any third party without the prior written consent of an authorized representative of the Company,
except that Consultant may disclose Confidential Information to the extent compelled by applicable law; <I>provided however</I>,
prior to such disclosure, Consultant shall provide prior written notice to Company and seek a protective order or such similar
confidential protection as may be available under applicable law. Consultant agrees that no ownership of Confidential Information
is conveyed to the Consultant. Without limiting the foregoing, Consultant shall not use or disclose any Company property, intellectual
property rights, trade secrets or other proprietary know-how of the Company to invent, author, make, develop, design, or otherwise
enable others to invent, author, make, develop, or design identical or substantially similar designs as those developed under
this Agreement for any third party. Consultant agrees that Consultant&rsquo;s obligations under this Section 2.B shall continue
after the termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
<B><I>Other Client Confidential Information</I>.</B> Consultant agrees that Consultant will not improperly use, disclose, or induce
the Company to use any proprietary information or trade secrets of any former or current employer of Consultant or other person
or entity with which Consultant has an obligation to keep in confidence. Consultant also agrees that Consultant will not bring
onto the Company&rsquo;s premises or transfer onto the Company&rsquo;s technology systems any unpublished document, proprietary
information, or trade secrets belonging to any third party unless disclosure to, and use by, the Company has been consented to
in writing by such third party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.
<B><I>Third Party Confidential Information</I>.</B> Consultant recognizes that the Company has received and in the future will
receive from third parties their confidential or proprietary information subject to a duty on the Company&rsquo;s part to maintain
the confidentiality of such information and to use it only for certain limited purposes. Consultant agrees that at all times during
the term of this Agreement and thereafter, Consultant owes the Company and such third parties a duty to hold all such confidential
or proprietary information in the strictest confidence and not to use it or to disclose it to any person, firm, corporation, or
other third party except as necessary in carrying out the Services for the Company consistent with the Company&rsquo;s agreement
with such third party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
Ownership</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
<B><I>Assignment of Inventions</I>.</B> Consultant agrees that all right, title, and interest in and to any copyrightable material,
notes, records, drawings, designs, inventions, improvements, developments, discoveries, ideas and trade secrets conceived, discovered,
authored, invented, developed or reduced to practice by Consultant, solely or in collaboration with others, during the term of
this Agreement and arising out of, or in connection with, performing the Services under this Agreement and any copyrights, patents,
trade secrets, mask work rights or other intellectual property rights relating to the foregoing (collectively, &ldquo;<B><I>Inventions</I></B>&rdquo;),
are the sole property of the Company. Consultant also agrees to promptly make full written disclosure to the Company of any Inventions
and to deliver and assign (or cause to be assigned) and hereby irrevocably assigns fully to the Company all right, title and interest
in and to the Inventions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
<B><I>Pre-Existing Material</I>s.</B> Subject to Section 3.A, Consultant will provide the Company with prior written notice if,
in the course of performing the Services, Consultant incorporates into any Invention or utilizes in the performance of the Services
any invention, discovery, idea, original works of authorship, development, improvements, trade secret, concept, or other proprietary
information or intellectual property right owned by Consultant or in which Consultant has an interest, prior to, or separate from,
performing the Services under this Agreement (&ldquo;<B><I>Prior Inventions</I></B>&rdquo;), and the Company is hereby granted
a nonexclusive, royalty-free, perpetual, irrevocable, transferable, worldwide license (with the right to grant and authorize sublicenses)
to make, have made, use, import, offer for sale, sell, reproduce, distribute, modify, adapt, prepare derivative works of, display,
perform, and otherwise exploit such Prior Inventions, without restriction, including, without limitation, as part of or in connection
with such Invention, and to practice any method related thereto. Consultant will not incorporate any invention, discovery, idea,
original works of authorship, development, improvements, trade secret, concept, or other proprietary information or intellectual
property right owned by any third party into any Invention without Company&rsquo;s prior written permission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
<B><I>Moral Rights</I>.</B> Any assignment to the Company of Inventions includes all rights of attribution, paternity, integrity,
modification, disclosure and withdrawal, and any other rights throughout the world that may be known as or referred to as &ldquo;moral
rights,&rdquo; &ldquo;artist&rsquo;s rights,&rdquo; &ldquo;droit moral,&rdquo; or the like (collectively, &ldquo;<B><I>Moral Rights</I></B>&rdquo;).
To the extent that Moral Rights cannot be assigned under applicable law, Consultant hereby waives and agrees not to enforce any
and all Moral Rights, including, without limitation, any limitation on subsequent modification, to the extent permitted under
applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.
<B><I>Maintenance of Records</I>.</B> Consultant agrees to keep and maintain adequate, current, accurate, and authentic written
records of all Inventions made by Consultant (solely or jointly with others) during the term of this Agreement, and for a period
of three (3) years thereafter. The records will be in the form of notes, sketches, drawings, electronic files, reports, or any
other format that is customary in the industry and/or otherwise specified by the Company. Such records are and remain the sole
property of the Company at all times and upon Company&rsquo;s request, Consultant shall deliver (or cause to be delivered) the
same.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.
<B><I>Further Assurances</I>.</B> Consultant agrees to assist Company, or its designee, at the Company&rsquo;s expense, in every
proper way to secure the Company&rsquo;s rights in Inventions in any and all countries, including the disclosure to the Company
of all pertinent information and data with respect thereto, the execution of all applications, specifications, oaths, assignments
and all other instruments that the Company may deem necessary in order to apply for, register, obtain, maintain, defend, and enforce
such rights, and in order to deliver, assign and convey to the Company, its successors, assigns and nominees the sole and exclusive
right, title, and interest in and to all Inventions and testifying in a suit or other proceeding relating to such Inventions.
Consultant further agrees that Consultant&rsquo;s obligations under this Section 3.E shall continue after the termination of this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.
<B><I>Attorney-in-Fact</I>.</B> Consultant agrees that, if the Company is unable because of Consultant&rsquo;s unavailability,
dissolution, mental or physical incapacity, or for any other reason, to secure Consultant&rsquo;s signature with respect to any
Inventions, including, without limitation, for the purpose of applying for or pursuing any application for any United States or
foreign patents or mask work or copyright registrations covering the Inventions assigned to the Company in Section 3.A, then Consultant
hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as Consultant&rsquo;s agent
and attorney-in-fact, to act for and on Consultant&rsquo;s behalf to execute and file any papers and oaths and to do all other
lawfully permitted acts with respect to such Inventions to further the prosecution and issuance of patents, copyright and mask
work registrations with the same legal force and effect as if executed by Consultant. This power of attorney shall be deemed coupled
with an interest, and shall be irrevocable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
Conflicting Obligations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
Consultant represents and warrants that Consultant has no agreements, relationships, or commitments to any other person or entity
that conflict with the provisions of this Agreement, Consultant&rsquo;s obligations to the Company under this Agreement, and/or
Consultant&rsquo;s ability to perform the Services. Consultant will not enter into any such conflicting agreement during the term
of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
Return of Company Materials</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the termination of this Agreement, or upon Company&rsquo;s earlier request, Consultant will immediately deliver to the Company,
and will not keep in Consultant&rsquo;s possession, recreate, or deliver to anyone else, any and all Company property, including,
but not limited to, Confidential Information, tangible embodiments of the Inventions, all devices and equipment belonging to the
Company, all electronically-stored information and passwords to access such property, those records maintained pursuant to Section
3.D and any reproductions of any of the foregoing items that Consultant may have in Consultant&rsquo;s possession or control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.
Term and Termination</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
<B><I>Term</I>.</B> Consultant commenced providing Services to the Company on or about December 1, 2019 and shall provide the
Services through the earlier of (i) one year from the Effective Date, (ii) a Change in Control (as defined in the Company&rsquo;s
2020 Equity Incentive Plan (the &ldquo;<B><I>Plan</I></B>&rdquo;)), (iii) the date of any underwriting agreement between the Company
and the underwriter(s) managing an initial public offering of Common Stock (as defined in the Plan), pursuant to which the Common
Stock is priced for an initial public offering, (iv) a Qualified Financing (as defined in Exhibit A attached hereto) or (v) such
earlier date as the Services are terminated by the Company or Consultant as provided in Section 6.B (the &ldquo;<B><I>Term</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
<B><I>Termination</I>.</B> The Company may terminate this Agreement upon giving Consultant fourteen (14) days prior written notice
of such termination pursuant to Section 12.G of this Agreement. The Company may terminate this Agreement immediately and without
prior notice if Consultant refuses to or is unable to perform the Services or is in breach of any material provision of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
<B><I>Survival</I>.</B> Upon any termination, all rights and duties of the Company and Consultant toward each other shall cease
except:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The Company will pay, within thirty (30) days after the effective date of termination, all amounts owing to Consultant for Services
completed and accepted by the Company prior to the termination date and related reimbursable expenses, if any, submitted in accordance
with the Company&rsquo;s policies and in accordance with the provisions of Section 1 of this Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Section 2 (Confidentiality), Section 3 (Ownership), Section 5 (Return of Company Materials), Section 6 (Term and Termination),
Section 7 (Independent Contractor; Benefits), Section 8 (Indemnification), Section 9 (Nonsolicitation), Section 10 (Limitation
of Liability), Section 11 (Dispute Resolution), and Section 12 (Miscellaneous) will survive termination or expiration of this
Agreement in accordance with their terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.
Independent Contractor; Benefits</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
<B><I>Independent Contractor.</I></B> It is the express intention of the Company and Consultant that Consultant perform the Services
as an independent contractor to the Company. Nothing in this Agreement shall in any way be construed to constitute Consultant
as an agent, employee or representative of the Company. Without limiting the generality of the foregoing, Consultant is not authorized
to bind the Company to any liability or obligation or to represent that Consultant has any such authority. Consultant agrees to
furnish (or reimburse the Company for) all tools and materials necessary to accomplish this Agreement and shall incur all expenses
associated with performance. Consultant acknowledges and agrees that Consultant is obligated to report as income all compensation
received by Consultant pursuant to this Agreement. Consultant agrees to and acknowledges the obligation to pay all self-employment
and other taxes on such income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
<B><I>Benefits</I>.</B> The Company and Consultant agree that Consultant will receive no Company-sponsored benefits from the Company
such as, but not limited to, paid vacation, sick leave, medical insurance and 401k participation; provided, however, that Consultant
shall be eligible for awards granted under the Plan. If Consultant is reclassified by a state or federal agency or court as the
Company&rsquo;s employee, Consultant will become a reclassified employee and will receive no benefits from the Company, except
those mandated by state or federal law, even if by the terms of the Company&rsquo;s benefit plans or programs of the Company in
effect at the time of such reclassification, Consultant would otherwise be eligible for such benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.
Indemnification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consultant
agrees to indemnify and hold harmless the Company and its affiliates and their directors, officers and employees from and against
all taxes, losses, damages, liabilities, costs and expenses, including attorneys&rsquo; fees and other legal expenses, arising
directly or indirectly from or in connection with (i) any negligent, reckless or intentionally wrongful act of Consultant, (ii)
a determination by a court or agency that the Consultant is not an independent contractor, (iii) any breach by the Consultant
of any of the covenants contained in this Agreement, (iv) any failure of Consultant to perform the Services in accordance with
all applicable laws, rules and regulations, or (v) any violation or claimed violation of a third party&rsquo;s rights resulting
in whole, or in part, from the Company&rsquo;s use of the Inventions or other deliverables of Consultant under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.
Nonsolicitation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the fullest extent permitted under applicable law, from the date of this Agreement until twelve (12) months after the termination
of this Agreement for any reason, Consultant will not, without the Company&rsquo;s prior written consent, directly or indirectly,
solicit any of the Company&rsquo;s employees to leave their employment, or attempt to solicit employees of the Company, either
for Consultant or for any other person or entity. Consultant agrees that nothing in this Section 9 shall affect Consultant&rsquo;s
continuing obligations under this Agreement during and after this twelve (12) month period, including, without limitation, Consultant&rsquo;s
obligations under Section 2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
Limitation of Liability</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
NO EVENT SHALL COMPANY BE LIABLE TO CONSULTANT OR TO ANY OTHER PARTY FOR ANY INDIRECT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES,
OR DAMAGES FOR LOST PROFITS OR LOSS OF BUSINESS, HOWEVER CAUSED AND UNDER ANY THEORY OF LIABILITY, WHETHER BASED IN CONTRACT,
TORT (INCLUDING NEGLIGENCE) OR OTHER THEORY OF LIABILITY, REGARDLESS OF WHETHER COMPANY WAS ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES AND NOTWITHSTANDING THE FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY. IN NO EVENT SHALL COMPANY&rsquo;S LIABILITY
ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT EXCEED THE AMOUNTS PAID BY COMPANY TO CONSULTANT UNDER THIS AGREEMENT FOR
THE SERVICES, DELIVERABLES OR INVENTION GIVING RISE TO SUCH LIABILITY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.
Dispute Resolution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
controversy, dispute or claim arising out of or relating to this Agreement or the breach or alleged breach hereof, including whether
the controversy, dispute or claim is arbitrable (each, a &ldquo;<B><I>Dispute</I></B>&rdquo;), shall be resolved by submitting
such Dispute to binding arbitration administered by the American Health Lawyers Association Dispute Resolution Services or its
successor (&ldquo;<B><I>AHLA</I></B>&rdquo;) and held in Nashville, Tennessee, and judgment on the arbitration award may be entered
in any court having jurisdiction thereof. The arbitration will be conducted in accordance with applicable AHLA rules and procedures
before a single arbitrator selected and appointed in accordance with such rules. Each party will bear and pay equally the fees
and expenses of AHLA (including the fees and expenses of the arbitrator), and each party will bear its own attorneys&rsquo; fees,
costs and other expenses; <I>provided, however</I>, that the arbitrator may award reasonable attorneys&rsquo; fees and expenses
to the prevailing party as contemplated in Section 12.H. Any arbitration will be governed by the Federal Arbitration Act (9 U.S.C.
&sect;&sect; 1 <I>et seq.</I>). The provisions of this Section 11 shall survive expiration or other termination of this Agreement
regardless of the cause of such expiration or termination, and shall not restrict the right of the parties hereto to institute
a proceeding in any court of law or equity to enable such party to obtain or otherwise seek injunctive relief, specific performance
or other equitable remedies during the pendency of any arbitration or without submitting such matter to arbitration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.
Miscellaneous</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
<B><I>Governing Law; Consent to Personal Jurisdiction and Venue; Waiver of Trial by Jury</I>.</B> This Agreement shall be governed
by the laws of the State of Delaware, without regard to the conflicts of law provisions of any jurisdiction. To the extent that
any lawsuit is permitted under this Agreement, the Parties hereby expressly consent to the personal and exclusive jurisdiction
and venue of the state and federal courts located in Nashville, Tennessee. Each party hereby waives any objection to the personal
or subject matter jurisdiction and venue of such courts. EACH PARTY HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE
LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY DISPUTE, ACTION OR CLAIM ARISING OUT OF THIS AGREEMENT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
<B><I>Assignability</I>.</B> This Agreement will be binding upon Consultant&rsquo;s heirs, executors, assigns, administrators,
and other legal representatives, and will be for the benefit of the Company, its successors, and its assigns. There are no intended
third-party beneficiaries to this Agreement, except as expressly stated. Except as may otherwise be provided in this Agreement,
Consultant may not sell, assign or delegate any rights or obligations under this Agreement. Notwithstanding anything to the contrary
herein, Company may assign this Agreement and its rights and obligations under this Agreement to any successor to all or substantially
all of Company&rsquo;s relevant assets, whether by merger, consolidation, reorganization, reincorporation, sale of assets or stock,
change of control or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
<B><I>Entire Agreement</I>.</B> This Agreement constitutes the entire agreement and understanding between the Parties with respect
to the subject matter herein and supersedes all prior written and oral agreements, discussions, or representations between the
Parties. Consultant represents and warrants that Consultant is not relying on any statement or representation not contained in
this Agreement. To the extent any terms set forth in any exhibit or schedule conflict with the terms set forth in this Agreement,
the terms of this Agreement shall control unless otherwise expressly agreed by the Parties in such exhibit or schedule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.
<B><I>Headings</I>.</B> Headings are used in this Agreement for reference only and shall not be considered when interpreting this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.
<B><I>Severability</I>.</B> If a court or other body of competent jurisdiction finds, or the Parties mutually believe, any provision
of this Agreement, or portion thereof, to be invalid or unenforceable, such provision will be enforced to the maximum extent permissible
so as to effect the intent of the Parties, and the remainder of this Agreement will continue in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.
<B><I>Modification, Waiver.</I></B> No modification of or amendment to this Agreement, nor any waiver of any rights under this
Agreement, will be effective unless in a writing signed by the Parties. Waiver by the Company of a breach of any provision of
this Agreement will not operate as a waiver of any other or subsequent breach.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.
<B><I>Notices</I>.</B> Any notice or other communication required or permitted by this Agreement to be given to a Party shall
be in writing and shall be deemed given (i) if delivered personally or by commercial messenger or courier service, (ii) when sent
by confirmed facsimile, or (iii) if mailed by U.S. registered or certified mail (return receipt requested), to the Party at the
Party&rsquo;s address written below or at such other address as the Party may have previously specified by like notice. If by
mail, delivery shall be deemed effective three business days after mailing in accordance with this Section 12.G.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
If to the Company, to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Visionology,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">102
Woodmont Blvd., Suite 610</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nashville,
TN 37205</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
If to Consultant, to the address for notice on the signature page to this Agreement or, if no such address is provided, to the
last address of Consultant provided by Consultant to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.
<B><I>Attorneys&rsquo; Fees</I>.</B> In any court action at law or equity that is brought by one of the Parties to this Agreement
to enforce or interpret the provisions of this Agreement, the prevailing Party will be entitled to reasonable attorneys&rsquo;
fees, in addition to any other relief to which that Party may be entitled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.
<B><I>Signatures.</I></B> This Agreement may be signed in two counterparts, each of which shall be deemed an original, with the
same force and effectiveness as though executed in a single document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.
<B><I>Applicability to Past Activities.</I></B> Consultant agrees that if and to the extent that Consultant provided any services
or made efforts on behalf of or for the benefit of Company, or related to the current or prospective business of Company in anticipation
of Consultant&rsquo;s involvement with the Company, that would have been &ldquo;Services&rdquo; if performed during the term of
this Agreement (the &ldquo;<B><I>Prior Consulting Period</I></B>&rdquo;) and to the extent that during the Prior Consulting Period:
(i) Consultant received access to any information from or on behalf of Company that would have been &ldquo;Confidential Information&rdquo;
if Consultant received access to such information during the term of this Agreement; or (ii) Consultant (a) conceived, created,
authored, invented, developed or reduced to practice any item (including any intellectual property rights with respect thereto)
on behalf of or for the benefit of Company, or related to the current or prospective business of Company in anticipation of Consultant&rsquo;s
involvement with Company, that would have been an Invention if conceived, created, authored, invented, developed or reduced to
practice during the term of this Agreement; or (b) incorporated into any such item any pre-existing invention, improvement, development,
concept, discovery or other proprietary information that would have been a Prior Invention if incorporated into such item during
the term of this Agreement; then any such information shall be deemed Confidential Information hereunder and any such item shall
be deemed an Invention or Prior Invention hereunder, and this Agreement shall apply to such activities, information or item as
if disclosed, conceived, created, authored, invented, developed or reduced to practice during the term of this Agreement. Consultant
further acknowledges that Consultant has been fully compensated for all services provided during any such Prior Consulting Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">K.
<B><I>Protected Activity Not Prohibited.</I></B> Consultant understands that nothing in this Agreement shall in any way limit
or prohibit Consultant from engaging in any Protected Activity. For purposes of this Agreement, &ldquo;<B><I>Protected Activity</I></B>&rdquo;
shall mean filing a charge, complaint, or report with, or otherwise communicating, cooperating, or participating in any investigation
or proceeding that may be conducted by, any federal, state or local government agency or commission, including the Securities
and Exchange Commission (&ldquo;<B><I>Government Agencies</I></B>&rdquo;). Consultant understands that in connection with such
Protected Activity, Consultant is permitted to disclose documents or other information as permitted by law, and without giving
notice to, or receiving authorization from, the Company. Notwithstanding the foregoing, Consultant agrees to take all reasonable
precautions to prevent any unauthorized use or disclosure of any information that may constitute Company confidential information
to any parties other than the Government Agencies. Consultant further understands that &ldquo;<B><I>Protected Activity</I></B>&rdquo;
does not include the disclosure of any Company attorney-client privileged communications. Pursuant to the Defend Trade Secrets
Act of 2016, Consultant is notified that an individual will not be held criminally or civilly liable under any federal or state
trade secret law for the disclosure of a trade secret that (i) is made in confidence to a federal, state, or local government
official (directly or indirectly) or to an attorney <I>solely</I> for the purpose of reporting or investigating a suspected violation
of law, or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if (and only if) such filing
is made under seal. In addition, an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation
of law may disclose the trade secret to the individual&rsquo;s attorney and use the trade secret information in the court proceeding,
if the individual files any document containing the trade secret under seal and does not disclose the trade secret, except pursuant
to court order.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<I>signature
page follows</I>)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Parties hereto have executed this Consulting Agreement as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSULTANT</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Visionology,
    Inc.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Andrew Boll</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Mark Baum</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    Boll</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
    Baum</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 3.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    for Notice:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SERVICES
AND COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<B><I>Contact</I>.</B> Consultant&rsquo;s principal Company contact:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
<U>Mark Baum____________</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
<U>CEO__________________</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
<U>mark@harrowinc.com_____</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone:
<U>(615) 733-4733__________</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<B><I>Services</I></B>. Consultant shall provide management advisory services to the Company relating to its establishment, financing
activities and other related services as may be requested from time to time by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<B><I>Compensation</I>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
Upon or shortly following commencement of Consultant&rsquo;s Services to the Company, and subject to the approval of the Company&rsquo;s
Board of Directors, the Company shall issue to Consultant 350,000 shares of the Company&rsquo;s common stock (&ldquo;<B><I>Common
Stock</I></B>&rdquo;), par value $0.001 per share (the &ldquo;<B><I>Shares</I></B>&rdquo;). The Shares shall be subject to the
terms and conditions of the Plan and a restricted stock award agreement between the Company and Consultant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
The Shares subject to the Restricted Stock Award shall vest upon the earliest of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    Change in Control (as defined in the Plan);</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date of any underwriting agreement between the Company and the underwriter(s) managing an initial public offering of Common
    Stock, pursuant to which the Common Stock is priced for initial public offering; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    date of closing of a bona-fide equity financing with third party investors resulting in cash gross proceeds to the Company
    of at least $10,000,000 (the &ldquo;<B><I>Qualified Financing</I></B>&rdquo;);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
in any case of (1), (2) and (3), (each a &ldquo;<B><I>Vesting Event</I></B>&rdquo;), subject to Consultant&rsquo;s continuous
status as a Service Provider (as defined in the Plan) through the date of such Vesting Event; provided, however, in the event
Consultant&rsquo;s continuous status as a Service Provider is terminated by the Company (other than for Cause or by the Consultant
(as defined in the Plan)) prior to the completion of the Term (as defined in this Agreement), the Shares shall vest immediately
upon such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
All payments and benefits provided for under this Agreement are intended to be exempt from or otherwise comply with the requirements
of Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations and guidance thereunder (together, &ldquo;<B><I>Section
409A</I></B>&rdquo;), <FONT STYLE="background-color: white">so that none of the payments and benefits to be provided hereunder
will be subject to the additional tax imposed under Section 409A</FONT>, and any ambiguities or ambiguous terms herein will be
interpreted to be exempt or so comply. Each payment and benefit payable under this Agreement is intended to constitute a separate
payment for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations. In no event will the Company reimburse Consultant
for any taxes that may be imposed on Consultant as a result of Section 409A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
<B>Exhibit A</B> is accepted and agreed upon as of July 1, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CONSULTANT</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VISIONOLOGY,
    INC.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 44%"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Andrew Boll</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Mark Baum</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    Boll</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
    Baum</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.60
<SEQUENCE>5
<FILENAME>ex10-60.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 10.60</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD ROWSPAN="6" STYLE="text-align: left; width: 65%"><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                         <P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="ex10-60_001.jpg" ALT="" STYLE="height: 54px; width: 240px"></P></TD>
    <TD STYLE="border-left: Black 1.5pt solid; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12264
    El Camino Real</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Suite
    350 </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">San
    Diego, CA 92130 </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Main:
    844.446.6979 </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Facsimile:
    858.345.1745 </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1.5pt solid; font: 11pt/115% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">www.imprimisrx.com</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 12, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VIA
EMAIL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EyePoint
Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">480
Pleasant Street</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suite
B300</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Watertown,
Massachusetts 02472</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Nancy Lurker</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
nlurker@eyepointpharma.com</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment
    One to the Commercial Alliance Agreement</FONT></TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Ms. Lurker:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EyePoint
Pharmaceuticals, Inc. (&ldquo;<B>EyePoint</B>&rdquo;) and ImprimisRx, LLC (&ldquo;<B>Imprimis</B>&rdquo;) have entered into a
Commercial Alliance Agreement effective as of August 1, 2020 (the &ldquo;<B>Agreement</B>&rdquo;). Capitalized terms used but
not defined in this letter have their respective meanings set forth in the Agreement. All changes to the Agreement described below
shall be effective as of October 1, 2020. For good and valuable consideration, the sufficiency of which is hereby acknowledged,
the Parties hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Changes
to the Agreement</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything to the contrary in the Agreement, the terms of this letter describe (a) the distinction between Customers and EyePoint
Accounts, (b) the Baseline Period and (c) certain definitions and provisions related to the term of the Agreement and the timing
of Imprimis&rsquo; obligations and minimum sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                         Group A Customers, Group B Customers, and Group 2 (Exhibit D) are Customers under the
                                         Agreement. Section 1.1.11 is thus amended and replaced with the following:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;<U>Customers</U>&rdquo;
means, collectively, (a) the Group A Customers, (b) the Group B Customers, (c) Group 2 (Referred to in Exhibit D and specifically
in Exhibit F to this Amendment One to the Commercial Alliance Agreement) and (c) if added to this Agreement pursuant to Section
3.4, any other such Third Party.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I><IMG SRC="ex10-60_002.jpg" ALT="" STYLE="height: 111px; width: 200px"></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                         mutually agreed by the Parties, EyePoint has identified certain customer accounts to
                                         be EyePoint growth accounts that are not and will not be &ldquo;Customers&rdquo; under
                                         the Agreement and for which Imprimis will receive no Remittance Amount unless otherwise
                                         agreed by the Parties in writing. These accounts consist fifty-one (51) Imprimis customers
                                         for products other than for steroid products for injectable administration and one hundred
                                         twelve (112) accounts that are not currently purchasing any products from Imprimis (collectively,
                                         &ldquo;EyePoint Accounts&rdquo;). The EyePoint Accounts are set forth on <I>Exhibit E
                                         </I>attached to this Amendment One to the Commercial Alliance Agreement. For purposes
                                         of clarity and the avoidance of doubt, if a surgeon uses a Product that was purchased
                                         by an Exhibit E EyePoint Account, the Remittance Percentage for such Product shall be
                                         zero.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                         Imprimis customer that is not a Customer and is not using Product purchased by an EyePoint
                                         Account (i) may be added as a Customer to the Agreement pursuant to Section 3.4 (in the
                                         event of a bona fide inquiry received by Imprimis for sale of a Product from a Third
                                         Party that is not an existing Customer or an EyePoint Account) or, in all other cases,
                                         (ii) may be added either as a Customer or as an EyePoint Account, as shall be determined
                                         in good faith by the Commercialization Committee.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Parties agree to simplify the calculation for the &ldquo;Baseline Period.&rdquo; Accordingly,
                                         Section 1.1.3 is amended and replaced with the following:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Baseline
                                         Period</U>&rdquo; means (a) with respect to the Group A Customers, the Group B Customers
                                         and the Group C Customers, the non-consecutive [***] period consisting of [***], and
                                         (b) with respect to any other Customer, such [***]period as determined by the Commercialization
                                         Committee pursuant to Section 7.1.2.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                         Imprimis achieves bona fide Customer orders (i.e., Customer Demand in excess of Baseline
                                         Demand) for [***] or more units of Product in the aggregate from the Effective Date through
                                         [***] (the &ldquo;[***] Threshold&rdquo;), then three months shall be added to the first
                                         Minimum Year. If the [***] Threshold is achieved, the definition of &ldquo;Minimum Year&rdquo;
                                         shall be amended to read as follows: &ldquo;(a) the first [***] period of the Term and
                                         (b) beginning the first day of the calendar quarter immediately after such period, each
                                         successive one-year period thereafter during the Term.&rdquo; Otherwise, regardless of
                                         whether the [***] Threshold may be achieved, the definition of &ldquo;Minimum Year&rdquo;
                                         is hereby amended to read as follows: &ldquo;(a) the [***] period of the Term and (b)
                                         beginning the first day of the calendar quarter immediately after such period, each successive
                                         one-year period thereafter during the Term.&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three
                                         months is added to the end of the Term. The Term commenced on the Effective Date (August
                                         1, 2020) and now expires on November 1, 2025. Section 13.1 is amended accordingly.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Additional
Terms</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Imprimis
understands that EyePoint may need to hire additional employees to ramp up production and sales of the Product. Imprimis also
understands that in order to support the growth of Imprimis&rsquo; sales of the Product, Imprimis will likely need to hire additional
employees, including employees focused on reimbursement matters and Customer training. Subject to the Parties&rsquo; mutual written
agreement, Imprimis will cover all or a substantial portion of these costs and will discuss the details in the Commercialization
Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to Group 2 (Exhibit D), the Parties agree that these are &ldquo;overlap accounts&rdquo; and that they shall collaboratively
work to determine sales tactics to sell Products to these accounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Imprimis
understands that EyePoint makes samples and training units of the Product available to Customers. Imprimis agrees that EyePoint
will have the right to deduct from the Remittance Amount an amount equal to EyePoint&rsquo;s cost (from its CMO and estimated
to be [***] per unit) for samples and training units of Product made available to Customers of Imprimis during each calendar quarter.
Any deductions for samples will not be included in the calculation of Net Sales and Net Selling Price associated with the Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Parties will engage in good faith discussions regarding EyePoint selling Imprimis products. This may include a commission rate
on those sales or a credit back to EyePoint based on Dexycu sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
letter will be governed by and construed under and in accordance with the laws of the State of Delaware, without regard to the
conflicts of laws principles thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the foregoing is acceptable to you, please sign and return one fully-executed copy of this letter to us at your earliest convenience,
which shall evidence your acknowledgement and acceptance thereto. This letter may be executed in counterparts, each of which shall
be deemed to be an original and together shall be deemed to be one and the same document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signature
Page Follows</I>.]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Very truly yours,</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ImprimisRx, LLC</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 45%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    John Saharek</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Saharek</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreed
    to and accepted:</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EyePoint
    Pharmaceuticals, Inc.</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 5%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 45%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 50%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Nancy Lurker</I></FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">Nancy Lurker</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">President &amp; CEO</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    </FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/13/2020</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><BR STYLE="clear: both"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>6
<FILENAME>ex21-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
21.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HARROW
HEALTH, INC. SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
of December 31, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    of Subsidiary</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>State
        of</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Incorporation
        or</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Organization</B></FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ImprimisRx,
    LLC</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Imprimis
    NJOF, LLC</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    Jersey</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ImprimisRx
    NJ, LLC</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    Jersey</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Park
    Compounding, Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">California</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harrow
    IP, LLC</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eton
    Pharma Equity, LLC</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Surface
    Pharma Equity, LLC</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melt
    Pharma Equity, LLC</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stowe
    Pharma Equity, LLC</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mayfield
    Pharma Equity, LLC</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Visionology
    Equity, LLC</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stowe
    Pharmaceuticals, Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radley
    Pharmaceuticals, Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mayfield
    Pharmaceuticals, Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Visionology,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Visionology
    MSO, Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in Registration Statement Nos. 333-159159, 333-183488, 333-198674 and 333-220186 on
Form S-8 and Registration Statement Nos. 333-215672 and 333-239669 on Form S-3 of our report dated March 8, 2021, relating to
the consolidated financial statements of Harrow Health, Inc. and subsidiaries, appearing in this Annual
Report on Form 10-K of Harrow Health, Inc. for the year ended December 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
KMJ Corbin &amp; Company LLP</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Irvine,
California</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
8, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">\</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CERTIFICATION
OF THE PRINCIPAL EXECUTIVE OFFICER UNDER</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
302 OF THE SARBANES-OXLEY ACT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Mark L. Baum, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Form 10-K for the fiscal year ended December 31, 2020 of Harrow Health, Inc.;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
    to the period covered by this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
    material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
    presented in this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
    and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
    defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
    our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in the report any change in this registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
    over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
    (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 8, 2021</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Mark L. Baum</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
    L. Baum</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CERTIFICATION
OF THE PRINCIPAL FINANCIAL OFFICER UNDER</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
302 OF THE SARBANES-OXLEY ACT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Andrew R. Boll, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Form 10-K for the fiscal year ended December 31, 2020 of Harrow Health, Inc.;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
    to the period covered by this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
    material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
    presented in this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
    and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
    defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
    our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in the report any change in this registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
    over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
    (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 50%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 8, 2021</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Andrew R. Boll</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    R. Boll</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HARROW
HEALTH, INC.<BR>
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Mark L. Baum, Chief Executive Officer of Harrow Health Inc. (the &ldquo;Company&rdquo;), do hereby certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
the Annual Report on Form 10-K of the Company for the annual period ended December 31, 2020 (the &ldquo;Report&rdquo;) fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 8, 2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Mark L. Baum</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
    L. Baum</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief
    Executive Officer</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing certification is being furnished as an exhibit to the Report pursuant to Item 601(b)(32) of Regulation S-K and Section
1350 of Title 18 of the United States Code and, accordingly, is not being filed with the U.S. Securities and Exchange Commission
as part of the Report and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933
or the Securities Exchange Act of 1934 (whether made before or after the date of the Report, irrespective of any general incorporation
language contained in such filing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>11
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HARROW
HEALTH, INC.<BR>
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Andrew R. Boll, Chief Financial Officer of Harrow Health Inc. (the &ldquo;Company&rdquo;), do hereby certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
the Annual Report on Form 10-K of the Company for the annual period ended December 31, 2020 (the &ldquo;Report&rdquo;) fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 8, 2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Andrew R. Boll</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
    R. Boll</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief
    Financial Officer</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing certification is being furnished as an exhibit to the Report pursuant to Item 601(b)(32) of Regulation S-K and Section
1350 of Title 18 of the United States Code and, accordingly, is not being filed with the U.S. Securities and Exchange Commission
as part of the Report and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933
or the Securities Exchange Act of 1934 (whether made before or after the date of the Report, irrespective of any general incorporation
language contained in such filing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ex10-60_001.jpg
<TEXT>
begin 644 ex10-60_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  _ 1@# 2(  A$! Q$!_\0
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MO^^!1]CMO^?>+_O@4)U5U7X@U2\_P/.OC?\ \B+!_P!?T?\ Z ]<S\!O^/\
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':BI/EV/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ex10-60_002.jpg
<TEXT>
begin 644 ex10-60_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "$ .T# 2(  A$! Q$!_\0
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MSA=F5:"A.R"BBBM3(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]5.:5U>P[.UQ]%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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(0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>hrow-20201231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWamLGbP9z5Z8SekhvWB3bSkqryIoB5SNSyfhTwDGwa4I -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:HROW="http://harrowinc.com/20201231" elementFormDefault="qualified" targetNamespace="http://harrowinc.com/20201231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://harrowinc.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
	  <link:definition>00000005 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/Organization" id="Organization">
	  <link:definition>00000007 - Disclosure - ORGANIZATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/Revenues" id="Revenues">
	  <link:definition>00000009 - Disclosure - REVENUES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactions" id="InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactions">
	  <link:definition>00000010 - Disclosure - INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactions" id="InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactions">
	  <link:definition>00000011 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/RestrictedCash" id="RestrictedCash">
	  <link:definition>00000012 - Disclosure - RESTRICTED CASH</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/Inventories" id="Inventories">
	  <link:definition>00000013 - Disclosure - INVENTORIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
	  <link:definition>00000014 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/PropertyPlantAndEquipment" id="PropertyPlantAndEquipment">
	  <link:definition>00000015 - Disclosure - PROPERTY, PLANT AND EQUIPMENT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/IntangibleAssetsAndGoodwill" id="IntangibleAssetsAndGoodwill">
	  <link:definition>00000016 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/AccountsPayableAndAccruedExpenses" id="AccountsPayableAndAccruedExpenses">
	  <link:definition>00000017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/Debt" id="Debt">
	  <link:definition>00000018 - Disclosure - DEBT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/Leases" id="Leases">
	  <link:definition>00000019 - Disclosure - LEASES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensation" id="StockholdersEquityAndStock-basedCompensation">
	  <link:definition>00000020 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000021 - Disclosure - INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/EmployeeSavingsPlan" id="EmployeeSavingsPlan">
	  <link:definition>00000022 - Disclosure - EMPLOYEE SAVINGS PLAN</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000023 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/SegmentInformationAndConcentrations" id="SegmentInformationAndConcentrations">
	  <link:definition>00000024 - Disclosure - SEGMENT INFORMATION AND CONCENTRATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000025 - Disclosure - SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/RevenuesTables" id="RevenuesTables">
	  <link:definition>00000028 - Disclosure - REVENUES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsTables" id="InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsTables">
	  <link:definition>00000029 - Disclosure - INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsTables" id="InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsTables">
	  <link:definition>00000030 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/InventoriesTables" id="InventoriesTables">
	  <link:definition>00000031 - Disclosure - INVENTORIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
	  <link:definition>00000032 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/PropertyPlantAndEquipmentTables" id="PropertyPlantAndEquipmentTables">
	  <link:definition>00000033 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/IntangibleAssetsAndGoodwillTables" id="IntangibleAssetsAndGoodwillTables">
	  <link:definition>00000034 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/AccountsPayableAndAccruedExpensesTables" id="AccountsPayableAndAccruedExpensesTables">
	  <link:definition>00000035 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/DebtTables" id="DebtTables">
	  <link:definition>00000036 - Disclosure - DEBT (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/LeasesTables" id="LeasesTables">
	  <link:definition>00000037 - Disclosure - LEASES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables" id="StockholdersEquityAndStock-basedCompensationTables">
	  <link:definition>00000038 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000039 - Disclosure - INCOME TAXES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/SegmentInformationAndConcentrationsTables" id="SegmentInformationAndConcentrationsTables">
	  <link:definition>00000040 - Disclosure - SEGMENT INFORMATION AND CONCENTRATIONS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfBasicEarningsPerCommonShareDetails" id="ScheduleOfBasicEarningsPerCommonShareDetails">
	  <link:definition>00000041 - Disclosure - SCHEDULE OF BASIC EARNINGS PER COMMON SHARE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails" id="ScheduleOfDilutedCommonEquivalentSharesDetails">
	  <link:definition>00000042 - Disclosure - SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfDilutedEarningsPerCommonShareDetails" id="ScheduleOfDilutedEarningsPerCommonShareDetails">
	  <link:definition>00000043 - Disclosure - SCHEDULE OF DILUTED EARNINGS PER COMMON SHARE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000044 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails" id="ScheduleOfDisaggregatedRevenueDetails">
	  <link:definition>00000045 - Disclosure - SCHEDULE OF DISAGGREGATED REVENUE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/RevenuesDetailsNarrative" id="RevenuesDetailsNarrative">
	  <link:definition>00000046 - Disclosure - REVENUES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails" id="ScheduleOfCondensedIncomeStatementDetails">
	  <link:definition>00000047 - Disclosure - SCHEDULE OF CONDENSED INCOME STATEMENT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails" id="ScheduleOfCondensedBalanceSheetDetails">
	  <link:definition>00000048 - Disclosure - SCHEDULE OF CONDENSED BALANCE SHEET (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative" id="InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative">
	  <link:definition>00000049 - Disclosure - INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails" id="SummaryOfCondensedIncomeStatementDetails">
	  <link:definition>00000050 - Disclosure - SUMMARY OF CONDENSED INCOME STATEMENT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails" id="SummaryOfCondensedBalanceSheetDetails">
	  <link:definition>00000051 - Disclosure - SUMMARY OF CONDENSED BALANCE SHEET (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative" id="InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative">
	  <link:definition>00000052 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/RestrictedCashDetailsNarrative" id="RestrictedCashDetailsNarrative">
	  <link:definition>00000053 - Disclosure - RESTRICTED CASH (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfInventoriesDetails" id="ScheduleOfInventoriesDetails">
	  <link:definition>00000054 - Disclosure - SCHEDULE OF INVENTORIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
	  <link:definition>00000055 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" id="ScheduleOfPropertyPlantAndEquipmentDetails">
	  <link:definition>00000056 - Disclosure - SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/PropertyPlantAndEquipmentDetailsNarrative" id="PropertyPlantAndEquipmentDetailsNarrative">
	  <link:definition>00000057 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails" id="ScheduleOfIntangibleAssetsDetails">
	  <link:definition>00000058 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" id="ScheduleOfAmortizationExpensesForIntangibleAssetsDetails">
	  <link:definition>00000059 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails" id="ScheduleOfEstimatedFutureAmortizationExpenseDetails">
	  <link:definition>00000060 - Disclosure - SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfGoodwillDetails" id="ScheduleOfGoodwillDetails">
	  <link:definition>00000061 - Disclosure - SCHEDULE OF GOODWILL (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" id="IntangibleAssetsAndGoodwillDetailsNarrative">
	  <link:definition>00000062 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" id="ScheduleOfAccountsPayableAndAccruedExpensesDetails">
	  <link:definition>00000063 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails" id="SummaryOfFutureMinimumPaymentsDetails">
	  <link:definition>00000064 - Disclosure - SUMMARY OF FUTURE MINIMUM PAYMENTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/DebtDetailsNarrative" id="DebtDetailsNarrative">
	  <link:definition>00000065 - Disclosure - DEBT (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails" id="ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails">
	  <link:definition>00000066 - Disclosure - SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails" id="ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails">
	  <link:definition>00000067 - Disclosure - SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
	  <link:definition>00000068 - Disclosure - LEASES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails" id="ScheduleOfStockOptionPlanActivityDetails">
	  <link:definition>00000069 - Disclosure - SCHEDULE OF STOCK OPTION PLAN ACTIVITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails" id="ScheduleOfFairValueAssumptionsDetails">
	  <link:definition>00000070 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails" id="ScheduleOfStockOptionOutstandingAndExercisableDetails">
	  <link:definition>00000071 - Disclosure - SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails" id="ScheduleOfRestrictedStockUnitsActivityDetails">
	  <link:definition>00000072 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" id="ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails">
	  <link:definition>00000073 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails" id="ScheduleOfWarrantsActivityDetails">
	  <link:definition>00000074 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" id="ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails">
	  <link:definition>00000075 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative" id="StockholdersEquityAndStock-basedCompensationDetailsNarrative">
	  <link:definition>00000076 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfProvisionForIncomeTaxesDetails" id="ScheduleOfProvisionForIncomeTaxesDetails">
	  <link:definition>00000077 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfIncomeTaxReconciliationDetails" id="ScheduleOfIncomeTaxReconciliationDetails">
	  <link:definition>00000078 - Disclosure - SCHEDULE OF INCOME TAX RECONCILIATION (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
	  <link:definition>00000079 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000080 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/EmployeeSavingsPlanDetailsNarrative" id="EmployeeSavingsPlanDetailsNarrative">
	  <link:definition>00000081 - Disclosure - EMPLOYEE SAVINGS PLAN (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000082 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails" id="ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails">
	  <link:definition>00000083 - Disclosure - SCHEDULE OF SEGMENT NET REVENUES, SEGMENT OPERATING EXPENSES AND SEGMENT CONTRIBUTION (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/SegmentInformationAndConcentrationsDetailsNarrative" id="SegmentInformationAndConcentrationsDetailsNarrative">
	  <link:definition>00000084 - Disclosure - SEGMENT INFORMATION AND CONCENTRATIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://harrowinc.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
	  <link:definition>00000085 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="hrow-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="hrow-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="hrow-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="hrow-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
    <element id="HROW_SurfaceOphthalmicsMember" name="SurfaceOphthalmicsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_MeltPharmaceuticalsMember" name="MeltPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ProductSalesNetMember" name="ProductSalesNetMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_OtherRevenuesMember" name="OtherRevenuesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_EtonPharmaceuticalsMember" name="EtonPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_MayfieldPharmaceuticalsIncMember" name="MayfieldPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_StowePharmaceuticalsIncMember" name="StowePharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_TGVHealthLLCMember" name="TGVHealthLLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_VisionologyMember" name="VisionologyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_EtonPharmaceuticalsIncMember" name="EtonPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_MeltPharmaceuticalsIncMember" name="MeltPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_SurfacePharmaceuticalsIncMember" name="SurfacePharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ParkCompoundingIncAndNoiceRxLLCMember" name="ParkCompoundingIncAndNoiceRxLLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_StockOptionsUnvestedRSUsAndWarrantsMember" name="StockOptionsUnvestedRSUsAndWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_StockOptionsMember" name="StockOptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CommissionsMember" name="CommissionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ManagementServicesAgreementMember" name="ManagementServicesAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_MSAMember" name="MSAMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_DrLindstromMember" name="DrLindstromMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_LicensesMember" name="LicensesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_NonCompetitionClauseMember" name="NonCompetitionClauseMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_StatePharmacyLicensesMember" name="StatePharmacyLicensesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember" name="CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ParkCompoundingIncMember" name="ParkCompoundingIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_PatentsFilingsAndTrademarksMember" name="PatentsFilingsAndTrademarksMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_TermLoanAndSecurityAgreementMember" name="TermLoanAndSecurityAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_SWKFundingLLCMember" name="SWKFundingLLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_SWKLoanAgreementMember" name="SWKLoanAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_LenderWarrantsMember" name="LenderWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_JoinderAndAmendmentMember" name="JoinderAndAmendmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_MarginRateMember" name="MarginRateMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_SWKSecondAmendmentMember" name="SWKSecondAmendmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_BusinessLoanAgreementMember" name="BusinessLoanAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_OfficeAndLaboratorySpaceMember" name="OfficeAndLaboratorySpaceMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_SanDiegoMember" name="SanDiegoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_LedgewoodMember" name="LedgewoodMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_NashvilleMember" name="NashvilleMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_IrvineMember" name="IrvineMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_RangeOneMember" name="RangeOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_RangeTwoMember" name="RangeTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CommonStockWarrantsOneMember" name="CommonStockWarrantsOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CommonStockWarrantsTwoMember" name="CommonStockWarrantsTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember" name="TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_StockOptionPlanOneMember" name="StockOptionPlanOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_StockOptionPlanMember" name="StockOptionPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_EmployeesAndConsultantMember" name="EmployeesAndConsultantMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_BaumPerformanceOptionMember" name="BaumPerformanceOptionMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_OptionsEmployeesMember" name="OptionsEmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_RangeThreeMember" name="RangeThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_RangeFourMember" name="RangeFourMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_EmployeesMember" name="EmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_BoardOfDirectorsMember" name="BoardOfDirectorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_UnvestedRSUMember" name="UnvestedRSUMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_EllePharmaceuticalLLCMember" name="EllePharmaceuticalLLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_MarkBaumCEOMember" name="MarkBaumCEOMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_AndrewBollCFOMember" name="AndrewBollCFOMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ConsultantMember" name="ConsultantMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_VisionologyIncMember" name="VisionologyIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_SellingGeneralAndAdministrativeMember" name="SellingGeneralAndAdministrativeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_SettlementWarrantsMember" name="SettlementWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_LenderWarrantsOneMember" name="LenderWarrantsOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_SettlementAgreementMember" name="SettlementAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_AllerganUSAIncMember" name="AllerganUSAIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_SalesAndMarketingAgreementsMember" name="SalesAndMarketingAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_KlarityLicenseAgreementMember" name="KlarityLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_RichardLLindstromMDMember" name="RichardLLindstromMDMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_InitialPaymentMember" name="InitialPaymentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_SecondPaymentMember" name="SecondPaymentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_FinalPaymentMember" name="FinalPaymentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_InjectableAssetPurchaseAgreementMember" name="InjectableAssetPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_PresbyopiaAssetPurchaseAgreementMember" name="PresbyopiaAssetPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_DexycuAgreementMember" name="DexycuAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_PharmaceuticalCompoundingMember" name="PharmaceuticalCompoundingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_PharmaceuticalDrugDevelopmentMember" name="PharmaceuticalDrugDevelopmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ThreeMainSuppliersMember" name="ThreeMainSuppliersMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_AndrewRBollMember" name="AndrewRBollMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_MarkLBaumMember" name="MarkLBaumMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_StockIssuedDuringPeriodForExerciseOfWarrants" name="StockIssuedDuringPeriodForExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_StockIssuedDuringPeriodSharesForExerciseOfWarrants" name="StockIssuedDuringPeriodSharesForExerciseOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_AmortizationOfIntangibleAsset" name="AmortizationOfIntangibleAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_AmortizationOfOperatingLeaseRightofuseAssets" name="AmortizationOfOperatingLeaseRightofuseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_GainLossOnInvestmentsOne" name="GainLossOnInvestmentsOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_GainLossOnInvestmentsTwo" name="GainLossOnInvestmentsTwo" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_GainLossOnInvestmentsThree" name="GainLossOnInvestmentsThree" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ImpairmentsOfLongLivedAssetsHeldForUse" name="ImpairmentsOfLongLivedAssetsHeldForUse" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_PaymentsOfCostsRelatedToAmendmentOfLoanPayable" name="PaymentsOfCostsRelatedToAmendmentOfLoanPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ProceedsFromExerciseOfWarrantsAndStockOptionsNetOfTaxes" name="ProceedsFromExerciseOfWarrantsAndStockOptionsNetOfTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract" name="ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod" name="CashCashEquivalentsAndRestrictedCashAtEndOfPeriod" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" name="PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_NewAndRevaluationOfRightofuseAssetObtainedInExchangeForLeaseObligation" name="NewAndRevaluationOfRightofuseAssetObtainedInExchangeForLeaseObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract" name="DisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock" name="InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_DisclosureRestrictedCashAbstract" name="DisclosureRestrictedCashAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_RestrictedCashTextBlock" name="RestrictedCashTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_RisksUncertaintiesAndLiquidityPolicyTextBlock" name="RisksUncertaintiesAndLiquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_NoncontrollingInterestPolicyTextBlock" name="NoncontrollingInterestPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CostOfSalePolicyTextBlock" name="CostOfSalePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_InvestmentOnePolicyTextBlock" name="InvestmentOnePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_InvestmentTwoPolicyTextBlock" name="InvestmentTwoPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_RestructuringPolicyTextBlock" name="RestructuringPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" name="RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock" name="ScheduleOfCondensedIncomeStatementOneTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock" name="ScheduleOfCondensedBalanceSheetOneTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ScheduleofWarrantsOutstandingAndExercisableTableTextBlock" name="ScheduleofWarrantsOutstandingAndExercisableTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_IncrementalCommonSharesAttributableDilutiveCommonEquivalents" name="IncrementalCommonSharesAttributableDilutiveCommonEquivalents" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ConsolidationBasisDescription" name="ConsolidationBasisDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_RetainedEarningsAccumulatedDeficit1" name="RetainedEarningsAccumulatedDeficit1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_NumberOfSharesOwned" name="NumberOfSharesOwned" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_RoyaltyPaymentPercentageOnNetSales" name="RoyaltyPaymentPercentageOnNetSales" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_FiniteLivedIntangibleAssetsImpairment" name="FiniteLivedIntangibleAssetsImpairment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_NotesPayableCurrent1" name="NotesPayableCurrent1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_LongTermNotesPayable1" name="LongTermNotesPayable1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_DeconsolidationPercentage" name="DeconsolidationPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_LeaseExpirationDateDescription" name="LeaseExpirationDateDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_AdditionalAreaOfLand" name="AdditionalAreaOfLand" nillable="true" xbrli:periodType="instant" type="num:areaItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_MonthlyPaymentsOfFinanceLeaseForEquipment" name="MonthlyPaymentsOfFinanceLeaseForEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_WarrantsIssuanceDate" name="WarrantsIssuanceDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_WarrantsAndRightsOutstandingMaturityDates" name="WarrantsAndRightsOutstandingMaturityDates" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_NumberOfCommonStockIssuedOnCashlessExercise" name="NumberOfCommonStockIssuedOnCashlessExercise" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CommonStockWithheldForPayrollTaxWithholdingsShare" name="CommonStockWithheldForPayrollTaxWithholdingsShare" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CommonStockWithheldForPayrollTaxWithholdingsValue" name="CommonStockWithheldForPayrollTaxWithholdingsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_RestrictedStockUnitsVested" name="RestrictedStockUnitsVested" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ClosingPriceOfCommonStockPricePerShare" name="ClosingPriceOfCommonStockPricePerShare" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_AverageStockPrice" name="AverageStockPrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ForfeitureFactorPercentage" name="ForfeitureFactorPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_AggregatePurchasePrice" name="AggregatePurchasePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_DeferredIncomeChangeInValuationAllowance" name="DeferredIncomeChangeInValuationAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization" name="DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_IncomeTaxBasisDifferenceInRelatedParty" name="IncomeTaxBasisDifferenceInRelatedParty" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_IncomeTaxBasisDifferenceInRelatedPartyOne" name="IncomeTaxBasisDifferenceInRelatedPartyOne" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_IncomeTaxBasisDifferenceInRelatedPartyTwo" name="IncomeTaxBasisDifferenceInRelatedPartyTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_DeferredTaxAssetsTaxDeferredExpenseCapitalLosses" name="DeferredTaxAssetsTaxDeferredExpenseCapitalLosses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_DeferredTaxAssetsTaxDeferredExpenseLimitations" name="DeferredTaxAssetsTaxDeferredExpenseLimitations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability" name="DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset" name="DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_StateNetOperatingLossExpirationDate" name="StateNetOperatingLossExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_FederalNetOperatingLossCarryforwardDescription" name="FederalNetOperatingLossCarryforwardDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_FederalResearchAndDevelopmentTaxCredits" name="FederalResearchAndDevelopmentTaxCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_StateResearchAndDevelopmentTaxCredits" name="StateResearchAndDevelopmentTaxCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_FederalResearchAndDevelopmentTaxCreditsExpirationDate" name="FederalResearchAndDevelopmentTaxCreditsExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount" name="PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_DamagesLowClaimRatePercentage" name="DamagesLowClaimRatePercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CommissionPaymentsPercentage" name="CommissionPaymentsPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_AdditionalPaidInCapitalAndShareBasedPayments" name="AdditionalPaidInCapitalAndShareBasedPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_RoyaltyPaymentDescription" name="RoyaltyPaymentDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_NetSalesRevenue" name="NetSalesRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_MilestonePaymentInCash" name="MilestonePaymentInCash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_MilestonePaymentsOnPayables" name="MilestonePaymentsOnPayables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_SegmentContribution" name="SegmentContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_ImpairmentAndDisposalOfLonglivedAssets" name="ImpairmentAndDisposalOfLonglivedAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_NumberOfOperatingSegmentsDescription" name="NumberOfOperatingSegmentsDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_CommonStockWithheldForPayrollTaxWithholdings" name="CommonStockWithheldForPayrollTaxWithholdings" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_IntangibleAssetsNetExcludingsGoodwill" name="IntangibleAssetsNetExcludingsGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="HROW_AdditionalSquareFootageOfLeaseMember" name="AdditionalSquareFootageOfLeaseMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>hrow-20201231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://harrowinc.com/role/Cover" xlink:href="hrow-20201231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/BalanceSheets" xlink:href="hrow-20201231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/BalanceSheetsParenthetical" xlink:href="hrow-20201231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StatementsOfOperations" xlink:href="hrow-20201231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StatementsOfStockholdersEquity" xlink:href="hrow-20201231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StatementsOfCashFlows" xlink:href="hrow-20201231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Organization" xlink:href="hrow-20201231.xsd#Organization" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="hrow-20201231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Revenues" xlink:href="hrow-20201231.xsd#Revenues" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactions" xlink:href="hrow-20201231.xsd#InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactions" xlink:href="hrow-20201231.xsd#InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/RestrictedCash" xlink:href="hrow-20201231.xsd#RestrictedCash" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Inventories" xlink:href="hrow-20201231.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="hrow-20201231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PropertyPlantAndEquipment" xlink:href="hrow-20201231.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/IntangibleAssetsAndGoodwill" xlink:href="hrow-20201231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/AccountsPayableAndAccruedExpenses" xlink:href="hrow-20201231.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Debt" xlink:href="hrow-20201231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Leases" xlink:href="hrow-20201231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensation" xlink:href="hrow-20201231.xsd#StockholdersEquityAndStock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/IncomeTaxes" xlink:href="hrow-20201231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/EmployeeSavingsPlan" xlink:href="hrow-20201231.xsd#EmployeeSavingsPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/CommitmentsAndContingencies" xlink:href="hrow-20201231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SegmentInformationAndConcentrations" xlink:href="hrow-20201231.xsd#SegmentInformationAndConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SubsequentEvents" xlink:href="hrow-20201231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="hrow-20201231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="hrow-20201231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/RevenuesTables" xlink:href="hrow-20201231.xsd#RevenuesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsTables" xlink:href="hrow-20201231.xsd#InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsTables" xlink:href="hrow-20201231.xsd#InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InventoriesTables" xlink:href="hrow-20201231.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="hrow-20201231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PropertyPlantAndEquipmentTables" xlink:href="hrow-20201231.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="hrow-20201231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/AccountsPayableAndAccruedExpensesTables" xlink:href="hrow-20201231.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/DebtTables" xlink:href="hrow-20201231.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/LeasesTables" xlink:href="hrow-20201231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables" xlink:href="hrow-20201231.xsd#StockholdersEquityAndStock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/IncomeTaxesTables" xlink:href="hrow-20201231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SegmentInformationAndConcentrationsTables" xlink:href="hrow-20201231.xsd#SegmentInformationAndConcentrationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfBasicEarningsPerCommonShareDetails" xlink:href="hrow-20201231.xsd#ScheduleOfBasicEarningsPerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails" xlink:href="hrow-20201231.xsd#ScheduleOfDilutedCommonEquivalentSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfDilutedEarningsPerCommonShareDetails" xlink:href="hrow-20201231.xsd#ScheduleOfDilutedEarningsPerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="hrow-20201231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails" xlink:href="hrow-20201231.xsd#ScheduleOfDisaggregatedRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/RevenuesDetailsNarrative" xlink:href="hrow-20201231.xsd#RevenuesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails" xlink:href="hrow-20201231.xsd#ScheduleOfCondensedIncomeStatementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails" xlink:href="hrow-20201231.xsd#ScheduleOfCondensedBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative" xlink:href="hrow-20201231.xsd#InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails" xlink:href="hrow-20201231.xsd#SummaryOfCondensedIncomeStatementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails" xlink:href="hrow-20201231.xsd#SummaryOfCondensedBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative" xlink:href="hrow-20201231.xsd#InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/RestrictedCashDetailsNarrative" xlink:href="hrow-20201231.xsd#RestrictedCashDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfInventoriesDetails" xlink:href="hrow-20201231.xsd#ScheduleOfInventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="hrow-20201231.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="hrow-20201231.xsd#ScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PropertyPlantAndEquipmentDetailsNarrative" xlink:href="hrow-20201231.xsd#PropertyPlantAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="hrow-20201231.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:href="hrow-20201231.xsd#ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:href="hrow-20201231.xsd#ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfGoodwillDetails" xlink:href="hrow-20201231.xsd#ScheduleOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:href="hrow-20201231.xsd#IntangibleAssetsAndGoodwillDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:href="hrow-20201231.xsd#ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails" xlink:href="hrow-20201231.xsd#SummaryOfFutureMinimumPaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/DebtDetailsNarrative" xlink:href="hrow-20201231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails" xlink:href="hrow-20201231.xsd#ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails" xlink:href="hrow-20201231.xsd#ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/LeasesDetailsNarrative" xlink:href="hrow-20201231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails" xlink:href="hrow-20201231.xsd#ScheduleOfStockOptionPlanActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:href="hrow-20201231.xsd#ScheduleOfFairValueAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails" xlink:href="hrow-20201231.xsd#ScheduleOfStockOptionOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails" xlink:href="hrow-20201231.xsd#ScheduleOfRestrictedStockUnitsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:href="hrow-20201231.xsd#ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="hrow-20201231.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:href="hrow-20201231.xsd#ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative" xlink:href="hrow-20201231.xsd#StockholdersEquityAndStock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="hrow-20201231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfIncomeTaxReconciliationDetails" xlink:href="hrow-20201231.xsd#ScheduleOfIncomeTaxReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="hrow-20201231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/IncomeTaxesDetailsNarrative" xlink:href="hrow-20201231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/EmployeeSavingsPlanDetailsNarrative" xlink:href="hrow-20201231.xsd#EmployeeSavingsPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="hrow-20201231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails" xlink:href="hrow-20201231.xsd#ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SegmentInformationAndConcentrationsDetailsNarrative" xlink:href="hrow-20201231.xsd#SegmentInformationAndConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SubsequentEventsDetailsNarrative" xlink:href="hrow-20201231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestments" xlink:label="loc_us-gaapOtherInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaapLoansPayableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLoansPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaapLongTermLoansPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermLoansPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AmortizationOfIntangibleAsset" xlink:label="loc_HROWAmortizationOfIntangibleAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_HROWAmortizationOfIntangibleAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AmortizationOfOperatingLeaseRightofuseAssets" xlink:label="loc_HROWAmortizationOfOperatingLeaseRightofuseAssets" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_HROWAmortizationOfOperatingLeaseRightofuseAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaapPaidInKindInterest" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapPaidInKindInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_GainLossOnInvestmentsOne" xlink:label="loc_HROWGainLossOnInvestmentsOne" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_HROWGainLossOnInvestmentsOne" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_GainLossOnInvestmentsTwo" xlink:label="loc_HROWGainLossOnInvestmentsTwo" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_HROWGainLossOnInvestmentsTwo" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_GainLossOnInvestmentsThree" xlink:label="loc_HROWGainLossOnInvestmentsThree" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_HROWGainLossOnInvestmentsThree" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets1" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets1" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ImpairmentsOfLongLivedAssetsHeldForUse" xlink:label="loc_HROWImpairmentsOfLongLivedAssetsHeldForUse" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_HROWImpairmentsOfLongLivedAssetsHeldForUse" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="loc_us-gaapProceedsFromSaleOfProductiveAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfProductiveAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromOtherDebt" xlink:label="loc_us-gaapProceedsFromOtherDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromOtherDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_PaymentsOfCostsRelatedToAmendmentOfLoanPayable" xlink:label="loc_HROWPaymentsOfCostsRelatedToAmendmentOfLoanPayable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_HROWPaymentsOfCostsRelatedToAmendmentOfLoanPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ProceedsFromExerciseOfWarrantsAndStockOptionsNetOfTaxes" xlink:label="loc_HROWProceedsFromExerciseOfWarrantsAndStockOptionsNetOfTaxes" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_HROWProceedsFromExerciseOfWarrantsAndStockOptionsNetOfTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Organization" xlink:title="00000007 - Disclosure - ORGANIZATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Revenues" xlink:title="00000009 - Disclosure - REVENUES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactions" xlink:title="00000010 - Disclosure - INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactions" xlink:title="00000011 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/RestrictedCash" xlink:title="00000012 - Disclosure - RESTRICTED CASH" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Inventories" xlink:title="00000013 - Disclosure - INVENTORIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000014 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PropertyPlantAndEquipment" xlink:title="00000015 - Disclosure - PROPERTY, PLANT AND EQUIPMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/IntangibleAssetsAndGoodwill" xlink:title="00000016 - Disclosure - INTANGIBLE ASSETS AND GOODWILL" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/AccountsPayableAndAccruedExpenses" xlink:title="00000017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Debt" xlink:title="00000018 - Disclosure - DEBT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Leases" xlink:title="00000019 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensation" xlink:title="00000020 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/IncomeTaxes" xlink:title="00000021 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/EmployeeSavingsPlan" xlink:title="00000022 - Disclosure - EMPLOYEE SAVINGS PLAN" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/CommitmentsAndContingencies" xlink:title="00000023 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SegmentInformationAndConcentrations" xlink:title="00000024 - Disclosure - SEGMENT INFORMATION AND CONCENTRATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SubsequentEvents" xlink:title="00000025 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/RevenuesTables" xlink:title="00000028 - Disclosure - REVENUES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsTables" xlink:title="00000029 - Disclosure - INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsTables" xlink:title="00000030 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InventoriesTables" xlink:title="00000031 - Disclosure - INVENTORIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000032 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PropertyPlantAndEquipmentTables" xlink:title="00000033 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/IntangibleAssetsAndGoodwillTables" xlink:title="00000034 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/AccountsPayableAndAccruedExpensesTables" xlink:title="00000035 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/DebtTables" xlink:title="00000036 - Disclosure - DEBT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/LeasesTables" xlink:title="00000037 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables" xlink:title="00000038 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/IncomeTaxesTables" xlink:title="00000039 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SegmentInformationAndConcentrationsTables" xlink:title="00000040 - Disclosure - SEGMENT INFORMATION AND CONCENTRATIONS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfBasicEarningsPerCommonShareDetails" xlink:title="00000041 - Disclosure - SCHEDULE OF BASIC EARNINGS PER COMMON SHARE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails" xlink:title="00000042 - Disclosure - SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfDilutedEarningsPerCommonShareDetails" xlink:title="00000043 - Disclosure - SCHEDULE OF DILUTED EARNINGS PER COMMON SHARE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000044 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails" xlink:title="00000045 - Disclosure - SCHEDULE OF DISAGGREGATED REVENUE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/RevenuesDetailsNarrative" xlink:title="00000046 - Disclosure - REVENUES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails" xlink:title="00000047 - Disclosure - SCHEDULE OF CONDENSED INCOME STATEMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails" xlink:title="00000048 - Disclosure - SCHEDULE OF CONDENSED BALANCE SHEET (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative" xlink:title="00000049 - Disclosure - INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails" xlink:title="00000050 - Disclosure - SUMMARY OF CONDENSED INCOME STATEMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails" xlink:title="00000051 - Disclosure - SUMMARY OF CONDENSED BALANCE SHEET (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative" xlink:title="00000052 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/RestrictedCashDetailsNarrative" xlink:title="00000053 - Disclosure - RESTRICTED CASH (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfInventoriesDetails" xlink:title="00000054 - Disclosure - SCHEDULE OF INVENTORIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000055 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="00000056 - Disclosure - SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="loc_us-gaapCapitalizedComputerSoftwareGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapCapitalizedComputerSoftwareGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapFurnitureAndFixturesGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaapMachineryAndEquipmentGross" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapMachineryAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapLeaseholdImprovementsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PropertyPlantAndEquipmentDetailsNarrative" xlink:title="00000057 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="00000058 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:title="00000059 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:title="00000060 - Disclosure - SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfGoodwillDetails" xlink:title="00000061 - Disclosure - SCHEDULE OF GOODWILL (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:title="00000062 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:title="00000063 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails" xlink:title="00000064 - Disclosure - SUMMARY OF FUTURE MINIMUM PAYMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/DebtDetailsNarrative" xlink:title="00000065 - Disclosure - DEBT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails" xlink:title="00000066 - Disclosure - SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails" xlink:title="00000067 - Disclosure - SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/LeasesDetailsNarrative" xlink:title="00000068 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails" xlink:title="00000069 - Disclosure - SCHEDULE OF STOCK OPTION PLAN ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:title="00000070 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails" xlink:title="00000071 - Disclosure - SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails" xlink:title="00000072 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:title="00000073 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000074 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:title="00000075 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative" xlink:title="00000076 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="00000077 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfIncomeTaxReconciliationDetails" xlink:title="00000078 - Disclosure - SCHEDULE OF INCOME TAX RECONCILIATION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000079 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000080 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/EmployeeSavingsPlanDetailsNarrative" xlink:title="00000081 - Disclosure - EMPLOYEE SAVINGS PLAN (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000082 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails" xlink:title="00000083 - Disclosure - SCHEDULE OF SEGMENT NET REVENUES, SEGMENT OPERATING EXPENSES AND SEGMENT CONTRIBUTION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SegmentInformationAndConcentrationsDetailsNarrative" xlink:title="00000084 - Disclosure - SEGMENT INFORMATION AND CONCENTRATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000085 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>hrow-20201231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://harrowinc.com/role/Cover" xlink:href="hrow-20201231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/BalanceSheets" xlink:href="hrow-20201231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/BalanceSheetsParenthetical" xlink:href="hrow-20201231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StatementsOfOperations" xlink:href="hrow-20201231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StatementsOfStockholdersEquity" xlink:href="hrow-20201231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StatementsOfCashFlows" xlink:href="hrow-20201231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Organization" xlink:href="hrow-20201231.xsd#Organization" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="hrow-20201231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Revenues" xlink:href="hrow-20201231.xsd#Revenues" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactions" xlink:href="hrow-20201231.xsd#InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactions" xlink:href="hrow-20201231.xsd#InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/RestrictedCash" xlink:href="hrow-20201231.xsd#RestrictedCash" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Inventories" xlink:href="hrow-20201231.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="hrow-20201231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PropertyPlantAndEquipment" xlink:href="hrow-20201231.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/IntangibleAssetsAndGoodwill" xlink:href="hrow-20201231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/AccountsPayableAndAccruedExpenses" xlink:href="hrow-20201231.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Debt" xlink:href="hrow-20201231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Leases" xlink:href="hrow-20201231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensation" xlink:href="hrow-20201231.xsd#StockholdersEquityAndStock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/IncomeTaxes" xlink:href="hrow-20201231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/EmployeeSavingsPlan" xlink:href="hrow-20201231.xsd#EmployeeSavingsPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/CommitmentsAndContingencies" xlink:href="hrow-20201231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SegmentInformationAndConcentrations" xlink:href="hrow-20201231.xsd#SegmentInformationAndConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SubsequentEvents" xlink:href="hrow-20201231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="hrow-20201231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="hrow-20201231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/RevenuesTables" xlink:href="hrow-20201231.xsd#RevenuesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsTables" xlink:href="hrow-20201231.xsd#InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsTables" xlink:href="hrow-20201231.xsd#InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InventoriesTables" xlink:href="hrow-20201231.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="hrow-20201231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PropertyPlantAndEquipmentTables" xlink:href="hrow-20201231.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="hrow-20201231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/AccountsPayableAndAccruedExpensesTables" xlink:href="hrow-20201231.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/DebtTables" xlink:href="hrow-20201231.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/LeasesTables" xlink:href="hrow-20201231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables" xlink:href="hrow-20201231.xsd#StockholdersEquityAndStock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/IncomeTaxesTables" xlink:href="hrow-20201231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SegmentInformationAndConcentrationsTables" xlink:href="hrow-20201231.xsd#SegmentInformationAndConcentrationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfBasicEarningsPerCommonShareDetails" xlink:href="hrow-20201231.xsd#ScheduleOfBasicEarningsPerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails" xlink:href="hrow-20201231.xsd#ScheduleOfDilutedCommonEquivalentSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfDilutedEarningsPerCommonShareDetails" xlink:href="hrow-20201231.xsd#ScheduleOfDilutedEarningsPerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="hrow-20201231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails" xlink:href="hrow-20201231.xsd#ScheduleOfDisaggregatedRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/RevenuesDetailsNarrative" xlink:href="hrow-20201231.xsd#RevenuesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails" xlink:href="hrow-20201231.xsd#ScheduleOfCondensedIncomeStatementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails" xlink:href="hrow-20201231.xsd#ScheduleOfCondensedBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative" xlink:href="hrow-20201231.xsd#InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails" xlink:href="hrow-20201231.xsd#SummaryOfCondensedIncomeStatementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails" xlink:href="hrow-20201231.xsd#SummaryOfCondensedBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative" xlink:href="hrow-20201231.xsd#InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/RestrictedCashDetailsNarrative" xlink:href="hrow-20201231.xsd#RestrictedCashDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfInventoriesDetails" xlink:href="hrow-20201231.xsd#ScheduleOfInventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="hrow-20201231.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="hrow-20201231.xsd#ScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PropertyPlantAndEquipmentDetailsNarrative" xlink:href="hrow-20201231.xsd#PropertyPlantAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="hrow-20201231.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:href="hrow-20201231.xsd#ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:href="hrow-20201231.xsd#ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfGoodwillDetails" xlink:href="hrow-20201231.xsd#ScheduleOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:href="hrow-20201231.xsd#IntangibleAssetsAndGoodwillDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:href="hrow-20201231.xsd#ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails" xlink:href="hrow-20201231.xsd#SummaryOfFutureMinimumPaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/DebtDetailsNarrative" xlink:href="hrow-20201231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails" xlink:href="hrow-20201231.xsd#ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails" xlink:href="hrow-20201231.xsd#ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/LeasesDetailsNarrative" xlink:href="hrow-20201231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails" xlink:href="hrow-20201231.xsd#ScheduleOfStockOptionPlanActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:href="hrow-20201231.xsd#ScheduleOfFairValueAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails" xlink:href="hrow-20201231.xsd#ScheduleOfStockOptionOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails" xlink:href="hrow-20201231.xsd#ScheduleOfRestrictedStockUnitsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:href="hrow-20201231.xsd#ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="hrow-20201231.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:href="hrow-20201231.xsd#ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative" xlink:href="hrow-20201231.xsd#StockholdersEquityAndStock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="hrow-20201231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfIncomeTaxReconciliationDetails" xlink:href="hrow-20201231.xsd#ScheduleOfIncomeTaxReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="hrow-20201231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/IncomeTaxesDetailsNarrative" xlink:href="hrow-20201231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/EmployeeSavingsPlanDetailsNarrative" xlink:href="hrow-20201231.xsd#EmployeeSavingsPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="hrow-20201231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails" xlink:href="hrow-20201231.xsd#ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SegmentInformationAndConcentrationsDetailsNarrative" xlink:href="hrow-20201231.xsd#SegmentInformationAndConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SubsequentEventsDetailsNarrative" xlink:href="hrow-20201231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:label="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SurfaceOphthalmicsMember" xlink:label="loc_HROWSurfaceOphthalmicsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWSurfaceOphthalmicsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MeltPharmaceuticalsMember" xlink:label="loc_HROWMeltPharmaceuticalsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWMeltPharmaceuticalsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapAssetsAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssetsCurrentAbstract_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestments" xlink:label="loc_us-gaapOtherInvestments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapOtherInvestments_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapInventoryNet_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapAssetsCurrent_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapInvestments_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapGoodwill_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapAssets_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaapLoansPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapLoansPayableCurrent_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapNotesPayableCurrent_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrent_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesNoncurrent_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaapLongTermLoansPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLongTermLoansPayable_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLongTermNotesPayable_70" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilities_70" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommitmentsAndContingencies_70" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquityAbstract_70" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommonStockValue_70" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapAdditionalPaidInCapital_70" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapMinorityInterest_70" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_70" xlink:type="arc" order="38" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ProductSalesNetMember" xlink:label="loc_HROWProductSalesNetMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_HROWProductSalesNetMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_OtherRevenuesMember" xlink:label="loc_HROWOtherRevenuesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_HROWOtherRevenuesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MeltPharmaceuticalsMember" xlink:label="loc_HROWMeltPharmaceuticalsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWMeltPharmaceuticalsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SurfaceOphthalmicsMember" xlink:label="loc_HROWSurfaceOphthalmicsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWSurfaceOphthalmicsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_EtonPharmaceuticalsMember" xlink:label="loc_HROWEtonPharmaceuticalsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWEtonPharmaceuticalsMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenuesAbstract_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGrossProfit_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_130" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_130" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_130" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_130" xlink:to="loc_us-gaapOperatingExpenses_130" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_130" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract_130" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_130" xlink:to="loc_us-gaapInterestIncomeExpenseNet_130" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainLossOnInvestments_130" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_130" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpense_130" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_130" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_130" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_130" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest_130" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_130" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_130" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_130" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_130" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_130" xlink:type="arc" order="23" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaapParentMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapParentMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapNoncontrollingInterestMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StockIssuedDuringPeriodForExerciseOfWarrants" xlink:label="loc_HROWStockIssuedDuringPeriodForExerciseOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_HROWStockIssuedDuringPeriodForExerciseOfWarrants_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StockIssuedDuringPeriodSharesForExerciseOfWarrants" xlink:label="loc_HROWStockIssuedDuringPeriodSharesForExerciseOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_HROWStockIssuedDuringPeriodSharesForExerciseOfWarrants_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_70" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Organization" xlink:title="00000007 - Disclosure - ORGANIZATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Revenues" xlink:title="00000009 - Disclosure - REVENUES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactions" xlink:title="00000010 - Disclosure - INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactions" xlink:title="00000011 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/RestrictedCash" xlink:title="00000012 - Disclosure - RESTRICTED CASH" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Inventories" xlink:title="00000013 - Disclosure - INVENTORIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000014 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PropertyPlantAndEquipment" xlink:title="00000015 - Disclosure - PROPERTY, PLANT AND EQUIPMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/IntangibleAssetsAndGoodwill" xlink:title="00000016 - Disclosure - INTANGIBLE ASSETS AND GOODWILL" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/AccountsPayableAndAccruedExpenses" xlink:title="00000017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Debt" xlink:title="00000018 - Disclosure - DEBT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Leases" xlink:title="00000019 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensation" xlink:title="00000020 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/IncomeTaxes" xlink:title="00000021 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/EmployeeSavingsPlan" xlink:title="00000022 - Disclosure - EMPLOYEE SAVINGS PLAN" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/CommitmentsAndContingencies" xlink:title="00000023 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SegmentInformationAndConcentrations" xlink:title="00000024 - Disclosure - SEGMENT INFORMATION AND CONCENTRATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SubsequentEvents" xlink:title="00000025 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/RevenuesTables" xlink:title="00000028 - Disclosure - REVENUES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsTables" xlink:title="00000029 - Disclosure - INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsTables" xlink:title="00000030 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InventoriesTables" xlink:title="00000031 - Disclosure - INVENTORIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000032 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PropertyPlantAndEquipmentTables" xlink:title="00000033 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/IntangibleAssetsAndGoodwillTables" xlink:title="00000034 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/AccountsPayableAndAccruedExpensesTables" xlink:title="00000035 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/DebtTables" xlink:title="00000036 - Disclosure - DEBT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/LeasesTables" xlink:title="00000037 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables" xlink:title="00000038 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/IncomeTaxesTables" xlink:title="00000039 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SegmentInformationAndConcentrationsTables" xlink:title="00000040 - Disclosure - SEGMENT INFORMATION AND CONCENTRATIONS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfBasicEarningsPerCommonShareDetails" xlink:title="00000041 - Disclosure - SCHEDULE OF BASIC EARNINGS PER COMMON SHARE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails" xlink:title="00000042 - Disclosure - SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StockOptionsMember" xlink:label="loc_HROWStockOptionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_HROWStockOptionsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaapWeightedAverageNumberDilutedSharesOutstandingAdjustment_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapWeightedAverageNumberDilutedSharesOutstandingAdjustment_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfDilutedEarningsPerCommonShareDetails" xlink:title="00000043 - Disclosure - SCHEDULE OF DILUTED EARNINGS PER COMMON SHARE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000044 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srtOwnershipAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtOwnershipAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srtOwnershipDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtOwnershipAxis" xlink:to="loc_srtOwnershipDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srtOwnershipDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtOwnershipAxis" xlink:to="loc_srtOwnershipDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MayfieldPharmaceuticalsIncMember" xlink:label="loc_HROWMayfieldPharmaceuticalsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_HROWMayfieldPharmaceuticalsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StowePharmaceuticalsIncMember" xlink:label="loc_HROWStowePharmaceuticalsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_HROWStowePharmaceuticalsIncMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_TGVHealthLLCMember" xlink:label="loc_HROWTGVHealthLLCMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWTGVHealthLLCMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_VisionologyMember" xlink:label="loc_HROWVisionologyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWVisionologyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_EtonPharmaceuticalsIncMember" xlink:label="loc_HROWEtonPharmaceuticalsIncMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWEtonPharmaceuticalsIncMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MeltPharmaceuticalsIncMember" xlink:label="loc_HROWMeltPharmaceuticalsIncMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWMeltPharmaceuticalsIncMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SurfacePharmaceuticalsIncMember" xlink:label="loc_HROWSurfacePharmaceuticalsIncMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWSurfacePharmaceuticalsIncMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ParkCompoundingIncAndNoiceRxLLCMember" xlink:label="loc_HROWParkCompoundingIncAndNoiceRxLLCMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWParkCompoundingIncAndNoiceRxLLCMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StockOptionsUnvestedRSUsAndWarrantsMember" xlink:label="loc_HROWStockOptionsUnvestedRSUsAndWarrantsMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_HROWStockOptionsUnvestedRSUsAndWarrantsMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_320" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ConsolidationBasisDescription" xlink:label="loc_HROWConsolidationBasisDescription_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_HROWConsolidationBasisDescription_320" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_320" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RetainedEarningsAccumulatedDeficit1" xlink:label="loc_HROWRetainedEarningsAccumulatedDeficit1_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_HROWRetainedEarningsAccumulatedDeficit1_320" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_320" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_320" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments_320" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDescription" xlink:label="loc_us-gaapMinorityInterestDescription_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapMinorityInterestDescription_320" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_320" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_NumberOfSharesOwned" xlink:label="loc_HROWNumberOfSharesOwned_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_HROWNumberOfSharesOwned_320" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_320" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapGainLossOnInvestments_320" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="loc_us-gaapInvestmentOwnedAtFairValue_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInvestmentOwnedAtFairValue_320" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaapAccountsReceivableNet_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccountsReceivableNet_320" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_320" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaapDeconsolidationGainOrLossAmount_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeconsolidationGainOrLossAmount_320" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments_320" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaapDueFromRelatedParties_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDueFromRelatedParties_320" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_320" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_320" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges_320" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapSeveranceCosts1_320" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_320" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_320" xlink:type="arc" order="24" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails" xlink:title="00000045 - Disclosure - SCHEDULE OF DISAGGREGATED REVENUE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ProductSalesNetMember" xlink:label="loc_HROWProductSalesNetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_HROWProductSalesNetMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CommissionsMember" xlink:label="loc_HROWCommissionsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_HROWCommissionsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/RevenuesDetailsNarrative" xlink:title="00000046 - Disclosure - REVENUES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails" xlink:title="00000047 - Disclosure - SCHEDULE OF CONDENSED INCOME STATEMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsLineItems" xlink:label="loc_deiEntityListingsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MeltPharmaceuticalsIncMember" xlink:label="loc_HROWMeltPharmaceuticalsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWMeltPharmaceuticalsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapNetIncomeLoss_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails" xlink:title="00000048 - Disclosure - SCHEDULE OF CONDENSED BALANCE SHEET (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsLineItems" xlink:label="loc_deiEntityListingsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MeltPharmaceuticalsIncMember" xlink:label="loc_HROWMeltPharmaceuticalsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWMeltPharmaceuticalsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapAssetsCurrent_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapAssetsNoncurrent_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapAssets_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapLiabilities_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapStockholdersEquity_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_30" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative" xlink:title="00000049 - Disclosure - INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsLineItems" xlink:label="loc_deiEntityListingsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MeltPharmaceuticalsIncMember" xlink:label="loc_HROWMeltPharmaceuticalsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWMeltPharmaceuticalsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SurfacePharmaceuticalsIncMember" xlink:label="loc_HROWSurfacePharmaceuticalsIncMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWSurfacePharmaceuticalsIncMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ManagementServicesAgreementMember" xlink:label="loc_HROWManagementServicesAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWManagementServicesAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MSAMember" xlink:label="loc_HROWMSAMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWMSAMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdministrativeFeesExpense" xlink:label="loc_us-gaapAdministrativeFeesExpense_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapAdministrativeFeesExpense_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaapDueFromRelatedParties_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapDueFromRelatedParties_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails" xlink:title="00000050 - Disclosure - SUMMARY OF CONDENSED INCOME STATEMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsLineItems" xlink:label="loc_deiEntityListingsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SurfacePharmaceuticalsIncMember" xlink:label="loc_HROWSurfacePharmaceuticalsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWSurfacePharmaceuticalsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapNetIncomeLoss_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails" xlink:title="00000051 - Disclosure - SUMMARY OF CONDENSED BALANCE SHEET (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsLineItems" xlink:label="loc_deiEntityListingsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SurfacePharmaceuticalsIncMember" xlink:label="loc_HROWSurfacePharmaceuticalsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWSurfacePharmaceuticalsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapAssetsCurrent_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapAssetsNoncurrent_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapAssets_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapLiabilities_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapStockholdersEquity_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_30" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative" xlink:title="00000052 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsLineItems" xlink:label="loc_deiEntityListingsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SurfacePharmaceuticalsIncMember" xlink:label="loc_HROWSurfacePharmaceuticalsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWSurfacePharmaceuticalsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DrLindstromMember" xlink:label="loc_HROWDrLindstromMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWDrLindstromMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapSharesOutstanding_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RoyaltyPaymentPercentageOnNetSales" xlink:label="loc_HROWRoyaltyPaymentPercentageOnNetSales_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_HROWRoyaltyPaymentPercentageOnNetSales_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/RestrictedCashDetailsNarrative" xlink:title="00000053 - Disclosure - RESTRICTED CASH (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfInventoriesDetails" xlink:title="00000054 - Disclosure - SCHEDULE OF INVENTORIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000055 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="00000056 - Disclosure - SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PropertyPlantAndEquipmentDetailsNarrative" xlink:title="00000057 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="00000058 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_LicensesMember" xlink:label="loc_HROWLicensesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWLicensesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember" xlink:label="loc_us-gaapTrademarksMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaapTradeNamesMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTradeNamesMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_NonCompetitionClauseMember" xlink:label="loc_HROWNonCompetitionClauseMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWNonCompetitionClauseMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StatePharmacyLicensesMember" xlink:label="loc_HROWStatePharmacyLicensesMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWStatePharmacyLicensesMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_370" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_370" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_370" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_FiniteLivedIntangibleAssetsImpairment" xlink:label="loc_HROWFiniteLivedIntangibleAssetsImpairment_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_HROWFiniteLivedIntangibleAssetsImpairment_370" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_370" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationMethod_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationMethod_370" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:title="00000059 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_LicensesMember" xlink:label="loc_HROWLicensesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWLicensesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaapTradeNamesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTradeNamesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StatePharmacyLicensesMember" xlink:label="loc_HROWStatePharmacyLicensesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWStatePharmacyLicensesMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:title="00000060 - Disclosure - SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfGoodwillDetails" xlink:title="00000061 - Disclosure - SCHEDULE OF GOODWILL (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:title="00000062 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember" xlink:label="loc_HROWCustomerRelationshipsTradeNameAndStatePharmacyLicensesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWCustomerRelationshipsTradeNameAndStatePharmacyLicensesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_PatentsFilingsAndTrademarksMember" xlink:label="loc_HROWPatentsFilingsAndTrademarksMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWPatentsFilingsAndTrademarksMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ParkCompoundingIncMember" xlink:label="loc_HROWParkCompoundingIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWParkCompoundingIncMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:title="00000063 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails" xlink:title="00000064 - Disclosure - SUMMARY OF FUTURE MINIMUM PAYMENTS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/DebtDetailsNarrative" xlink:title="00000065 - Disclosure - DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_TermLoanAndSecurityAgreementMember" xlink:label="loc_HROWTermLoanAndSecurityAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWTermLoanAndSecurityAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SWKLoanAgreementMember" xlink:label="loc_HROWSWKLoanAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWSWKLoanAgreementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_JoinderAndAmendmentMember" xlink:label="loc_HROWJoinderAndAmendmentMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWJoinderAndAmendmentMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SWKSecondAmendmentMember" xlink:label="loc_HROWSWKSecondAmendmentMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWSWKSecondAmendmentMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_BusinessLoanAgreementMember" xlink:label="loc_HROWBusinessLoanAgreementMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWBusinessLoanAgreementMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SWKFundingLLCMember" xlink:label="loc_HROWSWKFundingLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWSWKFundingLLCMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaapVariableRateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapVariableRateAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaapLondonInterbankOfferedRateLIBORMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_us-gaapLondonInterbankOfferedRateLIBORMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MarginRateMember" xlink:label="loc_HROWMarginRateMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_HROWMarginRateMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_LenderWarrantsMember" xlink:label="loc_HROWLenderWarrantsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_HROWLenderWarrantsMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_270" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaapDebtInstrumentDescription_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentDescription_270" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis_270" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1_270" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfDebt_270" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaapDebtInstrumentMaturityDateDescription_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateDescription_270" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaapDebtInstrumentFeeAmount_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFeeAmount_270" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_270" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_270" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_270" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_270" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_270" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSharesIssued_270" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_270" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_270" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLegalFees_270" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DeconsolidationPercentage" xlink:label="loc_HROWDeconsolidationPercentage_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_HROWDeconsolidationPercentage_270" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseDebt_270" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium_270" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_270" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails" xlink:title="00000066 - Disclosure - SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails" xlink:title="00000067 - Disclosure - SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/LeasesDetailsNarrative" xlink:title="00000068 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaapLesseeLeaseDescriptionLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaapLesseeLeaseDescriptionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeLeaseDescriptionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_OfficeAndLaboratorySpaceMember" xlink:label="loc_HROWOfficeAndLaboratorySpaceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_HROWOfficeAndLaboratorySpaceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SanDiegoMember" xlink:label="loc_HROWSanDiegoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_HROWSanDiegoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_LedgewoodMember" xlink:label="loc_HROWLedgewoodMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_HROWLedgewoodMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_NashvilleMember" xlink:label="loc_HROWNashvilleMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_HROWNashvilleMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_IrvineMember" xlink:label="loc_HROWIrvineMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_HROWIrvineMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapAreaOfLand_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_LeaseExpirationDateDescription" xlink:label="loc_HROWLeaseExpirationDateDescription_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_HROWLeaseExpirationDateDescription_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaapLesseeOperatingLeaseOptionToExtend_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseOptionToExtend_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AdditionalAreaOfLand" xlink:label="loc_HROWAdditionalAreaOfLand_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_HROWAdditionalAreaOfLand_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="loc_us-gaapGainLossOnTerminationOfLease_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapGainLossOnTerminationOfLease_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_150" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeasePayments_150" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_150" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MonthlyPaymentsOfFinanceLeaseForEquipment" xlink:label="loc_HROWMonthlyPaymentsOfFinanceLeaseForEquipment_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_HROWMonthlyPaymentsOfFinanceLeaseForEquipment_150" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent_150" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageRemainingLeaseTerm1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageRemainingLeaseTerm1_150" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium_150" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization_150" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapFinanceLeaseInterestExpense_150" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails" xlink:title="00000069 - Disclosure - SCHEDULE OF STOCK OPTION PLAN ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StockOptionPlanOneMember" xlink:label="loc_HROWStockOptionPlanOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_HROWStockOptionPlanOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_40" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:title="00000070 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_OptionsEmployeesMember" xlink:label="loc_HROWOptionsEmployeesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_HROWOptionsEmployeesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails" xlink:title="00000071 - Disclosure - SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RangeOneMember" xlink:label="loc_HROWRangeOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RangeTwoMember" xlink:label="loc_HROWRangeTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RangeThreeMember" xlink:label="loc_HROWRangeThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RangeFourMember" xlink:label="loc_HROWRangeFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeFourMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_110" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails" xlink:title="00000072 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_60" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:title="00000073 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_EmployeesMember" xlink:label="loc_HROWEmployeesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWEmployeesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ConsultantMember" xlink:label="loc_HROWConsultantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWConsultantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SellingGeneralAndAdministrativeMember" xlink:label="loc_HROWSellingGeneralAndAdministrativeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_HROWSellingGeneralAndAdministrativeMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000074 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:label="loc_HROWShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_HROWShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber" xlink:label="loc_HROWShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_HROWShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1" xlink:label="loc_HROWShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_HROWShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_HROWSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_HROWSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_40" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:title="00000075 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_LenderWarrantsMember" xlink:label="loc_HROWLenderWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWLenderWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SettlementWarrantsMember" xlink:label="loc_HROWSettlementWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWSettlementWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_LenderWarrantsOneMember" xlink:label="loc_HROWLenderWarrantsOneMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWLenderWarrantsOneMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_WarrantsIssuanceDate" xlink:label="loc_HROWWarrantsIssuanceDate_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_HROWWarrantsIssuanceDate_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" xlink:label="loc_HROWShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_HROWShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_WarrantsAndRightsOutstandingMaturityDates" xlink:label="loc_HROWWarrantsAndRightsOutstandingMaturityDates_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_HROWWarrantsAndRightsOutstandingMaturityDates_80" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative" xlink:title="00000076 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StockOptionPlanMember" xlink:label="loc_HROWStockOptionPlanMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_HROWStockOptionPlanMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_UnvestedRSUMember" xlink:label="loc_HROWUnvestedRSUMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_HROWUnvestedRSUMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_350" xlink:type="arc" order="352" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RangeOneMember" xlink:label="loc_HROWRangeOneMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeOneMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RangeTwoMember" xlink:label="loc_HROWRangeTwoMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeTwoMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CommonStockWarrantsOneMember" xlink:label="loc_HROWCommonStockWarrantsOneMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_HROWCommonStockWarrantsOneMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CommonStockWarrantsTwoMember" xlink:label="loc_HROWCommonStockWarrantsTwoMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_HROWCommonStockWarrantsTwoMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_EmployeesAndConsultantMember" xlink:label="loc_HROWEmployeesAndConsultantMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWEmployeesAndConsultantMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_EmployeesMember" xlink:label="loc_HROWEmployeesMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWEmployeesMember_260" xlink:type="arc" order="262" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_BoardOfDirectorsMember" xlink:label="loc_HROWBoardOfDirectorsMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWBoardOfDirectorsMember_270" xlink:type="arc" order="272" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MarkBaumCEOMember" xlink:label="loc_HROWMarkBaumCEOMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWMarkBaumCEOMember_360" xlink:type="arc" order="362" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AndrewBollCFOMember" xlink:label="loc_HROWAndrewBollCFOMember_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWAndrewBollCFOMember_370" xlink:type="arc" order="372" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ConsultantMember" xlink:label="loc_HROWConsultantMember_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWConsultantMember_390" xlink:type="arc" order="393" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember" xlink:label="loc_HROWTwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_HROWTwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_BaumPerformanceOptionMember" xlink:label="loc_HROWBaumPerformanceOptionMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWBaumPerformanceOptionMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_LicenseAgreementMember" xlink:label="loc_HROWLicenseAgreementMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWLicenseAgreementMember_340" xlink:type="arc" order="342" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_230" xlink:type="arc" order="232" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MayfieldPharmaceuticalsIncMember" xlink:label="loc_HROWMayfieldPharmaceuticalsIncMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWMayfieldPharmaceuticalsIncMember_330" xlink:type="arc" order="331" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StowePharmaceuticalsIncMember" xlink:label="loc_HROWStowePharmaceuticalsIncMember_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWStowePharmaceuticalsIncMember_420" xlink:type="arc" order="421" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_VisionologyIncMember" xlink:label="loc_HROWVisionologyIncMember_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWVisionologyIncMember_430" xlink:type="arc" order="431" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_EllePharmaceuticalLLCMember" xlink:label="loc_HROWEllePharmaceuticalLLCMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWEllePharmaceuticalLLCMember_330" xlink:type="arc" order="332" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_470" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_470" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_470" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_470" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_NumberOfCommonStockIssuedOnCashlessExercise" xlink:label="loc_HROWNumberOfCommonStockIssuedOnCashlessExercise_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWNumberOfCommonStockIssuedOnCashlessExercise_470" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_470" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_470" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_470" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CommonStockWithheldForPayrollTaxWithholdingsShare" xlink:label="loc_HROWCommonStockWithheldForPayrollTaxWithholdingsShare_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWCommonStockWithheldForPayrollTaxWithholdingsShare_470" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CommonStockWithheldForPayrollTaxWithholdingsValue" xlink:label="loc_HROWCommonStockWithheldForPayrollTaxWithholdingsValue_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWCommonStockWithheldForPayrollTaxWithholdingsValue_470" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_470" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_470" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_470" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_470" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RestrictedStockUnitsVested" xlink:label="loc_HROWRestrictedStockUnitsVested_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWRestrictedStockUnitsVested_470" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_470" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_470" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_470" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_470" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_470" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_470" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ClosingPriceOfCommonStockPricePerShare" xlink:label="loc_HROWClosingPriceOfCommonStockPricePerShare_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWClosingPriceOfCommonStockPricePerShare_470" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_470" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_470" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_470" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_470" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_470" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AverageStockPrice" xlink:label="loc_HROWAverageStockPrice_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWAverageStockPrice_470" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_470" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_470" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_470" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_470" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ForfeitureFactorPercentage" xlink:label="loc_HROWForfeitureFactorPercentage_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWForfeitureFactorPercentage_470" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_470" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_470" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensation_470" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_470" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_470" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AggregatePurchasePrice" xlink:label="loc_HROWAggregatePurchasePrice_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWAggregatePurchasePrice_470" xlink:type="arc" order="38" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="00000077 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfIncomeTaxReconciliationDetails" xlink:title="00000078 - Disclosure - SCHEDULE OF INCOME TAX RECONCILIATION (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000079 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000080 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/EmployeeSavingsPlanDetailsNarrative" xlink:title="00000081 - Disclosure - EMPLOYEE SAVINGS PLAN (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000082 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SettlementAgreementMember" xlink:label="loc_HROWSettlementAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWSettlementAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SalesAndMarketingAgreementsMember" xlink:label="loc_HROWSalesAndMarketingAgreementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWSalesAndMarketingAgreementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_LicenseAgreementMember" xlink:label="loc_HROWLicenseAgreementMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWLicenseAgreementMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_KlarityLicenseAgreementMember" xlink:label="loc_HROWKlarityLicenseAgreementMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWKlarityLicenseAgreementMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_InjectableAssetPurchaseAgreementMember" xlink:label="loc_HROWInjectableAssetPurchaseAgreementMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWInjectableAssetPurchaseAgreementMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_PresbyopiaAssetPurchaseAgreementMember" xlink:label="loc_HROWPresbyopiaAssetPurchaseAgreementMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWPresbyopiaAssetPurchaseAgreementMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DexycuAgreementMember" xlink:label="loc_HROWDexycuAgreementMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWDexycuAgreementMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AllerganUSAIncMember" xlink:label="loc_HROWAllerganUSAIncMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWAllerganUSAIncMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MayfieldPharmaceuticalsIncMember" xlink:label="loc_HROWMayfieldPharmaceuticalsIncMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWMayfieldPharmaceuticalsIncMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StowePharmaceuticalsIncMember" xlink:label="loc_HROWStowePharmaceuticalsIncMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWStowePharmaceuticalsIncMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RichardLLindstromMDMember" xlink:label="loc_HROWRichardLLindstromMDMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWRichardLLindstromMDMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_InitialPaymentMember" xlink:label="loc_HROWInitialPaymentMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_HROWInitialPaymentMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SecondPaymentMember" xlink:label="loc_HROWSecondPaymentMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_HROWSecondPaymentMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_FinalPaymentMember" xlink:label="loc_HROWFinalPaymentMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_HROWFinalPaymentMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaapLossContingencyAccrualAtCarryingValue_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingencyAccrualAtCarryingValue_310" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DamagesLowClaimRatePercentage" xlink:label="loc_HROWDamagesLowClaimRatePercentage_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWDamagesLowClaimRatePercentage_310" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="loc_us-gaapLossContingencyDamagesPaidValue_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingencyDamagesPaidValue_310" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaapLossContingencyDamagesAwardedValue_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingencyDamagesAwardedValue_310" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CommissionPaymentsPercentage" xlink:label="loc_HROWCommissionPaymentsPercentage_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWCommissionPaymentsPercentage_310" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AdditionalPaidInCapitalAndShareBasedPayments" xlink:label="loc_HROWAdditionalPaidInCapitalAndShareBasedPayments_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWAdditionalPaidInCapitalAndShareBasedPayments_310" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaapSalesCommissionsAndFees_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapSalesCommissionsAndFees_310" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="loc_us-gaapBusinessAcquisitionDescriptionOfAcquiredEntity_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapBusinessAcquisitionDescriptionOfAcquiredEntity_310" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities_310" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRoyaltyExpense_310" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_310" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RoyaltyPaymentDescription" xlink:label="loc_HROWRoyaltyPaymentDescription_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWRoyaltyPaymentDescription_310" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_NetSalesRevenue" xlink:label="loc_HROWNetSalesRevenue_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWNetSalesRevenue_310" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MilestonePaymentInCash" xlink:label="loc_HROWMilestonePaymentInCash_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWMilestonePaymentInCash_310" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MilestonePaymentsOnPayables" xlink:label="loc_HROWMilestonePaymentsOnPayables_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWMilestonePaymentsOnPayables_310" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails" xlink:title="00000083 - Disclosure - SCHEDULE OF SEGMENT NET REVENUES, SEGMENT OPERATING EXPENSES AND SEGMENT CONTRIBUTION (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srtConsolidationItemsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_srtConsolidationItemsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srtConsolidationItemsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidationItemsAxis" xlink:to="loc_srtConsolidationItemsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srtConsolidationItemsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidationItemsAxis" xlink:to="loc_srtConsolidationItemsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaapOperatingSegmentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidationItemsDomain" xlink:to="loc_us-gaapOperatingSegmentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="loc_us-gaapCorporateNonSegmentMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidationItemsDomain" xlink:to="loc_us-gaapCorporateNonSegmentMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_PharmaceuticalCompoundingMember" xlink:label="loc_HROWPharmaceuticalCompoundingMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_HROWPharmaceuticalCompoundingMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_PharmaceuticalDrugDevelopmentMember" xlink:label="loc_HROWPharmaceuticalDrugDevelopmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_HROWPharmaceuticalDrugDevelopmentMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapGrossProfit_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SegmentContribution" xlink:label="loc_HROWSegmentContribution_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_HROWSegmentContribution_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapAdjustmentForAmortization_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ImpairmentAndDisposalOfLonglivedAssets" xlink:label="loc_HROWImpairmentAndDisposalOfLonglivedAssets_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_HROWImpairmentAndDisposalOfLonglivedAssets_110" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SegmentInformationAndConcentrationsDetailsNarrative" xlink:title="00000084 - Disclosure - SEGMENT INFORMATION AND CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaapEntityWideRevenueMajorCustomerLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEntityWideRevenueMajorCustomerLineItems" xlink:to="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ThreeMainSuppliersMember" xlink:label="loc_HROWThreeMainSuppliersMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_HROWThreeMainSuppliersMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_NumberOfOperatingSegmentsDescription" xlink:label="loc_HROWNumberOfOperatingSegmentsDescription_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEntityWideRevenueMajorCustomerLineItems" xlink:to="loc_HROWNumberOfOperatingSegmentsDescription_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEntityWideRevenueMajorCustomerLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000085 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AndrewRBollMember" xlink:label="loc_HROWAndrewRBollMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWAndrewRBollMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MarkLBaumMember" xlink:label="loc_HROWMarkLBaumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWMarkLBaumMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CommonStockWithheldForPayrollTaxWithholdings" xlink:label="loc_HROWCommonStockWithheldForPayrollTaxWithholdings_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_HROWCommonStockWithheldForPayrollTaxWithholdings_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CommonStockWithheldForPayrollTaxWithholdingsValue" xlink:label="loc_HROWCommonStockWithheldForPayrollTaxWithholdingsValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_HROWCommonStockWithheldForPayrollTaxWithholdingsValue_60" xlink:type="arc" order="7" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>hrow-20201231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SurfaceOphthalmicsMember" xlink:label="HROW_SurfaceOphthalmicsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SurfaceOphthalmicsMember" xlink:to="HROW_SurfaceOphthalmicsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_SurfaceOphthalmicsMember_lbl" xml:lang="en-US">Surface Ophthalmics [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MeltPharmaceuticalsMember" xlink:label="HROW_MeltPharmaceuticalsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MeltPharmaceuticalsMember" xlink:to="HROW_MeltPharmaceuticalsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_MeltPharmaceuticalsMember_lbl" xml:lang="en-US">Melt Pharmaceuticals [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ProductSalesNetMember" xlink:label="HROW_ProductSalesNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ProductSalesNetMember" xlink:to="HROW_ProductSalesNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ProductSalesNetMember_lbl" xml:lang="en-US">Product Sales, Net [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_OtherRevenuesMember" xlink:label="HROW_OtherRevenuesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_OtherRevenuesMember" xlink:to="HROW_OtherRevenuesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_OtherRevenuesMember_lbl" xml:lang="en-US">Other Revenues [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_EtonPharmaceuticalsMember" xlink:label="HROW_EtonPharmaceuticalsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_EtonPharmaceuticalsMember" xlink:to="HROW_EtonPharmaceuticalsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_EtonPharmaceuticalsMember_lbl" xml:lang="en-US">Eton Pharmaceuticals [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParentMember_lbl" xml:lang="en-US">Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MayfieldPharmaceuticalsIncMember" xlink:label="HROW_MayfieldPharmaceuticalsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MayfieldPharmaceuticalsIncMember" xlink:to="HROW_MayfieldPharmaceuticalsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_MayfieldPharmaceuticalsIncMember_lbl" xml:lang="en-US">Mayfield Pharmaceuticals, Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StowePharmaceuticalsIncMember" xlink:label="HROW_StowePharmaceuticalsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StowePharmaceuticalsIncMember" xlink:to="HROW_StowePharmaceuticalsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_StowePharmaceuticalsIncMember_lbl" xml:lang="en-US">Stowe Pharmaceuticals, Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_TGVHealthLLCMember" xlink:label="HROW_TGVHealthLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_TGVHealthLLCMember" xlink:to="HROW_TGVHealthLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_TGVHealthLLCMember_lbl" xml:lang="en-US">TGV-Health, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_VisionologyMember" xlink:label="HROW_VisionologyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_VisionologyMember" xlink:to="HROW_VisionologyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_VisionologyMember_lbl" xml:lang="en-US">Visionology [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_EtonPharmaceuticalsIncMember" xlink:label="HROW_EtonPharmaceuticalsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_EtonPharmaceuticalsIncMember" xlink:to="HROW_EtonPharmaceuticalsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_EtonPharmaceuticalsIncMember_lbl" xml:lang="en-US">Eton Pharmaceuticals, Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MeltPharmaceuticalsIncMember" xlink:label="HROW_MeltPharmaceuticalsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MeltPharmaceuticalsIncMember" xlink:to="HROW_MeltPharmaceuticalsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_MeltPharmaceuticalsIncMember_lbl" xml:lang="en-US">Melt Pharmaceuticals, Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SurfacePharmaceuticalsIncMember" xlink:label="HROW_SurfacePharmaceuticalsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SurfacePharmaceuticalsIncMember" xlink:to="HROW_SurfacePharmaceuticalsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_SurfacePharmaceuticalsIncMember_lbl" xml:lang="en-US">Surface Pharmaceuticals Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ParkCompoundingIncAndNoiceRxLLCMember" xlink:label="HROW_ParkCompoundingIncAndNoiceRxLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ParkCompoundingIncAndNoiceRxLLCMember" xlink:to="HROW_ParkCompoundingIncAndNoiceRxLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ParkCompoundingIncAndNoiceRxLLCMember_lbl" xml:lang="en-US">Park Compounding Inc And Noice Rx L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StockOptionsUnvestedRSUsAndWarrantsMember" xlink:label="HROW_StockOptionsUnvestedRSUsAndWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StockOptionsUnvestedRSUsAndWarrantsMember" xlink:to="HROW_StockOptionsUnvestedRSUsAndWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_StockOptionsUnvestedRSUsAndWarrantsMember_lbl" xml:lang="en-US">Stock Options Unvested R S Us And Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StockOptionsMember" xlink:label="HROW_StockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StockOptionsMember" xlink:to="HROW_StockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_StockOptionsMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CommissionsMember" xlink:label="HROW_CommissionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommissionsMember" xlink:to="HROW_CommissionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CommissionsMember_lbl" xml:lang="en-US">Commissions [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseMember_lbl" xml:lang="en-US">License [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ManagementServicesAgreementMember" xlink:label="HROW_ManagementServicesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ManagementServicesAgreementMember" xlink:to="HROW_ManagementServicesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ManagementServicesAgreementMember_lbl" xml:lang="en-US">Management Services Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MSAMember" xlink:label="HROW_MSAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MSAMember" xlink:to="HROW_MSAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="HROW_MSAMember_lbl" xml:lang="en-US">Management Services Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DrLindstromMember" xlink:label="HROW_DrLindstromMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DrLindstromMember" xlink:to="HROW_DrLindstromMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_DrLindstromMember_lbl" xml:lang="en-US">Dr. Lindstrom [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_LicensesMember" xlink:label="HROW_LicensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LicensesMember" xlink:to="HROW_LicensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_LicensesMember_lbl" xml:lang="en-US">Licenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember" xlink:label="us-gaap_TrademarksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TrademarksMember" xlink:to="us-gaap_TrademarksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TrademarksMember_lbl" xml:lang="en-US">Trademarks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="us-gaap_CustomerRelationshipsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerRelationshipsMember_lbl" xml:lang="en-US">Customer Relationships [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="us-gaap_TradeNamesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeNamesMember" xlink:to="us-gaap_TradeNamesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeNamesMember_lbl" xml:lang="en-US">Trade Names [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_NonCompetitionClauseMember" xlink:label="HROW_NonCompetitionClauseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_NonCompetitionClauseMember" xlink:to="HROW_NonCompetitionClauseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_NonCompetitionClauseMember_lbl" xml:lang="en-US">Non-Competition Clause [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StatePharmacyLicensesMember" xlink:label="HROW_StatePharmacyLicensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StatePharmacyLicensesMember" xlink:to="HROW_StatePharmacyLicensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_StatePharmacyLicensesMember_lbl" xml:lang="en-US">State Pharmacy Licenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember" xlink:label="HROW_CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember" xlink:to="HROW_CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember_lbl" xml:lang="en-US">Customer Relationships, Trade Name and State Pharmacy Licenses [Member</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ParkCompoundingIncMember" xlink:label="HROW_ParkCompoundingIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ParkCompoundingIncMember" xlink:to="HROW_ParkCompoundingIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ParkCompoundingIncMember_lbl" xml:lang="en-US">Park Compounding, Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_PatentsFilingsAndTrademarksMember" xlink:label="HROW_PatentsFilingsAndTrademarksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_PatentsFilingsAndTrademarksMember" xlink:to="HROW_PatentsFilingsAndTrademarksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_PatentsFilingsAndTrademarksMember_lbl" xml:lang="en-US">Patents Filings and Trademarks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_TermLoanAndSecurityAgreementMember" xlink:label="HROW_TermLoanAndSecurityAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_TermLoanAndSecurityAgreementMember" xlink:to="HROW_TermLoanAndSecurityAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_TermLoanAndSecurityAgreementMember_lbl" xml:lang="en-US">Term Loan and Security Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SWKFundingLLCMember" xlink:label="HROW_SWKFundingLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SWKFundingLLCMember" xlink:to="HROW_SWKFundingLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_SWKFundingLLCMember_lbl" xml:lang="en-US">SWK Funding LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US">Variable Rate [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember_lbl" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SWKLoanAgreementMember" xlink:label="HROW_SWKLoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SWKLoanAgreementMember" xlink:to="HROW_SWKLoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_SWKLoanAgreementMember_lbl" xml:lang="en-US">SWK Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_LenderWarrantsMember" xlink:label="HROW_LenderWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LenderWarrantsMember" xlink:to="HROW_LenderWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_LenderWarrantsMember_lbl" xml:lang="en-US">Lender Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_JoinderAndAmendmentMember" xlink:label="HROW_JoinderAndAmendmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_JoinderAndAmendmentMember" xlink:to="HROW_JoinderAndAmendmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_JoinderAndAmendmentMember_lbl" xml:lang="en-US">Joinder and Amendment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MarginRateMember" xlink:label="HROW_MarginRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MarginRateMember" xlink:to="HROW_MarginRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_MarginRateMember_lbl" xml:lang="en-US">Margin Rate [Member].</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SWKSecondAmendmentMember" xlink:label="HROW_SWKSecondAmendmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SWKSecondAmendmentMember" xlink:to="HROW_SWKSecondAmendmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_SWKSecondAmendmentMember_lbl" xml:lang="en-US">SWK Second Amendment [Member].</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_BusinessLoanAgreementMember" xlink:label="HROW_BusinessLoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_BusinessLoanAgreementMember" xlink:to="HROW_BusinessLoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_BusinessLoanAgreementMember_lbl" xml:lang="en-US">Business Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_OfficeAndLaboratorySpaceMember" xlink:label="HROW_OfficeAndLaboratorySpaceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_OfficeAndLaboratorySpaceMember" xlink:to="HROW_OfficeAndLaboratorySpaceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_OfficeAndLaboratorySpaceMember_lbl" xml:lang="en-US">Office And Laboratory Space [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SanDiegoMember" xlink:label="HROW_SanDiegoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SanDiegoMember" xlink:to="HROW_SanDiegoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_SanDiegoMember_lbl" xml:lang="en-US">San Diego [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_LedgewoodMember" xlink:label="HROW_LedgewoodMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LedgewoodMember" xlink:to="HROW_LedgewoodMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_LedgewoodMember_lbl" xml:lang="en-US">Ledgewood [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_NashvilleMember" xlink:label="HROW_NashvilleMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_NashvilleMember" xlink:to="HROW_NashvilleMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_NashvilleMember_lbl" xml:lang="en-US">Nashville [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_IrvineMember" xlink:label="HROW_IrvineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_IrvineMember" xlink:to="HROW_IrvineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_IrvineMember_lbl" xml:lang="en-US">Irvine [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RangeOneMember" xlink:label="HROW_RangeOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeOneMember" xlink:to="HROW_RangeOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_RangeOneMember_lbl" xml:lang="en-US">Range One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RangeTwoMember" xlink:label="HROW_RangeTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeTwoMember" xlink:to="HROW_RangeTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_RangeTwoMember_lbl" xml:lang="en-US">Range Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CommonStockWarrantsOneMember" xlink:label="HROW_CommonStockWarrantsOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommonStockWarrantsOneMember" xlink:to="HROW_CommonStockWarrantsOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CommonStockWarrantsOneMember_lbl" xml:lang="en-US">Common Stock Warrants One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CommonStockWarrantsTwoMember" xlink:label="HROW_CommonStockWarrantsTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommonStockWarrantsTwoMember" xlink:to="HROW_CommonStockWarrantsTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CommonStockWarrantsTwoMember_lbl" xml:lang="en-US">Common Stock Warrants Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember" xlink:label="HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember" xlink:to="HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_lbl" xml:lang="en-US">2017 Incentive Stock and Awards Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StockOptionPlanOneMember" xlink:label="HROW_StockOptionPlanOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StockOptionPlanOneMember" xlink:to="HROW_StockOptionPlanOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_StockOptionPlanOneMember_lbl" xml:lang="en-US">Stock Option Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StockOptionPlanMember" xlink:label="HROW_StockOptionPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StockOptionPlanMember" xlink:to="HROW_StockOptionPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="HROW_StockOptionPlanMember_lbl" xml:lang="en-US">Stock Option Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_EmployeesAndConsultantMember" xlink:label="HROW_EmployeesAndConsultantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_EmployeesAndConsultantMember" xlink:to="HROW_EmployeesAndConsultantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_EmployeesAndConsultantMember_lbl" xml:lang="en-US">Employees and Consultant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_BaumPerformanceOptionMember" xlink:label="HROW_BaumPerformanceOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_BaumPerformanceOptionMember" xlink:to="HROW_BaumPerformanceOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_BaumPerformanceOptionMember_lbl" xml:lang="en-US">Baum Performance Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_OptionsEmployeesMember" xlink:label="HROW_OptionsEmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_OptionsEmployeesMember" xlink:to="HROW_OptionsEmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_OptionsEmployeesMember_lbl" xml:lang="en-US">Options Granted to Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RangeThreeMember" xlink:label="HROW_RangeThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeThreeMember" xlink:to="HROW_RangeThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_RangeThreeMember_lbl" xml:lang="en-US">Range Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RangeFourMember" xlink:label="HROW_RangeFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeFourMember" xlink:to="HROW_RangeFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_RangeFourMember_lbl" xml:lang="en-US">Range Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_EmployeesMember" xlink:label="HROW_EmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_EmployeesMember" xlink:to="HROW_EmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_EmployeesMember_lbl" xml:lang="en-US">Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_BoardOfDirectorsMember" xlink:label="HROW_BoardOfDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_BoardOfDirectorsMember" xlink:to="HROW_BoardOfDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_BoardOfDirectorsMember_lbl" xml:lang="en-US">Board of Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_UnvestedRSUMember" xlink:label="HROW_UnvestedRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_UnvestedRSUMember" xlink:to="HROW_UnvestedRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_UnvestedRSUMember_lbl" xml:lang="en-US">Unvested RSUs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_EllePharmaceuticalLLCMember" xlink:label="HROW_EllePharmaceuticalLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_EllePharmaceuticalLLCMember" xlink:to="HROW_EllePharmaceuticalLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_EllePharmaceuticalLLCMember_lbl" xml:lang="en-US">Elle Pharmaceutical, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_LicenseAgreementMember" xlink:label="HROW_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LicenseAgreementMember" xlink:to="HROW_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MarkBaumCEOMember" xlink:label="HROW_MarkBaumCEOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MarkBaumCEOMember" xlink:to="HROW_MarkBaumCEOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_MarkBaumCEOMember_lbl" xml:lang="en-US">Mark Baum C E O [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AndrewBollCFOMember" xlink:label="HROW_AndrewBollCFOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_AndrewBollCFOMember" xlink:to="HROW_AndrewBollCFOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_AndrewBollCFOMember_lbl" xml:lang="en-US">Andrew Boll C F O [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ConsultantMember" xlink:label="HROW_ConsultantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ConsultantMember" xlink:to="HROW_ConsultantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ConsultantMember_lbl" xml:lang="en-US">Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_VisionologyIncMember" xlink:label="HROW_VisionologyIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_VisionologyIncMember" xlink:to="HROW_VisionologyIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_VisionologyIncMember_lbl" xml:lang="en-US">Visionology Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SellingGeneralAndAdministrativeMember" xlink:label="HROW_SellingGeneralAndAdministrativeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SellingGeneralAndAdministrativeMember" xlink:to="HROW_SellingGeneralAndAdministrativeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_SellingGeneralAndAdministrativeMember_lbl" xml:lang="en-US">Selling, General and Administrative [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SettlementWarrantsMember" xlink:label="HROW_SettlementWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SettlementWarrantsMember" xlink:to="HROW_SettlementWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_SettlementWarrantsMember_lbl" xml:lang="en-US">Settlement Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_LenderWarrantsOneMember" xlink:label="HROW_LenderWarrantsOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LenderWarrantsOneMember" xlink:to="HROW_LenderWarrantsOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_LenderWarrantsOneMember_lbl" xml:lang="en-US">Lender Warrants One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SettlementAgreementMember" xlink:label="HROW_SettlementAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SettlementAgreementMember" xlink:to="HROW_SettlementAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_SettlementAgreementMember_lbl" xml:lang="en-US">Settlement Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AllerganUSAIncMember" xlink:label="HROW_AllerganUSAIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_AllerganUSAIncMember" xlink:to="HROW_AllerganUSAIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_AllerganUSAIncMember_lbl" xml:lang="en-US">Allergan USA, Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SalesAndMarketingAgreementsMember" xlink:label="HROW_SalesAndMarketingAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SalesAndMarketingAgreementsMember" xlink:to="HROW_SalesAndMarketingAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_SalesAndMarketingAgreementsMember_lbl" xml:lang="en-US">Sales and Marketing Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_KlarityLicenseAgreementMember" xlink:label="HROW_KlarityLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_KlarityLicenseAgreementMember" xlink:to="HROW_KlarityLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_KlarityLicenseAgreementMember_lbl" xml:lang="en-US">Klarity License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RichardLLindstromMDMember" xlink:label="HROW_RichardLLindstromMDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RichardLLindstromMDMember" xlink:to="HROW_RichardLLindstromMDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_RichardLLindstromMDMember_lbl" xml:lang="en-US">Richard L. Lindstrom, M.D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_InitialPaymentMember" xlink:label="HROW_InitialPaymentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_InitialPaymentMember" xlink:to="HROW_InitialPaymentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_InitialPaymentMember_lbl" xml:lang="en-US">Initial Payment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SecondPaymentMember" xlink:label="HROW_SecondPaymentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SecondPaymentMember" xlink:to="HROW_SecondPaymentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_SecondPaymentMember_lbl" xml:lang="en-US">DirectorSellingAndAdminstrativeMember</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_FinalPaymentMember" xlink:label="HROW_FinalPaymentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_FinalPaymentMember" xlink:to="HROW_FinalPaymentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_FinalPaymentMember_lbl" xml:lang="en-US">Final Payment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_InjectableAssetPurchaseAgreementMember" xlink:label="HROW_InjectableAssetPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_InjectableAssetPurchaseAgreementMember" xlink:to="HROW_InjectableAssetPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_InjectableAssetPurchaseAgreementMember_lbl" xml:lang="en-US">Injectable Asset Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_PresbyopiaAssetPurchaseAgreementMember" xlink:label="HROW_PresbyopiaAssetPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_PresbyopiaAssetPurchaseAgreementMember" xlink:to="HROW_PresbyopiaAssetPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_PresbyopiaAssetPurchaseAgreementMember_lbl" xml:lang="en-US">Presbyopia Asset Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DexycuAgreementMember" xlink:label="HROW_DexycuAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DexycuAgreementMember" xlink:to="HROW_DexycuAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_DexycuAgreementMember_lbl" xml:lang="en-US">Dexycu Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidationItemsAxis_lbl" xml:lang="en-US">Consolidation Items [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xml:lang="en-US">Operating Segments [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_PharmaceuticalCompoundingMember" xlink:label="HROW_PharmaceuticalCompoundingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_PharmaceuticalCompoundingMember" xlink:to="HROW_PharmaceuticalCompoundingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_PharmaceuticalCompoundingMember_lbl" xml:lang="en-US">Pharmaceutical Compounding [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_PharmaceuticalDrugDevelopmentMember" xlink:label="HROW_PharmaceuticalDrugDevelopmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_PharmaceuticalDrugDevelopmentMember" xlink:to="HROW_PharmaceuticalDrugDevelopmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_PharmaceuticalDrugDevelopmentMember_lbl" xml:lang="en-US">Pharmaceutical Drug Development [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="us-gaap_CorporateNonSegmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateNonSegmentMember" xlink:to="us-gaap_CorporateNonSegmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateNonSegmentMember_lbl" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ThreeMainSuppliersMember" xlink:label="HROW_ThreeMainSuppliersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ThreeMainSuppliersMember" xlink:to="HROW_ThreeMainSuppliersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ThreeMainSuppliersMember_lbl" xml:lang="en-US">Three Main Suppliers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AndrewRBollMember" xlink:label="HROW_AndrewRBollMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_AndrewRBollMember" xlink:to="HROW_AndrewRBollMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_AndrewRBollMember_lbl" xml:lang="en-US">Andrew R Boll [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MarkLBaumMember" xlink:label="HROW_MarkLBaumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MarkLBaumMember" xlink:to="HROW_MarkLBaumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_MarkLBaumMember_lbl" xml:lang="en-US">Mark L Baum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:label="srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems_lbl" xml:lang="en-US">Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents, including restricted cash of $200</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestments" xlink:label="us-gaap_OtherInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInvestments" xlink:to="us-gaap_OtherInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherInvestments_lbl" xml:lang="en-US">Investment in Eton Pharmaceuticals</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Investments" xlink:to="us-gaap_Investments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Investments_lbl" xml:lang="en-US">Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued payroll and related liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Deferred revenue and customer deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableCurrent" xlink:to="us-gaap_LoansPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayableCurrent_lbl" xml:lang="en-US">Current portion of paycheck protection program loan payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Current portion of loan payable, net of unamortized debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of finance lease obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Finance lease obligations, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Accrued expenses, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US">Paycheck protection program loan payable, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Loan payable, net of current portion and unamortized debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value, 50,000,000 shares authorized, 25,749,875 and 25,526,931 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL HARROW HEALTH STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Noncontrolling interests</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">TOTAL EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, sharess authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Total revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of sales</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US">Impairment of long-lived assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Income (loss) from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnInvestments_lbl" xml:lang="en-US">Investment (loss) gain, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other (loss) income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other (loss) income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income tax provision</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax provision</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Total net loss including noncontrolling interests</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net loss attributable to noncontrolling interests</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net (loss) income attributable to Harrow Health, Inc.</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic net (loss) income per share of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net (loss) income per share of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of common shares outstanding, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of common shares outstanding, diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StockIssuedDuringPeriodForExerciseOfWarrants" xlink:label="HROW_StockIssuedDuringPeriodForExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StockIssuedDuringPeriodForExerciseOfWarrants" xlink:to="HROW_StockIssuedDuringPeriodForExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_StockIssuedDuringPeriodForExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StockIssuedDuringPeriodSharesForExerciseOfWarrants" xlink:label="HROW_StockIssuedDuringPeriodSharesForExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StockIssuedDuringPeriodSharesForExerciseOfWarrants" xlink:to="HROW_StockIssuedDuringPeriodSharesForExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_StockIssuedDuringPeriodSharesForExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl" xml:lang="en-US">Exercise of employee options, net of tax withholding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl" xml:lang="en-US">Exercise of employee stock-based options, net of tax withholding , shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of common stock related to vesting of RSUs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of common stock related to vesting of RSUs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock-based payment for services provided</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Stock-based payment for services provided, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_3_lbl" xml:lang="en-US">Net loss (including noncontrolling interests)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization of property, plant and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AmortizationOfIntangibleAsset" xlink:label="HROW_AmortizationOfIntangibleAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_AmortizationOfIntangibleAsset" xlink:to="HROW_AmortizationOfIntangibleAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_AmortizationOfIntangibleAsset_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AmortizationOfOperatingLeaseRightofuseAssets" xlink:label="HROW_AmortizationOfOperatingLeaseRightofuseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_AmortizationOfOperatingLeaseRightofuseAssets" xlink:to="HROW_AmortizationOfOperatingLeaseRightofuseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_AmortizationOfOperatingLeaseRightofuseAssets_lbl" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provision for bad debt expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US">Interest paid-in-kind on SWK Loan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt issuance costs and discount</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_GainLossOnInvestmentsOne" xlink:label="HROW_GainLossOnInvestmentsOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_GainLossOnInvestmentsOne" xlink:to="HROW_GainLossOnInvestmentsOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="HROW_GainLossOnInvestmentsOne_lbl" xml:lang="en-US">Investment gain from Eton Pharmaceuticals, net</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_GainLossOnInvestmentsTwo" xlink:label="HROW_GainLossOnInvestmentsTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_GainLossOnInvestmentsTwo" xlink:to="HROW_GainLossOnInvestmentsTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="HROW_GainLossOnInvestmentsTwo_lbl" xml:lang="en-US">Investment loss from Surface Ophthalmics, net</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_GainLossOnInvestmentsThree" xlink:label="HROW_GainLossOnInvestmentsThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_GainLossOnInvestmentsThree" xlink:to="HROW_GainLossOnInvestmentsThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="HROW_GainLossOnInvestmentsThree_lbl" xml:lang="en-US">Investment loss (gain) from Melt Pharmaceuticals, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US">Loss on disposal of equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ImpairmentsOfLongLivedAssetsHeldForUse" xlink:label="HROW_ImpairmentsOfLongLivedAssetsHeldForUse" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ImpairmentsOfLongLivedAssetsHeldForUse" xlink:to="HROW_ImpairmentsOfLongLivedAssetsHeldForUse_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="HROW_ImpairmentsOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US">Impairment of long-lived assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Stock-based payment of consulting services</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Accrued payroll and related liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Deferred revenue and customer deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xml:lang="en-US">Proceeds on sale and disposal of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Investment in patent and trademark assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">NET CASH USED IN INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payments on finance lease obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromOtherDebt" xlink:label="us-gaap_ProceedsFromOtherDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherDebt" xlink:to="us-gaap_ProceedsFromOtherDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherDebt_lbl" xml:lang="en-US">Proceeds from SWK loan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Principal payments on SWK loan</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_PaymentsOfCostsRelatedToAmendmentOfLoanPayable" xlink:label="HROW_PaymentsOfCostsRelatedToAmendmentOfLoanPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_PaymentsOfCostsRelatedToAmendmentOfLoanPayable" xlink:to="HROW_PaymentsOfCostsRelatedToAmendmentOfLoanPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="HROW_PaymentsOfCostsRelatedToAmendmentOfLoanPayable_lbl" xml:lang="en-US">Payments of costs related to amendment of SWK loan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from Paycheck protection program loan payable</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ProceedsFromExerciseOfWarrantsAndStockOptionsNetOfTaxes" xlink:label="HROW_ProceedsFromExerciseOfWarrantsAndStockOptionsNetOfTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ProceedsFromExerciseOfWarrantsAndStockOptionsNetOfTaxes" xlink:to="HROW_ProceedsFromExerciseOfWarrantsAndStockOptionsNetOfTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ProceedsFromExerciseOfWarrantsAndStockOptionsNetOfTaxes_lbl" xml:lang="en-US">Net proceeds from exercise of warrants and stock options, net of taxes remitted for RSU&#8217;s and options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract" xlink:label="HROW_ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract" xlink:to="HROW_ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract_lbl" xml:lang="en-US">RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_RestrictedCash_2_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod" xlink:label="HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod" xlink:to="HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod_lbl" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" xlink:label="HROW_PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" xlink:to="HROW_PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedExpenses_lbl" xml:lang="en-US">Purchase of property, plant and equipment included in accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_NewAndRevaluationOfRightofuseAssetObtainedInExchangeForLeaseObligation" xlink:label="HROW_NewAndRevaluationOfRightofuseAssetObtainedInExchangeForLeaseObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_NewAndRevaluationOfRightofuseAssetObtainedInExchangeForLeaseObligation" xlink:to="HROW_NewAndRevaluationOfRightofuseAssetObtainedInExchangeForLeaseObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_NewAndRevaluationOfRightofuseAssetObtainedInExchangeForLeaseObligation_lbl" xml:lang="en-US">New and revaluation of right-of-use assets obtained in exchange for lease obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">ORGANIZATION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">REVENUES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract" xlink:label="HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract" xlink:to="HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Investment In Surface Ophthalmics Inc. And Agreements - Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock" xlink:label="HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock" xlink:to="HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock_lbl" xml:lang="en-US">INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DisclosureRestrictedCashAbstract" xlink:label="HROW_DisclosureRestrictedCashAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DisclosureRestrictedCashAbstract" xlink:to="HROW_DisclosureRestrictedCashAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="HROW_DisclosureRestrictedCashAbstract_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RestrictedCashTextBlock" xlink:label="HROW_RestrictedCashTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RestrictedCashTextBlock" xlink:to="HROW_RestrictedCashTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_RestrictedCashTextBlock_lbl" xml:lang="en-US">RESTRICTED CASH</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS AND GOODWILL</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">DEBT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">EMPLOYEE SAVINGS PLAN</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT INFORMATION AND CONCENTRATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RisksUncertaintiesAndLiquidityPolicyTextBlock" xlink:label="HROW_RisksUncertaintiesAndLiquidityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RisksUncertaintiesAndLiquidityPolicyTextBlock" xlink:to="HROW_RisksUncertaintiesAndLiquidityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_RisksUncertaintiesAndLiquidityPolicyTextBlock_lbl" xml:lang="en-US">Risks, Uncertainties and Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segments</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_NoncontrollingInterestPolicyTextBlock" xlink:label="HROW_NoncontrollingInterestPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_NoncontrollingInterestPolicyTextBlock" xlink:to="HROW_NoncontrollingInterestPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_NoncontrollingInterestPolicyTextBlock_lbl" xml:lang="en-US">Noncontrolling Interests</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition and Deferred Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CostOfSalePolicyTextBlock" xlink:label="HROW_CostOfSalePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CostOfSalePolicyTextBlock" xlink:to="HROW_CostOfSalePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CostOfSalePolicyTextBlock_lbl" xml:lang="en-US">Cost of Sales</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Debt Issuance Costs and Debt Discount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xml:lang="en-US">Intellectual Property</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">Investment in Eton Pharmaceuticals, Inc. &#8211; Related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US">Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_InvestmentOnePolicyTextBlock" xlink:label="HROW_InvestmentOnePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_InvestmentOnePolicyTextBlock" xlink:to="HROW_InvestmentOnePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_InvestmentOnePolicyTextBlock_lbl" xml:lang="en-US">Investment in Melt Pharmaceuticals, Inc. &#8211; Related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_InvestmentTwoPolicyTextBlock" xlink:label="HROW_InvestmentTwoPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_InvestmentTwoPolicyTextBlock" xlink:to="HROW_InvestmentTwoPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_InvestmentTwoPolicyTextBlock_lbl" xml:lang="en-US">Investment in Surface Ophthalmics, Inc. &#8211; Related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xml:lang="en-US">Business Combinations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RestructuringPolicyTextBlock" xlink:label="HROW_RestructuringPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RestructuringPolicyTextBlock" xlink:to="HROW_RestructuringPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_RestructuringPolicyTextBlock_lbl" xml:lang="en-US">Park Restructuring</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Net Income (Loss) per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:label="HROW_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:to="HROW_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassifications</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_lbl" xml:lang="en-US">SCHEDULE OF BASIC EARNINGS PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DILUTED EARNINGS PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DISAGGREGATED REVENUE</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock" xlink:label="HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock" xlink:to="HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF CONDENSED INCOME STATEMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock" xlink:label="HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock" xlink:to="HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF CONDENSED BALANCE SHEET</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl" xml:lang="en-US">SUMMARY OF CONDENSED INCOME STATEMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xml:lang="en-US">SUMMARY OF CONDENSED BALANCE SHEET</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INVENTORIES</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xml:lang="en-US">SCHEDULE OF GOODWILL</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US">SUMMARY OF FUTURE MINIMUM PAYMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION PLAN ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE ASSUMPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WARRANTS ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ScheduleofWarrantsOutstandingAndExercisableTableTextBlock" xlink:label="HROW_ScheduleofWarrantsOutstandingAndExercisableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ScheduleofWarrantsOutstandingAndExercisableTableTextBlock" xlink:to="HROW_ScheduleofWarrantsOutstandingAndExercisableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ScheduleofWarrantsOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROVISION FOR INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INCOME TAX RECONCILIATION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF SEGMENT NET REVENUES, SEGMENT OPERATING EXPENSES AND SEGMENT CONTRIBUTION</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Numerator &#8211; net (loss) income attributable to Harrow Health, Inc.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Denominator &#8211; weighted average number of shares outstanding, basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">Net (loss) income per share, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xml:lang="en-US">Dilutive common equivalent shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Numerator &#8211; net income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3_lbl" xml:lang="en-US">Weighted average number of shares outstanding, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_IncrementalCommonSharesAttributableDilutiveCommonEquivalents" xlink:label="HROW_IncrementalCommonSharesAttributableDilutiveCommonEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_IncrementalCommonSharesAttributableDilutiveCommonEquivalents" xlink:to="HROW_IncrementalCommonSharesAttributableDilutiveCommonEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_IncrementalCommonSharesAttributableDilutiveCommonEquivalents_lbl" xml:lang="en-US">Dilutive common equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:label="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:to="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_lbl" xml:lang="en-US">Denominator &#8211; number of shares used for diluted earnings per share computation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_2_lbl" xml:lang="en-US">Net income per share, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ConsolidationBasisDescription" xlink:label="HROW_ConsolidationBasisDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ConsolidationBasisDescription" xlink:to="HROW_ConsolidationBasisDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ConsolidationBasisDescription_lbl" xml:lang="en-US">Consolidation basis, description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingIncomeLoss_3_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RetainedEarningsAccumulatedDeficit1" xlink:label="HROW_RetainedEarningsAccumulatedDeficit1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RetainedEarningsAccumulatedDeficit1" xlink:to="HROW_RetainedEarningsAccumulatedDeficit1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="HROW_RetainedEarningsAccumulatedDeficit1_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of Reportable Segments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDescription" xlink:label="us-gaap_MinorityInterestDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDescription" xlink:to="us-gaap_MinorityInterestDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestDescription_lbl" xml:lang="en-US">Noncontrolling Interest, Description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash, FDIC Insured Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_NumberOfSharesOwned" xlink:label="HROW_NumberOfSharesOwned" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_NumberOfSharesOwned" xlink:to="HROW_NumberOfSharesOwned_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_NumberOfSharesOwned_lbl" xml:lang="en-US">Number of shares owned</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainLossOnInvestments_2_lbl" xml:lang="en-US">Gain (Loss) on Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="us-gaap_InvestmentOwnedAtFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtFairValue" xlink:to="us-gaap_InvestmentOwnedAtFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl" xml:lang="en-US">Investment Owned, at Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="us-gaap_DeconsolidationGainOrLossAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeconsolidationGainOrLossAmount" xlink:to="us-gaap_DeconsolidationGainOrLossAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeconsolidationGainOrLossAmount_lbl" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="us-gaap_DueFromRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedParties" xlink:to="us-gaap_DueFromRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedParties_lbl" xml:lang="en-US">Due from Related Parties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Asset Impairment Charges</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US">Severance Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_2_lbl" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsLineItems" xlink:label="dei_EntityListingsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityListingsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityListingsLineItems_lbl" xml:lang="en-US">Entity Listings [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Revenues, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingIncomeLoss_4_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Non current assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Total assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Total preferred stock and stockholders' equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdministrativeFeesExpense" xlink:label="us-gaap_AdministrativeFeesExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdministrativeFeesExpense" xlink:to="us-gaap_AdministrativeFeesExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdministrativeFeesExpense_lbl" xml:lang="en-US">Administrative Fees Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Repayments of Related Party Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Total stockholders equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RoyaltyPaymentPercentageOnNetSales" xlink:label="HROW_RoyaltyPaymentPercentageOnNetSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RoyaltyPaymentPercentageOnNetSales" xlink:to="HROW_RoyaltyPaymentPercentageOnNetSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_RoyaltyPaymentPercentageOnNetSales_lbl" xml:lang="en-US">Royalty payment percentage on net sales</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work in progress</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">Total inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Deposits and other current assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl" xml:lang="en-US">Computer software and hardware</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xml:lang="en-US">Furniture and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentGross_lbl" xml:lang="en-US">Lab and pharmacy equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Leasehold improvements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">&#160;Property, plant and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property, plant and equipment, net&#160;</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_2_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="us-gaap_DepreciationAmortizationAndAccretionNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAmortizationAndAccretionNet" xlink:to="us-gaap_DepreciationAmortizationAndAccretionNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DepreciationAmortizationAndAccretionNet_lbl" xml:lang="en-US">Depreciation, Amortization and Accretion, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_FiniteLivedIntangibleAssetsImpairment" xlink:label="HROW_FiniteLivedIntangibleAssetsImpairment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_FiniteLivedIntangibleAssetsImpairment" xlink:to="HROW_FiniteLivedIntangibleAssetsImpairment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_FiniteLivedIntangibleAssetsImpairment_lbl" xml:lang="en-US">Impairment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xml:lang="en-US">Net Carrying value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Method</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Goodwill_2_lbl" xml:lang="en-US">Balance at December 31, 2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Impairment of Park goodwill (see Note 2)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Goodwill_3_lbl" xml:lang="en-US">Balance at December 31, 2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Other accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued interest (see Note 12)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued exit fee for note payable (see Note 12)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Total accounts payable and accrued expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Less: Current portion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Non-current total accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Total minimum payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Less: amount representing interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Notes payable, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Less: unamortized discount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_NotesPayableCurrent1" xlink:label="HROW_NotesPayableCurrent1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_NotesPayableCurrent1" xlink:to="HROW_NotesPayableCurrent1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_NotesPayableCurrent1_lbl" xml:lang="en-US">Less: current portion, net of unamortized discount</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_LongTermNotesPayable1" xlink:label="HROW_LongTermNotesPayable1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LongTermNotesPayable1" xlink:to="HROW_LongTermNotesPayable1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_LongTermNotesPayable1_lbl" xml:lang="en-US">Note payable, net of current portion and unamortized debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xml:lang="en-US">Debt Instrument, Description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xml:lang="en-US">Debt instrument interest rate description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US">Loan bear interest at variable rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repayments of Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xml:lang="en-US">Debt Instrument, Maturity Date, Description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2_lbl" xml:lang="en-US">Accrued Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal Fees</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DeconsolidationPercentage" xlink:label="HROW_DeconsolidationPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DeconsolidationPercentage" xlink:to="HROW_DeconsolidationPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_DeconsolidationPercentage_lbl" xml:lang="en-US">Deconsolidation percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest Expense, Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: amount representing interest payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Less: current portion, operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: amount representing interest payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Present value of future minimum lease payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Less: current portion, finance lease obligation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Finance lease obligation, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of Land</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_LeaseExpirationDateDescription" xlink:label="HROW_LeaseExpirationDateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LeaseExpirationDateDescription" xlink:to="HROW_LeaseExpirationDateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_LeaseExpirationDateDescription_lbl" xml:lang="en-US">Lease expiration date description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xml:lang="en-US">Lessee, Operating Lease, Option to Extend</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AdditionalAreaOfLand" xlink:label="HROW_AdditionalAreaOfLand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_AdditionalAreaOfLand" xlink:to="HROW_AdditionalAreaOfLand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_AdditionalAreaOfLand_lbl" xml:lang="en-US">Additional square footage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnTerminationOfLease" xlink:to="us-gaap_GainLossOnTerminationOfLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xml:lang="en-US">Gain (Loss) on Termination of Lease</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating Lease, Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MonthlyPaymentsOfFinanceLeaseForEquipment" xlink:label="HROW_MonthlyPaymentsOfFinanceLeaseForEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MonthlyPaymentsOfFinanceLeaseForEquipment" xlink:to="HROW_MonthlyPaymentsOfFinanceLeaseForEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_MonthlyPaymentsOfFinanceLeaseForEquipment_lbl" xml:lang="en-US">Monthly payments of finance lease</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of shares, Outstanding, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Avg. Exercise Price, Outstanding, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of shares, Options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Avg. Exercise Price, Options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of shares, Options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Avg. Exercise Price, Options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of shares, Options cancelled/forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Avg. Exercise Price, Options cancelled/forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of shares, Outstanding, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Avg. Exercise Price, Outstanding, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Avg. Remaining Contractual Life, Options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of shares, Options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Avg. Exercise Price, Exercisable Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Avg. Remaining Contractual Life, Options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of shares, Options vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Avg. Exercise Price, Vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Avg. Remaining Contractual Life, Options vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average fair value of options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected terms (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Expected volatility, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Expected volatility, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Range of Exercise Prices, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of Exercise Prices, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Number of Options Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Number Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Weighted Average Exercisable Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of RSUs unvested, Outstanding, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of RSUs granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, RSUs granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of RSUs vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, RSUs vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of RSUs cancelled/forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of RSUs unvested, Outstanding, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_lbl" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock based compensation related to equity instruments granted to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares Warrants Outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:label="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:to="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Weighted Avg. Exercise Price, Outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Shares Warrants Outstanding, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Shares Warrants Outstanding, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Number of Shares Warrants Outstanding, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber" xlink:label="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber" xlink:to="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_lbl" xml:lang="en-US">Number of Shares Warrants Outstanding and Exercisable, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1" xlink:label="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1" xlink:to="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Weighted Avg. Exercise Price, Outstanding and Exercisable, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life of the outstanding warrants in years</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_WarrantsIssuanceDate" xlink:label="HROW_WarrantsIssuanceDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_WarrantsIssuanceDate" xlink:to="HROW_WarrantsIssuanceDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_WarrantsIssuanceDate_lbl" xml:lang="en-US">Issue Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" xlink:label="HROW_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" xlink:to="HROW_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_lbl" xml:lang="en-US">Warrants Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_WarrantsAndRightsOutstandingMaturityDates" xlink:label="HROW_WarrantsAndRightsOutstandingMaturityDates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_WarrantsAndRightsOutstandingMaturityDates" xlink:to="HROW_WarrantsAndRightsOutstandingMaturityDates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_WarrantsAndRightsOutstandingMaturityDates_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_2_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xml:lang="en-US">Shares issued of restricted common stock, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2_lbl" xml:lang="en-US">Number of restrcited shares, value</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_NumberOfCommonStockIssuedOnCashlessExercise" xlink:label="HROW_NumberOfCommonStockIssuedOnCashlessExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_NumberOfCommonStockIssuedOnCashlessExercise" xlink:to="HROW_NumberOfCommonStockIssuedOnCashlessExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_NumberOfCommonStockIssuedOnCashlessExercise_lbl" xml:lang="en-US">Number of common stock issued on cashless exercise</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2_lbl" xml:lang="en-US">Common shares issued under share-based arrangement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_2_lbl" xml:lang="en-US">Options exercise price, minimum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_2_lbl" xml:lang="en-US">Options exercise price, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CommonStockWithheldForPayrollTaxWithholdingsShare" xlink:label="HROW_CommonStockWithheldForPayrollTaxWithholdingsShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommonStockWithheldForPayrollTaxWithholdingsShare" xlink:to="HROW_CommonStockWithheldForPayrollTaxWithholdingsShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CommonStockWithheldForPayrollTaxWithholdingsShare_lbl" xml:lang="en-US">Common stock withheld for payroll tax withholdings, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CommonStockWithheldForPayrollTaxWithholdingsValue" xlink:label="HROW_CommonStockWithheldForPayrollTaxWithholdingsValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommonStockWithheldForPayrollTaxWithholdingsValue" xlink:to="HROW_CommonStockWithheldForPayrollTaxWithholdingsValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CommonStockWithheldForPayrollTaxWithholdingsValue_lbl" xml:lang="en-US">Common stock withheld for payroll tax withholdings, value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Warrants exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from issuance of warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RestrictedStockUnitsVested" xlink:label="HROW_RestrictedStockUnitsVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RestrictedStockUnitsVested" xlink:to="HROW_RestrictedStockUnitsVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_RestrictedStockUnitsVested_lbl" xml:lang="en-US">Restricted stock units vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Maximum number of common stock issuance under the plan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for future issuances</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ClosingPriceOfCommonStockPricePerShare" xlink:label="HROW_ClosingPriceOfCommonStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ClosingPriceOfCommonStockPricePerShare" xlink:to="HROW_ClosingPriceOfCommonStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ClosingPriceOfCommonStockPricePerShare_lbl" xml:lang="en-US">Closing price of common stock price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Intrinsic value of options exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xml:lang="en-US">Weighted avg. remaining contractual life, options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_lbl" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, plan modification, description and terms</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Number of shares, options granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Exercise price of options</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AverageStockPrice" xlink:label="HROW_AverageStockPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_AverageStockPrice" xlink:to="HROW_AverageStockPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_AverageStockPrice_lbl" xml:lang="en-US">Average stock price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Weighted avg. remaining contractual life, options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, vested in period, fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ForfeitureFactorPercentage" xlink:label="HROW_ForfeitureFactorPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ForfeitureFactorPercentage" xlink:to="HROW_ForfeitureFactorPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ForfeitureFactorPercentage_lbl" xml:lang="en-US">Forfeiture factor, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation expense related to unvested stock options granted under the plan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Expense expected to recognize over the weighted-average remaining vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Stock issued during period, shares, acquisitions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Number of common stock issued for consultants services</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AggregatePurchasePrice" xlink:label="HROW_AggregatePurchasePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_AggregatePurchasePrice" xlink:to="HROW_AggregatePurchasePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_AggregatePurchasePrice_lbl" xml:lang="en-US">Aggregate purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Current: Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">Current: State</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred: Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred: State</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DeferredIncomeChangeInValuationAllowance" xlink:label="HROW_DeferredIncomeChangeInValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DeferredIncomeChangeInValuationAllowance" xlink:to="HROW_DeferredIncomeChangeInValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_DeferredIncomeChangeInValuationAllowance_lbl" xml:lang="en-US">Deferred: Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income tax provision (benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S. federal statutory tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax benefit, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends_lbl" xml:lang="en-US">Employee stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">NOL&#8217;s</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization" xlink:label="HROW_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization" xlink:to="HROW_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development credits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Deferred stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_IncomeTaxBasisDifferenceInRelatedParty" xlink:label="HROW_IncomeTaxBasisDifferenceInRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_IncomeTaxBasisDifferenceInRelatedParty" xlink:to="HROW_IncomeTaxBasisDifferenceInRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="HROW_IncomeTaxBasisDifferenceInRelatedParty_lbl" xml:lang="en-US">Basis difference in Melt</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_IncomeTaxBasisDifferenceInRelatedPartyOne" xlink:label="HROW_IncomeTaxBasisDifferenceInRelatedPartyOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_IncomeTaxBasisDifferenceInRelatedPartyOne" xlink:to="HROW_IncomeTaxBasisDifferenceInRelatedPartyOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="HROW_IncomeTaxBasisDifferenceInRelatedPartyOne_lbl" xml:lang="en-US">Basis difference in Surface</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_IncomeTaxBasisDifferenceInRelatedPartyTwo" xlink:label="HROW_IncomeTaxBasisDifferenceInRelatedPartyTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_IncomeTaxBasisDifferenceInRelatedPartyTwo" xlink:to="HROW_IncomeTaxBasisDifferenceInRelatedPartyTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="HROW_IncomeTaxBasisDifferenceInRelatedPartyTwo_lbl" xml:lang="en-US">Basis difference in Eton</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DeferredTaxAssetsTaxDeferredExpenseCapitalLosses" xlink:label="HROW_DeferredTaxAssetsTaxDeferredExpenseCapitalLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DeferredTaxAssetsTaxDeferredExpenseCapitalLosses" xlink:to="HROW_DeferredTaxAssetsTaxDeferredExpenseCapitalLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_DeferredTaxAssetsTaxDeferredExpenseCapitalLosses_lbl" xml:lang="en-US">Capital losses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xml:lang="en-US">Park stock purchase identifiable intangibles</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DeferredTaxAssetsTaxDeferredExpenseLimitations" xlink:label="HROW_DeferredTaxAssetsTaxDeferredExpenseLimitations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DeferredTaxAssetsTaxDeferredExpenseLimitations" xlink:to="HROW_DeferredTaxAssetsTaxDeferredExpenseLimitations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_DeferredTaxAssetsTaxDeferredExpenseLimitations_lbl" xml:lang="en-US">Limitation under 163(j)</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability" xlink:label="HROW_DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability" xlink:to="HROW_DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability_lbl" xml:lang="en-US">ASC 842 lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset" xlink:label="HROW_DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset" xlink:to="HROW_DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="HROW_DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset_lbl" xml:lang="en-US">ASC 842 ROU asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Total deferred tax assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Deferred tax asset valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US">Federal net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">State net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StateNetOperatingLossExpirationDate" xlink:label="HROW_StateNetOperatingLossExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StateNetOperatingLossExpirationDate" xlink:to="HROW_StateNetOperatingLossExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_StateNetOperatingLossExpirationDate_lbl" xml:lang="en-US">State net operating loss expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_FederalNetOperatingLossCarryforwardDescription" xlink:label="HROW_FederalNetOperatingLossCarryforwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_FederalNetOperatingLossCarryforwardDescription" xlink:to="HROW_FederalNetOperatingLossCarryforwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_FederalNetOperatingLossCarryforwardDescription_lbl" xml:lang="en-US">Federal net operating loss carryforward description</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_FederalResearchAndDevelopmentTaxCredits" xlink:label="HROW_FederalResearchAndDevelopmentTaxCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_FederalResearchAndDevelopmentTaxCredits" xlink:to="HROW_FederalResearchAndDevelopmentTaxCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_FederalResearchAndDevelopmentTaxCredits_lbl" xml:lang="en-US">Federal research and development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StateResearchAndDevelopmentTaxCredits" xlink:label="HROW_StateResearchAndDevelopmentTaxCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StateResearchAndDevelopmentTaxCredits" xlink:to="HROW_StateResearchAndDevelopmentTaxCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_StateResearchAndDevelopmentTaxCredits_lbl" xml:lang="en-US">State research and development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_FederalResearchAndDevelopmentTaxCreditsExpirationDate" xlink:label="HROW_FederalResearchAndDevelopmentTaxCreditsExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_FederalResearchAndDevelopmentTaxCreditsExpirationDate" xlink:to="HROW_FederalResearchAndDevelopmentTaxCreditsExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_FederalResearchAndDevelopmentTaxCreditsExpirationDate_lbl" xml:lang="en-US">Federal research and development tax credits expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount" xlink:label="HROW_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount" xlink:to="HROW_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount_lbl" xml:lang="en-US">Percentage of salary deposits in tax deferred investment account</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Percentage of contributions made by the company</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xml:lang="en-US">Contributions by the company</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xml:lang="en-US">Accrued damages</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DamagesLowClaimRatePercentage" xlink:label="HROW_DamagesLowClaimRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DamagesLowClaimRatePercentage" xlink:to="HROW_DamagesLowClaimRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_DamagesLowClaimRatePercentage_lbl" xml:lang="en-US">Damages low claim rate, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="us-gaap_LossContingencyDamagesPaidValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesPaidValue" xlink:to="us-gaap_LossContingencyDamagesPaidValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesPaidValue_lbl" xml:lang="en-US">Litigation amount paid</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="us-gaap_LossContingencyDamagesAwardedValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesAwardedValue" xlink:to="us-gaap_LossContingencyDamagesAwardedValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesAwardedValue_lbl" xml:lang="en-US">Lost profit damages</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CommissionPaymentsPercentage" xlink:label="HROW_CommissionPaymentsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommissionPaymentsPercentage" xlink:to="HROW_CommissionPaymentsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CommissionPaymentsPercentage_lbl" xml:lang="en-US">Commission payments, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AdditionalPaidInCapitalAndShareBasedPayments" xlink:label="HROW_AdditionalPaidInCapitalAndShareBasedPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_AdditionalPaidInCapitalAndShareBasedPayments" xlink:to="HROW_AdditionalPaidInCapitalAndShareBasedPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_AdditionalPaidInCapitalAndShareBasedPayments_lbl" xml:lang="en-US">Additional paid in capital and stock based payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="us-gaap_SalesCommissionsAndFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesCommissionsAndFees" xlink:to="us-gaap_SalesCommissionsAndFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesCommissionsAndFees_lbl" xml:lang="en-US">Commission expense incurred</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl" xml:lang="en-US">Business acquisition description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty payments</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RoyaltyPaymentDescription" xlink:label="HROW_RoyaltyPaymentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RoyaltyPaymentDescription" xlink:to="HROW_RoyaltyPaymentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_RoyaltyPaymentDescription_lbl" xml:lang="en-US">Royalty payment description</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_NetSalesRevenue" xlink:label="HROW_NetSalesRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_NetSalesRevenue" xlink:to="HROW_NetSalesRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_NetSalesRevenue_lbl" xml:lang="en-US">Sales revenue net</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MilestonePaymentInCash" xlink:label="HROW_MilestonePaymentInCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MilestonePaymentInCash" xlink:to="HROW_MilestonePaymentInCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_MilestonePaymentInCash_lbl" xml:lang="en-US">Milestone payment in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MilestonePaymentsOnPayables" xlink:label="HROW_MilestonePaymentsOnPayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MilestonePaymentsOnPayables" xlink:to="HROW_MilestonePaymentsOnPayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_MilestonePaymentsOnPayables_lbl" xml:lang="en-US">Milestone payments on payables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xml:lang="en-US">Net Revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_2_lbl" xml:lang="en-US">Cost of sales</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SegmentContribution" xlink:label="HROW_SegmentContribution" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SegmentContribution" xlink:to="HROW_SegmentContribution_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_SegmentContribution_lbl" xml:lang="en-US">Segment contribution</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLoss_5_lbl" xml:lang="en-US">Operating income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortization" xlink:to="us-gaap_AdjustmentForAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentForAmortization_lbl" xml:lang="en-US">Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ImpairmentAndDisposalOfLonglivedAssets" xlink:label="HROW_ImpairmentAndDisposalOfLonglivedAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ImpairmentAndDisposalOfLonglivedAssets" xlink:to="HROW_ImpairmentAndDisposalOfLonglivedAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ImpairmentAndDisposalOfLonglivedAssets_lbl" xml:lang="en-US">Asset sales and impairments, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_EntityWideRevenueMajorCustomerLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems_lbl" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_NumberOfOperatingSegmentsDescription" xlink:label="HROW_NumberOfOperatingSegmentsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_NumberOfOperatingSegmentsDescription" xlink:to="HROW_NumberOfOperatingSegmentsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_NumberOfOperatingSegmentsDescription_lbl" xml:lang="en-US">Number of operating segments, description.</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Percentage of sales derived from large number of customer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_3_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_3_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CommonStockWithheldForPayrollTaxWithholdings" xlink:label="HROW_CommonStockWithheldForPayrollTaxWithholdings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommonStockWithheldForPayrollTaxWithholdings" xlink:to="HROW_CommonStockWithheldForPayrollTaxWithholdings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CommonStockWithheldForPayrollTaxWithholdings_lbl" xml:lang="en-US">Common stock withheld for payroll tax withholdings</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SurfaceOphthalmicsMember" xlink:to="HROW_SurfaceOphthalmicsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_SurfaceOphthalmicsMember_doc" xml:lang="en-US">Surface Ophthalmics [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MeltPharmaceuticalsMember" xlink:to="HROW_MeltPharmaceuticalsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_MeltPharmaceuticalsMember_doc" xml:lang="en-US">Melt Pharmaceuticals [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_EtonPharmaceuticalsMember" xlink:to="HROW_EtonPharmaceuticalsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_EtonPharmaceuticalsMember_doc" xml:lang="en-US">Eton Pharmaceuticals [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ProductSalesNetMember" xlink:to="HROW_ProductSalesNetMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ProductSalesNetMember_doc" xml:lang="en-US">Product Sales, Net [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_OtherRevenuesMember" xlink:to="HROW_OtherRevenuesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_OtherRevenuesMember_doc" xml:lang="en-US">Other Revenues [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StockIssuedDuringPeriodSharesForExerciseOfWarrants" xlink:to="HROW_StockIssuedDuringPeriodSharesForExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_StockIssuedDuringPeriodSharesForExerciseOfWarrants_doc" xml:lang="en-US">Stock issued during period shares for exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StockIssuedDuringPeriodForExerciseOfWarrants" xlink:to="HROW_StockIssuedDuringPeriodForExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_StockIssuedDuringPeriodForExerciseOfWarrants_doc" xml:lang="en-US">Stock issued during period for exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_NewAndRevaluationOfRightofuseAssetObtainedInExchangeForLeaseObligation" xlink:to="HROW_NewAndRevaluationOfRightofuseAssetObtainedInExchangeForLeaseObligation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_NewAndRevaluationOfRightofuseAssetObtainedInExchangeForLeaseObligation_doc" xml:lang="en-US">New and revaluation of right-of-use asset obtained in exchange for lease obligation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RestructuringPolicyTextBlock" xlink:to="HROW_RestructuringPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_RestructuringPolicyTextBlock_doc" xml:lang="en-US">Restructuring [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:to="HROW_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_doc" xml:lang="en-US">Recently Adopted Accounting Pronouncements [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MayfieldPharmaceuticalsIncMember" xlink:to="HROW_MayfieldPharmaceuticalsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_MayfieldPharmaceuticalsIncMember_doc" xml:lang="en-US">Mayfield Pharmaceuticals, Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StowePharmaceuticalsIncMember" xlink:to="HROW_StowePharmaceuticalsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_StowePharmaceuticalsIncMember_doc" xml:lang="en-US">Stowe Pharmaceuticals, Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_TGVHealthLLCMember" xlink:to="HROW_TGVHealthLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_TGVHealthLLCMember_doc" xml:lang="en-US">TGV-Health, LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_VisionologyMember" xlink:to="HROW_VisionologyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_VisionologyMember_doc" xml:lang="en-US">Visionology [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ConsolidationBasisDescription" xlink:to="HROW_ConsolidationBasisDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ConsolidationBasisDescription_doc" xml:lang="en-US">Consolidation basis, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RetainedEarningsAccumulatedDeficit1" xlink:to="HROW_RetainedEarningsAccumulatedDeficit1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_RetainedEarningsAccumulatedDeficit1_doc" xml:lang="en-US">The cumulative amount of the reporting entity's undistributed earnings or deficit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_NumberOfSharesOwned" xlink:to="HROW_NumberOfSharesOwned_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_NumberOfSharesOwned_doc" xml:lang="en-US">Number of shares owned.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_EtonPharmaceuticalsIncMember" xlink:to="HROW_EtonPharmaceuticalsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_EtonPharmaceuticalsIncMember_doc" xml:lang="en-US">Eton Pharmaceuticals, Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MeltPharmaceuticalsIncMember" xlink:to="HROW_MeltPharmaceuticalsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_MeltPharmaceuticalsIncMember_doc" xml:lang="en-US">Melt Pharmaceuticals, Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SurfacePharmaceuticalsIncMember" xlink:to="HROW_SurfacePharmaceuticalsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_SurfacePharmaceuticalsIncMember_doc" xml:lang="en-US">Surface Pharmaceuticals Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ParkCompoundingIncAndNoiceRxLLCMember" xlink:to="HROW_ParkCompoundingIncAndNoiceRxLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ParkCompoundingIncAndNoiceRxLLCMember_doc" xml:lang="en-US">Park Compounding, Inc. and Noice Rx, LLC [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StockOptionsUnvestedRSUsAndWarrantsMember" xlink:to="HROW_StockOptionsUnvestedRSUsAndWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_StockOptionsUnvestedRSUsAndWarrantsMember_doc" xml:lang="en-US">Stock Options, Unvested RSUs and Warrants [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod" xlink:to="HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod_doc" xml:lang="en-US">Cash and cash equivalents and Restricted cash at end of period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StockOptionsMember" xlink:to="HROW_StockOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_StockOptionsMember_doc" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_IncrementalCommonSharesAttributableDilutiveCommonEquivalents" xlink:to="HROW_IncrementalCommonSharesAttributableDilutiveCommonEquivalents_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_IncrementalCommonSharesAttributableDilutiveCommonEquivalents_doc" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive common equivalents.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommissionsMember" xlink:to="HROW_CommissionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CommissionsMember_doc" xml:lang="en-US">Commissions [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ManagementServicesAgreementMember" xlink:to="HROW_ManagementServicesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ManagementServicesAgreementMember_doc" xml:lang="en-US">Management Services Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MSAMember" xlink:to="HROW_MSAMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_MSAMember_doc" xml:lang="en-US">Management Services Agreement [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock" xlink:to="HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock_doc" xml:lang="en-US">Schedule of Condensed Balance Sheet [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock" xlink:to="HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock_doc" xml:lang="en-US">Schedule of Condensed Balance Sheet [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock" xlink:to="HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock_doc" xml:lang="en-US">Investments and Agreements Related Party Transactions [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RoyaltyPaymentPercentageOnNetSales" xlink:to="HROW_RoyaltyPaymentPercentageOnNetSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_RoyaltyPaymentPercentageOnNetSales_doc" xml:lang="en-US">Royalty payment percentage on net sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DrLindstromMember" xlink:to="HROW_DrLindstromMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_DrLindstromMember_doc" xml:lang="en-US">Dr. Lindstrom [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RestrictedCashTextBlock" xlink:to="HROW_RestrictedCashTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_RestrictedCashTextBlock_doc" xml:lang="en-US">Restricted Cash [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_doc" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LicensesMember" xlink:to="HROW_LicensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_LicensesMember_doc" xml:lang="en-US">Licenses [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_NonCompetitionClauseMember" xlink:to="HROW_NonCompetitionClauseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_NonCompetitionClauseMember_doc" xml:lang="en-US">Non-Competition Clause [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StatePharmacyLicensesMember" xlink:to="HROW_StatePharmacyLicensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_StatePharmacyLicensesMember_doc" xml:lang="en-US">State Pharmacy Licenses [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_FiniteLivedIntangibleAssetsImpairment" xlink:to="HROW_FiniteLivedIntangibleAssetsImpairment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_FiniteLivedIntangibleAssetsImpairment_doc" xml:lang="en-US">Finite Lived Intangible Assets Impairment.</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_IntangibleAssetsNetExcludingsGoodwill" xlink:label="HROW_IntangibleAssetsNetExcludingsGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_IntangibleAssetsNetExcludingsGoodwill" xlink:to="HROW_IntangibleAssetsNetExcludingsGoodwill_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_IntangibleAssetsNetExcludingsGoodwill_doc" xml:lang="en-US">Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember" xlink:to="HROW_CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember_doc" xml:lang="en-US">Customer Relationships, Trade Name and State Pharmacy Licenses [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ParkCompoundingIncMember" xlink:to="HROW_ParkCompoundingIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ParkCompoundingIncMember_doc" xml:lang="en-US">Park Compounding, Inc. [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_PatentsFilingsAndTrademarksMember" xlink:to="HROW_PatentsFilingsAndTrademarksMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_PatentsFilingsAndTrademarksMember_doc" xml:lang="en-US">Patents Filings and Trademarks [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_TermLoanAndSecurityAgreementMember" xlink:to="HROW_TermLoanAndSecurityAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_TermLoanAndSecurityAgreementMember_doc" xml:lang="en-US">Term Loan and Security Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SWKFundingLLCMember" xlink:to="HROW_SWKFundingLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_SWKFundingLLCMember_doc" xml:lang="en-US">SWK Funding LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SWKLoanAgreementMember" xlink:to="HROW_SWKLoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_SWKLoanAgreementMember_doc" xml:lang="en-US">SWK Loan Agreement [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LenderWarrantsMember" xlink:to="HROW_LenderWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_LenderWarrantsMember_doc" xml:lang="en-US">Lender Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_JoinderAndAmendmentMember" xlink:to="HROW_JoinderAndAmendmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_JoinderAndAmendmentMember_doc" xml:lang="en-US">Joinder and Amendment [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MarginRateMember" xlink:to="HROW_MarginRateMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_MarginRateMember_doc" xml:lang="en-US">Margin Rate [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DeconsolidationPercentage" xlink:to="HROW_DeconsolidationPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_DeconsolidationPercentage_doc" xml:lang="en-US">Deconsolidation percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SWKSecondAmendmentMember" xlink:to="HROW_SWKSecondAmendmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_SWKSecondAmendmentMember_doc" xml:lang="en-US">SWK Second Amendment [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_BusinessLoanAgreementMember" xlink:to="HROW_BusinessLoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_BusinessLoanAgreementMember_doc" xml:lang="en-US">Business Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_NotesPayableCurrent1" xlink:to="HROW_NotesPayableCurrent1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_NotesPayableCurrent1_doc" xml:lang="en-US">Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LongTermNotesPayable1" xlink:to="HROW_LongTermNotesPayable1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_LongTermNotesPayable1_doc" xml:lang="en-US">Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SanDiegoMember" xlink:to="HROW_SanDiegoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_SanDiegoMember_doc" xml:lang="en-US">San Diego [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LeaseExpirationDateDescription" xlink:to="HROW_LeaseExpirationDateDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_LeaseExpirationDateDescription_doc" xml:lang="en-US">Lease expiration date description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LedgewoodMember" xlink:to="HROW_LedgewoodMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_LedgewoodMember_doc" xml:lang="en-US">Ledgewood [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AdditionalSquareFootageOfLeaseMember" xlink:label="HROW_AdditionalSquareFootageOfLeaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_AdditionalSquareFootageOfLeaseMember" xlink:to="HROW_AdditionalSquareFootageOfLeaseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_AdditionalSquareFootageOfLeaseMember_doc" xml:lang="en-US">Additional Square Footage of Lease [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_NashvilleMember" xlink:to="HROW_NashvilleMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_NashvilleMember_doc" xml:lang="en-US">Nashville [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_IrvineMember" xlink:to="HROW_IrvineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_IrvineMember_doc" xml:lang="en-US">Irvine [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MonthlyPaymentsOfFinanceLeaseForEquipment" xlink:to="HROW_MonthlyPaymentsOfFinanceLeaseForEquipment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_MonthlyPaymentsOfFinanceLeaseForEquipment_doc" xml:lang="en-US">Monthly payments of finance lease for equipment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_NumberOfCommonStockIssuedOnCashlessExercise" xlink:to="HROW_NumberOfCommonStockIssuedOnCashlessExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_NumberOfCommonStockIssuedOnCashlessExercise_doc" xml:lang="en-US">Number of common stock issued on cashless exercise.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeOneMember" xlink:to="HROW_RangeOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_RangeOneMember_doc" xml:lang="en-US">Range One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommonStockWithheldForPayrollTaxWithholdingsShare" xlink:to="HROW_CommonStockWithheldForPayrollTaxWithholdingsShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CommonStockWithheldForPayrollTaxWithholdingsShare_doc" xml:lang="en-US">Common stock withheld for payroll tax withholdings, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommonStockWithheldForPayrollTaxWithholdingsValue" xlink:to="HROW_CommonStockWithheldForPayrollTaxWithholdingsValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CommonStockWithheldForPayrollTaxWithholdingsValue_doc" xml:lang="en-US">Common stock withheld for payroll tax withholdings, value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeTwoMember" xlink:to="HROW_RangeTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_RangeTwoMember_doc" xml:lang="en-US">Range Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommonStockWarrantsOneMember" xlink:to="HROW_CommonStockWarrantsOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CommonStockWarrantsOneMember_doc" xml:lang="en-US">Common Stock Warrants One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommonStockWarrantsTwoMember" xlink:to="HROW_CommonStockWarrantsTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CommonStockWarrantsTwoMember_doc" xml:lang="en-US">Common Stock Warrants Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RestrictedStockUnitsVested" xlink:to="HROW_RestrictedStockUnitsVested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_RestrictedStockUnitsVested_doc" xml:lang="en-US">Restricted stock units vested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember" xlink:to="HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_doc" xml:lang="en-US">2017 Incentive Stock and Awards Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ClosingPriceOfCommonStockPricePerShare" xlink:to="HROW_ClosingPriceOfCommonStockPricePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ClosingPriceOfCommonStockPricePerShare_doc" xml:lang="en-US">Closing price of common stock price per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StockOptionPlanMember" xlink:to="HROW_StockOptionPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_StockOptionPlanMember_doc" xml:lang="en-US">Stock Option Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_EmployeesAndConsultantMember" xlink:to="HROW_EmployeesAndConsultantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_EmployeesAndConsultantMember_doc" xml:lang="en-US">Employees and Consultant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_BaumPerformanceOptionMember" xlink:to="HROW_BaumPerformanceOptionMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_BaumPerformanceOptionMember_doc" xml:lang="en-US">Baum Performance Option [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_AverageStockPrice" xlink:to="HROW_AverageStockPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_AverageStockPrice_doc" xml:lang="en-US">Average stock price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ForfeitureFactorPercentage" xlink:to="HROW_ForfeitureFactorPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ForfeitureFactorPercentage_doc" xml:lang="en-US">Forfeiture factor, percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_EmployeesMember" xlink:to="HROW_EmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_EmployeesMember_doc" xml:lang="en-US">Employees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_BoardOfDirectorsMember" xlink:to="HROW_BoardOfDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_BoardOfDirectorsMember_doc" xml:lang="en-US">Board of Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_UnvestedRSUMember" xlink:to="HROW_UnvestedRSUMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_UnvestedRSUMember_doc" xml:lang="en-US">Unvested RSUs [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_EllePharmaceuticalLLCMember" xlink:to="HROW_EllePharmaceuticalLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_EllePharmaceuticalLLCMember_doc" xml:lang="en-US">Elle Pharmaceutical, LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LicenseAgreementMember" xlink:to="HROW_LicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_LicenseAgreementMember_doc" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MarkBaumCEOMember" xlink:to="HROW_MarkBaumCEOMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_MarkBaumCEOMember_doc" xml:lang="en-US">Mark Baum, CEO [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_AndrewBollCFOMember" xlink:to="HROW_AndrewBollCFOMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_AndrewBollCFOMember_doc" xml:lang="en-US">Andrew Boll, CFO [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_AggregatePurchasePrice" xlink:to="HROW_AggregatePurchasePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_AggregatePurchasePrice_doc" xml:lang="en-US">Aggregate purchase price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ConsultantMember" xlink:to="HROW_ConsultantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ConsultantMember_doc" xml:lang="en-US">Consultants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_VisionologyIncMember" xlink:to="HROW_VisionologyIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_VisionologyIncMember_doc" xml:lang="en-US">Visionology, Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StockOptionPlanOneMember" xlink:to="HROW_StockOptionPlanOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_StockOptionPlanOneMember_doc" xml:lang="en-US">Stock Option Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_OptionsEmployeesMember" xlink:to="HROW_OptionsEmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_OptionsEmployeesMember_doc" xml:lang="en-US">Options Granted to Employees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeThreeMember" xlink:to="HROW_RangeThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_RangeThreeMember_doc" xml:lang="en-US">Range Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RangeFourMember" xlink:to="HROW_RangeFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_RangeFourMember_doc" xml:lang="en-US">Range Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SellingGeneralAndAdministrativeMember" xlink:to="HROW_SellingGeneralAndAdministrativeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_SellingGeneralAndAdministrativeMember_doc" xml:lang="en-US">Selling, General and Administrative [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:to="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options equity instruments outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber" xlink:to="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_doc" xml:lang="en-US">Number of shares warrants outstanding and exercisable, ending balance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1" xlink:to="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options equity instruments outstanding and exercisable weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award non options outstanding weighted average remaining contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_WarrantsIssuanceDate" xlink:to="HROW_WarrantsIssuanceDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_WarrantsIssuanceDate_doc" xml:lang="en-US">Warrants issuance date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" xlink:to="HROW_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_doc" xml:lang="en-US">Warrants exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_WarrantsAndRightsOutstandingMaturityDates" xlink:to="HROW_WarrantsAndRightsOutstandingMaturityDates_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_WarrantsAndRightsOutstandingMaturityDates_doc" xml:lang="en-US">Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SettlementWarrantsMember" xlink:to="HROW_SettlementWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_SettlementWarrantsMember_doc" xml:lang="en-US">Settlement Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_LenderWarrantsOneMember" xlink:to="HROW_LenderWarrantsOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_LenderWarrantsOneMember_doc" xml:lang="en-US">Lender Warrants One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DeferredIncomeChangeInValuationAllowance" xlink:to="HROW_DeferredIncomeChangeInValuationAllowance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_DeferredIncomeChangeInValuationAllowance_doc" xml:lang="en-US">Deferred Income Change In Valuation Allowance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization" xlink:to="HROW_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization_doc" xml:lang="en-US">Deferred Tax Asset Tax Credit carry Forwards Depreciation And Amortization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_IncomeTaxBasisDifferenceInRelatedParty" xlink:to="HROW_IncomeTaxBasisDifferenceInRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_IncomeTaxBasisDifferenceInRelatedParty_doc" xml:lang="en-US">Basis Difference in Melt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_IncomeTaxBasisDifferenceInRelatedPartyOne" xlink:to="HROW_IncomeTaxBasisDifferenceInRelatedPartyOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_IncomeTaxBasisDifferenceInRelatedPartyOne_doc" xml:lang="en-US">Basis Difference in Surface.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_IncomeTaxBasisDifferenceInRelatedPartyTwo" xlink:to="HROW_IncomeTaxBasisDifferenceInRelatedPartyTwo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_IncomeTaxBasisDifferenceInRelatedPartyTwo_doc" xml:lang="en-US">Basis Difference in Eton.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DeferredTaxAssetsTaxDeferredExpenseCapitalLosses" xlink:to="HROW_DeferredTaxAssetsTaxDeferredExpenseCapitalLosses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_DeferredTaxAssetsTaxDeferredExpenseCapitalLosses_doc" xml:lang="en-US">Capital losses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DeferredTaxAssetsTaxDeferredExpenseLimitations" xlink:to="HROW_DeferredTaxAssetsTaxDeferredExpenseLimitations_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_DeferredTaxAssetsTaxDeferredExpenseLimitations_doc" xml:lang="en-US">Limitation Under 163(j).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability" xlink:to="HROW_DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability_doc" xml:lang="en-US">ASC 842 Lease Liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset" xlink:to="HROW_DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset_doc" xml:lang="en-US">ASC 842 ROU Asset.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount" xlink:to="HROW_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount_doc" xml:lang="en-US">Percentage of salary deposits in tax deferred investment account.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SettlementAgreementMember" xlink:to="HROW_SettlementAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_SettlementAgreementMember_doc" xml:lang="en-US">Settlement Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DamagesLowClaimRatePercentage" xlink:to="HROW_DamagesLowClaimRatePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_DamagesLowClaimRatePercentage_doc" xml:lang="en-US">Damages low claim rate, percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_AllerganUSAIncMember" xlink:to="HROW_AllerganUSAIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_AllerganUSAIncMember_doc" xml:lang="en-US">Allergan USA, Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommissionPaymentsPercentage" xlink:to="HROW_CommissionPaymentsPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CommissionPaymentsPercentage_doc" xml:lang="en-US">Commission payments, percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SalesAndMarketingAgreementsMember" xlink:to="HROW_SalesAndMarketingAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_SalesAndMarketingAgreementsMember_doc" xml:lang="en-US">Sales and Marketing Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_AdditionalPaidInCapitalAndShareBasedPayments" xlink:to="HROW_AdditionalPaidInCapitalAndShareBasedPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_AdditionalPaidInCapitalAndShareBasedPayments_doc" xml:lang="en-US">Additional paid in capital and stock based payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RoyaltyPaymentDescription" xlink:to="HROW_RoyaltyPaymentDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_RoyaltyPaymentDescription_doc" xml:lang="en-US">Royalty payment description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_KlarityLicenseAgreementMember" xlink:to="HROW_KlarityLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_KlarityLicenseAgreementMember_doc" xml:lang="en-US">Klarity License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RichardLLindstromMDMember" xlink:to="HROW_RichardLLindstromMDMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_RichardLLindstromMDMember_doc" xml:lang="en-US">Richard L. Lindstrom, M.D [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_InitialPaymentMember" xlink:to="HROW_InitialPaymentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_InitialPaymentMember_doc" xml:lang="en-US">Initial Payment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SecondPaymentMember" xlink:to="HROW_SecondPaymentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_SecondPaymentMember_doc" xml:lang="en-US">Second Payment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_FinalPaymentMember" xlink:to="HROW_FinalPaymentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_FinalPaymentMember_doc" xml:lang="en-US">Final Payment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_NetSalesRevenue" xlink:to="HROW_NetSalesRevenue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_NetSalesRevenue_doc" xml:lang="en-US">Net sales of product.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MilestonePaymentInCash" xlink:to="HROW_MilestonePaymentInCash_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_MilestonePaymentInCash_doc" xml:lang="en-US">Milestone payment in cash.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MilestonePaymentsOnPayables" xlink:to="HROW_MilestonePaymentsOnPayables_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_MilestonePaymentsOnPayables_doc" xml:lang="en-US">Milestone payments on payables.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_InjectableAssetPurchaseAgreementMember" xlink:to="HROW_InjectableAssetPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_InjectableAssetPurchaseAgreementMember_doc" xml:lang="en-US">Injectable Asset Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_PresbyopiaAssetPurchaseAgreementMember" xlink:to="HROW_PresbyopiaAssetPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_PresbyopiaAssetPurchaseAgreementMember_doc" xml:lang="en-US">Presbyopia Asset Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DexycuAgreementMember" xlink:to="HROW_DexycuAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_DexycuAgreementMember_doc" xml:lang="en-US">Dexycu Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_NumberOfOperatingSegmentsDescription" xlink:to="HROW_NumberOfOperatingSegmentsDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_NumberOfOperatingSegmentsDescription_doc" xml:lang="en-US">Number of operating segments, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ThreeMainSuppliersMember" xlink:to="HROW_ThreeMainSuppliersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ThreeMainSuppliersMember_doc" xml:lang="en-US">Three Main Suppliers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_PharmaceuticalCompoundingMember" xlink:to="HROW_PharmaceuticalCompoundingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_PharmaceuticalCompoundingMember_doc" xml:lang="en-US">Pharmaceutical Compounding [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_SegmentContribution" xlink:to="HROW_SegmentContribution_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_SegmentContribution_doc" xml:lang="en-US">Segment contribution.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_PharmaceuticalDrugDevelopmentMember" xlink:to="HROW_PharmaceuticalDrugDevelopmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_PharmaceuticalDrugDevelopmentMember_doc" xml:lang="en-US">Pharmaceutical Drug Development [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ImpairmentAndDisposalOfLonglivedAssets" xlink:to="HROW_ImpairmentAndDisposalOfLonglivedAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_ImpairmentAndDisposalOfLonglivedAssets_doc" xml:lang="en-US">Impairment and disposal of long-lived assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_AndrewRBollMember" xlink:to="HROW_AndrewRBollMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_AndrewRBollMember_doc" xml:lang="en-US">Andrew R. Boll [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CommonStockWithheldForPayrollTaxWithholdings" xlink:to="HROW_CommonStockWithheldForPayrollTaxWithholdings_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_CommonStockWithheldForPayrollTaxWithholdings_doc" xml:lang="en-US">Common stock withheld for payroll tax withholdings.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MarkLBaumMember" xlink:to="HROW_MarkLBaumMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_MarkLBaumMember_doc" xml:lang="en-US">Mark L. Baum [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_FederalResearchAndDevelopmentTaxCredits" xlink:to="HROW_FederalResearchAndDevelopmentTaxCredits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_FederalResearchAndDevelopmentTaxCredits_doc" xml:lang="en-US">Federal Research And Development Tax Credits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StateResearchAndDevelopmentTaxCredits" xlink:to="HROW_StateResearchAndDevelopmentTaxCredits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_StateResearchAndDevelopmentTaxCredits_doc" xml:lang="en-US">State Research And Development Tax Credits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_FederalResearchAndDevelopmentTaxCreditsExpirationDate" xlink:to="HROW_FederalResearchAndDevelopmentTaxCreditsExpirationDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_FederalResearchAndDevelopmentTaxCreditsExpirationDate_doc" xml:lang="en-US">Federal Research And Development Tax Credits Expiration Date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StateNetOperatingLossExpirationDate" xlink:to="HROW_StateNetOperatingLossExpirationDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_StateNetOperatingLossExpirationDate_doc" xml:lang="en-US">State net operating loss expiration date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_FederalNetOperatingLossCarryforwardDescription" xlink:to="HROW_FederalNetOperatingLossCarryforwardDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_FederalNetOperatingLossCarryforwardDescription_doc" xml:lang="en-US">Federal net operating loss carryforward description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_AdditionalAreaOfLand" xlink:to="HROW_AdditionalAreaOfLand_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="HROW_AdditionalAreaOfLand_doc" xml:lang="en-US">Additional area of land.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_MSAMember" xlink:to="HROW_MSAMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_MSAMember_3_lbl" xml:lang="en-US">Management Services Agreement [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_StockOptionPlanMember" xlink:to="HROW_StockOptionPlanMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_StockOptionPlanMember_3_lbl" xml:lang="en-US">Stock Option Plan [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_3_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, Employee Benefit Plan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_GainLossOnInvestmentsOne" xlink:to="HROW_GainLossOnInvestmentsOne_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_GainLossOnInvestmentsOne_2_lbl" xml:lang="en-US">GainLossOnInvestmentsOne</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_GainLossOnInvestmentsTwo" xlink:to="HROW_GainLossOnInvestmentsTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_GainLossOnInvestmentsTwo_2_lbl" xml:lang="en-US">GainLossOnInvestmentsTwo</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_GainLossOnInvestmentsThree" xlink:to="HROW_GainLossOnInvestmentsThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_GainLossOnInvestmentsThree_2_lbl" xml:lang="en-US">GainLossOnInvestmentsThree</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_3_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ImpairmentsOfLongLivedAssetsHeldForUse" xlink:to="HROW_ImpairmentsOfLongLivedAssetsHeldForUse_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ImpairmentsOfLongLivedAssetsHeldForUse_2_lbl" xml:lang="en-US">ImpairmentsOfLongLivedAssetsHeldForUse</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_2_lbl" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_PaymentsOfCostsRelatedToAmendmentOfLoanPayable" xlink:to="HROW_PaymentsOfCostsRelatedToAmendmentOfLoanPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_PaymentsOfCostsRelatedToAmendmentOfLoanPayable_2_lbl" xml:lang="en-US">PaymentsOfCostsRelatedToAmendmentOfLoanPayable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod" xlink:to="HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod_3_lbl" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_2_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_RetainedEarningsAccumulatedDeficit1" xlink:to="HROW_RetainedEarningsAccumulatedDeficit1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_RetainedEarningsAccumulatedDeficit1_3_lbl" xml:lang="en-US">Accumulated deficit [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAmortizationAndAccretionNet" xlink:to="us-gaap_DepreciationAmortizationAndAccretionNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAmortizationAndAccretionNet_2_lbl" xml:lang="en-US">Depreciation, Amortization and Accretion, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization of Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_2_lbl" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_2_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_2_lbl" xml:lang="en-US">Long-term Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_2_lbl" xml:lang="en-US">Interest Payable, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_2_lbl" xml:lang="en-US">Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Operating Lease, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_2_lbl" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:to="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_3_lbl" xml:lang="en-US">Weighted Avg. Exercise Price, Outstanding, beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber" xlink:to="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_3_lbl" xml:lang="en-US">Number of Shares Warrants Outstanding and Exercisable, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1" xlink:to="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1_3_lbl" xml:lang="en-US">Warrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_IncomeTaxBasisDifferenceInRelatedParty" xlink:to="HROW_IncomeTaxBasisDifferenceInRelatedParty_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_IncomeTaxBasisDifferenceInRelatedParty_3_lbl" xml:lang="en-US">Basis Difference in Melt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_IncomeTaxBasisDifferenceInRelatedPartyOne" xlink:to="HROW_IncomeTaxBasisDifferenceInRelatedPartyOne_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_IncomeTaxBasisDifferenceInRelatedPartyOne_3_lbl" xml:lang="en-US">Basis Difference in Surface</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_IncomeTaxBasisDifferenceInRelatedPartyTwo" xlink:to="HROW_IncomeTaxBasisDifferenceInRelatedPartyTwo_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_IncomeTaxBasisDifferenceInRelatedPartyTwo_3_lbl" xml:lang="en-US">Basis Difference in Eton</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HROW_DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset" xlink:to="HROW_DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="HROW_DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset_3_lbl" xml:lang="en-US">ASC 842 ROU Asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_2_lbl" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>hrow-20201231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://harrowinc.com/role/Cover" xlink:href="hrow-20201231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/BalanceSheets" xlink:href="hrow-20201231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/BalanceSheetsParenthetical" xlink:href="hrow-20201231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StatementsOfOperations" xlink:href="hrow-20201231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StatementsOfStockholdersEquity" xlink:href="hrow-20201231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StatementsOfCashFlows" xlink:href="hrow-20201231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Organization" xlink:href="hrow-20201231.xsd#Organization" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="hrow-20201231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Revenues" xlink:href="hrow-20201231.xsd#Revenues" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactions" xlink:href="hrow-20201231.xsd#InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactions" xlink:href="hrow-20201231.xsd#InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/RestrictedCash" xlink:href="hrow-20201231.xsd#RestrictedCash" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Inventories" xlink:href="hrow-20201231.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="hrow-20201231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PropertyPlantAndEquipment" xlink:href="hrow-20201231.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/IntangibleAssetsAndGoodwill" xlink:href="hrow-20201231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/AccountsPayableAndAccruedExpenses" xlink:href="hrow-20201231.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Debt" xlink:href="hrow-20201231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/Leases" xlink:href="hrow-20201231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensation" xlink:href="hrow-20201231.xsd#StockholdersEquityAndStock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/IncomeTaxes" xlink:href="hrow-20201231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/EmployeeSavingsPlan" xlink:href="hrow-20201231.xsd#EmployeeSavingsPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/CommitmentsAndContingencies" xlink:href="hrow-20201231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SegmentInformationAndConcentrations" xlink:href="hrow-20201231.xsd#SegmentInformationAndConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SubsequentEvents" xlink:href="hrow-20201231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="hrow-20201231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="hrow-20201231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/RevenuesTables" xlink:href="hrow-20201231.xsd#RevenuesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsTables" xlink:href="hrow-20201231.xsd#InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsTables" xlink:href="hrow-20201231.xsd#InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InventoriesTables" xlink:href="hrow-20201231.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="hrow-20201231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PropertyPlantAndEquipmentTables" xlink:href="hrow-20201231.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="hrow-20201231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/AccountsPayableAndAccruedExpensesTables" xlink:href="hrow-20201231.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/DebtTables" xlink:href="hrow-20201231.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/LeasesTables" xlink:href="hrow-20201231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables" xlink:href="hrow-20201231.xsd#StockholdersEquityAndStock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/IncomeTaxesTables" xlink:href="hrow-20201231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SegmentInformationAndConcentrationsTables" xlink:href="hrow-20201231.xsd#SegmentInformationAndConcentrationsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfBasicEarningsPerCommonShareDetails" xlink:href="hrow-20201231.xsd#ScheduleOfBasicEarningsPerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails" xlink:href="hrow-20201231.xsd#ScheduleOfDilutedCommonEquivalentSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfDilutedEarningsPerCommonShareDetails" xlink:href="hrow-20201231.xsd#ScheduleOfDilutedEarningsPerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="hrow-20201231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails" xlink:href="hrow-20201231.xsd#ScheduleOfDisaggregatedRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/RevenuesDetailsNarrative" xlink:href="hrow-20201231.xsd#RevenuesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails" xlink:href="hrow-20201231.xsd#ScheduleOfCondensedIncomeStatementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails" xlink:href="hrow-20201231.xsd#ScheduleOfCondensedBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative" xlink:href="hrow-20201231.xsd#InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails" xlink:href="hrow-20201231.xsd#SummaryOfCondensedIncomeStatementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails" xlink:href="hrow-20201231.xsd#SummaryOfCondensedBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative" xlink:href="hrow-20201231.xsd#InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/RestrictedCashDetailsNarrative" xlink:href="hrow-20201231.xsd#RestrictedCashDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfInventoriesDetails" xlink:href="hrow-20201231.xsd#ScheduleOfInventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="hrow-20201231.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="hrow-20201231.xsd#ScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/PropertyPlantAndEquipmentDetailsNarrative" xlink:href="hrow-20201231.xsd#PropertyPlantAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="hrow-20201231.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:href="hrow-20201231.xsd#ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:href="hrow-20201231.xsd#ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfGoodwillDetails" xlink:href="hrow-20201231.xsd#ScheduleOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:href="hrow-20201231.xsd#IntangibleAssetsAndGoodwillDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:href="hrow-20201231.xsd#ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails" xlink:href="hrow-20201231.xsd#SummaryOfFutureMinimumPaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/DebtDetailsNarrative" xlink:href="hrow-20201231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails" xlink:href="hrow-20201231.xsd#ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails" xlink:href="hrow-20201231.xsd#ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/LeasesDetailsNarrative" xlink:href="hrow-20201231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails" xlink:href="hrow-20201231.xsd#ScheduleOfStockOptionPlanActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:href="hrow-20201231.xsd#ScheduleOfFairValueAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails" xlink:href="hrow-20201231.xsd#ScheduleOfStockOptionOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails" xlink:href="hrow-20201231.xsd#ScheduleOfRestrictedStockUnitsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:href="hrow-20201231.xsd#ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="hrow-20201231.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:href="hrow-20201231.xsd#ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative" xlink:href="hrow-20201231.xsd#StockholdersEquityAndStock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="hrow-20201231.xsd#ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfIncomeTaxReconciliationDetails" xlink:href="hrow-20201231.xsd#ScheduleOfIncomeTaxReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="hrow-20201231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/IncomeTaxesDetailsNarrative" xlink:href="hrow-20201231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/EmployeeSavingsPlanDetailsNarrative" xlink:href="hrow-20201231.xsd#EmployeeSavingsPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="hrow-20201231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails" xlink:href="hrow-20201231.xsd#ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SegmentInformationAndConcentrationsDetailsNarrative" xlink:href="hrow-20201231.xsd#SegmentInformationAndConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://harrowinc.com/role/SubsequentEventsDetailsNarrative" xlink:href="hrow-20201231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:label="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SurfaceOphthalmicsMember" xlink:label="loc_HROWSurfaceOphthalmicsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWSurfaceOphthalmicsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MeltPharmaceuticalsMember" xlink:label="loc_HROWMeltPharmaceuticalsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWMeltPharmaceuticalsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInvestments" xlink:label="loc_us-gaapOtherInvestments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments" xlink:label="loc_us-gaapInvestments" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtDiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaapLoansPayableCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLoansPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesNoncurrent" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaapLongTermLoansPayable" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLongTermLoansPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ProductSalesNetMember" xlink:label="loc_HROWProductSalesNetMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_HROWProductSalesNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_OtherRevenuesMember" xlink:label="loc_HROWOtherRevenuesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_HROWOtherRevenuesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MeltPharmaceuticalsMember" xlink:label="loc_HROWMeltPharmaceuticalsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWMeltPharmaceuticalsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SurfaceOphthalmicsMember" xlink:label="loc_HROWSurfaceOphthalmicsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWSurfaceOphthalmicsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_EtonPharmaceuticalsMember" xlink:label="loc_HROWEtonPharmaceuticalsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWEtonPharmaceuticalsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenuesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaapParentMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapParentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapNoncontrollingInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StockIssuedDuringPeriodForExerciseOfWarrants" xlink:label="loc_HROWStockIssuedDuringPeriodForExerciseOfWarrants" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_HROWStockIssuedDuringPeriodForExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StockIssuedDuringPeriodSharesForExerciseOfWarrants" xlink:label="loc_HROWStockIssuedDuringPeriodSharesForExerciseOfWarrants" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_HROWStockIssuedDuringPeriodSharesForExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AmortizationOfIntangibleAsset" xlink:label="loc_HROWAmortizationOfIntangibleAsset" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_HROWAmortizationOfIntangibleAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AmortizationOfOperatingLeaseRightofuseAssets" xlink:label="loc_HROWAmortizationOfOperatingLeaseRightofuseAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_HROWAmortizationOfOperatingLeaseRightofuseAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaapPaidInKindInterest" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapPaidInKindInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_GainLossOnInvestmentsOne" xlink:label="loc_HROWGainLossOnInvestmentsOne" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_HROWGainLossOnInvestmentsOne" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_GainLossOnInvestmentsTwo" xlink:label="loc_HROWGainLossOnInvestmentsTwo" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_HROWGainLossOnInvestmentsTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_GainLossOnInvestmentsThree" xlink:label="loc_HROWGainLossOnInvestmentsThree" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_HROWGainLossOnInvestmentsThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ImpairmentsOfLongLivedAssetsHeldForUse" xlink:label="loc_HROWImpairmentsOfLongLivedAssetsHeldForUse" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_HROWImpairmentsOfLongLivedAssetsHeldForUse" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="loc_us-gaapProceedsFromSaleOfProductiveAssets" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfProductiveAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromOtherDebt" xlink:label="loc_us-gaapProceedsFromOtherDebt" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromOtherDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_PaymentsOfCostsRelatedToAmendmentOfLoanPayable" xlink:label="loc_HROWPaymentsOfCostsRelatedToAmendmentOfLoanPayable" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_HROWPaymentsOfCostsRelatedToAmendmentOfLoanPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ProceedsFromExerciseOfWarrantsAndStockOptionsNetOfTaxes" xlink:label="loc_HROWProceedsFromExerciseOfWarrantsAndStockOptionsNetOfTaxes" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_HROWProceedsFromExerciseOfWarrantsAndStockOptionsNetOfTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract" xlink:label="loc_HROWReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_HROWReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod" xlink:label="loc_HROWCashCashEquivalentsAndRestrictedCashAtEndOfPeriod" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract" xlink:to="loc_HROWCashCashEquivalentsAndRestrictedCashAtEndOfPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" xlink:label="loc_HROWPurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_HROWPurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_NewAndRevaluationOfRightofuseAssetObtainedInExchangeForLeaseObligation" xlink:label="loc_HROWNewAndRevaluationOfRightofuseAssetObtainedInExchangeForLeaseObligation" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_HROWNewAndRevaluationOfRightofuseAssetObtainedInExchangeForLeaseObligation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Organization" xlink:title="00000007 - Disclosure - ORGANIZATION">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Revenues" xlink:title="00000009 - Disclosure - REVENUES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactions" xlink:title="00000010 - Disclosure - INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaapInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactions" xlink:title="00000011 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract" xlink:label="loc_HROWDisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock" xlink:label="loc_HROWInvestmentsAndAgreementsRelatedPartyTransactionsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract" xlink:to="loc_HROWInvestmentsAndAgreementsRelatedPartyTransactionsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/RestrictedCash" xlink:title="00000012 - Disclosure - RESTRICTED CASH">
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DisclosureRestrictedCashAbstract" xlink:label="loc_HROWDisclosureRestrictedCashAbstract" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RestrictedCashTextBlock" xlink:label="loc_HROWRestrictedCashTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureRestrictedCashAbstract" xlink:to="loc_HROWRestrictedCashTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Inventories" xlink:title="00000013 - Disclosure - INVENTORIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000014 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PropertyPlantAndEquipment" xlink:title="00000015 - Disclosure - PROPERTY, PLANT AND EQUIPMENT">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/IntangibleAssetsAndGoodwill" xlink:title="00000016 - Disclosure - INTANGIBLE ASSETS AND GOODWILL">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/AccountsPayableAndAccruedExpenses" xlink:title="00000017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Debt" xlink:title="00000018 - Disclosure - DEBT">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/Leases" xlink:title="00000019 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaapLeasesOfLesseeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeasesOfLesseeDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensation" xlink:title="00000020 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/IncomeTaxes" xlink:title="00000021 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/EmployeeSavingsPlan" xlink:title="00000022 - Disclosure - EMPLOYEE SAVINGS PLAN">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/CommitmentsAndContingencies" xlink:title="00000023 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SegmentInformationAndConcentrations" xlink:title="00000024 - Disclosure - SEGMENT INFORMATION AND CONCENTRATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SubsequentEvents" xlink:title="00000025 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RisksUncertaintiesAndLiquidityPolicyTextBlock" xlink:label="loc_HROWRisksUncertaintiesAndLiquidityPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_HROWRisksUncertaintiesAndLiquidityPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_NoncontrollingInterestPolicyTextBlock" xlink:label="loc_HROWNoncontrollingInterestPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_HROWNoncontrollingInterestPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CostOfSalePolicyTextBlock" xlink:label="loc_HROWCostOfSalePolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_HROWCostOfSalePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaapDebtPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDebtPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaapInvestmentPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInvestmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaapReceivablesPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapReceivablesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_InvestmentOnePolicyTextBlock" xlink:label="loc_HROWInvestmentOnePolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_HROWInvestmentOnePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_InvestmentTwoPolicyTextBlock" xlink:label="loc_HROWInvestmentTwoPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_HROWInvestmentTwoPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaapBusinessCombinationsPolicy" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessCombinationsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RestructuringPolicyTextBlock" xlink:label="loc_HROWRestructuringPolicyTextBlock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_HROWRestructuringPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:label="loc_HROWRecentlyAdoptedAccountingPronouncementsPolicyTextBlock" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_HROWRecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/RevenuesTables" xlink:title="00000028 - Disclosure - REVENUES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaapDisaggregationOfRevenueTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsTables" xlink:title="00000029 - Disclosure - INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock" xlink:label="loc_HROWScheduleOfCondensedIncomeStatementOneTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_HROWScheduleOfCondensedIncomeStatementOneTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock" xlink:label="loc_HROWScheduleOfCondensedBalanceSheetOneTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_HROWScheduleOfCondensedBalanceSheetOneTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsTables" xlink:title="00000030 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Tables)">
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract" xlink:label="loc_HROWDisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:label="loc_srtScheduleOfCondensedIncomeStatementTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract" xlink:to="loc_srtScheduleOfCondensedIncomeStatementTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:label="loc_srtScheduleOfCondensedBalanceSheetTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract" xlink:to="loc_srtScheduleOfCondensedBalanceSheetTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InventoriesTables" xlink:title="00000031 - Disclosure - INVENTORIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000032 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="loc_HROWScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_HROWScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PropertyPlantAndEquipmentTables" xlink:title="00000033 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/IntangibleAssetsAndGoodwillTables" xlink:title="00000034 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaapScheduleOfGoodwillTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfGoodwillTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/AccountsPayableAndAccruedExpensesTables" xlink:title="00000035 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/DebtTables" xlink:title="00000036 - Disclosure - DEBT (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/LeasesTables" xlink:title="00000037 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables" xlink:title="00000038 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ScheduleofWarrantsOutstandingAndExercisableTableTextBlock" xlink:label="loc_HROWScheduleofWarrantsOutstandingAndExercisableTableTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_HROWScheduleofWarrantsOutstandingAndExercisableTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/IncomeTaxesTables" xlink:title="00000039 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SegmentInformationAndConcentrationsTables" xlink:title="00000040 - Disclosure - SEGMENT INFORMATION AND CONCENTRATIONS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfBasicEarningsPerCommonShareDetails" xlink:title="00000041 - Disclosure - SCHEDULE OF BASIC EARNINGS PER COMMON SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails" xlink:title="00000042 - Disclosure - SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StockOptionsMember" xlink:label="loc_HROWStockOptionsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_HROWStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaapWeightedAverageNumberDilutedSharesOutstandingAdjustment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapWeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfDilutedEarningsPerCommonShareDetails" xlink:title="00000043 - Disclosure - SCHEDULE OF DILUTED EARNINGS PER COMMON SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_IncrementalCommonSharesAttributableDilutiveCommonEquivalents" xlink:label="loc_HROWIncrementalCommonSharesAttributableDilutiveCommonEquivalents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_HROWIncrementalCommonSharesAttributableDilutiveCommonEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:label="loc_us-gaapIncrementalCommonSharesAttributableToContingentlyIssuableShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000044 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srtOwnershipAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtOwnershipAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srtOwnershipDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtOwnershipAxis" xlink:to="loc_srtOwnershipDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MayfieldPharmaceuticalsIncMember" xlink:label="loc_HROWMayfieldPharmaceuticalsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_HROWMayfieldPharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StowePharmaceuticalsIncMember" xlink:label="loc_HROWStowePharmaceuticalsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtOwnershipDomain" xlink:to="loc_HROWStowePharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_TGVHealthLLCMember" xlink:label="loc_HROWTGVHealthLLCMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWTGVHealthLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_VisionologyMember" xlink:label="loc_HROWVisionologyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWVisionologyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_EtonPharmaceuticalsIncMember" xlink:label="loc_HROWEtonPharmaceuticalsIncMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWEtonPharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MeltPharmaceuticalsIncMember" xlink:label="loc_HROWMeltPharmaceuticalsIncMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWMeltPharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SurfacePharmaceuticalsIncMember" xlink:label="loc_HROWSurfacePharmaceuticalsIncMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWSurfacePharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ParkCompoundingIncAndNoiceRxLLCMember" xlink:label="loc_HROWParkCompoundingIncAndNoiceRxLLCMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWParkCompoundingIncAndNoiceRxLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StockOptionsUnvestedRSUsAndWarrantsMember" xlink:label="loc_HROWStockOptionsUnvestedRSUsAndWarrantsMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_HROWStockOptionsUnvestedRSUsAndWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapAwardTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ConsolidationBasisDescription" xlink:label="loc_HROWConsolidationBasisDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_HROWConsolidationBasisDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RetainedEarningsAccumulatedDeficit1" xlink:label="loc_HROWRetainedEarningsAccumulatedDeficit1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_HROWRetainedEarningsAccumulatedDeficit1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDescription" xlink:label="loc_us-gaapMinorityInterestDescription" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapMinorityInterestDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_NumberOfSharesOwned" xlink:label="loc_HROWNumberOfSharesOwned" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_HROWNumberOfSharesOwned" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaapGainLossOnInvestments" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapGainLossOnInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="loc_us-gaapInvestmentOwnedAtFairValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapInvestmentOwnedAtFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaapAccountsReceivableNet" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccountsReceivableNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaapDeconsolidationGainOrLossAmount" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDeconsolidationGainOrLossAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaapUnrealizedGainLossOnInvestments" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapUnrealizedGainLossOnInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaapDueFromRelatedParties" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDueFromRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaapSeveranceCosts1" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapSeveranceCosts1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails" xlink:title="00000045 - Disclosure - SCHEDULE OF DISAGGREGATED REVENUE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapDisaggregationOfRevenueLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ProductSalesNetMember" xlink:label="loc_HROWProductSalesNetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_HROWProductSalesNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CommissionsMember" xlink:label="loc_HROWCommissionsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_HROWCommissionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/RevenuesDetailsNarrative" xlink:title="00000046 - Disclosure - REVENUES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails" xlink:title="00000047 - Disclosure - SCHEDULE OF CONDENSED INCOME STATEMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsLineItems" xlink:label="loc_deiEntityListingsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiEntityListingsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MeltPharmaceuticalsIncMember" xlink:label="loc_HROWMeltPharmaceuticalsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWMeltPharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails" xlink:title="00000048 - Disclosure - SCHEDULE OF CONDENSED BALANCE SHEET (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsLineItems" xlink:label="loc_deiEntityListingsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiEntityListingsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MeltPharmaceuticalsIncMember" xlink:label="loc_HROWMeltPharmaceuticalsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWMeltPharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative" xlink:title="00000049 - Disclosure - INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsLineItems" xlink:label="loc_deiEntityListingsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiEntityListingsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MeltPharmaceuticalsIncMember" xlink:label="loc_HROWMeltPharmaceuticalsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWMeltPharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SurfacePharmaceuticalsIncMember" xlink:label="loc_HROWSurfacePharmaceuticalsIncMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWSurfacePharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ManagementServicesAgreementMember" xlink:label="loc_HROWManagementServicesAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWManagementServicesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MSAMember" xlink:label="loc_HROWMSAMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWMSAMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdministrativeFeesExpense" xlink:label="loc_us-gaapAdministrativeFeesExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapAdministrativeFeesExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaapDueFromRelatedParties" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapDueFromRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails" xlink:title="00000050 - Disclosure - SUMMARY OF CONDENSED INCOME STATEMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract" xlink:label="loc_HROWDisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsLineItems" xlink:label="loc_deiEntityListingsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiEntityListingsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SurfacePharmaceuticalsIncMember" xlink:label="loc_HROWSurfacePharmaceuticalsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWSurfacePharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails" xlink:title="00000051 - Disclosure - SUMMARY OF CONDENSED BALANCE SHEET (Details)">
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract" xlink:label="loc_HROWDisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsLineItems" xlink:label="loc_deiEntityListingsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiEntityListingsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SurfacePharmaceuticalsIncMember" xlink:label="loc_HROWSurfacePharmaceuticalsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWSurfacePharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative" xlink:title="00000052 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract" xlink:label="loc_HROWDisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsLineItems" xlink:label="loc_deiEntityListingsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiEntityListingsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SurfacePharmaceuticalsIncMember" xlink:label="loc_HROWSurfacePharmaceuticalsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWSurfacePharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DrLindstromMember" xlink:label="loc_HROWDrLindstromMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWDrLindstromMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RoyaltyPaymentPercentageOnNetSales" xlink:label="loc_HROWRoyaltyPaymentPercentageOnNetSales" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_HROWRoyaltyPaymentPercentageOnNetSales" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/RestrictedCashDetailsNarrative" xlink:title="00000053 - Disclosure - RESTRICTED CASH (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DisclosureRestrictedCashAbstract" xlink:label="loc_HROWDisclosureRestrictedCashAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_HROWDisclosureRestrictedCashAbstract" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfInventoriesDetails" xlink:title="00000054 - Disclosure - SCHEDULE OF INVENTORIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000055 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="00000056 - Disclosure - SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="loc_us-gaapCapitalizedComputerSoftwareGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapCapitalizedComputerSoftwareGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapFurnitureAndFixturesGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaapMachineryAndEquipmentGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapMachineryAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapLeaseholdImprovementsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/PropertyPlantAndEquipmentDetailsNarrative" xlink:title="00000057 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="loc_us-gaapDepreciationAmortizationAndAccretionNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciationAmortizationAndAccretionNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="00000058 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_LicensesMember" xlink:label="loc_HROWLicensesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWLicensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksMember" xlink:label="loc_us-gaapTrademarksMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaapTradeNamesMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTradeNamesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_NonCompetitionClauseMember" xlink:label="loc_HROWNonCompetitionClauseMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWNonCompetitionClauseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StatePharmacyLicensesMember" xlink:label="loc_HROWStatePharmacyLicensesMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWStatePharmacyLicensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_FiniteLivedIntangibleAssetsImpairment" xlink:label="loc_HROWFiniteLivedIntangibleAssetsImpairment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_HROWFiniteLivedIntangibleAssetsImpairment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationMethod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationMethod" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:title="00000059 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_LicensesMember" xlink:label="loc_HROWLicensesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWLicensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaapTradeNamesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTradeNamesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StatePharmacyLicensesMember" xlink:label="loc_HROWStatePharmacyLicensesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWStatePharmacyLicensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:title="00000060 - Disclosure - SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfGoodwillDetails" xlink:title="00000061 - Disclosure - SCHEDULE OF GOODWILL (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwill_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/IntangibleAssetsAndGoodwillDetailsNarrative" xlink:title="00000062 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember" xlink:label="loc_HROWCustomerRelationshipsTradeNameAndStatePharmacyLicensesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWCustomerRelationshipsTradeNameAndStatePharmacyLicensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_PatentsFilingsAndTrademarksMember" xlink:label="loc_HROWPatentsFilingsAndTrademarksMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_HROWPatentsFilingsAndTrademarksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ParkCompoundingIncMember" xlink:label="loc_HROWParkCompoundingIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWParkCompoundingIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:title="00000063 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails" xlink:title="00000064 - Disclosure - SUMMARY OF FUTURE MINIMUM PAYMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_NotesPayableCurrent1" xlink:label="loc_HROWNotesPayableCurrent1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_HROWNotesPayableCurrent1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_LongTermNotesPayable1" xlink:label="loc_HROWLongTermNotesPayable1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_HROWLongTermNotesPayable1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/DebtDetailsNarrative" xlink:title="00000065 - Disclosure - DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_TermLoanAndSecurityAgreementMember" xlink:label="loc_HROWTermLoanAndSecurityAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWTermLoanAndSecurityAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SWKLoanAgreementMember" xlink:label="loc_HROWSWKLoanAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWSWKLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_JoinderAndAmendmentMember" xlink:label="loc_HROWJoinderAndAmendmentMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWJoinderAndAmendmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SWKSecondAmendmentMember" xlink:label="loc_HROWSWKSecondAmendmentMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWSWKSecondAmendmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_BusinessLoanAgreementMember" xlink:label="loc_HROWBusinessLoanAgreementMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWBusinessLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SWKFundingLLCMember" xlink:label="loc_HROWSWKFundingLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWSWKFundingLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaapVariableRateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapVariableRateAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaapLondonInterbankOfferedRateLIBORMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_us-gaapLondonInterbankOfferedRateLIBORMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MarginRateMember" xlink:label="loc_HROWMarginRateMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_HROWMarginRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_LenderWarrantsMember" xlink:label="loc_HROWLenderWarrantsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_HROWLenderWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaapDebtInstrumentDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaapDebtInstrumentMaturityDateDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaapDebtInstrumentFeeAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentFeeAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DeconsolidationPercentage" xlink:label="loc_HROWDeconsolidationPercentage" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_HROWDeconsolidationPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails" xlink:title="00000066 - Disclosure - SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails" xlink:title="00000067 - Disclosure - SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/LeasesDetailsNarrative" xlink:title="00000068 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaapLesseeLeaseDescriptionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeLeaseDescriptionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaapLesseeLeaseDescriptionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapLesseeLeaseDescriptionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_OfficeAndLaboratorySpaceMember" xlink:label="loc_HROWOfficeAndLaboratorySpaceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_HROWOfficeAndLaboratorySpaceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_srtStatementGeographicalAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SanDiegoMember" xlink:label="loc_HROWSanDiegoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_HROWSanDiegoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_LedgewoodMember" xlink:label="loc_HROWLedgewoodMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_HROWLedgewoodMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_NashvilleMember" xlink:label="loc_HROWNashvilleMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_HROWNashvilleMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_IrvineMember" xlink:label="loc_HROWIrvineMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_HROWIrvineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapAreaOfLand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_LeaseExpirationDateDescription" xlink:label="loc_HROWLeaseExpirationDateDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_HROWLeaseExpirationDateDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaapLesseeOperatingLeaseOptionToExtend" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseOptionToExtend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AdditionalAreaOfLand" xlink:label="loc_HROWAdditionalAreaOfLand" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_HROWAdditionalAreaOfLand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="loc_us-gaapGainLossOnTerminationOfLease" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapGainLossOnTerminationOfLease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MonthlyPaymentsOfFinanceLeaseForEquipment" xlink:label="loc_HROWMonthlyPaymentsOfFinanceLeaseForEquipment" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_HROWMonthlyPaymentsOfFinanceLeaseForEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="loc_us-gaapFinanceLeaseInterestExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapFinanceLeaseInterestExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails" xlink:title="00000069 - Disclosure - SCHEDULE OF STOCK OPTION PLAN ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StockOptionPlanOneMember" xlink:label="loc_HROWStockOptionPlanOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_HROWStockOptionPlanOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:title="00000070 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_OptionsEmployeesMember" xlink:label="loc_HROWOptionsEmployeesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_HROWOptionsEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails" xlink:title="00000071 - Disclosure - SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RangeOneMember" xlink:label="loc_HROWRangeOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RangeTwoMember" xlink:label="loc_HROWRangeTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RangeThreeMember" xlink:label="loc_HROWRangeThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RangeFourMember" xlink:label="loc_HROWRangeFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails" xlink:title="00000072 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:title="00000073 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_EmployeesMember" xlink:label="loc_HROWEmployeesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ConsultantMember" xlink:label="loc_HROWConsultantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SellingGeneralAndAdministrativeMember" xlink:label="loc_HROWSellingGeneralAndAdministrativeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_HROWSellingGeneralAndAdministrativeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000074 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:label="loc_HROWShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_HROWShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber" xlink:label="loc_HROWShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_HROWShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1" xlink:label="loc_HROWShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_HROWShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_HROWSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_HROWSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:title="00000075 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_LenderWarrantsMember" xlink:label="loc_HROWLenderWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWLenderWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SettlementWarrantsMember" xlink:label="loc_HROWSettlementWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWSettlementWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_LenderWarrantsOneMember" xlink:label="loc_HROWLenderWarrantsOneMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWLenderWarrantsOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_WarrantsIssuanceDate" xlink:label="loc_HROWWarrantsIssuanceDate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_HROWWarrantsIssuanceDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" xlink:label="loc_HROWShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_HROWShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_WarrantsAndRightsOutstandingMaturityDates" xlink:label="loc_HROWWarrantsAndRightsOutstandingMaturityDates" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_HROWWarrantsAndRightsOutstandingMaturityDates" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative" xlink:title="00000076 - Disclosure - STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StockOptionPlanMember" xlink:label="loc_HROWStockOptionPlanMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_HROWStockOptionPlanMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_UnvestedRSUMember" xlink:label="loc_HROWUnvestedRSUMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_HROWUnvestedRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RangeOneMember" xlink:label="loc_HROWRangeOneMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RangeTwoMember" xlink:label="loc_HROWRangeTwoMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_HROWRangeTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CommonStockWarrantsOneMember" xlink:label="loc_HROWCommonStockWarrantsOneMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_HROWCommonStockWarrantsOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CommonStockWarrantsTwoMember" xlink:label="loc_HROWCommonStockWarrantsTwoMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_HROWCommonStockWarrantsTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_EmployeesAndConsultantMember" xlink:label="loc_HROWEmployeesAndConsultantMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWEmployeesAndConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_EmployeesMember" xlink:label="loc_HROWEmployeesMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_BoardOfDirectorsMember" xlink:label="loc_HROWBoardOfDirectorsMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWBoardOfDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MarkBaumCEOMember" xlink:label="loc_HROWMarkBaumCEOMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWMarkBaumCEOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AndrewBollCFOMember" xlink:label="loc_HROWAndrewBollCFOMember" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWAndrewBollCFOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ConsultantMember" xlink:label="loc_HROWConsultantMember" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapPlanNameAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember" xlink:label="loc_HROWTwoThousandAndSeventeenIncentiveStockandAwardsPlanMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_HROWTwoThousandAndSeventeenIncentiveStockandAwardsPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_BaumPerformanceOptionMember" xlink:label="loc_HROWBaumPerformanceOptionMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWBaumPerformanceOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_LicenseAgreementMember" xlink:label="loc_HROWLicenseAgreementMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MayfieldPharmaceuticalsIncMember" xlink:label="loc_HROWMayfieldPharmaceuticalsIncMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWMayfieldPharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StowePharmaceuticalsIncMember" xlink:label="loc_HROWStowePharmaceuticalsIncMember" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWStowePharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_VisionologyIncMember" xlink:label="loc_HROWVisionologyIncMember" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_HROWVisionologyIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_deiLegalEntityAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_EllePharmaceuticalLLCMember" xlink:label="loc_HROWEllePharmaceuticalLLCMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWEllePharmaceuticalLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_NumberOfCommonStockIssuedOnCashlessExercise" xlink:label="loc_HROWNumberOfCommonStockIssuedOnCashlessExercise" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWNumberOfCommonStockIssuedOnCashlessExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CommonStockWithheldForPayrollTaxWithholdingsShare" xlink:label="loc_HROWCommonStockWithheldForPayrollTaxWithholdingsShare" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWCommonStockWithheldForPayrollTaxWithholdingsShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CommonStockWithheldForPayrollTaxWithholdingsValue" xlink:label="loc_HROWCommonStockWithheldForPayrollTaxWithholdingsValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWCommonStockWithheldForPayrollTaxWithholdingsValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RestrictedStockUnitsVested" xlink:label="loc_HROWRestrictedStockUnitsVested" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWRestrictedStockUnitsVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ClosingPriceOfCommonStockPricePerShare" xlink:label="loc_HROWClosingPriceOfCommonStockPricePerShare" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWClosingPriceOfCommonStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AverageStockPrice" xlink:label="loc_HROWAverageStockPrice" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWAverageStockPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ForfeitureFactorPercentage" xlink:label="loc_HROWForfeitureFactorPercentage" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWForfeitureFactorPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AggregatePurchasePrice" xlink:label="loc_HROWAggregatePurchasePrice" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_HROWAggregatePurchasePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="00000077 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DeferredIncomeChangeInValuationAllowance" xlink:label="loc_HROWDeferredIncomeChangeInValuationAllowance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_HROWDeferredIncomeChangeInValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfIncomeTaxReconciliationDetails" xlink:title="00000078 - Disclosure - SCHEDULE OF INCOME TAX RECONCILIATION (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000079 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization" xlink:label="loc_HROWDeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_HROWDeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseOther" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_IncomeTaxBasisDifferenceInRelatedParty" xlink:label="loc_HROWIncomeTaxBasisDifferenceInRelatedParty" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_HROWIncomeTaxBasisDifferenceInRelatedParty" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_IncomeTaxBasisDifferenceInRelatedPartyOne" xlink:label="loc_HROWIncomeTaxBasisDifferenceInRelatedPartyOne" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_HROWIncomeTaxBasisDifferenceInRelatedPartyOne" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_IncomeTaxBasisDifferenceInRelatedPartyTwo" xlink:label="loc_HROWIncomeTaxBasisDifferenceInRelatedPartyTwo" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_HROWIncomeTaxBasisDifferenceInRelatedPartyTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DeferredTaxAssetsTaxDeferredExpenseCapitalLosses" xlink:label="loc_HROWDeferredTaxAssetsTaxDeferredExpenseCapitalLosses" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_HROWDeferredTaxAssetsTaxDeferredExpenseCapitalLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DeferredTaxAssetsTaxDeferredExpenseLimitations" xlink:label="loc_HROWDeferredTaxAssetsTaxDeferredExpenseLimitations" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_HROWDeferredTaxAssetsTaxDeferredExpenseLimitations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability" xlink:label="loc_HROWDeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_HROWDeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset" xlink:label="loc_HROWDeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_HROWDeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000080 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StateNetOperatingLossExpirationDate" xlink:label="loc_HROWStateNetOperatingLossExpirationDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_HROWStateNetOperatingLossExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_FederalNetOperatingLossCarryforwardDescription" xlink:label="loc_HROWFederalNetOperatingLossCarryforwardDescription" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_HROWFederalNetOperatingLossCarryforwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_FederalResearchAndDevelopmentTaxCredits" xlink:label="loc_HROWFederalResearchAndDevelopmentTaxCredits" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_HROWFederalResearchAndDevelopmentTaxCredits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StateResearchAndDevelopmentTaxCredits" xlink:label="loc_HROWStateResearchAndDevelopmentTaxCredits" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_HROWStateResearchAndDevelopmentTaxCredits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_FederalResearchAndDevelopmentTaxCreditsExpirationDate" xlink:label="loc_HROWFederalResearchAndDevelopmentTaxCreditsExpirationDate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_HROWFederalResearchAndDevelopmentTaxCreditsExpirationDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/EmployeeSavingsPlanDetailsNarrative" xlink:title="00000081 - Disclosure - EMPLOYEE SAVINGS PLAN (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount" xlink:label="loc_HROWPercentageOfSalaryDepositsInTaxDeferredInvestmentAccount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_HROWPercentageOfSalaryDepositsInTaxDeferredInvestmentAccount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaapDefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapDefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaapDefinedBenefitPlanContributionsByEmployer" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapDefinedBenefitPlanContributionsByEmployer" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000082 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SettlementAgreementMember" xlink:label="loc_HROWSettlementAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWSettlementAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SalesAndMarketingAgreementsMember" xlink:label="loc_HROWSalesAndMarketingAgreementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWSalesAndMarketingAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_LicenseAgreementMember" xlink:label="loc_HROWLicenseAgreementMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_KlarityLicenseAgreementMember" xlink:label="loc_HROWKlarityLicenseAgreementMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWKlarityLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_InjectableAssetPurchaseAgreementMember" xlink:label="loc_HROWInjectableAssetPurchaseAgreementMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWInjectableAssetPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_PresbyopiaAssetPurchaseAgreementMember" xlink:label="loc_HROWPresbyopiaAssetPurchaseAgreementMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWPresbyopiaAssetPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DexycuAgreementMember" xlink:label="loc_HROWDexycuAgreementMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_HROWDexycuAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AllerganUSAIncMember" xlink:label="loc_HROWAllerganUSAIncMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWAllerganUSAIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MayfieldPharmaceuticalsIncMember" xlink:label="loc_HROWMayfieldPharmaceuticalsIncMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWMayfieldPharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_StowePharmaceuticalsIncMember" xlink:label="loc_HROWStowePharmaceuticalsIncMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_HROWStowePharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RichardLLindstromMDMember" xlink:label="loc_HROWRichardLLindstromMDMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWRichardLLindstromMDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtStatementScenarioAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_InitialPaymentMember" xlink:label="loc_HROWInitialPaymentMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_HROWInitialPaymentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SecondPaymentMember" xlink:label="loc_HROWSecondPaymentMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_HROWSecondPaymentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_FinalPaymentMember" xlink:label="loc_HROWFinalPaymentMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_HROWFinalPaymentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaapLossContingencyAccrualAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingencyAccrualAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_DamagesLowClaimRatePercentage" xlink:label="loc_HROWDamagesLowClaimRatePercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWDamagesLowClaimRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="loc_us-gaapLossContingencyDamagesPaidValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingencyDamagesPaidValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaapLossContingencyDamagesAwardedValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingencyDamagesAwardedValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CommissionPaymentsPercentage" xlink:label="loc_HROWCommissionPaymentsPercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWCommissionPaymentsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AdditionalPaidInCapitalAndShareBasedPayments" xlink:label="loc_HROWAdditionalPaidInCapitalAndShareBasedPayments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWAdditionalPaidInCapitalAndShareBasedPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaapSalesCommissionsAndFees" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapSalesCommissionsAndFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="loc_us-gaapBusinessAcquisitionDescriptionOfAcquiredEntity" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapBusinessAcquisitionDescriptionOfAcquiredEntity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapRoyaltyExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_RoyaltyPaymentDescription" xlink:label="loc_HROWRoyaltyPaymentDescription" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWRoyaltyPaymentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_NetSalesRevenue" xlink:label="loc_HROWNetSalesRevenue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWNetSalesRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MilestonePaymentInCash" xlink:label="loc_HROWMilestonePaymentInCash" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWMilestonePaymentInCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MilestonePaymentsOnPayables" xlink:label="loc_HROWMilestonePaymentsOnPayables" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_HROWMilestonePaymentsOnPayables" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails" xlink:title="00000083 - Disclosure - SCHEDULE OF SEGMENT NET REVENUES, SEGMENT OPERATING EXPENSES AND SEGMENT CONTRIBUTION (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapSegmentReportingInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srtConsolidationItemsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_srtConsolidationItemsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srtConsolidationItemsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidationItemsAxis" xlink:to="loc_srtConsolidationItemsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaapOperatingSegmentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidationItemsDomain" xlink:to="loc_us-gaapOperatingSegmentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="loc_us-gaapCorporateNonSegmentMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidationItemsDomain" xlink:to="loc_us-gaapCorporateNonSegmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_PharmaceuticalCompoundingMember" xlink:label="loc_HROWPharmaceuticalCompoundingMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_HROWPharmaceuticalCompoundingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_PharmaceuticalDrugDevelopmentMember" xlink:label="loc_HROWPharmaceuticalDrugDevelopmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_HROWPharmaceuticalDrugDevelopmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_SegmentContribution" xlink:label="loc_HROWSegmentContribution" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_HROWSegmentContribution" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaapAdjustmentForAmortization" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapAdjustmentForAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ImpairmentAndDisposalOfLonglivedAssets" xlink:label="loc_HROWImpairmentAndDisposalOfLonglivedAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_HROWImpairmentAndDisposalOfLonglivedAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SegmentInformationAndConcentrationsDetailsNarrative" xlink:title="00000084 - Disclosure - SEGMENT INFORMATION AND CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaapEntityWideRevenueMajorCustomerLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="loc_us-gaapEntityWideRevenueMajorCustomerLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_ThreeMainSuppliersMember" xlink:label="loc_HROWThreeMainSuppliersMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_HROWThreeMainSuppliersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_NumberOfOperatingSegmentsDescription" xlink:label="loc_HROWNumberOfOperatingSegmentsDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEntityWideRevenueMajorCustomerLineItems" xlink:to="loc_HROWNumberOfOperatingSegmentsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEntityWideRevenueMajorCustomerLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://harrowinc.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000085 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_AndrewRBollMember" xlink:label="loc_HROWAndrewRBollMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWAndrewRBollMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_MarkLBaumMember" xlink:label="loc_HROWMarkLBaumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_HROWMarkLBaumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CommonStockWithheldForPayrollTaxWithholdings" xlink:label="loc_HROWCommonStockWithheldForPayrollTaxWithholdings" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_HROWCommonStockWithheldForPayrollTaxWithholdings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="hrow-20201231.xsd#HROW_CommonStockWithheldForPayrollTaxWithholdingsValue" xlink:label="loc_HROWCommonStockWithheldForPayrollTaxWithholdingsValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_HROWCommonStockWithheldForPayrollTaxWithholdingsValue" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:HROW="http://harrowinc.com/20201231"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="hrow-20201231.xsd" xlink:type="simple"/>
    <context id="From2020-01-01to2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-03-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
        </entity>
        <period>
            <instant>2021-03-08</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_SurfaceOphthalmicsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:SurfaceOphthalmicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_SurfaceOphthalmicsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:SurfaceOphthalmicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_MeltPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MeltPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_MeltPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MeltPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_ProductSalesNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:ProductSalesNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_ProductSalesNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:ProductSalesNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OtherRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_OtherRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_MeltPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MeltPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_MeltPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MeltPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_SurfaceOphthalmicsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:SurfaceOphthalmicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_SurfaceOphthalmicsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:SurfaceOphthalmicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_EtonPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:EtonPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_EtonPharmaceuticalsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:EtonPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_MayfieldPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">HROW:MayfieldPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_StowePharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">HROW:StowePharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_MayfieldPharmaceuticalsIncMember_custom_TGVHealthLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">HROW:MayfieldPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:TGVHealthLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_StowePharmaceuticalsIncMember_custom_TGVHealthLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">HROW:StowePharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:TGVHealthLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_VisionologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:VisionologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_EtonPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:EtonPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_EtonPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:EtonPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_EtonPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:EtonPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_EtonPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:EtonPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_MeltPharmaceuticalsIncMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-03-31_custom_MeltPharmaceuticalsIncMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-01-31_custom_MeltPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_MeltPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_MeltPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_MeltPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:SurfacePharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_SurfacePharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:SurfacePharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_SurfacePharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:SurfacePharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_SurfacePharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:SurfacePharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_ParkCompoundingIncAndNoiceRxLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:ParkCompoundingIncAndNoiceRxLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_StockOptionsUnvestedRSUsAndWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">HROW:StockOptionsUnvestedRSUsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_StockOptionsUnvestedRSUsAndWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">HROW:StockOptionsUnvestedRSUsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">HROW:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_CommissionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:CommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CommissionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">HROW:CommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-02-012019-02-28_custom_MeltPharmaceuticalsIncMember_custom_ManagementServicesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:ManagementServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember_custom_ManagementServicesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:ManagementServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_MeltPharmaceuticalsIncMember_custom_ManagementServicesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:ManagementServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MeltPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_SurfacePharmaceuticalsIncMember_custom_MSAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:MSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:SurfacePharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_SurfacePharmaceuticalsIncMember_custom_DrLindstromMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:DrLindstromMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:SurfacePharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_PatentsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_PatentsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_LicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_LicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_TrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_TrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_CustomerRelationshipsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_CustomerRelationshipsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_TradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_TradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_NonCompetitionClauseMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:NonCompetitionClauseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_NonCompetitionClauseMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:NonCompetitionClauseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_NonCompetitionClauseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:NonCompetitionClauseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_StatePharmacyLicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:StatePharmacyLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_StatePharmacyLicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:StatePharmacyLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember_custom_ParkCompoundingIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:ParkCompoundingIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_PatentsMember_custom_ParkCompoundingIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:ParkCompoundingIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_PatentsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_PatentsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_LicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_LicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_TrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_TrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_CustomerRelationshipsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_CustomerRelationshipsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_TradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_TradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_NonCompetitionClauseMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:NonCompetitionClauseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_NonCompetitionClauseMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:NonCompetitionClauseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_NonCompetitionClauseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:NonCompetitionClauseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_StatePharmacyLicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:StatePharmacyLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_StatePharmacyLicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:StatePharmacyLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_PatentsFilingsAndTrademarksMember_custom_ParkCompoundingIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">HROW:PatentsFilingsAndTrademarksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:ParkCompoundingIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2017-07-31_custom_TermLoanAndSecurityAgreementMember_custom_SWKFundingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:TermLoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:SWKFundingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-31</instant>
        </period>
    </context>
    <context id="From2017-07-012017-07-31_custom_TermLoanAndSecurityAgreementMember_custom_SWKFundingLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:TermLoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:SWKFundingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012019-04-30_us-gaap_LondonInterbankOfferedRateLIBORMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="From2019-04-012019-04-30_us-gaap_LondonInterbankOfferedRateLIBORMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="From2019-04-012019-04-30_us-gaap_LondonInterbankOfferedRateLIBORMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="From2019-04-292019-04-30_custom_SWKLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SWKLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-29</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-04-30_custom_SWKLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SWKLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="AsOf2017-07-31_custom_LenderWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">HROW:LenderWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-31</instant>
        </period>
    </context>
    <context id="AsOf2017-08-31_custom_LenderWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">HROW:LenderWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="AsOf2017-08-31_us-gaap_WarrantMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="AsOf2017-08-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="AsOf2017-08-31_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="From2019-05-012019-05-31_custom_JoinderAndAmendmentMember_us-gaap_LondonInterbankOfferedRateLIBORMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:JoinderAndAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="From2019-05-012019-05-31_custom_JoinderAndAmendmentMember_custom_MarginRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:JoinderAndAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">HROW:MarginRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="From2019-05-012019-05-31_custom_JoinderAndAmendmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:JoinderAndAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-05-31_custom_JoinderAndAmendmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:JoinderAndAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="AsOf2020-04-02_custom_SWKSecondAmendmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SWKSecondAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-02</instant>
        </period>
    </context>
    <context id="From2020-05-132020-05-14_custom_SWKSecondAmendmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SWKSecondAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-13</startDate>
            <endDate>2020-05-14</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_SWKSecondAmendmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SWKSecondAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_SWKSecondAmendmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SWKSecondAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-04-30_custom_BusinessLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:BusinessLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="From2020-04-032020-04-30_custom_BusinessLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:BusinessLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-03</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OfficeAndLaboratorySpaceMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">HROW:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OfficeAndLaboratorySpaceMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">HROW:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_SanDiegoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:SanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_SanDiegoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:SanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_LedgewoodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:LedgewoodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_LedgewoodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:LedgewoodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_NashvilleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:NashvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_NashvilleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:NashvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_IrvineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:IrvineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_IrvineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">HROW:IrvineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CommonStockWarrantsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">HROW:CommonStockWarrantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_CommonStockWarrantsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">HROW:CommonStockWarrantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_CommonStockWarrantsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">HROW:CommonStockWarrantsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_CommonStockWarrantsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">HROW:CommonStockWarrantsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">HROW:TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_StockOptionPlanOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_StockOptionPlanOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_StockOptionPlanOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_StockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_StockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_StockOptionPlanMember_custom_EmployeesAndConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:EmployeesAndConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2015-07-302015-07-31_custom_BaumPerformanceOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:BaumPerformanceOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-07-30</startDate>
            <endDate>2015-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2015-07-31_custom_BaumPerformanceOptionMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:BaumPerformanceOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-07-31</instant>
        </period>
    </context>
    <context id="AsOf2015-07-31_custom_BaumPerformanceOptionMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:BaumPerformanceOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-07-31</instant>
        </period>
    </context>
    <context id="From2020-06-032020-06-04_custom_BaumPerformanceOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:BaumPerformanceOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-03</startDate>
            <endDate>2020-06-04</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:OptionsEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_OptionsEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:OptionsEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsEmployeesMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:OptionsEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_OptionsEmployeesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:OptionsEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_OptionsEmployeesMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:OptionsEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_OptionsEmployeesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:OptionsEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">HROW:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_StockOptionPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_BoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_BoardOfDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_UnvestedRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:UnvestedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_UnvestedRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:UnvestedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_UnvestedRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">HROW:UnvestedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-02-022019-02-28_custom_MayfieldPharmaceuticalsIncMember_custom_EllePharmaceuticalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MayfieldPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:EllePharmaceuticalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-02</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-07-31_custom_MayfieldPharmaceuticalsIncMember_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MayfieldPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_MayfieldPharmaceuticalsIncMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MayfieldPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_MayfieldPharmaceuticalsIncMember_custom_MarkBaumCEOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:MarkBaumCEOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MayfieldPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_MayfieldPharmaceuticalsIncMember_custom_AndrewBollCFOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:AndrewBollCFOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MayfieldPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_MayfieldPharmaceuticalsIncMember_custom_EllePharmaceuticalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MayfieldPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:EllePharmaceuticalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_MayfieldPharmaceuticalsIncMember_us-gaap_RestrictedStockMember_custom_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MayfieldPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_MayfieldPharmaceuticalsIncMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MayfieldPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_MayfieldPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:MayfieldPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-07-31_custom_StowePharmaceuticalsIncMember_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:StowePharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_VisionologyIncMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:VisionologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_VisionologyIncMember_custom_MarkBaumCEOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:MarkBaumCEOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:VisionologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_VisionologyIncMember_custom_AndrewBollCFOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:AndrewBollCFOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:VisionologyIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_EmployeesMember_custom_SellingGeneralAndAdministrativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">HROW:SellingGeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_EmployeesMember_custom_SellingGeneralAndAdministrativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">HROW:SellingGeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_srt_DirectorMember_custom_SellingGeneralAndAdministrativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">HROW:SellingGeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_srt_DirectorMember_custom_SellingGeneralAndAdministrativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">HROW:SellingGeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_ConsultantMember_custom_SellingGeneralAndAdministrativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">HROW:SellingGeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_ConsultantMember_custom_SellingGeneralAndAdministrativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">HROW:SellingGeneralAndAdministrativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_LenderWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:LenderWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_LenderWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:LenderWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_SettlementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:SettlementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_SettlementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:SettlementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_LenderWarrantsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:LenderWarrantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_LenderWarrantsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">HROW:LenderWarrantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_SettlementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_SettlementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2019-10-022019-10-31_custom_SettlementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-02</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="From2019-05-012019-05-31_custom_AllerganUSAIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:AllerganUSAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="From2017-01-012019-12-31_custom_SalesAndMarketingAgreementsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SalesAndMarketingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2017-01-012019-12-31_custom_SalesAndMarketingAgreementsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SalesAndMarketingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_SalesAndMarketingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SalesAndMarketingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_SalesAndMarketingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:SalesAndMarketingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-07-31_custom_MayfieldPharmaceuticalsIncMember_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:MayfieldPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-07-31_custom_StowePharmaceuticalsIncMember_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">HROW:StowePharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="From2017-04-012017-04-30_custom_KlarityLicenseAgreementMember_custom_RichardLLindstromMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:KlarityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-04-30</endDate>
        </period>
    </context>
    <context id="From2017-04-012017-04-30_custom_InitialPaymentMember_custom_LicenseAgreementMember_custom_RichardLLindstromMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">HROW:InitialPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-04-30</endDate>
        </period>
    </context>
    <context id="From2017-04-012017-04-30_custom_SecondPaymentMember_custom_LicenseAgreementMember_custom_RichardLLindstromMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">HROW:SecondPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-04-30</endDate>
        </period>
    </context>
    <context id="From2017-04-012017-04-30_custom_FinalPaymentMember_custom_LicenseAgreementMember_custom_RichardLLindstromMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">HROW:FinalPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-04-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_RichardLLindstromMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_RichardLLindstromMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_KlarityLicenseAgreementMember_custom_RichardLLindstromMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:KlarityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_KlarityLicenseAgreementMember_custom_RichardLLindstromMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:KlarityLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-12-012019-12-31_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:InjectableAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-12-012019-12-31_custom_InitialPaymentMember_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">HROW:InitialPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:InjectableAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:InjectableAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:InjectableAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-12-012019-12-31_custom_PresbyopiaAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:PresbyopiaAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_PresbyopiaAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:PresbyopiaAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_PresbyopiaAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:RichardLLindstromMDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:PresbyopiaAssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_DexycuAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">HROW:DexycuAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">HROW:PharmaceuticalCompoundingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalDrugDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">HROW:PharmaceuticalDrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">HROW:PharmaceuticalCompoundingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_PharmaceuticalDrugDevelopmentMember_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">HROW:PharmaceuticalDrugDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_ThreeMainSuppliersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">HROW:ThreeMainSuppliersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-12-31_custom_ThreeMainSuppliersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">HROW:ThreeMainSuppliersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2021-03-012021-03-31_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-03-012021-03-31_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-03-012020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2021-02-012021-02-28_us-gaap_RestrictedStockUnitsRSUMember_custom_AndrewRBollMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:AndrewRBollMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="From2021-02-012021-02-28_us-gaap_RestrictedStockUnitsRSUMember_custom_MarkLBaumMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001360214</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">HROW:MarkLBaumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Percent">
        <measure>pure</measure>
    </unit>
    <unit id="Segment">
        <measure>HROW:Segment</measure>
    </unit>
    <unit id="Sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2020-01-01to2020-12-31">0001360214</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-01-01to2020-12-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-01-01to2020-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-01-01to2020-12-31">2020</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-01-01to2020-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityFilerCategory contextRef="From2020-01-01to2020-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2019-12-31"
      id="xdx2ixbrl0109"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermLoansPayable
      contextRef="AsOf2019-12-31"
      id="xdx2ixbrl0133"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2018-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <HROW:StockIssuedDuringPeriodForExerciseOfWarrants
      contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <HROW:StockIssuedDuringPeriodForExerciseOfWarrants
      contextRef="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2019-01-012019-12-31_us-gaap_ParentMember"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0304"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0307"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-01-012020-12-31_us-gaap_ParentMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-01-01to2020-12-31"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0368"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaidInKindInterest
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromOtherDebt
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0494"
      unitRef="USD"
      xsi:nil="true"/>
    <HROW:PaymentsOfCostsRelatedToAmendmentOfLoanPayable
      contextRef="From2020-01-01to2020-12-31"
      id="xdx2ixbrl0499"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="From2020-01-012020-12-31_srt_MinimumMember"
      id="xdx2ixbrl0633">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_custom_CommissionsMember"
      id="xdx2ixbrl0706"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-12-31_custom_MeltPharmaceuticalsIncMember"
      id="xdx2ixbrl0725"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_custom_MeltPharmaceuticalsIncMember"
      id="xdx2ixbrl0727"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-12-31_custom_SurfacePharmaceuticalsIncMember"
      id="xdx2ixbrl0770"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_custom_SurfacePharmaceuticalsIncMember"
      id="xdx2ixbrl0772"
      unitRef="USD"
      xsi:nil="true"/>
    <HROW:FiniteLivedIntangibleAssetsImpairment
      contextRef="AsOf2019-12-31_custom_LicensesMember"
      id="xdx2ixbrl0891"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2019-12-31_us-gaap_TrademarksMember"
      id="xdx2ixbrl0898"
      unitRef="USD"
      xsi:nil="true"/>
    <HROW:FiniteLivedIntangibleAssetsImpairment
      contextRef="AsOf2019-12-31_us-gaap_TrademarksMember"
      id="xdx2ixbrl0900"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2019-12-31_us-gaap_TradeNamesMember"
      id="xdx2ixbrl0921"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2019-12-31_custom_NonCompetitionClauseMember"
      id="xdx2ixbrl0931"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2020-12-31_us-gaap_TrademarksMember"
      id="xdx2ixbrl0967"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2020-12-31_us-gaap_TrademarksMember"
      id="xdx2ixbrl0974"
      unitRef="USD"
      xsi:nil="true"/>
    <HROW:FiniteLivedIntangibleAssetsImpairment
      contextRef="AsOf2020-12-31_us-gaap_TrademarksMember"
      id="xdx2ixbrl0976"
      unitRef="USD"
      xsi:nil="true"/>
    <HROW:FiniteLivedIntangibleAssetsImpairment
      contextRef="AsOf2020-12-31_us-gaap_CustomerRelationshipsMember"
      id="xdx2ixbrl0986"
      unitRef="USD"
      xsi:nil="true"/>
    <HROW:FiniteLivedIntangibleAssetsImpairment
      contextRef="AsOf2020-12-31_us-gaap_TradeNamesMember"
      id="xdx2ixbrl0995"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2020-12-31_us-gaap_TradeNamesMember"
      id="xdx2ixbrl0997"
      unitRef="USD"
      xsi:nil="true"/>
    <HROW:FiniteLivedIntangibleAssetsImpairment
      contextRef="AsOf2020-12-31_custom_NonCompetitionClauseMember"
      id="xdx2ixbrl1005"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2020-12-31_custom_NonCompetitionClauseMember"
      id="xdx2ixbrl1007"
      unitRef="USD"
      xsi:nil="true"/>
    <HROW:FiniteLivedIntangibleAssetsImpairment
      contextRef="AsOf2020-12-31_custom_StatePharmacyLicensesMember"
      id="xdx2ixbrl1014"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-01-012020-12-31_us-gaap_TradeNamesMember"
      id="xdx2ixbrl1041"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-01-012020-12-31_custom_StatePharmacyLicensesMember"
      id="xdx2ixbrl1045"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="AsOf2020-12-31_custom_OfficeAndLaboratorySpaceMember_srt_MinimumMember"
      id="xdx2ixbrl1169">P1Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-01-012020-12-31_custom_OptionsEmployeesMember"
      id="xdx2ixbrl1448"
      unitRef="Percent"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2019-01-012019-12-31_custom_OptionsEmployeesMember"
      id="xdx2ixbrl1450"
      unitRef="Percent"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1554"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1580"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1652"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1654"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1656"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2020-01-01to2020-12-31"
      id="xdx2ixbrl1706"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl1708"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2020-01-01to2020-12-31"
      id="xdx2ixbrl1730"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2019-01-012019-12-31"
      id="xdx2ixbrl1732"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl1811"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2019-12-31"
      id="xdx2ixbrl1812"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalDrugDevelopmentMember"
      id="xdx2ixbrl1930"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalDrugDevelopmentMember"
      id="xdx2ixbrl1936"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalDrugDevelopmentMember"
      id="xdx2ixbrl1942"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_custom_PharmaceuticalDrugDevelopmentMember_us-gaap_OperatingSegmentsMember"
      id="xdx2ixbrl1974"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2019-01-012019-12-31_custom_PharmaceuticalDrugDevelopmentMember_us-gaap_OperatingSegmentsMember"
      id="xdx2ixbrl1980"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="From2019-01-012019-12-31_custom_PharmaceuticalDrugDevelopmentMember_us-gaap_OperatingSegmentsMember"
      id="xdx2ixbrl1986"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2020-01-01to2020-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2020-01-01to2020-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2020-01-01to2020-12-31">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2020-01-01to2020-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2020-01-01to2020-12-31">001-35814</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2020-01-01to2020-12-31">HARROW HEALTH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-01-01to2020-12-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2020-01-01to2020-12-31">45-0567010</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2020-01-01to2020-12-31">102 Woodmont Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2020-01-01to2020-12-31">Suite 610</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2020-01-01to2020-12-31">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2020-01-01to2020-12-31">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2020-01-01to2020-12-31">37205</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2020-01-01to2020-12-31">(615)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2020-01-01to2020-12-31">733-4730</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2020-01-01to2020-12-31">Common     Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2020-01-01to2020-12-31">HROW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2020-01-01to2020-12-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2020-01-01to2020-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2020-01-01to2020-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2020-01-01to2020-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2020-01-01to2020-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntitySmallBusiness contextRef="From2020-01-01to2020-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-01-01to2020-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2020-01-01to2020-12-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">125000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2021-03-08" decimals="INF" unitRef="Shares">25983364</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:RestrictedCash contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">200000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">200000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">4301000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">4949000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OtherInvestments contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">28455000</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">25200000</us-gaap:OtherInvestments>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">2662000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">2009000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">3962000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">3301000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">751000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">586000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">40131000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">36045000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">4453000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">5375000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">6799000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">6559000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1939000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">2337000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Investments
      contextRef="AsOf2020-12-31_custom_SurfaceOphthalmicsMember"
      decimals="-3"
      unitRef="USD">1314000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="AsOf2019-12-31_custom_SurfaceOphthalmicsMember"
      decimals="-3"
      unitRef="USD">3747000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="AsOf2020-12-31_custom_MeltPharmaceuticalsMember"
      decimals="-3"
      unitRef="USD">2506000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="AsOf2019-12-31_custom_MeltPharmaceuticalsMember"
      decimals="-3"
      unitRef="USD">4690000</us-gaap:Investments>
    <us-gaap:Goodwill contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">332000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">332000</us-gaap:Goodwill>
    <us-gaap:Assets contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">57474000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">59085000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">3932000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">7702000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">2315000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">2117000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">66000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">57000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LoansPayableCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1259000</us-gaap:LoansPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">2639000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">1772000</us-gaap:NotesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">580000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">629000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">8000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">7000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">10799000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">12284000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">6652000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">6338000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">17000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">26000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">800000</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">800000</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
    <us-gaap:LongTermLoansPayable contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">708000</us-gaap:LongTermLoansPayable>
    <us-gaap:LongTermNotesPayable contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">11670000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">12219000</us-gaap:LongTermNotesPayable>
    <us-gaap:Liabilities contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">30646000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">31667000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2019-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">25749875</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">25749875</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">25526931</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">25526931</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">26000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">26000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">104557000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">101728000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">-77400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">-74043000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">27183000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">27711000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">-355000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">-293000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">26828000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">27418000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">57474000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">59085000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-12-31_custom_ProductSalesNetMember"
      decimals="-3"
      unitRef="USD">48479000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_custom_ProductSalesNetMember"
      decimals="-3"
      unitRef="USD">51137000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-12-31_custom_OtherRevenuesMember"
      decimals="-3"
      unitRef="USD">392000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_custom_OtherRevenuesMember"
      decimals="-3"
      unitRef="USD">28000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">48871000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">51165000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">14463000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">16749000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">34408000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">34416000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">31247000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">33088000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">2413000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">2083000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">363000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">4040000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:OperatingExpenses
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">34023000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">39211000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">385000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-4795000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-2236000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-2500000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:GainLossOnInvestments
      contextRef="From2020-01-012020-12-31_custom_MeltPharmaceuticalsMember"
      decimals="-3"
      unitRef="USD">-2313000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2019-01-012019-12-31_custom_MeltPharmaceuticalsMember"
      decimals="-3"
      unitRef="USD">3968000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2020-01-012020-12-31_custom_SurfaceOphthalmicsMember"
      decimals="-3"
      unitRef="USD">-2433000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2019-01-012019-12-31_custom_SurfaceOphthalmicsMember"
      decimals="-3"
      unitRef="USD">-1200000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2020-01-012020-12-31_custom_EtonPharmaceuticalsMember"
      decimals="-3"
      unitRef="USD">3255000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2019-01-012019-12-31_custom_EtonPharmaceuticalsMember"
      decimals="-3"
      unitRef="USD">3780000</us-gaap:GainLossOnInvestments>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-73000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">630000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-3800000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">4678000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-3415000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-117000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">4000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">8000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-3419000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-125000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-62000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-293000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-3357000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">168000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Shares">25895352</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="Shares">25323159</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Shares">25895352</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="Shares">26466098</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2018-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">24339610</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2018-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">24000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">98938000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-74211000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2018-12-31_us-gaap_ParentMember"
      decimals="-3"
      unitRef="USD">24751000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-12-31" decimals="-3" unitRef="USD">24751000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <HROW:StockIssuedDuringPeriodSharesForExerciseOfWarrants
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1142528</HROW:StockIssuedDuringPeriodSharesForExerciseOfWarrants>
    <HROW:StockIssuedDuringPeriodForExerciseOfWarrants
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">2000</HROW:StockIssuedDuringPeriodForExerciseOfWarrants>
    <HROW:StockIssuedDuringPeriodForExerciseOfWarrants
      contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">811000</HROW:StockIssuedDuringPeriodForExerciseOfWarrants>
    <HROW:StockIssuedDuringPeriodForExerciseOfWarrants
      contextRef="From2019-01-012019-12-31_us-gaap_ParentMember"
      decimals="-3"
      unitRef="USD">813000</HROW:StockIssuedDuringPeriodForExerciseOfWarrants>
    <HROW:StockIssuedDuringPeriodForExerciseOfWarrants
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">813000</HROW:StockIssuedDuringPeriodForExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">29793</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">44000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2019-01-012019-12-31_us-gaap_ParentMember"
      decimals="-3"
      unitRef="USD">44000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">44000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2019-01-012019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">15000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">234000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2019-01-012019-12-31_us-gaap_ParentMember"
      decimals="-3"
      unitRef="USD">234000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">234000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">1789000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-12-31_us-gaap_ParentMember"
      decimals="-3"
      unitRef="USD">1789000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">1789000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="From2019-01-012019-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">168000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2019-01-012019-12-31_us-gaap_ParentMember"
      decimals="-3"
      unitRef="USD">168000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2019-01-012019-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      unitRef="USD">-293000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-125000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">25526931</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">26000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">101728000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-74043000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_us-gaap_ParentMember"
      decimals="-3"
      unitRef="USD">27711000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      unitRef="USD">-293000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">27418000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">25526931</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">26000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">101728000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-74043000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_us-gaap_ParentMember"
      decimals="-3"
      unitRef="USD">27711000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2019-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      unitRef="USD">-293000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">27418000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">7159</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">29000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2020-01-012020-12-31_us-gaap_ParentMember"
      decimals="-3"
      unitRef="USD">29000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">29000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">185785</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">30000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">83000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-01-012020-12-31_us-gaap_ParentMember"
      decimals="-3"
      unitRef="USD">83000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">83000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">2775000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-12-31_us-gaap_ParentMember"
      decimals="-3"
      unitRef="USD">2775000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">2775000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-3357000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-12-31_us-gaap_ParentMember"
      decimals="-3"
      unitRef="USD">-3357000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-012020-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      unitRef="USD">-62000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-3419000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">25749875</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      unitRef="USD">26000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      unitRef="USD">104557000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      unitRef="USD">-77400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_ParentMember"
      decimals="-3"
      unitRef="USD">27183000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      unitRef="USD">-355000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">26828000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-3419000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-125000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1880000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">1936000</us-gaap:DepreciationAndAmortization>
    <HROW:AmortizationOfIntangibleAsset
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">167000</HROW:AmortizationOfIntangibleAsset>
    <HROW:AmortizationOfIntangibleAsset
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">209000</HROW:AmortizationOfIntangibleAsset>
    <HROW:AmortizationOfOperatingLeaseRightofuseAssets
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">696000</HROW:AmortizationOfOperatingLeaseRightofuseAssets>
    <HROW:AmortizationOfOperatingLeaseRightofuseAssets
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">518000</HROW:AmortizationOfOperatingLeaseRightofuseAssets>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">213000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:PaidInKindInterest
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">358000</us-gaap:PaidInKindInterest>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">457000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">512000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <HROW:GainLossOnInvestmentsOne
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">3255000</HROW:GainLossOnInvestmentsOne>
    <HROW:GainLossOnInvestmentsOne
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">3780000</HROW:GainLossOnInvestmentsOne>
    <HROW:GainLossOnInvestmentsTwo
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-2433000</HROW:GainLossOnInvestmentsTwo>
    <HROW:GainLossOnInvestmentsTwo
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-1200000</HROW:GainLossOnInvestmentsTwo>
    <HROW:GainLossOnInvestmentsThree
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-2313000</HROW:GainLossOnInvestmentsThree>
    <HROW:GainLossOnInvestmentsThree
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">3968000</HROW:GainLossOnInvestmentsThree>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-105000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-108000</us-gaap:GainLossOnDispositionOfAssets1>
    <HROW:ImpairmentsOfLongLivedAssetsHeldForUse
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">363000</HROW:ImpairmentsOfLongLivedAssetsHeldForUse>
    <HROW:ImpairmentsOfLongLivedAssetsHeldForUse
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">4040000</HROW:ImpairmentsOfLongLivedAssetsHeldForUse>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">83000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">234000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">2775000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">1789000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">866000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">95000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">661000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">2271000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">294000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">471000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-4655000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">1342000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">198000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-166000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">9000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-62000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-1100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">950000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">13000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">4000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">132000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">369000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">862000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">1468000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-981000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-1833000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">8000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">743000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromOtherDebt
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1000000</us-gaap:ProceedsFromOtherDebt>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1497000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">750000</us-gaap:RepaymentsOfNotesPayable>
    <HROW:PaymentsOfCostsRelatedToAmendmentOfLoanPayable
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">282000</HROW:PaymentsOfCostsRelatedToAmendmentOfLoanPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1967000</us-gaap:ProceedsFromNotesPayable>
    <HROW:ProceedsFromExerciseOfWarrantsAndStockOptionsNetOfTaxes
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-29000</HROW:ProceedsFromExerciseOfWarrantsAndStockOptionsNetOfTaxes>
    <HROW:ProceedsFromExerciseOfWarrantsAndStockOptionsNetOfTaxes
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">769000</HROW:ProceedsFromExerciseOfWarrantsAndStockOptionsNetOfTaxes>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1433000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-1006000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-648000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-1889000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">4949000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2018-12-31" decimals="-3" unitRef="USD">6838000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">4301000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">4949000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">4101000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">4749000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">200000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">200000</us-gaap:RestrictedCash>
    <HROW:CashCashEquivalentsAndRestrictedCashAtEndOfPeriod contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">4301000</HROW:CashCashEquivalentsAndRestrictedCashAtEndOfPeriod>
    <HROW:CashCashEquivalentsAndRestrictedCashAtEndOfPeriod contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">4949000</HROW:CashCashEquivalentsAndRestrictedCashAtEndOfPeriod>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">4000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">17000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1791000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">1967000</us-gaap:InterestPaidNet>
    <HROW:PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedExpenses
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">214000</HROW:PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedExpenses>
    <HROW:PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedExpenses
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">39000</HROW:PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedExpenses>
    <HROW:NewAndRevaluationOfRightofuseAssetObtainedInExchangeForLeaseObligation
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">936000</HROW:NewAndRevaluationOfRightofuseAssetObtainedInExchangeForLeaseObligation>
    <HROW:NewAndRevaluationOfRightofuseAssetObtainedInExchangeForLeaseObligation
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">753000</HROW:NewAndRevaluationOfRightofuseAssetObtainedInExchangeForLeaseObligation>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zyvgbrUmEEH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
1. &lt;span id="xdx_82A_zCKsoyU89C83"&gt;ORGANIZATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Harrow
Health, Inc. (together with its subsidiaries, partially owned companies and royalty arrangements unless the context indicates
or otherwise requires, the &#x201c;Company&#x201d; or &#x201c;Harrow&#x201d;) specializes in the development, production and sale
of innovative medications that offer unique competitive advantages and serve unmet needs in the marketplace through its subsidiaries
and deconsolidated companies. The Company owns one of the nation&#x2019;s leading ophthalmology-focused pharmaceutical businesses,
ImprimisRx. In addition to wholly owning ImprimisRx, the Company also has equity positions in Eton Pharmaceuticals, Inc. (&#x201c;Eton&#x201d;),
Surface Ophthalmics, Inc. (&#x201c;Surface&#x201d;), and Melt Pharmaceuticals, Inc. (&#x201c;Melt&#x201d;), all companies that began
as subsidiaries of Harrow. In 2020, Harrow created Visionology, Inc. (&#x201c;Visionology&#x201d;), which intends to launch an online
eye health platform business. Harrow also owns royalty rights in various drug candidates being developed by Surface and Melt.
The Company intends to continue to create, and hold equity and royalty rights in, new businesses that commercialize drug candidates
that are internally developed or otherwise acquired or licensed from third parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
and subsequent to the year ended December 31, 2020, the Company discontinued the majority of operational efforts related to its
subsidiaries Stowe Pharmaceuticals, Inc. (&#x201c;Stowe&#x201d;), Radley Pharmaceuticals, Inc. (&#x201c;Radley&#x201d;) and Mayfield
Pharmaceuticals, Inc. (&#x201c;Mayfield&#x201d;) to allocate resources to other areas of the Company&#x2019;s business. The Company
does not expect the suspension of these operations to have a material impact on the financial results of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_807_eus-gaap--SignificantAccountingPoliciesTextBlock_zj1B6xAxJlNf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
2. &lt;span id="xdx_82D_zBpWLEXAj7Bj"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zB2g7lpJjhz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_866_z5k7PSmrvwA3" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Basis
of Presentation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Harrow
has prepared the accompanying consolidated financial statements in accordance with accounting principles generally accepted in
the United States of America (&#x201c;GAAP&#x201d;). The accompanying consolidated financial statements include the accounts of
the Company and its wholly-owned subsidiaries, as well as Mayfield, &lt;span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__srt--OwnershipAxis__custom--MayfieldPharmaceuticalsIncMember_zzFi1Xe7zli6"&gt;79&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
majority controlled, and Stowe, &lt;span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__srt--OwnershipAxis__custom--StowePharmaceuticalsIncMember_zaCIkRXxt1I3"&gt;70&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
majority controlled as of December 31, 2020. The remaining &lt;span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__srt--OwnershipAxis__custom--MayfieldPharmaceuticalsIncMember__dei--LegalEntityAxis__custom--TGVHealthLLCMember_zejqdJASHqdl"&gt;21&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
of Mayfield is owned by Elle Pharmaceutical, LLC (&#x201c;Elle&#x201d;), TGV-Health, LLC and its affiliated entities (collectively
&#x201c;TGV&#x201d;) or other consultants. Mayfield was organized to develop women&#x2019;s health and urological focused drug candidates.
The remaining &lt;span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__srt--OwnershipAxis__custom--StowePharmaceuticalsIncMember__dei--LegalEntityAxis__custom--TGVHealthLLCMember_zVvLbLg0IAcb"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
of Stowe was owned by TGV. Stowe was organized to develop ophthalmic drug candidates. The Company controls &lt;span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__dei--LegalEntityAxis__custom--VisionologyMember_zkoNfOuU98G"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
of the equity interests in Visionology. All inter-company accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Harrow
consolidates entities in which we have a controlling financial interest. &lt;span id="xdx_90A_ecustom--ConsolidationBasisDescription_c20200101__20201231_zIrQSZmahuie"&gt;We
consolidate subsidiaries in which we hold and/or control, directly or indirectly, more than 50% of the voting rights&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;.
All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--UseOfEstimates_zpQsid6VybDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_867_z7UJDpJDayr5" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Use
of Estimates&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management are, among
others, allowance for doubtful accounts and contractual adjustments, renewal periods and discount rates for leases, realizability
of inventories, valuation of investments, realizability of deferred taxes, recoverability of goodwill and long-lived assets,
valuation of contingent acquisition obligations and deferred acquisition obligations, fair value of loans payable, and valuation
of stock-based transactions with employees and non-employees. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--RisksUncertaintiesAndLiquidityPolicyTextBlock_zs7OziXE2Ufl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_863_zxtiQMgtw2R2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Risks,
Uncertainties and Liquidity&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. On March 18, 2020, the Centers for Medicare
&amp;amp; Medicaid Services (&#x201c;CMS&#x201d;) released guidance for U.S. healthcare providers to limit all elective medical procedures
in order to conserve personal protective equipment and limit exposure to COVID-19 during the pendency of the pandemic. In addition
to limiting elective medical procedures, many hospitals and other healthcare providers have strictly limited access to their facilities
during the pandemic. The COVID-19 pandemic has negatively impacted the global economy, disrupted global supply chains and healthcare
delivery, led to social distancing recommendations, stay-at-home orders and other restrictive measures, and created significant
volatility in financial markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Many
of the Company&#x2019;s customers use its drugs in procedures impacted by the CMS guidance to limit elective procedures. In addition,
the Company and our business partners need access to healthcare providers and facilities to conduct clinical trials and other
activities required to achieve regulatory clearance of products under development.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Management
believes reductions in elective procedures in response to CMS guidance have had, and will continue to have, an adverse impact,
which may be material, on the Company&#x2019;s financial condition, liquidity and results of operations. The severity of the impact
of the COVID-19 pandemic on the Company&#x2019;s business will depend on a number of factors, including, but not limited to, the
duration and severity of the pandemic and the extent and severity of the impact on its customers, all of which are uncertain and
cannot be predicted. As of the date of the filing of this Annual Report on Form 10-K, the extent to which the COVID-19 pandemic
may materially impact the Company&#x2019;s financial condition, liquidity or results of operations is uncertain. In addition, the
Company is subject to certain regulatory standards, guidelines and inspections which could impact the Company&#x2019;s ability
to make, dispense, and sell certain products. If the Company was required to cease compounding and selling certain products as
a result of regulatory guidelines or inspections, this may have a material impact on the Company&#x2019;s financial condition,
liquidity and results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Prior
to 2020, the Company had incurred significant operating losses and negative cash flows from operations since its inception. The
Company recorded operating income of $&lt;span id="xdx_900_eus-gaap--OperatingIncomeLoss_pn3n3_c20200101__20201231_zrqkwi258fMh"&gt;385
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;for the year ended December 31, 2020 and
recorded an operating loss of $&lt;span id="xdx_908_eus-gaap--OperatingIncomeLoss_iN_pn3n3_di_c20190101__20191231_zeWB0DB2LjV2"&gt;4,795
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;for the year ended December 31, 2019.
The Company has an accumulated deficit of $&lt;span id="xdx_90C_ecustom--RetainedEarningsAccumulatedDeficit1_iI_pn3n3_c20201231_zSluZYSmXt7l"&gt;77,400
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_902_ecustom--RetainedEarningsAccumulatedDeficit1_c20191231_pn3n3"&gt;74,043
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;as of December 31, 2020 and 2019, respectively.
In addition, the Company used cash in operating activities of $&lt;span id="xdx_90A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20200101__20201231_zzvRseKWRTyk"&gt;1,100
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;for the year ended December 31, 2020 and
cash provided by operating activities was $&lt;span id="xdx_90B_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20190101__20191231_pn3n3"&gt;950
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;for the year ended December 31, 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;While
there is no assurance, management of the Company believes existing cash resources and restricted cash of $&lt;span id="xdx_904_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c20201231_pn3n3"&gt;4,301
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;at December 31, 2020 together with cash
generated from operations, will be sufficient to sustain the Company&#x2019;s planned level of operations for at least the next
twelve months. However, estimates of operating expenses and working capital requirements and the future impact of the COVID-19
pandemic on its business could be incorrect. The Company could use its cash resources faster than anticipated. Further, some or
all of the ongoing or planned activities may not be successful and could result in further losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company may seek to increase liquidity and capital resources through a variety of means which may include, but are not limited
to: the sale of assets, investments and/or businesses, obtaining financing through the issuance of equity, debt, or convertible
securities; and working to increase revenue growth through sales. There is no guarantee that the Company will be able to obtain
capital when needed on terms management deems acceptable, or at all.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zpKEVQaOaRf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_862_zVPS8MSdP6Ni" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Segments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s chief operating decision-maker is its Chief Executive Officer who makes resource allocation decisions and assesses
performance based on financial information presented as operating segments. The Company has identified &lt;span id="xdx_903_eus-gaap--NumberOfReportableSegments_pii_dc_uSegment_c20200101__20201231_zZ5WqNKZm3U2"&gt;two
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;operating segments as reportable segments.
See Note 18 for more information regarding the Company&#x2019;s reportable segments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--NoncontrollingInterestPolicyTextBlock_zmlNb8sMDXV7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_864_ziIUmOoVZ9f7" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Noncontrolling
Interests&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company recognizes any noncontrolling interest as a separate line item in equity in the consolidated financial statements. A noncontrolling
interest represents the portion of equity ownership in a less-than-wholly-owned subsidiary not attributable to the Company. &lt;span id="xdx_901_eus-gaap--MinorityInterestDescription_c20200101__20201231"&gt;Generally,
any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there
are other factors, such as decision-making rights, that are considered as well.&lt;/span&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company includes the amount of net loss attributable to noncontrolling interests in consolidated net loss on the face of the consolidated
statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company provides in the consolidated statements of stockholders&#x2019; equity a reconciliation at the beginning and the end of
the period of the carrying amount of total equity, equity attributable to the parent, and equity attributable to the noncontrolling
interests that separately discloses:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;net
    income or loss;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;transactions
    with owners acting in their capacity as owners, showing separately contributions from and distributions to owners; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;each
    component of other income or loss.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zwbvARH7jyOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86B_zdyYS700LCO1" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Revenue
Recognition and Deferred Revenue&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company recognizes revenue at the time of transfer of promised goods to customers in an amount that reflects the consideration
to which the Company expects to be entitled in exchange for those goods or services (see Note 3).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--CostOfSalePolicyTextBlock_zNULLezY0Jaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86C_zVGLpbcWyQqj" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Cost
of Sales&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cost
of sales includes direct and indirect costs to manufacture formulations and other products sold, including active pharmaceutical
ingredients, personnel costs, packaging, storage, royalties, shipping and handling costs and the write-off of obsolete inventory.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_zi0BbAIaxsOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_869_zXwXtE0Lq2Ta" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Research
and Development&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company expenses all costs related to research and development as they are incurred. Research and development expenses consist
of expenses incurred in performing research and development activities, including salaries and benefits, other overhead expenses,
and costs related to clinical trials, contract services and outsourced contracts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--DebtPolicyTextBlock_zUNT5Nkwu00h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86A_zj9yw1nxbvQk" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Debt
Issuance Costs and Debt Discount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Debt
issuance costs and the debt discount are recorded net of loans payable and finance lease obligations in the consolidated balance
sheets. Amortization of debt issuance costs and the debt discount is calculated using the effective interest method over the term
of the related debt and is recorded in interest expense in the accompanying consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zxVT0PJq49oi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86D_zju760bhyMl8" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Intellectual
Property&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
costs of acquiring intellectual property rights to be used in the research and development process, including licensing fees and
milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified
an alternative future use for the acquired rights, and are capitalized in situations where we have identified an alternative future
use for the acquired rights. Patents and trademarks are recorded at cost and capitalized at a time when the future economic benefits
of such patents and trademarks become more certain (see &#x201c;&#x2014;Goodwill and Intangible Assets&#x201d; below). The Company
began capitalizing certain costs associated with acquiring intellectual property rights during 2015; if costs are not capitalized
they are expensed as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zsSvygYBqgej" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_865_zpB7sR0mJIUh" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Income
Taxes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company accounts for income taxes under the provisions of Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting
Standards Codification (&#x201c;ASC&#x201d;) 740, &lt;i&gt;Income Taxes&lt;/i&gt;.&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;
&lt;span style="font-size: 10pt"&gt;As part of the process of preparing the Company&#x2019;s consolidated financial statements, the Company
must estimate the actual current tax assets and liabilities and assess permanent and temporary differences that result from differing
treatment of items for tax and accounting purposes. The temporary differences result in deferred tax assets and liabilities, which
are included within the consolidated balance sheets. The Company must assess the likelihood that the deferred tax assets will
be recovered from future taxable income and, to the extent the Company believes that recovery is not more likely than not, a valuation
allowance must be established which reduces the amount of deferred tax assets recorded on the consolidated balance sheets. To
the extent the Company establishes a valuation allowance or increase or decrease this allowance in a period, the impact will be
included in income tax expense in the consolidated statements of operations.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zuJwTGl323H2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_865_zZc9Bcgsjwok" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Cash
and Cash Equivalents&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cash
equivalents include short-term, highly liquid investments with maturities of three months or less at the time of acquisition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zcW8Et4GKXgc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_866_za6tIB3JWyPe" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Concentrations
of Credit Risk&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company places its cash with financial institutions deemed by management to be of high credit quality. The Federal Deposit Insurance
Corporation (&#x201c;FDIC&#x201d;) provides basic deposit coverage with limits up to $&lt;span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_pn3n3_c20201231_zoSZhuyxZU2d"&gt;250
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;per owner. From time to time the Company
has cash deposits in excess of FDIC limits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--InvestmentPolicyTextBlock_zxoMNsKe1V7l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86D_zv7fnV1OYq7i" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Investment
in Eton Pharmaceuticals, Inc. &#x2013; Related Party&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company owns &lt;span id="xdx_903_ecustom--NumberOfSharesOwned_c20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pii"&gt;3,500,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;shares of Eton common stock, which represents
approximately &lt;span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zM8adaGIWvig"&gt;14.4&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
of the equity and voting interests of Eton as of December 31, 2020. At December 31, 2020, the fair market value of Eton&#x2019;s
common stock was $&lt;span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_c20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pii"&gt;8.13
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;per share. In accordance with Accounting
Standard Update (&#x201c;ASU&#x201d;) 2016-01, &lt;i&gt;Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of
Financial Assets and Financial Liabilities&lt;/i&gt;, for the years ended December 31, 2020 and 2019, the Company recorded investment
gains from its Eton common stock position of $&lt;span id="xdx_900_eus-gaap--GainLossOnInvestments_c20200101__20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pn3n3"&gt;3,255
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_903_eus-gaap--GainLossOnInvestments_c20190101__20191231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pn3n3"&gt;3,780&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;,
respectively, related to the change in fair market value of the Company&#x2019;s investment in Eton during the measurement periods.
As of December 31, 2020 and 2019, the fair market value of the Company&#x2019;s investment in Eton was $&lt;span id="xdx_909_eus-gaap--InvestmentOwnedAtFairValue_c20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pn3n3"&gt;28,455
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_905_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3n3_c20191231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zAouulE0m7Wh"&gt;25,200&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Mark
Baum, the Company&#x2019;s Chief Executive Officer, is a member of the board of directors of Eton.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--ReceivablesPolicyTextBlock_zKwwq9dhkrS7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_868_zPimghJtW8eh" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Accounts
Receivable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts
receivable are stated net of allowances for doubtful accounts and contractual adjustments. The accounts receivable balance primarily
includes amounts due from customers the Company has invoiced or from third-party providers (e.g., insurance companies and governmental
agencies), but for which payment has not been received. Charges to bad debt are based on both historical write-offs and specifically
identified receivables. Accounts receivable are presented net of allowances for doubtful accounts and contractual adjustments
in the amount of $&lt;span id="xdx_90F_eus-gaap--AccountsReceivableNet_iI_pn3n3_c20201231_ze7GjI1AvVz9"&gt;98&lt;/span&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and
$&lt;span id="xdx_905_eus-gaap--AccountsReceivableNet_c20191231_pn3n3"&gt;76&lt;/span&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;as
of December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--InventoryPolicyTextBlock_zsJGwgCCeaIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86B_zgKKlzO6KBkg" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Inventories&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Inventories
are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. The Company evaluates
the carrying value of inventories on a regular basis, based on the price expected to be obtained for products in their respective
markets compared with historical cost. Write-downs of inventories are considered to be permanent reductions in the cost basis
of inventories.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company also regularly evaluates its inventories for excess quantities and obsolescence (expiration), taking into account such
factors as historical and anticipated future sales or use in production compared to quantities on hand and the remaining shelf
life of products and active pharmaceutical ingredients on hand. The Company establishes reserves for excess and obsolete inventories
as required based on its analyses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--InvestmentOnePolicyTextBlock_zZz6UKxpUsPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_864_zDoIglvrr3j6" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Investment
in Melt Pharmaceuticals, Inc. &#x2013; Related Party&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
April 2018, the Company formed Melt as a wholly-owned subsidiary. In January and March of 2019, Melt entered into definitive stock
purchase agreements (collectively, the &#x201c;Melt Series A Preferred Stock Agreement&#x201d;) with certain investors and closed
on the sale of Melt&#x2019;s Series A Preferred Stock (the &#x201c;Melt Series A Stock&#x201d;), totaling approximately $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20200101__20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pn3n3"&gt;11,400
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;of proceeds (collectively, the &#x201c;Melt
Series A Round&#x201d;) at a purchase price of $&lt;span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_c20190331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pii"&gt;5.00
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;per share. As a result, the Company lost
voting and ownership control of Melt and ceased consolidating Melt&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
January 2019, the Company deconsolidated Melt and recorded a gain of $&lt;span id="xdx_902_eus-gaap--DeconsolidationGainOrLossAmount_c20190101__20190131__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3"&gt;5,810
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and adjusted the carrying value in Melt
to reflect the increased valuation of Melt and the Company&#x2019;s new ownership interest in accordance with ASC 810-10-40-4(c),
&lt;i&gt;Consolidation&lt;/i&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company owns &lt;span id="xdx_907_ecustom--NumberOfSharesOwned_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pii"&gt;3,500,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;common shares of Melt (which is approximately
&lt;span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zSd66pRu69Lj"&gt;44&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
of the equity interests as of December 31, 2020) and uses the equity method of accounting for this investment, as management has
determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Melt.
Under this method, the Company recognizes earnings and losses in Melt in its consolidated financial statements and adjusts the
carrying amount of its investment in Melt accordingly. The Company&#x2019;s share of earnings and losses are based on the Company&#x2019;s
ownership interest of Melt. Any intra-entity profits and losses are eliminated. The Company recorded equity in the net gain of
Melt of $&lt;span id="xdx_90E_eus-gaap--UnrealizedGainLossOnInvestments_c20190101__20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3"&gt;3,968
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;during the year ended December 31, 2019.
The Company recorded equity in the net loss of Melt of $&lt;span id="xdx_90F_eus-gaap--UnrealizedGainLossOnInvestments_c20200101__20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3"&gt;2,313
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;during the year ended December 31, 2020.
As of December 31, 2020 and 2019, the Company&#x2019;s investment in Melt was $&lt;span id="xdx_90D_eus-gaap--InvestmentOwnedAtFairValue_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3"&gt;2,506
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_905_eus-gaap--InvestmentOwnedAtFairValue_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3"&gt;4,690&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;,
respectively, which includes $&lt;span id="xdx_904_eus-gaap--DueFromRelatedParties_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3"&gt;851
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_90F_eus-gaap--DueFromRelatedParties_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3"&gt;722&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;,
respectively, due from Melt for reimbursable expenses and amounts due under the Melt Master Services Agreement (&#x201c;MSA&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;See
Note 4 for more information and related party disclosure regarding Melt.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_ecustom--InvestmentTwoPolicyTextBlock_zSDPZ9bcLUy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86C_zzuv4slLijWa" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Investment
in Surface Ophthalmics, Inc. &#x2013; Related Party&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company owns &lt;span id="xdx_90F_ecustom--NumberOfSharesOwned_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pii"&gt;3,500,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;common shares (which is approximately
&lt;span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_z8ILJkeZxVa8"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
of the equity interests as of December 31, 2020) of Surface and uses the equity method of accounting for this investment, as management
has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of
Surface. Under this method, the Company recognizes earnings and losses in Surface in its consolidated financial statements and
adjusts the carrying amount of its investment in Surface accordingly. The Company&#x2019;s share of earnings and losses are based
on the Company&#x2019;s ownership interest of Surface. Any intra-entity profits and losses are eliminated. The Company recorded
equity in the net loss of Surface of $&lt;span id="xdx_901_eus-gaap--UnrealizedGainLossOnInvestments_c20190101__20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3"&gt;1,200
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;during the year ended December 31, 2019.
The Company recorded equity in the net loss of Surface of $&lt;span id="xdx_902_eus-gaap--UnrealizedGainLossOnInvestments_c20200101__20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3"&gt;2,433
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;during the year ended December 31, 2020.
As of December 31, 2020 and 2019, the carrying value of the Company&#x2019;s investment in Surface was $&lt;span id="xdx_900_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zanCLi0APkHc"&gt;1,314
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_90E_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3n3_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_ziyzEpkI1lBk"&gt;3,747&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;See
Note 5 for more information and related party disclosure regarding Surface.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zj1FOkOL4wDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_863_zVg2Wgs9avOk" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Property,
Plant and Equipment&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Property,
plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization is calculated
using the straight-line method over the estimated useful life of the asset. Leasehold improvements and capital lease equipment
are amortized over the estimated useful life or remaining lease term, whichever is shorter. Computer software and hardware and
furniture and equipment are depreciated over &lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_z6frLmTXqxJd" title="::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0633"&gt;three
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;to &lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_zOKLGLpu2APa"&gt;five years&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--BusinessCombinationsPolicy_zmi63BiVPK49" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86F_zkYgk8tkZ8c2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Business
Combinations&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company accounts for business combinations by recognizing the assets acquired, liabilities assumed, contractual contingencies,
and contingent consideration at their fair values on the acquisition date. The purchase price allocation process requires management
to make significant estimates and assumptions, especially with respect to intangible assets, estimated contingent consideration
payments and pre-acquisition contingencies. Examples of critical estimates in valuing certain of the intangible assets the Company
has acquired or may acquire in the future include but are not limited to:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;future
    expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed
    technologies and patents; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;discount
    rates utilized in valuation estimates.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Unanticipated
events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates or actual results.
Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date,
including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets,
will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related
contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have
a material effect on the consolidated financial position, statements of operations or cash flows in the period of the change in
the estimate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zEJZfx8SqBth" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86E_zkvFkR2slN9h" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Goodwill
and Intangible Assets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Patents
and trademarks are recorded at cost and capitalized at a time when the future economic benefits of such patents and trademarks
become more certain. At that time, the Company capitalizes third-party legal costs and filing fees associated with obtaining and
prosecuting claims related to its patents and trademarks. Once the patents have been issued, the Company amortizes these costs
over the shorter of the legal life of the patent or its estimated economic life, generally &lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231_zFaqwWWcwHJb"&gt;20
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;years, using the straight-line method.
Trademarks are an indefinite life intangible asset and are assessed for impairment based on future projected cash flows as further
described below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company reviews its goodwill and indefinite-lived intangible assets for impairment as of January 1 of each year and when an event
or a change in circumstances indicates the fair value of a reporting unit may be below its carrying amount. Events or changes
in circumstances considered as impairment indicators include but are not limited to the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;significant
    underperformance of the Company&#x2019;s business relative to expected operating results;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;significant
    adverse economic and industry trends;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;significant
    decline in the Company&#x2019;s market capitalization for an extended period of time relative to net book value; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;expectations
    that a reporting unit will be sold or otherwise disposed.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
goodwill impairment test consists of a two-step process as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Step
1. The Company compares the fair value of each reporting unit to its carrying amount, including the existing goodwill. The fair
value of each reporting unit is determined using a discounted cash flow valuation analysis. The carrying amount of each reporting
unit is determined by specifically identifying and allocating the assets and liabilities to each reporting unit based on headcount,
relative revenues or other methods as deemed appropriate by management. If the carrying amount of a reporting unit exceeds its
fair value, an indication exists that the reporting unit&#x2019;s goodwill may be impaired and the Company then performs the second
step of the impairment test. If the fair value of a reporting unit exceeds its carrying amount, no further analysis is required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Step
2. If further analysis is required, the Company compares the implied fair value of the reporting unit&#x2019;s goodwill, determined
by allocating the reporting unit&#x2019;s fair value to all of its assets and its liabilities in a manner similar to a purchase
price allocation, to its carrying amount. If the carrying amount of the reporting unit&#x2019;s goodwill exceeds its fair value,
an impairment loss will be recognized in an amount equal to the excess.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zLkCQtKREeZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_869_zx0R114RXQna" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Impairment
of Long-Lived Assets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Long-lived
assets, such as property, plant and equipment, purchased intangibles subject to amortization and patents and trademarks, are reviewed
for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted
future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash
flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the
asset. Assets to be disposed of would be separately presented in the consolidated balance sheet and reported at the lower of the
carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposal group
classified as held-for-sale would be presented separately in the appropriate asset and liability sections of the consolidated
balance sheet, if material.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--RestructuringPolicyTextBlock_zhaksSxtf4ja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86B_zTQVhvsTGKc2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Park
Restructuring&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
August 2019, the Company&#x2019;s subsidiary, Park Compounding, Inc. (&#x201c;Park&#x201d;), and Noice Rx, LLC (&#x201c;Noice&#x201d;)
terminated an Asset Purchase Agreement dated July 26, 2019 (the &#x201c;Park Purchase Agreement&#x201d;), between the parties. Under
the terms of the Park Purchase Agreement, Park had agreed to sell substantially all its assets associated with its non-ophthalmology
pharmaceutical compounding business to Noice, including its pharmacy facility and equipment located in Irvine, California. The
closing of the sale transaction was dependent on the California State Board of Pharmacy approving of the sale and issuing a temporary
pharmacy and sterile license permit to Noice, which did not occur and led to Park ceasing operations at the close of business
on August 27, 2019. As a result, the Company restructured its Park business, ceased operations at its Irvine, California-based
pharmacy, and facilitated the transition of certain compounded formulations and related equipment from Park to the Company&#x2019;s
New Jersey-based compounded pharmaceutical production facilities (the &#x201c;Park Restructuring&#x201d;). As a result of the Park
Restructuring, the Company incurred non-cash impairment costs of approximately $&lt;span id="xdx_90B_eus-gaap--AssetImpairmentCharges_c20190101__20191231__dei--LegalEntityAxis__custom--ParkCompoundingIncAndNoiceRxLLCMember_pn3n3"&gt;3,781
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;related to assets held at Park, primarily
associated with property, plant, equipment, inventory, goodwill and other intangible assets, and $&lt;span id="xdx_901_eus-gaap--SeveranceCosts1_c20190101__20191231__dei--LegalEntityAxis__custom--ParkCompoundingIncAndNoiceRxLLCMember_pn3n3"&gt;480
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;in one-time costs related to severance
packages and other costs associated with the Park Restructuring during the year ended December 31, 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company has reduced the Park compounded product formulary to seven base formulations, based on factors including unit order volumes,
revenues and gross margin percentages, and ImprimisRx retained approximately half of Park&#x2019;s historical revenues during
the first quarter of 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zn2PInmnHdN3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_865_zNTAJLxBgAx1" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair
Value Measurements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Fair
value measurements are determined based on the assumptions that market participants would use in pricing an asset or liability.
GAAP establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes
the use of unobservable inputs by requiring that the most observable inputs be used when available. The established fair value
hierarchy prioritizes the use of inputs used in valuation methodologies into the following three levels:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in
    active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure
    fair value whenever available.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such
    as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are
    observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entity&#x2019;s
    own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level
    3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
December 31, 2020 and 2019, the Company measured its investment in Eton on a recurring basis. The Company&#x2019;s investment in
Eton is classified as Level 1 as the fair value is determined using quoted market prices in active markets for the same securities.
As of December 31, 2020 and 2019, the fair market value of the Company&#x2019;s investment in Eton was $&lt;span id="xdx_90B_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zmGvFIrjU5u5"&gt;28,455
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_90C_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3n3_c20191231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zieiRNKDybR8"&gt;25,200&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s financial instruments include cash and cash equivalents, restricted cash, investment in Eton, accounts receivable,
accounts payable and accrued expenses, accrued payroll and related liabilities, deferred revenue and customer deposits, loans
payable and operating and finance lease liabilities. The carrying amount of these financial instruments, except for loans payable
and operating and finance lease liabilities, approximates fair value due to the short-term maturities of these instruments. The
Company&#x2019;s restricted cash which is comprised of short-term investments are carried at amortized cost, which approximates
fair value. Based on borrowing rates currently available to the Company, the carrying values of the loans payable and operating
and finance lease liabilities approximate their respective fair values.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z0tL4ZLkV5ea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_867_zG75iJYyM3Ff" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Stock-Based
Compensation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;All
stock-based payments to employees, directors and consultants, including grants of stock options, warrants, restricted stock units
(&#x201c;RSUs&#x201d;) and restricted stock, are recognized in the consolidated financial statements based upon their estimated
fair values. The Company uses the Black-Scholes-Merton option pricing model and Monte Carlo simulation model to estimate the fair
value of stock-based awards. The estimated fair value is determined at the date of grant. The financial statement effect of forfeitures
is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_z4ZjFTL2yy96" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86B_zzrhTO0IGfpe" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Basic
and Diluted Net Income (Loss) per Common Share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Basic
net income (loss) per common share is computed by dividing income (loss) attributable to common stockholders for the period by
the weighted average number of common shares outstanding during the period. Diluted income (loss) per share is computed
by dividing the income (loss) attributable to common stockholders for the period by the weighted average number of common
and common equivalent shares, such as stock options and warrants, outstanding during the period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Basic
and diluted net income (loss) per share is computed using the weighted average number of shares of common stock outstanding during
the period. Common stock equivalents (using the treasury stock or &#x201c;if converted&#x201d; method) from stock options, unvested
restricted stock units (&#x201c;RSUs&#x201d;) and warrants were &lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndWarrantsMember_pii"&gt;5,411,929
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and &lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndWarrantsMember_pii"&gt;4,848,459
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;at December 31, 2020 and 2019, respectively,
and are excluded in the calculation of diluted net income (loss) per share for the periods presented, because the effect is anti-dilutive
for that time period. Included in the basic and diluted net income (loss) per share calculation were RSUs awarded to directors
that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number of shares underlying
vested RSUs at December 31, 2020 and 2019 was &lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii"&gt;200,463
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii"&gt;324,303&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zqanQOau63d3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table shows the computation of basic net income (loss) per share of common stock for the years ended December 31, 2020
and 2019 (in 000&#x2019;s, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B1_zLJrrZUGtTT2" style="display: none"&gt;SCHEDULE
OF BASIC EARNINGS PER COMMON SHARE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20200101_20201231" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20190101_20191231" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--NetIncomeLoss_pn3n3_zmcAh0QiiBul" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; width: 54%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Numerator
    &#x2013; net (loss) income attributable to Harrow Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 19%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,357&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 19%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;168&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zL46cNFU7Am2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Denominator &#x2013; weighted average
    number of shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,895,352&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,323,159&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--EarningsPerShareBasic_pii_zA4JlFNRV9og" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    (loss) income per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.13&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p id="xdx_8AB_zZxuL4amfJk7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ze4eYR6UJYuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;For
the year end December 31, 2019, the Company computed diluted net income per share using the weighted-average number of common
shares and dilutive common equivalent shares outstanding during that period. Diluted common equivalent shares for the year ended
December 31, 2019 consisted of the following (in 000&#x2019;s, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BD_z64O4FuEUht4" style="display: none"&gt;SCHEDULE
OF DILUTED COMMON EQUIVALENT SHARES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Diluted shares related to:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 74%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_c20190101__20191231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pii" style="width: 22%; text-align: right" title="Dilutive common equivalent shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;488,498&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock
    options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_c20190101__20191231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Dilutive common equivalent shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;654,441&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dilutive common
    equivalent shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_c20190101__20191231_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Dilutive common equivalent shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,142,939&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AE_zc1WXHrFzthb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_zPt4kPLVPCb3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table shows the computation of diluted net income per share using the weighted-average number of common shares and dilutive
common equivalent shares outstanding for the year ended December 31, 2019 (in 000&#x2019;s, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B2_z8V4339e2Hag"&gt;SCHEDULE
OF DILUTED EARNINGS PER COMMON SHARE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20190101__20191231_zXVzwvokF3d6" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--NetIncomeLoss_pn3n3_za3KraIwjsR8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; width: 74%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Numerator
    &#x2013; net income&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 22%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;168&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zyac3j8t4tk1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average number of shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,323,159&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--IncrementalCommonSharesAttributableDilutiveCommonEquivalents_pii_z2WVbHP00Xv7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dilutive common
    equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,142,939&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--IncrementalCommonSharesAttributableToContingentlyIssuableShares_pii_zQSHI8sYiMX2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Denominator &#x2013;
    number of shares used for diluted earnings per share computation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;26,466,098&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--EarningsPerShareDiluted_pii_zj3nKy7HkFoc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net income per
    share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p id="xdx_8A7_zPGABlO5l2jk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_zdg1yXLxkuUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_868_zlyKoit7XDYg" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Recently
Adopted Accounting Pronouncements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
June 2016, the FASB issued ASU 2016-13, &lt;i&gt;Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments&lt;/i&gt;,
which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13
replaces the existing incurred loss impairment model with a forward-looking expected credit loss model which will result in earlier
recognition of credit losses. The Company adopted ASU 2016-13 on January 1, 2020, and adoption of the standard did not have a
material effect on the Company&#x2019;s consolidated financial position, results of operations and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
January 2017, the FASB issued ASU 2017-04, &lt;i&gt;Intangibles-Goodwill and Other&lt;/i&gt;. This guidance simplifies the accounting for
goodwill impairment for all entities by requiring impairment charges to be based on the first step in the current two-step impairment
test under ASC 350. The updated standard eliminates the requirement to calculate a goodwill impairment charge using Step 2. If
a reporting unit&#x2019;s carrying amount exceeds its fair value, an entity will record an impairment charge based on that difference.
The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. The Company adopted ASU 2017-04
on January 1, 2020, and adoption of the standard did not have a material effect on the Company&#x2019;s consolidated financial
position, results of operations and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
August 2018, the FASB issued ASU 2018-13, &lt;i&gt;Changes to Disclosure Requirements for Fair Value Measurements&lt;/i&gt;, which improved
the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies,
and adds certain disclosure requirements. The Company adopted ASU 2018-13 on January 1, 2020, and adoption of the standard did
not have a material effect on the Company&#x2019;s consolidated financial position, results of operations and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zblzoMl5axM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86B_ze9IvWDrTEAa" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Recently
Issued Accounting Pronouncements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
December 2019, the FASB issued ASU 2019-12, &lt;i&gt;Income Taxes&lt;/i&gt;: &lt;i&gt;Simplifying the Accounting for Income Taxes&lt;/i&gt;, which simplifies
the accounting for income taxes. This guidance will be effective for the Company in the first quarter of 2021 on a prospective
basis, and early adoption is permitted. The Company does not expect a material impact of the new guidance on its consolidated
financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z4MuVNqxYXnj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86C_z3kWjNHVTIXb" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Reclassifications&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Certain
prior period items and amounts have been reclassified to conform to the classifications used to prepare the consolidated financial
statements for the year ended December 31, 2020. These reclassifications had no material impact on the Company&#x2019;s consolidated
financial position, results of operations, or cash flows as previously reported.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zB2g7lpJjhz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_866_z5k7PSmrvwA3" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Basis
of Presentation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Harrow
has prepared the accompanying consolidated financial statements in accordance with accounting principles generally accepted in
the United States of America (&#x201c;GAAP&#x201d;). The accompanying consolidated financial statements include the accounts of
the Company and its wholly-owned subsidiaries, as well as Mayfield, &lt;span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__srt--OwnershipAxis__custom--MayfieldPharmaceuticalsIncMember_zzFi1Xe7zli6"&gt;79&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
majority controlled, and Stowe, &lt;span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__srt--OwnershipAxis__custom--StowePharmaceuticalsIncMember_zaCIkRXxt1I3"&gt;70&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
majority controlled as of December 31, 2020. The remaining &lt;span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__srt--OwnershipAxis__custom--MayfieldPharmaceuticalsIncMember__dei--LegalEntityAxis__custom--TGVHealthLLCMember_zejqdJASHqdl"&gt;21&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
of Mayfield is owned by Elle Pharmaceutical, LLC (&#x201c;Elle&#x201d;), TGV-Health, LLC and its affiliated entities (collectively
&#x201c;TGV&#x201d;) or other consultants. Mayfield was organized to develop women&#x2019;s health and urological focused drug candidates.
The remaining &lt;span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__srt--OwnershipAxis__custom--StowePharmaceuticalsIncMember__dei--LegalEntityAxis__custom--TGVHealthLLCMember_zVvLbLg0IAcb"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
of Stowe was owned by TGV. Stowe was organized to develop ophthalmic drug candidates. The Company controls &lt;span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__dei--LegalEntityAxis__custom--VisionologyMember_zkoNfOuU98G"&gt;100&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
of the equity interests in Visionology. All inter-company accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Harrow
consolidates entities in which we have a controlling financial interest. &lt;span id="xdx_90A_ecustom--ConsolidationBasisDescription_c20200101__20201231_zIrQSZmahuie"&gt;We
consolidate subsidiaries in which we hold and/or control, directly or indirectly, more than 50% of the voting rights&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;.
All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2020-12-31_custom_MayfieldPharmaceuticalsIncMember"
      decimals="INF"
      unitRef="Percent">0.79</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2020-12-31_custom_StowePharmaceuticalsIncMember"
      decimals="INF"
      unitRef="Percent">0.70</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2020-12-31_custom_MayfieldPharmaceuticalsIncMember_custom_TGVHealthLLCMember"
      decimals="INF"
      unitRef="Percent">0.21</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2020-12-31_custom_StowePharmaceuticalsIncMember_custom_TGVHealthLLCMember"
      decimals="INF"
      unitRef="Percent">0.30</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2020-12-31_custom_VisionologyMember"
      decimals="INF"
      unitRef="Percent">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <HROW:ConsolidationBasisDescription contextRef="From2020-01-01to2020-12-31">We
consolidate subsidiaries in which we hold and/or control, directly or indirectly, more than 50% of the voting rights</HROW:ConsolidationBasisDescription>
    <us-gaap:UseOfEstimates contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_844_eus-gaap--UseOfEstimates_zpQsid6VybDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_867_z7UJDpJDayr5" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Use
of Estimates&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management are, among
others, allowance for doubtful accounts and contractual adjustments, renewal periods and discount rates for leases, realizability
of inventories, valuation of investments, realizability of deferred taxes, recoverability of goodwill and long-lived assets,
valuation of contingent acquisition obligations and deferred acquisition obligations, fair value of loans payable, and valuation
of stock-based transactions with employees and non-employees. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <HROW:RisksUncertaintiesAndLiquidityPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_843_ecustom--RisksUncertaintiesAndLiquidityPolicyTextBlock_zs7OziXE2Ufl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span id="xdx_863_zxtiQMgtw2R2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Risks,
Uncertainties and Liquidity&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. On March 18, 2020, the Centers for Medicare
&amp;amp; Medicaid Services (&#x201c;CMS&#x201d;) released guidance for U.S. healthcare providers to limit all elective medical procedures
in order to conserve personal protective equipment and limit exposure to COVID-19 during the pendency of the pandemic. In addition
to limiting elective medical procedures, many hospitals and other healthcare providers have strictly limited access to their facilities
during the pandemic. The COVID-19 pandemic has negatively impacted the global economy, disrupted global supply chains and healthcare
delivery, led to social distancing recommendations, stay-at-home orders and other restrictive measures, and created significant
volatility in financial markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Many
of the Company&#x2019;s customers use its drugs in procedures impacted by the CMS guidance to limit elective procedures. In addition,
the Company and our business partners need access to healthcare providers and facilities to conduct clinical trials and other
activities required to achieve regulatory clearance of products under development.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Management
believes reductions in elective procedures in response to CMS guidance have had, and will continue to have, an adverse impact,
which may be material, on the Company&#x2019;s financial condition, liquidity and results of operations. The severity of the impact
of the COVID-19 pandemic on the Company&#x2019;s business will depend on a number of factors, including, but not limited to, the
duration and severity of the pandemic and the extent and severity of the impact on its customers, all of which are uncertain and
cannot be predicted. As of the date of the filing of this Annual Report on Form 10-K, the extent to which the COVID-19 pandemic
may materially impact the Company&#x2019;s financial condition, liquidity or results of operations is uncertain. In addition, the
Company is subject to certain regulatory standards, guidelines and inspections which could impact the Company&#x2019;s ability
to make, dispense, and sell certain products. If the Company was required to cease compounding and selling certain products as
a result of regulatory guidelines or inspections, this may have a material impact on the Company&#x2019;s financial condition,
liquidity and results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Prior
to 2020, the Company had incurred significant operating losses and negative cash flows from operations since its inception. The
Company recorded operating income of $&lt;span id="xdx_900_eus-gaap--OperatingIncomeLoss_pn3n3_c20200101__20201231_zrqkwi258fMh"&gt;385
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;for the year ended December 31, 2020 and
recorded an operating loss of $&lt;span id="xdx_908_eus-gaap--OperatingIncomeLoss_iN_pn3n3_di_c20190101__20191231_zeWB0DB2LjV2"&gt;4,795
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;for the year ended December 31, 2019.
The Company has an accumulated deficit of $&lt;span id="xdx_90C_ecustom--RetainedEarningsAccumulatedDeficit1_iI_pn3n3_c20201231_zSluZYSmXt7l"&gt;77,400
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_902_ecustom--RetainedEarningsAccumulatedDeficit1_c20191231_pn3n3"&gt;74,043
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;as of December 31, 2020 and 2019, respectively.
In addition, the Company used cash in operating activities of $&lt;span id="xdx_90A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20200101__20201231_zzvRseKWRTyk"&gt;1,100
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;for the year ended December 31, 2020 and
cash provided by operating activities was $&lt;span id="xdx_90B_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20190101__20191231_pn3n3"&gt;950
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;for the year ended December 31, 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;While
there is no assurance, management of the Company believes existing cash resources and restricted cash of $&lt;span id="xdx_904_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c20201231_pn3n3"&gt;4,301
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;at December 31, 2020 together with cash
generated from operations, will be sufficient to sustain the Company&#x2019;s planned level of operations for at least the next
twelve months. However, estimates of operating expenses and working capital requirements and the future impact of the COVID-19
pandemic on its business could be incorrect. The Company could use its cash resources faster than anticipated. Further, some or
all of the ongoing or planned activities may not be successful and could result in further losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company may seek to increase liquidity and capital resources through a variety of means which may include, but are not limited
to: the sale of assets, investments and/or businesses, obtaining financing through the issuance of equity, debt, or convertible
securities; and working to increase revenue growth through sales. There is no guarantee that the Company will be able to obtain
capital when needed on terms management deems acceptable, or at all.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</HROW:RisksUncertaintiesAndLiquidityPolicyTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">385000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-4795000</us-gaap:OperatingIncomeLoss>
    <HROW:RetainedEarningsAccumulatedDeficit1 contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">77400000</HROW:RetainedEarningsAccumulatedDeficit1>
    <HROW:RetainedEarningsAccumulatedDeficit1 contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">74043000</HROW:RetainedEarningsAccumulatedDeficit1>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-1100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">950000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">4301000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_846_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zpKEVQaOaRf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_862_zVPS8MSdP6Ni" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Segments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s chief operating decision-maker is its Chief Executive Officer who makes resource allocation decisions and assesses
performance based on financial information presented as operating segments. The Company has identified &lt;span id="xdx_903_eus-gaap--NumberOfReportableSegments_pii_dc_uSegment_c20200101__20201231_zZ5WqNKZm3U2"&gt;two
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;operating segments as reportable segments.
See Note 18 for more information regarding the Company&#x2019;s reportable segments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Segment">2</us-gaap:NumberOfReportableSegments>
    <HROW:NoncontrollingInterestPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_84A_ecustom--NoncontrollingInterestPolicyTextBlock_zmlNb8sMDXV7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_864_ziIUmOoVZ9f7" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Noncontrolling
Interests&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company recognizes any noncontrolling interest as a separate line item in equity in the consolidated financial statements. A noncontrolling
interest represents the portion of equity ownership in a less-than-wholly-owned subsidiary not attributable to the Company. &lt;span id="xdx_901_eus-gaap--MinorityInterestDescription_c20200101__20201231"&gt;Generally,
any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there
are other factors, such as decision-making rights, that are considered as well.&lt;/span&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company includes the amount of net loss attributable to noncontrolling interests in consolidated net loss on the face of the consolidated
statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company provides in the consolidated statements of stockholders&#x2019; equity a reconciliation at the beginning and the end of
the period of the carrying amount of total equity, equity attributable to the parent, and equity attributable to the noncontrolling
interests that separately discloses:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;net
    income or loss;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;transactions
    with owners acting in their capacity as owners, showing separately contributions from and distributions to owners; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;each
    component of other income or loss.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</HROW:NoncontrollingInterestPolicyTextBlock>
    <us-gaap:MinorityInterestDescription contextRef="From2020-01-01to2020-12-31">Generally,
any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there
are other factors, such as decision-making rights, that are considered as well.</us-gaap:MinorityInterestDescription>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_842_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zwbvARH7jyOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86B_zdyYS700LCO1" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Revenue
Recognition and Deferred Revenue&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company recognizes revenue at the time of transfer of promised goods to customers in an amount that reflects the consideration
to which the Company expects to be entitled in exchange for those goods or services (see Note 3).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <HROW:CostOfSalePolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_84F_ecustom--CostOfSalePolicyTextBlock_zNULLezY0Jaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86C_zVGLpbcWyQqj" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Cost
of Sales&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cost
of sales includes direct and indirect costs to manufacture formulations and other products sold, including active pharmaceutical
ingredients, personnel costs, packaging, storage, royalties, shipping and handling costs and the write-off of obsolete inventory.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</HROW:CostOfSalePolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_zi0BbAIaxsOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_869_zXwXtE0Lq2Ta" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Research
and Development&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company expenses all costs related to research and development as they are incurred. Research and development expenses consist
of expenses incurred in performing research and development activities, including salaries and benefits, other overhead expenses,
and costs related to clinical trials, contract services and outsourced contracts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:DebtPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_84C_eus-gaap--DebtPolicyTextBlock_zUNT5Nkwu00h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86A_zj9yw1nxbvQk" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Debt
Issuance Costs and Debt Discount&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Debt
issuance costs and the debt discount are recorded net of loans payable and finance lease obligations in the consolidated balance
sheets. Amortization of debt issuance costs and the debt discount is calculated using the effective interest method over the term
of the related debt and is recorded in interest expense in the accompanying consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_84F_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zxVT0PJq49oi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86D_zju760bhyMl8" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Intellectual
Property&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
costs of acquiring intellectual property rights to be used in the research and development process, including licensing fees and
milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified
an alternative future use for the acquired rights, and are capitalized in situations where we have identified an alternative future
use for the acquired rights. Patents and trademarks are recorded at cost and capitalized at a time when the future economic benefits
of such patents and trademarks become more certain (see &#x201c;&#x2014;Goodwill and Intangible Assets&#x201d; below). The Company
began capitalizing certain costs associated with acquiring intellectual property rights during 2015; if costs are not capitalized
they are expensed as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zsSvygYBqgej" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_865_zpB7sR0mJIUh" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Income
Taxes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company accounts for income taxes under the provisions of Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting
Standards Codification (&#x201c;ASC&#x201d;) 740, &lt;i&gt;Income Taxes&lt;/i&gt;.&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;
&lt;span style="font-size: 10pt"&gt;As part of the process of preparing the Company&#x2019;s consolidated financial statements, the Company
must estimate the actual current tax assets and liabilities and assess permanent and temporary differences that result from differing
treatment of items for tax and accounting purposes. The temporary differences result in deferred tax assets and liabilities, which
are included within the consolidated balance sheets. The Company must assess the likelihood that the deferred tax assets will
be recovered from future taxable income and, to the extent the Company believes that recovery is not more likely than not, a valuation
allowance must be established which reduces the amount of deferred tax assets recorded on the consolidated balance sheets. To
the extent the Company establishes a valuation allowance or increase or decrease this allowance in a period, the impact will be
included in income tax expense in the consolidated statements of operations.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zuJwTGl323H2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_865_zZc9Bcgsjwok" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Cash
and Cash Equivalents&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cash
equivalents include short-term, highly liquid investments with maturities of three months or less at the time of acquisition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zcW8Et4GKXgc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_866_za6tIB3JWyPe" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Concentrations
of Credit Risk&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company places its cash with financial institutions deemed by management to be of high credit quality. The Federal Deposit Insurance
Corporation (&#x201c;FDIC&#x201d;) provides basic deposit coverage with limits up to $&lt;span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_pn3n3_c20201231_zoSZhuyxZU2d"&gt;250
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;per owner. From time to time the Company
has cash deposits in excess of FDIC limits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:InvestmentPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_849_eus-gaap--InvestmentPolicyTextBlock_zxoMNsKe1V7l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86D_zv7fnV1OYq7i" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Investment
in Eton Pharmaceuticals, Inc. &#x2013; Related Party&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company owns &lt;span id="xdx_903_ecustom--NumberOfSharesOwned_c20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pii"&gt;3,500,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;shares of Eton common stock, which represents
approximately &lt;span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zM8adaGIWvig"&gt;14.4&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
of the equity and voting interests of Eton as of December 31, 2020. At December 31, 2020, the fair market value of Eton&#x2019;s
common stock was $&lt;span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_c20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pii"&gt;8.13
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;per share. In accordance with Accounting
Standard Update (&#x201c;ASU&#x201d;) 2016-01, &lt;i&gt;Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of
Financial Assets and Financial Liabilities&lt;/i&gt;, for the years ended December 31, 2020 and 2019, the Company recorded investment
gains from its Eton common stock position of $&lt;span id="xdx_900_eus-gaap--GainLossOnInvestments_c20200101__20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pn3n3"&gt;3,255
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_903_eus-gaap--GainLossOnInvestments_c20190101__20191231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pn3n3"&gt;3,780&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;,
respectively, related to the change in fair market value of the Company&#x2019;s investment in Eton during the measurement periods.
As of December 31, 2020 and 2019, the fair market value of the Company&#x2019;s investment in Eton was $&lt;span id="xdx_909_eus-gaap--InvestmentOwnedAtFairValue_c20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pn3n3"&gt;28,455
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_905_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3n3_c20191231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zAouulE0m7Wh"&gt;25,200&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Mark
Baum, the Company&#x2019;s Chief Executive Officer, is a member of the board of directors of Eton.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InvestmentPolicyTextBlock>
    <HROW:NumberOfSharesOwned
      contextRef="AsOf2020-12-31_custom_EtonPharmaceuticalsIncMember"
      decimals="INF"
      unitRef="Shares">3500000</HROW:NumberOfSharesOwned>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2020-12-31_custom_EtonPharmaceuticalsIncMember"
      decimals="INF"
      unitRef="Percent">0.144</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2020-12-31_custom_EtonPharmaceuticalsIncMember"
      decimals="INF"
      unitRef="USDPShares">8.13</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:GainLossOnInvestments
      contextRef="From2020-01-012020-12-31_custom_EtonPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">3255000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="From2019-01-012019-12-31_custom_EtonPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">3780000</us-gaap:GainLossOnInvestments>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2020-12-31_custom_EtonPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">28455000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2019-12-31_custom_EtonPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">25200000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_842_eus-gaap--ReceivablesPolicyTextBlock_zKwwq9dhkrS7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_868_zPimghJtW8eh" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Accounts
Receivable&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts
receivable are stated net of allowances for doubtful accounts and contractual adjustments. The accounts receivable balance primarily
includes amounts due from customers the Company has invoiced or from third-party providers (e.g., insurance companies and governmental
agencies), but for which payment has not been received. Charges to bad debt are based on both historical write-offs and specifically
identified receivables. Accounts receivable are presented net of allowances for doubtful accounts and contractual adjustments
in the amount of $&lt;span id="xdx_90F_eus-gaap--AccountsReceivableNet_iI_pn3n3_c20201231_ze7GjI1AvVz9"&gt;98&lt;/span&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and
$&lt;span id="xdx_905_eus-gaap--AccountsReceivableNet_c20191231_pn3n3"&gt;76&lt;/span&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;as
of December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:AccountsReceivableNet contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">98000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">76000</us-gaap:AccountsReceivableNet>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_841_eus-gaap--InventoryPolicyTextBlock_zsJGwgCCeaIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86B_zgKKlzO6KBkg" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Inventories&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Inventories
are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. The Company evaluates
the carrying value of inventories on a regular basis, based on the price expected to be obtained for products in their respective
markets compared with historical cost. Write-downs of inventories are considered to be permanent reductions in the cost basis
of inventories.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company also regularly evaluates its inventories for excess quantities and obsolescence (expiration), taking into account such
factors as historical and anticipated future sales or use in production compared to quantities on hand and the remaining shelf
life of products and active pharmaceutical ingredients on hand. The Company establishes reserves for excess and obsolete inventories
as required based on its analyses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <HROW:InvestmentOnePolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_84A_ecustom--InvestmentOnePolicyTextBlock_zZz6UKxpUsPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_864_zDoIglvrr3j6" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Investment
in Melt Pharmaceuticals, Inc. &#x2013; Related Party&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
April 2018, the Company formed Melt as a wholly-owned subsidiary. In January and March of 2019, Melt entered into definitive stock
purchase agreements (collectively, the &#x201c;Melt Series A Preferred Stock Agreement&#x201d;) with certain investors and closed
on the sale of Melt&#x2019;s Series A Preferred Stock (the &#x201c;Melt Series A Stock&#x201d;), totaling approximately $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20200101__20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pn3n3"&gt;11,400
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;of proceeds (collectively, the &#x201c;Melt
Series A Round&#x201d;) at a purchase price of $&lt;span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_c20190331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pii"&gt;5.00
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;per share. As a result, the Company lost
voting and ownership control of Melt and ceased consolidating Melt&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
January 2019, the Company deconsolidated Melt and recorded a gain of $&lt;span id="xdx_902_eus-gaap--DeconsolidationGainOrLossAmount_c20190101__20190131__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3"&gt;5,810
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and adjusted the carrying value in Melt
to reflect the increased valuation of Melt and the Company&#x2019;s new ownership interest in accordance with ASC 810-10-40-4(c),
&lt;i&gt;Consolidation&lt;/i&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company owns &lt;span id="xdx_907_ecustom--NumberOfSharesOwned_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pii"&gt;3,500,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;common shares of Melt (which is approximately
&lt;span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zSd66pRu69Lj"&gt;44&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
of the equity interests as of December 31, 2020) and uses the equity method of accounting for this investment, as management has
determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Melt.
Under this method, the Company recognizes earnings and losses in Melt in its consolidated financial statements and adjusts the
carrying amount of its investment in Melt accordingly. The Company&#x2019;s share of earnings and losses are based on the Company&#x2019;s
ownership interest of Melt. Any intra-entity profits and losses are eliminated. The Company recorded equity in the net gain of
Melt of $&lt;span id="xdx_90E_eus-gaap--UnrealizedGainLossOnInvestments_c20190101__20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3"&gt;3,968
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;during the year ended December 31, 2019.
The Company recorded equity in the net loss of Melt of $&lt;span id="xdx_90F_eus-gaap--UnrealizedGainLossOnInvestments_c20200101__20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3"&gt;2,313
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;during the year ended December 31, 2020.
As of December 31, 2020 and 2019, the Company&#x2019;s investment in Melt was $&lt;span id="xdx_90D_eus-gaap--InvestmentOwnedAtFairValue_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3"&gt;2,506
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_905_eus-gaap--InvestmentOwnedAtFairValue_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3"&gt;4,690&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;,
respectively, which includes $&lt;span id="xdx_904_eus-gaap--DueFromRelatedParties_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3"&gt;851
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_90F_eus-gaap--DueFromRelatedParties_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3"&gt;722&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;,
respectively, due from Melt for reimbursable expenses and amounts due under the Melt Master Services Agreement (&#x201c;MSA&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;See
Note 4 for more information and related party disclosure regarding Melt.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</HROW:InvestmentOnePolicyTextBlock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2020-01-012020-12-31_custom_MeltPharmaceuticalsIncMember_us-gaap_SeriesAPreferredStockMember"
      decimals="-3"
      unitRef="USD">11400000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2019-03-31_custom_MeltPharmaceuticalsIncMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      unitRef="USDPShares">5.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="From2019-01-012019-01-31_custom_MeltPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">5810000</us-gaap:DeconsolidationGainOrLossAmount>
    <HROW:NumberOfSharesOwned
      contextRef="AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="INF"
      unitRef="Shares">3500000</HROW:NumberOfSharesOwned>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="INF"
      unitRef="Percent">0.44</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2019-01-012019-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">3968000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2020-01-012020-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">2313000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">2506000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2019-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">4690000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:DueFromRelatedParties
      contextRef="AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">851000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="AsOf2019-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">722000</us-gaap:DueFromRelatedParties>
    <HROW:InvestmentTwoPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_847_ecustom--InvestmentTwoPolicyTextBlock_zSDPZ9bcLUy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86C_zzuv4slLijWa" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Investment
in Surface Ophthalmics, Inc. &#x2013; Related Party&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company owns &lt;span id="xdx_90F_ecustom--NumberOfSharesOwned_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pii"&gt;3,500,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;common shares (which is approximately
&lt;span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_z8ILJkeZxVa8"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
of the equity interests as of December 31, 2020) of Surface and uses the equity method of accounting for this investment, as management
has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of
Surface. Under this method, the Company recognizes earnings and losses in Surface in its consolidated financial statements and
adjusts the carrying amount of its investment in Surface accordingly. The Company&#x2019;s share of earnings and losses are based
on the Company&#x2019;s ownership interest of Surface. Any intra-entity profits and losses are eliminated. The Company recorded
equity in the net loss of Surface of $&lt;span id="xdx_901_eus-gaap--UnrealizedGainLossOnInvestments_c20190101__20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3"&gt;1,200
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;during the year ended December 31, 2019.
The Company recorded equity in the net loss of Surface of $&lt;span id="xdx_902_eus-gaap--UnrealizedGainLossOnInvestments_c20200101__20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3"&gt;2,433
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;during the year ended December 31, 2020.
As of December 31, 2020 and 2019, the carrying value of the Company&#x2019;s investment in Surface was $&lt;span id="xdx_900_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zanCLi0APkHc"&gt;1,314
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_90E_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3n3_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_ziyzEpkI1lBk"&gt;3,747&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;See
Note 5 for more information and related party disclosure regarding Surface.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</HROW:InvestmentTwoPolicyTextBlock>
    <HROW:NumberOfSharesOwned
      contextRef="AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember"
      decimals="INF"
      unitRef="Shares">3500000</HROW:NumberOfSharesOwned>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember"
      decimals="INF"
      unitRef="Percent">0.30</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2019-01-012019-12-31_custom_SurfacePharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">1200000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="From2020-01-012020-12-31_custom_SurfacePharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">2433000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">1314000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2019-12-31_custom_SurfacePharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">3747000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zj1FOkOL4wDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_863_zVg2Wgs9avOk" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Property,
Plant and Equipment&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Property,
plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization is calculated
using the straight-line method over the estimated useful life of the asset. Leasehold improvements and capital lease equipment
are amortized over the estimated useful life or remaining lease term, whichever is shorter. Computer software and hardware and
furniture and equipment are depreciated over &lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_z6frLmTXqxJd" title="::XDX::P3Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0633"&gt;three
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;to &lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_zOKLGLpu2APa"&gt;five years&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2020-01-012020-12-31_srt_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:BusinessCombinationsPolicy contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_84A_eus-gaap--BusinessCombinationsPolicy_zmi63BiVPK49" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86F_zkYgk8tkZ8c2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Business
Combinations&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company accounts for business combinations by recognizing the assets acquired, liabilities assumed, contractual contingencies,
and contingent consideration at their fair values on the acquisition date. The purchase price allocation process requires management
to make significant estimates and assumptions, especially with respect to intangible assets, estimated contingent consideration
payments and pre-acquisition contingencies. Examples of critical estimates in valuing certain of the intangible assets the Company
has acquired or may acquire in the future include but are not limited to:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;future
    expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed
    technologies and patents; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;discount
    rates utilized in valuation estimates.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Unanticipated
events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates or actual results.
Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date,
including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets,
will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related
contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have
a material effect on the consolidated financial position, statements of operations or cash flows in the period of the change in
the estimate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_843_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zEJZfx8SqBth" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86E_zkvFkR2slN9h" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Goodwill
and Intangible Assets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Patents
and trademarks are recorded at cost and capitalized at a time when the future economic benefits of such patents and trademarks
become more certain. At that time, the Company capitalizes third-party legal costs and filing fees associated with obtaining and
prosecuting claims related to its patents and trademarks. Once the patents have been issued, the Company amortizes these costs
over the shorter of the legal life of the patent or its estimated economic life, generally &lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231_zFaqwWWcwHJb"&gt;20
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;years, using the straight-line method.
Trademarks are an indefinite life intangible asset and are assessed for impairment based on future projected cash flows as further
described below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company reviews its goodwill and indefinite-lived intangible assets for impairment as of January 1 of each year and when an event
or a change in circumstances indicates the fair value of a reporting unit may be below its carrying amount. Events or changes
in circumstances considered as impairment indicators include but are not limited to the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;significant
    underperformance of the Company&#x2019;s business relative to expected operating results;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;significant
    adverse economic and industry trends;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;significant
    decline in the Company&#x2019;s market capitalization for an extended period of time relative to net book value; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;expectations
    that a reporting unit will be sold or otherwise disposed.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
goodwill impairment test consists of a two-step process as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Step
1. The Company compares the fair value of each reporting unit to its carrying amount, including the existing goodwill. The fair
value of each reporting unit is determined using a discounted cash flow valuation analysis. The carrying amount of each reporting
unit is determined by specifically identifying and allocating the assets and liabilities to each reporting unit based on headcount,
relative revenues or other methods as deemed appropriate by management. If the carrying amount of a reporting unit exceeds its
fair value, an indication exists that the reporting unit&#x2019;s goodwill may be impaired and the Company then performs the second
step of the impairment test. If the fair value of a reporting unit exceeds its carrying amount, no further analysis is required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Step
2. If further analysis is required, the Company compares the implied fair value of the reporting unit&#x2019;s goodwill, determined
by allocating the reporting unit&#x2019;s fair value to all of its assets and its liabilities in a manner similar to a purchase
price allocation, to its carrying amount. If the carrying amount of the reporting unit&#x2019;s goodwill exceeds its fair value,
an impairment loss will be recognized in an amount equal to the excess.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2020-01-01to2020-12-31">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zLkCQtKREeZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_869_zx0R114RXQna" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Impairment
of Long-Lived Assets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Long-lived
assets, such as property, plant and equipment, purchased intangibles subject to amortization and patents and trademarks, are reviewed
for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted
future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash
flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the
asset. Assets to be disposed of would be separately presented in the consolidated balance sheet and reported at the lower of the
carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposal group
classified as held-for-sale would be presented separately in the appropriate asset and liability sections of the consolidated
balance sheet, if material.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <HROW:RestructuringPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_843_ecustom--RestructuringPolicyTextBlock_zhaksSxtf4ja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86B_zTQVhvsTGKc2" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Park
Restructuring&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
August 2019, the Company&#x2019;s subsidiary, Park Compounding, Inc. (&#x201c;Park&#x201d;), and Noice Rx, LLC (&#x201c;Noice&#x201d;)
terminated an Asset Purchase Agreement dated July 26, 2019 (the &#x201c;Park Purchase Agreement&#x201d;), between the parties. Under
the terms of the Park Purchase Agreement, Park had agreed to sell substantially all its assets associated with its non-ophthalmology
pharmaceutical compounding business to Noice, including its pharmacy facility and equipment located in Irvine, California. The
closing of the sale transaction was dependent on the California State Board of Pharmacy approving of the sale and issuing a temporary
pharmacy and sterile license permit to Noice, which did not occur and led to Park ceasing operations at the close of business
on August 27, 2019. As a result, the Company restructured its Park business, ceased operations at its Irvine, California-based
pharmacy, and facilitated the transition of certain compounded formulations and related equipment from Park to the Company&#x2019;s
New Jersey-based compounded pharmaceutical production facilities (the &#x201c;Park Restructuring&#x201d;). As a result of the Park
Restructuring, the Company incurred non-cash impairment costs of approximately $&lt;span id="xdx_90B_eus-gaap--AssetImpairmentCharges_c20190101__20191231__dei--LegalEntityAxis__custom--ParkCompoundingIncAndNoiceRxLLCMember_pn3n3"&gt;3,781
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;related to assets held at Park, primarily
associated with property, plant, equipment, inventory, goodwill and other intangible assets, and $&lt;span id="xdx_901_eus-gaap--SeveranceCosts1_c20190101__20191231__dei--LegalEntityAxis__custom--ParkCompoundingIncAndNoiceRxLLCMember_pn3n3"&gt;480
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;in one-time costs related to severance
packages and other costs associated with the Park Restructuring during the year ended December 31, 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company has reduced the Park compounded product formulary to seven base formulations, based on factors including unit order volumes,
revenues and gross margin percentages, and ImprimisRx retained approximately half of Park&#x2019;s historical revenues during
the first quarter of 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</HROW:RestructuringPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2019-01-012019-12-31_custom_ParkCompoundingIncAndNoiceRxLLCMember"
      decimals="-3"
      unitRef="USD">3781000</us-gaap:AssetImpairmentCharges>
    <us-gaap:SeveranceCosts1
      contextRef="From2019-01-012019-12-31_custom_ParkCompoundingIncAndNoiceRxLLCMember"
      decimals="-3"
      unitRef="USD">480000</us-gaap:SeveranceCosts1>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_84A_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zn2PInmnHdN3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_865_zNTAJLxBgAx1" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Fair
Value Measurements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Fair
value measurements are determined based on the assumptions that market participants would use in pricing an asset or liability.
GAAP establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes
the use of unobservable inputs by requiring that the most observable inputs be used when available. The established fair value
hierarchy prioritizes the use of inputs used in valuation methodologies into the following three levels:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in
    active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure
    fair value whenever available.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such
    as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are
    observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entity&#x2019;s
    own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level
    3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
December 31, 2020 and 2019, the Company measured its investment in Eton on a recurring basis. The Company&#x2019;s investment in
Eton is classified as Level 1 as the fair value is determined using quoted market prices in active markets for the same securities.
As of December 31, 2020 and 2019, the fair market value of the Company&#x2019;s investment in Eton was $&lt;span id="xdx_90B_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zmGvFIrjU5u5"&gt;28,455
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_90C_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3n3_c20191231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zieiRNKDybR8"&gt;25,200&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s financial instruments include cash and cash equivalents, restricted cash, investment in Eton, accounts receivable,
accounts payable and accrued expenses, accrued payroll and related liabilities, deferred revenue and customer deposits, loans
payable and operating and finance lease liabilities. The carrying amount of these financial instruments, except for loans payable
and operating and finance lease liabilities, approximates fair value due to the short-term maturities of these instruments. The
Company&#x2019;s restricted cash which is comprised of short-term investments are carried at amortized cost, which approximates
fair value. Based on borrowing rates currently available to the Company, the carrying values of the loans payable and operating
and finance lease liabilities approximate their respective fair values.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2020-12-31_custom_EtonPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">28455000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2019-12-31_custom_EtonPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">25200000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_846_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z0tL4ZLkV5ea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_867_zG75iJYyM3Ff" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Stock-Based
Compensation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;All
stock-based payments to employees, directors and consultants, including grants of stock options, warrants, restricted stock units
(&#x201c;RSUs&#x201d;) and restricted stock, are recognized in the consolidated financial statements based upon their estimated
fair values. The Company uses the Black-Scholes-Merton option pricing model and Monte Carlo simulation model to estimate the fair
value of stock-based awards. The estimated fair value is determined at the date of grant. The financial statement effect of forfeitures
is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_z4ZjFTL2yy96" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86B_zzrhTO0IGfpe" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Basic
and Diluted Net Income (Loss) per Common Share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Basic
net income (loss) per common share is computed by dividing income (loss) attributable to common stockholders for the period by
the weighted average number of common shares outstanding during the period. Diluted income (loss) per share is computed
by dividing the income (loss) attributable to common stockholders for the period by the weighted average number of common
and common equivalent shares, such as stock options and warrants, outstanding during the period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Basic
and diluted net income (loss) per share is computed using the weighted average number of shares of common stock outstanding during
the period. Common stock equivalents (using the treasury stock or &#x201c;if converted&#x201d; method) from stock options, unvested
restricted stock units (&#x201c;RSUs&#x201d;) and warrants were &lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndWarrantsMember_pii"&gt;5,411,929
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and &lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndWarrantsMember_pii"&gt;4,848,459
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;at December 31, 2020 and 2019, respectively,
and are excluded in the calculation of diluted net income (loss) per share for the periods presented, because the effect is anti-dilutive
for that time period. Included in the basic and diluted net income (loss) per share calculation were RSUs awarded to directors
that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number of shares underlying
vested RSUs at December 31, 2020 and 2019 was &lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii"&gt;200,463
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii"&gt;324,303&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zqanQOau63d3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table shows the computation of basic net income (loss) per share of common stock for the years ended December 31, 2020
and 2019 (in 000&#x2019;s, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B1_zLJrrZUGtTT2" style="display: none"&gt;SCHEDULE
OF BASIC EARNINGS PER COMMON SHARE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20200101_20201231" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20190101_20191231" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--NetIncomeLoss_pn3n3_zmcAh0QiiBul" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; width: 54%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Numerator
    &#x2013; net (loss) income attributable to Harrow Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 19%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,357&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 19%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;168&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zL46cNFU7Am2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Denominator &#x2013; weighted average
    number of shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,895,352&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,323,159&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--EarningsPerShareBasic_pii_zA4JlFNRV9og" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    (loss) income per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.13&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p id="xdx_8AB_zZxuL4amfJk7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ze4eYR6UJYuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;For
the year end December 31, 2019, the Company computed diluted net income per share using the weighted-average number of common
shares and dilutive common equivalent shares outstanding during that period. Diluted common equivalent shares for the year ended
December 31, 2019 consisted of the following (in 000&#x2019;s, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BD_z64O4FuEUht4" style="display: none"&gt;SCHEDULE
OF DILUTED COMMON EQUIVALENT SHARES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Diluted shares related to:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 74%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_c20190101__20191231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pii" style="width: 22%; text-align: right" title="Dilutive common equivalent shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;488,498&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock
    options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_c20190101__20191231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Dilutive common equivalent shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;654,441&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dilutive common
    equivalent shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_c20190101__20191231_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Dilutive common equivalent shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,142,939&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AE_zc1WXHrFzthb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_zPt4kPLVPCb3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table shows the computation of diluted net income per share using the weighted-average number of common shares and dilutive
common equivalent shares outstanding for the year ended December 31, 2019 (in 000&#x2019;s, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B2_z8V4339e2Hag"&gt;SCHEDULE
OF DILUTED EARNINGS PER COMMON SHARE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20190101__20191231_zXVzwvokF3d6" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--NetIncomeLoss_pn3n3_za3KraIwjsR8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; width: 74%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Numerator
    &#x2013; net income&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 22%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;168&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zyac3j8t4tk1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average number of shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,323,159&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--IncrementalCommonSharesAttributableDilutiveCommonEquivalents_pii_z2WVbHP00Xv7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dilutive common
    equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,142,939&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--IncrementalCommonSharesAttributableToContingentlyIssuableShares_pii_zQSHI8sYiMX2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Denominator &#x2013;
    number of shares used for diluted earnings per share computation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;26,466,098&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--EarningsPerShareDiluted_pii_zj3nKy7HkFoc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net income per
    share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p id="xdx_8A7_zPGABlO5l2jk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-12-31_custom_StockOptionsUnvestedRSUsAndWarrantsMember"
      decimals="INF"
      unitRef="Shares">5411929</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-012019-12-31_custom_StockOptionsUnvestedRSUsAndWarrantsMember"
      decimals="INF"
      unitRef="Shares">4848459</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">200463</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">324303</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_899_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zqanQOau63d3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table shows the computation of basic net income (loss) per share of common stock for the years ended December 31, 2020
and 2019 (in 000&#x2019;s, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B1_zLJrrZUGtTT2" style="display: none"&gt;SCHEDULE
OF BASIC EARNINGS PER COMMON SHARE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20200101_20201231" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20190101_20191231" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--NetIncomeLoss_pn3n3_zmcAh0QiiBul" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; width: 54%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Numerator
    &#x2013; net (loss) income attributable to Harrow Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 19%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,357&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 19%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;168&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zL46cNFU7Am2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Denominator &#x2013; weighted average
    number of shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,895,352&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,323,159&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--EarningsPerShareBasic_pii_zA4JlFNRV9og" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    (loss) income per share, basic&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.13&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-3357000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">168000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Shares">25895352</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="Shares">25323159</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ze4eYR6UJYuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;For
the year end December 31, 2019, the Company computed diluted net income per share using the weighted-average number of common
shares and dilutive common equivalent shares outstanding during that period. Diluted common equivalent shares for the year ended
December 31, 2019 consisted of the following (in 000&#x2019;s, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BD_z64O4FuEUht4" style="display: none"&gt;SCHEDULE
OF DILUTED COMMON EQUIVALENT SHARES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Diluted shares related to:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 74%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_c20190101__20191231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pii" style="width: 22%; text-align: right" title="Dilutive common equivalent shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;488,498&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock
    options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_c20190101__20191231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Dilutive common equivalent shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;654,441&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dilutive common
    equivalent shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_c20190101__20191231_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Dilutive common equivalent shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,142,939&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="From2019-01-012019-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">488498</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="From2019-01-012019-12-31_custom_StockOptionsMember"
      decimals="INF"
      unitRef="Shares">654441</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="Shares">1142939</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_898_eus-gaap--ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_zPt4kPLVPCb3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table shows the computation of diluted net income per share using the weighted-average number of common shares and dilutive
common equivalent shares outstanding for the year ended December 31, 2019 (in 000&#x2019;s, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B2_z8V4339e2Hag"&gt;SCHEDULE
OF DILUTED EARNINGS PER COMMON SHARE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20190101__20191231_zXVzwvokF3d6" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year Ended&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x202f;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--NetIncomeLoss_pn3n3_za3KraIwjsR8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; width: 74%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Numerator
    &#x2013; net income&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 22%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;168&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zyac3j8t4tk1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average number of shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,323,159&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--IncrementalCommonSharesAttributableDilutiveCommonEquivalents_pii_z2WVbHP00Xv7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dilutive common
    equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,142,939&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--IncrementalCommonSharesAttributableToContingentlyIssuableShares_pii_zQSHI8sYiMX2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Denominator &#x2013;
    number of shares used for diluted earnings per share computation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;26,466,098&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--EarningsPerShareDiluted_pii_zj3nKy7HkFoc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net income per
    share, diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.01&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

</us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">168000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="Shares">25323159</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <HROW:IncrementalCommonSharesAttributableDilutiveCommonEquivalents
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="Shares">1142939</HROW:IncrementalCommonSharesAttributableDilutiveCommonEquivalents>
    <us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="Shares">26466098</us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:EarningsPerShareDiluted>
    <HROW:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_84F_ecustom--RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_zdg1yXLxkuUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_868_zlyKoit7XDYg" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Recently
Adopted Accounting Pronouncements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
June 2016, the FASB issued ASU 2016-13, &lt;i&gt;Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments&lt;/i&gt;,
which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13
replaces the existing incurred loss impairment model with a forward-looking expected credit loss model which will result in earlier
recognition of credit losses. The Company adopted ASU 2016-13 on January 1, 2020, and adoption of the standard did not have a
material effect on the Company&#x2019;s consolidated financial position, results of operations and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
January 2017, the FASB issued ASU 2017-04, &lt;i&gt;Intangibles-Goodwill and Other&lt;/i&gt;. This guidance simplifies the accounting for
goodwill impairment for all entities by requiring impairment charges to be based on the first step in the current two-step impairment
test under ASC 350. The updated standard eliminates the requirement to calculate a goodwill impairment charge using Step 2. If
a reporting unit&#x2019;s carrying amount exceeds its fair value, an entity will record an impairment charge based on that difference.
The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. The Company adopted ASU 2017-04
on January 1, 2020, and adoption of the standard did not have a material effect on the Company&#x2019;s consolidated financial
position, results of operations and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
August 2018, the FASB issued ASU 2018-13, &lt;i&gt;Changes to Disclosure Requirements for Fair Value Measurements&lt;/i&gt;, which improved
the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies,
and adds certain disclosure requirements. The Company adopted ASU 2018-13 on January 1, 2020, and adoption of the standard did
not have a material effect on the Company&#x2019;s consolidated financial position, results of operations and cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</HROW:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zblzoMl5axM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86B_ze9IvWDrTEAa" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Recently
Issued Accounting Pronouncements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
December 2019, the FASB issued ASU 2019-12, &lt;i&gt;Income Taxes&lt;/i&gt;: &lt;i&gt;Simplifying the Accounting for Income Taxes&lt;/i&gt;, which simplifies
the accounting for income taxes. This guidance will be effective for the Company in the first quarter of 2021 on a prospective
basis, and early adoption is permitted. The Company does not expect a material impact of the new guidance on its consolidated
financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z4MuVNqxYXnj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_86C_z3kWjNHVTIXb" style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Reclassifications&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Certain
prior period items and amounts have been reclassified to conform to the classifications used to prepare the consolidated financial
statements for the year ended December 31, 2020. These reclassifications had no material impact on the Company&#x2019;s consolidated
financial position, results of operations, or cash flows as previously reported.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_800_eus-gaap--RevenueFromContractWithCustomerTextBlock_z8KoT16n7bs8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
3. &lt;span id="xdx_828_zqVLltb8COE7"&gt;REVENUES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company accounts for contracts with customers in accordance with ASC 606, &lt;i&gt;Revenues from Contracts with Customers.&lt;/i&gt; The Company
has three primary streams of revenue: (1) revenue recognized from our sale of products within our pharmacy services (2)
revenue recognized from a commission agreement with a third party and (3) revenue recognized from intellectual property
license and asset purchase agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Product
Revenues from Pharmacy Services&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company sells prescription drugs directly through our pharmacy and outsourcing facility network. Revenue from our pharmacy services
divisions includes: (i) the portion of the price the client pays directly to us, net of any volume-related or other discounts
paid back to the client, (ii) the price paid to us by individuals, and (iii) customer copayments made directly to the pharmacy
network. Sales taxes are not included in revenue. Following the core principles of ASC 606, we have identified the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Identify
    the contract(s) with a customer: A contract exists with a customer at the time the prescription or order is received by the
    Company.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Identify
    the performance obligations in the contract: The order received contains the performance obligations to be met, in almost
    all cases the product the customer is wishing to receive. If we are unable to be meet the performance obligation the customer
    is notified.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Determine
    the transaction price: the transaction price is based on the product being sold to the customer, and any related customer
    discounts. These amounts are pre-determined and built into our order management software.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Allocate
    the transaction price to the performance obligations in the contract: The transaction price associated with the product(s)
    being ordered is allocated according to the pre-determined amounts.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Recognize
    revenue when (or as) the entity satisfies a performance obligation: At the time of shipment from the pharmacy or outsourcing
    facility the performance obligation has been met.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following revenue recognition policy has been established for the pharmacy services division:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Revenues
generated from prescription or office use drugs sold by our pharmacies and outsourcing facility are recognized when the prescription
is shipped. At the time of shipment, the pharmacy services division has performed substantially all of its obligations under its
client contracts and does not experience a significant level of returns or reshipments. Determination of criteria (3) and (4)
is based on management&#x2019;s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability
of those amounts. The Company records reductions to revenue for discounts at the time of the initial sale. Estimated returns and
allowances and other adjustments are provided for in the same period during which the related sales are recorded and are based
on actual returns history. The rate of returns is analyzed annually to determine historical returns experience. If the historical
data we use to calculate these estimates do not properly reflect future returns, then a change in the allowance would be made
in the period in which such a determination is made and revenues in that period could be materially affected. The Company will
defer any revenues received for a product that has not been delivered or is subject to refund until such time that the Company
and the customer jointly determine that the product has been delivered and no refund will be required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Commission
Revenues&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;During
the year ended December 31, 2020, the Company entered into an agreement whereby&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;it
is paid a fee calculated based on sales it generates from a pharmaceutical product that is owned by a third party. The revenue
earned from this arrangement is recognized at the time a customer has ordered the pharmaceutical product and it has shipped from
the third party (or one of its distributors or affiliates), at which point there is no future performance obligation required
by the Company and no consequential continuing involvement on the part of the Company to recognize the associated revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Intellectual
Property License Revenues&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company currently holds five intellectual property license and related agreements in which the Company has promised to grant a
license or sale which provides a customer with the right to access the Company&#x2019;s intellectual property. License arrangements
may consist of non-refundable upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights
to patented or patent pending compounds, technology access fees, and various performance or sales milestones. These arrangements
can be multiple-element arrangements, the revenue of which is recognized at the point of time the performance obligation is met.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Non-refundable
fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on the
part of the Company are recognized as revenue when the license term commences and the licensed data, technology, compounded drug
preparation and/or other deliverable is delivered. Such deliverables may include physical quantities of compounded drug preparations,
design of the compounded drug preparations and structure-activity relationships, the conceptual framework and mechanism of action,
and rights to the patents or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable
fees if it has continuing performance obligations without which the technology, right, product or service conveyed in conjunction
with the non-refundable fee has no utility to the licensee and that are separate and independent of the Company&#x2019;s performance
under the other elements of the arrangement. In addition, if the Company&#x2019;s continued involvement is required, through research
and development services that are related to its proprietary know-how and expertise of the delivered technology or can only be
performed by the Company, then such non-refundable fees are deferred and recognized over the period of continuing involvement.
Guaranteed minimum annual royalties are recognized on a straight-line basis over the applicable term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--DisaggregationOfRevenueTableTextBlock_ztse0XPjc8Kh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue
disaggregated by revenue source for the years ended December 31, 2020 and 2019, consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_8B1_zgDCXutC9LY2" style="display: none"&gt;SCHEDULE
OF DISAGGREGATED REVENUE&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20200101__20201231_zXjkmt7RQjS5" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20190101__20191231_zCgJERXstHci" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Product
    sales, net&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_z2vy7QHcd335" style="width: 18%; text-align: right" title="Total Revenues"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;48,479&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20191231__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_zXQYsT0UskV4" style="width: 18%; text-align: right" title="Total Revenues"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,137&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Commissions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--CommissionsMember_z9qdAGyt5GH7" style="text-align: right" title="Total Revenues"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;356&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--CommissionsMember_pn3n3" style="text-align: right" title="Total Revenues"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0706"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zam5zkBhjPH1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_z6WY4vLl8aul" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;48,871&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,165&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AD_zyu4urvGWrfl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred
revenue and customer deposits at December 31, 2020 and 2019, were $&lt;span id="xdx_909_eus-gaap--ContractWithCustomerLiabilityCurrent_c20201231_pn3n3"&gt;66
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_901_eus-gaap--ContractWithCustomerLiabilityCurrent_c20191231_pn3n3"&gt;57&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;,
respectively. All deferred revenue and customer deposit amounts at December 31, 2019 were recognized as revenue during the year
ended December 31, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_897_eus-gaap--DisaggregationOfRevenueTableTextBlock_ztse0XPjc8Kh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Revenue
disaggregated by revenue source for the years ended December 31, 2020 and 2019, consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_8B1_zgDCXutC9LY2" style="display: none"&gt;SCHEDULE
OF DISAGGREGATED REVENUE&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20200101__20201231_zXjkmt7RQjS5" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20190101__20191231_zCgJERXstHci" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Product
    sales, net&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_z2vy7QHcd335" style="width: 18%; text-align: right" title="Total Revenues"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;48,479&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20191231__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_zXQYsT0UskV4" style="width: 18%; text-align: right" title="Total Revenues"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,137&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Commissions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--CommissionsMember_z9qdAGyt5GH7" style="text-align: right" title="Total Revenues"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;356&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--CommissionsMember_pn3n3" style="text-align: right" title="Total Revenues"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0706"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zam5zkBhjPH1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_z6WY4vLl8aul" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;48,871&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,165&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-12-31_custom_ProductSalesNetMember"
      decimals="-3"
      unitRef="USD">48479000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_custom_ProductSalesNetMember"
      decimals="-3"
      unitRef="USD">51137000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-12-31_custom_CommissionsMember"
      decimals="-3"
      unitRef="USD">356000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-12-31_us-gaap_LicenseMember"
      decimals="-3"
      unitRef="USD">36000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_us-gaap_LicenseMember"
      decimals="-3"
      unitRef="USD">28000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">48871000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">51165000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">66000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">57000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_80A_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zUV64Zjsdnk7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
4. &lt;span id="xdx_825_zcEcINQa0uN2"&gt;INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
December 2018, the Company entered into an asset purchase agreement with Melt (the &#x201c;Melt Asset Purchase Agreement&#x201d;).
Pursuant to the terms of the Melt Asset Purchase Agreement, Melt was assigned certain intellectual property and related rights
from the Company to develop, formulate, make, sell, and sub-license certain Company conscious sedation and analgesia related formulations
(collectively, the &#x201c;Melt Products&#x201d;). Under the terms of the Melt Asset Purchase Agreement, Melt is required to make
mid-single digit royalty payments to the Company on net sales of the Melt Products while any patent rights remain outstanding,
as well as other conditions. In January and March 2019, the Company entered into the Melt Series A Preferred Stock Agreement,
see also Note 2, under the subheading &lt;i&gt;Investment in Melt Pharmaceuticals, Inc&lt;/i&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
February 2019, the Company and Melt entered into a Management Services Agreement (the &#x201c;Melt MSA&#x201d;), whereby the Company
provides to Melt certain administrative services and support, including bookkeeping, web services and human resources related
activities, and Melt is required to pay the Company a monthly amount of $&lt;span id="xdx_907_eus-gaap--AdministrativeFeesExpense_pn3n3_c20190201__20190228__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_zC3CEx4f7Ssk"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of December 31, 2020 and 2019, the Company was due $&lt;span id="xdx_906_eus-gaap--DueFromRelatedParties_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_pn3n3"&gt;851
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_90E_eus-gaap--DueFromRelatedParties_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_pn3n3"&gt;722&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;,
respectively, from Melt for reimbursable expenses and amounts due under the Melt MSA. Melt did no&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;t
make any payments to the Company during the year ended December 31, 2020 and paid the Company $&lt;span id="xdx_902_eus-gaap--RepaymentsOfRelatedPartyDebt_c20190101__20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--MSAMember_pn3n3"&gt;50
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;during the year ended December 31, 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s Chief Executive Officer, Mark L. Baum, and Chief Medical Officer, Larry Dillaha, are members of the Melt board
of directors, and several employees of the Company (including Mr. Baum, Mr. Dillaha and the Company&#x2019;s Chief Financial Officer,
Andrew Boll) entered into consulting agreements and provide consulting services to Melt.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_ecustom--ScheduleOfCondensedIncomeStatementOneTableTextBlock_zRZArcCQNL66" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
unaudited condensed results of operations information of Melt is summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BC_zLmh3RyFHgLk" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;SCHEDULE
OF CONDENSED INCOME STATEMENT&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Revenues, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Revenues, net"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0725"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Revenues, net"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0727"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss
    from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OperatingIncomeLoss_c20200101__20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Loss from operations"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OperatingIncomeLoss_c20190101__20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Loss from operations"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,381&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--NetIncomeLoss_c20200101__20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5,019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--NetIncomeLoss_c20190101__20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,381&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A4_zVJzaHs0NPVj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--ScheduleOfCondensedBalanceSheetOneTableTextBlock_zwmQcbAYH4Hd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
unaudited condensed balance sheet information of Melt is summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B5_zA39cAzGTzFi" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;SCHEDULE
OF CONDENSED BALANCE SHEET&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AssetsCurrent_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="width: 18%; text-align: right" title="Current assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,947&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AssetsCurrent_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="width: 18%; text-align: right" title="Current assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,449&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non current
    assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AssetsNoncurrent_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AssetsNoncurrent_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--Assets_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,958&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Assets_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,454&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--Liabilities_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,778&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Liabilities_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,691&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total preferred
    stock and stockholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--StockholdersEquity_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total preferred stock and stockholders' equity"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,180&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--StockholdersEquity_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total preferred stock and stockholders' equity"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,763&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total liabilities
    and stockholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--LiabilitiesAndStockholdersEquity_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,958&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LiabilitiesAndStockholdersEquity_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,454&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A4_zXJ9p3IO4ggh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:AdministrativeFeesExpense
      contextRef="From2019-02-012019-02-28_custom_MeltPharmaceuticalsIncMember_custom_ManagementServicesAgreementMember"
      decimals="-3"
      unitRef="USD">10000</us-gaap:AdministrativeFeesExpense>
    <us-gaap:DueFromRelatedParties
      contextRef="AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember_custom_ManagementServicesAgreementMember"
      decimals="-3"
      unitRef="USD">851000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="AsOf2019-12-31_custom_MeltPharmaceuticalsIncMember_custom_ManagementServicesAgreementMember"
      decimals="-3"
      unitRef="USD">722000</us-gaap:DueFromRelatedParties>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2019-01-012019-12-31_custom_SurfacePharmaceuticalsIncMember_custom_MSAMember"
      decimals="-3"
      unitRef="USD">50000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <HROW:ScheduleOfCondensedIncomeStatementOneTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89A_ecustom--ScheduleOfCondensedIncomeStatementOneTableTextBlock_zRZArcCQNL66" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
unaudited condensed results of operations information of Melt is summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BC_zLmh3RyFHgLk" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;SCHEDULE
OF CONDENSED INCOME STATEMENT&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Revenues, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Revenues, net"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0725"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Revenues, net"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0727"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss
    from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OperatingIncomeLoss_c20200101__20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Loss from operations"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OperatingIncomeLoss_c20190101__20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Loss from operations"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,381&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--NetIncomeLoss_c20200101__20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5,019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--NetIncomeLoss_c20190101__20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,381&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</HROW:ScheduleOfCondensedIncomeStatementOneTableTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-012020-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">5019000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-01-012019-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">4381000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">-5019000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">-4381000</us-gaap:NetIncomeLoss>
    <HROW:ScheduleOfCondensedBalanceSheetOneTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89B_ecustom--ScheduleOfCondensedBalanceSheetOneTableTextBlock_zwmQcbAYH4Hd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
unaudited condensed balance sheet information of Melt is summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B5_zA39cAzGTzFi" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;SCHEDULE
OF CONDENSED BALANCE SHEET&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AssetsCurrent_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="width: 18%; text-align: right" title="Current assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,947&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AssetsCurrent_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="width: 18%; text-align: right" title="Current assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,449&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non current
    assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AssetsNoncurrent_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AssetsNoncurrent_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--Assets_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,958&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Assets_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,454&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--Liabilities_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,778&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Liabilities_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,691&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total preferred
    stock and stockholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--StockholdersEquity_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total preferred stock and stockholders' equity"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,180&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--StockholdersEquity_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total preferred stock and stockholders' equity"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,763&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total liabilities
    and stockholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--LiabilitiesAndStockholdersEquity_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,958&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LiabilitiesAndStockholdersEquity_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,454&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</HROW:ScheduleOfCondensedBalanceSheetOneTableTextBlock>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">2947000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2019-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">7449000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">11000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2019-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">5000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">2958000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2019-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">7454000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">1778000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2019-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">1691000</us-gaap:Liabilities>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">1180000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">5763000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">2958000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2019-12-31_custom_MeltPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">7454000</us-gaap:LiabilitiesAndStockholdersEquity>
    <HROW:InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_802_ecustom--InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock_z0Zp9bskmkk8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
5. &lt;span id="xdx_82D_zycWZ1Ojflz5"&gt;INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company entered into an asset purchase and license agreement with Surface in 2017 and amended it in April 2018 (the &#x201c;Surface
License Agreements&#x201d;). Pursuant to the terms of the Surface License Agreements, the Company assigned and licensed to Surface
certain intellectual property and related rights associated with Surface&#x2019;s drug candidates (collectively, the &#x201c;Surface
Products&#x201d;). Surface is required to make mid-single-digit royalty payments to the Company on net sales of the Surface
Products while any patent rights remain outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of December 31, 2020, the Company owned &lt;span id="xdx_901_eus-gaap--SharesOutstanding_iI_pii_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zUf2Wpf5UMpe"&gt;3,500,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;shares of Surface common stock (approximately
&lt;span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zDa6O5oJ228d"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
of the issued and outstanding equity interests). A Company director, Richard L. Lindstrom, and the Company&#x2019;s Chief Executive
Officer, Mark L. Baum, are directors of Surface. Surface is required to make royalty payments to Dr. Lindstrom of &lt;span id="xdx_905_ecustom--RoyaltyPaymentPercentageOnNetSales_pii_dp_uPercent_c20200101__20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember__srt--TitleOfIndividualAxis__custom--DrLindstromMember_zb6EbmhuIKj2"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
of net sales of certain Surface Products while certain patent rights remain outstanding. Dr. Lindstrom is also a principal of
Flying L Partners, an affiliate of the funding investor who purchased the Surface Series A Preferred Stock. Several employees
and a director of the Company (including Mr. Baum and Dr. Lindstrom) entered into consulting agreements and provided consulting
services to Surface.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_esrt--ScheduleOfCondensedIncomeStatementTableTextBlock_zVSrka9hJfF" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
unaudited condensed results of operations information of Surface is summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B5_zaAtubQHO5k8" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;SUMMARY
OF CONDENSED INCOME STATEMENT&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year&lt;b&gt;s&lt;/b&gt; Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Revenues, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Revenues, net"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0770"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Revenues, net"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0772"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss
    from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--OperatingIncomeLoss_c20200101__20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Loss from operations"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,109&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OperatingIncomeLoss_c20190101__20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Loss from operations"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--NetIncomeLoss_c20200101__20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(8,109&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--NetIncomeLoss_c20190101__20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A2_zGGDHlBuasi9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_zshJRTO0n9Bk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
unaudited condensed balance sheet information of Surface is summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B5_zqOuNIJAasqj" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;SUMMARY
OF CONDENSED BALANCE SHEET&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;
    December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsCurrent_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="width: 18%; text-align: right" title="Current assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,074&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AssetsCurrent_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="width: 18%; text-align: right" title="Current assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,942&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non current
    assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsNoncurrent_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AssetsNoncurrent_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;47&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Assets_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,119&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--Assets_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,989&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--Liabilities_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,666&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Liabilities_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;619&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total stockholders&#x2019;
    equity&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--StockholdersEquity_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders equity"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,453&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockholdersEquity_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders equity"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,370&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    liabilities and stockholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LiabilitiesAndStockholdersEquity_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,119&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--LiabilitiesAndStockholdersEquity_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,989&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AE_z4SoyS3XYfv5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</HROW:InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember"
      decimals="INF"
      unitRef="Shares">3500000</us-gaap:SharesOutstanding>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember"
      decimals="INF"
      unitRef="Percent">0.30</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <HROW:RoyaltyPaymentPercentageOnNetSales
      contextRef="From2020-01-012020-12-31_custom_SurfacePharmaceuticalsIncMember_custom_DrLindstromMember"
      decimals="INF"
      unitRef="Percent">0.03</HROW:RoyaltyPaymentPercentageOnNetSales>
    <srt:ScheduleOfCondensedIncomeStatementTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_896_esrt--ScheduleOfCondensedIncomeStatementTableTextBlock_zVSrka9hJfF" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
unaudited condensed results of operations information of Surface is summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B5_zaAtubQHO5k8" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;SUMMARY
OF CONDENSED INCOME STATEMENT&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year&lt;b&gt;s&lt;/b&gt; Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Revenues, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Revenues, net"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0770"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Revenues, net"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0772"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss
    from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--OperatingIncomeLoss_c20200101__20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Loss from operations"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,109&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OperatingIncomeLoss_c20190101__20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Loss from operations"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--NetIncomeLoss_c20200101__20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(8,109&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--NetIncomeLoss_c20190101__20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</srt:ScheduleOfCondensedIncomeStatementTableTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-012020-12-31_custom_SurfacePharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">8109000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-01-012019-12-31_custom_SurfacePharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">4000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-12-31_custom_SurfacePharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">-8109000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-12-31_custom_SurfacePharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">-4000000</us-gaap:NetIncomeLoss>
    <srt:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_897_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_zshJRTO0n9Bk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
unaudited condensed balance sheet information of Surface is summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B5_zqOuNIJAasqj" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;SUMMARY
OF CONDENSED BALANCE SHEET&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;
    December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsCurrent_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="width: 18%; text-align: right" title="Current assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,074&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AssetsCurrent_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="width: 18%; text-align: right" title="Current assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,942&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non current
    assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsNoncurrent_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AssetsNoncurrent_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;47&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Assets_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,119&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--Assets_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,989&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--Liabilities_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,666&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Liabilities_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;619&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total stockholders&#x2019;
    equity&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--StockholdersEquity_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders equity"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,453&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--StockholdersEquity_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders equity"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,370&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    liabilities and stockholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LiabilitiesAndStockholdersEquity_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,119&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--LiabilitiesAndStockholdersEquity_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,989&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">9074000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2019-12-31_custom_SurfacePharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">15942000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">45000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2019-12-31_custom_SurfacePharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">47000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">9119000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2019-12-31_custom_SurfacePharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">15989000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">1666000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2019-12-31_custom_SurfacePharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">619000</us-gaap:Liabilities>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">7453000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_custom_SurfacePharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">15370000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">9119000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2019-12-31_custom_SurfacePharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">15989000</us-gaap:LiabilitiesAndStockholdersEquity>
    <HROW:RestrictedCashTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_809_ecustom--RestrictedCashTextBlock_zWdfTOfggzq4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
6. &lt;span id="xdx_82F_z9fWDjic99Qa"&gt;RESTRICTED CASH&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
restricted cash at December 31, 2020 and 2019 consisted of funds held in a money market account. At December 31, 2020 and 2019,
the restricted cash was recorded at amortized cost, which approximates fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
December 31, 2020 and 2019, the funds held in a money market account of $&lt;span id="xdx_90F_eus-gaap--RestrictedCash_iI_pn3n3_c20201231_zJ7PsU3yXhdj"&gt;&lt;span id="xdx_90C_eus-gaap--RestrictedCash_iI_pn3n3_c20191231_zgUbebkvmXca"&gt;200&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;were classified as a current asset. The
money market account funds are required as collateral as additional security for the Company&#x2019;s New Jersey facility lease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</HROW:RestrictedCashTextBlock>
    <us-gaap:RestrictedCash contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">200000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">200000</us-gaap:RestrictedCash>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_809_eus-gaap--InventoryDisclosureTextBlock_zhZ42oWSglNk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
7. &lt;span id="xdx_827_z70OLwL0XVqg"&gt;INVENTORIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zVM9xZ4mT2g5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Inventories
are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, commercial pharmaceutical
products, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of December 31,
2020 and 2019 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B0_zIjxVAkLNoc5" style="display: none; font-family: Times New Roman, Times, Serif"&gt;SCHEDULE
OF INVENTORIES&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20201231" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20191231" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINz6Re_zTVNBcbUSdw8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,501&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,405&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINz6Re_z6vJj1koPK5i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINz6Re_zJzeTHthaeq9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,444&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;876&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--InventoryNet_iTI_pn3n3_mtINz6Re_znCqFTxzdDdi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,962&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,301&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A0_zVn7719gfAa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_894_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zVM9xZ4mT2g5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Inventories
are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, commercial pharmaceutical
products, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of December 31,
2020 and 2019 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B0_zIjxVAkLNoc5" style="display: none; font-family: Times New Roman, Times, Serif"&gt;SCHEDULE
OF INVENTORIES&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20201231" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20191231" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINz6Re_zTVNBcbUSdw8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,501&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,405&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINz6Re_z6vJj1koPK5i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINz6Re_zJzeTHthaeq9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,444&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;876&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--InventoryNet_iTI_pn3n3_mtINz6Re_znCqFTxzdDdi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,962&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,301&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">2501000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">2405000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">17000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">20000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1444000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">876000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">3962000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">3301000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_80C_eus-gaap--OtherAssetsDisclosureTextBlock_zJnfWJhnF8Il" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
8. &lt;span id="xdx_822_zIDflze9QU82"&gt;PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zMM0nyOgIy16" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid
expenses and other current assets consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BB_zlAuHGfL9hd1" style="display: none; font-family: Times New Roman, Times, Serif"&gt;SCHEDULE
OF PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20201231_zIEkQ4Z1pGU2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20191231_zIrCXcI8M0a2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAzQA0_z7lY8f1LmF06" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;160&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;123&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maPEAOAzQA0_zRr4mVc6ivQl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;401&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;358&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--OtherAssetsCurrent_iI_pn3n3_maPEAOAzQA0_z3cZ6ho4SpT6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deposits and
    other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;190&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;105&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzQA0_zIRBNErWxx65" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total prepaid
    expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;751&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;586&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A9_zMiTfBeTWgf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OtherAssetsDisclosureTextBlock>
    <HROW:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_890_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zMM0nyOgIy16" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid
expenses and other current assets consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BB_zlAuHGfL9hd1" style="display: none; font-family: Times New Roman, Times, Serif"&gt;SCHEDULE
OF PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20201231_zIEkQ4Z1pGU2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20191231_zIrCXcI8M0a2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAzQA0_z7lY8f1LmF06" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;160&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;123&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maPEAOAzQA0_zRr4mVc6ivQl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;401&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;358&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--OtherAssetsCurrent_iI_pn3n3_maPEAOAzQA0_z3cZ6ho4SpT6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deposits and
    other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;190&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;105&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzQA0_zIRBNErWxx65" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total prepaid
    expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;751&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;586&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</HROW:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidInsurance contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">160000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">123000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">401000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">358000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">190000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">105000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">751000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">586000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_803_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zOByKcPBfMde" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
9. &lt;span id="xdx_82D_z2jwdajAZQM9"&gt;PROPERTY, PLANT AND EQUIPMENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--PropertyPlantAndEquipmentTextBlock_zU7a0HAL9JCh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Property,
plant and equipment, net at December 31, 2020 and 2019 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B8_zJzr49I67J88" style="display: none; font-family: Times New Roman, Times, Serif"&gt;SCHEDULE
OF PROPERTY, PLANT AND EQUIPMENT&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20201231_zmAaGU4dJKh9" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20191231_zXOV4No9klFg" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property, plant and equipment, net:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_maPPAEGzzle_zpt88c4SRsr1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 56%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computer
    software and hardware&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,707&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,732&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAEGzzle_ztjBM8L8AUh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Furniture and
    equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;418&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;363&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_maPPAEGzzle_zSP7XrWC6eq" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lab and pharmacy
    equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,426&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,164&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--LeaseholdImprovementsGross_iI_pn3n3_maPPAEGzzle_z1SmBOq4b4Dk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Leasehold
    improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,720&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,510&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_mtPPAEGzzle_maPPAENzQqn_zC4fNjsEzm0a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&#160;Property, plant
    and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,271&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,769&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzQqn_z4uHdoRGQXtk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accumulated
    depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(6,818&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5,394&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzQqn_zVbprQkbhqt3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Property,
    plant and equipment, net&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,453&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,375&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A6_zeuIAuTRzWk8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended December 31, 2020, the Company disposed of property, plant and equipment with a net book value of $&lt;span id="xdx_904_eus-gaap--GainLossOnDispositionOfAssets1_iN_pn3n3_di_c20200101__20201231_ziUP7FbpOVo4"&gt;105
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;related to the discontinued use of certain
computer software and hardware and was included within other (loss) income of the consolidated statements of operations.
The Company recorded depreciation and amortization expense of $&lt;span id="xdx_904_eus-gaap--DepreciationAmortizationAndAccretionNet_c20200101__20201231_pn3n3"&gt;1,880&lt;/span&gt;
&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_903_eus-gaap--DepreciationAmortizationAndAccretionNet_c20190101__20191231_pn3n3"&gt;1,936&lt;/span&gt;
&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;during the years ended December 31, 2020
and 2019, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89D_eus-gaap--PropertyPlantAndEquipmentTextBlock_zU7a0HAL9JCh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Property,
plant and equipment, net at December 31, 2020 and 2019 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B8_zJzr49I67J88" style="display: none; font-family: Times New Roman, Times, Serif"&gt;SCHEDULE
OF PROPERTY, PLANT AND EQUIPMENT&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20201231_zmAaGU4dJKh9" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20191231_zXOV4No9klFg" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property, plant and equipment, net:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_maPPAEGzzle_zpt88c4SRsr1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 56%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computer
    software and hardware&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,707&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,732&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAEGzzle_ztjBM8L8AUh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Furniture and
    equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;418&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;363&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_maPPAEGzzle_zSP7XrWC6eq" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lab and pharmacy
    equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,426&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,164&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--LeaseholdImprovementsGross_iI_pn3n3_maPPAEGzzle_z1SmBOq4b4Dk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Leasehold
    improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,720&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,510&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_mtPPAEGzzle_maPPAENzQqn_zC4fNjsEzm0a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;&#160;Property, plant
    and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,271&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,769&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzQqn_z4uHdoRGQXtk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accumulated
    depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(6,818&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5,394&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzQqn_zVbprQkbhqt3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Property,
    plant and equipment, net&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,453&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,375&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:CapitalizedComputerSoftwareGross contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1707000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">1732000</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:FurnitureAndFixturesGross contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">418000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">363000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:MachineryAndEquipmentGross contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">3426000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">3164000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:LeaseholdImprovementsGross contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">5720000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">5510000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">11271000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">10769000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">6818000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">5394000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">4453000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">5375000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-105000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1880000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">1936000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_80E_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zj8WgHcD7qKf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
10. &lt;span id="xdx_822_z8IuEPqvmch2"&gt;INTANGIBLE ASSETS AND GOODWILL&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_z9CnciC2W6x1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s intangible assets at December 31, 2019 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BE_z7uGUwecGrci" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;SCHEDULE
OF INTANGIBLE ASSETS&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;periods&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accumulated&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(in
    years)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Carrying
    value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 21%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 13%; text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MinimumMember_zJDQd12aOYyc" style="font-family: Times New Roman, Times, Serif"&gt;17&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MaximumMember_ztZBmwpM1WE8"&gt;19
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zhbD2JrfAgrk" style="width: 13%; text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,102&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_ziIZt3BHrsDc" style="width: 13%; text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(97&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zIqUTTOPJ39h" style="width: 13%; text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(259&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zna80rxILWI9" style="width: 13%; text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;746&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z3k89bh0bBW1" style="font-family: Times New Roman, Times, Serif"&gt;20
    years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zY1AHJtP3hO6" style="text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z99Wqkb89VBg" style="text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zbcA2GUkwVLc" style="text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0891"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zxyIg2UbCCRl" style="text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zBY0yKcqo9b3" style="font-family: Times New Roman, Times, Serif"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zw6q7xgAUXgd" style="text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;340&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zWn3zLg1I8Eb" style="text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0898"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z1LJRv60q221" style="text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0900"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zgT4x7HeEPZi" style="text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;340&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MinimumMember_zKR67nTo16Fj" style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MaximumMember_z5kmYX467Uuf"&gt;15
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z1cDt2HRe15c" style="text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zZmeiVV6yvx6" style="text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,165&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zxgKZB53Hakd" style="text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(630&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z2SFsTRf6t7d" style="text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,205&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zVZNFy9f5Brd" style="font-family: Times New Roman, Times, Serif"&gt;5
    years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zF275xxnyRp1" style="text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zC0NwhC2l5Af" style="text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(14&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zsqVqOTODgV7" style="text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zs4tRqxbxU4f" style="text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0921"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-competition clause&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MinimumMember_zKrDhGjvHJdj" style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MaximumMember_zyrkJ6baCHA9"&gt;4
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zqn1b3j6nWjj" style="text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;294&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zEsaUUYHCIHl" style="text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(274&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zAfJs3Z6l5Me" style="text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zzJzn6bvsGbi" style="text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0931"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State pharmacy
    licenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zfur4GTZ1z6j" style="font-family: Times New Roman, Times, Serif"&gt;25
    years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zgiz2zfbxlZj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zGhmR1USem05" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zdTRXTlUiIY5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(35&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zzd4Eso5bG6b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231_zNlAG0V5AI5a" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,847&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231_zOAZLafkIIs9" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,564&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231_zfwFghU4otk" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(946&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231_zXhHwMCoYw24" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,337&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended December 31, 2019, the Company incurred impairment charges of $&lt;span id="xdx_908_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember__dei--LegalEntityAxis__custom--ParkCompoundingIncMember_pn3n3"&gt;612
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;related to intangible assets, including
customer relationships, trade name, and state pharmacy licenses as a part of the Park Restructuring and $&lt;span id="xdx_907_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__dei--LegalEntityAxis__custom--ParkCompoundingIncMember_pn3n3"&gt;259
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;of impairment charges related to patents
associated with the termination of an asset agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s intangible assets at December 31, 2020 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;periods&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accumulated&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(in
    years)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Carrying
    value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 21%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MinimumMember_zhP46VZLxkA5" style="font-family: Times New Roman, Times, Serif"&gt;17&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MaximumMember_zlrwlaXJYgnj"&gt;19
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 13%; text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;929&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 13%; text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(93&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 13%; text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(363&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 13%; text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;473&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_ztvth0XwlEM2" style="font-family: Times New Roman, Times, Serif"&gt;20
    years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0967"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;44&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember" style="font-family: Times New Roman, Times, Serif"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;356&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zyVZb9RLmQSk" style="text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0974"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0976"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;356&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MinimumMember_zTIJEmYmkAi1" style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MaximumMember_zMyTp3xvOvye"&gt;15
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,519&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(454&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0986"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,065&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zFoEcLU36Rml" style="font-family: Times New Roman, Times, Serif"&gt;5
    years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0995"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0997"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-competition clause&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MinimumMember_zHCLJgySguOh" style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MaximumMember_zz3yOhc7RnC2"&gt;4
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1005"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1007"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State pharmacy
    licenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zspTSXx0fi16" style="font-family: Times New Roman, Times, Serif"&gt;25
    years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1014"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,917&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(615&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(363&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,939&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AE_zzzWCuzuBtXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended December 31, 2020, the Company recorded impairment charges of $&lt;span id="xdx_902_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsFilingsAndTrademarksMember__dei--LegalEntityAxis__custom--ParkCompoundingIncMember_pn3n3"&gt;363
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;related to patent filings and trademarks
that were abandoned and/or were associated with products the Company was no longer actively selling.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zAj2eB9v1R98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Amortization
expense for intangible assets for the years ended December 31, 2020 and 2019 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BB_zlrxcSZGQuah" style="display: none; font-family: Times New Roman, Times, Serif"&gt;SCHEDULE
OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;For
                                         the Years Ended&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;December
                                         31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 18%; text-align: right" title="Amortization of intangible assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 18%; text-align: right" title="Amortization of intangible assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;48&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;134&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;151&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1041"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State pharmacy
    licenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1045"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;167&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;209&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A3_z80cgrtyrZCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zCrnqtoou5C7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated
future amortization expense for the Company&#x2019;s intangible assets at December 31, 2020 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B5_zWrE2YLiAiU1" style="display: none; font-family: Times New Roman, Times, Serif"&gt;SCHEDULE
OF ESTIMATED FUTURE AMORTIZATION EXPENSE&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Years
    ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20201231_z08ve1nggkf4" style="display: none; text-align: center; vertical-align: middle"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dec&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzZax_zun3XUYwvgmk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;187&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzZax_zqXKKurZLBq4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;187&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzZax_zClalTV8kFt6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;187&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzZax_zUTxlWzgqgA7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;160&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANzZax_zLNYUz6Wy1q8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;147&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANzZax_z1idoaLAGGd7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;715&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzZax_zGYl8T2Be8Ak" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,583&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AF_zBGCJpC4cQX9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfGoodwillTextBlock_zjexslfNY2lb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;There
were &lt;span id="xdx_90D_eus-gaap--GoodwillAndIntangibleAssetImpairment_pn3n3_do_c20200101__20201231_zB80rURDddwl"&gt;no&lt;/span&gt;&lt;/span&gt;
&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;changes in the carrying value of the Company&#x2019;s
goodwill during the year ended December 31, 2020. Changes in the carrying value of the Company&#x2019;s goodwill during the year
ended December 31, 2019 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B9_zfvkaevAckXe" style="display: none; font-family: Times New Roman, Times, Serif"&gt;SCHEDULE
OF GOODWILL&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
&lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_49D_20190101__20191231_zFUhKXfZ0Moj" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dec&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--Goodwill_iS_pn3n3_zllUwXCIesg3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at December 31,
    2018&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,227&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--GoodwillImpairmentLoss_iN_pn3n3_di_zWCIoVCs7YF3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Impairment
    of Park goodwill (see Note 2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,895&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--Goodwill_iE_pn3n3_zn1KMrun4BX1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at
    December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;332&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A8_zaqi1mldLqdg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_895_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_z9CnciC2W6x1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s intangible assets at December 31, 2019 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BE_z7uGUwecGrci" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;SCHEDULE
OF INTANGIBLE ASSETS&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;periods&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accumulated&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(in
    years)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Carrying
    value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 21%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 13%; text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MinimumMember_zJDQd12aOYyc" style="font-family: Times New Roman, Times, Serif"&gt;17&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MaximumMember_ztZBmwpM1WE8"&gt;19
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zhbD2JrfAgrk" style="width: 13%; text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,102&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_ziIZt3BHrsDc" style="width: 13%; text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(97&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zIqUTTOPJ39h" style="width: 13%; text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(259&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zna80rxILWI9" style="width: 13%; text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;746&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z3k89bh0bBW1" style="font-family: Times New Roman, Times, Serif"&gt;20
    years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zY1AHJtP3hO6" style="text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z99Wqkb89VBg" style="text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zbcA2GUkwVLc" style="text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0891"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zxyIg2UbCCRl" style="text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zBY0yKcqo9b3" style="font-family: Times New Roman, Times, Serif"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zw6q7xgAUXgd" style="text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;340&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zWn3zLg1I8Eb" style="text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0898"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z1LJRv60q221" style="text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0900"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zgT4x7HeEPZi" style="text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;340&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MinimumMember_zKR67nTo16Fj" style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MaximumMember_z5kmYX467Uuf"&gt;15
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z1cDt2HRe15c" style="text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zZmeiVV6yvx6" style="text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,165&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zxgKZB53Hakd" style="text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(630&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z2SFsTRf6t7d" style="text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,205&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zVZNFy9f5Brd" style="font-family: Times New Roman, Times, Serif"&gt;5
    years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zF275xxnyRp1" style="text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zC0NwhC2l5Af" style="text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(14&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zsqVqOTODgV7" style="text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zs4tRqxbxU4f" style="text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0921"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-competition clause&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MinimumMember_zKrDhGjvHJdj" style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MaximumMember_zyrkJ6baCHA9"&gt;4
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zqn1b3j6nWjj" style="text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;294&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zEsaUUYHCIHl" style="text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(274&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zAfJs3Z6l5Me" style="text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zzJzn6bvsGbi" style="text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0931"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State pharmacy
    licenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zfur4GTZ1z6j" style="font-family: Times New Roman, Times, Serif"&gt;25
    years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zgiz2zfbxlZj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zGhmR1USem05" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zdTRXTlUiIY5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(35&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zzd4Eso5bG6b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231_zNlAG0V5AI5a" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,847&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231_zOAZLafkIIs9" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,564&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231_zfwFghU4otk" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(946&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231_zXhHwMCoYw24" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,337&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended December 31, 2019, the Company incurred impairment charges of $&lt;span id="xdx_908_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember__dei--LegalEntityAxis__custom--ParkCompoundingIncMember_pn3n3"&gt;612
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;related to intangible assets, including
customer relationships, trade name, and state pharmacy licenses as a part of the Park Restructuring and $&lt;span id="xdx_907_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__dei--LegalEntityAxis__custom--ParkCompoundingIncMember_pn3n3"&gt;259
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;of impairment charges related to patents
associated with the termination of an asset agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s intangible assets at December 31, 2020 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;periods&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accumulated&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(in
    years)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Carrying
    value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 21%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 13%; text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MinimumMember_zhP46VZLxkA5" style="font-family: Times New Roman, Times, Serif"&gt;17&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MaximumMember_zlrwlaXJYgnj"&gt;19
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 13%; text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;929&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 13%; text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(93&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 13%; text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(363&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 13%; text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;473&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_ztvth0XwlEM2" style="font-family: Times New Roman, Times, Serif"&gt;20
    years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0967"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;44&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember" style="font-family: Times New Roman, Times, Serif"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;356&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zyVZb9RLmQSk" style="text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0974"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0976"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;356&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MinimumMember_zTIJEmYmkAi1" style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MaximumMember_zMyTp3xvOvye"&gt;15
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,519&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(454&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0986"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,065&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zFoEcLU36Rml" style="font-family: Times New Roman, Times, Serif"&gt;5
    years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0995"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0997"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-competition clause&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MinimumMember_zHCLJgySguOh" style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MaximumMember_zz3yOhc7RnC2"&gt;4
    years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1005"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1007"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State pharmacy
    licenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zspTSXx0fi16" style="font-family: Times New Roman, Times, Serif"&gt;25
    years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1014"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,917&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(615&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(363&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,939&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2019-01-012019-12-31_us-gaap_PatentsMember_srt_MinimumMember">P17Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2019-01-012019-12-31_us-gaap_PatentsMember_srt_MaximumMember">P19Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2019-12-31_us-gaap_PatentsMember"
      decimals="-3"
      unitRef="USD">1102000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2019-12-31_us-gaap_PatentsMember"
      decimals="-3"
      unitRef="USD">-97000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <HROW:FiniteLivedIntangibleAssetsImpairment
      contextRef="AsOf2019-12-31_us-gaap_PatentsMember"
      decimals="-3"
      unitRef="USD">-259000</HROW:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2019-12-31_us-gaap_PatentsMember"
      decimals="-3"
      unitRef="USD">746000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2019-01-012019-12-31_custom_LicensesMember">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2019-12-31_custom_LicensesMember"
      decimals="-3"
      unitRef="USD">50000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2019-12-31_custom_LicensesMember"
      decimals="-3"
      unitRef="USD">-5000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2019-12-31_custom_LicensesMember"
      decimals="-3"
      unitRef="USD">45000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod contextRef="From2019-01-012019-12-31_us-gaap_TrademarksMember">Indefinite</us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2019-12-31_us-gaap_TrademarksMember"
      decimals="-3"
      unitRef="USD">340000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2019-12-31_us-gaap_TrademarksMember"
      decimals="-3"
      unitRef="USD">340000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2019-01-012019-12-31_us-gaap_CustomerRelationshipsMember_srt_MinimumMember">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2019-01-012019-12-31_us-gaap_CustomerRelationshipsMember_srt_MaximumMember">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2019-12-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      unitRef="USD">3000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2019-12-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      unitRef="USD">-1165000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <HROW:FiniteLivedIntangibleAssetsImpairment
      contextRef="AsOf2019-12-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      unitRef="USD">-630000</HROW:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2019-12-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      unitRef="USD">1205000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2019-01-012019-12-31_us-gaap_TradeNamesMember">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2019-12-31_us-gaap_TradeNamesMember"
      decimals="-3"
      unitRef="USD">16000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2019-12-31_us-gaap_TradeNamesMember"
      decimals="-3"
      unitRef="USD">-14000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <HROW:FiniteLivedIntangibleAssetsImpairment
      contextRef="AsOf2019-12-31_us-gaap_TradeNamesMember"
      decimals="-3"
      unitRef="USD">-2000</HROW:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2019-01-012019-12-31_custom_NonCompetitionClauseMember_srt_MinimumMember">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2019-01-012019-12-31_custom_NonCompetitionClauseMember_srt_MaximumMember">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2019-12-31_custom_NonCompetitionClauseMember"
      decimals="-3"
      unitRef="USD">294000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2019-12-31_custom_NonCompetitionClauseMember"
      decimals="-3"
      unitRef="USD">-274000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <HROW:FiniteLivedIntangibleAssetsImpairment
      contextRef="AsOf2019-12-31_custom_NonCompetitionClauseMember"
      decimals="-3"
      unitRef="USD">-20000</HROW:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2019-01-012019-12-31_custom_StatePharmacyLicensesMember">P25Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2019-12-31_custom_StatePharmacyLicensesMember"
      decimals="-3"
      unitRef="USD">45000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2019-12-31_custom_StatePharmacyLicensesMember"
      decimals="-3"
      unitRef="USD">-9000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <HROW:FiniteLivedIntangibleAssetsImpairment
      contextRef="AsOf2019-12-31_custom_StatePharmacyLicensesMember"
      decimals="-3"
      unitRef="USD">-35000</HROW:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2019-12-31_custom_StatePharmacyLicensesMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">4847000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">-1564000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <HROW:FiniteLivedIntangibleAssetsImpairment contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">-946000</HROW:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">2337000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2019-01-012019-12-31_custom_CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember_custom_ParkCompoundingIncMember"
      decimals="-3"
      unitRef="USD">612000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2019-01-012019-12-31_us-gaap_PatentsMember_custom_ParkCompoundingIncMember"
      decimals="-3"
      unitRef="USD">259000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2020-01-012020-12-31_us-gaap_PatentsMember_srt_MinimumMember">P17Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2020-01-012020-12-31_us-gaap_PatentsMember_srt_MaximumMember">P19Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2020-12-31_us-gaap_PatentsMember"
      decimals="-3"
      unitRef="USD">929000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2020-12-31_us-gaap_PatentsMember"
      decimals="-3"
      unitRef="USD">-93000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <HROW:FiniteLivedIntangibleAssetsImpairment
      contextRef="AsOf2020-12-31_us-gaap_PatentsMember"
      decimals="-3"
      unitRef="USD">-363000</HROW:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2020-12-31_us-gaap_PatentsMember"
      decimals="-3"
      unitRef="USD">473000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2020-01-012020-12-31_custom_LicensesMember">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2020-12-31_custom_LicensesMember"
      decimals="-3"
      unitRef="USD">50000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2020-12-31_custom_LicensesMember"
      decimals="-3"
      unitRef="USD">-6000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2020-12-31_custom_LicensesMember"
      decimals="-3"
      unitRef="USD">44000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod contextRef="From2020-01-012020-12-31_us-gaap_TrademarksMember">Indefinite</us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2020-12-31_us-gaap_TrademarksMember"
      decimals="-3"
      unitRef="USD">356000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2020-12-31_us-gaap_TrademarksMember"
      decimals="-3"
      unitRef="USD">356000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2020-01-012020-12-31_us-gaap_CustomerRelationshipsMember_srt_MinimumMember">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2020-01-012020-12-31_us-gaap_CustomerRelationshipsMember_srt_MaximumMember">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2020-12-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      unitRef="USD">1519000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2020-12-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      unitRef="USD">-454000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2020-12-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      unitRef="USD">1065000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2020-01-012020-12-31_us-gaap_TradeNamesMember">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2020-12-31_us-gaap_TradeNamesMember"
      decimals="-3"
      unitRef="USD">5000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2020-12-31_us-gaap_TradeNamesMember"
      decimals="-3"
      unitRef="USD">-5000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2020-01-012020-12-31_custom_NonCompetitionClauseMember_srt_MinimumMember">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2020-01-012020-12-31_custom_NonCompetitionClauseMember_srt_MaximumMember">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2020-12-31_custom_NonCompetitionClauseMember"
      decimals="-3"
      unitRef="USD">50000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2020-12-31_custom_NonCompetitionClauseMember"
      decimals="-3"
      unitRef="USD">-50000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2020-01-012020-12-31_custom_StatePharmacyLicensesMember">P25Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2020-12-31_custom_StatePharmacyLicensesMember"
      decimals="-3"
      unitRef="USD">8000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2020-12-31_custom_StatePharmacyLicensesMember"
      decimals="-3"
      unitRef="USD">-7000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2020-12-31_custom_StatePharmacyLicensesMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">2917000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">-615000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <HROW:FiniteLivedIntangibleAssetsImpairment contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">-363000</HROW:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1939000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2020-01-012020-12-31_custom_PatentsFilingsAndTrademarksMember_custom_ParkCompoundingIncMember"
      decimals="-3"
      unitRef="USD">363000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zAj2eB9v1R98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Amortization
expense for intangible assets for the years ended December 31, 2020 and 2019 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BB_zlrxcSZGQuah" style="display: none; font-family: Times New Roman, Times, Serif"&gt;SCHEDULE
OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;For
                                         the Years Ended&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;December
                                         31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 18%; text-align: right" title="Amortization of intangible assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 18%; text-align: right" title="Amortization of intangible assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;48&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;134&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;151&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1041"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State pharmacy
    licenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1045"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;167&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;209&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-01-012020-12-31_us-gaap_PatentsMember"
      decimals="-3"
      unitRef="USD">32000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2019-01-012019-12-31_us-gaap_PatentsMember"
      decimals="-3"
      unitRef="USD">48000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-01-012020-12-31_custom_LicensesMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2019-01-012019-12-31_custom_LicensesMember"
      decimals="-3"
      unitRef="USD">5000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-01-012020-12-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      unitRef="USD">134000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2019-01-012019-12-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      unitRef="USD">151000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2019-01-012019-12-31_us-gaap_TradeNamesMember"
      decimals="-3"
      unitRef="USD">1000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2019-01-012019-12-31_custom_StatePharmacyLicensesMember"
      decimals="-3"
      unitRef="USD">4000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">167000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">209000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_897_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zCrnqtoou5C7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Estimated
future amortization expense for the Company&#x2019;s intangible assets at December 31, 2020 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B5_zWrE2YLiAiU1" style="display: none; font-family: Times New Roman, Times, Serif"&gt;SCHEDULE
OF ESTIMATED FUTURE AMORTIZATION EXPENSE&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Years
    ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20201231_z08ve1nggkf4" style="display: none; text-align: center; vertical-align: middle"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dec&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzZax_zun3XUYwvgmk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;187&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzZax_zqXKKurZLBq4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;187&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzZax_zClalTV8kFt6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;187&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzZax_zUTxlWzgqgA7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;160&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANzZax_zLNYUz6Wy1q8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;147&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANzZax_z1idoaLAGGd7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;715&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzZax_zGYl8T2Be8Ak" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,583&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">187000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">187000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">187000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">160000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">147000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">715000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1583000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_898_eus-gaap--ScheduleOfGoodwillTextBlock_zjexslfNY2lb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;There
were &lt;span id="xdx_90D_eus-gaap--GoodwillAndIntangibleAssetImpairment_pn3n3_do_c20200101__20201231_zB80rURDddwl"&gt;no&lt;/span&gt;&lt;/span&gt;
&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;changes in the carrying value of the Company&#x2019;s
goodwill during the year ended December 31, 2020. Changes in the carrying value of the Company&#x2019;s goodwill during the year
ended December 31, 2019 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B9_zfvkaevAckXe" style="display: none; font-family: Times New Roman, Times, Serif"&gt;SCHEDULE
OF GOODWILL&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
&lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_49D_20190101__20191231_zFUhKXfZ0Moj" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dec&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--Goodwill_iS_pn3n3_zllUwXCIesg3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at December 31,
    2018&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,227&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--GoodwillImpairmentLoss_iN_pn3n3_di_zWCIoVCs7YF3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Impairment
    of Park goodwill (see Note 2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,895&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--Goodwill_iE_pn3n3_zn1KMrun4BX1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance at
    December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;332&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="AsOf2018-12-31" decimals="-3" unitRef="USD">2227000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">1895000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">332000</us-gaap:Goodwill>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_804_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z85dyRTKf31k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
11. &lt;span id="xdx_82A_z4P77nLTTW4d"&gt;ACCOUNTS PAYABLE AND ACCRUED EXPENSES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zSTbfZT5E0Gh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts
payable and accrued expenses at December 31, 2020 and 2019 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BF_zNnrDhjj9D91" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;SCHEDULE
OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20201231_zOQWq8Mbsmch" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20191231_zJeZIV8iuay5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn3n3_maAPAALzPeR_zPXROrIZN1d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,645&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,409&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maAPAALzPeR_zdhO5q7IVid6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;49&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;49&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_maAPAALzPeR_zcEkRYmBjvdk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued interest (see Note 12)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;238&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;244&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maAPAALzPeR_zOuy8vW3Rud3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued exit
    fee for note payable (see Note 12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;800&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;800&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_pn3n3_mtAPAALzPeR_zmszDR9tOXkj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total accounts payable and accrued
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,732&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,502&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iNI_pn3n3_di_zHTQw7cSETZd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: Current
    portion&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,932&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(7,702&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--AccountsPayableAndAccruedLiabilitiesNoncurrent_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-current
    total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;800&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;800&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AE_zQNChrfo0NTg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89E_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zSTbfZT5E0Gh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts
payable and accrued expenses at December 31, 2020 and 2019 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BF_zNnrDhjj9D91" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;SCHEDULE
OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20201231_zOQWq8Mbsmch" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20191231_zJeZIV8iuay5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn3n3_maAPAALzPeR_zPXROrIZN1d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,645&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,409&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maAPAALzPeR_zdhO5q7IVid6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;49&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;49&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_maAPAALzPeR_zcEkRYmBjvdk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued interest (see Note 12)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;238&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;244&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maAPAALzPeR_zOuy8vW3Rud3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued exit
    fee for note payable (see Note 12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;800&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;800&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_pn3n3_mtAPAALzPeR_zmszDR9tOXkj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total accounts payable and accrued
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,732&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,502&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iNI_pn3n3_di_zHTQw7cSETZd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: Current
    portion&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,932&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(7,702&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--AccountsPayableAndAccruedLiabilitiesNoncurrent_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-current
    total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;800&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;800&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">3645000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">7409000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">49000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">49000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">238000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">244000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">800000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">800000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">4732000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">8502000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">3932000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">7702000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">800000</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">800000</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_809_eus-gaap--DebtDisclosureTextBlock_ze5UvGsiekF7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
12. &lt;span id="xdx_82B_zVTvWXWJj8J"&gt;DEBT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;SWK
Senior Note &#x2013; 2017&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
July 2017, the Company entered into a term loan and security agreement in the principal amount of $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20170731__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember_zWwKP1oKmQt9"&gt;16,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(the &#x201c;SWK Loan Agreement&#x201d;
or &#x201c;SWK Loan&#x201d;) with SWK Funding LLC and its partners (&#x201c;SWK&#x201d;), as lender and collateral agent. &lt;span id="xdx_90F_eus-gaap--DebtInstrumentDescription_c20170701__20170731__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember"&gt;The
SWK Loan Agreement was fully funded at closing with a five-year term, however, such term could be reduced to four years if certain
revenue requirements are not achieved.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190401__20190430__us-gaap--VariableRateAxis__us-gaap--LondonInterbankOfferedRateLIBORMember" title="Debt instrument interest rate description"&gt;Prior
to the loan refinance in May 2019 (see below), the SWK Loan bore interest at a variable rate equal to the three-month London Inter-Bank
Offered Rate (subject to a minimum of &lt;span id="xdx_901_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_uPercent_c20190401__20190430__us-gaap--VariableRateAxis__us-gaap--LondonInterbankOfferedRateLIBORMember__srt--RangeAxis__srt--MinimumMember_zdHatem99rpj" title="Loan bear interest at variable rate"&gt;1.50&lt;/span&gt;%
and maximum of &lt;span id="xdx_90A_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_uPercent_c20190401__20190430__us-gaap--VariableRateAxis__us-gaap--LondonInterbankOfferedRateLIBORMember__srt--RangeAxis__srt--MaximumMember_zSbc7F7EDeSa" title="Loan bear interest at variable rate"&gt;3.00&lt;/span&gt;%),
plus an applicable margin of &lt;span id="xdx_90F_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_uPercent_c20190401__20190430__us-gaap--VariableRateAxis__us-gaap--LondonInterbankOfferedRateLIBORMember_z4WLWy8fCz51" title="Loan bear interest at variable rate"&gt;10.50&lt;/span&gt;%.&lt;/span&gt;
&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The SWK Loan Agreement permitted the Company
to pay interest only on the principal amount borrowed thereunder for the first six payments (payments are due on a quarterly basis),
which interest-only period could have been reduced to four payments if the Company had not met certain minimum revenue requirements.
Following the interest-only period, the Company was required to pay interest, plus repayments of the principal amount borrowed
under the SWK Loan Agreement, in quarterly payments, which shall not exceed $&lt;span id="xdx_90B_eus-gaap--RepaymentsOfDebt_pn3n3_c20190429__20190430__us-gaap--TypeOfArrangementAxis__custom--SWKLoanAgreementMember_z81y6psk9il6"&gt;750
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;per quarter. &lt;span id="xdx_903_eus-gaap--DebtInstrumentMaturityDateDescription_c20190429__20190430__us-gaap--TypeOfArrangementAxis__custom--SWKLoanAgreementMember"&gt;All
amounts owed under the SWK Loan Agreement, including an exit fee equal to 5% of the aggregate principal amount loaned thereunder,
were originally due and payable on July 19, 2022.&lt;/span&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company is obligated under the SWK Loan Agreement to pay for certain expenses incurred by SWK through and after the date of the
SWK Loan Agreement, including certain fees and expenses relating to the preparation and administration of the SWK Loan Agreement.
The Company incurred expenses and an exit fee of approximately $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentFeeAmount_c20190430__us-gaap--TypeOfArrangementAxis__custom--SWKLoanAgreementMember_pn3n3"&gt;1,282
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;in connection with the SWK Loan Agreement.
The exit fee and expenses were recorded as a debt discount and are being amortized as interest expense over the term of the SWK
Loan using the effective interest rate method and the related liability of $&lt;span id="xdx_90D_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_c20201231_zbCQFVx2F7r7"&gt;&lt;span id="xdx_908_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_c20191231_pn3n3"&gt;800&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;for the exit fee is included in accrued
expenses (see Note 11) in the accompanying consolidated balance sheets as of December 31, 2020 and 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
connection with the SWK Loan Agreement, the Company issued to SWK warrants to purchase up to &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20170731__us-gaap--StatementEquityComponentsAxis__custom--LenderWarrantsMember_zlXZJ4EwuSK9"&gt;415,586
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;shares of the Company&#x2019;s common stock
(the &#x201c;Lender Warrants&#x201d;) with an exercise price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20170731__us-gaap--StatementEquityComponentsAxis__custom--LenderWarrantsMember_pii"&gt;3.08&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;.
In August 2017, the Company and SWK amended the warrants, to allow for the purchase of up to &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20170831__us-gaap--StatementEquityComponentsAxis__custom--LenderWarrantsMember_zy4W0iUAcqD2"&gt;615,386
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;warrants with an exercise price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20170831__us-gaap--StatementEquityComponentsAxis__custom--LenderWarrantsMember_pii"&gt;2.08&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;.
The Lender Warrants are exercisable immediately, and have a term of &lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dt_c20170731__us-gaap--StatementEquityComponentsAxis__custom--LenderWarrantsMember_zsck4JNX6Vcj"&gt;seven
years&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;. The Lender Warrants are subject
to a cashless exercise feature, with the exercise price and number of shares issuable upon exercise subject to change in connection
with stock splits, dividends, reclassifications and other conditions. The relative fair value of the Lender Warrants was approximately
$&lt;span id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_c20200101__20201231_pn3n3"&gt;982&lt;/span&gt;&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and
was estimated using the Black-Scholes-Merton option pricing model with the following assumptions: fair value of the Company&#x2019;s
common stock at issuance of $&lt;span id="xdx_902_eus-gaap--SharesIssued_c20170831__us-gaap--StatementEquityComponentsAxis__custom--LenderWarrantsMember_pii"&gt;2.08
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;per share; seven-year contractual term;
&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pii_dp_uPercent_c20170831__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zoKrPzP5lJJg"&gt;113.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
volatility; &lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pii_dp_uPercent_c20170831__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z8iBgC34qAWj"&gt;0&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
dividend rate; and a risk-free interest rate of &lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pii_dp_uPercent_c20170831__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zJGDRNQprik7"&gt;1.77&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%.
The relative fair value of the Lender Warrants was recorded as a debt discount which is being amortized as interest expense over
the term of the SWK Loan using the effective interest rate method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;SWK
Refinance &#x2013; May 2019&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
May 2019, the Company entered into a joinder and amendment (the &#x201c;Amendment&#x201d;) to the SWK Loan and with SWK, as lender
and collateral agent. A summary of the material changes contained in the Amendment are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
    interest rate calculation that the loan bears is now equal to the three-month London Inter-Bank Offered Rate (subject to a
    minimum of &lt;span id="xdx_901_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--JoinderAndAmendmentMember__us-gaap--VariableRateAxis__us-gaap--LondonInterbankOfferedRateLIBORMember__srt--RangeAxis__srt--MinimumMember_zeDhU0aeb4b7"&gt;2.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%),
    plus an applicable margin of &lt;span id="xdx_900_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--JoinderAndAmendmentMember__us-gaap--VariableRateAxis__custom--MarginRateMember_znvEES1EYcx8"&gt;10.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
    (the &#x201c;Margin Rate&#x201d;); provided that, if, two days prior to a payment date, the &lt;span id="xdx_90B_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--JoinderAndAmendmentMember"&gt;Company
    provides SWK evidence that the Company has achieved a leverage ratio as of such date of less than 4.00:1:00, the Margin Rate
    shall equal 9.00%; and if the Company has achieved a leverage ratio as of such date of less than 3.00:1:00, the Margin Rate
    shall equal 7.00%;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Leverage
    ratio in the Amendment means, as of any date of determination, the ratio of: (a) indebtedness as of such date to (b) EBITDA
    (as defined in the SWK Loan), of the Company for the immediately preceding twelve (12) month period, adding-back (i) actual
    litigation expenses for the immediately preceding twelve (12) month period, minus (ii) actual litigation expenses for the
    immediately preceding three (3) month period multiplied by four (4);&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
    definition of the first amortization date was changed to May 14, 2020, permitting the Company to pay interest only on the
    principal amount loaned for the next four payments (payments are due on a quarterly basis) following the Amendment; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Subject
    to the satisfaction of certain revenue and market capitalization requirements and conditions, SWK agreed to make available
    to the Company an additional principal amount of up to $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20190531__us-gaap--TypeOfArrangementAxis__custom--JoinderAndAmendmentMember_z16G7gMhLfj6"&gt;5,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;;
    and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
    maturity date was changed to &lt;span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--JoinderAndAmendmentMember__us-gaap--VariableRateAxis__custom--MarginRateMember_zTh86uO0sqYd"&gt;July
    19, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Related
to the Amendment, the Company incurred expenses related to legal and lender costs of $&lt;span id="xdx_90E_eus-gaap--LegalFees_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--JoinderAndAmendmentMember__us-gaap--VariableRateAxis__custom--MarginRateMember_pn3n3"&gt;282
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;that are included in debt discount and
will be amortized over the remaining term of the SWK Loan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
addition to the terms described above, the Amendment joined the Company&#x2019;s recently created subsidiaries to the SWK Loan
and added definitions related to excluded subsidiaries that are not considered co-borrowers and are subsidiaries of the Company
which the Company believes it will eventually deconsolidate from its financial statements and lose &lt;span id="xdx_90B_ecustom--DeconsolidationPercentage_pii_dp_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--JoinderAndAmendmentMember__us-gaap--VariableRateAxis__custom--MarginRateMember_z9KbGtnwpbp"&gt;50&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
or more of the equity interests of the subsidiary.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Second
Amendment to SWK Loan&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
April 1, 2020, the Company and several of its wholly owned subsidiaries entered into a second amendment (the &#x201c;SWK Second
Amendment&#x201d;) to the SWK Loan with SWK. A summary of the material changes contained in the SWK Second Amendment are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;SWK
    agreed to make available to the Company, and the Company drew down on, an additional principal amount of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_c20200402__us-gaap--TypeOfArrangementAxis__custom--SWKSecondAmendmentMember_pn3n3"&gt;1,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
    definition of the first amortization date was changed to August 14, 2020, permitting the Company to pay interest only on the
    principal amount loaned for the next payment (payments are due on a quarterly basis) following the SWK Second Amendment; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
    interest payment of $&lt;span id="xdx_900_eus-gaap--InterestExpenseDebt_c20200513__20200514__us-gaap--TypeOfArrangementAxis__custom--SWKSecondAmendmentMember_pn3n3"&gt;358
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;due May 14, 2020 was paid in-kind
    by increasing the principal amount of the term loans by an amount equal to the interest accrued as of such date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Interest
expense related to the SWK Loan Agreement, as amended, amounted to $&lt;span id="xdx_90B_eus-gaap--InterestExpenseDebt_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--SWKSecondAmendmentMember_pn3n3"&gt;1,768
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_90D_eus-gaap--InterestExpenseDebt_pn3n3_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--SWKSecondAmendmentMember_zEDV9TOdVkP"&gt;1,960
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;for the years ended December 31, 2020
and 2019, respectively, and included amortization of debt issuance costs and discount of $&lt;span id="xdx_908_eus-gaap--AmortizationOfDebtDiscountPremium_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--SWKSecondAmendmentMember_pn3n3"&gt;457
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_909_eus-gaap--AmortizationOfDebtDiscountPremium_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--SWKSecondAmendmentMember_pn3n3"&gt;512
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;for the years ended December 31, 2020
and 2019, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Paycheck
Protection Program Loan&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
April 2020, the Company entered into an unsecured promissory note and related Business Loan Agreement with Renasant Bank, as lender,
for a loan (the &#x201c;PPP Loan&#x201d;) in the principal amount of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_c20200430__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember_pn3n3"&gt;1,967
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and received cash proceeds of the same
amount, pursuant to the Paycheck Protection Program (the &#x201c;PPP&#x201d;) under the Federal Coronavirus Aid, Relief, and Economic
Security Act (the &#x201c;CARES Act&#x201d;), which was enacted March 27, 2020. The PPP is administered by the U.S. Small Business
Administration (the &#x201c;SBA&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Under
the terms of the PPP Loan, interest accrues on the outstanding principal at the rate of &lt;span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_c20200430__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember_zQ1cZ59nM5U5"&gt;1.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
per annum. The term of the PPP Loan is two years, unless payment is sooner required in connection with an event of default under
the PPP Loan. To the extent the PPP Loan amount is not forgiven under the PPP, the Company is obligated to make equal monthly
payments of principal and interest, beginning seven months from the date of the PPP Loan, until the maturity date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
CARES Act and the PPP provide a mechanism for forgiveness of up to the full amount borrowed. Under the PPP, the Company applied
for forgiveness for all of the PPP Loan during the year ended December 31, 2020, however the SBA has not made a decision related
to the Company&#x2019;s application for forgiveness. The amount of loan proceeds eligible for forgiveness is based on a formula
that takes into account a number of factors, including the amount of loan proceeds used by the Company during the 24-week period
after the loan origination for certain purposes including payroll costs, interest on certain mortgage obligations, rent payments
on certain leases, and certain qualified utility payments (&lt;span id="xdx_907_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20200403__20200430__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember"&gt;it
being anticipated that at least 75% of the loan amount will be required to be used for eligible payroll costs&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;);
the employer maintaining or rehiring employees and maintaining salaries at certain levels; and other factors. Subject to the other
requirements and limitations on loan forgiveness, only loan proceeds spent on payroll and other eligible expenses during the covered
twenty-four-week period will qualify for forgiveness. While the Company has used proceeds from the PPP Loan for such qualifying
expenses, in particular maintaining continuity of its payroll and workforce (including staff critical to the timely production
and dispensing of medicines the Company produces), no assurance can be provided that the Company will obtain forgiveness of the
PPP Loan in whole or in part. &lt;span id="xdx_90B_eus-gaap--InterestExpenseDebt_pn3n3_do_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember_z03zsm6G9Z5"&gt;No
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;interest expense was recognized for the
year ended December 31, 2020 related to the PPP Loan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zXNJcHgSyYGf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
December 31, 2020, future minimum payments under the Company&#x2019;s debt were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BD_zizdE1NSyEMa" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;SUMMARY
OF FUTURE MINIMUM PAYMENTS&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20201231_zLJmPpoPTFI6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maLTDzahg_zABGlu8wOMFe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,794&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maLTDzahg_zaeVDqElNOY5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,700&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maLTDzahg_zL7MRHjzyf0f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,511&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDzahg_zvgwAcLonrK6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20,005&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--InterestPayableCurrent_iNI_pn3n3_di_zN3aVQMerpM8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: amount
    representing interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,927&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_zvYFCbAYDpB4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Notes payable, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,078&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_zBlvNm0isV8g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: unamortized
    discount&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(802&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--NotesPayable_iTI_pn3n3_zKOyQNKTAAV8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Notes payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,276&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_ecustom--NotesPayableCurrent1_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: current
    portion, net of unamortized discount&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,898&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--LongTermNotesPayable1_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Note payable,
    net of current portion and unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,378&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A8_zx7jYDbayZG5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2017-07-31_custom_TermLoanAndSecurityAgreementMember_custom_SWKFundingLLCMember"
      decimals="-3"
      unitRef="USD">16000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentDescription contextRef="From2017-07-012017-07-31_custom_TermLoanAndSecurityAgreementMember_custom_SWKFundingLLCMember">The
SWK Loan Agreement was fully funded at closing with a five-year term, however, such term could be reduced to four years if certain
revenue requirements are not achieved.</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="From2019-04-012019-04-30_us-gaap_LondonInterbankOfferedRateLIBORMember">Prior
to the loan refinance in May 2019 (see below), the SWK Loan bore interest at a variable rate equal to the three-month London Inter-Bank
Offered Rate (subject to a minimum of 1.50%
and maximum of 3.00%),
plus an applicable margin of 10.50%.</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2019-04-012019-04-30_us-gaap_LondonInterbankOfferedRateLIBORMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Percent">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2019-04-012019-04-30_us-gaap_LondonInterbankOfferedRateLIBORMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Percent">0.0300</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2019-04-012019-04-30_us-gaap_LondonInterbankOfferedRateLIBORMember"
      decimals="INF"
      unitRef="Percent">0.1050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2019-04-292019-04-30_custom_SWKLoanAgreementMember"
      decimals="-3"
      unitRef="USD">750000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentMaturityDateDescription contextRef="From2019-04-292019-04-30_custom_SWKLoanAgreementMember">All
amounts owed under the SWK Loan Agreement, including an exit fee equal to 5% of the aggregate principal amount loaned thereunder,
were originally due and payable on July 19, 2022.</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="AsOf2019-04-30_custom_SWKLoanAgreementMember"
      decimals="-3"
      unitRef="USD">1282000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">800000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">800000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2017-07-31_custom_LenderWarrantsMember"
      decimals="INF"
      unitRef="Shares">415586</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2017-07-31_custom_LenderWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">3.08</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2017-08-31_custom_LenderWarrantsMember"
      decimals="INF"
      unitRef="Shares">615386</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2017-08-31_custom_LenderWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">2.08</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2017-07-31_custom_LenderWarrantsMember">P7Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">982000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:SharesIssued
      contextRef="AsOf2017-08-31_custom_LenderWarrantsMember"
      decimals="INF"
      unitRef="Shares">2.08</us-gaap:SharesIssued>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2017-08-31_us-gaap_WarrantMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      unitRef="Percent">1.135</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2017-08-31_us-gaap_WarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      unitRef="Percent">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2017-08-31_us-gaap_WarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      unitRef="Percent">0.0177</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2019-05-012019-05-31_custom_JoinderAndAmendmentMember_us-gaap_LondonInterbankOfferedRateLIBORMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Percent">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2019-05-012019-05-31_custom_JoinderAndAmendmentMember_custom_MarginRateMember"
      decimals="INF"
      unitRef="Percent">0.1000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="From2019-05-012019-05-31_custom_JoinderAndAmendmentMember">Company
    provides SWK evidence that the Company has achieved a leverage ratio as of such date of less than 4.00:1:00, the Margin Rate
    shall equal 9.00%; and if the Company has achieved a leverage ratio as of such date of less than 3.00:1:00, the Margin Rate
    shall equal 7.00%;</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2019-05-31_custom_JoinderAndAmendmentMember"
      decimals="-3"
      unitRef="USD">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2019-05-012019-05-31_custom_JoinderAndAmendmentMember_custom_MarginRateMember">2023-07-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LegalFees
      contextRef="From2019-05-012019-05-31_custom_JoinderAndAmendmentMember_custom_MarginRateMember"
      decimals="-3"
      unitRef="USD">282000</us-gaap:LegalFees>
    <HROW:DeconsolidationPercentage
      contextRef="From2019-05-012019-05-31_custom_JoinderAndAmendmentMember_custom_MarginRateMember"
      decimals="INF"
      unitRef="Percent">0.50</HROW:DeconsolidationPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-04-02_custom_SWKSecondAmendmentMember"
      decimals="-3"
      unitRef="USD">1000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:InterestExpenseDebt
      contextRef="From2020-05-132020-05-14_custom_SWKSecondAmendmentMember"
      decimals="-3"
      unitRef="USD">358000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2020-01-012020-12-31_custom_SWKSecondAmendmentMember"
      decimals="-3"
      unitRef="USD">1768000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2019-01-012019-12-31_custom_SWKSecondAmendmentMember"
      decimals="-3"
      unitRef="USD">1960000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2020-01-012020-12-31_custom_SWKSecondAmendmentMember"
      decimals="-3"
      unitRef="USD">457000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2019-01-012019-12-31_custom_SWKSecondAmendmentMember"
      decimals="-3"
      unitRef="USD">512000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2020-04-30_custom_BusinessLoanAgreementMember"
      decimals="-3"
      unitRef="USD">1967000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2020-04-30_custom_BusinessLoanAgreementMember"
      decimals="INF"
      unitRef="Percent">0.010</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="From2020-04-032020-04-30_custom_BusinessLoanAgreementMember">it
being anticipated that at least 75% of the loan amount will be required to be used for eligible payroll costs</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89B_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zXNJcHgSyYGf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
December 31, 2020, future minimum payments under the Company&#x2019;s debt were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BD_zizdE1NSyEMa" style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;SUMMARY
OF FUTURE MINIMUM PAYMENTS&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20201231_zLJmPpoPTFI6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maLTDzahg_zABGlu8wOMFe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,794&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maLTDzahg_zaeVDqElNOY5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,700&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maLTDzahg_zL7MRHjzyf0f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,511&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDzahg_zvgwAcLonrK6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20,005&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--InterestPayableCurrent_iNI_pn3n3_di_zN3aVQMerpM8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: amount
    representing interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,927&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_zvYFCbAYDpB4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Notes payable, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17,078&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_zBlvNm0isV8g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: unamortized
    discount&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(802&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--NotesPayable_iTI_pn3n3_zKOyQNKTAAV8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Notes payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16,276&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_ecustom--NotesPayableCurrent1_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: current
    portion, net of unamortized discount&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,898&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--LongTermNotesPayable1_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Note payable,
    net of current portion and unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,378&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">5794000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">4700000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">9511000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebt contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">20005000</us-gaap:LongTermDebt>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">2927000</us-gaap:InterestPayableCurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">17078000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">802000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:NotesPayable contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">16276000</us-gaap:NotesPayable>
    <HROW:NotesPayableCurrent1 contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">-3898000</HROW:NotesPayableCurrent1>
    <HROW:LongTermNotesPayable1 contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">12378000</HROW:LongTermNotesPayable1>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_805_eus-gaap--LeasesOfLesseeDisclosureTextBlock_za1ngAJwHxB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
13. &lt;span id="xdx_820_zJpYFUmOR7Lc"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company leases office and laboratory space under the non-cancelable operating leases listed below. These lease agreements have
remaining lease terms between &lt;span id="xdx_90F_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtYxL_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember__srt--RangeAxis__srt--MinimumMember_zV9nVi3OtnBg" title="::XDX::P1Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1169"&gt;one
&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;to &lt;span id="xdx_90F_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember__srt--RangeAxis__srt--MaximumMember_zzeGYKmm635f"&gt;four years&lt;/span&gt; and contain various clauses
for renewal at the Company&#x2019;s option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;An
    operating lease for &lt;span id="xdx_904_eus-gaap--AreaOfLand_iI_pii_uSqft_c20201231__srt--StatementGeographicalAxis__custom--SanDiegoMember_zAkrDPYkY75f"&gt;10,200
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;square feet
    of office space in San Diego, California, that expires in &lt;span id="xdx_906_ecustom--LeaseExpirationDateDescription_c20200101__20201231__srt--StatementGeographicalAxis__custom--SanDiegoMember_zHw0khCE3uMc"&gt;December
    2021&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;, with
    an &lt;span id="xdx_90F_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20200101__20201231__srt--StatementGeographicalAxis__custom--SanDiegoMember_z9i7qTEO1CT4"&gt;option
    to extend the term for a five-year period&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;An
    operating lease for &lt;span id="xdx_905_eus-gaap--AreaOfLand_iI_pii_uSqft_c20201231__srt--StatementGeographicalAxis__custom--LedgewoodMember_z9Cpzr0f9szl"&gt;26,400
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;square feet
    of lab, warehouse and office space in Ledgewood, New Jersey, that expires in &lt;span id="xdx_90E_ecustom--LeaseExpirationDateDescription_c20200101__20201231__srt--StatementGeographicalAxis__custom--LedgewoodMember_z7HS8z3U0AFh"&gt;July
    2026&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;, with
    &lt;span id="xdx_90B_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20200101__20201231__srt--StatementGeographicalAxis__custom--LedgewoodMember_zUkbx8fTEood"&gt;an
    option to extend the term for two additional five-year periods&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;.
    This includes an amendment that was made effective July 2020 that extended the term of the original lease and added &lt;span id="xdx_902_ecustom--AdditionalAreaOfLand_iI_pii_uSqft_c20201231__srt--StatementGeographicalAxis__custom--LedgewoodMember_zb4ngO58o8Df" title="Additional square footage"&gt;1,400
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;of additional
    square footage to the lease; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;An
    operating lease for &lt;span id="xdx_904_eus-gaap--AreaOfLand_iI_pii_uSqft_c20201231__srt--StatementGeographicalAxis__custom--NashvilleMember_zODv94I0Lh8f"&gt;5,500
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;square feet of office space in Nashville,
    Tennessee, that expires in &lt;span id="xdx_908_ecustom--LeaseExpirationDateDescription_c20200101__20201231__srt--StatementGeographicalAxis__custom--NashvilleMember"&gt;December
    2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;, with an &lt;span id="xdx_901_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20200101__20201231__srt--StatementGeographicalAxis__custom--NashvilleMember"&gt;option
    to extend the term for two additional five-year periods&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;During
the year ended December 31, 2020, the Company terminated its operating lease for &lt;span id="xdx_909_eus-gaap--AreaOfLand_iI_pii_uSqft_c20201231__srt--StatementGeographicalAxis__custom--IrvineMember_zNVcLKqqULV"&gt;4,500
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;square feet of
office and lab space in Irvine, California, that had an expiration date in December 2020. In connection with the termination,
the Company recorded a gain of $&lt;span id="xdx_908_eus-gaap--GainLossOnTerminationOfLease_c20200101__20201231__srt--StatementGeographicalAxis__custom--IrvineMember_pn3n3"&gt;4
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;which was recognized
in other income (expense) on the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
December 31, 2020 and 2019, the weighted-average discount rate and the weighted-average remaining lease term for the operating
leases held by the Company were &lt;span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_uPercent_c20201231_zNoiPzgLgIc5"&gt;6.3&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
and &lt;span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_uPercent_c20191231_zpxXjiyJR571"&gt;6.3&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
and &lt;span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zFigVgEPCSfk"&gt;11.2&lt;/span&gt;&lt;/span&gt;
&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and &lt;span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20191231_z1CXzUB5jLh"&gt;10.21
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;years, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the years ended December 31, 2020 and 2019, cash paid for amounts included for the operating lease liabilities was $&lt;span id="xdx_906_eus-gaap--OperatingLeasePayments_c20200101__20201231_pn3n3"&gt;1,052
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_901_eus-gaap--OperatingLeasePayments_pn3n3_c20190101__20191231_zD9j5V5z3Shj"&gt;905&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;,
respectively, and the Company recorded operating lease expense of $&lt;span id="xdx_900_eus-gaap--OperatingLeaseExpense_c20200101__20201231_pn3n3"&gt;1,066
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_90F_eus-gaap--OperatingLeaseExpense_c20190101__20191231_pn3n3"&gt;892&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;,
respectively, included in selling, general and administrative expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zBHaDku5PJ05" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Future
lease payments under operating leases (including options to extend) as of December 31, 2020 were as follows&lt;b&gt;: &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8BA_zCGIKH544meg" style="display: none"&gt;SCHEDULE
OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20201231_z7vEciE6mGM9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dec
    31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    Leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzHYL_ztSvJXG01Clg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right" title="2021"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,017&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzHYL_z7dClBFBQ3Wa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right" title="2022"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,038&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzHYL_zbURxCwGXWIi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right" title="2023"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,064&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzHYL_z0YO91yBCbig" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,090&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maLOLLPzHYL_zgIv5ehjhyEb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;916&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPzHYL_zM4UDNvZZjrk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,141&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzHYL_zLehlB1IYAz8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,266&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_z4XSssBwVWBb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: amount
    representing interest payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,034&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zXfD1mp0LnE3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total operating
    lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,232&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_zRcbHFWH26Ga" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: current
    portion, operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(580&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,652&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A5_zepq4jRCP57" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company also has a finance lease for equipment which requires monthly payments of $&lt;span id="xdx_905_ecustom--MonthlyPaymentsOfFinanceLeaseForEquipment_pn3n3_c20200101__20201231_zDMM54Im8Mm5" title="Monthly payments of finance lease"&gt;1
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;through January 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_z8hLwse0aLEb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Future
lease payments under the finance lease as of December 31, 2020 were as follows&lt;b&gt;: &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B9_zMAS9lkCNBG4" style="display: none"&gt;SCHEDULE
OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20201231_zQ8cj1fDi9x3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dec
    31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance
    Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maFLLPDzqJW_zbhPbELo62cb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maFLLPDzqJW_z1r0Hki6hbTf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maFLLPDzqJW_zZY2ZHZ47DF" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maFLLPDzqJW_zlhD50S62qNj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_pn3n3_mtFLLPDzqJW_z6THCmSKI286" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zGQmkwS8O0Q8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: amount
    representing interest payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--FinanceLeaseLiability_iI_pn3n3_zbbH2BQ1BGz3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Present value of future minimum lease
    payments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_pn3n3_di_ze37uSaOytll" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: current
    portion, finance lease obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance lease
    obligation, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A3_zAa0VS9yabwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
December 31, 2020 and 2019, the weighted-average discount rate and the weighted-average remaining lease term for the finance lease
held by the Company were &lt;span id="xdx_901_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_c20201231_pii"&gt;6.36&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
and &lt;span id="xdx_904_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_uPercent_c20191231_zvicejXg1Gh4"&gt;6.36&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%
and &lt;span id="xdx_90E_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zA51YxXsd3j2"&gt;3.08&lt;/span&gt;&lt;/span&gt;
&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and &lt;span id="xdx_904_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20191231_zKZPUyQvCQlb"&gt;4.08
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;years, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;For
the years ended December 31, 2020 and 2019:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;debt
    discount amortization related to a finance lease obligation was $&lt;span id="xdx_908_eus-gaap--AmortizationOfDebtDiscountPremium_c20200101__20201231_pn3n3"&gt;0
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_909_eus-gaap--AmortizationOfDebtDiscountPremium_c20190101__20191231_pn3n3"&gt;17&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;,
    respectively;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;amortization
    expense related to the equipment held under the finance lease obligations was $&lt;span id="xdx_902_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_c20200101__20201231_pn3n3"&gt;8
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_903_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_c20190101__20191231_pn3n3"&gt;150&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;,
    respectively; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;cash
    paid and expense recognized for interest expense related to the finance lease obligation was $&lt;span id="xdx_906_eus-gaap--FinanceLeaseInterestExpense_c20200101__20201231_pn3n3"&gt;2
    &lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_907_eus-gaap--FinanceLeaseInterestExpense_c20190101__20191231_pn3n3"&gt;18&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;,
    respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="AsOf2020-12-31_custom_OfficeAndLaboratorySpaceMember_srt_MaximumMember">P4Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:AreaOfLand
      contextRef="AsOf2020-12-31_custom_SanDiegoMember"
      decimals="INF"
      unitRef="Sqft">10200</us-gaap:AreaOfLand>
    <HROW:LeaseExpirationDateDescription contextRef="From2020-01-012020-12-31_custom_SanDiegoMember">December
    2021</HROW:LeaseExpirationDateDescription>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="From2020-01-012020-12-31_custom_SanDiegoMember">option
    to extend the term for a five-year period</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:AreaOfLand
      contextRef="AsOf2020-12-31_custom_LedgewoodMember"
      decimals="INF"
      unitRef="Sqft">26400</us-gaap:AreaOfLand>
    <HROW:LeaseExpirationDateDescription contextRef="From2020-01-012020-12-31_custom_LedgewoodMember">July
    2026</HROW:LeaseExpirationDateDescription>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="From2020-01-012020-12-31_custom_LedgewoodMember">an
    option to extend the term for two additional five-year periods</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <HROW:AdditionalAreaOfLand
      contextRef="AsOf2020-12-31_custom_LedgewoodMember"
      decimals="INF"
      unitRef="Sqft">1400</HROW:AdditionalAreaOfLand>
    <us-gaap:AreaOfLand
      contextRef="AsOf2020-12-31_custom_NashvilleMember"
      decimals="INF"
      unitRef="Sqft">5500</us-gaap:AreaOfLand>
    <HROW:LeaseExpirationDateDescription contextRef="From2020-01-012020-12-31_custom_NashvilleMember">December
    2024</HROW:LeaseExpirationDateDescription>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="From2020-01-012020-12-31_custom_NashvilleMember">option
    to extend the term for two additional five-year periods</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:AreaOfLand
      contextRef="AsOf2020-12-31_custom_IrvineMember"
      decimals="INF"
      unitRef="Sqft">4500</us-gaap:AreaOfLand>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="From2020-01-012020-12-31_custom_IrvineMember"
      decimals="-3"
      unitRef="USD">4000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="Percent">0.063</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2019-12-31"
      decimals="INF"
      unitRef="Percent">0.063</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2020-12-31">P11Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2019-12-31">P10Y2M15D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeasePayments
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1052000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">905000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1066000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">892000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zBHaDku5PJ05" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Future
lease payments under operating leases (including options to extend) as of December 31, 2020 were as follows&lt;b&gt;: &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8BA_zCGIKH544meg" style="display: none"&gt;SCHEDULE
OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20201231_z7vEciE6mGM9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dec
    31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    Leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzHYL_ztSvJXG01Clg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right" title="2021"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,017&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzHYL_z7dClBFBQ3Wa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right" title="2022"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,038&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzHYL_zbURxCwGXWIi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right" title="2023"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,064&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzHYL_z0YO91yBCbig" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,090&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maLOLLPzHYL_zgIv5ehjhyEb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;916&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPzHYL_zM4UDNvZZjrk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,141&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzHYL_zLehlB1IYAz8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,266&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_z4XSssBwVWBb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: amount
    representing interest payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,034&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zXfD1mp0LnE3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total operating
    lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,232&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_zRcbHFWH26Ga" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: current
    portion, operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(580&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,652&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1017000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1038000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1064000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1090000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">916000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">5141000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">10266000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">3034000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">7232000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">580000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">6652000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <HROW:MonthlyPaymentsOfFinanceLeaseForEquipment
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">1000</HROW:MonthlyPaymentsOfFinanceLeaseForEquipment>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_892_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_z8hLwse0aLEb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Future
lease payments under the finance lease as of December 31, 2020 were as follows&lt;b&gt;: &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B9_zMAS9lkCNBG4" style="display: none"&gt;SCHEDULE
OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20201231_zQ8cj1fDi9x3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dec
    31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance
    Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maFLLPDzqJW_zbhPbELo62cb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maFLLPDzqJW_z1r0Hki6hbTf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maFLLPDzqJW_zZY2ZHZ47DF" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maFLLPDzqJW_zlhD50S62qNj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_pn3n3_mtFLLPDzqJW_z6THCmSKI286" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zGQmkwS8O0Q8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: amount
    representing interest payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--FinanceLeaseLiability_iI_pn3n3_zbbH2BQ1BGz3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Present value of future minimum lease
    payments&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_pn3n3_di_ze37uSaOytll" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: current
    portion, finance lease obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance lease
    obligation, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">9000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">9000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">9000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">1000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">28000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">3000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">25000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">8000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">17000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="Percent">6.36</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2019-12-31"
      decimals="INF"
      unitRef="Percent">0.0636</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2020-12-31">P3Y29D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2019-12-31">P4Y29D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">17000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">8000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">150000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">2000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">18000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_80F_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zNZ3jL7CR8s8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
14. &lt;span id="xdx_822_zYHe9NP6Sdx4"&gt;STOCKHOLDERS&#x2019; EQUITY AND STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Common
Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
December 31, 2020 and 2019, the Company had &lt;span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pii_c20201231_zDDq1EK97VTk" title="Common stock, shares authorized"&gt;&lt;span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pii_c20191231_zD0ElZopPIH2" title="Common stock, shares authorized"&gt;50,000,000&lt;/span&gt;&lt;/span&gt; shares of common stock, $&lt;span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pii_c20201231_zrqPlGwJ7Hh1" title="Common stock, par value"&gt;&lt;span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pii_c20191231_zq3KoOUSP7A5" title="Common stock, par value"&gt;0.001&lt;/span&gt;&lt;/span&gt; par value, authorized, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Issuances
During the Year Ended December 31, 2019&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended December 31, 2019:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;the
    Company issued &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" title="Shares issued of restricted common stock, shares"&gt;15,000&lt;/span&gt; shares of its restricted common stock, with a fair value of $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJAfkvI70YOf" title="Fair value of restricted common stock issued"&gt;75&lt;/span&gt;, as consideration for commission expenses
    incurred during the year ended December 31, 2018;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;the
    Company issued &lt;span id="xdx_90B_ecustom--NumberOfCommonStockIssuedOnCashlessExercise_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Number of common stock issued on cashless exercise"&gt;27,671&lt;/span&gt; shares of its common stock upon the cashless exercise of options to purchase &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Common shares issued under share-based arrangement"&gt;82,929&lt;/span&gt; shares of common
    stock, with exercise prices ranging from $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Options exercise price, minimum"&gt;1.70&lt;/span&gt; to $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zBMBD7ZEBqu9" title="Options exercise price, maximum"&gt;4.17&lt;/span&gt; per share, net of &lt;span id="xdx_906_ecustom--CommonStockWithheldForPayrollTaxWithholdingsShare_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pii" title="Common stock withheld for payroll tax withholdings, shares"&gt;8,806&lt;/span&gt; shares of common stock withheld for payroll
    tax withholdings totaling $&lt;span id="xdx_907_ecustom--CommonStockWithheldForPayrollTaxWithholdingsValue_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pn3n3" title="Common stock withheld for payroll tax withholdings, value"&gt;50&lt;/span&gt;;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;the
    Company issued &lt;span id="xdx_902_ecustom--NumberOfCommonStockIssuedOnCashlessExercise_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Number of common stock issued on cashless exercise"&gt;2,122&lt;/span&gt; shares of its common stock upon the exercise of options to purchase &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Common shares issued under share-based arrangement"&gt;2,122&lt;/span&gt; shares of common stock, with
    exercise prices ranging from $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Options exercise price, minimum"&gt;1.70&lt;/span&gt; to $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Options exercise price, maximum"&gt;3.20&lt;/span&gt; per share, and received net proceeds of $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pn3n3" title="Proceeds from issuance of common stock"&gt;6&lt;/span&gt;;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;the
    Company issued &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsOneMember_pii" title="Number of shares issued"&gt;688,473&lt;/span&gt; shares of its common stock upon the cashless exercise of warrants to purchase &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsOneMember_pii" title="Common shares issued under share-based arrangement"&gt;964,532&lt;/span&gt; shares of common
    stock with an exercise price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20191231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsOneMember_pii" title="Warrants exercise price"&gt;1.79&lt;/span&gt; per share;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;the
    Company issued &lt;span title="Common shares issued under share-based arrangement"&gt;&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsTwoMember_pii" title="Number of shares issued"&gt;454,055&lt;/span&gt;&lt;/span&gt; shares of its common stock upon the exercise of warrants to purchase &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsTwoMember_pii" title="Common shares issued under share-based arrangement"&gt;454,055&lt;/span&gt; shares of common stock
    with an exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20191231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsTwoMember_pii" title="Warrants exercise price"&gt;1.79&lt;/span&gt; per share, and received net proceeds of $&lt;span id="xdx_900_eus-gaap--ProceedsFromWarrantExercises_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsTwoMember_pn3n3" title="Proceeds from issuance of warrant"&gt;813&lt;/span&gt;; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;the
    Company issued&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zjNKaEvK4Fx1"&gt;87,610&lt;/span&gt; shares of its
    common stock underlying RSUs issued to directors vested, but the issuance and delivery of these shares are deferred until
    the director resigns.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Issuances
During the Year Ended December 31, 2020&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended December 31, 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.15pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;the
    Company issued &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" title="Shares issued of restricted common stock, shares"&gt;30,000&lt;/span&gt; shares of its restricted common stock, with an initial fair value of $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pn3n3" title="Fair value of restricted common stock issued"&gt;167&lt;/span&gt;, as consideration for commission
    expenses incurred during the year ended December 31, 2019 and the year ended December 31, 2020;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;the
    Company issued &lt;span id="xdx_904_ecustom--NumberOfCommonStockIssuedOnCashlessExercise_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Number of common stock issued on cashless exercise"&gt;4,161&lt;/span&gt; shares of its common stock upon the cashless exercise of options to purchase &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Common shares issued under share-based arrangement"&gt;16,750&lt;/span&gt; shares of common
    stock, with exercise prices ranging from $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Options exercise price, minimum"&gt;1.70&lt;/span&gt; to $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Options exercise price, maximum"&gt;4.05&lt;/span&gt; per share, net of &lt;span id="xdx_905_ecustom--CommonStockWithheldForPayrollTaxWithholdingsShare_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pii" title="Common stock withheld for payroll tax withholdings, shares"&gt;3,564&lt;/span&gt; shares of common stock withheld for payroll
    tax withholdings;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;the
    Company issued &lt;span id="xdx_903_ecustom--NumberOfCommonStockIssuedOnCashlessExercise_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Number of common stock issued on cashless exercise"&gt;2,998&lt;/span&gt; shares of its common stock upon the exercise of options to purchase &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Common shares issued under share-based arrangement"&gt;2,998&lt;/span&gt; shares of common stock, with
    exercise prices ranging from $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Options exercise price, minimum"&gt;3.04&lt;/span&gt; to $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Options exercise price, maximum"&gt;3.20&lt;/span&gt; per share, and paid $&lt;span id="xdx_906_ecustom--CommonStockWithheldForPayrollTaxWithholdingsValue_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pn3n3" title="Common stock withheld for payroll tax withholdings, value"&gt;8 &lt;/span&gt;related to payroll tax withholdings;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;the
    Company issued &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" title="Shares issued of restricted common stock, shares"&gt;185,785&lt;/span&gt; shares of its common stock underlying RSUs held by directors that resigned. The RSUs had previously
    vested, including &lt;span id="xdx_902_ecustom--RestrictedStockUnitsVested_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" title="Restricted stock units vested"&gt;26,721&lt;/span&gt; RSUs during the year ended December 31, 2020, but the issuance and delivery of the shares
    were deferred until the director resigned; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_pii" title="Shares issued of restricted common stock, shares"&gt;35,224&lt;/span&gt;
    &lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;shares of the Company&#x2019;s common stock underlying RSUs
    issued to directors vested, but the issuance and delivery of these shares are deferred until the resignation of a director.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Preferred
Stock &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
December 31, 2020 and 2019, the Company had &lt;span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_c20201231_pii" title="Preferred stock, shares authorized"&gt;&lt;span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_c20191231_pii" title="Preferred stock, shares authorized"&gt;5,000,000&lt;/span&gt;&lt;/span&gt; shares of preferred stock, $&lt;span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_c20201231_pii" title="Preferred stock, par value"&gt;&lt;span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_c20191231_pii" title="Preferred stock, par value"&gt;0.001&lt;/span&gt;&lt;/span&gt; par value, authorized and &lt;span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pii_do_c20201231_zjkHWXQIjgC8" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pii_do_c20201231_zLFCisVtY8tj" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_pii_do_c20191231_zZUgl1b55R7k" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pii_do_c20191231_zY8BHLZ34SF8" title="Preferred stock, shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; shares of
preferred stock issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Stock
Option Plan &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
September 17, 2007, the Company&#x2019;s Board of Directors and stockholders adopted the Company&#x2019;s 2007 Incentive Stock and
Awards Plan, which was subsequently amended on November 5, 2008, February 26, 2012, July 18, 2012, May 2, 2013 and September 27,
2013 (as amended, the &#x201c;2007 Plan&#x201d;). The 2007 Plan reached its term in September 2017, and we can no longer issue additional
awards under this plan, however, options previously issued under the 2007 Plan will remain outstanding until they are exercised,
reach their maturity or are otherwise cancelled/forfeited. On June 13, 2017, the Company&#x2019;s Board of Directors and stockholders
adopted the Company&#x2019;s 2017 Incentive Stock and Awards Plan (the &#x201c;2017 Plan&#x201d; together with the 2007 Plan, the
&#x201c;Plans&#x201d;). As of December 31, 2020, the 2017 Plan provides for the issuance of a maximum of &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20201231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_pii" title="Maximum number of common stock issuance under the plan"&gt;2,000,000&lt;/span&gt; shares of the
Company&#x2019;s common stock. The purpose of the Plans are to attract and retain directors, officers, consultants, advisors and
employees whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of
such persons in the Company&#x2019;s development and financial success. Under the Plans, the Company is authorized to issue incentive
stock options intended to qualify under Section 422 of the Internal Revenue Code, non-qualified stock options, restricted stock
units and restricted stock. The Plans are administered by the Compensation Committee of the Company&#x2019;s Board of Directors.
The Company had &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20201231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_pii" title="Shares available for future issuances"&gt;342,882&lt;/span&gt; shares available for future issuances under the 2017 Plan at December 31, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Stock
Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zFVMg4isXzGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
summary of stock option activity under the Plan for the year ended December 31, 2020 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BA_zXtj7wc3j72" style="display: none"&gt;SCHEDULE OF STOCK OPTION PLAN ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    Avg. Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    Avg. Remaining Contractual Life&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate
    Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options outstanding -
    January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20191231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z0wvlfZb3Fn5" style="width: 11%; text-align: right" title="Number of shares, Outstanding, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,656,683&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20191231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z0vDY4ja3755" style="width: 11%; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.31&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="text-align: right" title="Number of shares, Options granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;414,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="text-align: right" title="Weighted Avg. Exercise Price, Options granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.44&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zd3fg6nsMnVl" style="text-align: right" title="Number of shares, Options exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(19,748&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="text-align: right" title="Weighted Avg. Exercise Price, Options exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zJClW6EHXCrh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Options cancelled/forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(21,402&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Avg. Exercise Price, Options cancelled/forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12.77&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options outstanding
    - December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zPqFOLroBC48" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Outstanding, Ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,030,033&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z8NK6nsAbH8j" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, Ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.43&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Remaining Contractual Life, Options outstanding"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zfsq95D078Lf" title="Weighted Avg. Remaining Contractual Life, Options outstanding"&gt;5.72&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zVWtCkyG1Zj8" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,569&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zRo6HTPothl3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,908,849&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zZ4f98mY0SBk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Avg. Exercise Price, Exercisable Ending Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.49&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Remaining Contractual Life, Options exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zA66gTouaDb6" title="Weighted Avg. Remaining Contractual Life, Options exercisable"&gt;5.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z0FlgEJo9dy" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,051&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options vested
    and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zQgK1tz9Qhu9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options vested and expected to vest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,918,298&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z3JdTHMSppok" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Avg. Exercise Price, Vested and expected to vest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.37&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Remaining Contractual Life, Options vested and expected to vest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zFknDYG1ZkKf" title="Weighted Avg. Remaining Contractual Life, Options vested and expected to vest"&gt;5.69&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pn3n3_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zWSdyEIPs5ti" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options vested and expected to vest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,519&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A1_zszb1uTZGa52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
aggregate intrinsic value in the table above represents the total pre-tax amount of the proceeds, net of exercise price, which
would have been received by option holders if all option holders had exercised and immediately sold all options with an exercise
price lower than the market price on December 31, 2020, based on the closing price of the Company&#x2019;s common stock of $&lt;span id="xdx_90E_ecustom--ClosingPriceOfCommonStockPricePerShare_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_pii" title="Closing price of common stock price per share"&gt;6.86&lt;/span&gt;
on that date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
intrinsic value of the options exercised in 2020 was $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn3n3_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zYEyXIXZ7lhe" title="Intrinsic value of options exercised"&gt;50&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended December 31, 2020, the Company granted stock options to certain employees and a consultant. The stock options were
granted with an exercise price equal to the current market price of the Company&#x2019;s common stock, as reported by the securities
exchange on which the common stock was then listed, at the grant date and have contractual terms of &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantMember_zK32wN7Q9pYe" title="Weighted avg. remaining contractual life, options exercisable"&gt;10&lt;/span&gt; years. &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantMember" title="Share-based compensation arrangement by share-based payment award, plan modification, description and terms"&gt;Vesting terms for
options granted to employees and consultants during the year ended December 31, 2020 generally included one of the following vesting
schedules: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and
the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over
three years; and 100% of the shares subject to the option vest on a quarterly basis in equal installments over three years. Certain
option awards provide for accelerated vesting if there is a change in control (as defined in the Plans) and in the event of certain
modifications to the option award agreement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
July 31, 2015, the Company granted to its Chief Executive Officer, Mark Baum, an option to purchase &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20150730__20150731__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_pii" title="Number of shares, options granted"&gt;600,000&lt;/span&gt; shares of the Company&#x2019;s
common stock (the &#x201c;Baum Performance Option&#x201d;) at an exercise price of $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20150730__20150731__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_pii" title="Exercise price of options"&gt;7.87&lt;/span&gt; per share under the 2007 Plan subject to
the satisfaction of certain market-based vesting criteria. The market-based vesting criteria are separated into five tranches
and require that the Company achieve and maintain certain average stock price targets ranging from $&lt;span id="xdx_90D_ecustom--AverageStockPrice_c20150731__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember__srt--RangeAxis__srt--MinimumMember_pii" title="Average stock price"&gt;9&lt;/span&gt; per share to $&lt;span id="xdx_90F_ecustom--AverageStockPrice_c20150731__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember__srt--RangeAxis__srt--MaximumMember_pii" title="Average stock price"&gt;15&lt;/span&gt; per share
during the five year period following the grant date. On June 4, 2020, the Company amended the Baum Performance Option, to extend
the vesting and contractual term by &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200603__20200604__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_zefhTPyjcQ6f" title="Weighted avg. remaining contractual life, options outstanding"&gt;5 &lt;/span&gt;years. The Company treated this amendment as a modification to the Baum Performance Option
for accounting purposes. The fair value of the modification was $&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20200603__20200604__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_pn3n3" title="Share-based compensation arrangement by share-based payment award, options, vested in period, fair value"&gt;1,876&lt;/span&gt; using a Monte Carlo simulation model with a five-year life,
&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_c20200603__20200604__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_zBs9hKVEyKJ6" title="Share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate"&gt;70%&lt;/span&gt; volatility and a risk-free interest rate of &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_c20200603__20200604__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_zF2XCLcrqGd8" title="Share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate"&gt;0.40%&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;With
the exception of the Baum Performance Option, the fair value of each option award is estimated on the date of grant using the
Black-Scholes-Merton option pricing model. Beginning on April 1, 2019, the Company began calculating expected volatility based
solely on the historical volatilities of the common stock of the Company. Prior to April 1, 2019, the expected volatility was
based on the historical volatilities of the common stock of the Company and comparable publicly traded companies. The Company
previously utilized this methodology based on its estimate that it had limited relevant historical data regarding the volatility
of its stock price on which to base a meaningful estimate of expected volatility. The expected term of options granted was determined
in accordance with the &#x201c;simplified approach,&#x201d; as the Company has limited, relevant, historical data on employee exercises
and post-vesting employment termination behavior. The expected risk-free interest rate is based on the U.S. Treasury yield for
a period consistent with the expected term of the option in effect at the time of the grant. The financial statement effect of
forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates. For
option grants to employees and directors, the Company assigns a forfeiture factor of &lt;span id="xdx_906_ecustom--ForfeitureFactorPercentage_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zLaRI7blgAug" title="Forfeiture factor, percentage"&gt;10%&lt;/span&gt;. These factors could change in the future,
which would affect the determination of stock-based compensation expense in future periods. Utilizing these assumptions, the fair
value is determined at the date of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zo943NhcDZV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following
assumptions used for valuing options granted to employees:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B9_z3pOk5YOPvRg" style="display: none"&gt;SCHEDULE OF FAIR VALUE ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-average fair
    value of options granted&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_pii" style="width: 16%; text-align: right" title="Weighted-average fair value of options granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.86&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_pii" style="width: 16%; text-align: right" title="Weighted-average fair value of options granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.72&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected terms (in years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right" title="Expected terms (in years)"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MinimumMember_zznoJH9sHdXh" title="Expected terms (in years)"&gt;0.50&lt;/span&gt;
                                         - &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MaximumMember_zDD1q3hBnOw5" title="Expected terms (in years)"&gt;6.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MinimumMember_zFrHUthfhXij" title="Expected terms (in years)"&gt;5.07&lt;/span&gt;
                                         - &lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MaximumMember_ztBeixpcpXRi" title="Expected terms (in years)"&gt;7.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right" title="Expected volatility, maximum"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_uPercent_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zBN829DrQFaa" title="Expected volatility, minimum"&gt;67&lt;/span&gt;
                                         &#x2013; &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_uPercent_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zLCFHkowlUWh" title="Expected volatility, maximum"&gt;71&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_uPercent_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zxnFxkILIhF" title="Expected volatility, minimum"&gt;64&lt;/span&gt;
                                         - &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_uPercent_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zZ5w84ysMSQ8" title="Expected volatility, maximum"&gt;78&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right" title="Risk-free interest rate, maximum"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_uPercent_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zs1woI2aLU04" title="Risk-free interest rate, minimum"&gt;0.34&lt;/span&gt;
                                         &#x2013; &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_uPercent_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zwiOkXCUpV07" title="Risk-free interest rate, maximum"&gt;1.64&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_uPercent_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zZ5vHvMSgbuh" title="Risk-free interest rate, minimum"&gt;1.83&lt;/span&gt;
                                         &#x2013;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_uPercent_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_z8MC2kbKhaHl" title="Risk-free interest rate, maximum"&gt; 2.68&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zcfIFI2EDx7b" style="text-align: right" title="Dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1448"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zyXdXXDOsZLf" style="text-align: right" title="Dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1450"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A3_z7YXHk5ckEk3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zTReyUQCrVXk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes information about stock options outstanding and exercisable at December 31, 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span&gt;&lt;span&gt;&lt;span id="xdx_8B6_zLHJLptFBOv1" style="display: none"&gt;SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Remaining&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contractual&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Range
    of Exercise Prices&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Life
    in Years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 34%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Range of Exercise Prices, minimum"&gt;1.47&lt;/span&gt; - $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Range of Exercise Prices, maximum"&gt;2.60&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" style="width: 10%; text-align: right" title="Number of Options Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;770,440&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right" title="Weighted Average Remaining Contractual Life in Years"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zFeE8JzfPS8f" title="Weighted Average Remaining Contractual Life in Years"&gt;5.64&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" style="width: 10%; text-align: right" title="Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.06&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" style="width: 10%; text-align: right" title="Number Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;745,255&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" style="width: 10%; text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.06&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_ziiFjkcDC772" title="Range of Exercise Prices, minimum"&gt;3.04&lt;/span&gt; - $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Range of Exercise Prices, maximum"&gt;4.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" style="text-align: right" title="Number of Options Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;517,002&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right" title="Weighted Average Remaining Contractual Life in Years"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z9eakblqqQSc" title="Weighted Average Remaining Contractual Life in Years"&gt;5.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" style="text-align: right" title="Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.98&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;438,873&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" style="text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.98&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Range of Exercise Prices, minimum"&gt;5.49&lt;/span&gt; - $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Range of Exercise Prices, maximum"&gt;6.36&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" style="text-align: right" title="Number of Options Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;496,350&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right" title="Weighted Average Remaining Contractual Life in Years"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_ztoyYSnJsWBa" title="Weighted Average Remaining Contractual Life in Years"&gt;7.22&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" style="text-align: right" title="Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;291,919&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" style="text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.13&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zBsCAhJkpYrl" title="Range of Exercise Prices, minimum"&gt;6.64&lt;/span&gt; - $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zRrw9dEctSpd" title="Range of Exercise Prices, maximum"&gt;8.99&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,246,241&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Remaining Contractual Life in Years"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zBhaXCRSQHqa" title="Weighted Average Remaining Contractual Life in Years"&gt;5.17&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.85&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;432,802&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8.09&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20200101__20201231_zTE4q6Dtgg96" title="Range of Exercise Prices, minimum"&gt;1.47&lt;/span&gt; - $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20200101__20201231_znbr9y4z6bkf" title="Range of Exercise Prices, maximum"&gt;8.99&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20201231_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,030,033&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Remaining Contractual Life in Years"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_z2pwY4UTeaQ" title="Weighted Average Remaining Contractual Life in Years"&gt;5.72&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20201231_pii" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.43&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20201231_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,908,849&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20201231_pii" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.49&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A0_z8EHcpGJe0a9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of December 31, 2020, there was approximately $&lt;span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_pn3n3" title="Unrecognized compensation expense related to unvested stock options granted under the plan"&gt;2,794&lt;/span&gt; of total unrecognized compensation expense related to unvested stock options
granted under the Plan. That expense is expected to be recognized over the weighted-average remaining vesting period of &lt;span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zNhD42KuyV98" title="Expense expected to recognize over the weighted-average remaining vesting period"&gt;3.96&lt;/span&gt; years.
The stock-based compensation for all stock options was $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_pn3n3" title="Stock-based compensation"&gt;1,579&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20190101__20191231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_pn3n3" title="Stock-based compensation"&gt;889&lt;/span&gt; during the years ended December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Restricted
Stock Units &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;RSU
awards are granted subject to certain vesting requirements and other restrictions, including performance and market-based
vesting criteria. The grant-date fair value of the RSUs, which has been determined based upon the market value of the Company&#x2019;s
common stock on the grant date, is expensed over the vesting period of the RSUs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Grants
During the Year Ended December 31, 2019&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended December 31, 2019, &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pii" title="Shares issued of restricted common stock, shares"&gt;185,000&lt;/span&gt; RSUs with a fair market value of $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pn3n3" title="Fair value of restricted common stock issued"&gt;1,139&lt;/span&gt; were issued to certain employees; the RSUs vest
in full on the third anniversary of the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended December 31, 2019, the Company&#x2019;s board of directors were granted &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pii" title="Shares issued of restricted common stock, shares"&gt;38,860&lt;/span&gt; RSUs with a fair market value of
$&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pn3n3" title="Fair value of restricted common stock issued"&gt;300&lt;/span&gt; which vests on a quarterly basis, over a one-year term in equal installments, subject to the director&#x2019;s
continued service at the vesting date, but the issuance and delivery of these shares are deferred until the director resigns.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zSBp8HaToScg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
summary of the Company&#x2019;s RSU activity and related information for the year ended December 31, 2019 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B0_z1u7f4VdIQV6" style="display: none"&gt;SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    Average Grant&lt;br/&gt;
    Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs unvested - January
    1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlcKzm3Vy0E1" style="width: 16%; text-align: right" title="Number of RSUs unvested, Outstanding, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,275,680&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_c20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzKbZvFFjXSl" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.16&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Number of RSUs granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;223,860&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.43&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pii_di_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgf1GrYmPyZ1" style="text-align: right" title="Number of RSUs vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(87,610&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.42&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pii_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztvt0TjCez4h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs cancelled/forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1554"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs unvested
    at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAbV7bsMtMHk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs unvested, Outstanding, Ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,411,930&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zuEsuPx7Uaxl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value, Ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.76&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Grants
During the Year Ended December 31, 2020&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended December 31, 2020, &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pii" title="Shares issued of restricted common stock, shares"&gt;161,000&lt;/span&gt; RSUs with a fair market value of $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pn3n3" title="Fair value of restricted common stock issued"&gt;1,025&lt;/span&gt; were issued to certain employees; the RSUs vest
in full on the third anniversary of the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended December 31, 2020, the Company&#x2019;s board of directors were granted &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pii" title="Shares issued of restricted common stock, shares"&gt;90,524&lt;/span&gt; RSUs with a fair market value $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pn3n3" title="Fair value of restricted common stock issued"&gt;511&lt;/span&gt;
which vest on a quarterly basis, over a one-year term in equal installments, subject to the director&#x2019;s continued
service at the vesting date, but the issuance and delivery of these shares are deferred until the director resigns.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
summary of the Company&#x2019;s RSU activity and related information for the year ended December 31, 2020 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    Average Grant&lt;br/&gt;
    Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs unvested - January
    1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwsDwbtXgcOg" style="width: 16%; text-align: right" title="Number of RSUs unvested, Outstanding, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,411,930&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_c20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNNoOi66nuCk" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.76&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Number of RSUs granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;251,524&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pii_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7tVOnlN9F0l" style="text-align: right" title="Number of RSUs vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(61,945&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.46&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs cancelled/forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1580"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs unvested
    at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgfUfvpFCBck" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs unvested, Outstanding, Ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,601,509&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCql18W0ey1i" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value, Ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.14&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A5_zcKNbdcJgvCc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of December 31, 2020, the total unrecognized compensation expense related to unvested RSUs was approximately $&lt;span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20201231__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_pn3n3" title="Unrecognized compensation expense related to unvested stock options granted under the plan"&gt;1,363&lt;/span&gt; which is expected
to be recognized over a weighted-average period of &lt;span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zl8CNWWZZLz3" title="Expense expected to recognize over the weighted-average remaining vesting period"&gt;3.14&lt;/span&gt; years, based on estimated vesting schedules. The stock-based compensation
for RSUs was $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensation_c20200101__20201231__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_pn3n3" title="Stock-based compensation"&gt;1,167&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensation_c20190101__20191231__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_pn3n3" title="Stock-based compensation"&gt;879&lt;/span&gt; during the years ended December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Subsidiary
Stock-Based Transactions&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Mayfield
Pharmaceuticals, Inc. - 2019&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended December 31, 2019:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Mayfield
    issued &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20190202__20190228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__dei--LegalEntityAxis__custom--EllePharmaceuticalLLCMember_pii" title="Stock issued during period, shares, acquisitions"&gt;1,000,000&lt;/span&gt; shares of its common stock to Elle in connection with the acquisition of certain drug candidate intellectual
    property and rights in February 2019;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Mayfield
    issued &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190701__20190731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_pii" title="Number of shares issued"&gt;300,000&lt;/span&gt; shares of its common stock to TGV in connection with the acquisition of certain drug candidate intellectual
    property and rights in July 2019; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;the
    Company recognized $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pn3n3" title="Stock-based compensation"&gt;26&lt;/span&gt; in stock-based compensation related to equity instruments granted by Mayfield for &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pii" title="Shares issued of restricted common stock, shares"&gt;2,450,000&lt;/span&gt; shares
    of its restricted common stock that vest upon various performance based milestones and service periods to consultants of Mayfield,
    including Mayfield&#x2019;s CEO candidate and to Harrow employees, including &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__srt--TitleOfIndividualAxis__custom--MarkBaumCEOMember_pii" title="Number of common stock issued for consultants services"&gt;725,000&lt;/span&gt; shares to Mark Baum, CEO of the Company,
    and &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__srt--TitleOfIndividualAxis__custom--AndrewBollCFOMember_pii" title="Number of common stock issued for consultants services"&gt;362,500&lt;/span&gt; shares to Andrew Boll, CFO of the Company.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Mayfield
Pharmaceuticals, Inc. - 2020&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended December 31, 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Mayfield
    repurchased &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__dei--LegalEntityAxis__custom--EllePharmaceuticalLLCMember_pii" title="Number of common stock issued for consultants services"&gt;650,000&lt;/span&gt; shares of its common stock from Elle, for an aggregate purchase price of $&lt;span id="xdx_901_ecustom--AggregatePurchasePrice_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__dei--LegalEntityAxis__custom--EllePharmaceuticalLLCMember_pii" title="Aggregate purchase price"&gt;1&lt;/span&gt;;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_pii" title="Shares issued of restricted common stock, shares"&gt;500,000&lt;/span&gt;
    shares of Mayfield&#x2019;s restricted common stock were forfeited by a consultant; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Mayfield
    issued &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pii" title="Shares issued of restricted common stock, shares"&gt;475,000&lt;/span&gt; shares of its restricted common stock, with a fair value of $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pn3n3" title="Fair value of restricted common stock issued"&gt;11&lt;/span&gt;, that vest upon various performance-based milestones
    and over a four-year service period to Mayfield&#x2019;s Chief Executive Officer candidate. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended December 31, 2020, the Company recognized $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensation_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember_pn3n3" title="Stock-based compensation"&gt;20&lt;/span&gt; in stock-based compensation for Mayfield stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Stowe
Pharmaceuticals, Inc. - 2019&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
July 2019, Stowe agreed to issue &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20190701__20190731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StowePharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_pii" title="Shares issued of restricted common stock, shares"&gt;1,750,000&lt;/span&gt; shares of its common stock to TGV in connection with the acquisition of certain drug
candidate intellectual property and rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Visionology,
Inc. - 2020&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended December 31, 2020, Visionology granted &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VisionologyIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pii" title="Shares issued of restricted common stock, shares"&gt;2,000,000&lt;/span&gt; shares of its restricted common stock, with a fair value of $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pii_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VisionologyIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1TFs6nM5AP9" title="Number of restrcited shares, value"&gt;96&lt;/span&gt;
that vest upon various performance based milestones and service periods to consultants of Visionology, including Visionology&#x2019;s
CEO candidate and to Harrow employees, including &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VisionologyIncMember__srt--TitleOfIndividualAxis__custom--MarkBaumCEOMember_pii" title="Number of common stock issued for consultants services"&gt;700,000&lt;/span&gt; shares to Mark Baum, CEO of the Company, and &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VisionologyIncMember__srt--TitleOfIndividualAxis__custom--AndrewBollCFOMember_pii" title="Number of common stock issued for consultants services"&gt;350,000&lt;/span&gt; shares to Andrew
Boll, CFO of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ziHtVmVZ22Sj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company recorded stock-based compensation (including issuance of common stock for services and accrual for stock-based compensation)
related to equity instruments granted to employees, directors and consultants as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B9_zurPvjdWON1b" style="display: none"&gt;SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Employees &#x2013; selling,
    general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="width: 18%; text-align: right" title="Stock based compensation related to equity instruments granted to related parties"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,289&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20191231__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="width: 18%; text-align: right" title="Stock based compensation related to equity instruments granted to related parties"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,464&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Directors &#x2013; selling, general
    and administrative&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="text-align: right" title="Stock based compensation related to equity instruments granted to related parties"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;473&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20191231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="text-align: right" title="Stock based compensation related to equity instruments granted to related parties"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;300&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Consultants
    &#x2013; selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock based compensation related to equity instruments granted to related parties"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;96&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20191231__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock based compensation related to equity instruments granted to related parties"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;259&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation related to equity instruments granted to related parties"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,858&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation related to equity instruments granted to related parties"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AA_zIhJl73Ks4Gf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;From
time to time, the Company issues warrants to purchase shares of the Company&#x2019;s common stock to investors, lenders (see Note
12), underwriters and other non-employees for services rendered or to be rendered in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z3hRwpJQzkLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
summary of warrant activity during the year ended December 31, 2020 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B7_zofGrHQAUGX1" style="display: none"&gt;SCHEDULE OF WARRANTS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of Shares Subject to Warrants Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    Avg. Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants outstanding
    - January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pii_c20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zF3vPI1IecUi" style="width: 16%; text-align: right" title="Number of Shares Warrants Outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;780,386&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_pii_c20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z4zzbdsSTAqe" style="width: 16%; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.12&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="text-align: right" title="Number of Shares Warrants Outstanding, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1652"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="text-align: right" title="Number of Shares Warrants Outstanding, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1654"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares Warrants Outstanding, Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1656"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants outstanding
    and exercisable - December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iE_pii_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zE0fOT4bX2R2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Warrants Outstanding and Exercisable, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;780,386&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1_iE_pii_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zGy9Yf4BTV6d" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Outstanding and Exercisable, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.12&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average
    remaining contractual life of the outstanding warrants in years - December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average remaining contractual life of the outstanding warrants in years"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zPVuFE6Md383" title="Weighted average remaining contractual life of the outstanding warrants in years"&gt;3.53&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8AD_zduARSswBOKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--ScheduleofWarrantsOutstandingAndExercisableTableTextBlock_zVJqdE4Kk2Ec" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;All
warrants outstanding as of December 31, 2020 are included in the following table:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B5_zdxFJYC54gQf" style="display: none"&gt;SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants
    Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants
    Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrant
    Series&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issue
    Date&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 25%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lender warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 12%; text-align: center" title="Issue Date"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_ecustom--WarrantsIssuanceDate_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zcIbfkNbtq0l" title="Issue Date"&gt;5/11/2015&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_pii" style="width: 12%; text-align: right" title="Warrants Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;125,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_pii" style="width: 11%; text-align: right" title="Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.79&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_pii" style="width: 12%; text-align: right" title="Warrants Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;125,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 12%; text-align: center" title="Expiration Date"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_ecustom--WarrantsAndRightsOutstandingMaturityDates_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zASHVdbs6vjf" title="Expiration Date"&gt;5/11/2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Settlement warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center" title="Issue Date"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_ecustom--WarrantsIssuanceDate_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_zIgKPdGA5Qt3" title="Issue Date"&gt;8/16/2016&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_pii" style="text-align: right" title="Warrants Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;40,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_pii" style="text-align: right" title="Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_pii" style="text-align: right" title="Warrants Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;40,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center" title="Expiration Date"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_ecustom--WarrantsAndRightsOutstandingMaturityDates_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_zWTTPiDABE55" title="Expiration Date"&gt;8/16/2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lender warrants
    (see Note 12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt" title="Issue Date"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_ecustom--WarrantsIssuanceDate_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_zwjV334F6VCl" title="Issue Date"&gt;7/19/2017&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;615,386&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_pii" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.08&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;615,386&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt" title="Expiration Date"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_ecustom--WarrantsAndRightsOutstandingMaturityDates_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_zrt915HjDe64" title="Expiration Date"&gt;7/19/2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;780,386&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="padding-bottom: 2.5pt; text-align: right" title="Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.12&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;780,386&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AC_z8t6DKVFp2K" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2019-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">15000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      unitRef="USD">75000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <HROW:NumberOfCommonStockIssuedOnCashlessExercise
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeOneMember"
      decimals="INF"
      unitRef="Shares">27671</HROW:NumberOfCommonStockIssuedOnCashlessExercise>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeOneMember"
      decimals="INF"
      unitRef="Shares">82929</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeOneMember"
      decimals="INF"
      unitRef="USDPShares">1.70</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeOneMember"
      decimals="INF"
      unitRef="USDPShares">4.17</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <HROW:CommonStockWithheldForPayrollTaxWithholdingsShare
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">8806</HROW:CommonStockWithheldForPayrollTaxWithholdingsShare>
    <HROW:CommonStockWithheldForPayrollTaxWithholdingsValue
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      unitRef="USD">50000</HROW:CommonStockWithheldForPayrollTaxWithholdingsValue>
    <HROW:NumberOfCommonStockIssuedOnCashlessExercise
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeTwoMember"
      decimals="INF"
      unitRef="Shares">2122</HROW:NumberOfCommonStockIssuedOnCashlessExercise>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeTwoMember"
      decimals="INF"
      unitRef="Shares">2122</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeTwoMember"
      decimals="INF"
      unitRef="USDPShares">1.70</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeTwoMember"
      decimals="INF"
      unitRef="USDPShares">3.20</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2019-01-012019-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeTwoMember"
      decimals="-3"
      unitRef="USD">6000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-01-012019-12-31_custom_CommonStockWarrantsOneMember"
      decimals="INF"
      unitRef="Shares">688473</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2019-01-012019-12-31_custom_CommonStockWarrantsOneMember"
      decimals="INF"
      unitRef="Shares">964532</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2019-12-31_custom_CommonStockWarrantsOneMember"
      decimals="INF"
      unitRef="USDPShares">1.79</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-01-012019-12-31_custom_CommonStockWarrantsTwoMember"
      decimals="INF"
      unitRef="Shares">454055</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2019-01-012019-12-31_custom_CommonStockWarrantsTwoMember"
      decimals="INF"
      unitRef="Shares">454055</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2019-12-31_custom_CommonStockWarrantsTwoMember"
      decimals="INF"
      unitRef="USDPShares">1.79</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2019-01-012019-12-31_custom_CommonStockWarrantsTwoMember"
      decimals="-3"
      unitRef="USD">813000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember"
      decimals="INF"
      unitRef="Shares">87610</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">30000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      unitRef="USD">167000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <HROW:NumberOfCommonStockIssuedOnCashlessExercise
      contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeOneMember"
      decimals="INF"
      unitRef="Shares">4161</HROW:NumberOfCommonStockIssuedOnCashlessExercise>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeOneMember"
      decimals="INF"
      unitRef="Shares">16750</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeOneMember"
      decimals="INF"
      unitRef="USDPShares">1.70</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeOneMember"
      decimals="INF"
      unitRef="USDPShares">4.05</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <HROW:CommonStockWithheldForPayrollTaxWithholdingsShare
      contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">3564</HROW:CommonStockWithheldForPayrollTaxWithholdingsShare>
    <HROW:NumberOfCommonStockIssuedOnCashlessExercise
      contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeTwoMember"
      decimals="INF"
      unitRef="Shares">2998</HROW:NumberOfCommonStockIssuedOnCashlessExercise>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeTwoMember"
      decimals="INF"
      unitRef="Shares">2998</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeTwoMember"
      decimals="INF"
      unitRef="USDPShares">3.04</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember_custom_RangeTwoMember"
      decimals="INF"
      unitRef="USDPShares">3.20</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <HROW:CommonStockWithheldForPayrollTaxWithholdingsValue
      contextRef="From2020-01-012020-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      unitRef="USD">8000</HROW:CommonStockWithheldForPayrollTaxWithholdingsValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">185785</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <HROW:RestrictedStockUnitsVested
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">26721</HROW:RestrictedStockUnitsVested>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember_srt_DirectorMember"
      decimals="INF"
      unitRef="Shares">35224</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2019-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2019-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2020-12-31_custom_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember"
      decimals="INF"
      unitRef="Shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2020-12-31_custom_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember"
      decimals="INF"
      unitRef="Shares">342882</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zFVMg4isXzGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
summary of stock option activity under the Plan for the year ended December 31, 2020 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BA_zXtj7wc3j72" style="display: none"&gt;SCHEDULE OF STOCK OPTION PLAN ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    Avg. Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    Avg. Remaining Contractual Life&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Aggregate
    Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options outstanding -
    January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20191231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z0wvlfZb3Fn5" style="width: 11%; text-align: right" title="Number of shares, Outstanding, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,656,683&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20191231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z0vDY4ja3755" style="width: 11%; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.31&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="text-align: right" title="Number of shares, Options granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;414,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="text-align: right" title="Weighted Avg. Exercise Price, Options granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.44&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zd3fg6nsMnVl" style="text-align: right" title="Number of shares, Options exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(19,748&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="text-align: right" title="Weighted Avg. Exercise Price, Options exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zJClW6EHXCrh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Options cancelled/forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(21,402&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Avg. Exercise Price, Options cancelled/forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12.77&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options outstanding
    - December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zPqFOLroBC48" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Outstanding, Ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,030,033&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z8NK6nsAbH8j" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, Ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.43&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Remaining Contractual Life, Options outstanding"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zfsq95D078Lf" title="Weighted Avg. Remaining Contractual Life, Options outstanding"&gt;5.72&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zVWtCkyG1Zj8" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,569&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zRo6HTPothl3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,908,849&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zZ4f98mY0SBk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Avg. Exercise Price, Exercisable Ending Balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.49&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Remaining Contractual Life, Options exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zA66gTouaDb6" title="Weighted Avg. Remaining Contractual Life, Options exercisable"&gt;5.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z0FlgEJo9dy" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,051&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options vested
    and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zQgK1tz9Qhu9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options vested and expected to vest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,918,298&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z3JdTHMSppok" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Avg. Exercise Price, Vested and expected to vest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.37&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Remaining Contractual Life, Options vested and expected to vest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zFknDYG1ZkKf" title="Weighted Avg. Remaining Contractual Life, Options vested and expected to vest"&gt;5.69&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pn3n3_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zWSdyEIPs5ti" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options vested and expected to vest"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,519&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-12-31_custom_StockOptionPlanOneMember"
      decimals="INF"
      unitRef="Shares">2656683</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31_custom_StockOptionPlanOneMember"
      decimals="INF"
      unitRef="USDPShares">5.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-01-012020-12-31_custom_StockOptionPlanOneMember"
      decimals="INF"
      unitRef="Shares">414500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_custom_StockOptionPlanOneMember"
      decimals="INF"
      unitRef="USDPShares">6.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-01-012020-12-31_custom_StockOptionPlanOneMember"
      decimals="INF"
      unitRef="Shares">19748</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_custom_StockOptionPlanOneMember"
      decimals="INF"
      unitRef="USDPShares">3.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2020-01-012020-12-31_custom_StockOptionPlanOneMember"
      decimals="INF"
      unitRef="Shares">21402</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-12-31_custom_StockOptionPlanOneMember"
      decimals="INF"
      unitRef="USDPShares">12.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_StockOptionPlanOneMember"
      decimals="INF"
      unitRef="Shares">3030033</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_StockOptionPlanOneMember"
      decimals="INF"
      unitRef="USDPShares">5.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_StockOptionPlanOneMember">P5Y8M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_StockOptionPlanOneMember"
      decimals="-3"
      unitRef="USD">5569000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_StockOptionPlanOneMember"
      decimals="INF"
      unitRef="Shares">1908849</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_StockOptionPlanOneMember"
      decimals="INF"
      unitRef="USDPShares">4.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2020-01-012020-12-31_custom_StockOptionPlanOneMember">P5Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_StockOptionPlanOneMember"
      decimals="-3"
      unitRef="USD">5051000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2020-12-31_custom_StockOptionPlanOneMember"
      decimals="INF"
      unitRef="Shares">2918298</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_StockOptionPlanOneMember"
      decimals="INF"
      unitRef="USDPShares">5.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2020-01-012020-12-31_custom_StockOptionPlanOneMember">P5Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="AsOf2020-12-31_custom_StockOptionPlanOneMember"
      decimals="-3"
      unitRef="USD">5519000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <HROW:ClosingPriceOfCommonStockPricePerShare
      contextRef="AsOf2020-12-31_custom_StockOptionPlanMember"
      decimals="INF"
      unitRef="USDPShares">6.86</HROW:ClosingPriceOfCommonStockPricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2020-01-012020-12-31_custom_StockOptionPlanMember"
      decimals="-3"
      unitRef="USD">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2020-01-012020-12-31_custom_StockOptionPlanMember_custom_EmployeesAndConsultantMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms contextRef="From2020-01-012020-12-31_custom_StockOptionPlanMember_custom_EmployeesAndConsultantMember">Vesting terms for
options granted to employees and consultants during the year ended December 31, 2020 generally included one of the following vesting
schedules: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and
the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over
three years; and 100% of the shares subject to the option vest on a quarterly basis in equal installments over three years. Certain
option awards provide for accelerated vesting if there is a change in control (as defined in the Plans) and in the event of certain
modifications to the option award agreement.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2015-07-302015-07-31_custom_BaumPerformanceOptionMember"
      decimals="INF"
      unitRef="Shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2015-07-302015-07-31_custom_BaumPerformanceOptionMember"
      decimals="INF"
      unitRef="USDPShares">7.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <HROW:AverageStockPrice
      contextRef="AsOf2015-07-31_custom_BaumPerformanceOptionMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">9</HROW:AverageStockPrice>
    <HROW:AverageStockPrice
      contextRef="AsOf2015-07-31_custom_BaumPerformanceOptionMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">15</HROW:AverageStockPrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2020-06-032020-06-04_custom_BaumPerformanceOptionMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2020-06-032020-06-04_custom_BaumPerformanceOptionMember"
      decimals="-3"
      unitRef="USD">1876000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-06-032020-06-04_custom_BaumPerformanceOptionMember"
      decimals="INF"
      unitRef="Percent">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-06-032020-06-04_custom_BaumPerformanceOptionMember"
      decimals="INF"
      unitRef="Percent">0.0040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <HROW:ForfeitureFactorPercentage
      contextRef="From2020-01-012020-12-31_custom_StockOptionPlanMember"
      decimals="INF"
      unitRef="Percent">0.10</HROW:ForfeitureFactorPercentage>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zo943NhcDZV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following
assumptions used for valuing options granted to employees:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B9_z3pOk5YOPvRg" style="display: none"&gt;SCHEDULE OF FAIR VALUE ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-average fair
    value of options granted&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_pii" style="width: 16%; text-align: right" title="Weighted-average fair value of options granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.86&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_pii" style="width: 16%; text-align: right" title="Weighted-average fair value of options granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.72&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected terms (in years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right" title="Expected terms (in years)"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MinimumMember_zznoJH9sHdXh" title="Expected terms (in years)"&gt;0.50&lt;/span&gt;
                                         - &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MaximumMember_zDD1q3hBnOw5" title="Expected terms (in years)"&gt;6.11&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MinimumMember_zFrHUthfhXij" title="Expected terms (in years)"&gt;5.07&lt;/span&gt;
                                         - &lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MaximumMember_ztBeixpcpXRi" title="Expected terms (in years)"&gt;7.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right" title="Expected volatility, maximum"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_uPercent_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zBN829DrQFaa" title="Expected volatility, minimum"&gt;67&lt;/span&gt;
                                         &#x2013; &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_uPercent_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zLCFHkowlUWh" title="Expected volatility, maximum"&gt;71&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_uPercent_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zxnFxkILIhF" title="Expected volatility, minimum"&gt;64&lt;/span&gt;
                                         - &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_uPercent_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zZ5w84ysMSQ8" title="Expected volatility, maximum"&gt;78&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right" title="Risk-free interest rate, maximum"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_uPercent_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zs1woI2aLU04" title="Risk-free interest rate, minimum"&gt;0.34&lt;/span&gt;
                                         &#x2013; &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_uPercent_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zwiOkXCUpV07" title="Risk-free interest rate, maximum"&gt;1.64&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_uPercent_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zZ5vHvMSgbuh" title="Risk-free interest rate, minimum"&gt;1.83&lt;/span&gt;
                                         &#x2013;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_uPercent_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_z8MC2kbKhaHl" title="Risk-free interest rate, maximum"&gt; 2.68&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zcfIFI2EDx7b" style="text-align: right" title="Dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1448"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zyXdXXDOsZLf" style="text-align: right" title="Dividend yield"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1450"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-12-31_custom_OptionsEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">3.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2019-01-012019-12-31_custom_OptionsEmployeesMember"
      decimals="INF"
      unitRef="USDPShares">3.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-012020-12-31_custom_OptionsEmployeesMember_srt_MinimumMember">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-012020-12-31_custom_OptionsEmployeesMember_srt_MaximumMember">P6Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-01-012019-12-31_custom_OptionsEmployeesMember_srt_MinimumMember">P5Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-01-012019-12-31_custom_OptionsEmployeesMember_srt_MaximumMember">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2020-01-012020-12-31_custom_OptionsEmployeesMember"
      decimals="INF"
      unitRef="Percent">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2020-01-012020-12-31_custom_OptionsEmployeesMember"
      decimals="INF"
      unitRef="Percent">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2019-01-012019-12-31_custom_OptionsEmployeesMember"
      decimals="INF"
      unitRef="Percent">0.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2019-01-012019-12-31_custom_OptionsEmployeesMember"
      decimals="INF"
      unitRef="Percent">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2020-01-012020-12-31_custom_OptionsEmployeesMember"
      decimals="INF"
      unitRef="Percent">0.0034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2020-01-012020-12-31_custom_OptionsEmployeesMember"
      decimals="INF"
      unitRef="Percent">0.0164</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2019-01-012019-12-31_custom_OptionsEmployeesMember"
      decimals="INF"
      unitRef="Percent">0.0183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2019-01-012019-12-31_custom_OptionsEmployeesMember"
      decimals="INF"
      unitRef="Percent">0.0268</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zTReyUQCrVXk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes information about stock options outstanding and exercisable at December 31, 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span&gt;&lt;span&gt;&lt;span id="xdx_8B6_zLHJLptFBOv1" style="display: none"&gt;SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Remaining&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contractual&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Range
    of Exercise Prices&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Life
    in Years&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 34%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Range of Exercise Prices, minimum"&gt;1.47&lt;/span&gt; - $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Range of Exercise Prices, maximum"&gt;2.60&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" style="width: 10%; text-align: right" title="Number of Options Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;770,440&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right" title="Weighted Average Remaining Contractual Life in Years"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zFeE8JzfPS8f" title="Weighted Average Remaining Contractual Life in Years"&gt;5.64&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" style="width: 10%; text-align: right" title="Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.06&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" style="width: 10%; text-align: right" title="Number Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;745,255&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" style="width: 10%; text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.06&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_ziiFjkcDC772" title="Range of Exercise Prices, minimum"&gt;3.04&lt;/span&gt; - $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Range of Exercise Prices, maximum"&gt;4.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" style="text-align: right" title="Number of Options Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;517,002&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right" title="Weighted Average Remaining Contractual Life in Years"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z9eakblqqQSc" title="Weighted Average Remaining Contractual Life in Years"&gt;5.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" style="text-align: right" title="Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.98&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;438,873&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" style="text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.98&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Range of Exercise Prices, minimum"&gt;5.49&lt;/span&gt; - $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Range of Exercise Prices, maximum"&gt;6.36&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" style="text-align: right" title="Number of Options Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;496,350&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right" title="Weighted Average Remaining Contractual Life in Years"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_ztoyYSnJsWBa" title="Weighted Average Remaining Contractual Life in Years"&gt;7.22&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" style="text-align: right" title="Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" style="text-align: right" title="Number Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;291,919&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" style="text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.13&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zBsCAhJkpYrl" title="Range of Exercise Prices, minimum"&gt;6.64&lt;/span&gt; - $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zRrw9dEctSpd" title="Range of Exercise Prices, maximum"&gt;8.99&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,246,241&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Remaining Contractual Life in Years"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zBhaXCRSQHqa" title="Weighted Average Remaining Contractual Life in Years"&gt;5.17&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.85&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;432,802&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8.09&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20200101__20201231_zTE4q6Dtgg96" title="Range of Exercise Prices, minimum"&gt;1.47&lt;/span&gt; - $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20200101__20201231_znbr9y4z6bkf" title="Range of Exercise Prices, maximum"&gt;8.99&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20201231_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,030,033&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Remaining Contractual Life in Years"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_z2pwY4UTeaQ" title="Weighted Average Remaining Contractual Life in Years"&gt;5.72&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20201231_pii" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.43&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20201231_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,908,849&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20201231_pii" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.49&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2020-01-012020-12-31_custom_RangeOneMember"
      decimals="INF"
      unitRef="USDPShares">1.47</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2020-01-012020-12-31_custom_RangeOneMember"
      decimals="INF"
      unitRef="USDPShares">2.60</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2020-12-31_custom_RangeOneMember"
      decimals="INF"
      unitRef="Shares">770440</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_RangeOneMember">P5Y7M20D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2020-12-31_custom_RangeOneMember"
      decimals="INF"
      unitRef="USDPShares">2.06</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2020-12-31_custom_RangeOneMember"
      decimals="INF"
      unitRef="Shares">745255</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2020-12-31_custom_RangeOneMember"
      decimals="INF"
      unitRef="USDPShares">2.06</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2020-01-012020-12-31_custom_RangeTwoMember"
      decimals="INF"
      unitRef="USDPShares">3.04</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2020-01-012020-12-31_custom_RangeTwoMember"
      decimals="INF"
      unitRef="USDPShares">4.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2020-12-31_custom_RangeTwoMember"
      decimals="INF"
      unitRef="Shares">517002</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_RangeTwoMember">P5Y9M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2020-12-31_custom_RangeTwoMember"
      decimals="INF"
      unitRef="USDPShares">3.98</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2020-12-31_custom_RangeTwoMember"
      decimals="INF"
      unitRef="Shares">438873</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2020-12-31_custom_RangeTwoMember"
      decimals="INF"
      unitRef="USDPShares">3.98</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2020-01-012020-12-31_custom_RangeThreeMember"
      decimals="INF"
      unitRef="USDPShares">5.49</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2020-01-012020-12-31_custom_RangeThreeMember"
      decimals="INF"
      unitRef="USDPShares">6.36</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2020-12-31_custom_RangeThreeMember"
      decimals="INF"
      unitRef="Shares">496350</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_RangeThreeMember">P7Y2M19D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2020-12-31_custom_RangeThreeMember"
      decimals="INF"
      unitRef="USDPShares">6.10</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2020-12-31_custom_RangeThreeMember"
      decimals="INF"
      unitRef="Shares">291919</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2020-12-31_custom_RangeThreeMember"
      decimals="INF"
      unitRef="USDPShares">6.13</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2020-01-012020-12-31_custom_RangeFourMember"
      decimals="INF"
      unitRef="USDPShares">6.64</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2020-01-012020-12-31_custom_RangeFourMember"
      decimals="INF"
      unitRef="USDPShares">8.99</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="AsOf2020-12-31_custom_RangeFourMember"
      decimals="INF"
      unitRef="Shares">1246241</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-012020-12-31_custom_RangeFourMember">P5Y2M1D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2020-12-31_custom_RangeFourMember"
      decimals="INF"
      unitRef="USDPShares">7.85</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="AsOf2020-12-31_custom_RangeFourMember"
      decimals="INF"
      unitRef="Shares">432802</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2020-12-31_custom_RangeFourMember"
      decimals="INF"
      unitRef="USDPShares">8.09</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="USDPShares">1.47</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="USDPShares">8.99</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">3030033</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2020-01-01to2020-12-31">P5Y8M19D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">5.43</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">1908849</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">4.49</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2020-12-31_custom_StockOptionPlanMember"
      decimals="-3"
      unitRef="USD">2794000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2020-01-012020-12-31_custom_StockOptionPlanMember">P3Y11M15D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-12-31_custom_StockOptionPlanMember"
      decimals="-3"
      unitRef="USD">1579000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-012019-12-31_custom_StockOptionPlanMember"
      decimals="-3"
      unitRef="USD">889000</us-gaap:ShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember"
      decimals="INF"
      unitRef="Shares">185000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember"
      decimals="-3"
      unitRef="USD">1139000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_BoardOfDirectorsMember"
      decimals="INF"
      unitRef="Shares">38860</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_BoardOfDirectorsMember"
      decimals="-3"
      unitRef="USD">300000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zSBp8HaToScg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
summary of the Company&#x2019;s RSU activity and related information for the year ended December 31, 2019 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B0_z1u7f4VdIQV6" style="display: none"&gt;SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    Average Grant&lt;br/&gt;
    Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs unvested - January
    1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlcKzm3Vy0E1" style="width: 16%; text-align: right" title="Number of RSUs unvested, Outstanding, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,275,680&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_c20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzKbZvFFjXSl" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.16&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Number of RSUs granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;223,860&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.43&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pii_di_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgf1GrYmPyZ1" style="text-align: right" title="Number of RSUs vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(87,610&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.42&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pii_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztvt0TjCez4h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs cancelled/forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1554"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs unvested
    at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAbV7bsMtMHk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs unvested, Outstanding, Ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,411,930&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zuEsuPx7Uaxl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value, Ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.76&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Grants
During the Year Ended December 31, 2020&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended December 31, 2020, &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pii" title="Shares issued of restricted common stock, shares"&gt;161,000&lt;/span&gt; RSUs with a fair market value of $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pn3n3" title="Fair value of restricted common stock issued"&gt;1,025&lt;/span&gt; were issued to certain employees; the RSUs vest
in full on the third anniversary of the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended December 31, 2020, the Company&#x2019;s board of directors were granted &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pii" title="Shares issued of restricted common stock, shares"&gt;90,524&lt;/span&gt; RSUs with a fair market value $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pn3n3" title="Fair value of restricted common stock issued"&gt;511&lt;/span&gt;
which vest on a quarterly basis, over a one-year term in equal installments, subject to the director&#x2019;s continued
service at the vesting date, but the issuance and delivery of these shares are deferred until the director resigns.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
summary of the Company&#x2019;s RSU activity and related information for the year ended December 31, 2020 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    Average Grant&lt;br/&gt;
    Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs unvested - January
    1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwsDwbtXgcOg" style="width: 16%; text-align: right" title="Number of RSUs unvested, Outstanding, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,411,930&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_c20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNNoOi66nuCk" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.76&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Number of RSUs granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;251,524&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pii_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7tVOnlN9F0l" style="text-align: right" title="Number of RSUs vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(61,945&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs vested"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.46&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs cancelled/forfeited"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1580"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs unvested
    at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgfUfvpFCBck" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs unvested, Outstanding, Ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,601,509&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCql18W0ey1i" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value, Ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.14&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2018-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">1275680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2018-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">2.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">223860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">6.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">87610</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2019-01-012019-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">3.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">1411930</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">2.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember"
      decimals="INF"
      unitRef="Shares">161000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember"
      decimals="-3"
      unitRef="USD">1025000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_BoardOfDirectorsMember"
      decimals="INF"
      unitRef="Shares">90524</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_BoardOfDirectorsMember"
      decimals="-3"
      unitRef="USD">511000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">1411930</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">2.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">251524</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">6.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">61945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">6.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">1601509</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">3.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2020-12-31_custom_UnvestedRSUMember"
      decimals="-3"
      unitRef="USD">1363000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2020-01-012020-12-31_custom_UnvestedRSUMember">P3Y1M20D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-12-31_custom_UnvestedRSUMember"
      decimals="-3"
      unitRef="USD">1167000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-012019-12-31_custom_UnvestedRSUMember"
      decimals="-3"
      unitRef="USD">879000</us-gaap:ShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2019-02-022019-02-28_custom_MayfieldPharmaceuticalsIncMember_custom_EllePharmaceuticalLLCMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-07-012019-07-31_custom_MayfieldPharmaceuticalsIncMember_custom_LicenseAgreementMember"
      decimals="INF"
      unitRef="Shares">300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-012019-12-31_custom_MayfieldPharmaceuticalsIncMember_us-gaap_RestrictedStockMember"
      decimals="-3"
      unitRef="USD">26000</us-gaap:ShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2019-01-012019-12-31_custom_MayfieldPharmaceuticalsIncMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">2450000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2019-01-012019-12-31_custom_MayfieldPharmaceuticalsIncMember_custom_MarkBaumCEOMember"
      decimals="INF"
      unitRef="Shares">725000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2019-01-012019-12-31_custom_MayfieldPharmaceuticalsIncMember_custom_AndrewBollCFOMember"
      decimals="INF"
      unitRef="Shares">362500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2020-01-012020-12-31_custom_MayfieldPharmaceuticalsIncMember_custom_EllePharmaceuticalLLCMember"
      decimals="INF"
      unitRef="Shares">650000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <HROW:AggregatePurchasePrice
      contextRef="From2020-01-012020-12-31_custom_MayfieldPharmaceuticalsIncMember_custom_EllePharmaceuticalLLCMember"
      decimals="INF"
      unitRef="USDPShares">1</HROW:AggregatePurchasePrice>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2020-01-012020-12-31_custom_MayfieldPharmaceuticalsIncMember_us-gaap_RestrictedStockMember_custom_ConsultantMember"
      decimals="INF"
      unitRef="Shares">500000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2020-01-012020-12-31_custom_MayfieldPharmaceuticalsIncMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">475000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-01-012020-12-31_custom_MayfieldPharmaceuticalsIncMember_us-gaap_RestrictedStockMember"
      decimals="-3"
      unitRef="USD">11000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-12-31_custom_MayfieldPharmaceuticalsIncMember"
      decimals="-3"
      unitRef="USD">20000</us-gaap:ShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2019-07-012019-07-31_custom_StowePharmaceuticalsIncMember_custom_LicenseAgreementMember"
      decimals="INF"
      unitRef="Shares">1750000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2020-01-012020-12-31_custom_VisionologyIncMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">2000000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-01-012020-12-31_custom_VisionologyIncMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">96</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2020-01-012020-12-31_custom_VisionologyIncMember_custom_MarkBaumCEOMember"
      decimals="INF"
      unitRef="Shares">700000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2020-01-012020-12-31_custom_VisionologyIncMember_custom_AndrewBollCFOMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_892_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ziHtVmVZ22Sj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company recorded stock-based compensation (including issuance of common stock for services and accrual for stock-based compensation)
related to equity instruments granted to employees, directors and consultants as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B9_zurPvjdWON1b" style="display: none"&gt;SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Employees &#x2013; selling,
    general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="width: 18%; text-align: right" title="Stock based compensation related to equity instruments granted to related parties"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,289&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20191231__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="width: 18%; text-align: right" title="Stock based compensation related to equity instruments granted to related parties"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,464&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Directors &#x2013; selling, general
    and administrative&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="text-align: right" title="Stock based compensation related to equity instruments granted to related parties"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;473&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20191231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="text-align: right" title="Stock based compensation related to equity instruments granted to related parties"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;300&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Consultants
    &#x2013; selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock based compensation related to equity instruments granted to related parties"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;96&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20191231__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock based compensation related to equity instruments granted to related parties"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;259&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation related to equity instruments granted to related parties"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,858&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation related to equity instruments granted to related parties"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-12-31_custom_EmployeesMember_custom_SellingGeneralAndAdministrativeMember"
      decimals="-3"
      unitRef="USD">2289000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-01-012019-12-31_custom_EmployeesMember_custom_SellingGeneralAndAdministrativeMember"
      decimals="-3"
      unitRef="USD">1464000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-12-31_srt_DirectorMember_custom_SellingGeneralAndAdministrativeMember"
      decimals="-3"
      unitRef="USD">473000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-01-012019-12-31_srt_DirectorMember_custom_SellingGeneralAndAdministrativeMember"
      decimals="-3"
      unitRef="USD">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-12-31_custom_ConsultantMember_custom_SellingGeneralAndAdministrativeMember"
      decimals="-3"
      unitRef="USD">96000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-01-012019-12-31_custom_ConsultantMember_custom_SellingGeneralAndAdministrativeMember"
      decimals="-3"
      unitRef="USD">259000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">2858000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">2023000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z3hRwpJQzkLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
summary of warrant activity during the year ended December 31, 2020 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B7_zofGrHQAUGX1" style="display: none"&gt;SCHEDULE OF WARRANTS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of Shares Subject to Warrants Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    Avg. Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants outstanding
    - January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pii_c20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zF3vPI1IecUi" style="width: 16%; text-align: right" title="Number of Shares Warrants Outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;780,386&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_pii_c20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z4zzbdsSTAqe" style="width: 16%; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, beginning balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.12&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="text-align: right" title="Number of Shares Warrants Outstanding, Granted"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1652"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="text-align: right" title="Number of Shares Warrants Outstanding, Exercised"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1654"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares Warrants Outstanding, Expired"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1656"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants outstanding
    and exercisable - December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iE_pii_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zE0fOT4bX2R2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Warrants Outstanding and Exercisable, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;780,386&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1_iE_pii_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zGy9Yf4BTV6d" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Outstanding and Exercisable, ending balance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.12&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average
    remaining contractual life of the outstanding warrants in years - December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average remaining contractual life of the outstanding warrants in years"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zPVuFE6Md383" title="Weighted average remaining contractual life of the outstanding warrants in years"&gt;3.53&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2019-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">780386</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <HROW:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1
      contextRef="AsOf2019-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">2.12</HROW:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1>
    <HROW:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">780386</HROW:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber>
    <HROW:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">2.12</HROW:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1>
    <HROW:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember">P3Y6M10D</HROW:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1>
    <HROW:ScheduleofWarrantsOutstandingAndExercisableTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_893_ecustom--ScheduleofWarrantsOutstandingAndExercisableTableTextBlock_zVJqdE4Kk2Ec" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;All
warrants outstanding as of December 31, 2020 are included in the following table:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B5_zdxFJYC54gQf" style="display: none"&gt;SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants
    Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants
    Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Warrant
    Series&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issue
    Date&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 25%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lender warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 12%; text-align: center" title="Issue Date"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_ecustom--WarrantsIssuanceDate_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zcIbfkNbtq0l" title="Issue Date"&gt;5/11/2015&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_pii" style="width: 12%; text-align: right" title="Warrants Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;125,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_pii" style="width: 11%; text-align: right" title="Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.79&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_pii" style="width: 12%; text-align: right" title="Warrants Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;125,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; width: 12%; text-align: center" title="Expiration Date"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_ecustom--WarrantsAndRightsOutstandingMaturityDates_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zASHVdbs6vjf" title="Expiration Date"&gt;5/11/2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Settlement warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center" title="Issue Date"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_ecustom--WarrantsIssuanceDate_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_zIgKPdGA5Qt3" title="Issue Date"&gt;8/16/2016&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_pii" style="text-align: right" title="Warrants Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;40,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_pii" style="text-align: right" title="Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_pii" style="text-align: right" title="Warrants Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;40,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center" title="Expiration Date"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_ecustom--WarrantsAndRightsOutstandingMaturityDates_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_zWTTPiDABE55" title="Expiration Date"&gt;8/16/2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lender warrants
    (see Note 12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt" title="Issue Date"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_ecustom--WarrantsIssuanceDate_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_zwjV334F6VCl" title="Issue Date"&gt;7/19/2017&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;615,386&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_pii" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.08&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;615,386&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt" title="Expiration Date"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_ecustom--WarrantsAndRightsOutstandingMaturityDates_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_zrt915HjDe64" title="Expiration Date"&gt;7/19/2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;780,386&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="padding-bottom: 2.5pt; text-align: right" title="Exercise Price"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.12&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Exercisable"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;780,386&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</HROW:ScheduleofWarrantsOutstandingAndExercisableTableTextBlock>
    <HROW:WarrantsIssuanceDate contextRef="From2020-01-012020-12-31_custom_LenderWarrantsMember">2015-05-11</HROW:WarrantsIssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2020-12-31_custom_LenderWarrantsMember"
      decimals="INF"
      unitRef="Shares">125000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-12-31_custom_LenderWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">1.79</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <HROW:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1
      contextRef="AsOf2020-12-31_custom_LenderWarrantsMember"
      decimals="INF"
      unitRef="Shares">125000</HROW:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1>
    <HROW:WarrantsAndRightsOutstandingMaturityDates contextRef="From2020-01-012020-12-31_custom_LenderWarrantsMember">2025-05-11</HROW:WarrantsAndRightsOutstandingMaturityDates>
    <HROW:WarrantsIssuanceDate contextRef="From2020-01-012020-12-31_custom_SettlementWarrantsMember">2016-08-16</HROW:WarrantsIssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2020-12-31_custom_SettlementWarrantsMember"
      decimals="INF"
      unitRef="Shares">40000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-12-31_custom_SettlementWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">3.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <HROW:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1
      contextRef="AsOf2020-12-31_custom_SettlementWarrantsMember"
      decimals="INF"
      unitRef="Shares">40000</HROW:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1>
    <HROW:WarrantsAndRightsOutstandingMaturityDates contextRef="From2020-01-012020-12-31_custom_SettlementWarrantsMember">2021-08-16</HROW:WarrantsAndRightsOutstandingMaturityDates>
    <HROW:WarrantsIssuanceDate contextRef="From2020-01-012020-12-31_custom_LenderWarrantsOneMember">2017-07-19</HROW:WarrantsIssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2020-12-31_custom_LenderWarrantsOneMember"
      decimals="INF"
      unitRef="Shares">615386</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-12-31_custom_LenderWarrantsOneMember"
      decimals="INF"
      unitRef="USDPShares">2.08</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <HROW:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1
      contextRef="AsOf2020-12-31_custom_LenderWarrantsOneMember"
      decimals="INF"
      unitRef="Shares">615386</HROW:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1>
    <HROW:WarrantsAndRightsOutstandingMaturityDates contextRef="From2020-01-012020-12-31_custom_LenderWarrantsOneMember">2024-07-19</HROW:WarrantsAndRightsOutstandingMaturityDates>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">780386</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">2.12</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <HROW:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">780386</HROW:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_801_eus-gaap--IncomeTaxDisclosureTextBlock_zjLNQPii2Bub" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
15. &lt;span id="xdx_82E_zO5a2A3Km4Oh"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zlEm43HAYNHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company is subject to taxation in the United States, California, Florida, Georgia, Illinois, New Jersey, New York, Tennessee and
Wisconsin. The Company&#x2019;s income tax provision consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B7_zId0N1D53NX" style="display: none"&gt;SCHEDULE OF PROVISION FOR INCOME TAXES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--CurrentFederalTaxExpenseBenefit_c20200101__20201231_pn3n3" style="text-align: right" title="Current: Federal"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1706"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--CurrentFederalTaxExpenseBenefit_c20190101__20191231_pn3n3" style="text-align: right" title="Current: Federal"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1708"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Current: State"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Current: State"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total current
    expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"/&gt;&lt;td id="xdx_989_eus-gaap--CurrentIncomeTaxExpenseBenefit_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total current"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"/&gt;&lt;td id="xdx_98A_eus-gaap--CurrentIncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total current"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"/&gt;&lt;td id="xdx_98C_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20200101__20201231_pn3n3" style="text-align: right" title="Deferred: Federal"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(771&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"/&gt;&lt;td id="xdx_98D_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" style="text-align: right" title="Deferred: Federal"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;669&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_c20200101__20201231_pn3n3" style="text-align: right" title="Deferred: State"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;138&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" style="text-align: right" title="Deferred: State"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(148&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change
    in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--DeferredIncomeChangeInValuationAllowance_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Deferred: Change in valuation allowance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;633&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--DeferredIncomeChangeInValuationAllowance_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Deferred: Change in valuation allowance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(521&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total deferred
    expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DeferredIncomeTaxExpenseBenefit_pn3n3_c20200101__20201231_zqMusmwdxIfk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total deferred"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1730"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DeferredIncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total deferred"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1732"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax provision (benefit)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax provision (benefit)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AE_znppQNdXsvyh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z9LbdBssC8ji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
reconciliation of income taxes computed by applying the statutory U.S. income tax rate to the Company&#x2019;s loss before income
tax provision to the income tax provision is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BD_zuFkQGm0bTbh" style="display: none"&gt;SCHEDULE OF INCOME TAX RECONCILIATION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. federal statutory tax
    rate&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercent_c20200101__20201231_zP6vtwy0Dy3c" style="width: 16%; text-align: right" title="U.S. federal statutory tax rate"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercent_c20190101__20191231_z1PJBplz43el" style="width: 16%; text-align: right" title="U.S. federal statutory tax rate"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State tax benefit, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPercent_c20200101__20201231_z9diswB8uWZ7" style="text-align: right" title="State tax benefit, net"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPercent_c20190101__20191231_zvEQ9o1W5937" style="text-align: right" title="State tax benefit, net"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(6.73&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock-based&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;
    compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends_pii_dp_uPercent_c20200101__20201231_zpefx0bFnuT5" style="text-align: right" title="Employee stock-based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.52&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends_pii_dp_uPercent_c20190101__20191231_zwJmbjxVw1O8" style="text-align: right" title="Employee stock-based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pii_dp_uPercent_c20200101__20201231_ze9Ok1KYy7a4" style="text-align: right" title="Other"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.38&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pii_dp_uPercent_c20190101__20191231_zaxdfNR43jV5" style="text-align: right" title="Other"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(358.67&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pii_dp_uPercent_c20200101__20201231_zUnkeblpXJOc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Valuation allowance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(26.14&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pii_dp_uPercent_c20190101__20191231_zZO9ilJ98515" style="border-bottom: Black 1.5pt solid; text-align: right" title="Valuation allowance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;334.57&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Effective income
    tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pii_dp_uPercent_c20200101__20201231_zyVR8plk3ERl" style="border-bottom: Black 2.5pt double; text-align: right" title="Effective income tax rate"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.11&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pii_dp_uPercent_c20190101__20191231_zibwEDGEb0Qg" style="border-bottom: Black 2.5pt double; text-align: right" title="Effective income tax rate"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(6.73&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A6_zYlLjCn3Moqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zY7wnvB540ob" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred
tax assets and liabilities reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities
for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#x2019;s deferred
tax assets are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B5_zwireou6UZee" style="display: none"&gt;SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20201231_zXNF58WN0wGa" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20191231_znibe2891vBa" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax assets (liabilities):&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTANzoCx_zrrz0DQDU3t" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;NOL&#x2019;s&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,685&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,827&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization_iI_pn3n3_maDTANzoCx_zCj3ad30Esyj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Depreciation and
    amortization&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;528&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;224&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iI_pn3n3_maDTANzoCx_zbGbREmoj8vf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;413&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;641&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTANzoCx_zYPT1JuSDvs6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development
    credits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;596&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;596&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTANzoCx_zqOYVTSFl1uc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred stock-based
    compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,024&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,533&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_ecustom--IncomeTaxBasisDifferenceInRelatedParty_iNI_pn3n3_di_maDTANzoCx_zkseA74WXrj7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basis difference
    in Melt&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(398&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,119&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--IncomeTaxBasisDifferenceInRelatedPartyOne_iNI_pn3n3_di_maDTANzoCx_z97k6sFu57m7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basis difference
    in Surface&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(502&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,185&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--IncomeTaxBasisDifferenceInRelatedPartyTwo_iNI_pn3n3_di_maDTANzoCx_zaCsNCEpnZC9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basis difference
    in Eton&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(8,626&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(7,528&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsTaxDeferredExpenseCapitalLosses_iI_pn3n3_maDTANzoCx_z55YDmrGFiw" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Capital losses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;63&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;63&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_pn3n3_di_msDTANzoCx_zv0QzbWLAS5a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Park stock purchase
    identifiable intangibles&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(274&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(270&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--DeferredTaxAssetsTaxDeferredExpenseLimitations_iI_pn3n3_maDTANzoCx_zZ3Wl9pY4vZ1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Limitation under
    163(j)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;195&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;299&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_ecustom--DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability_iI_pn3n3_msDTANzoCx_zgbdDB0ObhZ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;ASC 842 lease
    liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,192&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,082&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_ecustom--DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset_iNI_pn3n3_di_maDTANzoCx_zO2zs3B6UGPh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;ASC
    842 ROU asset&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,061&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,959&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_ziQ8saIOP4Z9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,835&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,202&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzB4N_zemVr1oMj36i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Valuation
    allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(15,835&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(15,202&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_zgGZ102KFEkj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1811"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1812"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AC_zVLQyOGlHLp" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Realization
of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the
net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by $&lt;span id="xdx_903_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20200101__20201231_pn3n3" title="Deferred tax asset valuation allowance"&gt;633&lt;/span&gt; and
decreased by $&lt;span id="xdx_900_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20190101__20191231_pn3n3" title="Deferred tax asset valuation allowance"&gt;521&lt;/span&gt; during 2020 and 2019, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; background-color: white"&gt;At
December 31, 2020, the Company has federal and state net operating loss carryforwards of approximately $&lt;span id="xdx_909_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_c20201231_pn3n3" title="Federal net operating loss carryforwards"&gt;62,856&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_c20201231_pn3n3" title="State net operating loss carryforwards"&gt;60,908&lt;/span&gt; which
will begin to expire in &lt;span title="Federal research and development tax credits expiration date"&gt;&lt;span id="xdx_901_ecustom--StateNetOperatingLossExpirationDate_c20200101__20201231" title="State net operating loss expiration date"&gt;2027&lt;/span&gt;&lt;/span&gt;, unless previously utilized, and will begin to expire for state purposes in 2026. &lt;span id="xdx_906_ecustom--FederalNetOperatingLossCarryforwardDescription_c20200101__20201231" title="Federal net operating loss carryforward description"&gt;In addition, the
Company has federal net operating loss carryforwards of $3,865 generated after 2017 that can be carried over indefinitely and
may be used to offset up to&#160;80% of federal taxable income.&lt;/span&gt; At December&#160;31, 2020, the Company has federal and state research
and development tax credits of approximately $&lt;span id="xdx_90D_ecustom--FederalResearchAndDevelopmentTaxCredits_c20200101__20201231_pn3n3" title="Federal research and development tax credits"&gt;354&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--StateResearchAndDevelopmentTaxCredits_c20200101__20201231_pn3n3" title="State research and development tax credits"&gt;305&lt;/span&gt;, respectively. The federal research tax credit begins to expire in
&lt;span id="xdx_907_ecustom--FederalResearchAndDevelopmentTaxCreditsExpirationDate_c20200101__20201231" title="Federal research and development tax credits expiration date"&gt;2026&lt;/span&gt;, unless previously utilized, and the state research and development  tax credit has no expiration date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Utilization
of the net operating loss (&#x201c;NOL&#x201d;) and research and development (&#x201c;R&amp;amp;D&#x201d;) carryforwards maybe subject
to a substantial annual limitation due to ownership change limitations that might have occurred or that could occur in the future,
as required by Section&#160;382 of the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;), as well as similar
state and foreign provisions. These ownership changes may limit the amount of NOL and R&amp;amp;D credit carryforwards that can be
utilized annually to offset future taxable income and tax, respectively. In general, an &#x201c;ownership change&#x201d; as defined
by Section&#160;382 of the Code results from a transaction or series of transactions over a three-year period resulting in an
ownership change of more than 50&#160;percentage points of the outstanding stock of a company by certain stockholders or public
groups. Since the Company&#x2019;s formation, the Company has raised capital through the issuance of capital stock on several occasions
which, combined with the purchasing stockholders&#x2019; subsequent disposition of those shares, may have resulted in such an ownership
change, or could result in an ownership change in the future upon subsequent disposition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company has not completed a study to assess whether an ownership change or changes have occurred. If the Company has experienced
an ownership change, utilization of the NOL or R&amp;amp;D credit carryforwards would be subject to an annual limitation under Section&#160;382
of the Code, which is determined by first multiplying the value of the Company&#x2019;s stock at the time of the ownership change
by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation
may result in expiration of a portion of the NOL or R&amp;amp;D credit carryforwards before utilization. Further, until a study is
complete and any limitation is known, no amounts are being considered as an uncertain tax position or disclosed as an unrecognized
tax benefit. Any carryforwards that will expire prior to utilization as a result of such limitations will be removed from deferred
tax assets with a corresponding reduction of the valuation allowance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of December 31, 2020 and 2019, there were no unrecognized tax benefits included in the consolidated balance sheets that would,
if recognized, affect the effective tax rate. The Company&#x2019;s practice is to recognize interest and/or penalties related to
income tax matters in income tax expense. The Company had no accrual for interest or penalties in its consolidated balance sheets
at December 31, 2020 and 2019, and has not recognized interest and/or penalties in the consolidated statements of operations for
the years ended December 31, 2020 and 2019. The Company&#x2019;s tax years since 2000 may be subject to examination by the federal
and state tax authorities due to the carryforward of unutilized net operating losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_890_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zlEm43HAYNHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company is subject to taxation in the United States, California, Florida, Georgia, Illinois, New Jersey, New York, Tennessee and
Wisconsin. The Company&#x2019;s income tax provision consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B7_zId0N1D53NX" style="display: none"&gt;SCHEDULE OF PROVISION FOR INCOME TAXES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--CurrentFederalTaxExpenseBenefit_c20200101__20201231_pn3n3" style="text-align: right" title="Current: Federal"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1706"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--CurrentFederalTaxExpenseBenefit_c20190101__20191231_pn3n3" style="text-align: right" title="Current: Federal"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1708"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Current: State"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Current: State"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total current
    expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"/&gt;&lt;td id="xdx_989_eus-gaap--CurrentIncomeTaxExpenseBenefit_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total current"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"/&gt;&lt;td id="xdx_98A_eus-gaap--CurrentIncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total current"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"/&gt;&lt;td id="xdx_98C_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20200101__20201231_pn3n3" style="text-align: right" title="Deferred: Federal"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(771&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"/&gt;&lt;td id="xdx_98D_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" style="text-align: right" title="Deferred: Federal"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;669&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_c20200101__20201231_pn3n3" style="text-align: right" title="Deferred: State"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;138&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" style="text-align: right" title="Deferred: State"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(148&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Change
    in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--DeferredIncomeChangeInValuationAllowance_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Deferred: Change in valuation allowance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;633&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--DeferredIncomeChangeInValuationAllowance_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Deferred: Change in valuation allowance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(521&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total deferred
    expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DeferredIncomeTaxExpenseBenefit_pn3n3_c20200101__20201231_zqMusmwdxIfk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total deferred"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1730"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DeferredIncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total deferred"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1732"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax provision (benefit)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--IncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax provision (benefit)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">4000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">8000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">4000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">8000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">-771000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">669000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">138000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-148000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <HROW:DeferredIncomeChangeInValuationAllowance
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">633000</HROW:DeferredIncomeChangeInValuationAllowance>
    <HROW:DeferredIncomeChangeInValuationAllowance
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">-521000</HROW:DeferredIncomeChangeInValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">4000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">8000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z9LbdBssC8ji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
reconciliation of income taxes computed by applying the statutory U.S. income tax rate to the Company&#x2019;s loss before income
tax provision to the income tax provision is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BD_zuFkQGm0bTbh" style="display: none"&gt;SCHEDULE OF INCOME TAX RECONCILIATION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S. federal statutory tax
    rate&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercent_c20200101__20201231_zP6vtwy0Dy3c" style="width: 16%; text-align: right" title="U.S. federal statutory tax rate"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercent_c20190101__20191231_z1PJBplz43el" style="width: 16%; text-align: right" title="U.S. federal statutory tax rate"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;State tax benefit, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPercent_c20200101__20201231_z9diswB8uWZ7" style="text-align: right" title="State tax benefit, net"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPercent_c20190101__20191231_zvEQ9o1W5937" style="text-align: right" title="State tax benefit, net"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(6.73&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock-based&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;
    compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends_pii_dp_uPercent_c20200101__20201231_zpefx0bFnuT5" style="text-align: right" title="Employee stock-based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.52&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends_pii_dp_uPercent_c20190101__20191231_zwJmbjxVw1O8" style="text-align: right" title="Employee stock-based compensation"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pii_dp_uPercent_c20200101__20201231_ze9Ok1KYy7a4" style="text-align: right" title="Other"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.38&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pii_dp_uPercent_c20190101__20191231_zaxdfNR43jV5" style="text-align: right" title="Other"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(358.67&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pii_dp_uPercent_c20200101__20201231_zUnkeblpXJOc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Valuation allowance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(26.14&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pii_dp_uPercent_c20190101__20191231_zZO9ilJ98515" style="border-bottom: Black 1.5pt solid; text-align: right" title="Valuation allowance"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;334.57&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Effective income
    tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pii_dp_uPercent_c20200101__20201231_zyVR8plk3ERl" style="border-bottom: Black 2.5pt double; text-align: right" title="Effective income tax rate"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.11&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pii_dp_uPercent_c20190101__20191231_zibwEDGEb0Qg" style="border-bottom: Black 2.5pt double; text-align: right" title="Effective income tax rate"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(6.73&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Percent">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="Percent">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Percent">-0.0011</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="Percent">-0.0673</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Percent">0.0552</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="Percent">0.0310</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Percent">-0.0038</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="Percent">-3.5867</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Percent">-0.2614</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="Percent">3.3457</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Percent">-0.0011</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="Percent">-0.0673</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zY7wnvB540ob" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred
tax assets and liabilities reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities
for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#x2019;s deferred
tax assets are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B5_zwireou6UZee" style="display: none"&gt;SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
&lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20201231_zXNF58WN0wGa" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20191231_znibe2891vBa" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax assets (liabilities):&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTANzoCx_zrrz0DQDU3t" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;NOL&#x2019;s&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,685&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,827&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization_iI_pn3n3_maDTANzoCx_zCj3ad30Esyj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Depreciation and
    amortization&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;528&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;224&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iI_pn3n3_maDTANzoCx_zbGbREmoj8vf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;413&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;641&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTANzoCx_zYPT1JuSDvs6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development
    credits&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;596&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;596&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTANzoCx_zqOYVTSFl1uc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred stock-based
    compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,024&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,533&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_ecustom--IncomeTaxBasisDifferenceInRelatedParty_iNI_pn3n3_di_maDTANzoCx_zkseA74WXrj7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basis difference
    in Melt&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(398&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,119&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--IncomeTaxBasisDifferenceInRelatedPartyOne_iNI_pn3n3_di_maDTANzoCx_z97k6sFu57m7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basis difference
    in Surface&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(502&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,185&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--IncomeTaxBasisDifferenceInRelatedPartyTwo_iNI_pn3n3_di_maDTANzoCx_zaCsNCEpnZC9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basis difference
    in Eton&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(8,626&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(7,528&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_ecustom--DeferredTaxAssetsTaxDeferredExpenseCapitalLosses_iI_pn3n3_maDTANzoCx_z55YDmrGFiw" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Capital losses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;63&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;63&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_pn3n3_di_msDTANzoCx_zv0QzbWLAS5a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Park stock purchase
    identifiable intangibles&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(274&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(270&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--DeferredTaxAssetsTaxDeferredExpenseLimitations_iI_pn3n3_maDTANzoCx_zZ3Wl9pY4vZ1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Limitation under
    163(j)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;195&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;299&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_ecustom--DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability_iI_pn3n3_msDTANzoCx_zgbdDB0ObhZ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;ASC 842 lease
    liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,192&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,082&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_ecustom--DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset_iNI_pn3n3_di_maDTANzoCx_zO2zs3B6UGPh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;ASC
    842 ROU asset&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,061&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,959&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_ziQ8saIOP4Z9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,835&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,202&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzB4N_zemVr1oMj36i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Valuation
    allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(15,835&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(15,202&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_zgGZ102KFEkj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1811"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1812"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">19685000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">19827000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <HROW:DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">528000</HROW:DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization>
    <HROW:DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">224000</HROW:DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">413000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">641000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">596000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">596000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">4024000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">3533000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <HROW:IncomeTaxBasisDifferenceInRelatedParty contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">398000</HROW:IncomeTaxBasisDifferenceInRelatedParty>
    <HROW:IncomeTaxBasisDifferenceInRelatedParty contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">1119000</HROW:IncomeTaxBasisDifferenceInRelatedParty>
    <HROW:IncomeTaxBasisDifferenceInRelatedPartyOne contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">502000</HROW:IncomeTaxBasisDifferenceInRelatedPartyOne>
    <HROW:IncomeTaxBasisDifferenceInRelatedPartyOne contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">1185000</HROW:IncomeTaxBasisDifferenceInRelatedPartyOne>
    <HROW:IncomeTaxBasisDifferenceInRelatedPartyTwo contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">8626000</HROW:IncomeTaxBasisDifferenceInRelatedPartyTwo>
    <HROW:IncomeTaxBasisDifferenceInRelatedPartyTwo contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">7528000</HROW:IncomeTaxBasisDifferenceInRelatedPartyTwo>
    <HROW:DeferredTaxAssetsTaxDeferredExpenseCapitalLosses contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">63000</HROW:DeferredTaxAssetsTaxDeferredExpenseCapitalLosses>
    <HROW:DeferredTaxAssetsTaxDeferredExpenseCapitalLosses contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">63000</HROW:DeferredTaxAssetsTaxDeferredExpenseCapitalLosses>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">274000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">270000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <HROW:DeferredTaxAssetsTaxDeferredExpenseLimitations contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">195000</HROW:DeferredTaxAssetsTaxDeferredExpenseLimitations>
    <HROW:DeferredTaxAssetsTaxDeferredExpenseLimitations contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">299000</HROW:DeferredTaxAssetsTaxDeferredExpenseLimitations>
    <HROW:DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">2192000</HROW:DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability>
    <HROW:DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">2082000</HROW:DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability>
    <HROW:DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">2061000</HROW:DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset>
    <HROW:DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">1959000</HROW:DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">15835000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">15202000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">15835000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">15202000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">633000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">521000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">62856000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">60908000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <HROW:StateNetOperatingLossExpirationDate contextRef="From2020-01-01to2020-12-31">2027</HROW:StateNetOperatingLossExpirationDate>
    <HROW:FederalNetOperatingLossCarryforwardDescription contextRef="From2020-01-01to2020-12-31">In addition, the
Company has federal net operating loss carryforwards of $3,865 generated after 2017 that can be carried over indefinitely and
may be used to offset up to&#160;80% of federal taxable income.</HROW:FederalNetOperatingLossCarryforwardDescription>
    <HROW:FederalResearchAndDevelopmentTaxCredits
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">354000</HROW:FederalResearchAndDevelopmentTaxCredits>
    <HROW:StateResearchAndDevelopmentTaxCredits
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">305000</HROW:StateResearchAndDevelopmentTaxCredits>
    <HROW:FederalResearchAndDevelopmentTaxCreditsExpirationDate contextRef="From2020-01-01to2020-12-31">2026</HROW:FederalResearchAndDevelopmentTaxCreditsExpirationDate>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_80F_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_zbbRN5HtuLa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
16. &lt;span id="xdx_825_zcTJ6Iizbmz7"&gt;EMPLOYEE SAVINGS PLAN&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company has established an employee savings plan pursuant to Section 401(k) of the Internal Revenue Code, effective January 1,
2014. The plan allows participating employees to deposit into tax deferred investment accounts up to &lt;span id="xdx_907_ecustom--PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount_pii_dp_uPercent_c20200101__20201231_zXnLyOPTysch" title="Percentage of salary deposits in tax deferred investment account"&gt;100%&lt;/span&gt; of their salary, subject
to annual limits. The Company makes certain matching contributions to the plan in amounts up to &lt;span id="xdx_903_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_pii_dp_uPercent_c20200101__20201231_zkcDLxUvmHNe" title="Percentage of contributions made by the company"&gt;4%&lt;/span&gt; of the participants&#x2019;
annual cash compensation, subject to annual limits. The Company contributed approximately $&lt;span id="xdx_901_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20200101__20201231_pn3n3" title="Contributions by the company"&gt;272&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20190101__20191231_pn3n3" title="Contributions by the company"&gt;312 &lt;/span&gt;to the plan during the
years ended December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <HROW:PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Percent">1</HROW:PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Percent">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">272000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">312000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zisERq8VLvB1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
17. &lt;span id="xdx_82B_z1xOJhmiRCyh"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Legal&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Dr.
Sobol &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
December 2016, Louis L. Sobol, M.D. (&#x201c;Sobol&#x201d;) filed a lawsuit in the U.S. District Court for the Eastern District
of Michigan, Southern Division against the Company, asserting claims on behalf of himself and an as-yet-uncertified class of consumers.
The claims allege violations under the Telephone Consumer Protection Act, 47 U.S.C. &#xa7; 227 via the Company&#x2019;s alleged
transmittal of advertisements to its clients via facsimile. The Court approved the parties&#x2019; proposed settlement agreement
in the spring of 2019. During the year ended December 31, 2018, the Company accrued $&lt;span id="xdx_90F_eus-gaap--LossContingencyAccrualAtCarryingValue_c20181231__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_pn3n3" title="Accrued damages"&gt;640&lt;/span&gt; for expected damages related to this
matter and the proposed settlement amount. As a result of the low claim rate of approximately &lt;span id="xdx_90B_ecustom--DamagesLowClaimRatePercentage_pii_dp_uPercent_c20180101__20181231__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zYgxfZXJkVP4" title="Damages low claim rate, percentage"&gt;1.4%&lt;/span&gt;, the Company&#x2019;s total
damages were $&lt;span id="xdx_901_eus-gaap--LossContingencyDamagesPaidValue_c20191002__20191031__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_pn3n3" title="Litigation amount paid"&gt;571&lt;/span&gt;, which was paid in October 2019. This formally resolved all known disputes between the parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Allergan
USA&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
September 2017, Allergan USA, Inc. (&#x201c;Allergan&#x201d;) filed a lawsuit in the U.S. District Court for the Central District
of California against the Company, primarily claiming violations under the federal Lanham Act and California&#x2019;s Sherman Act.
The Court granted in part and denied in part each parties&#x2019; motions for summary judgement, resolving all issues except for
whether Allergan was entitled to damages related to the Company&#x2019;s purported Lanham Act violations. The parties went to trial
in May 2019 to litigate damages related to the Lanham Act, and a jury found the Company liable for only $&lt;span id="xdx_901_eus-gaap--LossContingencyDamagesAwardedValue_c20190501__20190531__dei--LegalEntityAxis__custom--AllerganUSAIncMember_pn3n3" title="Lost profit damages"&gt;49&lt;/span&gt; in lost profit damages,
which was accrued as an expense during the year ended December 31, 2019 (see Note 11). In July 2019, the Court entered a permanent
injunction, the scope of which is limited to compounded drugs prepared in, dispensed from within, or shipped to the state of California.
The injunction requires the Company to: (1) only dispense drugs from a 503(a) facility with a &#x201c;Valid Prescription Order&#x201d;;
(2) abide by the FDA&#x2019;s anticipatory compounding guidelines; and (3) only use bulk drug substances identified on a list established
by the Secretary of Health and Human Services or FDA&#x2019;s interim &#x201c;Category 1&#x201d; list. The Company believes it was
already in compliance with the order, prior to the injunction being ordered. On October 2, 2019, Allergan and the Company filed
a joint stipulation to voluntarily dismiss each parties&#x2019; respective pending appeals arising out of the lawsuit. No economic
consideration was exchanged between the parties related to the filing of the joint stipulation. This formally resolved all known
disputes between the parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;California
Board of Pharmacy&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
March 2018, the California Board of Pharmacy filed an accusation against Park related to a compounded formulation the Company
believes was legally dispensed and was, without its knowledge, inappropriately administered to a patient unknown to Park, by the
prescribing healthcare professional. Park filed a response to the accusation and requested a formal hearing. In April 2019, Park
agreed to, and the California State Board of Pharmacy approved terms of a settlement agreement (the &#x201c;Settlement Agreement&#x201d;)
that became effective on May 29, 2019. Pursuant to the terms of the Settlement Agreement, Park was required to, and did, surrender
its California pharmacy license by August 27, 2019. This formally resolved all known disputes between the parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Novel
Drug Solutions et al.&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;In
April 2018, Novel Drug Solutions, LLC and Eyecare Northwest, PA (collectively &#x201c;NDS&#x201d;) filed a lawsuit against the Company
in the U.S. District Court of Delaware asserting claims for breach of contract. The claims stem from an asset purchase agreement
between the Company and NDS entered into in 2013. In July 2019, NDS filed a second amended complaint which added a claim related
to its purported termination of the APA. In October 2019, NDS voluntarily dismissed all claims related to breach of contract,
leaving only claims related to the scope of the post-termination obligations to be litigated. On October 29, 2020, at a hearing
on the various dispositive motions before it, the Court found that there were triable issues of fact and reopened discovery for
limited purposes. NDS is seeking unspecified damages, interest, attorney&#x2019;s fees and other costs. The Company believes the
claims are meritless and has previously and will continue to dispute all claims asserted against it and intends to vigorously
defend against these allegations. Nonetheless, the Company cannot predict the eventual outcome of this litigation and it could
result in substantial costs, losses and a diversion of management&#x2019;s resources and attention, which could harm the Company&#x2019;s
business and the value of its common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Product
and Professional Liability&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Product
and professional liability litigation represents an inherent risk to all firms in the pharmaceutical and pharmacy industry. We
utilize traditional third-party insurance policies with regard to our product and professional liability claims. Such insurance
coverage at any given time reflects current market conditions, including cost and availability, when the policy is written.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;John
Erick et al.&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
January 2018, John Erick and Deborah Ferrell, successors-in-interest and heirs of Jade Erick, (collectively &#x201c;Erick&#x201d;)
filed a lawsuit in the San Diego County Superior against Kim Kelly, ND, MPH asserting claims related to the death of Jade Erick.
In April 2018, Erick filed an amendment to the lawsuit, naming the Company as a co-defendant. In September 2018, co-defendant
Dr. Kelly filed a cross-complaint against the Company and various entities affiliated with Spectrum Laboratory Products, Inc.,
Spectrum Chemical Manufacturing Corp. and Spectrum Pharmacy Products, Inc. (collectively &#x201c;Spectrum&#x201d;). The cross-complaint
seeks indemnity and contribution from the Company and Spectrum. The Company answered the claims filed by Dr. Kelly in October
2018. The case is currently in the discovery phase. Erick is seeking unspecified damages, interest, attorney&#x2019;s fees and
other costs. The Company believes the claims are meritless and has previously and will continue to dispute all claims asserted
against it and intends to vigorously defend against these allegations. Nonetheless, the Company cannot predict the eventual outcome
of this litigation, it could result in substantial costs, losses and a diversion of management&#x2019;s resources and attention,
which could harm the Company&#x2019;s business and the value of its common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Anna
Sue Gaukel et al.&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
June 2019, Anna Sue Gaukel and Lawrence Gaukel served the Company with a lawsuit filed in state court in Idaho against Imprimis
Pharmaceuticals, Inc. asserting class action allegations and product liability claims related to Mrs. Gaukel&#x2019;s doctor&#x2019;s
use of a compounded drug injection in each of her eyes. In June 2019, the Company removed the case to Federal Court and subsequently
answered the complaint. On January 24, 2019, the plaintiffs and the Company filed a joint stipulation, and the case was dismissed
with prejudice. No economic consideration was exchanged between the parties related to the filing of the joint stipulation. This
formally resolved all known disputes between the parties as connected to this matter.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;General
and Other&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
the ordinary course of business, the Company may face various claims brought by third parties and it may, from time to time, make
claims or take legal actions to assert its rights, including intellectual property disputes, contractual disputes and other commercial
disputes. Any of these claims could subject the Company to litigation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Indemnities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
addition to the indemnification provisions contained in the Company&#x2019;s charter documents, the Company generally enters into
separate indemnification agreements with each of the Company&#x2019;s directors and officers. These agreements require the Company,
among other things, to indemnify the director or officer against specified expenses and liabilities, such as attorneys&#x2019;
fees, judgments, fines and settlements, paid by the individual in connection with any action, suit or proceeding arising out of
the individual&#x2019;s status or service as the Company&#x2019;s director or officer, other than liabilities arising from willful
misconduct or conduct that is knowingly fraudulent or deliberately dishonest, and to advance expenses incurred by the individual
in connection with any proceeding against the individual with respect to which the individual may be entitled to indemnification
by the Company. The Company also indemnifies its lessors in connection with its facility leases for certain claims arising from
the use of the facilities. These indemnities do not provide for any limitation of the maximum potential future payments the Company
could be obligated to make. Historically, the Company has not incurred any payments for these obligations and, therefore, no liabilities
have been recorded for these indemnities in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Sales
and Marketing Agreements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company has entered various sales and marketing agreements with certain organizations, to provide sales and marketing representation
services to ImprimisRx in select geographies in the U.S., in connection with the Company&#x2019;s ophthalmic compounded formulations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Under
the terms of the sales and marketing agreements, the Company is required to make commission payments generally equal to &lt;span id="xdx_90A_ecustom--CommissionPaymentsPercentage_c20170101__20191231__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember__srt--RangeAxis__srt--MinimumMember_pii" title="Commission payments, percentage"&gt;10%&lt;/span&gt; to
&lt;span id="xdx_908_ecustom--CommissionPaymentsPercentage_c20170101__20191231__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember__srt--RangeAxis__srt--MaximumMember_pii" title="Commission payments, percentage"&gt;14%&lt;/span&gt; of net sales for products above and beyond the initial existing sales amounts. In addition, the Company is required to make
periodic milestone payments to certain organizations in shares of the Company&#x2019;s restricted common stock if net sales in
the assigned territory reach certain future levels by the end of their terms, as applicable. The Company accrued and recorded
in additional paid in capital $&lt;span id="xdx_908_ecustom--AdditionalPaidInCapitalAndShareBasedPayments_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_pn3n3" title="Additional paid in capital and stock based payments"&gt;83&lt;/span&gt; and $&lt;span id="xdx_909_ecustom--AdditionalPaidInCapitalAndShareBasedPayments_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_pn3n3" title="Additional paid in capital and stock based payments"&gt;159&lt;/span&gt; related to stock-based payments for these agreements during the year ended December
31, 2020 and 2019, respectively, and $&lt;span id="xdx_902_eus-gaap--SalesCommissionsAndFees_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_pn3n3" title="Commission expense incurred"&gt;2,434&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--SalesCommissionsAndFees_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_pn3n3" title="Commission expense incurred"&gt;2,700&lt;/span&gt; were incurred under these agreements for commission expenses during the
years ended December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Asset
Purchase, License and Related Agreements &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company has acquired and sourced intellectual property rights related to certain proprietary innovations from certain inventors
and related parties (the &#x201c;Inventors&#x201d;) through multiple asset purchase agreements, license agreements, strategic agreements
and commission agreements. In general, these agreements provide that the Inventors will cooperate with the Company in obtaining
patent protection for the acquired intellectual property and that the Company will use commercially reasonable efforts to research,
develop and commercialize a product based on the acquired intellectual property. In addition, the Company has acquired a right
of first refusal on additional intellectual property and drug development opportunities presented by these Inventors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--BusinessAcquisitionDescriptionOfAcquiredEntity_c20200101__20201231" title="Business acquisition description"&gt;In
consideration for the acquisition of the intellectual property rights, the Company is obligated to make payments to the Inventors
based on the completion of certain milestones, generally consisting of: (1) a payment payable within 30 days after the issuance
of the first patent in the United States arising from the acquired intellectual property (if any); (2) a payment payable within
30 days after the Company files the first investigational new drug application (&#x201c;IND&#x201d;) with the FDA for the first
product arising from the acquired intellectual property (if any); (3) for certain of the Inventors, a payment payable within 30
days after the Company files the first new drug application with the FDA for the first product arising from the acquired intellectual
property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection with the sale
or licensing of any product based on the acquired intellectual property (if any), after deducting (among other things) the Company&#x2019;s
development costs associated with such product. If, following five years after the date of the applicable asset purchase agreement,
the Company either (a) for certain of the Inventors, has not filed an IND or, for the remaining Inventors, has not initiated a
study where data is derived, or (b) has failed to generate royalty payments to the Inventors for any product based on the acquired
intellectual property, the Inventors may terminate the applicable asset purchase agreement and request that the Company re-assign
the acquired technology to the Inventors.&lt;/span&gt; $&lt;span id="xdx_90D_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_c20201231_pn3n3" title="Accounts payable and accrued expenses"&gt;224&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_c20191231_pn3n3" title="Accounts payable and accrued expenses"&gt;371&lt;/span&gt; were accrued in accounts payable and accrued expenses under these agreements
during the years ended December 31, 2020 and 2019, respectively, and $&lt;span id="xdx_90A_eus-gaap--RoyaltyExpense_c20200101__20201231_pn3n3" title="Royalty payments"&gt;682&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--RoyaltyExpense_c20190101__20191231_pn3n3" title="Royalty payments"&gt;846&lt;/span&gt; were incurred under these agreements as royalty
expenses for the years ended December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Mayfield
License&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
July 2020, Mayfield entered into a License Agreement (the &#x201c;TGV License&#x201d;) with TGV to acquire intellectual property
rights for use in the women&#x2019;s health field, related to Mayfield&#x2019;s proprietary drug candidate MAY-66. The TGV License
provides that TGV will cooperate with Mayfield in transferring all embodiments of the intellectual property (including know-how)
related to the TGV License, assist in obtaining and protecting its patent rights for the acquired intellectual property and that
Mayfield will use commercially reasonable efforts to research, develop and commercialize products based on the acquired intellectual
property. In connection with the TGV License, Mayfield is obligated to make royalty payments to TGV equal to a low single digit
percentage of net sales received by Mayfield in connection with the sale or licensing of any product based on the licensed intellectual
property. In addition, Mayfield issued &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200701__20200731__dei--LegalEntityAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_pii" title="Number of shares issued"&gt;300,000&lt;/span&gt; shares of its common stock to TGV and is required to make certain milestone payments
to TGV over the development of MAY-66 and any related products based on the licensed intellectual property.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Stowe
License&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
July 2020, Stowe entered into a License Agreement (the &#x201c;Stowe License&#x201d;) with TGV, to acquire intellectual property
rights for use in the ophthalmology and otic health field, related to Stowe&#x2019;s proprietary drug candidate STE-006. The Stowe
License provides that TGV will cooperate with Stowe in transferring all embodiments of the intellectual property (including know-how)
related to the Stowe License, assist in obtaining and protecting its patent rights for the acquired intellectual property and
that Stowe will use commercially reasonable efforts to research, develop and commercialize products based on the acquired intellectual
property. In connection with the Stowe License, Stowe is obligated to make royalty payments to TGV equal to a low single digit
percentage of net sales received by Stowe in connection with the sale or licensing of any product based on the licensed intellectual
property. In addition, Stowe issued &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200701__20200731__dei--LegalEntityAxis__custom--StowePharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_pii" title="Number of shares issued"&gt;1,750,000&lt;/span&gt; shares of its common stock to TGV and is required to make certain milestone payments
to TGV over the development of STE-006 and any related products based on the licensed intellectual property.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Klarity
License Agreement &#x2013; Related Party&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
April 2017, the Company entered into a license agreement (the &#x201c;Klarity License Agreement&#x201d;) with Richard L. Lindstrom,
M.D., a member of its Board of Directors. Pursuant to the terms of the Klarity License Agreement, the Company licensed certain
intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license the topical ophthalmic
solution Klarity designed to protect and rehabilitate the ocular surface (the &#x201c;Klarity Product&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span id="xdx_90D_ecustom--RoyaltyPaymentDescription_c20170401__20170430__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember" style="font: 10pt Times New Roman, Times, Serif"&gt;Under
the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3%
to 6% of net sales, dependent upon the final formulation of the Klarity Product sold.&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
addition, the Company is required to make certain milestone payments to Dr. Lindstrom including: (i) an initial payment of $&lt;span id="xdx_904_eus-gaap--RoyaltyExpense_c20170401__20170430__srt--StatementScenarioAxis__custom--InitialPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3"&gt;50
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;upon execution of the Klarity License
Agreement, (ii) a second payment of $&lt;span id="xdx_90A_eus-gaap--RoyaltyExpense_c20170401__20170430__srt--StatementScenarioAxis__custom--SecondPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3"&gt;50
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;following the first $&lt;span id="xdx_901_eus-gaap--RoyaltyExpense_c20170401__20170430__srt--StatementScenarioAxis__custom--FinalPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3"&gt;50
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;in net sales of the Klarity Product; and
(iii) a final payment of $&lt;span id="xdx_906_ecustom--NetSalesRevenue_c20170401__20170430__srt--StatementScenarioAxis__custom--SecondPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3"&gt;50
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;following the first $&lt;span id="xdx_909_ecustom--NetSalesRevenue_c20170401__20170430__srt--StatementScenarioAxis__custom--FinalPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3"&gt;100
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;in net sales of the Klarity Product. All
of the above referenced milestone payments were payable at the Company&#x2019;s election in cash or shares of the Company&#x2019;s
restricted common stock. Dr. Lindstrom was paid $&lt;span id="xdx_90A_eus-gaap--RoyaltyExpense_pn3n3_c20200101__20201231__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zOTin8xI59Pk"&gt;149
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_902_ecustom--MilestonePaymentInCash_pn3n3_c20190101__20191231__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zizsoZftpNkl"&gt;63
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;in cash during the years ended December
31, 2020 and 2019, respectively, and was due an additional $&lt;span id="xdx_90F_ecustom--MilestonePaymentsOnPayables_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3"&gt;35
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_900_ecustom--MilestonePaymentsOnPayables_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3"&gt;55
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;at December 31, 2020 and 2019, respectively.
The Company incurred $&lt;span id="xdx_907_eus-gaap--RoyaltyExpense_pn3n3_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zVczfS5hEP52"&gt;129
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_90B_eus-gaap--RoyaltyExpense_pn3n3_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zio2OpquTpnl"&gt;103
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;for royalty expenses related to the Klarity
License Agreement during the years ended December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Injectable
Asset Purchase Agreement &#x2013; Related Party&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
December 2019, the Company entered into an asset purchase agreement (the &#x201c;Lindstrom APA&#x201d;) with Dr. Lindstrom, a member
of its Board of Directors. Pursuant to the terms of the Lindstrom APA, the Company acquired certain intellectual property and
related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license an ophthalmic injectable product (the &#x201c;Lindstrom
Product&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Under
the terms of the Lindstrom APA, t&lt;span id="xdx_906_ecustom--RoyaltyPaymentDescription_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember" title="Royalty payment description"&gt;he Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net
sales, dependent upon the final formulation and patent protection of the Lindstrom Product sold.&lt;/span&gt; In addition, the Company is required
to make certain milestone payments to Dr. Lindstrom including an initial payment of $&lt;span id="xdx_908_eus-gaap--RoyaltyExpense_c20191201__20191231__srt--StatementScenarioAxis__custom--InitialPaymentMember__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Royalty payments"&gt;33&lt;/span&gt; upon execution of the Lindstrom APA. Dr.
Lindstrom was paid $&lt;span id="xdx_900_ecustom--MilestonePaymentInCash_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payment in cash"&gt;55&lt;/span&gt; and $&lt;span id="xdx_903_ecustom--MilestonePaymentInCash_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payment in cash"&gt;0&lt;/span&gt; in cash during the years ended December 31, 2020 and 2019, respectively, and was due $&lt;span id="xdx_90B_ecustom--MilestonePaymentsOnPayables_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payments on payables"&gt;7&lt;/span&gt; and
$&lt;span id="xdx_90A_ecustom--MilestonePaymentsOnPayables_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payments on payables"&gt;40&lt;/span&gt; at December 31, 2020 and 2019, respectively. The Company incurred $&lt;span id="xdx_902_eus-gaap--RoyaltyExpense_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Royalty payments"&gt;55&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--RoyaltyExpense_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Royalty payments"&gt;40&lt;/span&gt; for royalty expenses related to the Lindstrom
APA during the years ended December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Presbyopia
Asset Purchase Agreement &#x2013; Related Party&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
December 2019, the Company entered into an asset purchase agreement (the &#x201c;Presbyopia APA&#x201d;) with Richard L. Lindstrom,
M.D., a member of its Board of Directors. Pursuant to the terms of the Presbyopia APA, the Company acquired certain intellectual
property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license an ophthalmic topical product
to treat presbyopia (the &#x201c;Presbyopia Product&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Under
the terms of the Presbyopia APA, &lt;span id="xdx_904_ecustom--RoyaltyPaymentDescription_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember" title="Royalty payment description"&gt;the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 4% of net
sales, dependent upon the final formulation and patent protection of the Presbyopia Product sold.&lt;/span&gt; Dr. Lindstrom was paid $&lt;span id="xdx_90B_ecustom--MilestonePaymentInCash_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payment in cash"&gt;&lt;span id="xdx_90A_ecustom--MilestonePaymentInCash_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payment in cash"&gt;0&lt;/span&gt;&lt;/span&gt; in
cash during the years ended December 31, 2020 and 2019, and was due $&lt;span id="xdx_904_ecustom--MilestonePaymentsOnPayables_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payments on payables"&gt;&lt;span id="xdx_905_ecustom--MilestonePaymentsOnPayables_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payments on payables"&gt;0&lt;/span&gt;&lt;/span&gt; at December 31, 2020 and 2019. The Company incurred $&lt;span id="xdx_902_eus-gaap--RoyaltyExpense_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Royalty payments"&gt;&lt;span id="xdx_901_eus-gaap--RoyaltyExpense_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Royalty payments"&gt;0&lt;/span&gt;&lt;/span&gt;
for royalty expenses related to the Presbyopia APA during the years ended December 31, 2020 and 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;&lt;b&gt;Eyepoint
Commercial Alliance Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;In
August 2020, the Company, through its wholly owned subsidiary ImprimisRx, LLC, entered into a Commercial Alliance Agreement (the
&#x201c;Dexycu Agreement&#x201d;) with Eyepoint Pharmaceuticals, Inc. (&#x201c;Eyepoint&#x201d;), pursuant to which Eyepoint granted
the Company the non-exclusive right to co-promote DEXYCU&lt;sup&gt;&#xae;&lt;/sup&gt; (dexamethasone intraocular suspension) 9% for the treatment
of post-operative inflammation following ocular surgery in the United States.&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Pursuant
to the &lt;span style="background-color: white"&gt;Dexycu Agreement&lt;/span&gt;, Eyepoint will pay the Company a fee calculated based on
the quarterly sales of DEXCYU in excess of predefined volumes to specific customers of the Company in the U.S. Under the terms
of the &lt;span style="background-color: white"&gt;Dexycu Agreement&lt;/span&gt;, the Company shall use commercially reasonable efforts to
promote and market DEXCYU in the U.S.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Subject
to early termination, the &lt;span style="background-color: white"&gt;Dexycu Agreement&lt;/span&gt; expires on August 1, 2025, subject to
specified notice periods and specified limitations, either party may terminate the &lt;span style="background-color: white"&gt;Dexycu
Agreement&lt;/span&gt; in the event of (i) uncured material breach by the other party or (ii) if DEXCYU ceases to have &#x201c;pass-through&#x201d;
payment status. In addition, subject to certain limitations, the Company may terminate the &lt;span style="background-color: white"&gt;Dexycu
Agreement&lt;/span&gt; (i) for convenience subject to an extended specified notice period or (ii) in the event Eyepoint undergoes a
change of control. Eyepoint may terminate the &lt;span style="background-color: white"&gt;Dexycu Agreement&lt;/span&gt;, subject to specified
notice periods and specified limitations, if the Company fails to achieve certain minimum sales levels during specified periods.
During the year ended December 31, 2020, the Company recorded $&lt;span id="xdx_90F_eus-gaap--SalesCommissionsAndFees_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--DexycuAgreementMember_pn3n3" title="Commission expense incurred"&gt;357&lt;/span&gt; in commission revenues related to the Dexycu Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="AsOf2018-12-31_custom_SettlementAgreementMember"
      decimals="-3"
      unitRef="USD">640000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <HROW:DamagesLowClaimRatePercentage
      contextRef="From2018-01-012018-12-31_custom_SettlementAgreementMember"
      decimals="INF"
      unitRef="Percent">0.014</HROW:DamagesLowClaimRatePercentage>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="From2019-10-022019-10-31_custom_SettlementAgreementMember"
      decimals="-3"
      unitRef="USD">571000</us-gaap:LossContingencyDamagesPaidValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="From2019-05-012019-05-31_custom_AllerganUSAIncMember"
      decimals="-3"
      unitRef="USD">49000</us-gaap:LossContingencyDamagesAwardedValue>
    <HROW:CommissionPaymentsPercentage
      contextRef="From2017-01-012019-12-31_custom_SalesAndMarketingAgreementsMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Percent">0.10</HROW:CommissionPaymentsPercentage>
    <HROW:CommissionPaymentsPercentage
      contextRef="From2017-01-012019-12-31_custom_SalesAndMarketingAgreementsMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Percent">0.14</HROW:CommissionPaymentsPercentage>
    <HROW:AdditionalPaidInCapitalAndShareBasedPayments
      contextRef="From2020-01-012020-12-31_custom_SalesAndMarketingAgreementsMember"
      decimals="-3"
      unitRef="USD">83000</HROW:AdditionalPaidInCapitalAndShareBasedPayments>
    <HROW:AdditionalPaidInCapitalAndShareBasedPayments
      contextRef="From2019-01-012019-12-31_custom_SalesAndMarketingAgreementsMember"
      decimals="-3"
      unitRef="USD">159000</HROW:AdditionalPaidInCapitalAndShareBasedPayments>
    <us-gaap:SalesCommissionsAndFees
      contextRef="From2020-01-012020-12-31_custom_SalesAndMarketingAgreementsMember"
      decimals="-3"
      unitRef="USD">2434000</us-gaap:SalesCommissionsAndFees>
    <us-gaap:SalesCommissionsAndFees
      contextRef="From2019-01-012019-12-31_custom_SalesAndMarketingAgreementsMember"
      decimals="-3"
      unitRef="USD">2700000</us-gaap:SalesCommissionsAndFees>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity contextRef="From2020-01-01to2020-12-31">In
consideration for the acquisition of the intellectual property rights, the Company is obligated to make payments to the Inventors
based on the completion of certain milestones, generally consisting of: (1) a payment payable within 30 days after the issuance
of the first patent in the United States arising from the acquired intellectual property (if any); (2) a payment payable within
30 days after the Company files the first investigational new drug application (&#x201c;IND&#x201d;) with the FDA for the first
product arising from the acquired intellectual property (if any); (3) for certain of the Inventors, a payment payable within 30
days after the Company files the first new drug application with the FDA for the first product arising from the acquired intellectual
property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection with the sale
or licensing of any product based on the acquired intellectual property (if any), after deducting (among other things) the Company&#x2019;s
development costs associated with such product. If, following five years after the date of the applicable asset purchase agreement,
the Company either (a) for certain of the Inventors, has not filed an IND or, for the remaining Inventors, has not initiated a
study where data is derived, or (b) has failed to generate royalty payments to the Inventors for any product based on the acquired
intellectual property, the Inventors may terminate the applicable asset purchase agreement and request that the Company re-assign
the acquired technology to the Inventors.</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="AsOf2020-12-31" decimals="-3" unitRef="USD">224000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="AsOf2019-12-31" decimals="-3" unitRef="USD">371000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:RoyaltyExpense
      contextRef="From2020-01-01to2020-12-31"
      decimals="-3"
      unitRef="USD">682000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2019-01-012019-12-31"
      decimals="-3"
      unitRef="USD">846000</us-gaap:RoyaltyExpense>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-07-012020-07-31_custom_MayfieldPharmaceuticalsIncMember_custom_LicenseAgreementMember"
      decimals="INF"
      unitRef="Shares">300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-07-012020-07-31_custom_StowePharmaceuticalsIncMember_custom_LicenseAgreementMember"
      decimals="INF"
      unitRef="Shares">1750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <HROW:RoyaltyPaymentDescription contextRef="From2017-04-012017-04-30_custom_KlarityLicenseAgreementMember_custom_RichardLLindstromMDMember">Under
the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3%
to 6% of net sales, dependent upon the final formulation of the Klarity Product sold.</HROW:RoyaltyPaymentDescription>
    <us-gaap:RoyaltyExpense
      contextRef="From2017-04-012017-04-30_custom_InitialPaymentMember_custom_LicenseAgreementMember_custom_RichardLLindstromMDMember"
      decimals="-3"
      unitRef="USD">50000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2017-04-012017-04-30_custom_SecondPaymentMember_custom_LicenseAgreementMember_custom_RichardLLindstromMDMember"
      decimals="-3"
      unitRef="USD">50000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2017-04-012017-04-30_custom_FinalPaymentMember_custom_LicenseAgreementMember_custom_RichardLLindstromMDMember"
      decimals="-3"
      unitRef="USD">50000</us-gaap:RoyaltyExpense>
    <HROW:NetSalesRevenue
      contextRef="From2017-04-012017-04-30_custom_SecondPaymentMember_custom_LicenseAgreementMember_custom_RichardLLindstromMDMember"
      decimals="-3"
      unitRef="USD">50000</HROW:NetSalesRevenue>
    <HROW:NetSalesRevenue
      contextRef="From2017-04-012017-04-30_custom_FinalPaymentMember_custom_LicenseAgreementMember_custom_RichardLLindstromMDMember"
      decimals="-3"
      unitRef="USD">100000</HROW:NetSalesRevenue>
    <us-gaap:RoyaltyExpense
      contextRef="From2020-01-012020-12-31_custom_RichardLLindstromMDMember"
      decimals="-3"
      unitRef="USD">149000</us-gaap:RoyaltyExpense>
    <HROW:MilestonePaymentInCash
      contextRef="From2019-01-012019-12-31_custom_RichardLLindstromMDMember"
      decimals="-3"
      unitRef="USD">63000</HROW:MilestonePaymentInCash>
    <HROW:MilestonePaymentsOnPayables
      contextRef="From2020-01-012020-12-31_custom_KlarityLicenseAgreementMember_custom_RichardLLindstromMDMember"
      decimals="-3"
      unitRef="USD">35000</HROW:MilestonePaymentsOnPayables>
    <HROW:MilestonePaymentsOnPayables
      contextRef="From2019-01-012019-12-31_custom_KlarityLicenseAgreementMember_custom_RichardLLindstromMDMember"
      decimals="-3"
      unitRef="USD">55000</HROW:MilestonePaymentsOnPayables>
    <us-gaap:RoyaltyExpense
      contextRef="From2020-01-012020-12-31_custom_KlarityLicenseAgreementMember_custom_RichardLLindstromMDMember"
      decimals="-3"
      unitRef="USD">129000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2019-01-012019-12-31_custom_KlarityLicenseAgreementMember_custom_RichardLLindstromMDMember"
      decimals="-3"
      unitRef="USD">103000</us-gaap:RoyaltyExpense>
    <HROW:RoyaltyPaymentDescription contextRef="From2019-12-012019-12-31_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember">he Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net
sales, dependent upon the final formulation and patent protection of the Lindstrom Product sold.</HROW:RoyaltyPaymentDescription>
    <us-gaap:RoyaltyExpense
      contextRef="From2019-12-012019-12-31_custom_InitialPaymentMember_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember"
      decimals="-3"
      unitRef="USD">33000</us-gaap:RoyaltyExpense>
    <HROW:MilestonePaymentInCash
      contextRef="From2020-01-012020-12-31_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember"
      decimals="-3"
      unitRef="USD">55000</HROW:MilestonePaymentInCash>
    <HROW:MilestonePaymentInCash
      contextRef="From2019-01-012019-12-31_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember"
      decimals="-3"
      unitRef="USD">0</HROW:MilestonePaymentInCash>
    <HROW:MilestonePaymentsOnPayables
      contextRef="From2020-01-012020-12-31_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember"
      decimals="-3"
      unitRef="USD">7000</HROW:MilestonePaymentsOnPayables>
    <HROW:MilestonePaymentsOnPayables
      contextRef="From2019-01-012019-12-31_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember"
      decimals="-3"
      unitRef="USD">40000</HROW:MilestonePaymentsOnPayables>
    <us-gaap:RoyaltyExpense
      contextRef="From2020-01-012020-12-31_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember"
      decimals="-3"
      unitRef="USD">55000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2019-01-012019-12-31_custom_InjectableAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember"
      decimals="-3"
      unitRef="USD">40000</us-gaap:RoyaltyExpense>
    <HROW:RoyaltyPaymentDescription contextRef="From2019-12-012019-12-31_custom_PresbyopiaAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember">the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 4% of net
sales, dependent upon the final formulation and patent protection of the Presbyopia Product sold.</HROW:RoyaltyPaymentDescription>
    <HROW:MilestonePaymentInCash
      contextRef="From2020-01-012020-12-31_custom_PresbyopiaAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember"
      decimals="-3"
      unitRef="USD">0</HROW:MilestonePaymentInCash>
    <HROW:MilestonePaymentInCash
      contextRef="From2019-01-012019-12-31_custom_PresbyopiaAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember"
      decimals="-3"
      unitRef="USD">0</HROW:MilestonePaymentInCash>
    <HROW:MilestonePaymentsOnPayables
      contextRef="From2020-01-012020-12-31_custom_PresbyopiaAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember"
      decimals="-3"
      unitRef="USD">0</HROW:MilestonePaymentsOnPayables>
    <HROW:MilestonePaymentsOnPayables
      contextRef="From2019-01-012019-12-31_custom_PresbyopiaAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember"
      decimals="-3"
      unitRef="USD">0</HROW:MilestonePaymentsOnPayables>
    <us-gaap:RoyaltyExpense
      contextRef="From2020-01-012020-12-31_custom_PresbyopiaAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember"
      decimals="-3"
      unitRef="USD">0</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2019-01-012019-12-31_custom_PresbyopiaAssetPurchaseAgreementMember_custom_RichardLLindstromMDMember"
      decimals="-3"
      unitRef="USD">0</us-gaap:RoyaltyExpense>
    <us-gaap:SalesCommissionsAndFees
      contextRef="From2020-01-012020-12-31_custom_DexycuAgreementMember"
      decimals="-3"
      unitRef="USD">357000</us-gaap:SalesCommissionsAndFees>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_80D_eus-gaap--SegmentReportingDisclosureTextBlock_za1vyYFAHsCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
18. &lt;span id="xdx_822_zW7oEugK6dV8"&gt;SEGMENT INFORMATION AND CONCENTRATIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Beginning
on January 1, 2019, the Company began evaluating performance of the Company based on operating segments. Segment performance for
its &lt;span id="xdx_905_ecustom--NumberOfOperatingSegmentsDescription_c20200101__20201231_zZKE0PNI1s2k" title="Number of operating segments, description."&gt;two operating segments&lt;/span&gt; are based on segment contribution. The Company&#x2019;s reportable segments consist of (i) its commercial
stage pharmaceutical compounding business (Pharmaceutical Compounding), generally including the operations of ImprimisRx and the
former Park businesses; and (ii) its start-up operations associated with pharmaceutical drug development business (Pharmaceutical
Drug Development). Segment contribution for the segments represents net revenues less cost of sales, research and development,
selling and marketing expenses, and select general and administrative expenses. The Company does not evaluate the following items
at the segment level:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Selling,
    general and administrative expenses that result from shared infrastructure, including certain expenses associated with legal
    matters, public company costs (e.g. investor relations), board of directors and principal executive officers and other like
    shared expenses;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Operating
    expenses within selling, general and administrative expenses that result from the impact of corporate initiatives. Corporate
    initiatives primarily include integration, restructuring, acquisition and other shared costs;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other
    select revenues and operating expenses including R&amp;amp;D expenses, amortization, and asset sales and impairments, net as not
    all such information has been accounted for at the segment level, or such information has not been used by all segments; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    assets including capital expenditures.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company defines segment net revenues as pharmaceutical compounded drug sales, licenses and other revenue derived from related
agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cost
of sales within segment contribution includes direct and indirect costs to manufacture formulations and sell products, including
active pharmaceutical ingredients, personnel costs, packaging, storage, royalties, shipping and handling costs, manufacturing
equipment and tenant improvements depreciation, the write-off of obsolete inventory and other related expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Selling,
general and administrative expenses consist mainly of personnel-related costs, marketing and promotion costs, distribution costs,
professional service costs, insurance, depreciation, facilities costs, transaction costs, and professional services costs which
are general in nature and attributable to the segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z7Np0d5rM4L" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Segment
net revenues, segment operating expenses and segment contribution information consisted of the following for the years ended December
31, 2020 and 2019:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt"&gt;&lt;span id="xdx_8B5_zVhOxt4bJ3l" style="display: none"&gt;SCHEDULE OF SEGMENT NET REVENUES, SEGMENT OPERATING EXPENSES AND SEGMENT CONTRIBUTION&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pharmaceutical
    Drug&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Compounding&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Development&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;48,871&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1930"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;48,871&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--CostOfGoodsAndServicesSold_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(14,463&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--CostOfGoodsAndServicesSold_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1936"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zgozMhXwOZ91" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(14,463&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--GrossProfit_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Gross profit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34,408&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--GrossProfit_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Gross profit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1942"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--GrossProfit_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34,408&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Selling, general
    and administrative&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Selling, general and administrative"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,691&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Selling, general and administrative"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;144&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,835&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
    and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;759&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;88&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;847&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Segment
    contribution&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--SegmentContribution_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Segment contribution"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,958&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--SegmentContribution_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Segment contribution"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(232&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"/&gt;&lt;td id="xdx_987_ecustom--SegmentContribution_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="padding-bottom: 1.5pt; text-align: right" title="Segment contribution"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,726&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--OperatingIncomeLoss_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_pn3n3" style="text-align: right" title="Operating income (loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(8,245&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--OperatingIncomeLoss_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="text-align: right" title="Operating income (loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,566&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AdjustmentForAmortization_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(167&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Asset sales and
    impairments, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(363&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    income&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ImpairmentAndDisposalOfLonglivedAssets_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Asset sales and impairments, net"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;385&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pharmaceutical
    Drug&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Compounding&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Development&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,165&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1974"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,165&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--CostOfGoodsAndServicesSold_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(16,749&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--CostOfGoodsAndServicesSold_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1980"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zF011mNHMFJ4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(16,749&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--GrossProfit_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Gross profit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34,416&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--GrossProfit_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1986"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--GrossProfit_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34,416&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Selling, general
    and administrative&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Selling, general and administrative"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;24,460&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;174&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;24,634&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ResearchAndDevelopmentExpense_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,006&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ResearchAndDevelopmentExpense_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;361&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ResearchAndDevelopmentExpense_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,367&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Segment
    contribution&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--SegmentContribution_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Segment contribution"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,934&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--SegmentContribution_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Segment contribution"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(535&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"/&gt;&lt;td id="xdx_980_ecustom--SegmentContribution_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="padding-bottom: 1.5pt; text-align: right" title="Segment contribution"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,399&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OperatingIncomeLoss_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_pn3n3" style="text-align: right" title="Operating income (loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(8,245&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--OperatingIncomeLoss_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="text-align: right" title="Operating income (loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(716&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AdjustmentForAmortization_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(209&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Asset sales and
    impairments, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ImpairmentAndDisposalOfLonglivedAssets_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Asset sales and impairments, net"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,040&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--OperatingIncomeLoss_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating income (loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,795&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AF_zIPAVqlakOli" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company categorizes revenues by geographic area based on selling location. All operations are currently located in the U.S.; therefore,
total revenues are attributed to the U.S. All long-lived assets at December 31, 2020 and December 31, 2019 are located in the
U.S.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Concentrations&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company sells its compounded formulations to a large number of customers. There were no customers who comprised more than &lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercent_c20200101__20201231_zkRMME5LjXof" title="Percentage of sales derived from large number of customer"&gt;&lt;span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercent_c20190101__20191231_zsO2Z2EGkZq1" title="Percentage of sales derived from large number of customer"&gt;10%&lt;/span&gt;&lt;/span&gt;
of the Company&#x2019;s total pharmacy sales for the years ended December 31, 2020 and 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company receives its active pharmaceutical ingredients from three main suppliers. These suppliers collectively accounted for &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercent_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--ThreeMainSuppliersMember_zJf5ak088ns9" title="Percentage of sales derived from large number of customer"&gt;77%&lt;/span&gt;
of active pharmaceutical ingredient purchases during the year ended December 31, 2020, and &lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercent_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--ThreeMainSuppliersMember_zLLQwOjuQ5f6" title="Percentage of sales derived from large number of customer"&gt;73%&lt;/span&gt; during the year ended December
31, 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <HROW:NumberOfOperatingSegmentsDescription contextRef="From2020-01-01to2020-12-31">two operating segments</HROW:NumberOfOperatingSegmentsDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_890_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z7Np0d5rM4L" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Segment
net revenues, segment operating expenses and segment contribution information consisted of the following for the years ended December
31, 2020 and 2019:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt"&gt;&lt;span id="xdx_8B5_zVhOxt4bJ3l" style="display: none"&gt;SCHEDULE OF SEGMENT NET REVENUES, SEGMENT OPERATING EXPENSES AND SEGMENT CONTRIBUTION&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pharmaceutical
    Drug&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Compounding&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Development&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;48,871&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1930"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;48,871&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--CostOfGoodsAndServicesSold_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(14,463&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--CostOfGoodsAndServicesSold_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1936"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zgozMhXwOZ91" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(14,463&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--GrossProfit_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Gross profit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34,408&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--GrossProfit_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Gross profit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1942"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--GrossProfit_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34,408&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Selling, general
    and administrative&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Selling, general and administrative"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,691&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Selling, general and administrative"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;144&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,835&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
    and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;759&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;88&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;847&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Segment
    contribution&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--SegmentContribution_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Segment contribution"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,958&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--SegmentContribution_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Segment contribution"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(232&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"/&gt;&lt;td id="xdx_987_ecustom--SegmentContribution_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="padding-bottom: 1.5pt; text-align: right" title="Segment contribution"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,726&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--OperatingIncomeLoss_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_pn3n3" style="text-align: right" title="Operating income (loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(8,245&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--OperatingIncomeLoss_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="text-align: right" title="Operating income (loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,566&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AdjustmentForAmortization_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(167&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Asset sales and
    impairments, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(363&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    income&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ImpairmentAndDisposalOfLonglivedAssets_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Asset sales and impairments, net"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;385&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
    the Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pharmaceutical
    Drug&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Compounding&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Development&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,165&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1974"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,165&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--CostOfGoodsAndServicesSold_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(16,749&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--CostOfGoodsAndServicesSold_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1980"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zF011mNHMFJ4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(16,749&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--GrossProfit_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Gross profit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34,416&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--GrossProfit_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1986"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--GrossProfit_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;34,416&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Selling, general
    and administrative&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Selling, general and administrative"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;24,460&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;174&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;24,634&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ResearchAndDevelopmentExpense_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,006&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ResearchAndDevelopmentExpense_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;361&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ResearchAndDevelopmentExpense_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,367&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Segment
    contribution&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--SegmentContribution_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Segment contribution"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,934&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--SegmentContribution_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Segment contribution"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(535&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"/&gt;&lt;td id="xdx_980_ecustom--SegmentContribution_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="padding-bottom: 1.5pt; text-align: right" title="Segment contribution"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,399&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OperatingIncomeLoss_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_pn3n3" style="text-align: right" title="Operating income (loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(8,245&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--OperatingIncomeLoss_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="text-align: right" title="Operating income (loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(716&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AdjustmentForAmortization_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Amortization"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(209&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Asset sales and
    impairments, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ImpairmentAndDisposalOfLonglivedAssets_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Asset sales and impairments, net"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,040&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--OperatingIncomeLoss_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating income (loss)"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4,795&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember"
      decimals="-3"
      unitRef="USD">48871000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      unitRef="USD">48871000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember"
      decimals="-3"
      unitRef="USD">-14463000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      unitRef="USD">14463000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember"
      decimals="-3"
      unitRef="USD">34408000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      unitRef="USD">34408000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember"
      decimals="-3"
      unitRef="USD">22691000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalDrugDevelopmentMember"
      decimals="-3"
      unitRef="USD">144000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      unitRef="USD">22835000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember"
      decimals="-3"
      unitRef="USD">759000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalDrugDevelopmentMember"
      decimals="-3"
      unitRef="USD">88000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      unitRef="USD">847000</us-gaap:ResearchAndDevelopmentExpense>
    <HROW:SegmentContribution
      contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember"
      decimals="-3"
      unitRef="USD">10958000</HROW:SegmentContribution>
    <HROW:SegmentContribution
      contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalDrugDevelopmentMember"
      decimals="-3"
      unitRef="USD">-232000</HROW:SegmentContribution>
    <HROW:SegmentContribution
      contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      unitRef="USD">10726000</HROW:SegmentContribution>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-012020-12-31_us-gaap_CorporateNonSegmentMember"
      decimals="-3"
      unitRef="USD">-8245000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      unitRef="USD">-1566000</us-gaap:OperatingIncomeLoss>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      unitRef="USD">-167000</us-gaap:AdjustmentForAmortization>
    <HROW:ImpairmentAndDisposalOfLonglivedAssets
      contextRef="From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      unitRef="USD">385000</HROW:ImpairmentAndDisposalOfLonglivedAssets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember"
      decimals="-3"
      unitRef="USD">51165000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      unitRef="USD">51165000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember"
      decimals="-3"
      unitRef="USD">-16749000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      unitRef="USD">16749000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember"
      decimals="-3"
      unitRef="USD">34416000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      unitRef="USD">34416000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember"
      decimals="-3"
      unitRef="USD">24460000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2019-01-012019-12-31_custom_PharmaceuticalDrugDevelopmentMember_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      unitRef="USD">174000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      unitRef="USD">24634000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember"
      decimals="-3"
      unitRef="USD">1006000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2019-01-012019-12-31_custom_PharmaceuticalDrugDevelopmentMember_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      unitRef="USD">361000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      unitRef="USD">1367000</us-gaap:ResearchAndDevelopmentExpense>
    <HROW:SegmentContribution
      contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember_custom_PharmaceuticalCompoundingMember"
      decimals="-3"
      unitRef="USD">8934000</HROW:SegmentContribution>
    <HROW:SegmentContribution
      contextRef="From2019-01-012019-12-31_custom_PharmaceuticalDrugDevelopmentMember_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      unitRef="USD">-535000</HROW:SegmentContribution>
    <HROW:SegmentContribution
      contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      unitRef="USD">8399000</HROW:SegmentContribution>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-01-012019-12-31_us-gaap_CorporateNonSegmentMember"
      decimals="-3"
      unitRef="USD">-8245000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      unitRef="USD">-716000</us-gaap:OperatingIncomeLoss>
    <us-gaap:AdjustmentForAmortization
      contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      unitRef="USD">-209000</us-gaap:AdjustmentForAmortization>
    <HROW:ImpairmentAndDisposalOfLonglivedAssets
      contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      unitRef="USD">-4040000</HROW:ImpairmentAndDisposalOfLonglivedAssets>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-01-012019-12-31_us-gaap_OperatingSegmentsMember"
      decimals="-3"
      unitRef="USD">-4795000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-01-01to2020-12-31"
      decimals="INF"
      unitRef="Percent">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-12-31"
      decimals="INF"
      unitRef="Percent">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2020-01-012020-12-31_custom_ThreeMainSuppliersMember"
      decimals="INF"
      unitRef="Percent">0.77</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-12-31_custom_ThreeMainSuppliersMember"
      decimals="INF"
      unitRef="Percent">0.73</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2020-01-01to2020-12-31">&lt;p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_z0qglOUjWSpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
19. &lt;span id="xdx_820_zilROz9sooWh"&gt;SUBSEQUENT EVENTS &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
March 2021, the Company issued &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20210301__20210331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zO0Cwh0QvdJb"&gt;10,989
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;shares of its common stock upon the exercise
of options to purchase &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20210301__20210331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPJgXQbXoSRc"&gt;10,989
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;shares of&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;
common stock, with exercise prices ranging between $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20210301__20210331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3C1WFfBG3gf"&gt;1.70
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;to $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20210301__20210331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTzZKIyAg7A2"&gt;3.96
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;per share, and received net proceeds of
$&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20200301__20200331_pn3n3"&gt;27&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Restricted
stock units granted in February 2015 to Andrew R. Boll, the Company&#x2019;s Chief Financial Officer, vested, and in February 2021,
&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20210201__20210228__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--AndrewRBollMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_pii" title="Shares issued of restricted common stock, shares"&gt;22,500&lt;/span&gt; shares the Company&#x2019;s common stock were issued to Mr. Boll, net of &lt;span id="xdx_90E_ecustom--CommonStockWithheldForPayrollTaxWithholdings_c20210201__20210228__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--AndrewRBollMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_pii" title="Common stock withheld for payroll tax withholdings"&gt;7,500&lt;/span&gt; shares of common stock withheld for payroll
tax withholdings totaling $&lt;span id="xdx_900_ecustom--CommonStockWithheldForPayrollTaxWithholdingsValue_c20210201__20210228__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--AndrewRBollMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_pn3n3" title="Common stock withheld for payroll tax withholdings, value"&gt;58&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Restricted
stock units granted in February 2015 to Mark L. Baum, the Company&#x2019;s Chief Executive Officer, vested, and in February 2021,
&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20210201__20210228__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--MarkLBaumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_pii" title="Shares issued of restricted common stock, shares"&gt;200,000&lt;/span&gt; shares the Company&#x2019;s common stock were issued to Mr. Baum.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company has performed an evaluation of events occurring subsequent to December 31, 2020 through the filing date of this Annual
Report and determined that no subsequent events have occurred that would require recognition in the consolidated financial
statements or disclosures in the notes thereto, other than as disclosed in the accompanying notes.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-03-012021-03-31_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">10989</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-03-012021-03-31_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">10989</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2021-03-012021-03-31_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="USDPShares">1.70</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2021-03-012021-03-31_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="USDPShares">3.96</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-03-012020-03-31"
      decimals="-3"
      unitRef="USD">27000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2021-02-012021-02-28_us-gaap_RestrictedStockUnitsRSUMember_custom_AndrewRBollMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">22500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <HROW:CommonStockWithheldForPayrollTaxWithholdings
      contextRef="From2021-02-012021-02-28_us-gaap_RestrictedStockUnitsRSUMember_custom_AndrewRBollMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">7500</HROW:CommonStockWithheldForPayrollTaxWithholdings>
    <HROW:CommonStockWithheldForPayrollTaxWithholdingsValue
      contextRef="From2021-02-012021-02-28_us-gaap_RestrictedStockUnitsRSUMember_custom_AndrewRBollMember_us-gaap_SubsequentEventMember"
      decimals="-3"
      unitRef="USD">58000</HROW:CommonStockWithheldForPayrollTaxWithholdingsValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2021-02-012021-02-28_us-gaap_RestrictedStockUnitsRSUMember_custom_MarkLBaumMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">200000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171682106504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 08, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HARROW
HEALTH, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001360214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-0567010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">102
Woodmont Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite
610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(615)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">733-4730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HROW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,983,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171681345912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, including restricted cash of $200</a></td>
<td class="nump">$ 4,301<span></span>
</td>
<td class="nump">$ 4,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Investment in Eton Pharmaceuticals</a></td>
<td class="nump">28,455<span></span>
</td>
<td class="nump">25,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">2,662<span></span>
</td>
<td class="nump">2,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">3,962<span></span>
</td>
<td class="nump">3,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">751<span></span>
</td>
<td class="nump">586<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">40,131<span></span>
</td>
<td class="nump">36,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">4,453<span></span>
</td>
<td class="nump">5,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">6,799<span></span>
</td>
<td class="nump">6,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">1,939<span></span>
</td>
<td class="nump">2,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">332<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">57,474<span></span>
</td>
<td class="nump">59,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">3,932<span></span>
</td>
<td class="nump">7,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related liabilities</a></td>
<td class="nump">2,315<span></span>
</td>
<td class="nump">2,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue and customer deposits</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Current portion of paycheck protection program loan payable</a></td>
<td class="nump">1,259<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of loan payable, net of unamortized debt discount</a></td>
<td class="nump">2,639<span></span>
</td>
<td class="nump">1,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">580<span></span>
</td>
<td class="nump">629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease obligations</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,799<span></span>
</td>
<td class="nump">12,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">6,652<span></span>
</td>
<td class="nump">6,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease obligations, net of current portion</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent', window );">Accrued expenses, net of current portion</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Paycheck protection program loan payable, net of current portion</a></td>
<td class="nump">708<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Loan payable, net of current portion and unamortized debt discount</a></td>
<td class="nump">11,670<span></span>
</td>
<td class="nump">12,219<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">30,646<span></span>
</td>
<td class="nump">31,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 50,000,000 shares authorized, 25,749,875 and 25,526,931 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">104,557<span></span>
</td>
<td class="nump">101,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(77,400)<span></span>
</td>
<td class="num">(74,043)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL HARROW HEALTH STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">27,183<span></span>
</td>
<td class="nump">27,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(355)<span></span>
</td>
<td class="num">(293)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">TOTAL EQUITY</a></td>
<td class="nump">26,828<span></span>
</td>
<td class="nump">27,418<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND EQUITY</a></td>
<td class="nump">57,474<span></span>
</td>
<td class="nump">59,085<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_SurfaceOphthalmicsMember', window );">Surface Ophthalmics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="nump">1,314<span></span>
</td>
<td class="nump">3,747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_MeltPharmaceuticalsMember', window );">Melt Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="nump">$ 2,506<span></span>
</td>
<td class="nump">$ 4,690<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f,g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_SurfaceOphthalmicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_SurfaceOphthalmicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_MeltPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_MeltPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171680140472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, sharess authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">25,749,875<span></span>
</td>
<td class="nump">25,526,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">25,749,875<span></span>
</td>
<td class="nump">25,526,931<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171680975528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 48,871<span></span>
</td>
<td class="nump">$ 51,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="num">(14,463)<span></span>
</td>
<td class="num">(16,749)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">34,408<span></span>
</td>
<td class="nump">34,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">31,247<span></span>
</td>
<td class="nump">33,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,413<span></span>
</td>
<td class="nump">2,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">363<span></span>
</td>
<td class="nump">4,040<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">34,023<span></span>
</td>
<td class="nump">39,211<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">385<span></span>
</td>
<td class="num">(4,795)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense, net</a></td>
<td class="num">(2,236)<span></span>
</td>
<td class="num">(2,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (loss) income, net</a></td>
<td class="num">(73)<span></span>
</td>
<td class="nump">630<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (loss) income, net</a></td>
<td class="num">(3,800)<span></span>
</td>
<td class="nump">4,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax provision</a></td>
<td class="num">(3,415)<span></span>
</td>
<td class="num">(117)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Total net loss including noncontrolling interests</a></td>
<td class="num">(3,419)<span></span>
</td>
<td class="num">(125)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to Harrow Health, Inc.</a></td>
<td class="num">$ (3,357)<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share of common stock</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share of common stock</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding, basic</a></td>
<td class="nump">25,895,352<span></span>
</td>
<td class="nump">25,323,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding, diluted</a></td>
<td class="nump">25,895,352<span></span>
</td>
<td class="nump">26,466,098<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_MeltPharmaceuticalsMember', window );">Melt Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Investment (loss) gain, net</a></td>
<td class="num">$ (2,313)<span></span>
</td>
<td class="nump">$ 3,968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_SurfaceOphthalmicsMember', window );">Surface Ophthalmics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Investment (loss) gain, net</a></td>
<td class="num">(2,433)<span></span>
</td>
<td class="num">(1,200)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_EtonPharmaceuticalsMember', window );">Eton Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Investment (loss) gain, net</a></td>
<td class="nump">3,255<span></span>
</td>
<td class="nump">3,780<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=HROW_ProductSalesNetMember', window );">Product Sales, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">48,479<span></span>
</td>
<td class="nump">51,137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=HROW_OtherRevenuesMember', window );">Other Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 392<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_MeltPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_MeltPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_SurfaceOphthalmicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_SurfaceOphthalmicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_EtonPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_EtonPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=HROW_ProductSalesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=HROW_ProductSalesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=HROW_OtherRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=HROW_OtherRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171681082648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Parent [Member]</div></th>
<th class="th"><div>Noncontrolling Interest [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance, value at Dec. 31, 2018</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 98,938<span></span>
</td>
<td class="num">$ (74,211)<span></span>
</td>
<td class="nump">$ 24,751<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 24,751<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2018</a></td>
<td class="nump">24,339,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_StockIssuedDuringPeriodForExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">813<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_StockIssuedDuringPeriodSharesForExerciseOfWarrants', window );">Exercise of warrants, shares</a></td>
<td class="nump">1,142,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Exercise of employee options, net of tax withholding</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Exercise of employee stock-based options, net of tax withholding , shares</a></td>
<td class="nump">29,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of common stock related to vesting of RSUs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock related to vesting of RSUs, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based payment for services provided</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based payment for services provided, shares</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,789<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,789<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="num">(293)<span></span>
</td>
<td class="num">(125)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value at Dec. 31, 2019</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">101,728<span></span>
</td>
<td class="num">(74,043)<span></span>
</td>
<td class="nump">27,711<span></span>
</td>
<td class="num">(293)<span></span>
</td>
<td class="nump">27,418<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="nump">25,526,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Exercise of employee options, net of tax withholding</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Exercise of employee stock-based options, net of tax withholding , shares</a></td>
<td class="nump">7,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of common stock related to vesting of RSUs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock related to vesting of RSUs, shares</a></td>
<td class="nump">185,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based payment for services provided</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based payment for services provided, shares</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,775<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,775<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,357)<span></span>
</td>
<td class="num">(3,357)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="num">(3,419)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 104,557<span></span>
</td>
<td class="num">$ (77,400)<span></span>
</td>
<td class="nump">$ 27,183<span></span>
</td>
<td class="num">$ (355)<span></span>
</td>
<td class="nump">$ 26,828<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="nump">25,749,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_StockIssuedDuringPeriodForExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_StockIssuedDuringPeriodForExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_StockIssuedDuringPeriodSharesForExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_StockIssuedDuringPeriodSharesForExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171684543576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss (including noncontrolling interests)</a></td>
<td class="num">$ (3,419)<span></span>
</td>
<td class="num">$ (125)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization of property, plant and equipment</a></td>
<td class="nump">1,880<span></span>
</td>
<td class="nump">1,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_AmortizationOfIntangibleAsset', window );">Amortization of intangible assets</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_AmortizationOfOperatingLeaseRightofuseAssets', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">696<span></span>
</td>
<td class="nump">518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debt expense</a></td>
<td class="nump">213<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Interest paid-in-kind on SWK Loan</a></td>
<td class="nump">358<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and discount</a></td>
<td class="nump">457<span></span>
</td>
<td class="nump">512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_GainLossOnInvestmentsOne', window );">Investment gain from Eton Pharmaceuticals, net</a></td>
<td class="num">(3,255)<span></span>
</td>
<td class="num">(3,780)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_GainLossOnInvestmentsTwo', window );">Investment loss from Surface Ophthalmics, net</a></td>
<td class="nump">2,433<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_GainLossOnInvestmentsThree', window );">Investment loss (gain) from Melt Pharmaceuticals, net</a></td>
<td class="nump">2,313<span></span>
</td>
<td class="num">(3,968)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of equipment</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ImpairmentsOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">363<span></span>
</td>
<td class="nump">4,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock-based payment of consulting services</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,775<span></span>
</td>
<td class="nump">1,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(866)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(661)<span></span>
</td>
<td class="num">(2,271)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(294)<span></span>
</td>
<td class="num">(471)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(4,655)<span></span>
</td>
<td class="nump">1,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued payroll and related liabilities</a></td>
<td class="nump">198<span></span>
</td>
<td class="num">(166)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue and customer deposits</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES</a></td>
<td class="num">(1,100)<span></span>
</td>
<td class="nump">950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds on sale and disposal of assets</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Investment in patent and trademark assets</a></td>
<td class="num">(132)<span></span>
</td>
<td class="num">(369)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(862)<span></span>
</td>
<td class="num">(1,468)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH USED IN INVESTING ACTIVITIES</a></td>
<td class="num">(981)<span></span>
</td>
<td class="num">(1,833)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on finance lease obligations</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(743)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherDebt', window );">Proceeds from SWK loan</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payments on SWK loan</a></td>
<td class="num">(1,497)<span></span>
</td>
<td class="num">(750)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_PaymentsOfCostsRelatedToAmendmentOfLoanPayable', window );">Payments of costs related to amendment of SWK loan</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(282)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Paycheck protection program loan payable</a></td>
<td class="nump">1,967<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ProceedsFromExerciseOfWarrantsAndStockOptionsNetOfTaxes', window );">Net proceeds from exercise of warrants and stock options, net of taxes remitted for RSU&#8217;s and options</a></td>
<td class="num">(29)<span></span>
</td>
<td class="nump">769<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES</a></td>
<td class="nump">1,433<span></span>
</td>
<td class="num">(1,006)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</a></td>
<td class="num">(648)<span></span>
</td>
<td class="num">(1,889)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period</a></td>
<td class="nump">4,949<span></span>
</td>
<td class="nump">6,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period</a></td>
<td class="nump">4,301<span></span>
</td>
<td class="nump">4,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract', window );"><strong>RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">4,101<span></span>
</td>
<td class="nump">4,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD</a></td>
<td class="nump">4,301<span></span>
</td>
<td class="nump">4,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,791<span></span>
</td>
<td class="nump">1,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedExpenses', window );">Purchase of property, plant and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_NewAndRevaluationOfRightofuseAssetObtainedInExchangeForLeaseObligation', window );">New and revaluation of right-of-use assets obtained in exchange for lease obligation</a></td>
<td class="nump">$ 936<span></span>
</td>
<td class="nump">$ 753<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_AmortizationOfIntangibleAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_AmortizationOfIntangibleAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_AmortizationOfOperatingLeaseRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_AmortizationOfOperatingLeaseRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents and Restricted cash at end of period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_GainLossOnInvestmentsOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_GainLossOnInvestmentsOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_GainLossOnInvestmentsThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_GainLossOnInvestmentsThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_GainLossOnInvestmentsTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_GainLossOnInvestmentsTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_ImpairmentsOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_ImpairmentsOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_NewAndRevaluationOfRightofuseAssetObtainedInExchangeForLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>New and revaluation of right-of-use asset obtained in exchange for lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_NewAndRevaluationOfRightofuseAssetObtainedInExchangeForLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_PaymentsOfCostsRelatedToAmendmentOfLoanPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_PaymentsOfCostsRelatedToAmendmentOfLoanPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_ProceedsFromExerciseOfWarrantsAndStockOptionsNetOfTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_ProceedsFromExerciseOfWarrantsAndStockOptionsNetOfTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171678102952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zyvgbrUmEEH" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
1. <span id="xdx_82A_zCKsoyU89C83">ORGANIZATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Harrow
Health, Inc. (together with its subsidiaries, partially owned companies and royalty arrangements unless the context indicates
or otherwise requires, the &#8220;Company&#8221; or &#8220;Harrow&#8221;) specializes in the development, production and sale
of innovative medications that offer unique competitive advantages and serve unmet needs in the marketplace through its subsidiaries
and deconsolidated companies. The Company owns one of the nation&#8217;s leading ophthalmology-focused pharmaceutical businesses,
ImprimisRx. In addition to wholly owning ImprimisRx, the Company also has equity positions in Eton Pharmaceuticals, Inc. (&#8220;Eton&#8221;),
Surface Ophthalmics, Inc. (&#8220;Surface&#8221;), and Melt Pharmaceuticals, Inc. (&#8220;Melt&#8221;), all companies that began
as subsidiaries of Harrow. In 2020, Harrow created Visionology, Inc. (&#8220;Visionology&#8221;), which intends to launch an online
eye health platform business. Harrow also owns royalty rights in various drug candidates being developed by Surface and Melt.
The Company intends to continue to create, and hold equity and royalty rights in, new businesses that commercialize drug candidates
that are internally developed or otherwise acquired or licensed from third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
and subsequent to the year ended December 31, 2020, the Company discontinued the majority of operational efforts related to its
subsidiaries Stowe Pharmaceuticals, Inc. (&#8220;Stowe&#8221;), Radley Pharmaceuticals, Inc. (&#8220;Radley&#8221;) and Mayfield
Pharmaceuticals, Inc. (&#8220;Mayfield&#8221;) to allocate resources to other areas of the Company&#8217;s business. The Company
does not expect the suspension of these operations to have a material impact on the financial results of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171679912120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_807_eus-gaap--SignificantAccountingPoliciesTextBlock_zj1B6xAxJlNf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
2. <span id="xdx_82D_zBpWLEXAj7Bj">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zB2g7lpJjhz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_866_z5k7PSmrvwA3" style="font: 10pt Times New Roman, Times, Serif"><b>Basis
of Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Harrow
has prepared the accompanying consolidated financial statements in accordance with accounting principles generally accepted in
the United States of America (&#8220;GAAP&#8221;). The accompanying consolidated financial statements include the accounts of
the Company and its wholly-owned subsidiaries, as well as Mayfield, <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__srt--OwnershipAxis__custom--MayfieldPharmaceuticalsIncMember_zzFi1Xe7zli6">79</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
majority controlled, and Stowe, <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__srt--OwnershipAxis__custom--StowePharmaceuticalsIncMember_zaCIkRXxt1I3">70</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
majority controlled as of December 31, 2020. The remaining <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__srt--OwnershipAxis__custom--MayfieldPharmaceuticalsIncMember__dei--LegalEntityAxis__custom--TGVHealthLLCMember_zejqdJASHqdl">21</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of Mayfield is owned by Elle Pharmaceutical, LLC (&#8220;Elle&#8221;), TGV-Health, LLC and its affiliated entities (collectively
&#8220;TGV&#8221;) or other consultants. Mayfield was organized to develop women&#8217;s health and urological focused drug candidates.
The remaining <span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__srt--OwnershipAxis__custom--StowePharmaceuticalsIncMember__dei--LegalEntityAxis__custom--TGVHealthLLCMember_zVvLbLg0IAcb">30</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of Stowe was owned by TGV. Stowe was organized to develop ophthalmic drug candidates. The Company controls <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__dei--LegalEntityAxis__custom--VisionologyMember_zkoNfOuU98G">100</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of the equity interests in Visionology. All inter-company accounts and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Harrow
consolidates entities in which we have a controlling financial interest. <span id="xdx_90A_ecustom--ConsolidationBasisDescription_c20200101__20201231_zIrQSZmahuie">We
consolidate subsidiaries in which we hold and/or control, directly or indirectly, more than 50% of the voting rights</span></span><span style="font: 10pt Times New Roman, Times, Serif">.
All intercompany accounts and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_844_eus-gaap--UseOfEstimates_zpQsid6VybDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_867_z7UJDpJDayr5" style="font: 10pt Times New Roman, Times, Serif"><b>Use
of Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management are, among
others, allowance for doubtful accounts and contractual adjustments, renewal periods and discount rates for leases, realizability
of inventories, valuation of investments, realizability of deferred taxes, recoverability of goodwill and long-lived assets,
valuation of contingent acquisition obligations and deferred acquisition obligations, fair value of loans payable, and valuation
of stock-based transactions with employees and non-employees. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_843_ecustom--RisksUncertaintiesAndLiquidityPolicyTextBlock_zs7OziXE2Ufl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span id="xdx_863_zxtiQMgtw2R2" style="font: 10pt Times New Roman, Times, Serif"><b>Risks,
Uncertainties and Liquidity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. On March 18, 2020, the Centers for Medicare
&amp; Medicaid Services (&#8220;CMS&#8221;) released guidance for U.S. healthcare providers to limit all elective medical procedures
in order to conserve personal protective equipment and limit exposure to COVID-19 during the pendency of the pandemic. In addition
to limiting elective medical procedures, many hospitals and other healthcare providers have strictly limited access to their facilities
during the pandemic. The COVID-19 pandemic has negatively impacted the global economy, disrupted global supply chains and healthcare
delivery, led to social distancing recommendations, stay-at-home orders and other restrictive measures, and created significant
volatility in financial markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Many
of the Company&#8217;s customers use its drugs in procedures impacted by the CMS guidance to limit elective procedures. In addition,
the Company and our business partners need access to healthcare providers and facilities to conduct clinical trials and other
activities required to achieve regulatory clearance of products under development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Management
believes reductions in elective procedures in response to CMS guidance have had, and will continue to have, an adverse impact,
which may be material, on the Company&#8217;s financial condition, liquidity and results of operations. The severity of the impact
of the COVID-19 pandemic on the Company&#8217;s business will depend on a number of factors, including, but not limited to, the
duration and severity of the pandemic and the extent and severity of the impact on its customers, all of which are uncertain and
cannot be predicted. As of the date of the filing of this Annual Report on Form 10-K, the extent to which the COVID-19 pandemic
may materially impact the Company&#8217;s financial condition, liquidity or results of operations is uncertain. In addition, the
Company is subject to certain regulatory standards, guidelines and inspections which could impact the Company&#8217;s ability
to make, dispense, and sell certain products. If the Company was required to cease compounding and selling certain products as
a result of regulatory guidelines or inspections, this may have a material impact on the Company&#8217;s financial condition,
liquidity and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Prior
to 2020, the Company had incurred significant operating losses and negative cash flows from operations since its inception. The
Company recorded operating income of $<span id="xdx_900_eus-gaap--OperatingIncomeLoss_pn3n3_c20200101__20201231_zrqkwi258fMh">385
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for the year ended December 31, 2020 and
recorded an operating loss of $<span id="xdx_908_eus-gaap--OperatingIncomeLoss_iN_pn3n3_di_c20190101__20191231_zeWB0DB2LjV2">4,795
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for the year ended December 31, 2019.
The Company has an accumulated deficit of $<span id="xdx_90C_ecustom--RetainedEarningsAccumulatedDeficit1_iI_pn3n3_c20201231_zSluZYSmXt7l">77,400
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_902_ecustom--RetainedEarningsAccumulatedDeficit1_c20191231_pn3n3">74,043
</span></span><span style="font: 10pt Times New Roman, Times, Serif">as of December 31, 2020 and 2019, respectively.
In addition, the Company used cash in operating activities of $<span id="xdx_90A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20200101__20201231_zzvRseKWRTyk">1,100
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for the year ended December 31, 2020 and
cash provided by operating activities was $<span id="xdx_90B_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20190101__20191231_pn3n3">950
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for the year ended December 31, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">While
there is no assurance, management of the Company believes existing cash resources and restricted cash of $<span id="xdx_904_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c20201231_pn3n3">4,301
</span></span><span style="font: 10pt Times New Roman, Times, Serif">at December 31, 2020 together with cash
generated from operations, will be sufficient to sustain the Company&#8217;s planned level of operations for at least the next
twelve months. However, estimates of operating expenses and working capital requirements and the future impact of the COVID-19
pandemic on its business could be incorrect. The Company could use its cash resources faster than anticipated. Further, some or
all of the ongoing or planned activities may not be successful and could result in further losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company may seek to increase liquidity and capital resources through a variety of means which may include, but are not limited
to: the sale of assets, investments and/or businesses, obtaining financing through the issuance of equity, debt, or convertible
securities; and working to increase revenue growth through sales. There is no guarantee that the Company will be able to obtain
capital when needed on terms management deems acceptable, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_846_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zpKEVQaOaRf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_862_zVPS8MSdP6Ni" style="font: 10pt Times New Roman, Times, Serif"><b>Segments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s chief operating decision-maker is its Chief Executive Officer who makes resource allocation decisions and assesses
performance based on financial information presented as operating segments. The Company has identified <span id="xdx_903_eus-gaap--NumberOfReportableSegments_pii_dc_uSegment_c20200101__20201231_zZ5WqNKZm3U2">two
</span></span><span style="font: 10pt Times New Roman, Times, Serif">operating segments as reportable segments.
See Note 18 for more information regarding the Company&#8217;s reportable segments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_84A_ecustom--NoncontrollingInterestPolicyTextBlock_zmlNb8sMDXV7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_864_ziIUmOoVZ9f7" style="font: 10pt Times New Roman, Times, Serif"><b>Noncontrolling
Interests</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recognizes any noncontrolling interest as a separate line item in equity in the consolidated financial statements. A noncontrolling
interest represents the portion of equity ownership in a less-than-wholly-owned subsidiary not attributable to the Company. <span id="xdx_901_eus-gaap--MinorityInterestDescription_c20200101__20201231">Generally,
any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there
are other factors, such as decision-making rights, that are considered as well.</span></span> <span style="font: 10pt Times New Roman, Times, Serif">The
Company includes the amount of net loss attributable to noncontrolling interests in consolidated net loss on the face of the consolidated
statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company provides in the consolidated statements of stockholders&#8217; equity a reconciliation at the beginning and the end of
the period of the carrying amount of total equity, equity attributable to the parent, and equity attributable to the noncontrolling
interests that separately discloses:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">net
    income or loss;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">transactions
    with owners acting in their capacity as owners, showing separately contributions from and distributions to owners; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">each
    component of other income or loss.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_842_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zwbvARH7jyOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86B_zdyYS700LCO1" style="font: 10pt Times New Roman, Times, Serif"><b>Revenue
Recognition and Deferred Revenue</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recognizes revenue at the time of transfer of promised goods to customers in an amount that reflects the consideration
to which the Company expects to be entitled in exchange for those goods or services (see Note 3).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_84F_ecustom--CostOfSalePolicyTextBlock_zNULLezY0Jaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86C_zVGLpbcWyQqj" style="font: 10pt Times New Roman, Times, Serif"><b>Cost
of Sales</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cost
of sales includes direct and indirect costs to manufacture formulations and other products sold, including active pharmaceutical
ingredients, personnel costs, packaging, storage, royalties, shipping and handling costs and the write-off of obsolete inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_zi0BbAIaxsOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_869_zXwXtE0Lq2Ta" style="font: 10pt Times New Roman, Times, Serif"><b>Research
and Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company expenses all costs related to research and development as they are incurred. Research and development expenses consist
of expenses incurred in performing research and development activities, including salaries and benefits, other overhead expenses,
and costs related to clinical trials, contract services and outsourced contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_84C_eus-gaap--DebtPolicyTextBlock_zUNT5Nkwu00h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86A_zj9yw1nxbvQk" style="font: 10pt Times New Roman, Times, Serif"><b>Debt
Issuance Costs and Debt Discount</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Debt
issuance costs and the debt discount are recorded net of loans payable and finance lease obligations in the consolidated balance
sheets. Amortization of debt issuance costs and the debt discount is calculated using the effective interest method over the term
of the related debt and is recorded in interest expense in the accompanying consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_84F_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zxVT0PJq49oi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86D_zju760bhyMl8" style="font: 10pt Times New Roman, Times, Serif"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
costs of acquiring intellectual property rights to be used in the research and development process, including licensing fees and
milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified
an alternative future use for the acquired rights, and are capitalized in situations where we have identified an alternative future
use for the acquired rights. Patents and trademarks are recorded at cost and capitalized at a time when the future economic benefits
of such patents and trademarks become more certain (see &#8220;&#8212;Goodwill and Intangible Assets&#8221; below). The Company
began capitalizing certain costs associated with acquiring intellectual property rights during 2015; if costs are not capitalized
they are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zsSvygYBqgej" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_865_zpB7sR0mJIUh" style="font: 10pt Times New Roman, Times, Serif"><b>Income
Taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for income taxes under the provisions of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting
Standards Codification (&#8220;ASC&#8221;) 740, <i>Income Taxes</i>.</span><span style="font-family: Times New Roman, Times, Serif">
<span style="font-size: 10pt">As part of the process of preparing the Company&#8217;s consolidated financial statements, the Company
must estimate the actual current tax assets and liabilities and assess permanent and temporary differences that result from differing
treatment of items for tax and accounting purposes. The temporary differences result in deferred tax assets and liabilities, which
are included within the consolidated balance sheets. The Company must assess the likelihood that the deferred tax assets will
be recovered from future taxable income and, to the extent the Company believes that recovery is not more likely than not, a valuation
allowance must be established which reduces the amount of deferred tax assets recorded on the consolidated balance sheets. To
the extent the Company establishes a valuation allowance or increase or decrease this allowance in a period, the impact will be
included in income tax expense in the consolidated statements of operations.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zuJwTGl323H2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_865_zZc9Bcgsjwok" style="font: 10pt Times New Roman, Times, Serif"><b>Cash
and Cash Equivalents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cash
equivalents include short-term, highly liquid investments with maturities of three months or less at the time of acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zcW8Et4GKXgc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_866_za6tIB3JWyPe" style="font: 10pt Times New Roman, Times, Serif"><b>Concentrations
of Credit Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company places its cash with financial institutions deemed by management to be of high credit quality. The Federal Deposit Insurance
Corporation (&#8220;FDIC&#8221;) provides basic deposit coverage with limits up to $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_pn3n3_c20201231_zoSZhuyxZU2d">250
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per owner. From time to time the Company
has cash deposits in excess of FDIC limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_849_eus-gaap--InvestmentPolicyTextBlock_zxoMNsKe1V7l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86D_zv7fnV1OYq7i" style="font: 10pt Times New Roman, Times, Serif"><b>Investment
in Eton Pharmaceuticals, Inc. &#8211; Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company owns <span id="xdx_903_ecustom--NumberOfSharesOwned_c20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pii">3,500,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of Eton common stock, which represents
approximately <span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zM8adaGIWvig">14.4</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of the equity and voting interests of Eton as of December 31, 2020. At December 31, 2020, the fair market value of Eton&#8217;s
common stock was $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_c20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pii">8.13
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per share. In accordance with Accounting
Standard Update (&#8220;ASU&#8221;) 2016-01, <i>Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of
Financial Assets and Financial Liabilities</i>, for the years ended December 31, 2020 and 2019, the Company recorded investment
gains from its Eton common stock position of $<span id="xdx_900_eus-gaap--GainLossOnInvestments_c20200101__20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pn3n3">3,255
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_903_eus-gaap--GainLossOnInvestments_c20190101__20191231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pn3n3">3,780</span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively, related to the change in fair market value of the Company&#8217;s investment in Eton during the measurement periods.
As of December 31, 2020 and 2019, the fair market value of the Company&#8217;s investment in Eton was $<span id="xdx_909_eus-gaap--InvestmentOwnedAtFairValue_c20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pn3n3">28,455
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_905_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3n3_c20191231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zAouulE0m7Wh">25,200</span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Mark
Baum, the Company&#8217;s Chief Executive Officer, is a member of the board of directors of Eton.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_842_eus-gaap--ReceivablesPolicyTextBlock_zKwwq9dhkrS7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_868_zPimghJtW8eh" style="font: 10pt Times New Roman, Times, Serif"><b>Accounts
Receivable</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Accounts
receivable are stated net of allowances for doubtful accounts and contractual adjustments. The accounts receivable balance primarily
includes amounts due from customers the Company has invoiced or from third-party providers (e.g., insurance companies and governmental
agencies), but for which payment has not been received. Charges to bad debt are based on both historical write-offs and specifically
identified receivables. Accounts receivable are presented net of allowances for doubtful accounts and contractual adjustments
in the amount of $<span id="xdx_90F_eus-gaap--AccountsReceivableNet_iI_pn3n3_c20201231_ze7GjI1AvVz9">98</span></span> <span style="font: 10pt Times New Roman, Times, Serif">and
$<span id="xdx_905_eus-gaap--AccountsReceivableNet_c20191231_pn3n3">76</span></span> <span style="font: 10pt Times New Roman, Times, Serif">as
of December 31, 2020 and 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_841_eus-gaap--InventoryPolicyTextBlock_zsJGwgCCeaIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86B_zgKKlzO6KBkg" style="font: 10pt Times New Roman, Times, Serif"><b>Inventories</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Inventories
are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. The Company evaluates
the carrying value of inventories on a regular basis, based on the price expected to be obtained for products in their respective
markets compared with historical cost. Write-downs of inventories are considered to be permanent reductions in the cost basis
of inventories.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company also regularly evaluates its inventories for excess quantities and obsolescence (expiration), taking into account such
factors as historical and anticipated future sales or use in production compared to quantities on hand and the remaining shelf
life of products and active pharmaceutical ingredients on hand. The Company establishes reserves for excess and obsolete inventories
as required based on its analyses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_84A_ecustom--InvestmentOnePolicyTextBlock_zZz6UKxpUsPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_864_zDoIglvrr3j6" style="font: 10pt Times New Roman, Times, Serif"><b>Investment
in Melt Pharmaceuticals, Inc. &#8211; Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
April 2018, the Company formed Melt as a wholly-owned subsidiary. In January and March of 2019, Melt entered into definitive stock
purchase agreements (collectively, the &#8220;Melt Series A Preferred Stock Agreement&#8221;) with certain investors and closed
on the sale of Melt&#8217;s Series A Preferred Stock (the &#8220;Melt Series A Stock&#8221;), totaling approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20200101__20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pn3n3">11,400
</span></span><span style="font: 10pt Times New Roman, Times, Serif">of proceeds (collectively, the &#8220;Melt
Series A Round&#8221;) at a purchase price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_c20190331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pii">5.00
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per share. As a result, the Company lost
voting and ownership control of Melt and ceased consolidating Melt&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
January 2019, the Company deconsolidated Melt and recorded a gain of $<span id="xdx_902_eus-gaap--DeconsolidationGainOrLossAmount_c20190101__20190131__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3">5,810
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and adjusted the carrying value in Melt
to reflect the increased valuation of Melt and the Company&#8217;s new ownership interest in accordance with ASC 810-10-40-4(c),
<i>Consolidation</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company owns <span id="xdx_907_ecustom--NumberOfSharesOwned_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pii">3,500,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">common shares of Melt (which is approximately
<span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zSd66pRu69Lj">44</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of the equity interests as of December 31, 2020) and uses the equity method of accounting for this investment, as management has
determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Melt.
Under this method, the Company recognizes earnings and losses in Melt in its consolidated financial statements and adjusts the
carrying amount of its investment in Melt accordingly. The Company&#8217;s share of earnings and losses are based on the Company&#8217;s
ownership interest of Melt. Any intra-entity profits and losses are eliminated. The Company recorded equity in the net gain of
Melt of $<span id="xdx_90E_eus-gaap--UnrealizedGainLossOnInvestments_c20190101__20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3">3,968
</span></span><span style="font: 10pt Times New Roman, Times, Serif">during the year ended December 31, 2019.
The Company recorded equity in the net loss of Melt of $<span id="xdx_90F_eus-gaap--UnrealizedGainLossOnInvestments_c20200101__20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3">2,313
</span></span><span style="font: 10pt Times New Roman, Times, Serif">during the year ended December 31, 2020.
As of December 31, 2020 and 2019, the Company&#8217;s investment in Melt was $<span id="xdx_90D_eus-gaap--InvestmentOwnedAtFairValue_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3">2,506
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_905_eus-gaap--InvestmentOwnedAtFairValue_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3">4,690</span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively, which includes $<span id="xdx_904_eus-gaap--DueFromRelatedParties_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3">851
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90F_eus-gaap--DueFromRelatedParties_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3">722</span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively, due from Melt for reimbursable expenses and amounts due under the Melt Master Services Agreement (&#8220;MSA&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">See
Note 4 for more information and related party disclosure regarding Melt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_847_ecustom--InvestmentTwoPolicyTextBlock_zSDPZ9bcLUy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86C_zzuv4slLijWa" style="font: 10pt Times New Roman, Times, Serif"><b>Investment
in Surface Ophthalmics, Inc. &#8211; Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company owns <span id="xdx_90F_ecustom--NumberOfSharesOwned_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pii">3,500,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">common shares (which is approximately
<span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_z8ILJkeZxVa8">30</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of the equity interests as of December 31, 2020) of Surface and uses the equity method of accounting for this investment, as management
has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of
Surface. Under this method, the Company recognizes earnings and losses in Surface in its consolidated financial statements and
adjusts the carrying amount of its investment in Surface accordingly. The Company&#8217;s share of earnings and losses are based
on the Company&#8217;s ownership interest of Surface. Any intra-entity profits and losses are eliminated. The Company recorded
equity in the net loss of Surface of $<span id="xdx_901_eus-gaap--UnrealizedGainLossOnInvestments_c20190101__20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3">1,200
</span></span><span style="font: 10pt Times New Roman, Times, Serif">during the year ended December 31, 2019.
The Company recorded equity in the net loss of Surface of $<span id="xdx_902_eus-gaap--UnrealizedGainLossOnInvestments_c20200101__20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3">2,433
</span></span><span style="font: 10pt Times New Roman, Times, Serif">during the year ended December 31, 2020.
As of December 31, 2020 and 2019, the carrying value of the Company&#8217;s investment in Surface was $<span id="xdx_900_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zanCLi0APkHc">1,314
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90E_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3n3_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_ziyzEpkI1lBk">3,747</span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">See
Note 5 for more information and related party disclosure regarding Surface.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zj1FOkOL4wDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_863_zVg2Wgs9avOk" style="font: 10pt Times New Roman, Times, Serif"><b>Property,
Plant and Equipment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Property,
plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization is calculated
using the straight-line method over the estimated useful life of the asset. Leasehold improvements and capital lease equipment
are amortized over the estimated useful life or remaining lease term, whichever is shorter. Computer software and hardware and
furniture and equipment are depreciated over <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_z6frLmTXqxJd" title="::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0633">three
</span></span></span><span style="font: 10pt Times New Roman, Times, Serif">to <span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_zOKLGLpu2APa">five years</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_84A_eus-gaap--BusinessCombinationsPolicy_zmi63BiVPK49" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86F_zkYgk8tkZ8c2" style="font: 10pt Times New Roman, Times, Serif"><b>Business
Combinations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company accounts for business combinations by recognizing the assets acquired, liabilities assumed, contractual contingencies,
and contingent consideration at their fair values on the acquisition date. The purchase price allocation process requires management
to make significant estimates and assumptions, especially with respect to intangible assets, estimated contingent consideration
payments and pre-acquisition contingencies. Examples of critical estimates in valuing certain of the intangible assets the Company
has acquired or may acquire in the future include but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">future
    expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed
    technologies and patents; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">discount
    rates utilized in valuation estimates.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Unanticipated
events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates or actual results.
Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date,
including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets,
will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related
contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have
a material effect on the consolidated financial position, statements of operations or cash flows in the period of the change in
the estimate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_843_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zEJZfx8SqBth" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86E_zkvFkR2slN9h" style="font: 10pt Times New Roman, Times, Serif"><b>Goodwill
and Intangible Assets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Patents
and trademarks are recorded at cost and capitalized at a time when the future economic benefits of such patents and trademarks
become more certain. At that time, the Company capitalizes third-party legal costs and filing fees associated with obtaining and
prosecuting claims related to its patents and trademarks. Once the patents have been issued, the Company amortizes these costs
over the shorter of the legal life of the patent or its estimated economic life, generally <span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231_zFaqwWWcwHJb">20
</span></span><span style="font: 10pt Times New Roman, Times, Serif">years, using the straight-line method.
Trademarks are an indefinite life intangible asset and are assessed for impairment based on future projected cash flows as further
described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company reviews its goodwill and indefinite-lived intangible assets for impairment as of January 1 of each year and when an event
or a change in circumstances indicates the fair value of a reporting unit may be below its carrying amount. Events or changes
in circumstances considered as impairment indicators include but are not limited to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">significant
    underperformance of the Company&#8217;s business relative to expected operating results;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">significant
    adverse economic and industry trends;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">significant
    decline in the Company&#8217;s market capitalization for an extended period of time relative to net book value; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">expectations
    that a reporting unit will be sold or otherwise disposed.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
goodwill impairment test consists of a two-step process as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Step
1. The Company compares the fair value of each reporting unit to its carrying amount, including the existing goodwill. The fair
value of each reporting unit is determined using a discounted cash flow valuation analysis. The carrying amount of each reporting
unit is determined by specifically identifying and allocating the assets and liabilities to each reporting unit based on headcount,
relative revenues or other methods as deemed appropriate by management. If the carrying amount of a reporting unit exceeds its
fair value, an indication exists that the reporting unit&#8217;s goodwill may be impaired and the Company then performs the second
step of the impairment test. If the fair value of a reporting unit exceeds its carrying amount, no further analysis is required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Step
2. If further analysis is required, the Company compares the implied fair value of the reporting unit&#8217;s goodwill, determined
by allocating the reporting unit&#8217;s fair value to all of its assets and its liabilities in a manner similar to a purchase
price allocation, to its carrying amount. If the carrying amount of the reporting unit&#8217;s goodwill exceeds its fair value,
an impairment loss will be recognized in an amount equal to the excess.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zLkCQtKREeZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_869_zx0R114RXQna" style="font: 10pt Times New Roman, Times, Serif"><b>Impairment
of Long-Lived Assets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Long-lived
assets, such as property, plant and equipment, purchased intangibles subject to amortization and patents and trademarks, are reviewed
for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted
future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash
flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the
asset. Assets to be disposed of would be separately presented in the consolidated balance sheet and reported at the lower of the
carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposal group
classified as held-for-sale would be presented separately in the appropriate asset and liability sections of the consolidated
balance sheet, if material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_843_ecustom--RestructuringPolicyTextBlock_zhaksSxtf4ja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86B_zTQVhvsTGKc2" style="font: 10pt Times New Roman, Times, Serif"><b>Park
Restructuring</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2019, the Company&#8217;s subsidiary, Park Compounding, Inc. (&#8220;Park&#8221;), and Noice Rx, LLC (&#8220;Noice&#8221;)
terminated an Asset Purchase Agreement dated July 26, 2019 (the &#8220;Park Purchase Agreement&#8221;), between the parties. Under
the terms of the Park Purchase Agreement, Park had agreed to sell substantially all its assets associated with its non-ophthalmology
pharmaceutical compounding business to Noice, including its pharmacy facility and equipment located in Irvine, California. The
closing of the sale transaction was dependent on the California State Board of Pharmacy approving of the sale and issuing a temporary
pharmacy and sterile license permit to Noice, which did not occur and led to Park ceasing operations at the close of business
on August 27, 2019. As a result, the Company restructured its Park business, ceased operations at its Irvine, California-based
pharmacy, and facilitated the transition of certain compounded formulations and related equipment from Park to the Company&#8217;s
New Jersey-based compounded pharmaceutical production facilities (the &#8220;Park Restructuring&#8221;). As a result of the Park
Restructuring, the Company incurred non-cash impairment costs of approximately $<span id="xdx_90B_eus-gaap--AssetImpairmentCharges_c20190101__20191231__dei--LegalEntityAxis__custom--ParkCompoundingIncAndNoiceRxLLCMember_pn3n3">3,781
</span></span><span style="font: 10pt Times New Roman, Times, Serif">related to assets held at Park, primarily
associated with property, plant, equipment, inventory, goodwill and other intangible assets, and $<span id="xdx_901_eus-gaap--SeveranceCosts1_c20190101__20191231__dei--LegalEntityAxis__custom--ParkCompoundingIncAndNoiceRxLLCMember_pn3n3">480
</span></span><span style="font: 10pt Times New Roman, Times, Serif">in one-time costs related to severance
packages and other costs associated with the Park Restructuring during the year ended December 31, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has reduced the Park compounded product formulary to seven base formulations, based on factors including unit order volumes,
revenues and gross margin percentages, and ImprimisRx retained approximately half of Park&#8217;s historical revenues during
the first quarter of 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_84A_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zn2PInmnHdN3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_865_zNTAJLxBgAx1" style="font: 10pt Times New Roman, Times, Serif"><b>Fair
Value Measurements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Fair
value measurements are determined based on the assumptions that market participants would use in pricing an asset or liability.
GAAP establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes
the use of unobservable inputs by requiring that the most observable inputs be used when available. The established fair value
hierarchy prioritizes the use of inputs used in valuation methodologies into the following three levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in
    active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure
    fair value whenever available.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such
    as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are
    observable or can be corroborated by observable market data.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entity&#8217;s
    own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level
    3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2020 and 2019, the Company measured its investment in Eton on a recurring basis. The Company&#8217;s investment in
Eton is classified as Level 1 as the fair value is determined using quoted market prices in active markets for the same securities.
As of December 31, 2020 and 2019, the fair market value of the Company&#8217;s investment in Eton was $<span id="xdx_90B_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zmGvFIrjU5u5">28,455
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90C_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3n3_c20191231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zieiRNKDybR8">25,200</span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s financial instruments include cash and cash equivalents, restricted cash, investment in Eton, accounts receivable,
accounts payable and accrued expenses, accrued payroll and related liabilities, deferred revenue and customer deposits, loans
payable and operating and finance lease liabilities. The carrying amount of these financial instruments, except for loans payable
and operating and finance lease liabilities, approximates fair value due to the short-term maturities of these instruments. The
Company&#8217;s restricted cash which is comprised of short-term investments are carried at amortized cost, which approximates
fair value. Based on borrowing rates currently available to the Company, the carrying values of the loans payable and operating
and finance lease liabilities approximate their respective fair values.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_846_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z0tL4ZLkV5ea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_867_zG75iJYyM3Ff" style="font: 10pt Times New Roman, Times, Serif"><b>Stock-Based
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">All
stock-based payments to employees, directors and consultants, including grants of stock options, warrants, restricted stock units
(&#8220;RSUs&#8221;) and restricted stock, are recognized in the consolidated financial statements based upon their estimated
fair values. The Company uses the Black-Scholes-Merton option pricing model and Monte Carlo simulation model to estimate the fair
value of stock-based awards. The estimated fair value is determined at the date of grant. The financial statement effect of forfeitures
is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_z4ZjFTL2yy96" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86B_zzrhTO0IGfpe" style="font: 10pt Times New Roman, Times, Serif"><b>Basic
and Diluted Net Income (Loss) per Common Share</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic
net income (loss) per common share is computed by dividing income (loss) attributable to common stockholders for the period by
the weighted average number of common shares outstanding during the period. Diluted income (loss) per share is computed
by dividing the income (loss) attributable to common stockholders for the period by the weighted average number of common
and common equivalent shares, such as stock options and warrants, outstanding during the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic
and diluted net income (loss) per share is computed using the weighted average number of shares of common stock outstanding during
the period. Common stock equivalents (using the treasury stock or &#8220;if converted&#8221; method) from stock options, unvested
restricted stock units (&#8220;RSUs&#8221;) and warrants were <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndWarrantsMember_pii">5,411,929
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndWarrantsMember_pii">4,848,459
</span></span><span style="font: 10pt Times New Roman, Times, Serif">at December 31, 2020 and 2019, respectively,
and are excluded in the calculation of diluted net income (loss) per share for the periods presented, because the effect is anti-dilutive
for that time period. Included in the basic and diluted net income (loss) per share calculation were RSUs awarded to directors
that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number of shares underlying
vested RSUs at December 31, 2020 and 2019 was <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii">200,463
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii">324,303</span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zqanQOau63d3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table shows the computation of basic net income (loss) per share of common stock for the years ended December 31, 2020
and 2019 (in 000&#8217;s, except share and per share amounts):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B1_zLJrrZUGtTT2" style="display: none">SCHEDULE
OF BASIC EARNINGS PER COMMON SHARE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
<tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20200101_20201231" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20190101_20191231" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended December 31,</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--NetIncomeLoss_pn3n3_zmcAh0QiiBul" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; width: 54%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Numerator
    &#8211; net (loss) income attributable to Harrow Health, Inc.</span></td><td style="padding-bottom: 2.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 19%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,357</span></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 19%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">168</span></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zL46cNFU7Am2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Denominator &#8211; weighted average
    number of shares outstanding, basic</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,895,352</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,323,159</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--EarningsPerShareBasic_pii_zA4JlFNRV9og" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    (loss) income per share, basic</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.13</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.01</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<p id="xdx_8AB_zZxuL4amfJk7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ze4eYR6UJYuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For
the year end December 31, 2019, the Company computed diluted net income per share using the weighted-average number of common
shares and dilutive common equivalent shares outstanding during that period. Diluted common equivalent shares for the year ended
December 31, 2019 consisted of the following (in 000&#8217;s, except share and per share amounts):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_z64O4FuEUht4" style="display: none">SCHEDULE
OF DILUTED COMMON EQUIVALENT SHARES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Diluted shares related to:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 74%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_c20190101__20191231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pii" style="width: 22%; text-align: right" title="Dilutive common equivalent shares"><span style="font-family: Times New Roman, Times, Serif">488,498</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Stock
    options</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_c20190101__20191231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Dilutive common equivalent shares"><span style="font-family: Times New Roman, Times, Serif">654,441</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Dilutive common
    equivalent shares</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_c20190101__20191231_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Dilutive common equivalent shares"><span style="font-family: Times New Roman, Times, Serif">1,142,939</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p id="xdx_8AE_zc1WXHrFzthb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_zPt4kPLVPCb3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table shows the computation of diluted net income per share using the weighted-average number of common shares and dilutive
common equivalent shares outstanding for the year ended December 31, 2019 (in 000&#8217;s, except share and per share amounts):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; display: none"><b>&#160;<span id="xdx_8B2_z8V4339e2Hag">SCHEDULE
OF DILUTED EARNINGS PER COMMON SHARE</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
<tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20190101__20191231_zXVzwvokF3d6" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2019</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2019</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--NetIncomeLoss_pn3n3_za3KraIwjsR8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; width: 74%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Numerator
    &#8211; net income</span></td><td style="padding-bottom: 2.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">168</span></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zyac3j8t4tk1" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Weighted average number of shares outstanding, basic</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,323,159</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_ecustom--IncrementalCommonSharesAttributableDilutiveCommonEquivalents_pii_z2WVbHP00Xv7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dilutive common
    equivalents</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,142,939</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--IncrementalCommonSharesAttributableToContingentlyIssuableShares_pii_zQSHI8sYiMX2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Denominator &#8211;
    number of shares used for diluted earnings per share computation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,466,098</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--EarningsPerShareDiluted_pii_zj3nKy7HkFoc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Net income per
    share, diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.01</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<p id="xdx_8A7_zPGABlO5l2jk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_84F_ecustom--RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_zdg1yXLxkuUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_868_zlyKoit7XDYg" style="font: 10pt Times New Roman, Times, Serif"><b>Recently
Adopted Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</i>,
which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13
replaces the existing incurred loss impairment model with a forward-looking expected credit loss model which will result in earlier
recognition of credit losses. The Company adopted ASU 2016-13 on January 1, 2020, and adoption of the standard did not have a
material effect on the Company&#8217;s consolidated financial position, results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
January 2017, the FASB issued ASU 2017-04, <i>Intangibles-Goodwill and Other</i>. This guidance simplifies the accounting for
goodwill impairment for all entities by requiring impairment charges to be based on the first step in the current two-step impairment
test under ASC 350. The updated standard eliminates the requirement to calculate a goodwill impairment charge using Step 2. If
a reporting unit&#8217;s carrying amount exceeds its fair value, an entity will record an impairment charge based on that difference.
The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. The Company adopted ASU 2017-04
on January 1, 2020, and adoption of the standard did not have a material effect on the Company&#8217;s consolidated financial
position, results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2018, the FASB issued ASU 2018-13, <i>Changes to Disclosure Requirements for Fair Value Measurements</i>, which improved
the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies,
and adds certain disclosure requirements. The Company adopted ASU 2018-13 on January 1, 2020, and adoption of the standard did
not have a material effect on the Company&#8217;s consolidated financial position, results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zblzoMl5axM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86B_ze9IvWDrTEAa" style="font: 10pt Times New Roman, Times, Serif"><b>Recently
Issued Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2019, the FASB issued ASU 2019-12, <i>Income Taxes</i>: <i>Simplifying the Accounting for Income Taxes</i>, which simplifies
the accounting for income taxes. This guidance will be effective for the Company in the first quarter of 2021 on a prospective
basis, and early adoption is permitted. The Company does not expect a material impact of the new guidance on its consolidated
financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z4MuVNqxYXnj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86C_z3kWjNHVTIXb" style="font: 10pt Times New Roman, Times, Serif"><b>Reclassifications</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Certain
prior period items and amounts have been reclassified to conform to the classifications used to prepare the consolidated financial
statements for the year ended December 31, 2020. These reclassifications had no material impact on the Company&#8217;s consolidated
financial position, results of operations, or cash flows as previously reported.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171678107480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUES</a></td>
<td class="text"><p id="xdx_800_eus-gaap--RevenueFromContractWithCustomerTextBlock_z8KoT16n7bs8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
3. <span id="xdx_828_zqVLltb8COE7">REVENUES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company accounts for contracts with customers in accordance with ASC 606, <i>Revenues from Contracts with Customers.</i> The Company
has three primary streams of revenue: (1) revenue recognized from our sale of products within our pharmacy services (2)
revenue recognized from a commission agreement with a third party and (3) revenue recognized from intellectual property
license and asset purchase agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Product
Revenues from Pharmacy Services</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company sells prescription drugs directly through our pharmacy and outsourcing facility network. Revenue from our pharmacy services
divisions includes: (i) the portion of the price the client pays directly to us, net of any volume-related or other discounts
paid back to the client, (ii) the price paid to us by individuals, and (iii) customer copayments made directly to the pharmacy
network. Sales taxes are not included in revenue. Following the core principles of ASC 606, we have identified the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Identify
    the contract(s) with a customer: A contract exists with a customer at the time the prescription or order is received by the
    Company.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Identify
    the performance obligations in the contract: The order received contains the performance obligations to be met, in almost
    all cases the product the customer is wishing to receive. If we are unable to be meet the performance obligation the customer
    is notified.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Determine
    the transaction price: the transaction price is based on the product being sold to the customer, and any related customer
    discounts. These amounts are pre-determined and built into our order management software.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Allocate
    the transaction price to the performance obligations in the contract: The transaction price associated with the product(s)
    being ordered is allocated according to the pre-determined amounts.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Recognize
    revenue when (or as) the entity satisfies a performance obligation: At the time of shipment from the pharmacy or outsourcing
    facility the performance obligation has been met.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following revenue recognition policy has been established for the pharmacy services division:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Revenues
generated from prescription or office use drugs sold by our pharmacies and outsourcing facility are recognized when the prescription
is shipped. At the time of shipment, the pharmacy services division has performed substantially all of its obligations under its
client contracts and does not experience a significant level of returns or reshipments. Determination of criteria (3) and (4)
is based on management&#8217;s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability
of those amounts. The Company records reductions to revenue for discounts at the time of the initial sale. Estimated returns and
allowances and other adjustments are provided for in the same period during which the related sales are recorded and are based
on actual returns history. The rate of returns is analyzed annually to determine historical returns experience. If the historical
data we use to calculate these estimates do not properly reflect future returns, then a change in the allowance would be made
in the period in which such a determination is made and revenues in that period could be materially affected. The Company will
defer any revenues received for a product that has not been delivered or is subject to refund until such time that the Company
and the customer jointly determine that the product has been delivered and no refund will be required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Commission
Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">During
the year ended December 31, 2020, the Company entered into an agreement whereby</span> <span style="font: 10pt Times New Roman, Times, Serif">it
is paid a fee calculated based on sales it generates from a pharmaceutical product that is owned by a third party. The revenue
earned from this arrangement is recognized at the time a customer has ordered the pharmaceutical product and it has shipped from
the third party (or one of its distributors or affiliates), at which point there is no future performance obligation required
by the Company and no consequential continuing involvement on the part of the Company to recognize the associated revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Intellectual
Property License Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company currently holds five intellectual property license and related agreements in which the Company has promised to grant a
license or sale which provides a customer with the right to access the Company&#8217;s intellectual property. License arrangements
may consist of non-refundable upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights
to patented or patent pending compounds, technology access fees, and various performance or sales milestones. These arrangements
can be multiple-element arrangements, the revenue of which is recognized at the point of time the performance obligation is met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Non-refundable
fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on the
part of the Company are recognized as revenue when the license term commences and the licensed data, technology, compounded drug
preparation and/or other deliverable is delivered. Such deliverables may include physical quantities of compounded drug preparations,
design of the compounded drug preparations and structure-activity relationships, the conceptual framework and mechanism of action,
and rights to the patents or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable
fees if it has continuing performance obligations without which the technology, right, product or service conveyed in conjunction
with the non-refundable fee has no utility to the licensee and that are separate and independent of the Company&#8217;s performance
under the other elements of the arrangement. In addition, if the Company&#8217;s continued involvement is required, through research
and development services that are related to its proprietary know-how and expertise of the delivered technology or can only be
performed by the Company, then such non-refundable fees are deferred and recognized over the period of continuing involvement.
Guaranteed minimum annual royalties are recognized on a straight-line basis over the applicable term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_897_eus-gaap--DisaggregationOfRevenueTableTextBlock_ztse0XPjc8Kh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Revenue
disaggregated by revenue source for the years ended December 31, 2020 and 2019, consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B1_zgDCXutC9LY2" style="display: none">SCHEDULE
OF DISAGGREGATED REVENUE</span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20200101__20201231_zXjkmt7RQjS5" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20190101__20191231_zCgJERXstHci" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Years Ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Product
    sales, net</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_z2vy7QHcd335" style="width: 18%; text-align: right" title="Total Revenues"><span style="font-family: Times New Roman, Times, Serif">48,479</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20191231__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_zXQYsT0UskV4" style="width: 18%; text-align: right" title="Total Revenues"><span style="font-family: Times New Roman, Times, Serif">51,137</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Commissions</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--CommissionsMember_z9qdAGyt5GH7" style="text-align: right" title="Total Revenues"><span style="font-family: Times New Roman, Times, Serif">356</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--CommissionsMember_pn3n3" style="text-align: right" title="Total Revenues"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0706">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">License</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zam5zkBhjPH1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues"><span style="font-family: Times New Roman, Times, Serif">36</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues"><span style="font-family: Times New Roman, Times, Serif">28</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_z6WY4vLl8aul" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    revenues</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">48,871</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,165</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p id="xdx_8AD_zyu4urvGWrfl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Deferred
revenue and customer deposits at December 31, 2020 and 2019, were $<span id="xdx_909_eus-gaap--ContractWithCustomerLiabilityCurrent_c20201231_pn3n3">66
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_901_eus-gaap--ContractWithCustomerLiabilityCurrent_c20191231_pn3n3">57</span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively. All deferred revenue and customer deposit amounts at December 31, 2019 were recognized as revenue during the year
ended December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171677754744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zUV64Zjsdnk7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
4. <span id="xdx_825_zcEcINQa0uN2">INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2018, the Company entered into an asset purchase agreement with Melt (the &#8220;Melt Asset Purchase Agreement&#8221;).
Pursuant to the terms of the Melt Asset Purchase Agreement, Melt was assigned certain intellectual property and related rights
from the Company to develop, formulate, make, sell, and sub-license certain Company conscious sedation and analgesia related formulations
(collectively, the &#8220;Melt Products&#8221;). Under the terms of the Melt Asset Purchase Agreement, Melt is required to make
mid-single digit royalty payments to the Company on net sales of the Melt Products while any patent rights remain outstanding,
as well as other conditions. In January and March 2019, the Company entered into the Melt Series A Preferred Stock Agreement,
see also Note 2, under the subheading <i>Investment in Melt Pharmaceuticals, Inc</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
February 2019, the Company and Melt entered into a Management Services Agreement (the &#8220;Melt MSA&#8221;), whereby the Company
provides to Melt certain administrative services and support, including bookkeeping, web services and human resources related
activities, and Melt is required to pay the Company a monthly amount of $<span id="xdx_907_eus-gaap--AdministrativeFeesExpense_pn3n3_c20190201__20190228__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_zC3CEx4f7Ssk">10</span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020 and 2019, the Company was due $<span id="xdx_906_eus-gaap--DueFromRelatedParties_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_pn3n3">851
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90E_eus-gaap--DueFromRelatedParties_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_pn3n3">722</span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively, from Melt for reimbursable expenses and amounts due under the Melt MSA. Melt did no</span><span style="font: 10pt Times New Roman, Times, Serif">t
make any payments to the Company during the year ended December 31, 2020 and paid the Company $<span id="xdx_902_eus-gaap--RepaymentsOfRelatedPartyDebt_c20190101__20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--MSAMember_pn3n3">50
</span></span><span style="font: 10pt Times New Roman, Times, Serif">during the year ended December 31, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s Chief Executive Officer, Mark L. Baum, and Chief Medical Officer, Larry Dillaha, are members of the Melt board
of directors, and several employees of the Company (including Mr. Baum, Mr. Dillaha and the Company&#8217;s Chief Financial Officer,
Andrew Boll) entered into consulting agreements and provide consulting services to Melt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89A_ecustom--ScheduleOfCondensedIncomeStatementOneTableTextBlock_zRZArcCQNL66" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
unaudited condensed results of operations information of Melt is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BC_zLmh3RyFHgLk" style="font: 10pt Times New Roman, Times, Serif; display: none">SCHEDULE
OF CONDENSED INCOME STATEMENT</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Years Ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Revenues, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Revenues, net"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0725">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Revenues, net"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0727">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    from operations</span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--OperatingIncomeLoss_c20200101__20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Loss from operations"><span style="font-family: Times New Roman, Times, Serif">5,019</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--OperatingIncomeLoss_c20190101__20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Loss from operations"><span style="font-family: Times New Roman, Times, Serif">4,381</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--NetIncomeLoss_c20200101__20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"><span style="font-family: Times New Roman, Times, Serif">(5,019</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--NetIncomeLoss_c20190101__20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"><span style="font-family: Times New Roman, Times, Serif">(4,381</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
</table>


<p id="xdx_8A4_zVJzaHs0NPVj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89B_ecustom--ScheduleOfCondensedBalanceSheetOneTableTextBlock_zwmQcbAYH4Hd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
unaudited condensed balance sheet information of Melt is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B5_zA39cAzGTzFi" style="font: 10pt Times New Roman, Times, Serif; display: none">SCHEDULE
OF CONDENSED BALANCE SHEET</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Current assets</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--AssetsCurrent_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="width: 18%; text-align: right" title="Current assets"><span style="font-family: Times New Roman, Times, Serif">2,947</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--AssetsCurrent_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="width: 18%; text-align: right" title="Current assets"><span style="font-family: Times New Roman, Times, Serif">7,449</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Non current
    assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--AssetsNoncurrent_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets"><span style="font-family: Times New Roman, Times, Serif">11</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--AssetsNoncurrent_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--Assets_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets"><span style="font-family: Times New Roman, Times, Serif">2,958</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--Assets_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets"><span style="font-family: Times New Roman, Times, Serif">7,454</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--Liabilities_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities"><span style="font-family: Times New Roman, Times, Serif">1,778</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--Liabilities_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities"><span style="font-family: Times New Roman, Times, Serif">1,691</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total preferred
    stock and stockholders&#8217; equity</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--StockholdersEquity_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total preferred stock and stockholders' equity"><span style="font-family: Times New Roman, Times, Serif">1,180</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--StockholdersEquity_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total preferred stock and stockholders' equity"><span style="font-family: Times New Roman, Times, Serif">5,763</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total liabilities
    and stockholders&#8217; equity</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--LiabilitiesAndStockholdersEquity_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity"><span style="font-family: Times New Roman, Times, Serif">2,958</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--LiabilitiesAndStockholdersEquity_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity"><span style="font-family: Times New Roman, Times, Serif">7,454</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p id="xdx_8A4_zXJ9p3IO4ggh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171684434456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract', window );"><strong>Investment In Surface Ophthalmics Inc. And Agreements - Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock', window );">INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_802_ecustom--InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock_z0Zp9bskmkk8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
5. <span id="xdx_82D_zycWZ1Ojflz5">INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company entered into an asset purchase and license agreement with Surface in 2017 and amended it in April 2018 (the &#8220;Surface
License Agreements&#8221;). Pursuant to the terms of the Surface License Agreements, the Company assigned and licensed to Surface
certain intellectual property and related rights associated with Surface&#8217;s drug candidates (collectively, the &#8220;Surface
Products&#8221;). Surface is required to make mid-single-digit royalty payments to the Company on net sales of the Surface
Products while any patent rights remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020, the Company owned <span id="xdx_901_eus-gaap--SharesOutstanding_iI_pii_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zUf2Wpf5UMpe">3,500,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of Surface common stock (approximately
<span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zDa6O5oJ228d">30</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of the issued and outstanding equity interests). A Company director, Richard L. Lindstrom, and the Company&#8217;s Chief Executive
Officer, Mark L. Baum, are directors of Surface. Surface is required to make royalty payments to Dr. Lindstrom of <span id="xdx_905_ecustom--RoyaltyPaymentPercentageOnNetSales_pii_dp_uPercent_c20200101__20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember__srt--TitleOfIndividualAxis__custom--DrLindstromMember_zb6EbmhuIKj2">3</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of net sales of certain Surface Products while certain patent rights remain outstanding. Dr. Lindstrom is also a principal of
Flying L Partners, an affiliate of the funding investor who purchased the Surface Series A Preferred Stock. Several employees
and a director of the Company (including Mr. Baum and Dr. Lindstrom) entered into consulting agreements and provided consulting
services to Surface.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_896_esrt--ScheduleOfCondensedIncomeStatementTableTextBlock_zVSrka9hJfF" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
unaudited condensed results of operations information of Surface is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B5_zaAtubQHO5k8" style="font: 10pt Times New Roman, Times, Serif; display: none">SUMMARY
OF CONDENSED INCOME STATEMENT</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year<b>s</b> Ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Revenues, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Revenues, net"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0770">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Revenues, net"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0772">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    from operations</span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--OperatingIncomeLoss_c20200101__20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Loss from operations"><span style="font-family: Times New Roman, Times, Serif">8,109</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--OperatingIncomeLoss_c20190101__20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Loss from operations"><span style="font-family: Times New Roman, Times, Serif">4,000</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--NetIncomeLoss_c20200101__20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"><span style="font-family: Times New Roman, Times, Serif">(8,109</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--NetIncomeLoss_c20190101__20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"><span style="font-family: Times New Roman, Times, Serif">(4,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
</table>

<p id="xdx_8A2_zGGDHlBuasi9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_897_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_zshJRTO0n9Bk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
unaudited condensed balance sheet information of Surface is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B5_zqOuNIJAasqj" style="font: 10pt Times New Roman, Times, Serif; display: none">SUMMARY
OF CONDENSED BALANCE SHEET</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">
    December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Current assets</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AssetsCurrent_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="width: 18%; text-align: right" title="Current assets"><span style="font-family: Times New Roman, Times, Serif">9,074</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--AssetsCurrent_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="width: 18%; text-align: right" title="Current assets"><span style="font-family: Times New Roman, Times, Serif">15,942</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Non current
    assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AssetsNoncurrent_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets"><span style="font-family: Times New Roman, Times, Serif">45</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--AssetsNoncurrent_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets"><span style="font-family: Times New Roman, Times, Serif">47</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--Assets_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets"><span style="font-family: Times New Roman, Times, Serif">9,119</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--Assets_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets"><span style="font-family: Times New Roman, Times, Serif">15,989</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--Liabilities_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities"><span style="font-family: Times New Roman, Times, Serif">1,666</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--Liabilities_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities"><span style="font-family: Times New Roman, Times, Serif">619</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total stockholders&#8217;
    equity</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--StockholdersEquity_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders equity"><span style="font-family: Times New Roman, Times, Serif">7,453</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--StockholdersEquity_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders equity"><span style="font-family: Times New Roman, Times, Serif">15,370</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    liabilities and stockholders&#8217; equity</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--LiabilitiesAndStockholdersEquity_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity"><span style="font-family: Times New Roman, Times, Serif">9,119</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--LiabilitiesAndStockholdersEquity_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity"><span style="font-family: Times New Roman, Times, Serif">15,989</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p id="xdx_8AE_z4SoyS3XYfv5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments and Agreements Related Party Transactions [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171679378232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRICTED CASH<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_DisclosureRestrictedCashAbstract', window );"><strong>Disclosure Restricted Cash Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_RestrictedCashTextBlock', window );">RESTRICTED CASH</a></td>
<td class="text"><p id="xdx_809_ecustom--RestrictedCashTextBlock_zWdfTOfggzq4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
6. <span id="xdx_82F_z9fWDjic99Qa">RESTRICTED CASH</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
restricted cash at December 31, 2020 and 2019 consisted of funds held in a money market account. At December 31, 2020 and 2019,
the restricted cash was recorded at amortized cost, which approximates fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2020 and 2019, the funds held in a money market account of $<span id="xdx_90F_eus-gaap--RestrictedCash_iI_pn3n3_c20201231_zJ7PsU3yXhdj"><span id="xdx_90C_eus-gaap--RestrictedCash_iI_pn3n3_c20191231_zgUbebkvmXca">200</span>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">were classified as a current asset. The
money market account funds are required as collateral as additional security for the Company&#8217;s New Jersey facility lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_DisclosureRestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_DisclosureRestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_RestrictedCashTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_RestrictedCashTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171679436024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p id="xdx_809_eus-gaap--InventoryDisclosureTextBlock_zhZ42oWSglNk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
7. <span id="xdx_827_z70OLwL0XVqg">INVENTORIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zVM9xZ4mT2g5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Inventories
are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, commercial pharmaceutical
products, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of December 31,
2020 and 2019 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B0_zIjxVAkLNoc5" style="display: none; font-family: Times New Roman, Times, Serif">SCHEDULE
OF INVENTORIES</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20201231" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20191231" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINz6Re_zTVNBcbUSdw8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Raw materials</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,501</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,405</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINz6Re_z6vJj1koPK5i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Work in progress</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">17</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">20</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINz6Re_zJzeTHthaeq9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Finished goods</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,444</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">876</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--InventoryNet_iTI_pn3n3_mtINz6Re_znCqFTxzdDdi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total inventories</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,962</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,301</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p id="xdx_8A0_zVn7719gfAa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171782321048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--OtherAssetsDisclosureTextBlock_zJnfWJhnF8Il" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
8. <span id="xdx_822_zIDflze9QU82">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_890_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zMM0nyOgIy16" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Prepaid
expenses and other current assets consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BB_zlAuHGfL9hd1" style="display: none; font-family: Times New Roman, Times, Serif">SCHEDULE
OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20201231_zIEkQ4Z1pGU2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20191231_zIrCXcI8M0a2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAzQA0_z7lY8f1LmF06" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Prepaid insurance</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">160</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">123</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maPEAOAzQA0_zRr4mVc6ivQl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Other prepaid expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">401</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">358</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--OtherAssetsCurrent_iI_pn3n3_maPEAOAzQA0_z3cZ6ho4SpT6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Deposits and
    other current assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">190</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">105</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzQA0_zIRBNErWxx65" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total prepaid
    expenses and other current assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">751</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">586</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p id="xdx_8A9_zMiTfBeTWgf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171684535288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, PLANT AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_803_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zOByKcPBfMde" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
9. <span id="xdx_82D_z2jwdajAZQM9">PROPERTY, PLANT AND EQUIPMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89D_eus-gaap--PropertyPlantAndEquipmentTextBlock_zU7a0HAL9JCh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Property,
plant and equipment, net at December 31, 2020 and 2019 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B8_zJzr49I67J88" style="display: none; font-family: Times New Roman, Times, Serif">SCHEDULE
OF PROPERTY, PLANT AND EQUIPMENT</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20201231_zmAaGU4dJKh9" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20191231_zXOV4No9klFg" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Property, plant and equipment, net:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_maPPAEGzzle_zpt88c4SRsr1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Computer
    software and hardware</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,707</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,732</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAEGzzle_ztjBM8L8AUh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Furniture and
    equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">418</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">363</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_maPPAEGzzle_zSP7XrWC6eq" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Lab and pharmacy
    equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,426</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,164</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--LeaseholdImprovementsGross_iI_pn3n3_maPPAEGzzle_z1SmBOq4b4Dk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Leasehold
    improvements</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,720</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,510</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_mtPPAEGzzle_maPPAENzQqn_zC4fNjsEzm0a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;Property, plant
    and equipment, gross</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,271</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,769</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzQqn_z4uHdoRGQXtk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    depreciation and amortization</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(6,818</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,394</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzQqn_zVbprQkbhqt3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Property,
    plant and equipment, net&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,453</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,375</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p id="xdx_8A6_zeuIAuTRzWk8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020, the Company disposed of property, plant and equipment with a net book value of $<span id="xdx_904_eus-gaap--GainLossOnDispositionOfAssets1_iN_pn3n3_di_c20200101__20201231_ziUP7FbpOVo4">105
</span></span><span style="font: 10pt Times New Roman, Times, Serif">related to the discontinued use of certain
computer software and hardware and was included within other (loss) income of the consolidated statements of operations.
The Company recorded depreciation and amortization expense of $<span id="xdx_904_eus-gaap--DepreciationAmortizationAndAccretionNet_c20200101__20201231_pn3n3">1,880</span>
</span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_903_eus-gaap--DepreciationAmortizationAndAccretionNet_c20190101__20191231_pn3n3">1,936</span>
</span><span style="font: 10pt Times New Roman, Times, Serif">during the years ended December 31, 2020
and 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171679446184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS AND GOODWILL</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zj8WgHcD7qKf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
10. <span id="xdx_822_z8IuEPqvmch2">INTANGIBLE ASSETS AND GOODWILL</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_z9CnciC2W6x1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s intangible assets at December 31, 2019 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BE_z7uGUwecGrci" style="font: 10pt Times New Roman, Times, Serif; display: none">SCHEDULE
OF INTANGIBLE ASSETS</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">periods</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(in
    years)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Cost</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">amortization</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Impairment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Carrying
    value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 21%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; width: 13%; text-align: center"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MinimumMember_zJDQd12aOYyc" style="font-family: Times New Roman, Times, Serif">17</span><span style="font-family: Times New Roman, Times, Serif">-<span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MaximumMember_ztZBmwpM1WE8">19
    years</span></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zhbD2JrfAgrk" style="width: 13%; text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">1,102</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_ziIZt3BHrsDc" style="width: 13%; text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(97</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zIqUTTOPJ39h" style="width: 13%; text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif">(259</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zna80rxILWI9" style="width: 13%; text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif">746</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Licenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z3k89bh0bBW1" style="font-family: Times New Roman, Times, Serif">20
    years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zY1AHJtP3hO6" style="text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">50</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z99Wqkb89VBg" style="text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zbcA2GUkwVLc" style="text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0891">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zxyIg2UbCCRl" style="text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif">45</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trademarks</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zBY0yKcqo9b3" style="font-family: Times New Roman, Times, Serif">Indefinite</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zw6q7xgAUXgd" style="text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">340</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zWn3zLg1I8Eb" style="text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0898">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z1LJRv60q221" style="text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0900">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zgT4x7HeEPZi" style="text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif">340</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Customer relationships</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MinimumMember_zKR67nTo16Fj" style="font-family: Times New Roman, Times, Serif">3</span><span style="font-family: Times New Roman, Times, Serif">-<span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MaximumMember_z5kmYX467Uuf">15
    years</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z1cDt2HRe15c" style="text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">3,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zZmeiVV6yvx6" style="text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(1,165</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zxgKZB53Hakd" style="text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif">(630</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z2SFsTRf6t7d" style="text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif">1,205</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trade name</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zVZNFy9f5Brd" style="font-family: Times New Roman, Times, Serif">5
    years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zF275xxnyRp1" style="text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">16</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zC0NwhC2l5Af" style="text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zsqVqOTODgV7" style="text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif">(2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zs4tRqxbxU4f" style="text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0921">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-competition clause</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MinimumMember_zKrDhGjvHJdj" style="font-family: Times New Roman, Times, Serif">3</span><span style="font-family: Times New Roman, Times, Serif">-<span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MaximumMember_zyrkJ6baCHA9">4
    years</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zqn1b3j6nWjj" style="text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">294</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zEsaUUYHCIHl" style="text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(274</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zAfJs3Z6l5Me" style="text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif">(20</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zzJzn6bvsGbi" style="text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0931">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State pharmacy
    licenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zfur4GTZ1z6j" style="font-family: Times New Roman, Times, Serif">25
    years</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zgiz2zfbxlZj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">45</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zGhmR1USem05" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(9</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zdTRXTlUiIY5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif">(35</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zzd4Eso5bG6b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231_zNlAG0V5AI5a" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">4,847</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231_zOAZLafkIIs9" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(1,564</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231_zfwFghU4otk" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif">(946</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231_zXhHwMCoYw24" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif">2,337</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2019, the Company incurred impairment charges of $<span id="xdx_908_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember__dei--LegalEntityAxis__custom--ParkCompoundingIncMember_pn3n3">612
</span></span><span style="font: 10pt Times New Roman, Times, Serif">related to intangible assets, including
customer relationships, trade name, and state pharmacy licenses as a part of the Park Restructuring and $<span id="xdx_907_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__dei--LegalEntityAxis__custom--ParkCompoundingIncMember_pn3n3">259
</span></span><span style="font: 10pt Times New Roman, Times, Serif">of impairment charges related to patents
associated with the termination of an asset agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s intangible assets at December 31, 2020 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">periods</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(in
    years)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Cost</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">amortization</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Impairment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Carrying
    value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 21%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 13%; text-align: center"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MinimumMember_zhP46VZLxkA5" style="font-family: Times New Roman, Times, Serif">17</span><span style="font-family: Times New Roman, Times, Serif">-<span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MaximumMember_zlrwlaXJYgnj">19
    years</span></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 13%; text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">929</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 13%; text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(93</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 13%; text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif">(363</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 13%; text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif">473</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Licenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_ztvth0XwlEM2" style="font-family: Times New Roman, Times, Serif">20
    years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">50</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(6</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0967">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif">44</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trademarks</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember" style="font-family: Times New Roman, Times, Serif">Indefinite</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">356</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zyVZb9RLmQSk" style="text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0974">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0976">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif">356</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Customer relationships</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MinimumMember_zTIJEmYmkAi1" style="font-family: Times New Roman, Times, Serif">3</span><span style="font-family: Times New Roman, Times, Serif">-<span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MaximumMember_zMyTp3xvOvye">15
    years</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">1,519</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(454</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0986">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif">1,065</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trade name</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zFoEcLU36Rml" style="font-family: Times New Roman, Times, Serif">5
    years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0995">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0997">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-competition clause</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MinimumMember_zHCLJgySguOh" style="font-family: Times New Roman, Times, Serif">3</span><span style="font-family: Times New Roman, Times, Serif">-<span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MaximumMember_zz3yOhc7RnC2">4
    years</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">50</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(50</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1005">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1007">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State pharmacy
    licenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zspTSXx0fi16" style="font-family: Times New Roman, Times, Serif">25
    years</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(7</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1014">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">2,917</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(615</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif">(363</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif">1,939</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p id="xdx_8AE_zzzWCuzuBtXd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020, the Company recorded impairment charges of $<span id="xdx_902_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsFilingsAndTrademarksMember__dei--LegalEntityAxis__custom--ParkCompoundingIncMember_pn3n3">363
</span></span><span style="font: 10pt Times New Roman, Times, Serif">related to patent filings and trademarks
that were abandoned and/or were associated with products the Company was no longer actively selling.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zAj2eB9v1R98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Amortization
expense for intangible assets for the years ended December 31, 2020 and 2019 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BB_zlrxcSZGQuah" style="display: none; font-family: Times New Roman, Times, Serif">SCHEDULE
OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">For
                                         the Years Ended</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">December
                                         31,</span></p></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 18%; text-align: right" title="Amortization of intangible assets"><span style="font-family: Times New Roman, Times, Serif">32</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 18%; text-align: right" title="Amortization of intangible assets"><span style="font-family: Times New Roman, Times, Serif">48</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Licenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Customer relationships</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"><span style="font-family: Times New Roman, Times, Serif">134</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"><span style="font-family: Times New Roman, Times, Serif">151</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Trade name</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1041">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State pharmacy
    licenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1045">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets"><span style="font-family: Times New Roman, Times, Serif">167</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets"><span style="font-family: Times New Roman, Times, Serif">209</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p id="xdx_8A3_z80cgrtyrZCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zCrnqtoou5C7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Estimated
future amortization expense for the Company&#8217;s intangible assets at December 31, 2020 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B5_zWrE2YLiAiU1" style="display: none; font-family: Times New Roman, Times, Serif">SCHEDULE
OF ESTIMATED FUTURE AMORTIZATION EXPENSE</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Years
    ending December 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20201231_z08ve1nggkf4" style="display: none; text-align: center; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif">Dec</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzZax_zun3XUYwvgmk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">187</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzZax_zqXKKurZLBq4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">187</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzZax_zClalTV8kFt6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">187</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzZax_zUTxlWzgqgA7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">160</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANzZax_zLNYUz6Wy1q8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">147</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANzZax_z1idoaLAGGd7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">715</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzZax_zGYl8T2Be8Ak" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Intangible assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,583</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p id="xdx_8AF_zBGCJpC4cQX9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfGoodwillTextBlock_zjexslfNY2lb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">There
were <span id="xdx_90D_eus-gaap--GoodwillAndIntangibleAssetImpairment_pn3n3_do_c20200101__20201231_zB80rURDddwl">no</span></span>
<span style="font: 10pt Times New Roman, Times, Serif">changes in the carrying value of the Company&#8217;s
goodwill during the year ended December 31, 2020. Changes in the carrying value of the Company&#8217;s goodwill during the year
ended December 31, 2019 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B9_zfvkaevAckXe" style="display: none; font-family: Times New Roman, Times, Serif">SCHEDULE
OF GOODWILL</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
<tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_49D_20190101__20191231_zFUhKXfZ0Moj" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">Dec</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--Goodwill_iS_pn3n3_zllUwXCIesg3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance at December 31,
    2018</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,227</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--GoodwillImpairmentLoss_iN_pn3n3_di_zWCIoVCs7YF3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Impairment
    of Park goodwill (see Note 2)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,895</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_406_eus-gaap--Goodwill_iE_pn3n3_zn1KMrun4BX1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at
    December 31, 2019</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">332</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p id="xdx_8A8_zaqi1mldLqdg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171678085400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</a></td>
<td class="text"><p id="xdx_804_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z85dyRTKf31k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
11. <span id="xdx_82A_z4P77nLTTW4d">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zSTbfZT5E0Gh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Accounts
payable and accrued expenses at December 31, 2020 and 2019 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BF_zNnrDhjj9D91" style="font: 10pt Times New Roman, Times, Serif; display: none">SCHEDULE
OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20201231_zOQWq8Mbsmch" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20191231_zJeZIV8iuay5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn3n3_maAPAALzPeR_zPXROrIZN1d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,645</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,409</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maAPAALzPeR_zdhO5q7IVid6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Other accrued expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">49</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">49</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_maAPAALzPeR_zcEkRYmBjvdk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accrued interest (see Note 12)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">238</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">244</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maAPAALzPeR_zOuy8vW3Rud3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued exit
    fee for note payable (see Note 12)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">800</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">800</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_pn3n3_mtAPAALzPeR_zmszDR9tOXkj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total accounts payable and accrued
    expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,732</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,502</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iNI_pn3n3_di_zHTQw7cSETZd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: Current
    portion</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,932</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7,702</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_400_eus-gaap--AccountsPayableAndAccruedLiabilitiesNoncurrent_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Non-current
    total accrued expenses</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">800</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">800</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p id="xdx_8AE_zQNChrfo0NTg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171684437800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text"><p id="xdx_809_eus-gaap--DebtDisclosureTextBlock_ze5UvGsiekF7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
12. <span id="xdx_82B_zVTvWXWJj8J">DEBT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>SWK
Senior Note &#8211; 2017</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2017, the Company entered into a term loan and security agreement in the principal amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20170731__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember_zWwKP1oKmQt9">16,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">(the &#8220;SWK Loan Agreement&#8221;
or &#8220;SWK Loan&#8221;) with SWK Funding LLC and its partners (&#8220;SWK&#8221;), as lender and collateral agent. <span id="xdx_90F_eus-gaap--DebtInstrumentDescription_c20170701__20170731__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember">The
SWK Loan Agreement was fully funded at closing with a five-year term, however, such term could be reduced to four years if certain
revenue requirements are not achieved.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190401__20190430__us-gaap--VariableRateAxis__us-gaap--LondonInterbankOfferedRateLIBORMember" title="Debt instrument interest rate description">Prior
to the loan refinance in May 2019 (see below), the SWK Loan bore interest at a variable rate equal to the three-month London Inter-Bank
Offered Rate (subject to a minimum of <span id="xdx_901_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_uPercent_c20190401__20190430__us-gaap--VariableRateAxis__us-gaap--LondonInterbankOfferedRateLIBORMember__srt--RangeAxis__srt--MinimumMember_zdHatem99rpj" title="Loan bear interest at variable rate">1.50</span>%
and maximum of <span id="xdx_90A_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_uPercent_c20190401__20190430__us-gaap--VariableRateAxis__us-gaap--LondonInterbankOfferedRateLIBORMember__srt--RangeAxis__srt--MaximumMember_zSbc7F7EDeSa" title="Loan bear interest at variable rate">3.00</span>%),
plus an applicable margin of <span id="xdx_90F_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_uPercent_c20190401__20190430__us-gaap--VariableRateAxis__us-gaap--LondonInterbankOfferedRateLIBORMember_z4WLWy8fCz51" title="Loan bear interest at variable rate">10.50</span>%.</span>
</span><span style="font: 10pt Times New Roman, Times, Serif">The SWK Loan Agreement permitted the Company
to pay interest only on the principal amount borrowed thereunder for the first six payments (payments are due on a quarterly basis),
which interest-only period could have been reduced to four payments if the Company had not met certain minimum revenue requirements.
Following the interest-only period, the Company was required to pay interest, plus repayments of the principal amount borrowed
under the SWK Loan Agreement, in quarterly payments, which shall not exceed $<span id="xdx_90B_eus-gaap--RepaymentsOfDebt_pn3n3_c20190429__20190430__us-gaap--TypeOfArrangementAxis__custom--SWKLoanAgreementMember_z81y6psk9il6">750
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per quarter. <span id="xdx_903_eus-gaap--DebtInstrumentMaturityDateDescription_c20190429__20190430__us-gaap--TypeOfArrangementAxis__custom--SWKLoanAgreementMember">All
amounts owed under the SWK Loan Agreement, including an exit fee equal to 5% of the aggregate principal amount loaned thereunder,
were originally due and payable on July 19, 2022.</span></span> <span style="font: 10pt Times New Roman, Times, Serif">The
Company is obligated under the SWK Loan Agreement to pay for certain expenses incurred by SWK through and after the date of the
SWK Loan Agreement, including certain fees and expenses relating to the preparation and administration of the SWK Loan Agreement.
The Company incurred expenses and an exit fee of approximately $<span id="xdx_90B_eus-gaap--DebtInstrumentFeeAmount_c20190430__us-gaap--TypeOfArrangementAxis__custom--SWKLoanAgreementMember_pn3n3">1,282
</span></span><span style="font: 10pt Times New Roman, Times, Serif">in connection with the SWK Loan Agreement.
The exit fee and expenses were recorded as a debt discount and are being amortized as interest expense over the term of the SWK
Loan using the effective interest rate method and the related liability of $<span id="xdx_90D_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_c20201231_zbCQFVx2F7r7"><span id="xdx_908_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_c20191231_pn3n3">800</span>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for the exit fee is included in accrued
expenses (see Note 11) in the accompanying consolidated balance sheets as of December 31, 2020 and 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
connection with the SWK Loan Agreement, the Company issued to SWK warrants to purchase up to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20170731__us-gaap--StatementEquityComponentsAxis__custom--LenderWarrantsMember_zlXZJ4EwuSK9">415,586
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of the Company&#8217;s common stock
(the &#8220;Lender Warrants&#8221;) with an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20170731__us-gaap--StatementEquityComponentsAxis__custom--LenderWarrantsMember_pii">3.08</span></span><span style="font: 10pt Times New Roman, Times, Serif">.
In August 2017, the Company and SWK amended the warrants, to allow for the purchase of up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pii_c20170831__us-gaap--StatementEquityComponentsAxis__custom--LenderWarrantsMember_zy4W0iUAcqD2">615,386
</span></span><span style="font: 10pt Times New Roman, Times, Serif">warrants with an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20170831__us-gaap--StatementEquityComponentsAxis__custom--LenderWarrantsMember_pii">2.08</span></span><span style="font: 10pt Times New Roman, Times, Serif">.
The Lender Warrants are exercisable immediately, and have a term of <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dt_c20170731__us-gaap--StatementEquityComponentsAxis__custom--LenderWarrantsMember_zsck4JNX6Vcj">seven
years</span></span><span style="font: 10pt Times New Roman, Times, Serif">. The Lender Warrants are subject
to a cashless exercise feature, with the exercise price and number of shares issuable upon exercise subject to change in connection
with stock splits, dividends, reclassifications and other conditions. The relative fair value of the Lender Warrants was approximately
$<span id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_c20200101__20201231_pn3n3">982</span></span> <span style="font: 10pt Times New Roman, Times, Serif">and
was estimated using the Black-Scholes-Merton option pricing model with the following assumptions: fair value of the Company&#8217;s
common stock at issuance of $<span id="xdx_902_eus-gaap--SharesIssued_c20170831__us-gaap--StatementEquityComponentsAxis__custom--LenderWarrantsMember_pii">2.08
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per share; seven-year contractual term;
<span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pii_dp_uPercent_c20170831__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zoKrPzP5lJJg">113.5</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
volatility; <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pii_dp_uPercent_c20170831__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z8iBgC34qAWj">0</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
dividend rate; and a risk-free interest rate of <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pii_dp_uPercent_c20170831__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zJGDRNQprik7">1.77</span></span><span style="font: 10pt Times New Roman, Times, Serif">%.
The relative fair value of the Lender Warrants was recorded as a debt discount which is being amortized as interest expense over
the term of the SWK Loan using the effective interest rate method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>SWK
Refinance &#8211; May 2019</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
May 2019, the Company entered into a joinder and amendment (the &#8220;Amendment&#8221;) to the SWK Loan and with SWK, as lender
and collateral agent. A summary of the material changes contained in the Amendment are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    interest rate calculation that the loan bears is now equal to the three-month London Inter-Bank Offered Rate (subject to a
    minimum of <span id="xdx_901_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--JoinderAndAmendmentMember__us-gaap--VariableRateAxis__us-gaap--LondonInterbankOfferedRateLIBORMember__srt--RangeAxis__srt--MinimumMember_zeDhU0aeb4b7">2.00</span></span><span style="font: 10pt Times New Roman, Times, Serif">%),
    plus an applicable margin of <span id="xdx_900_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pii_dp_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--JoinderAndAmendmentMember__us-gaap--VariableRateAxis__custom--MarginRateMember_znvEES1EYcx8">10.00</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
    (the &#8220;Margin Rate&#8221;); provided that, if, two days prior to a payment date, the <span id="xdx_90B_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--JoinderAndAmendmentMember">Company
    provides SWK evidence that the Company has achieved a leverage ratio as of such date of less than 4.00:1:00, the Margin Rate
    shall equal 9.00%; and if the Company has achieved a leverage ratio as of such date of less than 3.00:1:00, the Margin Rate
    shall equal 7.00%;</span></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Leverage
    ratio in the Amendment means, as of any date of determination, the ratio of: (a) indebtedness as of such date to (b) EBITDA
    (as defined in the SWK Loan), of the Company for the immediately preceding twelve (12) month period, adding-back (i) actual
    litigation expenses for the immediately preceding twelve (12) month period, minus (ii) actual litigation expenses for the
    immediately preceding three (3) month period multiplied by four (4);</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    definition of the first amortization date was changed to May 14, 2020, permitting the Company to pay interest only on the
    principal amount loaned for the next four payments (payments are due on a quarterly basis) following the Amendment; </span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Subject
    to the satisfaction of certain revenue and market capitalization requirements and conditions, SWK agreed to make available
    to the Company an additional principal amount of up to $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20190531__us-gaap--TypeOfArrangementAxis__custom--JoinderAndAmendmentMember_z16G7gMhLfj6">5,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">;
    and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    maturity date was changed to <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--JoinderAndAmendmentMember__us-gaap--VariableRateAxis__custom--MarginRateMember_zTh86uO0sqYd">July
    19, 2023</span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Related
to the Amendment, the Company incurred expenses related to legal and lender costs of $<span id="xdx_90E_eus-gaap--LegalFees_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--JoinderAndAmendmentMember__us-gaap--VariableRateAxis__custom--MarginRateMember_pn3n3">282
</span></span><span style="font: 10pt Times New Roman, Times, Serif">that are included in debt discount and
will be amortized over the remaining term of the SWK Loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
addition to the terms described above, the Amendment joined the Company&#8217;s recently created subsidiaries to the SWK Loan
and added definitions related to excluded subsidiaries that are not considered co-borrowers and are subsidiaries of the Company
which the Company believes it will eventually deconsolidate from its financial statements and lose <span id="xdx_90B_ecustom--DeconsolidationPercentage_pii_dp_c20190501__20190531__us-gaap--TypeOfArrangementAxis__custom--JoinderAndAmendmentMember__us-gaap--VariableRateAxis__custom--MarginRateMember_z9KbGtnwpbp">50</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
or more of the equity interests of the subsidiary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Second
Amendment to SWK Loan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On
April 1, 2020, the Company and several of its wholly owned subsidiaries entered into a second amendment (the &#8220;SWK Second
Amendment&#8221;) to the SWK Loan with SWK. A summary of the material changes contained in the SWK Second Amendment are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">SWK
    agreed to make available to the Company, and the Company drew down on, an additional principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_c20200402__us-gaap--TypeOfArrangementAxis__custom--SWKSecondAmendmentMember_pn3n3">1,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    definition of the first amortization date was changed to August 14, 2020, permitting the Company to pay interest only on the
    principal amount loaned for the next payment (payments are due on a quarterly basis) following the SWK Second Amendment; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
    interest payment of $<span id="xdx_900_eus-gaap--InterestExpenseDebt_c20200513__20200514__us-gaap--TypeOfArrangementAxis__custom--SWKSecondAmendmentMember_pn3n3">358
    </span></span><span style="font: 10pt Times New Roman, Times, Serif">due May 14, 2020 was paid in-kind
    by increasing the principal amount of the term loans by an amount equal to the interest accrued as of such date.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Interest
expense related to the SWK Loan Agreement, as amended, amounted to $<span id="xdx_90B_eus-gaap--InterestExpenseDebt_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--SWKSecondAmendmentMember_pn3n3">1,768
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90D_eus-gaap--InterestExpenseDebt_pn3n3_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--SWKSecondAmendmentMember_zEDV9TOdVkP">1,960
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for the years ended December 31, 2020
and 2019, respectively, and included amortization of debt issuance costs and discount of $<span id="xdx_908_eus-gaap--AmortizationOfDebtDiscountPremium_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--SWKSecondAmendmentMember_pn3n3">457
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_909_eus-gaap--AmortizationOfDebtDiscountPremium_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--SWKSecondAmendmentMember_pn3n3">512
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for the years ended December 31, 2020
and 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Paycheck
Protection Program Loan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
April 2020, the Company entered into an unsecured promissory note and related Business Loan Agreement with Renasant Bank, as lender,
for a loan (the &#8220;PPP Loan&#8221;) in the principal amount of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_c20200430__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember_pn3n3">1,967
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and received cash proceeds of the same
amount, pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic
Security Act (the &#8220;CARES Act&#8221;), which was enacted March 27, 2020. The PPP is administered by the U.S. Small Business
Administration (the &#8220;SBA&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Under
the terms of the PPP Loan, interest accrues on the outstanding principal at the rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_dp_c20200430__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember_zQ1cZ59nM5U5">1.0</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
per annum. The term of the PPP Loan is two years, unless payment is sooner required in connection with an event of default under
the PPP Loan. To the extent the PPP Loan amount is not forgiven under the PPP, the Company is obligated to make equal monthly
payments of principal and interest, beginning seven months from the date of the PPP Loan, until the maturity date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
CARES Act and the PPP provide a mechanism for forgiveness of up to the full amount borrowed. Under the PPP, the Company applied
for forgiveness for all of the PPP Loan during the year ended December 31, 2020, however the SBA has not made a decision related
to the Company&#8217;s application for forgiveness. The amount of loan proceeds eligible for forgiveness is based on a formula
that takes into account a number of factors, including the amount of loan proceeds used by the Company during the 24-week period
after the loan origination for certain purposes including payroll costs, interest on certain mortgage obligations, rent payments
on certain leases, and certain qualified utility payments (<span id="xdx_907_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20200403__20200430__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember">it
being anticipated that at least 75% of the loan amount will be required to be used for eligible payroll costs</span></span><span style="font: 10pt Times New Roman, Times, Serif">);
the employer maintaining or rehiring employees and maintaining salaries at certain levels; and other factors. Subject to the other
requirements and limitations on loan forgiveness, only loan proceeds spent on payroll and other eligible expenses during the covered
twenty-four-week period will qualify for forgiveness. While the Company has used proceeds from the PPP Loan for such qualifying
expenses, in particular maintaining continuity of its payroll and workforce (including staff critical to the timely production
and dispensing of medicines the Company produces), no assurance can be provided that the Company will obtain forgiveness of the
PPP Loan in whole or in part. <span id="xdx_90B_eus-gaap--InterestExpenseDebt_pn3n3_do_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember_z03zsm6G9Z5">No
</span></span><span style="font: 10pt Times New Roman, Times, Serif">interest expense was recognized for the
year ended December 31, 2020 related to the PPP Loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zXNJcHgSyYGf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2020, future minimum payments under the Company&#8217;s debt were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BD_zizdE1NSyEMa" style="font: 10pt Times New Roman, Times, Serif; display: none">SUMMARY
OF FUTURE MINIMUM PAYMENTS</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20201231_zLJmPpoPTFI6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maLTDzahg_zABGlu8wOMFe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,794</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maLTDzahg_zaeVDqElNOY5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,700</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maLTDzahg_zL7MRHjzyf0f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,511</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDzahg_zvgwAcLonrK6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total minimum payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,005</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--InterestPayableCurrent_iNI_pn3n3_di_zN3aVQMerpM8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: amount
    representing interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,927</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_409_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_zvYFCbAYDpB4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Notes payable, gross</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,078</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_zBlvNm0isV8g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: unamortized
    discount</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(802</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_406_eus-gaap--NotesPayable_iTI_pn3n3_zKOyQNKTAAV8" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Notes payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,276</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_ecustom--NotesPayableCurrent1_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: current
    portion, net of unamortized discount</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,898</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_409_ecustom--LongTermNotesPayable1_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Note payable,
    net of current portion and unamortized debt discount</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,378</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p id="xdx_8A8_zx7jYDbayZG5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171679690104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_805_eus-gaap--LeasesOfLesseeDisclosureTextBlock_za1ngAJwHxB3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
13. <span id="xdx_820_zJpYFUmOR7Lc">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company leases office and laboratory space under the non-cancelable operating leases listed below. These lease agreements have
remaining lease terms between <span id="xdx_90F_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtYxL_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember__srt--RangeAxis__srt--MinimumMember_zV9nVi3OtnBg" title="::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl1169">one
</span></span></span><span style="font: 10pt Times New Roman, Times, Serif">to <span id="xdx_90F_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dc_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember__srt--RangeAxis__srt--MaximumMember_zzeGYKmm635f">four years</span> and contain various clauses
for renewal at the Company&#8217;s option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">An
    operating lease for <span id="xdx_904_eus-gaap--AreaOfLand_iI_pii_uSqft_c20201231__srt--StatementGeographicalAxis__custom--SanDiegoMember_zAkrDPYkY75f">10,200
    </span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">square feet
    of office space in San Diego, California, that expires in <span id="xdx_906_ecustom--LeaseExpirationDateDescription_c20200101__20201231__srt--StatementGeographicalAxis__custom--SanDiegoMember_zHw0khCE3uMc">December
    2021</span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">, with
    an <span id="xdx_90F_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20200101__20201231__srt--StatementGeographicalAxis__custom--SanDiegoMember_z9i7qTEO1CT4">option
    to extend the term for a five-year period</span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">An
    operating lease for <span id="xdx_905_eus-gaap--AreaOfLand_iI_pii_uSqft_c20201231__srt--StatementGeographicalAxis__custom--LedgewoodMember_z9Cpzr0f9szl">26,400
    </span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">square feet
    of lab, warehouse and office space in Ledgewood, New Jersey, that expires in <span id="xdx_90E_ecustom--LeaseExpirationDateDescription_c20200101__20201231__srt--StatementGeographicalAxis__custom--LedgewoodMember_z7HS8z3U0AFh">July
    2026</span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">, with
    <span id="xdx_90B_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20200101__20201231__srt--StatementGeographicalAxis__custom--LedgewoodMember_zUkbx8fTEood">an
    option to extend the term for two additional five-year periods</span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">.
    This includes an amendment that was made effective July 2020 that extended the term of the original lease and added <span id="xdx_902_ecustom--AdditionalAreaOfLand_iI_pii_uSqft_c20201231__srt--StatementGeographicalAxis__custom--LedgewoodMember_zb4ngO58o8Df" title="Additional square footage">1,400
    </span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">of additional
    square footage to the lease; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An
    operating lease for <span id="xdx_904_eus-gaap--AreaOfLand_iI_pii_uSqft_c20201231__srt--StatementGeographicalAxis__custom--NashvilleMember_zODv94I0Lh8f">5,500
    </span></span><span style="font: 10pt Times New Roman, Times, Serif">square feet of office space in Nashville,
    Tennessee, that expires in <span id="xdx_908_ecustom--LeaseExpirationDateDescription_c20200101__20201231__srt--StatementGeographicalAxis__custom--NashvilleMember">December
    2024</span></span><span style="font: 10pt Times New Roman, Times, Serif">, with an <span id="xdx_901_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20200101__20201231__srt--StatementGeographicalAxis__custom--NashvilleMember">option
    to extend the term for two additional five-year periods</span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">During
the year ended December 31, 2020, the Company terminated its operating lease for <span id="xdx_909_eus-gaap--AreaOfLand_iI_pii_uSqft_c20201231__srt--StatementGeographicalAxis__custom--IrvineMember_zNVcLKqqULV">4,500
</span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">square feet of
office and lab space in Irvine, California, that had an expiration date in December 2020. In connection with the termination,
the Company recorded a gain of $<span id="xdx_908_eus-gaap--GainLossOnTerminationOfLease_c20200101__20201231__srt--StatementGeographicalAxis__custom--IrvineMember_pn3n3">4
</span></span><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">which was recognized
in other income (expense) on the consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2020 and 2019, the weighted-average discount rate and the weighted-average remaining lease term for the operating
leases held by the Company were <span id="xdx_90E_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_uPercent_c20201231_zNoiPzgLgIc5">6.3</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
and <span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_uPercent_c20191231_zpxXjiyJR571">6.3</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
and <span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zFigVgEPCSfk">11.2</span></span>
<span style="font: 10pt Times New Roman, Times, Serif">and <span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20191231_z1CXzUB5jLh">10.21
</span></span><span style="font: 10pt Times New Roman, Times, Serif">years, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the years ended December 31, 2020 and 2019, cash paid for amounts included for the operating lease liabilities was $<span id="xdx_906_eus-gaap--OperatingLeasePayments_c20200101__20201231_pn3n3">1,052
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_901_eus-gaap--OperatingLeasePayments_pn3n3_c20190101__20191231_zD9j5V5z3Shj">905</span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively, and the Company recorded operating lease expense of $<span id="xdx_900_eus-gaap--OperatingLeaseExpense_c20200101__20201231_pn3n3">1,066
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90F_eus-gaap--OperatingLeaseExpense_c20190101__20191231_pn3n3">892</span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively, included in selling, general and administrative expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zBHaDku5PJ05" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Future
lease payments under operating leases (including options to extend) as of December 31, 2020 were as follows<b>: </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;<span id="xdx_8BA_zCGIKH544meg" style="display: none">SCHEDULE
OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20201231_z7vEciE6mGM9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Dec
    31, 2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Operating
    Leases</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzHYL_ztSvJXG01Clg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right" title="2021"><span style="font-family: Times New Roman, Times, Serif">1,017</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzHYL_z7dClBFBQ3Wa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right" title="2022"><span style="font-family: Times New Roman, Times, Serif">1,038</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzHYL_zbURxCwGXWIi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right" title="2023"><span style="font-family: Times New Roman, Times, Serif">1,064</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzHYL_z0YO91yBCbig" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,090</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maLOLLPzHYL_zgIv5ehjhyEb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">916</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPzHYL_zM4UDNvZZjrk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,141</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzHYL_zLehlB1IYAz8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total minimum lease payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,266</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_z4XSssBwVWBb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: amount
    representing interest payments</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,034</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zXfD1mp0LnE3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total operating
    lease liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,232</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_zRcbHFWH26Ga" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: current
    portion, operating lease liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(580</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    lease liabilities, net of current portion</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,652</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p id="xdx_8A5_zepq4jRCP57" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company also has a finance lease for equipment which requires monthly payments of $<span id="xdx_905_ecustom--MonthlyPaymentsOfFinanceLeaseForEquipment_pn3n3_c20200101__20201231_zDMM54Im8Mm5" title="Monthly payments of finance lease">1
</span></span><span style="font: 10pt Times New Roman, Times, Serif">through January 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_892_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_z8hLwse0aLEb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Future
lease payments under the finance lease as of December 31, 2020 were as follows<b>: </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;<span id="xdx_8B9_zMAS9lkCNBG4" style="display: none">SCHEDULE
OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20201231_zQ8cj1fDi9x3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Dec
    31, 2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Finance
    Lease</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maFLLPDzqJW_zbhPbELo62cb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maFLLPDzqJW_z1r0Hki6hbTf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maFLLPDzqJW_zZY2ZHZ47DF" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maFLLPDzqJW_zlhD50S62qNj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_pn3n3_mtFLLPDzqJW_z6THCmSKI286" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total minimum lease payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">28</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zGQmkwS8O0Q8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: amount
    representing interest payments</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40C_eus-gaap--FinanceLeaseLiability_iI_pn3n3_zbbH2BQ1BGz3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Present value of future minimum lease
    payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">25</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_pn3n3_di_ze37uSaOytll" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: current
    portion, finance lease obligation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Finance lease
    obligation, net of current portion</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p id="xdx_8A3_zAa0VS9yabwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2020 and 2019, the weighted-average discount rate and the weighted-average remaining lease term for the finance lease
held by the Company were <span id="xdx_901_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_c20201231_pii">6.36</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
and <span id="xdx_904_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_uPercent_c20191231_zvicejXg1Gh4">6.36</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
and <span id="xdx_90E_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20201231_zA51YxXsd3j2">3.08</span></span>
<span style="font: 10pt Times New Roman, Times, Serif">and <span id="xdx_904_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20191231_zKZPUyQvCQlb">4.08
</span></span><span style="font: 10pt Times New Roman, Times, Serif">years, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For
the years ended December 31, 2020 and 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">debt
    discount amortization related to a finance lease obligation was $<span id="xdx_908_eus-gaap--AmortizationOfDebtDiscountPremium_c20200101__20201231_pn3n3">0
    </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_909_eus-gaap--AmortizationOfDebtDiscountPremium_c20190101__20191231_pn3n3">17</span></span><span style="font: 10pt Times New Roman, Times, Serif">,
    respectively;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">amortization
    expense related to the equipment held under the finance lease obligations was $<span id="xdx_902_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_c20200101__20201231_pn3n3">8
    </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_903_eus-gaap--FinanceLeaseRightOfUseAssetAmortization_c20190101__20191231_pn3n3">150</span></span><span style="font: 10pt Times New Roman, Times, Serif">,
    respectively; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">cash
    paid and expense recognized for interest expense related to the finance lease obligation was $<span id="xdx_906_eus-gaap--FinanceLeaseInterestExpense_c20200101__20201231_pn3n3">2
    </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_907_eus-gaap--FinanceLeaseInterestExpense_c20190101__20191231_pn3n3">18</span></span><span style="font: 10pt Times New Roman, Times, Serif">,
    respectively.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171679929032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zNZ3jL7CR8s8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
14. <span id="xdx_822_zYHe9NP6Sdx4">STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2020 and 2019, the Company had <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pii_c20201231_zDDq1EK97VTk" title="Common stock, shares authorized"><span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pii_c20191231_zD0ElZopPIH2" title="Common stock, shares authorized">50,000,000</span></span> shares of common stock, $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pii_c20201231_zrqPlGwJ7Hh1" title="Common stock, par value"><span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pii_c20191231_zq3KoOUSP7A5" title="Common stock, par value">0.001</span></span> par value, authorized, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Issuances
During the Year Ended December 31, 2019</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" title="Shares issued of restricted common stock, shares">15,000</span> shares of its restricted common stock, with a fair value of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJAfkvI70YOf" title="Fair value of restricted common stock issued">75</span>, as consideration for commission expenses
    incurred during the year ended December 31, 2018;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company issued <span id="xdx_90B_ecustom--NumberOfCommonStockIssuedOnCashlessExercise_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Number of common stock issued on cashless exercise">27,671</span> shares of its common stock upon the cashless exercise of options to purchase <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Common shares issued under share-based arrangement">82,929</span> shares of common
    stock, with exercise prices ranging from $<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Options exercise price, minimum">1.70</span> to $<span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zBMBD7ZEBqu9" title="Options exercise price, maximum">4.17</span> per share, net of <span id="xdx_906_ecustom--CommonStockWithheldForPayrollTaxWithholdingsShare_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pii" title="Common stock withheld for payroll tax withholdings, shares">8,806</span> shares of common stock withheld for payroll
    tax withholdings totaling $<span id="xdx_907_ecustom--CommonStockWithheldForPayrollTaxWithholdingsValue_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pn3n3" title="Common stock withheld for payroll tax withholdings, value">50</span>;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company issued <span id="xdx_902_ecustom--NumberOfCommonStockIssuedOnCashlessExercise_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Number of common stock issued on cashless exercise">2,122</span> shares of its common stock upon the exercise of options to purchase <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Common shares issued under share-based arrangement">2,122</span> shares of common stock, with
    exercise prices ranging from $<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Options exercise price, minimum">1.70</span> to $<span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Options exercise price, maximum">3.20</span> per share, and received net proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pn3n3" title="Proceeds from issuance of common stock">6</span>;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsOneMember_pii" title="Number of shares issued">688,473</span> shares of its common stock upon the cashless exercise of warrants to purchase <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsOneMember_pii" title="Common shares issued under share-based arrangement">964,532</span> shares of common
    stock with an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20191231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsOneMember_pii" title="Warrants exercise price">1.79</span> per share;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company issued <span title="Common shares issued under share-based arrangement"><span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsTwoMember_pii" title="Number of shares issued">454,055</span></span> shares of its common stock upon the exercise of warrants to purchase <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsTwoMember_pii" title="Common shares issued under share-based arrangement">454,055</span> shares of common stock
    with an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20191231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsTwoMember_pii" title="Warrants exercise price">1.79</span> per share, and received net proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromWarrantExercises_c20190101__20191231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsTwoMember_pn3n3" title="Proceeds from issuance of warrant">813</span>; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company issued</span> <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zjNKaEvK4Fx1">87,610</span> shares of its
    common stock underlying RSUs issued to directors vested, but the issuance and delivery of these shares are deferred until
    the director resigns.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Issuances
During the Year Ended December 31, 2020</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.15pt; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" title="Shares issued of restricted common stock, shares">30,000</span> shares of its restricted common stock, with an initial fair value of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pn3n3" title="Fair value of restricted common stock issued">167</span>, as consideration for commission
    expenses incurred during the year ended December 31, 2019 and the year ended December 31, 2020;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company issued <span id="xdx_904_ecustom--NumberOfCommonStockIssuedOnCashlessExercise_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Number of common stock issued on cashless exercise">4,161</span> shares of its common stock upon the cashless exercise of options to purchase <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Common shares issued under share-based arrangement">16,750</span> shares of common
    stock, with exercise prices ranging from $<span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Options exercise price, minimum">1.70</span> to $<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Options exercise price, maximum">4.05</span> per share, net of <span id="xdx_905_ecustom--CommonStockWithheldForPayrollTaxWithholdingsShare_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pii" title="Common stock withheld for payroll tax withholdings, shares">3,564</span> shares of common stock withheld for payroll
    tax withholdings;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company issued <span id="xdx_903_ecustom--NumberOfCommonStockIssuedOnCashlessExercise_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Number of common stock issued on cashless exercise">2,998</span> shares of its common stock upon the exercise of options to purchase <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Common shares issued under share-based arrangement">2,998</span> shares of common stock, with
    exercise prices ranging from $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Options exercise price, minimum">3.04</span> to $<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Options exercise price, maximum">3.20</span> per share, and paid $<span id="xdx_906_ecustom--CommonStockWithheldForPayrollTaxWithholdingsValue_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pn3n3" title="Common stock withheld for payroll tax withholdings, value">8 </span>related to payroll tax withholdings;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" title="Shares issued of restricted common stock, shares">185,785</span> shares of its common stock underlying RSUs held by directors that resigned. The RSUs had previously
    vested, including <span id="xdx_902_ecustom--RestrictedStockUnitsVested_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" title="Restricted stock units vested">26,721</span> RSUs during the year ended December 31, 2020, but the issuance and delivery of the shares
    were deferred until the director resigned; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_pii" title="Shares issued of restricted common stock, shares">35,224</span>
    </span><span style="font: 10pt Times New Roman, Times, Serif">shares of the Company&#8217;s common stock underlying RSUs
    issued to directors vested, but the issuance and delivery of these shares are deferred until the resignation of a director.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Preferred
Stock </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2020 and 2019, the Company had <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_c20201231_pii" title="Preferred stock, shares authorized"><span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_c20191231_pii" title="Preferred stock, shares authorized">5,000,000</span></span> shares of preferred stock, $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_c20201231_pii" title="Preferred stock, par value"><span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_c20191231_pii" title="Preferred stock, par value">0.001</span></span> par value, authorized and <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pii_do_c20201231_zjkHWXQIjgC8" title="Preferred stock, shares issued"><span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pii_do_c20201231_zLFCisVtY8tj" title="Preferred stock, shares outstanding"><span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_pii_do_c20191231_zZUgl1b55R7k" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pii_do_c20191231_zY8BHLZ34SF8" title="Preferred stock, shares outstanding">no</span></span></span></span> shares of
preferred stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Stock
Option Plan </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
September 17, 2007, the Company&#8217;s Board of Directors and stockholders adopted the Company&#8217;s 2007 Incentive Stock and
Awards Plan, which was subsequently amended on November 5, 2008, February 26, 2012, July 18, 2012, May 2, 2013 and September 27,
2013 (as amended, the &#8220;2007 Plan&#8221;). The 2007 Plan reached its term in September 2017, and we can no longer issue additional
awards under this plan, however, options previously issued under the 2007 Plan will remain outstanding until they are exercised,
reach their maturity or are otherwise cancelled/forfeited. On June 13, 2017, the Company&#8217;s Board of Directors and stockholders
adopted the Company&#8217;s 2017 Incentive Stock and Awards Plan (the &#8220;2017 Plan&#8221; together with the 2007 Plan, the
&#8220;Plans&#8221;). As of December 31, 2020, the 2017 Plan provides for the issuance of a maximum of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20201231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_pii" title="Maximum number of common stock issuance under the plan">2,000,000</span> shares of the
Company&#8217;s common stock. The purpose of the Plans are to attract and retain directors, officers, consultants, advisors and
employees whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of
such persons in the Company&#8217;s development and financial success. Under the Plans, the Company is authorized to issue incentive
stock options intended to qualify under Section 422 of the Internal Revenue Code, non-qualified stock options, restricted stock
units and restricted stock. The Plans are administered by the Compensation Committee of the Company&#8217;s Board of Directors.
The Company had <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20201231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_pii" title="Shares available for future issuances">342,882</span> shares available for future issuances under the 2017 Plan at December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zFVMg4isXzGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of stock option activity under the Plan for the year ended December 31, 2020 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BA_zXtj7wc3j72" style="display: none">SCHEDULE OF STOCK OPTION PLAN ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Avg. Exercise Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Avg. Remaining Contractual Life</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate
    Intrinsic Value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Options outstanding -
    January 1, 2020</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20191231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z0wvlfZb3Fn5" style="width: 11%; text-align: right" title="Number of shares, Outstanding, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">2,656,683</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20191231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z0vDY4ja3755" style="width: 11%; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">5.31</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Options granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="text-align: right" title="Number of shares, Options granted"><span style="font-family: Times New Roman, Times, Serif">414,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="text-align: right" title="Weighted Avg. Exercise Price, Options granted"><span style="font-family: Times New Roman, Times, Serif">6.44</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Options exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zd3fg6nsMnVl" style="text-align: right" title="Number of shares, Options exercised"><span style="font-family: Times New Roman, Times, Serif">(19,748</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="text-align: right" title="Weighted Avg. Exercise Price, Options exercised"><span style="font-family: Times New Roman, Times, Serif">3.19</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Options cancelled/forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zJClW6EHXCrh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Options cancelled/forfeited"><span style="font-family: Times New Roman, Times, Serif">(21,402</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Avg. Exercise Price, Options cancelled/forfeited"><span style="font-family: Times New Roman, Times, Serif">12.77</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Options outstanding
    - December 31, 2020</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zPqFOLroBC48" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Outstanding, Ending balance"><span style="font-family: Times New Roman, Times, Serif">3,030,033</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z8NK6nsAbH8j" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, Ending balance"><span style="font-family: Times New Roman, Times, Serif">5.43</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Remaining Contractual Life, Options outstanding"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zfsq95D078Lf" title="Weighted Avg. Remaining Contractual Life, Options outstanding">5.72</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zVWtCkyG1Zj8" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options outstanding"><span style="font-family: Times New Roman, Times, Serif">5,569</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Options exercisable</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zRo6HTPothl3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options exercisable"><span style="font-family: Times New Roman, Times, Serif">1,908,849</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zZ4f98mY0SBk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Avg. Exercise Price, Exercisable Ending Balance"><span style="font-family: Times New Roman, Times, Serif">4.49</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Remaining Contractual Life, Options exercisable"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zA66gTouaDb6" title="Weighted Avg. Remaining Contractual Life, Options exercisable">5.25</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z0FlgEJo9dy" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options exercisable"><span style="font-family: Times New Roman, Times, Serif">5,051</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Options vested
    and expected to vest</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zQgK1tz9Qhu9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options vested and expected to vest"><span style="font-family: Times New Roman, Times, Serif">2,918,298</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z3JdTHMSppok" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Avg. Exercise Price, Vested and expected to vest"><span style="font-family: Times New Roman, Times, Serif">5.37</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Remaining Contractual Life, Options vested and expected to vest"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zFknDYG1ZkKf" title="Weighted Avg. Remaining Contractual Life, Options vested and expected to vest">5.69</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pn3n3_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zWSdyEIPs5ti" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options vested and expected to vest"><span style="font-family: Times New Roman, Times, Serif">5,519</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p id="xdx_8A1_zszb1uTZGa52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
aggregate intrinsic value in the table above represents the total pre-tax amount of the proceeds, net of exercise price, which
would have been received by option holders if all option holders had exercised and immediately sold all options with an exercise
price lower than the market price on December 31, 2020, based on the closing price of the Company&#8217;s common stock of $<span id="xdx_90E_ecustom--ClosingPriceOfCommonStockPricePerShare_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_pii" title="Closing price of common stock price per share">6.86</span>
on that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
intrinsic value of the options exercised in 2020 was $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn3n3_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zYEyXIXZ7lhe" title="Intrinsic value of options exercised">50</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020, the Company granted stock options to certain employees and a consultant. The stock options were
granted with an exercise price equal to the current market price of the Company&#8217;s common stock, as reported by the securities
exchange on which the common stock was then listed, at the grant date and have contractual terms of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantMember_zK32wN7Q9pYe" title="Weighted avg. remaining contractual life, options exercisable">10</span> years. <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantMember" title="Share-based compensation arrangement by share-based payment award, plan modification, description and terms">Vesting terms for
options granted to employees and consultants during the year ended December 31, 2020 generally included one of the following vesting
schedules: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and
the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over
three years; and 100% of the shares subject to the option vest on a quarterly basis in equal installments over three years. Certain
option awards provide for accelerated vesting if there is a change in control (as defined in the Plans) and in the event of certain
modifications to the option award agreement.</span></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
July 31, 2015, the Company granted to its Chief Executive Officer, Mark Baum, an option to purchase <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20150730__20150731__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_pii" title="Number of shares, options granted">600,000</span> shares of the Company&#8217;s
common stock (the &#8220;Baum Performance Option&#8221;) at an exercise price of $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20150730__20150731__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_pii" title="Exercise price of options">7.87</span> per share under the 2007 Plan subject to
the satisfaction of certain market-based vesting criteria. The market-based vesting criteria are separated into five tranches
and require that the Company achieve and maintain certain average stock price targets ranging from $<span id="xdx_90D_ecustom--AverageStockPrice_c20150731__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember__srt--RangeAxis__srt--MinimumMember_pii" title="Average stock price">9</span> per share to $<span id="xdx_90F_ecustom--AverageStockPrice_c20150731__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember__srt--RangeAxis__srt--MaximumMember_pii" title="Average stock price">15</span> per share
during the five year period following the grant date. On June 4, 2020, the Company amended the Baum Performance Option, to extend
the vesting and contractual term by <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200603__20200604__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_zefhTPyjcQ6f" title="Weighted avg. remaining contractual life, options outstanding">5 </span>years. The Company treated this amendment as a modification to the Baum Performance Option
for accounting purposes. The fair value of the modification was $<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20200603__20200604__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_pn3n3" title="Share-based compensation arrangement by share-based payment award, options, vested in period, fair value">1,876</span> using a Monte Carlo simulation model with a five-year life,
<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_c20200603__20200604__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_zBs9hKVEyKJ6" title="Share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate">70%</span> volatility and a risk-free interest rate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_c20200603__20200604__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_zF2XCLcrqGd8" title="Share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate">0.40%</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">With
the exception of the Baum Performance Option, the fair value of each option award is estimated on the date of grant using the
Black-Scholes-Merton option pricing model. Beginning on April 1, 2019, the Company began calculating expected volatility based
solely on the historical volatilities of the common stock of the Company. Prior to April 1, 2019, the expected volatility was
based on the historical volatilities of the common stock of the Company and comparable publicly traded companies. The Company
previously utilized this methodology based on its estimate that it had limited relevant historical data regarding the volatility
of its stock price on which to base a meaningful estimate of expected volatility. The expected term of options granted was determined
in accordance with the &#8220;simplified approach,&#8221; as the Company has limited, relevant, historical data on employee exercises
and post-vesting employment termination behavior. The expected risk-free interest rate is based on the U.S. Treasury yield for
a period consistent with the expected term of the option in effect at the time of the grant. The financial statement effect of
forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates. For
option grants to employees and directors, the Company assigns a forfeiture factor of <span id="xdx_906_ecustom--ForfeitureFactorPercentage_pii_dp_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zLaRI7blgAug" title="Forfeiture factor, percentage">10%</span>. These factors could change in the future,
which would affect the determination of stock-based compensation expense in future periods. Utilizing these assumptions, the fair
value is determined at the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zo943NhcDZV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following
assumptions used for valuing options granted to employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B9_z3pOk5YOPvRg" style="display: none">SCHEDULE OF FAIR VALUE ASSUMPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Weighted-average fair
    value of options granted</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_pii" style="width: 16%; text-align: right" title="Weighted-average fair value of options granted"><span style="font-family: Times New Roman, Times, Serif">3.86</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_pii" style="width: 16%; text-align: right" title="Weighted-average fair value of options granted"><span style="font-family: Times New Roman, Times, Serif">3.72</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expected terms (in years)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right" title="Expected terms (in years)"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MinimumMember_zznoJH9sHdXh" title="Expected terms (in years)">0.50</span>
                                         - <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MaximumMember_zDD1q3hBnOw5" title="Expected terms (in years)">6.11</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MinimumMember_zFrHUthfhXij" title="Expected terms (in years)">5.07</span>
                                         - <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MaximumMember_ztBeixpcpXRi" title="Expected terms (in years)">7.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right" title="Expected volatility, maximum"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_uPercent_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zBN829DrQFaa" title="Expected volatility, minimum">67</span>
                                         &#8211; <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_uPercent_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zLCFHkowlUWh" title="Expected volatility, maximum">71</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_uPercent_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zxnFxkILIhF" title="Expected volatility, minimum">64</span>
                                         - <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_uPercent_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zZ5w84ysMSQ8" title="Expected volatility, maximum">78</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right" title="Risk-free interest rate, maximum"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_uPercent_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zs1woI2aLU04" title="Risk-free interest rate, minimum">0.34</span>
                                         &#8211; <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_uPercent_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zwiOkXCUpV07" title="Risk-free interest rate, maximum">1.64</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_uPercent_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zZ5vHvMSgbuh" title="Risk-free interest rate, minimum">1.83</span>
                                         &#8211;<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_uPercent_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_z8MC2kbKhaHl" title="Risk-free interest rate, maximum"> 2.68</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zcfIFI2EDx7b" style="text-align: right" title="Dividend yield"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1448">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zyXdXXDOsZLf" style="text-align: right" title="Dividend yield"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1450">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p id="xdx_8A3_z7YXHk5ckEk3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zTReyUQCrVXk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes information about stock options outstanding and exercisable at December 31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span><span><span id="xdx_8B6_zLHJLptFBOv1" style="display: none">SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Contractual</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Range
    of Exercise Prices</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Outstanding</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Life
    in Years</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercisable</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Range of Exercise Prices, minimum">1.47</span> - $<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Range of Exercise Prices, maximum">2.60</span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" style="width: 10%; text-align: right" title="Number of Options Outstanding"><span style="font-family: Times New Roman, Times, Serif">770,440</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 10%; text-align: right" title="Weighted Average Remaining Contractual Life in Years"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zFeE8JzfPS8f" title="Weighted Average Remaining Contractual Life in Years">5.64</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" style="width: 10%; text-align: right" title="Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif">2.06</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" style="width: 10%; text-align: right" title="Number Exercisable"><span style="font-family: Times New Roman, Times, Serif">745,255</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" style="width: 10%; text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-family: Times New Roman, Times, Serif">2.06</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_ziiFjkcDC772" title="Range of Exercise Prices, minimum">3.04</span> - $<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Range of Exercise Prices, maximum">4.50</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" style="text-align: right" title="Number of Options Outstanding"><span style="font-family: Times New Roman, Times, Serif">517,002</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right" title="Weighted Average Remaining Contractual Life in Years"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z9eakblqqQSc" title="Weighted Average Remaining Contractual Life in Years">5.75</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif">3.98</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" style="text-align: right" title="Number Exercisable"><span style="font-family: Times New Roman, Times, Serif">438,873</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-family: Times New Roman, Times, Serif">3.98</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Range of Exercise Prices, minimum">5.49</span> - $<span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Range of Exercise Prices, maximum">6.36</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" style="text-align: right" title="Number of Options Outstanding"><span style="font-family: Times New Roman, Times, Serif">496,350</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right" title="Weighted Average Remaining Contractual Life in Years"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_ztoyYSnJsWBa" title="Weighted Average Remaining Contractual Life in Years">7.22</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif">6.10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" style="text-align: right" title="Number Exercisable"><span style="font-family: Times New Roman, Times, Serif">291,919</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-family: Times New Roman, Times, Serif">6.13</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">$<span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zBsCAhJkpYrl" title="Range of Exercise Prices, minimum">6.64</span> - $<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zRrw9dEctSpd" title="Range of Exercise Prices, maximum">8.99</span></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding"><span style="font-family: Times New Roman, Times, Serif">1,246,241</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Remaining Contractual Life in Years"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zBhaXCRSQHqa" title="Weighted Average Remaining Contractual Life in Years">5.17</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif">7.85</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number Exercisable"><span style="font-family: Times New Roman, Times, Serif">432,802</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-family: Times New Roman, Times, Serif">8.09</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">$<span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20200101__20201231_zTE4q6Dtgg96" title="Range of Exercise Prices, minimum">1.47</span> - $<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20200101__20201231_znbr9y4z6bkf" title="Range of Exercise Prices, maximum">8.99</span></span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20201231_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding"><span style="font-family: Times New Roman, Times, Serif">3,030,033</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Remaining Contractual Life in Years"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_z2pwY4UTeaQ" title="Weighted Average Remaining Contractual Life in Years">5.72</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20201231_pii" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif">5.43</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20201231_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Exercisable"><span style="font-family: Times New Roman, Times, Serif">1,908,849</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20201231_pii" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-family: Times New Roman, Times, Serif">4.49</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p id="xdx_8A0_z8EHcpGJe0a9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020, there was approximately $<span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_pn3n3" title="Unrecognized compensation expense related to unvested stock options granted under the plan">2,794</span> of total unrecognized compensation expense related to unvested stock options
granted under the Plan. That expense is expected to be recognized over the weighted-average remaining vesting period of <span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zNhD42KuyV98" title="Expense expected to recognize over the weighted-average remaining vesting period">3.96</span> years.
The stock-based compensation for all stock options was $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_pn3n3" title="Stock-based compensation">1,579</span> and $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20190101__20191231__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_pn3n3" title="Stock-based compensation">889</span> during the years ended December 31, 2020 and 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Restricted
Stock Units </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">RSU
awards are granted subject to certain vesting requirements and other restrictions, including performance and market-based
vesting criteria. The grant-date fair value of the RSUs, which has been determined based upon the market value of the Company&#8217;s
common stock on the grant date, is expensed over the vesting period of the RSUs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Grants
During the Year Ended December 31, 2019</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2019, <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pii" title="Shares issued of restricted common stock, shares">185,000</span> RSUs with a fair market value of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pn3n3" title="Fair value of restricted common stock issued">1,139</span> were issued to certain employees; the RSUs vest
in full on the third anniversary of the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2019, the Company&#8217;s board of directors were granted <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pii" title="Shares issued of restricted common stock, shares">38,860</span> RSUs with a fair market value of
$<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pn3n3" title="Fair value of restricted common stock issued">300</span> which vests on a quarterly basis, over a one-year term in equal installments, subject to the director&#8217;s
continued service at the vesting date, but the issuance and delivery of these shares are deferred until the director resigns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zSBp8HaToScg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the Company&#8217;s RSU activity and related information for the year ended December 31, 2019 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B0_z1u7f4VdIQV6" style="display: none">SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of RSUs</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Average Grant<br/>
    Date Fair Value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">RSUs unvested - January
    1, 2019</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlcKzm3Vy0E1" style="width: 16%; text-align: right" title="Number of RSUs unvested, Outstanding, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">1,275,680</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_c20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzKbZvFFjXSl" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">2.16</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">RSUs granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Number of RSUs granted"><span style="font-family: Times New Roman, Times, Serif">223,860</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs granted"><span style="font-family: Times New Roman, Times, Serif">6.43</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">RSUs vested</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pii_di_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgf1GrYmPyZ1" style="text-align: right" title="Number of RSUs vested"><span style="font-family: Times New Roman, Times, Serif">(87,610</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs vested"><span style="font-family: Times New Roman, Times, Serif">3.42</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">RSUs cancelled/forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pii_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztvt0TjCez4h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs cancelled/forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1554">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">RSUs unvested
    at December 31, 2019</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAbV7bsMtMHk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs unvested, Outstanding, Ending balance"><span style="font-family: Times New Roman, Times, Serif">1,411,930</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zuEsuPx7Uaxl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value, Ending balance"><span style="font-family: Times New Roman, Times, Serif">2.76</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Grants
During the Year Ended December 31, 2020</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020, <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pii" title="Shares issued of restricted common stock, shares">161,000</span> RSUs with a fair market value of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pn3n3" title="Fair value of restricted common stock issued">1,025</span> were issued to certain employees; the RSUs vest
in full on the third anniversary of the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020, the Company&#8217;s board of directors were granted <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pii" title="Shares issued of restricted common stock, shares">90,524</span> RSUs with a fair market value $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pn3n3" title="Fair value of restricted common stock issued">511</span>
which vest on a quarterly basis, over a one-year term in equal installments, subject to the director&#8217;s continued
service at the vesting date, but the issuance and delivery of these shares are deferred until the director resigns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the Company&#8217;s RSU activity and related information for the year ended December 31, 2020 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span/></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of RSUs</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Average Grant<br/>
    Date Fair Value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">RSUs unvested - January
    1, 2020</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwsDwbtXgcOg" style="width: 16%; text-align: right" title="Number of RSUs unvested, Outstanding, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">1,411,930</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_c20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNNoOi66nuCk" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">2.76</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">RSUs granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Number of RSUs granted"><span style="font-family: Times New Roman, Times, Serif">251,524</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs granted"><span style="font-family: Times New Roman, Times, Serif">6.11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">RSUs vested</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pii_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7tVOnlN9F0l" style="text-align: right" title="Number of RSUs vested"><span style="font-family: Times New Roman, Times, Serif">(61,945</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs vested"><span style="font-family: Times New Roman, Times, Serif">6.46</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">RSUs cancelled/forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs cancelled/forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1580">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">RSUs unvested
    at December 31, 2020</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgfUfvpFCBck" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs unvested, Outstanding, Ending balance"><span style="font-family: Times New Roman, Times, Serif">1,601,509</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCql18W0ey1i" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value, Ending balance"><span style="font-family: Times New Roman, Times, Serif">3.14</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p id="xdx_8A5_zcKNbdcJgvCc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020, the total unrecognized compensation expense related to unvested RSUs was approximately $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20201231__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_pn3n3" title="Unrecognized compensation expense related to unvested stock options granted under the plan">1,363</span> which is expected
to be recognized over a weighted-average period of <span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zl8CNWWZZLz3" title="Expense expected to recognize over the weighted-average remaining vesting period">3.14</span> years, based on estimated vesting schedules. The stock-based compensation
for RSUs was $<span id="xdx_902_eus-gaap--ShareBasedCompensation_c20200101__20201231__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_pn3n3" title="Stock-based compensation">1,167</span> and $<span id="xdx_903_eus-gaap--ShareBasedCompensation_c20190101__20191231__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_pn3n3" title="Stock-based compensation">879</span> during the years ended December 31, 2020 and 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Subsidiary
Stock-Based Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Mayfield
Pharmaceuticals, Inc. - 2019</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Mayfield
    issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20190202__20190228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__dei--LegalEntityAxis__custom--EllePharmaceuticalLLCMember_pii" title="Stock issued during period, shares, acquisitions">1,000,000</span> shares of its common stock to Elle in connection with the acquisition of certain drug candidate intellectual
    property and rights in February 2019;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Mayfield
    issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190701__20190731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_pii" title="Number of shares issued">300,000</span> shares of its common stock to TGV in connection with the acquisition of certain drug candidate intellectual
    property and rights in July 2019; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    Company recognized $<span id="xdx_90C_eus-gaap--ShareBasedCompensation_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pn3n3" title="Stock-based compensation">26</span> in stock-based compensation related to equity instruments granted by Mayfield for <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pii" title="Shares issued of restricted common stock, shares">2,450,000</span> shares
    of its restricted common stock that vest upon various performance based milestones and service periods to consultants of Mayfield,
    including Mayfield&#8217;s CEO candidate and to Harrow employees, including <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__srt--TitleOfIndividualAxis__custom--MarkBaumCEOMember_pii" title="Number of common stock issued for consultants services">725,000</span> shares to Mark Baum, CEO of the Company,
    and <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20190101__20191231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__srt--TitleOfIndividualAxis__custom--AndrewBollCFOMember_pii" title="Number of common stock issued for consultants services">362,500</span> shares to Andrew Boll, CFO of the Company.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Mayfield
Pharmaceuticals, Inc. - 2020</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Mayfield
    repurchased <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__dei--LegalEntityAxis__custom--EllePharmaceuticalLLCMember_pii" title="Number of common stock issued for consultants services">650,000</span> shares of its common stock from Elle, for an aggregate purchase price of $<span id="xdx_901_ecustom--AggregatePurchasePrice_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__dei--LegalEntityAxis__custom--EllePharmaceuticalLLCMember_pii" title="Aggregate purchase price">1</span>;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_pii" title="Shares issued of restricted common stock, shares">500,000</span>
    shares of Mayfield&#8217;s restricted common stock were forfeited by a consultant; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Mayfield
    issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pii" title="Shares issued of restricted common stock, shares">475,000</span> shares of its restricted common stock, with a fair value of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pn3n3" title="Fair value of restricted common stock issued">11</span>, that vest upon various performance-based milestones
    and over a four-year service period to Mayfield&#8217;s Chief Executive Officer candidate. </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020, the Company recognized $<span id="xdx_906_eus-gaap--ShareBasedCompensation_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember_pn3n3" title="Stock-based compensation">20</span> in stock-based compensation for Mayfield stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Stowe
Pharmaceuticals, Inc. - 2019</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2019, Stowe agreed to issue <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20190701__20190731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StowePharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_pii" title="Shares issued of restricted common stock, shares">1,750,000</span> shares of its common stock to TGV in connection with the acquisition of certain drug
candidate intellectual property and rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Visionology,
Inc. - 2020</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020, Visionology granted <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VisionologyIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pii" title="Shares issued of restricted common stock, shares">2,000,000</span> shares of its restricted common stock, with a fair value of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pii_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VisionologyIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1TFs6nM5AP9" title="Number of restrcited shares, value">96</span>
that vest upon various performance based milestones and service periods to consultants of Visionology, including Visionology&#8217;s
CEO candidate and to Harrow employees, including <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VisionologyIncMember__srt--TitleOfIndividualAxis__custom--MarkBaumCEOMember_pii" title="Number of common stock issued for consultants services">700,000</span> shares to Mark Baum, CEO of the Company, and <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VisionologyIncMember__srt--TitleOfIndividualAxis__custom--AndrewBollCFOMember_pii" title="Number of common stock issued for consultants services">350,000</span> shares to Andrew
Boll, CFO of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ziHtVmVZ22Sj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recorded stock-based compensation (including issuance of common stock for services and accrual for stock-based compensation)
related to equity instruments granted to employees, directors and consultants as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B9_zurPvjdWON1b" style="display: none">SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Years Ended December 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Employees &#8211; selling,
    general and administrative</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="width: 18%; text-align: right" title="Stock based compensation related to equity instruments granted to related parties"><span style="font-family: Times New Roman, Times, Serif">2,289</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20191231__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="width: 18%; text-align: right" title="Stock based compensation related to equity instruments granted to related parties"><span style="font-family: Times New Roman, Times, Serif">1,464</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Directors &#8211; selling, general
    and administrative</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="text-align: right" title="Stock based compensation related to equity instruments granted to related parties"><span style="font-family: Times New Roman, Times, Serif">473</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20191231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="text-align: right" title="Stock based compensation related to equity instruments granted to related parties"><span style="font-family: Times New Roman, Times, Serif">300</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Consultants
    &#8211; selling, general and administrative</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock based compensation related to equity instruments granted to related parties"><span style="font-family: Times New Roman, Times, Serif">96</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20191231__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock based compensation related to equity instruments granted to related parties"><span style="font-family: Times New Roman, Times, Serif">259</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation related to equity instruments granted to related parties"><span style="font-family: Times New Roman, Times, Serif">2,858</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation related to equity instruments granted to related parties"><span style="font-family: Times New Roman, Times, Serif">2,023</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p id="xdx_8AA_zIhJl73Ks4Gf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Warrants</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">From
time to time, the Company issues warrants to purchase shares of the Company&#8217;s common stock to investors, lenders (see Note
12), underwriters and other non-employees for services rendered or to be rendered in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z3hRwpJQzkLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of warrant activity during the year ended December 31, 2020 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B7_zofGrHQAUGX1" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of Shares Subject to Warrants Outstanding</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Avg. Exercise Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding
    - January 1, 2020</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pii_c20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zF3vPI1IecUi" style="width: 16%; text-align: right" title="Number of Shares Warrants Outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif">780,386</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_pii_c20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z4zzbdsSTAqe" style="width: 16%; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif">2.12</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="text-align: right" title="Number of Shares Warrants Outstanding, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1652">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="text-align: right" title="Number of Shares Warrants Outstanding, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1654">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares Warrants Outstanding, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1656">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding
    and exercisable - December 31, 2020</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iE_pii_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zE0fOT4bX2R2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Warrants Outstanding and Exercisable, ending balance"><span style="font-family: Times New Roman, Times, Serif">780,386</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1_iE_pii_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zGy9Yf4BTV6d" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Outstanding and Exercisable, ending balance"><span style="font-family: Times New Roman, Times, Serif">2.12</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average
    remaining contractual life of the outstanding warrants in years - December 31, 2020</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average remaining contractual life of the outstanding warrants in years"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zPVuFE6Md383" title="Weighted average remaining contractual life of the outstanding warrants in years">3.53</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8AD_zduARSswBOKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_893_ecustom--ScheduleofWarrantsOutstandingAndExercisableTableTextBlock_zVJqdE4Kk2Ec" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">All
warrants outstanding as of December 31, 2020 are included in the following table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B5_zdxFJYC54gQf" style="display: none">SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="9" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants
    Outstanding</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants
    Exercisable</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Expiration</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Warrant
    Series</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Issue
    Date</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Outstanding</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercisable</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Date</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Lender warrants</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; width: 12%; text-align: center" title="Issue Date"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_ecustom--WarrantsIssuanceDate_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zcIbfkNbtq0l" title="Issue Date">5/11/2015</span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_pii" style="width: 12%; text-align: right" title="Warrants Outstanding"><span style="font-family: Times New Roman, Times, Serif">125,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_pii" style="width: 11%; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">1.79</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_pii" style="width: 12%; text-align: right" title="Warrants Exercisable"><span style="font-family: Times New Roman, Times, Serif">125,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; width: 12%; text-align: center" title="Expiration Date"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_ecustom--WarrantsAndRightsOutstandingMaturityDates_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zASHVdbs6vjf" title="Expiration Date">5/11/2025</span></span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Settlement warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center" title="Issue Date"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_ecustom--WarrantsIssuanceDate_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_zIgKPdGA5Qt3" title="Issue Date">8/16/2016</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_pii" style="text-align: right" title="Warrants Outstanding"><span style="font-family: Times New Roman, Times, Serif">40,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_pii" style="text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">3.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_pii" style="text-align: right" title="Warrants Exercisable"><span style="font-family: Times New Roman, Times, Serif">40,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center" title="Expiration Date"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_ecustom--WarrantsAndRightsOutstandingMaturityDates_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_zWTTPiDABE55" title="Expiration Date">8/16/2021</span></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Lender warrants
    (see Note 12)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt" title="Issue Date"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--WarrantsIssuanceDate_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_zwjV334F6VCl" title="Issue Date">7/19/2017</span></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Outstanding"><span style="font-family: Times New Roman, Times, Serif">615,386</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_pii" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">2.08</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Exercisable"><span style="font-family: Times New Roman, Times, Serif">615,386</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt" title="Expiration Date"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--WarrantsAndRightsOutstandingMaturityDates_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_zrt915HjDe64" title="Expiration Date">7/19/2024</span></span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding"><span style="font-family: Times New Roman, Times, Serif">780,386</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="padding-bottom: 2.5pt; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">2.12</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Exercisable"><span style="font-family: Times New Roman, Times, Serif">780,386</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p id="xdx_8AC_z8t6DKVFp2K" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171678102952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_801_eus-gaap--IncomeTaxDisclosureTextBlock_zjLNQPii2Bub" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
15. <span id="xdx_82E_zO5a2A3Km4Oh">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zlEm43HAYNHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company is subject to taxation in the United States, California, Florida, Georgia, Illinois, New Jersey, New York, Tennessee and
Wisconsin. The Company&#8217;s income tax provision consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B7_zId0N1D53NX" style="display: none">SCHEDULE OF PROVISION FOR INCOME TAXES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Current:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Federal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--CurrentFederalTaxExpenseBenefit_c20200101__20201231_pn3n3" style="text-align: right" title="Current: Federal"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1706">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--CurrentFederalTaxExpenseBenefit_c20190101__20191231_pn3n3" style="text-align: right" title="Current: Federal"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1708">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State</span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Current: State"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Current: State"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total current
    expense</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"/><td id="xdx_989_eus-gaap--CurrentIncomeTaxExpenseBenefit_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total current"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"/><td id="xdx_98A_eus-gaap--CurrentIncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total current"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Deferred:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Federal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"/><td id="xdx_98C_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20200101__20201231_pn3n3" style="text-align: right" title="Deferred: Federal"><span style="font-family: Times New Roman, Times, Serif">(771</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"/><td id="xdx_98D_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" style="text-align: right" title="Deferred: Federal"><span style="font-family: Times New Roman, Times, Serif">669</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">State</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_c20200101__20201231_pn3n3" style="text-align: right" title="Deferred: State"><span style="font-family: Times New Roman, Times, Serif">138</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" style="text-align: right" title="Deferred: State"><span style="font-family: Times New Roman, Times, Serif">(148</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Change
    in valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--DeferredIncomeChangeInValuationAllowance_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Deferred: Change in valuation allowance"><span style="font-family: Times New Roman, Times, Serif">633</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--DeferredIncomeChangeInValuationAllowance_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Deferred: Change in valuation allowance"><span style="font-family: Times New Roman, Times, Serif">(521</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total deferred
    expense</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--DeferredIncomeTaxExpenseBenefit_pn3n3_c20200101__20201231_zqMusmwdxIfk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total deferred"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1730">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--DeferredIncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total deferred"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1732">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Income tax provision</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax provision (benefit)"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--IncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax provision (benefit)"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p id="xdx_8AE_znppQNdXsvyh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z9LbdBssC8ji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
reconciliation of income taxes computed by applying the statutory U.S. income tax rate to the Company&#8217;s loss before income
tax provision to the income tax provision is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zuFkQGm0bTbh" style="display: none">SCHEDULE OF INCOME TAX RECONCILIATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. federal statutory tax
    rate</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercent_c20200101__20201231_zP6vtwy0Dy3c" style="width: 16%; text-align: right" title="U.S. federal statutory tax rate"><span style="font-family: Times New Roman, Times, Serif">21.00</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercent_c20190101__20191231_z1PJBplz43el" style="width: 16%; text-align: right" title="U.S. federal statutory tax rate"><span style="font-family: Times New Roman, Times, Serif">21.00</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">State tax benefit, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPercent_c20200101__20201231_z9diswB8uWZ7" style="text-align: right" title="State tax benefit, net"><span style="font-family: Times New Roman, Times, Serif">(0.11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPercent_c20190101__20191231_zvEQ9o1W5937" style="text-align: right" title="State tax benefit, net"><span style="font-family: Times New Roman, Times, Serif">(6.73</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based</span><span style="font-family: Times New Roman, Times, Serif">
    compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends_pii_dp_uPercent_c20200101__20201231_zpefx0bFnuT5" style="text-align: right" title="Employee stock-based compensation"><span style="font-family: Times New Roman, Times, Serif">5.52</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends_pii_dp_uPercent_c20190101__20191231_zwJmbjxVw1O8" style="text-align: right" title="Employee stock-based compensation"><span style="font-family: Times New Roman, Times, Serif">3.10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pii_dp_uPercent_c20200101__20201231_ze9Ok1KYy7a4" style="text-align: right" title="Other"><span style="font-family: Times New Roman, Times, Serif">(0.38</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pii_dp_uPercent_c20190101__20191231_zaxdfNR43jV5" style="text-align: right" title="Other"><span style="font-family: Times New Roman, Times, Serif">(358.67</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pii_dp_uPercent_c20200101__20201231_zUnkeblpXJOc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Valuation allowance"><span style="font-family: Times New Roman, Times, Serif">(26.14</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pii_dp_uPercent_c20190101__20191231_zZO9ilJ98515" style="border-bottom: Black 1.5pt solid; text-align: right" title="Valuation allowance"><span style="font-family: Times New Roman, Times, Serif">334.57</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Effective income
    tax rate</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pii_dp_uPercent_c20200101__20201231_zyVR8plk3ERl" style="border-bottom: Black 2.5pt double; text-align: right" title="Effective income tax rate"><span style="font-family: Times New Roman, Times, Serif">(0.11</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pii_dp_uPercent_c20190101__20191231_zibwEDGEb0Qg" style="border-bottom: Black 2.5pt double; text-align: right" title="Effective income tax rate"><span style="font-family: Times New Roman, Times, Serif">(6.73</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
</table>

<p id="xdx_8A6_zYlLjCn3Moqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zY7wnvB540ob" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Deferred
tax assets and liabilities reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities
for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred
tax assets are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B5_zwireou6UZee" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20201231_zXNF58WN0wGa" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20191231_znibe2891vBa" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets (liabilities):</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTANzoCx_zrrz0DQDU3t" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%"><span style="font-family: Times New Roman, Times, Serif">NOL&#8217;s</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,685</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,827</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_ecustom--DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization_iI_pn3n3_maDTANzoCx_zCj3ad30Esyj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Depreciation and
    amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">528</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">224</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iI_pn3n3_maDTANzoCx_zbGbREmoj8vf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">413</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">641</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTANzoCx_zYPT1JuSDvs6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development
    credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">596</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">596</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTANzoCx_zqOYVTSFl1uc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred stock-based
    compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,024</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,533</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_ecustom--IncomeTaxBasisDifferenceInRelatedParty_iNI_pn3n3_di_maDTANzoCx_zkseA74WXrj7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basis difference
    in Melt</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(398</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,119</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_409_ecustom--IncomeTaxBasisDifferenceInRelatedPartyOne_iNI_pn3n3_di_maDTANzoCx_z97k6sFu57m7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basis difference
    in Surface</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(502</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,185</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40A_ecustom--IncomeTaxBasisDifferenceInRelatedPartyTwo_iNI_pn3n3_di_maDTANzoCx_zaCsNCEpnZC9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basis difference
    in Eton</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8,626</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7,528</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40F_ecustom--DeferredTaxAssetsTaxDeferredExpenseCapitalLosses_iI_pn3n3_maDTANzoCx_z55YDmrGFiw" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Capital losses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">63</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">63</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_pn3n3_di_msDTANzoCx_zv0QzbWLAS5a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Park stock purchase
    identifiable intangibles</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(274</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(270</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_409_ecustom--DeferredTaxAssetsTaxDeferredExpenseLimitations_iI_pn3n3_maDTANzoCx_zZ3Wl9pY4vZ1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Limitation under
    163(j)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">195</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">299</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_ecustom--DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability_iI_pn3n3_msDTANzoCx_zgbdDB0ObhZ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">ASC 842 lease
    liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,192</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,082</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_ecustom--DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset_iNI_pn3n3_di_maDTANzoCx_zO2zs3B6UGPh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">ASC
    842 ROU asset</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,061</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,959</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_ziQ8saIOP4Z9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    deferred tax assets, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,835</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,202</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzB4N_zemVr1oMj36i" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Valuation
    allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(15,835</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(15,202</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_406_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_zgGZ102KFEkj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    deferred tax assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1811">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1812">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p id="xdx_8AC_zVLQyOGlHLp" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Realization
of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the
net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by $<span id="xdx_903_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20200101__20201231_pn3n3" title="Deferred tax asset valuation allowance">633</span> and
decreased by $<span id="xdx_900_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20190101__20191231_pn3n3" title="Deferred tax asset valuation allowance">521</span> during 2020 and 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; background-color: white">At
December 31, 2020, the Company has federal and state net operating loss carryforwards of approximately $<span id="xdx_909_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsDomestic_c20201231_pn3n3" title="Federal net operating loss carryforwards">62,856</span> and $<span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_c20201231_pn3n3" title="State net operating loss carryforwards">60,908</span> which
will begin to expire in <span title="Federal research and development tax credits expiration date"><span id="xdx_901_ecustom--StateNetOperatingLossExpirationDate_c20200101__20201231" title="State net operating loss expiration date">2027</span></span>, unless previously utilized, and will begin to expire for state purposes in 2026. <span id="xdx_906_ecustom--FederalNetOperatingLossCarryforwardDescription_c20200101__20201231" title="Federal net operating loss carryforward description">In addition, the
Company has federal net operating loss carryforwards of $3,865 generated after 2017 that can be carried over indefinitely and
may be used to offset up to&#160;80% of federal taxable income.</span> At December&#160;31, 2020, the Company has federal and state research
and development tax credits of approximately $<span id="xdx_90D_ecustom--FederalResearchAndDevelopmentTaxCredits_c20200101__20201231_pn3n3" title="Federal research and development tax credits">354</span> and $<span id="xdx_905_ecustom--StateResearchAndDevelopmentTaxCredits_c20200101__20201231_pn3n3" title="State research and development tax credits">305</span>, respectively. The federal research tax credit begins to expire in
<span id="xdx_907_ecustom--FederalResearchAndDevelopmentTaxCreditsExpirationDate_c20200101__20201231" title="Federal research and development tax credits expiration date">2026</span>, unless previously utilized, and the state research and development  tax credit has no expiration date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Utilization
of the net operating loss (&#8220;NOL&#8221;) and research and development (&#8220;R&amp;D&#8221;) carryforwards maybe subject
to a substantial annual limitation due to ownership change limitations that might have occurred or that could occur in the future,
as required by Section&#160;382 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), as well as similar
state and foreign provisions. These ownership changes may limit the amount of NOL and R&amp;D credit carryforwards that can be
utilized annually to offset future taxable income and tax, respectively. In general, an &#8220;ownership change&#8221; as defined
by Section&#160;382 of the Code results from a transaction or series of transactions over a three-year period resulting in an
ownership change of more than 50&#160;percentage points of the outstanding stock of a company by certain stockholders or public
groups. Since the Company&#8217;s formation, the Company has raised capital through the issuance of capital stock on several occasions
which, combined with the purchasing stockholders&#8217; subsequent disposition of those shares, may have resulted in such an ownership
change, or could result in an ownership change in the future upon subsequent disposition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has not completed a study to assess whether an ownership change or changes have occurred. If the Company has experienced
an ownership change, utilization of the NOL or R&amp;D credit carryforwards would be subject to an annual limitation under Section&#160;382
of the Code, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change
by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation
may result in expiration of a portion of the NOL or R&amp;D credit carryforwards before utilization. Further, until a study is
complete and any limitation is known, no amounts are being considered as an uncertain tax position or disclosed as an unrecognized
tax benefit. Any carryforwards that will expire prior to utilization as a result of such limitations will be removed from deferred
tax assets with a corresponding reduction of the valuation allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2020 and 2019, there were no unrecognized tax benefits included in the consolidated balance sheets that would,
if recognized, affect the effective tax rate. The Company&#8217;s practice is to recognize interest and/or penalties related to
income tax matters in income tax expense. The Company had no accrual for interest or penalties in its consolidated balance sheets
at December 31, 2020 and 2019, and has not recognized interest and/or penalties in the consolidated statements of operations for
the years ended December 31, 2020 and 2019. The Company&#8217;s tax years since 2000 may be subject to examination by the federal
and state tax authorities due to the carryforward of unutilized net operating losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171679431096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE SAVINGS PLAN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">EMPLOYEE SAVINGS PLAN</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_zbbRN5HtuLa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
16. <span id="xdx_825_zcTJ6Iizbmz7">EMPLOYEE SAVINGS PLAN</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has established an employee savings plan pursuant to Section 401(k) of the Internal Revenue Code, effective January 1,
2014. The plan allows participating employees to deposit into tax deferred investment accounts up to <span id="xdx_907_ecustom--PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount_pii_dp_uPercent_c20200101__20201231_zXnLyOPTysch" title="Percentage of salary deposits in tax deferred investment account">100%</span> of their salary, subject
to annual limits. The Company makes certain matching contributions to the plan in amounts up to <span id="xdx_903_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_pii_dp_uPercent_c20200101__20201231_zkcDLxUvmHNe" title="Percentage of contributions made by the company">4%</span> of the participants&#8217;
annual cash compensation, subject to annual limits. The Company contributed approximately $<span id="xdx_901_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20200101__20201231_pn3n3" title="Contributions by the company">272</span> and $<span id="xdx_90E_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20190101__20191231_pn3n3" title="Contributions by the company">312 </span>to the plan during the
years ended December 31, 2020 and 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171676895336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zisERq8VLvB1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
17. <span id="xdx_82B_z1xOJhmiRCyh">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Legal</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Dr.
Sobol </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2016, Louis L. Sobol, M.D. (&#8220;Sobol&#8221;) filed a lawsuit in the U.S. District Court for the Eastern District
of Michigan, Southern Division against the Company, asserting claims on behalf of himself and an as-yet-uncertified class of consumers.
The claims allege violations under the Telephone Consumer Protection Act, 47 U.S.C. &#167; 227 via the Company&#8217;s alleged
transmittal of advertisements to its clients via facsimile. The Court approved the parties&#8217; proposed settlement agreement
in the spring of 2019. During the year ended December 31, 2018, the Company accrued $<span id="xdx_90F_eus-gaap--LossContingencyAccrualAtCarryingValue_c20181231__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_pn3n3" title="Accrued damages">640</span> for expected damages related to this
matter and the proposed settlement amount. As a result of the low claim rate of approximately <span id="xdx_90B_ecustom--DamagesLowClaimRatePercentage_pii_dp_uPercent_c20180101__20181231__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_zYgxfZXJkVP4" title="Damages low claim rate, percentage">1.4%</span>, the Company&#8217;s total
damages were $<span id="xdx_901_eus-gaap--LossContingencyDamagesPaidValue_c20191002__20191031__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_pn3n3" title="Litigation amount paid">571</span>, which was paid in October 2019. This formally resolved all known disputes between the parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Allergan
USA</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
September 2017, Allergan USA, Inc. (&#8220;Allergan&#8221;) filed a lawsuit in the U.S. District Court for the Central District
of California against the Company, primarily claiming violations under the federal Lanham Act and California&#8217;s Sherman Act.
The Court granted in part and denied in part each parties&#8217; motions for summary judgement, resolving all issues except for
whether Allergan was entitled to damages related to the Company&#8217;s purported Lanham Act violations. The parties went to trial
in May 2019 to litigate damages related to the Lanham Act, and a jury found the Company liable for only $<span id="xdx_901_eus-gaap--LossContingencyDamagesAwardedValue_c20190501__20190531__dei--LegalEntityAxis__custom--AllerganUSAIncMember_pn3n3" title="Lost profit damages">49</span> in lost profit damages,
which was accrued as an expense during the year ended December 31, 2019 (see Note 11). In July 2019, the Court entered a permanent
injunction, the scope of which is limited to compounded drugs prepared in, dispensed from within, or shipped to the state of California.
The injunction requires the Company to: (1) only dispense drugs from a 503(a) facility with a &#8220;Valid Prescription Order&#8221;;
(2) abide by the FDA&#8217;s anticipatory compounding guidelines; and (3) only use bulk drug substances identified on a list established
by the Secretary of Health and Human Services or FDA&#8217;s interim &#8220;Category 1&#8221; list. The Company believes it was
already in compliance with the order, prior to the injunction being ordered. On October 2, 2019, Allergan and the Company filed
a joint stipulation to voluntarily dismiss each parties&#8217; respective pending appeals arising out of the lawsuit. No economic
consideration was exchanged between the parties related to the filing of the joint stipulation. This formally resolved all known
disputes between the parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>California
Board of Pharmacy</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
March 2018, the California Board of Pharmacy filed an accusation against Park related to a compounded formulation the Company
believes was legally dispensed and was, without its knowledge, inappropriately administered to a patient unknown to Park, by the
prescribing healthcare professional. Park filed a response to the accusation and requested a formal hearing. In April 2019, Park
agreed to, and the California State Board of Pharmacy approved terms of a settlement agreement (the &#8220;Settlement Agreement&#8221;)
that became effective on May 29, 2019. Pursuant to the terms of the Settlement Agreement, Park was required to, and did, surrender
its California pharmacy license by August 27, 2019. This formally resolved all known disputes between the parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Novel
Drug Solutions et al.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">In
April 2018, Novel Drug Solutions, LLC and Eyecare Northwest, PA (collectively &#8220;NDS&#8221;) filed a lawsuit against the Company
in the U.S. District Court of Delaware asserting claims for breach of contract. The claims stem from an asset purchase agreement
between the Company and NDS entered into in 2013. In July 2019, NDS filed a second amended complaint which added a claim related
to its purported termination of the APA. In October 2019, NDS voluntarily dismissed all claims related to breach of contract,
leaving only claims related to the scope of the post-termination obligations to be litigated. On October 29, 2020, at a hearing
on the various dispositive motions before it, the Court found that there were triable issues of fact and reopened discovery for
limited purposes. NDS is seeking unspecified damages, interest, attorney&#8217;s fees and other costs. The Company believes the
claims are meritless and has previously and will continue to dispute all claims asserted against it and intends to vigorously
defend against these allegations. Nonetheless, the Company cannot predict the eventual outcome of this litigation and it could
result in substantial costs, losses and a diversion of management&#8217;s resources and attention, which could harm the Company&#8217;s
business and the value of its common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Product
and Professional Liability</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Product
and professional liability litigation represents an inherent risk to all firms in the pharmaceutical and pharmacy industry. We
utilize traditional third-party insurance policies with regard to our product and professional liability claims. Such insurance
coverage at any given time reflects current market conditions, including cost and availability, when the policy is written.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>John
Erick et al.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
January 2018, John Erick and Deborah Ferrell, successors-in-interest and heirs of Jade Erick, (collectively &#8220;Erick&#8221;)
filed a lawsuit in the San Diego County Superior against Kim Kelly, ND, MPH asserting claims related to the death of Jade Erick.
In April 2018, Erick filed an amendment to the lawsuit, naming the Company as a co-defendant. In September 2018, co-defendant
Dr. Kelly filed a cross-complaint against the Company and various entities affiliated with Spectrum Laboratory Products, Inc.,
Spectrum Chemical Manufacturing Corp. and Spectrum Pharmacy Products, Inc. (collectively &#8220;Spectrum&#8221;). The cross-complaint
seeks indemnity and contribution from the Company and Spectrum. The Company answered the claims filed by Dr. Kelly in October
2018. The case is currently in the discovery phase. Erick is seeking unspecified damages, interest, attorney&#8217;s fees and
other costs. The Company believes the claims are meritless and has previously and will continue to dispute all claims asserted
against it and intends to vigorously defend against these allegations. Nonetheless, the Company cannot predict the eventual outcome
of this litigation, it could result in substantial costs, losses and a diversion of management&#8217;s resources and attention,
which could harm the Company&#8217;s business and the value of its common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Anna
Sue Gaukel et al.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2019, Anna Sue Gaukel and Lawrence Gaukel served the Company with a lawsuit filed in state court in Idaho against Imprimis
Pharmaceuticals, Inc. asserting class action allegations and product liability claims related to Mrs. Gaukel&#8217;s doctor&#8217;s
use of a compounded drug injection in each of her eyes. In June 2019, the Company removed the case to Federal Court and subsequently
answered the complaint. On January 24, 2019, the plaintiffs and the Company filed a joint stipulation, and the case was dismissed
with prejudice. No economic consideration was exchanged between the parties related to the filing of the joint stipulation. This
formally resolved all known disputes between the parties as connected to this matter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>General
and Other</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
the ordinary course of business, the Company may face various claims brought by third parties and it may, from time to time, make
claims or take legal actions to assert its rights, including intellectual property disputes, contractual disputes and other commercial
disputes. Any of these claims could subject the Company to litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Indemnities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
addition to the indemnification provisions contained in the Company&#8217;s charter documents, the Company generally enters into
separate indemnification agreements with each of the Company&#8217;s directors and officers. These agreements require the Company,
among other things, to indemnify the director or officer against specified expenses and liabilities, such as attorneys&#8217;
fees, judgments, fines and settlements, paid by the individual in connection with any action, suit or proceeding arising out of
the individual&#8217;s status or service as the Company&#8217;s director or officer, other than liabilities arising from willful
misconduct or conduct that is knowingly fraudulent or deliberately dishonest, and to advance expenses incurred by the individual
in connection with any proceeding against the individual with respect to which the individual may be entitled to indemnification
by the Company. The Company also indemnifies its lessors in connection with its facility leases for certain claims arising from
the use of the facilities. These indemnities do not provide for any limitation of the maximum potential future payments the Company
could be obligated to make. Historically, the Company has not incurred any payments for these obligations and, therefore, no liabilities
have been recorded for these indemnities in the accompanying consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Sales
and Marketing Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has entered various sales and marketing agreements with certain organizations, to provide sales and marketing representation
services to ImprimisRx in select geographies in the U.S., in connection with the Company&#8217;s ophthalmic compounded formulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
the terms of the sales and marketing agreements, the Company is required to make commission payments generally equal to <span id="xdx_90A_ecustom--CommissionPaymentsPercentage_c20170101__20191231__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember__srt--RangeAxis__srt--MinimumMember_pii" title="Commission payments, percentage">10%</span> to
<span id="xdx_908_ecustom--CommissionPaymentsPercentage_c20170101__20191231__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember__srt--RangeAxis__srt--MaximumMember_pii" title="Commission payments, percentage">14%</span> of net sales for products above and beyond the initial existing sales amounts. In addition, the Company is required to make
periodic milestone payments to certain organizations in shares of the Company&#8217;s restricted common stock if net sales in
the assigned territory reach certain future levels by the end of their terms, as applicable. The Company accrued and recorded
in additional paid in capital $<span id="xdx_908_ecustom--AdditionalPaidInCapitalAndShareBasedPayments_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_pn3n3" title="Additional paid in capital and stock based payments">83</span> and $<span id="xdx_909_ecustom--AdditionalPaidInCapitalAndShareBasedPayments_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_pn3n3" title="Additional paid in capital and stock based payments">159</span> related to stock-based payments for these agreements during the year ended December
31, 2020 and 2019, respectively, and $<span id="xdx_902_eus-gaap--SalesCommissionsAndFees_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_pn3n3" title="Commission expense incurred">2,434</span> and $<span id="xdx_901_eus-gaap--SalesCommissionsAndFees_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember_pn3n3" title="Commission expense incurred">2,700</span> were incurred under these agreements for commission expenses during the
years ended December 31, 2020 and 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Asset
Purchase, License and Related Agreements </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has acquired and sourced intellectual property rights related to certain proprietary innovations from certain inventors
and related parties (the &#8220;Inventors&#8221;) through multiple asset purchase agreements, license agreements, strategic agreements
and commission agreements. In general, these agreements provide that the Inventors will cooperate with the Company in obtaining
patent protection for the acquired intellectual property and that the Company will use commercially reasonable efforts to research,
develop and commercialize a product based on the acquired intellectual property. In addition, the Company has acquired a right
of first refusal on additional intellectual property and drug development opportunities presented by these Inventors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--BusinessAcquisitionDescriptionOfAcquiredEntity_c20200101__20201231" title="Business acquisition description">In
consideration for the acquisition of the intellectual property rights, the Company is obligated to make payments to the Inventors
based on the completion of certain milestones, generally consisting of: (1) a payment payable within 30 days after the issuance
of the first patent in the United States arising from the acquired intellectual property (if any); (2) a payment payable within
30 days after the Company files the first investigational new drug application (&#8220;IND&#8221;) with the FDA for the first
product arising from the acquired intellectual property (if any); (3) for certain of the Inventors, a payment payable within 30
days after the Company files the first new drug application with the FDA for the first product arising from the acquired intellectual
property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection with the sale
or licensing of any product based on the acquired intellectual property (if any), after deducting (among other things) the Company&#8217;s
development costs associated with such product. If, following five years after the date of the applicable asset purchase agreement,
the Company either (a) for certain of the Inventors, has not filed an IND or, for the remaining Inventors, has not initiated a
study where data is derived, or (b) has failed to generate royalty payments to the Inventors for any product based on the acquired
intellectual property, the Inventors may terminate the applicable asset purchase agreement and request that the Company re-assign
the acquired technology to the Inventors.</span> $<span id="xdx_90D_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_c20201231_pn3n3" title="Accounts payable and accrued expenses">224</span> and $<span id="xdx_90B_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_c20191231_pn3n3" title="Accounts payable and accrued expenses">371</span> were accrued in accounts payable and accrued expenses under these agreements
during the years ended December 31, 2020 and 2019, respectively, and $<span id="xdx_90A_eus-gaap--RoyaltyExpense_c20200101__20201231_pn3n3" title="Royalty payments">682</span> and $<span id="xdx_909_eus-gaap--RoyaltyExpense_c20190101__20191231_pn3n3" title="Royalty payments">846</span> were incurred under these agreements as royalty
expenses for the years ended December 31, 2020 and 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Mayfield
License</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2020, Mayfield entered into a License Agreement (the &#8220;TGV License&#8221;) with TGV to acquire intellectual property
rights for use in the women&#8217;s health field, related to Mayfield&#8217;s proprietary drug candidate MAY-66. The TGV License
provides that TGV will cooperate with Mayfield in transferring all embodiments of the intellectual property (including know-how)
related to the TGV License, assist in obtaining and protecting its patent rights for the acquired intellectual property and that
Mayfield will use commercially reasonable efforts to research, develop and commercialize products based on the acquired intellectual
property. In connection with the TGV License, Mayfield is obligated to make royalty payments to TGV equal to a low single digit
percentage of net sales received by Mayfield in connection with the sale or licensing of any product based on the licensed intellectual
property. In addition, Mayfield issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200701__20200731__dei--LegalEntityAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_pii" title="Number of shares issued">300,000</span> shares of its common stock to TGV and is required to make certain milestone payments
to TGV over the development of MAY-66 and any related products based on the licensed intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Stowe
License</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2020, Stowe entered into a License Agreement (the &#8220;Stowe License&#8221;) with TGV, to acquire intellectual property
rights for use in the ophthalmology and otic health field, related to Stowe&#8217;s proprietary drug candidate STE-006. The Stowe
License provides that TGV will cooperate with Stowe in transferring all embodiments of the intellectual property (including know-how)
related to the Stowe License, assist in obtaining and protecting its patent rights for the acquired intellectual property and
that Stowe will use commercially reasonable efforts to research, develop and commercialize products based on the acquired intellectual
property. In connection with the Stowe License, Stowe is obligated to make royalty payments to TGV equal to a low single digit
percentage of net sales received by Stowe in connection with the sale or licensing of any product based on the licensed intellectual
property. In addition, Stowe issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200701__20200731__dei--LegalEntityAxis__custom--StowePharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_pii" title="Number of shares issued">1,750,000</span> shares of its common stock to TGV and is required to make certain milestone payments
to TGV over the development of STE-006 and any related products based on the licensed intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Klarity
License Agreement &#8211; Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
April 2017, the Company entered into a license agreement (the &#8220;Klarity License Agreement&#8221;) with Richard L. Lindstrom,
M.D., a member of its Board of Directors. Pursuant to the terms of the Klarity License Agreement, the Company licensed certain
intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license the topical ophthalmic
solution Klarity designed to protect and rehabilitate the ocular surface (the &#8220;Klarity Product&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_90D_ecustom--RoyaltyPaymentDescription_c20170401__20170430__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember" style="font: 10pt Times New Roman, Times, Serif">Under
the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3%
to 6% of net sales, dependent upon the final formulation of the Klarity Product sold.</span> <span style="font: 10pt Times New Roman, Times, Serif">In
addition, the Company is required to make certain milestone payments to Dr. Lindstrom including: (i) an initial payment of $<span id="xdx_904_eus-gaap--RoyaltyExpense_c20170401__20170430__srt--StatementScenarioAxis__custom--InitialPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3">50
</span></span><span style="font: 10pt Times New Roman, Times, Serif">upon execution of the Klarity License
Agreement, (ii) a second payment of $<span id="xdx_90A_eus-gaap--RoyaltyExpense_c20170401__20170430__srt--StatementScenarioAxis__custom--SecondPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3">50
</span></span><span style="font: 10pt Times New Roman, Times, Serif">following the first $<span id="xdx_901_eus-gaap--RoyaltyExpense_c20170401__20170430__srt--StatementScenarioAxis__custom--FinalPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3">50
</span></span><span style="font: 10pt Times New Roman, Times, Serif">in net sales of the Klarity Product; and
(iii) a final payment of $<span id="xdx_906_ecustom--NetSalesRevenue_c20170401__20170430__srt--StatementScenarioAxis__custom--SecondPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3">50
</span></span><span style="font: 10pt Times New Roman, Times, Serif">following the first $<span id="xdx_909_ecustom--NetSalesRevenue_c20170401__20170430__srt--StatementScenarioAxis__custom--FinalPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3">100
</span></span><span style="font: 10pt Times New Roman, Times, Serif">in net sales of the Klarity Product. All
of the above referenced milestone payments were payable at the Company&#8217;s election in cash or shares of the Company&#8217;s
restricted common stock. Dr. Lindstrom was paid $<span id="xdx_90A_eus-gaap--RoyaltyExpense_pn3n3_c20200101__20201231__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zOTin8xI59Pk">149
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_902_ecustom--MilestonePaymentInCash_pn3n3_c20190101__20191231__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zizsoZftpNkl">63
</span></span><span style="font: 10pt Times New Roman, Times, Serif">in cash during the years ended December
31, 2020 and 2019, respectively, and was due an additional $<span id="xdx_90F_ecustom--MilestonePaymentsOnPayables_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3">35
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_900_ecustom--MilestonePaymentsOnPayables_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3">55
</span></span><span style="font: 10pt Times New Roman, Times, Serif">at December 31, 2020 and 2019, respectively.
The Company incurred $<span id="xdx_907_eus-gaap--RoyaltyExpense_pn3n3_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zVczfS5hEP52">129
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90B_eus-gaap--RoyaltyExpense_pn3n3_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zio2OpquTpnl">103
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for royalty expenses related to the Klarity
License Agreement during the years ended December 31, 2020 and 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Injectable
Asset Purchase Agreement &#8211; Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2019, the Company entered into an asset purchase agreement (the &#8220;Lindstrom APA&#8221;) with Dr. Lindstrom, a member
of its Board of Directors. Pursuant to the terms of the Lindstrom APA, the Company acquired certain intellectual property and
related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license an ophthalmic injectable product (the &#8220;Lindstrom
Product&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
the terms of the Lindstrom APA, t<span id="xdx_906_ecustom--RoyaltyPaymentDescription_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember" title="Royalty payment description">he Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net
sales, dependent upon the final formulation and patent protection of the Lindstrom Product sold.</span> In addition, the Company is required
to make certain milestone payments to Dr. Lindstrom including an initial payment of $<span id="xdx_908_eus-gaap--RoyaltyExpense_c20191201__20191231__srt--StatementScenarioAxis__custom--InitialPaymentMember__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Royalty payments">33</span> upon execution of the Lindstrom APA. Dr.
Lindstrom was paid $<span id="xdx_900_ecustom--MilestonePaymentInCash_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payment in cash">55</span> and $<span id="xdx_903_ecustom--MilestonePaymentInCash_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payment in cash">0</span> in cash during the years ended December 31, 2020 and 2019, respectively, and was due $<span id="xdx_90B_ecustom--MilestonePaymentsOnPayables_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payments on payables">7</span> and
$<span id="xdx_90A_ecustom--MilestonePaymentsOnPayables_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payments on payables">40</span> at December 31, 2020 and 2019, respectively. The Company incurred $<span id="xdx_902_eus-gaap--RoyaltyExpense_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Royalty payments">55</span> and $<span id="xdx_90E_eus-gaap--RoyaltyExpense_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Royalty payments">40</span> for royalty expenses related to the Lindstrom
APA during the years ended December 31, 2020 and 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Presbyopia
Asset Purchase Agreement &#8211; Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2019, the Company entered into an asset purchase agreement (the &#8220;Presbyopia APA&#8221;) with Richard L. Lindstrom,
M.D., a member of its Board of Directors. Pursuant to the terms of the Presbyopia APA, the Company acquired certain intellectual
property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license an ophthalmic topical product
to treat presbyopia (the &#8220;Presbyopia Product&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
the terms of the Presbyopia APA, <span id="xdx_904_ecustom--RoyaltyPaymentDescription_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember" title="Royalty payment description">the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 4% of net
sales, dependent upon the final formulation and patent protection of the Presbyopia Product sold.</span> Dr. Lindstrom was paid $<span id="xdx_90B_ecustom--MilestonePaymentInCash_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payment in cash"><span id="xdx_90A_ecustom--MilestonePaymentInCash_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payment in cash">0</span></span> in
cash during the years ended December 31, 2020 and 2019, and was due $<span id="xdx_904_ecustom--MilestonePaymentsOnPayables_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payments on payables"><span id="xdx_905_ecustom--MilestonePaymentsOnPayables_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payments on payables">0</span></span> at December 31, 2020 and 2019. The Company incurred $<span id="xdx_902_eus-gaap--RoyaltyExpense_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Royalty payments"><span id="xdx_901_eus-gaap--RoyaltyExpense_c20190101__20191231__us-gaap--TypeOfArrangementAxis__custom--PresbyopiaAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Royalty payments">0</span></span>
for royalty expenses related to the Presbyopia APA during the years ended December 31, 2020 and 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>Eyepoint
Commercial Alliance Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">In
August 2020, the Company, through its wholly owned subsidiary ImprimisRx, LLC, entered into a Commercial Alliance Agreement (the
&#8220;Dexycu Agreement&#8221;) with Eyepoint Pharmaceuticals, Inc. (&#8220;Eyepoint&#8221;), pursuant to which Eyepoint granted
the Company the non-exclusive right to co-promote DEXYCU<sup>&#174;</sup> (dexamethasone intraocular suspension) 9% for the treatment
of post-operative inflammation following ocular surgery in the United States.</span> <span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the <span style="background-color: white">Dexycu Agreement</span>, Eyepoint will pay the Company a fee calculated based on
the quarterly sales of DEXCYU in excess of predefined volumes to specific customers of the Company in the U.S. Under the terms
of the <span style="background-color: white">Dexycu Agreement</span>, the Company shall use commercially reasonable efforts to
promote and market DEXCYU in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Subject
to early termination, the <span style="background-color: white">Dexycu Agreement</span> expires on August 1, 2025, subject to
specified notice periods and specified limitations, either party may terminate the <span style="background-color: white">Dexycu
Agreement</span> in the event of (i) uncured material breach by the other party or (ii) if DEXCYU ceases to have &#8220;pass-through&#8221;
payment status. In addition, subject to certain limitations, the Company may terminate the <span style="background-color: white">Dexycu
Agreement</span> (i) for convenience subject to an extended specified notice period or (ii) in the event Eyepoint undergoes a
change of control. Eyepoint may terminate the <span style="background-color: white">Dexycu Agreement</span>, subject to specified
notice periods and specified limitations, if the Company fails to achieve certain minimum sales levels during specified periods.
During the year ended December 31, 2020, the Company recorded $<span id="xdx_90F_eus-gaap--SalesCommissionsAndFees_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--DexycuAgreementMember_pn3n3" title="Commission expense incurred">357</span> in commission revenues related to the Dexycu Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171679097448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION AND CONCENTRATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION AND CONCENTRATIONS</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--SegmentReportingDisclosureTextBlock_za1vyYFAHsCj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
18. <span id="xdx_822_zW7oEugK6dV8">SEGMENT INFORMATION AND CONCENTRATIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Beginning
on January 1, 2019, the Company began evaluating performance of the Company based on operating segments. Segment performance for
its <span id="xdx_905_ecustom--NumberOfOperatingSegmentsDescription_c20200101__20201231_zZKE0PNI1s2k" title="Number of operating segments, description.">two operating segments</span> are based on segment contribution. The Company&#8217;s reportable segments consist of (i) its commercial
stage pharmaceutical compounding business (Pharmaceutical Compounding), generally including the operations of ImprimisRx and the
former Park businesses; and (ii) its start-up operations associated with pharmaceutical drug development business (Pharmaceutical
Drug Development). Segment contribution for the segments represents net revenues less cost of sales, research and development,
selling and marketing expenses, and select general and administrative expenses. The Company does not evaluate the following items
at the segment level:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Selling,
    general and administrative expenses that result from shared infrastructure, including certain expenses associated with legal
    matters, public company costs (e.g. investor relations), board of directors and principal executive officers and other like
    shared expenses;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Operating
    expenses within selling, general and administrative expenses that result from the impact of corporate initiatives. Corporate
    initiatives primarily include integration, restructuring, acquisition and other shared costs;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Other
    select revenues and operating expenses including R&amp;D expenses, amortization, and asset sales and impairments, net as not
    all such information has been accounted for at the segment level, or such information has not been used by all segments; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Total
    assets including capital expenditures.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company defines segment net revenues as pharmaceutical compounded drug sales, licenses and other revenue derived from related
agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cost
of sales within segment contribution includes direct and indirect costs to manufacture formulations and sell products, including
active pharmaceutical ingredients, personnel costs, packaging, storage, royalties, shipping and handling costs, manufacturing
equipment and tenant improvements depreciation, the write-off of obsolete inventory and other related expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Selling,
general and administrative expenses consist mainly of personnel-related costs, marketing and promotion costs, distribution costs,
professional service costs, insurance, depreciation, facilities costs, transaction costs, and professional services costs which
are general in nature and attributable to the segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z7Np0d5rM4L" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Segment
net revenues, segment operating expenses and segment contribution information consisted of the following for the years ended December
31, 2020 and 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt"><span id="xdx_8B5_zVhOxt4bJ3l" style="display: none">SCHEDULE OF SEGMENT NET REVENUES, SEGMENT OPERATING EXPENSES AND SEGMENT CONTRIBUTION</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended December 31, 2020</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Pharmaceutical</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Pharmaceutical
    Drug</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Compounding</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Development</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net revenues</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues"><span style="font-family: Times New Roman, Times, Serif">48,871</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1930">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues"><span style="font-family: Times New Roman, Times, Serif">48,871</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Cost of sales</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--CostOfGoodsAndServicesSold_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"><span style="font-family: Times New Roman, Times, Serif">(14,463</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--CostOfGoodsAndServicesSold_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1936">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zgozMhXwOZ91" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"><span style="font-family: Times New Roman, Times, Serif">(14,463</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gross profit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--GrossProfit_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Gross profit"><span style="font-family: Times New Roman, Times, Serif">34,408</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--GrossProfit_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Gross profit"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1942">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--GrossProfit_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit"><span style="font-family: Times New Roman, Times, Serif">34,408</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Selling, general
    and administrative</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Selling, general and administrative"><span style="font-family: Times New Roman, Times, Serif">22,691</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Selling, general and administrative"><span style="font-family: Times New Roman, Times, Serif">144</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative"><span style="font-family: Times New Roman, Times, Serif">22,835</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research
    and development</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development"><span style="font-family: Times New Roman, Times, Serif">759</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development"><span style="font-family: Times New Roman, Times, Serif">88</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development"><span style="font-family: Times New Roman, Times, Serif">847</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Segment
    contribution</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">$</span></p></td><td id="xdx_987_ecustom--SegmentContribution_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Segment contribution"><span style="font-family: Times New Roman, Times, Serif">10,958</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">$</span></p></td><td id="xdx_980_ecustom--SegmentContribution_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Segment contribution"><span style="font-family: Times New Roman, Times, Serif">(232</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"/><td id="xdx_987_ecustom--SegmentContribution_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="padding-bottom: 1.5pt; text-align: right" title="Segment contribution"><span style="font-family: Times New Roman, Times, Serif">10,726</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Corporate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--OperatingIncomeLoss_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_pn3n3" style="text-align: right" title="Operating income (loss)"><span style="font-family: Times New Roman, Times, Serif">(8,245</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--OperatingIncomeLoss_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="text-align: right" title="Operating income (loss)"><span style="font-family: Times New Roman, Times, Serif">(1,566</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--AdjustmentForAmortization_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Amortization"><span style="font-family: Times New Roman, Times, Serif">(167</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Asset sales and
    impairments, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(363</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    income</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_ecustom--ImpairmentAndDisposalOfLonglivedAssets_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Asset sales and impairments, net"><span style="font-family: Times New Roman, Times, Serif">385</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended December 31, 2019</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Pharmaceutical</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Pharmaceutical
    Drug</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Compounding</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Development</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net revenues</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues"><span style="font-family: Times New Roman, Times, Serif">51,165</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1974">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues"><span style="font-family: Times New Roman, Times, Serif">51,165</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Cost of sales</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--CostOfGoodsAndServicesSold_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"><span style="font-family: Times New Roman, Times, Serif">(16,749</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--CostOfGoodsAndServicesSold_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1980">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zF011mNHMFJ4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"><span style="font-family: Times New Roman, Times, Serif">(16,749</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gross profit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--GrossProfit_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Gross profit"><span style="font-family: Times New Roman, Times, Serif">34,416</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--GrossProfit_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1986">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--GrossProfit_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit"><span style="font-family: Times New Roman, Times, Serif">34,416</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Selling, general
    and administrative</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Selling, general and administrative"><span style="font-family: Times New Roman, Times, Serif">24,460</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative"><span style="font-family: Times New Roman, Times, Serif">174</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative"><span style="font-family: Times New Roman, Times, Serif">24,634</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ResearchAndDevelopmentExpense_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development"><span style="font-family: Times New Roman, Times, Serif">1,006</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ResearchAndDevelopmentExpense_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development"><span style="font-family: Times New Roman, Times, Serif">361</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ResearchAndDevelopmentExpense_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development"><span style="font-family: Times New Roman, Times, Serif">1,367</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Segment
    contribution</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--SegmentContribution_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Segment contribution"><span style="font-family: Times New Roman, Times, Serif">8,934</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--SegmentContribution_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Segment contribution"><span style="font-family: Times New Roman, Times, Serif">(535</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"/><td id="xdx_980_ecustom--SegmentContribution_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="padding-bottom: 1.5pt; text-align: right" title="Segment contribution"><span style="font-family: Times New Roman, Times, Serif">8,399</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Corporate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--OperatingIncomeLoss_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_pn3n3" style="text-align: right" title="Operating income (loss)"><span style="font-family: Times New Roman, Times, Serif">(8,245</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--OperatingIncomeLoss_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="text-align: right" title="Operating income (loss)"><span style="font-family: Times New Roman, Times, Serif">(716</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AdjustmentForAmortization_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Amortization"><span style="font-family: Times New Roman, Times, Serif">(209</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Asset sales and
    impairments, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--ImpairmentAndDisposalOfLonglivedAssets_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Asset sales and impairments, net"><span style="font-family: Times New Roman, Times, Serif">(4,040</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    loss</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--OperatingIncomeLoss_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating income (loss)"><span style="font-family: Times New Roman, Times, Serif">(4,795</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
</table>

<p id="xdx_8AF_zIPAVqlakOli" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company categorizes revenues by geographic area based on selling location. All operations are currently located in the U.S.; therefore,
total revenues are attributed to the U.S. All long-lived assets at December 31, 2020 and December 31, 2019 are located in the
U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Concentrations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company sells its compounded formulations to a large number of customers. There were no customers who comprised more than <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercent_c20200101__20201231_zkRMME5LjXof" title="Percentage of sales derived from large number of customer"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercent_c20190101__20191231_zsO2Z2EGkZq1" title="Percentage of sales derived from large number of customer">10%</span></span>
of the Company&#8217;s total pharmacy sales for the years ended December 31, 2020 and 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company receives its active pharmaceutical ingredients from three main suppliers. These suppliers collectively accounted for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercent_c20200101__20201231__us-gaap--ConcentrationRiskByTypeAxis__custom--ThreeMainSuppliersMember_zJf5ak088ns9" title="Percentage of sales derived from large number of customer">77%</span>
of active pharmaceutical ingredient purchases during the year ended December 31, 2020, and <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pii_dp_uPercent_c20190101__20191231__us-gaap--ConcentrationRiskByTypeAxis__custom--ThreeMainSuppliersMember_zLLQwOjuQ5f6" title="Percentage of sales derived from large number of customer">73%</span> during the year ended December
31, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171679225384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_z0qglOUjWSpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
19. <span id="xdx_820_zilROz9sooWh">SUBSEQUENT EVENTS </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
March 2021, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20210301__20210331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zO0Cwh0QvdJb">10,989
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of its common stock upon the exercise
of options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20210301__20210331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPJgXQbXoSRc">10,989
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of</span><span style="font: 10pt Times New Roman, Times, Serif">
common stock, with exercise prices ranging between $<span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20210301__20210331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z3C1WFfBG3gf">1.70
</span></span><span style="font: 10pt Times New Roman, Times, Serif">to $<span id="xdx_906_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20210301__20210331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTzZKIyAg7A2">3.96
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per share, and received net proceeds of
$<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20200301__20200331_pn3n3">27</span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Restricted
stock units granted in February 2015 to Andrew R. Boll, the Company&#8217;s Chief Financial Officer, vested, and in February 2021,
<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20210201__20210228__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--AndrewRBollMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_pii" title="Shares issued of restricted common stock, shares">22,500</span> shares the Company&#8217;s common stock were issued to Mr. Boll, net of <span id="xdx_90E_ecustom--CommonStockWithheldForPayrollTaxWithholdings_c20210201__20210228__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--AndrewRBollMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_pii" title="Common stock withheld for payroll tax withholdings">7,500</span> shares of common stock withheld for payroll
tax withholdings totaling $<span id="xdx_900_ecustom--CommonStockWithheldForPayrollTaxWithholdingsValue_c20210201__20210228__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--AndrewRBollMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_pn3n3" title="Common stock withheld for payroll tax withholdings, value">58</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Restricted
stock units granted in February 2015 to Mark L. Baum, the Company&#8217;s Chief Executive Officer, vested, and in February 2021,
<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20210201__20210228__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--MarkLBaumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_pii" title="Shares issued of restricted common stock, shares">200,000</span> shares the Company&#8217;s common stock were issued to Mr. Baum.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has performed an evaluation of events occurring subsequent to December 31, 2020 through the filing date of this Annual
Report and determined that no subsequent events have occurred that would require recognition in the consolidated financial
statements or disclosures in the notes thereto, other than as disclosed in the accompanying notes.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171685760488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_849_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zB2g7lpJjhz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_866_z5k7PSmrvwA3" style="font: 10pt Times New Roman, Times, Serif"><b>Basis
of Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Harrow
has prepared the accompanying consolidated financial statements in accordance with accounting principles generally accepted in
the United States of America (&#8220;GAAP&#8221;). The accompanying consolidated financial statements include the accounts of
the Company and its wholly-owned subsidiaries, as well as Mayfield, <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__srt--OwnershipAxis__custom--MayfieldPharmaceuticalsIncMember_zzFi1Xe7zli6">79</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
majority controlled, and Stowe, <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__srt--OwnershipAxis__custom--StowePharmaceuticalsIncMember_zaCIkRXxt1I3">70</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
majority controlled as of December 31, 2020. The remaining <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__srt--OwnershipAxis__custom--MayfieldPharmaceuticalsIncMember__dei--LegalEntityAxis__custom--TGVHealthLLCMember_zejqdJASHqdl">21</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of Mayfield is owned by Elle Pharmaceutical, LLC (&#8220;Elle&#8221;), TGV-Health, LLC and its affiliated entities (collectively
&#8220;TGV&#8221;) or other consultants. Mayfield was organized to develop women&#8217;s health and urological focused drug candidates.
The remaining <span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__srt--OwnershipAxis__custom--StowePharmaceuticalsIncMember__dei--LegalEntityAxis__custom--TGVHealthLLCMember_zVvLbLg0IAcb">30</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of Stowe was owned by TGV. Stowe was organized to develop ophthalmic drug candidates. The Company controls <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__dei--LegalEntityAxis__custom--VisionologyMember_zkoNfOuU98G">100</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of the equity interests in Visionology. All inter-company accounts and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Harrow
consolidates entities in which we have a controlling financial interest. <span id="xdx_90A_ecustom--ConsolidationBasisDescription_c20200101__20201231_zIrQSZmahuie">We
consolidate subsidiaries in which we hold and/or control, directly or indirectly, more than 50% of the voting rights</span></span><span style="font: 10pt Times New Roman, Times, Serif">.
All intercompany accounts and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_844_eus-gaap--UseOfEstimates_zpQsid6VybDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_867_z7UJDpJDayr5" style="font: 10pt Times New Roman, Times, Serif"><b>Use
of Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management are, among
others, allowance for doubtful accounts and contractual adjustments, renewal periods and discount rates for leases, realizability
of inventories, valuation of investments, realizability of deferred taxes, recoverability of goodwill and long-lived assets,
valuation of contingent acquisition obligations and deferred acquisition obligations, fair value of loans payable, and valuation
of stock-based transactions with employees and non-employees. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_RisksUncertaintiesAndLiquidityPolicyTextBlock', window );">Risks, Uncertainties and Liquidity</a></td>
<td class="text"><p id="xdx_843_ecustom--RisksUncertaintiesAndLiquidityPolicyTextBlock_zs7OziXE2Ufl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span id="xdx_863_zxtiQMgtw2R2" style="font: 10pt Times New Roman, Times, Serif"><b>Risks,
Uncertainties and Liquidity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. On March 18, 2020, the Centers for Medicare
&amp; Medicaid Services (&#8220;CMS&#8221;) released guidance for U.S. healthcare providers to limit all elective medical procedures
in order to conserve personal protective equipment and limit exposure to COVID-19 during the pendency of the pandemic. In addition
to limiting elective medical procedures, many hospitals and other healthcare providers have strictly limited access to their facilities
during the pandemic. The COVID-19 pandemic has negatively impacted the global economy, disrupted global supply chains and healthcare
delivery, led to social distancing recommendations, stay-at-home orders and other restrictive measures, and created significant
volatility in financial markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Many
of the Company&#8217;s customers use its drugs in procedures impacted by the CMS guidance to limit elective procedures. In addition,
the Company and our business partners need access to healthcare providers and facilities to conduct clinical trials and other
activities required to achieve regulatory clearance of products under development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Management
believes reductions in elective procedures in response to CMS guidance have had, and will continue to have, an adverse impact,
which may be material, on the Company&#8217;s financial condition, liquidity and results of operations. The severity of the impact
of the COVID-19 pandemic on the Company&#8217;s business will depend on a number of factors, including, but not limited to, the
duration and severity of the pandemic and the extent and severity of the impact on its customers, all of which are uncertain and
cannot be predicted. As of the date of the filing of this Annual Report on Form 10-K, the extent to which the COVID-19 pandemic
may materially impact the Company&#8217;s financial condition, liquidity or results of operations is uncertain. In addition, the
Company is subject to certain regulatory standards, guidelines and inspections which could impact the Company&#8217;s ability
to make, dispense, and sell certain products. If the Company was required to cease compounding and selling certain products as
a result of regulatory guidelines or inspections, this may have a material impact on the Company&#8217;s financial condition,
liquidity and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Prior
to 2020, the Company had incurred significant operating losses and negative cash flows from operations since its inception. The
Company recorded operating income of $<span id="xdx_900_eus-gaap--OperatingIncomeLoss_pn3n3_c20200101__20201231_zrqkwi258fMh">385
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for the year ended December 31, 2020 and
recorded an operating loss of $<span id="xdx_908_eus-gaap--OperatingIncomeLoss_iN_pn3n3_di_c20190101__20191231_zeWB0DB2LjV2">4,795
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for the year ended December 31, 2019.
The Company has an accumulated deficit of $<span id="xdx_90C_ecustom--RetainedEarningsAccumulatedDeficit1_iI_pn3n3_c20201231_zSluZYSmXt7l">77,400
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_902_ecustom--RetainedEarningsAccumulatedDeficit1_c20191231_pn3n3">74,043
</span></span><span style="font: 10pt Times New Roman, Times, Serif">as of December 31, 2020 and 2019, respectively.
In addition, the Company used cash in operating activities of $<span id="xdx_90A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20200101__20201231_zzvRseKWRTyk">1,100
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for the year ended December 31, 2020 and
cash provided by operating activities was $<span id="xdx_90B_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20190101__20191231_pn3n3">950
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for the year ended December 31, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">While
there is no assurance, management of the Company believes existing cash resources and restricted cash of $<span id="xdx_904_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c20201231_pn3n3">4,301
</span></span><span style="font: 10pt Times New Roman, Times, Serif">at December 31, 2020 together with cash
generated from operations, will be sufficient to sustain the Company&#8217;s planned level of operations for at least the next
twelve months. However, estimates of operating expenses and working capital requirements and the future impact of the COVID-19
pandemic on its business could be incorrect. The Company could use its cash resources faster than anticipated. Further, some or
all of the ongoing or planned activities may not be successful and could result in further losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company may seek to increase liquidity and capital resources through a variety of means which may include, but are not limited
to: the sale of assets, investments and/or businesses, obtaining financing through the issuance of equity, debt, or convertible
securities; and working to increase revenue growth through sales. There is no guarantee that the Company will be able to obtain
capital when needed on terms management deems acceptable, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p id="xdx_846_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zpKEVQaOaRf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_862_zVPS8MSdP6Ni" style="font: 10pt Times New Roman, Times, Serif"><b>Segments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s chief operating decision-maker is its Chief Executive Officer who makes resource allocation decisions and assesses
performance based on financial information presented as operating segments. The Company has identified <span id="xdx_903_eus-gaap--NumberOfReportableSegments_pii_dc_uSegment_c20200101__20201231_zZ5WqNKZm3U2">two
</span></span><span style="font: 10pt Times New Roman, Times, Serif">operating segments as reportable segments.
See Note 18 for more information regarding the Company&#8217;s reportable segments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_NoncontrollingInterestPolicyTextBlock', window );">Noncontrolling Interests</a></td>
<td class="text"><p id="xdx_84A_ecustom--NoncontrollingInterestPolicyTextBlock_zmlNb8sMDXV7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_864_ziIUmOoVZ9f7" style="font: 10pt Times New Roman, Times, Serif"><b>Noncontrolling
Interests</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recognizes any noncontrolling interest as a separate line item in equity in the consolidated financial statements. A noncontrolling
interest represents the portion of equity ownership in a less-than-wholly-owned subsidiary not attributable to the Company. <span id="xdx_901_eus-gaap--MinorityInterestDescription_c20200101__20201231">Generally,
any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there
are other factors, such as decision-making rights, that are considered as well.</span></span> <span style="font: 10pt Times New Roman, Times, Serif">The
Company includes the amount of net loss attributable to noncontrolling interests in consolidated net loss on the face of the consolidated
statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company provides in the consolidated statements of stockholders&#8217; equity a reconciliation at the beginning and the end of
the period of the carrying amount of total equity, equity attributable to the parent, and equity attributable to the noncontrolling
interests that separately discloses:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">net
    income or loss;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">transactions
    with owners acting in their capacity as owners, showing separately contributions from and distributions to owners; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">each
    component of other income or loss.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition and Deferred Revenue</a></td>
<td class="text"><p id="xdx_842_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zwbvARH7jyOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86B_zdyYS700LCO1" style="font: 10pt Times New Roman, Times, Serif"><b>Revenue
Recognition and Deferred Revenue</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recognizes revenue at the time of transfer of promised goods to customers in an amount that reflects the consideration
to which the Company expects to be entitled in exchange for those goods or services (see Note 3).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CostOfSalePolicyTextBlock', window );">Cost of Sales</a></td>
<td class="text"><p id="xdx_84F_ecustom--CostOfSalePolicyTextBlock_zNULLezY0Jaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86C_zVGLpbcWyQqj" style="font: 10pt Times New Roman, Times, Serif"><b>Cost
of Sales</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cost
of sales includes direct and indirect costs to manufacture formulations and other products sold, including active pharmaceutical
ingredients, personnel costs, packaging, storage, royalties, shipping and handling costs and the write-off of obsolete inventory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_zi0BbAIaxsOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_869_zXwXtE0Lq2Ta" style="font: 10pt Times New Roman, Times, Serif"><b>Research
and Development</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company expenses all costs related to research and development as they are incurred. Research and development expenses consist
of expenses incurred in performing research and development activities, including salaries and benefits, other overhead expenses,
and costs related to clinical trials, contract services and outsourced contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs and Debt Discount</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--DebtPolicyTextBlock_zUNT5Nkwu00h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86A_zj9yw1nxbvQk" style="font: 10pt Times New Roman, Times, Serif"><b>Debt
Issuance Costs and Debt Discount</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Debt
issuance costs and the debt discount are recorded net of loans payable and finance lease obligations in the consolidated balance
sheets. Amortization of debt issuance costs and the debt discount is calculated using the effective interest method over the term
of the related debt and is recorded in interest expense in the accompanying consolidated statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intellectual Property</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zxVT0PJq49oi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86D_zju760bhyMl8" style="font: 10pt Times New Roman, Times, Serif"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
costs of acquiring intellectual property rights to be used in the research and development process, including licensing fees and
milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified
an alternative future use for the acquired rights, and are capitalized in situations where we have identified an alternative future
use for the acquired rights. Patents and trademarks are recorded at cost and capitalized at a time when the future economic benefits
of such patents and trademarks become more certain (see &#8220;&#8212;Goodwill and Intangible Assets&#8221; below). The Company
began capitalizing certain costs associated with acquiring intellectual property rights during 2015; if costs are not capitalized
they are expensed as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zsSvygYBqgej" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_865_zpB7sR0mJIUh" style="font: 10pt Times New Roman, Times, Serif"><b>Income
Taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for income taxes under the provisions of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting
Standards Codification (&#8220;ASC&#8221;) 740, <i>Income Taxes</i>.</span><span style="font-family: Times New Roman, Times, Serif">
<span style="font-size: 10pt">As part of the process of preparing the Company&#8217;s consolidated financial statements, the Company
must estimate the actual current tax assets and liabilities and assess permanent and temporary differences that result from differing
treatment of items for tax and accounting purposes. The temporary differences result in deferred tax assets and liabilities, which
are included within the consolidated balance sheets. The Company must assess the likelihood that the deferred tax assets will
be recovered from future taxable income and, to the extent the Company believes that recovery is not more likely than not, a valuation
allowance must be established which reduces the amount of deferred tax assets recorded on the consolidated balance sheets. To
the extent the Company establishes a valuation allowance or increase or decrease this allowance in a period, the impact will be
included in income tax expense in the consolidated statements of operations.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zuJwTGl323H2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_865_zZc9Bcgsjwok" style="font: 10pt Times New Roman, Times, Serif"><b>Cash
and Cash Equivalents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cash
equivalents include short-term, highly liquid investments with maturities of three months or less at the time of acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zcW8Et4GKXgc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_866_za6tIB3JWyPe" style="font: 10pt Times New Roman, Times, Serif"><b>Concentrations
of Credit Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company places its cash with financial institutions deemed by management to be of high credit quality. The Federal Deposit Insurance
Corporation (&#8220;FDIC&#8221;) provides basic deposit coverage with limits up to $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_pn3n3_c20201231_zoSZhuyxZU2d">250
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per owner. From time to time the Company
has cash deposits in excess of FDIC limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment in Eton Pharmaceuticals, Inc. &#8211; Related Party</a></td>
<td class="text"><p id="xdx_849_eus-gaap--InvestmentPolicyTextBlock_zxoMNsKe1V7l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86D_zv7fnV1OYq7i" style="font: 10pt Times New Roman, Times, Serif"><b>Investment
in Eton Pharmaceuticals, Inc. &#8211; Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company owns <span id="xdx_903_ecustom--NumberOfSharesOwned_c20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pii">3,500,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of Eton common stock, which represents
approximately <span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zM8adaGIWvig">14.4</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of the equity and voting interests of Eton as of December 31, 2020. At December 31, 2020, the fair market value of Eton&#8217;s
common stock was $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_c20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pii">8.13
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per share. In accordance with Accounting
Standard Update (&#8220;ASU&#8221;) 2016-01, <i>Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of
Financial Assets and Financial Liabilities</i>, for the years ended December 31, 2020 and 2019, the Company recorded investment
gains from its Eton common stock position of $<span id="xdx_900_eus-gaap--GainLossOnInvestments_c20200101__20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pn3n3">3,255
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_903_eus-gaap--GainLossOnInvestments_c20190101__20191231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pn3n3">3,780</span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively, related to the change in fair market value of the Company&#8217;s investment in Eton during the measurement periods.
As of December 31, 2020 and 2019, the fair market value of the Company&#8217;s investment in Eton was $<span id="xdx_909_eus-gaap--InvestmentOwnedAtFairValue_c20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_pn3n3">28,455
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_905_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3n3_c20191231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zAouulE0m7Wh">25,200</span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Mark
Baum, the Company&#8217;s Chief Executive Officer, is a member of the board of directors of Eton.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><p id="xdx_842_eus-gaap--ReceivablesPolicyTextBlock_zKwwq9dhkrS7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_868_zPimghJtW8eh" style="font: 10pt Times New Roman, Times, Serif"><b>Accounts
Receivable</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Accounts
receivable are stated net of allowances for doubtful accounts and contractual adjustments. The accounts receivable balance primarily
includes amounts due from customers the Company has invoiced or from third-party providers (e.g., insurance companies and governmental
agencies), but for which payment has not been received. Charges to bad debt are based on both historical write-offs and specifically
identified receivables. Accounts receivable are presented net of allowances for doubtful accounts and contractual adjustments
in the amount of $<span id="xdx_90F_eus-gaap--AccountsReceivableNet_iI_pn3n3_c20201231_ze7GjI1AvVz9">98</span></span> <span style="font: 10pt Times New Roman, Times, Serif">and
$<span id="xdx_905_eus-gaap--AccountsReceivableNet_c20191231_pn3n3">76</span></span> <span style="font: 10pt Times New Roman, Times, Serif">as
of December 31, 2020 and 2019, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p id="xdx_841_eus-gaap--InventoryPolicyTextBlock_zsJGwgCCeaIc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86B_zgKKlzO6KBkg" style="font: 10pt Times New Roman, Times, Serif"><b>Inventories</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Inventories
are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. The Company evaluates
the carrying value of inventories on a regular basis, based on the price expected to be obtained for products in their respective
markets compared with historical cost. Write-downs of inventories are considered to be permanent reductions in the cost basis
of inventories.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company also regularly evaluates its inventories for excess quantities and obsolescence (expiration), taking into account such
factors as historical and anticipated future sales or use in production compared to quantities on hand and the remaining shelf
life of products and active pharmaceutical ingredients on hand. The Company establishes reserves for excess and obsolete inventories
as required based on its analyses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_InvestmentOnePolicyTextBlock', window );">Investment in Melt Pharmaceuticals, Inc. &#8211; Related Party</a></td>
<td class="text"><p id="xdx_84A_ecustom--InvestmentOnePolicyTextBlock_zZz6UKxpUsPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_864_zDoIglvrr3j6" style="font: 10pt Times New Roman, Times, Serif"><b>Investment
in Melt Pharmaceuticals, Inc. &#8211; Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
April 2018, the Company formed Melt as a wholly-owned subsidiary. In January and March of 2019, Melt entered into definitive stock
purchase agreements (collectively, the &#8220;Melt Series A Preferred Stock Agreement&#8221;) with certain investors and closed
on the sale of Melt&#8217;s Series A Preferred Stock (the &#8220;Melt Series A Stock&#8221;), totaling approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20200101__20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pn3n3">11,400
</span></span><span style="font: 10pt Times New Roman, Times, Serif">of proceeds (collectively, the &#8220;Melt
Series A Round&#8221;) at a purchase price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_c20190331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pii">5.00
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per share. As a result, the Company lost
voting and ownership control of Melt and ceased consolidating Melt&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
January 2019, the Company deconsolidated Melt and recorded a gain of $<span id="xdx_902_eus-gaap--DeconsolidationGainOrLossAmount_c20190101__20190131__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3">5,810
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and adjusted the carrying value in Melt
to reflect the increased valuation of Melt and the Company&#8217;s new ownership interest in accordance with ASC 810-10-40-4(c),
<i>Consolidation</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company owns <span id="xdx_907_ecustom--NumberOfSharesOwned_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pii">3,500,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">common shares of Melt (which is approximately
<span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zSd66pRu69Lj">44</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of the equity interests as of December 31, 2020) and uses the equity method of accounting for this investment, as management has
determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Melt.
Under this method, the Company recognizes earnings and losses in Melt in its consolidated financial statements and adjusts the
carrying amount of its investment in Melt accordingly. The Company&#8217;s share of earnings and losses are based on the Company&#8217;s
ownership interest of Melt. Any intra-entity profits and losses are eliminated. The Company recorded equity in the net gain of
Melt of $<span id="xdx_90E_eus-gaap--UnrealizedGainLossOnInvestments_c20190101__20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3">3,968
</span></span><span style="font: 10pt Times New Roman, Times, Serif">during the year ended December 31, 2019.
The Company recorded equity in the net loss of Melt of $<span id="xdx_90F_eus-gaap--UnrealizedGainLossOnInvestments_c20200101__20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3">2,313
</span></span><span style="font: 10pt Times New Roman, Times, Serif">during the year ended December 31, 2020.
As of December 31, 2020 and 2019, the Company&#8217;s investment in Melt was $<span id="xdx_90D_eus-gaap--InvestmentOwnedAtFairValue_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3">2,506
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_905_eus-gaap--InvestmentOwnedAtFairValue_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3">4,690</span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively, which includes $<span id="xdx_904_eus-gaap--DueFromRelatedParties_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3">851
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90F_eus-gaap--DueFromRelatedParties_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3">722</span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively, due from Melt for reimbursable expenses and amounts due under the Melt Master Services Agreement (&#8220;MSA&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">See
Note 4 for more information and related party disclosure regarding Melt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_InvestmentTwoPolicyTextBlock', window );">Investment in Surface Ophthalmics, Inc. &#8211; Related Party</a></td>
<td class="text"><p id="xdx_847_ecustom--InvestmentTwoPolicyTextBlock_zSDPZ9bcLUy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86C_zzuv4slLijWa" style="font: 10pt Times New Roman, Times, Serif"><b>Investment
in Surface Ophthalmics, Inc. &#8211; Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company owns <span id="xdx_90F_ecustom--NumberOfSharesOwned_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pii">3,500,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">common shares (which is approximately
<span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_uPercent_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_z8ILJkeZxVa8">30</span></span><span style="font: 10pt Times New Roman, Times, Serif">%
of the equity interests as of December 31, 2020) of Surface and uses the equity method of accounting for this investment, as management
has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of
Surface. Under this method, the Company recognizes earnings and losses in Surface in its consolidated financial statements and
adjusts the carrying amount of its investment in Surface accordingly. The Company&#8217;s share of earnings and losses are based
on the Company&#8217;s ownership interest of Surface. Any intra-entity profits and losses are eliminated. The Company recorded
equity in the net loss of Surface of $<span id="xdx_901_eus-gaap--UnrealizedGainLossOnInvestments_c20190101__20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3">1,200
</span></span><span style="font: 10pt Times New Roman, Times, Serif">during the year ended December 31, 2019.
The Company recorded equity in the net loss of Surface of $<span id="xdx_902_eus-gaap--UnrealizedGainLossOnInvestments_c20200101__20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3">2,433
</span></span><span style="font: 10pt Times New Roman, Times, Serif">during the year ended December 31, 2020.
As of December 31, 2020 and 2019, the carrying value of the Company&#8217;s investment in Surface was $<span id="xdx_900_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zanCLi0APkHc">1,314
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90E_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3n3_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_ziyzEpkI1lBk">3,747</span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">See
Note 5 for more information and related party disclosure regarding Surface.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zj1FOkOL4wDf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_863_zVg2Wgs9avOk" style="font: 10pt Times New Roman, Times, Serif"><b>Property,
Plant and Equipment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Property,
plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization is calculated
using the straight-line method over the estimated useful life of the asset. Leasehold improvements and capital lease equipment
are amortized over the estimated useful life or remaining lease term, whichever is shorter. Computer software and hardware and
furniture and equipment are depreciated over <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_z6frLmTXqxJd" title="::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0633">three
</span></span></span><span style="font: 10pt Times New Roman, Times, Serif">to <span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_zOKLGLpu2APa">five years</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--BusinessCombinationsPolicy_zmi63BiVPK49" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86F_zkYgk8tkZ8c2" style="font: 10pt Times New Roman, Times, Serif"><b>Business
Combinations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company accounts for business combinations by recognizing the assets acquired, liabilities assumed, contractual contingencies,
and contingent consideration at their fair values on the acquisition date. The purchase price allocation process requires management
to make significant estimates and assumptions, especially with respect to intangible assets, estimated contingent consideration
payments and pre-acquisition contingencies. Examples of critical estimates in valuing certain of the intangible assets the Company
has acquired or may acquire in the future include but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">future
    expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed
    technologies and patents; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">discount
    rates utilized in valuation estimates.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Unanticipated
events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates or actual results.
Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date,
including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets,
will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related
contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have
a material effect on the consolidated financial position, statements of operations or cash flows in the period of the change in
the estimate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><p id="xdx_843_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zEJZfx8SqBth" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86E_zkvFkR2slN9h" style="font: 10pt Times New Roman, Times, Serif"><b>Goodwill
and Intangible Assets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Patents
and trademarks are recorded at cost and capitalized at a time when the future economic benefits of such patents and trademarks
become more certain. At that time, the Company capitalizes third-party legal costs and filing fees associated with obtaining and
prosecuting claims related to its patents and trademarks. Once the patents have been issued, the Company amortizes these costs
over the shorter of the legal life of the patent or its estimated economic life, generally <span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231_zFaqwWWcwHJb">20
</span></span><span style="font: 10pt Times New Roman, Times, Serif">years, using the straight-line method.
Trademarks are an indefinite life intangible asset and are assessed for impairment based on future projected cash flows as further
described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company reviews its goodwill and indefinite-lived intangible assets for impairment as of January 1 of each year and when an event
or a change in circumstances indicates the fair value of a reporting unit may be below its carrying amount. Events or changes
in circumstances considered as impairment indicators include but are not limited to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">significant
    underperformance of the Company&#8217;s business relative to expected operating results;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">significant
    adverse economic and industry trends;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">significant
    decline in the Company&#8217;s market capitalization for an extended period of time relative to net book value; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">expectations
    that a reporting unit will be sold or otherwise disposed.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
goodwill impairment test consists of a two-step process as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Step
1. The Company compares the fair value of each reporting unit to its carrying amount, including the existing goodwill. The fair
value of each reporting unit is determined using a discounted cash flow valuation analysis. The carrying amount of each reporting
unit is determined by specifically identifying and allocating the assets and liabilities to each reporting unit based on headcount,
relative revenues or other methods as deemed appropriate by management. If the carrying amount of a reporting unit exceeds its
fair value, an indication exists that the reporting unit&#8217;s goodwill may be impaired and the Company then performs the second
step of the impairment test. If the fair value of a reporting unit exceeds its carrying amount, no further analysis is required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Step
2. If further analysis is required, the Company compares the implied fair value of the reporting unit&#8217;s goodwill, determined
by allocating the reporting unit&#8217;s fair value to all of its assets and its liabilities in a manner similar to a purchase
price allocation, to its carrying amount. If the carrying amount of the reporting unit&#8217;s goodwill exceeds its fair value,
an impairment loss will be recognized in an amount equal to the excess.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zLkCQtKREeZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_869_zx0R114RXQna" style="font: 10pt Times New Roman, Times, Serif"><b>Impairment
of Long-Lived Assets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Long-lived
assets, such as property, plant and equipment, purchased intangibles subject to amortization and patents and trademarks, are reviewed
for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted
future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash
flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the
asset. Assets to be disposed of would be separately presented in the consolidated balance sheet and reported at the lower of the
carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposal group
classified as held-for-sale would be presented separately in the appropriate asset and liability sections of the consolidated
balance sheet, if material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_RestructuringPolicyTextBlock', window );">Park Restructuring</a></td>
<td class="text"><p id="xdx_843_ecustom--RestructuringPolicyTextBlock_zhaksSxtf4ja" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86B_zTQVhvsTGKc2" style="font: 10pt Times New Roman, Times, Serif"><b>Park
Restructuring</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2019, the Company&#8217;s subsidiary, Park Compounding, Inc. (&#8220;Park&#8221;), and Noice Rx, LLC (&#8220;Noice&#8221;)
terminated an Asset Purchase Agreement dated July 26, 2019 (the &#8220;Park Purchase Agreement&#8221;), between the parties. Under
the terms of the Park Purchase Agreement, Park had agreed to sell substantially all its assets associated with its non-ophthalmology
pharmaceutical compounding business to Noice, including its pharmacy facility and equipment located in Irvine, California. The
closing of the sale transaction was dependent on the California State Board of Pharmacy approving of the sale and issuing a temporary
pharmacy and sterile license permit to Noice, which did not occur and led to Park ceasing operations at the close of business
on August 27, 2019. As a result, the Company restructured its Park business, ceased operations at its Irvine, California-based
pharmacy, and facilitated the transition of certain compounded formulations and related equipment from Park to the Company&#8217;s
New Jersey-based compounded pharmaceutical production facilities (the &#8220;Park Restructuring&#8221;). As a result of the Park
Restructuring, the Company incurred non-cash impairment costs of approximately $<span id="xdx_90B_eus-gaap--AssetImpairmentCharges_c20190101__20191231__dei--LegalEntityAxis__custom--ParkCompoundingIncAndNoiceRxLLCMember_pn3n3">3,781
</span></span><span style="font: 10pt Times New Roman, Times, Serif">related to assets held at Park, primarily
associated with property, plant, equipment, inventory, goodwill and other intangible assets, and $<span id="xdx_901_eus-gaap--SeveranceCosts1_c20190101__20191231__dei--LegalEntityAxis__custom--ParkCompoundingIncAndNoiceRxLLCMember_pn3n3">480
</span></span><span style="font: 10pt Times New Roman, Times, Serif">in one-time costs related to severance
packages and other costs associated with the Park Restructuring during the year ended December 31, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has reduced the Park compounded product formulary to seven base formulations, based on factors including unit order volumes,
revenues and gross margin percentages, and ImprimisRx retained approximately half of Park&#8217;s historical revenues during
the first quarter of 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zn2PInmnHdN3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_865_zNTAJLxBgAx1" style="font: 10pt Times New Roman, Times, Serif"><b>Fair
Value Measurements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Fair
value measurements are determined based on the assumptions that market participants would use in pricing an asset or liability.
GAAP establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes
the use of unobservable inputs by requiring that the most observable inputs be used when available. The established fair value
hierarchy prioritizes the use of inputs used in valuation methodologies into the following three levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in
    active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure
    fair value whenever available.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such
    as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are
    observable or can be corroborated by observable market data.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entity&#8217;s
    own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level
    3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2020 and 2019, the Company measured its investment in Eton on a recurring basis. The Company&#8217;s investment in
Eton is classified as Level 1 as the fair value is determined using quoted market prices in active markets for the same securities.
As of December 31, 2020 and 2019, the fair market value of the Company&#8217;s investment in Eton was $<span id="xdx_90B_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3n3_c20201231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zmGvFIrjU5u5">28,455
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90C_eus-gaap--InvestmentOwnedAtFairValue_iI_pn3n3_c20191231__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zieiRNKDybR8">25,200</span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s financial instruments include cash and cash equivalents, restricted cash, investment in Eton, accounts receivable,
accounts payable and accrued expenses, accrued payroll and related liabilities, deferred revenue and customer deposits, loans
payable and operating and finance lease liabilities. The carrying amount of these financial instruments, except for loans payable
and operating and finance lease liabilities, approximates fair value due to the short-term maturities of these instruments. The
Company&#8217;s restricted cash which is comprised of short-term investments are carried at amortized cost, which approximates
fair value. Based on borrowing rates currently available to the Company, the carrying values of the loans payable and operating
and finance lease liabilities approximate their respective fair values.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_846_eus-gaap--CompensationRelatedCostsPolicyTextBlock_z0tL4ZLkV5ea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_867_zG75iJYyM3Ff" style="font: 10pt Times New Roman, Times, Serif"><b>Stock-Based
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">All
stock-based payments to employees, directors and consultants, including grants of stock options, warrants, restricted stock units
(&#8220;RSUs&#8221;) and restricted stock, are recognized in the consolidated financial statements based upon their estimated
fair values. The Company uses the Black-Scholes-Merton option pricing model and Monte Carlo simulation model to estimate the fair
value of stock-based awards. The estimated fair value is determined at the date of grant. The financial statement effect of forfeitures
is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Income (Loss) per Common Share</a></td>
<td class="text"><p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_z4ZjFTL2yy96" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86B_zzrhTO0IGfpe" style="font: 10pt Times New Roman, Times, Serif"><b>Basic
and Diluted Net Income (Loss) per Common Share</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic
net income (loss) per common share is computed by dividing income (loss) attributable to common stockholders for the period by
the weighted average number of common shares outstanding during the period. Diluted income (loss) per share is computed
by dividing the income (loss) attributable to common stockholders for the period by the weighted average number of common
and common equivalent shares, such as stock options and warrants, outstanding during the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic
and diluted net income (loss) per share is computed using the weighted average number of shares of common stock outstanding during
the period. Common stock equivalents (using the treasury stock or &#8220;if converted&#8221; method) from stock options, unvested
restricted stock units (&#8220;RSUs&#8221;) and warrants were <span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndWarrantsMember_pii">5,411,929
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and <span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20190101__20191231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsUnvestedRSUsAndWarrantsMember_pii">4,848,459
</span></span><span style="font: 10pt Times New Roman, Times, Serif">at December 31, 2020 and 2019, respectively,
and are excluded in the calculation of diluted net income (loss) per share for the periods presented, because the effect is anti-dilutive
for that time period. Included in the basic and diluted net income (loss) per share calculation were RSUs awarded to directors
that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number of shares underlying
vested RSUs at December 31, 2020 and 2019 was <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii">200,463
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii">324,303</span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zqanQOau63d3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table shows the computation of basic net income (loss) per share of common stock for the years ended December 31, 2020
and 2019 (in 000&#8217;s, except share and per share amounts):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B1_zLJrrZUGtTT2" style="display: none">SCHEDULE
OF BASIC EARNINGS PER COMMON SHARE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
<tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20200101_20201231" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20190101_20191231" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended December 31,</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--NetIncomeLoss_pn3n3_zmcAh0QiiBul" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; width: 54%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Numerator
    &#8211; net (loss) income attributable to Harrow Health, Inc.</span></td><td style="padding-bottom: 2.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 19%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,357</span></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 19%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">168</span></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zL46cNFU7Am2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Denominator &#8211; weighted average
    number of shares outstanding, basic</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,895,352</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,323,159</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--EarningsPerShareBasic_pii_zA4JlFNRV9og" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    (loss) income per share, basic</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.13</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.01</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<p id="xdx_8AB_zZxuL4amfJk7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ze4eYR6UJYuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For
the year end December 31, 2019, the Company computed diluted net income per share using the weighted-average number of common
shares and dilutive common equivalent shares outstanding during that period. Diluted common equivalent shares for the year ended
December 31, 2019 consisted of the following (in 000&#8217;s, except share and per share amounts):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_z64O4FuEUht4" style="display: none">SCHEDULE
OF DILUTED COMMON EQUIVALENT SHARES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Diluted shares related to:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 74%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_c20190101__20191231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pii" style="width: 22%; text-align: right" title="Dilutive common equivalent shares"><span style="font-family: Times New Roman, Times, Serif">488,498</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Stock
    options</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_c20190101__20191231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Dilutive common equivalent shares"><span style="font-family: Times New Roman, Times, Serif">654,441</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Dilutive common
    equivalent shares</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_c20190101__20191231_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Dilutive common equivalent shares"><span style="font-family: Times New Roman, Times, Serif">1,142,939</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p id="xdx_8AE_zc1WXHrFzthb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_zPt4kPLVPCb3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table shows the computation of diluted net income per share using the weighted-average number of common shares and dilutive
common equivalent shares outstanding for the year ended December 31, 2019 (in 000&#8217;s, except share and per share amounts):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; display: none"><b>&#160;<span id="xdx_8B2_z8V4339e2Hag">SCHEDULE
OF DILUTED EARNINGS PER COMMON SHARE</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
<tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20190101__20191231_zXVzwvokF3d6" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2019</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2019</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--NetIncomeLoss_pn3n3_za3KraIwjsR8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; width: 74%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Numerator
    &#8211; net income</span></td><td style="padding-bottom: 2.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">168</span></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zyac3j8t4tk1" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Weighted average number of shares outstanding, basic</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,323,159</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_ecustom--IncrementalCommonSharesAttributableDilutiveCommonEquivalents_pii_z2WVbHP00Xv7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dilutive common
    equivalents</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,142,939</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--IncrementalCommonSharesAttributableToContingentlyIssuableShares_pii_zQSHI8sYiMX2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Denominator &#8211;
    number of shares used for diluted earnings per share computation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,466,098</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--EarningsPerShareDiluted_pii_zj3nKy7HkFoc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Net income per
    share, diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.01</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<p id="xdx_8A7_zPGABlO5l2jk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84F_ecustom--RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_zdg1yXLxkuUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_868_zlyKoit7XDYg" style="font: 10pt Times New Roman, Times, Serif"><b>Recently
Adopted Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</i>,
which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13
replaces the existing incurred loss impairment model with a forward-looking expected credit loss model which will result in earlier
recognition of credit losses. The Company adopted ASU 2016-13 on January 1, 2020, and adoption of the standard did not have a
material effect on the Company&#8217;s consolidated financial position, results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
January 2017, the FASB issued ASU 2017-04, <i>Intangibles-Goodwill and Other</i>. This guidance simplifies the accounting for
goodwill impairment for all entities by requiring impairment charges to be based on the first step in the current two-step impairment
test under ASC 350. The updated standard eliminates the requirement to calculate a goodwill impairment charge using Step 2. If
a reporting unit&#8217;s carrying amount exceeds its fair value, an entity will record an impairment charge based on that difference.
The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. The Company adopted ASU 2017-04
on January 1, 2020, and adoption of the standard did not have a material effect on the Company&#8217;s consolidated financial
position, results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2018, the FASB issued ASU 2018-13, <i>Changes to Disclosure Requirements for Fair Value Measurements</i>, which improved
the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies,
and adds certain disclosure requirements. The Company adopted ASU 2018-13 on January 1, 2020, and adoption of the standard did
not have a material effect on the Company&#8217;s consolidated financial position, results of operations and cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zblzoMl5axM9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86B_ze9IvWDrTEAa" style="font: 10pt Times New Roman, Times, Serif"><b>Recently
Issued Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2019, the FASB issued ASU 2019-12, <i>Income Taxes</i>: <i>Simplifying the Accounting for Income Taxes</i>, which simplifies
the accounting for income taxes. This guidance will be effective for the Company in the first quarter of 2021 on a prospective
basis, and early adoption is permitted. The Company does not expect a material impact of the new guidance on its consolidated
financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z4MuVNqxYXnj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86C_z3kWjNHVTIXb" style="font: 10pt Times New Roman, Times, Serif"><b>Reclassifications</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Certain
prior period items and amounts have been reclassified to conform to the classifications used to prepare the consolidated financial
statements for the year ended December 31, 2020. These reclassifications had no material impact on the Company&#8217;s consolidated
financial position, results of operations, or cash flows as previously reported.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_CostOfSalePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_CostOfSalePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_InvestmentOnePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_InvestmentOnePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_InvestmentTwoPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_InvestmentTwoPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_NoncontrollingInterestPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_NoncontrollingInterestPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recently Adopted Accounting Pronouncements [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_RestructuringPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_RestructuringPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_RisksUncertaintiesAndLiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_RisksUncertaintiesAndLiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171679218024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock', window );">SCHEDULE OF BASIC EARNINGS PER COMMON SHARE</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_zqanQOau63d3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table shows the computation of basic net income (loss) per share of common stock for the years ended December 31, 2020
and 2019 (in 000&#8217;s, except share and per share amounts):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B1_zLJrrZUGtTT2" style="display: none">SCHEDULE
OF BASIC EARNINGS PER COMMON SHARE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
<tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20200101_20201231" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20190101_20191231" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended December 31,</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--NetIncomeLoss_pn3n3_zmcAh0QiiBul" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; width: 54%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Numerator
    &#8211; net (loss) income attributable to Harrow Health, Inc.</span></td><td style="padding-bottom: 2.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 19%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,357</span></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 19%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">168</span></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zL46cNFU7Am2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Denominator &#8211; weighted average
    number of shares outstanding, basic</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,895,352</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,323,159</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--EarningsPerShareBasic_pii_zA4JlFNRV9og" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    (loss) income per share, basic</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.13</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.01</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ze4eYR6UJYuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For
the year end December 31, 2019, the Company computed diluted net income per share using the weighted-average number of common
shares and dilutive common equivalent shares outstanding during that period. Diluted common equivalent shares for the year ended
December 31, 2019 consisted of the following (in 000&#8217;s, except share and per share amounts):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_z64O4FuEUht4" style="display: none">SCHEDULE
OF DILUTED COMMON EQUIVALENT SHARES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Diluted shares related to:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 74%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_c20190101__20191231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pii" style="width: 22%; text-align: right" title="Dilutive common equivalent shares"><span style="font-family: Times New Roman, Times, Serif">488,498</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Stock
    options</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_c20190101__20191231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Dilutive common equivalent shares"><span style="font-family: Times New Roman, Times, Serif">654,441</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Dilutive common
    equivalent shares</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_c20190101__20191231_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Dilutive common equivalent shares"><span style="font-family: Times New Roman, Times, Serif">1,142,939</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock', window );">SCHEDULE OF DILUTED EARNINGS PER COMMON SHARE</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_zPt4kPLVPCb3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table shows the computation of diluted net income per share using the weighted-average number of common shares and dilutive
common equivalent shares outstanding for the year ended December 31, 2019 (in 000&#8217;s, except share and per share amounts):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; display: none"><b>&#160;<span id="xdx_8B2_z8V4339e2Hag">SCHEDULE
OF DILUTED EARNINGS PER COMMON SHARE</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
<tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20190101__20191231_zXVzwvokF3d6" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2019</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended</span></td><td style="text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2019</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--NetIncomeLoss_pn3n3_za3KraIwjsR8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; width: 74%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Numerator
    &#8211; net income</span></td><td style="padding-bottom: 2.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; width: 22%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">168</span></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zyac3j8t4tk1" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Weighted average number of shares outstanding, basic</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,323,159</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_ecustom--IncrementalCommonSharesAttributableDilutiveCommonEquivalents_pii_z2WVbHP00Xv7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dilutive common
    equivalents</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,142,939</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--IncrementalCommonSharesAttributableToContingentlyIssuableShares_pii_zQSHI8sYiMX2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Denominator &#8211;
    number of shares used for diluted earnings per share computation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,466,098</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--EarningsPerShareDiluted_pii_zj3nKy7HkFoc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Net income per
    share, diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.01</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on basic earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1278-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171771599928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">SCHEDULE OF DISAGGREGATED REVENUE</a></td>
<td class="text"><p id="xdx_897_eus-gaap--DisaggregationOfRevenueTableTextBlock_ztse0XPjc8Kh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Revenue
disaggregated by revenue source for the years ended December 31, 2020 and 2019, consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B1_zgDCXutC9LY2" style="display: none">SCHEDULE
OF DISAGGREGATED REVENUE</span></span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20200101__20201231_zXjkmt7RQjS5" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20190101__20191231_zCgJERXstHci" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Years Ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Product
    sales, net</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_z2vy7QHcd335" style="width: 18%; text-align: right" title="Total Revenues"><span style="font-family: Times New Roman, Times, Serif">48,479</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20191231__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_zXQYsT0UskV4" style="width: 18%; text-align: right" title="Total Revenues"><span style="font-family: Times New Roman, Times, Serif">51,137</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Commissions</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__custom--CommissionsMember_z9qdAGyt5GH7" style="text-align: right" title="Total Revenues"><span style="font-family: Times New Roman, Times, Serif">356</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__custom--CommissionsMember_pn3n3" style="text-align: right" title="Total Revenues"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0706">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">License</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20201231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zam5zkBhjPH1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues"><span style="font-family: Times New Roman, Times, Serif">36</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ProductOrServiceAxis__us-gaap--LicenseMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues"><span style="font-family: Times New Roman, Times, Serif">28</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_z6WY4vLl8aul" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    revenues</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">48,871</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,165</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171679331240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock', window );">SCHEDULE OF CONDENSED INCOME STATEMENT</a></td>
<td class="text"><p id="xdx_89A_ecustom--ScheduleOfCondensedIncomeStatementOneTableTextBlock_zRZArcCQNL66" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
unaudited condensed results of operations information of Melt is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BC_zLmh3RyFHgLk" style="font: 10pt Times New Roman, Times, Serif; display: none">SCHEDULE
OF CONDENSED INCOME STATEMENT</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Years Ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Revenues, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Revenues, net"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0725">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Revenues, net"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0727">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    from operations</span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--OperatingIncomeLoss_c20200101__20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Loss from operations"><span style="font-family: Times New Roman, Times, Serif">5,019</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--OperatingIncomeLoss_c20190101__20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Loss from operations"><span style="font-family: Times New Roman, Times, Serif">4,381</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--NetIncomeLoss_c20200101__20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"><span style="font-family: Times New Roman, Times, Serif">(5,019</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--NetIncomeLoss_c20190101__20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"><span style="font-family: Times New Roman, Times, Serif">(4,381</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock', window );">SCHEDULE OF CONDENSED BALANCE SHEET</a></td>
<td class="text"><p id="xdx_89B_ecustom--ScheduleOfCondensedBalanceSheetOneTableTextBlock_zwmQcbAYH4Hd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
unaudited condensed balance sheet information of Melt is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B5_zA39cAzGTzFi" style="font: 10pt Times New Roman, Times, Serif; display: none">SCHEDULE
OF CONDENSED BALANCE SHEET</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Current assets</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--AssetsCurrent_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="width: 18%; text-align: right" title="Current assets"><span style="font-family: Times New Roman, Times, Serif">2,947</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--AssetsCurrent_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="width: 18%; text-align: right" title="Current assets"><span style="font-family: Times New Roman, Times, Serif">7,449</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Non current
    assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--AssetsNoncurrent_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets"><span style="font-family: Times New Roman, Times, Serif">11</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--AssetsNoncurrent_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--Assets_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets"><span style="font-family: Times New Roman, Times, Serif">2,958</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--Assets_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets"><span style="font-family: Times New Roman, Times, Serif">7,454</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--Liabilities_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities"><span style="font-family: Times New Roman, Times, Serif">1,778</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--Liabilities_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities"><span style="font-family: Times New Roman, Times, Serif">1,691</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total preferred
    stock and stockholders&#8217; equity</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--StockholdersEquity_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total preferred stock and stockholders' equity"><span style="font-family: Times New Roman, Times, Serif">1,180</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--StockholdersEquity_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total preferred stock and stockholders' equity"><span style="font-family: Times New Roman, Times, Serif">5,763</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total liabilities
    and stockholders&#8217; equity</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--LiabilitiesAndStockholdersEquity_c20201231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity"><span style="font-family: Times New Roman, Times, Serif">2,958</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--LiabilitiesAndStockholdersEquity_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity"><span style="font-family: Times New Roman, Times, Serif">7,454</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Condensed Balance Sheet [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Condensed Balance Sheet [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171677757272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract', window );"><strong>Investment In Surface Ophthalmics Inc. And Agreements - Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock', window );">SUMMARY OF CONDENSED INCOME STATEMENT</a></td>
<td class="text"><p id="xdx_896_esrt--ScheduleOfCondensedIncomeStatementTableTextBlock_zVSrka9hJfF" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
unaudited condensed results of operations information of Surface is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B5_zaAtubQHO5k8" style="font: 10pt Times New Roman, Times, Serif; display: none">SUMMARY
OF CONDENSED INCOME STATEMENT</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year<b>s</b> Ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Revenues, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Revenues, net"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0770">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Revenues, net"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0772">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    from operations</span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--OperatingIncomeLoss_c20200101__20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Loss from operations"><span style="font-family: Times New Roman, Times, Serif">8,109</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--OperatingIncomeLoss_c20190101__20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Loss from operations"><span style="font-family: Times New Roman, Times, Serif">4,000</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--NetIncomeLoss_c20200101__20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"><span style="font-family: Times New Roman, Times, Serif">(8,109</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--NetIncomeLoss_c20190101__20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"><span style="font-family: Times New Roman, Times, Serif">(4,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock', window );">SUMMARY OF CONDENSED BALANCE SHEET</a></td>
<td class="text"><p id="xdx_897_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_zshJRTO0n9Bk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
unaudited condensed balance sheet information of Surface is summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B5_zqOuNIJAasqj" style="font: 10pt Times New Roman, Times, Serif; display: none">SUMMARY
OF CONDENSED BALANCE SHEET</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">
    December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Current assets</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--AssetsCurrent_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="width: 18%; text-align: right" title="Current assets"><span style="font-family: Times New Roman, Times, Serif">9,074</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--AssetsCurrent_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="width: 18%; text-align: right" title="Current assets"><span style="font-family: Times New Roman, Times, Serif">15,942</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Non current
    assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AssetsNoncurrent_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets"><span style="font-family: Times New Roman, Times, Serif">45</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--AssetsNoncurrent_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets"><span style="font-family: Times New Roman, Times, Serif">47</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--Assets_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets"><span style="font-family: Times New Roman, Times, Serif">9,119</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--Assets_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets"><span style="font-family: Times New Roman, Times, Serif">15,989</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--Liabilities_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities"><span style="font-family: Times New Roman, Times, Serif">1,666</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--Liabilities_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities"><span style="font-family: Times New Roman, Times, Serif">619</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total stockholders&#8217;
    equity</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--StockholdersEquity_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders equity"><span style="font-family: Times New Roman, Times, Serif">7,453</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--StockholdersEquity_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders equity"><span style="font-family: Times New Roman, Times, Serif">15,370</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    liabilities and stockholders&#8217; equity</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--LiabilitiesAndStockholdersEquity_c20201231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity"><span style="font-family: Times New Roman, Times, Serif">9,119</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--LiabilitiesAndStockholdersEquity_c20191231__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity"><span style="font-family: Times New Roman, Times, Serif">15,989</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 3<br> -Paragraph i<br> -Subsection 10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 3<br> -Paragraph i<br> -Subsection 10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedIncomeStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171798809528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">SCHEDULE OF INVENTORIES</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zVM9xZ4mT2g5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Inventories
are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, commercial pharmaceutical
products, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of December 31,
2020 and 2019 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B0_zIjxVAkLNoc5" style="display: none; font-family: Times New Roman, Times, Serif">SCHEDULE
OF INVENTORIES</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_494_20201231" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49D_20191231" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINz6Re_zTVNBcbUSdw8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Raw materials</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,501</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,405</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINz6Re_z6vJj1koPK5i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Work in progress</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">17</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">20</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINz6Re_zJzeTHthaeq9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Finished goods</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,444</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">876</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--InventoryNet_iTI_pn3n3_mtINz6Re_znCqFTxzdDdi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total inventories</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,962</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,301</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171679380456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_890_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zMM0nyOgIy16" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Prepaid
expenses and other current assets consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BB_zlAuHGfL9hd1" style="display: none; font-family: Times New Roman, Times, Serif">SCHEDULE
OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20201231_zIEkQ4Z1pGU2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_490_20191231_zIrCXcI8M0a2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAzQA0_z7lY8f1LmF06" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Prepaid insurance</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">160</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">123</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maPEAOAzQA0_zRr4mVc6ivQl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Other prepaid expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">401</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">358</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--OtherAssetsCurrent_iI_pn3n3_maPEAOAzQA0_z3cZ6ho4SpT6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Deposits and
    other current assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">190</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">105</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzQA0_zIRBNErWxx65" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total prepaid
    expenses and other current assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">751</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">586</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Prepaid Expenses and Other Current Assets [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171680815896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--PropertyPlantAndEquipmentTextBlock_zU7a0HAL9JCh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Property,
plant and equipment, net at December 31, 2020 and 2019 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B8_zJzr49I67J88" style="display: none; font-family: Times New Roman, Times, Serif">SCHEDULE
OF PROPERTY, PLANT AND EQUIPMENT</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="display: none; vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20201231_zmAaGU4dJKh9" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20191231_zXOV4No9klFg" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Property, plant and equipment, net:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_maPPAEGzzle_zpt88c4SRsr1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Computer
    software and hardware</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,707</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,732</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAEGzzle_ztjBM8L8AUh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Furniture and
    equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">418</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">363</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_maPPAEGzzle_zSP7XrWC6eq" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Lab and pharmacy
    equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,426</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,164</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--LeaseholdImprovementsGross_iI_pn3n3_maPPAEGzzle_z1SmBOq4b4Dk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Leasehold
    improvements</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,720</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,510</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_mtPPAEGzzle_maPPAENzQqn_zC4fNjsEzm0a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif">&#160;Property, plant
    and equipment, gross</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,271</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,769</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzQqn_z4uHdoRGQXtk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    depreciation and amortization</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(6,818</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,394</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzQqn_zVbprQkbhqt3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Property,
    plant and equipment, net&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,453</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,375</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171679478904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">SCHEDULE OF INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_z9CnciC2W6x1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s intangible assets at December 31, 2019 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BE_z7uGUwecGrci" style="font: 10pt Times New Roman, Times, Serif; display: none">SCHEDULE
OF INTANGIBLE ASSETS</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">periods</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(in
    years)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Cost</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">amortization</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Impairment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Carrying
    value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 21%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; width: 13%; text-align: center"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MinimumMember_zJDQd12aOYyc" style="font-family: Times New Roman, Times, Serif">17</span><span style="font-family: Times New Roman, Times, Serif">-<span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MaximumMember_ztZBmwpM1WE8">19
    years</span></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zhbD2JrfAgrk" style="width: 13%; text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">1,102</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_ziIZt3BHrsDc" style="width: 13%; text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(97</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zIqUTTOPJ39h" style="width: 13%; text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif">(259</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zna80rxILWI9" style="width: 13%; text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif">746</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Licenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z3k89bh0bBW1" style="font-family: Times New Roman, Times, Serif">20
    years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zY1AHJtP3hO6" style="text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">50</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_z99Wqkb89VBg" style="text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zbcA2GUkwVLc" style="text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0891">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zxyIg2UbCCRl" style="text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif">45</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trademarks</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zBY0yKcqo9b3" style="font-family: Times New Roman, Times, Serif">Indefinite</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zw6q7xgAUXgd" style="text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">340</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zWn3zLg1I8Eb" style="text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0898">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_z1LJRv60q221" style="text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0900">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zgT4x7HeEPZi" style="text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif">340</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Customer relationships</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MinimumMember_zKR67nTo16Fj" style="font-family: Times New Roman, Times, Serif">3</span><span style="font-family: Times New Roman, Times, Serif">-<span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MaximumMember_z5kmYX467Uuf">15
    years</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z1cDt2HRe15c" style="text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">3,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zZmeiVV6yvx6" style="text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(1,165</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zxgKZB53Hakd" style="text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif">(630</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z2SFsTRf6t7d" style="text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif">1,205</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trade name</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zVZNFy9f5Brd" style="font-family: Times New Roman, Times, Serif">5
    years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zF275xxnyRp1" style="text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">16</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zC0NwhC2l5Af" style="text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zsqVqOTODgV7" style="text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif">(2</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zs4tRqxbxU4f" style="text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0921">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-competition clause</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MinimumMember_zKrDhGjvHJdj" style="font-family: Times New Roman, Times, Serif">3</span><span style="font-family: Times New Roman, Times, Serif">-<span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MaximumMember_zyrkJ6baCHA9">4
    years</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zqn1b3j6nWjj" style="text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">294</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zEsaUUYHCIHl" style="text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(274</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zAfJs3Z6l5Me" style="text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif">(20</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_zzJzn6bvsGbi" style="text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0931">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State pharmacy
    licenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt"><span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zfur4GTZ1z6j" style="font-family: Times New Roman, Times, Serif">25
    years</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zgiz2zfbxlZj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">45</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zGhmR1USem05" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(9</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zdTRXTlUiIY5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif">(35</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zzd4Eso5bG6b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20191231_zNlAG0V5AI5a" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">4,847</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20191231_zOAZLafkIIs9" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(1,564</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--FiniteLivedIntangibleAssetsImpairment_iI_pn3n3_c20191231_zfwFghU4otk" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif">(946</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20191231_zXhHwMCoYw24" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif">2,337</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2019, the Company incurred impairment charges of $<span id="xdx_908_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember__dei--LegalEntityAxis__custom--ParkCompoundingIncMember_pn3n3">612
</span></span><span style="font: 10pt Times New Roman, Times, Serif">related to intangible assets, including
customer relationships, trade name, and state pharmacy licenses as a part of the Park Restructuring and $<span id="xdx_907_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__dei--LegalEntityAxis__custom--ParkCompoundingIncMember_pn3n3">259
</span></span><span style="font: 10pt Times New Roman, Times, Serif">of impairment charges related to patents
associated with the termination of an asset agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s intangible assets at December 31, 2020 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">periods</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(in
    years)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Cost</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">amortization</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Impairment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Carrying
    value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 21%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 13%; text-align: center"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MinimumMember_zhP46VZLxkA5" style="font-family: Times New Roman, Times, Serif">17</span><span style="font-family: Times New Roman, Times, Serif">-<span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MaximumMember_zlrwlaXJYgnj">19
    years</span></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 13%; text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">929</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 13%; text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(93</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 13%; text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif">(363</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 13%; text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif">473</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Licenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_ztvth0XwlEM2" style="font-family: Times New Roman, Times, Serif">20
    years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">50</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(6</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0967">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif">44</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trademarks</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember" style="font-family: Times New Roman, Times, Serif">Indefinite</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">356</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zyVZb9RLmQSk" style="text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0974">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0976">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif">356</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Customer relationships</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MinimumMember_zTIJEmYmkAi1" style="font-family: Times New Roman, Times, Serif">3</span><span style="font-family: Times New Roman, Times, Serif">-<span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MaximumMember_zMyTp3xvOvye">15
    years</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">1,519</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(454</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0986">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif">1,065</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trade name</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zFoEcLU36Rml" style="font-family: Times New Roman, Times, Serif">5
    years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0995">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0997">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-competition clause</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MinimumMember_zHCLJgySguOh" style="font-family: Times New Roman, Times, Serif">3</span><span style="font-family: Times New Roman, Times, Serif">-<span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MaximumMember_zz3yOhc7RnC2">4
    years</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">50</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(50</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1005">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1007">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State pharmacy
    licenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dt_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_zspTSXx0fi16" style="font-family: Times New Roman, Times, Serif">25
    years</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(7</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1014">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"><span style="font-family: Times New Roman, Times, Serif">2,917</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">(615</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_ecustom--FiniteLivedIntangibleAssetsImpairment_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment"><span style="font-family: Times New Roman, Times, Serif">(363</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_c20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying value"><span style="font-family: Times New Roman, Times, Serif">1,939</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zAj2eB9v1R98" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Amortization
expense for intangible assets for the years ended December 31, 2020 and 2019 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BB_zlrxcSZGQuah" style="display: none; font-family: Times New Roman, Times, Serif">SCHEDULE
OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">For
                                         the Years Ended</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">December
                                         31,</span></p></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 18%; text-align: right" title="Amortization of intangible assets"><span style="font-family: Times New Roman, Times, Serif">32</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 18%; text-align: right" title="Amortization of intangible assets"><span style="font-family: Times New Roman, Times, Serif">48</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Licenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Customer relationships</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"><span style="font-family: Times New Roman, Times, Serif">134</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"><span style="font-family: Times New Roman, Times, Serif">151</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Trade name</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1041">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State pharmacy
    licenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1045">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets"><span style="font-family: Times New Roman, Times, Serif">167</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets"><span style="font-family: Times New Roman, Times, Serif">209</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zCrnqtoou5C7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Estimated
future amortization expense for the Company&#8217;s intangible assets at December 31, 2020 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B5_zWrE2YLiAiU1" style="display: none; font-family: Times New Roman, Times, Serif">SCHEDULE
OF ESTIMATED FUTURE AMORTIZATION EXPENSE</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Years
    ending December 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49E_20201231_z08ve1nggkf4" style="display: none; text-align: center; vertical-align: middle"><span style="font-family: Times New Roman, Times, Serif">Dec</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzZax_zun3XUYwvgmk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">187</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzZax_zqXKKurZLBq4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">187</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzZax_zClalTV8kFt6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">187</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzZax_zUTxlWzgqgA7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">160</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANzZax_zLNYUz6Wy1q8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">147</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANzZax_z1idoaLAGGd7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">715</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzZax_zGYl8T2Be8Ak" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Intangible assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,583</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">SCHEDULE OF GOODWILL</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfGoodwillTextBlock_zjexslfNY2lb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">There
were <span id="xdx_90D_eus-gaap--GoodwillAndIntangibleAssetImpairment_pn3n3_do_c20200101__20201231_zB80rURDddwl">no</span></span>
<span style="font: 10pt Times New Roman, Times, Serif">changes in the carrying value of the Company&#8217;s
goodwill during the year ended December 31, 2020. Changes in the carrying value of the Company&#8217;s goodwill during the year
ended December 31, 2019 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B9_zfvkaevAckXe" style="display: none; font-family: Times New Roman, Times, Serif">SCHEDULE
OF GOODWILL</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
<tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_49D_20190101__20191231_zFUhKXfZ0Moj" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">Dec</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--Goodwill_iS_pn3n3_zllUwXCIesg3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Balance at December 31,
    2018</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,227</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--GoodwillImpairmentLoss_iN_pn3n3_di_zWCIoVCs7YF3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Impairment
    of Park goodwill (see Note 2)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,895</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_406_eus-gaap--Goodwill_iE_pn3n3_zn1KMrun4BX1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at
    December 31, 2019</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">332</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171677848008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zSTbfZT5E0Gh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Accounts
payable and accrued expenses at December 31, 2020 and 2019 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BF_zNnrDhjj9D91" style="font: 10pt Times New Roman, Times, Serif; display: none">SCHEDULE
OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="display: none; vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_497_20201231_zOQWq8Mbsmch" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20191231_zJeZIV8iuay5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn3n3_maAPAALzPeR_zPXROrIZN1d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accounts payable</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,645</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,409</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maAPAALzPeR_zdhO5q7IVid6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Other accrued expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">49</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">49</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_maAPAALzPeR_zcEkRYmBjvdk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Accrued interest (see Note 12)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">238</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">244</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maAPAALzPeR_zOuy8vW3Rud3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued exit
    fee for note payable (see Note 12)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">800</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">800</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_pn3n3_mtAPAALzPeR_zmszDR9tOXkj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total accounts payable and accrued
    expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,732</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,502</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iNI_pn3n3_di_zHTQw7cSETZd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: Current
    portion</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,932</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7,702</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_400_eus-gaap--AccountsPayableAndAccruedLiabilitiesNoncurrent_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Non-current
    total accrued expenses</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">800</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">800</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171678075672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">SUMMARY OF FUTURE MINIMUM PAYMENTS</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zXNJcHgSyYGf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2020, future minimum payments under the Company&#8217;s debt were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8BD_zizdE1NSyEMa" style="font: 10pt Times New Roman, Times, Serif; display: none">SUMMARY
OF FUTURE MINIMUM PAYMENTS</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49B_20201231_zLJmPpoPTFI6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maLTDzahg_zABGlu8wOMFe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,794</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maLTDzahg_zaeVDqElNOY5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,700</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maLTDzahg_zL7MRHjzyf0f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,511</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDzahg_zvgwAcLonrK6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total minimum payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,005</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--InterestPayableCurrent_iNI_pn3n3_di_zN3aVQMerpM8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: amount
    representing interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,927</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_409_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_zvYFCbAYDpB4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Notes payable, gross</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,078</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_zBlvNm0isV8g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: unamortized
    discount</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(802</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_406_eus-gaap--NotesPayable_iTI_pn3n3_zKOyQNKTAAV8" style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Notes payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,276</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_ecustom--NotesPayableCurrent1_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: current
    portion, net of unamortized discount</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,898</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_409_ecustom--LongTermNotesPayable1_iI_pn3n3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Note payable,
    net of current portion and unamortized debt discount</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,378</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171776247960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES</a></td>
<td class="text"><p id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zBHaDku5PJ05" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Future
lease payments under operating leases (including options to extend) as of December 31, 2020 were as follows<b>: </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;<span id="xdx_8BA_zCGIKH544meg" style="display: none">SCHEDULE
OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_491_20201231_z7vEciE6mGM9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Dec
    31, 2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Operating
    Leases</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzHYL_ztSvJXG01Clg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right" title="2021"><span style="font-family: Times New Roman, Times, Serif">1,017</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzHYL_z7dClBFBQ3Wa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right" title="2022"><span style="font-family: Times New Roman, Times, Serif">1,038</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzHYL_zbURxCwGXWIi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right" title="2023"><span style="font-family: Times New Roman, Times, Serif">1,064</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzHYL_z0YO91yBCbig" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,090</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_maLOLLPzHYL_zgIv5ehjhyEb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">916</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPzHYL_zM4UDNvZZjrk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,141</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzHYL_zLehlB1IYAz8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total minimum lease payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,266</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_z4XSssBwVWBb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: amount
    representing interest payments</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,034</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_zXfD1mp0LnE3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total operating
    lease liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,232</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_zRcbHFWH26Ga" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: current
    portion, operating lease liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(580</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    lease liabilities, net of current portion</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,652</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE</a></td>
<td class="text"><p id="xdx_892_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_z8hLwse0aLEb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Future
lease payments under the finance lease as of December 31, 2020 were as follows<b>: </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;<span id="xdx_8B9_zMAS9lkCNBG4" style="display: none">SCHEDULE
OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE</span></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20201231_zQ8cj1fDi9x3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Dec
    31, 2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Finance
    Lease</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maFLLPDzqJW_zbhPbELo62cb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 18%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maFLLPDzqJW_z1r0Hki6hbTf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maFLLPDzqJW_zZY2ZHZ47DF" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maFLLPDzqJW_zlhD50S62qNj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_pn3n3_mtFLLPDzqJW_z6THCmSKI286" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Total minimum lease payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">28</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_zGQmkwS8O0Q8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: amount
    representing interest payments</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40C_eus-gaap--FinanceLeaseLiability_iI_pn3n3_zbbH2BQ1BGz3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Present value of future minimum lease
    payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">25</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_pn3n3_di_ze37uSaOytll" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: current
    portion, finance lease obligation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Finance lease
    obligation, net of current portion</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171677831896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF STOCK OPTION PLAN ACTIVITY</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zFVMg4isXzGh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of stock option activity under the Plan for the year ended December 31, 2020 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BA_zXtj7wc3j72" style="display: none">SCHEDULE OF STOCK OPTION PLAN ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Avg. Exercise Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Avg. Remaining Contractual Life</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate
    Intrinsic Value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Options outstanding -
    January 1, 2020</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20191231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z0wvlfZb3Fn5" style="width: 11%; text-align: right" title="Number of shares, Outstanding, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">2,656,683</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20191231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z0vDY4ja3755" style="width: 11%; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">5.31</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Options granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="text-align: right" title="Number of shares, Options granted"><span style="font-family: Times New Roman, Times, Serif">414,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="text-align: right" title="Weighted Avg. Exercise Price, Options granted"><span style="font-family: Times New Roman, Times, Serif">6.44</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Options exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zd3fg6nsMnVl" style="text-align: right" title="Number of shares, Options exercised"><span style="font-family: Times New Roman, Times, Serif">(19,748</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="text-align: right" title="Weighted Avg. Exercise Price, Options exercised"><span style="font-family: Times New Roman, Times, Serif">3.19</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Options cancelled/forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zJClW6EHXCrh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Options cancelled/forfeited"><span style="font-family: Times New Roman, Times, Serif">(21,402</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Avg. Exercise Price, Options cancelled/forfeited"><span style="font-family: Times New Roman, Times, Serif">12.77</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Options outstanding
    - December 31, 2020</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zPqFOLroBC48" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Outstanding, Ending balance"><span style="font-family: Times New Roman, Times, Serif">3,030,033</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z8NK6nsAbH8j" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, Ending balance"><span style="font-family: Times New Roman, Times, Serif">5.43</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Remaining Contractual Life, Options outstanding"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zfsq95D078Lf" title="Weighted Avg. Remaining Contractual Life, Options outstanding">5.72</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zVWtCkyG1Zj8" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options outstanding"><span style="font-family: Times New Roman, Times, Serif">5,569</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Options exercisable</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zRo6HTPothl3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options exercisable"><span style="font-family: Times New Roman, Times, Serif">1,908,849</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zZ4f98mY0SBk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Avg. Exercise Price, Exercisable Ending Balance"><span style="font-family: Times New Roman, Times, Serif">4.49</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Remaining Contractual Life, Options exercisable"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zA66gTouaDb6" title="Weighted Avg. Remaining Contractual Life, Options exercisable">5.25</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z0FlgEJo9dy" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options exercisable"><span style="font-family: Times New Roman, Times, Serif">5,051</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Options vested
    and expected to vest</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zQgK1tz9Qhu9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options vested and expected to vest"><span style="font-family: Times New Roman, Times, Serif">2,918,298</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pii_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z3JdTHMSppok" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Avg. Exercise Price, Vested and expected to vest"><span style="font-family: Times New Roman, Times, Serif">5.37</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Remaining Contractual Life, Options vested and expected to vest"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zFknDYG1ZkKf" title="Weighted Avg. Remaining Contractual Life, Options vested and expected to vest">5.69</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pn3n3_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zWSdyEIPs5ti" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options vested and expected to vest"><span style="font-family: Times New Roman, Times, Serif">5,519</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF FAIR VALUE ASSUMPTIONS</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zo943NhcDZV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following
assumptions used for valuing options granted to employees:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B9_z3pOk5YOPvRg" style="display: none">SCHEDULE OF FAIR VALUE ASSUMPTIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Weighted-average fair
    value of options granted</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_pii" style="width: 16%; text-align: right" title="Weighted-average fair value of options granted"><span style="font-family: Times New Roman, Times, Serif">3.86</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_pii" style="width: 16%; text-align: right" title="Weighted-average fair value of options granted"><span style="font-family: Times New Roman, Times, Serif">3.72</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expected terms (in years)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right" title="Expected terms (in years)"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MinimumMember_zznoJH9sHdXh" title="Expected terms (in years)">0.50</span>
                                         - <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MaximumMember_zDD1q3hBnOw5" title="Expected terms (in years)">6.11</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MinimumMember_zFrHUthfhXij" title="Expected terms (in years)">5.07</span>
                                         - <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MaximumMember_ztBeixpcpXRi" title="Expected terms (in years)">7.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right" title="Expected volatility, maximum"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_uPercent_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zBN829DrQFaa" title="Expected volatility, minimum">67</span>
                                         &#8211; <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_uPercent_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zLCFHkowlUWh" title="Expected volatility, maximum">71</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_dp_uPercent_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zxnFxkILIhF" title="Expected volatility, minimum">64</span>
                                         - <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_dp_uPercent_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zZ5w84ysMSQ8" title="Expected volatility, maximum">78</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right" title="Risk-free interest rate, maximum"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_uPercent_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zs1woI2aLU04" title="Risk-free interest rate, minimum">0.34</span>
                                         &#8211; <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_uPercent_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zwiOkXCUpV07" title="Risk-free interest rate, maximum">1.64</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_dp_uPercent_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zZ5vHvMSgbuh" title="Risk-free interest rate, minimum">1.83</span>
                                         &#8211;<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_dp_uPercent_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_z8MC2kbKhaHl" title="Risk-free interest rate, maximum"> 2.68</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_c20200101__20201231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zcfIFI2EDx7b" style="text-align: right" title="Dividend yield"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1448">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_c20190101__20191231__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zyXdXXDOsZLf" style="text-align: right" title="Dividend yield"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1450">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zTReyUQCrVXk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes information about stock options outstanding and exercisable at December 31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span><span><span id="xdx_8B6_zLHJLptFBOv1" style="display: none">SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Contractual</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Range
    of Exercise Prices</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Outstanding</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Life
    in Years</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercisable</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Range of Exercise Prices, minimum">1.47</span> - $<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Range of Exercise Prices, maximum">2.60</span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" style="width: 10%; text-align: right" title="Number of Options Outstanding"><span style="font-family: Times New Roman, Times, Serif">770,440</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 10%; text-align: right" title="Weighted Average Remaining Contractual Life in Years"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zFeE8JzfPS8f" title="Weighted Average Remaining Contractual Life in Years">5.64</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" style="width: 10%; text-align: right" title="Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif">2.06</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" style="width: 10%; text-align: right" title="Number Exercisable"><span style="font-family: Times New Roman, Times, Serif">745,255</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" style="width: 10%; text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-family: Times New Roman, Times, Serif">2.06</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_ziiFjkcDC772" title="Range of Exercise Prices, minimum">3.04</span> - $<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Range of Exercise Prices, maximum">4.50</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" style="text-align: right" title="Number of Options Outstanding"><span style="font-family: Times New Roman, Times, Serif">517,002</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right" title="Weighted Average Remaining Contractual Life in Years"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z9eakblqqQSc" title="Weighted Average Remaining Contractual Life in Years">5.75</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif">3.98</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" style="text-align: right" title="Number Exercisable"><span style="font-family: Times New Roman, Times, Serif">438,873</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-family: Times New Roman, Times, Serif">3.98</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Range of Exercise Prices, minimum">5.49</span> - $<span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Range of Exercise Prices, maximum">6.36</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" style="text-align: right" title="Number of Options Outstanding"><span style="font-family: Times New Roman, Times, Serif">496,350</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right" title="Weighted Average Remaining Contractual Life in Years"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_ztoyYSnJsWBa" title="Weighted Average Remaining Contractual Life in Years">7.22</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" style="text-align: right" title="Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif">6.10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" style="text-align: right" title="Number Exercisable"><span style="font-family: Times New Roman, Times, Serif">291,919</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" style="text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-family: Times New Roman, Times, Serif">6.13</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">$<span id="xdx_904_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zBsCAhJkpYrl" title="Range of Exercise Prices, minimum">6.64</span> - $<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zRrw9dEctSpd" title="Range of Exercise Prices, maximum">8.99</span></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding"><span style="font-family: Times New Roman, Times, Serif">1,246,241</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Remaining Contractual Life in Years"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zBhaXCRSQHqa" title="Weighted Average Remaining Contractual Life in Years">5.17</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif">7.85</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number Exercisable"><span style="font-family: Times New Roman, Times, Serif">432,802</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-family: Times New Roman, Times, Serif">8.09</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">$<span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20200101__20201231_zTE4q6Dtgg96" title="Range of Exercise Prices, minimum">1.47</span> - $<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pii_c20200101__20201231_znbr9y4z6bkf" title="Range of Exercise Prices, maximum">8.99</span></span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20201231_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding"><span style="font-family: Times New Roman, Times, Serif">3,030,033</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Remaining Contractual Life in Years"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_z2pwY4UTeaQ" title="Weighted Average Remaining Contractual Life in Years">5.72</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_c20201231_pii" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price"><span style="font-family: Times New Roman, Times, Serif">5.43</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20201231_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Number Exercisable"><span style="font-family: Times New Roman, Times, Serif">1,908,849</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20201231_pii" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercisable Exercise Price"><span style="font-family: Times New Roman, Times, Serif">4.49</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zSBp8HaToScg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the Company&#8217;s RSU activity and related information for the year ended December 31, 2019 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B0_z1u7f4VdIQV6" style="display: none">SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of RSUs</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Average Grant<br/>
    Date Fair Value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">RSUs unvested - January
    1, 2019</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zlcKzm3Vy0E1" style="width: 16%; text-align: right" title="Number of RSUs unvested, Outstanding, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">1,275,680</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_c20181231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzKbZvFFjXSl" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">2.16</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">RSUs granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Number of RSUs granted"><span style="font-family: Times New Roman, Times, Serif">223,860</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs granted"><span style="font-family: Times New Roman, Times, Serif">6.43</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">RSUs vested</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pii_di_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgf1GrYmPyZ1" style="text-align: right" title="Number of RSUs vested"><span style="font-family: Times New Roman, Times, Serif">(87,610</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs vested"><span style="font-family: Times New Roman, Times, Serif">3.42</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">RSUs cancelled/forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pii_c20190101__20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztvt0TjCez4h" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs cancelled/forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1554">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">RSUs unvested
    at December 31, 2019</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zAbV7bsMtMHk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs unvested, Outstanding, Ending balance"><span style="font-family: Times New Roman, Times, Serif">1,411,930</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zuEsuPx7Uaxl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value, Ending balance"><span style="font-family: Times New Roman, Times, Serif">2.76</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Grants
During the Year Ended December 31, 2020</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020, <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pii" title="Shares issued of restricted common stock, shares">161,000</span> RSUs with a fair market value of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pn3n3" title="Fair value of restricted common stock issued">1,025</span> were issued to certain employees; the RSUs vest
in full on the third anniversary of the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2020, the Company&#8217;s board of directors were granted <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pii" title="Shares issued of restricted common stock, shares">90,524</span> RSUs with a fair market value $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_pn3n3" title="Fair value of restricted common stock issued">511</span>
which vest on a quarterly basis, over a one-year term in equal installments, subject to the director&#8217;s continued
service at the vesting date, but the issuance and delivery of these shares are deferred until the director resigns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the Company&#8217;s RSU activity and related information for the year ended December 31, 2020 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span/></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of RSUs</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Average Grant<br/>
    Date Fair Value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">RSUs unvested - January
    1, 2020</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwsDwbtXgcOg" style="width: 16%; text-align: right" title="Number of RSUs unvested, Outstanding, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">1,411,930</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_c20191231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNNoOi66nuCk" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance"><span style="font-family: Times New Roman, Times, Serif">2.76</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">RSUs granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Number of RSUs granted"><span style="font-family: Times New Roman, Times, Serif">251,524</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs granted"><span style="font-family: Times New Roman, Times, Serif">6.11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">RSUs vested</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pii_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7tVOnlN9F0l" style="text-align: right" title="Number of RSUs vested"><span style="font-family: Times New Roman, Times, Serif">(61,945</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs vested"><span style="font-family: Times New Roman, Times, Serif">6.46</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">RSUs cancelled/forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs cancelled/forfeited"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1580">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">RSUs unvested
    at December 31, 2020</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgfUfvpFCBck" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs unvested, Outstanding, Ending balance"><span style="font-family: Times New Roman, Times, Serif">1,601,509</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCql18W0ey1i" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value, Ending balance"><span style="font-family: Times New Roman, Times, Serif">3.14</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ziHtVmVZ22Sj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recorded stock-based compensation (including issuance of common stock for services and accrual for stock-based compensation)
related to equity instruments granted to employees, directors and consultants as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B9_zurPvjdWON1b" style="display: none">SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Years Ended December 31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Employees &#8211; selling,
    general and administrative</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="width: 18%; text-align: right" title="Stock based compensation related to equity instruments granted to related parties"><span style="font-family: Times New Roman, Times, Serif">2,289</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20191231__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="width: 18%; text-align: right" title="Stock based compensation related to equity instruments granted to related parties"><span style="font-family: Times New Roman, Times, Serif">1,464</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Directors &#8211; selling, general
    and administrative</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="text-align: right" title="Stock based compensation related to equity instruments granted to related parties"><span style="font-family: Times New Roman, Times, Serif">473</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20191231__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="text-align: right" title="Stock based compensation related to equity instruments granted to related parties"><span style="font-family: Times New Roman, Times, Serif">300</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Consultants
    &#8211; selling, general and administrative</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock based compensation related to equity instruments granted to related parties"><span style="font-family: Times New Roman, Times, Serif">96</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20191231__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock based compensation related to equity instruments granted to related parties"><span style="font-family: Times New Roman, Times, Serif">259</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation related to equity instruments granted to related parties"><span style="font-family: Times New Roman, Times, Serif">2,858</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation related to equity instruments granted to related parties"><span style="font-family: Times New Roman, Times, Serif">2,023</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">SCHEDULE OF WARRANTS ACTIVITY</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z3hRwpJQzkLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of warrant activity during the year ended December 31, 2020 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B7_zofGrHQAUGX1" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of Shares Subject to Warrants Outstanding</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted
    Avg. Exercise Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding
    - January 1, 2020</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pii_c20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zF3vPI1IecUi" style="width: 16%; text-align: right" title="Number of Shares Warrants Outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif">780,386</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_pii_c20191231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_z4zzbdsSTAqe" style="width: 16%; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif">2.12</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="text-align: right" title="Number of Shares Warrants Outstanding, Granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1652">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="text-align: right" title="Number of Shares Warrants Outstanding, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1654">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares Warrants Outstanding, Expired"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1656">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Warrants outstanding
    and exercisable - December 31, 2020</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iE_pii_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zE0fOT4bX2R2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Warrants Outstanding and Exercisable, ending balance"><span style="font-family: Times New Roman, Times, Serif">780,386</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1_iE_pii_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zGy9Yf4BTV6d" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Outstanding and Exercisable, ending balance"><span style="font-family: Times New Roman, Times, Serif">2.12</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average
    remaining contractual life of the outstanding warrants in years - December 31, 2020</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average remaining contractual life of the outstanding warrants in years"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zPVuFE6Md383" title="Weighted average remaining contractual life of the outstanding warrants in years">3.53</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ScheduleofWarrantsOutstandingAndExercisableTableTextBlock', window );">SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE</a></td>
<td class="text"><p id="xdx_893_ecustom--ScheduleofWarrantsOutstandingAndExercisableTableTextBlock_zVJqdE4Kk2Ec" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">All
warrants outstanding as of December 31, 2020 are included in the following table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B5_zdxFJYC54gQf" style="display: none">SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="9" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants
    Outstanding</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants
    Exercisable</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Expiration</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Warrant
    Series</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Issue
    Date</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Outstanding</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercisable</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Date</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Lender warrants</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; width: 12%; text-align: center" title="Issue Date"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_ecustom--WarrantsIssuanceDate_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zcIbfkNbtq0l" title="Issue Date">5/11/2015</span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_pii" style="width: 12%; text-align: right" title="Warrants Outstanding"><span style="font-family: Times New Roman, Times, Serif">125,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_pii" style="width: 11%; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">1.79</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_pii" style="width: 12%; text-align: right" title="Warrants Exercisable"><span style="font-family: Times New Roman, Times, Serif">125,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; width: 12%; text-align: center" title="Expiration Date"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_ecustom--WarrantsAndRightsOutstandingMaturityDates_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_zASHVdbs6vjf" title="Expiration Date">5/11/2025</span></span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Settlement warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center" title="Issue Date"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_ecustom--WarrantsIssuanceDate_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_zIgKPdGA5Qt3" title="Issue Date">8/16/2016</span></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_pii" style="text-align: right" title="Warrants Outstanding"><span style="font-family: Times New Roman, Times, Serif">40,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_pii" style="text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">3.75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_pii" style="text-align: right" title="Warrants Exercisable"><span style="font-family: Times New Roman, Times, Serif">40,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center" title="Expiration Date"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_ecustom--WarrantsAndRightsOutstandingMaturityDates_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_zWTTPiDABE55" title="Expiration Date">8/16/2021</span></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Lender warrants
    (see Note 12)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt" title="Issue Date"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--WarrantsIssuanceDate_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_zwjV334F6VCl" title="Issue Date">7/19/2017</span></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Outstanding"><span style="font-family: Times New Roman, Times, Serif">615,386</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_pii" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">2.08</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Exercisable"><span style="font-family: Times New Roman, Times, Serif">615,386</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt" title="Expiration Date"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--WarrantsAndRightsOutstandingMaturityDates_dd_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_zrt915HjDe64" title="Expiration Date">7/19/2024</span></span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding"><span style="font-family: Times New Roman, Times, Serif">780,386</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="padding-bottom: 2.5pt; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">2.12</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Exercisable"><span style="font-family: Times New Roman, Times, Serif">780,386</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_ScheduleofWarrantsOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_ScheduleofWarrantsOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171679263176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">SCHEDULE OF PROVISION FOR INCOME TAXES</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zlEm43HAYNHf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company is subject to taxation in the United States, California, Florida, Georgia, Illinois, New Jersey, New York, Tennessee and
Wisconsin. The Company&#8217;s income tax provision consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B7_zId0N1D53NX" style="display: none">SCHEDULE OF PROVISION FOR INCOME TAXES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Current:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Federal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--CurrentFederalTaxExpenseBenefit_c20200101__20201231_pn3n3" style="text-align: right" title="Current: Federal"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1706">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--CurrentFederalTaxExpenseBenefit_c20190101__20191231_pn3n3" style="text-align: right" title="Current: Federal"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1708">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 60%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State</span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Current: State"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Current: State"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total current
    expense</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"/><td id="xdx_989_eus-gaap--CurrentIncomeTaxExpenseBenefit_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total current"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"/><td id="xdx_98A_eus-gaap--CurrentIncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total current"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Deferred:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Federal</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"/><td id="xdx_98C_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20200101__20201231_pn3n3" style="text-align: right" title="Deferred: Federal"><span style="font-family: Times New Roman, Times, Serif">(771</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"/><td id="xdx_98D_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" style="text-align: right" title="Deferred: Federal"><span style="font-family: Times New Roman, Times, Serif">669</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">State</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_c20200101__20201231_pn3n3" style="text-align: right" title="Deferred: State"><span style="font-family: Times New Roman, Times, Serif">138</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" style="text-align: right" title="Deferred: State"><span style="font-family: Times New Roman, Times, Serif">(148</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Change
    in valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--DeferredIncomeChangeInValuationAllowance_c20200101__20201231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Deferred: Change in valuation allowance"><span style="font-family: Times New Roman, Times, Serif">633</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_ecustom--DeferredIncomeChangeInValuationAllowance_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Deferred: Change in valuation allowance"><span style="font-family: Times New Roman, Times, Serif">(521</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total deferred
    expense</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--DeferredIncomeTaxExpenseBenefit_pn3n3_c20200101__20201231_zqMusmwdxIfk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total deferred"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1730">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--DeferredIncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total deferred"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1732">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Income tax provision</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--IncomeTaxExpenseBenefit_c20200101__20201231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax provision (benefit)"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--IncomeTaxExpenseBenefit_c20190101__20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax provision (benefit)"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">SCHEDULE OF INCOME TAX RECONCILIATION</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z9LbdBssC8ji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
reconciliation of income taxes computed by applying the statutory U.S. income tax rate to the Company&#8217;s loss before income
tax provision to the income tax provision is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zuFkQGm0bTbh" style="display: none">SCHEDULE OF INCOME TAX RECONCILIATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">U.S. federal statutory tax
    rate</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercent_c20200101__20201231_zP6vtwy0Dy3c" style="width: 16%; text-align: right" title="U.S. federal statutory tax rate"><span style="font-family: Times New Roman, Times, Serif">21.00</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pii_dp_uPercent_c20190101__20191231_z1PJBplz43el" style="width: 16%; text-align: right" title="U.S. federal statutory tax rate"><span style="font-family: Times New Roman, Times, Serif">21.00</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">State tax benefit, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPercent_c20200101__20201231_z9diswB8uWZ7" style="text-align: right" title="State tax benefit, net"><span style="font-family: Times New Roman, Times, Serif">(0.11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pii_dp_uPercent_c20190101__20191231_zvEQ9o1W5937" style="text-align: right" title="State tax benefit, net"><span style="font-family: Times New Roman, Times, Serif">(6.73</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based</span><span style="font-family: Times New Roman, Times, Serif">
    compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends_pii_dp_uPercent_c20200101__20201231_zpefx0bFnuT5" style="text-align: right" title="Employee stock-based compensation"><span style="font-family: Times New Roman, Times, Serif">5.52</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends_pii_dp_uPercent_c20190101__20191231_zwJmbjxVw1O8" style="text-align: right" title="Employee stock-based compensation"><span style="font-family: Times New Roman, Times, Serif">3.10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pii_dp_uPercent_c20200101__20201231_ze9Ok1KYy7a4" style="text-align: right" title="Other"><span style="font-family: Times New Roman, Times, Serif">(0.38</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pii_dp_uPercent_c20190101__20191231_zaxdfNR43jV5" style="text-align: right" title="Other"><span style="font-family: Times New Roman, Times, Serif">(358.67</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pii_dp_uPercent_c20200101__20201231_zUnkeblpXJOc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Valuation allowance"><span style="font-family: Times New Roman, Times, Serif">(26.14</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pii_dp_uPercent_c20190101__20191231_zZO9ilJ98515" style="border-bottom: Black 1.5pt solid; text-align: right" title="Valuation allowance"><span style="font-family: Times New Roman, Times, Serif">334.57</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Effective income
    tax rate</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pii_dp_uPercent_c20200101__20201231_zyVR8plk3ERl" style="border-bottom: Black 2.5pt double; text-align: right" title="Effective income tax rate"><span style="font-family: Times New Roman, Times, Serif">(0.11</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pii_dp_uPercent_c20190101__20191231_zibwEDGEb0Qg" style="border-bottom: Black 2.5pt double; text-align: right" title="Effective income tax rate"><span style="font-family: Times New Roman, Times, Serif">(6.73</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)%</span></td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zY7wnvB540ob" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Deferred
tax assets and liabilities reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities
for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred
tax assets are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B5_zwireou6UZee" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
<tr style="display: none; vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20201231_zXNF58WN0wGa" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_493_20191231_znibe2891vBa" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">December
    31,</span></td><td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets (liabilities):</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTANzoCx_zrrz0DQDU3t" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%"><span style="font-family: Times New Roman, Times, Serif">NOL&#8217;s</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,685</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,827</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_ecustom--DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization_iI_pn3n3_maDTANzoCx_zCj3ad30Esyj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Depreciation and
    amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">528</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">224</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_iI_pn3n3_maDTANzoCx_zbGbREmoj8vf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">413</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">641</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTANzoCx_zYPT1JuSDvs6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development
    credits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">596</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">596</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTANzoCx_zqOYVTSFl1uc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred stock-based
    compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,024</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,533</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_ecustom--IncomeTaxBasisDifferenceInRelatedParty_iNI_pn3n3_di_maDTANzoCx_zkseA74WXrj7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basis difference
    in Melt</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(398</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,119</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_409_ecustom--IncomeTaxBasisDifferenceInRelatedPartyOne_iNI_pn3n3_di_maDTANzoCx_z97k6sFu57m7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basis difference
    in Surface</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(502</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,185</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40A_ecustom--IncomeTaxBasisDifferenceInRelatedPartyTwo_iNI_pn3n3_di_maDTANzoCx_zaCsNCEpnZC9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Basis difference
    in Eton</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8,626</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7,528</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40F_ecustom--DeferredTaxAssetsTaxDeferredExpenseCapitalLosses_iI_pn3n3_maDTANzoCx_z55YDmrGFiw" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Capital losses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">63</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">63</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_iNI_pn3n3_di_msDTANzoCx_zv0QzbWLAS5a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Park stock purchase
    identifiable intangibles</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(274</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(270</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_409_ecustom--DeferredTaxAssetsTaxDeferredExpenseLimitations_iI_pn3n3_maDTANzoCx_zZ3Wl9pY4vZ1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Limitation under
    163(j)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">195</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">299</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_ecustom--DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability_iI_pn3n3_msDTANzoCx_zgbdDB0ObhZ3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">ASC 842 lease
    liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,192</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,082</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_ecustom--DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset_iNI_pn3n3_di_maDTANzoCx_zO2zs3B6UGPh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">ASC
    842 ROU asset</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,061</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,959</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_ziQ8saIOP4Z9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    deferred tax assets, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,835</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,202</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTALNzB4N_zemVr1oMj36i" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Valuation
    allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(15,835</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(15,202</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_406_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_zgGZ102KFEkj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    deferred tax assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1811">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1812">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171679400552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION AND CONCENTRATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">SCHEDULE OF SEGMENT NET REVENUES, SEGMENT OPERATING EXPENSES AND SEGMENT CONTRIBUTION</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z7Np0d5rM4L" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Segment
net revenues, segment operating expenses and segment contribution information consisted of the following for the years ended December
31, 2020 and 2019:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt"><span id="xdx_8B5_zVhOxt4bJ3l" style="display: none">SCHEDULE OF SEGMENT NET REVENUES, SEGMENT OPERATING EXPENSES AND SEGMENT CONTRIBUTION</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended December 31, 2020</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Pharmaceutical</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Pharmaceutical
    Drug</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Compounding</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Development</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net revenues</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues"><span style="font-family: Times New Roman, Times, Serif">48,871</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1930">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues"><span style="font-family: Times New Roman, Times, Serif">48,871</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Cost of sales</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--CostOfGoodsAndServicesSold_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"><span style="font-family: Times New Roman, Times, Serif">(14,463</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--CostOfGoodsAndServicesSold_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1936">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zgozMhXwOZ91" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"><span style="font-family: Times New Roman, Times, Serif">(14,463</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gross profit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--GrossProfit_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Gross profit"><span style="font-family: Times New Roman, Times, Serif">34,408</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--GrossProfit_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Gross profit"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1942">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--GrossProfit_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit"><span style="font-family: Times New Roman, Times, Serif">34,408</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Selling, general
    and administrative</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Selling, general and administrative"><span style="font-family: Times New Roman, Times, Serif">22,691</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Selling, general and administrative"><span style="font-family: Times New Roman, Times, Serif">144</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative"><span style="font-family: Times New Roman, Times, Serif">22,835</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research
    and development</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development"><span style="font-family: Times New Roman, Times, Serif">759</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development"><span style="font-family: Times New Roman, Times, Serif">88</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development"><span style="font-family: Times New Roman, Times, Serif">847</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Segment
    contribution</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">$</span></p></td><td id="xdx_987_ecustom--SegmentContribution_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Segment contribution"><span style="font-family: Times New Roman, Times, Serif">10,958</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">$</span></p></td><td id="xdx_980_ecustom--SegmentContribution_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Segment contribution"><span style="font-family: Times New Roman, Times, Serif">(232</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"/><td id="xdx_987_ecustom--SegmentContribution_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="padding-bottom: 1.5pt; text-align: right" title="Segment contribution"><span style="font-family: Times New Roman, Times, Serif">10,726</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Corporate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--OperatingIncomeLoss_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_pn3n3" style="text-align: right" title="Operating income (loss)"><span style="font-family: Times New Roman, Times, Serif">(8,245</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--OperatingIncomeLoss_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="text-align: right" title="Operating income (loss)"><span style="font-family: Times New Roman, Times, Serif">(1,566</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--AdjustmentForAmortization_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Amortization"><span style="font-family: Times New Roman, Times, Serif">(167</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Asset sales and
    impairments, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(363</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    income</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_ecustom--ImpairmentAndDisposalOfLonglivedAssets_c20200101__20201231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Asset sales and impairments, net"><span style="font-family: Times New Roman, Times, Serif">385</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
    the Year Ended December 31, 2019</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Pharmaceutical</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Pharmaceutical
    Drug</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Compounding</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Development</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net revenues</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues"><span style="font-family: Times New Roman, Times, Serif">51,165</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1974">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 13%; text-align: right" title="Net Revenues"><span style="font-family: Times New Roman, Times, Serif">51,165</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Cost of sales</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--CostOfGoodsAndServicesSold_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"><span style="font-family: Times New Roman, Times, Serif">(16,749</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--CostOfGoodsAndServicesSold_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1980">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zF011mNHMFJ4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales"><span style="font-family: Times New Roman, Times, Serif">(16,749</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gross profit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--GrossProfit_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Gross profit"><span style="font-family: Times New Roman, Times, Serif">34,416</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--GrossProfit_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1986">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--GrossProfit_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit"><span style="font-family: Times New Roman, Times, Serif">34,416</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating expenses:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Selling, general
    and administrative</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Selling, general and administrative"><span style="font-family: Times New Roman, Times, Serif">24,460</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative"><span style="font-family: Times New Roman, Times, Serif">174</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative"><span style="font-family: Times New Roman, Times, Serif">24,634</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ResearchAndDevelopmentExpense_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development"><span style="font-family: Times New Roman, Times, Serif">1,006</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ResearchAndDevelopmentExpense_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development"><span style="font-family: Times New Roman, Times, Serif">361</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--ResearchAndDevelopmentExpense_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development"><span style="font-family: Times New Roman, Times, Serif">1,367</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Segment
    contribution</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_ecustom--SegmentContribution_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Segment contribution"><span style="font-family: Times New Roman, Times, Serif">8,934</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_ecustom--SegmentContribution_c20190101__20191231__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Segment contribution"><span style="font-family: Times New Roman, Times, Serif">(535</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"/><td id="xdx_980_ecustom--SegmentContribution_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="padding-bottom: 1.5pt; text-align: right" title="Segment contribution"><span style="font-family: Times New Roman, Times, Serif">8,399</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Corporate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--OperatingIncomeLoss_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_pn3n3" style="text-align: right" title="Operating income (loss)"><span style="font-family: Times New Roman, Times, Serif">(8,245</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--OperatingIncomeLoss_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="text-align: right" title="Operating income (loss)"><span style="font-family: Times New Roman, Times, Serif">(716</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--AdjustmentForAmortization_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Amortization"><span style="font-family: Times New Roman, Times, Serif">(209</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Asset sales and
    impairments, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--ImpairmentAndDisposalOfLonglivedAssets_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Asset sales and impairments, net"><span style="font-family: Times New Roman, Times, Serif">(4,040</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    loss</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--OperatingIncomeLoss_c20190101__20191231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating income (loss)"><span style="font-family: Times New Roman, Times, Serif">(4,795</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171679402168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF BASIC EARNINGS PER COMMON SHARE (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Numerator &#8211; net (loss) income attributable to Harrow Health, Inc.</a></td>
<td class="num">$ (3,357)<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Denominator &#8211; weighted average number of shares outstanding, basic</a></td>
<td class="nump">25,895,352<span></span>
</td>
<td class="nump">25,323,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) income per share, basic</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171679989176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive common equivalent shares</a></td>
<td class="nump">1,142,939<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive common equivalent shares</a></td>
<td class="nump">488,498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=HROW_StockOptionsMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive common equivalent shares</a></td>
<td class="nump">654,441<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=HROW_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=HROW_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171677813272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF DILUTED EARNINGS PER COMMON SHARE (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Numerator &#8211; net income</a></td>
<td class="num">$ (3,357)<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding, basic</a></td>
<td class="nump">25,895,352<span></span>
</td>
<td class="nump">25,323,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_IncrementalCommonSharesAttributableDilutiveCommonEquivalents', window );">Dilutive common equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,142,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares', window );">Denominator &#8211; number of shares used for diluted earnings per share computation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,466,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share, diluted</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_IncrementalCommonSharesAttributableDilutiveCommonEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incremental Common Shares Attributable to Dilutive common equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_IncrementalCommonSharesAttributableDilutiveCommonEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of contingently issuable shares.  Contingently issuable shares are those shares that are issuable for little or no cash contingent on certain conditions being met.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 54<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2603-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 44<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2062-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1828-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2600-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2597-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 48<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2538-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 48<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2538-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 51<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2574-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171769766680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ConsolidationBasisDescription', window );">Consolidation basis, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">We
consolidate subsidiaries in which we hold and/or control, directly or indirectly, more than 50% of the voting rights<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 385<span></span>
</td>
<td class="num">$ (4,795)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(385)<span></span>
</td>
<td class="nump">4,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_RetainedEarningsAccumulatedDeficit1', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,400<span></span>
</td>
<td class="nump">74,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="num">(950)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,301<span></span>
</td>
<td class="nump">4,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDescription', window );">Noncontrolling Interest, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Generally,
any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there
are other factors, such as decision-making rights, that are considered as well.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash, FDIC Insured Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts Receivable, after Allowance for Credit Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,463<span></span>
</td>
<td class="nump">324,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=HROW_StockOptionsUnvestedRSUsAndWarrantsMember', window );">Stock Options Unvested R S Us And Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,411,929<span></span>
</td>
<td class="nump">4,848,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_VisionologyMember', window );">Visionology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_EtonPharmaceuticalsIncMember', window );">Eton Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_NumberOfSharesOwned', window );">Number of shares owned | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain (Loss) on Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,255<span></span>
</td>
<td class="nump">$ 3,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investment Owned, at Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,455<span></span>
</td>
<td class="nump">25,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember', window );">Melt Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,019<span></span>
</td>
<td class="nump">4,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,019)<span></span>
</td>
<td class="num">(4,381)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_NumberOfSharesOwned', window );">Number of shares owned | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investment Owned, at Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,506<span></span>
</td>
<td class="nump">4,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Deconsolidation, Gain (Loss), Amount</a></td>
<td class="nump">$ 5,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized Gain (Loss) on Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,313<span></span>
</td>
<td class="nump">3,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851<span></span>
</td>
<td class="nump">722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember', window );">Melt Pharmaceuticals, Inc. [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from Issuance of Preferred Stock and Preference Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_SurfacePharmaceuticalsIncMember', window );">Surface Pharmaceuticals Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,109<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,109)<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_NumberOfSharesOwned', window );">Number of shares owned | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investment Owned, at Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,314<span></span>
</td>
<td class="nump">3,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized Gain (Loss) on Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,433<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_ParkCompoundingIncAndNoiceRxLLCMember', window );">Park Compounding Inc And Noice Rx L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset Impairment Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=HROW_MayfieldPharmaceuticalsIncMember', window );">Mayfield Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=HROW_MayfieldPharmaceuticalsIncMember', window );">Mayfield Pharmaceuticals, Inc. [Member] | TGV-Health, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=HROW_StowePharmaceuticalsIncMember', window );">Stowe Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=HROW_StowePharmaceuticalsIncMember', window );">Stowe Pharmaceuticals, Inc. [Member] | TGV-Health, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_ConsolidationBasisDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidation basis, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_ConsolidationBasisDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_NumberOfSharesOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_NumberOfSharesOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_RetainedEarningsAccumulatedDeficit1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_RetainedEarningsAccumulatedDeficit1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 5D<br> -Subparagraph (SX 210.12-13D(Column C))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=SL120429264-123010<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of noncontrolling interest which might include background information, terms of the ownership arrangement, and type and terms of equity interest owned by the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=HROW_StockOptionsUnvestedRSUsAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=HROW_StockOptionsUnvestedRSUsAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_VisionologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_VisionologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_EtonPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_EtonPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_SurfacePharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_SurfacePharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_ParkCompoundingIncAndNoiceRxLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_ParkCompoundingIncAndNoiceRxLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=HROW_MayfieldPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=HROW_MayfieldPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_TGVHealthLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_TGVHealthLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=HROW_StowePharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=HROW_StowePharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171776242424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF DISAGGREGATED REVENUE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 48,871<span></span>
</td>
<td class="nump">$ 51,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=HROW_ProductSalesNetMember', window );">Product Sales, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">48,479<span></span>
</td>
<td class="nump">51,137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=HROW_CommissionsMember', window );">Commissions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">356<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=HROW_ProductSalesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=HROW_ProductSalesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=HROW_CommissionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=HROW_CommissionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171678110344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>REVENUES (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract with Customer, Liability, Current</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171682130184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF CONDENSED INCOME STATEMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues, net</a></td>
<td class="nump">$ 48,871<span></span>
</td>
<td class="nump">$ 51,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="nump">385<span></span>
</td>
<td class="num">(4,795)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,357)<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember', window );">Melt Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="nump">5,019<span></span>
</td>
<td class="nump">4,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,019)<span></span>
</td>
<td class="num">$ (4,381)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171772884216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF CONDENSED BALANCE SHEET (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">$ 40,131<span></span>
</td>
<td class="nump">$ 36,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">57,474<span></span>
</td>
<td class="nump">59,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">30,646<span></span>
</td>
<td class="nump">31,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total preferred stock and stockholders' equity</a></td>
<td class="nump">27,183<span></span>
</td>
<td class="nump">27,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">57,474<span></span>
</td>
<td class="nump">59,085<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember', window );">Melt Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">2,947<span></span>
</td>
<td class="nump">7,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Non current assets</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,958<span></span>
</td>
<td class="nump">7,454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,778<span></span>
</td>
<td class="nump">1,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total preferred stock and stockholders' equity</a></td>
<td class="nump">1,180<span></span>
</td>
<td class="nump">5,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 2,958<span></span>
</td>
<td class="nump">$ 7,454<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171679137208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember', window );">Melt Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 722<span></span>
</td>
<td class="nump">$ 851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember', window );">Melt Pharmaceuticals, Inc. [Member] | Management Services Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdministrativeFeesExpense', window );">Administrative Fees Expense</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722<span></span>
</td>
<td class="nump">$ 851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_SurfacePharmaceuticalsIncMember', window );">Surface Pharmaceuticals Inc [Member] | Management Services Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayments of Related Party Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdministrativeFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for administrative services provided to the limited liability company (LLC) or limited partnership (LP) by the managing member or general partner, affiliate of managing member or general partner, or affiliate of LLC or LP, for example, but not limited to, salaries, rent, or overhead costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdministrativeFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_MeltPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_ManagementServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_ManagementServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_SurfacePharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_SurfacePharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_MSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_MSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171681200728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF CONDENSED INCOME STATEMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues, net</a></td>
<td class="nump">$ 48,871<span></span>
</td>
<td class="nump">$ 51,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="nump">385<span></span>
</td>
<td class="num">(4,795)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,357)<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_SurfacePharmaceuticalsIncMember', window );">Surface Pharmaceuticals Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="nump">8,109<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,109)<span></span>
</td>
<td class="num">$ (4,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_SurfacePharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_SurfacePharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171679793992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF CONDENSED BALANCE SHEET (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">$ 40,131<span></span>
</td>
<td class="nump">$ 36,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">57,474<span></span>
</td>
<td class="nump">59,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">30,646<span></span>
</td>
<td class="nump">31,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders equity</a></td>
<td class="nump">27,183<span></span>
</td>
<td class="nump">27,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">57,474<span></span>
</td>
<td class="nump">59,085<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_SurfacePharmaceuticalsIncMember', window );">Surface Pharmaceuticals Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">9,074<span></span>
</td>
<td class="nump">15,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Non current assets</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">9,119<span></span>
</td>
<td class="nump">15,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,666<span></span>
</td>
<td class="nump">619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders equity</a></td>
<td class="nump">7,453<span></span>
</td>
<td class="nump">15,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 9,119<span></span>
</td>
<td class="nump">$ 15,989<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_SurfacePharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_SurfacePharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171684922408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Details Narrative) - Surface Pharmaceuticals Inc [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares, Outstanding</a></td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_SurfacePharmaceuticalsIncMember', window );">Dr. Lindstrom [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_RoyaltyPaymentPercentageOnNetSales', window );">Royalty payment percentage on net sales</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_RoyaltyPaymentPercentageOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty payment percentage on net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_RoyaltyPaymentPercentageOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_SurfacePharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_SurfacePharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=HROW_DrLindstromMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=HROW_DrLindstromMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171679171672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RESTRICTED CASH (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_DisclosureRestrictedCashAbstract', window );"><strong>Disclosure Restricted Cash Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_DisclosureRestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_DisclosureRestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171675198152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF INVENTORIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 2,501<span></span>
</td>
<td class="nump">$ 2,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in progress</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">1,444<span></span>
</td>
<td class="nump">876<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 3,962<span></span>
</td>
<td class="nump">$ 3,301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171679329192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">401<span></span>
</td>
<td class="nump">358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Deposits and other current assets</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 751<span></span>
</td>
<td class="nump">$ 586<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171679990392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Computer software and hardware</a></td>
<td class="nump">$ 1,707<span></span>
</td>
<td class="nump">$ 1,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture and equipment</a></td>
<td class="nump">418<span></span>
</td>
<td class="nump">363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Lab and pharmacy equipment</a></td>
<td class="nump">3,426<span></span>
</td>
<td class="nump">3,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">5,720<span></span>
</td>
<td class="nump">5,510<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">&#160;Property, plant and equipment, gross</a></td>
<td class="nump">11,271<span></span>
</td>
<td class="nump">10,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(6,818)<span></span>
</td>
<td class="num">(5,394)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net&#160;</a></td>
<td class="nump">$ 4,453<span></span>
</td>
<td class="nump">$ 5,375<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171680958776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain (Loss) on Disposition of Assets</a></td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">Depreciation, Amortization and Accretion, Net</a></td>
<td class="num">$ (1,880)<span></span>
</td>
<td class="num">$ (1,936)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171769466808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF INTANGIBLE ASSETS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 2,917<span></span>
</td>
<td class="nump">$ 4,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(615)<span></span>
</td>
<td class="num">(1,564)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="num">(363)<span></span>
</td>
<td class="num">(946)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying value</a></td>
<td class="nump">1,939<span></span>
</td>
<td class="nump">2,337<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">929<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(93)<span></span>
</td>
<td class="num">(97)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="num">(363)<span></span>
</td>
<td class="num">(259)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying value</a></td>
<td class="nump">$ 473<span></span>
</td>
<td class="nump">$ 746<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">17 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">19 years<span></span>
</td>
<td class="text">19 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_LicensesMember', window );">Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying value</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">356<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying value</a></td>
<td class="nump">$ 356<span></span>
</td>
<td class="nump">$ 340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod', window );">Finite-Lived Intangible Assets, Amortization Method</a></td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">Indefinite<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 1,519<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(454)<span></span>
</td>
<td class="num">(1,165)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(630)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying value</a></td>
<td class="nump">$ 1,065<span></span>
</td>
<td class="nump">$ 1,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_NonCompetitionClauseMember', window );">Non-Competition Clause [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(274)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_NonCompetitionClauseMember', window );">Non-Competition Clause [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_NonCompetitionClauseMember', window );">Non-Competition Clause [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_StatePharmacyLicensesMember', window );">State Pharmacy Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">25 years<span></span>
</td>
<td class="text">25 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying value</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_FiniteLivedIntangibleAssetsImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Intangible Assets Impairment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_FiniteLivedIntangibleAssetsImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amortization method of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar either by their nature or by their use in the operations of a company. The straight-line method is the preferred amortization method, unless another method better reflects the pattern in which the asset is consumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 35<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121554622&amp;loc=d3e15372-109273<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_LicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_LicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_NonCompetitionClauseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_NonCompetitionClauseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_StatePharmacyLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_StatePharmacyLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171681037960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 167<span></span>
</td>
<td class="nump">$ 209<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_LicensesMember', window );">Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_StatePharmacyLicensesMember', window );">State Pharmacy Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_LicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_LicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_StatePharmacyLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_StatePharmacyLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171677833016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2025</a></td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">715<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets</a></td>
<td class="nump">$ 1,583<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171679896728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF GOODWILL (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at December 31, 2018</a></td>
<td class="nump">$ 2,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of Park goodwill (see Note 2)</a></td>
<td class="num">(1,895)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at December 31, 2019</a></td>
<td class="nump">$ 332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171674899192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Details Narrative) - Park Compounding, Inc. [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember', window );">Customer Relationships, Trade Name and State Pharmacy Licenses [Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of Intangible Assets, Finite-lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of Intangible Assets, Finite-lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_PatentsFilingsAndTrademarksMember', window );">Patents Filings and Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of Intangible Assets, Finite-lived</a></td>
<td class="nump">$ 363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_ParkCompoundingIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_ParkCompoundingIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_PatentsFilingsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=HROW_PatentsFilingsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171674859304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="nump">$ 3,645<span></span>
</td>
<td class="nump">$ 7,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other accrued expenses</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest (see Note 12)</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued exit fee for note payable (see Note 12)</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Total accounts payable and accrued expenses</a></td>
<td class="nump">4,732<span></span>
</td>
<td class="nump">8,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Less: Current portion</a></td>
<td class="num">(3,932)<span></span>
</td>
<td class="num">(7,702)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent', window );">Non-current total accrued expenses</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(1),(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171674785448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF FUTURE MINIMUM PAYMENTS (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 5,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">4,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">9,511<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total minimum payments</a></td>
<td class="nump">20,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Less: amount representing interest</a></td>
<td class="num">(2,927)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Notes payable, gross</a></td>
<td class="nump">17,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: unamortized discount</a></td>
<td class="num">(802)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="nump">16,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_NotesPayableCurrent1', window );">Less: current portion, net of unamortized discount</a></td>
<td class="num">(3,898)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_LongTermNotesPayable1', window );">Note payable, net of current portion and unamortized debt discount</a></td>
<td class="nump">$ 12,378<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_LongTermNotesPayable1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_LongTermNotesPayable1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_NotesPayableCurrent1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_NotesPayableCurrent1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171681974696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Details Narrative)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 14, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 02, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of Debt Discount (Premium)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=HROW_LenderWarrantsMember', window );">Lender Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">615,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares, Issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.08<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember', window );">London Interbank Offered Rate (LIBOR) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt instrument interest rate description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Prior
to the loan refinance in May 2019 (see below), the SWK Loan bore interest at a variable rate equal to the three-month London Inter-Bank
Offered Rate (subject to a minimum of 1.50%
and maximum of 3.00%),
plus an applicable margin of 10.50%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Loan bear interest at variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember', window );">London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Loan bear interest at variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember', window );">London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Loan bear interest at variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_TermLoanAndSecurityAgreementMember', window );">Term Loan and Security Agreement [Member] | SWK Funding LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt Instrument, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
SWK Loan Agreement was fully funded at closing with a five-year term, however, such term could be reduced to four years if certain
revenue requirements are not achieved.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_SWKLoanAgreementMember', window );">SWK Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Debt Instrument, Maturity Date, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">All
amounts owed under the SWK Loan Agreement, including an exit fee equal to 5% of the aggregate principal amount loaned thereunder,
were originally due and payable on July 19, 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt Instrument, Fee Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_JoinderAndAmendmentMember', window );">Joinder and Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt instrument interest rate description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Company
    provides SWK evidence that the Company has achieved a leverage ratio as of such date of less than 4.00:1:00, the Margin Rate
    shall equal 9.00%; and if the Company has achieved a leverage ratio as of such date of less than 3.00:1:00, the Margin Rate
    shall equal 7.00%;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_JoinderAndAmendmentMember', window );">Joinder and Amendment [Member] | London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Loan bear interest at variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_JoinderAndAmendmentMember', window );">Joinder and Amendment [Member] | Margin Rate [Member].</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Loan bear interest at variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 19,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_DeconsolidationPercentage', window );">Deconsolidation percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_SWKSecondAmendmentMember', window );">SWK Second Amendment [Member].</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="nump">$ 358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,768<span></span>
</td>
<td class="nump">1,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of Debt Discount (Premium)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 457<span></span>
</td>
<td class="nump">$ 512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_BusinessLoanAgreementMember', window );">Business Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt instrument interest rate description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">it
being anticipated that at least 75% of the loan amount will be required to be used for eligible payroll costs<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_DeconsolidationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deconsolidation percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_DeconsolidationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=HROW_LenderWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=HROW_LenderWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_TermLoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_TermLoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_SWKFundingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_SWKFundingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_SWKLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_SWKLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_JoinderAndAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_JoinderAndAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=HROW_MarginRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=HROW_MarginRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_SWKSecondAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_SWKSecondAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_BusinessLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_BusinessLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171769985768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 1,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">1,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">1,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">1,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">5,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">10,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount representing interest payments</a></td>
<td class="num">(3,034)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">7,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion, operating lease liabilities</a></td>
<td class="num">(580)<span></span>
</td>
<td class="num">$ (629)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">$ 6,652<span></span>
</td>
<td class="nump">$ 6,338<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171684959128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount representing interest payments</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current portion, finance lease obligation</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease obligation, net of current portion</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171771641080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details Narrative)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">6.30%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">11 years 2 months 12 days<span></span>
</td>
<td class="text">10 years 2 months 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments</a></td>
<td class="nump">$ 1,052<span></span>
</td>
<td class="nump">$ 905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="nump">1,066<span></span>
</td>
<td class="nump">$ 892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_MonthlyPaymentsOfFinanceLeaseForEquipment', window );">Monthly payments of finance lease</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">636.00%<span></span>
</td>
<td class="nump">6.36%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">3 years 29 days<span></span>
</td>
<td class="text">4 years 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of Debt Discount (Premium)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Finance Lease, Right-of-Use Asset, Amortization</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Finance Lease, Interest Expense</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=HROW_SanDiegoMember', window );">San Diego [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of Land | ft&#178;</a></td>
<td class="nump">10,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_LeaseExpirationDateDescription', window );">Lease expiration date description</a></td>
<td class="text">December
    2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, Operating Lease, Option to Extend</a></td>
<td class="text">option
    to extend the term for a five-year period<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=HROW_LedgewoodMember', window );">Ledgewood [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of Land | ft&#178;</a></td>
<td class="nump">26,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_LeaseExpirationDateDescription', window );">Lease expiration date description</a></td>
<td class="text">July
    2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, Operating Lease, Option to Extend</a></td>
<td class="text">an
    option to extend the term for two additional five-year periods<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_AdditionalAreaOfLand', window );">Additional square footage | ft&#178;</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=HROW_NashvilleMember', window );">Nashville [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of Land | ft&#178;</a></td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_LeaseExpirationDateDescription', window );">Lease expiration date description</a></td>
<td class="text">December
    2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, Operating Lease, Option to Extend</a></td>
<td class="text">option
    to extend the term for two additional five-year periods<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=HROW_IrvineMember', window );">Irvine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of Land | ft&#178;</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain (Loss) on Termination of Lease</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=HROW_OfficeAndLaboratorySpaceMember', window );">Office And Laboratory Space [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lessee, Operating Lease, Remaining Lease Term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=HROW_OfficeAndLaboratorySpaceMember', window );">Office And Laboratory Space [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lessee, Operating Lease, Remaining Lease Term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_AdditionalAreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional area of land.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_AdditionalAreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_LeaseExpirationDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease expiration date description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_LeaseExpirationDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_MonthlyPaymentsOfFinanceLeaseForEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monthly payments of finance lease for equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_MonthlyPaymentsOfFinanceLeaseForEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121604053&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=HROW_SanDiegoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=HROW_SanDiegoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=HROW_LedgewoodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=HROW_LedgewoodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=HROW_NashvilleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=HROW_NashvilleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=HROW_IrvineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=HROW_IrvineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=HROW_OfficeAndLaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=HROW_OfficeAndLaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171684419016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION PLAN ACTIVITY (Details) - Stock Option Plan [Member]<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding, Beginning balance | shares</a></td>
<td class="nump">2,656,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Avg. Exercise Price, Outstanding, Beginning balance | $ / shares</a></td>
<td class="nump">$ 5.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Options granted | shares</a></td>
<td class="nump">414,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Avg. Exercise Price, Options granted | $ / shares</a></td>
<td class="nump">$ 6.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Options exercised | shares</a></td>
<td class="num">(19,748)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Avg. Exercise Price, Options exercised | $ / shares</a></td>
<td class="nump">$ 3.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, Options cancelled/forfeited | shares</a></td>
<td class="num">(21,402)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Avg. Exercise Price, Options cancelled/forfeited | $ / shares</a></td>
<td class="nump">$ 12.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding, Ending balance | shares</a></td>
<td class="nump">3,030,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Avg. Exercise Price, Outstanding, Ending balance | $ / shares</a></td>
<td class="nump">$ 5.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Avg. Remaining Contractual Life, Options outstanding</a></td>
<td class="text">5 years 8 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Options outstanding | $</a></td>
<td class="nump">$ 5,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, Options exercisable | shares</a></td>
<td class="nump">1,908,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Avg. Exercise Price, Exercisable Ending Balance | $ / shares</a></td>
<td class="nump">$ 4.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Avg. Remaining Contractual Life, Options exercisable</a></td>
<td class="text">5 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Options exercisable | $</a></td>
<td class="nump">$ 5,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares, Options vested and expected to vest | shares</a></td>
<td class="nump">2,918,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Avg. Exercise Price, Vested and expected to vest | $ / shares</a></td>
<td class="nump">$ 5.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Avg. Remaining Contractual Life, Options vested and expected to vest</a></td>
<td class="text">5 years 8 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Options vested and expected to vest | $</a></td>
<td class="nump">$ 5,519<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=HROW_StockOptionPlanOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=HROW_StockOptionPlanOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171684969288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details) - Options Granted to Employees [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of options granted</a></td>
<td class="nump">$ 3.86<span></span>
</td>
<td class="nump">$ 3.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.34%<span></span>
</td>
<td class="nump">1.83%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.64%<span></span>
</td>
<td class="nump">2.68%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=HROW_OptionsEmployeesMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected terms (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">5 years 25 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=HROW_OptionsEmployeesMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected terms (in years)</a></td>
<td class="text">6 years 1 month 9 days<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=HROW_OptionsEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=HROW_OptionsEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171676663176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum</a></td>
<td class="nump">$ 1.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum</a></td>
<td class="nump">$ 8.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding | shares</a></td>
<td class="nump">3,030,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life in Years</a></td>
<td class="text">5 years 8 months 19 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 5.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable | shares</a></td>
<td class="nump">1,908,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercisable Exercise Price</a></td>
<td class="nump">$ 4.49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeOneMember', window );">Range One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum</a></td>
<td class="nump">1.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum</a></td>
<td class="nump">$ 2.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding | shares</a></td>
<td class="nump">770,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life in Years</a></td>
<td class="text">5 years 7 months 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 2.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable | shares</a></td>
<td class="nump">745,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercisable Exercise Price</a></td>
<td class="nump">$ 2.06<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeTwoMember', window );">Range Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum</a></td>
<td class="nump">3.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum</a></td>
<td class="nump">$ 4.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding | shares</a></td>
<td class="nump">517,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life in Years</a></td>
<td class="text">5 years 9 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable | shares</a></td>
<td class="nump">438,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercisable Exercise Price</a></td>
<td class="nump">$ 3.98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeThreeMember', window );">Range Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum</a></td>
<td class="nump">5.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum</a></td>
<td class="nump">$ 6.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding | shares</a></td>
<td class="nump">496,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life in Years</a></td>
<td class="text">7 years 2 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 6.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable | shares</a></td>
<td class="nump">291,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercisable Exercise Price</a></td>
<td class="nump">$ 6.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeFourMember', window );">Range Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum</a></td>
<td class="nump">6.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum</a></td>
<td class="nump">$ 8.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of Options Outstanding | shares</a></td>
<td class="nump">1,246,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life in Years</a></td>
<td class="text">5 years 2 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 7.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable | shares</a></td>
<td class="nump">432,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercisable Exercise Price</a></td>
<td class="nump">$ 8.09<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171681752200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs unvested, Outstanding, Beginning balance</a></td>
<td class="nump">1,411,930<span></span>
</td>
<td class="nump">1,275,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Beginning balance</a></td>
<td class="nump">$ 2.76<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSUs granted</a></td>
<td class="nump">251,524<span></span>
</td>
<td class="nump">223,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, RSUs granted</a></td>
<td class="nump">$ 6.11<span></span>
</td>
<td class="nump">$ 6.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of RSUs vested</a></td>
<td class="num">(61,945)<span></span>
</td>
<td class="num">(87,610)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, RSUs vested</a></td>
<td class="nump">$ 6.46<span></span>
</td>
<td class="nump">$ 3.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of RSUs cancelled/forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs unvested, Outstanding, Ending balance</a></td>
<td class="nump">1,601,509<span></span>
</td>
<td class="nump">1,411,930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending balance</a></td>
<td class="nump">$ 3.14<span></span>
</td>
<td class="nump">$ 2.76<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171680309400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation related to equity instruments granted to related parties</a></td>
<td class="nump">$ 2,858<span></span>
</td>
<td class="nump">$ 2,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=HROW_EmployeesMember', window );">Employees [Member] | Selling, General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation related to equity instruments granted to related parties</a></td>
<td class="nump">2,289<span></span>
</td>
<td class="nump">1,464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Selling, General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation related to equity instruments granted to related parties</a></td>
<td class="nump">473<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=HROW_ConsultantMember', window );">Consultants [Member] | Selling, General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation related to equity instruments granted to related parties</a></td>
<td class="nump">$ 96<span></span>
</td>
<td class="nump">$ 259<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=HROW_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=HROW_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=HROW_SellingGeneralAndAdministrativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=HROW_SellingGeneralAndAdministrativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=HROW_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=HROW_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171684597624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WARRANTS ACTIVITY (Details) - Warrant [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares Warrants Outstanding, beginning balance</a></td>
<td class="nump">780,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1', window );">Weighted Avg. Exercise Price, Outstanding, beginning balance | $ / shares</a></td>
<td class="nump">$ 2.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Shares Warrants Outstanding, Granted</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Shares Warrants Outstanding, Exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of Shares Warrants Outstanding, Expired</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber', window );">Number of Shares Warrants Outstanding and Exercisable, ending balance</a></td>
<td class="nump">780,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1', window );">Weighted Avg. Exercise Price, Outstanding and Exercisable, ending balance | $ / shares</a></td>
<td class="nump">$ 2.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life of the outstanding warrants in years</a></td>
<td class="text">3 years 6 months 10 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares warrants outstanding and exercisable, ending balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options equity instruments outstanding and exercisable weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options equity instruments outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award non options outstanding weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171682129384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding</a></td>
<td class="nump">780,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Warrants Exercisable</a></td>
<td class="nump">780,386<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_LenderWarrantsMember', window );">Lender Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_WarrantsIssuanceDate', window );">Issue Date</a></td>
<td class="text">May 11,  2015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding</a></td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Warrants Exercisable</a></td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_WarrantsAndRightsOutstandingMaturityDates', window );">Expiration Date</a></td>
<td class="text">May 11,  2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_SettlementWarrantsMember', window );">Settlement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_WarrantsIssuanceDate', window );">Issue Date</a></td>
<td class="text">Aug. 16,  2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding</a></td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Warrants Exercisable</a></td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_WarrantsAndRightsOutstandingMaturityDates', window );">Expiration Date</a></td>
<td class="text">Aug. 16,  2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_LenderWarrantsOneMember', window );">Lender Warrants One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_WarrantsIssuanceDate', window );">Issue Date</a></td>
<td class="text">Jul. 19,  2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding</a></td>
<td class="nump">615,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Warrants Exercisable</a></td>
<td class="nump">615,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_WarrantsAndRightsOutstandingMaturityDates', window );">Expiration Date</a></td>
<td class="text">Jul. 19,  2024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_WarrantsAndRightsOutstandingMaturityDates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_WarrantsAndRightsOutstandingMaturityDates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_WarrantsIssuanceDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants issuance date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_WarrantsIssuanceDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_LenderWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_LenderWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_SettlementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_SettlementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_LenderWarrantsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_LenderWarrantsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171668653176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY AND STOCK-BASED COMPENSATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 04, 2020</div></th>
<th class="th"><div>Jul. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Number of restrcited shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Options exercise price, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options exercise price, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,775,000<span></span>
</td>
<td class="nump">$ 1,789,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_MayfieldPharmaceuticalsIncMember', window );">Mayfield Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_MayfieldPharmaceuticalsIncMember', window );">Mayfield Pharmaceuticals, Inc. [Member] | Elle Pharmaceutical, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period, shares, acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of common stock issued for consultants services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_AggregatePurchasePrice', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_BaumPerformanceOptionMember', window );">Baum Performance Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted avg. remaining contractual life, options outstanding</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share-based compensation arrangement by share-based payment award, options, vested in period, fair value</a></td>
<td class="nump">$ 1,876,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_BaumPerformanceOptionMember', window );">Baum Performance Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_AverageStockPrice', window );">Average stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_BaumPerformanceOptionMember', window );">Baum Performance Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_AverageStockPrice', window );">Average stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_LicenseAgreementMember', window );">License Agreement [Member] | Mayfield Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_LicenseAgreementMember', window );">License Agreement [Member] | Stowe Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued of restricted common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember', window );">2017 Incentive Stock and Awards Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of common stock issuance under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">342,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=HROW_MarkBaumCEOMember', window );">Mark Baum C E O [Member] | Mayfield Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of common stock issued for consultants services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=HROW_MarkBaumCEOMember', window );">Mark Baum C E O [Member] | Visionology Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of common stock issued for consultants services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=HROW_AndrewBollCFOMember', window );">Andrew Boll C F O [Member] | Mayfield Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of common stock issued for consultants services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=HROW_AndrewBollCFOMember', window );">Andrew Boll C F O [Member] | Visionology Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of common stock issued for consultants services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=HROW_CommonStockWarrantsOneMember', window );">Common Stock Warrants One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">964,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=HROW_CommonStockWarrantsTwoMember', window );">Common Stock Warrants Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from issuance of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 813,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued of restricted common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,785<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Number of restrcited shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeOneMember', window );">Range One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Options exercise price, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options exercise price, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeTwoMember', window );">Range Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Options exercise price, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options exercise price, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued of restricted common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Number of restrcited shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 167,000<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued of restricted common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued of restricted common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,000<span></span>
</td>
<td class="nump">185,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Number of restrcited shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,025,000<span></span>
</td>
<td class="nump">$ 1,139,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued of restricted common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,524<span></span>
</td>
<td class="nump">38,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Number of restrcited shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 511,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued of restricted common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_RestrictedStockUnitsVested', window );">Restricted stock units vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CommonStockWithheldForPayrollTaxWithholdingsShare', window );">Common stock withheld for payroll tax withholdings, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,564<span></span>
</td>
<td class="nump">8,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CommonStockWithheldForPayrollTaxWithholdingsValue', window );">Common stock withheld for payroll tax withholdings, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member] | Range One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_NumberOfCommonStockIssuedOnCashlessExercise', window );">Number of common stock issued on cashless exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,161<span></span>
</td>
<td class="nump">27,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,750<span></span>
</td>
<td class="nump">82,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Options exercise price, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options exercise price, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.05<span></span>
</td>
<td class="nump">$ 4.17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member] | Range Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_NumberOfCommonStockIssuedOnCashlessExercise', window );">Number of common stock issued on cashless exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,998<span></span>
</td>
<td class="nump">2,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,998<span></span>
</td>
<td class="nump">2,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Options exercise price, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.04<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options exercise price, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.20<span></span>
</td>
<td class="nump">$ 3.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=HROW_StockOptionPlanMember', window );">Stock Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ClosingPriceOfCommonStockPricePerShare', window );">Closing price of common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ForfeitureFactorPercentage', window );">Forfeiture factor, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense related to unvested stock options granted under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,794,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expense expected to recognize over the weighted-average remaining vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 11 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,579,000<span></span>
</td>
<td class="nump">889,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=HROW_StockOptionPlanMember', window );">Stock Option Plan [Member] | Employees and Consultant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted avg. remaining contractual life, options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms', window );">Share-based compensation arrangement by share-based payment award, plan modification, description and terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Vesting terms for
options granted to employees and consultants during the year ended December 31, 2020 generally included one of the following vesting
schedules: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and
the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over
three years; and 100% of the shares subject to the option vest on a quarterly basis in equal installments over three years. Certain
option awards provide for accelerated vesting if there is a change in control (as defined in the Plans) and in the event of certain
modifications to the option award agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=HROW_UnvestedRSUMember', window );">Unvested RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense related to unvested stock options granted under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,363,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expense expected to recognize over the weighted-average remaining vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,167,000<span></span>
</td>
<td class="nump">$ 879,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Mayfield Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued of restricted common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,000<span></span>
</td>
<td class="nump">2,450,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Number of restrcited shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Visionology Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued of restricted common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Number of restrcited shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Consultants [Member] | Mayfield Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued of restricted common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_AggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate purchase price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_AggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_AverageStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_AverageStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_ClosingPriceOfCommonStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Closing price of common stock price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_ClosingPriceOfCommonStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_CommonStockWithheldForPayrollTaxWithholdingsShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock withheld for payroll tax withholdings, shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_CommonStockWithheldForPayrollTaxWithholdingsShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_CommonStockWithheldForPayrollTaxWithholdingsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock withheld for payroll tax withholdings, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_CommonStockWithheldForPayrollTaxWithholdingsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_ForfeitureFactorPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Forfeiture factor, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_ForfeitureFactorPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_NumberOfCommonStockIssuedOnCashlessExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock issued on cashless exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_NumberOfCommonStockIssuedOnCashlessExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_RestrictedStockUnitsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted stock units vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_RestrictedStockUnitsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of modification of award under share-based payment arrangement. Includes, but is not limited to, terms for expiration date, vesting rights and exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_MayfieldPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_MayfieldPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_EllePharmaceuticalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_EllePharmaceuticalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_BaumPerformanceOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_BaumPerformanceOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_StowePharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_StowePharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=HROW_MarkBaumCEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=HROW_MarkBaumCEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_VisionologyIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=HROW_VisionologyIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=HROW_AndrewBollCFOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=HROW_AndrewBollCFOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=HROW_CommonStockWarrantsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=HROW_CommonStockWarrantsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=HROW_CommonStockWarrantsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=HROW_CommonStockWarrantsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=HROW_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=HROW_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=HROW_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=HROW_BoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=HROW_BoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=HROW_StockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=HROW_StockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=HROW_EmployeesAndConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=HROW_EmployeesAndConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=HROW_UnvestedRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=HROW_UnvestedRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=HROW_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=HROW_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171675198152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF PROVISION FOR INCOME TAXES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current: Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current: State</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred: Federal</a></td>
<td class="num">(771)<span></span>
</td>
<td class="nump">669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred: State</a></td>
<td class="nump">138<span></span>
</td>
<td class="num">(148)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_DeferredIncomeChangeInValuationAllowance', window );">Deferred: Change in valuation allowance</a></td>
<td class="nump">633<span></span>
</td>
<td class="num">(521)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision (benefit)</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_DeferredIncomeChangeInValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Income Change In Valuation Allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_DeferredIncomeChangeInValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171680586408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF INCOME TAX RECONCILIATION (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax benefit, net</a></td>
<td class="num">(0.11%)<span></span>
</td>
<td class="num">(6.73%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends', window );">Employee stock-based compensation</a></td>
<td class="nump">5.52%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.38%)<span></span>
</td>
<td class="num">(358.67%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(26.14%)<span></span>
</td>
<td class="nump">334.57%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="num">(0.11%)<span></span>
</td>
<td class="num">(6.73%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for dividend paid to employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171685679528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOL&#8217;s</a></td>
<td class="nump">$ 19,685<span></span>
</td>
<td class="nump">$ 19,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">528<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther', window );">Other</a></td>
<td class="nump">413<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">596<span></span>
</td>
<td class="nump">596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Deferred stock-based compensation</a></td>
<td class="nump">4,024<span></span>
</td>
<td class="nump">3,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_IncomeTaxBasisDifferenceInRelatedParty', window );">Basis difference in Melt</a></td>
<td class="num">(398)<span></span>
</td>
<td class="num">(1,119)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_IncomeTaxBasisDifferenceInRelatedPartyOne', window );">Basis difference in Surface</a></td>
<td class="num">(502)<span></span>
</td>
<td class="num">(1,185)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_IncomeTaxBasisDifferenceInRelatedPartyTwo', window );">Basis difference in Eton</a></td>
<td class="num">(8,626)<span></span>
</td>
<td class="num">(7,528)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_DeferredTaxAssetsTaxDeferredExpenseCapitalLosses', window );">Capital losses</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Park stock purchase identifiable intangibles</a></td>
<td class="num">(274)<span></span>
</td>
<td class="num">(270)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_DeferredTaxAssetsTaxDeferredExpenseLimitations', window );">Limitation under 163(j)</a></td>
<td class="nump">195<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability', window );">ASC 842 lease liability</a></td>
<td class="nump">2,192<span></span>
</td>
<td class="nump">2,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset', window );">ASC 842 ROU asset</a></td>
<td class="num">(2,061)<span></span>
</td>
<td class="num">(1,959)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets, net</a></td>
<td class="nump">15,835<span></span>
</td>
<td class="nump">15,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(15,835)<span></span>
</td>
<td class="num">(15,202)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset Tax Credit carry Forwards Depreciation And Amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ASC 842 ROU Asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ASC 842 Lease Liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_DeferredTaxAssetsTaxDeferredExpenseCapitalLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_DeferredTaxAssetsTaxDeferredExpenseCapitalLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_DeferredTaxAssetsTaxDeferredExpenseLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Limitation Under 163(j).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_DeferredTaxAssetsTaxDeferredExpenseLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_IncomeTaxBasisDifferenceInRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basis Difference in Melt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_IncomeTaxBasisDifferenceInRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_IncomeTaxBasisDifferenceInRelatedPartyOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basis Difference in Surface.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_IncomeTaxBasisDifferenceInRelatedPartyOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_IncomeTaxBasisDifferenceInRelatedPartyTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basis Difference in Eton.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_IncomeTaxBasisDifferenceInRelatedPartyTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171680148280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax asset valuation allowance</a></td>
<td class="nump">$ 633<span></span>
</td>
<td class="nump">$ 521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">62,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforwards</a></td>
<td class="nump">$ 60,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_StateNetOperatingLossExpirationDate', window );">State net operating loss expiration date</a></td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_FederalNetOperatingLossCarryforwardDescription', window );">Federal net operating loss carryforward description</a></td>
<td class="text">In addition, the
Company has federal net operating loss carryforwards of $3,865 generated after 2017 that can be carried over indefinitely and
may be used to offset up to&#160;80% of federal taxable income.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_FederalResearchAndDevelopmentTaxCredits', window );">Federal research and development tax credits</a></td>
<td class="nump">$ 354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_StateResearchAndDevelopmentTaxCredits', window );">State research and development tax credits</a></td>
<td class="nump">$ 305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_FederalResearchAndDevelopmentTaxCreditsExpirationDate', window );">Federal research and development tax credits expiration date</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_FederalNetOperatingLossCarryforwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal net operating loss carryforward description</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_FederalNetOperatingLossCarryforwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_FederalResearchAndDevelopmentTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal Research And Development Tax Credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_FederalResearchAndDevelopmentTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_FederalResearchAndDevelopmentTaxCreditsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal Research And Development Tax Credits Expiration Date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_FederalResearchAndDevelopmentTaxCreditsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_StateNetOperatingLossExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State net operating loss expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_StateNetOperatingLossExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_StateResearchAndDevelopmentTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State Research And Development Tax Credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_StateResearchAndDevelopmentTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171674963144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE SAVINGS PLAN (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount', window );">Percentage of salary deposits in tax deferred investment account</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Percentage of contributions made by the company</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions by the company</a></td>
<td class="nump">$ 272<span></span>
</td>
<td class="nump">$ 312<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of salary deposits in tax deferred investment account.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171680325720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Apr. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Business acquisition description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In
consideration for the acquisition of the intellectual property rights, the Company is obligated to make payments to the Inventors
based on the completion of certain milestones, generally consisting of: (1) a payment payable within 30 days after the issuance
of the first patent in the United States arising from the acquired intellectual property (if any); (2) a payment payable within
30 days after the Company files the first investigational new drug application (&#8220;IND&#8221;) with the FDA for the first
product arising from the acquired intellectual property (if any); (3) for certain of the Inventors, a payment payable within 30
days after the Company files the first new drug application with the FDA for the first product arising from the acquired intellectual
property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection with the sale
or licensing of any product based on the acquired intellectual property (if any), after deducting (among other things) the Company&#8217;s
development costs associated with such product. If, following five years after the date of the applicable asset purchase agreement,
the Company either (a) for certain of the Inventors, has not filed an IND or, for the remaining Inventors, has not initiated a
study where data is derived, or (b) has failed to generate royalty payments to the Inventors for any product based on the acquired
intellectual property, the Inventors may terminate the applicable asset purchase agreement and request that the Company re-assign
the acquired technology to the Inventors.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
<td class="nump">$ 371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">682<span></span>
</td>
<td class="nump">846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=HROW_RichardLLindstromMDMember', window );">Richard L. Lindstrom, M.D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_MilestonePaymentInCash', window );">Milestone payment in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=HROW_AllerganUSAIncMember', window );">Allergan USA, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Lost profit damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_SettlementAgreementMember', window );">Settlement Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Accrued damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_DamagesLowClaimRatePercentage', window );">Damages low claim rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Litigation amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_SalesAndMarketingAgreementsMember', window );">Sales and Marketing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_AdditionalPaidInCapitalAndShareBasedPayments', window );">Additional paid in capital and stock based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesCommissionsAndFees', window );">Commission expense incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,434<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_SalesAndMarketingAgreementsMember', window );">Sales and Marketing Agreements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CommissionPaymentsPercentage', window );">Commission payments, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_SalesAndMarketingAgreementsMember', window );">Sales and Marketing Agreements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CommissionPaymentsPercentage', window );">Commission payments, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_LicenseAgreementMember', window );">License Agreement [Member] | Richard L. Lindstrom, M.D [Member] | Initial Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_LicenseAgreementMember', window );">License Agreement [Member] | Richard L. Lindstrom, M.D [Member] | DirectorSellingAndAdminstrativeMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_NetSalesRevenue', window );">Sales revenue net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_LicenseAgreementMember', window );">License Agreement [Member] | Richard L. Lindstrom, M.D [Member] | Final Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_NetSalesRevenue', window );">Sales revenue net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_LicenseAgreementMember', window );">License Agreement [Member] | Mayfield Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_LicenseAgreementMember', window );">License Agreement [Member] | Stowe Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_KlarityLicenseAgreementMember', window );">Klarity License Agreement [Member] | Richard L. Lindstrom, M.D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_RoyaltyPaymentDescription', window );">Royalty payment description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Under
the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3%
to 6% of net sales, dependent upon the final formulation of the Klarity Product sold.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_MilestonePaymentsOnPayables', window );">Milestone payments on payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_InjectableAssetPurchaseAgreementMember', window );">Injectable Asset Purchase Agreement [Member] | Richard L. Lindstrom, M.D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_RoyaltyPaymentDescription', window );">Royalty payment description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">he Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net
sales, dependent upon the final formulation and patent protection of the Lindstrom Product sold.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_MilestonePaymentInCash', window );">Milestone payment in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_MilestonePaymentsOnPayables', window );">Milestone payments on payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_InjectableAssetPurchaseAgreementMember', window );">Injectable Asset Purchase Agreement [Member] | Richard L. Lindstrom, M.D [Member] | Initial Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_PresbyopiaAssetPurchaseAgreementMember', window );">Presbyopia Asset Purchase Agreement [Member] | Richard L. Lindstrom, M.D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_RoyaltyPaymentDescription', window );">Royalty payment description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 4% of net
sales, dependent upon the final formulation and patent protection of the Presbyopia Product sold.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_MilestonePaymentInCash', window );">Milestone payment in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_MilestonePaymentsOnPayables', window );">Milestone payments on payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=HROW_DexycuAgreementMember', window );">Dexycu Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesCommissionsAndFees', window );">Commission expense incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_AdditionalPaidInCapitalAndShareBasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional paid in capital and stock based payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_AdditionalPaidInCapitalAndShareBasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_CommissionPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission payments, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_CommissionPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_DamagesLowClaimRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Damages low claim rate, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_DamagesLowClaimRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_MilestonePaymentInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_MilestonePaymentInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_MilestonePaymentsOnPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments on payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_MilestonePaymentsOnPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_NetSalesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net sales of product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_NetSalesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_RoyaltyPaymentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty payment description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_RoyaltyPaymentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages paid to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesCommissionsAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesCommissionsAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=HROW_RichardLLindstromMDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=HROW_RichardLLindstromMDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_AllerganUSAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_AllerganUSAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_SettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_SettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_SalesAndMarketingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_SalesAndMarketingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=HROW_InitialPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=HROW_InitialPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=HROW_SecondPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=HROW_SecondPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=HROW_FinalPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=HROW_FinalPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_MayfieldPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_MayfieldPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=HROW_StowePharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=HROW_StowePharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_KlarityLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_KlarityLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_InjectableAssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_InjectableAssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_PresbyopiaAssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_PresbyopiaAssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=HROW_DexycuAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=HROW_DexycuAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171685640440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF SEGMENT NET REVENUES, SEGMENT OPERATING EXPENSES AND SEGMENT CONTRIBUTION (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net Revenues</a></td>
<td class="nump">$ 48,871<span></span>
</td>
<td class="nump">$ 51,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">14,463<span></span>
</td>
<td class="nump">16,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="num">(14,463)<span></span>
</td>
<td class="num">(16,749)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">34,408<span></span>
</td>
<td class="nump">34,416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">31,247<span></span>
</td>
<td class="nump">33,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,413<span></span>
</td>
<td class="nump">2,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">385<span></span>
</td>
<td class="num">(4,795)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net Revenues</a></td>
<td class="nump">48,871<span></span>
</td>
<td class="nump">51,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">14,463<span></span>
</td>
<td class="nump">16,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="num">(14,463)<span></span>
</td>
<td class="num">(16,749)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">34,408<span></span>
</td>
<td class="nump">34,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">22,835<span></span>
</td>
<td class="nump">24,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">847<span></span>
</td>
<td class="nump">1,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_SegmentContribution', window );">Segment contribution</a></td>
<td class="nump">10,726<span></span>
</td>
<td class="nump">8,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,795)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="num">(167)<span></span>
</td>
<td class="num">(209)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_ImpairmentAndDisposalOfLonglivedAssets', window );">Asset sales and impairments, net</a></td>
<td class="nump">385<span></span>
</td>
<td class="num">(4,040)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(1,566)<span></span>
</td>
<td class="num">(716)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Pharmaceutical Compounding [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net Revenues</a></td>
<td class="nump">48,871<span></span>
</td>
<td class="nump">51,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="num">(14,463)<span></span>
</td>
<td class="num">(16,749)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">14,463<span></span>
</td>
<td class="nump">16,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">34,408<span></span>
</td>
<td class="nump">34,416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">22,691<span></span>
</td>
<td class="nump">24,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">759<span></span>
</td>
<td class="nump">1,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_SegmentContribution', window );">Segment contribution</a></td>
<td class="nump">10,958<span></span>
</td>
<td class="nump">8,934<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Pharmaceutical Drug Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_SegmentContribution', window );">Segment contribution</a></td>
<td class="num">(232)<span></span>
</td>
<td class="num">(535)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">$ (8,245)<span></span>
</td>
<td class="num">$ (8,245)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_ImpairmentAndDisposalOfLonglivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment and disposal of long-lived assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_ImpairmentAndDisposalOfLonglivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_SegmentContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Segment contribution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_SegmentContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=HROW_PharmaceuticalCompoundingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=HROW_PharmaceuticalCompoundingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=HROW_PharmaceuticalDrugDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=HROW_PharmaceuticalDrugDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171677737336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION AND CONCENTRATIONS (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_NumberOfOperatingSegmentsDescription', window );">Number of operating segments, description.</a></td>
<td class="text">two operating segments<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of sales derived from large number of customer</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=HROW_ThreeMainSuppliersMember', window );">Three Main Suppliers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of sales derived from large number of customer</a></td>
<td class="nump">77.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_NumberOfOperatingSegmentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_NumberOfOperatingSegmentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=HROW_ThreeMainSuppliersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=HROW_ThreeMainSuppliersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140171769944776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued of restricted common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued of restricted common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,785<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued of restricted common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">10,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</a></td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</a></td>
<td class="nump">$ 3.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Restricted Stock Units (RSUs) [Member] | Andrew R Boll [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued of restricted common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CommonStockWithheldForPayrollTaxWithholdings', window );">Common stock withheld for payroll tax withholdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_HROW_CommonStockWithheldForPayrollTaxWithholdingsValue', window );">Common stock withheld for payroll tax withholdings, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Restricted Stock Units (RSUs) [Member] | Mark L Baum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued of restricted common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">10,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_CommonStockWithheldForPayrollTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock withheld for payroll tax withholdings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_CommonStockWithheldForPayrollTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_HROW_CommonStockWithheldForPayrollTaxWithholdingsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock withheld for payroll tax withholdings, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">HROW_CommonStockWithheldForPayrollTaxWithholdingsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>HROW_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=HROW_AndrewRBollMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=HROW_AndrewRBollMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=HROW_MarkLBaumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=HROW_MarkLBaumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>105
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M44^EPR@(!J(:;T7&!Z-:22X8=88OMEZ)4TN7PVAW2NSI2K:Z$J^N>T'7A.6
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M5Z3*Y2-[^DS;@"+M;\ER47^"I\8VQ@.PK(1D13M8(2BRLODFSVTBC@; N&<
M:@>@[H"P9P!N!^ ZT 99'=8-D60ZX>P)<&VMO.D?=6[JT2J:K-2/<2ZY^C=3
MX^1TQDK!\BPEDJ9@+M67>D92 +8"]UO*B<ZU .?@Z_P&O'_W ;P#60F^;%@E
M2)F*R5 J#-K3<-G.=]W,AWKF@PC<L5)N!/A4IC1]Z6"HP!\B0/L(KI'7XPU=
M7@ ,SP *4.  -#MY.!Q[X.!#0G'M#_?X>Z0[6E947'I\A0=?8>TK[/'UA4F2
MJ\72>'0ENQD?U>/UBMU-PR09P<EP=YP!VRJ",(X.5B_ 10=PD1?<C FIRT20
MW(VM&1X?S7H.PS#&'7 NLW@4CMWHX@.ZV(ON=\Z$ %O.5IET@8NM67$8!DD'
MF],*QFYHHP.TD;="VG55K@%]5FPL_+62'+PFWH#GB@F5SS.PIJ7RGP.U/@%)
M%65D0NKY=M25A\2.$*)PU,F#PPH'2>+.P_B >.Q%_$@%)7RYJ9&FJLASMM7D
MXX(YM@"@$'8KR6$4)-@-$@:&( ,OS-MB2S*N@>EJSUFY/L]5,E5RA:#238&!
MG2^K[AU&81 &/7"/^!R>P!G,JC$G3NBH[P!92!UF8P1A#U1DH")_9LLE*RAX
MGZNE^@&L."OVN)7F./$B&T@2==':1N?A:-S#=M#P.O03^[W<4*[4K\'<IO6#
M;^E"P_/03_2WI:2<*CYMW9Z!DCK70>OG17 (X;B; Y=9%/05EZ%\Z.?\)@?M
M VM2T0_50>PCJ[1LHQCWP33<#_WDWZZ!MX"UF?X<)T<):^':9F$\ZN%!: 0!
MCKQX_]!:M:"J*:?[ I/D6:O7+M/]LA/QR($XA-9J<)A!..I!;,0&^M7F]E24
MMG*$782V25]"C;) O[0T!:">-=!/7^<TKU+-AB53P$O)62V6ZH]FW;G9QM83
MG>%Q%[_##*(>ND%&=I!?=O[<@R=2\FQ12;+(5<+9FT) ML;$J(/?88/&/:J)
MC PAOPQI^"^6GA7'9\*UU\^4Y')S!E1%73A#@%;S>HYQU.U0'&8P[JDC9!0*
M^17JFHAL6=?1RUB42@&Q(6JYJI9 W2G4AE1MU9;?G1$T<R3'$0075O?B, LN
M@AZ114:V$/:&<)/EE=[;_6P0^+0@;#-/$$8?D5\?O]6[<=US[51_L*:@K(J%
M@G\$7 >BMJV5%%+UDW4GO-!/SQF,+8\H2L81CJS%X;+$",.H9W^"C)8BOY;^
M6$QI\SB=4=E:VA>5PS(.XS@8]ZT8([W(+[UW-)?@00$OR))6,EN27("_[Z@.
M[1_?;M^()7IE^_3F/@P964.OR=I.46G=Z[=K94VRLK=K:+V]X"95&]:BL,WP
MN)><C,@AO\C-*[Y220;WVXW<D+S(EB=E&AL)PL$OSC0V^H#]^O#&3&-["W*.
M0MS-M,L,HKZ^%QL=P'X=^"35<OR!JL9'IT:_>G>!#7OBUW87;\NUS7D81=W&
MTF4U2OHR;5@1^UGQ@;.T6DHPUZ=*9T"W$:?DV? 3CG_Z> X;+L+^QOWU SIL
M]]]AHK:CW6S:9A&$N*=/QX;0L)_0FK+:!WU2*@W_X/'/GW0:L@G]_>X)9YV!
M@T:[TN8P0EVF'1X=EQ>4K^NW"$*I;E7*YMSY</?PIN)C?3[?N7\-+V?-^P;C
MIGG]<4?X.BL%R.E*N0PN1@H0;]XH-!>2;>M#^063DA7USPTE*>7:0/V_8DSN
M+_0$A_<ZT_\!4$L#!!0    ( !F%:%)\J9U)U@4  ,DB   8    >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&ULQ5I1CYLX$/XK5E3I[J2FP08"J;*1V@1R?6BU
MVFWO'D[WX 5O@@HXQ4ZR^^_/)FP(8)SDZMM[V4"8^;YA9K#G6S+=T^([6Q/"
MP5.6YNQFL.9\\WXT8M&:9)B]HQN2BRN/M,@P%Z?%:L0V!<%QZ92E(V19XU&&
MDWPPFY;?W1:S*=WR-,G);0'8-LMP\?R1I'1_,X"#ER_NDM6:RR]&L^D&K\@]
MX=\VMX4X&QU1XB0C.4MH#@KR>#/X -\OD2L=2HL_$K)G)\= WLH#I=_ER:?X
M9F#)B$A*(BXAL/C8D3E)4XDDXOA1@0Z.G-+Q]/@%/2QO7MS, V9D3M,_DYBO
M;P;^ ,3D$6]3?D?WOY/JALH (YJR\B_8'VP]9P"B+>,TJYQ%!%F2'S[Q4Y6(
M$P>$>AQ0Y8!:#O:XQ\&N'.PV@]?CX%0.3LL!]C&XE8/;#LGN<1A7#N,V0Y^#
M5SEX9;$.V2U+L\ <SZ8%W8-"6@LT>5#6M_06%4ERV8KWO!!7$^''9W.:,YHF
M,>8D!O=<?(@^XPS01W%&H^]KFL:D8+^ X,<VX<]@"+[=+\"O;WX#;T"2@Z]K
MNF4XC]ETQ$4T$G,45<P?#\RHESG+1"^6+."OSR1[(,7?"IBY'N9#'">RJ7$*
M;G$2#T50<[Q)N#C7@"[TH'>$BZ=89"3 19[D*Z;#"O18M[@0&=4!A'J +S2/
M:,X+FHHK*_ IYZ0@3(NXU"-^I2(]3;>1Z)MC\Z!C\Z 2Q^G!^4A622[S(U:#
M%.<1>0MV.-T2@#E8D.@=L.%;@"SHJ[KC .V6T'+!W,V0,QWM3BO?-9GX$]MO
M6BVZ5D//01 VS0(5G^>VK$+M#<M]X3W;X(C<#,3"STBQ(X,94!7@'%LCW_8Q
MW[8^WR]99FO15.RB-!\0QXU ;'LRAI8Z%N<8BZ.-)7@B190P(E>*/2X*+%8-
M%;_3342KRDXG0K]=O(4VELO+$JBX[%8+&.):ZKD:27>/27>O3OI+-ZB2[W9"
M@-!!+O+588R/88PO#H-DFY0^$W&\D<NP""<7 Y2XP/&3V,OX6NX@8HE0A:=E
MN3S3\W'G-H=.:RU9&.(*+N *#7$M]5R-TGG'TGG7EX[)/7@H)[KX7!F!KMV\
M[EHS\28]/>\?(_:U$7]B;"M7/1E,=)@9RGC%()R64PNG8"?V0QF<,+F[_Z:,
M34MR1:\9PED8P@D,X82&<)8_C]/HDLFQ2R:FNT37R5JRZ^\"6O4X;FGOX_[D
M4=S@9SF, R$X@21)(K'G;PJZ2V(2*P=N+?8535X!-9YDN[VBFF(++F$+3;$M
MS[ UZW8BHZ"9NNFZKN)H[->N9?5,:K >TZ%^3C\-3CP<&Y(S7/XC@#S)8Z*,
MQ= D/*^ &C?E^9-V,QFB"RZB"TW1+<_1-2M6#_I0/^E_$9MO2IFZ2[2NUU3&
M$- "=D4&'+=D6G")4:@P&J)):T)?JJP@<GN27BL:>$;2Y/%Y+3M1ED2A<L8M
MF0.[>@!:T$-M.:NP$WK6<NQV/KMVR//:RBE4P2DRJ@)S8(].@+5>@7K!<D:Q
MJI/952W(==%X8O?(9UCK%O@ZPD5/<\TCJ!CQ46=M-*5=+F$+3;$MS[ U2UCK
M%_@_"AC853 >=/MBKA4,?!4)HV>YINM,B1A30($IH- 4T-( 4+-;:B4#7U7*
M5&R-?<=W/;]GNT2U5$'_H5318U_1RZ@[SONMW6UABBRX@"PT1;;4DS6+5NL4
M] HZ!75UBFWUZA1T\CK!O$[10U[32-U)7LQ3;KN53.F4B^A"4W3+<W3-BM4Z
M!?U[G:)WO:8RIG0*4N@&VW:]]INBB\Q"E=FX]7)CJ<1R8,](@6JM@GY>JR!+
M698+M(K"!EJ.VT[!0F$W](18L=H957!ZL+MT*N!LUVVG5'4#?M\[#51K%?0S
M6J4GF2JMXCD3O_-HC4[>T<L?>7S&Q2K)&4C)HW"UWGD"J3C\;N)PPNFF?&W_
M0#FG67FX)C@FA300UQ\IY2\G\I< QU^OS/X!4$L#!!0    ( !F%:%(Q!ZW>
MF0D  # G   8    >&PO=V]R:W-H965T<R]S:&5E=#8N>&ULG5K=<N(Z$GX5
M%7MJ:Z8J#$@V?]DD50PA9ZB3  O)3.VE8@O0QE@<6R29??IMR0896U9^;A+;
MM*2O6]W]=<N^>!')4[IA3*+7;12GEXV-E+OS5BL--FQ+TV]BQV+X9262+95P
MFZQ;Z2YA--2#ME&+M-O=UI;RN'%UH9_-DZL+L9<1C]D\0>E^NZ7)[^\L$B^7
M#=PX/%CP]4:J!ZVKBQU=LR63#[MY G>MXRPAW[(XY2)&"5M=-H;X?-0A:H"6
M^,G92UJX1DJ51R&>U,TDO&RT%2(6L4"J*2C\>V8C%D5J)L#Q=SYIX[BF&EB\
M/LQ^HY4'91YIRD8B^L5#N;EL]!LH9"NZC^1"O/Q@N4(=-5\@HE3_12^Y;+N!
M@GTJQ38?# BV/,[^T]?<$(4!N%LS@.0#2'F 7S/ RP=X6M$,F5;KFDIZ=9&(
M%Y0H:9A-76C;Z-&@#8_5-BYE K]R&">O1B).1<1#*EF(EA+^P1[)%(D5&M%T
M@VY@GU/41 _+:_3ECZ_H#\1C=+\1^Y3&87K1DH!!S=0*\O6^9^N1FO4P07<B
MEIL4C>.0A:<3M #\40-RT. [<<YXS8)OR,-GB+1)VP)H].[A>." XQT-ZNGY
MO#J##I<_T,WM[-<2W2QF=V@V'R^&]Y/IGV@XNI_\G-Q/QDO',OYQ&5\OX]<L
M,X4(CT2:HB\\#J)]R.,UBD4<@&T3$47JEL>2)2R5Z5?;-F73=_3T*M:?KYJ>
MKRSP7+2=10J3SE'H!'KG"+WCM- P_"_X=>9F4D N - !CQB*#SK!4W4=* ?\
MLD_!,WG\%>T2\<S!9]#C;P1I+*%2::GS )><I><.LW:/V+I.LUXS2(8!IUF*
MB4-$MR*1_'_9 P@*  %+R]]G:!?16&H9]O>>[Y0^-CMGZW4+%L3]?KMD9HO0
MP.O:S=P[JM)SJC(L(0=WH/&:/X*A:9HR:0W>7A5(MU<"6Y4A[8$=:_^(M?\A
MK&9[(P8Y&B4J&3?%J@G.X$#?KR#K#KHE]%69#N[;T0^.Z =.]'/EF)K7@%:!
M5$+@D4>)V"MP;<IL0 =5$V*O!-2YIF+W\W1' W;9 (]-6?+,&E?($0&X;1BA
M[51GDN<-M*,\;/*X^<3!R4&[Y:^_T*V@L37KMRLJ>9U^227WPI_0J<!R^$,.
MIC>(I^F>Q@%#@8 LJ4,YY&D@]O9(SI<HJNAWRL%A$>I@8O<O3 Q\\L:6/+,L
M9:(UE&9HE8@M&DO09;ZA4,P$;"]Y0*/T3"5.*WA2P=7T2*=3AF\3ZQ7RU:D"
MAA2Q]UX%=(;7"BSWR0J@H]EN(S<TVO+ @=^KAHSOE6/&(H6AH*U!;[@6N\FV
MC/Z+VH2OF1)W+)+OWP6_JH57B7R+5-,;=&NR%#:\BSM.-6X5=O 9</*=2&FD
M L')7?E\)^9L5US&)E2'U? P=A/Q9 O9)]$F!Y21B-?-".K]T)']<95%O6[%
MME4AO^W7>8CA6NPFVZ44P5-3]1,AI,W?!]Q0V:303R@B4^F,!\R.O$JI_0IP
M"^UZ?@UNP[O83;Q%W('8*L+2.=**LDJ=I->KN$-5"O?Z-?4!-A2+!^ZR>@/%
M"TM5]Y%Y@$[7$:>//'JS^B.&^XB;^X:!3O^IJDH9?Z90+=E,0:ILU^QWRZ6&
M36I04SP30V7$364J&<52)-SN2Z1*0,UN%Y>A6:0(Z>$:<(:HB)NHY@E35<.A
M]LEV2<@-2Z"931(5%O4!3"SD0P9^&;I%RJ]%;AB*N!GJN/,0OE07R:KZ#X)D
MSXPZ5M15SFGZW0JS6L2PY]=4!L10$W%3TS!'"*A5WZ=1)RS2[7PA.JS JS2#
M!^62S2+4Q-V:UH08*B)N*KIF*P;NH+""-^\S:V?''> J(0-^XC5.4J6;<M-J
M$6EVZRQM&(FX&6DZOD>ZN?_RL!Q?H\GT*YHO9C\GUW#S_3_OZ/-S_%4":F+<
M+G>$%K%!IX:FB*$ITOO0X<1D^G.\?/_A!#&\0MR\ BU1P%BHRPVH--BAN#[6
M'8XL8"&0,AE:9&JHD!B&(>XNKE#D <GL((+R]EXF-&1;FCRY0%<[NB;V2!FV
M1<KKUG"C9TC+<Y/6?)\$&ZJR[6<.*#PKEY6AVZ2P7U>3>H;-/#>;':,J#ZIW
MN&0.V\)@@WZ9YVQ2N%_H&TYA&Y[SR(<"Z68R'4Y'[PXDKW":Z*:E>59,ZD!:
M\5BWJ]F9B'B,^%H7:U:/]"RT5$[N-IF>7V<<PTF>FY..P9]U>;_^@OK=?FK@
M62BH7<F%[N4^?FS@&9KRW#0U3W@<\!VDK%UA'YP:6;@'^X/R,8%-K%>7WSW#
M49Z;HXRWK/)#C4,M( 6B\%-XZ$R<.C@7>9>]<RTM7$?Z-4SL&1;SW,W6J7^!
MSL&&!4\J\\G\Y1!<KA.ZU1H>"CJKII;SSD'EP-,-YQ/^9VC4<].H.N7?G6C+
M7ED2<!7^*_1"DX3&>2N4JDX.B9U."/H 0HE(^LJ4$VRY5%Z@SB<7RX=__J-/
M<.]?>76^J\\A59J%@KQLG:I0KY;3#!M[;C8^\D*QQC*5U]OY-M>@RKBX>FQD
MD6I"'JJI<GU#S+Z;F+42/X;3/\>*V90Z9YE2XW\_3'X.;\?3^R4:3J_1 BAO
M,1G=@W;J=^O[&@L!=_UR1K=)X7Y=^^T;FO;=-/U^[&?HD:UY'*LS#U6.L(2+
MT*J0Y3AUX%=>0%6ENGVOINSP#7_[[C[U(_HP%21.3:H=J>^URZ6(3:JH[ZDF
MID#PW>\;%^/1#"+A=@+-QVR*9C>?]K-3 (47D6ZVUZ^)=?NF+E2I^0P%?VRO
MD_TJX?NX:BJ+5*_65(;-?3>;+Z"^3WB@$J'":L57Y652J4?>$#I%9[C;=W/W
M^[<-#>_1&![#7D/3.9E=6S6Q''1:G-(B5>^4AJ%]=Y^Y?)C/;\=WH,#P%EU/
MEJ/;V?)A,3YXIZZ<(27>S!9WVFU=AW>^84O?S9;:$_7QD^(YJ-S$EF4,:#60
MJX?,K6,[RZRQC6$VW\UL9939RS8K0@MY]0:5+;1(%6N8TW?TAKLZ[<]LX5+M
MX70V;>I]+#1KX(\V4G;M;,?03\=-/X<.]\T&%V5?0^@O!M3IW>>.]#I5TB&X
M[!P6(:\F<#J&ESIN7IJRE_P(#Y+H_OBZTO+^&_H_26&TUI2]!OI\7+M4N3VT
M:IC!*'[84?S@(->P*M3KE+O#5N';HRU+UOJ3K!1IRV<?\1R?'C_[&NJ/G4K/
MO^/S4?;QEIDF^Y;LCB904:2@V JF;'_K :(D^SPKNY%BI[]P>A12BJV^W# :
MLD0)P.\K 9U!?J,6.'XD=_5_4$L#!!0    ( !F%:%(0R-LN%04  (8+   8
M    >&PO=V]R:W-H965T<R]S:&5E=#<N>&ULG5;;;MPV$'W75Q J4+3 =F]V
MFB"Q%["=I/%#8L-.4Z!%'[CB[(H-12HDY?7FZWN&NEAV&[OHRZY$S0S/G#DS
MY-'.^<^A)(KBMC(V'.=EC/7+V2P4)54R3%U-%E\VSE<RXM5O9Z'V)%5RJLQL
M.9__/*NDMOGJ**U=^M61:Z+1EBZ]"$U52;\_)>-VQ_DB[Q>N]+:,O#!;'=5R
M2]<4?ZTO/=YF0Q2E*[)!.RL\;8[SD\7+TT.V3P:?-.W"Z%EP)FOG/O/+N3K.
MYPR(#!61(TC\W= 9&<.! .-+%S,?MF3'\7,?_6W*';FL9: S9W[3*I;'^8M<
M*-K(QL0KMWM'73[/.%[A3$B_8M?9SG-1-"&ZJG,&@DK;]E_>=CS\%X=EY[!,
MN-N-$LK7,LK5D7<[X=D:T?@AI9J\ 4Y;+LIU]/BJX1=7%U>_G'PX__WDX_G%
MAZ-91$1>GQ6=]VGKO?R&]V(IWCL;RR#>6$7J?H 9H QXECV>T^6C$5]3,14'
MBXE8SI?S1^(=#/D=I'@'W\K/;Z757R5+8"+.G W.:"5;15@E+CT%LK%=<!OQ
M5EMI"RV-N,8B07XQB#].UB%Z".C/1Q =#H@.$Z+#_\GXH][<HR]#+0LZSFN&
M[F\H7WVX^/@F6TS%.+1X)SV09>](FEA.Q+D%L3]$MZ58DH?*8BDT<@O-.FBE
MI=<4)J*6/B)YLQ=N9TF)PE4U^*.0R/)NCV![@<C2;CMR&FLH!(&HL+:1;J/0
M5ND"[(7,>>%XOYT.A![^TFC/V[#Q]]^]6"[GK\[2#OOTMG@EX-!]:/%WZS^*
M4!.717\%%FU3!$4W&"HUPP!R[U13#'4-TE"&>FIKW8WDSA<5)52P8+0RHMP;
M,-%8_:6AE"E%G2RENI'0Q+9+.[$,NPHSTA*I 0#&V&>*M4$Y\.Y=L_TGIQE'
M4%0,RANS.A4?$::C@"D/PEEB'7)XF\ R XOGKX(PF+G:;H6K2\ WE3-NN_]I
MXS E$+,N)89404U$DD:LFP#EA "VL_.J]KK2X>IV"AD@.Z433]&)7>FZ8G/D
M.\.V1#TP:8(3I0R""XCZUR[HED<0\28BU.6]W4,OMZZ4;-(7<I)=-W[#C%UT
M>>CBH7UG,;BD*KPG$Y_8ATU&3L:,])LJOB9,@TS>KQ#3W8HMT<.#9](MB ('
M'5?LD^93*#'^8,_1E[NM=Z4N( 5T@X5:P+.1C<6*Q(Q)+9W1GD296E- /Y%/
MUZ%FTW[WQ'M21=]YG@^91/L-L+LF".6;K2A 4-)60(I<R:XU@'R]%SWA/8O3
M;*RZ$4KN7VW1#/R<,F^IATA47_OQ'!C03- 7NY'F6K9!?D6^Z]J'0+-D(CTE
M -ZFH7,'^][@D$4:'&G5Z )7 CQOO*NPC_:JG5K<3:\;C^Q3RW&% 1FS@;-A
M->])>D%\3@F<,E2MT?S]27-?[TJ'G@K5-?I?SG/VD K@^=28Z#+:H'!@P)-)
M,L%.Z/_LGKJNH]O1$\)--G?RN9+*T/X)G]9HF(^IN'*_T614]D2;=&:#+V"#
M?L<C&ZD$U_B"DB!2";A(,O1#:32OTU2Z$^U(5)ER"&!=%'2+N1V39V@PP]O;
M7!L+E1W(3-N5DH<OV(8@^ C6" 9GUT[;S7 T R,N70\A3<6_G<ZST=T(:MRF
M&V" -AL;VVO2L#I<,D_:N]6=>7M#?2_]5EL>Q!NXSJ?/G^5M"_0OT=7IIK5V
M$?>V](@>5^39 -\WSL7^A3<8KMZKOP%02P,$%     @ &85H4I9/CK0A*@
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M ,]79=G8#[@ _K 1@??R?P%02P,$%     @ &85H4AV\\YNB"P  OAT  !@
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MHV4;ZZ,."Z;7+/BT&(])=,D^L,7X/EB-K]D\6*R^LM4BF"Z#T>IN-EV>=RV
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MRF)0=J\Q?ID(30+87RMEZP]RT/S6N?P34$L#!!0    ( !F%:%(ZPJ%&U@(
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M[3&2$,N\5%QC C*%E!><*B!Q5EG9IP#;KI5@MO)U"^0&U;G)\#RF8X,*6)&
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MF?JMVZX+LAY+M:!%94?!5F@:+':;T21':13H/A5"GP3CH/DWC/X 4$L#!!0
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M@;\>(#R18P8AN$&;8%_$X\4<.RBT4>&C5S,P(@H[/EA#8HF '$0EY$8)/+=
MQ'7G MNYUGWR*WC(8OTQF%3=_UN"/(/^#Z2!0VG(@3WT.+O7GW'$0'M-4YK'
M[.ME13C=CMVZ/:]-7CJZV=7LKK<IZ40Q!F.!7/3>FMV_T\6.M166O*X.^8\"
MV/=1W-HZB: 2%O:\I7"_*G-='4HV3S='NEYUDGDQK\Z#=]C8>*X@97-T=<[:
M80-D=<:J;K0H[+EF)C3*S@Z7>"QETAC@^[G 2=4W)L'FH'OU#U!+ P04
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M5EC#NXQY'VNX*C4Y';"8>^-A6YFKFUCH%*]*F@T0BER)DNKMK=B[;\0>;/>
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M_;.6VI-O$2Z @VG2-*++$LDJX=4-HBUK(E\FZ,O^;#J.J?_P@JHP8T>T/,!
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M$K'98"'P;#_:9L2+KEG4#0V(!- +REJH(UTLR?!HH4;+@NSN2J[8VNC#0K=
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MU6,)$V!$:J<,Y/A))-II:<4'I <*1[4V*A$N&@$[E'DZ<(5#O6%[]X^E3_C
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MI /8WRAEZPD]T'S4.O\?4$L#!!0    ( !F%:%)6>TUXI0,  -X'   9
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;*552V_C-A"^ZU<,U* GPY+E9&UO
M;0-QUD$7Z.ZF=K(]%#W0U-@B0I$*'W'VWW=(R5X'VQA%>Z%(:N:;;YZ<[K5Y
MM!6B@Y=:*CM+*^>:]UEF>84ULWW=H*(_6VUJYNAH=IEM#+(R*M4R*_+\758S
MH=+Y--[=F?E4>R>%PCL#UM<U,]\6*/5^E@[2P\5*["H7+K+YM&$[7*-[:.X,
MG;(C2BEJ5%9H!0:WL_1Z\'YQ&>2CP%>!>WNRA^#)1NO'</A8SM(\$$*)W 4$
M1I]GO$$I Q#1>.HPTZ/)H'BZ/Z#?1M_)EPVS>*/E'Z)TU2P=IU#BEGGI5GK_
M*W;^7 4\KJ6-*^Q;V6*2 O?6Z;I3)@:U4.V7O71Q.%$8YV\H%)U"$7FWAB++
M#\RQ^=3H/9@@36AA$UV-VD1.J)"4M3/T5Y">FZ\?%NOE[P_+S_>P_$KK>IHY
M@@T_,]Y!+%J(X@V(00&?M'*5A:4JL7P-D!&?(ZGB0&I1G$7\@+P/PT$/BKS(
MS^ -CTX.(][P+2?]QN*31^5@^4RKA3^O-]89*HF_SL!?'N$O(_SE_XGA>8C/
M7^Z7R6#2AQ^PX*-*/C'#JQ ,"HFK$&YTW3#U#82U'DL8Y+W)>)+8BAFTH+<@
MR$.NZYJJG@J(/X)O:!LT\04-%Q83DM)-Z L+3D/CR0#5]@]0R2E,CVK354<,
M:(S@)&68V@FU@PVZ/:*""QCT1WE"L!<P[$_>)0W2% B(/6"JI%;F2)U8@J*9
MTQC-$<MHZP**$?1AA90:P1V62<=>!8=V9(?N0"BXQ8WQ-$(H)(.KP/]:E88&
MP*H/"RWEJR#]_-.X&(Q^L7!3"=S"K5!,<<$D?-ENB;[IP3/9P[+E]AJ<XIT4
M1>\JSV$4UZOQ?V%'Z7N$WX@;\_4Y;LL7Y#X,J7_-+<][.=&ZKS YU 2E$2C@
M85P3':8 GYGT+(Y 2CJV]:\Y]\:$K-GOO4%4J?.PWE"^#MU'=(WVNRK2W@H9
M5$KF,&"Y2E@*O?),)BMLM'&19XD.#8TJ,N\JYD#I4R,=@8J1FRV+@]Q>>QFJ
MX\D+@Z%*](Y"&WB+MG@Y5:N6(I@OB4N72$H#7=2M6P9*8;G4UH?Z[?24=G2@
MG4&G>Z##+IBD-\$>Y-O4!6G&>1O*X&I4[?_3C,A.9FZ-9A=?EM!V7KEV_!YO
MCX_7=3NSOXNW+Q_5!S60!8E;4LW[HZL43/N:M >GFSC!-]K1>Q"W%3W :((
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MWT>_FC1OUOR4/7BZ6F5Y1D@$I&4-TOC#!8))LC'?*5D.%K"KZ;+2)6"QHDL
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M L'IZ.RBW"Z :":*FMTBC"QS3%0VP;Q25:^S+64]09'5]0A%_*@_9\CR.FU
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MPT)OWX5!*91C"9*(I#(KC.'5CE=0!J0V#A[$8P06--[I<1)-E+/..8UKOBQ
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M\(;WL;"_%@KX2IT#$^8H$D_CFF=,\IDE+TD540?*CLA*_7M:M!B.(D.1PO5
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M\C .S0 JM?Y93-/N6'<(R^!$^Q19E&Y8E240[@QE'VG,W#"CO88>[%@6(;L
MV'D6&]"N)W40:TE >VJ^ZY+7@5\'VV I$ _WRKA7SI(C_AF2)'6#;'#@5P52
M<9-A;1;^V$4+5#=:D!S@\2%:NP^AA)<5D!^V9 ;73_'??G?&SX<PV G@&X10
MS@W;W+X593;<BG+E(8%CO<9QYJ_)8A@PNK^A(<5OH_JVX4_(5%$VE&(]Q:V+
MWO:$3A-WK:&-$TT%C2*A04"@8[<F8N*C1050=,PCM'XHVFBZQLAA\\>+E#YA
M58C!&$RB<[/F<S.FL23QX'D;R*$BOK7AUT=(NW)M:\!)LJ?"M5E=NHC0$ PH
MQGWXM?#:1XF5&MBFG6I&/^]01C9+8'A 3-M=0_X(?'._HZ(=65[[J^#F:=OS
M[KDEJ)8%4/RXE /<&\/0&S=1<I;S$/'62,%G;NU4PV#0CJ\"OK/34+(A]DT-
MG3+7WM*+,#K*20(WY01'QOKF;5 &^&X"FB/M@MI2"=ZORTG?\.E UMQ49;M5
MX/C5M;1VUT1S(V",$562N</[$P=HL!<2*'+O(-EM<7KBPC5P=9&E(F0EV-QL
M0Q[#PL\WD<V&F\C> ^/CR)"F:G$Z#""Z5]Y]0^<8KJRBE:D6L;W!_LO#M1B^
M[##1!-R%GPLL^7A;XX!?^R(\Q.I;K,+7'[[$KRNB3^V#BG4PIYH*)FS]WH;1
M?2$%$^O?6_26GW!",RH()-CV?^?AF9OFUD@(!",1&0=1P7^BP!&/:I0[/["8
M8 #G!5.8>&F)G+"$[T;BJ#R:!:%-T(EJX%?XB@O[9B)ZDY#JE.N&XY>=]P;;
M$?)"6Y_B'OS;G9T+O^MDDLBN8/Z_JC[#6HF^ $<+&*?(4O9M,..9V;'<4ID9
M3/RB="O/*2?%+(Z<6X3?[B7MZK#&>PL1L=OG[LH\(J1NV;=PS=7*'81:'Y"S
M<B-C++A*G-T?00)+U&6V)'7%46YB9KX9NBRLG*3=?5#1JD L146H+'HQZ6_Y
MX:D=[GNP@+-RK&38Y*/M[%J)+=F,]\7G]F^ 7XOB#L^\(U>9VDI+NHS,O<7%
M#6I@,N&P3CQ'R@;'/!U0.)?@C <5NGJVM^96_QV=_)V\JB58OT.@0?%Z\#:"
M/9:,)(XO@0K0&C)=+*!BA+N9(\@[/!HZ4,%NL$JGY!?;WZ8JB!,*4[*UTM"N
M2=!NU&76CJV7A(:>&WZ5Q+$N.X]N+Q<GE6NG$WJ326%&%,G8F[A$0_FICY;G
M=MG^!$X\]8[F<%(KEO#W+0V)8GCK5-[D()3'?!00@F3.A."JG86Y(#<[(L2@
M_<2V2GC110XDO]#E<YFW&TS(1J^$ I5?4WCHAL=@8>LSHH,Q"18\7%M6?_@"
MX$H'2WS](%UI7)G53/PR.M^GX39C/)$BH%X<[,&P,5[N.QW2[KY'>#;<(_P*
M+:7?R5(*FCO[79IO:/[%Y=7^\OJ5C_ELPL^YP, '8,)*US#'(YE#"M*1ZL2L
M(_7>^QG9!:6\.58C=A5VWENS:JSHG6;QA(5U!F0.2G8GXU*V;5.[84<,*:4&
M I^;(8$+MN%YVITGT@$29((%+80D @?C1U7P:%OL/TRU!7:ZC?.2-M37M?^P
MC&3B /3G%#QZ=)#(E W'6'C E3_J%E]$D#5=^#NG]Y$U#D79]#&U<T2!8:X(
MX8'LM8\2O\:_U?29/M]B@*0.1%]P+[8ARODF%3<._J,MJ1ZJXKF,;6&+_A_Q
M55%HCCJ=>I?,"B5-2.Y-/.?1FC:6$#[D9P(XU(-,S+@0%[^0^'9 #G3%,C^$
M,(>5%$SA07C-N\K^KCIXFGTCGJ*W19!XWJ<6R1/C&!3:3$\%KQQ0P/:I&-VX
MD8T3]8+RO/,#Y!9IS',3>VDT,:'WN0]K"D3V(14 2YG6 A&)T_#+>>E<Z. A
MN2BPQ=,N!H^^ P;[&#.<0QI%'[G",JS$CV16.L=VRG^%),,7U("73F4PB3V]
M!?=69O7G%&TI\<@&;!6V36SF-:P\#>(8EO>C8/M^N$-2@?J\4?<LK/>1F/W"
M66J;E[91M*_(W]AK0NVOQ53T8RSEBYQR2^7I7A"C+[4@I.QD@*7H6("X:6UU
MNJ'PM8Q[^?\U5."WGC'Y\<@5&0/A4G\+.W>'_A%,P4FZK_Y(>D!+^GKH$^4^
M#"=,PH=5:X)IG^X3> J'1$<^0S2WRHU<<@.&$6!; &4'K"0\UE*%F_;5FMLA
ME\$6![-&G'_O16%"D;(M=VU$ S755^R<A!9C%-Y?MFZ2MA]$M#=HR)#$<$#U
MDT#W)2ZN 0&-ZBJ3T%VP2_3:C(HQDTDUAZM314? ^L#A(0+--]8O_)@!?*DP
MY7CII#)U#:,55BEVG,*^$FT7(=F?8.H0K@81'H(JU96>A\)"RV&3V\_.F W/
MSJ#6T!&C 0\&M'_PW>O#2QUX189?7X7KXXNA5?C24U=DB:%M^W+3))@9(J6H
M]BW;88SGIDK#J?2 :_L"'[B=M"LM^!ETKFIE8VX?KC_:69"/A-'CYQ-73Q3'
MK^_NU^#CM=O2S@MPD7,576>8\79M,B]R\'!'UXLU=MZ/WH"GC>IH*R6SK(8W
MY=*P='I3@D[4%VF5EV@AB9,I#P0I R?R?:8[O(KT%F<E.GM]OP0OUE.=MQS3
M94@R?1\?KO1MA8)I9:BPNU99F%#HC"*C!>52/J,TH,!R83"G1G'7S);\4=6E
M;, 5>O77OP%WYH=KS(:':[R@V5P(V,LL;Q'RMZ:QPR,?O@;?_!%ZY7BKV%]U
MC:TUO7SU#5,X:&_U=7MK_A%6@\A4O8>Y>S!L K.RMQ43=YF!?\$#'L*?==^J
M$,Z/DC=#.+M$JE/F._(T;PV6;N%5RSPS_UK'3L-Q\**/Z%VTN-K8G7W_.'OG
M4.$Y*#/^U\^B[W46*:*G];P%(R?T6=-(='$!EY->=Z#!$\-2$-)_Q_N7Z^OI
M!H[AF[^C"6'[0*D0J(OPV7!^X4._*8X;!<M[9U>L;&R4QN+2^ZN,G2H@AOTC
MYNB.H&_)(C#XMK\^.:\/RGF+8S@_H.8D.9Y.D[/9&2'S.#D]1JOVK/]=<OV#
M>[AG@H?V^BF6;"IP0X\=0GZ/JXHIKO:).\S7<%$RU1>PR,.63?#Z1K0RCJ/A
MGTOYJ;N8JR*&:^[$V'U "D]!.$.4LLK@ (/3V%Q-AMD@OAN>#$6L9T>OTZ;R
MDF27 &%JX^";&-;8&)JSEI'5$>?@&HN6VJ-5*OS+T3!3O+F .72/Y,B VY(<
M/SFB2SR:X9L$CWK=F""^Q*^F6J/OR18!\I:[9L;N$$:[?!6^5;$^U$*H'-0/
MX1HGDXFUIIW=SXM3^83;2GJT'SW3UQ>_7K[\^/I2O7NE7YQ?7UWHR_,/;Z_>
M_G*MWU]^T!?OWKQY]U9?_WK^X5(1EG O]:KD;.!_8;#\<@^RX,FW8/!76,:I
M;#LRHD#.;F?H=F3NKRG:X/I7>JNS)$]_T ^/DJ.3I_H1=C,^.06?'HLK"US:
M=3IW99?:EUU>5B5R)>"CGIZ=P-HS_.?1["B9 J>#%E4QE Y[]H< TF0\/2*(
M)N/)5%NLV!3"?@)AOT"+^*R'W_Q=[8OFT4$-8WG&\C"]?_6 QNE7)FFSIU0/
M+K#_VL]NI 7(4FH^C6M$\!SSURGVY=7KC[]=OK1D>OF?'Z]^/W]]^?8WIMCK
M'D)U("H+HK('E6/Y#-,S]8=5"\>GH '.3A7Y,<IJYR<GQ\GQ\917\,A6^[B:
M)M/C67)V=/9U4N-[48;NH0QU+\JXS[M=O^--'I8^N/C1V7.]?W\]EWSXX7Z!
M)+AET?+'W290KQBQLN,P-01TT"? ]N55:QL1+"&XH&B@B0.2F3T!K?4DF0"E
MOHU(1HGHLNN(R!KP?X[\P+&CX8%C.!.30B3G2V ,+ WT,QS>5V51X@O!#V;P
MAA<_]'HBWE'=N2.-=FH+0_-F6?SBVP&DGT6?7W_D2;33HT.3:&5P]&L:2_"L
M,VU61]_2:]G[%ND,F'IZ$)"GH\EQ$O0VU:.HM>H=I2>B>J33@VN=TJ$NI-@1
M].I+W[#_(7Q#,-+7@93K(('XL2E'=[VM2@CD2@#\*OKXIM=7"7W<M2'BTHDS
MKZ%[L'DVFL[B-T+H:RJJYLI[_-5Y/+HD>G8(CWX<PM'P. 0XEF00%H?[SH?7
M.(BO>&%]P84SBM*PUM/E%T&$0WY\@UAE@NP&.<XT/,)-3NZL;].0_.X,,Q!#
M"U]9>9\WF)-=3EV:W3W1!2E*WWUI7X7=WVT3%33V=6/:-M"H%3/I]&)2&;3Y
MG)5MG>]<R6A_X.DQE4N^3)OTYQ]!2=V8"Y/GU#I:P%4BM[E/,=6'4U^?G<\>
M/(9?^L=__G$+*NL-U8+@6U-7\-/)^.G) W[MC/VC*;>X)([5;<H-_1-;/DR%
M#\#WJ[)L[!^X ;XIFL#[^7\!4$L#!!0    ( !F%:%)M\1.AF00  ,,,   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;*U76V_B.!1^SZ\XRJY6K92%
M)%P*+46B0*=(A;)0IAJM]L$$0Z(F,6,[I?WW<^Q<H,-E.MJ^$#LYYSNW[QR;
MUH;Q9^%3*N$U"F-Q;?I2KB_+9>'Y-"*BQ-8TQB]+QB,B<<M79;'FE"RT4A26
M7=NNER,2Q&:[I=^->;O%$AD&,1US$$D4$?YV0T.VN38=,W\Q"5:^5"_*[=::
MK.B4RMEZS'%7+E 6041C$; 8.%U>FQWG\J:NY+7 UX!NQ,X:5"1SQI[59K"X
M-FWE$ VI)Q4"P<<+[=(P5$#HQO<,TRQ,*L7==8Y^JV/'6.9$T"X+GX*%]*_-
MA@D+NB1)*"=L<T>S>&H*SV.AT+^P265KK@E>(B2+,F7T( KB]$E>LSSL*#3L
M(PININ!JOU-#VLL>D:3=XFP#7$DCFEKH4+4V.A?$JBA3R?%K@'JR/9T-AYW)
M-WBXA>G@RVAP.^AV1H_0Z78?9J/'P>@+C!_N!]U!?PIGCV0>4G'>*DLTK-3+
M7F;D)C7B'C'BN#!DL?0%].,%7;P'**/'A=MN[O:->Q*Q1[T25!P+7-NU3^!5
MBC14-%[E"%['\U@2RR!>P9B%@1=0 ?]VYD)RI,U_)PQ4"P-5;:!Z+,_=NWYO
M=M]7B;[I3 ==Z'<F(\SO%,;]"70?AL.'$4SO.I/^H?R>!%>->RG6Q*/7)G:F
MH/R%FNU'GQI+%F+7J:BDJAT(GVT$2)^"QZ)U(HGN#+94Q X\B'$(!#%^HG 6
M,B'.84VQ@7W"J1+"#Q&*(R>]9\!YH('>*.$"J*HK8%5H-$>5O#(&B1>X<)IP
M%L1@V_9??S1<Y^)*6$!?/;J6&;@2VYHBD:J%.+^$/&O&K[-F*'O:EH'M:BC7
MOJ%K*>/>>;8C.4HBRHE$>>V8<Z53D,6>98)(R8-YDB90,K@C7-7^CI)0^A8,
M8F3BGW!6L2JU"SC'I5-O&#T:,^Q6!0TY]$9/"'2&O*#1%37B1+N$F=5Q"\"A
M*23F @MF925Q:U:C64-L5RTK;L5R:N@WE<9[+XOLY8KHDEUR*MHCNV0[<(+$
MM8+$M0^3N#>XGSWV>WD-^O_,!E\[]WV<';H<TT,L/HE^F,5Y+17-%,M^YIC3
MM#0-N\AG$K]EO,8D+X)0/W<XO658(G1/H%Y>E+^SHL"V*"G=C:PVBJ(:$P^1
MO!/H]R1X(2&-Y8$*PB+AJ14BE>F +4K0R[PZ"K#;5FE7&7L1HS8>BD+AH)M*
M>MOG_[_/?E78 ^U5N&CD+AIYH%E8G(9$;26[-)ZP@0C:A6JC856;#6.J!HK!
MUFH8":C7JE:UZJ0(VV0;^[ER+*?J6LU*\Q2WZP6WZ[_-[=\:T2?A/V%$?Q:A
MX0"AC0\1>I^;^]WXB00\/NH5>*5Y!?NT.\#-X\*'IW^6VW2./_TTL^&#,SL?
MU,=)O$/?0Z?%_N&0"'1#E2 G H88HU6QD]!=RKAUJUJO6S8VV.@=98SLG,AQ
M3IP/Y9V+)>9JI:_/ O1=*;UC%F^+&WHGO9ANQ=/K_9#P58#M'=(EJMJE"SP,
M>'IE3C>2K?4U=<XD7GKUTL=_&90K ?R^9$SF&V6@^-_2_@%02P,$%     @
M&85H4@^<7=*Z @  IP4  !D   !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M?53;;MLP#'WW5Q#&'C8@K6/GVB )D(M[ =HM2-H.P[ 'Q:8OJ&UEDMRT?S]*
M=KP,:_)B4Q)Y> XE<KSGXD4FB K>\JR0$SM1:C=R'!DDF#-YR7=8T$G$1<X4
M+47LR)U %IJ@/'.\=KOOY"PM[.G8[*W$=,Q+E:4%K@3(,L^9>)]CQO<3V[4/
M&^LT3I3><*;C'8MQ@^IIMQ*T<AJ4,,VQD"DO0& TL6?N:-[5_L;A.<6]/+)!
M*]ER_J(7=^'$;FM"F&&@- *CWRLN,,LT$-'X76/:34H=>&P?T*^-=M*R91(7
M//N>ABJ9V$,;0HQ8F:DUW]]BK:>G\0*>2?.%?>7;'=@0E%+QO XF!GE:5'_V
M5M?A*&#8/A'@U0&>X5TE,BR73+'I6/ ]".U-:-HP4DTTD4L+?2D;)>@TI3@U
M7?O/_M<G?P.?']DV0_EE["B"U8=.4$/,*PCO!(3KP0,O5"+!+T(,_P5PB$]#
MRCN0FGMG$9<87$+';8'7]MIG\#J-R([!ZYP2B:]8E B1X#DLB*N@QT"%5@DL
M3(E1P,_95IK]7V<2=IN$79.P>R+A9G'K+Y_N??AV#<N[S>SF9NW?S![])=3U
M_JC*9R%U<X[DC@4XL:G[)(I7M _"K#"5+(X%QDQA"-MW:I=*L>2E"$@X%Z 2
MA'=D0@+J:P(J,N9;4GXH-+ B),.]:D' J>NDDL C$Q?QC+HW+>(1'*19IZ19
M!DOC6-0WE@[_8=+Z_Z4]<ET)'I:!LB2C1]B"@L;1)^@.6]W!%1D]M^5V!M:"
MYWDJ]3R0T.GUX<*Z3P,:$ B=/GA#ZY$KEEFU=ED!# =N#=#OP4=7ZQPU#SV$
MV(P(224H"U7U4;/;3*%9U7Q_W:L1]L!$G!*W#",*;5\.>C:(:BQ4"\5WIA6W
M7-&K,V9"DQ2%=J#SB'-U6.@$S6R>_@%02P,$%     @ &85H4K-,0 6* P
MY <  !D   !X;"]W;W)K<VAE971S+W-H965T,CDN>&ULI55M;^)&$/[N7S'R
MG:J+1&-L() 4D!SP79# 0=BYZE3UP]H>L!7;R^VNPUU_?6=MPR5M0JOV WA?
MYN69>69FQP<N'F6*J.!;D9=R8J9*[6\L2\8I%DQ>\CV6=+/EHF"*MF)GR;U
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M[5X.J4A$\Z8T&\7W]1R/N*)7H5ZF] RCT )TO^5<'3?:P>EAG_X)4$L#!!0
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M-'Q*M;-!XTD"-UDUZ\NZON^;K_,@-,L,]TN)1UUUG@6U>IT ^JVN'SBWJ-0
MIGLID6NG$-(.I,M.ZX92KN"RU^KYM' 6@K^+JRQ=<[WT>6'%E+^O/9G>T2C(
M46[MP%-@%9=3H8DV,S4J1\ES>CF0/S.Y3;F"##=4ZE_WNB[(<LB5&RT*.UC6
M0M.8LLL=O1=0F@2ZOQ'4P&IC")HWS?@?4$L#!!0    ( !F%:%)9&\>L^0(
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M:(\GVJ*#P7R%LCT<!]:E-B'1LTCS,H>"/5&Z: 4EW84$O46X$'G!^-/'#_W
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M6:GB9BT&1N[SVVPM#=V-N;FCGQ%4=@'Y8RG-<6 35+\WPU]02P,$%     @
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M5RIJZ/#'UO!>,2WW5"T,2C#198[B&"ZL,GIP,7N:*78P<V_G,\_1SW R;-X
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M6VPE!Z0K45,]V-/QGHFK->6UY/<C@JXYO9RKQF06)+ #@'C,^CF='AB*]$X
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ME;:=I@,)+DF1J2G?C'"K)S)X,<^D_<)FZ^LY$!=2\7P;K!GDE)5_\KJMPUZ
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ML>RLW%A/G; TQJ&_&X'U=KX'T&_)L:Y)LJX]RY8.K1X"''M?/ 6Z1C.(0#0
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M>#2_'Z-?UVAT-^O?W$S'-_VG\0A-Q\_CQ_D8G8U 8)+P<_03S6<C=/;C'/U
M)$-/,<TYSD+>-86,1/&90>EU4'AU3GBU'?1 ,Q%S-,Y""-\3F#*%*@]GF\?
MJ64<07")7/L".99C?1#0\--PNU,3CEO)ZFH^]Q0?X3B*&$18_ZQTB::PABP'
M]'(O3=&=@)3_J7'4J!PUM*/&"4=/5.!$GB=-_N%.%/BFQJM#O?8;[7;+[IKK
M?7F.K9JV[34KJW?!-:O@FK7!31@-\T"@&4Z 7Z!'695>'B!= *M+W:O8O>_5
MN%4Y:GU1XP+OO=.XT>H<:'QL)35V6Q]KW*Z":]<&-Z1I2KBJJOPSXG8JVL[W
MBFM;NPID?5'>DF!?.;?I':A;[T6UPRN^P@'T#-GO.+ U&#ZJ2V"OA-JU"=R3
M0/8U^(S\MK,C=;YY W:URG:_N@'N47EPC_0_MG':!_^VN=>H4F"1[M\<!33/
M1%'KJ]7JCM#7G?%@?:#N#KH![FB*B\<#9A&19R&!I:2T+ELR(%;T\F(BZ$JW
MPP45LKGJ82SO/\"4@?R^I%1L)\I!=:/R_P-02P,$%     @ &85H4FXMP"42
M @  A@0  !D   !X;"]W;W)K<VAE971S+W-H965T-#8N>&ULC511;]HP$/XK
MIZ@/K<1P"(5N58C40J=-ZBH$HWN8]F"2"['JV)GMD/;?SW9"Q#28^D)\Y_N^
M[[[CDKB1ZD47B 9>2R[T+"B,J6X)T6F!)=5#6:&P-[E4)34V5#NB*X4T\Z"2
MDR@,IZ2D3 1)['-+E<2R-IP)7"K0=5E2]7:/7#:S8!0<$BNV*XQ+D"2NZ [7
M:#;54MF(]"P9*U%H)@4HS&?!W>AV/G;UON"98:./SN"<;*5\<<'7;!:$KB'D
MF!K'0.UCCW/DW!'9-GYWG$$OZ8#'YP/[9^_=>ME2C7/)?[#,%+/@8P 9YK3F
M9B6;+]CYF3B^5'+M?Z%I:R?7 :2U-K+LP+:#DHGV25^[.1P!1N< 40>(W@L8
M=P _.=)VYFTMJ*%)K&0#RE5;-G?PL_%HZX8)]R^NC;*WS.),LGIX?GC:/*SA
M<H&&,J[AB2I%W6ROX -LU@NXO+B""V "OA>RUE1D.B;&2CL"DG8R]ZU,=$9F
M@>D0QJ,!1&$4GH#/WPT???H;3JSAWG74NXX\W_B<:]RCJ!%R)4N82V&472<[
M>5/ W,\<%?R\VVJ?__4?P7$O./:"UV<$3VL,X)'1+>/,O UL4BD4YM1L6^Z)
MYW:OY3Z93F.R/Y[?OR63F[ZD;9D<;8E[0[]1M6-" \?<@L+AC46K=NO;P,C*
M+\Y6&MNN/Q;V0X'*%=C[7$IS"-PN]I^>Y ]02P,$%     @ &85H4IIX/K$1
M P  ,@D  !D   !X;"]W;W)K<VAE971S+W-H965T-#<N>&ULM59-3^,P$/TK
MHV@/( %IDJ8?J*T$;1!(M" *NP>T!Y-.&XO$[MIN"_]^;2>$%-)JM>Q>$MN9
M]^:-,YYQ;\/%LTP0%;QD*9-])U%J>>JZ,DXP(_*$+Y'I+W,N,J+T5"Q<N11(
M9A:4I:[?:+3<C%#F#'IV[58,>GRE4LKP5H!<91D1K^>8\DW?\9RWA3NZ2)19
M< >])5G@%-7#\E;HF5NRS&B&3%+.0."\[YQYIT// JS%=XH;61F#">6)\V<S
MN9KUG891A"G&RE 0_5KC$-/4,&D=OPI2I_1I@-7Q&_N%#5X'\T0D#GGZ@\Y4
MTG<Z#LQP3E:INN.;2RP""@U?S%-IG[#);=M-!^*55#PKP%I!1EG^)B_%1E0
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MHMMO$+F!?C_G7+U.\@:O;N@'?P%02P,$%     @ &85H4B)9XHA- P  X@D
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MAJEZA"'7!FI_QYA\FF@'[;-N]B]02P,$%     @ &85H4H*>8EL0 P  ,@D
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MQIVQ^R:+*N5;S</FP["-MA^EF]?IMM!MS!T?=O>C7*K,L54\#'==JB$JQ&V
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MKAW4^8HQ^6'HR=']423_ 5!+ P04    "  9A6A2.[ PV*X"  "W!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6R5E5UOFS 4AO_*$=I%*W7E*] /
M)9%2H&JEK8U"LDV:=N' 2; *F-E.T^W7SP:*TH9$W4VPS7E?/^?8.0RWC#^)
M#%'"2Y&78F1D4E;7IBF2# LBSEF%I7JS8KP@4DWYVA051Y+6HB(W'<ORS8+0
MTA@/Z[4I'P_91N:TQ"D'L2D*PO_<8,ZV(\,V7A=F=)U)O6".AQ598XQR44VY
MFIF=2TH++ 5E)7!<C8R)?1WX.KX.^$9Q*W;&H#-9,O:D)_?IR+ T$.:82.U
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MH>2\:9/-1+*J[C1+)E7?JH>9^K(@UP'J_8HQ^3K1S:O[5HW_ 5!+ P04
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M\)F(,X'T]WD4R;>';(#-K?'A_U!+ P04    "  9A6A27)$=&VP#  #F#
M&0   'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6R]5UUOXC@4_2M6- \STDX3
M)T"A B2^NH/44D3H[FI7^V"2"[$FL5G;E)GY]6L[:4(I1!UIR@O$SKWGGGM,
M#C?=/1=?90*@T+<L9;+G)$IM;UQ71@ED1%[Q+3!]9\U%1I1>BHTKMP)(;).R
MU/4]K^5FA#*GW[5[<]'O\IU**8.Y0'*7941\'T+*]ST'.\\;"[I)E-EP^]TM
MV4 (ZG$[%WKEEB@QS8!)RAD2L.XY WPSPAV38"/^H+"7!]?(M++B_*M93..>
MXQE&D$*D# 317T\P@C0U2)K'?P6H4]8TB8?7S^BWMGG=S(I(&/'T3QJKI.>T
M'13#FNQ2M>#[+U TU#1X$4^E_43[(M9S4+23BF=%LF:0499_DV^%$ <)N'4F
MP2\2_..$QIF$H$@(;*,Y,]O6F"C2[PJ^1\)$:S1S8;6QV;H;RLPQADKHNU3G
MJ7XX^C(9/]Y-T,,M&MP_+);3OP?+Z<,,3?Z:3V;A)$2W#PLTG2T'L]^G0QTW
M",/),D0?QZ (3>4G]!D]AF/T\<,G] %1AI8)WTG"8MEUE>9GJKA1P668<_'/
M<,$^NN=,)1)-6 SQ2P!7-U9VYS]W-_1K$<<07:$ _X9\S_=.$!J].1UW:N@$
MI=B!Q0O.X-U21A5\OM,_W!A-F2)L0U<IH(&4H"3ZYT['HZF"3/Y;4ZU15FO8
M:HTSU089%XK^(/9QX6M].&5!8@N>.J$<LFDAC04\]7'KNNL^'8KV.L;W.F7,
M"Z[-DFNSENN<*&!&@GO(5B#JVF^5D*T+B'U=5KO^]6+GD*T#(0/_2.O7(8WV
M::G;)=-V+=,[&FD7AC=IW2DQ.Q?0&GN5:7F_7NT"\U!+?*3VB9#F:;7Q@<'B
M6JXC:^(@T )22U@F=/LF];%?U? OH7_E8SAX!_V#U_H'C>,3.!'4Q&?.H')"
M7&^%2T%B0#.2O>UGCRO;PLU+"%]Y&FZ]@_"UF&90O)%;$D'/T9.@!/$$3A^=
M^K<L@$X_02\[JGP3UQMGJ+3UHWE"]$P6?4<_XTZXLCS<OL0Q57:(.^]P3+68
M/W-,G5=_T(VC8W(/)D;M31L[2$L4\1U3^7A5[I;#^L".J$?[0S/$VTFT@LG?
M .Z)V% F40IK#>E=76L^(A^J\X7B6SN7KKC2!FDO$_TB L($Z/MKSM7SPA0H
M7VWZ_P-02P,$%     @ &85H4N,S%.M[ @  A@8  !D   !X;"]W;W)K<VAE
M971S+W-H965T-C N>&ULC95=;YLP%(;_BH5ZT4I3^4C(1T60TD+72&L;)62;
M-NW"@9-@U>#,=D+W[V>;%&4+:7H#/K;?]SD'S"&H&'\1.8!$KP4MQ<C*I=S<
MV+9(<RBPN&8;*-7*BO$"2Q7RM2TV''!F1 6U/<?IV04FI14&9F[*PX!M)24E
M3#D2VZ+ _,\M4%:-+-=ZFYB1=2[UA!T&&[R&.<C%9LI59#<N&2F@%(25B,-J
M9(W=F]NAWF\V?"50B8,QTI4L&7O1P20;68Y.""BD4CM@==O!'5"JC50:O_>>
M5H/4PL/QF_N]J5W5LL0"[AC]1C*9CZR!A3)8X2V5,U8]P+X>7_NEC IS156]
MM^];*-T*R8J]6&50D+*^X]?]<S@0>.X)@;<7>";O&F2RC+#$8<!9A;C>K=ST
MP)1JU"HY4NJ7,I=<K1*ED^'\[B&.%E]B]'R/XGDR>1PG<83N%\EB%J/QX_,L
MF?P8)Y/G)Q1_G\9/\QA=1B QH>(*72!2HB1G6X'+3 2V5/EH5SO=LV]KMG>"
M'4%ZC3KN)^0YGK.81^CRXNI?%UM5TY3D-25YQK9SPO8S8UE%*$4J*S0I)2[7
M9$D!C84 *5!$1$J9V') /\=+(;DZ&+_>P78:;,=@NR>PJ@BW[1G4*M^H]">R
M"]U!/[!W+:AN@^J>0WEMJ%K5^PC*;U#^.52G#>5_'-5K4+USJ&X;JG>,ZCGM
MJ'Z#ZI]#^6VH_C&J>Z*J08,:O(M*<E#-<B6!MP$'1\"^Z[<#APUP^"[PX,1C
M<^+;N,/C0^D/.O^![8.VHCOT(^9K4@I$8:5DSK7N:;SN>G4@V<9TFB63JF^9
M8:Y^%,#U!K6^8DR^!;IY-;^>\"]02P,$%     @ &85H4HHW*)]T @  C04
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M'HY2U(0R=0P?@'+X4HI:$9ZKV-<FI07Z64<_;>G#/?1!" ^"ZU+!-<\Q_Y/
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MD5KVO^7 R,*UD(DT5*W<:TK?#*CL!EJ?2FE6 QN@^@II_P-02P,$%     @
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M<>U(.2MZ7S$1-,W;QXH*V8SR82 _%Y I _E\0^7Q+2>J(U4?(*/_4$L#!!0
M   ( !F%:%)?T@$"^0(  &\(   9    >&PO=V]R:W-H965T<R]S:&5E=#8T
M+GAM;(V676^;,!2&_XJ%>M%*70$G0%(ED=*FU2HM792/3=6T"P><Q"K8S#9)
MNU^_8Z T'23-36(#YWW><VR.Z>V$?%8;2C5Z26*N^M9&Z_3:ME6XH0E15R*E
M'.ZLA$R(AJE<VRJ5E$1Y4!+;V'%\.R&,6X->?FTB!SV1Z9AQ.I%(94E"Y.L-
MC<6N;[G6VX4I6V^TN6 />BE9TQG5BW0B8697*A%+*%=,<"3IJF\-W>L;%YN
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MUE'K R3&2:[A!.Z3>RK1G%0:H_"%\H\2QK<@=*N(8<E!B"YA0#&/;LY48BX
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M;0'7NQ6;'N2YR=$J&IKHOW$JN5JE"B=[T\%=,)R/ O!T"V[GL_DD *.@/PW
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M5J4!:I'>A6E'\2BY3E9<P>64-+?P_4"$G@#C/N?JT-$W5/Y%TOT+4$L#!!0
M   ( !F%:%(NI\ ?K 4  "\:   9    >&PO=V]R:W-H965T<R]S:&5E=#8X
M+GAM;+5977/:.!1]WU^A8;L[R4P:+ D,9$EF2$B[V2%M)K3;A\X^*/@"GMH6
ME02$G?WQ*W]@\6'+D$SZT&!;.CKWZMYSK^SNDHL?<@J@T',81/*R-E5J=E&O
MR]$40B;/^0PB_63,1<B4OA23NIP)8%XR*0SJQ''<>LC\J';53>X]B*LNGZO
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M$0_0S^.N97T1+Y!_([KZ'U!+ P04    "  9A6A2 FE]%)$$  #1$0  &0
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M3\OVSHOVD*8]B,!MFO!E!JZ2&9WM"MC"?-4#M.W!.3(J7M*I!3 \ <A!SD_
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M*U5:(]<&:G[!F'SIZ 7R8KWS%U!+ P04    "  9A6A2ZV%Y\6T#  "Y"P
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M>&PT)4],/$W+R??RAS069;P9;"V:.-YQ-[%*U\SWC8;;-384IHG1+?.]S7(
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MFZ;BP].6(YU(MC%5>\FDZ@',,%1M&G!MH+ZO&)/O$QT@;_SZOP%02P,$%
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M/I].T'+T)QHM%M/E HWN)NAV-KJ>W<Z6L^D"G4V8ICQ6Y^@"/2XFZ.S#.?J
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M0L/!)+M<P]F126, [U="Z/<;<SHI3J/#_P!02P,$%     @ &85H4K_DJ;N
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M$&70."5'JFIXU<3(PO6,N334@=PPI6\$*AM ^PLIS79B!>JO3O\/4$L#!!0
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M-^0W/%W)U]@?4\[36%XN"8:%F!@ O\]3F(W%C1!0?F)R]7]02P,$%     @
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MOK*6-7D[!4U3ILB"2DG-R;_KNQK]&Q8WJGR-2U_!&5]^0.:"ZT21&QY#_)+
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( !F%:%*ACT*[M 4  " 8   8
M          " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    "  9A6A2UT<3 $H'  !*'@  &               @('X#0  >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ &85H4LUS>).: @  . <
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M965T-RYX;6Q02P$"% ,4    "  9A6A2ED^.M"$J  "RA   &
M    @('%,P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
M&85H4AV\\YNB"P  OAT  !@              ("!'%X  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( !F%:%+4GZSH@08  !,/   9
M          " @?1I  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#
M%     @ &85H4C_:VEFO!0  ]PP  !D              ("!K'   'AL+W=O
M<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  9A6A2.L*A1M8"  !
M!@  &0              @(&2=@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM
M;%!+ 0(4 Q0    ( !F%:%+6D;FM^ (  #L&   9              " @9]Y
M  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ &85H4OQ3
MD<7  @  )P8  !D              ("!SGP  'AL+W=O<FMS:&5E=',O<VAE
M970Q-"YX;6Q02P$"% ,4    "  9A6A2,)7JQ+L#  !;"   &0
M    @('%?P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M !F%:%)V)>!GV@4  /0.   9              " @;>#  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ &85H4F5Y]V7R @  CP8  !D
M             ("!R(D  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    "  9A6A2NQ>F6.</  !T*P  &0              @('QC   >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( !F%:%)K N(5S08
M  L2   9              " @0^=  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ &85H4I@T \SS$   $"\  !D              ("!
M$Z0  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  9A6A2
M^.:T8P4+   6&@  &0              @($]M0  >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( !F%:%)<IN-WHP(  '8%   9
M      " @7G   !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ &85H4I1'$Z#6%0  .40  !D              ("!4\,  'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  9A6A2^D*?SM('  #@$@
M&0              @(%@V0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( !F%:%)6>TUXI0,  -X'   9              " @6GA  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ &85H4DILG09T
M+   #9<  !D              ("!1>4  'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    "  9A6A2;?$3H9D$  ###   &0
M@('P$0$ >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( !F%
M:%(/G%W2N@(  *<%   9              " @< 6 0!X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ &85H4K-,0 6* P  Y <  !D
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M=#,S+GAM;%!+ 0(4 Q0    ( !F%:%+"+^AGT 4   80   9
M  " @;0J 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
M&85H4I)5VESQ @  =08  !D              ("!NS ! 'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    "  9A6A261O'K/D"   P!@  &0
M            @('C,P$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    ( !F%:%+_G%3[?P,  .H(   9              " @1,W 0!X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ &85H4JQLR;C-"
M!!D  !D              ("!R3H! 'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    "  9A6A2^)E_6>D%  "##0  &0              @('-
M0P$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( !F%:%*L
M<)AJ^ ,  'H)   9              " @>U) 0!X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ &85H4F8-A1?U @  ]P8  !D
M     ("!'$X! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !F%:%)N+< E$@(  (8$   9              "
M@?!D 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ &85H
M4IIX/K$1 P  ,@D  !D              ("!.6<! 'AL+W=O<FMS:&5E=',O
M<VAE970T-RYX;6Q02P$"% ,4    "  9A6A2 ^&/B%8#  #<"P  &0
M        @(&!:@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0
M   ( !F%:%(B6>*(30,  .()   9              " @0YN 0!X;"]W;W)K
M<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ &85H4H*>8EL0 P  ,@D
M !D              ("!DG$! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q0
M2P$"% ,4    "  9A6A2+5>E\U(#  "V"P  &0              @('9= $
M>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( !F%:%*)EC_K
MV (  +T&   9              " @6)X 0!X;"]W;W)K<VAE971S+W-H965T
M-3(N>&UL4$L! A0#%     @ &85H4@]?UL3_ 0  :00  !D
M ("!<7L! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    "  9
MA6A2V6:@LW0"   T!@  &0              @(&G?0$ >&PO=V]R:W-H965T
M<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( !F%:%([L##8K@(  +<&   9
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M970U.2YX;6Q02P$"% ,4    "  9A6A2XS,4ZWL"  "&!@  &0
M    @(%1E $ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    (
M !F%:%**-RB?= (  (T%   9              " @0.7 0!X;"]W;W)K<VAE
M971S+W-H965T-C$N>&UL4$L! A0#%     @ &85H4CEI@17Z @  D0@  !D
M             ("!KID! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"
M% ,4    "  9A6A2?ZL=B/<"  ","   &0              @('?G $ >&PO
M=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( !F%:%)?T@$"^0(
M &\(   9              " @0V@ 0!X;"]W;W)K<VAE971S+W-H965T-C0N
M>&UL4$L! A0#%     @ &85H4H7]12!W"0  ]BP  !D              ("!
M/:,! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    "  9A6A2
MCXPZ&Q\#  "8"0  &0              @('KK $ >&PO=V]R:W-H965T<R]S
M:&5E=#8V+GAM;%!+ 0(4 Q0    ( !F%:%*D(L>4ZP(  )T(   9
M      " @4&P 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%
M  @ &85H4BZGP!^L!0  +QH  !D              ("!8[,! 'AL+W=O<FMS
M:&5E=',O<VAE970V."YX;6Q02P$"% ,4    "  9A6A2 FE]%)$$  #1$0
M&0              @(%&N0$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+
M 0(4 Q0    ( !F%:%(N]W!KL ,  "T-   9              " @0Z^ 0!X
M;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ &85H4C19_)Q5
M!0  '!P  !D              ("!]<$! 'AL+W=O<FMS:&5E=',O<VAE970W
M,2YX;6Q02P$"% ,4    "  9A6A28IO&FZP#  "X"P  &0
M@(&!QP$ >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( !F%
M:%+K87GQ;0,  +D+   9              " @63+ 0!X;"]W;W)K<VAE971S
M+W-H965T-S,N>&UL4$L! A0#%     @ &85H4BR!0@\B P  S@D  !D
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M=#<X+GAM;%!+ 0(4 Q0    ( !F%:%(V$^<)2@0  )D.   9
M  " @5OL 0!X;"]W;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @
M&85H4K_DJ;N  P  -@H  !D              ("!W/ ! 'AL+W=O<FMS:&5E
M=',O<VAE970X,"YX;6Q02P$"% ,4    "  9A6A2AK:_.: "  "!!@  &0
M            @(&3] $ >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4
M Q0    ( !F%:%))2FD^40H  &XR   9              " @6KW 0!X;"]W
M;W)K<VAE971S+W-H965T.#(N>&UL4$L! A0#%     @ &85H4D+Y5$(E!@
M:A\  !D              ("!\@$" 'AL+W=O<FMS:&5E=',O<VAE970X,RYX
M;6Q02P$"% ,4    "  9A6A2)=B[ +4"  #'!P  &0              @(%.
M" ( >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4 Q0    ( !F%:%)W
M]9DD\P0  ,85   9              " @3H+ @!X;"]W;W)K<VAE971S+W-H
M965T.#4N>&UL4$L! A0#%     @ &85H4@5&!_)1 @  1@P   T
M     ( !9! " 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  9A6A2EXJ[',
M   3 @  "P              @ '@$@( 7W)E;',O+G)E;'-02P$"% ,4
M"  9A6A2- 7%^J8&  #3-P  #P              @ ')$P( >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ &85H4B 5OA"$ @  )C(  !H
M ( !G!H" 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M&85H4HENS'XK @  NS   !,              ( !6!T" %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&     %T 70""&0  M!\"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>277</ContextCount>
  <ElementCount>538</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>110</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - ORGANIZATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/Organization</Role>
      <ShortName>ORGANIZATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/Revenues</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactions</Role>
      <ShortName>INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactions</Role>
      <ShortName>INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - RESTRICTED CASH</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/RestrictedCash</Role>
      <ShortName>RESTRICTED CASH</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/Inventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - PROPERTY, PLANT AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/PropertyPlantAndEquipment</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/AccountsPayableAndAccruedExpenses</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/Debt</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - STOCKHOLDERS??? EQUITY AND STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensation</Role>
      <ShortName>STOCKHOLDERS??? EQUITY AND STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - EMPLOYEE SAVINGS PLAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/EmployeeSavingsPlan</Role>
      <ShortName>EMPLOYEE SAVINGS PLAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - SEGMENT INFORMATION AND CONCENTRATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/SegmentInformationAndConcentrations</Role>
      <ShortName>SEGMENT INFORMATION AND CONCENTRATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/RevenuesTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/Revenues</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsTables</Role>
      <ShortName>INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactions</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsTables</Role>
      <ShortName>INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactions</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/InventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/Inventories</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/PropertyPlantAndEquipmentTables</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/PropertyPlantAndEquipment</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/IntangibleAssetsAndGoodwill</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/AccountsPayableAndAccruedExpensesTables</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/AccountsPayableAndAccruedExpenses</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/DebtTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/Debt</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/Leases</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - STOCKHOLDERS??? EQUITY AND STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY AND STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/IncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - SEGMENT INFORMATION AND CONCENTRATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/SegmentInformationAndConcentrationsTables</Role>
      <ShortName>SEGMENT INFORMATION AND CONCENTRATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://harrowinc.com/role/SegmentInformationAndConcentrations</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - SCHEDULE OF BASIC EARNINGS PER COMMON SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfBasicEarningsPerCommonShareDetails</Role>
      <ShortName>SCHEDULE OF BASIC EARNINGS PER COMMON SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails</Role>
      <ShortName>SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - SCHEDULE OF DILUTED EARNINGS PER COMMON SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfDilutedEarningsPerCommonShareDetails</Role>
      <ShortName>SCHEDULE OF DILUTED EARNINGS PER COMMON SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - SCHEDULE OF DISAGGREGATED REVENUE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails</Role>
      <ShortName>SCHEDULE OF DISAGGREGATED REVENUE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - REVENUES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/RevenuesDetailsNarrative</Role>
      <ShortName>REVENUES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/RevenuesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - SCHEDULE OF CONDENSED INCOME STATEMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails</Role>
      <ShortName>SCHEDULE OF CONDENSED INCOME STATEMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - SCHEDULE OF CONDENSED BALANCE SHEET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails</Role>
      <ShortName>SCHEDULE OF CONDENSED BALANCE SHEET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - SUMMARY OF CONDENSED INCOME STATEMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails</Role>
      <ShortName>SUMMARY OF CONDENSED INCOME STATEMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - SUMMARY OF CONDENSED BALANCE SHEET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails</Role>
      <ShortName>SUMMARY OF CONDENSED BALANCE SHEET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - RESTRICTED CASH (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/RestrictedCashDetailsNarrative</Role>
      <ShortName>RESTRICTED CASH (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/RestrictedCash</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - SCHEDULE OF INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfInventoriesDetails</Role>
      <ShortName>SCHEDULE OF INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/PropertyPlantAndEquipmentDetailsNarrative</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/PropertyPlantAndEquipmentTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails</Role>
      <ShortName>SCHEDULE OF INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails</Role>
      <ShortName>SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails</Role>
      <ShortName>SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - SCHEDULE OF GOODWILL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfGoodwillDetails</Role>
      <ShortName>SCHEDULE OF GOODWILL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/IntangibleAssetsAndGoodwillDetailsNarrative</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails</Role>
      <ShortName>SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - SUMMARY OF FUTURE MINIMUM PAYMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails</Role>
      <ShortName>SUMMARY OF FUTURE MINIMUM PAYMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>00000065 - Disclosure - DEBT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/DebtDetailsNarrative</Role>
      <ShortName>DEBT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/DebtTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>00000066 - Disclosure - SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails</Role>
      <ShortName>SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>00000067 - Disclosure - SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails</Role>
      <ShortName>SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>00000068 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/LeasesTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>00000069 - Disclosure - SCHEDULE OF STOCK OPTION PLAN ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION PLAN ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>00000070 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>00000071 - Disclosure - SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>00000072 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails</Role>
      <ShortName>SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>00000073 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails</Role>
      <ShortName>SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>00000074 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails</Role>
      <ShortName>SCHEDULE OF WARRANTS ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>00000075 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails</Role>
      <ShortName>SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>00000076 - Disclosure - STOCKHOLDERS??? EQUITY AND STOCK-BASED COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? EQUITY AND STOCK-BASED COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>00000077 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>SCHEDULE OF PROVISION FOR INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>00000078 - Disclosure - SCHEDULE OF INCOME TAX RECONCILIATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfIncomeTaxReconciliationDetails</Role>
      <ShortName>SCHEDULE OF INCOME TAX RECONCILIATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>00000079 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>00000080 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/IncomeTaxesTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>00000081 - Disclosure - EMPLOYEE SAVINGS PLAN (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/EmployeeSavingsPlanDetailsNarrative</Role>
      <ShortName>EMPLOYEE SAVINGS PLAN (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/EmployeeSavingsPlan</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>00000082 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>00000083 - Disclosure - SCHEDULE OF SEGMENT NET REVENUES, SEGMENT OPERATING EXPENSES AND SEGMENT CONTRIBUTION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails</Role>
      <ShortName>SCHEDULE OF SEGMENT NET REVENUES, SEGMENT OPERATING EXPENSES AND SEGMENT CONTRIBUTION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>00000084 - Disclosure - SEGMENT INFORMATION AND CONCENTRATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/SegmentInformationAndConcentrationsDetailsNarrative</Role>
      <ShortName>SEGMENT INFORMATION AND CONCENTRATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/SegmentInformationAndConcentrationsTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>00000085 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://harrowinc.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://harrowinc.com/role/SubsequentEvents</ParentRole>
      <Position>85</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="form10-k.htm">form10-k.htm</File>
    <File>ex10-57.htm</File>
    <File>ex10-58.htm</File>
    <File>ex10-60.htm</File>
    <File>ex21-1.htm</File>
    <File>ex23-1.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>ex32-2.htm</File>
    <File>ex4-1.htm</File>
    <File>hrow-20201231.xsd</File>
    <File>hrow-20201231_cal.xml</File>
    <File>hrow-20201231_def.xml</File>
    <File>hrow-20201231_lab.xml</File>
    <File>hrow-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>111
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form10-k.htm": {
   "axisCustom": 0,
   "axisStandard": 25,
   "contextCount": 277,
   "dts": {
    "calculationLink": {
     "local": [
      "hrow-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "hrow-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "hrow-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hrow-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "hrow-20201231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 730,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 77,
    "http://harrowinc.com/20201231": 10,
    "http://xbrl.sec.gov/dei/2020-01-31": 6,
    "total": 93
   },
   "keyCustom": 79,
   "keyStandard": 459,
   "memberCustom": 78,
   "memberStandard": 26,
   "nsprefix": "HROW",
   "nsuri": "http://harrowinc.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://harrowinc.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS",
     "role": "http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactions",
     "shortName": "INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS",
     "role": "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactions",
     "shortName": "INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:RestrictedCashTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - RESTRICTED CASH",
     "role": "http://harrowinc.com/role/RestrictedCash",
     "shortName": "RESTRICTED CASH",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:RestrictedCashTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - INVENTORIES",
     "role": "http://harrowinc.com/role/Inventories",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "role": "http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssets",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - PROPERTY, PLANT AND EQUIPMENT",
     "role": "http://harrowinc.com/role/PropertyPlantAndEquipment",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - INTANGIBLE ASSETS AND GOODWILL",
     "role": "http://harrowinc.com/role/IntangibleAssetsAndGoodwill",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES",
     "role": "http://harrowinc.com/role/AccountsPayableAndAccruedExpenses",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - DEBT",
     "role": "http://harrowinc.com/role/Debt",
     "shortName": "DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - LEASES",
     "role": "http://harrowinc.com/role/Leases",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "role": "http://harrowinc.com/role/BalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - STOCKHOLDERS\u2019 EQUITY AND STOCK-BASED COMPENSATION",
     "role": "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensation",
     "shortName": "STOCKHOLDERS\u2019 EQUITY AND STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - INCOME TAXES",
     "role": "http://harrowinc.com/role/IncomeTaxes",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - EMPLOYEE SAVINGS PLAN",
     "role": "http://harrowinc.com/role/EmployeeSavingsPlan",
     "shortName": "EMPLOYEE SAVINGS PLAN",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://harrowinc.com/role/CommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - SEGMENT INFORMATION AND CONCENTRATIONS",
     "role": "http://harrowinc.com/role/SegmentInformationAndConcentrations",
     "shortName": "SEGMENT INFORMATION AND CONCENTRATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://harrowinc.com/role/SubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - REVENUES (Tables)",
     "role": "http://harrowinc.com/role/RevenuesTables",
     "shortName": "REVENUES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:ScheduleOfCondensedIncomeStatementOneTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Tables)",
     "role": "http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsTables",
     "shortName": "INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:ScheduleOfCondensedIncomeStatementOneTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://harrowinc.com/role/BalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "HROW:InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Tables)",
     "role": "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsTables",
     "shortName": "INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "HROW:InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - INVENTORIES (Tables)",
     "role": "http://harrowinc.com/role/InventoriesTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "role": "http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)",
     "role": "http://harrowinc.com/role/PropertyPlantAndEquipmentTables",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "role": "http://harrowinc.com/role/IntangibleAssetsAndGoodwillTables",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)",
     "role": "http://harrowinc.com/role/AccountsPayableAndAccruedExpensesTables",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - DEBT (Tables)",
     "role": "http://harrowinc.com/role/DebtTables",
     "shortName": "DEBT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - LEASES (Tables)",
     "role": "http://harrowinc.com/role/LeasesTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - STOCKHOLDERS\u2019 EQUITY AND STOCK-BASED COMPENSATION (Tables)",
     "role": "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables",
     "shortName": "STOCKHOLDERS\u2019 EQUITY AND STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://harrowinc.com/role/IncomeTaxesTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Consolidated Statements of Operations",
     "role": "http://harrowinc.com/role/StatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - SEGMENT INFORMATION AND CONCENTRATIONS (Tables)",
     "role": "http://harrowinc.com/role/SegmentInformationAndConcentrationsTables",
     "shortName": "SEGMENT INFORMATION AND CONCENTRATIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - SCHEDULE OF BASIC EARNINGS PER COMMON SHARE (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfBasicEarningsPerCommonShareDetails",
     "shortName": "SCHEDULE OF BASIC EARNINGS PER COMMON SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2019-01-012019-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails",
     "shortName": "SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2019-01-012019-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - SCHEDULE OF DILUTED EARNINGS PER COMMON SHARE (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfDilutedEarningsPerCommonShareDetails",
     "shortName": "SCHEDULE OF DILUTED EARNINGS PER COMMON SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2019-01-012019-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "HROW:IncrementalCommonSharesAttributableDilutiveCommonEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:ConsolidationBasisDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "role": "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:ConsolidationBasisDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - SCHEDULE OF DISAGGREGATED REVENUE (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails",
     "shortName": "SCHEDULE OF DISAGGREGATED REVENUE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_CommissionsMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - REVENUES (Details Narrative)",
     "role": "http://harrowinc.com/role/RevenuesDetailsNarrative",
     "shortName": "REVENUES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - SCHEDULE OF CONDENSED INCOME STATEMENT (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails",
     "shortName": "SCHEDULE OF CONDENSED INCOME STATEMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "HROW:ScheduleOfCondensedIncomeStatementOneTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_MeltPharmaceuticalsIncMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - SCHEDULE OF CONDENSED BALANCE SHEET (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails",
     "shortName": "SCHEDULE OF CONDENSED BALANCE SHEET (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "HROW:ScheduleOfCondensedBalanceSheetOneTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_custom_MeltPharmaceuticalsIncMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "HROW:InvestmentOnePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2019-12-31_custom_MeltPharmaceuticalsIncMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueFromRelatedParties",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "role": "http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative",
     "shortName": "INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2019-02-012019-02-28_custom_MeltPharmaceuticalsIncMember_custom_ManagementServicesAgreementMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AdministrativeFeesExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2018-12-31_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://harrowinc.com/role/StatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2018-12-31_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - SUMMARY OF CONDENSED INCOME STATEMENT (Details)",
     "role": "http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails",
     "shortName": "SUMMARY OF CONDENSED INCOME STATEMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
       "HROW:InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_SurfacePharmaceuticalsIncMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000051 - Disclosure - SUMMARY OF CONDENSED BALANCE SHEET (Details)",
     "role": "http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails",
     "shortName": "SUMMARY OF CONDENSED BALANCE SHEET (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "HROW:InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "HROW:InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000052 - Disclosure - INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "role": "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative",
     "shortName": "INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "HROW:InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_custom_SurfacePharmaceuticalsIncMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000053 - Disclosure - RESTRICTED CASH (Details Narrative)",
     "role": "http://harrowinc.com/role/RestrictedCashDetailsNarrative",
     "shortName": "RESTRICTED CASH (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000054 - Disclosure - SCHEDULE OF INVENTORIES (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfInventoriesDetails",
     "shortName": "SCHEDULE OF INVENTORIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "HROW:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000055 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "HROW:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalizedComputerSoftwareGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000056 - Disclosure - SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
     "shortName": "SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalizedComputerSoftwareGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainLossOnDispositionOfAssets1",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000057 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Details Narrative)",
     "role": "http://harrowinc.com/role/PropertyPlantAndEquipmentDetailsNarrative",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationAmortizationAndAccretionNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000058 - Disclosure - SCHEDULE OF INTANGIBLE ASSETS (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails",
     "shortName": "SCHEDULE OF INTANGIBLE ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000059 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails",
     "shortName": "SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://harrowinc.com/role/StatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000060 - Disclosure - SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails",
     "shortName": "SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2018-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000061 - Disclosure - SCHEDULE OF GOODWILL (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfGoodwillDetails",
     "shortName": "SCHEDULE OF GOODWILL (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2018-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2019-01-012019-12-31_custom_CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember_custom_ParkCompoundingIncMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000062 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Details Narrative)",
     "role": "http://harrowinc.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2019-01-012019-12-31_custom_CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember_custom_ParkCompoundingIncMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000063 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails",
     "shortName": "SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsPayableCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000064 - Disclosure - SUMMARY OF FUTURE MINIMUM PAYMENTS (Details)",
     "role": "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails",
     "shortName": "SUMMARY OF FUTURE MINIMUM PAYMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedLiabilitiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000065 - Disclosure - DEBT (Details Narrative)",
     "role": "http://harrowinc.com/role/DebtDetailsNarrative",
     "shortName": "DEBT (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000066 - Disclosure - SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails",
     "shortName": "SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000067 - Disclosure - SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails",
     "shortName": "SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Percent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000068 - Disclosure - LEASES (Details Narrative)",
     "role": "http://harrowinc.com/role/LeasesDetailsNarrative",
     "shortName": "LEASES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Percent",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2019-12-31_custom_StockOptionPlanOneMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000069 - Disclosure - SCHEDULE OF STOCK OPTION PLAN ACTIVITY (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails",
     "shortName": "SCHEDULE OF STOCK OPTION PLAN ACTIVITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2019-12-31_custom_StockOptionPlanOneMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - ORGANIZATION",
     "role": "http://harrowinc.com/role/Organization",
     "shortName": "ORGANIZATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_OptionsEmployeesMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000070 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails",
     "shortName": "SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_custom_OptionsEmployeesMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000071 - Disclosure - SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails",
     "shortName": "SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000072 - Disclosure - SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails",
     "shortName": "SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2018-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000073 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails",
     "shortName": "SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_WarrantMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000074 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails",
     "shortName": "SCHEDULE OF WARRANTS ACTIVITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_WarrantMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "HROW:ScheduleofWarrantsOutstandingAndExercisableTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_WarrantMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000075 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails",
     "shortName": "SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "HROW:ScheduleofWarrantsOutstandingAndExercisableTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_WarrantMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000076 - Disclosure - STOCKHOLDERS\u2019 EQUITY AND STOCK-BASED COMPENSATION (Details Narrative)",
     "role": "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
     "shortName": "STOCKHOLDERS\u2019 EQUITY AND STOCK-BASED COMPENSATION (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000077 - Disclosure - SCHEDULE OF PROVISION FOR INCOME TAXES (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfProvisionForIncomeTaxesDetails",
     "shortName": "SCHEDULE OF PROVISION FOR INCOME TAXES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Percent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000078 - Disclosure - SCHEDULE OF INCOME TAX RECONCILIATION (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfIncomeTaxReconciliationDetails",
     "shortName": "SCHEDULE OF INCOME TAX RECONCILIATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Percent",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000079 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://harrowinc.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000080 - Disclosure - INCOME TAXES (Details Narrative)",
     "role": "http://harrowinc.com/role/IncomeTaxesDetailsNarrative",
     "shortName": "INCOME TAXES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "HROW:PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Percent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000081 - Disclosure - EMPLOYEE SAVINGS PLAN (Details Narrative)",
     "role": "http://harrowinc.com/role/EmployeeSavingsPlanDetailsNarrative",
     "shortName": "EMPLOYEE SAVINGS PLAN (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "HROW:PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Percent",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000082 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "role": "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000083 - Disclosure - SCHEDULE OF SEGMENT NET REVENUES, SEGMENT OPERATING EXPENSES AND SEGMENT CONTRIBUTION (Details)",
     "role": "http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails",
     "shortName": "SCHEDULE OF SEGMENT NET REVENUES, SEGMENT OPERATING EXPENSES AND SEGMENT CONTRIBUTION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-012020-12-31_us-gaap_OperatingSegmentsMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:NumberOfOperatingSegmentsDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000084 - Disclosure - SEGMENT INFORMATION AND CONCENTRATIONS (Details Narrative)",
     "role": "http://harrowinc.com/role/SegmentInformationAndConcentrationsDetailsNarrative",
     "shortName": "SEGMENT INFORMATION AND CONCENTRATIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "HROW:NumberOfOperatingSegmentsDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000085 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "role": "http://harrowinc.com/role/SubsequentEventsDetailsNarrative",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2021-03-012021-03-31_us-gaap_SubsequentEventMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - REVENUES",
     "role": "http://harrowinc.com/role/Revenues",
     "shortName": "REVENUES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-k.htm",
      "contextRef": "From2020-01-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 110,
   "tag": {
    "HROW_AdditionalAreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional area of land.",
        "label": "Additional square footage"
       }
      }
     },
     "localname": "AdditionalAreaOfLand",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "HROW_AdditionalPaidInCapitalAndShareBasedPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional paid in capital and stock based payments.",
        "label": "Additional paid in capital and stock based payments"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalAndShareBasedPayments",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_AggregatePurchasePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate purchase price.",
        "label": "Aggregate purchase price"
       }
      }
     },
     "localname": "AggregatePurchasePrice",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "HROW_AllerganUSAIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allergan USA, Inc [Member]",
        "label": "Allergan USA, Inc. [Member]"
       }
      }
     },
     "localname": "AllerganUSAIncMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_AmortizationOfIntangibleAsset": {
     "auth_ref": [],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAsset",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_AmortizationOfOperatingLeaseRightofuseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of operating lease right-of-use assets"
       }
      }
     },
     "localname": "AmortizationOfOperatingLeaseRightofuseAssets",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_AndrewBollCFOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Andrew Boll, CFO [Member]",
        "label": "Andrew Boll C F O [Member]"
       }
      }
     },
     "localname": "AndrewBollCFOMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_AndrewRBollMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Andrew R. Boll [Member]",
        "label": "Andrew R Boll [Member]"
       }
      }
     },
     "localname": "AndrewRBollMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_AverageStockPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average stock price.",
        "label": "Average stock price"
       }
      }
     },
     "localname": "AverageStockPrice",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "HROW_BaumPerformanceOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baum Performance Option [Member]",
        "label": "Baum Performance Option [Member]"
       }
      }
     },
     "localname": "BaumPerformanceOptionMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_BoardOfDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Board of Directors [Member]",
        "label": "Board of Directors [Member]"
       }
      }
     },
     "localname": "BoardOfDirectorsMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_BusinessLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Loan Agreement [Member]",
        "label": "Business Loan Agreement [Member]"
       }
      }
     },
     "localname": "BusinessLoanAgreementMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_CashCashEquivalentsAndRestrictedCashAtEndOfPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents and Restricted cash at end of period.",
        "label": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD",
        "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD"
       }
      }
     },
     "localname": "CashCashEquivalentsAndRestrictedCashAtEndOfPeriod",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_ClosingPriceOfCommonStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing price of common stock price per share.",
        "label": "Closing price of common stock price per share"
       }
      }
     },
     "localname": "ClosingPriceOfCommonStockPricePerShare",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "HROW_CommissionPaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission payments, percentage.",
        "label": "Commission payments, percentage"
       }
      }
     },
     "localname": "CommissionPaymentsPercentage",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "HROW_CommissionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commissions [Member]",
        "label": "Commissions [Member]"
       }
      }
     },
     "localname": "CommissionsMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_CommonStockWarrantsOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants One [Member]",
        "label": "Common Stock Warrants One [Member]"
       }
      }
     },
     "localname": "CommonStockWarrantsOneMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_CommonStockWarrantsTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants Two [Member]",
        "label": "Common Stock Warrants Two [Member]"
       }
      }
     },
     "localname": "CommonStockWarrantsTwoMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_CommonStockWithheldForPayrollTaxWithholdings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock withheld for payroll tax withholdings.",
        "label": "Common stock withheld for payroll tax withholdings"
       }
      }
     },
     "localname": "CommonStockWithheldForPayrollTaxWithholdings",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "HROW_CommonStockWithheldForPayrollTaxWithholdingsShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock withheld for payroll tax withholdings, shares",
        "label": "Common stock withheld for payroll tax withholdings, shares"
       }
      }
     },
     "localname": "CommonStockWithheldForPayrollTaxWithholdingsShare",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "HROW_CommonStockWithheldForPayrollTaxWithholdingsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock withheld for payroll tax withholdings, value.",
        "label": "Common stock withheld for payroll tax withholdings, value"
       }
      }
     },
     "localname": "CommonStockWithheldForPayrollTaxWithholdingsValue",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_ConsolidationBasisDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidation basis, description.",
        "label": "Consolidation basis, description"
       }
      }
     },
     "localname": "ConsolidationBasisDescription",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "HROW_ConsultantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consultants [Member]",
        "label": "Consultants [Member]"
       }
      }
     },
     "localname": "ConsultantMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_CostOfSalePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Sales"
       }
      }
     },
     "localname": "CostOfSalePolicyTextBlock",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HROW_CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer Relationships, Trade Name and State Pharmacy Licenses [Member].",
        "label": "Customer Relationships, Trade Name and State Pharmacy Licenses [Member"
       }
      }
     },
     "localname": "CustomerRelationshipsTradeNameAndStatePharmacyLicensesMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_DamagesLowClaimRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Damages low claim rate, percentage.",
        "label": "Damages low claim rate, percentage"
       }
      }
     },
     "localname": "DamagesLowClaimRatePercentage",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "HROW_DeconsolidationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deconsolidation percentage.",
        "label": "Deconsolidation percentage"
       }
      }
     },
     "localname": "DeconsolidationPercentage",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "HROW_DeferredIncomeChangeInValuationAllowance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Income Change In Valuation Allowance.",
        "label": "Deferred: Change in valuation allowance"
       }
      }
     },
     "localname": "DeferredIncomeChangeInValuationAllowance",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Asset Tax Credit carry Forwards Depreciation And Amortization.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASC 842 ROU Asset.",
        "label": "ASC 842 ROU Asset",
        "negatedLabel": "ASC 842 ROU asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseAccountingStandardRightUseOfAsset",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASC 842 Lease Liability.",
        "label": "ASC 842 lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseAcountingStandardLeaseLiability",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_DeferredTaxAssetsTaxDeferredExpenseCapitalLosses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital losses.",
        "label": "Capital losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCapitalLosses",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_DeferredTaxAssetsTaxDeferredExpenseLimitations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Limitation Under 163(j).",
        "label": "Limitation under 163(j)"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseLimitations",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_DexycuAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dexycu Agreement [Member]",
        "label": "Dexycu Agreement [Member]"
       }
      }
     },
     "localname": "DexycuAgreementMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_DisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment In Surface Ophthalmics Inc. And Agreements - Related Party Transactions"
       }
      }
     },
     "localname": "DisclosureInvestmentInSurfaceOphthalmicsInc.AndAgreementsRelatedPartyTransactionsAbstract",
     "nsuri": "http://harrowinc.com/20201231",
     "xbrltype": "stringItemType"
    },
    "HROW_DisclosureRestrictedCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "DisclosureRestrictedCashAbstract",
     "nsuri": "http://harrowinc.com/20201231",
     "xbrltype": "stringItemType"
    },
    "HROW_DrLindstromMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr. Lindstrom [Member]",
        "label": "Dr. Lindstrom [Member]"
       }
      }
     },
     "localname": "DrLindstromMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_EllePharmaceuticalLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Elle Pharmaceutical, LLC [Member]",
        "label": "Elle Pharmaceutical, LLC [Member]"
       }
      }
     },
     "localname": "EllePharmaceuticalLLCMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_EmployeesAndConsultantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees and Consultant [Member]",
        "label": "Employees and Consultant [Member]"
       }
      }
     },
     "localname": "EmployeesAndConsultantMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_EmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees [Member]",
        "label": "Employees [Member]"
       }
      }
     },
     "localname": "EmployeesMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_EtonPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eton Pharmaceuticals, Inc. [Member]",
        "label": "Eton Pharmaceuticals, Inc. [Member]"
       }
      }
     },
     "localname": "EtonPharmaceuticalsIncMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_EtonPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eton Pharmaceuticals [Member]",
        "label": "Eton Pharmaceuticals [Member]"
       }
      }
     },
     "localname": "EtonPharmaceuticalsMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_FederalNetOperatingLossCarryforwardDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal net operating loss carryforward description",
        "label": "Federal net operating loss carryforward description"
       }
      }
     },
     "localname": "FederalNetOperatingLossCarryforwardDescription",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "HROW_FederalResearchAndDevelopmentTaxCredits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Research And Development Tax Credits.",
        "label": "Federal research and development tax credits"
       }
      }
     },
     "localname": "FederalResearchAndDevelopmentTaxCredits",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_FederalResearchAndDevelopmentTaxCreditsExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Research And Development Tax Credits Expiration Date.",
        "label": "Federal research and development tax credits expiration date"
       }
      }
     },
     "localname": "FederalResearchAndDevelopmentTaxCreditsExpirationDate",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "gYearItemType"
    },
    "HROW_FinalPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Final Payment [Member]",
        "label": "Final Payment [Member]"
       }
      }
     },
     "localname": "FinalPaymentMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_FiniteLivedIntangibleAssetsImpairment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite Lived Intangible Assets Impairment.",
        "label": "Impairment"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsImpairment",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_ForfeitureFactorPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forfeiture factor, percentage.",
        "label": "Forfeiture factor, percentage"
       }
      }
     },
     "localname": "ForfeitureFactorPercentage",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "HROW_GainLossOnInvestmentsOne": {
     "auth_ref": [],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "GainLossOnInvestmentsOne",
        "negatedLabel": "Investment gain from Eton Pharmaceuticals, net"
       }
      }
     },
     "localname": "GainLossOnInvestmentsOne",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_GainLossOnInvestmentsThree": {
     "auth_ref": [],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "GainLossOnInvestmentsThree",
        "negatedLabel": "Investment loss (gain) from Melt Pharmaceuticals, net"
       }
      }
     },
     "localname": "GainLossOnInvestmentsThree",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_GainLossOnInvestmentsTwo": {
     "auth_ref": [],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "GainLossOnInvestmentsTwo",
        "negatedLabel": "Investment loss from Surface Ophthalmics, net"
       }
      }
     },
     "localname": "GainLossOnInvestmentsTwo",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_ImpairmentAndDisposalOfLonglivedAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment and disposal of long-lived assets.",
        "label": "Asset sales and impairments, net"
       }
      }
     },
     "localname": "ImpairmentAndDisposalOfLonglivedAssets",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_ImpairmentsOfLongLivedAssetsHeldForUse": {
     "auth_ref": [],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ImpairmentsOfLongLivedAssetsHeldForUse",
        "verboseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentsOfLongLivedAssetsHeldForUse",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_IncomeTaxBasisDifferenceInRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis Difference in Melt.",
        "label": "Basis Difference in Melt",
        "negatedLabel": "Basis difference in Melt"
       }
      }
     },
     "localname": "IncomeTaxBasisDifferenceInRelatedParty",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_IncomeTaxBasisDifferenceInRelatedPartyOne": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis Difference in Surface.",
        "label": "Basis Difference in Surface",
        "negatedLabel": "Basis difference in Surface"
       }
      }
     },
     "localname": "IncomeTaxBasisDifferenceInRelatedPartyOne",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_IncomeTaxBasisDifferenceInRelatedPartyTwo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis Difference in Eton.",
        "label": "Basis Difference in Eton",
        "negatedLabel": "Basis difference in Eton"
       }
      }
     },
     "localname": "IncomeTaxBasisDifferenceInRelatedPartyTwo",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_IncrementalCommonSharesAttributableDilutiveCommonEquivalents": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental Common Shares Attributable to Dilutive common equivalents.",
        "label": "Dilutive common equivalents"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableDilutiveCommonEquivalents",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "HROW_InitialPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Payment [Member]",
        "label": "Initial Payment [Member]"
       }
      }
     },
     "localname": "InitialPaymentMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_InjectableAssetPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Injectable Asset Purchase Agreement [Member]",
        "label": "Injectable Asset Purchase Agreement [Member]"
       }
      }
     },
     "localname": "InjectableAssetPurchaseAgreementMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_InvestmentOnePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Melt Pharmaceuticals, Inc. \u2013 Related Party"
       }
      }
     },
     "localname": "InvestmentOnePolicyTextBlock",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HROW_InvestmentTwoPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Surface Ophthalmics, Inc. \u2013 Related Party"
       }
      }
     },
     "localname": "InvestmentTwoPolicyTextBlock",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HROW_InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments and Agreements Related Party Transactions [Text Block]",
        "label": "INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "InvestmentsAndAgreementsRelatedPartyTransactionsTextBlock",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HROW_IrvineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Irvine [Member]",
        "label": "Irvine [Member]"
       }
      }
     },
     "localname": "IrvineMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_JoinderAndAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joinder and Amendment [Member].",
        "label": "Joinder and Amendment [Member]"
       }
      }
     },
     "localname": "JoinderAndAmendmentMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_KlarityLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Klarity License Agreement [Member]",
        "label": "Klarity License Agreement [Member]"
       }
      }
     },
     "localname": "KlarityLicenseAgreementMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_LeaseExpirationDateDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expiration date description.",
        "label": "Lease expiration date description"
       }
      }
     },
     "localname": "LeaseExpirationDateDescription",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "HROW_LedgewoodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ledgewood [Member]",
        "label": "Ledgewood [Member]"
       }
      }
     },
     "localname": "LedgewoodMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_LenderWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lender Warrants [Member]",
        "label": "Lender Warrants [Member]"
       }
      }
     },
     "localname": "LenderWarrantsMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_LenderWarrantsOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lender Warrants One [Member]",
        "label": "Lender Warrants One [Member]"
       }
      }
     },
     "localname": "LenderWarrantsOneMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement [Member]",
        "label": "License Agreement [Member]"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_LicensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licenses [Member]",
        "label": "Licenses [Member]"
       }
      }
     },
     "localname": "LicensesMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_LongTermNotesPayable1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Note payable, net of current portion and unamortized debt discount"
       }
      }
     },
     "localname": "LongTermNotesPayable1",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_MSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Management Services Agreement [Member].",
        "label": "Management Services Agreement [Member] [Default Label]",
        "verboseLabel": "Management Services Agreement [Member]"
       }
      }
     },
     "localname": "MSAMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_ManagementServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Management Services Agreement [Member]",
        "label": "Management Services Agreement [Member]"
       }
      }
     },
     "localname": "ManagementServicesAgreementMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_MarginRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Margin Rate [Member].",
        "label": "Margin Rate [Member]."
       }
      }
     },
     "localname": "MarginRateMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_MarkBaumCEOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mark Baum, CEO [Member]",
        "label": "Mark Baum C E O [Member]"
       }
      }
     },
     "localname": "MarkBaumCEOMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_MarkLBaumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mark L. Baum [Member]",
        "label": "Mark L Baum [Member]"
       }
      }
     },
     "localname": "MarkLBaumMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_MayfieldPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mayfield Pharmaceuticals, Inc. [Member]",
        "label": "Mayfield Pharmaceuticals, Inc. [Member]"
       }
      }
     },
     "localname": "MayfieldPharmaceuticalsIncMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_MeltPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Melt Pharmaceuticals, Inc. [Member]",
        "label": "Melt Pharmaceuticals, Inc. [Member]"
       }
      }
     },
     "localname": "MeltPharmaceuticalsIncMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_MeltPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Melt Pharmaceuticals [Member]",
        "label": "Melt Pharmaceuticals [Member]"
       }
      }
     },
     "localname": "MeltPharmaceuticalsMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_MilestonePaymentInCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment in cash.",
        "label": "Milestone payment in cash"
       }
      }
     },
     "localname": "MilestonePaymentInCash",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_MilestonePaymentsOnPayables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments on payables.",
        "label": "Milestone payments on payables"
       }
      }
     },
     "localname": "MilestonePaymentsOnPayables",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_MonthlyPaymentsOfFinanceLeaseForEquipment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly payments of finance lease for equipment.",
        "label": "Monthly payments of finance lease"
       }
      }
     },
     "localname": "MonthlyPaymentsOfFinanceLeaseForEquipment",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_NashvilleMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nashville [Member]",
        "label": "Nashville [Member]"
       }
      }
     },
     "localname": "NashvilleMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_NetSalesRevenue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net sales of product.",
        "label": "Sales revenue net"
       }
      }
     },
     "localname": "NetSalesRevenue",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_NewAndRevaluationOfRightofuseAssetObtainedInExchangeForLeaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New and revaluation of right-of-use asset obtained in exchange for lease obligation.",
        "label": "New and revaluation of right-of-use assets obtained in exchange for lease obligation"
       }
      }
     },
     "localname": "NewAndRevaluationOfRightofuseAssetObtainedInExchangeForLeaseObligation",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_NonCompetitionClauseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Competition Clause [Member]",
        "label": "Non-Competition Clause [Member]"
       }
      }
     },
     "localname": "NonCompetitionClauseMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_NoncontrollingInterestPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestPolicyTextBlock",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HROW_NotesPayableCurrent1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Less: current portion, net of unamortized discount"
       }
      }
     },
     "localname": "NotesPayableCurrent1",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_NumberOfCommonStockIssuedOnCashlessExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock issued on cashless exercise.",
        "label": "Number of common stock issued on cashless exercise"
       }
      }
     },
     "localname": "NumberOfCommonStockIssuedOnCashlessExercise",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "HROW_NumberOfOperatingSegmentsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments, description.",
        "label": "Number of operating segments, description."
       }
      }
     },
     "localname": "NumberOfOperatingSegmentsDescription",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/SegmentInformationAndConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "HROW_NumberOfSharesOwned": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares owned.",
        "label": "Number of shares owned"
       }
      }
     },
     "localname": "NumberOfSharesOwned",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "HROW_OfficeAndLaboratorySpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office And Laboratory Space [Member]"
       }
      }
     },
     "localname": "OfficeAndLaboratorySpaceMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_OptionsEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options Granted to Employees [Member]",
        "label": "Options Granted to Employees [Member]"
       }
      }
     },
     "localname": "OptionsEmployeesMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_OtherRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Revenues [Member]",
        "label": "Other Revenues [Member]"
       }
      }
     },
     "localname": "OtherRevenuesMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_ParkCompoundingIncAndNoiceRxLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Park Compounding, Inc. and Noice Rx, LLC [Member].",
        "label": "Park Compounding Inc And Noice Rx L L C [Member]"
       }
      }
     },
     "localname": "ParkCompoundingIncAndNoiceRxLLCMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_ParkCompoundingIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Park Compounding, Inc. [Member].",
        "label": "Park Compounding, Inc. [Member]"
       }
      }
     },
     "localname": "ParkCompoundingIncMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_PatentsFilingsAndTrademarksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patents Filings and Trademarks [Member].",
        "label": "Patents Filings and Trademarks [Member]"
       }
      }
     },
     "localname": "PatentsFilingsAndTrademarksMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_PaymentsOfCostsRelatedToAmendmentOfLoanPayable": {
     "auth_ref": [],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "PaymentsOfCostsRelatedToAmendmentOfLoanPayable",
        "negatedLabel": "Payments of costs related to amendment of SWK loan"
       }
      }
     },
     "localname": "PaymentsOfCostsRelatedToAmendmentOfLoanPayable",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of salary deposits in tax deferred investment account.",
        "label": "Percentage of salary deposits in tax deferred investment account"
       }
      }
     },
     "localname": "PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/EmployeeSavingsPlanDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "HROW_PharmaceuticalCompoundingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical Compounding [Member]",
        "label": "Pharmaceutical Compounding [Member]"
       }
      }
     },
     "localname": "PharmaceuticalCompoundingMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_PharmaceuticalDrugDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical Drug Development [Member]",
        "label": "Pharmaceutical Drug Development [Member]"
       }
      }
     },
     "localname": "PharmaceuticalDrugDevelopmentMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_PresbyopiaAssetPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Presbyopia Asset Purchase Agreement [Member]",
        "label": "Presbyopia Asset Purchase Agreement [Member]"
       }
      }
     },
     "localname": "PresbyopiaAssetPurchaseAgreementMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_ProceedsFromExerciseOfWarrantsAndStockOptionsNetOfTaxes": {
     "auth_ref": [],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from exercise of warrants and stock options, net of taxes remitted for RSU\u2019s and options"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfWarrantsAndStockOptionsNetOfTaxes",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_ProductSalesNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Sales, Net [Member]",
        "label": "Product Sales, Net [Member]"
       }
      }
     },
     "localname": "ProductSalesNetMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails",
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of property, plant and equipment included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "PurchaseOfPropertyPlantAndEquipmentIncludedInAccountsPayableAndAccruedExpenses",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_RangeFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Four [Member]",
        "label": "Range Four [Member]"
       }
      }
     },
     "localname": "RangeFourMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_RangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range One [Member]",
        "label": "Range One [Member]"
       }
      }
     },
     "localname": "RangeOneMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_RangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Three [Member]",
        "label": "Range Three [Member]"
       }
      }
     },
     "localname": "RangeThreeMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_RangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range Two [Member]",
        "label": "Range Two [Member]"
       }
      }
     },
     "localname": "RangeTwoMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently Adopted Accounting Pronouncements [Policy Text Block]",
        "label": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "RecentlyAdoptedAccountingPronouncementsPolicyTextBlock",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HROW_ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH"
       }
      }
     },
     "localname": "ReconciliationOfCashCashEquivalentsAndRestricedCashAtEndOfPeriodAbstract",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "HROW_RestrictedCashTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash [Text Block]",
        "label": "RESTRICTED CASH"
       }
      }
     },
     "localname": "RestrictedCashTextBlock",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/RestrictedCash"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HROW_RestrictedStockUnitsVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock units vested.",
        "label": "Restricted stock units vested"
       }
      }
     },
     "localname": "RestrictedStockUnitsVested",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "HROW_RestructuringPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring [Policy Text Block]",
        "label": "Park Restructuring"
       }
      }
     },
     "localname": "RestructuringPolicyTextBlock",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HROW_RetainedEarningsAccumulatedDeficit1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit [Default Label]",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit1",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_RichardLLindstromMDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Richard L. Lindstrom, M.D [Member]",
        "label": "Richard L. Lindstrom, M.D [Member]"
       }
      }
     },
     "localname": "RichardLLindstromMDMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_RisksUncertaintiesAndLiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks, Uncertainties and Liquidity"
       }
      }
     },
     "localname": "RisksUncertaintiesAndLiquidityPolicyTextBlock",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HROW_RoyaltyPaymentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty payment description.",
        "label": "Royalty payment description"
       }
      }
     },
     "localname": "RoyaltyPaymentDescription",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "HROW_RoyaltyPaymentPercentageOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty payment percentage on net sales.",
        "label": "Royalty payment percentage on net sales"
       }
      }
     },
     "localname": "RoyaltyPaymentPercentageOnNetSales",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "HROW_SWKFundingLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SWK Funding LLC [Member]",
        "label": "SWK Funding LLC [Member]"
       }
      }
     },
     "localname": "SWKFundingLLCMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_SWKLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SWK Loan Agreement [Member].",
        "label": "SWK Loan Agreement [Member]"
       }
      }
     },
     "localname": "SWKLoanAgreementMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_SWKSecondAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SWK Second Amendment [Member].",
        "label": "SWK Second Amendment [Member]."
       }
      }
     },
     "localname": "SWKSecondAmendmentMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_SalesAndMarketingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales and Marketing Agreements [Member]",
        "label": "Sales and Marketing Agreements [Member]"
       }
      }
     },
     "localname": "SalesAndMarketingAgreementsMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_SanDiegoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "San Diego [Member]",
        "label": "San Diego [Member]"
       }
      }
     },
     "localname": "SanDiegoMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_ScheduleOfCondensedBalanceSheetOneTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Condensed Balance Sheet [Table Text Block]",
        "label": "SCHEDULE OF CONDENSED BALANCE SHEET"
       }
      }
     },
     "localname": "ScheduleOfCondensedBalanceSheetOneTableTextBlock",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HROW_ScheduleOfCondensedIncomeStatementOneTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Condensed Balance Sheet [Table Text Block]",
        "label": "SCHEDULE OF CONDENSED INCOME STATEMENT"
       }
      }
     },
     "localname": "ScheduleOfCondensedIncomeStatementOneTableTextBlock",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HROW_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Prepaid Expenses and Other Current Assets [Table Text Block]",
        "label": "SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HROW_ScheduleofWarrantsOutstandingAndExercisableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE"
       }
      }
     },
     "localname": "ScheduleofWarrantsOutstandingAndExercisableTableTextBlock",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "HROW_SecondPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Payment [Member]",
        "label": "DirectorSellingAndAdminstrativeMember"
       }
      }
     },
     "localname": "SecondPaymentMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_SegmentContribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment contribution.",
        "label": "Segment contribution"
       }
      }
     },
     "localname": "SegmentContribution",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_SellingGeneralAndAdministrativeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selling, General and Administrative [Member]",
        "label": "Selling, General and Administrative [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_SettlementAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement Agreement [Member]",
        "label": "Settlement Agreement [Member]"
       }
      }
     },
     "localname": "SettlementAgreementMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_SettlementWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement Warrants [Member]",
        "label": "Settlement Warrants [Member]"
       }
      }
     },
     "localname": "SettlementWarrantsMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares warrants outstanding and exercisable, ending balance.",
        "label": "Number of Shares Warrants Outstanding and Exercisable, ending balance",
        "periodEndLabel": "Number of Shares Warrants Outstanding and Exercisable, ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non options equity instruments outstanding and exercisable weighted average exercise price.",
        "label": "Warrant",
        "periodEndLabel": "Weighted Avg. Exercise Price, Outstanding and Exercisable, ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "HROW_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non options equity instruments outstanding weighted average exercise price.",
        "label": "Weighted Avg. Exercise Price, Outstanding, beginning balance",
        "periodStartLabel": "Weighted Avg. Exercise Price, Outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "HROW_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercisable.",
        "label": "Warrants Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "HROW_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sharebased compensation arrangement by sharebased payment award non options outstanding weighted average remaining contractual term.",
        "label": "Weighted average remaining contractual life of the outstanding warrants in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "HROW_StateNetOperatingLossExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "State net operating loss expiration date.",
        "label": "State net operating loss expiration date"
       }
      }
     },
     "localname": "StateNetOperatingLossExpirationDate",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "gYearItemType"
    },
    "HROW_StatePharmacyLicensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "State Pharmacy Licenses [Member]",
        "label": "State Pharmacy Licenses [Member]"
       }
      }
     },
     "localname": "StatePharmacyLicensesMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_StateResearchAndDevelopmentTaxCredits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "State Research And Development Tax Credits.",
        "label": "State research and development tax credits"
       }
      }
     },
     "localname": "StateResearchAndDevelopmentTaxCredits",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_StockIssuedDuringPeriodForExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period for exercise of warrants.",
        "label": "Exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodForExerciseOfWarrants",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "HROW_StockIssuedDuringPeriodSharesForExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares for exercise of warrants.",
        "label": "Exercise of warrants, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesForExerciseOfWarrants",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "HROW_StockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Option Plan [Member]",
        "label": "Stock Option Plan [Member] [Default Label]",
        "verboseLabel": "Stock Option Plan [Member]"
       }
      }
     },
     "localname": "StockOptionPlanMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_StockOptionPlanOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Option Plan [Member]",
        "label": "Stock Option Plan [Member]"
       }
      }
     },
     "localname": "StockOptionPlanOneMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_StockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options [Member]",
        "label": "Stock Options [Member]"
       }
      }
     },
     "localname": "StockOptionsMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_StockOptionsUnvestedRSUsAndWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options, Unvested RSUs and Warrants [Member].",
        "label": "Stock Options Unvested R S Us And Warrants [Member]"
       }
      }
     },
     "localname": "StockOptionsUnvestedRSUsAndWarrantsMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_StowePharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stowe Pharmaceuticals, Inc. [Member]",
        "label": "Stowe Pharmaceuticals, Inc. [Member]"
       }
      }
     },
     "localname": "StowePharmaceuticalsIncMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_SurfaceOphthalmicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surface Ophthalmics [Member].",
        "label": "Surface Ophthalmics [Member]"
       }
      }
     },
     "localname": "SurfaceOphthalmicsMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_SurfacePharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surface Pharmaceuticals Inc [Member]",
        "label": "Surface Pharmaceuticals Inc [Member]"
       }
      }
     },
     "localname": "SurfacePharmaceuticalsIncMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_TGVHealthLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TGV-Health, LLC [Member]",
        "label": "TGV-Health, LLC [Member]"
       }
      }
     },
     "localname": "TGVHealthLLCMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_TermLoanAndSecurityAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan and Security Agreement [Member]",
        "label": "Term Loan and Security Agreement [Member]"
       }
      }
     },
     "localname": "TermLoanAndSecurityAgreementMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_ThreeMainSuppliersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Main Suppliers [Member]",
        "label": "Three Main Suppliers [Member]"
       }
      }
     },
     "localname": "ThreeMainSuppliersMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/SegmentInformationAndConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Incentive Stock and Awards Plan [Member]",
        "label": "2017 Incentive Stock and Awards Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_UnvestedRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested RSUs [Member]",
        "label": "Unvested RSUs [Member]"
       }
      }
     },
     "localname": "UnvestedRSUMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_VisionologyIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Visionology, Inc. [Member]",
        "label": "Visionology Inc [Member]"
       }
      }
     },
     "localname": "VisionologyIncMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_VisionologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Visionology [Member].",
        "label": "Visionology [Member]"
       }
      }
     },
     "localname": "VisionologyMember",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "HROW_WarrantsAndRightsOutstandingMaturityDates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.",
        "label": "Expiration Date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDates",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "HROW_WarrantsIssuanceDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants issuance date.",
        "label": "Issue Date"
       }
      }
     },
     "localname": "WarrantsIssuanceDate",
     "nsuri": "http://harrowinc.com/20201231",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r584",
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/DebtDetailsNarrative",
      "http://harrowinc.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
      "http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Listings [Line Items]"
       }
      }
     },
     "localname": "EntityListingsLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails",
      "http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/DebtDetailsNarrative",
      "http://harrowinc.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
      "http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r163",
      "r182",
      "r183",
      "r184",
      "r185",
      "r187",
      "r189",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.",
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r163",
      "r182",
      "r183",
      "r184",
      "r185",
      "r187",
      "r189",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person serving on board of directors.",
        "label": "Director [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]"
       }
      }
     },
     "localname": "DiscountedFutureNetCashFlowsRelatingToProvedOilAndGasReservesLineItems",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r334",
      "r336",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r546",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/DebtDetailsNarrative",
      "http://harrowinc.com/role/LeasesDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r334",
      "r336",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r546",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/DebtDetailsNarrative",
      "http://harrowinc.com/role/LeasesDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r196",
      "r307",
      "r310",
      "r488",
      "r545",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails",
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r196",
      "r307",
      "r310",
      "r488",
      "r545",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails",
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r323",
      "r334",
      "r336",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r546",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/DebtDetailsNarrative",
      "http://harrowinc.com/role/LeasesDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r323",
      "r334",
      "r336",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r546",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/DebtDetailsNarrative",
      "http://harrowinc.com/role/LeasesDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.",
        "label": "SUMMARY OF CONDENSED BALANCE SHEET"
       }
      }
     },
     "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_ScheduleOfCondensedIncomeStatementTableTextBlock": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.",
        "label": "SUMMARY OF CONDENSED INCOME STATEMENT"
       }
      }
     },
     "localname": "ScheduleOfCondensedIncomeStatementTableTextBlock",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r197",
      "r198",
      "r307",
      "r311",
      "r548",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area."
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r197",
      "r198",
      "r307",
      "r311",
      "r548",
      "r560",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r591",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r263",
      "r335",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r202",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals."
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts payable and accrued expenses",
        "negatedLabel": "Less: Current portion"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r513",
      "r538"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.",
        "label": "Accounts Payable and Accrued Liabilities",
        "totalLabel": "Total accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/AccountsPayableAndAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.",
        "label": "Accrued expenses, net of current portion",
        "verboseLabel": "Non-current total accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.",
        "label": "Accounts Payable and Other Accrued Liabilities",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r514",
      "r537"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r30",
      "r526"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r6",
      "r30",
      "r203",
      "r204"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r514",
      "r537"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "Accrued exit fee for note payable (see Note 12)",
        "verboseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r45",
      "r247"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r31",
      "r380"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r377",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r92",
      "r238"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r338",
      "r340",
      "r383",
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdministrativeFeesExpense": {
     "auth_ref": [
      "r474"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for administrative services provided to the limited liability company (LLC) or limited partnership (LP) by the managing member or general partner, affiliate of managing member or general partner, or affiliate of LLC or LP, for example, but not limited to, salaries, rent, or overhead costs.",
        "label": "Administrative Fees Expense"
       }
      }
     },
     "localname": "AdministrativeFeesExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r340",
      "r373",
      "r382"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Stock based compensation related to equity instruments granted to related parties"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r79",
      "r92",
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative",
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r92",
      "r453"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of debt issuance costs and discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r92",
      "r231",
      "r238"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of Land"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/DebtDetailsNarrative",
      "http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r92",
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r102",
      "r171",
      "r184",
      "r191",
      "r214",
      "r426",
      "r432",
      "r442",
      "r507",
      "r527"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Total assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r9",
      "r11",
      "r65",
      "r102",
      "r214",
      "r426",
      "r432",
      "r442"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "verboseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r102",
      "r214",
      "r426",
      "r432",
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Non current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r342",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails",
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.",
        "label": "Business acquisition description"
       }
      }
     },
     "localname": "BusinessAcquisitionDescriptionOfAcquiredEntity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r99",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareGross": {
     "auth_ref": [
      "r574"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.",
        "label": "Computer software and hardware"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r41",
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r16",
      "r95",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r88",
      "r94",
      "r97"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and cash equivalents, including restricted cash of $200",
        "verboseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r88",
      "r94",
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period",
        "periodStartLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r88",
      "r443"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, FDIC Insured Amount"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r101",
      "r102",
      "r123",
      "r126",
      "r134",
      "r136",
      "r138",
      "r145",
      "r146",
      "r147",
      "r214",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r286",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants exercise price",
        "verboseLabel": "Exercise Price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Warrants Outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r286",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r56",
      "r262",
      "r515",
      "r534"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r108",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheetsParenthetical",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, sharess authorized",
        "verboseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheetsParenthetical",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r29",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.001 par value, 50,000,000 shares authorized, 25,749,875 and 25,526,931 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r320",
      "r321",
      "r337",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "EMPLOYEE SAVINGS PLAN"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/EmployeeSavingsPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r98",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r153",
      "r154",
      "r200",
      "r440",
      "r441",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SegmentInformationAndConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r150",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r153",
      "r154",
      "r200",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Percentage of sales derived from large number of customer"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SegmentInformationAndConcentrationsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r153",
      "r154",
      "r200",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SegmentInformationAndConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r288",
      "r289",
      "r308"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred revenue and customer deposits",
        "verboseLabel": "Contract with Customer, Liability, Current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/RevenuesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r185",
      "r187",
      "r193",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r74",
      "r488"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of sales",
        "negatedLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails",
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r103",
      "r401",
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current: Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r103",
      "r401",
      "r408",
      "r410"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Total current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r103",
      "r401",
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current: State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "DEBT"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Loan bear interest at variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r26",
      "r275",
      "r509",
      "r525"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Notes payable, gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDescription": {
     "auth_ref": [
      "r25",
      "r26",
      "r281",
      "r508",
      "r509",
      "r522",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.",
        "label": "Debt Instrument, Description"
       }
      }
     },
     "localname": "DebtInstrumentDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.",
        "label": "Debt instrument interest rate description"
       }
      }
     },
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r452",
      "r454"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r52",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentMaturityDateDescription": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.",
        "label": "Debt Instrument, Maturity Date, Description"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDateDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r54",
      "r104",
      "r281",
      "r282",
      "r283",
      "r284",
      "r451",
      "r452",
      "r454",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r451",
      "r454"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Less: unamortized discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r99",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt Issuance Costs and Debt Discount"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "auth_ref": [
      "r431"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.",
        "label": "Deconsolidation, Gain (Loss), Amount"
       }
      }
     },
     "localname": "DeconsolidationGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r103",
      "r402",
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred: Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r103",
      "r402",
      "r408",
      "r409",
      "r410"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Total deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r103",
      "r402",
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred: State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r399",
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "NOL\u2019s"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r399",
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Federal net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r399",
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "State net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r398",
      "r399",
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r399",
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": {
     "auth_ref": [
      "r399",
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Other",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r394"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r399",
      "r400"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedLabel": "Park stock purchase identifiable intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r322",
      "r324",
      "r325",
      "r331",
      "r332",
      "r333"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Contributions by the company"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/EmployeeSavingsPlanDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Percentage of contributions made by the company"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/EmployeeSavingsPlanDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationAmortizationAndAccretionNet": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Depreciation, Amortization and Accretion, Net",
        "negatedLabel": "Depreciation, Amortization and Accretion, Net"
       }
      }
     },
     "localname": "DepreciationAmortizationAndAccretionNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/PropertyPlantAndEquipmentDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r92",
      "r245"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation and amortization of property, plant and equipment"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r307",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "SCHEDULE OF DISAGGREGATED REVENUE"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r105",
      "r473",
      "r512",
      "r539"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due from Related Parties"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r71",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r121",
      "r123",
      "r136",
      "r137",
      "r138",
      "r141",
      "r142",
      "r518",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic net (loss) income per share of common stock",
        "verboseLabel": "Net (loss) income per share, basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfBasicEarningsPerCommonShareDetails",
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r71",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r123",
      "r136",
      "r137",
      "r138",
      "r141",
      "r142",
      "r518",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Diluted net (loss) income per share of common stock",
        "verboseLabel": "Net income per share, diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDilutedEarningsPerCommonShareDetails",
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r99",
      "r139",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Basic and Diluted Net Income (Loss) per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r390",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "U.S. federal statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r390",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends": {
     "auth_ref": [
      "r390",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for dividend paid to employee stock ownership plan.",
        "label": "Employee stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r390",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r390",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "State tax benefit, net"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued payroll and related liabilities"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r375"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Unrecognized compensation expense related to unvested stock options granted under the plan"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expense expected to recognize over the weighted-average remaining vesting period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SegmentInformationAndConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r112",
      "r118",
      "r120",
      "r144",
      "r215",
      "r280",
      "r285",
      "r377",
      "r378",
      "r379",
      "r404",
      "r405",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative",
      "http://harrowinc.com/role/StatementsOfStockholdersEquity",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r92",
      "r279"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r459",
      "r466",
      "r471"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r458",
      "r470"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Present value of future minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Current portion of finance lease obligations",
        "negatedLabel": "Less: current portion, finance lease obligation"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance lease obligations, net of current portion",
        "verboseLabel": "Finance lease obligation, net of current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r470"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r470"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r470"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r470"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r470"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r470"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: amount representing interest payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderFinanceLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r461",
      "r467"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payments on finance lease obligations"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r459",
      "r466",
      "r471"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r469",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r468",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amortization method of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar either by their nature or by their use in the operations of a company. The straight-line method is the preferred amortization method, unless another method better reflects the pattern in which the asset is consumed.",
        "label": "Finite-Lived Intangible Assets, Amortization Method"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationMethod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r232",
      "r233",
      "r237",
      "r240",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r237",
      "r490"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r232",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r237",
      "r489"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesGross": {
     "auth_ref": [
      "r246"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Loss on disposal of equipment",
        "negatedTerseLabel": "Gain (Loss) on Disposition of Assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/PropertyPlantAndEquipmentDetailsNarrative",
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r77",
      "r92",
      "r210"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Investment (loss) gain, net",
        "verboseLabel": "Gain (Loss) on Investments"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "auth_ref": [
      "r456"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.",
        "label": "Gain (Loss) on Termination of Lease"
       }
      }
     },
     "localname": "GainLossOnTerminationOfLease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r222",
      "r224",
      "r506"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance at December 31, 2019",
        "periodStartLabel": "Balance at December 31, 2018"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "INTANGIBLE ASSETS AND GOODWILL"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/IntangibleAssetsAndGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r99",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Intellectual Property"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r99",
      "r226",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r92",
      "r223",
      "r225",
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedLabel": "Impairment of Park goodwill (see Note 2)"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r73",
      "r102",
      "r171",
      "r183",
      "r187",
      "r190",
      "r193",
      "r214",
      "r442"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails",
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r92",
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/IntangibleAssetsAndGoodwillDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r92",
      "r244",
      "r249"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r99",
      "r243",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r69",
      "r171",
      "r183",
      "r187",
      "r190",
      "r193",
      "r503",
      "r516",
      "r520",
      "r543"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Loss before income tax provision"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails",
      "http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails",
      "http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r391",
      "r392",
      "r397",
      "r406",
      "r412",
      "r414",
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r103",
      "r119",
      "r120",
      "r169",
      "r389",
      "r407",
      "r413",
      "r544"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income tax provision",
        "verboseLabel": "Income tax provision (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfProvisionForIncomeTaxesDetails",
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r68",
      "r99",
      "r387",
      "r388",
      "r392",
      "r393",
      "r396",
      "r403",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Deferred revenue and customer deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "verboseLabel": "Accrued payroll and related liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares": {
     "auth_ref": [
      "r124",
      "r125",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of contingently issuable shares.  Contingently issuable shares are those shares that are issuable for little or no cash contingent on certain conditions being met.",
        "label": "Denominator \u2013 number of shares used for diluted earnings per share computation"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToContingentlyIssuableShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r230",
      "r235"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible assets, net",
        "verboseLabel": "Net Carrying value"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r79",
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r519"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r86",
      "r89",
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "negatedLabel": "Less: amount representing interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r514",
      "r537"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "Accrued interest (see Note 12)"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r62"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://harrowinc.com/role/ScheduleOfInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventories",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r15",
      "r63",
      "r99",
      "r143",
      "r217",
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedAtFairValue": {
     "auth_ref": [
      "r556",
      "r557",
      "r558"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.",
        "label": "Investment Owned, at Fair Value"
       }
      }
     },
     "localname": "InvestmentOwnedAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r213",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment in Eton Pharmaceuticals, Inc. \u2013 Related Party"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r536"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r211",
      "r504",
      "r521",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Stock-based payment of consulting services"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r12",
      "r246"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "LEASES"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal Fees"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r470"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r470"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "verboseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r470"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r470"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r470"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r470"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r470"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r470"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: amount representing interest payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r48",
      "r102",
      "r185",
      "r214",
      "r427",
      "r432",
      "r433",
      "r442"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Total liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r35",
      "r102",
      "r214",
      "r442",
      "r511",
      "r532"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Total liabilities and stockholders' equity",
        "totalLabel": "TOTAL LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r50",
      "r102",
      "r214",
      "r427",
      "r432",
      "r433",
      "r442"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.",
        "label": "Current portion of paycheck protection program loan payable"
       }
      }
     },
     "localname": "LoansPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r26",
      "r276",
      "r509",
      "r528"
     ],
     "calculation": {
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Total minimum payments"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r106",
      "r274"
     ],
     "calculation": {
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r106",
      "r274"
     ],
     "calculation": {
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r106",
      "r274"
     ],
     "calculation": {
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermLoansPayable": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Paycheck protection program loan payable, net of current portion"
       }
      }
     },
     "localname": "LongTermLoansPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Loan payable, net of current portion and unamortized debt discount"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r270",
      "r272",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Accrued damages"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r262",
      "r265",
      "r269"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Lost profit damages"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesPaidValue": {
     "auth_ref": [
      "r262",
      "r265",
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages paid to the plaintiff in the legal matter.",
        "label": "Litigation amount paid"
       }
      }
     },
     "localname": "LossContingencyDamagesPaidValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r12",
      "r246"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Lab and pharmacy equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r58",
      "r102",
      "r214",
      "r442",
      "r510",
      "r531"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of noncontrolling interest which might include background information, terms of the ownership arrangement, and type and terms of equity interest owned by the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Description"
       }
      }
     },
     "localname": "MinorityInterestDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r88",
      "r90",
      "r93"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r66",
      "r67",
      "r70",
      "r93",
      "r102",
      "r111",
      "r113",
      "r114",
      "r115",
      "r116",
      "r119",
      "r120",
      "r135",
      "r171",
      "r183",
      "r187",
      "r190",
      "r193",
      "r214",
      "r442",
      "r517",
      "r540"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Numerator \u2013 net (loss) income attributable to Harrow Health, Inc.",
        "terseLabel": "Net loss",
        "totalLabel": "Net (loss) income attributable to Harrow Health, Inc.",
        "verboseLabel": "Numerator \u2013 net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfBasicEarningsPerCommonShareDetails",
      "http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails",
      "http://harrowinc.com/role/ScheduleOfDilutedEarningsPerCommonShareDetails",
      "http://harrowinc.com/role/StatementsOfOperations",
      "http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r66",
      "r67",
      "r119",
      "r120",
      "r429",
      "r435"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net loss attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r285",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other (loss) income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r26",
      "r509",
      "r528"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "totalLabel": "Notes payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Current portion of loan payable, net of unamortized debt discount"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r171",
      "r183",
      "r187",
      "r190",
      "r193"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "negatedLabel": "Operating Income (Loss)",
        "terseLabel": "Operating income (loss)",
        "totalLabel": "Income (loss) from operations",
        "verboseLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails",
      "http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails",
      "http://harrowinc.com/role/StatementsOfOperations",
      "http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Current portion of operating lease liabilities",
        "negatedLabel": "Less: current portion, operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfFutureLeasePaymentUnderOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r462",
      "r467"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r457"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r469",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r468",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r185",
      "r187",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "ORGANIZATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r514",
      "r537"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other.",
        "label": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfAccountsPayableAndAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Deposits and other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.",
        "label": "PREPAID EXPENSES AND OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "OtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/PrepaidExpensesAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherInvestments": {
     "auth_ref": [
      "r42",
      "r535"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments classified as other.",
        "label": "Investment in Eton Pharmaceuticals"
       }
      }
     },
     "localname": "OtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other (loss) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r7",
      "r10",
      "r221"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Interest paid-in-kind on SWK Loan"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Investment in patent and trademark assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r342",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r9",
      "r39",
      "r40"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r8",
      "r10",
      "r220",
      "r221"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of common stock",
        "verboseLabel": "Proceeds from Issuance of Common Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Paycheck protection program loan payable"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherDebt": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from debt classified as other.",
        "label": "Proceeds from SWK loan"
       }
      }
     },
     "localname": "ProceedsFromOtherDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds on sale and disposal of assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from issuance of warrant"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r66",
      "r67",
      "r87",
      "r102",
      "r111",
      "r119",
      "r120",
      "r171",
      "r183",
      "r187",
      "r190",
      "r193",
      "r214",
      "r425",
      "r428",
      "r430",
      "r435",
      "r436",
      "r442",
      "r520"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net loss",
        "totalLabel": "Total net loss including noncontrolling interests",
        "verboseLabel": "Net loss (including noncontrolling interests)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows",
      "http://harrowinc.com/role/StatementsOfOperations",
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r45",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r253",
      "r562",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "PROPERTY, PLANT AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/PropertyPlantAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r44",
      "r246"
     ],
     "calculation": {
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r20",
      "r21",
      "r248",
      "r533"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r43",
      "r99",
      "r248",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r20",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/PropertyPlantAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r20",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r72",
      "r216"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Provision for bad debt expense"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r99",
      "r205",
      "r207",
      "r208",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r326",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails",
      "http://harrowinc.com/role/StatementsOfOperations",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r326",
      "r472",
      "r476",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails",
      "http://harrowinc.com/role/StatementsOfOperations",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Principal payments on SWK loan"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.",
        "label": "Repayments of Related Party Debt"
       }
      }
     },
     "localname": "RepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r386",
      "r574"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails",
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r99",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r97",
      "r505",
      "r529"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "periodEndLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheetsParenthetical",
      "http://harrowinc.com/role/RestrictedCashDetailsNarrative",
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r32",
      "r285",
      "r380",
      "r530",
      "r553",
      "r554"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r112",
      "r118",
      "r120",
      "r215",
      "r377",
      "r378",
      "r379",
      "r404",
      "r405",
      "r550",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r162",
      "r163",
      "r182",
      "r188",
      "r189",
      "r196",
      "r197",
      "r200",
      "r306",
      "r307",
      "r488"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Total revenues",
        "terseLabel": "Net Revenues",
        "verboseLabel": "Revenues, net"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails",
      "http://harrowinc.com/role/ScheduleOfDisaggregatedRevenueDetails",
      "http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails",
      "http://harrowinc.com/role/StatementsOfOperations",
      "http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r100",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue Recognition and Deferred Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r309",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "REVENUES"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty payments"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesCommissionsAndFees": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).",
        "label": "Commission expense incurred"
       }
      }
     },
     "localname": "SalesCommissionsAndFees",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/AccountsPayableAndAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "SCHEDULE OF PROVISION FOR INCOME TAXES"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": {
     "auth_ref": [
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]"
       }
      }
     },
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r330",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": {
     "auth_ref": [
      "r126",
      "r138",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share.",
        "label": "SCHEDULE OF BASIC EARNINGS PER COMMON SHARE"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": {
     "auth_ref": [
      "r126",
      "r138",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.",
        "label": "SCHEDULE OF DILUTED EARNINGS PER COMMON SHARE"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "SCHEDULE OF INCOME TAX RECONCILIATION"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r340",
      "r372",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SegmentInformationAndConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r232",
      "r236",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/IntangibleAssetsAndGoodwillDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r226",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "SCHEDULE OF GOODWILL"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "SCHEDULE OF INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r15",
      "r36",
      "r37",
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "SCHEDULE OF INVENTORIES"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "SUMMARY OF FUTURE MINIMUM PAYMENTS"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r45",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r171",
      "r174",
      "r186",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r171",
      "r174",
      "r186",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "SCHEDULE OF SEGMENT NET REVENUES, SEGMENT OPERATING EXPENSES AND SEGMENT CONTRIBUTION"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SegmentInformationAndConcentrationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r342",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails",
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r347",
      "r360",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "SCHEDULE OF STOCK OPTION PLAN ACTIVITY"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "SCHEDULE OF FAIR VALUE ASSUMPTIONS"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r286",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "SCHEDULE OF WARRANTS ACTIVITY"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/IntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r158",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r182",
      "r183",
      "r184",
      "r185",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r193",
      "r200",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r158",
      "r160",
      "r161",
      "r171",
      "r175",
      "r187",
      "r191",
      "r192",
      "r193",
      "r194",
      "r196",
      "r199",
      "r200",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "SEGMENT INFORMATION AND CONCENTRATIONS"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SegmentInformationAndConcentrations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r99",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails",
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r92",
      "r254",
      "r256",
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://harrowinc.com/role/StatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Number of RSUs cancelled/forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Number of RSUs granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Weighted-average fair value of options granted",
        "verboseLabel": "Weighted Average Grant Date Fair Value, RSUs granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of RSUs unvested, Outstanding, Ending balance",
        "periodStartLabel": "Number of RSUs unvested, Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of RSUs vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Weighted Average Grant Date Fair Value, RSUs vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails",
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Number of Shares Warrants Outstanding, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.",
        "label": "Number of Shares Warrants Outstanding, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Number of Shares Warrants Outstanding, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r348",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodStartLabel": "Number of Shares Warrants Outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Maximum number of common stock issuance under the plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Shares available for future issuances"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Number of shares, Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Avg. Exercise Price, Exercisable Ending Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of shares, Options cancelled/forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of shares, Options granted",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Number of shares, options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r349",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of shares, Outstanding, Ending balance",
        "periodStartLabel": "Number of shares, Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Avg. Exercise Price, Outstanding, Ending balance",
        "periodStartLabel": "Weighted Avg. Exercise Price, Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Options vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "periodEndLabel": "Number of shares, Options vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Avg. Exercise Price, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of modification of award under share-based payment arrangement. Includes, but is not limited to, terms for expiration date, vesting rights and exercise price.",
        "label": "Share-based compensation arrangement by share-based payment award, plan modification, description and terms"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r339",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://harrowinc.com/role/ScheduleOfRestrictedStockUnitsActivityDetails",
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative",
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted Avg. Exercise Price, Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted Avg. Exercise Price, Options cancelled/forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted Avg. Exercise Price, Options granted",
        "verboseLabel": "Exercise price of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Range of Exercise Prices, minimum",
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "verboseLabel": "Options exercise price, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Number Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Number of Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Range of Exercise Prices, maximum",
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "verboseLabel": "Options exercise price, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r367",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected terms (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Avg. Remaining Contractual Life, Options exercisable",
        "verboseLabel": "Weighted avg. remaining contractual life, options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Avg. Remaining Contractual Life, Options outstanding",
        "verboseLabel": "Weighted avg. remaining contractual life, options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Weighted Avg. Remaining Contractual Life, Options vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based compensation arrangement by share-based payment award, options, vested in period, fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Weighted Average Exercisable Exercise Price"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Contractual Life in Years"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionOutstandingAndExercisableDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r287",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "STOCKHOLDERS\u2019 EQUITY AND STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r1",
      "r158",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r182",
      "r183",
      "r184",
      "r185",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r193",
      "r200",
      "r226",
      "r251",
      "r255",
      "r258",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfSegmentNetRevenuesSegmentOperatingExpensesAndSegmentContributionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r101",
      "r102",
      "r123",
      "r126",
      "r134",
      "r136",
      "r138",
      "r145",
      "r146",
      "r147",
      "r214",
      "r280",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r57",
      "r108",
      "r109",
      "r110",
      "r112",
      "r118",
      "r120",
      "r144",
      "r215",
      "r280",
      "r285",
      "r377",
      "r378",
      "r379",
      "r404",
      "r405",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative",
      "http://harrowinc.com/role/StatementsOfStockholdersEquity",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations",
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r144",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/InvestmentInSurfaceOphthalmicsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/ScheduleOfCondensedIncomeStatementDetails",
      "http://harrowinc.com/role/StatementsOfOperations",
      "http://harrowinc.com/role/StatementsOfStockholdersEquity",
      "http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/SummaryOfCondensedIncomeStatementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r28",
      "r29",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock issued during period, shares, acquisitions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.",
        "label": "Exercise of employee stock-based options, net of tax withholding , shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Number of common stock issued for consultants services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r28",
      "r29",
      "r280",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Number of shares issued",
        "verboseLabel": "Stock Issued During Period, Shares, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r280",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Issuance of common stock related to vesting of RSUs, shares",
        "verboseLabel": "Shares issued of restricted common stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative",
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r28",
      "r29",
      "r280",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Stock-based payment for services provided, shares",
        "verboseLabel": "Common shares issued under share-based arrangement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r28",
      "r29",
      "r280",
      "r285",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of shares, Options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.",
        "label": "Stock Issued During Period, Value, Employee Benefit Plan",
        "negatedLabel": "Exercise of employee options, net of tax withholding"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r28",
      "r29",
      "r280",
      "r285"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Issuance of common stock related to vesting of RSUs",
        "verboseLabel": "Number of restrcited shares, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r28",
      "r29",
      "r285",
      "r341",
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock-based payment for services provided"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r29",
      "r33",
      "r34",
      "r102",
      "r206",
      "r214",
      "r442"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Total preferred stock and stockholders' equity",
        "totalLabel": "TOTAL HARROW HEALTH STOCKHOLDERS\u2019 EQUITY",
        "verboseLabel": "Total stockholders equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/ScheduleOfCondensedBalanceSheetDetails",
      "http://harrowinc.com/role/SummaryOfCondensedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r102",
      "r108",
      "r109",
      "r110",
      "r112",
      "r118",
      "r214",
      "r215",
      "r285",
      "r377",
      "r378",
      "r379",
      "r404",
      "r405",
      "r423",
      "r424",
      "r434",
      "r442",
      "r444",
      "r445",
      "r449",
      "r551",
      "r552"
     ],
     "calculation": {
      "http://harrowinc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "TOTAL EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/BalanceSheets",
      "http://harrowinc.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r450",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r450",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r450",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r450",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r477",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfAmortizationExpensesForIntangibleAssetsDetails",
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://harrowinc.com/role/DebtDetailsNarrative",
      "http://harrowinc.com/role/InvestmentInMeltPharmaceuticalsInc.AndAgreements-RelatedPartyTransactionsDetailsNarrative",
      "http://harrowinc.com/role/StockholdersEquityAndStock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r148",
      "r149",
      "r151",
      "r152",
      "r155",
      "r156",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Deferred tax asset valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative",
      "http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails",
      "http://harrowinc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://harrowinc.com/role/ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Dilutive common equivalent shares"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfDilutedCommonEquivalentSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r122",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted average number of common shares outstanding, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r121",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted average number of common shares outstanding, basic",
        "terseLabel": "Weighted average number of shares outstanding, basic",
        "verboseLabel": "Denominator \u2013 weighted average number of shares outstanding, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://harrowinc.com/role/ScheduleOfBasicEarningsPerCommonShareDetails",
      "http://harrowinc.com/role/ScheduleOfDilutedEarningsPerCommonShareDetails",
      "http://harrowinc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1828-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2062-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "48",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2538-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "48",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2538-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "51",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2574-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2597-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2600-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "54",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2603-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8475-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27405-111563"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121554622&loc=d3e15372-109273"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4587-114921"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121604053&loc=SL77918607-209975"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(1),(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f,g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r575": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r576": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r577": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r578": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r579": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r581": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r582": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r583": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r584": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r585": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r586": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r587": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r588": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r589": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r591": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r592": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29"
  },
  "r593": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "i",
   "Publisher": "SEC",
   "Section": "3",
   "Subsection": "10"
  },
  "r594": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r595": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r596": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>112
<FILENAME>0001493152-21-005583-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-21-005583-xbrl.zip
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M",WC4S,T.T?&-+9D[QHOFQA)36%FIH#E)#%+]D.04##>Q%C*M6*0K[R7\7_
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MJI*-KB,08G.C4&RN _'C];'CK(WPL!$,NJ\5")IILS&&FU?E4TI%,&)?B)L
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M/#OI\C!@9.>7G_$%G$/OM-?_W!*_O^_2B(\Z^$+O#,?2O^S 8)N-_OEE7^S
MF$\_HF%<G'7?G?;>=<^.N[O8/4^UMM7+[KO.Y<EIE\=G^C"K^'OG2G1./O6P
M1_@9?A,7,)4>OXU?77T\?M]LF+GC-,[.^[_W^N^O8+EI+/C2VT[O].-E%U^
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MJK6Z[)*#\BZB+US\Q]FZ4962PZCD5!&2?A'MO]"%Q%VM)H8WSLP*:&CGJ@W
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M(ME#+5;.T 26R+3,B4H+B3QQF&:CG!@:7$;(=/#6P>WV[JMON*X\FAE(.-G
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MM!Q_MA'3VQ!AJ8.^-LZA!%Z5+QAROV0/#YG&*C5M.-3&KQ83J$L:4<JD&%#
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MCJS$%T& [R_5:^#"9=@[0@EC)GO%LU-U0E.TEL=X!PL3+A\OC!?%C&]NUB^
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M:3QXQKR2$U-OSBL5>X\[E#)ZD(O#$+5VG"S8#^N8.6P'%@O Q5'D\G0 "'H
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M9%07R]C.==% 7J3KA1^LRWG(L0$D7!E$VVQ0Z"X)M*.1,B$Z?G%GC+'T*W#
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MSO+NP8B^_M]IE&7I+7#.]C"=;?=O[>=S,4T3??IV7AV\W!4_/W^^]P+^V![
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M*$C)NV8@^I,TLF;PU4$YP'A9UE3\*&; ">AR:82 V8TZ.WWO'V6F&T2,RET
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MA@_D0WL?'5<%+J1C[.48\2N@N#P<$,:(&[W#T"/+00>/O0JPD<<0S=2^>H/
MKRJ%WHZ7W;@ Q>,)R]24FV['6@V:&T$7._/*6V&C<P/\A$06/%*CICU.\ "S
M=.JRE"\IA08W/0Q?.T#ZL3][S3\V^^P2;]7[_>[O=(J#;5BM+- [S3PP?S5,
M7=7K?5TSSTT3#-(I,@(JLI$[0!242UEP6;PLGI.&F*:7&5OUAJ&!IF889J_>
MU#L_KS/%3'3<JZMJ?/QA53,\9)/PU.)%%0P('2*:LXGC0#_@"<5_A<U+L?J?
MZ7FBE:KQT,4EXN[5<*#] $KY;SQ40!P\%'Z\+_>_B#)L0R<NA0BZU'3UXV+/
MTZ4#7204<<;,Z2# 0PSI_,4DL=1-T3X<#K$W7JJ.].ZBE-\+EC(O+XX,Y#:%
MARSKJEA1TR3/7HZ)R2!;<")8V>BB\4=)5Z)[-J$^H9!AXJTHHF>KJ$O'T,-/
MD: U$1'9_%=_;\WN_19L=(BP/[S6WPYKDN[Z%+LXZ#]FA2##:/YW[N\XLT_>
MN_9<I2.(4I$#9Y"B55F?!W>KA/W3?!QJ1=:=V^Y-=H_@GCNCA\V?GRD2OD4T
M0'-)Y99>&G,IJ914GMJ9'J0/(N,F<7TR]<($^)=_S\Y+,H_@?Y-''A'J82BA
M7)K2@I22Q8S5>[)-'LMW^2RY88G&XB^[O0FD+@3:GREF<\FD9/)DEIA3.H(V
MDEA*+)-D21LY3#(IF4R2)28C,]DH)92)LJ0-YR.,G*'D4G*9)$ON<(")1QPR
MGHO$)9.2R:3=P&TTC30%\I^4DLO36=*'0P?-)9@2S(19LNWA4J(IT4R )2O/
MEXOE1))&26,":!2)M\VN[(^)(+(0+7"OG>/:?)[SEUP.W(2WX KHP3&J\@!_
MILBSPX%5T/7#Y:9!!1@P8""7B\NFZG=Q5FN[>KZ'Q7AK4347]KPK8'47P/HN
M@9>+M#>7]Z]M ]A0O=(NWESMZ*!1-&))Y")TN7SQ;%]8]^<S-DNV3*A\]>JH
MU^*&/,4T*05N<>SV2HT*89%$(78$;J_+D]>V?!3"?69BXUFX/^T?4$L#!!0
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MCDB#."/Y@J!9<78/2254O&!3Y 1QCO@7QZ[[DF8Y0_1:_PC,4%#K'I7(8BR
M]))(%]NGMD8%7$]8%,NY+M"F8"RT41Q[XW32&8^F>BMPTLZ$W*Q'=E>0JB"U
MBY#ZUY9 :C@!9]S2F7]1^G,F3W6.H3S%03I$1I' PWW]P7IZCW$%EBG("#&*
MP09;@#0;Q4)/J 852U"+D1ZCXQ"CL%CJ#.N12E,RSOE !:=*!A#B-<WV$2@A
M(*$<,/S[8,+3,; .JK%!%F.)QC&O-4[VP9G2. G=D3L4E']+'=FH$T8":05X
MCCUD$';D#'A6;]&#WB+LK0@O5UF()2@D;59HVVVT_91DXUL"MBYH;+H08#;6
MV@"?->YX% L&/$/A]MPJ%(J- /'ANLLC/)DI;  5T$QHTE5EU :I;8SRQ4M9
MMJKO%,3<DBD/\99@\7+M1Q<%2C0T2,M8A-Q8:T=:A((K0:,0+AJUBA/EEG3=
M9YHB1$MU;6-**\6D!K3*H/ZCFE-.SI+%G+0D#M!:LHPTL88+7E<#;_QK!%00
M11[6AW"CJ/O^KON#.NL/:M:W7F.J1^7;FC7:7I _6]X]XOGSA>$FK.?!_!K;
MJ2BN!S,1$JVYEBDG+<PUDIZR?H1PKL*"I AXP4<B%F9!@?2FOFF%L="U/'7K
MPFK1?"J6J4.KN^_SH4TS-46H:YL"" (45]8*FT0<0XI!?8QLQRLPI96#BF2I
M<?S&%49,4?!687FE77=/NP9;@CQ_QN.,9%TN&Q$%$$40&#%#_]4;$G!ES/X,
MP>H.-Z?C+-RP(NI,8EL1G(]D9IXVXSFZFI>E@1*<T9>W+]CH0?[4XAO<Q*!E
MI]1#!:D*4CL'J7!+(-5U7E^XJ.4(%+Y+6Z]Y$FT)F$>P>H$:HWA9!D&F"!0K
M<>GC5O,M#ZD-7J0W\8I7/SYG&-MB^_M/H#-"]J%$6BN=CRM &-F]8]I63K/2
MN _.M G793@?Y]O$W+(20BM"[03DVG#!8G$'^&$WDHM*>7GO*;(_>[).RXQJ
MQ<?=YN-/NK=RLB6$_+J]%?M66UA UG-RB)002;15O"U%$0%J'1.Y@'HR0'Z4
M9BQ-Y%DHC%2Z#$?M"6PW280Q '^C0D<2 UZZ'@HTDAIQ9NPC"5'T:=I3QD_*
M>A8@A\^9P(%87F=I8/>=/U1;*#M.L)\28-NRA=(IWA^A')A /-'N)NV3!@*0
M(WDH6>YBS('?45CH,D\V,+39,_M^7?$NR29$/2W[[%Y#+F<4;%90/,3:&DH!
M]23.\IP;5D$FH;]X+D#5. ,Z2Q ,.'0[HES#KJ7;5C9IJN"S0M-NHFE;-@4Z
M:1YD10I5B8>@ "NH$#7VW=F<29Z+SD0ZD_$,*$1+^3A_#UCE&@R2:2P7@%?G
M$^E4%W] /"04+,/;S>'FLY%V\';8J CQ-828\I"V:,KO638.3J;&S<R+?/*$
M+'W%+ L^R4UG[$>N@@G[S7Y7I?&W;II/:#&4LY@'=VY S+XQ\/V'U>JUZ[I>
MCJO\1EVKWFM7.\+?R2RZ$<Z0\FY4=^*[F'4^$1 Y2_Q["#+:<6'7+D/PK73G
MJW]=?O.:\H]:C5T(B,,FN\&U^12K?\XPO*!JI^QZ:A,!3=;GVK!:K;@]W=Z?
MA4UKWX__E:C])0#BL)9KV>K:M;ZV/03J%U:H39Q;NLL&)W@XX3%$MD;YY#W^
M2OG:@EC,:/$D%,]!JX[S4TS5R@37:89I%K<Q/'G])[MHN4[_9L/]WPWZ]QS_
M!U!+ P04    "  9A6A2]4X(U2$(  !D1   "@   &5X,S$M,BYH=&WMG&]S
MXC@2A]]/U7P'7:IV*U-E DDN5U? 4D4"N5#')BG";MV\%'8;M+$MCR3#<)_^
MNB4;") =<I.9#8SS(F!;?UJR^M&O)9OFS?#7?NO]N^9-M]W!3T9_S6%OV.^V
MFE7WB5>K^>7FY5WG(WL8?NQW?SD*96+J[+26&C84,6AV"S,VD#%//'?"8P^@
M1'B$&3'K_4OS-5C,U5@D%2/3.JLM#D?2&!G;,P8^FPJ/Q#BI,Q\2 ^JHU;R^
MNQVNUE4)>2RB>?U+M=FT6OP7G'%'K9^3D4X;S2H5B+UQ_Y7MV+!8B?'$O*;!
MS<M6]_-$C(1Y_^[\].2L6;ULO9KY!WL;7M_BJ^Y@V+ON7;6'O;O;]^_NKMGP
MILON![W;J]Y]N\^N>[=M_(K?[JXQ67? ?KOM= ?[U,2'[I5KW'GMC.4-?&@/
M+MNWW8?*W7_ZW8^L?34L!]^7[LP?F38BG+^FR3WO_;MV$BC*<,(N911YV#&*
MJF%FPDU]KUJS_08,VY?]+KOJ]OL/]^VKWNV_?CFJ'=GC^W:G4QR_N%DCJ0)0
M%1_[C*<:;2B^-=A,!&9"I=1^H@FM.1R\O/@IW06?1T5WX: ^RB?=YK#S\O)R
MFVHG9Q<B^8:=/NR\22N/3S^\DHG?VB.=:1,^!:9@*F & ;JBT.Q:JA@35?Z-
MF12> A8*C2.$S8$K!DF "3O@0SP"Q<Y//796.ZLQ&;(;KI2<L1O@D9EXK)?X
M)T_N%_X;6.5F/:55>GGIY?OJY6=[XN677$/@S),)B^?L,9&S"((Q>,[9%:12
M&19(+#:1!H==8KA(&$_F+$N,RH!IPPW$J&+(QSDZ(,H9@3@(N8^G%).Q,#B@
M7+J-! F20FNNYLX*3!?S1[!8612L\5R %F&]$<4?5!$E\(7RLQB3)5@&FH,>
MPF83X4^8SNC?,O\,%.2%4"MBH2/@@4C&. ;,!%NI4_#-P@0J/$4C98 -1M]
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M\BP01BJ]"$?M"2PWCH4Q '^B0D<2 UZZ'@@TD@IQ9APC"5'T:=I3QD]:]2Q
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MC\7.3JBQ.CX]^T>Y2B_2SL@X9Z9OQ,N9.Q(CDP,FJN].4@E%=W</H2"0!9U
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M.!WN7>%X<K0!Z:FCLXAB.XRQN-5!NASUIO2[D9\)KHAUD*X['=[)_$1]GIF
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M+KXN& &5]/F:3KL2'DLE/#YO!N)4_?!>!Q@6+@\N11C4HQL3O@X0E4J@7'9
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MO:1"0J7#73GJ!LT7=ZD,N*L+\L%?VQ7#+"/#5.<TK<1%1[H8)8*W+M(R[,O
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M\BLX5\BY!SF'03@(8"/%6>#+G7SYV!F[Z H]L^&X1E-[88,&VH1II33^^&Z
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MW @VT!H*.[2$[PC'RE/"HQPEO" ;X3%;$(M)X6'SQ[7XY[>;QID]$U+H8*0
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MM8.KQ$5FM%O$CB7P#/'MV3"X7[1KA_#G>7@=W/K%>[;S^9?_36ZC^-+SRH#
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MM].S$X.HJ0YLFSNU_;VMVM;N]KS(6TH7)I*MU15YB]-%5Q!_]/PN4%<"XD)
M'[/ORKES@[[7X&YH1:I).%$<U' 09!8W/["^"D%J$;R0,-H+/-##F'REY6 X
M"B04';A'?AO(-0C@%R""6*>GIYI4VOS&5)T$OM.WL)E*#:FDMC_$/"7'PJOI
M^A4>UM)WS[@7W(3V2&.ZP>GN<06;MCSMD^9R\-GCP9E_A.>QL2GF235X&62#
M'3V3"7E9N5RW7>I<E;H+3?=@WGV8'6/4[Y?S#YH J/,PV@=08-G/;BGV[%HS
MNY]D8*@V3-F E058M6,<V1:0RGZLMP20))C-@/;2S 'D7<BE!\(Q#^)TK$'V
M[2:VRMF5:VG**E\W/WTY7ETY/[$.S\^NC\^NKV951KDHBW!>N9^OR!$/[\=5
M_KSVJ((=<TMKFF52ZFP1C@1BSD4@ 0:PW&X8)+Z#4 C"#U;8;;W9K&_7-K?V
M:IL[.V]G$4Q1WWC/';@6GIWVE /YR;9Z(:HP_[?UO5YO@*S;O+SFF9S^],X^
MF'U-5VI<EL45-:&<@SMTCHCZ$W.U%^&#/P6E@D=M;"P8/1GH;*X=J*@(QLU,
M,#,[E#26E^3, BO-4H%E:^W@THU^\#1.;#1BEA0UFZ^0KGPJ%5:VUPZ^^=AZ
MWKM1L6U7L=WI6&CAPP224@('^\Z\8GJS62H([8!8$P8#W$A1P:4L=&:K5!C9
M73OX(KJJX # I2TH?Z;"2PG)RW:IH/-^[> K"+Z2-]D=$0^M(S="GW,25@1G
MP02G#(KVW$K1+*'F7 9*4@9,C!A?]C+&EUE;7Y8<-2605W9*Q73V@>E0T)%,
M]PE":[0*L,51$-;QWXD;#VOPA$<>8,/E;'W%R&/T//N.Q855K(LD;/=L&8[#
MO[72>@,SY&</*>?X1#ZW\PK)6XK9W3)AME%?.[B2&1+2]*,#TC$UNYR"TG,#
MJ 24[GVI4-- 2I?/A.!)H92=4)=4(E]-W_:&D4MD*X768> [G'*#SUR**/%B
M>N1\(+CE4DE%]-U73;K>E\IDO;F[=O [)E:YF*-SHS*A 5#PJ2<_-+4^J]D*
MDE@%!J.U^YE!]M"HH>V]UT?@]LH$K<;FVH&F5MK '<OJ2 BQJV0P\.C?=C@L
M+ZM\=B25BV#MEPI46VL'AY26)5FER^P/*)3=#84$%V6;-CE)S\8/@$DVTYP]
M_($AHFGB5J&O)'1LOU0\LK&--<$IWS1*^2.9TIW2&D)?.]$JE;.WL;-V<(ZI
M(]((YG,N!HCHE?!4F=$K,WK)R$@9,)$WHS=VLV;TRHY>#OIAQ!?52\5RWJ\=
M',E$VJ@F>X_G^EM*Z_BARLJR/F,Y#92+GUL4?C!?VG^%Y,B 6*EB8QM[:P<:
M4CP7K"TA_&@1HLT#Q>+G!E 9"%.IHM8:^VNJ3\>0IW)^ZP,IZKD#-%X?PK;:
MH-1_$KX &H4*.G]/I"HUF$NC]UB_WU)Y\UX[62M5R-QF'=1]1B'/A%"&[A2
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MZF!J'+5IT5DE@<XJJ6%Y;3B@ENOA8]P#MPV+ZR2XT[@XMA/@4[I./1**FN7
M,7G!@""")7U%V%9'#@_#,0^ #5(X.$)&5LJ.*,K7 @*!A>,!2#Y&TB%&8FPW
M7$MI(^&T3:* I:@[+&_<>VNR%PD/WK,!I.VAN5(K8M,[/>"(%B O:+%G2&X>
MG(4O</'X;M@*_K'(K+V&%?C#Q(WES2,'Y]^87]%!%'");U]X>CI8QUOVZR$
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M8+IT3L?GWX#N.> Y5P3N66IQJK).H&5F4&4@U0O:LBR#]44X77$+2*A9:0T
M+F%AU 0PZ_BRQQ149.*]'1HG8CLJ!KCP/6*%-AVRIJI,L1V8V)ZN%DIW2X5]
M,4TL(H:C-R!#PSG4F\%ZAL6#Y-P[^1H&EW=GOVIG+MD5-%O/%RZ^]]IQS4E#
MRX>[?<OZ?XT*79+?TC!>B;16KO+<OC3%N^1SQCMBACO)N "S;'0!,1[FRVI+
MS/ _$+@,Z% '7V&I#+*1D4&>2L?GTHJ1.K>I<)QI[S(,\M[0J!>M)F=4YL;P
M6'C#0,AL-"Z:8^DF#:K0.25Z]:45B>*-43I >+,9#NO'4]*4?R.K:\OBJZV
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M7W,)$K$=N9%\476#%G>#L,_SB6B%C[\]#[\PFWAA\M=B=>5A]T(,7+Q<Z<4
M"AQ*TQ23<NS"R9Y]O!?X$CVJ4O=MIX]Y":I^,OJ],'94941@55$J?N8K'T!&
MK8=9C%QJ4^20"^ I\79P83,?M4*KL5E'%MW83O.5R6V!34+R\@"9Z3B;C\J6
M!C=";00.3/S+K,B+;!*DG4C&-)\%8=RS#FT8U_5MRB;&LDE?*0Z87G1%3HN6
M+*,NT';4 R%E6-W%^7=S ,QS<JRZ:4A"91"4S]T9B&2SM'Q%Q8^LIG6A<EO1
M4M;^L6$U8UFW"EY/UB^/TCDIGCVU1.B&JZ--A8!?R!GH8O>9GD-I V2SQZAL
M.;-5VY&%D*(>WD3#LER3YE<43;/5P+;J.@>?.\>P/'43Q.94(YF.>23:5,31
MVI)UT#=4ZT:80(2A\^N828!)(6X7;D2N TV '6CBM$*U8HZUE#!0!2@EF9KV
M-K4Q,JS#$]3T1G:()6F;\F%5CV.\QY(:^( 4; ?A47XMUF-Y$=F>DT.Q=ZI0
M[!F$8F]5H=A+40SR*=-$1QNF*19Y.<H]^67DM;S;CS-@%CF$"HV8F7;&H&A1
MG;8;K!.$R8VR8"<S.ML']M83D6N/VCM["2S 4HFC1EU!8"R] $MCV5[-*("H
M"G_*/C0P4HQ<%-@-^8*Y?QLW7!#BQ^J*V0[>=-6R/2I=0BS:/:K+2S%?[/P<
M!%'DMCQV*6JVS%+,K<BU)/&M9@23L2Z2L$W*@6Y6(:M1T/S,D'3Z8-R/C-Y\
ML%XI -A16J>"?HUO(X^Q-U2BA(?1N@GO)?7UI92YK*M;1>0,W(%  V;&)QUS
M]\2\,O/U^,LURA&RG&H@N]6-#,<3(U&%$*@Z/JVN1$*U$#1KG2%V@H$;N(Y&
M34%,LG(NJF(JN ,4*M#']@7H8D;@91IP5T+]_ F-Q(0D-CXH;!YF-F,1Q2YG
M/TB+-.8PXDF?_@&7F4Z;;9(YD.7;-")R%4U @5P"1%[VCNN12Q^-81C_Y79M
MZ?N>&.9P>G:4;0*D(CC1I): HHE"M[1F80],O!$Z!)L*--I]FIF^$N22SQD4
M9&B*LB; Q&U2.&JJ)J%1(5Q)VTQ::TR<B!XT6+&7"V8Q7;K L4B2?A"4*\,$
MH":F<SRX/J0JHEM5$W\VE3<UT6(<"AVBU'N?6^GE&S,;C9?7P>6C(ISA>-UW
M>QMUW]655/FU"G5?-XH2&9^#(=2RWM1XE3A56ID1/DAC94X\067-MZ>"V?5U
MC:2)_%H>KANE$5%4P>J',#1V-+N9*KM,38_4<(=2'LOK\.H^TS93'OE0\E6E
M]8>B;[N^N74U,Z^!-R0MG[<A\8"%S52E57,"N)U4C]8,*/;<'T9;(%E]"Q&)
M4\P'#:7BPFE'5TXAZ'(&B6Z/!#(J=M148N7X 17'Q]*,F-N"95M@MNU852HS
M8_U]$]6R.C5&V%5D;]:J'09E5JK=<P&"=UO6RU9:V;31*:HLB:G7,376<2DD
M/*FK!W<8Y0RI+!A-8"/J$F.DD1#CR86_IFVY+9HG9_29*B9W?K'I,<&V?%EG
MAVKID/KUU28F^KZVND)MU&?"1;M(3Y+!=(R4AI^&D<+LS]"5(95'D -X!9)?
M.9PQS)6KJ7!L>V1-)J_ES(=QK%F]NI U>]1C!HMI;^9-TM-P9<K_+&3+RW69
M2D]=*0!S?/3EX7*'7BY_80,5T0U$B>.X\:+(&').-S2(0R:(&6X/VW0VTNAQ
M+E"?$L9'D/75E21456DY!RE'C3=DP+D;33+ZY<Q[N7Z4F=?)U1;/7>='Y2=/
M9+A'44O"GV(F>=YB_#*D0JXJ6M*ZE+V^:K+^D&KSXU!98BP?QP6]*,, :P)R
M@IC:-NKO(P_7TF>[NL++K>F2=)B.@'%P?92?T1]OO$OK&79(BD1%'9\E@T@R
M<JZ4OO,4/D=ZS"@*] TOK)Z[NI(IG[MDA[X\+B6C)(9*?\+'J1),TS #EWLA
MRWC)FI0DK\MB4G1MC^R.>2, FF&Q%HXJIPF/X$?Y^"+LU8;Z@3=,>R KE:+&
MF@YQ#22X://%V*'1Y+<SKMD0H^^"<MVDN9=N,^Q'X*L<*IR'_+*3>)[Z] Q+
M5(^^UZRV@D*T\.TVB6+P-Z;KJ@<(>1=4@.]01ANJZB07;*NY!B9 88"!#+3"
M(D7PZ\;^WG;-R(3ZX:-T+^N2_&+'[=[ZG_9=GZO1^PZK%68-(S75"9E_/NW/
MC)/Z5E>FRNJSGI#4=X53%4895P40-"W:L:H/:V-K(.;?W"8(7F?L#P)5M^6!
M)=FZS:"42,B^1-Z#5 &M6:K<:PUMBDSJ55 =GV1-UZ5D.U9HP'[)., R4J1K
M#.<;<U'DI<BACFJ]8)6"09#V=TV[MOB!KST^6&=?_:V265/(RXI?BFZITAFZ
M))!9S@>C++EB::1Z/+C4:O#&A94%'2YT(\=@/RM25+,G9IJ,C,W<V:YI)'VN
MKJ@9PGO[<,<37;P'NTL,4"(AZW&[9_M==9OEUF0(;W;X&(M$JV96+-3>ZOK6
MM 4H36/:DD%1/+LE//*/IQP@2P7T_=;OTCI!:C(V<AQXLX<YOJ(6AKLO\SU&
M2:/A"-RP_B0KNAX]XF8CZ9&3<4S]@SQW2*&X]9J159+"B:E><=:R[J4DJ<LH
M=>-BM$RYN.ZXH0+55.%9)$.RB4J-2[EVU :03&N3HDDB$4W94&6X^J]1+XE^
MH<K!RN,RC[0/EQ3)J;3T<= SLQ#B*U2U*U]@1FYU1>_F3^\"Z5"[([E"]G&=
M 'M?>J8X3*2@TIA)FD+1M3GA:SRY\["WS% U^DC)1BT'_IP_#"DM%5H.M-.=
M0L]#GT&IW%H1E563XQ61)ZE<KZZ8BVBJAZ0H)HW2Y.._-I*LT%8&UX6NWC'\
MD=BQ+L-^C@'UPOH4!#] Z, *_!VN-Y]?&5X14#;5@N (/EAOW+>2KLDE2R>=
M*5LI>8<M'QC!\!%^)W\H5RU_AH^*NP&^B9XI>@@K9O +Y9,UZM6I>HLCS^ R
MD]29D8J;D;9*<5E*#()3BK 8#? &ZJ,DQZ??TZQ)9'[CWA1.@/IK$OFAQG X
M,B^0Z@;!P:84TZ QS& F$FKN]6:^4,,@\6,7Z?0015!_74^80'Q#)%)5C3,^
MY Q;$C0);X:JPE)?NR?ZW&L(RX'!2^12I2G' (=")D:8%3$Q>1JX2@R(N^]V
M(I.518SL3.MINQ\DLM$P>EJY6037XU)7(&<ODY%MC'VJ'2I3)%-WL#F  VR"
MK2)R$[%4$@?26!Q0FWVC:L1@^(Y>1@G0R;'>NU6L]PQBO;>K6.^E*.OTE&E>
M8=0*!_YR2TGJC53R22]KR2S2?,D+DNU.POX)N?O< ;N@9B-&43E!+6UAG.FF
M*MM 9)TO&=L=]:F3-;N,;B)4TQ:+_K"%W5=1F;)]@VX+0;]3=8K--B/,YLSP
MZB")904A8MPA,6+2;#F\6:GP<A/,:>?[3:A'46Z@YH-Z6FD0]*'MVX[-U42+
M-E1TL)TR500#&3 M>!1V03G_1TT:"XS&V/6G)O5A++20UA)EYU64AB^9725S
MCK.TR*(,'I4] $'9P]]R$/6$WQ>57!^_/,.))3OXREQ-+"Z,::ER^3'H(=C@
M$ 5*)U ]/_HM%7&O2DLP_X#OC,Y4T1 D*]P:%>4O&]G0NK"-C6X]@K6<8]TI
MLD6EG3-==#+&M\B,#51AXRBTX$<A]P9+JTN2I52%V>61,V8/1QM'P002K(R)
M%ADW<&0=1Q:WL0(\5IV62K]9K9.$+L_VT>KIV8D/TF>DS.;9(M&%21AMNS^P
M@;*@+5BW=)2+E?*R$6*,I32I)R=5M>P)VF<G$4H7PPH:VK(0DR%7-@)S/:-I
MD+D_XTZ X8Z2B+(MJ,8M>%5)+L\^SO<A[7J);<94H_I;=9@U%6\H/7,RLQ_3
MEH<HA7NV+,JBD_VI?(7V(Y#ZEEN1V=IKW/&R7R/U3,C>9516A*S]&-Z::^N4
M>8$Y-7/ 5$@/S7CP281<7KQ:6HU8-]Z!.3 =T8UV0>I/7,^1[8#(%"[-1M+5
M:3L@@%'# ";3GARS U"L+-?3S'E"K8$G>+(5$0NL7-$\J?&9U?XR$,T%;*CF
M .0/2<C:Z5'D7I>-N0;KSE?Z!2QB)CY<NNCRCFS.8= /8L']S9B38P:.C/9N
MA;((390-W&4$4S\RNL^BS97ZT?# M6TY4(-T?0S[]8A>4\C%N+N G+7&5#U&
MKYFA&I/Q'-Y]2Q1%-?8C B!WS" @LJ1O]D7X<JM/T6W<] S]9B%V/M.OPZ"2
M)(K2EGT#>XBR2VH^X[V-=+%YZDMF<AK>G[1RJ!J0$KVB6.58L['/G'JV0Y<T
M\*H<.M [VT,N5S347;BX3X3N_\Q+Y_:&-!95QT^G'@H7V'@8R00VT-,P;&DQ
M!&'VEVL9;;ZZ.&Y&+M:1M452G,I-B+(=,*24*KD3WVGL(:(M9:+P=:&@DE)^
M+)T,$?>6HS<8-$+W:[.Z E.E!CTC%@I%N!H)X0%(/6P.TT7,B]O2:>FGB+=N
M8/LW53 WDZPQ>4-T"\"19 VDA=)MKK(S:M+S@^ELR# ]*FA2_S>)OPW*;S'2
M-63*FIQZ"QUF?/N'@13=5:RON)-W7,Z5+'U1KCK9N'FRI(DUA_JNAR$%OLBD
MDQ0?-AZ.#A7&/<?P)Q!B4"<T@X:QA5"Z)'EX:?:I"$.7!/P0^Y&S%9RJG[$4
MC,P%Q'EI\Q6<A,,4CLZ(?'K2]DGIM=F&BM%]IZ?*/W%$'S>]!R+.-=\RDC3I
M1NA;S>I&G,.GRN&C=Q@?5.?2MDD?R38_X=W!N$'=99Z1ZV/'!F7YU6-SDC(6
MY<7P1!2%:3X:(NVJHN/LC3A&V$UE<)JGP2E'J3/M5V&8!&F*X'KI/5!\O:&I
MDM%UYW\+7;&M%=II-RJCERQ17AUWK#]'J;"XE9$V(13W):+!R?R0ND!@>AF-
M,S*:N1IUX[39"O3KU14R]'.),)7SD8X-5!7GAGY_(1S9=8UE=M4H B3HM&=5
M3<NB.46?4_U&5>^LODTA*G)#D?W(EQ&EE\0[HB1@7(:L'6;F]Q@=OU57"G4>
MI#L6GH&L:L"*Z$A?5S4=DE@R 1W&#%4@0I16Y>(00M1-<TRO948PD/0#>Y">
M.R734-=@%G4^?[VP= ,I[.6!K<-@7;="=D,3(\=<;-I!SA*$W#RJX-5LYR;S
M'9U\UFP3*BT(=S)?1C7M;R7E+_*29@RTJBY\, B$:UMOOEU=O+7^QXL_OM_?
M^9]N_)%CTN%3^>%[]:'!73D5B4/P9,M$S[ZM33#FC"Z"H]S-P^#+@*?+,8!X
MQ+4ISIA405N6D*WQ60S2+O;2R9CXR.GEGLF>;VIL_HG-)>5 "BKX11*)V@@T
M862M-:-7GZ-8U-;0FV,6(VY-(86R:._IM*-:6/&=?& C)BWBX39F6N)IH(ZX
M@[EPKA7)\ 1S?508U'9N;%E3-]M@LI;VV3,Z[)%7G,NI)!&USU'59FTK;?=-
MCV5:V*C^.L;N?L3Q*0:W-O%BJ0 CN48GTVG**=(0C [8!3TSLSTW81(C33<W
M<DT63"XC V+X"@,+P"@LLS\XAI^Q_)HQLY@:.+<M'.0:R&2:I<,_*.$:*7(2
M^O*UW.4:0]B #V5MX2'<3-?+<*]CK#N<TC(BKT9#,FS=I&M:4'!,+=>3W+ -
MPPQIA7+U$9 98;*"(,\!V8RD>H,5&469&^ @)%:S\2;MZB1UHX[+_N_TMJA>
M*UA]+K60&+>)>C#) (;,@G#KC8Z.N1FC 4MF4HY.5V\&CEI)XW.?\R<WT%66
M9 E$%:.8$RC-8DSY[I0A:&=,+DRZR/&L[-&26J@RIY.RR&9R\L3P1;7#0HLY
M5E$@5=;.>A$"[M#%=PNHCS+,LFAESG<C#3Q+Z]A@8'Q>FM3>1KJG>6Q.,'KH
M!C;X5B)9*86H22]**(CI9.R$;-<T=C9H10%F(,-& ,GWU:V7LALP2G\XVB%0
MV9Z9X;9)B)+O4?%"MTB3VI1_I0RRN-HDE 5HC31T]J)(%XV*GS4#GM/&A.*'
M:>_N)%3F2X7^D[RA25N&B"D[08ZDJ#I6Z2$+_\8- Y\MGG)\[NGH=P.JJ$'Q
MEFP@$W;(;BQM=\UN;YN,Z9Q/KUQX9$1)L::M^-K,(>%D_&YU10 !0W>L\(:F
M!J*6:BZ@&)PH,I/<?Z[U(O4#^57&0LY^P+0?'LLU+$@8(9ZCWCW5O-I\JMA;
M9TWOK.,I/,Q;-\E3ET[P7K?<F$G$/3=TUI%^#+-6\EK>B3?1@4<*%EV3KI\F
M"A7Y*"-L28BR3)MI)F%,XBL-*V6_N%Y=5N51QC4I:2IJ)ASCN@,8;H(0+LUP
M!$=]5D+)#9$"JH9&PHG!%CC6"%E)2VZE_L\"75NA'/U4%AH)Y"9BYV5\+YYS
MNT>K4A(%-YY>+I[XB$C$]U4DX@PB$7>J2,2E,%X^99HG3*A65YK,0X'^HGQX
MD9:#*OT2EM5,G.U5+'2I?R5QV/I$B(.D)T),(R>4*T<*9LH)D.0*@[7&" 3,
M,\V8OTR$E^;U'""#UD[RFFGCC=D3F/H+IXY*L[LX5K5$8><?%C64U8MS#5":
M- 0%>E0EPSUP&36I$$A1%JU#6*KN0;5Z*3D.FR>0U;8@6C+K'4O-V#;6NDLE
M?S(VH-@Y%"AT.V;@"#K&M-!M1Q/\M7]FQ!&V#R<NULJT8NQE02\@54W_,QN4
M8J6]+,V(%FY(K1&BSBWF^#N*OP0Y?IT*<0!%T-4_LC4[Z+5*]\@HF#J.(V?B
MU_654K&<>]B&I(DH2TJ+':14-DJCAA0OV>*9W_82Q)=R4=#+;"3+^2#5QR[D
M33WGJVM7CL,Y0@4X+_G)BZH*3?(]I-'5:0AR2FHHMZUM1SW0R(;8',8%1=<,
MAKT-PA]*Y="*&QFI@92@HJ&)N8S/0FT'!"\9A-Y**&.2^L81F2%[HK(IKVL+
M?!MV+$ ,D30];CDJV RI&FX&AL^01[)/O9UO@EBD:5YY5Z(L:9Y5.E7B%O4G
MPBW(4'L56A:9;QP?M6N&Y?<X?U%OCHO^414M1!JN8B(ZC"7/Y/(3T5$B68:0
M#UTF+TXV<)DUO32TL!M0C4D[8M745,EE$!ZMP86%<OA%2L=5P L;"T98<R>8
MZ P,J:H4,$ ;#2I?0>X/:.JC,S"S";Z2A2@4[%60T@P6A$4K:!R+_B"6'BMD
M\+A%'"=/38TEYVE)DSH^2*8U5 Z4R8 ";CBE/+\850E;PAEM%AVTG7=KY$(E
M+UH;2V;5S$@P/0*^@I,4.B,YN)'R")%L-C[+'UVZ*DFU&]I8#)YK W I09F$
MN6&=)"$"E.TH%Q+3%R$:C;6!I(GV$X=NV2%N3A,M31A-A/4>TCS37WC_Z!'\
MV3$E*5#)%?D"%BXOL;8C.I&E[TP69-FL-^K6&U1N4]-;G!;N-]]^*:@$PQ?[
M-JW8CRB6R?Z4/H&N19)C=+E:3MZ6]X;R&C@=@L4S*BFE.GD:I6S9DF9B@R4^
M-/A2&K5[0_:;?)E<-B&J/),T_2/C@LU%?)*DD@*7_Y*&=Z8C!;<NM=ADC+"J
M;$,^<#4(R8:D'ZPI"0IU!RM*E C'%CI#U)/^.#/--6>P)T[ GG!,<8U</@$V
M W+S41T*@E)LXA-X=<!M%R^ KRFL6NL0'5B\5HJMH]!#&9$W$@.1L4+W@S!U
M5ZN)*9W!T4H#A\Z95!$V*#>9L=O/E97U)=;A_1EZD241,E1/:2(9?L!AQT:4
M]("CA&D.FKH/"W^L*#G1K)>1'USR.6>B&E97%!]/:VNQRI:F;A$S<\E_G!,H
M,,5 J[/*>DZ!5IB^8X;-:-DLQ7K>!3Y6H4WY(T99#-7[8^ 0D?+R#$ %75<Q
M2=EY8I1&(I'KBZ)8A U@(NG/L30._8(HB4Q%PN #KF!&D;/6&W=#;%"[&:3:
MM/86S-VC, )ZY*T,YU"D$<8(8^M3 :_E:ZJ\0Z;C396L$AB"C_V*L3.H*CW4
M#ETBVRJZ@YF:BD^1[6SHBC%9H'3%KU?X.$6C4/SP%=Q557!XL\Z"L A5D2]9
M* =_I1,]S;(+Y*8W=UYM#_5W%KXK(WS&[CLZ#J47UL ;B#IL6Y%$CR5@XFIA
M7GCL&#%5#XE28B;8 1!FL\DT9=:L@FH@PU1"TOJU[].DU9G0(@ZN8Y\JQ3W@
MV_A>5]KZS+7;4Z.ET.K*A>PI5&ZE?!FY!6GCRE=)TDAJ;E6..HZ9B+A&6LXD
M.V"Q7,;-%[2!DE&^5#<(9#-0Y.A6@6[M#5$T4SU!BGM(>3"EJ&T/A"R1IE/@
M2,_DEA=4XB^7)-MQ*?9/5C+)=(/*-7VGT" L4 "D@JN7-XA,!K<^1Z,A$^2,
M<_AWH[X#X\54*D=7BI4$MV@TG: I'>N-79;RY:]ED2-@TXUZ+D<^]P0-]'Y?
MYCYS&44!J'B7_96<@II1=N%&.G1 %8<R!>,*9F]FZ_!*V=:L1DE5L@)C<EYE
M9AJ.JC@\YL?9Y:ZN_)6$;N0HA5P.S+RCHJ[/4LJU\!KT*( 3M:K;(/2<6Y2&
M2*>"9][O*)0"$W4$*@AH1Y/8TY])Y70PY()WV>N!Q?*,N$7C,;YYZ9M3.9$K
M6Z&&([4*P/,'G7KV4Y0,#KBW.IP!_%TSLM(*ON3RZZ!HD3I=\, 1$",4%@J^
M^@(?X]=%WZF?68<V2"PV=]7%*@@3GEU=T0]SG;))#T]XY.MOY]2&J. K/(PK
M%ZNG6L4S9]<,JFWM7H"5S%,?4WJDQM775SM[@[6N[Y,+A-1>[6C1W@YULM5M
M?VZG+)54H]*G<(:)K[HS\AECCD@HI'T"JQ"O]Z175'H>.>^Z.,8M8Q%1L6T%
M1@7M+B-K=BI+4%XHVC-JJ/# @!T.XN9R%/ED5GRQ #@'0\%1CSZ:L6SBF125
MTL(BRZJ6#*$N&W.IV)9,8U56DU#:A7";V(CLW^ LN*JO8I:4"<GJ<L&\5(Z
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MMNU(CWU9!9]TEQ&&66V.@AW!?=S=3,N!'D=%PZOY PO'9;FXK >)!L+USY6
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ML@296$@^]*<^(Q_.C;-R2 >X3$.X.AS6OX>W7RGGY9FE=\ZK:@4U(..I@)_
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M(;4<'M^9EN =?L*[Z"0A]VQIUG*QJH64+65I4.*!IT3&Q4G.^2D3JB(-6_/
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M1>KED9I.*O3D@A0DOE!\B%.A8*U7&B%DY4'509:>EY^_[>4GGK)_FE-KNAP
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M<6$W.M-<B[$H1?U$G+_[#&P8/Q2%4Y1Q!D_GG/UQA/DSQ1JV=$5>WIBX3G?
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M,L2R V.4G'Z5YK5R/M13B0,(]S-@P/Y2?2$H<W?A5. LLL*GW4Y.^6U&P66
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M_#ZJ8ZM^=KL5JF>V"SBJ^F;3EEWBY\B.):*I&:L*@NQL&Q_D0^KZPJ]L=C!
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M_4I2X;O9)\I#^_+Q]Z],"E6I9DE5ASD S=*VL\B.4T_N)'M$/U3.<(<;^^N
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M4.#@+%X7U_S/SE_%>Z9#)T"'FC[*7#KQ^[*3:T3_H76+IEV^=FYC-8;6J2"
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M';PX? ^+&^@2Z'KG1/HW)U$KN(NV["]I#<8B>&1#I_D'?YU-2Y&\G>P$TX
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M^QA0!]I2L0F#YO7P4I?:A?8+,[_YJ\K3P*,V,#OR63(, FNFNF;1?MX0K.[
MZEX;&WT!.0%"]QS*'P.)1DM&)?5W2U',*#RS3:RM3MUDN3Y [IRX'%N01IX6
MD.YV?@D&WAK'A*U-PV[K8'#AO,,*B75 RZ7>ZY5$B&^B!;''K!]%XF5-:7MR
M4'>/4C7W+:LQ*+VMU/TU/U5!/EK7<[:L+.$;UM5^]0!$R(F[*IQ1,?\5C'3,
M ^DRYH',$^C/IS5-XR8E)F32!,PP0?.SGRO+SQS,X_SAOS""]N=??B2K\P=+
M:<1,SL\>[GN=X'[Y7D;TQ:\;TC=__-,W[VM,[]/L$"*(D?SLGF=X9-J;(3U9
M&QQ A+<H:AW4U@*EK+BD<^\/%F!''13<_J:IEM_.T@EB*NXHUN4QK,1C&,/[
M77G[ YO>^'L:P[$:&RMDR7!6:1RKS!:I57$UE*&$ZF_-\%"JGIJQT[2JZ%%:
MNG5:3T<]ALF"G,@;/U8+4JCI$/J28>?8/6D-Z4*G [S'G"3YH)SJ^ "N *EB
M#*!W*+,4+3%3+5V?HA8^N>YFV\^6D,/3]%6N@J(H@#PK)2/(>NO3F@'E0YJN
MHUQ>85&^FE%_S9'"U$':I,G).NXQ3";R1-[XT9I() ,QDL4-*@F!D6O4&DAY
M6O/<,=_';&&'XMAD+HY[#).Y.)$W?JSF(H_)%C=-TXDKE=4=>Q2AZ1L9]"#-
M\>,S105*=5[A!G2YQOH3&U6!9\>D$,OK_4VH>"]3/!FBXQ[#9(A.Y(V?AB$*
MW!4BN0%Y"J$$BI $;U0>6!4H5]>>C,61CV$R%B?RQH_56(@RCR62T7R]ETD&
MJX3)PKC%3=U4S34YQNJ$7JHM2KH[D(838@<0"3NPR@"QM&CJA?>!)GMRY&.8
M[,F)O/%CM2<)BE,#$3,G>7M?)=&1 "FK<N%JX>MB[;OODA3*H19<PP@G:'0+
MDR(HG2EFU?:0HE?*+V.L-&0A7&^J9D?-3=??-*30W)=GS^^>]+CN9:/G).5B
M7MFT)Y.6^<&@4Z2UJ807=5'MNK++F" ""E3(!FOT\DS[ZYC',%G4$WGCQVI1
MD_[I4*<:8'\$'9_VF_\,N2YO4IZ^_$M'I0.A @K?2PIN0G.#V^>]K6P[ZD'*
M0YYO82DMM,DX8;%.0+01\FUZ9XE2NSR*I<; =5V&-I[!@0*DDTE)@TD O\9T
MS /'3E!ZW:KJGNBKBKQ\F\H;TP"70I\&@D0M?HYW6G^K*V/:A4<\ALGNGL@;
M/U:[N^_)-M+N _?U"B+M J*^*MI6.EG$R"VU61!>WUT)!A@TUY?_^A5HB0CS
MRB$0!WLCO273UKFB<^.2-L)R1,WMY,D.M>"H)]U0/"_8ST ]+_8S\#08BUHZ
M8^]L7">[>M1CF.SJB;SQ8[6K3:W6Q%P^>I^M6XES%M@8G8F,+ 5P%KU&!<"+
M[TLZFB2Y($0Z<"/!+>0"[RXQL$KY*O=/>'>L9#)/M4Q83D43H#4:JJUCZ ]-
M\V)Q0^L55"V;.I6H%=5(H[()%/YH+]4!I"W="=>1]+;+SZ,.BO3W)*25[*;L
M<,G:73=]6834 8SW+=O-<MF4=8,3JURM7,N.>0PB-)<G YAL\'&/8;+!)_+&
MC]4&+]VMF(N84LA;BAB%"Q=OENAD:+YLFXU"4H1 VTSBM(:.>0R3U3B1-WZL
M5D/Z9V4PM?_2F.\R&8'C'L-D!$[DC1^K$0A]SE$NI F$81*6@.38,3LT1@ 7
MI>N^9=PQK9YC'L-D+T[DC1^KO8CY[9#U2=+6RD'B/X0*[Q>??9M5]RC-^\7G
MWVIVF[6[^PJ)&HA<C-H4Y2+]E;0F\K^+/WU=UN_"</+@5_-=_'R"VR\F@MOW
M0'#[Y6<3P>WI\7^]US&_$'#K^5E*^BED6V_C?@,S9Z!W$[%'*M FU&&&KFV3
M!'.KW[52G4+$5-P1I%Z@-=_7H9A1 0I"%#6X1C-QO]"^F-/G99W3(M-7E0MC
MJF\ ,DMJ@>=G-B2_32B"CMQ[S J1/G15"4\O=0'DIGXL^'[471HRHU/*J0\Z
M$X-K&IY%.-??$=""40NBA6>->Q,:O8U0E-)X(H,59+[F@8 UI1),6+>HAT%8
M"0=J'*J)-FA\N0,..'NO[TR[+U_T#S$/WP2SZFWI[J28T4?PSA@9?PH+TB)*
M1K5X\$=OY::#S"H)#$<($;7[-=+A*O7AO?R&IN6JA'11C,-X#JD+&*96V?>E
M;CPF)I!OO4"Y.)]U57,G= )#'E^B+4>H]F<_N<8ONJ5(9H7AGY\)13'IV<+X
MJ?HG6B #CCV5NPPB[=Q;K<@_8\HP29D2T3QAH@1_=1D*.V&N,\'=:C=@E%XG
ME?F5UM^Y<BF1R%53N0+;>3Y[*]MAH92"(W2'5, >K/6]Y81'I%@!Y#JQ-ORZ
MT+LKAW-=2G%MC-SS((%Q\KQ4_DU!9'MCD%9*KJ>Y:9ZA/9(SH\O6F$:OK*U;
M&ANH;@J@@HEQ0+>WB<IR<2><G]V624A\S_$0N#SS^IR*:D[,GA^ #_)A@(0/
MZ=M-)!5LL)6KK_L;T2<B333+JV82A$2XGFUKTUYJMKU__VZ>R(#2?KJBA>9H
M7']67U4N7$76;/P;+Z4J#+%X4:R49&H09)P(-S_\$HZ+(WAE(UPP7;(D6+J'
M[!>0KS2W.__.NT!>[WI=%#@L=97,B.6_8>V]VL55=#%[(IS,%/TRUTM4=KS%
M)'_Z'NE?*,N)0N,/%(X)Z\\OK ?[1A"+VB_,_;2<+LGSL[TUV>?718]H^Z#K
M$7<,+G*/_- ["R:=G^U)#\'ER491=&*! \@7TY1NG;<)I_*R@&Y ,$SPQ;?A
M\A?G9X_V.8#XV#,^=I?!KY/Y,^V"[J:YTW.-O!])1UQLA^O; @O#?V7C?32$
M!GKF7/MQD+$[R&@=>I/^(ZHV[[V&RX3UE;-=ERXP&5V5S0;^1K%PVU[;<I9^
M1[4[B4^Z+<$AR\R_F'6NASZWM*(L;Z$A,42N=$;2Q+0"3* ]*UP(;2K6J?#/
MN2JI!>T7"XPJ]=]T!M;L(X2W*^_;W]*L:7C"^,8'^\%^=$AH)+&]T<>?SML/
MKP$ 88;@GJ:\Q.:>BDM$P&AYM15!BR(LIE5QVXC1&-M-Z5N_1_3B_.P)-1@+
MV.>Y(%2#2LPA;NW;H@U.G=&0%2W[Q!!>(<ZEHDP+P?M%-P^2\54C.U:5#8DZ
M6W@_=!X 6 O9ELZ[N5OQOT4S3U6J_<N1+MS%35W^<ZOGR6 ,8/U@5B(?1L;R
MO(8BR,8'ON=G-MNXDNK=^Q'VVTD'XT.X1(]]^ =+3D.NF.J"XN,B6;!!TD;=
M49A;603"W)TOWK?HX::7BJAJ]\:O@0Y2H+N+R8O\*+3M\.%*='<.%>E#8];C
M[R^UNZEL@P>4RFO2/1$>Z,2S21#R;UL\]XD>YYJ#U%+?PE@X/RM!"I:Z1!$;
MFRPC2>0P;W7E:K<J511K?#"33?G@8_Y1!#'QQI[+2Z#W>KGH8ZH19D/6TZ%%
MPZ.6GXJ*FR1ZR50%A10F3\I.\FEMS$CI8N**EYP74G[%Z'?551=2F=G*W;$C
MV@_FB\\^FW_VV6=DP;HMEUN5$,/@?_0>KA^*2N)BZ45ZK)[*-=QJ<!6!)J!-
M%%*;(M[2\KN,Z"*9EJ"D7_,_Y=&+6^_ \QKI[3N[O6P,?\-^MV%D%)\2*4E[
MS*@DO$#=$T(, %%*<E#C*4TM7=@KVWL?IH>*7+F/1]%0(ZDG29;W2BOV[-&E
M]X57O:T O&R^Z.[0FY9%42Z9/PX90LQEL6$\,/,1CB9$L;<W#;K?F9V3"Z+[
M1Y?#HFK@'VVV5]XP0?DL-C>%)[/<:/IPR\9)^[N?M%NWHY%C3,&@LI0DI(\!
M_9V'XF%Y^8*189JZI?B9A,-)=M#2C/%9U,M"C!)-VSS,6?HBO('LC,G?CS,S
MD[*G5EOM3_#NG8BM_E]?Z9+V]V%6@-]>P1J'','2K5K*EW7]2$"I>0:6 8HW
MLP4B<G5OPQ>]K^HOYG>"?5>4S^)3NC=NO9$S@3!>DW9.#A+_-OW G)L,]<<1
M00O[@9;IINC&UAS:\EAKEHSPPI6WK._Y15>VWB[H2XS25]PD8R8W6LN2=_,Q
M/6*3/7M@HT*""X:A$ON?VI!LHV@-S15UEQTRS/Q(ZXZ$82D7LX+-8S:='3P%
MLENX0=!AQ">)"",^!VE9+7L'LH+HKV%2!OI&R$.4[6*[1J"U<$G\]4GYJ4R-
MOSQ@))__Z=L.]8J]"2_1?'3;O 9%ZR>E_U7)4E;2FRAS77:A,ZCF-_4&>LG4
M30)VQ?%5=/3IU 1%0\4,538_=6^#M/>!>]R^[19^4%' 4=-NO)6<9K$8P<P.
MZKNHVOQS6X03 //S+1;.)_YF!=-7F@"-::<M36:KI;MTS3 E/C*\JYV:32FR
MQ#-/-D)V,*% B//=KA,K@KKX1UZ&A/KI2KEJFV)I7L4=-EC9);>88Q.D><YW
M6.I,J[;.6J]JG6%*J'(+WSF3'>=([P_I@E.N)8A]FO&#3*#>\:A?B\#?NKR^
MZ444<+6;*US 5=H2UCGW6G= J@Q_6K;REV">OIPP3^\#\_3Y[QWS=%KIBU\Y
MVDS &[9QLVV[K0112YZM8Q7Y3='?W &,,9ZHBF;6K!2_&*^9EEY!.%"N "F1
MN."MO\BN+]*K"9R@F*V*#J6:_!XC<4.*NK*HX51>VRGGR+(E=^7C*13A))@W
M&(;W T@3L:W5WT!+=26(FH'F-[T4*\6/5_NLCI;"0Q"KJ>,:G*ZXVDS,/;J2
M6%0HV2U>BXCY:[NH1,[^&(Y#7&9HOHVY3;+L1#:;-5+Z(.*P+6,=\[Z29;HW
M.#(;Z&_A>#_R,3]!EB=4C@K+M(NH<9H42+T^.+6CZ\6DG27EUH6LF[]RI>M4
M,(17!LR"F^VCAG0-,WC %9 EB-FZ#I[ZMA,!V)5[X&\-U?.:3/ #+)E#"%6#
M)R"X^GZ9+GGDJR_JNI!&4[<53XV:4MWUW)*DD2DDYU"N&?W)UKREU'K9&5^#
M?W*B"^M1J%:5D15X[WRY:?R\H-H;3$8VE^E,"RLB53B:)/3<V],<O'VZ;TSV
MSP0>-Y:Q.C\34*N23UAA;Y7\SD"AL<HS^OZ'8[]GQ&DEF_B0D,E/0^^E$QB?
MQB7X@;_ AAFZ'I#A/@V5HDZ2 C>'2-!T5@ J-CET1HZY$=H;\<4,92\-3(HV
M+;0SN\>*E>1=WVENTO?JM\#X-&7UL021.^(. %%# 7:YNL! ]'LCSH'@521,
M9,:REK+(^1GFGLMDZ6TXUFDRT@-+CS#(*Q?S""DCE)^QLK<S,6Z[8:["1Z'>
M2%PCZ:M\2D*X1 8FIOH.OTI[0SD^7-YIFG%AKC-Q CDKX5F3#>%JS3@DP7 "
M\WR+:+NDH[*S;CK+WK?#^++L7G?G9R^#RO/LJ3]NR#3KW_OLA3<3WH/:';?C
M>P+S[!USY+;4Z,6D'/H9D)TQF^PM4X\CMT4BISM4V-\0.]Z+G<[(*W&=,GV#
M&WV#H1PG;1: $AM F5FXTE_0@.V G"3X/I5^Z#K7GT(8=(H>Y/,M#?9"@<05
M+#/;,KQ]!,=@H*>.+1)J/:54Z5]YP:_V:LE[I8HV!P%]0EOC!B3>>,#5S^2[
MK:N<C9K+JZQ7@)EBC6TW.IK]!4N8)PN4/,RP]*@;6\))Z_<N(N/5^^]?C9X'
MEW@J3'^U2]V$C?P,=U&><!ZR=N7@S(Q<_<952KKHG];?7QZ76=/ +R[86?_+
M-7XH50W_DY![M8KNV'Z^?\YET]8*:?T70)6HG]IXPNR77?*V_<XL!0'F:G_Y
MA>-][6&EB8.NM7]F?Y+_K;F#I,O<Z@LAYQLZSH"T9/,/N[CP+TLW*[1$J"%Q
MR1U2;/F]TJ<MS?LQ .J($3(C8I#FY,GTN@B]T4,5RA' (_.)WCZC EMAX<>6
MIVV#XMK?HU.#29O7:&56\:YA%_AEVOD?+T0DF?*G7!2$,)0+B^U,XX]K<X"9
MC;#:"(BQMWEWTW!*F8JGT^B=6ATL.TKFW @TSZ')) FB& BIV@;U!KG$L7"R
MJ3CX"[_8A/*SN:NY6;D*UL52 82"D- >)O_[6@"%*'7/LQ!,*/6D<P_A:)YG
M27=;]M*8\K RD>).!(]M"XMOFQA?Z8=*?[['/VJEE;2 Y3_T+Z96[F<T6*9#
M79F1Y'V0+4YU88,M29>OF":NWV1)E8)3D.6K76R"VSI\I"Z= $>GI,Q'P=O!
MIO<!L3)JD(Q!7/HB,EMP<%NGAQ%VX%Q].ML#<C=V#5D_XIM9Y:[]-0A3DL3T
MC.@=%N"TD#@*#8RMP8S4E#W8%AWY*-G1F-IL_2[!1VI>Z<G)L2>GE%@6J;WB
MK+.8$H\BLX:C9:YV7O>FW*M#%8#'%_>M4G!FQXMV7_C'KXIRW8%+W1]%RW!<
M)KLU.32%UU+-V&[\T=>QUW#O:7&M<#+CI^=GQ8(-Q0=^JG_-PF!S9+*6R9"8
MQ>#M/6=3PUE9"@>R/*:E<1<W_NF=C\E19:YY@FO)6;PA&9S@%'"$RI]2;R?O
M2(P$]LE+I2EEKMBO)++N<Q T74C:I48I JJ$HW^R1A]^S/_ 6H1+W#+S@2Y!
M63EX9ZT_?KU'X,\&;;9_73=W#] IQ$8R.8>9)PUGO/3FU,VM9GYJT5P7])CN
MAX'#Y#V+L#G,_="=-[<X8X[UYF^X$A1@P6 C,-AJCR,N+'HX#D\(',NV@K?!
M?U15<=6T16@DV'/@O5'0#=2Y]K841P=KM)7P@=/$C1]<2A$R%5/>P0N1QNR1
M<4GO=!_')U.H-TR&>G%^]JRIG1]<Q4QN]E V[_9E2>:3TE=]BGCO/9^$0_=O
M])];Z?)>.W9E&89)+N-O[V.^P:LGM4(@AB>)O.-:X 1<,>W.L%#\8L L%4;*
MMQ9[E@GTTB;B:#V)NO''7N<G5(P3G&!^7"=S/3;#,L';[@!W/!_9GUWQA*%'
M&H,. <[J'29S\P&R2S PTFBXR/#YP>XS9N\[G 6:V?GQXM6%E*&TM8E(,&NJ
M&KK)V*]8C[UK6ZPR\Y*2?J7SLRP'T8'IS>I)&J]R,57%'8,&:W#P:[5&='0*
M[<RG>/@\\5%L?2V1I;P4_R^@C,UU"^]'F\8D=;*?Y,E".2W-(*^#U737M-[@
ML VZA]&K=K$AFG9]V9R?$=DM)KI2L[&?LQI;IC&UT:6E\(.#2XI8R#BH-ZKI
MUS@"0EK\0U_,'@XH'[9*#Y*%U<GI*J$>3'-PIOV*_FG;EAT;I)EDH5MO;BQ-
M;O#<]QY[LHH??,S2<:?E=<2#K13.!+;$ ^]M.;)! ,&$6<'8C>Y_J TJI-1O
MAZI\C;T0Z^3^T)8>D63)JP<4M5%"Q!6.<>/E9^0U5TXF?U1?$>'4"<F39/KD
M#NDUJ;[5;9I:'#!N*;W%Q>PR'@%SFP@]R77##!H*LS[I/)"3_+$ERY+#YV+V
M9-MB1\X%74-Y@B#VDK\,Q8"G0!]%4P3W1_+'O%!RL,1C2\?/E*E"'C3UMT4/
M,?M]\U9X_3PZ.(CY./M\R6,+1#R]V4W9L7H),097O,Y&I$JWF(BM]VO]MR1+
MS=?@?S">E; 8]'M_0#8A@2LIA&[7]4ZD'Z);JX.?2YYQX<T@B1ST[TEG4_SJ
M^9E4[:5[6IRU:Q(,($0<G=4TH7D@G1*6]& HDG=D+4ED/+SW639)L*\3E>=<
MQCH2 ;DHL>C@L:R8_"2VN?=&N4ARY[N]ND5R;AQ([^W/>]'W;)01Z1&=%3EZ
MA@O-O)G\#!CVCJ> &#;X2&?.L@3(5Z*0U0J:R]*\U/?JE4OM?@R78;Q0OX4#
MY"TX[J\F'/?[P'%_,>&X3PEB^RM'R]KR04=YKXHF!BMT"E:2#_*G5J)S/"S/
M3JB #UC":!THD0(#7U&YMT8_>*D,8%;[,8PXL9)Y-GU4/<M"T'3O\9B\=N 9
MT^)E<N%V9-G<=YNA\Y/4_N$PIA5Q36V1]4K+*GK86IG7NP0L/(AX]IJ9;M*F
M./<Z'.4_-66M2H-6S8V]W]929CU9TILN@#T^ZH4WJ'P:%(BO _X.1WHE3 B
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M3O> A+5^:X>>OOE>+UEL%;/^L.Q'G:8VD^X].M?V\X%C'SO%>"YW2698HA:
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M ?PVGLM-R_J!NAW_,<#GQE8M'48*00.. "LV?Y3&/P/J*.$A@!@$\&$Z$#]
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MMX_5K&HD-26]\N,3Z^D -.5NUK,M$[5&6(;W$S<[-U1?F0(OFWP31F8&$>P
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MP] W)EX?B$GD@5  RSJ<IO^DSH<DC#:_'@X<M_=_J8?'U0,;T4>"Z-0E;EA
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M!O3C*>0)T"@-&>,Y/.B,W)MT.7/\T21IA*EMHH)_4@5I!H"<N1F1K<1L%E6
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M!HBF\$U4IZ(^$VBB,>87^R+.>FOF+2\-4-)FIZ+^L872-9L\RB5WW[_GU;J
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MJK $VJN"DC/7G7>M.T?(L5YX5KS\JF(T!^%V*TN4<_%V-W'ZY_2_3/^E\":
M)TK9&/7!".AN+>Q,<->Z$S6K9KOS;^+D1_YT,IM57S,0-%AT,ZC,SFQ;9A,,
M8+Y06K]UD:_E5O2]@J1->PH)E5;_\Q).M7H5[YM5A>CFS26RJ5>WXLCL5E1S
MXO^(Q!\7/74KQ.\GI\N+E*(6 ?CT946FX&H.?'"SP(:%';.F2LT!<W%XFGIH
MOT^N&_JX4_E>BOUPAE:MVFQ4Z^?U2J?>; C-$^[V?3?M)C@VXH2-%1S(8RD
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M[TG2#3H;:%^%SFP"*ZCH8D_N?Q4:P @98!L:@K#@ONEO^R[\97&\[</]S]\
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M5 <"8JP+CPDUBDTD"&0*,]2]B;_N[64;DJNEH,4Q;S4="0C.FV;W& 1N109
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M'',Y!<CYT&S'5,$X=$9DL\+Y/&[64<:=%<,B?2"^N#-<7#5;4[-'@R$YB)1
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M[O URA(@/+!M"#TGIPU<;DWBCS++G7;9(4-VL$$$'P0#&!3)V#'=QQJOXT(
M.*S9(Y[2FFOU0V,WDH4P^?"@:5L_Q5O($VU'WLT4)3^9KLD";#-?Y;NUO@?V
M,3XPQY:[D'9#KR)IOHH?."(1.:I*3>C\;H+G\B8K"G1JM8!JA#TL[!<["SJ:
MB)^#[0HXSH@NY%BH3@])6G:$,,5OSAFRV6J$%G0*T^ORPR&DT1&A6RB[4SAG
M2<:$PEKK3YV'[B0._**1 M%%:'XK"O 1'7!VB-*9QEO4>H+Q^ 2VE!.6AU?&
MH(,$(Z@[K1_/4[2.B38 YBM-XDJ+XDKGFB8!R595J6'Y@712W^+TD&O:FN^'
MM";U[W^Z[^6[OR?FZO- UHL[U5N3E]>SE]NLH5Q5UAQ"PG=((Q/V)ME0P_BK
MBETH7[JA[@0]8^R02 BZ:%/\JMVHBZ6%'&D5(F1)8T#,\4AXZR-76 *Z8VD#
MS"]MI"*"C>7*C?DO@OM]AP=M_!7\( *]8,$2,E>5PJ+Q.]R89'L9AFO\B )P
M);):@V&?2:_-+J)1,(WE5DBLB+869RCIPP/LV1EDJ!)H,D64!X9S<A[LP7OM
MQ\(U2'4B'-D'0"33224R:1KH7CM//I&@CT&;B$.?#9Z)8MDD+F/IEIS)+_H:
MD,^P*EN36:<.'TX)6!F1$:*STXN= V7/H/TJ:L(XE2E!XDXC>69*)F?BW[>G
MI\[;Q??V"ED0MZSTR'I TF):;/I9Z*=OV?2T! \(74?R*"EA<?82,+QN)H)S
M5UF36T1O<3KX1P, .OV78;!>]S(F%EDGF4&K/POC+DRISS/1"6Q'=4<Z6$;0
M/\?HZ'(;FG4C_,>8J^-=D).N"#TV167T1EO/]YB6(I=HWS0FBE?:XG@JSCMU
MM;3JA#=1S-":!2PF"088'DDD*UXQL1BQD,"_=1BG;I\#OQX[]2:K3W$;KM";
M$R)50+T ;B0>21M1 J%5&^X2C&.A3HU4, .I@4X*#MVO=$Q+@,E0]L;86J"W
M\N(8-5VK!H.3\,NCB5BS7\)UP4.)1YM$L<.,8B=![(B"1HZ\&5T1Z0^ O3:B
M99G[Z54*8&4:B=$#R %2<,;"X'9%&7-4DU!DK->0!)]WY,9W1HZ($KXWP^':
M,8,'OP=;+J:.5"D1"O%>0R(4=N3&=T8H2*A#O%_9NY":3F2S@S4T(@XN$'@T
M[R8M<G2$E"&6Y+0_H-JUK6DOU(])DMZQ7T,B8G;DQN,J8JC'002%P2 P?1)G
MG@I?\)R? >!_GA-\@]X8DFP,89!3R+GP;0468A@7LV)@COB/"5TS2'3(H-%_
M43#?M"/#1$,+  HA2Q+X,782J!BO-=[ADST\R+A;C;"IDUX!01)FG&(JEN>8
MB@2F!#O%3[*\[_A.X1_\WND[X?&'!PN?[YXT2T/IHL!Q+LYXM@/<0D=,\M&S
M'HUBW&\Z//!X57OLFO0NL$'O8]XBAZ.3I\#4T,_% :.&@(C'KJSP?!^)$MD)
M*>IF5@S#+1@V<(&F"@CY2P :E&@#JJ$.N2E8JHV'/A8:W7G]<69$(DSQA#%?
M,F23[,M.L1R$S.#7Y/H,N]^0^RF6[68Q-0L44]Y&]JA23F,F1*A9@(D2F@$^
MHG1X0)B=(Y[=HL':V)(HM6-/LV2I:CSE81$)W#N?5+J+:8\5"K#+20%VT 78
MF:0 ^^.IS"R118L$R13TP*E3L5A39#>(C F\)6(UY5!/AP?M\;0*FO-UQWM@
M5+6B\$YI#I4%_W2J+9B/!3I%A;I4>2##_'7XLE6B ]@'=XU.:HXIL$@?^=$E
M3G'NT%  /W%J"-+@RAO5AS_(7HDO1U1X I%.L(ZYQ-\R[JQA'?"U?DJ<)%&Y
M[C8UM4= %7X0:"5G-Z$U'M>:-%]J/\T?MW7T9_7^M^MAT2JMR7OZ-I/)W_[Z
MJ:[;=-?:*VD@"9L\(KM,P&@!KI$<*P%.P,1Y6K+',<)#WL- \&AAD+)$F1-R
M80!^^9E5 [HZ$C@*::; 7"F&? . !RQC"JX!: Q2](^FL1'ST1BVI>UEQ*L,
M P16-@ CF,##[P KX_CPX);_BW8!A>^PBD$-/MS'9@'O2RH)I(.G"&V)B,\C
M,F4E&YI5>KAH$>#@V&T05-LQ@ZX%!'KD !Q9N6&Z$(HV,^F+'2T:%C@P_+5.
MK># 9=MOQ*^'5U)/QKX-?/0ZX&",*1U!WDY?@]="V_PN4%KN17C"YAD]'C-V
M9UOFD2;XT!O!8D- "N$#IS.]A]A*0,2OE3VPV&U1(?EXHX\0GXP*VI,"*PGR
M3WNS8( >$\&<Q;BT90?%/>+%&0@L#(XKPWZ2@ED+/\O17X*ZTW,\7>**24RH
M"]!K"QM*'1BPC%UHBO4!PCO"['%$YJ1;V[?W[#@(?B<.-]=&OO'WCL%O-/D8
MMNGCPC:2\[Q2@MRU$.\Q5_O>HC?DAOFWF)'T4<<D;267PLIY4[]%WVI-^N*+
M<?=N=O//4>GND];D_N=C_]6X/_^Q;O^"&RS708PZ=A9_=;U#%5$P!;HZZN&G
M+)C"!95$LB2+.E;@<"'D ]#!#]\&FU? YY/ G_F $BK#KC3P3F[?4T*S6;,^
M1W[+/WAX0)TIVL9(I7):N.$]".PI*%3V?A]AJ90MTL:[PF=8L>/M'M^S%]1&
MYAMB:/<AG5/#.FC3&AA8AR7!YCR-G4%?E&CAL,1E-CDG$RK,2)@2_#NG<S<%
M8(<_89EQI+'9#U G/,;.G*L1)C$!V$G;("_\/G)^SM@N@;C3[XZQ:NE0H>QN
M4D0<1*K0&OHK?E9*J&$ZPGI E46B4D!/:"2RR\Z Z =L8:D&Z_WY1@*?0T22
M)-;82>LIPAT4) DGFJ@3S7K#ET34Q^OTDXG':Q@C&DLV$=ZLCLG,.@:Z QB*
M(RL P.[ &!V(5PYHP)L= [42)%DB5ABMW"/:B5X.N2\834]>;]=(<<L.;YG8
M"FVK60K>%^>*$FOPC*F21#@!0#?=8IU+)T3]=_(^_K 4>;.-PF,OAL_-7L(1
MZVW.MT]9B%VGR*=TD_N0^=1MWIV"DPJ%H)/F7_1ECOZ7-BV0 C6R4.:$SXP.
M!9GQ'5!#8[HJYPNFJ)35U1-\ %TKV"$SG.D2X]88(^?!.EEO2NR[SQP3/E3D
M282%B%WK-"TUGK9RSH:8;:_KK*0@,L?V%&O$.EVK!3NLW2$@L7BLJA(AU-MW
M+ )7Z;'MO:C5^J_[6DXP;7;+H<U <]3R,'%*72>34$H*VM1@)2G# )!I.3OE
M>Z:<CB=TT%9-#?2:JQ2 IGH\>M!X=FEVMO2_ P<3+-T:T&!FR_0SM9IX$DZ^
M'%KS?JA)5M$10291H> @)(,?#K0-ZKR($ >P+Y]5H4T1DV46N$23X'=(0+QM
MP5V(,KE*>:#3$M8!HP[3BU3/.[04:_?"U*$^YM>NDK2O2TVF'(5:F CMTA<K
MFTF29<*KIHQ@09 D9KEA(!KL91L&VSC8)VPL#Q,96(1C 24;M^]XO:"L>=K8
MTDW8 NP2>XG9S\3N[LN8$76B8:V745*CUFI7UK&%\G<D\HI#,F0@WA>XY3"Z
MU9O^DD;:[)Z\B]UL9Y= W\]H3=3L34,=J!?25513Z@JMR=5]]7OS_:17?<^L
MYW2?$3 (V:+@V&,2* ]DC6<.J,W <;JLAZP->^'RB(4YK<X1K"<)0><2)Q8:
MFL #:!P/&E* $,(L0Q$R+%RGZ7:T[OCPX+Q:O8& K=A69*,/8@S+&ZP0L;L[
MIH6.ZG"$'TI#TRI;*JG'=J0QZ5*P&.,ET>3UT(JB;2#]E: 1V(- $ Z@0RU\
ME HP]MF1.OMITB41,KA4L3)7;0"5[!X?1G29M-[R5905$G\G05)[B\Y$[^&!
MO5E\4AKT_YO:P=3^;4P3A0#QOE[82IPJ@Q1(LUSL?+XB93?!<4G]XT>H-FP"
M@=*U9+X(U2& (0R'B^40&/ 'D E6.@8*WO'__QUI9*R&3L85?QZI="P<DOZE
M(H0@]<!^\7XDM)XAY4ED@ J3:0:T\'$^F",'G!\22#1)8AQ+Q (V[64Z;1G^
MP(HE';**R!\(Z7!I =U*J?REJW!\UDH5VL)D[X#L.T"6V37)TME_EKISLSJ#
M]:'JXR62-PH91L8T;<T(TY@B<7@;A^%XKN?KU!= <U*R9EAX5D-/J?FK#2QE
MR^(?HN]W+)LT=%*!>#N:KFM8?/)\K>-#C#DDT103@MT"P>8"(%@O:XA0A8ZZ
M"@ BG#A;.L32#MH2HGE37?:BV-9&9BA6I'"&_XEH'^64X#P'OG#Z,!IU@2,!
M8&5'9.%9WF_(.>?3@5'@EI<+9#X+96#-6[90,++7;DK5/#Q8-J>0!V(LV,KL
MV->Z"5D*E1 MA.Q)(DNT*@(6SC0\/"#?AA$D+O0"E]?B#.##JT:!R6/+;N!B
MV6UTL*F_D)<:$!#\2"?LZGMF(UD%>\D*8QO)#CUG-IZ$-;,17CE_\M_@_/6L
MH3\_%$:%9>'ES08V+EI&$ ,_RZE\H1#IN,9:6.,:%]^8C.3;JQ^GX_;MTGGB
MF\UJ#/O&"IZ#?'=W4N/6JDLJ275)T-4EV:2ZY"-9/\X\DUV_837@E55(_]&P
M+>^01DQ2RX2%V"4V ^A0 8(0D:VF?RD/&R!ECX[!AA*2B?D/M17\MT-Q3+B/
M#ASHZ". <[P/ 1!CI*S?X$_I&LMB\URGP_F PI4N(L )WI*9K)@/-I 0:2V,
M/Z=H(M1P.]]JMY&BS3E5@NBD<]4<[YA;ZDD;9GH>8HH@>(<D54=?S?=+FYOZ
M?'7*F55SU=M(M.;&ZM!Y!$8B8%"9F6>OS[$J!HF:)H.IVV3.G$S&_&#SDF&*
M':^Q;YL&^>%L9-:"U9IE!PEGCF1R[L)9#7HLG/"D0!N" "3:3'O+TP;5)N#.
M>,AJ"MGC-5K<PKJYSMQ]V_0&YIZY<[%LS)"M:9T3AW91YT:0D83;P4Q,4@NW
ME&,)6F-Q/M(Y*<_G$UJ3M-G,_VF^/!905!#@4FMR7BK(WW^/+W-GJP\X)=G(
M.Q,O_NB$ N.<>XTL'?GA&D-4H7&W0<Z=9B&MN5I09#(8*MH8$64B8UU%L!)L
M_AA@^$0BSVWP1$\767MZ\D0L6!C@X@V+(G%:/]+/@&. )1]'"]_>/1@<+\A4
MF_L+*:OGM;N09$[_?$?7?+J_T9#F666[8;_D%+SN: 5$IFCH@1C.1W>=OJ8@
MX^@26ZL0[1BR26DT=#;0)$05\B6("Z$FZHH&060&/6$?<)3O6/$$1T<&YVV(
M^.0DPTIOSHY"<(=!6.X4#@&>1.Z#=7V8/1%K $$7='$7D6&GT#S66=W#GDAP
M5?R)[%Y>0?^1 @\5054G 8W+?/8"F8#!WD G);"!$V8?,+@>HU!VG*_#UQ]U
M%CV]0?H=]LW18KV1=>B-)=]L3?)_GL_NF]GQN%*,KF1DHO?OK].-\^X0K3GR
M4C3D#C5:3F5E!/1ZA4PH4X >]9^;FF'\"Q MX.8!9C^R]P3:$L0:V=%#XS>9
M';=B'7>''K<!Q\VMY1%+86&/5J9E#*ZOB2:6\NV1R:U9_@B0A3 XFH@/%K=E
MC>C:8PHM>4/0WAUD%: \L6.LCDCT%@#SCH5@O30RH6A#FL)QTL<=6R0TNY^9
MC9!. -9.2(.!S7<C^-H,'P!*'FB[GFR/=B&N2P/3%N66$EY\$/$FO!UB#CAT
MB1&5-Z/,<H@]MV !)7!Z[KH(R^-:*8-P J\Y/^R(6@B?[;>:.DGPC/DC=5[6
M(</+5(C2(8D9:"P?]R_5ZU,FWXAXPL JWB:?,-?BXW2*3P ?SJ+)ZE75E,D!
M8__SSLKCU&D\3 (U2P>]$^/KNCNM!:LD7N$]6CRH=YR,O1_@COH3Q^>:'MT#
M.S@XEZHJ/;'3X,4 LKRTE"2(4_$J(/ 8CL[2!;[7[S-WT+@Z<Z0,R+*,3]\*
MJ7PFDZID*V&F>J;IK1(&O<T6BB3TMDK!2C3TED^5\Y!:#(_>S(6Y9F<:BPW^
M!G7!XOVVYRLJ'>Y@8I7@1^.X;0_#[@8 =;-TT!WIUD/=-QGL!U,^XI=,VVU8
M$Y\L_=)0W0N#Y#_M/^YG3<YM$,D/%TH=8(K@LT(0H-7PNZ$LEUY]BLPL(6:8
M88Q(\)*\%4&3$GULU:%2M4G!URPVCDE/5JC3S!X/QXZM .9TSRA=,J=!&1/E
M2M_.%KKH+DG:?UJR.!TT0G+$Y7>&O:I RK3#X,G8_L@-#=%4X6@8$SR2E5R1
MQ5YW*0$O4VSP=4B%4=%@_?[64M>$RQY 6>,=^I<'8>S%ISIB2V@MW,-&,@$?
M:"I?S$6I@4XCH)-%"FG7Z<1#C81/)[EL/I5+S])) G%@:PP^/';7Z2-II" /
MHP@4T<F8^C\U )C-"9I5G-;>6L]K3?Z*ZL]K<53,2>$6@JV7Z':4KI#@A-$'
M8"4-H%M&&NF00)3W(H4][7YRHX),X/,NC,VFJ1E#VWE@,R&=3O-DJY48ID\G
MO;^L=]'4LO'O;M38N$.=)YG6I/E=U_\\G)OW]W9W'.C;I(CC+]#8 'WZ=E>[
MJ)\^-.N'!]=GPDGUKE$3ZM7;J\;5^9UP4[\5:M>7E]=7PMU%];8^)45FBWE\
M@';\']AR>$\)X#8NT+EK<[/(<@HV\@"7LX5;:"2"5')?$L?ZS'OFS-T==<6!
MK."UK":H .NSUL+(.VGX!E:E2)&LU3Y*?#WPZ__]A&F-4V&^<MJRS$%N#4X#
MN!: Q+:U3UCJKM[(+JUU&?746I:1R&W$G:">3&57;V2VD&<S(1HQ:<\<6MCD
M6MP!>CS3=#XL!0F_H7](?<9,2N@U4?H;BNW8\T&BU1/R2-0VOYR J3-T HKQ
M>C_Z]FWBLTQW5W7A%3(I.@JP4:PV;3+H5/OIG[)\,E(^+2;:KT(;"PGH,ZU*
M$ _0]"^"WFM_SJ;SJ6RNG,H6"O_ZT.]9RK0L>%#(_^-9Z;/NL9"8(HRTI^L@
M\:7,5Q+*8C$L%M&:1NE<B "T%RZ0J)A]VNW6IQ1R;RC[3TA"?)'@)DL0)&V$
M-V/7005[LO\SYSA66%!E:D4ZB.<-EO1Y<8[!1>^+DDCN,/,:!8Z0,\2_F^V5
MF2N4YF<!5B&K@"_SWX2V8T[;&Y+V;-XK@,K=3+$<2VKVJ0N=@W&>&,"N2O%U
M[D3BM8VE(]D>2&BV)LU\L7-U]E"J#K)K:,JGOFRB",(UIP@FOZN@ BWM-XTF
MI(N8A13:VT[1%- J=O@61,-<?R5X>EIW)>&*@96H.& -. <B44B5*P6L][+K
M2@H/IR[,ZTQH>5]H>6V5-Y>2<]E<*N.! (P3)7LINLJ"ZA^'0JOFORMG5[>/
M%:T7J>OG$9L)T@-$)EV(V]^SX 2KJ;;LEL2!V\B,AZD;H>OF2;5A*#!/S^V&
MRX#T<68!BLN7Q;LMIRVAV<!I-B"2#4A/N>DT/3N38VMT.E]+68WZ0@1OS2O)
M=2#]JB>MR9_W43,O#KK?7TKQ0NK%!#%95256$WD/=S8/,UGPCYF<]\36!.71
M[]OBP_??HTZ\[H*D[)WC/F:'?<S.G2;%#AY%#S:@<;;.[VA^Q2<O7."5%-!N
M95X%J'=QIVC.E+G.?8 3QTEAG#/M(3,5TF]!)N4/K+K"1I9^&&#G:6M2S%_G
MST;UA[Z9]P7L/&TT'^[KIQS-6?_YT'BL-NM7]Q38>1<W9&>Y,(WLC#J=Z7I0
ME( B]QS+!=X*33@'#PO:RD%L/W^]X-2CC-2LA9@(FU*X'&:]EYDPCA,RSR_]
MK!E/\"?4?1\GTX5,\]DCP[Y,'6FHGE14H;X@'2'?+PHSW!5X!@862S6G7=HP
MC4[8G.IXB?*<TXLHTQI9'@Z_TBIF+&>6)> 82\[$?*MDW C4 &ZS@-Y>.[U#
M1[6C8,HFG-;I,@O]T_1%9R/-&Z]YZBM65KK.9[,J_'(YE:_XSCIO(;T<9MS<
M*9$\^YH%;1*10E@V78+6V299LWV49%ZM0#:29K%/) 8FXSR:D 0@YXJ%?"J?
M7SN&&W&F,3#3*Q*A-D7%=!$SI)P(.D]!=Q*2H$O$3'C(A4PJD\^F*KF= "XX
M4T*+4C;UUJ23>?IUH9]-S'X[7FF"#>=XE-+)'(^@YWCDDCD>^Y.09%+55Q.7
MLJ^$Y,(GMB8W9O[EIOEX4VOO=!N7H)*0@D<.\O# 5Q)R-I\XFT+=OYSA5V$J
M#?C?]IPL8K8U*3_F<[D*REZ(O3GYPN6M8&:[6L<H:;B;[6#*V5QE)=!PG I1
MEW7T*+4\;/+)K\?)VZOV<I:3['X*,=MJ$#FP^%S3!FT3MM\?(3['N#!O&[-V
M'[$_S)UMY;&' GNML$<BCG<7_I+T+Y@J94DOZU\@YG[H8N/MV;@M;Z-_P0Q"
M(+S^!=2#2PJWG6O;O' [X@1\4KB]H1!8HW![+'9RSV4S;[YD BC<W@#ZLWRH
MR[(*[ 2*MGF.9J=J2J-GMFH+<7@ EE0Z:<8N*C1.2O=1=;3.X;D[^O>Z/5>(
MLE[VZ;%]<9-._WHM1:.=@T]=+4D?)XGCF-:57]Q>/WW9A(*33.T"*>&<2^'C
MD.^U&EX#7CF97=V 02WXMVP$!9$4/^\N&F7CMWSY*_3N*L&*A]E^*W/:JXQ@
MIBOD0WA:!K&DE',.CIW 2>1*/.4*MRTVI/HHK(UB*E\LIM+^\;.Q$2_I!1TL
M6.Z6BHWGG/IC7+IX.=,ZV^UAL5G'"D=ZEJZ M:I@HB(I_-^APG]&GTGI?RQ+
M_TNMR<UY]42Y+BC9YY=XH3MLE(!'0C^\$>/$4KY%':*EJI(V!(^YTP&<!::6
M&UU3\8\=HNN,Q6/'SVS?<;WGM292+S/^U7Q_&3V($0TC+[<FROB')INE7Z>_
M>RN_E%P;W^WA =NO8&]8<.\X&4'N0GO/*N4W:LNON?@&]M"_CU0$B:@B;<YP
M5KT[(<,AX5KN'LA?CC*YE/!?^=L9-MW5CBPJ0D,U,%.0*SJJZ4B230%BM,CX
M(ER2L<CD^L">=_U5P/K \R&886%6&]Y-IR_H$#  )P#6,W \#L!-.NIH/2S;
M&6H+O<-P-VC20-^CT/> Y]"U7B3BWYF&T$>*!-,GQ8&&;9X)Z>Q@F,?.;<*X
MN"%6D.SEZ%TV3#:"?42F8,+S!7DP%&6=+&F@24@1WF2S+XCP5IBZ=Z1HV@M\
MRVMQ_!MDIV^RHL 4S9$"1@WX.(H,1LW4)EU[H],V>0\-D7.0O0<XY.^B.A+U
ML<!FB:7(T9'/LD>2*9\0T,/KQ8:3)*@:S E]18)X>(!5+*8/?'!LK*FF.OMV
M<.09:6P!C@2I!+9/>Z@99.4IMC,R?EL;0J;&FK#>$8V^T%6T-R.:D7S!L\[N
M\STC$4PUI;FL7SK"!C^P?@.[;FI/QE:)<72N:1*A7+C):_Q-'=@7Z%(VA-X(
M$P2@APW,)8K<E1DKB;:([T+"KL<?XF FX%H1_PK_3.JOA/:8"0/"@_8'.]B>
MZ\&#-:%-IN="<Q5*I%U9-["#:Z*A-?47.!=_R7S3CNCOK0<='I@(?YI,JL5;
MK@FY0IKRUVA(R=KB$:3()'+!ML-D%%D-7@4?R8OW*7CMC"Z8P4CO8!'98Z'1
M/3P0\9.&(([P[\%DM9E+U'68G<LPG 3EB20L>S _=?%CA5< P0-CT^,:<V'2
MP>8^_';V[8YSPE)0DC%SZP#T/CX\@"W/?H$\$1\P;)U6^].KI"O"7&UM%=^:
MUA&MS^#'N[>U4&@!D1T>;"BUA(V$UN%!(K5BOWB06M51#S\>J*8\5VB5N;U2
MZ\. 7"(F3F6C@_7G"*9EVZQ+#84S8"=24^(T7JA-PA0UY@U=>X7^3O:T;_D5
MJ<@P*';<>KH^_70=RDF)  ,2PEZ(_0N;CYUF#M/P%IWCW^)7XV/ E@.1IWS"
MN83%00?IIH@%W9P5+.2[\KK&PN%!4'P72V-AUUQ2&R[QMMAS7.R/EEWHH=4>
MU9JTE8EVJ13$]\M*1*[H26N"*HW7IU/]OEY=W?^=<D4;3(0DGFB8:P01;I6T
MV!T!/80XA/R8Y4F"O??B.R(B^0O\\HX:EV->E5-U69?"]'>X&+=M4BK(W48I
MCRN;\+5I<Y;;0I;LMZIUN'25G0;H7RQ139K1PNR; :DH"EB'\%GDAP> 6#&H
MK 6_;VQ+7)DDN;#)A46E6X!+&CY<D+W4LW1*7[#>.B:7UBJ^ &OI\$C3+8$/
M#VP1C"6[R;1%O(EGR^+U1I<U_8;TAL1B XK@,"5UB)ZR*Y9/\1-TF=SCE'C-
M.L3KJH]J3?*7H\>KO^^_?ZG/$8G76FN2>WEZOKIXO&_\6KV&F(M7U^82*1K(
M&FO4Z,-."] 1ZU>*>1P-J,'$ROZHA=9&2 4CE%T$==$P/T JA7MT4[=$L^_X
M;T/LQ4&FG99+>CM.MOCP4;^8I>ZU@1PKXB_MBV >STJTY?:D4YHM,2A3 EZC
M;5 *H@&;?)6UD:&,F=.*I6Z\[]^;1J<E8/@2\19A%VB$:'\=U82$VI-L]FLD
MJX'T.8:F*U_M]Q&M2?F'=I\IJJ6V48Y=(NKJ^KY^>) [%J:$:+;<FOQ];"IF
MNUR[KI<^?;NM/]:O'AS-:^,N#A?JW'@ME91[6ZXNM>RH3.HPRC)HH+[#B,L
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M._-6[TDCV3G#+DN.LC-?WV]-3 .E?]T\=\H_^O&J.;OEX2G)W@B5ZMS"(]E
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MYX'5W]/1?X45HJ:(GB)-=5+X(E[P?T,7.]KFP!BUCWB).'^KU<9"4XT.:8*
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M+ R>-$W3!=L.OJ7?OZ%?M^GA6KU"YAVH(V]"7JVOW])I>89N'AW=0XSHNMO
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M'5<HS)*]&,OH6.-K(I'QGR%V#DLC ;HXX(_6ZA\6Z)G4-&.:'Z([B ][ZK&
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M<)L,E"WXKNY..&A]#F)T>85,@8<@:/3ADX.YG(5YT_2"OUE_!SPU_B8';47
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M9C,Q\P\KZ71">P'17BX&&<U9VNO=Y]]+%ZA^\T?>,Q?Q(U@,\<YMUHBH1;I
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MK?;>=IN!18Q4[7XW<G^*2N$2[4<T)5I62; .>Q%7\<,ID^\3M=A^-<[;T1?
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M@*Y2 GP"T#6B.A9DM3/2=?PYV1+>0J>/5XE?I76%_UF$3[#E_75WFLZIFE!
M382!3_#L!6+58E55:5'LJR4A^>BHB7JB4E>Q/!F[GWTCZB]P/!#SP"?:4#OL
M>T0P+65X?X?R:278PT;;9<^8MZT )$PQ,UO6"/SLPC^M1]6D$2TF3U/#I,I/
M4Q#)<:: >JDH/3SH>+:NQ<1N]2A)":(*<LZ)++) 1?B1@B@,1=T$L@<.@?,2
M;I%AZJ..27B+?'^&(TK;Y8@YLV]WB,8]1]M&0+5>PZ,#HEI,0A[RU$'+0[K7
MPP-\CUI')K]^D\T^H3P3Z0-9)40,Q(@70.A=$'LZ0O#$XWAK(D]MB5>)SQH1
MVP=]^^__.3H2SF2D2%\PH_6P27:'_HZ0VD%?A%+AJ_ (%AU^FW!TQ*U;27[U
MGXR@N[,^420&-S$OA Y2%&;E_.^G]"?R;[S2#O^W^QT=35'$H8'7PG_Z*O!!
MR.GT/U\%8OH8\@31LX'7S(VIF]K0TY3RCJ'SR+'C=9^^G1TYCXX?VE?A?CS$
M*ZCJ8EON?!5 *]"#O=+@"#-EY[?^P[\&?[(M,&Y__?<_^*B]3EU'XLM1&V'&
MPP\?DEMCYXPWQ@_9(D4'@=DD,70_W;DH6"U=D(-.=H6Z8[;&^SXZ/& FWO_[
MO^5LIO35F-6?@FA.FX?9-,AL0S9 (#%%V,6$K[UA]O@2[TU[7\Q*3.]_'\O%
M0P78U4>*+=Q:]NU6RKEKU-=XGS/T&LDF\#7"K__W4S;.AYYL/]G^Q]V^3^Q"
M(E@7O&^(_T>3HAGMLB-D%<'VP]&1=J9RQX\GQNO=6>JX0N;'E,4[ T3=^(H_
MRZJC4"T.@%P/HH[X3 "PM;6#^+"G+LYWUY+3#_WT[;!\<O:1RQN&1:!K(H"$
M[5U"N-7_++Z5S?P3*"Z I7_FG!I_Z3_A:FX>:\_]LX@^[.2?OQ%NL\T6LVF>
M_<NFP\C^^6FPV+_)%Q__--]?JH5PROBS:9[KPS\MRO6%W50Q4PJ]JV)EO;X-
MVZ$#=R=%17]3Q%_??_?4Y\ O->39D965VR=.,WI$\B184;D <+=2_X5.2&1'
M002>M1/S!&S\BB06DW< ^(-*UG>M=3ADM-!\VU<&\2>HYQ9"1,,R2\LHPF*C
M2.HE0N"L>?CPW'8Y;%XL9E^9J[AJ240T[.1141$Q VU6.A$=P^2*"<=$RC'E
M50LDHN&8!>45V['@UJVC"-V*RY>VS#$[-UZCZ=W'<4NY<]N%SVW7A>>*<[I1
MA_EJ]M._WI3Z93:R, T#7X?>8#']\<9"5B-UT.<0U0('?4><\N44NIXX+VRC
MD?1>CS/8L/- -"RP?R,+0N"4>8/FD];K@3&+O_G4$42G2''A0-1?8L OKB\N
MZ+I>+&VYZ_K^T&$F<K?4EYB.JLU_N*YH6+9+/B:CF*(=/K#!VFTA%S=?U&_+
M9H?HO41F7Y-"22I/*X/(X0*S"_!O,LT<T:=O#55"7?*5#^)TGFXG*[S$B-A%
MOW,^16XLOG.%;5C2>VC&++51O</O&[;%"XMG)N/'/^W*;7/P\^YEJ^9U*9^8
MUP')X\+V\J1+9'+((^=\TUHQH;5M-2*/C-;VPYO["!9!O!.*-<_63W%SZ?R%
M]B* BGLV$UL%.'[?^%X?_!Z\5.5,Y)[@HL6'#2//A8XB7W/Z7QQ(Q(TIOQS?
M#W/OK]>O8Q3R?8>,,/<U G O[09_I2V!QPP67?C^A \6[#*(T2.I0L8WMCRQ
MHP,%;H2?FO//(7N<U0Z+D>;DN/.%;>16]C7+G=M>^,,_\\0D$E).(B$!1MVV
M%0GQ3W;[%10)V\Y)%WV/0HQMA&0+.6]RW7$+D&P9?^V.6D('72L#<Z;5.\V'
M7/%VH&PG]>U83? ^[@I3[O=%$^2WF ]W4M;^.+0+R71-*'8\)/O^4'TZ+A[L
M$C[X &YK(.PRQU?=!M_LJZ>:W7*B?CZ3Q,0]K102]S0@6CO9<J)^/JU%Y9/Z
MI;EMX_SCG0Z_TE3\ML$0X=L#A=91Q)$1.V]OV^EP+M;Q:=7LPZJ1LUHE&7Y1
M:W[OC>]ZH^M^U.6Y"Y:^^ZEP?V.\0Z_&7IT\W(GP26Y\W>^4;M5:-M2[#C<-
MGO^P6?!H^ZGYH+K=#QDLI>BDC#N&C%",21FW;];8XRA".!PT+YRP#5;:UWA"
M.O)XPLI\$XO 0B:=3@(+8<1]HRWF]DUTL8HP8.+;X0C#&NGDKT+03>GO7%.6
MZ0(4[[Y?_/%;F-/B-6UUX3)B@]3F#+9H[O?$&-[?_7I/=^5,,>K0Q()UA=!&
M;(4,]A:I;;6)%"'K!)^%KP'[M8O(=8%CN]K)Q=_U]<L=Z_F^9;_VNB</1-=A
M_*.SH,_04N@>M7^F7.I21\NH6W&Z@^;=.5YW*3Y,'(>!<G'DW^A1[*MSK(<S
M'[$R]>EQ998WETC4U5;)?7LMX?R3^X(P0IQLR* ZR(5K1V;BHX*V@\&8#09D
MHQR8&/S+U@J [-N>/04!>:\@:2/,DS$?U;6JGSQ_:_%UE .07ME4);.V$9W=
MKFGQD;A@PPYL\_AB/5<U/%Z)U%<-M+MWQC>>/'PN\NN*?B0&VL -7<]7C)Q)
M@AF>M:4Q60E3;(,I-L#2;^91;LO:VM2E#*0:NY+SW75F*Q87\QG_8XKXG/!/
M\/-4MG!H$5&Y6F]-)I.GVF@R.C%_2:X4*G9RT_B>%R[AJS 0]9Z,=P(?3;LW
M]XQ%MMP=>^S/SZ-G=C>DNQG&:HVG(QU?\>&!V4<D-RL@5<+FV"GJD!"%D,ND
M!*# E "? *"(J(X%'76 L3 W6V)=Z/3Q*O&KM*[P/].9>*<;96N"Z^XT1U %
MHH ""2,3S^;*G<D*WK-15:69YI<M"<E'1TW4$Y6ZBL7+>/H!^@N< 40J\",:
M:L<5XEK&__YV_FFE+/[R/5D?]%Y[$#TP/50M\*TK4KP>?9)VD9C03$T8DIT*
M7;I3053Q;ZV] @6+IO"&="2(;?PW306O0I7^H^GLMX:A=63RL#?9[ M#79-&
M'=-P$?:;: BJ)BB:VL/$#UMY1<I8,) "+SV.-R][RQN_ !%3<VH:A.]Z"-$G
M';3I6IW\Z^]#"';>@R"_Q^\\4;3.RR>7^*[X;=BU[+&M2?4YBTXJKYG;2CE>
M6L"Y]L,#1%<//"?(UBZ!./$VR6^Y)#;FB6)"^5@@5CA=XZ\IBO9F?(F4/*U+
M/#EI313]O7/WY_SG2+0KK"39&"HB-@(P^6$[:R5H6NVB?OK0K!\>7)\)U<OK
MV_O&G^I]X_I*J/^ZJ5_=U>^$L^M;H7%U7[TZ;YPTZT+U[JY^?[>9K/'F'V*(
M"!TL 9@]]+^?TI_(O_'G.OS?*Q\TLTP[^.K$H8&^"/RGKP*;05HJ_//)3_C<
M(TH>?AYL>6J!//\-@44-*U6DD-P:?&[PZ__]5%PACS2S.#>I6P61%@=1OC@R
MM>$7X OV3_Z&]-K2X4S3Z59\_1_(AM]$-M1!-KA(U?=#?/Y?^'OGDFV%M6,9
MZ-AT+"C1;Y;+P:8A,:('44>9$+<8,1L"(ZZ[8%"8<9);R74MN2YHBANCZPH7
MY,\T?:'XCU^;T^]6F%LXYRS9>[/_A!MJ#&>8^H*0HA/_XK2[9_WM4+K2N>;6
M3R>[',N!&,F,\?]I^M3*_T09G%Q\7#YC$KQUDNL@@@@P9/W&+,,AN85R?%^9
MZ6PE9LI4.#-E*@DSK<Q,F0IG)OQ3N,R4]UU\$!DSA0P4VUR=-KWKXO:E^K2\
M%;WI;^J[;U:/,WO/C]]O#Q*:E&;[8X[MZ,$/Q!P>NB\LYHA)O]KH2L<W5WWQ
MFMP680'%%AS(%<;&[ 7GKS=4+ @EF=O&K)B]5I/9[;J+'XUU%CB,(;-.(286
M9NR=QNV/\8BP&_(6M.6R%O7;X7/G%Q<4T^8S2>^L@,BPNEW-$T\RC$[=A#!6
M9/<US'INVD=M\A6K(OK3K09#5^CTXENPQ+.=1'YY]\BDG41LNA]%'_G< TZ(
M+% :;I<)W[&2?>DRD?17B ACL*&N#50,;*LL</VPJ;MD8W.KNY@T8X@_RVSH
M[7Y0EIE5G4'T+TGO52UMKC4IISL]W1SK?VIRO*JHHJIMN^OTD312D-9=8+.>
MC<R1CE:M=2LY&#?(U[0F-5W]:VK:J% KQ>O6ZOCK RBY/#SHDLVX^KP(SF(X
M1Q7F__N_Y6RF]-7P*) 338]Z.-F(01%<H35YTNO9WTVY*C]D B^"J]_=-RZK
M]_53X>SA_N&V[ED5MU?E;\7UR]]6\_(V3_20DBRZ"D2*JUU$&H/@@K/6@Y-L
MOE*W#>E)NOR*,FJO]]+-SZ-=KT9TTU<RD"5)01OL A_<UL[+X4E:A^1S!J)7
MA?(5/J_[-Z2\HDN\K+[1DAO4^FH-Q+-FHWHU^2.^MR8C-??KX??;:V_P\FDQ
MI6]69%*:AD!O3O>8?#+["(KW _>/&%&^&>F%W56F[-MQW *DW.9EO]W<9P\4
M)/S]FS:'A?_^^O%CI/]IGOS-K\'"T8 1\(5G]RK_&WG2="V*B0_G1<]NN<W8
MK:\C-(?A:HJHW#^67\[,8C@Z,W#>RR6\%S'O ?DDW+<N]YUI(WT.\SW<ORM/
MD][?7K449VV73S@N6HX#D@F;X8HQF1D< L/AS\YAN.;5[X=)\6F<^5O>$6U7
M2'@O8M[#GPV;]_(Q5G;K]Y&K=DVD+V' C"QI8K-Z?BZ%K/&"Q__=]Y&.1-AC
M#,*0\<$XQ1 .M '9ALSYI?7;RT<, +(%PJD_@7"%S)9\;S&]Z6#Z\]]*^3Y[
M@LK5D.*R?D ,&Z2/&M/)LP1+X8/Y8SB)!=-HZ%W!"^48-<O?',EPUIJ<G->^
M#VOYSL]?E7CEQ*-&,EQW>6_Y><"$L@<PP>-;K<DS>C>4[M7OK-*.UYD2*^?P
M@/3#G>X][M0$?$]5=9K+'+,WJ"Z0-$_$X>2DG-8?;D\EZ4WY]$W5W/AU?)'K
M;:#3QXM!@'@@0(B.:YH! +,\X!&'!SVV'4$B7=R%94W<CX7:&N\1YKWF\,#S
M/?%I3%QI3;JO+R)ZK79>?J' ,1GGU]>G3XUF<Z]@%Z7T-.QBZKAB''G8XRK'
M?.6TY8'FG)P]]'_\ZOY)7VK/H=01SL=C1&_3GWA(\I9\QP3V1%$>WG[5&LCH
MY78-2'$B*J+:0=/P-KH"?-GE?419S+/+MP.P6#2 )U,.<.1A-KL;8(F\![?9
M5E(3!E[*5]Q8DEN3IUI#>ZP9I=]GZ[#?LDH<V#-5<9Z\%WS@S-XJ71.VC6""
MBFT,?380^O_L?6M3XDK7Z'>K_ ]Y/6>?VKL*W-PONM^I0H71&15'T;E\L0(T
MDC$D3!)4^/5GK>[<24* !(+FU'GWXT!(=Z]>]RMW+6N$*Z33U[?N6ULPN]$;
M@3=6*)#/U.H)\J']LY#X*YZBMFF(6BG_]4J92*63'_F-1:2BGWIL25VV_IP=
MDWK,$NPQ"Q38T9%N,7SOZ5WPC-4>9_P?(3\2^Y=_^D_K>G'8?P^K94'R$<OT
M0T'J$WQ_ECT:L>O,?=SH76F-7@_XEZ;>\%.$<D/JPR?P7/]2X+N"*&@"4<\$
MM2?*ZD3QJ_]Q*%0KOO%Q5BOWI[>=KX-B_GG'+N^_[J?K=J>YOY?/'[J<=+5"
MXW%6NJE6I<M.YWNI?_"I<7K:OK_NW'$WC9\-.M_I^HR##V_OFV?F#"@3$;J?
M-NI@V@&7;QC\"BQ6:WKZA)=_[>/LKM,=_.J4F[G/PV0YC8W#[.^-V7'H8#6>
M'<BH3?,I.3-'L,&UJ8**0P5UYRES>8(8V);3L_4XNY:4L^'OW_6S>GX%D#O\
M?>Y9;,O0Y?OPA\Z5H87RAWZH:4^6D[)JBY2TOWW_4[OJJJ.>1?A)F#"4#H1:
MYD9/;<[F+^37Q4--F/#3<J)N=#=G1J5S&QFZQ3&W<8UPAVTDX9+%NPE$K/?/
MJ1*#.JE@V;'K2JS4L-RP37^7P>E$40 &8()=RU*/_<.>OMRX:30N9S?D]G%V
M\^.VK5S\NL[W8XV+QC#%T#@SIUMH:1@T]LY*B[$LYF3$8J92"ATK2<?]?4!D
MB]"[7\V4PO?PVFHXWBX*VMJ0*/.>MR5$0G_8+O^I7CP(_54*J#=3PTE/.>>/
M>U?973$D; 53W!*8$S.;+X4FNW0,PGM"H0B9=U)0:%';J LT58BJ+:^Y]YK/
MMS]')[]?^C'5($6NKE->+>@'MN5(Y>>2I%*R6XKL0B!1S!P;T"@9]);BSF9P
M)\I.N:6$S-OSXM5UIY=E=:VZ/9G67KX7;R?]*%-@-Y+NVC#5;$'/AAL0UIA5
M0O9M1,B#&'J:];KT3F(WK[>OY]=RH5NVI-->4KQ=#V\CE%A)QULO0=9:,L/0
M6[39VB'89-M(G9W=UK7VC^??NV"*=&2-%]%YY(@?V#.\]'[-J5LI>D=N:&2+
MV\>4J8;/WDYMEG>+4E&*A4PYEQ"4BE "/ K7%[92OO/.M]=J[Z[9^;5*Q'BK
M=LPE4=4C3C\6V\(8FR?)4JKU;5OK6U"CMP2^QAZ"KJ]>]1-WN5Z*NN\.=2,-
M:%?#RZ<D5)KFEI18'DZX'2Y!A=-D>W9AI1EV2U#0V^_^TD+4K0RC6PIKD^MN
M2V<XILB[ O(FP^>6Q%KKYN/LV_7I4!G(N>O.VK76&RA)946IY*TG3OKDTW__
MD\UR+8&(_2/NAG\"M+PC?R9$ZI$CKEHYYAZP9QRLQF6S!JGUA9?P^AD[G?E$
MA5+_4G5^BZOW\KG<7WKFMBK,"(,-+N-;0J')8T\T\E8,C#EHMN4./K6R=M 9
M0#OF.M,Q[*"A &'UCKEKH$,&V&L909BOVW_UK_$S_,K"/@/W_OL70.T%=87P
MS]DN 5*$EX_IK>EPAH,90#8K46T(9J'$V/EV^Z9PMVQ#-CQ)8,'U?UWS-/.U
MX?'W"S@C76UQ/P![V-GG%X\S4KY_^:P*Y+FU]FC/K=7[%^;K_4\>9P^=E^\_
MOG_Y7?MR\.FL>=*)L9H_$6TJ$D8APJ>[[U_W]^Z(),@*"^G3AI_Y8RQLQQ9E
M.]E4(5E[O)#V][Y,Q"D%:<;>7)6C@H/ERLD<#ZLJ(TZ481$,4:D$%"Y!FW+\
MDT((MJLR.K:.%4'J"6.T$4>HN&';@?_K;GE;=G&6"TD%-H6O:?$]'"@\L:>P
MX)3P:JY:S#\^FK]"4=4>-!0%V\7B#QMO@OKXV -XR"/X&G9["9L%=?%.WVK#
MV.D5+:!\?.P3(9N])$^\V)0T?,#Q!D"^UH3.2KV\/-5_,OO^^O4F+W\=?=/J
MB_16OV-Y:JC5;*X*3%M?_#'$[O4G/789R12;3,Y#TT71I",S^Y_5<.YO1!,D
MY4+N&/;/X4DY\WSTB_SQ_AX0O>LA_:M_0)G1AAQ^JI^=@\-3M!1H)%71)**H
MW-_6SXU?9K#GKXA-@17Z/%7' +,16Y]@<;<<J#OB%<XK/0,!JPACA(R!H7KG
MTR3@ZL%BM8%A'6TD%RW^!1&"#6JT*S8P^#D4X%ZQ,_-$!+8TF- &SKS&H>:!
M5TWOGN<&P@O)TE;2R)@RW%!^): I9SAUTALR9@5VH]CGNH0#+C;IP5N CPWD
MB4);0ZN<, #E6-%X 5B@ K^5)OCDGXF@T$VH'*\0S"WC^-Y0@._[AW.*F9,:
MDLGA=T$*N8FN&(;HVH,'7A'0V+@%$C[A5:"('NU 7#(Z$.=*Q9R-#NW/,P(R
MO[J4I;XLT334+B\]MP<#E'WXX.7%2?O6P&P@/3P9[@GDG;$I*YU<@1\ C[6A
M^&(JK&=S):.=(_P%.]9W]1AR4R')S0->!Y]N%%"N]O> ,I I4_&ND($@T;:#
M(-&O^"EK(T3S*KM$E%__86J"2;9@XQ(+ D"I//>B+\3@ 30%_%5?0L.IA]D1
M@&'(L?-Q](#9$SCA_IY^1@ZW"&M.NK])3^.H C(2)&$T&:$^X<:7O"^^T&/>
MC<'H[+<E^_GSCV-!>.R/'R<W1$$C.6;<>7Q4%2V;O441P'Y/_WW%#F7H%_US
M^-6H7E?&OTUD8T!&3F<'L@/$R^DB_C#Q:S>Z#G[B.1\=QPRIH%Q<MTP-)5NP
MJ2CZA8&:<ECV=<?]M;^' G[$O_DA36-WD88=RD":NVZOVJHVS\@=_[Z0QG[,
MR)"F>.COP_WKG\S^WEB<@.P',V<\%H4>!1<3?5Y(Y*\>)@>)9J7OE]^GM<'I
MK)Q_+P@2'0_)!3$1/Y7/LH164W@Z=@%JZ;UC4%L%#7OUV0QQ*IW'((?-BY(E
MT(QE'W,;Q+$"NC!]A4(FU-3!*@G:^D]0X.>J\(;O8TKNW^9?J.[V<<8*H#X'
M(EN!U6"=+MXKTL7K4 #-VMA$EFX"-BS(?5W3'O(OJ"(0:4[A-M<0'/-;X!=]
MJF&/B&;HXJ:8]U+)#_?W6D;W0OHBK]TXO1AH2NBOH/NQ S+#45I7B+D_O46B
M+U#W]QA -<_[RZ#&9$'.>&N&8Z!3A[PHTO.2MQZ![<RY1>SS(V[-7;4'2&DV
M7PAPB$+=DU<LL#1AR]2L<]ERLUI^6AFKSW5!K"PB>O>V_(F[4+<1MV4N>FP@
MBJP2#R*.R%T!6&5<ZKQ[P-]2N>(U:CB? >-RNPHBOL#05L8R5Q+$ZWW.=O"I
M(8J@=XU82COE0HOH!2,T2,WP.59VT:(NTV H_V50)/\$/WI"HV".-M%H<;"[
MC#YG2U8$D-H\NA&0KZ$Z:&39 UI3KV>^3MNE%A:8]MSJ;'Y_S^!$ D"D"_8R
MKRT B\&FD&L;7-%L]BJP2'>?ZT[I3\&>DB=/0U8W@",WZ4O[""D&.B\'BQWP
MQ@H >)6^Q5Q*(2*O44XKZUP1:!\4 V0*=+D^\FK "?:1?E/SJP'7[M@XLGD"
MJX$MOLQV__ F4+X4&=0_. =<4R"C=#E:B>$^[D7&'UD.UW+^7A+D[MT45\QG
M"K7Y7+N(^"+@#!Q-(@P8U"T7>/_F]3J0C%*J0GH8*.^C=Y:'LW4U[/%+\SX8
M<BBH6% VP0;-LD=-A4A_&R>_Z/A/_7\60N[OT1U-5$-O(*!4PKY?B,MU XK(
M4.[3-?$Q2@&PEJBGFDP]@QEG:U3G]JQNM-W3;ZV'MT*KJE3G/6*UY=?HF6U1
M0^%O(NIA=K;LSMM^B(C2#/7=I"!!U1DX#<]9]6(F5=FJH//_&)$YK#6C+)BR
M?5FB62X4O[OZG!%U2 A: E01]N\I?K@1;[(KY@UVVCN/>&,L-AQ'=9HX@JI.
MF'&#3[[R*-W@%E&+F"B](0^,<3+&?P8IKZ<BKP*I?&>_;BNWF-0'VA @0'N@
M!X&0X$"=(OV3J?Z<JC^H4HXF")ZAVCL-G9JP[2:88=H4MRU+:$$XA>\E#<L9
M+S9,$_''KR^EYNOD[NO"B.N:1P@3F/7:XS*N").5W U!IJD'GTKY<J9<J\0E
MHU6ZC-_85& '(QG?*O>>]_?L85EV3LXXJ#/P2E4UHO0$E6KC/>(I%>N+D*NI
MO^,&7V%^:5Y'/G)< OQ<"846;72CB ,RZ,9 GN)A+J#AS3IX RK;!?";R1/L
MWB,U! 4!\AJ '0W/XG<&W\G0: TZ:4RWD\F& $^\.=%I7)RH%ATGFI:^YX3[
M1N_/66%+G*@6)R>J "<JQL>)3+&T! NI1<1"HD."3;.06&[<SD(*<;(0M/I<
MDH2:<OK54T^,,!J1OD#-_ SE*]2+S)L67)#.8KP4U'\&Q_9$4S6>IJ-@"@NR
M@KX6O4ZB]IY+7ZY_5!YZOP-=;RN*@JQ*>D?]B?(*-K%*)+<K;M&I0>JCZWQ_
MCZ:Y+,A96?%N.;^KU2/V-&;!<SU>'8I$52UB'Q!T'9*,I=VZ^ "B@$0Y)=Z^
MKK^@ADNQ90*W9/W"EA[ QM-S#I_$_AY=A*HWG#H&BQ%.T!=>!# H^O"G0GI(
MJ\) Z%$/%G-$R;2I*[RE+] /V5F9+PPP<\ +BG,8O1L,&'%PN*_V]^8XF[U7
M;@O>2"L5&GVT(! I+0[!' 3&3&W=51#*G@]\K9?7WCN+?&U[N>[A@8K&NPJW
M!5<,T"9@=XV86]7T\-!R#AP,)@,"9J^(HJ&+DKJI*:;A<R.Y3T0+$\W!6&
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M3ZYQ?<;1K[,GC;OF&7?:OKII7M\U.A?MZX#V,,GR0^]0  "V>BJ/1F@JWFF
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M(,2*F5]Q*^/1WT$"M/5"/E/*^5;&A*+)2*G"K<1_%&X08 04HC0"/+ PT69
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MJ&#J%PD_&D\4P!E0-=TB+\J653YCX_+E7+680TE'_[)+.A1R[8%M!:?8PH/
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M&J76HH_KP@_,=:?B$TV*\25_>U'MBD^-R9.IZK3<.\X@#NB;"'3M^>]]<^G
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MZ@ 9_/A_#PI+#(SUV/-\,<0:&UYB@)\^.W%N1W%U$DBOR^NZL(@[0=<5;_]
MG854L*(HVF(5(VR6-?(LF/*%Z\\5X>DBQ@?N^AX+?\7;Y,(H=_IK4XTM(LD%
M;/Z9@+E^(8'Z,*&92FW,6^V \ATF-8E^>09ZA^G>7,U0,LH&#/T@8/BW Q]\
M4>' ?2N5OW:BAT74U[&<">A]#6MG=A0#JKE]B#5B*@H48^^5/T0RR"$._I"O
M&_PA7T_Y0^+X0[YN\ ?X:S/\P9IKEQC^L)G!5FOLN6GW ZO<WX+$:E;^<4$N
M5J:VJ1Z$OH<]\-J)'_&&L_YC:1L8E,&P9M6K#W,,D_D[FTGRE_.Z>M[_,3Q8
M#.MUR@!]=AF<[AM+BM["J\"8=]FO&)610*C_EXTG#30QJ.3(3IZ=G>7_%(<G
M4ONUO$54\DU)WA8J50[S^>7Z0\;-4W=;(,3.[N>Z[<=*HY'IPJ'8?4LYO]>&
M@^$/X7<D-+JLJIA0=E\^S%7C8/=S8X%W&I6<[%X[(<+;N#?^<2ML$942Q^ZK
MASD_S6$K['[CXV.BL&BL/*)W);K<5&(=,\.-&"9OP)R9Z^X3;T*VSNV-/)J)
MGA$2J7XZ.[FN%>IGRK<6S\\S(P>8V6X2D*BNPV73#MK ))V*;T'O$F*0EJ/G
MC^>$822#29: +R.H>/'N\K1U_BR_BO??/<QG+_). -X9C"9!>%<-&,$6M\S\
MZUV)F-BE1R1!A4BD1V3J[NQ-:KT]7UQ>#%OO0'C$Z;T/%AZE"(3'O U538S8
MB [A?I5?:Z6I>G7WK?8.Q,;6,*X:,(]NLV(C\<&B6^^2A'<E^W1"\CGJ)DVL
MTTV69F[$P%+SK_)%@;^\SY4.%@-Z"W(R #*)4G5SA\4HY*2?D;71HN"-F%BO
M0OOYQ^G]^"%7#8%Y6Y"7 9!)%.;E#_TUM-3,^BAFUI(2)$J=]^7\Y>KNJ3L9
MO@L)LC6M-W]8*T8G03R*(A,A0*)#O-K5:>&Y^W7(GXM+"!!NVYB70'NK<%AY
M#Q;7QN-:9]CDG4A]5N+]K@2AE6T\ES81M3_"@*+9CB92-;,WN&A=%)IG;]6N
MR26<][:4W;C<B&+]AQBSS@IOV:'0AV6/. !L07CK*F*^5*H=?,JF:4-1(&IA
M&X@:G3B;_NC_^''65G]=#I*(J.7<EA%UR2&EQ<=9]>>/\^=R[[GYO':=-_OO
M8;4L2)[U</J'@@1@@_=GV:.K6PU=$P+=N7KBS53RV^F&Y?,W)MI05K"'S3VV
M?G:UE5!/IHY^UC3+R*^Z/[^@NC_:Q1]GG5LRO?]VJCS\>-XQ3* M 6S];VDM
M.7 FV!,  \==,!T0-5F^*T\THW_1?.]5?3RT-:^#U^;'F$1>P+]A>-DJ_#_9
M_FNK]J\\SB[/OUR.M=9)^R4?IMK_KM,^_<JU:9$_U[[OW'4:UV<7UY\Y^!^N
M^:-Y>WIQUSBY;+JYH_-_MMT-@(WKVVH[@-C+Q1.\WTT<WTL0KUWX;I2:[3AL
M$KS?]/@?^O@A/1XI6]Y5Y(N%+>N5OREH4HF54DVB4"/EYREFKI#(98P/28'S
M7H5=@O>;8L9'YN>QW P;!IKB[/S:M@%1*7B\JD69)S^%34I4R<*:Y26!\>#B
M_J71*I,8_V*;D.E\:C;^EL;&5)_H;>([O$8*(=L<OZW!8Y> _XK5+%GX78]@
MB.Q5X<<1W\BE,-!15I"XG]A=(KV835,%91 IV#<-]J85E$^!_\%P?B-MO(NE
MOR*&VMQTV+F62*LE\LRG\5S*KT1A?^'<IP79H1'G$#E3]^A';8EX=*FE7WDH
M6VN6/$0#L^7*E9RG7'_\]V')M_L(EYT?,SS72C$JH-R/Q[N-2.O4P$4#LZTB
M4N&P,C]K*C@C=:<[@"_*=UY<C+SBI3,G0WM@LY'TI&5&,PFA%+9-)!5]=YQM
MPW-]P-V#++;1!SSR^W#28T-M#V*A0H,"J]5<IN0Q-#:8^K;0\C__C@C>U0:?
MTR,>G!DPY&S^9 ZM:-. CI\(7+)[<8O5%4E@'O5='?!-:-B @9T;"R%Z)F^2
M@<U:I%G[,AO<W-4&<R,.EKK;=1HM!_"$Y?MK;OQ*L:^K5?(>KAEGRHN6M>]\
M]8[%;?/CP@C'3\QQU2>\B%.%\XE23N9(VJG.)T$]2<BU;4B'<5H2N1V86[2;
MC&.1U9*+VVJQ.5,3;+78=ID$7A#_)6S:5"F5T2>:4OG&U8.YOHY1R9EYG J2
M,[NA#M!BP/>K&BQY9:DJL)&ND]$'?V+SV;N#/XO;@\1/X9U7V3#F!:'U^[EW
M=EJM%MYM),@\;@3C '.^C>J\(D&+Y^"^DTB0A5'O.1(4'2*5;%/<%D2"WDMS
MF\7=LM]+L,>;&,(%>W;<:EHCP+,><1F$5<Y7,[E<Z)FM:6>JN ,W<09KYEJ1
M;M^SGXA@C4V_JQ/^N2O^^?/MKK?E8(TW?>](L*9:3M+DM-WA*P%>ENU%6A,9
MA/%6&L(&87;4N[*IP$N4%F ]H-%LR@16L0P6]V=]+P&50,O *Z"RX^; &D&4
M:,R!4K&6J55]FY*G%+NTV"Y^[.#(<F(Z*#BRHR([KH#(>Q31F^L$GU;#K$[1
M0X5\A'H8VSG7)K'R8:F^3!RD]&'B(,LCTVY&0B)$ILIA,2" O9/ZT_J-_M]-
M+,2'(-)HR )U:$T",PV@>B53#(HUI@;0^XF'S(G9[3O/DQ$/L3&AF29/?]Y)
M7]3O)_RV(R(^-+X3,9'J8:&0QD0B=JYL+Z"9S)B(C_*01D6BB8I$JL3G4R4C
M8BMA\<3D=Q,7";82TLA('*9!H9[/U/.^?IR4:I<6WW-)Y!\L-K*DN$ZC(]L2
MU0D)B&ZD2N28B[H'VN;<VTDL'FG)$\6PI4_4T\;PR_/XIR*^V[B)==X(**^R
M5/E(;#$X=]@D:7AUJ[S6^\V>=C?NO]L02H1X53NL!ZAQGHQ]DQTR5^J*&;-M
M%1MI)2X"8Z.KY0,PR]W9#MIA:X1HUB1@@WCSF4*I O^7#ZN3>9+NYJK^M\ Y
MMG7B*.(](?8>=1@HMA2]'0\#.337(?_C]/;NV_F?;4>!?-C(3@2!RH?YZG)!
MH)1Y17_B (_421I0"J$+A8TG;8*7O[\P4X2&3O6P%KHATL?C-!_+P$I,\"K8
MP/**7;U[JVJ-Z%9$5E6I6,C4PO<!^'C,8JMJR5Q?G(\5*%M2#0F*D[TOE22N
M\%FDOM9<Z)#Y5KC*IHN.YN-KA:CC:W-6S*;C:[-.L_2G<J8]/=4KNQ_HTF2+
M3-[O<!S?NY2Z2GU:FE6ZSX/=#RY%>I<1Q)'6I?U5S1RZ+M>7)R Z-FKG;+>4
M)Z*(CC_T=M#X6"ZDLY:54<SDBCGXO]#Y-)[DLCT[8P/4NJT3QQ&[\=C[1VYI
M-BN,7W^6[CN$_[:I&(JON-N1<$EUR9J9E%]$?^)M)/!&%RZ)(FX1!Q][%W&+
M*!HCI+K CFCNVRVO62=4\*[4]>5B!6NF6M5SM4S-OW=)2J);%;^Q*;^KAP6B
M]L_OMNB-T#\?00O]A-.Q[HC_5T-PP5_XMTOW'YO(7VOD'F>UYGEO_/D+R?'U
M _LF<(0.,/S +1QS(UX!5>>(PT=S[+^'U;(@.<_Y>Z)JPF"J?RC O>/[L^Q1
M#P"$67ON^&-VW/%N'2+J[7ON>>7=-=3]/7G G9$>#61QQ7R&0W+*<-J0*(1[
MY56.'X\5^0U(1R/B=-[W;I][V1R-17E*"+S]!6C56[1?R](+49&\7WFEKW9D
MC1?MWY_*JG8M:S\)D&=/?I*0E7C&5.GO.].Q*QKJXCA&3%0J2D63Z]Y+BOEN
MX"?6XAQYP[\)IQ"11[:LR< IV'X!O/!F3M8=H4\*+^&G$V1S""]N#,LM8IVQ
M@2A,W-(3-"&99A:@I_9XA%[1R3T//A4RU;I_$1(@F(8G@!^M#?7]O7FPXU$.
MN<Z0U\SW""K]LZ>_JXMO-E>67_0?ONIR)LOKLE<Q_4JX-O[O&.A$[N,1@L;P
MQ':I-W3YEJSH'^%S^1!YSTN1QNQZ>%8J?)U,'^HUDT*:.B3M8#1AN ((U\II
M7HRW0:ZZS=X.[15:\?'(<;@_]7!_KP.PHXB=I6J4DQK@7!POBBY^@[QXA<AG
ME)CB9*)W/OM?S>);KMHM+DZ6SY2K_ETH>:D_?P6GH:X@7S>N(%_?I2O(UXTK
M@+\V<@6UFO\% (4C2T'.0RF)(R %^O/Z"[TIW'(&&)**'$QX >WE,-G:V/M0
M>+N?;H&1 M,#9KJ_1[&$NX<;5KG__NTF7!^.YP:BW>/MW?W^'D^E% =4;.JA
MZJ3[&Q =!76/*!I(85,$*^3/1 #)#!>L4M*04;U'TJ#WA.(EPPE23YST=8E-
MJ5CJ$?HT'.:9:(S-[.\9+^TI@@8[XE'UTG>1[8/VQ@UX0>%>>'%"DU^05F'+
ML,#K4.@-N2&(L2XA$G #^/E(D&#KC(%-QL"G\'&VGO,5R*=X:?K__D^MD*\>
M@QX([&XD2X:,9#^DF^!P$QE#!914N\8WK]89VTLX:P"J,G!SCH9@L\ NR1M>
M'_GTW_]DLUQ+(&+_B+L!C>P87O%G0N NC[A:X9A[0*C"HEPV:WCJ^L)+^"QR
M=DCSB0IU'E)W!*"=*.I>D?\]R!W0?\-.>\:_G6OT9%'DQRKLQ?CKF#.'^^)T
M7^HJ44'18B#"97SS#S5Y[.EZ"4XRM"UW\*F5M8/. -HQAY+YB&LH?%?H'7/7
M($<98*]E!&&A;/_5O\;/\"O+8V/X:_[[%T#M!76%\"#&"5 =O'Q,;TV',QS,
M +*)D38\LUC6V/EV^Z9PMVQ#-CS9,21/VE:%3Y^1V0 C.K-T$LP\X)I>*@EM
MB97P,^V"\&/ WM\S-$!O!1#U/K>:[A@5BD+C0E4GI,]>R"PYY@6VM!?Z&-7.
M/RNRJBZGQIN?N]Y'52&0.+H^_Z@J6C;;076^/;B0@(*%_H07G:: 8<&J'@G^
M;-,@[O T*-$4<SW.+B,SG*H[N1>8!BO!)J3IH"_R& P3W<!PG7J]*%VMG,GE
M?+M)4A4 Q($VY'BFO[AUD&#+VQMF5-3N CHY;,J60WWSP28=WU9$IF# ) >7
M@CT%^:*_H?J*WG.=)FT*.3&V<6PJGE0GW=^#+P<3430T66TH*'U0OB6P6Q65
M5Z:&KFJIN G76-^7-/$P0;BN#!B+]]('VZJGR8K*KMTPR +3,'=, IW@6=N#
M,^.D'TH0>1]^O23O6J9665T<[>_-R:/"[LHC/^1Z_V)I+<P*DD[% %V'^6%0
M[*@H;GCNSX17P!X6I^B($8 ]4G\)#U^2+&6+Z*C!S&HP;GD1_E U7A2I-REC
M=SLADS1XH=U1(VF"A#Q!90$8CM<<SACFK^E.V*=X@Z;GJ4]$%("&]%.)SCNH
MXZM/!D11:"A0$T3'ZH@?("&2[M7QEI&KY:T30(4Q^CF4"9E+5N\-27^").CM
M^/?"58KX#72<"]JT@^Z+#FSC1(3O#QQ))G5'I])H5WJ<W9V,:^=\1[[K/:V;
MOA)QZL3^GCH9C6RJF5L_ &KG>/U8%)N-Z+8@,?HV8GV+U _T9?(J/"J*\JMZ
MM!,X[9!.M9/<XRP_J0Y*#_V+;P\5\R;[@CH6^>D1!PA/#C[=G9XWS^XOFUR[
MQ=TV[SJW%Z>=YAEWUVF??N7NKR\Z=USCM'/Q<-'YZ2YQT&&QE",R/+P6NRQK
MZ$(,42)M*W]^!WT?  SX\?\>%%;L0[+VC$F6\<MV!'2(BM/6X/)A+\%(V&1[
M,C)9J8/TOZ["_:MO]@RC0U2/HYK6]NXIWG8&.D>H8 PC'&<->Q1J%IB)45GN
M"R^!ZC9E.S#]S)Y0U3=5^"O>5&\CHO+71JLN*@M3,!J*@KG&J+.>3*U';O@I
M?D0UD.:?"0CJ"U!NE0G5;=L8).T,>4E/2S93A!C/>13NC'X ^5HDQM),['V=
MC8H/TUPS[U&![;C]C+T0.\.9%4F LK0DZ<!](Y6_ME_5$<,M>*4]YFO+V&+K
M-MJMEC.56N@Y19LDD/= ^@&5'<W-4KVK*H%*-Y1H*-"H/(N!(<R^=G^]M%J_
M?]R)_A4C="=NX?HA6<+"*]H2M["7F!0.\P&3B;?$+&(>FA*1YJ,[UG=TQM,B
M)6:NPW8LM,*R%BXDYO&,Q>?KW3_&?H.)&;@6/42C]!*O-XFM4 P*,:23V!*J
M;SC1:;'2$3<%AU4W/@A]+ZEB;($!.(=#A6\=D5@-8\D.DA$I&TRCW%$NE@Q=
MXX&"T-0UA&MJ'O6%6'C6[&F0_ZS\'-U,?_DZ3]B=QL*=_MX6>W(">>O<QVS[
M6,U4MC*]^9\=)=D Q6-Q.\CH$6G'%(\8*3L9A+U;>D?QL!2Z37YB]8XE/!O1
MSX.E6-U#MYTHDOZ_<!\#(LPK)-N(-ZX48XQ9H5D\+3<*DFP9MV#J-(:_-W)M
M1GO1<IW?IV16&OII,Q[8L:UI(/8?8BE^5GC+#H5^G\#+X8(*PEM7$?/E<NG@
M4S:=Y94X.MH*TBQ_#PGV@J]FHT8_YL 1(V9;X#6O8K104/]P[1NKVTDD:%IR
M)!KIT>@^5+OJE79U_KQD(D&3_N]<R' '6D9N*KE@<S9T/E/*YS/U8F@S^N.U
MEMPL^UAF^M36DQ$B9RJ3ICJY>:O>\V_+)R.D;&6-!(7-VNZ%PVKH!(6D],!,
M5@K\?X*Y[:37_"_;QZ"02_Z9WD_E*3;B=-?Y52*I(@W?$2[M8^#1A6Y[?0PJ
M^8C[&#2CJ!M-"#HEOV!T.[@4W,<@5_"=?YWV,7AGTB2*/@:U'99 .]W'8%WF
M$4,?@WHN4R[XMWX.%D=SLJBXN[)H=WL8;!6K@B13.9_W0ZS]/:N)0?P]##BS
MA<'^7MK#8 ?EX\9J]0NY7:W5_^0.RZ8%]1^SECLMJ$_ ):0%]4DIJ$>'9U!M
MWFY6U2Z*@^>W75 ?4<CJ53U[[6H_GGKMI[2@_GW&O-."^LABV)M)HERMH#XB
MAG!]+;>%2D6:G#ZG!?4?+UZ=%M1_H(+ZW)8*ZB-W0*8%]1&Y+-<KJ"_G@WS=
M:4']TOK&9JR,%0KJ8Z7@M*!^_8+ZC3( 9T&]?U!B9PK;TH+ZR'6-S?0&"2JH
MCYQGS:K:0UL2K^NMG)@6U&]=_:CD,_62;Z).6E"_C.*Q>&KNE@KJDZ-XI 7U
M6Z=\5R.?T$Z.Q.H=:4%]T@N!+1:Y>*IU/ 7U&_:?[%X-?2V7UM GD732&OH/
M54/OFQ?P[HM@%TF.VI9KZ*,R?Y\&]X.7<>OTI)?6T$><3[!!LSF?J>3RF7+.
M=U1G(DI:/Q#[V,T:^JB8RND?,5_[GB/3_/)V><I65L])V+"Y7CS,APX4)J6&
M_E_'W$''B+]&^7'6^WK=[?>^/+V<]I(UB&\G"A#4_3U0&GP*\C19XT5 )(7T
MY"=)F+&"()-Z./*&?Q.S)D&3K9Q55F'%JQP_'BOR&V"F1L1I<&F5441ZQVI9
MO&G6I#=*GFH']VC__E16M6M9^TD ^XUMA^&41L'4O?YZFYGNJ)6Z7PD<K()*
M9BS#K& $(X.PTHTQ\,Y%/"PV\ 0R)KV::@XLD93X%BN^;<#U<;""2N':HR8/
M0+2+\#7AKQ=3O>JL-\OKDFI,G3:H#[OQ+;<)?&,^HY:LZ!_A<_G'OO9S.3>2
M/TK.Q-KI]??OOWY=SBS,;.KX9\ +$="$%0,5HMH<L!0RX@6:/VA4C3'PF?BX
M>.3KLOB"?J2C_D3!BB7W4-C-WHI3)II"1L=!W!]PRRXNC_5\")\1)6X#5*H^
M6%8]Y#H 7$KG6?:\G3GL[V&1ELD4@Z=D>YXX*M1Q<K,[G_VNID^%#$W$RE+R
ME:HO2\$"NN#B7E_0A^^DFAS0>[19CA'TM:JO+<OUK1X^E*1\JQ3QAG"[&:PR
M138FO(#:$'FI*?OO8;4L2)X*E?ZA +O$]V?9HZMW,^J:VF W\B9%FS_+W:2K
M"GV!%B0Q+*;HR'5 K5'9S:MQG/0C=\.ZXJ<#@8B@!-T _8_X'IE0]S4\="'U
M#KFLWC\UZ4?9!:LH7-N2?'TWJJA]"Z=56Z&TNY!ZZ7,8%0PY+(;TK:)V54Z'
M?[T[6J/)8X\PS-+;S1T6UN&%(9R8F]]2O5*M1[6G*-'1XF"X';V-C5L9JX;M
MX=/H_9D(*M7A55T_ P6"Z6>Y0J'F<'U2>_R&5[2I742=3.W?.)4W8[,N9@NL
MUFB^TB="-GM)GGBQ*8%&Y_I]4Q2)\[>7EZ=>37ULG54,+8E97T8;GPS'VXZZ
M5E,?.\S\],4"_'_C+X"BKB\N!(?1!LS_V&M&2W*Y7&"#.;UW"5C\@J8Z^]:
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M'3VL-]]A*6FGMEX.FKPN"M8&/OLHNLR6:]#8%V41\0591%$43#JBN=3KR^I
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M4A<)8V$"-QOG&(S*Z"168&TWL&G%1/$KB/AC+)=- WKK'- 6: 8"]QTO9]#
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MZXI1"PI_P/NI*N2M?._O,<\CDII)(GJ$XMY5>(^=1D-;#G-D<9&1FERV8F?
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M&"NY=T:G^$X!8&<Y,8O,E3,)QA%*6X A2[6C6Y\;\?>U^VEJ6\9*U(!/3@+
MW'VSZ[QWM4@.I:W<T/6":AZ-1J(S,@.<-,3Q_B(6WI/:7:]4ZW&WH4TQI"<O
MWHK];%AK))<_OLTX*ALE.G"B/IXD[XGH3F AW()R2[0E0/IW<:<JK4%5(I!>
M3$^BMTS3E"*?5I6LXA?J9**U\%)KNLY$UN%'8:HW2@?1*-.81E&+\Z<ST2VO
M7F$: >W*528V X*^--SZTAA@V'FL55VR<6#=NI*U64]%J;@618DLX6_3DF9O
M>G4J4BR2285026)<=*<EA6.-H"5=R+PFH3R=E-=$+,9^V3EJ->Q4''X]:AL
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MK/*SG0PMOSIU1,/31YXS%:/&#Y&M(N( G72'[_.C0TUYKBV*')QGRZ0"P^H
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M^O^^Q28";C.">MZ0&45B&C1;8MDG*O-*(6$^8D9OR3NC=PH8O2)XGJ"=MI]
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M<SGDHV/<?EGI%?2.1'$'@'D0/^(F@71+1Y5D5()BN3B=B .\W&8!#WWIABF
M34\'C2U'*H0*W$98(H>P%+#Y#"#E\XLT$D2[C 87:OJ-A>4G%&$,E"M[+BW?
MQFT9TJOK"MF#^[01R1=$3L[+2<R->G8^$&PH%Y,TN2%HBER3W]I!#=SI;TLY
MVMR32U&YB(#]*OK-$+?OP_30)J*: GTSFW&[ 5%K^M[BAB<&(Z#JCWWD>83C
M@CL-(ZI;1^W.J(3*D'!W2$UA2.YGEYS5VB/EI?@;/8*ML&KN#$4H]F>JA.NL
M2VB@[9<CD'J+"]__4M:V.7E$^[,# ;H-S88'!946SBNO.Y^5XL-SF2/@4,(L
ME:@S3<5L>P[)8OQ'%-%QY1= D#$@3B3!G-&%+2Y&\B:T@ KPFS5ZR$/Z3=/3
MM^XXZT<;2K^0R"_77U[N%P'ZM*\^N!"L,A<LE \4BU;B'<KV9:R@CR''3\_Z
M@WYR4F,A!@T?J6W*EY$%AJG7K*==C$>[XXV(:%";>>4:3-YST+,*N[F\Y::7
M*T>H);Z2/>6DS[8JJ* G#65Y![GF;+QWL1IFD-EPEN>Y#L.=]6G,(QN). !N
MN)!\2K.^_>),4K-J_'VUG7>]H<,*5O%[)77L321RQ '<B1TTW(&D'C7[+<O4
M.'ZXQLG7]+:[X>W8C43W.7RGC0Q_PUHXM8LT2]F0^;W[R/G;X@7RXV]8UUEY
M=D]V>>V6>%.V;14T@=%2Y!QZ*VK@.423P;P0"41]%&1]T)Q[50DL?BD@D30X
MVIE EUO"!5MVQF04% _@5U'>=^)#)6P6\I'@"S1J,:-_$GUJW6$$$,)&!COO
MKP6DRQ/WY.(T5JY]24<"I%W=+V\&&1FY?3L;7VKS,<0J"*$$-UZO GXNKD[#
M%UK(3 /FKKMAK>]7A)3V(U.*9$H%[!$C./>[WUW0H\)RV;X_?CKXZ:LR#2\B
ME(OY(OEQV:5/3PY26YYKZBK''UD23S+TAC6-U"EC3RPAP3721&X"R?16FI]9
M6*=P7,O74SHUGKFFE&,P5H^1UH(>5BGY!* ?=AKF3;=*XND>R%0/GZ3%Y9<3
MK;D=3&8IDA1DX(F#?82$^0 %_IU5LSS8S&=L6WE6R\S#OF5CX-S<8Z6CNF>$
MG$1T2R^1(,2(KOG0KSR=S O.L@&%I.F\O?>LZ0,H5.+Z'5,4WK82%(:!W$"+
MY+E5:W7^5A]^3K; U^6:MS/A+=K]63I^!M#B+^"WC%ZK!";!O._+#WL=$UA&
M:QUF\0';</U9RV$DHEXS(N9Y^'C$(4TOOQO\4TW45^6:ZC3H:N]8%9V'6PRG
MDD:>+$T$;]--H]D2__K4SD-4W=::'<!K"/ DYY/8Y_F&.I:O3![E6L^6Z(5+
MN=W3]&G_/_[X<YH@KFCDUHBLAGM=\H&G[5JW6W]&W83K[[LCD%&3T@G(9GA,
M*"!@'@C-@Q8.;!#1JK,<_&;;Y\Z.UN4<TQ)A1\/DX004[]A-YCV$X73XW604
M08 $@A(A-3&JXIIG+8/6O(/@&X.X^P:-<ZD/%VQR*XMX'VE>7&9,V]1 2J9-
M+6^"]8^/;$V+'D3H_SI6(9G</E?1"3D90M?='1JD4B\[-5S]#J=$-OD17K<1
M/THTYRN6ZG]'F#5"]E']F*QD!W[1/@D$>&%IQ*G]@_#PSJG7\EFO"D$X:BF[
M1GT[T?/I:<.:[<R/^N?(/P%TFYY8F+&-5Z]0VC Y?U4#94U!=6G^^0VJP6MZ
M,*?QEI6C7:^3JL[NN%*]UH7;A3.F1W2&?)N9%'VDEHAVGQ 8A;JT\VJV^E6;
MT<6O3X;L:*%O D7")ZJRB:O-*1IPQQ1LA?LI?<^&?[K=E=MG1!9I+1)_;M^/
M-)[]\([K 0:7->I@7,R1;P$,T$]]@>]B .%6;%@GDD,YLAY7]-%0VG *IF70
MGF!XZ,J#C^,3N:8^>4+?S@EW!)28@W6O:OFK15$]B/@# **"*D[ )$$^Z(O6
M*5HS%G*RW= Y8>'<4$,3UT0/I]-TC\++\]:$2<)P XP1GFM=H_>@MW=A ;+@
MK\8 <7XV49:N?']4X6L>IBK[#UHN2_"W.H<O7&DC3;*$J&!1/$(^C=/4[TOA
MF0XE<6"$'<G&O97QMY(P8YS5^YNTI :;O8OL4GDPZVBR$+8[CF[7"7%6$$>1
MW7RB\JSWY*DJ'^@L;/:+\IOI^09NWK7MI!#%T[V_FB('?Q[#^T;-8.]-,;/E
M+%LQ%^")<X#H=E)H5E&][B9LT@ KUZ/NNI+50P(SMMV_CTU[1\R3T(:H*=)Z
M5X4=T<$PNV*\*<OEQ&#R"YD^7@01TVMT!K"Y%!>M;1W,UX05Z+52MNY:(L>@
MY-5.JC>IIA5J%E>.FDM ( 9C1_!5=^"W>GA\#@ML85X>@5>P8JR53L/SEB%6
M_Y[<8/<#V']]8,:'2TRY0S_45X9<0)R2P8ED;"*)_F8SM/:&QUBYDR9*)2>(
M\B-R1@:IPJ=G990:!\#)ER#*PDZIZV7E*ABPJA(U+(28B8VD!@#=$:Z\,2:Q
M3")*."NUMN[DTS+X*B5R,L;K!1R 1 N#%Z0LF3EF;CF /]X.QITR15^$:@AW
MU@HH%S>4?O/Y:&!B'D6[394=;"#L @$RS:Z,L@A&J;$*U1?#G$LJ^%I9?7Q:
MZ&[=-)CQ8;_[105!:_BAY<\?)0&%T%V(VTFHJ%<6]WX;IAV]A'&75L27QA1@
M6N>:Q^2R?XW5+&S514GYC7^Y)P346KW3JM=NBSXOO>NHSXQZ8;*C/EY?"91P
M98@0^Y/HJU9:;_2!S(53#%P=SWH2XZA&JV=M2QYT^54+1^<>$.9HEIV@&9.L
M(ENMLYWZ<E1UGG6$JO'2^'>2Z3"W;BTD"^\RS$G1N)6G]7X&.G^$J2W!O"_%
MHRI\PUBY1%)OH\RSLVXUC@D?2BXV./RHHISM%0&"&;5Y;2?6E1Y@!_<1BO*T
M.@$5V2!'*_E9Q/=R@?,:.4\"Y",3E"XCH+9\S"&2V:ZD:ZZ\_6HA 6G\+HT&
M-DX_RWZ%09VB44]F_FG9XB 9GX'TCZ+!VQB?:/M ,LS,V$5K-:!%^.'0VK2[
M>F/ ^')Y(B%BY(P$4S5R\5"*WC?K(XZ*<)'^/:VPV#::.<A=U9ZA.<T/#5B"
MN:F'1@ @_=4X0H:+H2TL.(E7#5?/LK[5B6 ,3B(<(+@4]<(4_F$7F#8D((G@
M:R?6^QOR<%A:8L;0)^:2LIJZAJ<. :#$B9LAP_Q;(ZKYZG@)-I*P<Q/_P',T
MGET86AE<,0Q5K-+"PBAW2NGE+D<R7V/"/-6L*PDQHF<W[S^V@"&/+I0*VD+H
M^\SD^WSK0#0?;S48>5W1[WW!D8[DHL4],&.,@A!J%+3?S[F$)\_U)PV6EL>Z
MRI37T;0;V&@9%TZ.^+JPO"5IT^^;!^D2+H M;9J)3.B<85P5,S&L<T"*Q;%1
M7NR60XMCZYUB\5<"[ ?2U?2OZ")&Z9NF4TUPDLRUEPGZ,OV9MP9EKBWZ[D.;
MDI\/]QEOC'4=5"H#I5*X%Y(<\BDR:)X/@'(W1/>XHAW7V)UCW%0@#JOD"I",
MV=V'1)N!D,PSNSI3PB0OY>B&\1@^4;,/&_4=!W^V56+]3*B0[^12GVNF[BR&
M[J_@Y.EF+>7DT8=C@=7"YX:!PLIXIOR(U4I0EV\B@7US;8"ZMH[N>KQZ>_FH
M'@8OHPGVF(*B.2?Y8N2<(\MF!6= .:'R>.;\]E1$<7LG/C5'9=J1+M#^4"0V
MX+>-!>@"<N%R+4<O@J3J'WU *,[>9: N?8*B U)UFLRX"-&B-)$<CZ.6$C]5
M"*O)D.=MCROT]1$DZ2EY\[;HWR_$?%X-\<<@+=<,"J/V!$)A?GJC$+0PH@;:
MOJP.1F"*3>7?O_]O:/X!4$L#!!0    ( !F%:%+A=SI8O1H  !4A 0 1
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M??_[V[__;."OJZ<OMV\>C:^_>2\JN7UK3(R7Q6JV'=YOT8]J^,B/U%SA-9(
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ME.VO5F%"(RQ=+ 0Y0\^\D#@,&<K';NK8VKWA]R3L W*"O82-&_;6P$_S KA
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M&;G(K"Z4R[8?OK$]I"7K 8 XHC%0V[@/1I9V"/SX <2N8WM<7-7V[(A%-&S
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MY9@,3XYD+=CPO1T&_6^SSKR0SU,+9ZM[9(4.&J^C6B.I$C/)U<6HT R]?^4
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M^2FQX'ZJV&7"JV_WV"&D^'&]5I;;=-I6?Q0 FB$PU%882*D,S>XH  VOI_Y
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MO36F?[37!:7/IC: WP;PVP!^&\!O _CGR;Y6%[N:N'+SPLH:VZCMO<'VWB"
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M7UY\:BP4;)Y )#Y)1N(J](G+X?OBBQ.CQ_)24:JJ!#RX;(%FW5EEBY_[:8^
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M%Q@PL?X-P:\(,WH&M7,/5$8AE=%XG50WH&R9CH.LJ]W^W#]I6/0077S@ABB
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ME-U1*Q454@L)-(]>2*)O)4MT9/KWC[;CL)W\DU;+NNNM%Y5H'KV01-]+ENC
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M7 /E&GMK9--RI@=)5&<QYGSLY]/,DC*"U$]M[OK9\S"'744+:D%*?C[%K4*
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MC0R'7796+MRC?I,%4EM<@%[81E'K@:=NAIT6!X!-?T:GY5M%&1"2*F%S68.
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M(8>,N;E!+O*B.P&&M252]8/X=3%N"JA8_R8"6(0S<(O4U]@I:>8T$4D!AB
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MX15"ED]+T- =WG17Q/Y+G0/!2L/MVA#DQ?BH):PBUX(]B==%FS#/K"DU7D.
M/H,Y"'W)]2A22D<=KWOD6-?8(T84$8HS-W]$/V*'EH2"[G,7&4)WW$KQ T%5
MNIC%^5!!#X 7Y2]^0/N9@?;$%(1<JL8%="$B^9W^OSNRAY-?_C]02P,$%
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M:,UM*(%6+D,HY9P$6F@R&C#A,T3$CSV,S+(GG,SQ,XYV6#& ",6L<4 !LF*
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M0PZ,"]V__@D5HL-F%1QDE>B+EP3>0XCGQ TJME%Y,9NK1#*0]56BMHQSFFB
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MVB17"[B:Z4HEG?/("%Z;,X5\?AF[U#CZ)5DO>0PBJ6>2R%B\42V&5[M W12
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M2_%B8.7Z>_-7Y\R00N)R.1="P*9C--1EJ6(4^\D-$:L;QP)PC1WBVN_.F:
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MSG<E5C$?!$VO_<RDW'$/HAVQ;U;-/B[P.DYP+K?T7G$Z?B6!9)SX0>0E;^P
M4:<+O4=]HMT [^BOKADC'NUQ8/SW\6WDLTBF*7I@C9:SG\Q[I?NZST$*)A%I
M96_A<"YPA.6[_5)I^[U#"IEG-B<*C)4R?)*E'( LRL\S*!;^Z@(VN<(#J]-C
M_RNL<(##)1[_:69:.OA3]Y(?74,1Z'0>9%J_]\,'9.[HT8[5"+6OF8W(M6LC
MT,Z_]36 RU!3LMRKM8&R^)2X;O**'')4RS]8[E$$3<2:QLR(H\]G+TGB%_09
M>V'V=(9(BS_"8$Z9,:Z\U'SAI<%*\BHDLE9++*O@-LHJBP3!A&(J=&URL=_8
M\-ND&)E+Y'?H6,+XVM4ZF,2Z"L)=)KV8*95V2:X69!6]"E&P!&OBX^H@Y[^>
M'LF^XN#QB2 ?/9.)]2.^W='\O+,U=\59Y=4ZMF&3D+W,J].T4P-@R-L'=9O2
M91O(RQM!$6NE3F/N1OL9>J M@J9VT55-TRIT;@4 O74F&A!<U@1TBFMP#T-R
M/W^(BN9'_.C@DTI^M$H2,L &L;_(O"13S4(&MHV+,?%C$-& @7C D)8$/(.4
MM,C4V3EV9T8.RZU+,F6;H?^Y*,F2NYF#V4*FR(P#'SX6#/@\GWW-N9\G%KG:
M)93QS(KK.!F_XF05I'BV_DKFUQY_ J:'O@W&]#:+,JFSLO-!KR_B-MU*03J^
MO12B=CF7=XQ#F:=LQ37_#$S4L5#1!&@NZG&;,'(P;SA<4G/>5);(<+S9AO$;
M+C<"[XAIJO"C2RO6TY1W-Y$+'<V;@+;[T0^^BLRXT$+QMED0FNX'OP39$XU%
MP22!4_;G@UFN: 8 S;5&&O!<VH9S=WT@<".*L_7,\P<O)1-I#=W1Z3CW?0YD
M)C4BPY//DCWT\"&*M@#T #-S3=V]M"'H?<$(/7?*AS1#IW#MY7V4X+PH5!8C
M>HR=<I^(S!?WL*F?.X2!N*]M# #Y#0TV'@1.EOYF\ ?@_^D, >76,O8OXPT]
M\L?.GO;P*K*& /#?P%!3SR]N!3KO]=#YY)G[>&?KO;$;2NLX06F1-2P_[^G#
M2<JKZ.]#4%S=$@".FYAJ[.!/D^4&V'O3')9#'_G_O2LN%BYC23U9]AX>VN]A
MCO^V"](@PT7ZO_S-S?$J?HQ8*ZIJUL=_K-V2PG9>8K,V\7&?"::+6C)4U9]7
MM4;+R]F.]K.-#_W;W5=6?4 !*-DYZ/]S2$"\D?Z+@VW;<:1?!![.,F[IC&T$
M=S@? &^GW<7)#MU'DX(\]E[[L*419FM::.TZC%]TZ5K5*HZ*+DK!2XHM<O)@
M?+L!2&5Q1:J$F!:XHHID3*+H[HJP_>+MGH0"DZC*3C5:9<%S7NE4D\JI1T.6
MK\OT-+1UIZ9C*V!(W!LZE^5\M/B,KJ>SKPMT/9_=H-G=>#Y:3FX_H='E<O*%
M5;:%'C?:#36><?(0IU@U9@FP2:_1?:^_+?H##._2F-70*4FT"D+<N/VUC(?Q
M/\=YE+/Y]< O2SJG'N@Y8+S<$8UK]\?:H^B.1E(^;'^KFUYQ)?]>T>'_^QV=
M8P?1#]42&7IXJR4$]:K' DFL=X6WQ*2 +0?0/.$;.M_YNVHI6*EALR<90*]W
M"(4X&%[K,7+WSVH:>:+VF@Z-2@D/"?NRMS.T)8H9DZ%K2</DUQ8? :WCGJW)
M_)@@#LC,F65?%ITJU"A8.]AI!+PZPZF4=LXI8XB<QVLQ**BTADI_;<*:RE-/
ML9?B.;VM$Z^)=\TS>.MMU>D[XI2961**J94A,LX(L8Z ^^$SI*V@A#9S'J_/
M24.@,K+?E=E^KN/D*MX]9.M=.%JMXIT\P:A:Q7(*'BWXUCQ+*N^<BAU MME7
MJ; MSP>/%J1XR$RV2BP2C6T8_2F(?$T&'I&@55))@3:HQ$G!(9 ,FC3A\99H
MG ?1^3>B@PB+%E__A*:Q!R0#6-,]7P>11V8ST2.M:4?+WUT%J=)=F:M;G5-W
M-*HQ3S;4!</(CH!U@RMS;D%YEF]%6\FK\!3M'"G8$Z:#GD7M,Q8:66M!G YN
M%;#)!*'<>S$!J4C'3?-PY\4IQAGAS]V3EVR\%=YEP<H+TV&RVG8@S/(E-K:/
MR;HE3 VNFC!$$#YA]B 5A&$K9(PPBUVR)E1!L^U3]N2%FV#E@"]$Q=S%%-*.
M.5.'K&$-%3T!WM1@ZICS/74X13F<&Q+?',?C#%Q6@@S!VS@-\@$ZG^E^D SF
M.B4WA294!H@K3H@TH#"Q$UIA=F@RTOE,A29S7Q]]^71??2XU+SC82=.:2^MF
M2N7>S-2@[.YVAWR2]0;+"S^S=7Y!*/++*_[$MK)N^BRY#+U@(YL_=FS#:KKR
M/N8UDIAW:0#,=+(/:I/[ NQ66)3N0K9P6]X<@,'D;E=?(-QN,;_  OR.2M]K
M*/5CZS!(-(E6"=V.N,+Y_ZX?+F!>6W.4I8.^Y:H-W<QJU7$P4P9#R*Z(N6-R
M3^2_,$WM7XS5;/$L#+R'((1TSH.WL]P&F>,5#I[IP7;C5R12=<M1N3%J>O)Z
MT&8M'3!S2[V%(#VT5$A")2.=]T?D:8&TBK5&QRW]!/#5O*LIP"<<#U:T;%-(
M0&7878+ISMP57N,DP7Y9$S?R6?$_X:F20QMSR\DN!JO):M(2?!9WL((_$L!4
MJW+N;(S/J_JM=J0Q>JP.TD1=.F3<>6]T%*!'"U>K9$=>X3Y0Z3S^J!N#$0^8
M&&P6(:A:@K(0-8@5TBABF^OFITQS[:I'0"5^F=]LGN>DZ4-W51-N2:XW3DUM
MN3Y\0FNQ"VC,&$M83._1,!:7F8IJTS6H1*:5,.DT]&N0/5WNTBS>X*0T^LWX
MK6E:<4MG(Q/5C%8V 9_4)O#Y"P!Y/$/(3&+P7>Z>5X4R\C';Z )":_/+B9)7
MUJ4!F-=.13PVUP97WZT;;NZNXWB)V#W3[^\7XRLTN?T!W<UG7R97Y#\N?NM\
MY=0YD?/3"P/<IU8V!(#8!H8:$%S1"ICUX=[0=?>I)[=?Q@N0Y":VKC#V60'N
MA1?BV9K\Q=]10\6W;[HH6K[18&A(ZUZ#1@L,.8VA"NXX,$5ZLB7UBCE=_8@+
MI.6,NWQ'F6;,6OUM%]#:[XUK;%(ZZO7L7H4P-*-Y,T*C!&W=S12PXN!?$)%)
M6H:+NZK$I_IXXR7?8'/RKKAF2S.H9Z/('Y=GQ$S?DZ(!IRS5&J:DJU0;/&]U
MR#F72D ]>71Q^.B7KBV'L ='1E!#UL-"U9.8B\EQ2^=BQ50,<( JL;6Z"G7H
M[$O9$  J&QAJ0&E%*V "W-[0=;.OZ\GMZ/82(KESVS"[+W^7!,3,+4T0FX].
MDM>DT;%)62/X=78J%:!%"29@N<"@^)G.M=:Y?I''('X(@T=VHA%*5%N;3[)=
M\2O\( U@Q;*NYO<<7-F4OA($X^14Z*03]_Q*W=<_H1#,U?(Y+LY^I[/U;9SA
M<K-98K9<W":'=*#K-)+)0O-2&IP\IPI'5I[=3\NT!8-P2WS'Z:Y"R"ZN%]NX
M9/9%_NKG25AIT@0QA7JU8.W.4S_3JKM/W=2A<*\_=/EXN2[2$=0*"GEE2_17
M6.ZO[L8-W)]<W-40JG-_,EF0 ZF1WZN/I41V]817W^C:3897+#T&^>=CXFT8
MR<KC3\?RAS7L? W=4907Y9KE-1;)M&BV7GJOW-K,84W9\Y"'&;MWE?W:<4[8
M <"+T@9O&X3&@@++;"$RK](F*->)J:O=!!GUM33WU7QQ_X__\*\?/_S+OQ4G
M7K> YBKF2P,'KRU 7?0Y;+'G)-8OY;BEZY?U$R3[<R5P%WRHV?1_Z ;#LQ=B
M=K.G+,5(?R"NH/F'FF1>!H@_259D#A^_KMC]M#F)G\;K-9:NA-H&8;-#N7G!
M]4YI%P&LCNW$=J%S^#RZ_32F.QO439SESF+\G_>3+Z/I^':Y0*/;*S0?+Y;S
MR>62> WZ^SOP$-7+NBJ.=WQ*XMVV3!0794&TPWYQ9(\,[L?XBITAG(QWZ/ER
M!_,-'9_OH(C3(O.2[&C^H9_]HLTA,W]PAA[P8Q!%14WCW$1'55!^5\0%6'_,
MB?V'4!?3*9P):0]8QBAK<01%>E+!2]J_EN(U9>1%S];Y4"_9L!^X;6L+'4._
MCFKE8ZB&82R%#&Q-NY/,QY<S,O>;3D;+R>P6S:Y/,@(D;Z#]3LB4.4G>B!=1
ME2<VU+4=<QF;TQYSM(HPAPI3V)R'IV6%V)TN^@^\5W<4=C2'-/$V:5T"XM M
M0<CYC4J,O?PC#9E*9Y<)O)W(@_9HQ-H@V-O :K3KW (<RAV$OW^TAT9+-"9_
M)F/=W7@^F5W!&,<6N^TV9 53O9 :3:NE3J)UG&SRDE>:^K>FVE93\W4SJ9&K
MSTS5>8S6#R^7S>_^[FXZOB&,'4W1U61Q.9TM[N?C,AQCIS/1Y/9Z-K]A<1J<
MQ&GQ!K.M-UH+Y)8K8*82M'RA7@*T=6>^)06&7E)HPI"()>2ANY0!4\OW+Z%0
M)B\%H^-+2\HN6800FTQIB "BB0B7CB.Y#@Q^E+[SEGPG\L_]'8W(%^QWTA6A
M,$YW"=8,CX<W:WL..,1+:$\/#VD3#,<',L1P"%[0,?AV=GO.QN':O1\20(KV
MS0\?F25GH(HK=.P:L_CR7;YN2D\&2#-:%8G=Q$>C!GZ"O1-31WDU^X-4@S;O
MO!L=SR;9K4_MI4\4%,]BF8*MI%03=[);_,+FGF0>NBN66UME.6</F1=$]*V4
M^^O7<<*NO,RJ"RNB%SY4R]8ZU;"OHNI,PS0+HQ,-:@M_9O&E2,-6-4_[D:"\
M*XJ+I]#>@XOGL,BN?9,*1H0W2QZ]J"BR=QE':1P&?EG4^XY\(#J%;M3O\\(%
M^0N;6^LNK0[4MLU8;]#740_X!FG8>4\[AC7MOE9O^PPU6F=]L-X^[835$]#^
M$>@OY4/^]SOH9ONH>8E?LPL"\]LQOHOP,2?3^10O:;!^*'C&^^B2<L.XWCG_
M-+J=_!=;]X31M8J F,PS[XC-*WTN!96"U5K 6N"-ZK]2:3 4U$*4)&RF9]1*
M#7">>Q$\1L$Z6-$)&6>?SA^;*EO=!NID4&,7R$@3#!T[P>47H&YN1O/?Z'K3
M8O+I=G(]N1S=+M'H\G)V?\O6G.YFT\DEF+L9\SRG+KVB)<K-JW&)QMIV+[QW
M,JEYL,-(%0Q5N^'E3W_D^9399;I2'[V0!E#9 CBWJK%8YUC-U0$Q5NE<375/
MA;,Z!SL??QG?WD-QG[6BSS2G2;'TFKTM\&J7F"3HZM* W>W3KH8U=U9-M<'0
MLC-D>7[/] S1)MBJ0]X(VK<"SJ/6<$^BPO0;+_F&,[IPS[V$R+_$"5VJ7":>
M7]40-%]J.-[C''6/H[PT26<:]%D0N]XQ#.0Z*MO^I7O$]*KDS7BZ1'>?1_.;
MT>7X?DG"]>GBC/QP^2/;'1Y]FH_9?O("G:/Y>#JBYP_O1O/E;V@Y']TNZ)[Q
M[/;PT4B\E;4W:O^.)M%BEZR]%9YMG[(G+]P$*WK9YD>ZH_>8X'QAIDA,<^<E
MV1MY35'JL7P?LM'HV ^SMN%U]!=6[8$=[4G.NZ45\Q39L2<1*IZ#:@]"]$F(
M/ KMGT6[9)$YB3T/U1]XI"Y9<U9&=LO&PT,;L]:E#C:XZC*]6X+1)0Z%KQZ'
M%O?S:S("H=G=Y^7GT?1F<@EQ&&J=Z#<:360Z#@8%-7R!;Q<K0*FSU06LXNK/
MY?&N_C0A*7VA5-3B758EV-K55*$<#"^E!L>OI@"\"UK66GXS/ABLU+ ]+]1
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MA,<OESYDD,/,IC$Z[RB5=D<DI7>3B *EDLX[78TO@$RX63X*73#7%K+)$3'
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M5(%N-S!>X5P%B-MAV(3G!D16MP2MTTA[P(&7@D4;$30^&<LV3H,LW]>(&7=
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MK0'G<]WD QE-FSIE3M?P"UC]RZFR^IJ\U\%>4MX8;$[7#3Z,TK2E$V9T#;Z
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M"SL;4]^RA^&QZE;UGL%T;<35F:Q^LY=N+3AG[T&P98=,3G'>HG@!YK.6KHT
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M[VKGQE_/&D?E:U?(-P]UR)&88A_+G"4TS^?A'R7+F:P:5$>7+5?B=WBKRVT
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M^.-<9T6_E?*9Y4V:]918=H _ZW75$-M[UU,V8.]3V95#[=[IF-6++86P-MN
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M\;_XS]5/_'_@+HO_\O\!4$L#!!0    ( !F%:%+?.2@8*W   ->8!P 5
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MKZ+-*K/_MG7"F(3>#L+O4F,@R[^WR7(!A5:YGCCV4,XE"-O+K8%\_\'JY41
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MD?'R5R<,G6KGSB3)@=80:"X^0B3U:6II,]="*!6T%G"2#H3F:E0'+0"+$!W
MY?DG>9[[ZXT7[,C>UVGB.1*+BO9 :"Y6H"-5GT67[W\BE>TVA$,RDNVHSZ;2
MH602_N5_3-V?M.J^.J&;Y >HMPE(AK,=(=K*5J!D%VK$4WEM#W+E>+:#3MM9
MX)<->B*W>Z\MXG+; O&C!()Z:UPTUL6$I=9G%&J@4V%M"6GY8)<3G]J 5SC
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M27WZ,KR*;N"XM#/O A!8 AU"W\LQD;\7)Z;^6_(DNS]4-X?"?NYH9WW8I?S
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MVS5EP0Z?1>]U72X9>J7IL2M"X%$W3?SH1#2Z)=$BI,GE07!]4O2Q'2NFCPF
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M>KN8AXY+UD[XAU+\RRUMVPW;60$B#N# 9U^.(A]TK81*V@F(VD^X40/P!0>
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M9:[]*5X34YU)"A MCCK/%E4FRH/IUM"#%.";Z&_$9W]? @.%2"#K,%!&Y^?
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M."YH=&U02P$"% ,4    "  9A6A2XJPBB%<1  #=E0  "P
M@ &):   97@Q,"TV,"YH=&U02P$"% ,4    "  9A6A2R*7V J4#  "F-@
M"@              @ $)>@  97@R,2TQ+FAT;5!+ 0(4 Q0    ( !F%:%(V
MR.B1-@,  %4-   *              "  =9]  !E>#(S+3$N:'1M4$L! A0#
M%     @ &85H4E(^;@4;"   I4,   H              ( !-($  &5X,S$M
M,2YH=&U02P$"% ,4    "  9A6A2]4X(U2$(  !D1   "@
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M,C,Q7V-A;"YX;6Q02P$"% ,4    "  9A6A2SUM/?=9.  "&8P4 %0
M        @ ' <@0 :')O=RTR,#(P,3(S,5]D968N>&UL4$L! A0#%     @
M&85H4F.&2V/RI   _6$) !4              ( !R<$$ &AR;W<M,C R,#$R
M,S%?;&%B+GAM;%!+ 0(4 Q0    ( !F%:%+?.2@8*W   ->8!P 5
M      "  >YF!0!H<F]W+3(P,C Q,C,Q7W!R92YX;6Q02P4&     !  $ "W
) P  3-<%

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
